

**WO 02/26931 A2**



(81) **Designated States (national):** AF, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

IT, IU, MC, NI., PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



## 71 Human Secreted Proteins

### *Field of the Invention*

The present invention relates to novel proteins. More specifically, isolated  
5 nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides  
and antibodies that bind to these polypeptides are provided. Also provided are  
vectors, host cells, and recombinant and synthetic methods for producing human  
polynucleotides and/or polypeptides, and antibodies. The invention further relates to  
diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or  
10 prognosing disorders related to these novel polypeptides. The invention further relates  
to screening methods for identifying agonists and antagonists of polynucleotides and  
polypeptides of the invention. The present invention further relates to methods and/or  
compositions for inhibiting or enhancing the production and function of the  
polypeptides of the present invention.

15

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a  
20 membrane, human cells and other eukaryotes are subdivided by membranes into  
many functionally distinct compartments. Each membrane-bounded compartment, or  
organelle, contains different proteins essential for the function of the organelle. The  
cell uses "sorting signals," which are amino acid motifs located within the protein, to  
target proteins to particular cellular organelles.

25 One type of sorting signal, called a signal sequence, a signal peptide, or a  
leader sequence, directs a class of proteins to an organelle called the endoplasmic  
reticulum (ER). The ER separates the membrane-bounded proteins from all other  
types of proteins. Once localized to the ER, both groups of proteins can be further  
directed to another organelle called the Golgi apparatus. Here, the Golgi distributes  
30 the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes,  
and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Thus there exists a clear need for identifying and using novel secreted polynucleotides and polypeptides. Identification and sequencing of human genes is a major goal of modern scientific research. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human "gene products." These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis).

### *Summary of the Invention*

The present invention relates to novel secreted proteins. More specifically, isolated nucleic acid molecules are provided encoding novel secreted polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further

relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

### ***Detailed Description***

5

#### **Polynucleotides and Polypeptides**

##### **Description of Table 1A**

Table 1A summarizes information concerning certain polynucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC Deposit Number and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, "Vector" refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, "Total NT Seq." refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." (seventh column) and the "3' NT of Clone Seq." (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep." In the

eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by  
5 the present invention.

In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." In the fourteenth column, the predicted first  
10 amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion". The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as "Last AA of ORF".

SEQ ID NO:X (where X may be any of the polynucleotide sequences  
15 disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID  
20 NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted  
25 proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino  
30 acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater

than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., *Nucleic Acids Res.* 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., *Nucleic Acids Res.* 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., *Strategies* 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into *E. coli* strain XL-1 Blue, also available from Stratagene

Vectors pSport1, pCMVSPORT 1.0, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All

Sport vectors contain an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, NY) contains an ampicillin resistance gene and can be transformed into *E. coli* strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into *E. coli* strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., *Nuc. Acids Res.* 16:9677-9686 (1988) and Mead, D. et al., *Bio/Technology* 9: (1991).

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA

contained in ATCC Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC Deposit No.Z.

5

### **Description of Table 1B**

Table 1B summarizes some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifier (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, "Clone ID NO:Z", for a cDNA clone related to each contig sequence disclosed in Table 1A and/or 1B. The third column provides a unique contig identifier, "Contig ID:" for each of the contig sequences disclosed in Table 1B. The fourth column provides the sequence identifier, "SEQ ID NO:X", for each of the contig sequences disclosed in Table 1A and/or 1B. The fifth column, "ORF (From-To)", provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineate the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table 1B as SEQ ID NO:Y (column 6). Column 7 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4; 181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1B as "Predicted Epitopes". In particular embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1B. It will be

30

appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 8, "Tissue Distribution" shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first number in column 8 (preceding the colon), represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. For those identifier codes in which the first two letters are not "AR", the second number in column 8 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are "AR" designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of <sup>33</sup>P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after "[array code]:" represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression. Column 9 provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding



exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). If the putative chromosomal location of the Query overlaps with the chromosomal location of a Morbid Map entry, an OMIM identification number is disclosed in column 10 labeled “OMIM Disease Reference(s)”. A key to the OMIM reference identification numbers is provided in Table 5.

#### **Description of Table 1C**

Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID NO:Z), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID NO:Z”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

**Description of Table 1D**

Table 1D: In preferred embodiments, the present invention encompasses a method of treating a disease or disorder listed in the "FEATURES OF PROTEIN" sections (below) and also as listed in the "Preferred Indications" column of Table 1D (below);  
5 comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A and Table 1D (in the same row as the disease or disorder to be treated is listed in the "Preferred Indications" column of Table 1D) in an amount effective to treat, prevent, or ameliorate the disease or  
10 disorder.

As indicated in Table 1D, the polynucleotides, polypeptides, agonists, or antagonists of the present invention (including antibodies) can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be  
15 involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to treat the associated disease.

The present invention encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder. In preferred embodiments, the  
20 present invention encompasses a method of treating a disease or disorder listed in the "Preferred Indications" column of Table 1D; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to treat, prevent, diagnose, or ameliorate the disease or disorder. The first and second  
25 columns of Table 1D show the "Gene No." and "cDNA Clone ID No.", respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in preventing, treating, diagnosing, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in Column 3 of Table 1D.

30 In another embodiment, the present invention also encompasses methods of preventing, treating, diagnosing, or ameliorating a disease or disorder listed in the "Preferred Indications" column of Table 1D; comprising administering to a patient

combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in Column 3 of Table 1D.

The "Preferred Indication" column describes diseases, disorders, and/or  
5 conditions that may be treated, prevented, diagnosed, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

The recitation of "Cancer" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to diagnose, treat,  
10 prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., leukemias, cancers, and/or as described below under "Hyperproliferative Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Cancer" recitation in the "Preferred Indication" column of Table 1D may be used for example, to diagnose, treat, prevent, and/or  
15 ameliorate a neoplasm located in a tissue selected from the group consisting of: colon, abdomen, bone, breast, digestive system, liver, pancreas, prostate, peritoneum, lung, blood (e.g., leukemia), endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), uterus, eye, head and neck, nervous (central and peripheral),  
20 lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Cancer" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a pre-neoplastic condition, selected from the group consisting of:  
25 hyperplasia (e.g., endometrial hyperplasia and/or as described in the section entitled "Hyperproliferative Disorders"), metaplasia (e.g., connective tissue metaplasia, atypical metaplasia, and/or as described in the section entitled "Hyperproliferative Disorders"), and/or dysplasia (e.g., cervical dysplasia, and bronchopulmonary dysplasia).

30 In another specific embodiment, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Cancer" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose,

treat, prevent, and/or ameliorate a benign dysproliferative disorder selected from the group consisting of: benign tumors, fibrocystic conditions, tissue hypertrophy, and/or as described in the section entitled "Hyperproliferative Disorders".

5           The recitation of "Immune/Hematopoietic" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"),  
10 blood disorders (e.g., as described below under "Immune Activity" "Cardiovascular Disorders" and/or "Blood-Related Disorders"), and infections (e.g., as described below under "Infectious Disease").

          In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having the "Immune/Hematopoietic" recitation in the  
15 "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, asthma, AIDS,  
20 autoimmune disease, rheumatoid arthritis, granulomatous disease, immune deficiency, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, systemic lupus erythematosus, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and allergies.

25           The recitation of "Reproductive" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"),  
30 and disorders of the reproductive system (e.g., as described below under "Reproductive System Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Reproductive" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of:

5 cryptorchism, prostatitis, inguinal hernia, varicocele, leydig cell tumors, verrucous carcinoma, prostatitis, malacoplakia, Peyronie's disease, penile carcinoma, squamous cell hyperplasia, dysmenorrhea, ovarian adenocarcinoma, Turner's syndrome, mucopurulent cervicitis, Sertoli-leydig tumors, ovarian cancer, uterine cancer, pelvic inflammatory disease, testicular cancer, prostate cancer, Klinefelter's syndrome,

10 Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, testicular atrophy, testicular feminization, anorchia, ectopic testis, epididymitis, orchitis, gonorrhea, syphilis, testicular torsion, vasitis nodosa, germ cell tumors, stromal tumors, dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome,

15 hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding, cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, cervical neoplasms, pseudohermaphroditism, and premenstrual syndrome.

20 The recitation of "Musculoskeletal" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"),

25 and disorders of the immune system (e.g., as described below under "Immune Activity").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Musculoskeletal" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose,

30 treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bone cancers (e.g., osteochondromas, benign chondromas, chondroblastoma, chondromyxoid fibromas, osteoid osteomas, giant cell tumors,

multiple myeloma, osteosarcomas), Paget's Disease, rheumatoid arthritis, systemic lupus erythematosus, osteomyelitis, Lyme Disease, gout, bursitis, tendonitis, osteoporosis, osteoarthritis, muscular dystrophy, mitochondrial myopathy, cachexia, and multiple sclerosis.

- 5 The recitation of "Cardiovascular" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and
- 10 disorders of the cardiovascular system (e.g., as described below under "Cardiovascular Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Cardiovascular" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent,

15 and/or ameliorate a disease or disorder selected from the group consisting of: myxomas, fibromas, rhabdomyomas, cardiovascular abnormalities (e.g., congenital heart defects, cerebral arteriovenous malformations, septal defects), heart disease (e.g., heart failure, congestive heart disease, arrhythmia, tachycardia, fibrillation, pericardial Disease, endocarditis), cardiac arrest, heart valve disease (e.g., stenosis,

20 regurgitation, prolapse), vascular disease (e.g., hypertension, coronary artery disease, angina, aneurysm, arteriosclerosis, peripheral vascular disease), hyponatremia, hypernatremia, hypokalemia, and hyperkalemia.

The recitation of "Mixed Fetal" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the

25 invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Mixed Fetal" recitation in the "Preferred

30 Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: spina bifida, hydranencephaly, neurofibromatosis, fetal alcohol syndrome, diabetes

mellitus, PKU, Down's syndrome, Patau syndrome, Edwards syndrome, Turner syndrome, Apert syndrome, Carpenter syndrome, Conradi syndrome, Crouzon syndrome, cutis laxa, Cornelia de Lange syndrome, Ellis-van Creveld syndrome, Holt-Oram syndrome, Kartagener syndrome, Meckel-Gruber syndrome, Noonan syndrome, Pallister-Hall syndrome, Rubinstein-Taybi syndrome, Scimitar syndrome, Smith-Lemli-Opitz syndrome, thrombocytopenia-absent radius (TAR) syndrome, Treacher Collins syndrome, Williams syndrome, Hirschsprung's disease, Meckel's diverticulum, polycystic kidney disease, Turner's syndrome, and gonadal dysgenesis, Klippel-Feil syndrome, Osteogenesis imperfecta, muscular dystrophy, Tay-Sachs disease, Wilm's tumor, neuroblastoma, and retinoblastoma.

The recitation of "Excretory" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and renal disorders (e.g., as described below under "Renal Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Excretory" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: bladder cancer, prostate cancer, benign prostatic hyperplasia, bladder disorders (e.g., urinary incontinence, urinary retention, urinary obstruction, urinary tract infections, interstitial cystitis, prostatitis, neurogenic bladder, hematuria), renal disorders (e.g., hydronephrosis, proteinuria, renal failure, pyelonephritis, urolithiasis, reflux nephropathy, and unilateral obstructive uropathy).

The recitation of "Neural/Sensory" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the nervous system (e.g., as described below under "Neural Activity and Neurological Diseases").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Neural/Sensory" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: brain cancer (e.g., brain stem glioma, brain tumors, central nervous system (Primary) lymphoma, central nervous system lymphoma, cerebellar astrocytoma, and cerebral astrocytoma, neurodegenerative disorders (e.g., Alzheimer's Disease, Creutzfeldt-Jakob Disease, Parkinson's Disease, and Idiopathic Presenile Dementia), encephalomyelitis, cerebral malaria, meningitis, metabolic brain diseases (e.g., phenylketonuria and pyruvate carboxylase deficiency), cerebellar ataxia, ataxia telangiectasia, and AIDS Dementia Complex, schizophrenia, attention deficit disorder, hyperactive attention deficit disorder, autism, and obsessive compulsive disorders.

The recitation of "Respiratory" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the respiratory system (e.g., as described below under "Respiratory Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Respiratory" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of the respiratory system such as larynx cancer, pharynx cancer, trachea cancer, epiglottis cancer, lung cancer, squamous cell carcinomas, small cell (oat cell) carcinomas, large cell carcinomas, and adenocarcinomas. Allergic reactions, cystic fibrosis, sarcoidosis, histiocytosis X, infiltrative lung diseases (e.g., pulmonary fibrosis and lymphoid interstitial pneumonia), obstructive airway diseases (e.g., asthma, emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis and asbestosis), pneumonia, and pleurisy.



The recitation of "Endocrine" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the respiratory system (e.g., as described below under "Respiratory Disorders"), renal disorders (e.g., as described below under "Renal Disorders"), and disorders of the endocrine system (e.g., as described below under "Endocrine Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having an "Endocrine" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of: cancers of endocrine tissues and organs (e.g., cancers of the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, pancreas, adrenal glands, ovaries, and testes), diabetes (e.g., diabetes insipidus, type I and type II diabetes mellitus), obesity, disorders related to pituitary glands (e.g., hyperpituitarism, hypopituitarism, and pituitary dwarfism), hypothyroidism, hyperthyroidism, goiter, reproductive disorders (e.g. male and female infertility), disorders related to adrenal glands (e.g., Addison's Disease, corticosteroid deficiency, and Cushing's Syndrome), kidney cancer (e.g., hypernephroma, transitional cell cancer, and Wilm's tumor), diabetic nephropathy, interstitial nephritis, polycystic kidney disease, glomerulonephritis (e.g., IgM mesangial proliferative glomerulonephritis and glomerulonephritis caused by autoimmune disorders; such as Goodpasture's syndrome), and nephrocalcinosis.

The recitation of "Digestive" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders") and diseases or disorders of the gastrointestinal system (e.g., as described below under "Gastrointestinal Disorders").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Digestive" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group consisting of:

5 ulcerative colitis, appendicitis, Crohn's disease, hepatitis, hepatic encephalopathy, portal hypertension, cholelithiasis, cancer of the digestive system (e.g., biliary tract cancer, stomach cancer, colon cancer, gastric cancer, pancreatic cancer, cancer of the bile duct, tumors of the colon (e.g., polyps or cancers), and cirrhosis), pancreatitis, ulcerative disease, pyloric stenosis, gastroenteritis, gastritis, gastric atrophy, benign

10 tumors of the duodenum, distension, irritable bowel syndrome, malabsorption, congenital disorders of the small intestine, bacterial and parasitic infection, megacolon, Hirschsprung's disease, aganglionic megacolon, acquired megacolon, colitis, anorectal disorders (e.g., anal fistulas, hemorrhoids), congenital disorders of the liver (e.g., Wilson's disease, hemochromatosis, cystic fibrosis, biliary atresia, and

15 alpha1-antitrypsin deficiency), portal hypertension, cholelithiasis, and jaundice.

The recitation of "Connective/Epithelial" in the "Preferred Indication" column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to

20 diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), cellular and genetic abnormalities (e.g., as described below under "Diseases at the Cellular Level"), angiogenesis (e.g., as described below under "Anti-Angiogenesis Activity"), and or to promote or inhibit regeneration (e.g., as described below under "Regeneration"), and wound healing (e.g., as described below under "Wound

25 Healing and Epithelial Cell Proliferation").

In specific embodiments, a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) having a "Connective/Epithelial" recitation in the "Preferred Indication" column of Table 1D, may be used for example, to diagnose, treat, prevent, and/or ameliorate a disease or disorder selected from the group

30 consisting of: connective tissue metaplasia, mixed connective tissue disease, focal epithelial hyperplasia, epithelial metaplasia, mucoepithelial dysplasia, graft v. host disease, polymyositis, cystic hyperplasia, cerebral dysplasia, tissue hypertrophy,

Alzheimer's disease, lymphoproliferative disorder, Waldenstrom's macroglobulinemia, Crohn's disease, pernicious anemia, idiopathic Addison's disease, glomerulonephritis, bullous pemphigoid, Sjogren's syndrome, diabetes mellitus, cystic fibrosis, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, osteoporosis, osteoarthritis, periodontal disease, wound healing, relapsing polychondritis, vasculitis, polyarteritis nodosa, Wegener's granulomatosis, cellulitis, rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma, CREST syndrome, Sjogren's syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, relapsing polychondritis, vasculitis, Henoch-Schonlein syndrome, erythema nodosum, polyarteritis nodosa, temporal (giant cell) arteritis, Takayasu's arteritis, Wegener's granulomatosis, Reiter's syndrome, Behcet's syndrome, ankylosing spondylitis, cellulitis, keloids, Ehler Danlos syndrome, Marfan syndrome, pseudoxantoma elasticum, osteogenesis imperfecta, chondrodysplasias, epidermolysis bullosa, Alport syndrome, and cutis laxa.

#### **Description of Table 1E**

Table 1E provides information related to biological activities and preferred indications for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Table 1E also provides information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column ("Gene No.") provides the gene number in the application for each clone identifier. The second column ("cDNA Clone ID No:Z") provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, 1C, and 1D. The third column ("AA SEQ ID NO:Y") indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column ("Biological Activity") indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The fifth column ("Exemplary Activity Assay") further describes the corresponding biological activity and provides information pertaining to the various

types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. The sixth column ("Preferred Indications") describes particular embodiments of the invention and indications (e.g. pathologies, diseases, disorders, abnormalities, etc.) for which polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) may be used in detecting, diagnosing, preventing, and/or treating.

Table 1E describes the use of FMAT technology, *inter alia*, for testing or demonstrating various biological activities. Fluorometric microvolume assay technology (FMAT) is a fluorescence-based system which provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound fluorophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays. *See*, Miraglia S et. al., "Homogeneous cell and bead based assays for highthroughput screening using fluorometric microvolume assay technology," Journal of Biomolecular Screening; 4:193-204 (1999). In particular, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways. For example, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).

Table 1E also describes the use of kinase assays for testing, demonstrating, or quantifying biological activity. In this regard, the phosphorylation and de-phosphorylation of specific amino acid residues (e.g. Tyrosine, Serine, Threonine) on cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways. Moreover, cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a

wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.). Accordingly, kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation.

- 5 See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. "Enzyme-Linked Immunosorbent Assay for Measurement of JNK, ERK, and p38 Kinase Activities" *Biol. Chem.* 379(8-9): 1101-1110 (1998).

### **Description of Table 2**

- 10 Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, "Clone ID NO:Z", corresponding to a cDNA clone disclosed in Table 1A or 1B. The second column provides the unique contig identifier, "Contig ID:" corresponding to contigs in Table 1B and allowing for correlation with the information in Table 1B. The third column
- 15 provides the sequence identifier, "SEQ ID NO:X", for the contig polynucleotide sequence. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. Comparisons were made between polypeptides encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as "NR"), or a database of protein
- 20 families (herein referred to as "PFAM") as further described below. The fifth column provides a description of the PFAM/NR hit having a significant match to a polypeptide of the invention. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, "Score/Percent Identity", provides a quality score or the percent identity, of the hit disclosed in columns five
- 25 and six. Columns 8 and 9, "NT From" and "NT To" respectively, delineate the polynucleotides in "SEQ ID NO:X" that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth and sixth columns. In specific embodiments polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ID NO:X as
- 30 delineated in columns 8 and 9, or fragments or variants thereof.

### **Description of Table 3**

Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone identifier, "Clone ID", for a cDNA clone related to contig sequences disclosed in Table 1B. The second column provides the sequence identifier, "SEQ ID NO:X", for contig sequences disclosed in Table 1A and/or 1B. The third column provides the unique contig identifier, "Contig ID:", for contigs disclosed in Table 1B. The fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

#### 25 Description of Table 4

Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1B, column 8. Column 1 provides the tissue/cell source identifier code disclosed in Table 1B, Column 8. Columns 2-5 provide a description of the tissue or cell source. Codes corresponding to diseased tissues are indicated in column 6 with the word "disease". The use of the word "disease" in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking

the "disease" designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

5

### Description of Table 5

Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 1B, column 10. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian  
10 Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, MD) 2000. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>). Column 2 provides diseases associated with the cytologic band disclosed in Table 1B, column 9, as determined using the  
15 Morbid Map database.

### Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

20 In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of  
25 matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing  
30 features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of

a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X (as described in column 5 of Table 1A), or cDNA clone (as described in column 2 of Table 1A and contained within a pool of plasmids deposited with the ATCC in ATCC Deposit No:Z). For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without a natural or artificial signal sequence, the protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

In the present invention, a representative plasmid containing the sequence of SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC") and/or described in Table 1A. As shown in Table 1A, each cDNA is identified by a cDNA clone identifier and the ATCC Deposit Number (ATCC Deposit No:Z). Plasmids that were pooled and deposited as a single deposit have the same ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein) and/or sequences of the cDNA contained in the deposited clone (e.g., the complement of any one, two, three, four, or more of the polynucleotide



fragments described herein). "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also included within "polynucleotides" of the present invention are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH<sub>2</sub>PO<sub>4</sub>; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA<sup>+</sup> sequences (such as any 3' terminal polyA<sup>+</sup> tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotides of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or

DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

"SEQ ID NO:X" refers to a polynucleotide sequence described in column 5 of Table 1A, while "SEQ ID NO:Y" refers to a polypeptide sequence described in column 10 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 6 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEQ ID NO:2 is the first polypeptide sequence shown in the sequence

listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:3, and so on.

The polypeptides of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992)).

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the polypeptides of the present invention in methods which are well known in the art.

By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein of the invention. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide for binding) to an anti-polypeptide antibody], immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

"A polypeptide having functional activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular assay, such as, for example, a biological assay, with or without dose dependency. In the case where

dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than  
5 about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

The functional activity of the polypeptides, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind  
10 or compete with full-length polypeptide of the present invention for binding to an antibody to the full length polypeptide, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion  
15 precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment,  
20 antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

25 In another embodiment, where a ligand is identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., Microbiol.  
30 Rev. 59:94-123 (1995). In another embodiment, physiological correlates polypeptide of the present invention binding to its substrates (signal transduction) can be assayed.

In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the present invention and fragments, variants derivatives and analogs thereof to elicit polypeptide related biological activity (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope of the invention.

### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

10 This gene is expressed primarily in pancreas islet cell tumors.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the pancreas, including cancer and diabetes. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pancreas, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
 PFCSGFFPSLWYLPFIFNVSDLWMGSLSGCALPFCLXVFFLTVSPSAVGLLXF  
 30 AGGPLQTLFAWVSPVEAAEQRLLPVLSSGSFVSEGTCQMPARALLYEVSVG  
 PYWEIPPSQDTRRSQTYLRRQSDP (SEQ ID NO: 197). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and

variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The tissue distribution in tumors of pancreatic islet cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment and intervention of such tumors, in addition to other endocrine or gastrointestinal tumors where expression has been indicated. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 2**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
HEGSCRAPGFSAHKGRGCPSRMTLPSRALASLGVGWGMRLRLNQVTVSCG  
GSRWSSRVALGAFSWVCGV  
ALVLQPSGGGLGLTSPSEGCWEGELALAVLRAPGGSPS (SEQ ID NO: 198).  
Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed equally in hemangiopericytoma cells, breast lymph node tissue, and bone marrow.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,

immune and hematopoietic disorders, particularly leukemia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular and immune  
5 systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hemolymphoid, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,  
10 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 105 as residues: Gly-29 to Ser-35, Ser-63 to Cys-68. Polynucleotides encoding said  
15 polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in hemangiopericytoma, breast lymph node, and bone marrow indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as  
20 anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. The uses include bone marrow cell ex vivo culture, bone marrow transplantation, bone marrow  
25 reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of  
30 various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional



supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

5           The protein product of this gene shares homology with *Drosophila*, mouse, and human Slit proteins (See Genbank Accession Numbers (protein) AAD25539 and AAD38940; all references available through this accession are hereby incorporated herein by reference; for example Rothberg et al., *Genes Dev.* 4:2169-87 (1990), Brose K., et al., *Cell* 1999 Mar 19;96(6):795-806, and Liang Y., et al., *J. Biol. Chem.* 1999 Jun 18;274(25):17885-92). Slit gene products are secreted proteins that contain both EGF domain and Leucine Rich Repeat domains; and function as ligands for cell-surface receptors. In *Drosophila*, Slits are important in the development of midline glia and commissural axon pathways. In vertebrates, Slit family proteins have been shown to function as ligands of receptors in nervous system tissue. Slit proteins are thought to be critical for certain stages of central nervous system histogenesis and to have evolutionarily conserved roles in axon guidance (Brose K., et al., *Cell* 1999 Mar 19;96(6):795-806 and Liang Y., et al., *J. Biol. Chem.* 1999 Jun 18;274(25):17885-92). Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with Slit proteins. Such activities are known in the art, some of which are described elsewhere herein.

20           This gene is expressed primarily in human hippocampus.

          Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neurological, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution within human hippocampus combined with the homology to the *Drosophila* slit protein, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention.

In specific embodiments, polypeptides of the invention comprise, or  
5 alternatively consists of, the following amino acid sequence:  
IPLTLPGIFLLIRLFWRLGQSICGPGKLVLPQFCCGCAVISGHCVPRGMPSSW  
LPGCFVLLCLVAVGCQLREWGVGGVSAVGLLALPHLQVLGMRGRGLISGG  
(SEQ ID NO: 199). Polynucleotides encoding these polypeptides are also  
encompassed by the invention. Moreover, fragments and variants of these  
10 polypeptides (such as, for example, fragments as described herein, polypeptides at  
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides  
and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
conditions, to the polynucleotide encoding these polypeptides, or the complement  
there of are encompassed by the invention. Antibodies that bind polypeptides of the  
15 invention are also encompassed by the invention. Polynucleotides encoding these  
polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
16. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 16.

20 This gene is expressed in KMH2 cells, osteoblasts, fetal spleen, Jurkat  
membrane bound polysomes, breast, and cerebellum.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
25 cancer, immune, and skeletal disorders. Similarly, polypeptides and antibodies  
directed to these polypeptides are useful in providing immunological probes for  
differential identification of the tissue(s) or cell type(s). For a number of disorders of  
the above tissues or cells, particularly of the immune system, expression of this gene  
at significantly higher or lower levels may be routinely detected in certain tissues or  
30 cell types (e.g., immune, skeletal, cancerous, or wounded tissues) or bodily fluids  
(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
cell sample taken from an individual having such a disorder, relative to the standard

gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in KMH2 cells, osteoblasts, and fetal spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product in fetal spleen and T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

The translation product of this gene shares sequence homology with phospholipase A2 which cleaves fatty acids from carbon 2 of glycerol (ref. Prosite pattern documentation for PS2\_HIS). Many snake venoms contain phospholipase A2, which prevents transmission of nerve impulses to muscles by blocking the release of acetylcholine from the neuron. Therefore, included in this invention as preferred domains are Phospholipase A2 histidine active site domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Phospholipase A2 is an enzyme which releases fatty acids from the second carbon group of glycerol. Structurally, PA2's are small and rigid proteins of 120 amino-acid residues that have four to seven disulfide bonds. PA2 binds a calcium ion which is required for activity. The side chains of two conserved residues, a histidine and an aspartic acid, participate in a 'catalytic network'. Two different signature patterns for PA2's were developed. The first is centered on the active site histidine and contains three cysteines involved in disulfide bonds. The consensus pattern is as follows: C-C-x(2)-H-x(2)-C [H is the active site residue]. Preferred polypeptides of the invention comprise a Phospholipase A2 histidine active site domain selected from the following amino acid sequences: CCNQHDRC (SEQ ID NO: 201), SLTKCCNQHDRCYET (SEQ ID NO: 202) and/or LTKCCNQHDRCYETCG (SEQ ID NO: 203). Polynucleotides encoding these polypeptides are also encompassed by the invention. Further preferred are polypeptides comprising the Phospholipase A2 histidine active site domain of the sequence listed in Table 1A for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues may be N-terminal or C-terminal to the Phospholipase A2 histidine active site domain. Alternatively, the additional contiguous amino acid residues may be both N-terminal and C-terminal to the Phospholipase A2 histidine active site domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to Phospholipase A2 proteins. Based on the sequence similarity, the translation product of this clone is

expected to share at least some biological activities with Phospholipase A2 proteins. Such activities are known in the art, some of which are described elsewhere herein, or see, for example, McIntosh, et al. J. Biol. Chem. 270 (8), 3518-3526 (1995), incorporated herein by reference.

5           In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
GPAGKEAWIWSWLLPSPGPAPLPSASWGLCGDAPRAAARGPVEPGAARMAL  
10   LSRPALTLLLLLMAAVVRCQEQAQTTDWRATLKTIRNGVHKIDTYLNAALDL  
LGGEDGLCQYKCS DGSKPFPRYGYKPSPPNGCGSPLFGXHLNIGIPSLTKCCN  
QHDRCYETCGKSKNDCDEE  
FQYCLSKICRDVQKTLGLTQHVQACETTVELLFDSVIHLGCKPYLDSQRAAC  
RCHYEEKTDL (SEQ ID NO: 200). Moreover, fragments and variants of these  
15   polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the  
20   invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 4. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 4.

25           This gene is expressed in a diverse variety of cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological disorders, or metabolism disorders, specifically phospholipase A2  
30   deficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,

particularly of the neuromuscular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pancreas, cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
5 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 108 as  
10 residues: Gln-23 to Asp-30, Lys-66 to Cys-87. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The ubiquitous tissue distribution and homology to phospholipase A2 indicates that polynucleotides and polypeptides corresponding to this gene are useful  
15 for diagnosis and treatment of neuromuscular disorders. Alternatively, considering the activity of phospholipase A2 as a block for neuro- transmission may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette  
20 Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked  
25 disorders, or disorders of the cardiovascular system.

Alternatively, the homology to Phospholipase A2 proteins may indicate a potential use for the protein product of this clone in diagnosis, treatment and/or prevention of metabolism disorders, specifically deficiencies in Phospholipase A2. Furthermore, the protein may also be used to determine biological activity, to raise  
30 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 6

5 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
 GTSSARPRGALPGGSAPSAPHGQLPGRAQPAPVSGPPPTSGLCHFDPAAPWPL  
 WPGPWQLPPHPQDWPAPHPDIPQDWVSFLRSFGQLTLCPRNGTVTGKWRGSH  
 VVGLLTTLNFGDGPDRNKTRTFQATVLGSQMGLKGSSAGQLVLITARVTTER  
 10 TAGTCLYFSAVPGLPSSQPPISCSEEGAGNATLSPRMGEECVSVWSHEGLVLT  
 KLLTSEELALCGSRLVLGSFLLFCGLLCCVTAMCFHPRRESHWSRTRL  
 (SEQ ID NO: 204). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at  
 15 least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these  
 20 polypeptides are also encompassed by the invention.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
 25 ARAPPGPEGLSPEAQPLLPMGNCQAGHNLHLCLAHHPPLVCATLILLGLLS  
 GLGLGSFLLTHRTGLRT LTSPRTGSLF (SEQ ID NO: 205). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which  
 30 hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the



invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed in a wide variety of tissue types including testes, cerebellum, dendritic cells, breast cancer, umbilical vein endothelial cells, 5 epididymus, corpus colosum, chronic synovitis, liver hepatoma, normal breast, osteoblasts, melanocytes, B cell lymphomas, and to a lesser extent in other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, 10 cancer, particularly of endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain 15 tissues or cell types (e.g., endothelial, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 109 as residues: Thr-52 to Gly-57. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

25 Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that the protein product of this clone may play a role in the regulation of cellular division and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative 30 Disorders" and "Regeneration" sections below and elsewhere herein. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages.

In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also relies on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

RFLSVXPQXEVPFLHPCVCFXGGHPSLLPDPCRAVGGGWEAPRCCLHEALC

QSLGCKAEEIVSVSESSSAQRCWYLLRGRKAGGRGPASPVLFALMRLESLCH  
LCLACLFFRLPATRTVYCMNEAEIVDVALGILIESRKQXKACEQPALAGADNP  
EHSPPCSVSPHTSSGSSSEEEEDSGKQALXPGLSPSQRPGGSSSACSRSPEEEE  
EEDVLKYVREIFFS (SEQ ID NO: 206). Polynucleotides encoding these

- 5 polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the
- 10 complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

- Polynucleotides of the invention do not consist of the nucleic acid sequences shown as GeneSeq Accession Nos: V59595 and V59744, which are hereby
- 15 incorporated herein by reference.

This gene is expressed primarily in a variety of immune cell types, including stromal cells, dendritic cells, leukocytes, activated T-cells, macrophages, monocytes, neutrophils and to a lesser extent in a variety of other adult and fetal tissues.

- Polynucleotides and polypeptides of the invention are useful as reagents for
- 20 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of
- 25 the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene
- 30 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product in fetal tissue and various hematopoietic cancers indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the NF-kB (Nuclear Factor kB) pathway. Thus, it is likely that this gene activates T-cells through the NF-kB signal transduction pathway.

- 5 NF-kB is a transcription factor activated by a wide variety of agents, leading to cell activation, differentiation, or apoptosis. Reporter constructs utilizing the NF-kB promoter element are used to screen supernatants for such activity. In a specific embodiment polypeptides of the invention comprise, or alternatively consist of, the following amino acid sequence:

10 VPGWPRACSPCQADSPRAHPPKLRGILRWAPVPLXCAALCPPLDSGMSMAA  
CPEAPEPSFLREVPSSTQWHRPCNFRQVEANPRKEPKNLVWRDVS LGQX  
SRTPRGSGLELVRVCGGGMQRDKTVVEERVGEERERERERESLG GAGKHGE  
MRCVYVRESVGAPGRAGGGGNGVNSVGCVRTVHSGSXPPPSAGVS (SEQ ID  
NO: 207). Also preferred are the polynucleotides encoding these polypeptides.

- 15 Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the  
20 invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in parts of the brain such as cerebellum and frontal lobe.

- 25 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
30 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell

types (e.g., neural, cancerous, or wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in cerebellum and frontal lobe indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, prevention and/or treatment of neurodegenerative disease states and behavioural disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

5 TRPGKELNLVFGLQLSMARIGSTVNMNLMGWLYSKIEALLGSAGHTTLGITL  
MIGGITCILSLICALALA  
YLDQRAERILHKEQGKTGEVIKLTVDKDFSLPLWLIFICVCYYVAVFPFIGLG  
KVFFTEKFGFSSQAAS AINSVVYVISAPMSPVFGLLVDKTGKNIIWVLCA  
(SEQ ID NO: 208). Polynucleotides encoding these polypeptides are also  
10 encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in fetal tissue, and to a lesser extent in a  
15 variety of adult human tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fetal abnormalities, particularly developmental disorders. Similarly, polypeptides and  
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing, or cancerous and wounded  
25 tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
30 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 112 as residues: Lys-30 to Thr-35. Polynucleotides encoding said polypeptides are also

encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in fetal tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional



supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 10

5

The translation product of this gene shares sequence homology with human histiocyte-secreted factor (HSF) which is a novel cytokine that shows in vivo antitumour activity without the cytotoxicity associated with tumor necrosis factor. Furthermore, the translation product of this gene also shares sequence homology with  
10 the human endogenous virus S71 gag polyprotein, the sequence of which is believed to represent a transformation locus for several cancers (See Genbank Accession No. pir|A46312|A46312; all references available through this accession are hereby incorporated by reference herein). Similarly, the translation product of this clone also shares homology with B219, a sequence that is expressed in at least four isoforms in  
15 very primitive hematopoietic cell populations which may represent a novel hemopoietin receptor (See, e.g., Cioffi, et al. Nat. Med. 2:585-589 (1996), which is hereby incorporated by reference herein).

In a preferred embodiment polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
20 CKDLCSR VYLLT LSP LLSYDPATSHSPRNTQ (SEQ ID NO: 209). Also preferred are the polynucleotides encoding these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
25 under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in tonsil, and colon, and to a lesser extent in a  
30 wide variety of human tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and gastrointestinal disorders, particularly tumors of the colon and tonsil. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, digestive and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, gastrointestinal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 113 as residues: Met-1 to Cys-6. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in tonsil and colon, combined with the homology to human histiocyte growth factor, the human endogenous viral protein, and B219 strongly indicate that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, treatment and/or prevention, of a variety of hematopoietic and immune system disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Expression of this gene product in tonsils indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including

arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 11

20

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

IIECWEEECQSCRLKITQPREICRMDFLVLFLFYLASVLMGLVLICVCSKTHS  
LKGLARGGAQIFSCIPECLQRAXHGLLHYLFHTRNHTFIVLHLVLQGMVYTE  
YTWEVFGYQCQELESLHYLLPYLLLGVNLFFFTLTCGTNPGIITKANELLFLH  
VYEFDEVMFPKNVRCSTCDLRKPARSKHCSVCNWCVHRFDHHCVWVNCCI  
GAWNIRYFLIYVLTLTASAATVAIVSTTFLVHLVVMSDLYQETYIDDLGHLHV

MDTVFLIQYLFLTFPRIVFMLGFVVVLSFLLGGYLLFVLYLAATNQTNEWYR  
GDWAWCQRCPLVAWPPSAEPQVHRNIHSHGLRSNLQEIFLPAFPCHERKKQE  
(SEQ ID NO: 210). Polynucleotides encoding these polypeptides are also

encompassed by the invention. Moreover, fragments and variants of these  
5 polypeptides (such as, for example, fragments as described herein, polypeptides at  
least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides  
and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
conditions, to the polynucleotide encoding these polypeptides, or the complement  
there of are encompassed by the invention. Antibodies that bind polypeptides of the  
10 invention are also encompassed by the invention. Polynucleotides encoding these  
polypeptides are also encompassed by the invention.

This gene is expressed primarily in colon and brain and to some extent in all  
tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for  
15 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
neurological and digestive disorders. Similarly, polypeptides and antibodies directed  
to these polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
20 tissues or cells, particularly of the central nervous system and digestive system,  
expression of this gene at significantly higher or lower levels may be routinely  
detected in certain tissues or cell types (e.g., neurological, gastrointestinal, or  
cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine,  
synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
25 individual having such a disorder, relative to the standard gene expression level, i.e.,  
the expression level in healthy tissue or bodily fluid from an individual not having the  
disorder.

The tissue distribution in brain indicates the protein product of this clone is  
useful for the detection, treatment, and/or prevention of neurodegenerative disease  
30 states, behavioral disorders, or inflammatory conditions. Representative uses are  
described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in  
Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not

limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Alternatively, expression of this gene in colon may indicate a role in the detection, prevention and/or treatment of colon disorders such as colon cancer, Crohn's disease, ulcers, and digestive tract disorders in general. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

When tested against Reh cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activation site) pathway. Thus, it is likely that this gene activates B-cells through the Jaks-STAT signal transduction pathway. GAS is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

30

This gene maps to chromosome 7, and therefore, may be used as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in brain, and in the developing embryo.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, behavioral, immune, and developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and developmental systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developing, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 115 as residues: Lys-60 to Asn-67. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive

compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the tissue distribution in developing embryo indicates that the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system.

Alternatively, the biological activity within B-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Activation of genes within B-cells indicates a role for this protein in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g., by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product may be involved in immune functions. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

This gene maps to chromosome 6, and therefore, may be used as a marker in linkage analysis for chromosome 6.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention

comprise, or alternatively consists of, the following amino acid sequence:

LLSFKIRGLRTEDAGWAQSSSGGLCVRGDAFWMPSSSSGLGSPSRPPSSFLCL  
LLLLLP

PAALALLLFFLDFFPPRAAVSPFLPDHCSARQPRVWRRETLNRSASGLGCWA

5 RSTEQGAVGVATGTVLDI SLPASCLSLWPPGPSGGI (SEQ ID NO: 211).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

In a specific embodiment polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

QLGLCLTSASLPPASRCGHQAPLGASDLAHHSAPGFSDSYFTMSCQSSLSRA

10 EILQCPLVPSVSPPTHL PQGRANKSSRASLPLLPQTHWCLFPSARGWRRGIQSG

LPPGGSCTSPRSPPQTLHQHITLVNHNTSYWQSPST (SEQ ID NO: 212),

HQPPCLLPLAVATRPLWGHLTCLPIHLVSVTLTSPCLANQAFQGQRSYNAL

WCPLFLLPTSPKGEQTNHPEPACPCFPKLTGVFSLQHVVGAEFSQVFLLD

PVPVLDHLLKLFTSTSHLLIIPHIGKAPAPDSLL EELSLSLATHCKVAVARFT

15 (SEQ ID NO: 213). Also preferred are the polynucleotides encoding these polypeptides.

Polynucleotides of the invention do not consist of the nucleic acid sequence shown as GeneSeq Accession No. X04377, which is hereby incorporated herein by reference.

20 This gene is expressed primarily in brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, behavioral and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
25 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
30 serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene



expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 116 as  
5 residues: Pro-2 to Gly-7, Ser-10 to Ser-16, Pro-52 to Val-62, Arg-64 to Ser-73. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in brain indicates that polynucleotides and polypeptides  
10 corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of  
15 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,  
20 psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore,  
25 the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

The translation product of this gene was shown to have homology to the lysosomal mannosidase alpha-B protein (See Genbank Accession No. P34098) which is thought to be important in protein metabolism.

In specific embodiments, polypeptides of the invention comprise, or  
5 alternatively consists of, the following amino acid sequence:  
MAAEGSRFSSQSPGLVDRQGPKCDPSRLVSPWGRHGLRILQIGHHHGRDGQH  
EATHHLLRVLRAPRVGKADEGAVSDPSTPLQLKHEAAHAEDHAQQVHVVR  
RRVVQGRVTFARRGLVPQH  
FVRPPWVRHIVSGHSESKARSRLFRCRNRSFRRAS (SEQ ID NO: 214), and/or  
10 RLVSPWGRHGLRILQIGHHHGRDGQH EATHHLLRVLRA (SEQ ID NO: 215).

An additional embodiment would be the polynucleotides encoding these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the  
15 polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 This gene maps to chromosome 19, and therefore, may be used as a marker in linkage analysis for chromosome 19.

This gene is expressed primarily in brain, placenta, fetal liver, and to a lesser extent in most tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for  
25 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological, reproductive, and hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
30 disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, hepatic, or cancerous and wounded tissues) or bodily

fluids (e.g., bile, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 117 as residues: Asn-34 to Lys-42, Leu-60 to Trp-70. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

10 The tissue distribution predominantly in brain indicates a role in the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder and panic disorder. Alternatively, the tissue distribution in liver indicates that polynucleotides  
15 and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies,  
20 pre-natal disorders and various wound-healing models and/or tissue trauma.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

25 This gene is expressed primarily in spinal cord, Merkel cells, and adipose tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the nervous and immune systems, particularly those disorders relating to  
30 the CNS involving lipid metabolism disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of the nervous and immune systems and adipose tissue, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord, Merkel cells and adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases the nervous systems, such as spinal cord injury, neurodegenerative diseases, muscular dystrophy or obesity. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## **15 FEATURES OF PROTEIN ENCODED BY GENE NO: 16**

The translation product of this gene shares sequence homology with the human uncoupling protein-2 which is thought to be important in energy metabolism, obesity, and the predisposition of hyperinsulinemia (See Genbank Accession No. gi|1857278). Recently, another group published on this gene, designating it brain mitochondrial carrier protein-1 (BCMP1) (J Biol Chem 1998 Dec 18;273(51):34611-5).

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence: PTDVLKIRMQAQ (SEQ ID NO: 216), and/or TYEQLKR (SEQ ID NO: 217). An additional embodiment would be the polynucleotides encoding these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the

invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene maps to the X chromosome, and therefore, may be used as a marker in linkage analysis for the X chromosome.

5 This gene is expressed primarily in manic depression brain tissue, epileptic frontal cortex, human erythroleukemia cell line, T-helper cells, and to a lesser extent in endothelial and amygdala cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system or hematopoietic/immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system or hematopoietic/immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, hemolymphoid, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 119 as residues: Ser-34 to Thr-39, Gln-198 to Leu-205. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in neural tissues combined with the homology to the human uncoupling protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and/or treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic

disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Alternatively, given the homology to uncoupling proteins, the gene and/or its translation product may also be used in the diagnosis, treatment, and/or prevention of thermogenesis disorders such as obesity, cachexia, and hyperinsulinemia. Uncoupling proteins dissipate the proton gradient created from the oxidation of fuels by the electron transport chain, thus releasing stored energy as heat. Dysfunction of thermogenesis can induce disorders such as obesity and cachexia. It is thought that obesity may result from decreased thermogenesis in humans.

Alternatively, cachexia is a metabolic state in which energy expenditure exceeds food intake, for example in anorexia nervosa. Uncoupling proteins may be useful for the treatment and/or prevention of diseases and/or disorders involved with aberrant metabolic and thermogenic pathways. The following method provides for the determination of respiration uncoupling activity of the polypeptides of the present invention, including fragments and variants of the full length proteins. Briefly, yeast are transfected with an expression vector expressing polypeptide of the present invention as previously described by Bouillaud et al., EMBO J., 13:1990 (1994) (incorporated by reference herein in its entirety). Rates of growth in liquid medium of transformed yeast are measured in the presence of galactose, which induces expression, as described in International Publication No. WO 98/31396 (incorporated by reference herein in its entirety). Instantaneous generation times are compared between the polypeptide of the present invention and appropriate controls. An in vivo decrease of membrane potential associated with uncoupling of respiration is analyzed by flow cytometry of yeast labeled with the potential sensitive probe DiOC6 (3) (3,3'-dihexyloxacarbocyanine iodine, Molecular Probes, Eugene, OR). The ability of a polypeptide of the present invention to influence mitochondrial activity and uncouple respiration is thus determined.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

The translation product of this gene shares sequence homology with 55 kD deglycosylated zona pellucida protein which is known to be important in egg fertilization (See Genbank Accession No.R39356).

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

RPRPSASSLARSASLLPAAHGXGVGGAGGGSSXLSRYQQQLQNEEESGEPEQ  
AAGDAPPPYSSISAESAHXFDYKDESGFPKPPSYNVATTLP SYDEAERTKAEA

10 TIPLVPGRDEDFVGRDDFDDADQLRIGNDGIF (SEQ ID NO: 218),  
RYQQQLQNEEESGEPEQAAGD (SEQ ID NO: 219), and/or  
PGRDEDFVGRDDFDDADQLRIG (SEQ ID NO: 220). Moreover, fragments and  
variants of these polypeptides (such as, for example, fragments as described herein,  
polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
15 these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
under stringent conditions, to the polynucleotide encoding these polypeptides , or the  
complement there of are encompassed by the invention. Antibodies that bind  
polypeptides of the invention are also encompassed by the invention. Polynucleotides  
encoding these polypeptides are also encompassed by the invention.

20 An additional embodiment would be the polynucleotides encoding these  
polypeptides. Preferred polypeptide fragments of the invention comprise, or  
alternatively consists of, the following amino acid sequence:

MLTFFMAFLFNWIGFFLSFCLTTSAAGRYGAISGFGLSLIKWILVRFSTYFPGY  
FDGQYWLWWVFLVLGFLLFLRGFINYAKVRKMPET FSNLPRTRVLFIY (SEQ

25 ID NO: 221). Polynucleotides encoding these polypeptides are also encompassed by  
the invention. Moreover, fragments and variants of these polypeptides (such as, for  
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
30 encoding these polypeptides , or the complement there of are encompassed by the  
invention. Antibodies that bind polypeptides of the invention are also encompassed by

the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide variants of the invention comprise, or alternatively consists of, the following amino acid sequence:

5 MKKSLENLNRLQVMLLHLTAAFLQRAQHXYFDYKDESGFPKPPSYNVATTLP  
YDEAERTKAEATIPLVGRDEDFVGRDDFDDADQLRIGNDGIFMLTFFMAFLF  
NWIGFFLSFCLTTSAAGRYGAISGFGLSLIKWILIVRFSTYFPGYFDGQYWLW  
WVFLVLGFLFLRGRFINYAKVR KMPETFSNLPRTVLFIY (SEQ ID NO: 222),  
MLLHLTAAFLQRAQFSTYFPGYFDGQYWLWWVFLVLGFLFLRGRFINYAKV  
10 RKMPETFSN LPRTVLFIY (SEQ ID NO: 223),  
MLTFFMAFLFNWIGFFLSFCLTTSAAGRYGAISGFGLSLIKWILIVRFSTYFPAF  
MNSLS RSKRTPAGSESRCTQRNNHLL (SEQ ID NO: 224), and/or  
MKKSLENLNRLQVMLLHLTAAFLQRAHXIL TTRMSLGFQSPHLTM (SEQ ID  
NO: 225) . Polynucleotides encoding these polypeptides are also encompassed by the  
15 invention. Moreover, fragments and variants of these polypeptides (such as, for  
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
encoding these polypeptides , or the complement there of are encompassed by the  
20 invention. Antibodies that bind polypeptides of the invention are also encompassed by  
the invention. Polynucleotides encoding these polypeptides are also encompassed by  
the invention.

When tested against U937 cell lines, supernatants removed from cells  
containing this gene activated the GAS (gamma activating sequence) promoter  
25 element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent,  
other immune and hematopoietic cells and JAK-STAT signal transduction pathway.  
GAS is a promoter element found upstream of many genes which are involved in the  
Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway  
involved in the differentiation and proliferation of cells. Therefore, activation of the  
30 Jak-STAT pathway, reflected by the binding of the GAS element, can be used to  
indicate proteins involved in the proliferation and differentiation of cells.



This gene is expressed primarily in adult kidney, colon adenocarcinoma, and fetal brain, and to a lesser extent, ubiquitously expression in many tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of kidney, colon cancers, and central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the renal and neural systems, and cancers, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, neural, urogenital, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 120 as residues: Cys-15 to Gly-36. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution adult kidney, colon adenocarcinoma, and fetal brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of kidney diseases, colon cancers, and disorders of the central nervous system. Additionally, the homology to the zona pellucida protein indicates that the gene product may be used for male contraceptive development, and infertility diagnosis etc. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 18**

The translation product of this gene shares sequence homology with the chicken transferrin receptor in addition to a human prostate-specific protein homolog (See Genbank Accession Nos. [pir|JH0570|JH0570](#) and [gi|2565338 \(AF026380\)](#), respectively).

5        This gene also shares significant homology with both the murine and the rat hematopoietic lineage switch 2 proteins (See Genbank Accession Nos. [g3169729](#) and [g3851632](#), respectively), which are induced during an erythroid to myeloid lineage switch.

10        A preferred polypeptide fragment of the invention comprises, or alternatively consists of, the following amino acid sequence:

MTVMDPKQMNVA AAVWAVVSYVVADMEEMPLRS (SEQ ID NO: 226).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
15    97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by  
20    the invention.

This gene is expressed primarily in fetal tissues, such as liver/spleen and brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pre-  
25    natal disorders, anomalies, deficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or  
30    cell types (e.g., developing, cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 121 as  
5 residues: Arg-31 to Lys-37, Lys-58 to Glu-65, Asp-157 to Gly-168, Ile-219 to Gly-225, Ala-260 to Ser-268, Thr-276 to Glu-282. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides  
10 corresponding to this gene are useful for treatment and diagnosis of pre-natal disorders, anomalies and deficiencies. The homology to the hematopoietic lineage switch 2 proteins indicates that the translation product of this clone is useful for the detection and/or treatment of immune system disorders. In addition, the homology to the transferrin receptor indicates that the translation product of the present invention  
15 may have utility in the regulation of iron metabolism as well as the numerous genes under the stringent control of physiologic iron levels. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 19

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention.

25 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
PRVRSREPVAGAPGCGTAGPPAMATLWGGLRLGSLLSLSCLALSVLLLAHC  
QTPPSDCLHVVEPMPVRGPDVEAYCLRCECKYEERSSVTIKVTIIYLSILGLLL  
LYMVYLTLVEPILKRRLFGHAQLIQSDDDIGDHQPFANAHDVLARSRSRANV  
30 LNKVEYAQQRWKLQVQEQRKSVFDRHVVLS (SEQ ID NO: 227).

Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example,

fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 72 - 88 of the amino acid sequence referenced in Table 1A for this gene. Moreover, a cytoplasmic tail encompassing amino acids 89 to 167 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

A preferred polypeptide variant of the invention comprise, or alternatively consists of, the following amino acid sequence:

MATLWGGLRLGSLLSCLALSVLLLAHCQTPPRISMSDVNVSA LPIKKNS  
GHIYNKN ISQKDCDCLHVVEPMPVRGPDVEAYCLRCE  
CKYEERSSVTIKVTIIYLSILGLLLLYMV  
YLTLVEPILKRRLFGHAQLIQSDDDIGHQPFANAHDV LARS SRANVLNKVE  
YGTAAL E  
ASSPRAAKSLSLTGMLSSANWGIEFKVTRKKQADNWKGTDWVLLGFILIPC  
(SEQ ID NO: 228). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in infant brain tissue, and to a lesser extent in other cell types and tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental and neurodegenerative diseases of the brain and nervous system, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mania, dementia, paranoia, addictive behavior, sleep disorders, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 122 as residues: Gln-110 to Pro-120, Val-152 to Val-159. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of developmental, degenerative and behavioral conditions of the brain and nervous system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette Syndrome, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD), mania, depression, dementia, paranoia, addictive behavior, obsessive-compulsive disorder and sleep

disorders. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
5 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

The translation product of this gene shares sequence homology with a recently  
10 published gene Dysferlin, which is thought to be a skeletal muscle gene that is mutated in Miyoshi myopathy and limb girdle muscular dystrophy (See Genbank Accession No. g3600028, and Nat. Genet. 20 (1), 31-36 (1998)).

This gene is expressed primarily in fetal liver, fetal heart tissue, and T-cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
15 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, lymphomas, auto-immunities, cancer, inflammation, anemias (leukemia) and liver disorders, vascular disorders, and cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are  
20 attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver and immune system, expression of this gene at significantly higher or lower levels may be  
25 routinely detected in certain tissues or cell types (e.g., hepatic, developmental, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from  
30 an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune

disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product may be applicable in conditions of general microbial infection, inflammation or cancer. Expression in liver may suggest a role for this gene product in the treatment and detection of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Alternatively, the tissue distribution in fetal heart tissue indicates that the protein product of this gene is useful for the diagnosis and treatment of conditions and pathologies of the cardiovascular system, such as heart disease, restenosis, atherosclerosis, stroke, angina, thrombosis, and wound healing. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Additionally, the homology to the dysferlin gene indicates that polynucleotides and polypeptides corresponding to this gene are useful for diseases related to degenerative myopathies that are characterized by the weakness and atrophy of muscles without neural degradation; such as Duchenne and Becker's muscular dystrophies. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

This gene is expressed primarily in haemopoietic cells and tumor cells, such as pancreatic tumor tissue, and to a lesser extent in bladder cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, haemopoietic disorders, diseases of the renal and pancreatic systems, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the

haemopoietic, pancreatic, and renal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., pancreas, renal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
5 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders  
10 of the renal, pancreatic and haemopoietic systems, and cancers thereof. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

This gene is expressed primarily in liver tissue, cancer cells and fetal lung tissue, and to a lesser extent in dendritic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
20 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic disorders, diseases of developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
25 a number of disorders of the above tissues or cells, particularly of the fetus, metabolic systems and cancers, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developing, metabolic, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
30 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 125 as residues: His-44 to Gly-49. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the fetus, metabolic systems and cancers. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g. hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

This gene is expressed primarily in central nervous system tissues and cancers, such as endometrial tumors, and to a lesser extent in other tissues and organs.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the CNS and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and cancerous tissues, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or

another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 126 as residues: Tyr-16 to Ser-22, Asp-209 to Leu-215. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of the central nervous system, as well as cancers of tissues where expression of this gene has been observed, such as in endometrial tumors. The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

The translation product of this gene shares sequence homology with low-density lipoprotein receptor (See Genbank Accession No. >dbj|BAA24580.1), which is thought to be important in the pathogenesis of atherosclerosis and other disorders. The translation product of this gene also shares sequence homology with a rat homolog of the human CD94 (See Genbank Accession No. gb|AAC10220.1).

This gene is expressed primarily in macrophages, eosinophils, neutrophil and other cells of the haemopoietic and immune system.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the immune and haemopoietic systems and diseases of the endothelial and vascular system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, haemopoietic and vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 127 as residues: Lys-9 to Ala-17, Met-55 to Leu-61, Tyr-105 to Cys-127, Asp-132 to Lys-141, Ser-165 to Tyr-172, Pro-178 to Met-186, His-222 to Gln-227. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution and homology to LDL receptor and rat CD94 homolog indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the immune, haemopoietic and vascular systems. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of hematopoietic disorders. This gene product is primarily expressed in hematopoietic cells and tissues, suggesting that it plays a role in the survival, proliferation, and/or differentiation of hematopoietic lineages. Expression of this gene product in eosinophils and macrophage also strongly indicates a role for this protein in immune function and immune surveillance. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 25

5 This gene is expressed primarily in infant brain and placental tissues, and to a lesser extent in several other tissues including immune and cancers.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 128 as residues: Leu-56 to Thr-62, Gln-80 to Pro-87, Gly-106 to Gln-113, Pro-122 to Lys-127, Gln-138 to Asn-146, Cys-280 to Lys-287, Asp-306 to Gly-311, Asp-321 to Thr-326, Gly-337 to Pro-345, Thr-354 to Gln-359, Asn-451 to Ile-457, Lys-526 to Glu-532, and Gln-591 to Glu-603. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

15 In a specific embodiment, polypeptides of the invention, comprise or alternatively consist of, one or more of the following amino acid sequences:

MAAAGRLPSSWALFSPLLAGLALLGVGPVPARALHNVTAELFGAEAWGTLA  
AFGDLNSDKQTDLFVLRERNDLIVFLADQNAPYFKPKVKVSFKNHSALITSVV  
PGDYDGDSQMDVLLTYLPKNYAKSELGAVIFWGQNQTLDPNMTILNRTFQ  
20 DEPLIMDFNGDLIPDIFGITNESNQPQILLGGNLSWHPALTTTSKMRIPHSHAFI  
DLTEDFTADLFLTTLNATTSTFQFEIWENLDGNFSVSTILEKPQNMMVVGQSA  
FADFDDGDGHMDHLLPGCEDKNCQKSTIYLVRSGMKQWVPVLQDFSNGKTL  
WGFVVPFVDEQQPTEIPIITLHIGDYNMDGYPDALVILKNTSGSNQQAFLLENV  
PCNNASCEEARRMFKVYWELTDLNQIKDAMVATFFDIYEDGILDIVVLSKGY  
25 TKNDFAIHTLKNNFEADAYFVKVIVLSGLCSNDCPRR (SEQ ID NO: 227).

Polynucleotides encoding these polypeptides are also encompassed by the invention as are antibodies that bind one or more of these polypeptides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical  
30 to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention.

Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also preferred are polypeptides, comprising or alternatively consisting of, the  
5 mature polypeptide which is predicted to consist of residues 34-612 of the foregoing  
sequence (SEQ ID NO:128), and biologically active fragments of the mature  
polypeptide (e.g., fragments that induce secretion of IFN $\gamma$ ). Polynucleotides encoding  
these polypeptides are also encompassed by the invention. Moreover, fragments and  
variants of these polypeptides (such as, for example, fragments as described herein,  
10 polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
under stringent conditions, to the polynucleotide encoding these polypeptides, or the  
complement thereof are encompassed by the invention. Antibodies that bind  
polypeptides of the invention are also encompassed by the invention. Polynucleotides  
15 encoding these polypeptides are also encompassed by the invention.

Figures 1A-C show the nucleotide (SEQ ID NO:35) and deduced amino acid  
sequence (SEQ ID NO:128) corresponding to this gene.

Figure 2 shows an analysis of the amino acid sequence (SEQ ID NO:128).  
Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic  
20 regions; flexible regions; antigenic index and surface probability are shown, and all  
were generated using the default settings of the recited computer algorithms. In the  
"Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the  
highly antigenic regions of the protein, i.e., regions from which epitope-bearing  
peptides of the invention can be obtained. Polypeptides comprising, or alternatively  
25 consisting of, domains defined by these graphs are contemplated by the present  
invention, as are polynucleotides encoding these polypeptides.

The data presented in Figure 2 are also represented in tabular form in Table 6.  
The columns are labeled with the headings "Res", "Position", and Roman Numerals  
I-XIV. The column headings refer to the following features of the amino acid  
30 sequence presented in Figure 2, and Table 6: "Res": amino acid residue of SEQ ID  
NO:128 and Figures 1A - 1C; "Position": position of the corresponding residue  
within SEQ ID NO:128 and Figures 1A - 1C; I: Alpha, Regions - Garnier-Robson;

II: Alpha, Regions - Chou-Fasman; III: Beta, Regions - Garnier-Robson; IV: Beta, Regions - Chou-Fasman; V: Turn, Regions - Garnier-Robson; VI: Turn, Regions - Chou-Fasman; VII: Coil, Regions - Garnier-Robson; VIII: Hydrophilicity Plot - Kyte-Doolittle; IX: Hydrophobicity Plot - Hopp-Woods; X: Alpha, Amphipathic Regions - Eisenberg; XI: Beta, Amphipathic Regions - Eisenberg; XII: Flexible Regions - Karplus-Schulz; XIII: Antigenic Index - Jameson-Wolf; and XIV: Surface Probability Plot - Emini.

Preferred embodiments of the invention in this regard include fragments that comprise, or alternatively consisting of, one or more of the following regions: alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-sheet and beta-sheet forming regions ("beta-regions"), turn and turn-forming regions ("turn-regions"), coil and coil-forming regions ("coil-regions"), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions and high antigenic index regions. The data representing the structural or functional attributes of the protein set forth in Figure 2 and/or Table 6, as described above, was generated using the various modules and algorithms of the DNA\*STAR set on default parameters. In a preferred embodiment, the data presented in columns VIII, IX, XIII, and XIV of Table 6 can be used to determine regions of the protein which exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from the data presented in columns VIII, IX, XIII, and/or XIV by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

Certain preferred regions in these regards are set out in Figure 2, but may, as shown in Table 6, be represented or identified by using tabular representations of the data presented in Figure 2. The DNA\*STAR computer algorithm used to generate Figure 2 (set on the original default parameters) was used to present the data in Figure 2 in a tabular format (See Table 6). The tabular format of the data in Figure 2 is used to easily determine specific boundaries of a preferred region.

The present invention is further directed to fragments of the polynucleotide sequences described herein. By a fragment of, for example, the polynucleotide sequence of a deposited cDNA or the nucleotide sequence shown in SEQ ID NO: 35,

is intended polynucleotide fragments at least about 15nt, and more preferably at least about 20 nt, at least about 25nt, still more preferably at least about 30 nt, at least about 35nt, and even more preferably, at least about 40 nt in length, at least about 45nt in length, at least about 50nt in length, at least about 60nt in length, at least about 70nt in length, at least about 80nt in length, at least about 90nt in length, at least about 100nt in length, at least about 125nt in length, at least about 150nt in length, at least about 175nt in length, which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 200-1500 nt in length are also useful according to the present invention, as are fragments corresponding to most, if not all, of the nucleotide sequence of a deposited cDNA or as shown in SEQ ID NO:35. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of a deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:35. In this context "about" includes the particularly recited size, and sizes larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Representative examples of polynucleotide fragments of the invention include, for example, fragments that comprise, or alternatively, consist of, a sequence from about nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about 150, from about 151 to about 200, from about 201 to about 250, from about 251 to about 300, from about 301 to about 350, from about 351 to about 400, from about 401 to about 450, from about 451 to about 500, and from about 501 to about 550, and from about 551 to about 600, from about 601 to about 650, from about 651 to about 700, from about 701 to about 750, from about 751 to about 800, from about 801 to about 850, from about 851 to about 900, from about 901 to about 950, from about 951 to about 1000, from about 1001 to about 1050, from about 1051 to about 1100, from about 1101 to about 1150, from about 1151 to about 1200, from about 1201 to about 1250, from about 1251 to about 1300, from about 1301 to about 1350, from about 1351 to about 1400, from about 1401 to about 1450, and from about 1451 to about 1500, from about 1501 to about 1550, from about 1551 to about 1600, from about 1601 to about 1650, from about 1651 to about 1700, from about 1701 to about 1750, from about 1751 to about 1800, from about 1801 to about 1850, from about 1851 to about 1900, from about 1901 to about 1950, and from about 1951 to about 2000,

from about 2001 to about 2050, from about 2051 to about 2100, from about 2101 to about 2150, from about 2151 to about 2200, from about 2201 to about 2250, or from about 2251 to about 2312 of SEQ ID NO:35, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. In additional embodiments, the polynucleotides of the invention encode functional attributes of the corresponding protein.

Preferred polypeptide fragments of the invention comprise, or alternatively consist of, the secreted protein having a continuous series of deleted residues from the amino or the carboxy terminus, or both. Particularly, N-terminal deletions of the polypeptide can be described by the general formula m-612 where m is an integer from 2 to 606, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:128. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: A-2 to M-612; A-3 to M-612; A-4 to M-612; G-5 to M-612; R-6 to M-612; L-7 to M-612; P-8 to M-612; S-9 to M-612; S-10 to M-612; W-11 to M-612; A-12 to M-612; L-13 to M-612; F-14 to M-612; S-15 to M-612; P-16 to M-612; L-17 to M-612; L-18 to M-612; A-19 to M-612; G-20 to M-612; L-21 to M-612; A-22 to M-612; L-23 to M-612; L-24 to M-612; G-25 to M-612; V-26 to M-612; G-27 to M-612; P-28 to M-612; V-29 to M-612; P-30 to M-612; A-31 to M-612; R-32 to M-612; A-33 to M-612; L-34 to M-612; H-35 to M-612; N-36 to M-612; V-37 to M-612; T-38 to M-612; A-39 to M-612; E-40 to M-612; L-41 to M-612; F-42 to M-612; G-43 to M-612; A-44 to M-612; E-45 to M-612; A-46 to M-612; W-47 to M-612; G-48 to M-612; T-49 to M-612; L-50 to M-612; A-51 to M-612; A-52 to M-612; F-53 to M-612; G-54 to M-612; D-55 to M-612; L-56 to M-612; N-57 to M-612; S-58 to M-612; D-59 to M-612; K-60 to M-612; Q-61 to M-612; T-62 to M-612; D-63 to M-612; L-64 to M-612; F-65 to M-612; V-66 to M-612; L-67 to M-612; R-68 to M-612; E-69 to M-612; R-70 to M-612; N-71 to M-612; D-72 to M-612; L-73 to M-612; I-74 to M-612; V-75 to M-612; F-76 to M-612; L-77 to M-612; A-78 to M-612; D-79 to M-612; Q-80 to M-612; N-81 to M-612; A-82 to M-612; P-83 to M-612; Y-84 to M-612; F-85 to M-612; K-86 to M-612; P-87 to M-612; K-88



to M-612; V-89 to M-612; K-90 to M-612; V-91 to M-612; S-92 to M-612; F-93 to M-612; K-94 to M-612; N-95 to M-612; H-96 to M-612; S-97 to M-612; A-98 to M-612; L-99 to M-612; I-100 to M-612; T-101 to M-612; S-102 to M-612; V-103 to M-612; V-104 to M-612; P-105 to M-612; G-106 to M-612; D-107 to M-612; Y-108 to M-612; D-109 to M-612; G-110 to M-612; D-111 to M-612; S-112 to M-612; Q-113 to M-612; M-114 to M-612; D-115 to M-612; V-116 to M-612; L-117 to M-612; L-118 to M-612; T-119 to M-612; Y-120 to M-612; L-121 to M-612; P-122 to M-612; K-123 to M-612; N-124 to M-612; Y-125 to M-612; A-126 to M-612; K-127 to M-612; S-128 to M-612; E-129 to M-612; L-130 to M-612; G-131 to M-612; A-132 to M-612; V-133 to M-612; I-134 to M-612; F-135 to M-612; W-136 to M-612; G-137 to M-612; Q-138 to M-612; N-139 to M-612; Q-140 to M-612; T-141 to M-612; L-142 to M-612; D-143 to M-612; P-144 to M-612; N-145 to M-612; N-146 to M-612; M-147 to M-612; T-148 to M-612; I-149 to M-612; L-150 to M-612; N-151 to M-612; R-152 to M-612; T-153 to M-612; F-154 to M-612; Q-155 to M-612; D-156 to M-612; E-157 to M-612; P-158 to M-612; L-159 to M-612; I-160 to M-612; M-161 to M-612; D-162 to M-612; F-163 to M-612; N-164 to M-612; G-165 to M-612; D-166 to M-612; L-167 to M-612; I-168 to M-612; P-169 to M-612; D-170 to M-612; I-171 to M-612; F-172 to M-612; G-173 to M-612; I-174 to M-612; T-175 to M-612; N-176 to M-612; E-177 to M-612; S-178 to M-612; N-179 to M-612; Q-180 to M-612; P-181 to M-612; Q-182 to M-612; I-183 to M-612; L-184 to M-612; L-185 to M-612; G-186 to M-612; G-187 to M-612; N-188 to M-612; L-189 to M-612; S-190 to M-612; W-191 to M-612; H-192 to M-612; P-193 to M-612; A-194 to M-612; L-195 to M-612; T-196 to M-612; T-197 to M-612; T-198 to M-612; S-199 to M-612; K-200 to M-612; M-201 to M-612; R-202 to M-612; I-203 to M-612; P-204 to M-612; H-205 to M-612; S-206 to M-612; H-207 to M-612; A-208 to M-612; F-209 to M-612; I-210 to M-612; D-211 to M-612; L-212 to M-612; T-213 to M-612; E-214 to M-612; D-215 to M-612; F-216 to M-612; T-217 to M-612; A-218 to M-612; D-219 to M-612; L-220 to M-612; F-221 to M-612; L-222 to M-612; T-223 to M-612; T-224 to M-612; L-225 to M-612; N-226 to M-612; A-227 to M-612; T-228 to M-612; T-229 to M-612; S-230 to M-612; T-231 to M-612; F-232 to M-612; Q-233 to M-612; F-234 to M-612; E-235 to M-612; I-236 to M-612; W-237 to M-612; E-238 to M-612; N-239 to M-612; L-240 to M-612; D-241 to M-612; G-242 to M-612; N-243 to M-612;

F-244 to M-612; S-245 to M-612; V-246 to M-612; S-247 to M-612; T-248 to M-612;  
I-249 to M-612; L-250 to M-612; E-251 to M-612; K-252 to M-612; P-253 to M-612;  
Q-254 to M-612; N-255 to M-612; M-256 to M-612; M-257 to M-612; V-258 to M-  
612; V-259 to M-612; G-260 to M-612; Q-261 to M-612; S-262 to M-612; A-263 to  
5 M-612; F-264 to M-612; A-265 to M-612; D-266 to M-612; F-267 to M-612; D-268  
to M-612; G-269 to M-612; D-270 to M-612; G-271 to M-612; H-272 to M-612; M-  
273 to M-612; D-274 to M-612; H-275 to M-612; L-276 to M-612; L-277 to M-612;  
P-278 to M-612; G-279 to M-612; C-280 to M-612; E-281 to M-612; D-282 to M-  
612; K-283 to M-612; N-284 to M-612; C-285 to M-612; Q-286 to M-612; K-287 to  
10 M-612; S-288 to M-612; T-289 to M-612; I-290 to M-612; Y-291 to M-612; L-292 to  
M-612; V-293 to M-612; R-294 to M-612; S-295 to M-612; G-296 to M-612; M-297  
to M-612; K-298 to M-612; Q-299 to M-612; W-300 to M-612; V-301 to M-612; P-  
302 to M-612; V-303 to M-612; L-304 to M-612; Q-305 to M-612; D-306 to M-612;  
F-307 to M-612; S-308 to M-612; N-309 to M-612; K-310 to M-612; G-311 to M-  
15 612; T-312 to M-612; L-313 to M-612; W-314 to M-612; G-315 to M-612; F-316 to  
M-612; V-317 to M-612; P-318 to M-612; F-319 to M-612; V-320 to M-612; D-321  
to M-612; E-322 to M-612; Q-323 to M-612; Q-324 to M-612; P-325 to M-612; T-  
326 to M-612; E-327 to M-612; I-328 to M-612; P-329 to M-612; I-330 to M-612; P-  
331 to M-612; I-332 to M-612; T-333 to M-612; L-334 to M-612; H-335 to M-612; I-  
20 336 to M-612; G-337 to M-612; D-338 to M-612; Y-339 to M-612; N-340 to M-612;  
M-341 to M-612; D-342 to M-612; G-343 to M-612; Y-344 to M-612; P-345 to M-  
612; D-346 to M-612; A-347 to M-612; L-348 to M-612; V-349 to M-612; I-350 to  
M-612; L-351 to M-612; K-352 to M-612; N-353 to M-612; T-354 to M-612; S-355  
to M-612; G-356 to M-612; S-357 to M-612; N-358 to M-612; Q-359 to M-612; Q-  
25 360 to M-612; A-361 to M-612; F-362 to M-612; L-363 to M-612; L-364 to M-612;  
E-365 to M-612; N-366 to M-612; V-367 to M-612; P-368 to M-612; C-369 to M-  
612; N-370 to M-612; N-371 to M-612; A-372 to M-612; S-373 to M-612; C-374 to  
M-612; E-375 to M-612; E-376 to M-612; A-377 to M-612; R-378 to M-612; R-379  
to M-612; M-380 to M-612; F-381 to M-612; K-382 to M-612; V-383 to M-612; Y-  
30 384 to M-612; W-385 to M-612; E-386 to M-612; L-387 to M-612; T-388 to M-612;  
D-389 to M-612; L-390 to M-612; N-391 to M-612; Q-392 to M-612; I-393 to M-  
612; K-394 to M-612; D-395 to M-612; A-396 to M-612; M-397 to M-612; V-398 to

M-612; A-399 to M-612; T-400 to M-612; F-401 to M-612; F-402 to M-612; D-403 to M-612; I-404 to M-612; Y-405 to M-612; E-406 to M-612; D-407 to M-612; G-408 to M-612; I-409 to M-612; L-410 to M-612; D-411 to M-612; I-412 to M-612; V-413 to M-612; V-414 to M-612; L-415 to M-612; S-416 to M-612; K-417 to M-612;  
5 G-418 to M-612; Y-419 to M-612; T-420 to M-612; K-421 to M-612; N-422 to M-612; D-423 to M-612; F-424 to M-612; A-425 to M-612; I-426 to M-612; H-427 to M-612; T-428 to M-612; L-429 to M-612; K-430 to M-612; N-431 to M-612; N-432 to M-612; F-433 to M-612; E-434 to M-612; A-435 to M-612; D-436 to M-612; A-437 to M-612; Y-438 to M-612; F-439 to M-612; V-440 to M-612; K-441 to M-612;  
10 V-442 to M-612; I-443 to M-612; V-444 to M-612; L-445 to M-612; S-446 to M-612; G-447 to M-612; L-448 to M-612; C-449 to M-612; S-450 to M-612; N-451 to M-612; D-452 to M-612; C-453 to M-612; P-454 to M-612; R-455 to M-612; K-456 to M-612; I-457 to M-612; T-458 to M-612; P-459 to M-612; F-460 to M-612; G-461 to M-612; V-462 to M-612; N-463 to M-612; Q-464 to M-612; P-465 to M-612; G-466 to M-612;  
15 P-467 to M-612; Y-468 to M-612; I-469 to M-612; M-470 to M-612; Y-471 to M-612; T-472 to M-612; T-473 to M-612; V-474 to M-612; D-475 to M-612; A-476 to M-612; N-477 to M-612; G-478 to M-612; Y-479 to M-612; L-480 to M-612; K-481 to M-612; N-482 to M-612; G-483 to M-612; S-484 to M-612; A-485 to M-612; G-486 to M-612; Q-487 to M-612; L-488 to M-612; S-489 to M-612; Q-490 to M-612;  
20 S-491 to M-612; A-492 to M-612; H-493 to M-612; L-494 to M-612; A-495 to M-612; L-496 to M-612; Q-497 to M-612; L-498 to M-612; P-499 to M-612; Y-500 to M-612; N-501 to M-612; V-502 to M-612; L-503 to M-612; G-504 to M-612; L-505 to M-612; G-506 to M-612; R-507 to M-612; S-508 to M-612; A-509 to M-612; N-510 to M-612; F-511 to M-612; L-512 to M-612; D-513 to M-612; H-514 to M-612;  
25 L-515 to M-612; Y-516 to M-612; V-517 to M-612; G-518 to M-612; I-519 to M-612; P-520 to M-612; R-521 to M-612; P-522 to M-612; S-523 to M-612; G-524 to M-612; E-525 to M-612; K-526 to M-612; S-527 to M-612; I-528 to M-612; R-529 to M-612; K-530 to M-612; Q-531 to M-612; E-532 to M-612; W-533 to M-612; T-534 to M-612; A-535 to M-612; I-536 to M-612; I-537 to M-612; P-538 to M-612;  
30 N-539 to M-612; S-540 to M-612; Q-541 to M-612; L-542 to M-612; I-543 to M-612; V-544 to M-612; I-545 to M-612; P-546 to M-612; Y-547 to M-612; P-548 to M-612; H-549 to M-612; N-550 to M-612; V-551 to M-612; P-552 to M-612; R-553

to M-612; S-554 to M-612; W-555 to M-612; S-556 to M-612; A-557 to M-612; K-558 to M-612; L-559 to M-612; Y-560 to M-612; L-561 to M-612; T-562 to M-612; P-563 to M-612; S-564 to M-612; N-565 to M-612; I-566 to M-612; V-567 to M-612; L-568 to M-612; L-569 to M-612; T-570 to M-612; A-571 to M-612; I-572 to M-612; 5 A-573 to M-612; L-574 to M-612; I-575 to M-612; G-576 to M-612; V-577 to M-612; C-578 to M-612; V-579 to M-612; F-580 to M-612; I-581 to M-612; L-582 to M-612; A-583 to M-612; I-584 to M-612; I-585 to M-612; G-586 to M-612; I-587 to M-612; L-588 to M-612; H-589 to M-612; W-590 to M-612; Q-591 to M-612; E-592 to M-612; K-593 to M-612; K-594 to M-612; A-595 to M-612; D-596 to M-612; D-10 597 to M-612; R-598 to M-612; E-599 to M-612; K-600 to M-612; R-601 to M-612; Q-602 to M-612; E-603 to M-612; A-604 to M-612; H-605 to M-612; R-606 to M-612; and F-607 to M-612 of SEQ ID NO: 128. Polypeptides encoded by these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, 15 polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides 20 encoding these polypeptides are also encompassed by the invention.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification or loss of one or more biological functions of the protein (e.g., ability to induce IFN gamma production), other functional activities (e.g., biological activities, ability to multimerize, ability to bind 25 ligand, ability to generate antibodies, ability to bind antibodies) may still be retained. For example the ability of the shortened polypeptide to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular 30 polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a polypeptide with a

large number of deleted C-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the polypeptide shown in Figures 1A-C (SEQ ID NO:128), as described by the general formula 1-n, where n is an integer from 6 to 611, where n corresponds to the position of the amino acid residue identified in SEQ ID NO:128. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: M-1 to A-611; M-1 to D-610; M-1 to F-609; M-1 to H-608; M-1 to F-607; M-1 to R-606; M-1 to H-605; M-1 to A-604; M-1 to E-603; M-1 to Q-602; M-1 to R-601; M-1 to K-600; M-1 to E-599; M-1 to R-598; M-1 to D-597; M-1 to D-596; M-1 to A-595; M-1 to K-594; M-1 to K-593; M-1 to E-592; M-1 to Q-591; M-1 to W-590; M-1 to H-589; M-1 to L-588; M-1 to I-587; M-1 to G-586; M-1 to I-585; M-1 to I-584; M-1 to A-583; M-1 to L-582; M-1 to I-581; M-1 to F-580; M-1 to V-579; M-1 to C-578; M-1 to V-577; M-1 to G-576; M-1 to I-575; M-1 to L-574; M-1 to A-573; M-1 to I-572; M-1 to A-571; M-1 to T-570; M-1 to L-569; M-1 to L-568; M-1 to V-567; M-1 to I-566; M-1 to N-565; M-1 to S-564; M-1 to P-563; M-1 to T-562; M-1 to L-561; M-1 to Y-560; M-1 to L-559; M-1 to K-558; M-1 to A-557; M-1 to S-556; M-1 to W-555; M-1 to S-554; M-1 to R-553; M-1 to P-552; M-1 to V-551; M-1 to N-550; M-1 to H-549; M-1 to P-548; M-1 to Y-547; M-1 to P-546; M-1 to I-545; M-1 to V-544; M-1 to I-543; M-1 to L-542; M-1 to Q-541; M-1 to S-540; M-1 to N-539; M-1 to P-538; M-1 to I-537; M-1 to I-536; M-1 to A-535; M-1 to T-534; M-1 to W-533; M-1 to E-532; M-1 to Q-531; M-1 to K-530; M-1 to R-529; M-1 to I-528; M-1 to S-527; M-1 to K-526; M-1 to E-525; M-1 to G-524; M-1 to S-523; M-1 to P-522; M-1 to R-521; M-1 to P-520; M-1 to I-519; M-1 to G-518; M-1 to V-517; M-1 to Y-516; M-1 to L-515; M-1 to H-514; M-1 to D-513; M-1 to L-512; M-1 to F-511; M-1 to N-510; M-1 to A-509; M-1 to S-508; M-1 to R-507; M-1 to G-506; M-1 to L-505; M-1 to G-504; M-1 to L-503; M-1 to V-502; M-1 to N-501; M-1 to Y-500; M-1 to P-499; M-1 to L-498; M-1 to Q-497; M-1 to L-496; M-1 to A-495; M-1 to L-494; M-1 to H-493; M-1 to A-492; M-1 to S-491; M-1 to Q-490; M-1 to S-489; M-1 to L-488; M-1 to Q-487; M-1

to G-486; M-1 to A-485; M-1 to S-484; M-1 to G-483; M-1 to N-482; M-1 to K-481;  
M-1 to L-480; M-1 to Y-479; M-1 to G-478; M-1 to N-477; M-1 to A-476; M-1 to D-  
475; M-1 to V-474; M-1 to T-473; M-1 to T-472; M-1 to Y-471; M-1 to M-470; M-1  
to I-469; M-1 to Y-468; M-1 to P-467; M-1 to G-466; M-1 to P-465; M-1 to Q-464;  
5 M-1 to N-463; M-1 to V-462; M-1 to G-461; M-1 to F-460; M-1 to P-459; M-1 to T-  
458; M-1 to I-457; M-1 to K-456; M-1 to R-455; M-1 to P-454; M-1 to C-453; M-1 to  
D-452; M-1 to N-451; M-1 to S-450; M-1 to C-449; M-1 to L-448; M-1 to G-447; M-  
1 to S-446; M-1 to L-445; M-1 to V-444; M-1 to I-443; M-1 to V-442; M-1 to K-441;  
M-1 to V-440; M-1 to F-439; M-1 to Y-438; M-1 to A-437; M-1 to D-436; M-1 to A-  
10 435; M-1 to E-434; M-1 to F-433; M-1 to N-432; M-1 to N-431; M-1 to K-430; M-1  
to L-429; M-1 to T-428; M-1 to H-427; M-1 to I-426; M-1 to A-425; M-1 to F-424;  
M-1 to D-423; M-1 to N-422; M-1 to K-421; M-1 to T-420; M-1 to Y-419; M-1 to G-  
418; M-1 to K-417; M-1 to S-416; M-1 to L-415; M-1 to V-414; M-1 to V-413; M-1  
to I-412; M-1 to D-411; M-1 to L-410; M-1 to I-409; M-1 to G-408; M-1 to D-407;  
15 M-1 to E-406; M-1 to Y-405; M-1 to I-404; M-1 to D-403; M-1 to F-402; M-1 to F-  
401; M-1 to T-400; M-1 to A-399; M-1 to V-398; M-1 to M-397; M-1 to A-396; M-1  
to D-395; M-1 to K-394; M-1 to I-393; M-1 to Q-392; M-1 to N-391; M-1 to L-390;  
M-1 to D-389; M-1 to T-388; M-1 to L-387; M-1 to E-386; M-1 to W-385; M-1 to Y-  
384; M-1 to V-383; M-1 to K-382; M-1 to F-381; M-1 to M-380; M-1 to R-379; M-1  
20 to R-378; M-1 to A-377; M-1 to E-376; M-1 to E-375; M-1 to C-374; M-1 to S-373;  
M-1 to A-372; M-1 to N-371; M-1 to N-370; M-1 to C-369; M-1 to P-368; M-1 to V-  
367; M-1 to N-366; M-1 to E-365; M-1 to L-364; M-1 to L-363; M-1 to F-362; M-1  
to A-361; M-1 to Q-360; M-1 to Q-359; M-1 to N-358; M-1 to S-357; M-1 to G-356;  
M-1 to S-355; M-1 to T-354; M-1 to N-353; M-1 to K-352; M-1 to L-351; M-1 to I-  
25 350; M-1 to V-349; M-1 to L-348; M-1 to A-347; M-1 to D-346; M-1 to P-345; M-1  
to Y-344; M-1 to G-343; M-1 to D-342; M-1 to M-341; M-1 to N-340; M-1 to Y-339;  
M-1 to D-338; M-1 to G-337; M-1 to I-336; M-1 to H-335; M-1 to L-334; M-1 to T-  
333; M-1 to I-332; M-1 to P-331; M-1 to I-330; M-1 to P-329; M-1 to I-328; M-1 to  
E-327; M-1 to T-326; M-1 to P-325; M-1 to Q-324; M-1 to Q-323; M-1 to E-322; M-  
30 1 to D-321; M-1 to V-320; M-1 to F-319; M-1 to P-318; M-1 to V-317; M-1 to F-316;  
M-1 to G-315; M-1 to W-314; M-1 to L-313; M-1 to T-312; M-1 to G-311; M-1 to K-  
310; M-1 to N-309; M-1 to S-308; M-1 to F-307; M-1 to D-306; M-1 to Q-305; M-1

to L-304; M-1 to V-303; M-1 to P-302; M-1 to V-301; M-1 to W-300; M-1 to Q-299;  
M-1 to K-298; M-1 to M-297; M-1 to G-296; M-1 to S-295; M-1 to R-294; M-1 to V-  
293; M-1 to L-292; M-1 to Y-291; M-1 to I-290; M-1 to T-289; M-1 to S-288; M-1 to  
K-287; M-1 to Q-286; M-1 to C-285; M-1 to N-284; M-1 to K-283; M-1 to D-282;  
5 M-1 to E-281; M-1 to C-280; M-1 to G-279; M-1 to P-278; M-1 to L-277; M-1 to L-  
276; M-1 to H-275; M-1 to D-274; M-1 to M-273; M-1 to H-272; M-1 to G-271; M-1  
to D-270; M-1 to G-269; M-1 to D-268; M-1 to F-267; M-1 to D-266; M-1 to A-265;  
M-1 to F-264; M-1 to A-263; M-1 to S-262; M-1 to Q-261; M-1 to G-260; M-1 to V-  
259; M-1 to V-258; M-1 to M-257; M-1 to M-256; M-1 to N-255; M-1 to Q-254; M-1  
10 to P-253; M-1 to K-252; M-1 to E-251; M-1 to L-250; M-1 to I-249; M-1 to T-248;  
M-1 to S-247; M-1 to V-246; M-1 to S-245; M-1 to F-244; M-1 to N-243; M-1 to G-  
242; M-1 to D-241; M-1 to L-240; M-1 to N-239; M-1 to E-238; M-1 to W-237; M-1  
to I-236; M-1 to E-235; M-1 to F-234; M-1 to Q-233; M-1 to F-232; M-1 to T-231;  
M-1 to S-230; M-1 to T-229; M-1 to T-228; M-1 to A-227; M-1 to N-226; M-1 to L-  
15 225; M-1 to T-224; M-1 to T-223; M-1 to L-222; M-1 to F-221; M-1 to L-220; M-1  
to D-219; M-1 to A-218; M-1 to T-217; M-1 to F-216; M-1 to D-215; M-1 to E-214;  
M-1 to T-213; M-1 to L-212; M-1 to D-211; M-1 to I-210; M-1 to F-209; M-1 to A-  
208; M-1 to H-207; M-1 to S-206; M-1 to H-205; M-1 to P-204; M-1 to I-203; M-1 to  
R-202; M-1 to M-201; M-1 to K-200; M-1 to S-199; M-1 to T-198; M-1 to T-197; M-  
20 1 to T-196; M-1 to L-195; M-1 to A-194; M-1 to P-193; M-1 to H-192; M-1 to W-  
191; M-1 to S-190; M-1 to L-189; M-1 to N-188; M-1 to G-187; M-1 to G-186; M-1  
to L-185; M-1 to L-184; M-1 to I-183; M-1 to Q-182; M-1 to P-181; M-1 to Q-180;  
M-1 to N-179; M-1 to S-178; M-1 to E-177; M-1 to N-176; M-1 to T-175; M-1 to I-  
174; M-1 to G-173; M-1 to F-172; M-1 to I-171; M-1 to D-170; M-1 to P-169; M-1 to  
25 I-168; M-1 to L-167; M-1 to D-166; M-1 to G-165; M-1 to N-164; M-1 to F-163; M-1  
to D-162; M-1 to M-161; M-1 to I-160; M-1 to L-159; M-1 to P-158; M-1 to E-157;  
M-1 to D-156; M-1 to Q-155; M-1 to F-154; M-1 to T-153; M-1 to R-152; M-1 to N-  
151; M-1 to L-150; M-1 to I-149; M-1 to T-148; M-1 to M-147; M-1 to N-146; M-1  
to N-145; M-1 to P-144; M-1 to D-143; M-1 to L-142; M-1 to T-141; M-1 to Q-140;  
30 M-1 to N-139; M-1 to Q-138; M-1 to G-137; M-1 to W-136; M-1 to F-135; M-1 to I-  
134; M-1 to V-133; M-1 to A-132; M-1 to G-131; M-1 to L-130; M-1 to E-129; M-1  
to S-128; M-1 to K-127; M-1 to A-126; M-1 to Y-125; M-1 to N-124; M-1 to K-123;

M-1 to P-122; M-1 to L-121; M-1 to Y-120; M-1 to T-119; M-1 to L-118; M-1 to L-117; M-1 to V-116; M-1 to D-115; M-1 to M-114; M-1 to Q-113; M-1 to S-112; M-1 to D-111; M-1 to G-110; M-1 to D-109; M-1 to Y-108; M-1 to D-107; M-1 to G-106; M-1 to P-105; M-1 to V-104; M-1 to V-103; M-1 to S-102; M-1 to T-101; M-1 to I-100; M-1 to L-99; M-1 to A-98; M-1 to S-97; M-1 to H-96; M-1 to N-95; M-1 to K-94; M-1 to F-93; M-1 to S-92; M-1 to V-91; M-1 to K-90; M-1 to V-89; M-1 to K-88; M-1 to P-87; M-1 to K-86; M-1 to F-85; M-1 to Y-84; M-1 to P-83; M-1 to A-82; M-1 to N-81; M-1 to Q-80; M-1 to D-79; M-1 to A-78; M-1 to L-77; M-1 to F-76; M-1 to V-75; M-1 to I-74; M-1 to L-73; M-1 to D-72; M-1 to N-71; M-1 to R-70; M-1 to E-69; M-1 to R-68; M-1 to L-67; M-1 to V-66; M-1 to F-65; M-1 to L-64; M-1 to D-63; M-1 to T-62; M-1 to Q-61; M-1 to K-60; M-1 to D-59; M-1 to S-58; M-1 to N-57; M-1 to L-56; M-1 to D-55; M-1 to G-54; M-1 to F-53; M-1 to A-52; M-1 to A-51; M-1 to L-50; M-1 to T-49; M-1 to G-48; M-1 to W-47; M-1 to A-46; M-1 to E-45; M-1 to A-44; M-1 to G-43; M-1 to F-42; M-1 to L-41; M-1 to E-40; M-1 to A-39; M-1 to T-38; M-1 to V-37; M-1 to N-36; M-1 to H-35; M-1 to L-34; M-1 to A-33; M-1 to R-32; M-1 to A-31; M-1 to P-30; M-1 to V-29; M-1 to P-28; M-1 to G-27; M-1 to V-26; M-1 to G-25; M-1 to L-24; M-1 to L-23; M-1 to A-22; M-1 to L-21; M-1 to G-20; M-1 to A-19; M-1 to L-18; M-1 to L-17; M-1 to P-16; M-1 to S-15; M-1 to F-14; M-1 to L-13; M-1 to A-12; M-1 to W-11; M-1 to S-10; M-1 to S-9; M-1 to P-8; M-1 to L-7; and M-1 to R-6 of SEQ ID NO:128. Polypeptides encoded by these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides comprising, or alternatively consisting of, one or more amino acids deleted from both the amino and the carboxyl termini, which may be described



generally as having residues m-n of SEQ ID NO:128, where n and m are integers as described above. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: A-2 to K-558; A-3 to K-558; A-4 to K-558; G-5  
5 to K-558; R-6 to K-558; L-7 to K-558; P-8 to K-558; S-9 to K-558; S-10 to K-558; W-11 to K-558; A-12 to K-558; L-13 to K-558; F-14 to K-558; S-15 to K-558; P-16 to K-558; L-17 to K-558; L-18 to K-558; A-19 to K-558; G-20 to K-558; L-21 to K-558; A-22 to K-558; L-23 to K-558; L-24 to K-558; G-25 to K-558; V-26 to K-558; G-27 to K-558; P-28 to K-558; V-29 to K-558; P-30 to K-558; A-31 to K-558; R-32  
10 to K-558; A-33 to K-558; L-34 to K-558; H-35 to K-558; N-36 to K-558; V-37 to K-558; T-38 to K-558; A-39 to K-558; E-40 to K-558; L-41 to K-558; F-42 to K-558; G-43 to K-558; A-44 to K-558; E-45 to K-558; A-46 to K-558; W-47 to K-558; G-48 to K-558; T-49 to K-558; L-50 to K-558; A-51 to K-558; A-52 to K-558; F-53 to K-558; G-54 to K-558; D-55 to K-558; L-56 to K-558; N-57 to K-558; S-58 to K-  
15 558; D-59 to K-558; K-60 to K-558; Q-61 to K-558; T-62 to K-558; D-63 to K-558; L-64 to K-558; F-65 to K-558; V-66 to K-558; L-67 to K-558; R-68 to K-558; E-69 to K-558; R-70 to K-558; N-71 to K-558; D-72 to K-558; L-73 to K-558; I-74 to K-558; V-75 to K-558; F-76 to K-558; L-77 to K-558; A-78 to K-558; D-79 to K-558; Q-80 to K-558; N-81 to K-558; A-82 to K-558; P-83 to K-558; Y-84 to K-558; F-85  
20 to K-558; K-86 to K-558; P-87 to K-558; K-88 to K-558; V-89 to K-558; K-90 to K-558; V-91 to K-558; S-92 to K-558; F-93 to K-558; K-94 to K-558; N-95 to K-558; H-96 to K-558; S-97 to K-558; A-98 to K-558; L-99 to K-558; I-100 to K-558; T-101 to K-558; S-102 to K-558; V-103 to K-558; V-104 to K-558; P-105 to K-558; G-106 to K-558; D-107 to K-558; Y-108 to K-558; D-109 to K-558; G-110 to K-  
25 558; D-111 to K-558; S-112 to K-558; Q-113 to K-558; M-114 to K-558; D-115 to K-558; V-116 to K-558; L-117 to K-558; L-118 to K-558; T-119 to K-558; Y-120 to K-558; L-121 to K-558; P-122 to K-558; K-123 to K-558; N-124 to K-558; Y-125 to K-558; A-126 to K-558; K-127 to K-558; S-128 to K-558; E-129 to K-558; L-130 to K-558; G-131 to K-558; A-132 to K-558; V-133 to K-558; I-134 to K-558; F-135 to  
30 K-558; W-136 to K-558; G-137 to K-558; Q-138 to K-558; N-139 to K-558; Q-140 to K-558; T-141 to K-558; L-142 to K-558; D-143 to K-558; P-144 to K-558; N-145 to K-558; N-146 to K-558; M-147 to K-558; T-148 to K-558; I-149 to K-558; L-150

to K-558; N-151 to K-558; R-152 to K-558; T-153 to K-558; F-154 to K-558; Q-155 to K-558; D-156 to K-558; E-157 to K-558; P-158 to K-558; L-159 to K-558; I-160 to K-558; M-161 to K-558; D-162 to K-558; F-163 to K-558; N-164 to K-558; G-165 to K-558; D-166 to K-558; L-167 to K-558; I-168 to K-558; P-169 to K-558; D-170 to K-558; I-171 to K-558; F-172 to K-558; G-173 to K-558; I-174 to K-558; T-175 to K-558; N-176 to K-558; E-177 to K-558; S-178 to K-558; N-179 to K-558; Q-180 to K-558; P-181 to K-558; Q-182 to K-558; I-183 to K-558; L-184 to K-558; L-185 to K-558; G-186 to K-558; G-187 to K-558; N-188 to K-558; L-189 to K-558; S-190 to K-558; W-191 to K-558; H-192 to K-558; P-193 to K-558; A-194 to K-558; L-195 to K-558; T-196 to K-558; T-197 to K-558; T-198 to K-558; S-199 to K-558; K-200 to K-558; M-201 to K-558; R-202 to K-558; I-203 to K-558; P-204 to K-558; H-205 to K-558; S-206 to K-558; H-207 to K-558; A-208 to K-558; F-209 to K-558; I-210 to K-558; D-211 to K-558; L-212 to K-558; T-213 to K-558; E-214 to K-558; D-215 to K-558; F-216 to K-558; T-217 to K-558; A-218 to K-558; D-219 to K-558; L-220 to K-558; F-221 to K-558; L-222 to K-558; T-223 to K-558; T-224 to K-558; L-225 to K-558; N-226 to K-558; A-227 to K-558; T-228 to K-558; T-229 to K-558; S-230 to K-558; T-231 to K-558; F-232 to K-558; Q-233 to K-558; F-234 to K-558; E-235 to K-558; I-236 to K-558; W-237 to K-558; E-238 to K-558; N-239 to K-558; L-240 to K-558; D-241 to K-558; G-242 to K-558; N-243 to K-558; F-244 to K-558; S-245 to K-558; V-246 to K-558; S-247 to K-558; T-248 to K-558; I-249 to K-558; L-250 to K-558; E-251 to K-558; K-252 to K-558; P-253 to K-558; Q-254 to K-558; N-255 to K-558; M-256 to K-558; M-257 to K-558; V-258 to K-558; V-259 to K-558; G-260 to K-558; Q-261 to K-558; S-262 to K-558; A-263 to K-558; F-264 to K-558; A-265 to K-558; D-266 to K-558; F-267 to K-558; D-268 to K-558; G-269 to K-558; D-270 to K-558; G-271 to K-558; H-272 to K-558; M-273 to K-558; D-274 to K-558; H-275 to K-558; L-276 to K-558; L-277 to K-558; P-278 to K-558; G-279 to K-558; C-280 to K-558; E-281 to K-558; D-282 to K-558; K-283 to K-558; N-284 to K-558; C-285 to K-558; Q-286 to K-558; K-287 to K-558; S-288 to K-558; T-289 to K-558; I-290 to K-558; Y-291 to K-558; L-292 to K-558; V-293 to K-558; R-294 to K-558; S-295 to K-558; G-296 to K-558; M-297 to K-558; K-298 to K-558; Q-299 to K-558; W-300 to K-558; V-301 to K-558; P-302 to K-558; V-303 to K-558; L-304 to K-558; Q-305 to K-558; D-306 to K-558; F-307 to K-558;

S-308 to K-558; N-309 to K-558; K-310 to K-558; G-311 to K-558; T-312 to K-558;  
L-313 to K-558; W-314 to K-558; G-315 to K-558; F-316 to K-558; V-317 to K-  
558; P-318 to K-558; F-319 to K-558; V-320 to K-558; D-321 to K-558; E-322 to  
K-558; Q-323 to K-558; Q-324 to K-558; P-325 to K-558; T-326 to K-558; E-327 to  
5 K-558; I-328 to K-558; P-329 to K-558; I-330 to K-558; P-331 to K-558; I-332 to  
K-558; T-333 to K-558; L-334 to K-558; H-335 to K-558; I-336 to K-558; G-337 to  
K-558; D-338 to K-558; Y-339 to K-558; N-340 to K-558; M-341 to K-558; D-342  
to K-558; G-343 to K-558; Y-344 to K-558; P-345 to K-558; D-346 to K-558; A-  
347 to K-558; L-348 to K-558; V-349 to K-558; I-350 to K-558; L-351 to K-558; K-  
10 352 to K-558; N-353 to K-558; T-354 to K-558; S-355 to K-558; G-356 to K-558;  
S-357 to K-558; N-358 to K-558; Q-359 to K-558; Q-360 to K-558; A-361 to K-  
558; F-362 to K-558; L-363 to K-558; L-364 to K-558; E-365 to K-558; N-366 to K-  
558; V-367 to K-558; P-368 to K-558; C-369 to K-558; N-370 to K-558; N-371 to  
K-558; A-372 to K-558; S-373 to K-558; C-374 to K-558; E-375 to K-558; E-376 to  
15 K-558; A-377 to K-558; R-378 to K-558; R-379 to K-558; M-380 to K-558; F-381  
to K-558; K-382 to K-558; V-383 to K-558; Y-384 to K-558; W-385 to K-558; E-  
386 to K-558; L-387 to K-558; T-388 to K-558; D-389 to K-558; L-390 to K-558;  
N-391 to K-558; Q-392 to K-558; I-393 to K-558; K-394 to K-558; D-395 to K-558;  
A-396 to K-558; M-397 to K-558; V-398 to K-558; A-399 to K-558; T-400 to K-  
20 558; F-401 to K-558; F-402 to K-558; D-403 to K-558; I-404 to K-558; Y-405 to K-  
558; E-406 to K-558; D-407 to K-558; G-408 to K-558; I-409 to K-558; L-410 to K-  
558; D-411 to K-558; I-412 to K-558; V-413 to K-558; V-414 to K-558; L-415 to K-  
558; S-416 to K-558; K-417 to K-558; G-418 to K-558; Y-419 to K-558; T-420 to  
K-558; K-421 to K-558; N-422 to K-558; D-423 to K-558; F-424 to K-558; A-425  
25 to K-558; I-426 to K-558; H-427 to K-558; T-428 to K-558; L-429 to K-558; K-430  
to K-558; N-431 to K-558; N-432 to K-558; F-433 to K-558; E-434 to K-558; A-435  
to K-558; D-436 to K-558; A-437 to K-558; Y-438 to K-558; F-439 to K-558; V-  
440 to K-558; K-441 to K-558; V-442 to K-558; I-443 to K-558; V-444 to K-558; L-  
445 to K-558; S-446 to K-558; G-447 to K-558; L-448 to K-558; C-449 to K-558; S-  
30 450 to K-558; N-451 to K-558; D-452 to K-558; C-453 to K-558; P-454 to K-558;  
R-455 to K-558; K-456 to K-558; I-457 to K-558; T-458 to K-558; P-459 to K-558;  
F-460 to K-558; G-461 to K-558; V-462 to K-558; N-463 to K-558; Q-464 to K-

558; P-465 to K-558; G-466 to K-558; P-467 to K-558; Y-468 to K-558; I-469 to K-558; M-470 to K-558; Y-471 to K-558; T-472 to K-558; T-473 to K-558; V-474 to K-558; D-475 to K-558; A-476 to K-558; N-477 to K-558; G-478 to K-558; Y-479 to K-558; L-480 to K-558; K-481 to K-558; N-482 to K-558; G-483 to K-558; S-484 to K-558; A-485 to K-558; G-486 to K-558; Q-487 to K-558; L-488 to K-558; S-489 to K-558; Q-490 to K-558; S-491 to K-558; A-492 to K-558; H-493 to K-558; L-494 to K-558; A-495 to K-558; L-496 to K-558; Q-497 to K-558; L-498 to K-558; P-499 to K-558; Y-500 to K-558; N-501 to K-558; V-502 to K-558; L-503 to K-558; G-504 to K-558; L-505 to K-558; G-506 to K-558; R-507 to K-558; S-508 to K-558; A-509 to K-558; N-510 to K-558; F-511 to K-558; L-512 to K-558; D-513 to K-558; H-514 to K-558; L-515 to K-558; Y-516 to K-558; V-517 to K-558; G-518 to K-558; I-519 to K-558; P-520 to K-558; R-521 to K-558; P-522 to K-558; S-523 to K-558; G-524 to K-558; E-525 to K-558; K-526 to K-558; S-527 to K-558; I-528 to K-558; R-529 to K-558; K-530 to K-558; Q-531 to K-558; E-532 to K-558; W-533 to K-558; T-534 to K-558; A-535 to K-558; I-536 to K-558; I-537 to K-558; P-538 to K-558; N-539 to K-558; S-540 to K-558; Q-541 to K-558; L-542 to K-558; I-543 to K-558; V-544 to K-558; I-545 to K-558; P-546 to K-558; Y-547 to K-558; P-548 to K-558; H-549 to K-558; N-550 to K-558; V-551 to K-558; P-552 to K-558; R-553 to K-558; M-1 to A-557; M-1 to S-556; M-1 to W-555; M-1 to S-554; M-1 to R-553; M-1 to P-552; M-1 to V-551; M-1 to N-550; M-1 to H-549; M-1 to P-548; M-1 to Y-547; M-1 to P-546; M-1 to I-545; M-1 to V-544; M-1 to I-543; M-1 to L-542; M-1 to Q-541; M-1 to S-540; M-1 to N-539; M-1 to P-538; M-1 to I-537; M-1 to I-536; M-1 to A-535; M-1 to T-534; M-1 to W-533; M-1 to E-532; M-1 to Q-531; M-1 to K-530; M-1 to R-529; M-1 to I-528; M-1 to S-527; M-1 to K-526; M-1 to E-525; M-1 to G-524; M-1 to S-523; M-1 to P-522; M-1 to R-521; M-1 to P-520; M-1 to I-519; M-1 to G-518; M-1 to V-517; M-1 to Y-516; M-1 to L-515; M-1 to H-514; M-1 to D-513; M-1 to L-512; M-1 to F-511; M-1 to N-510; M-1 to A-509; M-1 to S-508; M-1 to R-507; M-1 to G-506; M-1 to L-505; M-1 to G-504; M-1 to L-503; M-1 to V-502; M-1 to N-501; M-1 to Y-500; M-1 to P-499; M-1 to L-498; M-1 to Q-497; M-1 to L-496; M-1 to A-495; M-1 to L-494; M-1 to H-493; M-1 to A-492; M-1 to S-491; M-1 to Q-490; M-1 to S-489; M-1 to L-488; M-1 to Q-487; M-1 to G-486; M-1 to A-485; M-1 to S-484; M-1 to G-483; M-1 to N-482; M-1 to K-481; M-1 to L-480;

M-1 to Y-479; M-1 to G-478; M-1 to N-477; M-1 to A-476; M-1 to D-475; M-1 to V-474; M-1 to T-473; M-1 to T-472; M-1 to Y-471; M-1 to M-470; M-1 to I-469; M-1 to Y-468; M-1 to P-467; M-1 to G-466; M-1 to P-465; M-1 to Q-464; M-1 to N-463; M-1 to V-462; M-1 to G-461; M-1 to F-460; M-1 to P-459; M-1 to T-458; 5 M-1 to I-457; M-1 to K-456; M-1 to R-455; M-1 to P-454; M-1 to C-453; M-1 to D-452; M-1 to N-451; M-1 to S-450; M-1 to C-449; M-1 to L-448; M-1 to G-447; M-1 to S-446; M-1 to L-445; M-1 to V-444; M-1 to I-443; M-1 to V-442; M-1 to K-441; M-1 to V-440; M-1 to F-439; M-1 to Y-438; M-1 to A-437; M-1 to D-436; M-1 to A-435; M-1 to E-434; M-1 to F-433; M-1 to N-432; M-1 to N-431; M-1 to K-430; 10 M-1 to L-429; M-1 to T-428; M-1 to H-427; M-1 to I-426; M-1 to A-425; M-1 to F-424; M-1 to D-423; M-1 to N-422; M-1 to K-421; M-1 to T-420; M-1 to Y-419; M-1 to G-418; M-1 to K-417; M-1 to S-416; M-1 to L-415; M-1 to V-414; M-1 to V-413; M-1 to I-412; M-1 to D-411; M-1 to L-410; M-1 to I-409; M-1 to G-408; M-1 to D-407; M-1 to E-406; M-1 to Y-405; M-1 to I-404; M-1 to D-403; M-1 to F-402; M-1 15 to F-401; M-1 to T-400; M-1 to A-399; M-1 to V-398; M-1 to M-397; M-1 to A-396; M-1 to D-395; M-1 to K-394; M-1 to I-393; M-1 to Q-392; M-1 to N-391; M-1 to L-390; M-1 to D-389; M-1 to T-388; M-1 to L-387; M-1 to E-386; M-1 to W-385; M-1 to Y-384; M-1 to V-383; M-1 to K-382; M-1 to F-381; M-1 to M-380; M-1 to R-379; M-1 to R-378; M-1 to A-377; M-1 to E-376; M-1 to E-375; M-1 to C-374; 20 M-1 to S-373; M-1 to A-372; M-1 to N-371; M-1 to N-370; M-1 to C-369; M-1 to P-368; M-1 to V-367; M-1 to N-366; M-1 to E-365; M-1 to L-364; M-1 to L-363; M-1 to F-362; M-1 to A-361; M-1 to Q-360; M-1 to Q-359; M-1 to N-358; M-1 to S-357; M-1 to G-356; M-1 to S-355; M-1 to T-354; M-1 to N-353; M-1 to K-352; M-1 to L-351; M-1 to I-350; M-1 to V-349; M-1 to L-348; M-1 to A-347; M-1 to D-346; M-1 25 to P-345; M-1 to Y-344; M-1 to G-343; M-1 to D-342; M-1 to M-341; M-1 to N-340; M-1 to Y-339; M-1 to D-338; M-1 to G-337; M-1 to I-336; M-1 to H-335; M-1 to L-334; M-1 to T-333; M-1 to I-332; M-1 to P-331; M-1 to I-330; M-1 to P-329; M-1 to I-328; M-1 to E-327; M-1 to T-326; M-1 to P-325; M-1 to Q-324; M-1 to Q-323; M-1 to E-322; M-1 to D-321; M-1 to V-320; M-1 to F-319; M-1 to P-318; M-1 30 to V-317; M-1 to F-316; M-1 to G-315; M-1 to W-314; M-1 to L-313; M-1 to T-312; M-1 to G-311; M-1 to K-310; M-1 to N-309; M-1 to S-308; M-1 to F-307; M-1 to D-306; M-1 to Q-305; M-1 to L-304; M-1 to V-303; M-1 to P-302; M-1 to V-301;

M-1 to W-300; M-1 to Q-299; M-1 to K-298; M-1 to M-297; M-1 to G-296; M-1 to S-295; M-1 to R-294; M-1 to V-293; M-1 to L-292; M-1 to Y-291; M-1 to I-290; M-1 to T-289; M-1 to S-288; M-1 to K-287; M-1 to Q-286; M-1 to C-285; M-1 to N-284; M-1 to K-283; M-1 to D-282; M-1 to E-281; M-1 to C-280; M-1 to G-279; M-1 to P-278; M-1 to L-277; M-1 to L-276; M-1 to H-275; M-1 to D-274; M-1 to M-273; M-1 to H-272; M-1 to G-271; M-1 to D-270; M-1 to G-269; M-1 to D-268; M-1 to F-267; M-1 to D-266; M-1 to A-265; M-1 to F-264; M-1 to A-263; M-1 to S-262; M-1 to Q-261; M-1 to G-260; M-1 to V-259; M-1 to V-258; M-1 to M-257; M-1 to M-256; M-1 to N-255; M-1 to Q-254; M-1 to P-253; M-1 to K-252; M-1 to E-251; M-1 to L-250; M-1 to I-249; M-1 to T-248; M-1 to S-247; M-1 to V-246; M-1 to S-245; M-1 to F-244; M-1 to N-243; M-1 to G-242; M-1 to D-241; M-1 to L-240; M-1 to N-239; M-1 to E-238; M-1 to W-237; M-1 to I-236; M-1 to E-235; M-1 to F-234; M-1 to Q-233; M-1 to F-232; M-1 to T-231; M-1 to S-230; M-1 to T-229; M-1 to T-228; M-1 to A-227; M-1 to N-226; M-1 to L-225; M-1 to T-224; M-1 to T-223; M-1 to L-222; M-1 to F-221; M-1 to L-220; M-1 to D-219; M-1 to A-218; M-1 to T-217; M-1 to F-216; M-1 to D-215; M-1 to E-214; M-1 to T-213; M-1 to L-212; M-1 to D-211; M-1 to I-210; M-1 to F-209; M-1 to A-208; M-1 to H-207; M-1 to S-206; M-1 to H-205; M-1 to P-204; M-1 to I-203; M-1 to R-202; M-1 to M-201; M-1 to K-200; M-1 to S-199; M-1 to T-198; M-1 to T-197; M-1 to T-196; M-1 to L-195; M-1 to A-194; M-1 to P-193; M-1 to H-192; M-1 to W-191; M-1 to S-190; M-1 to L-189; M-1 to N-188; M-1 to G-187; M-1 to G-186; M-1 to L-185; M-1 to L-184; M-1 to I-183; M-1 to Q-182; M-1 to P-181; M-1 to Q-180; M-1 to N-179; M-1 to S-178; M-1 to E-177; M-1 to N-176; M-1 to T-175; M-1 to I-174; M-1 to G-173; M-1 to F-172; M-1 to I-171; M-1 to D-170; M-1 to P-169; M-1 to I-168; M-1 to L-167; M-1 to D-166; M-1 to G-165; M-1 to N-164; M-1 to F-163; M-1 to D-162; M-1 to M-161; M-1 to I-160; M-1 to L-159; M-1 to P-158; M-1 to E-157; M-1 to D-156; M-1 to Q-155; M-1 to F-154; M-1 to T-153; M-1 to R-152; M-1 to N-151; M-1 to L-150; M-1 to I-149; M-1 to T-148; M-1 to M-147; M-1 to N-146; M-1 to N-145; M-1 to P-144; M-1 to D-143; M-1 to L-142; M-1 to T-141; M-1 to Q-140; M-1 to N-139; M-1 to Q-138; M-1 to G-137; M-1 to W-136; M-1 to F-135; M-1 to I-134; M-1 to V-133; M-1 to A-132; M-1 to G-131; M-1 to L-130; M-1 to E-129; M-1 to S-128; M-1 to K-127; M-1 to A-126; M-1 to Y-125; M-1 to N-124; M-1 to K-123; M-1 to P-122; M-1 to

L-121; M-1 to Y-120; M-1 to T-119; M-1 to L-118; M-1 to L-117; M-1 to V-116; M-1 to D-115; M-1 to M-114; M-1 to Q-113; M-1 to S-112; M-1 to D-111; M-1 to G-110; M-1 to D-109; M-1 to Y-108; M-1 to D-107; M-1 to G-106; M-1 to P-105; M-1 to V-104; M-1 to V-103; M-1 to S-102; M-1 to T-101; M-1 to I-100; M-1 to L-99; M-1 to A-98; M-1 to S-97; M-1 to H-96; M-1 to N-95; M-1 to K-94; M-1 to F-93; M-1 to S-92; M-1 to V-91; M-1 to K-90; M-1 to V-89; M-1 to K-88; M-1 to P-87; M-1 to K-86; M-1 to F-85; M-1 to Y-84; M-1 to P-83; M-1 to A-82; M-1 to N-81; M-1 to Q-80; M-1 to D-79; M-1 to A-78; M-1 to L-77; M-1 to F-76; M-1 to V-75; M-1 to I-74; M-1 to L-73; M-1 to D-72; M-1 to N-71; M-1 to R-70; M-1 to E-69; M-1 to R-68; M-1 to L-67; M-1 to V-66; M-1 to F-65; M-1 to L-64; M-1 to D-63; M-1 to T-62; M-1 to Q-61; M-1 to K-60; M-1 to D-59; M-1 to S-58; M-1 to N-57; M-1 to L-56; M-1 to D-55; M-1 to G-54; M-1 to F-53; M-1 to A-52; M-1 to A-51; M-1 to L-50; M-1 to T-49; M-1 to G-48; M-1 to W-47; M-1 to A-46; M-1 to E-45; M-1 to A-44; M-1 to G-43; M-1 to F-42; M-1 to L-41; M-1 to E-40; M-1 to A-39; M-1 to T-38; M-1 to V-37; M-1 to N-36; M-1 to H-35; M-1 to L-34; M-1 to A-33; M-1 to R-32; M-1 to A-31; M-1 to P-30; M-1 to V-29; M-1 to P-28; M-1 to G-27; M-1 to V-26; M-1 to G-25; M-1 to L-24; M-1 to L-23; M-1 to A-22; M-1 to L-21; M-1 to G-20; M-1 to A-19; M-1 to L-18; M-1 to L-17; M-1 to P-16; M-1 to S-15; M-1 to F-14; M-1 to L-13; M-1 to A-12; M-1 to W-11; M-1 to S-10; M-1 to S-9; M-1 to P-8; M-1 to L-7; and M-1 to R-6 of SEQ ID NO:128. Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The present invention is also directed to proteins containing polypeptides at least 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a polypeptide sequence set forth herein as m-n. In preferred embodiments, the

application is directed to proteins containing polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to polypeptides having the amino acid sequence of the specific N- and C-terminal deletions recited herein. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5 Also included are polynucleotide sequences encoding a polypeptide consisting of a portion of the complete amino acid sequence encoded by a cDNA clone contained in ATCC Deposit No. 209877, where this portion excludes any integer of amino acid residues from 1 to about 606 amino acids from the amino terminus of the complete amino acid sequence encoded by a cDNA clone contained in ATCC Deposit  
10 No. 209877, or any integer of amino acid residues from 6 to about 612 amino acids from the carboxy terminus, or any combination of the above amino terminal and carboxy terminal deletions, of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209877. Polypeptides encoded by these polynucleotides also are encompassed by the invention. Moreover, fragments and  
15 variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind  
20 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Additional preferred polypeptide fragments of the invention comprise, or alternatively consist of, an amino acid sequence selected from the group: M-1 to S-15; A-2 to P-16; A-3 to L-17; A-4 to L-18; G-5 to A-19; R-6 to G-20; L-7 to L-21; P-8 to  
25 A-22; S-9 to L-23; S-10 to L-24; W-11 to G-25; A-12 to V-26; L-13 to G-27; F-14 to P-28; S-15 to V-29; P-16 to P-30; L-17 to A-31; L-18 to R-32; A-19 to A-33; G-20 to L-34; L-21 to H-35; A-22 to N-36; L-23 to V-37; L-24 to T-38; G-25 to A-39; V-26 to E-40; G-27 to L-41; P-28 to F-42; V-29 to G-43; P-30 to A-44; A-31 to E-45; R-32 to A-46; A-33 to W-47; L-34 to G-48; H-35 to T-49; N-36 to L-50; V-37 to A-51; T-  
30 38 to A-52; A-39 to F-53; E-40 to G-54; L-41 to D-55; F-42 to L-56; G-43 to N-57; A-44 to S-58; E-45 to D-59; A-46 to K-60; W-47 to Q-61; G-48 to T-62; T-49 to D-63; L-50 to L-64; A-51 to F-65; A-52 to V-66; F-53 to L-67; G-54 to R-68; D-55 to



E-69; L-56 to R-70; N-57 to N-71; S-58 to D-72; D-59 to L-73; K-60 to I-74; Q-61 to V-75; T-62 to F-76; D-63 to L-77; L-64 to A-78; F-65 to D-79; V-66 to Q-80; L-67 to N-81; R-68 to A-82; E-69 to P-83; R-70 to Y-84; N-71 to F-85; D-72 to K-86; L-73 to P-87; I-74 to K-88; V-75 to V-89; F-76 to K-90; L-77 to V-91; A-78 to S-92; D-79  
5 to F-93; Q-80 to K-94; N-81 to N-95; A-82 to H-96; P-83 to S-97; Y-84 to A-98; F-85 to L-99; K-86 to I-100; P-87 to T-101; K-88 to S-102; V-89 to V-103; K-90 to V-104; V-91 to P-105; S-92 to G-106; F-93 to D-107; K-94 to Y-108; N-95 to D-109; H-96 to G-110; S-97 to D-111; A-98 to S-112; L-99 to Q-113; I-100 to M-114; T-101 to D-115; S-102 to V-116; V-103 to L-117; V-104 to L-118; P-105 to T-119; G-106  
10 to Y-120; D-107 to L-121; Y-108 to P-122; D-109 to K-123; G-110 to N-124; D-111 to Y-125; S-112 to A-126; Q-113 to K-127; M-114 to S-128; D-115 to E-129; V-116 to L-130; L-117 to G-131; L-118 to A-132; T-119 to V-133; Y-120 to I-134; L-121 to F-135; P-122 to W-136; K-123 to G-137; N-124 to Q-138; Y-125 to N-139; A-126 to Q-140; K-127 to T-141; S-128 to L-142; E-129 to D-143; L-130 to P-144; G-131 to  
15 N-145; A-132 to N-146; V-133 to M-147; I-134 to T-148; F-135 to I-149; W-136 to L-150; G-137 to N-151; Q-138 to R-152; N-139 to T-153; Q-140 to F-154; T-141 to Q-155; L-142 to D-156; D-143 to E-157; P-144 to P-158; N-145 to L-159; N-146 to I-160; M-147 to M-161; T-148 to D-162; I-149 to F-163; L-150 to N-164; N-151 to G-165; R-152 to D-166; T-153 to L-167; F-154 to I-168; Q-155 to P-169; D-156 to  
20 D-170; E-157 to I-171; P-158 to F-172; L-159 to G-173; I-160 to I-174; M-161 to T-175; D-162 to N-176; F-163 to E-177; N-164 to S-178; G-165 to N-179; D-166 to Q-180; L-167 to P-181; I-168 to Q-182; P-169 to I-183; D-170 to L-184; I-171 to L-185; F-172 to G-186; G-173 to G-187; I-174 to N-188; T-175 to L-189; N-176 to S-190; E-177 to W-191; S-178 to H-192; N-179 to P-193; Q-180 to A-194; P-181 to L-195;  
25 Q-182 to T-196; I-183 to T-197; L-184 to T-198; L-185 to S-199; G-186 to K-200; G-187 to M-201; N-188 to R-202; L-189 to I-203; S-190 to P-204; W-191 to H-205; H-192 to S-206; P-193 to H-207; A-194 to A-208; L-195 to F-209; T-196 to I-210; T-197 to D-211; T-198 to L-212; S-199 to T-213; K-200 to E-214; M-201 to D-215; R-202 to F-216; I-203 to T-217; P-204 to A-218; H-205 to D-219; S-206 to L-220; H-  
30 207 to F-221; A-208 to L-222; F-209 to T-223; I-210 to T-224; D-211 to L-225; L-212 to N-226; T-213 to A-227; E-214 to T-228; D-215 to T-229; F-216 to S-230; T-217 to T-231; A-218 to F-232; D-219 to Q-233; L-220 to F-234; F-221 to E-235; L-

222 to I-236; T-223 to W-237; T-224 to E-238; L-225 to N-239; N-226 to L-240; A-227 to D-241; T-228 to G-242; T-229 to N-243; S-230 to F-244; T-231 to S-245; F-232 to V-246; Q-233 to S-247; F-234 to T-248; E-235 to I-249; I-236 to L-250; W-237 to E-251; E-238 to K-252; N-239 to P-253; L-240 to Q-254; D-241 to N-255; G-242 to M-256; N-243 to M-257; F-244 to V-258; S-245 to V-259; V-246 to G-260; S-247 to Q-261; T-248 to S-262; I-249 to A-263; L-250 to F-264; E-251 to A-265; K-252 to D-266; P-253 to F-267; Q-254 to D-268; N-255 to G-269; M-256 to D-270; M-257 to G-271; V-258 to H-272; V-259 to M-273; G-260 to D-274; Q-261 to H-275; S-262 to L-276; A-263 to L-277; F-264 to P-278; A-265 to G-279; D-266 to C-280; F-267 to E-281; D-268 to D-282; G-269 to K-283; D-270 to N-284; G-271 to C-285; H-272 to Q-286; M-273 to K-287; D-274 to S-288; H-275 to T-289; L-276 to I-290; L-277 to Y-291; P-278 to L-292; G-279 to V-293; C-280 to R-294; E-281 to S-295; D-282 to G-296; K-283 to M-297; N-284 to K-298; C-285 to Q-299; Q-286 to W-300; K-287 to V-301; S-288 to P-302; T-289 to V-303; I-290 to L-304; Y-291 to Q-305; L-292 to D-306; V-293 to F-307; R-294 to S-308; S-295 to N-309; G-296 to K-310; M-297 to G-311; K-298 to T-312; Q-299 to L-313; W-300 to W-314; V-301 to G-315; P-302 to F-316; V-303 to V-317; L-304 to P-318; Q-305 to F-319; D-306 to V-320; F-307 to D-321; S-308 to E-322; N-309 to Q-323; K-310 to Q-324; G-311 to P-325; T-312 to T-326; L-313 to E-327; W-314 to I-328; G-315 to P-329; F-316 to I-330; V-317 to P-331; P-318 to I-332; F-319 to T-333; V-320 to L-334; D-321 to H-335; E-322 to I-336; Q-323 to G-337; Q-324 to D-338; P-325 to Y-339; T-326 to N-340; E-327 to M-341; I-328 to D-342; P-329 to G-343; I-330 to Y-344; P-331 to P-345; I-332 to D-346; T-333 to A-347; L-334 to L-348; H-335 to V-349; I-336 to I-350; G-337 to L-351; D-338 to K-352; Y-339 to N-353; N-340 to T-354; M-341 to S-355; D-342 to G-356; G-343 to S-357; Y-344 to N-358; P-345 to Q-359; D-346 to Q-360; A-347 to A-361; L-348 to F-362; V-349 to L-363; I-350 to L-364; L-351 to E-365; K-352 to N-366; N-353 to V-367; T-354 to P-368; S-355 to C-369; G-356 to N-370; S-357 to N-371; N-358 to A-372; Q-359 to S-373; Q-360 to C-374; A-361 to E-375; F-362 to E-376; L-363 to A-377; L-364 to R-378; E-365 to R-379; N-366 to M-380; V-367 to F-381; P-368 to K-382; C-369 to V-383; N-370 to Y-384; N-371 to W-385; A-372 to E-386; S-373 to L-387; C-374 to T-388; E-375 to D-389; E-376 to L-390; A-377 to N-391; R-378 to Q-392; R-379 to I-393; M-380 to K-394; F-381 to D-

395; K-382 to A-396; V-383 to M-397; Y-384 to V-398; W-385 to A-399; E-386 to T-400; L-387 to F-401; T-388 to F-402; D-389 to D-403; L-390 to I-404; N-391 to Y-405; Q-392 to E-406; I-393 to D-407; K-394 to G-408; D-395 to I-409; A-396 to L-410; M-397 to D-411; V-398 to I-412; A-399 to V-413; T-400 to V-414; F-401 to L-415; F-402 to S-416; D-403 to K-417; I-404 to G-418; Y-405 to Y-419; E-406 to T-420; D-407 to K-421; G-408 to N-422; I-409 to D-423; L-410 to F-424; D-411 to A-425; I-412 to I-426; V-413 to H-427; V-414 to T-428; L-415 to L-429; S-416 to K-430; K-417 to N-431; G-418 to N-432; Y-419 to F-433; T-420 to E-434; K-421 to A-435; N-422 to D-436; D-423 to A-437; F-424 to Y-438; A-425 to F-439; I-426 to V-440; H-427 to K-441; T-428 to V-442; L-429 to I-443; K-430 to V-444; N-431 to L-445; N-432 to S-446; F-433 to G-447; E-434 to L-448; A-435 to C-449; D-436 to S-450; A-437 to N-451; Y-438 to D-452; F-439 to C-453; V-440 to P-454; K-441 to R-455; V-442 to K-456; I-443 to I-457; V-444 to T-458; L-445 to P-459; S-446 to F-460; G-447 to G-461; L-448 to V-462; C-449 to N-463; S-450 to Q-464; N-451 to P-465; D-452 to G-466; C-453 to P-467; P-454 to Y-468; R-455 to I-469; K-456 to M-470; I-457 to Y-471; T-458 to T-472; P-459 to T-473; F-460 to V-474; G-461 to D-475; V-462 to A-476; N-463 to N-477; Q-464 to G-478; P-465 to Y-479; G-466 to L-480; P-467 to K-481; Y-468 to N-482; I-469 to G-483; M-470 to S-484; Y-471 to A-485; T-472 to G-486; T-473 to Q-487; V-474 to L-488; D-475 to S-489; A-476 to Q-490; N-477 to S-491; G-478 to A-492; Y-479 to H-493; L-480 to L-494; K-481 to A-495; N-482 to L-496; G-483 to Q-497; S-484 to L-498; A-485 to P-499; G-486 to Y-500; Q-487 to N-501; L-488 to V-502; S-489 to L-503; Q-490 to G-504; S-491 to L-505; A-492 to G-506; H-493 to R-507; L-494 to S-508; A-495 to A-509; L-496 to N-510; Q-497 to F-511; L-498 to L-512; P-499 to D-513; Y-500 to H-514; N-501 to L-515; V-502 to Y-516; L-503 to V-517; G-504 to G-518; L-505 to I-519; G-506 to P-520; R-507 to R-521; S-508 to P-522; A-509 to S-523; N-510 to G-524; F-511 to E-525; L-512 to K-526; D-513 to S-527; H-514 to I-528; L-515 to R-529; Y-516 to K-530; V-517 to Q-531; G-518 to E-532; I-519 to W-533; P-520 to T-534; R-521 to A-535; P-522 to I-536; S-523 to I-537; G-524 to P-538; E-525 to N-539; K-526 to S-540; S-527 to Q-541; I-528 to L-542; R-529 to I-543; K-530 to V-544; Q-531 to I-545; E-532 to P-546; W-533 to Y-547; T-534 to P-548; A-535 to H-549; I-536 to N-550; I-537 to V-551; P-538 to P-552; N-539 to R-553; S-540 to S-554; Q-541 to W-

555; L-542 to S-556; I-543 to A-557; V-544 to K-558; I-545 to L-559; P-546 to Y-560; Y-547 to L-561; P-548 to T-562; H-549 to P-563; N-550 to S-564; V-551 to N-565; P-552 to I-566; R-553 to V-567; S-554 to L-568; W-555 to L-569; S-556 to T-570; A-557 to A-571; K-558 to I-572; L-559 to A-573; Y-560 to L-574; L-561 to I-575; T-562 to G-576; P-563 to V-577; S-564 to C-578; N-565 to V-579; I-566 to F-580; V-567 to I-581; L-568 to L-582; L-569 to A-583; T-570 to I-584; A-571 to I-585; I-572 to G-586; A-573 to I-587; L-574 to L-588; I-575 to H-589; G-576 to W-590; V-577 to Q-591; C-578 to E-592; V-579 to K-593; F-580 to K-594; I-581 to A-595; L-582 to D-596; A-583 to D-597; I-584 to R-598; I-585 to E-599; G-586 to K-600; I-587 to R-601; L-588 to Q-602; H-589 to E-603; W-590 to A-604; Q-591 to H-605; E-592 to R-606; K-593 to F-607; K-594 to H-608; A-595 to F-609; D-596 to D-610; D-597 to A-611; and R-598 to M-612 of SEQ ID NO:128. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

As described herein or otherwise known in the art, the polynucleotides of the invention have uses that include, but are not limited to, serving as probes or primers in chromosome identification, chromosome mapping, and linkage analysis.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, brain disorders and diseases of developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and fetal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural,

developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
5 having the disorder.

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent, other immune and hematopoietic cells and tissue cell types, through the JAK-STAT  
10 signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and  
15 differentiation of cells.

Interferons (IFNs) are a well known family of cytokines secreted by a large variety of eukaryotic cells upon exposure to various mitogens. The interferons have been classified by their chemical and biological characteristics into three groups: IFN-alpha (leukocytes), IFN-beta (fibroblasts), and IFN-gamma (lymphocytes). IFN-  
20 alpha and beta are known as Type I interferons; IFN-gamma is known as Type II or immune interferon. The IFNs exhibit anti-viral, immunoregulatory, and antiproliferative activity. The clinical potential of interferons is widely recognized.

IFNg plays a central role in the immune system and is considered to be a proinflammatory cytokine. IFNg promotes TH1 and inhibits TH2 differentiation; promotes IgG2a and inhibits IgE secretion; induces macrophage activation; and  
25 increases MHC expression. Assays for immunomodulatory proteins produced by T cells and NK cells that regulate a variety of inflammatory activities and inhibit TH2 helper cell functions are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and  
30 agonists or antagonists of the invention) to mediate immunomodulation, regulate inflammatory activities, modulate TH2 helper cell function, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory

proteins evaluate the production of cytokines, such as Interferon gamma (IFN $\gamma$ ), and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Gonzalez et al., J Clin Lab Anal 8(5):225-233 (1995); Billiau et al., Ann NY Acad Sci 856:22-32 (1998); Boehm et al., Annu Rev Immunol 15:749-795 (1997), and Rheumatology (Oxford) 38(3):214-20 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.

Polypeptides of the invention were found to induce secretion of IFN $\gamma$  when added to PBLs in the presence of anti-CD3 and anti-CD28 (See assay, Example 33). Therefore, it is likely that polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes suggests a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as

autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof, are used to treat, prevent, and/or diagnose diseases and disorders of the pulmonary system (e.g., bronchi such as, for example, sinopulmonary and bronchial infections) and conditions associated with such diseases and disorders and other respiratory diseases and disorders. In specific embodiments, such diseases and disorders include, but are not limited to, pulmonary fibrosis, bronchial adenoma, bronchial asthma, pneumonia (such as, e.g., bronchial pneumonia, bronchopneumonia, and tuberculous bronchopneumonia), chronic obstructive pulmonary disease (COPD), bronchial polyps, bronchiectasia (such as, e.g., bronchiectasia sicca, cylindrical bronchiectasis, and saccular bronchiectasis), bronchiolar adenocarcinoma, bronchiolar carcinoma, bronchiolitis (such as, e.g., exudative bronchiolitis, bronchiolitis fibrosa obliterans, and proliferative bronchiolitis), bronchiolo-alveolar carcinoma, bronchitic asthma, bronchitis (such as, e.g., asthmatic bronchitis, Castellani's bronchitis, chronic bronchitis, croupous bronchitis, fibrinous bronchitis, hemorrhagic bronchitis, infectious avian bronchitis, obliterative bronchitis, plastic bronchitis, pseudomembranous bronchitis, putrid bronchitis, and verminous bronchitis), bronchocentric granulomatosis, bronchoedema, bronchoesophageal fistula, bronchogenic carcinoma, bronchogenic cyst, broncholithiasis, bronchomalacia, bronchomycosis (such as, e.g., bronchopulmonary aspergillosis), bronchopulmonary spirochetosis, hemorrhagic bronchitis, bronchorrhea, bronchospasm, bronchostaxis, bronchostenosis, Biot's respiration, bronchial respiration, Kussmaul respiration, Kussmaul-Kien respiration, respiratory acidosis, respiratory alkalosis, respiratory distress syndrome of the newborn, respiratory insufficiency, respiratory scleroma, respiratory syncytial virus, and the like.

In addition, expression of this gene in lung and the ability of polypeptides of the invention to induce interferon gamma production indicates that the polynucleotides and/or polypeptides corresponding to this gene, (and/or antibodies raised against those polypeptides) are particularly useful in the diagnosis and treatment of diseases and disorder of the lung or lung function including for example, lung cancer, pulmonary edema, pulmonary fibrosis, respiratory distress syndrome, asthma, bronchitis, and infections that affect the lung such as influenza and pneumonia. It is specifically contemplated that the polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof could be delivered to the patient as a therapeutic into the lungs by way of inhalants, spray mist, or other delivery systems that involve directly inhaling the therapeutic.

The fact that polypeptides of the invention have been found to induce secretion of IFN $\gamma$  when added to PBLs indicates that polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof would be useful for the treatment and/or diagnosis of a variety of diseases and disorders. Examples of viral diseases and disorders that can be treated or prevented using polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof, include, but are not limited to, the following: AIDS, viral hepatitis including chronic hepatitis B and hepatitis C, papilloma viruses, herpes, cytomegalovirus (CMV), viral encephalitis, and in the prophylaxis of rhinitis.

Examples of antiparasitic and bacterial diseases and disorders using polynucleotides and polypeptides of the invention, or fragments, variants, antagonists/agonists and derivatives thereof, include, but are not limited to, the following: *Cryptosporidium parvum* infection and multidrug-resistant pulmonary tuberculosis.

Polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof, may be useful as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting



of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, Respiratory syncytial virus, Dengue, Rotavirus, Japanese B encephalitis, Influenza A and B, Parainfluenza, Measles, Cytomegalovirus, Rabies, Junin, Chikungunya, Rift Valley fever, Herpes simplex, and yellow fever.

Polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof, may be useful as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meissneria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella* spp., Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, *Borrelia burgdorferi*, and Plasmodium (malaria).

Polynucleotides or polypeptides of the invention and/or agonists and/or antagonists thereof, may be useful as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria).

Examples of cancers that can be treated or prevented using polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof,

include, but are not limited to, the following: hairy cell leukemia, acute myeloid leukemia, osteosarcoma, basal cell carcinoma, glioma, renal cell carcinoma, multiple myeloma, melanoma, Hodgkin's disease, synergistic treatment of advanced cancer with a combination of alpha interferon and temozolomide. Representative uses are described in the "Hyperproliferative Disorders" and "Immune Activity" sections below and elsewhere herein.

Polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof may also be useful in immunotherapies. For example, immunosuppression such as the prevention of graft vs. host rejection or to curtail the progression of autoimmune diseases, such as arthritis, multiple sclerosis, and/or diabetes.

In addition, polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof may also be useful for anti-allergy treatments or vaccine adjuvantation.

Alternatively, polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof may be employed clinically to stimulate interferon production in a mammalian, preferably human, host. Particularly, the polypeptides of the present invention, including fragments, variants, and derivatives thereof, may be administered to a patient (e.g., mammal, preferably human), to stimulate alpha, beta, and/or gamma interferon production. Thus, polypeptides, fragments, variants, and derivatives of the present invention have prophylactic and therapeutic uses which include, but are not limited to, anti-viral therapy, anti-cancer therapy, anti-parasitic therapy, anti-bacterial therapy, treatment and prevention of allergy, immunotherapy, and/or in the treatment of any condition, such as those mentioned above, where an increased production of interferon is desired. The polypeptides of the invention may also be used as an adjuvant or co-adjuvant to enhance or stimulate the immune response in cases of prophylactic or therapeutic vaccination.

Further, there is provided a method of treating infection in a patient comprising administering an effective amount of a polypeptide, or fragment, variant, or derivative of the invention to a patient in need of anti-infective

therapy. In a preferred embodiment the infection is of viral, bacterial, or parasitic etiology. In a particularly preferred embodiment, the infection is a viral infection.

Further, there is provided a method of treating cancer in a patient comprising  
5 administering an effective amount of a polypeptide, or fragment, variant, or derivative of the invention to a patient in need of anti-cancer therapy.

Polynucleotides of the invention may also be employed in gene therapy to treat patients in need of increased interferon production. Representative uses are described in the "Gene Therapy" section below. Such patients include those in need  
10 of anti-viral, anti-bacterial, anti-parasitic, anti-cancer therapy, or immunotherapy.

The tissue distribution in neural tissues and developing tissues indicates that polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof are useful for the treatment and/or diagnosis of disorders of the central nervous system, disorders of developing systems, and cancers.

15 The tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, multiple sclerosis, schizophrenia, mania, dementia, paranoia,  
20 obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

25 The tissue distribution in placenta indicates that polynucleotides and polypeptides of the invention, or fragments, variants, and derivatives thereof are useful for the diagnosis and/or treatment of disorders of the placenta. Relatively high expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene  
30 product may be produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta

also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

A highly preferred embodiment of the invention includes a method for stimulating the production of IFN $\gamma$ . An alternative highly preferred embodiment of the invention includes a method for inhibiting the production of IFN $\gamma$ .

Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or as described below under "Infectious Disease"). Highly preferred indications include autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiency (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders. Additional preferred indications include idiopathic pulmonary fibrosis.

Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.

Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 26

10

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

MTKREDGGYTFTATPEDFPKKHKAPVIDIGIANTGKFIMTASSDTTVLIWSLK  
 GQVLSTINTNQMNNTAAVSPCGRFVASCFTPDVKVWEVCFGKKGEFQEV  
 15 VRAFELKGHSAAVHSFAFSNDSRRMASVSKDGTWKLWDTXVEYKKKQDPY  
 LLKTGRFEEAAGAXPCRLALSPNAQVLALASGSSIHLYNTRRGEKEECFERVH  
 GECIANLSFDITGRFLASCGDRAVRLFHNTPGHRAMVEEMQGHLKRASNEST  
 RQRLQQQLTQAQETLKSIGALKK (SEQ ID NO: 231). Moreover, fragments and  
 variants of these polypeptides (such as, for example, fragments as described herein,  
 20 polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to  
 these polypeptides and polypeptides encoded by the polynucleotide which hybridizes,  
 under stringent conditions, to the polynucleotide encoding these polypeptides, or the  
 complement thereof are encompassed by the invention. Antibodies that bind  
 polypeptides of the invention are also encompassed by the invention. Polynucleotides  
 25 encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is thought to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

When tested against U937 Myeloid cell lines, supernatants removed from cells  
 30 containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes

which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and  
5 differentiation of cells.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 12 - 28 of the amino acid sequence referenced in Table 1A for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

10 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
VIRHEGSTNMELSQMSXLMGLSVLLGLLALMATAAVXRGWLRAGEERSGRP  
15 ACQKANGFPPDKSSGSKKQKQYQIRKEKPQQHNFTHRLAAALKSHSGNIS  
CMDFFSSNGKYLATCADDRITRIWSTKDFLQREHRSMRANVELDHATLVRFSP  
DCRAFIVWLANGDTLRVFKMTKREDGGYTFTATPEDFPKKHKAPVIDIGIAN  
TGKFIMTASSDTTVLIWSLKGQVLSTINTNQMNNTAAVSPCGRFVASCGFTP  
DVKVWEVCFGKKGEFQEVVRAFELKGHSAAVHSFAFSNDSRRMASVSKDGT  
20 WKLWDTXVEYKKKQDPYLLKTGRFEEAAGAXPCRLALSPNAQVLALASGSS  
IHLYNTRRGEKEECFERVHGECIANLSFDITGRFLASCGDRAVRLFHNTPGHR  
AMVEEMQGHLKRASNESTRQLQQQLTQAQETLKSLGALKK (SEQ ID NO:  
232). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for  
25 example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by  
30 the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in testes, synovial sarcoma and fetal tissues, and to a lesser extent in several other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the reproductive and developing systems and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and developing systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in testes tissue, synovial sarcoma, and fetal tissues, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of the reproductive and developing systems, and cancers.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target

indications. Furthermore, The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders.

Expression within embryonic tissue and other cellular sources marked by  
5 proliferating cells indicates that this protein may play a role in the regulation of cellular division.

Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene may be useful in the treatment  
10 of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer  
15 therapy. This protein is useful for the treatment, detection, and/or prevention of William's disease. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
20 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

In specific embodiments, polypeptides of the invention comprise, or  
25 alternatively consists of, an amino acid sequence selected from the group: 1-363, 2-363, 4-363, 5-363, 30-363, 31-363, 32-363, 75-363, 76-363 and 82-363 of the following amino acid sequence:

MSVMVVRKKVTRKWEKLPGRNTFCCDGRVMMARQKGIFYLTLFLILGTCTL  
FFAFECRYLAVQLSPAIPVFAAMLFLFSMATLLRTSFSDPGVIPRALPDEAAFI  
30 MEIEATNGAVPQGQRPPPRIKNFQINNQIVKLKYCYTCKIFRPPRASHCSICDN  
CVERFDHHCPWVGNCVGRNRYFYFLFILSLSLLTTYVFAFNIVYVALKSLKI  
GFLETLKETPGTVLEVLCFFTLWSVVGTLTGFTFLVALNQTNEDIKGSWTG



KNRVQNPYSHGNIVKNCCEVLCGPLPPSVLDRRGILPLEESGSRPPSTQETSSS

LLPQSPAPTELNSNEMPEDSSTPEEMPPEPPEPPQEAAEAEK (SEQ ID NO:

233). Polynucleotides encoding such polypeptides are also encompassed by the

invention. Moreover, fragments and variants of these polypeptides (such as, for

5 example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by

10 the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

A preferred polypeptide variant of the invention comprises the following amino acid sequence:

MLFLFSMATLLRTSFSDPGVIPRALPDEAAFIEMEIEATNGAVPQGQRPPPRIK

15 NFAQINN QIVKLKCYTCKIFRPPRASHCSICDNCVE

RFDHHCPWVGNCVVGKRNRYRYFYLFILSLSL

LTIYVFAFNIVYVALKSLKIGFLETCLKGNS

WNCSRSPHLLLYTLVRRGTDWISYFPRGSQ PDNQ (SEQ ID NO: 234).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

20 Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the

25 invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

30 This gene is expressed primarily in ovarian and endometrial tumors, fetal liver, spleen and brain tissues, and to a lesser extent in several other tissues and organs.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the developing systems, and cancers of the female reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing, female reproductive and fetal systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, developing, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 130 as residues: Pro-44 to Lys-54, Cys-88 to His-95, Val-103 to Tyr-108, Gln-181 to Ser-190, Thr-192 to Ile-206, Glu-233 to Ser-245, Ser-252 to Ala-286. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in developing systems indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of disorders of developing and fetal systems, and cancers. Furthermore, the tissue distribution in ovarian and endometrial tumor tissues indicates that the translation product of this clone is useful for the detection, diagnosis, and/or treatment of cancers of the female reproductive system. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene. Also provided is a kit for detecting these tumors. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting these tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other

treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 28**

5

This gene is expressed primarily in normal and cancerous colon tissue, macrophages, endothelial cells and placental tissue, and to a lesser extent in several other tissues and organs.

Polynucleotides and polypeptides of the invention are useful as reagents for  
10 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, colon cancer and gastrointestinal disorders, immune disorders, vascular diseases and disorders of developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, vascular and developing systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, developmental, vascular, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
20 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
25 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 131 as residues: Thr-27 to Ser-33. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in macrophage, endothelial and placental tissues, and  
30 normal and cancerous colon tissues, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of immune, gastrointestinal and vascular disorders and diseases. Expression of this gene product

in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene.

- 5 Also provided is a kit for detecting colon cancer. Such a kit comprises in one embodiment an antibody specific for the translation product of this gene bound to a solid support. Also provided is a method of detecting colon cancer in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining  
10 whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein.

- Alternatively, the tissue distribution in placental tissue indicates that  
15 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product may be produced by the placenta and then transported to the embryo, where it may play a  
20 crucial role in the development and/or survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta and endothelial cells also indicates that this gene product may be produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be  
25 produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body.

- Additionally, expression of this gene product in macrophage also strongly  
30 indicates a role for this protein in immune function and immune surveillance. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of

cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

The translation product of this gene shares homology with HNK-sulfotransferase, which directs glycan synthesis (see, e.g., Genbank Accession no. AF033827).

This gene is expressed primarily in activated T cells, osteoclastoma, and glioblastoma, and to a lesser extent in various other normal and transformed cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, immune defects, cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hemopoietic systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative

to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 132 as  
5 residues: Pro-32 to Gly-48, Gln-63 to Thr-69, Pro-77 to Trp-84, Val-88 to Leu-94. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in T-cells and various types of neoplasms indicates that  
10 polynucleotides and polypeptides corresponding to this gene are useful for the detection, study and/or treatment of inflammatory and general immune defects, and various types of neoplasms. Expression of this gene product in T cells strongly indicates a role for this protein in immune function and immune surveillance. This gene product may be involved in the regulation of cytokine production, antigen  
15 presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Therefore it may be also used as an agent for immunological  
20 disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

25 Alternatively, the tissue distribution in various cancerous tissues indicates that the translation product of the clone is useful for the detection, diagnosis, and/or treatment of these cancers, as well as cancers of other tissues where expression has been observed. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 30

Preferred polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

LHECLPGSISYLHPRTPWLCCLPPQHLSFSTFSPWPQAMSPVPGTGGPPCGL

5 (SEQ ID NO: 235), and/or

MLPLLIICLLPAIEGKNCLRCWPELSALIDYDLQILWVTPGPPTELSQSIHSLFLE  
DNNFLK

PWYLDNRDHLEETAKFFTQVHQAIKTLRDDKTVLLEEIYTHKNLFTERLNKIS  
DGLKEKGAPPLHECLP

10 GSISYLHPRTPWLCCLPPQHLSFSTFSPWPQAMSPVPGTGGPPCGL (SEQ ID  
NO: 236). Polynucleotides encoding these polypeptides are also encompassed by the  
invention. Moreover, fragments and variants of these polypeptides (such as, for  
example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
15 the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
encoding these polypeptides, or the complement thereof are encompassed by the  
invention. Antibodies that bind polypeptides of the invention are also encompassed by  
the invention. Polynucleotides encoding these polypeptides are also encompassed by  
the invention.

20 This gene is expressed primarily in infant brain, testes and activated T cells,  
and to a lesser extent in various other normal and transformed cell types.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
25 neurological, reproductive and inflammatory conditions. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological  
probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the neural, immune and male  
reproductive systems, expression of this gene at significantly higher or lower levels  
30 may be routinely detected in certain tissues or cell types (e.g., neural, immune,  
reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken

from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
5 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 133 as residues: Gly-41 to Leu-46, Asp-67 to Thr-75, Ile-114 to Ala-123. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in infant brain tissue, testes tissue, and activated T-  
10 cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study, diagnosis, and/or treatment of neurological, reproductive and immune system disorders. Expression of this gene product in T-cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene  
15 product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the gene or protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the  
20 above listed tissues. Therefore it may be also used as an agent for immunological disorders including arthritis, asthma, immune deficiency diseases such as AIDS, leukemia, rheumatoid arthritis, inflammatory bowel disease, sepsis, acne, and psoriasis. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the  
25 differentiation and/or proliferation of various cell type.

Alternatively, the tissue distribution in testes tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product  
30 is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful



in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other  
5 processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications.

Furthermore, the tissue distribution in infant brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders  
10 such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of  
15 developmental disorders associated with the developing embryo, or sexually-linked disorders. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

20

The translation product of this gene shares sequence homology with some human and rodent melanoma and leukocyte specific antigens (see, for example, Genbank accession nos: gi|189384, gi|205898 and gi|180926). In addition, the translation product of this gene shares sequence homology with Tetraspan protein  
25 (see, for example, Genbank accession number: GI 3152703). Therefore, it is likely that the polypeptide of this gene shares some biological functions, such as cell-to-cell signaling, adhesion, proliferation, and differentiation with Tetraspan.

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 52-68 and 197 - 213 of the amino acid sequence  
30 referenced in Table 1A for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

The transmembrane 4 superfamily (TM4SF) or tetraspan superfamily has at least 16 members (including CD9, CD20, CD37, CD53, CD63, CD81, CD82, A15, CO-029, Sm23, RDS, Uro B, Uro A, SAS, Rom-1, PETA3, and YKK8), is the second biggest subfamily among CD antigen superfamily. and activation antigen of T- cells.

- 5 All TM4SF member contains four putative transmembrane domains, two extracellular loops, and two short cytoplasmic tails. They are variously expressed on Immature, early, mature, activated lymphocytes, monocytes, macrophages, granulocytes, platelets, eosinophils, basophils, certain leukemic and lymphoma cells, and a variety of other cells and tissues. CD9 cell surface protein is expressed by both hematopoietic and neural cells, and may play a role for CD9 in intercellular signaling in the immune and nervous system. CD63 is a 53-Kd lysosomal membrane glycoprotein that has been identified as a platelet activation molecule, which play important role in cell adhesion of platelets and endothelial cells. Increased mRNA for CD63 antigen was found in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits,
- 15 suggesting a potential role of CD63 in progression of atherosclerosis. CD63 is also a mast cell marker. CD82 was originally identified as the target of several mAbs inhibitory to syncytium formation induced by human T-cell leukemia virus type I (HTLV-I), the etiological agent of adult T-cell leukemia. Therefore, this gene could be a target for the development of a drug for this leukemia. CD81 is the target of an antiproliferative antibody. A diverse group of human cell lines, including
- 20 hematolymphoid, neuroectodermal, and mesenchymal cells, express the CD81 protein. Many of the lymphoid cell lines, in particular those derived from large cell lymphomas, were susceptible to the antiproliferative effects of the antibody. CD81 may therefore play an important role in the regulation of lymphoma cell growth. CD9, CD20, CD37, CD63, CD81 and CD82 have been implicated in the regulation of cell growth, adhesion, and signal transduction of B, T lymphocytes and some other non-lymphoid cells. They associate with CD2, CD21, CD4, CD8, MHC Class II molecules, integrins, function as co-receptor for T, B and other lymphoid cells. Some TM4SF are leukocyte antigens, highly expressed in activated leukocytes,
- 25 lymphocytes, are highly specific surface marker for lymphoblastic leukemia, lymphoma, melanoma, and neuroblastoma. CD9 has been show to be involved in cell motility and tumor metastasis. These antigens could be a valuable immunogen or
- 30

target to implement active and passive immunotherapy in patients with cancer. Others have been shown to be involved in inhibition of prostate cancer metastasis. This gene has close homology to C33 antigen (CD82), which is a member of the transmembrane 4 superfamily (TMSF) and activation antigen of T-cells. C33 Ag (CD82 was  
5 originally identified as the target of several mAbs inhibitory to syncytium formation induced by human T-cell leukemia virus type I (HTLV-I), the etiological agent of adult T-cell leukemia. Therefore, this gene could be very important target for developing drug for leukemia. Other members of this family are Sm23, CO-029, R2, TAPA-1, CD9, CD37, CD53, and CD63. CD63 is a 53-Kd lysosomal membrane  
10 glycoprotein that has been identified as a platelet activation molecule. There are strong evidence indicating that CD63 and P1tg40, a platelet membrane glycoprotein are the same molecule and that CD63/P1tg40 is identical to the well-characterized, stage-specific melanoma-associated antigen ME491. These antigen could be valuable immunogens or target to implement active and passive immunotherapy in patients  
15 with cancer.

This gene is expressed primarily in fetal tissue (kidney, heart, liver, spleen, brain), macrophages, dendritic cells, retina and to a lesser extent in various other tissues, mostly of lymphoid origin or epithelial cell types. In addition This gene is expressed in cancerous tissues (e.g. breast).

20 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders and cancers in a variety of organs and cell types. Similarly, polypeptides and antibodies directed to these  
25 polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., developmental, proliferating, immune, hematopoietic, integumentary, and  
30 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid, spinal fluid, or amniotic fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 134 as  
5 residues: Tyr-123 to Tyr-131, Cys-134 to Ser-145, Tyr-234 to Tyr-244. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution fetal cells and tissues and homology to tumor antigens  
10 indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of lymphoid and epithelial disorders and neoplasms.

Additionally, tissue distribution in immune cells and other tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the  
15 diagnosis and treatment of disorders affecting hematopoiesis, including cancers. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell  
20 lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders  
25 including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as  
30 autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that

influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

5           Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"

10   and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain

15   neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,

20   detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

25   proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

30   antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

The translation product of this gene shares limited sequence homology with  
5 VEGF which is thought to be important in regulation of endothelial cell growth.  
Therefore, it is likely that the protein encoded by this gene would share some similar  
biological functions. When tested against U937 Myeloid cell lines, supernatants  
removed from cells containing this gene activated the GAS assay. Thus, it is likely  
that this gene activates myeloid cells, and to a lesser extent, other immune and  
10 hematopoietic cells and tissue cell types, through the Jak-STAT signal transduction  
pathway. The gamma activating sequence (GAS) is a promoter element found  
upstream of many genes which are involved in the Jak-STAT pathway. The Jak-  
STAT pathway is a large, signal transduction pathway involved in the differentiation  
and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected  
15 by the binding of the GAS element, can be used to indicate proteins involved in the  
proliferation and differentiation of cells.

This gene is expressed in brain.

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
20 and for diagnosis of diseases and conditions which include, but are not limited to,  
nervous system disease and/or disorders. Similarly, polypeptides and antibodies  
directed to these polypeptides are useful in providing immunological probes for  
differential identification of the tissue(s) or cell type(s). For a number of disorders of  
the above tissues or cells, particularly of the central nervous system, expression of  
25 this gene at significantly higher or lower levels may be routinely detected in certain  
tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids  
(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
cell sample taken from an individual having such a disorder, relative to the standard  
gene expression level, i.e., the expression level in healthy tissue or bodily fluid from  
30 an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 135 as

residues: Thr-25 to Pro-46. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in brain indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

The translation product of this gene shares sequence homology with human p150 which is thought to be important in signal transduction in neuronal cells. Therefore, it is likely that the protein encoded by this polynucleotide would share some similar biological functions with p150.

This gene is expressed primarily in whole embryo and cerebellum.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and growth defects/disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the CNS, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of central nervous system, neurodevelopmental, cognitive, and memory disorders.

The tissue distribution also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.



Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

This gene is expressed primarily in PMA stimulated HL-60 cells and to a lesser extent in 6 week embryo.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting cell differentiation, particularly hematopoietic disorders and/or defects. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 137 as residues: Pro-61 to Asp-68. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study of cellular differentiation and for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia. The tissue distribution also indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful  
5 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment,  
10 and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in  
15 inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the  
20 treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection,  
25 treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise  
30 antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in colon.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or defects of the digestive tract including but not limited to cancers of the gastrointestinal tract. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the digestive system particularly disorders involving the colon. Further, expression of this gene product in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the colon and/or other gastrointestinal tissue including, but not limited to, stomach, small intestine, large intestine, and rectum.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

This gene is expressed primarily in blood cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
5 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
immune and hematopoietic diseases. Similarly, polypeptides and antibodies directed  
to these polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
10 tissues or cells, particularly of the immune and hematopoietic system, expression of  
this gene at significantly higher or lower levels may be routinely detected in certain  
tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g.,  
lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell  
sample taken from an individual having such a disorder, relative to the standard gene  
15 expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 139 as  
residues: Pro-19 to Cys-29, Thr-35 to Glu-44, Val-72 to Lys-78. Polynucleotides  
20 encoding said polypeptides are also encompassed by the invention. Antibodies that  
bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides  
corresponding to this gene are useful for treatment and diagnosis and/or treatment of  
disorders of the immune and hematopoietic system. Representative uses are described  
25 in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13,  
14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene  
product indicates a role in regulating the proliferation; survival; differentiation; and/or  
activation of hematopoietic cell lineages, including blood stem cells. This gene  
product is involved in the regulation of cytokine production, antigen presentation, or  
30 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting  
immune responses).

**FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

This gene is expressed in multiple tissue systems such as brain, immune cells,  
5 prostate, uterus, testes, placenta, and fetal heart as well as in cancerous tissues such as  
ovarian tumors. .

Polynucleotides and polypeptides of the invention are useful as reagents for  
differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
10 disorders of the immune, reproductive, urogenital, and central nervous system.  
Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
central nervous system and immune system, expression of this gene at significantly  
15 higher or lower levels may be routinely detected in certain tissues or cell types (e.g.,  
immune, reproductive, urogenital, cancerous and wounded tissues) or bodily fluids  
(e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
cell sample taken from an individual having such a disorder, relative to the standard  
gene expression level, i.e., the expression level in healthy tissue or bodily fluid from  
20 an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 140 as  
residues: Tyr-33 to Lys-38. Polynucleotides encoding said polypeptides are also  
encompassed by the invention. Antibodies that bind said epitopes or other  
25 polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides  
corresponding to this gene are useful for treatment and diagnosis of disorders of the  
immune, urogenital, reproductive, and central nervous systems. The tissue  
distribution in central nervous system tissues indicates that polynucleotides and  
30 polypeptides corresponding to this gene are useful for the treatment and/or diagnosis  
of diseases of the central nervous system, as well as cancers of tissues where  
expression of this gene has been observed, such as in ovarian tumors.

The tissue distribution in central nervous system tissues also indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette  
5 Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo. .

10 Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"  
15 and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain  
20 neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating,  
25 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in  
30 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution in uterus  
5 indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally.

Alternatively, this gene could be transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced.

10 Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium.

The tissue distribution in testes indicates that polynucleotides and  
15 polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male  
20 contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that may be expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product may be expressed in other specific tissues or organs where it may play related functional roles in other processes, such as  
25 hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

**FEATURES OF PROTEIN ENCODED BY GENE NO: 38**



This gene is expressed in a wide range of tissue systems such as brain, immune cells, fetal liver, kidney, testes, breast, and pancreas as well as cancerous tissue such as ovarian tumors.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the central nervous system, immune system, urogenital, and reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, CNS, urogenital, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 141 as residues: Met-1 to Ser-7, Asp-32 to Pro-43, Ser-96 to Arg-102. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, reproductive, urogenital and central nervous systems.

The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or diagnosis of diseases of the central nervous system, as well as cancers of tissues where expression of this gene has been observed, such as in ovarian tumors.

The tissue distribution in central nervous system tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

detection/treatment of neurodegenerative disease states and behavioural disorders such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention

of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

30

This gene is expressed primarily in macrophages and fetal cells and to a lesser extent in cancerous ovarian tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune diseases, disorders of developing tissues, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal and immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of developmental abnormalities and disorders of the immune systems.

The tissue distribution cancerous ovaries indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of these tumors. Protein, as well as, antibodies directed against the protein may show utility as a tissue-specific marker and/or immunotherapy target for the above listed tissues.

Expression of this gene product in macrophage cells strongly indicates a role for this protein in immune function and immune surveillance. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). This gene product may have clinical utility in the treatment of immune dysfunction; in the correction of autoimmunity; in immune modulation; and in the control of inflammation.

The tissue distribution indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the

expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may

also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue  
5 differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the  
10 protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution also  
15 indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders such as melanomas.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 40

This gene is expressed primarily in neutrophils, bone marrow, brain, and fetal cells.

Polynucleotides and polypeptides of the invention are useful as reagents for  
25 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders, Limbic system dysfunction/defects and disorders of the immune system and developing systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
30 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, Limbic system and developing systems, expression of this gene at significantly higher or lower levels may be

5 routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 143 as residues: Ala-84 to Gln-93. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other  
10 polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the immune, Limbic system, CNS and developing systems. Expression of this gene product in bone marrow, eosinophils, and neutrophils strongly indicates a role for this  
15 protein in hematopoiesis and immune surveillance. This gene product may be involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses). This gene product may have clinical utility in the treatment of immune dysfunction; in the correction of autoimmunity; in immune  
20 modulation; and in the control of inflammation.

The tissue distribution indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
25 expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed  
30 in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis,

granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, 5 lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem 10 cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, 15 and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in 20 inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the 25 treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, 30 treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be



used to gain new insight into the regulation of cellular growth and proliferation.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

- 5 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

10

- When tested against MVEC endothelial cell lines, supernatants removed from cells containing this gene activated the expression of ICAM-1. Thus, this gene activates signal transduction pathways which upregulate cell-surface expression and/or secretion of ICAM-1. ICAM-1 - is found on the cell surface of endothelial
- 15 cells, smooth muscle cells, epithelial cells, and fibroblasts. It binds to its ligand, LFA-1, a heterodimer complex that is a member of the leukocyte integrin family of cell adhesion receptors. Inflammatory mediators and cytokines, such as, IL-1, TNF $\alpha$  and IFN $\gamma$ , stimulate ICAM-1 expression on vascular cells, in addition to the aforementioned cells and tissue cell types. Polypeptides which increase ICAM
- 20 expression are useful in the treatment of cancer, cardiovascular, autoimmune and inflammatory diseases and/or disorders.

This gene is expressed primarily in ovary and to a lesser extent in fetal tissue, colon, and immune cells.

- Polynucleotides and polypeptides of the invention are useful as reagents for
- 25 differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, ovarian cancer, gastrointestinal and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of
- 30 disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, gastrointestinal, immune,

cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 144 as residues: Ile-23 to Ala-29. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of ovarian cancer and related metastases. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility.

The tissue distribution in colon tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders involving the gastrointestinal tract. This may include diseases associated with digestion and food absorption, as well as hematopoietic disorders involving the Peyer's patches of the small intestine, or other hematopoietic cells and tissues within the body. Similarly, expression of this gene product in colon tissue indicates again involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 42**

The translation product of this gene shares sequence homology with retrovirus-related reverse transcriptase pseudogene. In addition, this gene shares homology with human interferon-beta (Genseq accession number T35524; all references available through this accession are hereby incorporated herein by reference), therefore, it is likely that this gene and the protein encoded by this gene shares some similar biological functions with this protein.

This gene is expressed primarily in frontal cortex.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,

neurodegenerative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in frontal cortex and homology to retrovirus-related reverse transcriptase pseudogene and human interferon-beta indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of neurodegenerative diseases of the brain, particularly of the frontal cortex. The tissue distribution indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, cystic fibrosis, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate

their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 43

This gene is expressed primarily in immune cells, brain, fetal tissue, and cancerous tissues (such as testes, stomach, lung, pancreas, ovaries) and to a lesser extent in other numerous tissues including, but not limited to, testes and kidney.

10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system and immune cells expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or  
20 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 146 as  
25 residues: Lys-23 to Lys-35, Met-46 to Tyr-52. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of  
30 neurodegenerative disorders of the frontal cortex, as well as, cancer or a number of tissues including but not limited to testes, stomach, lung, pancreas, and ovaries.

The tissue distribution indicates the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

The tissue distribution indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility,

lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

This gene is expressed primarily in epithelioid sarcoma and to a lesser extent in pancreatic carcinoma, aorta endothelial cells induced with TNF-alpha, and amniotic cells induced with TNF. This gene is also expressed, to a lesser extent, in  
10 cancerous lung and ovary tissue and fetal tissue.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, epithelioid sarcoma and related cancers. Similarly, polypeptides and antibodies  
15 directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic,  
20 lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
25 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 147 as residues: Tyr-39 to Arg-51. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution indicates that polynucleotides and polypeptides  
30 corresponding to this gene are useful for diagnosis and treatment of certain cancers, including epithelioid sarcoma and pancreatic carcinoma. The tissue distribution in tumors of lung, ovary, and pancreas origins indicates that polynucleotides and



polypeptides corresponding to this gene are useful for the diagnosis and intervention of these tumors, in addition to other tumors where expression has been indicated.

Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation.

The tissue distribution indicates the protein product of this clone is useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the

treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 45

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
PPVPPWISLPLTGSPPRPGFVPVSPFCFSPMTNGHQVLLLLLLTSAVAAGPWPQ  
VHAGQWGWMLPPLPSVQARSLGGLPGGPQWVPGGARGY (SEQ ID NO: 237). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for

example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in fetal and infant tissue, particularly infant brain and fetal liver/spleen libraries, and to a lesser extent in breast, ovary tumor, pharynx carcinoma, endometrial stromal cells, thymus, islet cell tumors, and adult cerebellum.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and breast, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, developmental, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in developing cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer and other proliferative disorders. The expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere

herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired

5 immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present

10 invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as

15 may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

20 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

25

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

30 IQQWGDSVLGRRCDLLQLYLQRPELRVPVPEVLLHSEGAASSSVCKLDGLI  
HRFITLLADTSDSRALENRGADASMCRKLAVAHPLLLLRHLPMAALLHGR  
THLNFQEFRQQNHLSCFLHVLGLLELLQPHVFRSEHQGALWDCLLSFIRLLN

YRKSSRHLAAFINKFVQFIHKYITYNAPAAISFLQKHADPLHDLSFDNSDLVM  
 LKSLLAGLSLPSRDDRTDRGLDEEGEEESSAGSLPLVSVSLFTPLTAAEMAPY  
 MKRLSRGQTVEDLLEVLSDIDEMSRRRPEILSFFSTNLQRLMSSAECCRNLA  
 FSLALRSMQNSPSIAAAFLPTFMYCLGSQDFEVVQTALRNLPYALLCQEHA  
 5 AVLLHRAFLVGMYGQMDPSAQISEALRILHMEAVM (SEQ ID NO: 238).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in breast cancer, and to a lesser extent in a variety of other cancers, including uterine cancer, synovial sarcoma, and pharynx carcinoma.

- 10 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; proliferative diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological
- 15 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the breast, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, breast, proliferative, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, breast milk, urine,
- 20 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- Preferred polypeptides of the present invention comprise, or alternatively
- 25 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 149 as residues: Glu-35 to His-41, Ser-62 to Ala-67, Pro-145 to Leu-155, Glu-157 to Ser-163, Arg-190 to Val-197, Asp-208 to Pro-215, Ser-247 to Pro-252. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

- 30 The tissue distribution in breast cancer tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of cancer. Elevated expression of this gene product in cancers, such as

breast cancer, suggest that it may be involved in the abnormal proliferation of cells, dedifferentiation, angiogenesis, and other processes that accompany the development of cancer. Thus, therapeutics targeted against this gene product may be useful therapeutic products in and of themselves. Alternately, expression of this gene product at elevated levels in breast tissue may be reflective of expression within breast lymph nodes, and may suggest a hematopoietic role for this protein. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

**FEATURES OF PROTEIN ENCODED BY GENE NO: 47**

The translation product of this gene shares limited sequence homology with cytochrome-c oxidase.

An alternative embodiment would be the polypeptide comprising, or  
5 alternatively consisting of, the following amino acid sequence:  
MLLKHLQRMVSVQVKASALKVVTLTANDKTSVSFSSLPGQGVYINVIVWD  
PFLNTSAAYIPAHTYACSFEAGEGSCASLGRVSSKVFFTLFALLGFFICFFGHR  
FWKTELEFFIGFIIMGFFFYILITRLTPIKYDVNLILTAVTGSVGGMFLVAVWWR  
FGILSICMLCVGLVLGFLISSVTFFTPLGNLKFHDDGVFWVTFSCIAILIPVVF  
10 MGCLRILNLTGCVIGSYSVVLAIWSYSTLSYITLNLKRALNKDFHRAFTN  
VPFQTNDIFILAVWGMLAVSGITLQIRRRERGRPFPPHPYKLWKQERERRVTNI  
LDPSYHIPPLRERLYGRLTQIKGLFQKEQPAGERTPLLL (SEQ ID NO: 239).

Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%,  
15 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by  
20 the invention.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
25 WARLRGPGAHARTSPQPWRGPSPAQAAMGFLQLLVVXVLXSEHRVAGAAE  
VFGNSSEGLIEFSVGKFRYF  
ELNRPFPEEAILHDISSNVTLFIQIHSQYQNTTVSFSPRRRSPTM (SEQ ID NO:  
240). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for  
30 example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide

encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

5           This gene is expressed primarily in keratinocytes, brain, and spinal cord and to a lesser extent in hematopoietic cells and tissues.

          Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,  
10   neurodegenerative disorders; hematopoietic disorders; integumentary disorders; immune dysfunction; learning disabilities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression  
15   of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., integumentary, neural, developmental, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in  
20   healthy tissue or bodily fluid from an individual not having the disorder.

          The tissue distribution in brain and spinal cord cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of neurological and hematopoietic disorders. For example, elevated levels of expression of this gene product in brain and spinal cord  
25   indicates that it may be involved in neurodegenerative disorders. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,  
30   encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive



disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product  
5 is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Alternately, expression of this gene product in hematopoietic cells indicates that it may be involved in the proliferation, differentiation, survival, and activation of all hematopoietic lineages, including stem and progenitor cells. Expression of this  
10 gene product in keratinocytes indicates that it may be involved in normal skin function, and could be involved in skin disorders, dermatitis, and fibrosis. The protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's disease, basal cell carcinoma, squamous cell  
15 carcinoma, malignant melanoma, Paget's disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae,  
20 purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this clone may also be useful for the treatment or diagnosis of various connective tissue  
25 disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid).  
30 Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 48

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention  
10 comprise, or alternatively consists of, the following amino acid sequence:  
PRVRPASPPVRSPARWGSMAGSPLLWGPRAGGVGLLVLLLLGLFRPPPALCA  
RPVKEPRGLSAASPPLARLALLAASGGQCPEVRRRGRCRPGAGAGASAGAER  
QERARAEAQRLRISRRASWRSCCASCAPPATLRLW  
AWTTTPTRLQRSSLALCSAPALTLP (SEQ ID NO: 241). Polynucleotides  
15 encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these  
20 polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in human pituitary and to a lesser extent in  
25 pineal gland, and other areas of the brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pituitary dysfunction; abnormal growth; neurological defects; insufficient milk  
30 secretion; abnormal smooth muscle contraction. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of

disorders of the above tissues or cells, particularly of the endocrine and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, breast milk, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 151 as residues: Pro-36 to Gly-42, Pro-64 to Ala-76, Gly-83 to Ala-90, Ser-100 to Cys-108, Thr-126 to Ser-135. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution primarily in pituitary cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene product in the pituitary indicates that it may be possibly a hormone-like substance that either controls pituitary development itself, or various processes controlled by the pituitary. These include growth, milk secretion, smooth muscle contraction, diuresis, blood pressure, and homeostasis. Thus, this gene product may have numerous clinical applications. Expression of this gene product in other regions of the brain also indicates that it may be involved in normal neurological function, and may be useful in the treatment of a variety of neurological disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to

isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility

5

## FEATURES OF PROTEIN ENCODED BY GENE NO: 49

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

PRVRLATPNIWDL SMLFAFISLLV MLPTWWIVSSWL VWGVILFVYLVIRALRL  
 WRTAKLQVTLKKYSVHLEDMATNSRAFTNLVRKALRLIQETEVISRGFTLVS  
 AACPFNKAGQHPSQHLIGLRKAVYRTL RANFQAARLATLYMLKNYPLNSES  
 DNVTNYICVVPFKELGLGLSEEQISEEEAHNFTDGFSLPALKVLFQLWVAQSS  
 EFFRRLALLSTANSPPGPLLTPALLPHRILSDVTQGLPHAHSACLEELKRSYE  
 FYRYFETQHQSV PQCLSKTQQKSRELNNVHTAVRSLQLHLKALLNEVILEDE  
 LEKLVCTKETQELVSEAYPILEQKLKLIQPHVQASNNCWEEAISQVDKLLRRN  
 TDKKGKPEIACENPHCTVSTFEAAYSTHCRQRSNPRGAGIRSLCR (SEQ ID  
 NO: 242). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 7 - 23 of the amino acid sequence referenced in Table 1A for this gene. Moreover, a cytoplasmic tail encompassing amino acids 24 to 390 of this protein has also been determined. Based upon these characteristics, it is

believed that the protein product of this gene shares structural features to type Ib membrane proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in  
5 linkage analysis for chromosome 12.

This gene is expressed primarily in prostate and placenta and to a lesser extent in pancreatic tumors and hematopoietic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample  
10 and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancer; pancreatic cancer; prostate dysfunction; hematopoietic disorders; reproductive diseases and/or disorders, and pancreatitis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of  
15 disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, prostate, pancreas, placental, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, seminal fluid, plasma, urine, synovial fluid and spinal fluid) or  
20 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 152 as  
25 residues: Pro-85 to Ser-94, Pro-127 to Thr-136, Glu-154 to Glu-160, Phe-240 to Ser-250, Leu-255 to Leu-265, Leu-341 to Lys-351, Thr-372 to Gly-384. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in prostate and placental cells and tissues indicates that  
30 polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of reproductive disorders. Elevated expression of this gene product in the prostate indicates that it may be involved in normal

prostate function, and may be a diagnostic marker for prostate cancer. Alternately, expression of this gene product in placenta indicates that it may play a role in normal vascular function, and may be involved in such processes as angiogenesis and endothelial cell chemotaxis. Thus, this gene product may be useful in the treatment of myocardial infarction, cancer, ischemia, and diabetic retinopathy.

Expression of this gene product in placenta may also be indicative of fetal health and development. Similarly, expression of this gene product in hematopoietic cells indicates that it may be involved in the proliferation, differentiation, survival, or activation of all hematopoietic cell lineages. Finally, expression of this gene product in pancreatic cancers indicates that it may play a role in cancer in general, or in pancreatic function. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 50**

When tested against Jurkat and K562 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) and ISRE (interferon-sensitive responsive element ) promoter elements, respectively. Thus, it is likely that this gene activates myeloid, leukemia, and to a lesser extent, other immune or hematopoietic cells and tissue cell-types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. ISRE is also a promoter element found upstream in many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
AAPHPLLRPLCLWCPLWPAWPLRGRPSAWKRWPPPLPVGPAKLGCSMTTR  
QPTAVSWPCWLMSSSLSTACLAWTLTGSLAREATRRARSLSPWNC SARQV  
PPSPPHSGLGRRGWAHCHLT CLLVTQLFRVGRIHPILSLPLVT (SEQ ID NO:  
243). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides , or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by

the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in brain and placenta.

Polynucleotides and polypeptides of the invention are useful as reagents for  
5 differential identification of the tissue(s) or cell type(s) present in a biological sample  
and for diagnosis of diseases and conditions which include, but are not limited to,  
vascular diseases; aberrant angiogenesis; neurological disorders; learning disorders;  
placental insufficiency; and fetal distress. Similarly, polypeptides and antibodies  
directed to these polypeptides are useful in providing immunological probes for  
10 differential identification of the tissue(s) or cell type(s). For a number of disorders of  
the above tissues or cells, particularly of the vascular and neurological systems  
(CNS/PNS), expression of this gene at significantly higher or lower levels may be  
routinely detected in certain tissues or cell types (e.g., neural, reproductive, vascular,  
and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma,  
15 urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
individual having such a disorder, relative to the standard gene expression level, i.e.,  
the expression level in healthy tissue or bodily fluid from an individual not having the  
disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
20 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 153 as  
residues: Met-1 to Thr-7, Glu-36 to Ser-43, Pro-46 to Gly-63. Polynucleotides  
encoding said polypeptides are also encompassed by the invention. Antibodies that  
bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in brain and placental cells and tissues, combined with  
25 the detected GAS and ISRE biological activities, indicates that the protein products of  
this clone are useful for the diagnosis and/or treatment of a variety of neural,  
reproductive, and vascular diseases and/or disorders. neurodegenerative disease  
states, behavioral disorders, or inflammatory conditions. Representative uses are  
described in the "Regeneration" and "Hyperproliferative Disorders" sections below,  
30 in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not  
limited to the detection, treatment, and/or prevention of Alzheimer's Disease,  
Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis,



encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival.

Expression of this gene product in placenta indicates that it may play a role in blood vessel development or function, as the placenta is a highly vascularized organ. Thus, this gene product may be involved in such processes as angiogenesis, endothelial cell chemotaxis, and vascular cord formation. Thus, it may be useful in the treatment of such conditions as myocardial infarction; ischemia; and cancer.

Alternately, expression of this gene product in the brain indicates that it may play a role in the survival, proliferation, or function of neurons, and thus may be useful in the diagnosis and treatment of such neurological disorders as ALS, schizophrenia, and Alzheimer's disease. It may likewise be involved in learning disorders as well.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 51

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

LQLASQSAGIKGMSHCARPTFLTLLLASCFWAAIPNRNVILSVSFRPLHMQ

FTLSILVFILRILILRSFL (SEQ ID NO: 244). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 40 - 56 of the amino acid sequence referenced in Table 1A for this gene. Moreover, a cytoplasmic tail encompassing amino acids 57 to 60 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in spleen derived from patients with chronic lymphocytic leukemia.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chronic lymphocytic leukemia; hematopoietic disorders; impaired immune function; cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of hematopoietic disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Elevated expression of this protein in the spleens of patients with CLL indicates that it may be a useful marker for this disease.

Alternately, it may be associated with the development and/or progression of the disease, and may be a useful target for therapeutic intervention. Additionally, this gene product may play more general roles in hematopoiesis, and may serve to control cellular decisions regarding proliferation, survival, activation, and/or differentiation of all hematopoietic cell lineages. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 52

The translation product of this gene shares sequence homology with a putative protein tyrosine kinase from the Chilo iridescent virus. See, for example, Genbank accession no. gi|2738451 (AF003534). Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities

with tyrosine kinases and signaling proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed in a variety of tissues, including microvascular endothelial cells, dendritic cells, and fetal tissues, as well as several tumors.

5 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular, immune, and developmental diseases and/or disorders, particularly cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
10 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., vascular, immune, developmental, proliferative, and cancerous and wounded tissues) or bodily fluids  
15 (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively  
20 consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 155 as residues: Ala-21 to Lys-31, Arg-41 to Cys-56, Thr-92 to Cys-102, Arg-132 to Val-137, Lys-152 to Ile-159, Pro-199 to Ser-205, Arg-210 to Asp-219, Ser-225 to Lys-230, Tyr-236 to Ala-241, Lys-243 to Leu-249, Thr-375 to Asp-381. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that  
25 bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution and homology to a tyrosine kinase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and  
30 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved

in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for

5 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders,

10 such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful

15 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the protein is useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or

20 embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore,

25 the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

**FEATURES OF PROTEIN ENCODED BY GENE NO: 53**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 2 - 18 of the amino acid sequence referenced in Table 1A for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

The translation product of this gene shares some homology with IL-6DPB (a nuclear, leucine-zipper containing, transcriptional regulator protein involved in interleukin-6 signal transduction); see GenBank Accession GI:204918 (all references available through this accession are hereby incorporated herein by reference; for example Roll, V. et al., Cell 63, 643-653 (1990). Therefore, this gene product is expected to have at least some biological activities in common with transcriptional regulatory proteins.

This gene is expressed primarily in neutrophils.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly cancer and immune suppression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 156 as residues: Gly-63 to Ser-72. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful as a marker for neutrophil monitoring in cancer and/or immune suppressed patients and/or during chemotherapy or radiation therapy. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30

**FEATURES OF PROTEIN ENCODED BY GENE NO: 54**

This gene is expressed primarily in IL-1 and LPS induced neutrophils, and to a lesser extent, in fetal brain.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and neural diseases and/or disorders, particularly cancer and immune suppression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, neural, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 157 as residues: Ile-28 to Trp-37, Ser-68 to Lys-81. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful as a marker in neutrophils to monitor patients who are immune suppressed or cancer patients during chemotherapy or radiation therapy. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune



responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the protein product of this clone is useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## **25 FEATURES OF PROTEIN ENCODED BY GENE NO: 55**

This gene is expressed primarily in prostate.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, urogenital diseases and/or disorders, particularly prostate cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing

immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urogenital system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., urogenital, prostate, renal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 158 as residues: Arg-30 to Gln-36. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in prostate cancer cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for study, treatment and diagnosis of prostate cancer and other urogenital disorders. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and

conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as  
5 may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.  
10 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 56**

15

A preferred polypeptide of the invention comprises the following amino acid sequence:

MVLVLRHPLCARERAFREPGRGLLTRTGQHDGAPAVTAVPGPLGAVAAAEG  
RRSAWGAGGSSPPRKVLWGDMRGRAGVDVLGPALSSEAAGAEARGWGM

20

PGMGVGVGASETRGALFLGREGVHGPCPMDGLGPWPWGPW (SEQ ID NO:  
245). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by  
25 the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

30

This gene is expressed primarily in rejected kidney.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample

and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the kidney. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urinary tract, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., urogenital, renal, kidney, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 159 as residues: Ala-30 to Gly-36, Asp-45 to Trp-50, Lys-65 to Cys-71, Pro-80 to Cys-87. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in kidney indicates the protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. The protein is useful for modulating the immune response to aberrant proteins, as may exist in proliferating cells and tissues. Such modulation of the immune response would also show utility in inhibiting the rejection of transplanted tissues, particularly of the renal system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 57**

5           The translation product of this gene shares sequence homology with both human and mouse Fibulin polypeptides which are extracellular matrix proteins found in heart tissue (See Genbank Accession Nos. emb|CAA57876.1 and emb|CAA53040.1, respectively; all references available through these accessions are hereby incorporated herein by reference; for example, J. Cell Biol. 123 (5), 1269-10 1277 (1993)).

          Preferred polypeptides encoded by this clone comprise, or alternatively consists of, the following amino acid sequence:

MGPAVKMWTNAWKGLDDCHYNQLCENTPGGHRCS CPRGYRMQGPSLPCL  
DVNECLQLPKACAYQCHNLQGSYRCLCPPGQTLLRDGKACTSLERNQNV  
15 TVSHRGPLLPLRPWASIPGTSYHAWVSLRPGPMALSSVGRAWCPPGFIRQN  
GVCTDLDECRVRNLCQHACRNTEGSYQCLCPAGYRLLPSGKNCQDINECEE  
SIECGPGQMCFNTRGSYQCVDTPCPATYRQGPSPGTCFRRCSQDCGTGGPSTL  
QYRLLPLPLGVRAHHDVARLTAFSEVGVPANRTELSMLEPDPRSPFALRPLRA  
GLGAVYTRRALTRAGLYRLTVRAAAPRHQS FVLLIAVSPYPY (SEQ ID NO:  
20 246). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as; for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
25 encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

          A preferred polypeptide fragment of the invention comprises the following  
30 amino acid sequence:

MRVLVVTIAPIYWALARESGEALNGHSLTGGKFRQSHTWSLLQGAAHDDPV  
ARGLDPDGLLLLDVVVNGVVPGRAWLTQIFKCR TLKKHYVQTRAWPAVRG

LHTALLPGRPPLVPTLQPQHPVQRGPGPPAPAGAAPAGLSYQLGL (SEQ ID NO: 247). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

HASGAFLVVRGEPQGSWGSMTGVINGRKFGVATLNTSVMQEAHSGVSSIHSS  
 IRHVPANVGPLMRVLVVTIAPYIYWALARESGEALNGHSLTGGKFRQESHVEF  
 ATGELLTMTQWPGVWIPMASCSSWWSMALSPDSLADADLQVQDFEEHYV  
 QTGPGQLFVGSTQRFFQGGLPSFLRCNHSIQYNAARGPQPQLVQHRLRASAISS  
 AFDPEAEALRFQLATALQAEENEVGCPEGFELDSQGAFCVDVDECAWDAHL  
 CREGQRCVNLLGSYRCLPDCGPGFRVADGAGCEDVDECLEGLDDCHYNQLC  
 ENTPGGHRCSCPRGYRMQGPSLPCLDVNECLQLPKACAYQC  
 HNLQGSYRCLCPPGQTLLRDGKACTSLERNQNVTTVSHRGPLLWLRPWA  
 SIPGTSYHAWVSLRPGPMALSSVGRAWCPPGFIRQNGVCTDLDECRVRNLCQ  
 HACRNTEGSYQCLCPAGYRLLPSGKNCQDINECEEEESIECGPGQMCFNTRGS  
 YQCVDTPCPATYRQGSPGTCFRRCSQDCGTGGPSTLQYRLLPLPLGVRAHH  
 DVARLTAFFSEVGVPANRTELSMLEPDPRSPFALRPLRAGLGAVYTRRALTRA  
 GLYRLTVRAAAPRHQS FVLLIAVSPYPY (SEQ ID NO: 248). Polynucleotides encoding these polypeptides are also encompassed by the invention.

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene repeatedly activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid, T-cells, and to a lesser extent, other immune and hematopoietic cells and tissue cell types, through the

JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in kidney.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the kidney and renal system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the urinary tract, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., renal, urogenital, kidney, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 160 as residues: Lys-32 to Ser-37, His-89 to Gly-94, Asn-124 to Gln-130, Ala-163 to Val-168, Cys-196 to Arg-201, Gln-244 to Gln-264, His-288 to Tyr-294, Leu-314 to Gln-319, Ala-392 to Ser-399, Pro-412 to Asp-419, Ala-452 to Pro-460, Arg-466 to Thr-473. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in rejected kidney, the homology to the conserved Fibulin-2 protein, in addition to the detected GAS biological activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

diagnosis and treatment of disorders affecting kidneys, particularly proliferative disorders. Representative uses are described here and elsewhere herein.

The protein product of this clone could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 58**

Preferred polypeptides encoded by this gene comprise, or alternatively consist of, the following amino acid sequence:

20 MG EK FLL LAM KEN HPE C FCK IL KIL H C MDP GE WLP QTE HCV HLT PKE FLI WT  
MD IAS NER SEI QS VAL RL ASK VISH HM QT C VEN REL IAA ELK QWV QLV LS CE  
DHL PTE SRL AV VE VLT STT PL FL TN PHP ILE LQD TL AL WK CV LT LL QSEE QAV  
RDA AT ET VTT AMS QENT CQ STE FA FC QVD ASIAL AL ALA VL CD LL QQ WD QL  
AP GL PILL GW LL G

25 ESDDL VAC VES MHQ VEED YL FEK AEV NFWA ET LIF VKYL CKHL FCLLS KSG  
WRPP SPE ML CHL QRM VSE QCHLL SQFF REL PPA AEF VKT VEF TRL RIQE ERTL  
ACL RLL AFLE GK EGED TL VLS VWDSY AES RQL TLP RTE AAC (SEQ ID NO:

249). Polynucleotides encoding such polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide

30





WRPPSPEMLCHLQRMVSEQCHLLSQFFRELPPAAEFVKTVEFTRLRIQEERTL  
ACLRLLAFLEGKEGEDTLVLSVWDSYAESRQLTLPRTEAAC (SEQ ID NO:

251). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for  
5 example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by  
10 the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 144 - 160, and 462 - 478 of the amino acid sequence referenced in Table 1A for this gene. Based upon these characteristics, it is  
15 believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

Included in this invention as a preferred domain is the formate and nitrite transporters domain, which was identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). A number of bacterial and archaeobacterial proteins  
20 involved in transporting formate or nitrite have been shown [1] to be related: - *focA* and *focB*, from *Escherichia coli*, transporters involved in the bidirectional transport of formate. - *fdhC*, from *Methanobacterium formicicum* and *thermoformicum*, a probable formate transporter. - *nirC*, from *Escherichia coli* and *Salmonella typhimurium*, a probable nitrite transporter. - *Bacillus subtilis* hypothetical protein  
25 *yrhG*. - *Bacillus subtilis* hypothetical protein *ywcJ* (*ipa-48R*). These transporters are proteins of about 280 residues and seem to contain six transmembrane regions. As signature patterns, we selected two conserved regions. The first one is located in what seems to be a cytoplasmic loop between the second and third transmembrane domains; the second is part of the fourth transmembrane region. The 70 Kd yeast  
30 hypothetical protein YHL008c is highly similar, in its N-terminal section, to the prokaryotic members of this family. The consensus pattern is as follows: [LIVMA]-[LIVMY]-x-G-[GSTA]-[DES]-L-[FI]-[TN]-[GS].

Preferred polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence: IISGSELITG (SEQ ID NO: 252).

Polynucleotides encoding these polypeptides are also encompassed by the invention.

Moreover, fragments and variants of these polypeptides (such as, for example,

5 fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by  
10 the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Further preferred are polypeptides comprising the formate and nitrite transporter domain of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this  
15 referenced sequence. The additional contiguous amino acid residues may be N-terminal or C-terminal to the formate and nitrite transporter domain. Alternatively, the additional contiguous amino acid residues may be both N-terminal and C-terminal to the formate and nitrite transporter domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred  
20 polypeptide domain is characteristic of a signature specific to formate and nitrite transporter proteins. Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with formate and nitrite transporter proteins. Such activities are known in the art, some of which are described elsewhere herein.

25 It is believed that this gene maps to chromosome 2. Accordingly, polynucleotides derived from this clone are useful in linkage analysis as markers for chromosome 2.

This gene is expressed primarily in cells of the immune system, primarily T-cells and to a lesser extent in spleen, liver, thymus, tonsils, and testis.

30 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,

immune and hematopoietic diseases and/or disorders, particularly disorders affecting hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of hematopoietic cells, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 161 as residues: Gly-2 to Pro-8, Ser-82 to His-92, Tyr-107 to Asp-117, Arg-162 to Pro-169, Ser-224 to Thr-229, Leu-310 to His-315, Ser-333 to Glu-338, Glu-381 to Ser-388, Gln-428 to Ala-433, Met-446 to Thr-455, Ser-548 to Ser-554, Gly-613 to Asp-618, Ser-627 to Gln-633. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in immune cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting hematopoiesis, including cancers. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia,

rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as

5 autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful

10 in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

15 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 59

This gene is expressed primarily in bone marrow, CD34 positive cells, and

20 immune cells, including, neutrophils, T-cells, B-cells, macrophages, monocytes, and dendritic cells and to a lesser extent in brain and tonsils.

In one embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention may comprise, or

25 alternatively consist of the following amino acid sequence:

VDGIDKLDIEFLQQFLETHSRGPRHLHSPGHASQEATPGANMSSGTELLWPGAA  
LLVLLGVAASLCVRCSRPGAKRSEKIYQQRSLREDQQSFTGSRTYSLVGQAW  
PGPLADMAPTRKDKLLQFYPSLEDPASSRYQNFSKGSRHGSEEAYIDPIAMEY  
YNWGRFSKPPEDDDANSYENVLICKQKTTETGAQQEGIGGLCRGDLSSLAL

30 KTGPTSGLCPSASPEEDEGI (SEQ ID NO: 253). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein,

polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind

5 polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments may comprise or alternatively consist of one, two, three, four or more of the following amino acid sequence:

ASSRYQNFSKGSRHGSEEAYIDPIA (SEQ ID NO:413),

10 MEYYNWGRFSKPPEDDDANSY (SEQ ID NO: 414),

ENVLICKQKTTETGAQQEGIGGLCRGD (SEQ ID NO: 415), VRCSR

PGAKRSEKIYQQRSLREDQQSFTGSRTYSLVGQAWPGPLADMAPTRKDKLLQ

FYPSLEDPASS (SEQ ID NO: 416) and LSLSLALKTGPTSGLCPSASPEEDEGI

(SEQ ID NO: 417). Polynucleotides encoding these polypeptide fragments (SEQ ID

15 NOS: 413, 414, 415, 416, and/or 417), polynucleotides that hybridize to the complementary strand of these polynucleotides (e.g., under the hybridization conditions described herein) are encompassed by the invention, as are the polypeptides encoded by these hybridizing polynucleotides. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described

20 herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the

25 invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptides of the present invention comprise, or alternatively consist of one, two, three, four, five, or more of the immunogenic epitopes shown in SEQ ID NO: 162 as residues: Ser-29 to Thr-57, Pro-74 to Lys-79, Pro-85 to Glu-107,

30 Tyr-118 to Tyr-136, Gln-144 to Gln-152, Ala-182 to Glu-188. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also preferred are polypeptides comprising the mature polypeptide which is predicted to consist of residues 26-190 of the foregoing sequence (SEQ ID NO:162), and biologically active fragments of the mature polypeptide (e.g., fragments that stimulate the proliferation of bone marrow CD34+ cells).

5        Figures 3A-B show the nucleotide (SEQ ID NO:69) and deduced amino acid sequence (SEQ ID NO:162) of this polypeptide.

Figure 4 shows an analysis of the amino acid sequence (SEQ ID NO:162). Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown, and all  
10        were generated using the default settings. In the "Antigenic Index or Jameson-Wolf" graph, the positive peaks indicate locations of the highly antigenic regions of the protein, i.e., regions from which epitope-bearing peptides of the invention can be obtained. The domains defined by these graphs are contemplated by the present invention.

15        The data presented in Figure 4 are also represented in tabular form in Table 7. The columns are labeled with the headings "Res", "Position", and Roman Numerals I-XIV. The column headings refer to the following features of the amino acid sequence presented in Figure 4, and Table 7: "Res": amino acid residue of SEQ ID NO:162 and Figures 3A and 3B; "Position": position of the corresponding residue  
20        within SEQ ID NO:162 and Figures 3A and 3B; I: Alpha, Regions - Garnier-Robson; II: Alpha, Regions - Chou-Fasman; III: Beta, Regions - Garnier-Robson; IV: Beta, Regions - Chou-Fasman; V: Turn, Regions - Garnier-Robson; VI: Turn, Regions - Chou-Fasman; VII: Coil, Regions - Garnier-Robson; VIII: Hydrophilicity Plot - Kyte-Doolittle; IX: Hydrophobicity Plot - Hopp-Woods; X: Alpha, Amphipathic  
25        Regions - Eisenberg; XI: Beta, Amphipathic Regions - Eisenberg; XII: Flexible Regions - Karplus-Schulz; XIII: Antigenic Index - Jameson-Wolf; and XIV: Surface Probability Plot - Emini.

Preferred embodiments of the invention in this regard include fragments that comprise alpha-helix and alpha-helix forming regions ("alpha-regions"), beta-sheet  
30        and beta-sheet forming regions ("beta-regions"), turn and turn-forming regions ("turn-regions"), coil and coil-forming regions ("coil-regions"), hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible

regions, surface-forming regions and high antigenic index regions. The data representing the structural or functional attributes of the protein set forth in Figure 4 and/or Table 7, as described above, was generated using the various modules and algorithms of the DNA\*STAR set on default parameters. In a preferred embodiment, the data presented in columns VIII, IX, XIII, and XIV of Table 7 can be used to determine regions of the protein which exhibit a high degree of potential for antigenicity. Regions of high antigenicity are determined from the data presented in columns VIII, IX, XIII, and/or XIV by choosing values which represent regions of the polypeptide which are likely to be exposed on the surface of the polypeptide in an environment in which antigen recognition may occur in the process of initiation of an immune response.

Certain preferred regions in these regards are set out in Figure 4, but may, as shown in Table 7, be represented or identified by using tabular representations of the data presented in Figure 4. The DNA\*STAR computer algorithm used to generate Figure 2 (set on the original default parameters) was used to present the data in Figure 4 in a tabular format (See Table 7). The tabular format of the data in Figure 4 is used to easily determine specific boundaries of a preferred region. The above-mentioned preferred regions set out in Figure 4 and in Table 7 include, but are not limited to, regions of the aforementioned types identified by analysis of the amino acid sequence set out in Figures 3A-B (SEQ ID NO:162). As set out in Figure 4 and in Table 7, such preferred regions include Garnier-Robson alpha-regions, beta-regions, turn-regions, and coil-regions, Chou-Fasman alpha-regions, beta-regions, and turn-regions, Kyte-Doolittle hydrophilic regions and Hopp-Woods hydrophobic regions, Eisenberg alpha- and beta-amphipathic regions, Karplus-Schulz flexible regions, Jameson-Wolf regions of high antigenic index and Emini surface-forming regions.

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated DNA molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in SEQ ID NO:69 is intended DNA fragments at least about 15nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50-1500 nt in length are also



useful according to the present invention, as are fragments corresponding to most, if not all, of the nucleotide sequence of the deposited cDNA or as shown in SEQ ID NO:69. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:69. In this context "about" includes the particularly recited size, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Representative examples of polynucleotide fragments of the invention include, for example, fragments that comprise, or alternatively, consist of, a sequence from about nucleotide 1 to about 50, from about 51 to about 100, from about 101 to about 150, from about 151 to about 200, from about 201 to about 250, from about 251 to about 300, from about 301 to about 350, from about 351 to about 400, from about 401 to about 450, from about 451 to about 500, and from about 501 to about 550, and from about 551 to about 600, and from about 601 to about 650, and from about 651 to about 700, and from about 701 to about 750, and from about 751 to about 800, and from about 801 to about 850, and from about 851 to about 900, and from about 901 to about 950, and from about 951 to about 1000, and from about 1001 to about 1050, and from about 1051 to about 1100, and from about 1101 to about 1150, and from about 1151 to about 1200, and from about 1201 to about 1250, and from about 1251 to about 1300, and from about 1301 to about 1350, and from about 1351 to about 1400, and from about 1401 to about 1450, and from about 1451 to about 1500, and from about 1501 to about 1551, and from about 1551 to about 1600, and from about 1601 to about 1650, and from about 1651 to about 1700, and from about 1701 to about 1750, and from about 1751 to about 1797 of SEQ ID NO:69, or the complementary strand thereto, or the cDNA contained in the deposited gene. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. In additional embodiments, the polynucleotides of the invention encode functional attributes of the corresponding protein.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the

carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

5 Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide

10 demonstrating a "functional activity" is meant to be a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) or mature-form of the protein. Such functional activities include, but are not limited to, biological activity (e.g., ability to regulate (e.g., stimulate) hematopoiesis *in vitro* or *in vivo*), antigenicity, and immunogenicity. The functional

15 activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods described herein.

In addition, assays described herein and otherwise known in the art may routinely be applied to measure biological activity of polypeptides and fragments of the invention, variants derivatives and analogs thereof (e.g., to regulate (e.g., to

20 stimulate or inhibit) hematopoiesis *in vitro* or *in vivo*). For example, techniques known in the art (such as for example assaying for thymidine incorporation), may be applied or routinely modified to assay for the ability of the compositions of the invention to inhibit proliferation of hematopoietic cells. Other methods will be known to the skilled artisan and are within the scope of the invention.

25 Even if deletion of one or more amino acids from the N-terminus of a protein results in modification or loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, etc.) may still be retained. For example, the ability of shortened muteins to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptides

30 generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete polypeptide retains such

immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that a mutein with a large number of deleted N-terminal amino acid residues may retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid  
5 residues may often evoke an immune response.

Accordingly, the present invention further provides polypeptides having one or more residues deleted from the amino terminus of the amino acid sequence shown in Figure 3A-B (i.e., SEQ ID NO:69), up to the Glu residue at position number 185 and polynucleotides encoding such polypeptides.

10 Particularly, N-terminal deletions of the polypeptide can be described by the general formula m-190, where m is an integer from 2 to 184, where m corresponds to the position of the amino acid residue identified in SEQ ID NO:162. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: V-26  
15 to I-190; R-27 to I-190; C-28 to I-190; S-29 to I-190; R-30 to I-190; P-31 to I-190; G-32 to I-190; A-33 to I-190; K-34 to I-190; R-35 to I-190; S-36 to I-190; E-37 to I-190; K-38 to I-190; I-39 to I-190; Y-40 to I-190; Q-41 to I-190; Q-42 to I-190; R-43 to I-190; S-44 to I-190; L-45 to I-190; R-46 to I-190; E-47 to I-190; D-48 to I-190; Q-49 to I-190; Q-50 to I-190; S-51 to I-190; F-52 to I-190; T-53 to I-190; G-54 to I-190; S-  
20 55 to I-190; R-56 to I-190; T-57 to I-190; Y-58 to I-190; S-59 to I-190; L-60 to I-190; V-61 to I-190; G-62 to I-190; Q-63 to I-190; A-64 to I-190; W-65 to I-190; P-66 to I-190; G-67 to I-190; P-68 to I-190; L-69 to I-190; A-70 to I-190; D-71 to I-190; M-72 to I-190; A-73 to I-190; P-74 to I-190; T-75 to I-190; R-76 to I-190; K-77 to I-190; D-78 to I-190; K-79 to I-190; L-80 to I-190; L-81 to I-190; Q-82 to I-190; F-83 to I-  
25 190; Y-84 to I-190; P-85 to I-190; S-86 to I-190; L-87 to I-190; E-88 to I-190; D-89 to I-190; P-90 to I-190; A-91 to I-190; S-92 to I-190; S-93 to I-190; R-94 to I-190; Y-95 to I-190; Q-96 to I-190; N-97 to I-190; F-98 to I-190; S-99 to I-190; K-100 to I-190; G-101 to I-190; S-102 to I-190; R-103 to I-190; H-104 to I-190; G-105 to I-190; S-106 to I-190; E-107 to I-190; E-108 to I-190; A-109 to I-190; Y-110 to I-190; I-111  
30 to I-190; D-112 to I-190; P-113 to I-190; I-114 to I-190; A-115 to I-190; M-116 to I-190; E-117 to I-190; Y-118 to I-190; Y-119 to I-190; N-120 to I-190; W-121 to I-190; G-122 to I-190; R-123 to I-190; F-124 to I-190; S-125 to I-190; K-126 to I-190; P-

127 to I-190; P-128 to I-190; E-129 to I-190; D-130 to I-190; D-131 to I-190; D-132 to I-190; A-133 to I-190; N-134 to I-190; S-135 to I-190; Y-136 to I-190; E-137 to I-190; N-138 to I-190; V-139 to I-190; L-140 to I-190; I-141 to I-190; C-142 to I-190; K-143 to I-190; Q-144 to I-190; K-145 to I-190; T-146 to I-190; T-147 to I-190; E-148 to I-190; T-149 to I-190; G-150 to I-190; A-151 to I-190; Q-152 to I-190; Q-153 to I-190; E-154 to I-190; G-155 to I-190; I-156 to I-190; G-157 to I-190; G-158 to I-190; L-159 to I-190; C-160 to I-190; R-161 to I-190; G-162 to I-190; D-163 to I-190; L-164 to I-190; S-165 to I-190; L-166 to I-190; S-167 to I-190; L-168 to I-190; A-169 to I-190; L-170 to I-190; K-171 to I-190; T-172 to I-190; G-173 to I-190; P-174 to I-190; T-175 to I-190; S-176 to I-190; G-177 to I-190; L-178 to I-190; C-179 to I-190; P-180 to I-190; S-181 to I-190; A-182 to I-190; S-183 to I-190; P-184 to I-190; and E-185 to I-190, of SEQ ID NO:162. Polypeptides encoding these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also as mentioned above, even if deletion of one or more amino acids from the C-terminus of a protein results in modification of loss of one or more biological functions of the protein, other functional activities (e.g., biological activities, ability to multimerize, ability to bind ligand) may still be retained. For example the ability of the shortened mutein to induce and/or bind to antibodies which recognize the complete or mature forms of the polypeptide generally will be retained when less than the majority of the residues of the complete or mature polypeptide are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete polypeptide retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art. It is not unlikely that an mutein with a large number of deleted C-terminal amino acid residues may

retain some biological or immunogenic activities. In fact, peptides composed of as few as six amino acid residues may often evoke an immune response.

Accordingly, the present invention further provides polypeptides having one or more residues deleted from the carboxy terminus of the amino acid sequence of the polypeptide shown in Figure 3A-B (SEQ ID NO:162), as described by the general formula 1-n, where n is an integer from 6 to 184 where n corresponds to the position of amino acid residue identified in SEQ ID NO:162. More in particular, the invention provides polynucleotides encoding polypeptides comprising, or alternatively consisting of, an amino acid sequence selected from the group: V-26 to G-189; V-26 to E-188; V-26 to D-187; V-26 to E-186; V-26 to E-185; V-26 to P-184; V-26 to S-183; V-26 to A-182; V-26 to S-181; V-26 to P-180; V-26 to C-179; V-26 to L-178; V-26 to G-177; V-26 to S-176; V-26 to T-175; V-26 to P-174; V-26 to G-173; V-26 to T-172; V-26 to K-171; V-26 to L-170; V-26 to A-169; V-26 to L-168; V-26 to S-167; V-26 to L-166; V-26 to S-165; V-26 to L-164; V-26 to D-163; V-26 to G-162; V-26 to R-161; V-26 to C-160; V-26 to L-159; V-26 to G-158; V-26 to G-157; V-26 to I-156; V-26 to G-155; V-26 to E-154; V-26 to Q-153; V-26 to Q-152; V-26 to A-151; V-26 to G-150; V-26 to T-149; V-26 to E-148; V-26 to T-147; V-26 to T-146; V-26 to K-145; V-26 to Q-144; V-26 to K-143; V-26 to C-142; V-26 to I-141; V-26 to L-140; V-26 to V-139; V-26 to N-138; V-26 to E-137; V-26 to Y-136; V-26 to S-135; V-26 to N-134; V-26 to A-133; V-26 to D-132; V-26 to D-131; V-26 to D-130; V-26 to E-129; V-26 to P-128; V-26 to P-127; V-26 to K-126; V-26 to S-125; V-26 to F-124; V-26 to R-123; V-26 to G-122; V-26 to W-121; V-26 to N-120; V-26 to Y-119; V-26 to Y-118; V-26 to E-117; V-26 to M-116; V-26 to A-115; V-26 to I-114; V-26 to P-113; V-26 to D-112; V-26 to I-111; V-26 to Y-110; V-26 to A-109; V-26 to E-108; V-26 to E-107; V-26 to S-106; V-26 to G-105; V-26 to H-104; V-26 to R-103; V-26 to S-102; V-26 to G-101; V-26 to K-100; V-26 to S-99; V-26 to F-98; V-26 to N-97; V-26 to Q-96; V-26 to Y-95; V-26 to R-94; V-26 to S-93; V-26 to S-92; V-26 to A-91; V-26 to P-90; V-26 to D-89; V-26 to E-88; V-26 to L-87; V-26 to S-86; V-26 to P-85; V-26 to Y-84; V-26 to F-83; V-26 to Q-82; V-26 to L-81; V-26 to L-80; V-26 to K-79; V-26 to D-78; V-26 to K-77; V-26 to R-76; V-26 to T-75; V-26 to P-74; V-26 to A-73; V-26 to M-72; V-26 to D-71; V-26 to A-70; V-26 to L-69; V-26 to P-68; V-26 to G-67; V-26 to P-66; V-26 to W-65; V-26 to A-64; V-26 to Q-63;

V-26 to G-62; V-26 to V-61; V-26 to L-60; V-26 to S-59; V-26 to Y-58; V-26 to T-57; V-26 to R-56; V-26 to S-55; V-26 to G-54; V-26 to T-53; V-26 to F-52; V-26 to S-51; V-26 to Q-50; V-26 to Q-49; V-26 to D-48; V-26 to E-47; V-26 to R-46; V-26 to L-45; V-26 to S-44; V-26 to R-43; V-26 to Q-42; V-26 to Q-41; V-26 to Y-40; V-26 to I-39; V-26 to K-38; V-26 to E-37; V-26 to S-36; V-26 to R-35; V-26 to K-34; V-26 to A-33; V-26 to G-32; and V-26 to P-31 of SEQ ID NO:162. Polypeptides encoding these polynucleotides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In addition, any of the above listed N- or C-terminal deletions can be combined to produce a N- and C-terminal deleted polypeptide. The invention also provides polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues m-n of SEQ ID NO:162, where n and m are integers as described above. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Also included are a nucleotide sequence encoding a polypeptide consisting of a portion of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209889, where this portion excludes any integer of amino acid residues from 1 to about 184 amino acids from the amino terminus of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209889, or any integer of amino acid residues from 1 to about 190 amino acids from the carboxy terminus, or any combination of the above amino terminal and carboxy terminal deletions, of the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 209889. Polynucleotides encoding all of the above deletion mutant polypeptide forms also are provided.

The present application is also directed to proteins containing polypeptides at

least 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide sequence set forth herein m-n. In preferred embodiments, the application is directed to proteins containing polypeptides at least 90%, 95%, 96%, 97%, 98% or 99% identical to polypeptides having the amino acid sequence of the specific N- and C-terminal deletions recited herein. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the immune and hematopoietic systems, particularly hematopoiesis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

This gene has been found to stimulate the proliferation of bone marrow CD34+ cells. This assay which is described in Example 53 herein is based on the ability of human CD34+ to proliferate in presence of hematopoietic growth factors and evaluates the ability of the polypeptides of the invention, and agonists and antagonists thereof, to stimulate or inhibit this proliferation.

The tissue distribution in immune and hematopoietic cells and tissues and the ability to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the

proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Moreover, the protein represents a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be  
5 useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The polynucleotides and/or polypeptides of the invention and/or agonists and/or antagonists thereof, can also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone  
10 marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

The polynucleotides and/or polypeptides of the invention and/or agonists and/or antagonists thereof, may also be employed for the expansion of immature  
15 hematopoietic progenitor cells, for example, granulocytes, macrophages or monocytes, by temporarily preventing their differentiation. These bone marrow cells may be cultured *in vitro*. Thus, polynucleotides and/or polypeptides of the invention, or agonists or antagonists thereof, may be useful as a modulator of hematopoietic stem cells *in vitro* for the purpose of bone marrow transplantation and/or gene  
20 therapy. Since stem cells are rare and are most useful for introducing genes into for gene therapy, polynucleotides and/or polypeptides of the invention can be used to isolate enriched populations of stem cells. Stem cells can be enriched by culturing cells in the presence of cytotoxins, such as 5-Fu, which kills rapidly dividing cells, where as the stem cells will be protected by polynucleotides and/or polypeptides of  
25 the invention. These stem cells can be returned to a bone marrow transplant patient or can then be used for transfection of the desired gene for gene therapy. In addition, this gene can be injected into animals which results in the release of stem cells from the bone marrow of the animal into the peripheral blood. These stem cells can be isolated for the purpose of autologous bone marrow transplantation or manipulation for gene  
30 therapy. After the patient has finished chemotherapy or radiation treatment, the isolated stem cells can be returned to the patient.



Polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

This gene product may also be involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma.

This gene may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/ immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for

regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Based upon the proteins immune cell specific message distribution, it may be involved in many aspects of the immune response, especially its initial stages, inflammation, allograft rejection, infectious disease response etc. It is frequently found in the hematopoietic cell cDNA libraries. Thus, this factor could be involved in the control of hematopoietic cell proliferation, differentiation, and function. Based on this one can postulate its use in the management of anemias, leukemias, neutropenia, thrombocytopenia, autoimmune diseases, blood tissue engraftment, and poikilothromerythromatosis. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 60

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
VLWREASALVLSNRLSSGLLHDLQLPAIHSRLFPRRSRGLSEGEGSSVSLQRS  
RVLSA  
MKHVLNLYLLGVVLTLLSIFVRVMESLEGLLESPPGTSWTTRSQLANTEPTK  
GLPDHPSRSM (SEQ ID NO: 259). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement

there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in immune cells including activated T cells,  
5 macrophages, jurkat cells, bone marrow cells, and osteoblasts and to a lesser extent in kidney cortex, brain, placenta and lung.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,  
10 immune and hematopoietic diseases and/or disorders, particularly inflammation and diseases related to inflammatory activity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene  
15 at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or  
20 bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 163 as residues: Pro-34 to Met-63. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other  
25 polypeptides of the invention are also encompassed.

The tissue distribution in immune cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing disease related to the normal or abnormal activation of T cells. Representative uses are described in the "Immune Activity" and "Infectious Disease"  
30 sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell

lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 61

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

YTFHTQIFLDFPMIFLTVLPLAFLFLHSGFYHYISFSLFSLALFFFLDVATFR  
RPGQLFCERSVLFD MFHFGFVSLFLEHWIQAKHFWAGLFIVLPDVFVSVHHL

EAPDGSFPNIAKLSLILLR (SEQ ID NO: 260). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 2 - 18 and 22 - 38 of the amino acid sequence referenced in Table 1A for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

This gene is expressed in many tissues including brain, liver, prostate, testes, cartilage, gall bladder. Expression is also seen in a number of tumors including colon carcinoma, pancreas tumor, osteoclastoma, ovarian cancer, B cell lymphoma and acute lymphocytic leukemias.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors of various organs including the pancreas, colon, and bone. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the major organs, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, hepatic, metabolic, reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors and proliferative tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating or diagnosing tumors of several major organs including the pancreas and large intestine. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 62**

This gene is expressed primarily in dendritic cells and fetal liver/spleen and to a lesser extent in many tissues including tonsils, fetal lung, stromal cell lines, bone marrow cell lines, placenta and tumors including hepatocellular carcinoma, pancreas tumor and osteosarcoma.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders of the immune and hematopoietic system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in dendritic cells and fetal liver/spleen indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders of the immune system particularly related to the control and generation of precursor cells. The protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed

progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 63**

10

This gene is expressed primarily in adrenal gland tumor and endothelial cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and vascular diseases and/or disorders, particularly diseases associated with the vascular endothelium. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the vascular system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., endocrine, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25

The tissue distribution in endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders that involve the vascular system including diseases such as atherosclerosis, neoangiogenesis associated with tumor growth and conditions associated with inflammation. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke,

30



embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, the protein is useful in the treatment, detection, and/or prevention of metabolic disorders, particularly lethargy and depression. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as  
5 tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 64**

The translation product of this gene is related to bovine PAM precursor. See Genbank record gi|163482 incorporated herein by reference. Moreover, see following  
15 patent publications are also incorporated herein by reference: J04311386 and WO8902460. Many bioactive peptides terminate with an amino acid alpha-amide at their COOH terminus. The enzyme responsible for this essential posttranslational modification is known as peptidyl-glycine alpha-amidating monooxygenase or PAM. An NH<sub>2</sub>-terminal signal sequence and short propeptide precede the NH<sub>2</sub> terminus of  
20 purified PAM. The sequences of several PAM cyanogen bromide peptides were localized in the NH<sub>2</sub>-terminal half of the predicted protein. The forms of PAM purified from bovine neurointermediate pituitary may be generated by endoproteolytic cleavage at a subset of the 10 pairs of basic amino acids in the precursor. High levels of PAM mRNA have been found in bovine pituitary and  
25 cerebral cortex. In corticotropic tumor cells, levels of PAM mRNA and pro-ACTH/endorphin mRNA are known to be regulated in parallel by glucocorticoids and CRF.

This gene is expressed primarily in endometrial tumors, dendritic cells, a multiple sclerosis library, kidney, hematopoietic cells, melanocytes, osteoblasts, the  
30 spleen, colon, ovary, stromal cells, fetal and adult brain, heart, and in tissues undergoing wound repair.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometriosis, endometrial cancer, multiple sclerosis, hematopoietic diseases, bone disease, and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly the hematopoietic system and female reproduction, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., reproductive, immune, hematopoietic, integumentary, skeletal, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in dendritic and hematopoietic cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic or diagnostic agent in diseases of hematopoietic origin as well as the female reproductive track due to the gene's primary pattern of expression. The protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The protein may also have a very wide range of biological activities. Representative uses are described in

the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 65

20

The translation product of this gene shares sequence similarity with several G-protein coupled receptors (See Genbank Accession No. gb|AAC77910.1| (AF061443); all references available through this accession are hereby incorporated herein by reference; for example, Mol. Endocrinol. 12, 1830-1845 (1998)). G-protein coupled receptors are well known in the art and affect a variety of functions. In particular, the translation product of this gene shares similarity with Follicular Stimulating Hormone Receptor.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

30 GTRFPTGETPSLGFTVTLVLLNSLAFLLMAYITKLYCNLEKEDLSENSQSSMI  
KHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFP (SEQ ID NO:  
261). Polynucleotides encoding such polypeptides are also encompassed by the


invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide  
5 encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptides of the invention comprise, or  
10 alternatively consists of, the following amino acid sequence:  
MIKHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFPCLLA (SEQ ID NO: 262). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%,  
15 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by  
20 the invention.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
25 GTRFPTGETPSLGFTVTLVLLNSLAFLLMAYITKLYCNLEKEDLSENSQSSMI  
KHVAWLIFTNCIFFCPVAFFSFAPLITAISISPEIMKSVTLIFFPLPACLNPNVLYVF  
FNPFKEDWKLLKRRVTKKSGSVSVSISSQGGCLEQDFYYDCGMYSHLQGN  
LTVCDCCESFLLTKPVSCKHLIKSHSCPALAVASCQRPEGYWSDCGTQSAHS  
DYADEEDSFVSDSSDQVQACGRACFYQSRGFPLVRYAYNLPRVKD (SEQ ID  
30 NO: 263). Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 43 - 59 of the amino acid sequence referenced in Table 1A for this gene. Moreover, a cytoplasmic tail encompassing amino acids 60 to 207 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

Included in this invention as preferred domains are Zinc finger, C2H2 type domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). 'Zinc finger' domains [1-5] are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:



Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc- dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains may be present. In addition to the conserved zinc ligand residues it has been shown that a number of other positions are also important for the structural integrity of the C2H2 zinc fingers. The best conserved position is found four residues after the second cysteine; it is generally an aromatic or aliphatic residue. The consensus pattern is as follows: C-x(2,4)-C-x(3)-[LIVMFYWC]-x(8)-H-x(3,5)-H. Preferred polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence: CDCCESFLLTKPVSCCKHLIKSH (SEQ ID NO: 264). Polynucleotides encoding these polypeptides are also encompassed by the invention. Further preferred are polypeptides comprising the Zinc finger, C2H2 type domain of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues may be N-terminal or C- terminal to the Zinc finger, C2H2 type domain. Alternatively, the additional contiguous amino acid residues may be both N-terminal and C-terminal to the Zinc finger, C2H2 type domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to zinc finger proteins. Based on the sequence similarity, the translation product of this clone is expected to share at least some biological activities with G-coupled proteins, their receptors, and zinc finger proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in adult and fetal liver, human placenta, colon carcinoma cell lines and fibroblasts and to a lesser extent in the fetal and adult brain, the developing nervous system, lung, pancreas, salivary gland, breast tissue, and dendritic cells.

5 Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the liver, developmental abnormalities, neurologic diseases, lung cancer, pancreatic cancer, and colon cancer. Similarly, polypeptides and antibodies directed  
10 to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurological and hepatic origin, as well as the proliferation and/or differentiation of numerous types of tissues. expression of this gene at significantly higher or lower levels may be routinely detected in certain  
15 tissues or cell types (e.g., hepatic, immune, hematopoietic, neural, gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
20 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 168 as residues: Pro-62 to Asp-67, Arg-74 to Gly-80, Gln-146 to Glu-168. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that  
25 bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for a diagnostic marker or therapeutic in a wide variety of disease states. The protein product of this clone is useful for the treatment and diagnosis of hematopoietic related disorders such as  
30 anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in

Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Alternatively, the protein expression in placental and brain tissue indicates the protein is useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons.

Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. The protein is useful in the treatment, detection, and/or prevention of bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 66**



In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention.

- 5 In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

ALENSGSPGLQDSARAHFNXSLRSFSFLRNQMYIFELSLYLEGTSFVVVLLFLL  
ISVSLDSPPTTKGWDS VLHIWVPLIVQ (SEQ ID NO: 265). Polynucleotides

- encoding these polypeptides are also encompassed by the invention. Moreover,  
10 fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention.  
15 Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

- This gene is expressed primarily in placenta and in hematopoietic cells, especially those of T-cell and monocyte origin and to a lesser extent in the brain,  
20 endothelial cells, and the lungs.

- Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic, vascular, and developmental diseases and/or disorders. Similarly,  
25 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., vascular, immune, hematopoietic, and  
30 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 169 as  
5 residues: Ser-30 to Trp-37. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in hematopoietic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for therapeutic and/or  
10 diagnostic intervention in hematopoietic and developmental disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia. The gene product may also  
15 be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the protein is useful in the detection, treatment,  
20 and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling  
25 the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional  
30 supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 67**

5 This gene is expressed primarily in the prostate and to a lesser extent in human B-cell lymphomas.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancer and diseases of hematopoietic origin, particularly of B-cells.

10 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the prostate and immune systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., prostate, 15 reproductive, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 170 as residues: Asp-33 to Lys-42. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

25 The tissue distribution in prostate tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic or diagnostic marker for prostate cancer and disorders involving hematopoietic cells, especially those of B-cell origin. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular 30 division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"

and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation. Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and would be useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The protein is useful in modulating the immune response to aberrant proteins and polypeptides, as may exist in rapidly proliferating cells and tissues. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 68**

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of

many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

GHESICGSCRSWIYFSIRCRRMRPWWSLLLEACATCAQTGPTRSTSCTQEVS  
HSSSTAYPAPMRRRCCLPSRSCT (SEQ ID NO: 266). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in the brain and the developing embryo and to a lesser extent in the heart, colon, adipose tissue, kidney, mammary tissue, activated T-cells and dendritic cells.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, developmental conditions, colon cancer, and hematopoietic diseases, especially of T-cell origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above

tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., neural, developmental, cardiovascular, adipose, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 171 as residues: Thr-18 to Cys-26, Glu-29 to Thr-36, Ser-50 to Thr-55. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in brain, combined with the detected GAS biological activity, indicates that polynucleotides and polypeptides corresponding to this gene are useful for therapeutic and/or diagnostic agents in neurological diseases, developmental abnormalities, colon cancer, and hematopoietic diseases, especially those of T-cell origin. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or

receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 69

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 2 - 18 of the amino acid sequence referenced in Table 1A for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:  
K R A G V E V G G L V M A L A G S V F V L G G V L V L C V E R N G E G E M G W P Q H L P K S Q P L S  
P P V A V R R C S F E R S W I D L L V E T S S S M V T C R Q Q V G T P N G M E G R G G G P K T T F P I R L  
Q L S G A C A V R P E I Q W E V (SEQ ID NO: 267). Polynucleotides encoding these polypeptides are also encompassed by the invention. Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement thereof are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

This gene is expressed primarily in activated monocytes, dendritic cells, and in the tonsils.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to,

immune and hematopoietic diseases and/or disorders, particularly leukemia, lymphomas, tumors of hematopoietic origin. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 172 as residues: Gln-30 to Leu-38, Asn-75 to Thr-86. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution in activated monocytes, dendritic cells, and tonsils indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic and/or diagnostic agent for leukemias, lymphomas, and other diseases associated with cells of hematopoietic origin. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to



transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may  
5 represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological  
10 activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 70**

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells, and to a lesser extent,  
20 other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS  
25 element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

The gene encoding the disclosed cDNA is believed to reside on chromosome 12. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 12.

30 This gene is expressed primarily in the placenta, brain, and liver and to a lesser extent in most other tissues.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic, neurological, vascular, and developmental diseases and/or disorders, particularly cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and nervous systems, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., hematopoietic, neurological, vascular, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, amniotic fluid, bile, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful therapeutic and/or diagnostic agent in a multitude of disease states, particularly those involving the immune and neurologic systems. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment,

and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 71

The translation product of this gene shares sequence homology with the murine Fig1 (interleukin-four induced gene 1) (See Genbank Accession No AAB51353; all references available through this accession are hereby incorporated herein by reference; for example Chu, C.C. and Paul, W.E., Proc. Natl. Acad. Sci. U.S.A. 94 (6), 2507-2512 (1997)) which shares homology to the monoamine oxidases, particularly in domains responsible for FAD binding.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

QDWKAERSQDPFEKCMQDPDYEQLLKVTILEADNRIGGRIFTYRDQXTGWIG  
ELGAMRMPSSHRILHKLCQGLGLNLTKFTQYDKNTWTEVHEXKLRNYVVEK  
VPEKLG YALRPQEKGHSPEDIYQMALNQALKDLKALGCRKAMKKFERHTLL  
EYLLGEGNLSRPAVQLLGDVMSDGGFFYLSFAEALRAXSCLSDRLQYSRIVG  
GWDLLPRALLSSLSGLVLLNAPVVAMTQGP HDVHVQIETSPARNLKV LKAD  
VVLLTASGPAVKRITFS (SEQ ID NO: 268), and/or  
LPRHMQEALRRLHYVPATKVFLSFRPFWRREEHIEGHSNTDRPSRMIFYPPP  
REGALLASYTWS DAAAAFAGLSREEALRLALDDVAALHGPVVRQLWDGT  
GVVKRWAEDQHSQGGFVVQXPALWQTEKDDWTVPYGRIYFAGEHTAYPHG  
WVETAVKSALRAAIKINSRKGPASDTASPEGHASDMEGQGHVHGVASSPSH  
DLAKEEGS (SEQ ID NO: 269). Polynucleotides encoding such polypeptides are also encompassed by the invention. Moreover, fragments and variants of these

polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent conditions, to the polynucleotide encoding these polypeptides, or the complement  
 5 there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

In specific embodiments, polypeptides of the invention comprise, or alternatively consists of, the following amino acid sequence:

10 MAPLALHLLVLPILLSLVASQDWKAERSQDPFEKCMQDPDYEQLLKVTILE  
 ADNRIIGGRIFTYRDQXTGWIGELGAMRMPSSHRILHKLCQGLGLNLTKFTQY  
 DKNTWTEVHEXKLARNYVVEKVPEKLGALYALRPQEKGHSPEDIYQMALNQAL  
 KDLKALGCRKAMKKFERHTLLEYLLGEGNLSRPAVQLLGDVMSSEDGFFYLS  
 FAEALRAXSCLSDRLQYSRIVGGWDLPRALLSSLSGLVLLNAPVVAMTQGP  
 15 HDVHVQIETSPPARNLKVLKADVLLTASGPAVKRITFSRCPATCRRRCGGC

TTCRPPRCS (SEQ ID NO: 270). Moreover, fragments and variants of these polypeptides (such as, for example, fragments as described herein, polypeptides at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to these polypeptides and polypeptides encoded by the polynucleotide which hybridizes, under stringent  
 20 conditions, to the polynucleotide encoding these polypeptides, or the complement there of are encompassed by the invention. Antibodies that bind polypeptides of the invention are also encompassed by the invention. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Based on the sequence similarity, the translation product of this clone is  
 25 expected to share at least some biological activities with monoamine oxidases, disintegrins, metalloproteinases, and apoptosis modulating proteins. Such activities are known in the art, some of which are described elsewhere herein. Polynucleotides encoding these polypeptides are also encompassed by the invention.

The polypeptide of this gene has been determined to have a transmembrane  
 30 domain at about amino acid position 235 - 251 of the amino acid sequence referenced in Table 1A for this gene. Moreover, a cytoplasmic tail encompassing amino acids 252 to 319 of this protein has also been determined. Based upon these characteristics,

it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in hematopoietic cells, particularly in dendritic cells, and activated monocytes and to a lesser extent in T-cells, endothelial cells, and cells associated with ulcerative colitis.

Polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemias, lymphomas, and diseases associated with antigen presenting cells, in addition to apoptosis dependant events. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels may be routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise, or alternatively consist of, one or more of the immunogenic epitopes shown in SEQ ID NO: 174 as residues: Gln-22 to Gln-44, Ala-90 to Gly-95, Lys-137 to Trp-146, Arg-171 to Asp-181, Glu-370 to Ser-380, Asp-447 to Gly-452, Gln-463 to Trp-469, Asn-504 to Ala-510, Asp-512 to His-519, Ala-541 to Val-550, Asn-558 to His-566. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind said epitopes or other polypeptides of the invention are also encompassed.

The tissue distribution immune and hematopoietic cells and tissues, combined with the homology to the murine Fig 1 gene indicates that polynucleotides and polypeptides corresponding to this gene are useful as a therapeutic and/or diagnostic agent for hematopoietic diseases, especially those associated with antigen presenting cells. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere

herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses). Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Table 1A

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HISCN02	209878 05/18/98	pSport1	11	1113	1	1113	232	232	104	1	26	27	106
2	HHGDM70	209878 05/18/98	Lambda ZAP II	12	983	102	983	69	69	105	1	57	58	86
3	HHPGO40	209878 05/18/98	Uni-ZAP XR	13	973	1	973	68	68	106	1	37	38	302
3	HHPGO40	209878 05/18/98	Uni-ZAP XR	82	984	1	984	74	74	175	1	37	38	224
4	HAMGG68	209878 05/18/98	pCMVSPORT 3.0	14	1458	1	1458	312	312	107	1	20	21	55
5	HAPOM49	209878 05/18/98	Uni-ZAP XR	15	2005	1	2005	251	251	108	1	22	23	189
5	HAPOM49	209878 05/18/98	Uni-ZAP XR	83	2664	1	2664	448	448	176	1	1	2	123
6	HBGBA69	209878 05/18/98	Uni-ZAP XR	16	943	1	933	62	62	109	1	38	39	60
7	HBIFJ26	209878 05/18/98	Uni-ZAP XR	17	1503	588	1480	290	290	110	1	26	27	128

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
7	HBJFJ26	209878 05/18/98	Uni-ZAP XR	84	1328	413	1305	591	591	177	1	20	21	59
8	HCEDH38	209878 05/18/98	Uni-ZAP XR	18	1512	1	1438	222	222	111	1	26	27	68
9	HDPOJ08	209878 05/18/98	pCMVSPORT 3.0	19	1655	1	1655	159	159	112	1	18	19	122
10	HDPRX82	209878 05/18/98	pCMVSPORT 3.0	20	2525	1	2525	128	128	113	1	32	33	82
11	HELK31	209878 05/18/98 209044 05/15/97	Uni-ZAP XR	21	1396	25	1334	209	209	114	1	29	30	344
11	HCNUA40	97898 02/26/97	pBluescript	85	1342	949	1237	960	960	178	1	33	34	105
12	HFPCX64	209878 05/18/98	Uni-ZAP XR	22	1069	1	1069	181	181	115	1	28	29	181
12	HFPCX64	209878 05/18/98	Uni-ZAP XR	86	1154	84	1154	257	257	179	1	28	29	87
12	HCEBW71	209225 08/28/97	Uni-ZAP XR	87	1197	141	1197	257	257	180	1	28	29	87
13	HFXDO60	209878 05/18/98	Lambda ZAP II	23	1658	1	1658	131	131	116	1	46	47	115



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
14	HHEPG41	209878 05/18/98	pCMVSPORT 3.0	24	1077	385	1043	514	514	117	1	35	36	70
14	HAUAI83	209626 02/12/98	Uni-ZAP XR	88	910	1	886	253	253	181	1	37	38	49
14	HJPAZ83	209626 02/12/98 97958 03/13/97	Uni-ZAP XR	89	1076	398	1076		575	182	1	11	12	23
15	HKG4H42	209878 05/18/98	pSPORT1	25	1205	1	1205	143	143	118	1	21	22	63
16	HMIAP86	209878 05/18/98	Uni-ZAP XR	26	1674	13	1674	182	182	119	1	19	20	334
17	HMUAP70	209878 05/18/98	pCMVSPORT 3.0	27	1965	531	1914	183	183	120	1	16	17	221
17	HMUAP70	209878 05/18/98	pCMVSPORT 3.0	90	1842	407	1783	413	413	183	1	25	26	103
17	HAGFY16	209626 02/12/98 97923 03/07/97	Uni-ZAP XR	91	1963	209	1922	251	251	184	1	28	29	198
17	HBMCF37	209683 03/20/98	pBluescript	92	1487	79	1487	170	170	185	1	44	45	70

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
17	HFLQB16	209641 02/25/98	Uni-ZAP XR	93	1653	394	1637	413	413	186	1	25	26	82
17	HAGFY16	209626 02/12/98	Uni-ZAP XR	94	1830	87	1786	128	128	187	1	26	27	45
18	HRACJ35	209878 05/18/98	pCMVSPORT 3.0	28	1863	8	1863	99	99	121	1	24	25	472
18	HAWAZ34	209141 07/09/97	pBluescript SK-	95	1134	472	1132	687	687	188	1			33
19	HTWDE26	209878 05/18/98	pSport1	29	1626	1	1626	68	68	122	1	30	31	167
19	HMHBN40	97901 02/26/97 209047 05/15/97	Uni-ZAP XR	96	1772	69	1772	129	129	189	1	30	31	231
20	HUSIB13	209878 05/18/98	pSport1	30	605	1	605	172	172	123	1	32	33	46
21	HBAFA02	209877 05/18/98	pSport1	31	931	359	931	46	46	124	1	21	22	108
22	H2CBT75	209877 05/18/98	pBluescript SK-	32	1407	1	1407	32	32	125	1	23	24	60
23	HAGDQ42	209877 05/18/98	Uni-ZAP XR	33	1526	1	1526	126	126	126	1	18	19	248

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HBM CJ42	209877 05/18/98	pBluescript	34	1737	41	1580	244	244	127	1	44	45	248
25	HDPBQ71	209877 05/18/98	pCMV Sport 3.0	35	2312	1	2312	93	93	128	1	33	34	612
25	HDPBQ71	209877 05/18/98	pCMV Sport 3.0	97	2242	6	2242	24	24	190	1	33	34	612
25	HDPFQ90	PTA-499 08/11/99	pCMV Sport 3.0	98	2381	162	2381	165	165	191	1	33	34	456
26	HCEJG71	209877 05/18/98	Uni-ZAP XR	36	2235	2	2235	28	28	129	1	25	26	447
27	HELHL48	209877 05/18/98	Uni-ZAP XR	37	2971	560	2557	629	629	130	1	16	17	291
27	HSKCT36	209580 01/14/98	Uni-ZAP XR	99	1955	1	1955	31	31	192	1	18	19	184
28	HISAQ04	209877 05/18/98	pSport1	38	1163	1	1163	61	61	131	1	21	22	78
29	HJACB89	209877 05/18/98	pBluescript SK-	39	1932	28	1930	95	95	132	1	23	24	333
30	HTECC05	209877 05/18/98	Uni-ZAP XR	40	881	1	881	27	27	133	1	15	16	164
31	HBJLF01	209877 05/18/98	Uni-ZAP XR	41	1932	201	1931	217	217	134	1	46	47	244

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
32	HBXGP60	209877 05/18/98	ZAP Express	42	1164	1	1164	143	143	135	1	22	23	55
33	HCE5B20	209877 05/18/98	Uni-ZAP XR	43	1105	1	1105	237	237	136	1	25	26	54
34	HCMQ56	209877 05/18/98	Uni-ZAP XR	44	1262	1	1262	148	148	137	1	19	20	88
35	HCNAH57	209877 05/18/98	Lambda ZAP II	45	517	1	517	35	35	138	1	33	34	61
36	HCUEP91	209877 05/18/98	ZAP Express	46	858	2	858	266	266	139	1	20	21	105
37	HDPCJ91	209877 05/18/98	pCMVSPORT 3.0	47	6107	1	6107	131	131	140	1	28	29	51
38	HDPGK25	209877 05/18/98	pCMVSPORT 3.0	48	703	1	703	345	345	141	1	33	34	119
39	HE2DY70	209877 05/18/98	Uni-ZAP XR	49	639	1	639	137	137	142	1	45	46	58
40	HE2NV57	209877 05/18/98	Uni-ZAP XR	50	867	1	867	99	99	143	1	36	37	99
41	HETBR16	209877 05/18/98	Uni-ZAP XR	51	1569	1	1569	161	161	144	1	21	22	64
42	HFXDG13	209877 05/18/98	Lambda ZAP II	52	1196	1	1196	43	43	145	1	37	38	66

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
43	HFXKY27	209877 05/18/98	Lambda ZAP II	53	945	1	945	44	44	146	1	19	20	58
44	HHPEC09	209877 05/18/98	Uni-ZAP XR	54	488	1	488	71	71	147	1	19	20	55
45	HISAD54	209877 05/18/98	pSport1	55	2860	1	2860	172	172	148	1	19	20	65
46	HJBCY35	209877 05/18/98	pBluescript SK-	56	1559	93	1272	232	232	149	1	23	24	327
47	HKAFA19	209877 05/18/98	pCMVSPORT 2.0	57	2064	1	1909	83	83	150	1	21	22	89
48	HKGDL36	209877 05/18/98	pSport1	58	1050	1	1050	55	55	151	1	33	34	148
49	HLDBS43	209877 05/18/98	pCMVSPORT 3.0	59	2533	1	2533	73	73	152	1	26	27	390
50	HLWAD92	209877 05/18/98	pCMVSPORT 3.0	60	899	1	899	197	197	153	1	34	35	98
51	HLYBI15	209877 05/18/98	pSport1	61	1079	1	1079	92	92	154	1	22	23	60
52	HMEIE05	209889 05/22/98	Lambda ZAP II	62	1928	1	1928	25	25	155	1	30	31	392
53	HNGIX55	209889 05/22/98	Uni-ZAP XR	63	781	1	781	121	121	156	1	19	20	74

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
54	HNHEX30	209889 05/22/98	Uni-ZAP XR	64	1194	1	1194	138	138	157	1	15	16	81
55	HPJBI33	209889 05/22/98	Uni-ZAP XR	65	1677	1	1677	236	236	158	1	31	32	53
56	HRABA80	209889 05/22/98	pCMVSPORT 3.0	66	1237	1	1237	130	130	159	1	28	29	102
57	HRACD80	209889 05/22/98	pCMVSPORT 3.0	67	1934	1	1934	191	191	160	1	16	17	575
57	HRACD80	209889 05/22/98	pCMVSPORT 3.0	100	1958	1	1958	191	191	193	1	16	17	146
58	HSLCX03	209889 05/22/98	Uni-ZAP XR	68	3300	984	2729	677	677	161	1	22	23	643
58	HSLCX03	209889 05/22/98	Uni-ZAP XR	101	2444	1	2444	392	392	194	1	22	23	124
59	HT5GJ57	209889 05/22/98	Uni-ZAP XR	69	1797	92	1797	122	122	162	1	25	26	190
60	HTACS42	209889 05/22/98	Uni-ZAP XR	70	1373	1	1373	213	213	163	1	29	30	63
61	HTEKE40	209889 05/22/98	Uni-ZAP XR	71	1579	1	1579	173	173	164	1	47	48	117
62	HTOBX69	209889 05/22/98	Uni-ZAP XR	72	1028	1	1028	28	28	165	1	20	21	42

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HUVEO77	209889 05/22/98	Uni-ZAP XR	73	3674	1	3674	55	55	166	1	27	28	47
64	H2CBG48	209889 05/22/98	pBluescript SK-	74	2797	1	2797	125	125	167	1	25	26	45
65	H2CBU83	209889 05/22/98	pBluescript SK-	75	2703	1	2703	157	157	168	1	30	31	207
65	H2CBU83	209889 05/22/98	pBluescript SK-	102	2709	1	2709	157	157	195	1	30	31	51
66	HAPNY94	209889 05/22/98	Uni-ZAP XR	76	742	1	742	94	94	169	1	29	30	50
67	HBJHZ58	209889 05/22/98	Uni-ZAP XR	77	1825	1	1825	102	102	170	1	29	30	42
68	HCE2B33	209878 05/18/98	Uni-ZAP XR	78	1674	1	1668	67	67	171	1	18	19	55
69	HDPBQ02	209889 05/22/98	pCMVSPORT 3.0	79	2191	291	2191	460	460	172	1	24	25	108
70	HFTYT70	209889 05/22/98	pSport1	80	1335	1	1335	43	43	173	1	15	16	50
71	HDPOZ56	209889 05/22/98	pCMVSPORT 3.0	81	1867	415	1867	103	103	174	1	21	22	566
71	HDPOZ56	209889 05/22/98	pCMVSPORT 3.0	103	1722	1	1722	59	59	196	1	21	22	319

**Table 1B**

Gene No:	Clone ID NO: Z	Contig ID:	SEQ ID NO: X	ORF (From-To)	AA SEQ ID NO: Y	Predicted Epitopes	Tissue Distribution Library code: count (see Table IV for Library Codes)	Cytologic Band	OMIM Disease Reference(s):
1	HISCN02	638033	11	232 - 549	104		AR183: 9, AR182: 7, AR269: 7, AR180: 6, AR161: 6, AR162: 6, AR163: 5, AR173: 5, AR245: 5, AR270: 5, AR257: 5, AR181: 5, AR171: 5, AR179: 4, AR263: 4, AR238: 4, AR268: 4, AR175: 4, AR296: 4, AR172: 4, AR176: 4, AR178: 4, AR264: 4, AR313: 4, AR165: 4, AR243: 4, AR290: 4, AR164: 4, AR096: 4, AR309: 3, AR300: 3, AR242: 3, AR222: 3, AR166: 3, AR240: 3, AR223: 3, AR293: 3, AR217: 3, AR193: 3, AR261: 3, AR291: 3, AR170: 3, AR311: 3, AR213: 3, AR267: 3, AR195: 3,		





								AR230: 1, AR060: 1, AR232: 1, AR203: 1, AR192: 1, AR214: 1, AR168: 1, AR256: 1 H0539: 1			
2	HHGDM70	623416	12	69 - 326	105	Gly-29 to Ser-35, Ser-63 to Cys-68.		AR060: 4, AR299: 4, AR283: 2, AR104: 2, AR185: 2, AR316: 2, AR277: 2, AR089: 1, AR313: 1 S0116: 1, H0255: 1 and H0333: 1.			
3	HHPGO40	753270	13	68 - 973	106			AR244: 5, AR202: 5, AR273: 5, AR194: 4, AR176: 4, AR253: 4, AR214: 4, AR206: 4, AR309: 3, AR235: 3, AR186: 3, AR251: 3, AR052: 3, AR222: 3, AR224: 3, AR204: 3, AR282: 3, AR289: 3, AR248: 3, AR215: 3, AR277: 3, AR284: 3, AR181: 3, AR269: 3, AR180: 2, AR312: 2, AR246: 2, AR061: 2, AR182: 2, AR162: 2, AR184: 2, AR163: 2, AR296: 2, AR198: 2,			

AR161:	2, AR223:	2,
AR291:	2, AR298:	2,
AR171:	2, AR267:	2,
AR229:	2, AR055:	2,
AR297:	2, AR225:	2,
AR265:	2, AR285:	2,
AR193:	2, AR228:	2,
AR270:	2, AR292:	2,
AR183:	2, AR261:	2,
AR033:	2, AR290:	2,
AR268:	2, AR169:	2,
AR310:	2, AR266:	2,
AR271:	2, AR205:	2,
AR264:	2, AR286:	2,
AR192:	2, AR039:	2,
AR247:	2, AR283:	2,
AR053:	2, AR240:	2,
AR300:	2, AR060:	2,
AR287:	2, AR293:	2,
AR257:	2, AR096:	2,
AR089:	2, AR239:	2,
AR104:	2, AR185:	1,
AR213:	1, AR178:	1,
AR294:	1, AR237:	1,
AR299:	1, AR177:	1,
AR275:	1, AR288:	1,
AR313:	1, AR175:	1,
AR238:	1, AR272:	1,
AR274:	1, AR173:	1,



							H0423: 1.			
4	HHPGO40 HAMGG68	560969 731859	82 14	74 - 745 312 - 479	175 107		AR313: 34, AR275: 32, AR104: 32, AR165: 29, AR039: 27, AR033: 27, AR164: 27, AR196: 26, AR161: 25, AR162: 24, AR089: 24, AR163: 23, AR271: 23, AR096: 22, AR240: 21, AR312: 21, AR174: 20, AR250: 20, AR205: 19, AR180: 19, AR264: 19, AR282: 18, AR175: 18, AR185: 18, AR183: 18, AR179: 18, AR269: 18, AR238: 18, AR193: 18, AR308: 17, AR300: 17, AR182: 17, AR173: 17, AR270: 17, AR192: 17, AR247: 16, AR191: 16, AR198: 16, AR299: 16, AR242: 16, AR268: 16, AR188: 16, AR309: 16, AR311: 15, AR211: 15, AR219: 15, AR207: 14, AR316: 14, AR178: 14, AR212: 14, AR060: 14, AR285: 14, AR201: 14, AR213:			

[illegible]

8, AR170: 8, AR239:								
8, AR217: 8, AR243:								
8, AR232: 8, AR230:								
8, AR266: 8, AR222:								
7, AR256: 7, AR204:								
6, AR228: 6, AR289:								
6, AR283: 6, AR227:								
6, AR055: 4, AR061:								
4								
L0805: 7, L0666: 3,								
L0439: 3, H0052: 2,								
L0773: 2, L0794: 2,								
L0740: 2, L0779: 2,								
H0685: 1, S0418: 1,								
S0222: 1, H0050: 1,								
H0320: 1, H0252: 1,								
H0030: 1, H0059: 1,								
H0560: 1, L0520: 1,								
L0770: 1, L0646: 1,								
L0771: 1, L0662: 1,								
L0363: 1, L0803: 1,								
L0774: 1, L0375: 1,								
L0776: 1, L0655: 1,								
L0659: 1, H0670: 1,								
S0378: 1, S0406: 1,								
L0748: 1, L0757: 1,								
L0758: 1, S0436: 1,								
L0597: 1, L0591: 1,								
L0366: 1 and S0412: 1.								

5	HAPOM49	769555	15	251 - 817	108	Gln-23 to Asp-30, Lys-66 to Cys-87.	AR089: 5, AR169: 5, AR060: 5, AR282: 4, AR171: 3, AR217: 3, AR283: 2, AR316: 2, AR240: 2, AR221: 2, AR163: 2, AR180: 2, AR183: 2, AR170: 2, AR277: 2, AR172: 2, AR165: 2, AR166: 2, AR242: 2, AR313: 2, AR195: 2, AR168: 2, AR104: 2, AR275: 2, AR096: 2, AR162: 2, AR164: 1, AR216: 1, AR193: 1, AR205: 1, AR264: 1, AR299: 1, AR173: 1, AR266: 1, AR161: 1, AR272: 1, AR214: 1, AR257: 1, AR196: 1, AR270: 1, AR268: 1, AR289: 1, AR245: 1, AR312: 1, AR223: 1, AR212: 1, AR261: 1, AR297: 1, AR192: 1 S0406: 5, L0750: 5, L0777: 4, L0749: 3, L0779: 3, H0662: 2, S0440: 2, L0770: 2,		
---	---------	--------	----	-----------	-----	--	--	--	--



									L0794: 2, L0776: 2, L0657: 2, L0783: 2, L0740: 2, L0747: 2, S0420: 1, S0442: 1, S0444: 1, S0045: 1, H0599: 1, H0575: 1, T0115: 1, H0083: 1, H0510: 1, H0644: 1, H0551: 1, S0386: 1, H0494: 1, H0561: 1, H0538: 1, S0422: 1, L0646: 1, L0804: 1, L0774: 1, L0809: 1, L0530: 1, L0663: 1, L0664: 1, L0665: 1, H0593: 1, S0380: 1, S0027: 1, L0748: 1, L0439: 1, L0756: 1, L0755: 1, L0758: 1, L0485: 1, H0542: 1 and H0423: 1.				
	HAPOM49	722386	83	448 - 816	176	Met-1 to Cys-21, Cys-41 to Asp-59, Pro-104 to His-116.							
6	HGBA69	709658	16	62 - 244	109	Thr-52 to Gly-57.	AR196: 22, AR089: 21, AR275: 21, AR188: 20, AR240: 19, AR177: 18, AR060: 18, AR096: 18, AR269: 17, AR238:						



[illegible]





7	HBJFJ26	772348	17	290 - 673	110	L0651: 1, L0653: 1, L0655: 1, L0657: 1, L0658: 1, L0663: 1, H0725: 1, H0519: 1, H0670: 1, S0380: 1, H0518: 1, S0044: 1, S0406: 1, H0555: 1, H0436: 1, S3014: 1, L0439: 1, L0749: 1, L0731: 1, L0759: 1, S0260: 1, H0445: 1, S0196: 1, H0423: 1 and H0506: 1.		
						AR309: 21, AR271: 17, AR272: 16, AR275: 16, AR197: 15, AR060: 15, AR282: 14, AR245: 14, AR162: 14, AR161: 14, AR268: 13, AR246: 13, AR291: 13, AR182: 13, AR163: 13, AR198: 13, AR308: 13, AR164: 12, AR165: 12, AR181: 12, AR289: 12, AR166: 12, AR176: 12, AR178: 12, AR312: 12, AR296: 11, AR205: 11, AR183: 11, AR269: 11, AR261: 11, AR175: 11, AR201:		

11, AR263: 10, AR214:							
10, AR177: 10, AR053:							
10, AR295: 10, AR192:							
10, AR266: 10, AR189:							
10, AR174: 10, AR188:							
10, AR089: 10, AR240:							
10, AR221: 10, AR207:							
10, AR274: 10, AR212:							
10, AR250: 10, AR264:							
10, AR288: 9, AR252:							
9, AR229: 9, AR238:							
9, AR237: 9, AR195:							
9, AR196: 9, AR193:							
9, AR180: 9, AR247:							
9, AR199: 9, AR191:							
9, AR253: 9, AR316:							
9, AR257: 9, AR242:							
9, AR225: 9, AR297:							
9, AR270: 8, AR190:							
8, AR267: 8, AR285:							
8, AR243: 8, AR293:							
8, AR185: 8, AR204:							
8, AR096: 8, AR169:							
8, AR254: 8, AR231:							
8, AR224: 8, AR255:							
8, AR290: 8, AR283:							
8, AR236: 8, AR210:							
8, AR239: 8, AR173:							
8, AR219: 8, AR235:							

[illegible]



							L0653: 2, L0517: 2, L0663: 2, H0701: 2, H0522: 2, L0779: 2, L0755: 2, H0265: 1, H0713: 1, H0295: 1, S0212: 1, S0420: 1, S0444: 1, S0408: 1, H0393: 1, H0549: 1, H0613: 1, H0592: 1, H0331: 1, H0250: 1, L0021: 1, H0706: 1, H0318: 1, H0263: 1, H0123: 1, L0471: 1, H0024: 1, H0510: 1, H0615: 1, H0031: 1, H0553: 1, H0169: 1, H0674: 1, S0366: 1, S0036: 1, S0016: 1, H0560: 1, H0714: 1, H0509: 1, H0652: 1, S0142: 1, L0762: 1, L0770: 1, L0769: 1, L0764: 1, L0767: 1, L0803: 1, L0651: 1, L0776: 1, L0655: 1, L0606: 1, L0661: 1, L0658: 1, L0512: 1, L0783: 1, L0384: 1, L0809: 1, S0052: 1,		
--	--	--	--	--	--	--	---	--	--

									H0593: 1, H0689: 1, H0672: 1, S0378: 1, L0439: 1, L0749: 1, L0750: 1, L0757: 1, L0758: 1, L0759: 1, S0031: 1, H0595: 1, S0434: 1, H0423: 1, H0422: 1 and H0506: 1.			

									8, AR174: 8, AR184: 7, AR235: 7, AR252: 7, AR229: 7, AR272: 7, AR176: 7, AR177: 6, AR178: 6, AR265: 6, AR239: 6, AR182: 6, AR175: 6, AR291: 5, AR189: 5, AR288: 5, AR287: 5, AR190: 5, AR096: 5, AR251: 5, AR263: 5, AR230: 5, AR179: 5, AR228: 5, AR236: 4, AR234: 4, AR257: 4, AR193: 4, AR238: 4, AR237: 4, AR285: 4, AR233: 4, AR289: 4, AR311: 4, AR286: 4, AR308: 4, AR226: 4, AR282: 4, AR089: 4, AR264: 4, AR240: 4, AR232: 4, AR201: 4, AR261: 4, AR292: 4, AR210: 4, AR212: 4, AR295: 4, AR247: 4, AR297: 4, AR275: 4, AR262: 4, AR245: 4, AR195: 4, AR188: 4, AR231: 4, AR185: 4, AR197:
--	--	--	--	--	--	--	--	--	---

								4, AR309: 4, AR196: 4, AR284: 4, AR191: 4, AR255: 3, AR199: 3, AR200: 3, AR293: 3, AR296: 3, AR313: 3, AR246: 3, AR203: 3, AR219: 3, AR243: 3, AR300: 3, AR294: 3, AR214: 3, AR274: 3, AR060: 3, AR298: 3, AR033: 3, AR227: 3, AR053: 3, AR316: 3, AR299: 3, AR221: 2, AR271: 2, AR312: 2, AR218: 2, AR223: 2, AR061: 2, AR055: 2, AR259: 2, AR224: 2, AR217: 2, AR277: 2, AR225: 2, AR258: 2, AR215: 2, AR104: 2, AR168: 2, AR266: 2, AR211: 2, AR039: 2, AR222: 2, AR205: 2, AR216: 2, AR202: 1, AR213: 1, AR260: 1, AR256: 1, AR314:  S0474: 19, L0766: 11, H0521: 10, L0803: 6,	
--	--	--	--	--	--	--	--	---	--

	L0748: 6, L0717: 5, L0759: 5, S0003: 4, H0663: 3, H0156: 3, L0598: 3, L0771: 3, L0804: 3, H0522: 3, L0731: 3, S0436: 3, H0486: 2, S0426: 2, L0770: 2, L0659: 2, S0126: 2, S0406: 2, L0749: 2, L0755: 2, L0757: 2, L0758: 2, L0590: 2, S0026: 2, H0716: 1, H0341: 1, S0212: 1, L0481: 1, S0444: 1, S0360: 1, H0637: 1, H0580: 1, H0734: 1, H0619: 1, H0586: 1, H0574: 1, H0427: 1, L0021: 1, H0575: 1, H0318: 1, H0545: 1, H0024: 1, H0373: 1, H0071: 1, H0179: 1, S0214: 1, H0428: 1, H0674: 1, H0591: 1, H0616: 1, H0488: 1, H0494: 1, S0438: 1, S0440: 1, H0647: 1, S0142: 1, UNKWN: 1, I0369: 1,								
--	---	--	--	--	--	--	--	--	--

10	HDPRX82	730518	20	128 - 376	113	Met-1 to Cys-6.	L0763: 1, L0769: 1, L0646: 1, L0648: 1, L0662: 1, L0650: 1, L0775: 1, L0805: 1, L0653: 1, L0776: 1, L0656: 1, L0782: 1, L0809: 1, L0519: 1, S0052: 1, H0144: 1, H0520: 1, H0547: 1, H0660: 1, S0380: 1, L0742: 1, L0439: 1, L0750: 1, L0777: 1, S0031: 1, H0445: 1, S0434: 1, H0665: 1, H0667: 1, S0194: 1, S0276: 1 and S0458: 1.		
							AR039: 5, AR225: 4, AR274: 4, AR245: 3, AR266: 3, AR264: 3, AR161: 3, AR272: 3, AR166: 3, AR242: 3, AR205: 3, AR254: 3, AR263: 2, AR311: 2, AR203: 2, AR192: 2, AR204: 2, AR201: 2, AR282: 2, AR217: 2, AR214: 2, AR165: 2, AR312: 2, AR271: 2, AR164: 2, AR309: 2,		

						AR195: 2, AR163: 2, AR213: 2, AR060: 2, AR162: 2, AR246: 2, AR212: 2, AR033: 1, AR193: 1, AR291: 1, AR283: 1, AR293: 1, AR089: 1, AR286: 1, AR216: 1, AR247: 1, AR235: 1, AR178: 1, AR224: 1, AR096: 1, AR061: 1, AR234: 1, AR182: 1, AR277: 1, AR183: 1, AR316: 1 S0001: 2, H0123: 2, T0067: 2, H0521: 2, S0114: 1, S0134: 1, H0341: 1, S0282: 1, S0356: 1, S0358: 1, H0580: 1, H0587: 1, H0574: 1, H0618: 1, H0085: 1, H0457: 1, N0006: 1, H0051: 1, S0051: 1, H0028: 1, H0328: 1, H0031: 1, H0169: 1, H0124: 1, H0038: 1, H0040: 1, H0272: 1, H0412: 1, H0144: 1, H0520: 1, H0519: 1, S0152: 1,			
--	--	--	--	--	--	--	--	--	--

11	HEL GK31	681138	21	209 - 1243	114	S0260: 1, H0445: 1 and S0192: 1. AR310: 67, AR259: 63, AR052: 53, AR289: 52, AR265: 49, AR292: 39, AR053: 38, AR256: 37, AR184: 36, AR283: 35, AR286: 35, AR298: 32, AR294: 31, AR312: 30, AR263: 28, AR273: 27, AR309: 26, AR258: 26, AR194: 26, AR284: 25, AR213: 25, AR266: 25, AR219: 22, AR218: 21, AR248: 21, AR293: 21, AR244: 20, AR246: 20, AR205: 20, AR291: 18, AR247: 18, AR206: 18, AR274: 17, AR269: 17, AR313: 15, AR268: 14, AR243: 14, AR270: 14, AR275: 13, AR186: 13, AR253: 12, AR177: 12, AR249: 11, AR202: 11, AR183: 11, AR290: 11, AR271: 11, AR267: 10, AR296: 10, AR175: 10, AR182: 9, AR039: 9, AR241: 9, AR033:		
----	----------	--------	----	------------	-----	---	--	--



									9, AR198: 9, AR096: 9, AR285: 9, AR089: 9, AR316: 8, AR282: 8, AR295: 8, AR231: 7, AR240: 7, AR237: 7, AR299: 7, AR104: 7, AR204: 6, AR061: 6, AR185: 6, AR251: 6, AR238: 6, AR055: 6, AR192: 5, AR232: 5, AR234: 5, AR300: 4, AR226: 4, AR162: 4, AR165: 4, AR161: 4, AR163: 4, AR257: 4, AR229: 4, AR164: 4, AR060: 4, AR179: 4, AR264: 4, AR166: 4, AR272: 4, AR217: 3, AR277: 3, AR308: 3, AR261: 3, AR196: 3, AR297: 3, AR255: 3, AR173: 3, AR195: 3, AR311: 3, AR288: 3, AR190: 3, AR193: 3, AR262: 3, AR233: 3, AR224: 3, AR221: 3, AR178: 3, AR216: 3, AR171: 2, AR191: 2, AR188: 2, AR287:
--	--	--	--	--	--	--	--	--	---

						2, AR181: 2, AR176: 2, AR180: 2, AR211: 2, AR189: 2, AR174: 2, AR225: 2, AR200: 2, AR210: 2, AR227: 2, AR223: 2, AR254: 2, AR214: 1, AR260: 1, AR235: 1, AR199: 1, AR215: 1, AR203: 1, AR281: 1, AR168: 1, AR230: 1, AR170: 1 L0771: 3, L0766: 3, L0783: 3, L0748: 3, L0749: 3, L0757: 3, L0758: 3, L0595: 3, H0031: 2, H0673: 2, L0369: 2, L0769: 2, S0374: 2, L0438: 2, H0547: 2, H0658: 2, H0696: 2, L0439: 2, L0750: 2, L0777: 2, L0596: 2, L0592: 2, H0543: 2, H0265: 1, H0713: 1, S0116: 1, H0661: 1, H0176: 1, S0444: 1, S0045: 1, H0640: 1, H0013: 1, S0010: 1, H0318: 1.
--	--	--	--	--	--	---

HCNUA40	340352	85	960 - 1274	178	Asn-45 to Trp-58, Pro-69 to Gln-74, Glu-100 to Glu-105.		H0232: 1, H0546: 1, H0065: 1, H0566: 1, H0024: 1, H0083: 1, H0266: 1, T0006: 1, H0617: 1, L0055: 1, H0165: 1, L0456: 1, H0040: 1, H0634: 1, H0551: 1, T0067: 1, H0100: 1, T0041: 1, H0560: 1, S0438: 1, S0440: 1, H0641: 1, S0144: 1, L0762: 1, L0763: 1, L0772: 1, L0648: 1, L0363: 1, L0767: 1, L0768: 1, L0651: 1, L0776: 1, L0636: 1, L0809: 1, L0545: 1, L0647: 1, L0793: 1, L0664: 1, H0435: 1, H0648: 1, H0436: 1, S014: 1, S0206: 1, L0742: 1, L0779: 1, L0752: 1, L0731: 1, S0260: 1, H0445: 1, S0434: 1, S0436: 1 and S0194: 1.		
---------	--------	----	------------	-----	---	--	--	--	--

12	HFPCX64	877637	22	181 - 723	115	Lys-60 to Asn-67.	AR254: 65, AR250: 61, AR253: 59, AR053: 38, AR210: 31, AR178: 31, AR252: 31, AR289: 31, AR218: 30, AR286: 30, AR211: 29, AR262: 28, AR309: 28, AR258: 28, AR293: 28, AR257: 28, AR260: 28, AR198: 27, AR196: 27, AR312: 27, AR240: 26, AR183: 26, AR266: 26, AR175: 26, AR256: 25, AR216: 25, AR190: 25, AR189: 25, AR219: 25, AR199: 25, AR203: 25, AR294: 24, AR191: 24, AR188: 24, AR172: 24, AR176: 24, AR177: 24, AR269: 24, AR264: 24, AR246: 24, AR270: 23, AR180: 23, AR173: 23, AR212: 23, AR217: 23, AR268: 22, AR213: 22, AR313: 22, AR290: 22, AR195: 22, AR285: 22, AR297: 22, AR039: 22, AR192: 22, AR181: 21, AR200: 21, AR287: 21, AR179:		
----	---------	--------	----	-----------	-----	-------------------	---	--	--

[illegible]

									12, AR162: 12, AR060: 12, AR163: 12, AR232: 12, AR165: 11, AR061: 11, AR185: 11, AR055: 11, AR282: 11, AR164: 11, AR166: 10, AR277: 8, AR104: 6 S0222: 1, H0244: 1, H0052: 1 and L0764: 1.			
	HFPCX64	638851	86	257 - 520	179	Lys-60 to Asn-67.						
	HCEBW71	514187	87	257 - 520	180							
13	HFXXDO60	731869	23	131 - 478	116	Pro-2 to Gly-7, Ser-10 to Ser-16, Pro-52 to Val-62, Arg-64 to Ser-73.			AR313: 21, AR173: 14, AR161: 14, AR162: 14, AR163: 13, AR096: 13, AR165: 13, AR247: 13, AR175: 13, AR164: 13, AR300: 12, AR166: 12, AR269: 12, AR258: 11, AR179: 11, AR192: 11, AR183: 11, AR262: 10, AR182: 10, AR270: 10, AR268: 10, AR180: 10, AR238: 10, AR257: 10, AR254: 10, AR253: 10, AR181: 9, AR039: 9, AR193: 9, AR299: 9, AR213: 9, AR312: 9, AR293: 9, AR229: 9, AR218: 9, AR264:			



									5, AR277: 5, AR223: 5, AR228: 5, AR246: 5, AR271: 5, AR239: 4, AR289: 4, AR060: 4, AR169: 4, AR230: 4, AR215: 4, AR311: 4, AR205: 4, AR316: 4, AR224: 4, AR172: 4, AR170: 4, AR227: 4, AR190: 4, AR061: 4, AR222: 3, AR217: 3, AR232: 3, AR272: 3, AR221: 3, AR256: 3, AR216: 3, AR210: 3, AR211: 3, AR055: 3, AR168: 3, AR171: 2, AR283: 2, AR104: 2, AR214: 2 S0001: 1				
14	HHEPG41	714102	24	514 - 726	117	Asn-34 to Lys-42, Leu-60 to Trp-70.	AR225: 20, AR215: 19, AR223: 18, AR170: 16, AR221: 15, AR217: 14, AR169: 13, AR171: 12, AR172: 12, AR266: 11, AR214: 11, AR168: 10, AR183: 10, AR216: 10, AR268: 10, AR222: 10, AR269: 9, AR291: 9, AR224: 8, AR238:						



[illegible]



									H0575: 1, T0082: 1, S0182: 1, H0309: 1, H0150: 1, H0041: 1, H0024: 1, H0014: 1, H0060: 1, H0271: 1, H0252: 1, H0033: 1, H0031: 1, H0553: 1, H0673: 1, H0068: 1, H0135: 1, H0163: 1, H0040: 1, H0059: 1, H0561: 1, S0144: 1, S0210: 1, S0330: 1, H0134: 1, H0214: 1, H0576: 1, H0445: 1, S0192: 1, H0543: 1, S0424: 1 and H0506: 1.			
	HAUAI83	639009	88	253 - 399	181	Asn-34 to Lys-42.						
	HJPAZ83	383592	89	575 - 643	182	Ala-17 to Lys-23.						
15	HKG4H42	731871	25	143 - 334	118		AR253: 9, AR245: 9, AR250: 8, AR243: 7, AR312: 7, AR213: 7, AR183: 6, AR309: 6, AR254: 6, AR215: 6, AR180: 6, AR240: 6, AR212: 6, AR039: 6, AR096: 6, AR311: 6, AR246: 6, AR313: 6, AR053: 6, AR308: 5, AR193: 5, AR165: 5,					

						AR161: 5, AR197: 5, AR164: 5, AR207: 5, AR162: 5, AR263: 5, AR163: 5, AR223: 5, AR089: 5, AR166: 5, AR204: 5, AR176: 5, AR195: 5, AR214: 5, AR264: 5, AR171: 4, AR247: 4, AR271: 4, AR222: 4, AR272: 4, AR270: 4, AR299: 4, AR224: 4, AR277: 4, AR174: 4, AR170: 4, AR205: 4, AR177: 4, AR173: 3, AR316: 3, AR242: 3, AR269: 3, AR201: 3, AR181: 3, AR221: 3, AR178: 3, AR235: 3, AR268: 3, AR175: 3, AR182: 3, AR289: 3, AR216: 3, AR060: 3, AR300: 3, AR225: 3, AR172: 3, AR238: 3, AR179: 3, AR297: 3, AR262: 3, AR033: 3, AR275: 3, AR291: 2, AR295: 2, AR055: 2, AR282: 2, AR236: 2, AR217: 2,		
--	--	--	--	--	--	---	--	--

16	HMLAP86	726831	26	182 - 1186	119	Ser-34 to Thr-39, Gln-198 to Leu-205.	AR185: 2, AR226: 2, AR288: 2, AR190: 2, AR290: 2, AR229: 2, AR257: 2, AR293: 2, AR286: 2, AR104: 2, AR274: 2, AR266: 2, AR287: 2, AR168: 2, AR283: 2, AR267: 2, AR285: 2, AR294: 2, AR232: 2, AR189: 2, AR237: 2, AR230: 2, AR255: 2, AR234: 2, AR261: 2, AR228: 2, AR231: 2, AR061: 2, AR239: 2, AR233: 2, AR210: 2, AR188: 2, AR258: 2, AR169: 1, AR191: 1, AR296: 1, AR252: 1, AR198: 1, AR200: 1, AR227: 1, AR196: 1 H0538: 1 and S0260: 1.	Xq24	300046, 300123, 301201, 301835, 301845, 307150, 310490,
----	---------	--------	----	------------	-----	--	--	------	---

[illegible]

[illegible]

17	HMUAP70	872208	27	183 - 845	120	Cys-15 to Gly-36.	2, AR235: 2, AR193: 2, AR236: 2, AR262: 2, AR169: 2, AR179: 2, AR222: 2, AR257: 2, AR256: 2, AR178: 2, AR286: 1, AR211: 1, AR188: 1, AR174: 1, AR255: 1, AR203: 1 L0439: 8, S6028: 4, L0745: 4, L0759: 4, L0756: 3, L0731: 3, L0761: 2, L0809: 2, L0740: 2, L0779: 2, S0360: 1, S0046: 1, S0222: 1, H0497: 1, H0486: 1, H0013: 1, S0010: 1, H0052: 1, L0763: 1, L0803: 1, L0653: 1, L0776: 1, L0787: 1, L0789: 1, L0663: 1, L0664: 1, H0539: 1, S0406: 1, L0747: 1, L0749: 1, L0752: 1, L0758: 1, S0308: 1 and H0542: 1. AR281: 39, AR104: 39, AR194: 37, AR202: 37, AR283: 35, AR089:		
----	---------	--------	----	-----------	-----	-------------------	--	--	--



[illegible]

								9, AR237: 8, AR258: 8, AR294: 8, AR249: 8, AR259: 8, AR061: 8, AR285: 7, AR266: 7, AR284: 7, AR233: 7, AR268: 6, AR286: 5, AR291: 5, AR289: 5, AR179: 5, AR267: 4, AR270: 4, AR296: 4, AR298: 4, AR182: 4, AR269: 4, AR184: 3, AR290: 3 L0752: 17, L0776: 11, L0439: 9, L0751: 9, H0556: 8, L0438: 7, L0747: 7, L0794: 6, L0774: 6, L0758: 6, H0052: 5, L0766: 5, L0740: 5, L0777: 5, L0757: 5, S0444: 4, S0360: 4, H0156: 4, H0090: 4, S0438: 4, L0770: 4, L0769: 4, L0803: 4, L0804: 4, L0809: 4, L0741: 4, L0754: 4, L0750: 4, L0755: 4, L0759: 4, H0265: 3, S0358: 3, H0587: 3, H0013: 3.
--	--	--	--	--	--	--	--	---

					S0049: 3, H0046: 3, H0510: 3, H0591: 3, H0059: 3, H0529: 3, L0662: 3, H0670: 3, S0380: 3, H0521: 3, S0404: 3, L0756: 3, L0599: 3, H0657: 2, H0663: 2, H0351: 2, S0222: 2, H0574: 2, H0599: 2, S0010: 2, H0620: 2, S0388: 2, S6028: 2, S0214: 2, H0644: 2, H0032: 2, S0036: 2, H0413: 2, H0056: 2, H0623: 2, S0386: 2, H0494: 2, S0440: 2, H0641: 2, S0422: 2, L0771: 2, L0768: 2, L0775: 2, L0653: 2, L0657: 2, L0783: 2, S0126: 2, H0648: 2, H0539: 2, S0044: 2, S0432: 2, S0206: 2, L0748: 2, L0745: 2, S0436: 2, L0605: 2, L0592: 2, H0423: 2, H0624: 1, H0170: 1, H0171: 1, L0615: 1, S6024: 1,				
--	--	--	--	--	---	--	--	--	--

	S0114: 1, S0134: 1, S0212: 1, S0029: 1, H0661: 1, L0005: 1, S0410: 1, H0580: 1, H0722: 1, S0140: 1, S0132: 1, S0476: 1, H0619: 1, H0431: 1, H0415: 1, H0643: 1, H0559: 1, H0485: 1, T0039: 1, T0112: 1, H0635: 1, L0021: 1, H0053: 1, H0575: 1, T0048: 1, H0581: 1, H0421: 1, L0738: 1, H0327: 1, H0009: 1, H0563: 1, H0123: 1, H0050: 1, L0471: 1, H0012: 1, H0107: 1, H0622: 1, H0553: 1, H0181: 1, H0617: 1, H0165: 1, H0673: 1, S0364: 1, H0708: 1, H0038: 1, H0616: 1, T0069: 1, S0038: 1, H0509: 1, L0369: 1, L0772: 1, L0641: 1, L0645: 1, L0764: 1, L0767: 1, L0805: 1, L0527: 1, L0659: 1,	
--	---	--

									L0635: 1, L0517: 1, L0647: 1, L0788: 1, L0666: 1, L0665: 1, H0144: 1, S0374: 1, H0659: 1, H0672: 1, S0378: 1, H0696: 1, H0704: 1, H0436: 1, S0392: 1, H0478: 1, L0742: 1, L0743: 1, L0749: 1, L0731: 1, S0434: 1, L0601: 1, L0366: 1, S0026: 1, S0192: 1, H0542: 1, H0543: 1 and H0422: 1.				
	HMUAP70	723302	90	413 - 724	183				Lys-83 to Thr-90.				
	HAGFY16	778820	91	251 - 844	184								
	HBMCF37	674913	92	170 - 379	185				Lys-50 to Thr-57.				
	HFLQB16	646810	93	413 - 658	186				Leu-59 to His-80.				
	HAGFY16	381964	94	128 - 262	187								
18	HRACJ35	730504	28	99 - 1517	121				Arg-31 to Lys-37, Lys-58 to Glu-65, Asp-157 to Gly-168, Ile-219 to Gly-225, Ala-260 to Ser-268, Thr-276 to Glu-282.	AR222: 51, AR224: 51, AR221: 28, AR223: 24, AR225: 20, AR172: 14, AR171: 9, AR170: 9, AR182: 9, AR215: 9, AR214: 9, AR183: 8, AR216: 8, AR169: 8, AR168: 7, AR268: 7, AR217: 7, AR180:	148900, 216550		

[illegible]

[illegible]

19	HAWAZ34	470546	95	687 - 788	188	Gln-110 to Pro-120, Val-152 to Val-159.	AR263: 12, AR033: 12, AR104: 12, AR291: 11, AR281: 10, AR285:	168450, 168450, 257200.
	HTWDE26	668265	29	68 - 571	122			



[illegible]

[illegible]



									L0371: 1, L0638: 1, L0637: 1, L0761: 1, L0373: 1, L0372: 1, L0646: 1, L0800: 1, L0804: 1, L0805: 1, L0776: 1, L0379: 1, L0607: 1, L0657: 1, L0518: 1, L0790: 1, L0532: 1, L0664: 1, L0665: 1, S0052: 1, S0374: 1, L0352: 1, H0365: 1, H0659: 1, H0651: 1, H0522: 1, H0696: 1, S0406: 1, H0436: 1, H0478: 1, L0747: 1, L0749: 1, L0750: 1, L0731: 1, L0759: 1, H0444: 1, H0445: 1, S0434: 1, H0665: 1, S0242: 1 and H0543: 1.			
	HMHBN40	638249	96	129 - 824	189	Gln-31 to Ser-37, Ile-49 to Gly-54, Tyr-57 to Asp-67, Gln-141 to Pro-151, Val-207 to Thr-219.						
20	HUSIB13	580885	30	172 - 312	123		AR254: 4, AR180: 3, AR171: 3, AR282: 3, AR309: 3, AR214: 2,	2p13.3-p13.1	203800, 253601, 253601			



			L0755: 2, L0759: 2, H0543: 2, H0624: 1, L0448: 1, H0185: 1, H0657: 1, S0116: 1, H0663: 1, H0638: 1, H0125: 1, S0418: 1, S0356: 1, S0408: 1, H0580: 1, S0046: 1, S0132: 1, H0351: 1, H0549: 1, S6014: 1, H0391: 1, H0409: 1, H0592: 1, H0586: 1, H0331: 1, H0486: 1, T0071: 1, H0581: 1, H0421: 1, H0196: 1, H0597: 1, H0530: 1, H0041: 1, H0081: 1, H0179: 1, H0687: 1, S0003: 1, H0328: 1, H0688: 1, H0181: 1, L0055: 1, H0674: 1, S0364: 1, S0366: 1, S0036: 1, H0090: 1, H0616: 1, H0412: 1, S0438: 1, H0509: 1, H0647: 1, H0649: 1, S0344: 1, L0520: 1, L0769: 1, L0646: 1, L0773: 1, L0766: 1,							
--	--	--	---	--	--	--	--	--	--	--

21	HBAFA02	679555	31	46 - 369	124			L0803: 1, L0804: 1, L0776: 1, L0659: 1, L0783: 1, L0790: 1, H0144: 1, S0374: 1, S0126: 1, H0689: 1, H0682: 1, H0658: 1, H0670: 1, H0672: 1, H0710: 1, H0521: 1, H0134: 1, S3012: 1, L0744: 1, L0756: 1, L0780: 1, L0753: 1, S0194: 1, S0276: 1, S0196: 1, H0542: 1, H0422: 1 and S0384: 1.			600281, 600281
								AR281: 67, AR315: 49, AR314: 42, AR280: 41, AR194: 38, AR202: 35, AR265: 31, AR244: 27, AR310: 26, AR206: 26, AR205: 23, AR207: 22, AR263: 21, AR241: 21, AR055: 21, AR292: 20, AR033: 20, AR039: 20, AR195: 18, AR052: 18, AR283: 18, AR309: 18, AR246: 18, AR251: 18, AR192: 17, AR271: 17, AR053: 17, AR096: 17, AR284: 16, AR282:	20q12-q13		

[illegible]





22	H2CBT75	703079	32	32 - 211	125	His-44 to Gly-49.	3, AR239: 3, AR173: 3, AR255: 3, AR180: 3, AR260: 2 L0769: 3, L0757: 3, H0622: 2, H0633: 2, L0662: 2, H0522: 2, L0758: 2, H0556: 1, H0411: 1, H0410: 1, H0333: 1, H0597: 1, H0546: 1, H0620: 1, S0022: 1, L0194: 1, H0628: 1, H0488: 1, L0351: 1, L0768: 1, L0794: 1, L0774: 1, H0520: 1, H0435: 1, H0539: 1 and L0751: 1. AR292: 12, AR241: 10, AR298: 9, AR184: 9, AR313: 9, AR186: 8, AR233: 7, AR052: 7, AR089: 7, AR182: 7, AR229: 7, AR284: 7, AR293: 6, AR296: 6, AR270: 6, AR060: 6, AR299: 6, AR269: 6, AR226: 6, AR248: 6, AR294: 6, AR267: 6, AR266: 6, AR289: 5, AR285: 5, AR238:		
----	---------	--------	----	----------	-----	-------------------	---	--	--

[illegible]



23	HAGDQ42	702035	33	126 - 869	126	Tyr-16 to Ser-22, Asp-209 to Leu-215.	AR251: 12, AR253: 10, AR089: 9, AR204: 8, AR312: 8, AR060: 8, AR309: 8, AR186: 8, AR270: 7, AR053: 7, AR275: 7, AR052: 7, AR292: 7, AR246: 7, AR218: 7, AR248: 7, AR219: 7, AR249: 7, AR241: 6, AR202: 6, AR104: 6, AR313: 6, AR267: 6, AR268: 6, AR033: 6, AR271: 6, AR185: 6, AR175: 6, AR183: 6, AR265: 6, AR274: 6, AR316: 6, AR273: 6, AR282: 6, AR269: 6, AR310: 5, AR290: 5, AR182: 5, AR285: 5, AR238: 5, AR299: 5, AR213: 5, AR177: 5, AR055: 5, AR258: 5, AR295: 5, AR198: 5, AR293: 5, AR259: 5, AR266: 4, AR263: 4, AR294: 4, AR284: 4, AR096: 4, AR240: 4, AR243: 4, AR300: 4, AR194:	14q22.1-q22.3	112262, 182600, 182870, 182870, 182870, 600225, 600225
----	---------	--------	----	-----------	-----	--	--	---------------	--

							4, AR277: 4, AR231: 3, AR291: 3, AR061: 3, AR298: 3, AR286: 3, AR247: 3, AR226: 3, AR296: 3, AR229: 3, AR289: 3, AR256: 3, AR192: 3, AR184: 3, AR237: 3, AR232: 2, AR283: 2, AR206: 2, AR233: 2, AR234: 2, AR227: 2, AR205: 2, AR179: 1, AR244: 1, AR039: 1 L0439: 12, H0046: 9, L0766: 6, L0777: 5, L0759: 5, L0438: 4, L0740: 4, H0486: 3, L0659: 3, H0539: 3, L0750: 3, S0358: 2, S6028: 2, H0688: 2, H0553: 2, H0038: 2, H0551: 2, L0666: 2, H0547: 2, L0752: 2, L0758: 2, S0434: 2, H0170: 1, S6024: 1, H0740: 1, H0638: 1, S0444: 1, S0360: 1, H0455: 1, H0013: 1, H0156: 1, H0575: 1,
--	--	--	--	--	--	--	--

24	HBMCI42	713345	34	244 - 987	127	Lys-9 to Ala-17, Met-55 to Leu-61, Tyr-105 to Cys-127, Asp-132 to Lys-141, Ser-165 to Tyr-172, Pro-178 to Met-186, His-222 to Gln-227.	S0010: 1, H0052: 1, H0327: 1, S0250: 1, S0214: 1, H0328: 1, H0428: 1, H0040: 1, H0268: 1, L0435: 1, H0560: 1, S0352: 1, L0769: 1, L0646: 1, L0662: 1, L0774: 1, L0775: 1, L0776: 1, L0655: 1, L0663: 1, L0664: 1, L0665: 1, H0144: 1, S0374: 1, H0520: 1, H0519: 1, H0659: 1, S0330: 1, H0525: 1, S0406: 1, S0028: 1, L0749: 1, L0753: 1, H0668: 1, S0026: 1 and H0667: 1.		
							AR254: 5, AR195: 4, AR096: 4, AR060: 4, AR316: 4, AR215: 4, AR165: 3, AR162: 3, AR164: 3, AR166: 3, AR270: 3, AR089: 3, AR283: 3, AR282: 3, AR216: 2, AR104: 2, AR313: 2, AR053: 2, AR172: 2, AR299: 2, AR296: 2, AR224: 2,		





25	HDPBQ71	1160316	35	93 - 1928	128	<p>Leu-56 to Thr-62,  Gln-80 to Pro-87,  Gly-106 to Gln-113,  Pro-122 to Lys-127,  Gln-138 to Asn-146,  Cys-280 to Lys-287,  Asp-306 to Gly-311,  Asp-321 to Thr-326,  Gly-337 to Pro-345,  Thr-354 to Gln-359,  Asn-451 to Ile-457,  Lys-526 to Glu-532,  Gln-591 to Glu-603.</p>	<p>AR281: 64, AR202:  46, AR280: 44, AR315:  42, AR314: 41, AR194:  37, AR206: 29, AR244:  28, AR265: 26, AR310:  25, AR241: 22, AR246:  21, AR249: 21, AR292:  20, AR284: 20, AR251:  19, AR273: 19, AR096:  19, AR033: 19, AR263:  19, AR039: 18, AR205:  18, AR248: 17, AR283:  17, AR052: 17, AR282:  16, AR213: 16, AR275:  15, AR243: 15, AR298:  15, AR232: 14, AR299:  14, AR300: 13, AR198:  13, AR274: 13, AR259:  13, AR271: 12, AR270:  12, AR295: 12, AR247:  11, AR186: 11, AR184:  11, AR192: 11, AR277:  11, AR266: 11, AR204:  11, AR291: 11, AR053:  10, AR296: 10, AR268:  10, AR089: 10, AR294:  10, AR253: 9, AR175:</p>	<p>HO710: 1, SO190: 1 and  L0747: 1.</p>		
----	---------	---------	----	-----------	-----	--	---	--	--	--

9, AR177: 9, AR183:							
9, AR312: 9, AR293:							
9, AR285: 9, AR185:							
8, AR269: 8, AR182:							
8, AR309: 8, AR256:							
8, AR238: 8, AR219:							
8, AR316: 8, AR055:							
8, AR240: 7, AR313:							
7, AR286: 7, AR226:							
7, AR234: 7, AR218:							
7, AR289: 7, AR237:							
7, AR290: 7, AR104:							
6, AR227: 6, AR245:							
6, AR231: 6, AR258:							
6, AR229: 6, AR267:							
6, AR061: 6, AR060:							
5, AR170: 5, AR250:							
4, AR179: 4, AR233:							
4, AR195: 3, AR212:							
3, AR162: 3, AR161:							
3, AR163: 3, AR166:							
3, AR252: 3, AR311:							
3, AR225: 2, AR221:							
2, AR308: 2, AR264:							
2, AR217: 2, AR165:							
2, AR164: 2, AR173:							
2, AR168: 2, AR176:							
2, AR181: 2, AR272:							
2, AR178: 1, AR174:							

1	L0439: 8, H0551: 5, L0754: 5, L0777: 5, H0624: 4, L0666: 4, L0438: 4, L0748: 4, L0759: 4, H0031: 3, S0422: 3, L0774: 3, H0521: 3, L0779: 3, S0222: 2, H0156: 2, L0471: 2, H0373: 2, H0038: 2, T0067: 2, H0494: 2, L0649: 2, L0776: 2, H0547: 2, H0539: 2, H0696: 2, L0756: 2, L0755: 2, L0731: 2, L0757: 2, L0592: 2, H0170: 1, H0171: 1, H0556: 1, S0116: 1, H0341: 1, H0661: 1, H0662: 1, H0125: 1, S0420: 1, S0442: 1, S0354: 1, S0444: 1, S0408: 1, H0580: 1, H0208: 1, S0132: 1, H0645: 1, S6016: 1, H0013: 1, H0427: 1, H0706: 1, H0510: 1, H0375: 1, S0250: 1, S0003: 1,								
---	--	--	--	--	--	--	--	--	--

								H0615: 1, S0036: 1, H0163: 1, H0090: 1, H0616: 1, H0412: 1, L0564: 1, L0065: 1, S0438: 1, H0633: 1, S0344: 1, S0002: 1, L0640: 1, L0803: 1, L0775: 1, L0807: 1, L0659: 1, L0663: 1, L0665: 1, S0126: 1, H0711: 1, H0658: 1, S0328: 1, S0380: 1, S0406: 1, S0392: 1, S0390: 1, S0037: 1, S0028: 1, L0751: 1, L0747: 1, L0749: 1, L0758: 1, L0599: 1, L0603: 1, L0366: 1, S0011: 1, S0242: 1, S0194: 1, H0542: 1, H0423: 1 and H0506: 1.			
	HDPBQ71	727200	97	24 - 1859	190	Leu-56 to Thr-62, Gln-80 to Pro-87, Gly-106 to Gln-113, Pro-122 to Lys-127, Gln-138 to Asn-146.					
	HDPFQ90	886067	98	165 - 1535	191	Leu-56 to Thr-62, Gln-80 to Pro-87, Gly-106 to Gln-113,					

26	HCEJG71	71592	36	28 - 1368	129	Pro-122 to Lys-127, Gln-138 to Asn-146, Cys-280 to Lys-287, Asp-306 to Gly-311, Asp-321 to Thr-326, Gly-337 to Pro-345, Thr-354 to Gln-359, Asn-451 to Arg-456.	AR060: 198, AR185: 189, AR299: 177, AR104: 153, AR283: 143, AR240: 119, AR282: 116, AR316: 113, AR277: 101, AR089: 100, AR096: 75, AR313: 54 H0038: 8, H0618: 7, L0747: 6, L0758: 5, H0135: 4, H0616: 4, H0024: 3, H0547: 3, S0406: 3, L0439: 3, L0777: 3, L0759: 3, S0420: 2, H0208: 2, H0370: 2, H0014: 2, S0344: 2, L0788: 2, L0666: 2, S0374: 2, L0438: 2, L0751: 2, S0436: 2, S0040: 1, S0342: 1, H0716: 1,	7q11.23	116860, 129900, 233700, 600079	
----	---------	-------	----	-----------	-----	--	--	---------	---	--

27	HELHL48	696945	37	629 - 1501	130	Pro-44 to Lys-54,	H0650: 1, S0212: 1, S0001: 1, S0356: 1, H0607: 1, H0270: 1, L0022: 1, H0036: 1, H0253: 1, H0581: 1, S0049: 1, H0052: 1, H0596: 1, H0327: 1, H0545: 1, H0123: 1, H0012: 1, T0010: 1, H0083: 1, H0687: 1, H0292: 1, S0250: 1, H0039: 1, H0031: 1, H0644: 1, S0366: 1, H0591: 1, H0634: 1, T0067: 1, H0264: 1, L0351: 1, H0494: 1, S0002: 1, L0369: 1, L0770: 1, L0769: 1, L0388: 1, L0804: 1, L0652: 1, L0659: 1, L0542: 1, L0809: 1, L0664: 1, H0593: 1, H0690: 1, H0659: 1, S0152: 1, S0037: 1, S0028: 1, L0745: 1, L0755: 1, L0603: 1, S0192: 1, S0242: 1, H0423: 1 and H0506: 1.	AR186: 437, AR104:	
----	---------	--------	----	------------	-----	-------------------	---	--------------------	--

Cys-88 to His-95, Val-103 to Tyr-108, Gln-181 to Ser-190, Thr-192 to Ile-206, Glu-233 to Ser-245, Ser-252 to Ala-286.	432, AR259: 388, AR284: 383, AR298: 371, AR229: 344, AR061: 337, AR226: 293, AR206: 282, AR227: 247, AR237: 242, AR292: 218, AR185: 211, AR184: 204, AR232: 190, AR194: 189, AR233: 186, AR231: 169, AR294: 167, AR267: 166, AR175: 165, AR182: 165, AR286: 163, AR243: 162, AR060: 161, AR241: 161, AR204: 155, AR192: 154, AR256: 152, AR052: 151, AR179: 148, AR275: 148, AR244: 148, AR198: 142, AR293: 139, AR238: 138, AR258: 136, AR273: 136, AR033: 135, AR285: 133, AR299: 131, AR300: 124, AR248: 122, AR289: 119, AR219: 118,
--	--

						AR249: 114, AR234: 112, AR316: 111, AR218: 109, AR295: 106, AR274: 104, AR205: 104, AR290: 103, AR282: 103, AR177: 102, AR240: 99, AR039: 95, AR291: 94, AR202: 89, AR270: 88, AR055: 88, AR268: 86, AR269: 85, AR251: 82, AR266: 81, AR089: 79, AR053: 75, AR183: 73, AR213: 68, AR310: 67, AR296: 66, AR283: 65, AR271: 63, AR312: 58, AR246: 57, AR313: 55, AR309: 55, AR247: 54, AR265: 46, AR253: 46, AR277: 45, AR096: 32, AR314: 22, AR263: 20, AR190: 11, AR280: 11, AR199: 11, AR176: 11, AR315: 11, AR181: 11, AR189: 11, AR228: 11, AR174: 11, AR163: 10, AR162: 10, AR196: 10, AR161: 10, AR272: 10, AR236: 9, AR180:
--	--	--	--	--	--	---



[illegible]



				S0040: 1, H0713: 1, H0717: 1, S0444: 1, T0008: 1, H0580: 1, S0132: 1, H0393: 1, H0411: 1, S0278: 1, H0441: 1, H0455: 1, H0632: 1, H0069: 1, L0021: 1, H0036: 1, H0590: 1, S0049: 1, H0052: 1, H0009: 1, H0570: 1, H0081: 1, L0471: 1, H0023: 1, H0014: 1, H0015: 1, H0373: 1, S0051: 1, H0188: 1, H0284: 1, S0250: 1, S0003: 1, H0615: 1, H0039: 1, T0006: 1, H0644: 1, L0455: 1, S0036: 1, H0163: 1, H0372: 1, H0634: 1, H0616: 1, H0063: 1, T0067: 1, H0433: 1, H0268: 1, H0269: 1, H0413: 1, L0564: 1, H0509: 1, S0150: 1, L0631: 1, L0646: 1, L0765: 1, L0653: 1, L0776: 1, L0606: 1, L0658: 1,				
--	--	--	--	---	--	--	--	--

								L0789: 1, L0664: 1, H0547: 1, S0126: 1, H0435: 1, S0152: 1, H0521: 1, H0696: 1, S0406: 1, H0555: 1, H0436: 1, H0631: 1, L0743: 1, L0744: 1, L0749: 1, L0755: 1, L0757: 1, S0434: 1, L0599: 1 and L0608: 1.			
	HSKCT36	610025	99	31 - 585	192	Pro-44 to Lys-54, Cys-88 to His-95, Val-103 to Tyr-108, Leu-146 to Pro-157, Pro-176 to Gln-184.					
28	HISAQ04	589960	38	61 - 294	131	Thr-27 to Ser-33.		AR313: 12, AR089: 10, AR165: 10, AR162: 10, AR164: 9, AR242: 9, AR161: 9, AR192: 9, AR166: 9, AR163: 9, AR207: 8, AR173: 8, AR300: 7, AR198: 7, AR263: 6, AR180: 6, AR195: 6, AR240: 6, AR247: 6, AR169: 6, AR096: 6, AR053: 6, AR039: 5, AR212: 5, AR229: 5, AR060: 5, AR174: 5, AR312:			

									5, AR177: 5, AR193: 5, AR204: 5, AR296: 5, AR185: 5, AR197: 5, AR236: 5, AR257: 5, AR183: 5, AR213: 5, AR275: 5, AR234: 5, AR205: 5, AR238: 5, AR214: 5, AR293: 5, AR178: 5, AR316: 4, AR171: 4, AR309: 4, AR274: 4, AR226: 4, AR271: 4, AR181: 4, AR299: 4, AR233: 4, AR308: 4, AR264: 4, AR243: 4, AR297: 4, AR282: 4, AR262: 4, AR182: 4, AR253: 4, AR179: 4, AR175: 4, AR033: 4, AR245: 4, AR230: 4, AR283: 4, AR277: 4, AR196: 4, AR222: 4, AR286: 4, AR285: 4, AR225: 4, AR270: 4, AR224: 3, AR261: 3, AR170: 3, AR201: 3, AR252: 3, AR104: 3, AR258: 3, AR266: 3, AR295: 3, AR268: 3, AR291:
--	--	--	--	--	--	--	--	--	---

								3, AR237: 3, AR228: 3, AR200: 3, AR287: 3, AR255: 3, AR294: 3, AR246: 3, AR239: 3, AR269: 3, AR231: 3, AR223: 3, AR221: 3, AR267: 2, AR289: 2, AR218: 2, AR217: 2, AR227: 2, AR216: 2, AR176: 2, AR055: 2, AR203: 2, AR290: 2, AR288: 2, AR191: 2, AR232: 2, AR219: 2, AR311: 2, AR188: 2, AR189: 2, AR260: 2, AR272: 2, AR199: 2, AR210: 1, AR061: 1, AR211: 1, AR254: 1, AR256: 1 H0662: 2, H0539: 1 and S0260: 1.		
29	HJACB89	689899	39	95 - 1093	132	Pro-32 to Gly-48, Gln-63 to Thr-69, Pro-77 to Trp-84, Val-88 to Leu-94.	AR176: 5, AR197: 5, AR192: 5, AR162: 5, AR161: 5, AR243: 5, AR163: 5, AR270: 5, AR271: 4, AR060: 4, AR183: 4, AR165: 4, AR172: 4, AR164: 4, AR309: 4, AR166: 4,			

AR240:	4, AR089:	4,
AR282:	4, AR096:	4,
AR274:	4, AR266:	3,
AR247:	3, AR275:	3,
AR178:	3, AR269:	3,
AR198:	3, AR268:	3,
AR180:	3, AR272:	3,
AR245:	3, AR181:	3,
AR201:	3, AR264:	3,
AR254:	3, AR316:	3,
AR182:	3, AR250:	3,
AR104:	3, AR222:	3,
AR291:	3, AR277:	3,
AR300:	3, AR216:	3,
AR207:	3, AR168:	3,
AR233:	3, AR224:	3,
AR257:	2, AR170:	2,
AR230:	2, AR173:	2,
AR267:	2, AR223:	2,
AR289:	2, AR290:	2,
AR175:	2, AR238:	2,
AR299:	2, AR177:	2,
AR229:	2, AR053:	2,
AR171:	2, AR228:	2,
AR193:	2, AR061:	2,
AR255:	2, AR195:	2,
AR237:	2, AR294:	2,
AR185:	2, AR239:	2,
AR283:	2, AR055:	2,

						AR217: 2, AR210: 2, AR179: 2, AR199: 2, AR312: 2, AR313: 2, AR286: 2, AR033: 2, AR174: 2, AR261: 2, AR227: 2, AR263: 2, AR234: 2, AR226: 2, AR225: 1, AR231: 1, AR311: 1, AR190: 1, AR242: 1, AR189: 1, AR293: 1, AR262: 1, AR191: 1, AR258: 1, AR205: 1, AR288: 1, AR236: 1, AR218: 1 L0769: 6, S0046: 2, H0213: 2, L0662: 2, L0657: 2, L0809: 2, L0439: 2, L0747: 2, L0731: 2, L0758: 2, S0434: 2, S0418: 1, H0619: 1, H0645: 1, H0441: 1, H0486: 1, H0544: 1, H0545: 1, H0046: 1, H0123: 1, H0428: 1, H0135: 1, H0264: 1, H0100: 1, T0041: 1, H0494: 1, S0002: 1, L0372: 1, L0771: 1, L0767: 1,
--	--	--	--	--	--	--



30	HTECC05	666743	40	27 - 518	133	Gly-41 to Leu-46, Asp-67 to Thr-75, Ile-114 to Ala-123.	L0665: 1, H0144: 1, H0547: 1, S0126: 1, S0350: 1, L0748: 1, L0750: 1, L0779: 1, S0436: 1 and S0242: 1. AR176: 5, AR169: 3, AR224: 3, AR180: 3, AR291: 3, AR225: 3, AR238: 3, AR267: 3, AR261: 2, AR245: 2, AR289: 2, AR270: 2, AR257: 2, AR175: 2, AR269: 2, AR168: 2, AR181: 2, AR228: 2, AR243: 2, AR309: 2, AR285: 2, AR295: 2, AR217: 2, AR230: 2, AR293: 2, AR239: 2, AR171: 2, AR177: 2, AR294: 2, AR236: 2, AR313: 1, AR296: 1, AR231: 1, AR096: 1, AR290: 1, AR190: 1, AR227: 1, AR179: 1, AR246: 1, AR312: 1, AR287: 1, AR247: 1, AR271: 1, AR266: 1, AR178: 1, AR250: 1, AR061: 1, AR182: 1,		
----	---------	--------	----	----------	-----	---	--	--	--





31	HBJLF01	732111	41	217 - 951	134	Tyr-123 to Tyr-131, Cys-134 to Ser-145,	H0181: 1, H0182: 1, H0606: 1, L0055: 1, H0163: 1, H0063: 1, T0067: 1, H0100: 1, H0560: 1, H0561: 1, H0647: 1, S0142: 1, L0598: 1, L3904: 1, L0761: 1, L0772: 1, L0764: 1, L0767: 1, L0768: 1, L0766: 1, L0649: 1, L0803: 1, L0375: 1, L0806: 1, L0776: 1, L0517: 1, L0526: 1, L0783: 1, L0789: 1, H0144: 1, L0438: 1, H0689: 1, H0690: 1, H0682: 1, H0683: 1, H0435: 1, H0659: 1, H0648: 1, H0521: 1, H0522: 1, S3014: 1, S0027: 1, L0755: 1, L0759: 1, H0445: 1, H0343: 1, H0595: 1, L0608: 1, H0136: 1, S0276: 1, H0542: 1, L0600: 1 and H0352: 1.	AR060: 20, AR213: 13, AR053: 11, AR052:	
----	---------	--------	----	-----------	-----	--	--	--	--

	Tyr-234 to Tyr-244.	11, AR249: 9, AR248: 9, AR251: 8, AR246: 8, AR055: 7, AR238: 7, AR282: 6, AR061: 6, AR253: 6, AR316: 6, AR182: 6, AR186: 5, AR313: 5, AR273: 5, AR204: 5, AR192: 5, AR309: 5, AR183: 5, AR234: 5, AR233: 5, AR312: 5, AR241: 4, AR277: 4, AR270: 4, AR247: 4, AR033: 4, AR198: 4, AR104: 4, AR039: 4, AR269: 4, AR096: 4, AR274: 4, AR232: 4, AR265: 4, AR267: 4, AR275: 4, AR283: 4, AR310: 4, AR299: 4, AR227: 4, AR268: 4, AR291: 3, AR229: 3, AR185: 3, AR202: 3, AR237: 3, AR205: 3, AR226: 3, AR300: 3, AR089: 3, AR243: 3, AR240: 3, AR294: 3, AR293: 3, AR295: 3, AR177: 3, AR271: 3, AR184:
--	---------------------	--

[illegible]

32	HBXGP60	566892	42	143 - 310	135	Thr-25 to Pro-46.	L0783: 1, L4501: 1, L0664: 1, L0438: 1, H0547: 1, S0328: 1, H0518: 1, L0746: 1, L0749: 1, H0445: 1, S0436: 1 and H0542: 1. AR253: 10, AR254: 7, 1 AR250: 7, AR297: 7, AR235: 7, AR287: 6, AR233: 6, AR226: 6, AR178: 6, AR165: 6, AR183: 6, AR182: 5, AR164: 5, AR296: 5, AR176: 5, AR293: 5, AR234: 5, AR286: 5, AR268: 5, AR267: 5, AR285: 5, AR166: 5, AR161: 5, AR291: 5, AR238: 5, AR060: 5, AR179: 4, AR283: 4, AR228: 4, AR294: 4, AR227: 4, AR270: 4, AR162: 4, AR239: 4, AR193: 4, AR089: 4, AR061: 4, AR175: 4, AR231: 4, AR180: 4, AR229: 4, AR289: 4, AR204: 4, AR257: 4, AR271: 4, AR295: 4,		
----	---------	--------	----	-----------	-----	-------------------	---	--	--

[illegible]



								AR243: 2, AR282: 2, AR198: 2, AR200: 2, AR215: 2, AR312: 2, AR311: 2, AR196: 2, AR272: 2, AR256: 1, AR214: 1, AR245: 1, AR309: 1, AR264: 1, AR168: 1, AR216: 1 L0764: 4, L0803: 3, H0586: 2, L0666: 2, L0664: 2, L0438: 2, S0360: 1, H0438: 1, S0364: 1, L0769: 1, L0772: 1, L0646: 1, L0805: 1, L0653: 1, L0518: 1, L0665: 1, H0684: 1, H0648: 1, H0672: 1 and L0759: 1.		
33	HCE5B20	544507	43	237 - 401	136			AR268: 9, AR242: 7, AR176: 7, AR309: 6, AR197: 6, AR243: 6, AR253: 6, AR300: 6, AR290: 6, AR161: 6, AR299: 6, AR163: 6, AR162: 6, AR267: 6, AR266: 5, AR039: 5, AR204: 5, AR181: 5, AR229: 5, AR228: 5, AR060: 5, AR165: 5,		



34	HCM5Q56	740781	44	148 - 414	137	Pro-61 to Asp-68.	AR287: 2, AR311: 2, AR263: 2, AR255: 2, AR174: 2, AR297: 2, AR203: 2, AR240: 2, AR185: 2, AR262: 2, AR188: 2, AR293: 2, AR200: 2, AR312: 2, AR277: 2, AR195: 2, AR294: 2, AR295: 2, AR172: 2, AR212: 2, AR291: 2, AR232: 2, AR191: 2, AR196: 2, AR210: 2, AR190: 2, AR225: 1, AR216: 1, AR219: 1, AR189: 1, AR256: 1, AR252: 1 H0013: 1 and H0052: 1.	5q31	121050, 131400, 138040, 153455, 159000, 179095, 181460, 192974, 192974, 600807, 601596,
----	---------	--------	----	-----------	-----	-------------------	--	------	---

								AR199: 1, AR162: 1 H0257: 19, H0559: 6, H0256: 3, L0595: 3, H0266: 2, L0744: 2, L0751: 2, S0134: 1, H0583: 1, S0212: 1, H0440: 1, L0717: 1, H0333: 1, H0575: 1, H0196: 1, H0123: 1, H0373: 1, H0252: 1, H0059: 1, S0144: 1, S0002: 1, H0529: 1, L0769: 1, L0800: 1, L0662: 1, L0767: 1, L0794: 1, L0658: 1, L0789: 1, L0666: 1, L0663: 1, L0664: 1, L0565: 1, H0651: 1, H0521: 1, L0439: 1, L0749: 1, L0757: 1, S0276: 1, S0196: 1 and H0352: 1.		601692, 601692, 601692, 601692, 602089, 602121, 602460
35	HCNAH57	694610	45	35 - 220	138			AR245: 6, AR204: 5, AR192: 5, AR193: 4, AR169: 4, AR253: 4, AR161: 3, AR162: 3, AR163: 3, AR266: 3, AR176: 3, AR170: 3, AR240: 3, AR165: 3,		

						AR089: 3, AR164: 3, AR250: 2, AR166: 2, AR282: 2, AR222: 2, AR277: 2, AR214: 2, AR269: 2, AR201: 2, AR216: 2, AR261: 2, AR173: 2, AR289: 2, AR268: 2, AR263: 2, AR291: 2, AR271: 2, AR033: 2, AR183: 2, AR182: 2, AR286: 2, AR213: 2, AR257: 2, AR274: 2, AR217: 2, AR233: 2, AR300: 1, AR096: 1, AR255: 1, AR270: 1, AR272: 1, AR267: 1, AR205: 1, AR226: 1, AR316: 1, AR288: 1, AR195: 1, AR264: 1, AR236: 1, AR283: 1, AR203: 1, AR181: 1, AR191: 1, AR171: 1, AR196: 1, AR297: 1, AR060: 1, AR239: 1, AR294: 1, AR296: 1, AR262: 1, AR308: 1, AR229: 1, AR185: 1 H0085: 1
--	--	--	--	--	--	---

36	HCUJEP91	610610	46	266 - 583	139	Pro-19 to Cys-29, Thr-35 to Glu-44, Val-72 to Lys-78.	AR104: 9, AR089: 9, AR185: 9, AR060: 8, AR277: 7, AR316: 6, AR240: 6, AR282: 5, AR299: 4, AR096: 4, AR313: 4, AR283: 2 H0402: 2		
37	HDPCJ91	740748	47	131 - 286	140	Tyr-33 to Lys-38.	AR274: 86, AR216: 79, AR214: 77, AR205: 65, AR222: 63, AR245: 61, AR246: 60, AR215: 59, AR223: 59, AR224: 58, AR212: 55, AR213: 53, AR217: 53, AR272: 53, AR168: 52, AR169: 51, AR171: 50, AR252: 48, AR195: 45, AR225: 45, AR170: 45, AR089: 44, AR308: 44, AR053: 44, AR039: 43, AR197: 43, AR312: 42, AR172: 42, AR313: 41, AR218: 41, AR165: 40, AR271: 40, AR221: 37, AR096: 37, AR254: 37, AR164: 37, AR166: 36, AR247: 36, AR309: 36, AR299: 35, AR163: 35, AR210: 33, AR161: 32, AR162:		

							32, AR253: 32, AR236: 30, AR311: 30, AR316: 29, AR173: 29, AR199: 28, AR060: 28, AR188: 28, AR179: 28, AR250: 27, AR189: 27, AR192: 27, AR174: 26, AR211: 26, AR263: 26, AR282: 26, AR185: 26, AR190: 25, AR204: 25, AR275: 24, AR283: 24, AR198: 24, AR175: 23, AR201: 23, AR243: 23, AR183: 23, AR219: 22, AR291: 22, AR240: 22, AR267: 22, AR288: 20, AR290: 20, AR295: 20, AR300: 20, AR180: 20, AR193: 19, AR277: 19, AR178: 19, AR177: 19, AR268: 19, AR296: 19, AR266: 18, AR269: 18, AR256: 18, AR264: 18, AR297: 18, AR293: 17, AR242: 17, AR191: 17, AR261: 17, AR262: 17, AR231: 17, AR255: 16, AR203: 16, AR237: 16, AR200: 16, AR181: 16, AR176:
--	--	--	--	--	--	--	---

38	HDPGK25	704067	48	345 - 701	141	Met-1 to Ser-7, Asp-32 to Pro-43, Ser-96 to Arg-102.	15, AR289: 15, AR182: 15, AR104: 15, AR270: 15, AR232: 14, AR230: 14, AR285: 13, AR287: 13, AR033: 13, AR257: 13, AR239: 13, AR229: 13, AR258: 13, AR061: 13, AR207: 12, AR234: 12, AR260: 12, AR055: 12, AR233: 11, AR294: 11, AR286: 11, AR227: 10, AR196: 10, AR238: 10, AR235: 10, AR226: 10, AR228: 9 S0442: 1, H0580: 1, S0045: 1, H0013: 1, H0581: 1, H0266: 1, L0766: 1, L0791: 1, H0521: 1 and L0740: 1. AR250: 5, AR263: 5, 12 AR216: 4, AR176: 4, AR172: 3, AR225: 3, AR183: 3, AR169: 3, AR221: 3, AR274: 3, AR165: 3, AR164: 3, AR166: 3, AR184: 3, AR168: 2, AR311: 2, AR053: 2, AR230: 2, AR282: 2, AR264: 2,		
----	---------	--------	----	-----------	-----	--	--	--	--





	L0747: 6, L0779: 6, L0752: 6, S0132: 5, L0664: 5, L0744: 5, L0754: 5, S0040: 4, H0662: 4, H0411: 4, H0251: 4, H0597: 4, L0471: 4, H0024: 4, S0022: 4, L0809: 4, L0663: 4, L0439: 4, L0749: 4, L0756: 4, L0362: 4, L0002: 3, H0600: 3, H0599: 3, S0250: 3, H0039: 3, H0622: 3, H0616: 3, L0805: 3, S0126: 3, H0521: 3, L0759: 3, H0170: 2, S0212: 2, H0255: 2, S0418: 2, L0717: 2, S0222: 2, H0592: 2, H0486: 2, H0590: 2, H0196: 2, H0231: 2, H0373: 2, L0483: 2, L0564: 2, S0002: 2, L0772: 2, L0641: 2, L0764: 2, L0806: 2, L0776: 2, L0384: 2, H0144: 2, S0044: 2, H0555: 2, H0595: 2, L0592: 2,						
--	---	--	--	--	--	--	--

		L0599: 2, L0603: 2, S0194: 2, H0624: 1, S0001: 1, H0663: 1, H0664: 1, H0638: 1, S0376: 1, H0637: 1, H0580: 1, H0393: 1, H0437: 1, H0453: 1, H0370: 1, H0586: 1, H0331: 1, H0574: 1, H0559: 1, H0485: 1, H0013: 1, H0635: 1, H0427: 1, H0118: 1, H0575: 1, H0036: 1, H0253: 1, L0105: 1, H0318: 1, H0234: 1, H0546: 1, H0050: 1, H0105: 1, S0388: 1, H0271: 1, S0318: 1, H0252: 1, H0428: 1, H0553: 1, H0644: 1, H0673: 1, S0364: 1, S0366: 1, H0591: 1, H0634: 1, H0412: 1, H0413: 1, H0100: 1, S0112: 1, T0041: 1, H0494: 1, H0641: 1, H0646: 1, S0208: 1, L0763: 1, L0372: 1, L0771: 1, L0648: 1,					
--	--	---	--	--	--	--	--

39	HE2DY70	722217	49	137 - 313	142		L0768: 1, L0364: 1, L0794: 1, L0774: 1, L0379: 1, L0512: 1, L0647: 1, L0788: 1, L0665: 1, S0374: 1, L0438: 1, H0684: 1, H0672: 1, S0330: 1, S0380: 1, S0152: 1, H0579: 1, H0522: 1, S0013: 1, S0146: 1, H0631: 1, S0432: 1, S0037: 1, L0745: 1, L0750: 1, L0777: 1, L0757: 1, H0444: 1, L0596: 1, L0597: 1, L0591: 1, S0011: 1, S0026: 1, S0192: 1, H0422: 1 and H0008: 1.	AR252: 8, AR215: 6, AR242: 3, AR225: 3, AR201: 2, AR180: 2, AR266: 2, AR231: 2, AR181: 2, AR271: 2, AR161: 1, AR162: 1, AR195: 1, AR257: 1, AR262: 1, AR089: 1, AR300: 1, AR217: 1, AR258: 1, AR193: 1, AR291: 1	IOpter-q23.33	
----	---------	--------	----	-----------	-----	--	---	--	---------------	--

40	HE2NV57	740750	50	99 - 398	143	Ala-84 to Gln-93.	S0003: 3, H0170: 1, S0278: 1, L0637: 1, L0777: 1, L0731: 1, L0758: 1 and L0362: 1. AR235: 6, AR282: 4, AR309: 4, AR171: 4, AR270: 4, AR178: 3, AR272: 3, AR245: 3, AR269: 3, AR291: 3, AR169: 3, AR268: 3, AR213: 3, AR215: 3, AR254: 3, AR267: 3, AR289: 3, AR274: 3, AR236: 3, AR300: 3, AR175: 3, AR053: 3, AR228: 3, AR261: 3, AR242: 2, AR161: 2, AR181: 2, AR308: 2, AR257: 2, AR238: 2, AR182: 2, AR266: 2, AR204: 2, AR237: 2, AR170: 2, AR288: 2, AR290: 2, AR188: 2, AR297: 2, AR168: 2, AR262: 2, AR162: 2, AR163: 2, AR296: 2, AR233: 2, AR210: 2, AR285: 2, AR295: 2, AR264: 2, AR293: 2,		
----	---------	--------	----	----------	-----	-------------------	--	--	--



41	HETBR16	703243	51	161 - 355	144	Πe-23 to Ala-29.	H0100: 1, S0052: 1, S0374: 1, H0696: 1 and L0743: 1. AR162: 11, AR176: 10, AR178: 10, AR163: 10, AR161: 10, AR165: 10, AR229: 10, AR164: 10, AR166: 10, AR313: 10, AR173: 9, AR257: 9, AR268: 9, AR293: 8, AR269: 8, AR179: 8, AR181: 8, AR309: 8, AR197: 8, AR180: 8, AR300: 7, AR182: 7, AR266: 7, AR196: 7, AR247: 7, AR233: 7, AR189: 7, AR089: 7, AR238: 7, AR264: 7, AR228: 7, AR239: 7, AR183: 7, AR174: 7, AR175: 7, AR177: 7, AR226: 7, AR191: 6, AR261: 6, AR296: 6, AR192: 6, AR267: 6, AR258: 6, AR270: 6, AR204: 6, AR190: 6, AR237: 6, AR262: 6, AR203: 6, AR236: 5, AR263: 5, AR286:		
----	---------	--------	----	-----------	-----	------------------	---	--	--

[illegible]



42	HFXDG13	657390	52	43 - 243	145			3, AR224: 2, AR207: 2, AR219: 2, AR246: 2, AR104: 2, AR243: 2, AR283: 2, AR210: 2, AR168: 2, AR252: 1, AR211: 1 H0597: 1, H0046: 1, H0110: 1, S0422: 1, L0598: 1, H0436: 1, H0445: 1 and L0608: 1.		
								AR252: 10, AR161: 8, AR162: 8, AR253: 8, AR163: 8, AR291: 7, AR269: 7, AR165: 6, AR250: 6, AR270: 6, AR164: 6, AR182: 6, AR166: 6, AR089: 6, AR264: 6, AR178: 6, AR053: 6, AR192: 5, AR296: 5, AR246: 5, AR060: 5, AR223: 5, AR096: 5, AR266: 5, AR181: 5, AR179: 5, AR191: 5, AR295: 5, AR168: 5, AR268: 5, AR274: 5, AR201: 5, AR299: 5, AR205: 5, AR183: 5, AR297: 5, AR243: 5, AR272: 5,		

					AR287: 5, AR263: 5, AR311: 5, AR271: 5, AR176: 5, AR207: 5, AR312: 4, AR175: 4, AR212: 4, AR285: 4, AR289: 4, AR313: 4, AR257: 4, AR236: 4, AR308: 4, AR262: 4, AR282: 4, AR214: 4, AR267: 4, AR309: 4, AR216: 4, AR171: 4, AR180: 4, AR169: 4, AR294: 4, AR185: 4, AR316: 4, AR255: 4, AR193: 4, AR261: 4, AR188: 4, AR288: 4, AR293: 4, AR204: 4, AR174: 4, AR195: 4, AR197: 4, AR189: 4, AR286: 4, AR173: 4, AR300: 4, AR290: 4, AR190: 4, AR240: 4, AR254: 3, AR275: 3, AR177: 3, AR200: 3, AR228: 3, AR196: 3, AR198: 3, AR222: 3, AR170: 3, AR238: 3, AR233: 3, AR213: 3, AR219: 3, AR224: 3,				
--	--	--	--	--	---	--	--	--	--

43	HFXKY27	634161	53	44 - 220	146	Lys-23 to Lys-35, Met-46 to Tyr-52.	AR237: 3, AR231: 3, AR033: 3, AR199: 3, AR104: 3, AR039: 3, AR245: 3, AR218: 3, AR260: 3, AR258: 3, AR230: 3, AR247: 3, AR229: 3, AR221: 3, AR061: 2, AR055: 2, AR172: 2, AR225: 2, AR226: 2, AR217: 2, AR277: 2, AR239: 2, AR232: 2, AR227: 2, AR234: 2, AR203: 2, AR210: 2, AR211: 2, AR283: 2, AR256: 2, AR215: 1 S0052: 6, S0216: 5, H0637: 3, S0152: 3, H0694: 2, S0114: 1, S0001: 1, H0305: 1, H0619: 1, H0036: 1, H0615: 1, H0030: 1, H0032: 1, H0059: 1, L0532: 1, S0428: 1, L0758: 1 and H0543: 1.		
							AR282: 4, AR225: 3, AR176: 3, AR250: 3, AR270: 3, AR173: 3, AR164: 3, AR165: 3,		

AR172:	3, AR166:	3,							
AR257:	3, AR161:	3,							
AR175:	2, AR178:	2,							
AR162:	2, AR163:	2,							
AR033:	2, AR242:	2,							
AR264:	2, AR196:	2,							
AR300:	2, AR169:	2,							
AR269:	2, AR313:	2,							
AR253:	2, AR234:	2,							
AR238:	2, AR247:	2,							
AR293:	2, AR289:	2,							
AR171:	2, AR239:	2,							
AR277:	2, AR229:	2,							
AR266:	2, AR237:	2,							
AR295:	2, AR228:	2,							
AR299:	2, AR226:	2,							
AR207:	2, AR227:	2,							
AR233:	2, AR268:	2,							
AR190:	2, AR291:	2,							
AR255:	2, AR271:	2,							
AR193:	2, AR055:	2,							
AR203:	1, AR174:	1,							
AR168:	1, AR212:	1,							
AR287:	1, AR236:	1,							
AR290:	1, AR311:	1,							
AR179:	1, AR089:	1,							
AR296:	1, AR267:	1,							
AR258:	1, AR256:	1,							
AR240:	1, AR180:	1,							

44	HHPEC09	695726	54	71 - 238	147	Tyr-39 to Arg-51.	AR199: 1, AR262: 1, AR294: 1, AR183: 1, AR285: 1, AR308: 1 H0257: 49, H0256: 15 and S0282: 1.		
							AR254: 11, AR309: 9, AR264: 8, AR253: 8, AR176: 8, AR173: 7, AR182: 7, AR169: 7, AR268: 7, AR269: 7, AR162: 7, AR161: 6, AR183: 6, AR163: 6, AR270: 6, AR266: 6, AR235: 6, AR229: 6, AR221: 6, AR204: 6, AR165: 6, AR228: 6, AR164: 6, AR267: 5, AR261: 5, AR233: 5, AR181: 5, AR166: 5, AR179: 5, AR175: 5, AR060: 5, AR255: 5, AR300: 5, AR293: 5, AR214: 5, AR174: 5, AR290: 5, AR177: 5, AR262: 5, AR239: 5, AR180: 4, AR296: 4, AR257: 4, AR178: 4, AR247: 4, AR236: 4, AR061: 4, AR237: 4,		



						AR039: 2, AR216: 2, AR242: 2, AR219: 2, AR222: 2, AR210: 2, AR274: 2, AR200: 2, AR243: 2, AR218: 1, AR275: 1, AR211: 1 S0360: 3, L0769: 3, L0747: 3, H0046: 2, H0708: 2, H0087: 2, L0774: 2, L0378: 2, L0663: 2, L0744: 2, H0713: 1, H0294: 1, T0049: 1, H0661: 1, S0356: 1, S0442: 1, S0444: 1, S0046: 1, S0476: 1, H0550: 1, S0222: 1, H0333: 1, H0618: 1, S0049: 1, H0086: 1, H0051: 1, H0687: 1, T0023: 1, L0483: 1, H0124: 1, H0264: 1, S0002: 1, L0763: 1, L0772: 1, L0646: 1, L0794: 1, L0766: 1, L0649: 1, L0803: 1, L0658: 1, L0540: 1, L0793: 1, L0665: 1, S0126: 1, H0670: 1, H0660: 1,
--	--	--	--	--	--	--

45	HISAD54	740754	55	172 - 369	148				H0672: 1, H0555: 1, L0751: 1, L0749: 1, L0779: 1, L0752: 1, L0731: 1, H0445: 1, S0436: 1, L0592: 1, L0361: 1, H0423: 1 and H0352: 1. AR252: 7, AR298: 6, AR235: 6, AR292: 5, AR194: 5, AR285: 4, AR296: 4, AR294: 4, AR165: 4, AR224: 4, AR284: 4, AR282: 4, AR166: 4, AR164: 4, AR169: 4, AR215: 4, AR249: 4, AR286: 4, AR293: 4, AR236: 3, AR291: 3, AR270: 3, AR161: 3, AR162: 3, AR269: 3, AR311: 3, AR263: 3, AR163: 3, AR297: 3, AR186: 3, AR262: 3, AR295: 3, AR268: 3, AR266: 3, AR289: 3, AR052: 3, AR182: 3, AR287: 3, AR172: 3, AR206: 3, AR229: 3, AR238: 3, AR309: 3, AR299: 3,		
----	---------	--------	----	-----------	-----	--	--	--	--	--	--





									AR213: 1, AR241: 1, AR211: 1, AR188: 1, AR181: 1, AR177: 1, AR251: 1, AR185: 1, AR216: 1, AR225: 1, AR265: 1, AR060: 1, AR258: 1, AR267: 1 L0751: 7, L0439: 3, L0769: 2, L0789: 2, L0596: 2, S0358: 1, S0222: 1, H0052: 1, H0545: 1, H0617: 1, H0087: 1, L0364: 1, L0803: 1, L0774: 1, H0539: 1, S0332: 1, L0743: 1, L0748: 1, L0777: 1 and S0436: 1.			
46	HJBCY35	719729	56	232 - 1215	149	Glu-35 to His-41, Ser-62 to Ala-67, Pro-145 to Leu-155, Glu-157 to Ser-163, Arg-190 to Val-197, Asp-208 to Pro-215, Ser-247 to Pro-252.	AR215: 11, AR291: 11, AR225: 10, AR217: 9, AR216: 8, AR296: 8, AR214: 8, AR297: 8, AR266: 7, AR183: 7, AR257: 7, AR223: 7, AR170: 7, AR269: 7, AR287: 7, AR221: 6, AR270: 6, AR171: 6, AR182: 6, AR286: 6, AR169: 6, AR172: 6, AR294: 6, AR176:					

6, AR235: 6, AR163:							
5, AR295: 5, AR161:							
5, AR168: 5, AR255:							
5, AR162: 5, AR224:							
5, AR285: 5, AR293:							
5, AR268: 5, AR289:							
5, AR288: 5, AR263:							
5, AR264: 5, AR165:							
4, AR173: 4, AR260:							
4, AR262: 4, AR175:							
4, AR164: 4, AR179:							
4, AR222: 4, AR166:							
4, AR060: 4, AR181:							
4, AR242: 4, AR258:							
4, AR240: 4, AR104:							
4, AR311: 4, AR290:							
3, AR180: 3, AR283:							
3, AR247: 3, AR231:							
3, AR282: 3, AR267:							
3, AR233: 3, AR313:							
3, AR228: 3, AR236:							
3, AR316: 3, AR177:							
3, AR212: 3, AR256:							
3, AR275: 3, AR300:							
3, AR237: 3, AR239:							
3, AR245: 3, AR229:							
3, AR299: 3, AR238:							
3, AR234: 3, AR191:							
3, AR219: 3, AR190:							

									2, AR277: 2, AR199: 2, AR185: 2, AR178: 2, AR089: 2, AR189: 2, AR174: 2, AR096: 2, AR205: 2, AR309: 2, AR061: 2, AR274: 2, AR227: 2, AR261: 2, AR218: 2, AR188: 2, AR272: 2, AR039: 2, AR312: 2, AR196: 2, AR195: 2, AR232: 2, AR200: 2, AR211: 2, AR055: 2, AR230: 2, AR203: 1, AR210: 1, AR226: 1, AR033: 1, AR252: 1 H0617: 18, H0618: 13, H0253: 13, H0457: 6, L0769: 5, L0766: 5, H0255: 4, H0559: 4, H0052: 4, H0181: 4, H0170: 3, H0341: 3, H0620: 3, S0051: 3, H0622: 3, H0135: 3, H0059: 3, L0770: 3, L0653: 3, L0748: 3, L0779: 3, H0484: 2, L0534: 2, S6014: 2, S0049: 2, H0266: 2,
--	--	--	--	--	--	--	--	--	--



[illegible]

				H0547: 2, L0748: 2, L0749: 2, S0031: 2, L0596: 2, L0605: 2, S0026: 2, S0242: 2, H0170: 1, S6024: 1, H0740: 1, H0657: 1, S0116: 1, S0444: 1, H0722: 1, S0132: 1, H0156: 1, H0545: 1, H0083: 1, H0266: 1, H0687: 1, H0617: 1, H0032: 1, H0388: 1, H0264: 1, S0112: 1, T0042: 1, S0344: 1, L0762: 1, L0770: 1, L0667: 1, L0772: 1, L0646: 1, L0374: 1, L0771: 1, L0648: 1, L0768: 1, L0766: 1, L5564: 1, L0804: 1, L0774: 1, L0806: 1, L0805: 1, L0653: 1, L0776: 1, L0659: 1, L0809: 1, L0647: 1, L0793: 1, H0520: 1, S0126: 1, H0690: 1, H0658: 1, H0670: 1, S0380: 1, S0404: 1, S0406: 1, L0439: 1,				
--	--	--	--	---	--	--	--	--

48	HKGDL36	704088	58	55 - 501	151	Pro-36 to Gly-42, Pro-64 to Ala-76, Gly-83 to Ala-90, Ser-100 to Cys-108, Thr-126 to Ser-135.	L0740: 1, L0779: 1, L0757: 1, L0758: 1, S0436: 1, L0591: 1, L0595: 1, L0362: 1, L0601: 1, H0543: 1, S0384: 1 and H0506: 1. AR274: 28, AR214: 24, AR168: 23, AR216: 22, AR205: 21, AR245: 20, AR224: 20, AR272: 18, AR222: 17, AR199: 17, AR171: 17, AR223: 17, AR252: 17, AR313: 17, AR215: 16, AR213: 16, AR312: 16, AR195: 15, AR217: 15, AR170: 15, AR247: 15, AR166: 14, AR212: 14, AR246: 14, AR225: 14, AR096: 13, AR165: 13, AR164: 13, AR172: 13, AR311: 13, AR308: 13, AR169: 12, AR162: 12, AR161: 12, AR053: 12, AR221: 12, AR163: 12, AR039: 12, AR210: 11, AR179: 11, AR188: 11, AR197: 10, AR275: 10, AR263: 10, AR250: 10, AR089:	Xp11.23	300047, 300071, 300110, 300600, 301000, 301000, 301830, 309470, 309500, 309610, 309850, 311050, 312060
----	---------	--------	----	----------	-----	---	--	---------	--



	10, AR218: 10, AR189: 9, AR174: 9, AR264: 9, AR299: 9, AR242: 9, AR236: 9, AR201: 9, AR254: 9, AR193: 8, AR271: 8, AR243: 8, AR175: 8, AR309: 8, AR185: 8, AR253: 8, AR291: 8, AR180: 8, AR219: 8, AR296: 8, AR190: 7, AR288: 7, AR173: 7, AR240: 7, AR300: 7, AR178: 7, AR295: 7, AR282: 7, AR293: 7, AR267: 7, AR277: 6, AR183: 6, AR211: 6, AR289: 6, AR262: 6, AR191: 6, AR316: 6, AR192: 6, AR290: 6, AR270: 6, AR177: 6, AR261: 6, AR269: 6, AR268: 6, AR266: 6, AR255: 6, AR060: 6, AR204: 6, AR297: 6, AR231: 5, AR203: 5, AR200: 5, AR230: 5, AR283: 5, AR257: 5, AR285: 5, AR198: 5, AR237:						
--	---	--	--	--	--	--	--

								5, AR294: 5, AR256: 5, AR181: 5, AR287: 4, AR239: 4, AR260: 4, AR229: 4, AR258: 4, AR104: 4, AR234: 4, AR233: 4, AR061: 4, AR207: 4, AR182: 4, AR176: 4, AR286: 4, AR232: 4, AR238: 3, AR055: 3, AR033: 3, AR226: 3, AR196: 3, AR227: 3, AR235: 2, AR228: 2 H0424: 28, L0803: 23, L0636: 7, L0805: 6, L0774: 5, L0770: 4, H0661: 2, S0222: 2, L0157: 2, L0638: 2, L0776: 2, L0659: 2, L0789: 2, H0539: 2, L0592: 2, H0295: 1, S0114: 1, H0663: 1, S6026: 1, H0549: 1, H0571: 1, S0051: 1, T0006: 1, H0033: 1, H0604: 1, H0213: 1, H0418: 1, H0417: 1, H0538: 1, L0769: 1, L0794: 1, L0809: 1,
--	--	--	--	--	--	--	--	---

49	HLDBS43	722228	59	73 - 1245	152	Pro-85 to Ser-94, Pro-127 to Thr-136, Glu-154 to Glu-160, Phe-240 to Ser-250, Leu-255 to Leu-265, Leu-341 to Lys-351, Thr-372 to Gly-384.	L0647: 1, L0787: 1, H0684: 1, H0672: 1, L0749: 1, L0753: 1, L0759: 1, S0260: 1, S0434: 1 and S0436: 1. AR291: 18, AR169: 15, AR171: 15, AR266: 14, AR168: 14, AR289: 13, AR297: 13, AR257: 13, AR170: 12, AR285: 12, AR214: 12, AR287: 12, AR260: 12, AR255: 11, AR216: 11, AR165: 11, AR296: 11, AR164: 11, AR183: 11, AR223: 11, AR213: 10, AR166: 10, AR215: 10, AR272: 10, AR311: 10, AR253: 10, AR193: 10, AR294: 10, AR261: 10, AR246: 10, AR295: 10, AR219: 9, AR288: 9, AR162: 9, AR161: 9, AR269: 9, AR308: 9, AR236: 9, AR231: 9, AR163: 9, AR313: 9, AR039: 9, AR256: 9, AR235: 9, AR250: 8, AR245: 8, AR312: 8, AR286:	12		
----	---------	--------	----	-----------	-----	---	--	----	--	--



[illegible]

50	HLWAD92	695736	60	197 - 493	153	Met-1 to Thr-7, Glu-36 to Ser-43, Pro-46 to Gly-63.	H0266: 1, S0250: 1, S0022: 1, S0214: 1, T0023: 1, H0383: 1, H0674: 1, H0090: 1, H0038: 1, H0413: 1, H0494: 1, S0438: 1, H0509: 1, L0638: 1, L0637: 1, L0646: 1, L0800: 1, L0363: 1, L0768: 1, L0804: 1, L0774: 1, L0382: 1, L0789: 1, L0792: 1, L0664: 1, H0144: 1, H0547: 1, S0126: 1, S0380: 1, H0518: 1, H0521: 1, S0013: 1, H0704: 1, H0478: 1, S0032: 1, L0749: 1, L0756: 1, L0752: 1, L0731: 1, L0584: 1, L0588: 1, H0542: 1, H0543: 1, S0462: 1 and : 1.	AR193: 5, AR039: 5, 9q34 AR243: 5, AR165: 5, AR164: 5, AR224: 5, AR242: 4, AR089: 4, AR264: 4, AR246: 4, AR161: 4, AR162: 4,	125270, 125270, 128100, 137350, 191100, 215700,
----	---------	--------	----	-----------	-----	---	---	---	--

[illegible]

							AR181: 2, AR168: 2, AR293: 2, AR237: 2, AR313: 2, AR231: 2, AR312: 2, AR213: 2, AR177: 2, AR185: 2, AR233: 2, AR171: 2, AR191: 2, AR173: 1, AR228: 1, AR294: 1, AR289: 1, AR169: 1, AR288: 1, AR262: 1, AR219: 1, AR055: 1, AR236: 1, AR296: 1, AR215: 1, AR192: 1, AR308: 1, AR227: 1, AR182: 1, AR179: 1, AR223: 1, AR286: 1, AR258: 1, AR211: 1 L0754: 29, L0747: 15, L0766: 14, L0758: 14, L0755: 12, L0750: 9, L0769: 6, L0666: 6, T0010: 5, L0741: 5, H0545: 4, L0771: 4, L0659: 4, L0783: 4, H0555: 4, L0743: 4, L0761: 3, L0764: 3, L0662: 3, L0776: 3, L0809: 3, H0593: 3, H0539: 3, L0742: 3,		
--	--	--	--	--	--	--	---	--	--





51	HLYBI15	645262	61	92 - 274	154		L0806: 1, L0654: 1, L0655: 1, L0657: 1, L0789: 1, L0790: 1, L0663: 1, L0665: 1, H0547: 1, H0660: 1, S0404: 1, L0748: 1, L0780: 1, L0757: 1, S0434: 1 and L0597: 1. AR215: 5, AR242: 4, AR205: 4, AR309: 4, AR214: 4, AR169: 4, AR161: 3, AR253: 3, AR162: 3, AR264: 3, AR096: 3, AR252: 3, AR178: 3, AR168: 3, AR311: 3, AR195: 2, AR230: 2, AR283: 2, AR238: 2, AR180: 2, AR274: 2, AR270: 2, AR240: 2, AR089: 2, AR183: 2, AR165: 2, AR290: 2, AR163: 2, AR173: 2, AR164: 2, AR282: 2, AR236: 2, AR176: 2, AR262: 2, AR217: 2, AR269: 2, AR257: 2, AR174: 2, AR267: 2, AR312: 2, AR268: 2, AR255: 2,		
----	---------	--------	----	----------	-----	--	--	--	--

52	HMEJE05	722231	62	25 - 1203	155			AR288: 2, AR247: 2, AR234: 2, AR277: 2, AR171: 2, AR228: 2, AR237: 2, AR224: 2, AR213: 2, AR190: 2, AR285: 2, AR060: 2, AR286: 1, AR316: 1, AR272: 1, AR239: 1, AR198: 1, AR181: 1, AR266: 1, AR231: 1, AR172: 1, AR191: 1, AR061: 1, AR182: 1, AR222: 1, AR216: 1, AR263: 1, AR189: 1, AR294: 1, AR295: 1, AR291: 1, AR243: 1, AR175: 1, AR179: 1, AR055: 1, AR193: 1, AR170: 1, AR201: 1 H0445: 1		
								AR060: 4, AR282: 4, 3 AR269: 3, AR283: 3, AR178: 3, AR180: 3, AR240: 3, AR089: 3, AR254: 3, AR215: 2, AR173: 2, AR252: 2, AR272: 2, AR217: 2, AR277: 2, AR313: 2, AR316: 2, AR268: 2,		
								Ala-21 to Lys-31, Arg-41 to Cys-56, Thr-92 to Cys-102, Arg-132 to Val-137, Lys-152 to Ile-159, Pro-199 to Ser-205, Arg-210 to Asp-219, Ser-225 to Lys-230, Tyr-236 to Ala-241,		



53	HNGIX55	695749	63	121 - 345	156	Gly-63 to Ser-72.	H0521: 1, S0028: 1, L0779: 1, L0759: 1 and S0424: 1. AR223: 5, AR282: 4, AR215: 4, AR168: 4, AR291: 4, AR266: 4, AR214: 4, AR253: 3, AR269: 3, AR308: 3, AR217: 3, AR235: 3, AR270: 3, AR225: 3, AR289: 3, AR261: 3, AR171: 3, AR183: 3, AR165: 3, AR222: 3, AR164: 3, AR166: 2, AR216: 2, AR196: 2, AR312: 2, AR268: 2, AR169: 2, AR287: 2, AR176: 2, AR293: 2, AR188: 2, AR290: 2, AR257: 2, AR267: 2, AR295: 2, AR053: 2, AR204: 2, AR182: 2, AR255: 2, AR228: 2, AR207: 2, AR286: 2, AR285: 2, AR232: 2, AR210: 2, AR175: 2, AR174: 2, AR236: 2, AR229: 2, AR271: 2, AR258: 2, AR313: 1,		
----	---------	--------	----	-----------	-----	-------------------	--	--	--

54	HNHEX30	634848	64	138 - 383	157	Ile-28 to Trp-37, Ser-68 to Lys-81.	AR316: 1, AR224: 1, AR185: 1, AR231: 1, AR233: 1, AR213: 1, AR256: 1, AR226: 1, AR274: 1, AR275: 1, AR211: 1, AR288: 1, AR193: 1, AR252: 1, AR283: 1, AR247: 1, AR180: 1, AR272: 1, AR089: 1, AR060: 1, AR264: 1 S0052: 1 AR199: 16, AR210: 16, AR272: 14, AR309: 13, AR195: 13, AR196: 13, AR197: 12, AR235: 12, AR245: 12, AR261: 11, AR308: 11, AR264: 10, AR253: 10, AR211: 10, AR162: 9, AR282: 9, AR218: 9, AR033: 9, AR207: 9, AR161: 9, AR188: 9, AR295: 8, AR165: 8, AR104: 8, AR163: 8, AR263: 8, AR164: 8, AR191: 8, AR166: 8, AR192: 8, AR198: 8, AR189: 8, AR089: 7, AR200:		
----	---------	--------	----	-----------	-----	--	--	--	--

[illegible]

								4, AR238: 4, AR243: 4, AR216: 4, AR299: 4, AR294: 4, AR290: 4, AR293: 4, AR055: 4, AR231: 4, AR267: 4, AR239: 4, AR242: 4, AR229: 3, AR232: 3, AR237: 3, AR228: 3, AR233: 3, AR179: 3, AR061: 3, AR277: 3, AR171: 3, AR230: 3, AR234: 3, AR222: 3, AR256: 3, AR180: 3, AR217: 3, AR169: 3, AR168: 2, AR227: 2, AR224: 2, AR226: 2, AR221: 2, AR225: 2, AR214: 1 S0053: 2, L0534: 1, L0773: 1, L0774: 1 and S0216: 1.		
55	HPJBI33	685699	65	236 - 397	158	Arg-30 to Gln-36.	AR161: 12, AR162: 12, AR163: 12, AR313: 9, AR165: 8, AR229: 8, AR164: 8, AR166: 7, AR275: 6, AR247: 6, AR180: 5, AR264: 5, AR270: 5, AR173: 5, AR233: 5, AR237:			





							2, AR055: 2, AR257: 2, AR285: 2, AR316: 2, AR223: 2, AR299: 2, AR266: 2, AR060: 2, AR287: 2, AR214: 2, AR190: 1, AR200: 1, AR061: 1, AR308: 1, AR216: 1, AR213: 1, AR224: 1, AR195: 1, AR289: 1 S0152: 1			
56	HRABA80	588460	66	130 - 438	159	Ala-30 to Gly-36, Asp-45 to Trp-50, Lys-65 to Cys-71, Pro-80 to Cys-87.	AR060: 929, AR089: 689, AR299: 592, AR283: 556, AR104: 537, AR316: 473, AR096: 359, AR185: 345, AR240: 317, AR282: 316, AR277: 211, AR313: 120, AR242: 4, AR221: 3, AR217: 2, AR291: 2, AR172: 2, AR205: 2, AR163: 2, AR165: 2, AR178: 2, AR161: 2, AR168: 2, AR166: 2, AR164: 1, AR171: 1, AR195: 1, AR268: 1, AR180: 1, AR266: 1, AR215: 1, AR234: 1,			

57	HRACD80	882163	67	191 - 1915	160	<p>Lys-32 to Ser-37, His-89 to Gly-94, Asn-124 to Gln-130, Ala-163 to Val-168, Cys-196 to Arg-201, Gln-244 to Gln-264, His-288 to Tyr-294, Leu-314 to Gln-319, Ala-392 to Ser-399, Pro-412 to Asp-419, Ala-452 to Pro-460, Arg-466 to Thr-473.</p>	<p>AR230: 1, AR257: 1, AR199: 1, AR270: 1, AR179: 1 H0555: 1</p> <p>AR290: 353, AR268: 210, AR241: 164, AR202: 124, AR313: 113, AR198: 111, AR242: 111, AR267: 111, AR243: 105, AR096: 96, AR203: 94, AR246: 93, AR213: 91, AR270: 88, AR201: 80, AR200: 78, AR300: 77, AR245: 69, AR183: 64, AR053: 61, AR173: 55, AR234: 55, AR244: 54, AR189: 43, AR240: 38, AR188: 38, AR193: 32, AR289: 31, AR231: 30, AR194: 29, AR207: 28, AR205: 27, AR206: 26, AR055: 26, AR228: 25, AR266: 25, AR164: 24, AR165: 24, AR175: 22, AR166: 22, AR273: 21, AR192: 20, AR299: 20, AR163: 20, AR039: 20, AR161: 19, AR162:</p>		
----	---------	--------	----	------------	-----	--	---	--	--

[illegible]

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

58	HSLCX03	889145	68	677 - 2605	161	Arg-84 to His-89, Pro-122 to Pro-129. Gly-2 to Pro-8, Ser-82 to His-92, Tyr-107 to Asp-117, Arg-162 to Pro-169, Ser-224 to Thr-229, Leu-310 to His-315, Ser-333 to Glu-338, Glu-381 to Ser-388, Gln-428 to Ala-433, Met-446 to Thr-455, Ser-548 to Ser-554, Gly-613 to Asp-618, Ser-627 to Gln-633.	AR241: 5, AR184: 5, AR202: 5, AR273: 4, AR206: 4, AR284: 4, AR225: 3, AR263: 3, AR235: 3, AR052: 3, AR186: 3, AR251: 3, AR282: 3, AR053: 3, AR275: 3, AR309: 3, AR183: 3, AR245: 2, AR312: 2, AR298: 2, AR055: 2, AR246: 2, AR292: 2, AR205: 2, AR264: 2, AR291: 2, AR270: 2, AR221: 2, AR267: 2, AR175: 2, AR061: 2, AR269: 2, AR201: 2, AR182: 2, AR180: 2, AR310: 2, AR224: 2, AR313: 2, AR033: 2, AR289: 2, AR257: 2, AR247: 2, AR161: 2, AR285: 2, AR290: 2, AR039: 2, AR162: 2, AR060: 2, AR299: 2, AR268: 2, AR168: 1, AR164: 1, AR096: 1, AR163: 1,		
----	---------	--------	----	------------	-----	---	---	--	--

									AR271: 1, AR283: 1, AR296: 1, AR240: 1, AR222: 1, AR185: 1, AR272: 1, AR294: 1, AR213: 1, AR166: 1, AR244: 1, AR199: 1, AR238: 1, AR089: 1, AR293: 1, AR295: 1, AR277: 1, AR286: 1, AR172: 1, AR259: 1, AR216: 1, AR316: 1, AR266: 1, AR196: 1, AR177: 1, AR230: 1, AR204: 1, AR178: 1, AR193: 1, AR104: 1 L0769: 3, L0748: 3, L0779: 3, L0777: 3, S0358: 2, S0005: 2, H0618: 2, H0046: 2, L0662: 2, L0776: 2, H0547: 2, L0439: 2, L0751: 2, L0600: 2, S0040: 1, S0134: 1, S0218: 1, H0650: 1, S0418: 1, S0045: 1, H0549: 1, H0333: 1, H0486: 1, H0253: 1, H0231: 1, H0620: 1, H0014: 1, S0250: 1,						
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

									H0063: 1, H0087: 1, H0264: 1, H0280: 1, L0640: 1, L0770: 1, L0764: 1, L0768: 1, L0806: 1, L0663: 1, L0664: 1, H0520: 1, H0539: 1, S0390: 1, S0028: 1, L0747: 1, L0758: 1 and S0424: 1.				
	HSLCX03	740788	101	392 - 766	194	Gly-2 to Pro-8, Ser-82 to Trp-95, Tyr-108 to Phe-117.							
59	HTSGJ57	740767	69	122 - 694	162	Ser-29 to Thr-57, Pro-74 to Lys-79, Pro-85 to Glu-107, Tyr-118 to Tyr-136, Gln-144 to Gln-152, Ala-182 to Glu-188.	AR213: 5, AR264: 4, AR224: 4, AR254: 4, AR253: 4, AR207: 4, AR053: 3, AR197: 3, AR161: 3, AR162: 3, AR163: 3, AR250: 3, AR221: 3, AR171: 3, AR311: 3, AR212: 3, AR165: 3, AR215: 3, AR282: 3, AR217: 2, AR309: 2, AR263: 2, AR193: 2, AR195: 2, AR089: 2, AR168: 2, AR166: 2, AR164: 2, AR312: 2, AR308: 2, AR223: 2, AR183: 2, AR267: 2, AR169: 2,	7q11.23	116860, 129900, 233700, 600079				



									AR198: 2, AR266: 2, AR033: 2, AR216: 2, AR271: 2, AR096: 1, AR210: 1, AR192: 1, AR277: 1, AR272: 1, AR240: 1, AR286: 1, AR313: 1, AR060: 1, AR180: 1, AR204: 1, AR299: 1, AR039: 1, AR246: 1, AR104: 1, AR201: 1, AR270: 1, AR205: 1, AR055: 1, AR225: 1, AR247: 1, AR258: 1, AR182: 1, AR274: 1, AR214: 1, AR287: 1, AR243: 1 H0584: 3, H0341: 3, H0271: 3, H0318: 2, H0090: 2, H0264: 2, S0052: 2, H0656: 1, H0580: 1, S0278: 1, H0431: 1, H0013: 1, H0457: 1, H0284: 1, S0003: 1, S0144: 1, S0142: 1, S0002: 1, H0702: 1, H0522: 1 and H0445: 1.				
60	HTACS42	722253	70	213 - 404	163	Pro-34 to Met-63.	AR313: 8, AR240: 5, AR299: 5, AR316: 3,						



61	HTEKE40	740768	71	173 - 526	164	AR251: 23, AR273: 14, AR310: 13, AR265: 11, AR052: 11, AR241: 10, AR244: 8, AR186: 8, AR309: 8, AR176: 7, AR312: 6, AR161: 6, AR263: 6, AR249: 6, AR162: 6, AR163: 6, AR271: 6, AR274: 6, AR053: 6, AR275: 5, AR266: 5, AR313: 5, AR243: 5, AR181: 5, AR178: 5, AR228: 5, AR215: 5, AR292: 5, AR183: 5, AR213: 5, AR198: 5, AR247: 5, AR257: 5, AR240: 4, AR096: 4, AR277: 4, AR039: 4, AR293: 4, AR267: 4, AR221: 4, AR283: 4, AR204: 4, AR061: 4, AR182: 4, AR175: 4, AR055: 4, AR177: 4, AR229: 4, AR185: 4, AR300: 4, AR261: 4, AR290: 4, AR206: 4, AR264: 4, AR282: 4, AR270: 4, AR255: 4, AR233:		
----	---------	--------	----	-----------	-----	--	--	--



[illegible]

62	HTOBX69	722255	72	28 - 156	165	AR242: 13, AR162: 11, AR245: 11, AR163: 11, AR161: 11, AR197: 11, AR313: 10, AR309: 10, AR271: 10, AR229: 10, AR192: 10, AR243: 10, AR089: 9, AR165: 9, AR178: 9, AR198: 9, AR164: 9, AR283: 9, AR264: 9, AR166: 9, AR207: 8, AR173: 8, AR181: 8, AR039: 8, AR204: 8, AR201: 8, AR252: 8, AR286: 8, AR215: 8, AR096: 8, AR193: 8, AR053: 8, AR177: 8, AR240: 8, AR180: 8, AR195: 7, AR250: 7, AR266: 7, AR291: 7, AR060: 7, AR238: 7, AR237: 7, AR289: 7, AR299: 7, AR293: 7, AR233: 7, AR246: 7, AR176: 7, AR267: 7, AR179: 7, AR311: 7, AR239: 7, AR296: 7, AR312: 7, AR226: 7, AR300: 6, AR253: 6, AR263:		
----	---------	--------	----	----------	-----	--	--	--

[illegible]

									3, AR210: 3, AR170: 3, AR216: 3, AR219: 3, AR225: 2, AR223: 2, AR211: 2, AR214: 2, AR224: 1, AR235: 1 L0766: 3, S0152: 3, H0640: 2, H0521: 2, L0750: 2, H0341: 1, S0358: 1, S0476: 1, H0331: 1, H0486: 1, T0040: 1, H0252: 1, H0551: 1, H0272: 1, H0623: 1, H0494: 1, H0561: 1, L0776: 1, H0682: 1, H0659: 1, H0539: 1, L0748: 1, L0749: 1, L0780: 1, L0755: 1 and S0026: 1.					
63	HUVE077	740776	73	55 - 198	166				AR173: 11, AR264: 10, AR180: 10, AR263: 10, AR176: 10, AR253: 10, AR183: 9, AR245: 9, AR195: 9, AR162: 8, AR197: 8, AR161: 8, AR175: 8, AR268: 8, AR163: 8, AR235: 8, AR269: 7, AR270: 7, AR300: 7, AR290:					



[illegible]

								4, AR213: 4, AR185: 4, AR201: 4, AR171: 3, AR218: 3, AR289: 3, AR262: 3, AR219: 3, AR247: 3, AR104: 3, AR204: 3, AR236: 3, AR033: 3, AR258: 3, AR222: 3, AR226: 3, AR223: 3, AR170: 2, AR237: 2, AR203: 2, AR234: 2, AR229: 2, AR260: 2, AR214: 2, AR238: 2, AR200: 2, AR172: 2, AR233: 2, AR239: 2, AR199: 2, AR227: 2, AR061: 2, AR216: 2, AR232: 2, AR228: 2, AR256: 2, AR277: 1, AR231: 1, AR283: 1, AR055: 1, AR230: 1, AR242: 1 H0056: 1					
64	H2CBG48	745365	74	125 - 262	167			AR223: 3, AR171: 3, AR282: 3, AR164: 3, AR166: 3, AR215: 3, AR246: 2, AR176: 2, AR195: 2, AR216: 2, AR165: 2, AR261: 2,					

						AR250: 2, AR222: 2, AR224: 1, AR288: 1, AR270: 1, AR290: 1, AR181: 1, AR193: 1, AR089: 1, AR308: 1, AR312: 1, AR162: 1 H0046: 7, L0805: 4, L0751: 4, H0620: 3, H0521: 3, L0756: 3, L0731: 3, S0045: 2, H0013: 2, H0090: 2, S0144: 2, L0794: 2, L0803: 2, L0774: 2, L0515: 2, L0783: 2, S0126: 2, H0555: 2, L0740: 2, H0624: 1, S0356: 1, S0360: 1, S0007: 1, H0393: 1, H0549: 1, S0222: 1, H0592: 1, H0156: 1, H0575: 1, T0110: 1, H0553: 1, H0591: 1, H0641: 1, S0002: 1, S0426: 1, L0767: 1, L0804: 1, L0775: 1, L0809: 1, L0665: 1, H0435: 1, H0522: 1, H0540: 1, L0742: 1, S0308: 1, S0434: 1,
--	--	--	--	--	--	--

							L0596: 1, S0026: 1, H0136: 1, H0542: 1 and S0458: 1.		
65	H2CBU83	884134	75	157 - 777	168	Pro-62 to Asp-67, Arg-74 to Gly-80, Gln-146 to Glu-168.	AR182: 8, AR314: 7, AR271: 7, AR280: 6, AR315: 6, AR216: 6, AR052: 6, AR224: 6, AR225: 5, AR164: 5, AR215: 5, AR270: 5, AR165: 5, AR162: 5, AR310: 5, AR245: 5, AR166: 5, AR161: 5, AR169: 5, AR223: 5, AR266: 5, AR172: 5, AR192: 5, AR163: 4, AR282: 4, AR193: 4, AR207: 4, AR176: 4, AR269: 4, AR175: 4, AR226: 4, AR243: 4, AR217: 4, AR273: 4, AR168: 4, AR204: 4, AR299: 4, AR291: 4, AR265: 4, AR183: 4, AR274: 4, AR214: 4, AR205: 4, AR206: 4, AR194: 4, AR060: 4, AR272: 4, AR238: 4, AR186: 4, AR222: 4, AR089: 4, AR053: 4,	102772, 106210, 106210, 106210, 106210, 107271, 114550, 115500, 136530, 151390, 179615, 179615, 179616, 180385, 194070, 194070, 194070, 245349, 602092	

AR197: 4, AR257: 3,								
AR295: 3, AR289: 3,								
AR311: 3, AR221: 3,								
AR171: 3, AR191: 3,								
AR250: 3, AR235: 3,								
AR252: 3, AR275: 3,								
AR309: 3, AR177: 3,								
AR180: 3, AR173: 3,								
AR178: 3, AR246: 3,								
AR312: 3, AR188: 3,								
AR292: 3, AR298: 3,								
AR284: 3, AR212: 3,								
AR201: 3, AR285: 3,								
AR189: 3, AR296: 3,								
AR181: 3, AR253: 3,								
AR202: 3, AR281: 3,								
AR300: 3, AR039: 3,								
AR277: 3, AR237: 3,								
AR184: 3, AR268: 3,								
AR233: 3, AR286: 3,								
AR232: 3, AR308: 3,								
AR267: 3, AR228: 3,								
AR288: 3, AR239: 3,								
AR195: 2, AR185: 2,								
AR242: 2, AR263: 2,								
AR033: 2, AR287: 2,								
AR096: 2, AR196: 2,								
AR210: 2, AR259: 2,								
AR316: 2, AR174: 2,								



								L0758: 2, L0759: 2, S0242: 2, H0624: 1, S0282: 1, H0393: 1, H0586: 1, H0574: 1, H0036: 1, H0004: 1, T0103: 1, T0110: 1, H0571: 1, H0569: 1, H0123: 1, H0594: 1, S0628: 1, H0622: 1, UNKWN: 1, L0649: 1, L0381: 1, L0776: 1, L0659: 1, L0528: 1, L0792: 1, L0793: 1, L0663: 1, L0664: 1, L0665: 1, H0144: 1, S0374: 1, H0547: 1, H0593: 1, H0690: 1, H0670: 1, H0648: 1, H0672: 1, H0651: 1, H0539: 1, S0378: 1, S0380: 1, H0521: 1, S0406: 1, H0555: 1, H0478: 1, L0744: 1, L0731: 1 and S0276: 1.				
	H2CBU83	745366	102	157 - 312	195			AR253: 10, AR309: 9, AR161: 6, AR162: 6, AR163: 6, AR263: 6, AR266: 5, AR264: 5,	6p25	134570, 601090, 602028		
66	HAPNY94	699770	76	94 - 246	169	Ser-30 to Trip-37.						









67	HBJHZ58	745372	77	102 - 230	170	Asp-33 to Lys-42.	L0777: 1, L0755: 1, H0542: 1, H0543: 1 and H0423: 1.		
							AR245: 7, AR161: 5, AR162: 5, AR163: 5, AR309: 5, AR197: 5, AR264: 4, AR225: 4, AR193: 4, AR271: 3, AR039: 3, AR250: 3, AR176: 3, AR246: 3, AR181: 3, AR198: 3, AR169: 2, AR242: 2, AR165: 2, AR195: 2, AR096: 2, AR269: 2, AR166: 2, AR201: 2, AR274: 2, AR272: 2, AR233: 2, AR089: 2, AR205: 2, AR267: 2, AR196: 2, AR270: 2, AR312: 2, AR228: 2, AR055: 1, AR174: 1, AR226: 1, AR296: 1, AR262: 1, AR164: 1, AR313: 1, AR168: 1, AR178: 1, AR293: 1, AR277: 1, AR185: 1, AR311: 1, AR239: 1, AR288: 1, AR282: 1, AR182: 1, AR216: 1,		

68	HCE2B33	745399	78	67 - 234	171	Thr-18 to Cys-26, Glu-29 to Thr-36, Ser-50 to Thr-55.	AR287: 1, AR229: 1, AR231: 1, AR061: 1, AR179: 1, AR275: 1, AR294: 1, AR252: 1, AR104: 1 H0318: 1 and H0032: 1.	17q25	114290, 138033, 162100, 170500, 170500, 170500, 180860, 264470
							AR254: 6, AR250: 6, AR039: 5, AR198: 5, AR165: 4, AR161: 4, AR176: 4, AR162: 4, AR180: 4, AR266: 4, AR163: 4, AR166: 4, AR164: 4, AR269: 4, AR168: 4, AR268: 4, AR181: 4, AR309: 4, AR252: 4, AR274: 4, AR242: 4, AR223: 4, AR172: 4, AR205: 3, AR282: 3, AR270: 3, AR207: 3, AR240: 3, AR216: 3, AR275: 3, AR296: 3, AR178: 3, AR238: 3, AR195: 3, AR277: 3, AR197: 3, AR173: 3, AR253: 3, AR289: 3, AR228: 3, AR183: 3, AR236: 3, AR104: 3, AR257: 3,		



							AR226: 2, AR218: 2, AR283: 1, AR299: 1, AR285: 1, AR169: 1, AR203: 1, AR308: 1, AR193: 1, AR212: 1, AR256: 1, AR222: 1, AR171: 1, AR235: 1, AR272: 1 H0013: 2, H0052: 2, L0439: 2, H0556: 1, H0650: 1, S0356: 1, H0261: 1, H0333: 1, H0427: 1, H0097: 1, S0049: 1, H0232: 1, H0100: 1, H0359: 1, H0144: 1, H0521: 1, H0555: 1, L0750: 1 and H0543: 1.				
69	HDPBQ02	745403	79	460 - 786	172	Gln-30 to Leu-38, Asn-75 to Thr-86.	AR313: 17, AR281: 12, AR314: 12, AR241: 12, AR315: 12, AR164: 11, AR280: 11, AR292: 10, AR096: 10, AR263: 10, AR299: 9, AR249: 9, AR194: 9, AR300: 9, AR247: 9, AR265: 9, AR052: 8, AR089: 8, AR184: 8, AR312: 8, AR310: 8, AR229:				



70	HFYI70	744906	80	43 - 195	173				2, AR055: 2, AR201: 2, AR266: 2, AR291: 2, AR254: 2, AR162: 2, AR271: 2, AR232: 2, AR104: 2, AR273: 2, AR161: 2, AR205: 2, AR060: 2, AR061: 2, AR206: 1, AR216: 1, AR163: 1, AR221: 1, AR188: 1, AR176: 1, AR311: 1, AR039: 1 H0264: 1, S0002: 1 and H0521: 1.			
									AR207: 47, AR263: 38, AR214: 35, AR223: 31, AR192: 30, AR264: 29, AR245: 28, AR235: 28, AR172: 27, AR222: 27, AR165: 26, AR169: 26, AR195: 26, AR213: 26, AR311: 25, AR217: 25, AR168: 25, AR224: 25, AR212: 25, AR164: 25, AR166: 25, AR221: 25, AR197: 25, AR309: 24, AR171: 24, AR216: 23, AR188: 23, AR308: 23, AR089: 21, AR215: 12			







71	HDPOZ56	815653	81	103 - 1800	174	Gln-22 to Gln-44, Ala-90 to Gly-95, Lys-137 to Trp-146, Arg-171 to Asp-181, Glu-370 to Ser-380, Asp-447 to Gly-452, Gln-463 to Trp-469, Asn-504 to Ala-510, Asp-512 to His-519, Ala-541 to Val-550, Asn-558 to His-566.	H0442: 1, H0333: 1, H0253: 1, H0052: 1, H0545: 1, H0046: 1, H0024: 1, L0185: 1, T0010: 1, H0628: 1, H0616: 1, H0433: 1, S0150: 1, H0641: 1, H0652: 1, S0426: 1, L0520: 1, L0800: 1, L0643: 1, L0764: 1, L0803: 1, L0804: 1, L0788: 1, L0665: 1, H0698: 1, S0126: 1, H0670: 1, H0539: 1, H0521: 1, L0744: 1, L0749: 1, L0758: 1, S0242: 1, H0423: 1 and H0352: 1.		
----	---------	--------	----	------------	-----	---	---	--	--





								4, AR193: 4, AR188: 4, AR211: 3, AR189: 3, AR060: 3, AR233: 3, AR185: 3, AR259: 3, AR260: 3, AR173: 3, AR201: 3, AR190: 3, AR179: 2 H0521: 23, H0522: 5, H0638: 4, L0665: 4, H0658: 3, H0255: 2, H0250: 2, H0618: 2, L0804: 2, L0779: 2, H0542: 2, H0663: 1, S0046: 1, H0586: 1, H0622: 1, H0617: 1, H0560: 1, H0641: 1, S0422: 1, S0426: 1, H0695: 1, L0655: 1, H0689: 1, H0435: 1, H0555: 1, H0543: 1, H0423: 1 and H0506: 1.		
HDPOZ56	743479	103	59 - 1018	196	Gln-22 to Gln-44, Ala-53 to Gly-58.					

Table 1C

Gene No.:	Clone ID	Preferred Indication Identifier
1	HISCN02	Digestive
2	HHGDM70	Immune/Hematopoietic
3	HHPGO40	Cancer
4	HAMGG68	Cancer
5	HAPOM49	Cancer
6	HGBGA69	Cancer
7	HBJFJ26	Cancer
8	HCEDH38	Mixed Fetal, Neural/Sensory
9	HDPOJ08	Cancer
10	HDPRX82	Cancer
11	HELK31	Cancer
12	HFPCX64	Mixed Fetal, Neural/Sensory
13	HFXXDO60	Neural/Sensory
14	HHEPG41	Cancer
15	HKGAI42	Neural/Sensory
16	HMLAP86	Cancer
17	HMUAP70	Cancer
18	HRACJ35	Cancer
19	HTWDE26	Cancer
20	HUSIB13	Cancer
21	HBAFA02	Cancer
22	H2CBT75	Cancer
23	HAGDQ42	Cancer

24	HBMCI42	Immune/Hematopoietic, Reproductive
25	HDPBQ71	Cancer
26	HCEJG71	Cancer
27	HELHL48	Cancer
28	HISAQ04	Digestive, Neural/Sensory, Reproductive
29	HJACB89	Cancer
30	HTECC05	Cancer
31	HBILF01	Cancer
32	HBXGP60	Cancer
33	HCE5B20	Mixed Fetal, Neural/Sensory
34	HCMSEQ56	Cancer
35	HCNAH57	Digestive
36	HCUEP91	Immune/Hematopoietic
37	HDPCJ91	Cancer
38	HDPGK25	Cancer
39	HE2DY70	Immune/Hematopoietic, Mixed Fetal, Musculoskeletal
40	HE2NV57	Cancer
41	HETBR16	Digestive, Immune/Hematopoietic, Reproductive
42	HFXDG13	Cancer
43	HFXKY27	Neural/Sensory



44	HHPEC09	Cancer
45	HISAD54	Cancer
46	HJBCY35	Cancer
47	HKAEA19	Cancer
48	HKGDL36	Cancer
49	HLDBS43	Cancer
50	HLWAD92	Cancer
51	HLYBI15	Immune/Hematopoietic
52	HMEJE05	Cancer
53	HNGIX55	Immune/Hematopoietic
54	HNHEX30	Immune/Hematopoietic
55	HPJBI33	Reproductive
56	HRABA80	Excretory
57	HRACD80	Excretory, Reproductive
58	HSLCX03	Cancer
59	HT5GJ57	Cancer
60	HTACS42	Cancer
61	HTEKE40	Cancer
62	HTOBX69	Cancer
63	HUVFO77	Reproductive
64	H2CBG48	Cancer
65	H2CBU83	Cancer
66	HAPNY94	Cancer
67	HBJHZ58	Immune/Hematopoietic, Reproductive
68	HCE2B33	Cancer

69	HDPBQ02	Immune/Hematopoietic
70	HFIYI70	Cancer
71	HDPOZ56	Cancer

Table 1D

Clone ID NO:Z	SEQ ID NO:X	CONTIG ID:	BAC ID: A	SEQ ID NO:B	EXON From-To
HISCN02	11	638033	AC012267	271	1-1102
HISCN02	11	638033	AL359715	272	1-1102
HISCN02	11	638033	AC012267	273	1-185
HISCN02	11	638033	AL359715	274	1-185
HHGDM70	12	623416	AL157996	275	1-950
HHGDM70	12	623416	AC019291	276	1-950
HHGDM70	12	623416	AL157996	277	1-297
HHGDM70	12	623416	AC019291	278	1-297
HAMGG68	14	731859	AL031009	279	1-4002
HAMGG68	14	731859	AL031009	280	1-106
HBJFJ26	17	772348	AC009542	281	1-1828 1863-2186 2203-3358 3604-4183 4279-4670 4877-7332
HBJFJ26	17	772348	AC009330	282	1-1826 1861-2184 2201-3356 3606-4185 4281-4672 4879-7334
HBJFJ26	17	772348	AC009542	283	1-5071
HBJFJ26	17	772348	AC009542	284	1-512
HBJFJ26	17	772348	AC009330	285	1-5072

HBJFJ26	17	772348	AC009330	286	1-512
HCEDH38	18	730529	Z99716	287	1-206 1530-1766 3318-3610 3864-3934 5454-6717
HCEDH38	18	730529	Z99716	288	1-141
HDPRX82	20	730518	AC024709	289	1-158 414-446 718-1302 2362-2568 4065-4153 6322-6378 10385-10716 10794-10904 12455-12525 14395-14918 15094-15719 17784-19328 20636-20676 21668-22019 22088-22288 22495-22724 23715-24901 25597-28046
HDPRX82	20	730518	AC024709	290	1-228
HDPRX82	20	730518	AC024709	291	1-156
HFPCX64	22	877637	AC016026	292	1-1397 1-1397

HFPCX64	22	877637	AC016025	293	1-1397 1-1397
HFPCX64	22	877637	AC007845	294	1-1397 1-1397
HFPCX64	22	877637	AC016026	295	1-224 1-224
HFPCX64	22	877637	AC016026	296	1-458 1-458 985-1079 985-1079 4755-5140 4755-5140 5272-5840 5272-5840 5994-6320 5994-6320 6956-7267 6956-7267 8830-8923 8830-8923 10972-11399 10972-11399 11431-12023 11431-12023 12157-13149 12157-13149 13422-14216 13422-14216
HFPCX64	22	877637	AC016025	297	1-224

HFPCX64	22	877637	AC016025	298	1-224
					1-458
					1-458
					985-1079
					985-1079
					4755-5140
					4755-5140
					5272-5840
					5272-5840
					5994-6320
					5994-6320
					6956-7267
					6956-7267
					8830-8923
HFPCX64	22	877637	AC007845	299	8830-8923
					10972-11399
					10972-11399
					11431-12023
					11431-12023
					12157-13149
					12157-13149
					13422-14216
					13422-14216
					1-224
					1-224
HFPCX64	22	877637	AC007845	300	1-795
					1068-2060
					2194-2786
HFPCX64	22	877637	AC007845	300	2818-3244
					2818-3244

HFDO60	23	731869	AL035587	301	5293-5386 6939-7252 7886-8212 8366-8934 9066-9451 13127-13221 13748-14379 1-795 1068-2060 2194-2786 2818-3244 5293-5386 6939-7252 7886-8212 8366-8934 9066-9451 13127-13221 13748-14379
					1-1096 1103-1298 1355-2108 2147-2246 3206-3757 3921-6267 7044-7857 7958-8018 8831-8962 10963-11298 11772-12052

					12669-13004 13542-13611 13708-14304
HFXDO60	23	731869	AL035587	302	1-219
HHEPG41	24	714102	AC010422	303	1-326 1552-2084 2162-2261 2300-2427 4485-5868 5948-6362 7914-8017 8569-8681 8765-8875 8968-9037 9284-9499 9742-9910 10837-11187 11271-11321 11554-11707 11783-12766 12866-13225 13256-13827 14284-14367 14890-15090 1-326 1552-2084 2162-2261 2300-2427 4485-5868



5948-6362					
7914-8017					
8569-8681					
8765-8875					
8968-9037					
9284-9499					
9742-9910					
10837-11187					
11271-11321					
11554-11707					
11783-12766					
12866-13225					
13256-13827					
14284-14367					
14890-15090					
1-326					
1552-2084					
2162-2261					
2300-2427					
4485-5868					
5948-6362					
7914-8017					
8569-8681					
8765-8875					
8968-9037					
9284-9499					
9742-9910					
10837-11187					
11271-11321					

11554-11707					
11783-12766					
12866-13225					
13256-13827					
14284-14367					
14890-15090					
1-326					
1552-2084					
2162-2261					
2300-2427					
4485-5868					
5948-6362					
7914-8017					
8569-8681					
8765-8875					
8968-9037					
9284-9499					
9742-9910					
10837-11187					
11271-11321					
11554-11707					
11783-12766					
12866-13225					
13256-13827					
14284-14367					
14890-15090					
1-326					
1552-2084					
2162-2261					

HHEPG41	24	714102	AC018761	304	2300-2427
					4485-5868
					5948-6362
					7914-8017
					8569-8681
					8765-8875
					8968-9037
					9284-9499
					9742-9910
					10837-11187
					11271-11321
					11554-11707
					11783-12766
					12866-13225
					13256-13827
					14284-14367
					14890-15090
					1-326
					1-326
					1-326
					1-326
					1-326
					1176-1284
					1176-1284
1176-1284					
1176-1284					
1176-1284					
1552-2084					
1552-2084					

1552-2084					
1552-2084					
1552-2084					
2162-2261					
2162-2261					
2162-2261					
2162-2261					
2162-2261					
2300-2426					
2300-2426					
2300-2426					
2300-2426					
2300-2426					
4485-5868					
4485-5868					
4485-5868					
4485-5868					
4485-5868					
5948-6362					
5948-6362					
5948-6362					
5948-6362					
5948-6362					
8569-8681					
8569-8681					
8569-8681					
8569-8681					
8569-8681					
8765-8875					



11271-11321	
11271-11321	
11271-11321	
11271-11321	
11271-11321	
11554-11707	
11554-11707	
11554-11707	
11554-11707	
11554-11707	
11783-12766	
11783-12766	
11783-12766	
11783-12766	
11783-12766	
12866-13225	
12866-13225	
12866-13225	
12866-13225	
12866-13225	
13256-13827	
13256-13827	
13256-13827	
13256-13827	
13256-13827	
14284-14367	
14284-14367	
14284-14367	
14284-14367	

					14284-14367 14890-15090 14890-15090 14890-15090 14890-15090 14890-15090 14890-15090
HHEPG41	24	714102	AC010422	305	1-315 2004-2289 2650-2741 3554-3830 1-315 2004-2289 2650-2741 3554-3830 1-315 2004-2289 2650-2741 3554-3830 1-315 2004-2289 2650-2741 3554-3830 1-315 2004-2289 2650-2741 3554-3830
HHEPG41	24	714102	AC010422	306	1-202 938-1047 1219-1395

1758-1956					
2907-3429					
3792-3935					
5366-5485					
6391-6688					
6899-7269					
7890-8316					
8400-8524					
8607-8682					
8824-8999					
9190-9302					
9691-9796					
10106-10177					
10571-11051					
11164-11490					
12565-12696					
13364-13501					
13964-14592					
14740-15540					
15610-15798					
15947-16642					
16717-16832					
16968-17408					
17521-17612					
18331-18579					
19120-19303					
19358-19514					
19599-19702					
20003-20245					



1-202					
938-1047					
1219-1395					
1758-1956					
2907-3429					
3792-3935					
5366-5485					
6391-6688					
6899-7269					
7890-8316					
8400-8524					
8607-8682					
8824-8999					
9190-9302					
9691-9796					
10106-10177					
10571-11051					
11164-11490					
12565-12696					
13364-13501					
13964-14592					
14740-15540					
15610-15798					
15947-16642					
16717-16832					
16968-17408					
17521-17612					
18331-18579					
19120-19303					

19358-19514	
19599-19702	
20003-20245	
1-202	
938-1047	
1219-1395	
1758-1956	
2907-3429	
3792-3935	
5366-5485	
6391-6688	
6899-7269	
7890-8316	
8400-8524	
8607-8682	
8824-8999	
9190-9302	
9691-9796	
10106-10177	
10571-11051	
11164-11490	
12565-12696	
13364-13501	
13964-14592	
14740-15540	
15610-15798	
15947-16642	
16717-16832	
16968-17408	

17521-17612	
18331-18579	
19120-19303	
19358-19514	
19599-19702	
20003-20245	
1-202	
938-1047	
1219-1395	
1758-1956	
2907-3429	
3792-3935	
5366-5485	
6391-6688	
6899-7269	
7890-8316	
8400-8524	
8607-8682	
8824-8999	
9190-9302	
9691-9796	
10106-10177	
10571-11051	
11164-11490	
12565-12696	
13364-13501	
13964-14592	
14740-15540	
15610-15798	

15947-16642				
16717-16832				
16968-17408				
17521-17612				
18331-18579				
19120-19303				
19358-19514				
19599-19702				
20003-20245				
1-202				
938-1047				
1219-1395				
1758-1956				
2907-3429				
3792-3935				
5366-5485				
6391-6688				
6899-7269				
7890-8316				
8400-8524				
8607-8682				
8824-8999				
9190-9302				
9691-9796				
10106-10177				
10571-11051				
11164-11490				
12565-12696				
13364-13501				



1758-1956					
1758-1956					
1758-1956					
2907-3429					
2907-3429					
2907-3429					
2907-3429					
2907-3429					
3792-3935					
3792-3935					
3792-3935					
3792-3935					
3792-3935					
5366-5485					
5366-5485					
5366-5485					
5366-5485					
5366-5485					
6391-6688					
6391-6688					
6391-6688					
6391-6688					
6391-6688					
6899-7269					
6899-7269					
6899-7269					
6899-7269					
6899-7269					
7591-7711					



					9691-9796 9691-9796 9691-9796 9691-9796 9691-9796
HHEPG41	24	714102	AC018761	308	1-82 1-82 1-82 1-82 1-82  128-293 128-293 128-293 128-293 128-293 1178-1447 1178-1447 1178-1447 1178-1447 1178-1447 1986-2278 1986-2278 1986-2278 1986-2278 2457-2711 2457-2711 2457-2711 2457-2711



						2457-2711 3543-3844 3543-3844 3543-3844 3543-3844 3543-3844
HBAFA02	31	679555	AL133293	309		1-2368
HBAFA02	31	679555	AL133293	310		1-715 1346-1420 2177-2336 2497-2626 2917-2996
H2CBT75	32	703079	AC027796	311		1-2572
H2CBT75	32	703079	AC027040	312		1-2238
H2CBT75	32	703079	AC027796	313		1-108
H2CBT75	32	703079	AC027040	314		1-101
HCEJG71	36	715592	AC005089	315		1-195 1913-2074 2140-2237 3151-3323 3477-4231 4490-4676 5141-5298 5641-5779 7183-7426 7638-9682
HCEJG71	36	715592	AC005089	316		1-441
HISAQ04	38	589960	AL022324	317		1-383

						2784-3607 5396-5615 5782-6932 7696-7805 7816-8217 8307-8790
HISAQ04	38	589960	AL022324	318		1-773 782-890
HISAQ04	38	589960	AL022324	319		1-404
HJACB89	39	689899	AC013356	320		1-1908
HJACB89	39	689899	AC019054	321		1-2203
HTECC05	40	666743	AC040950	322		1-222 321-532 627-717 817-958 1040-1124 2310-2386 2468-2507 2833-3202
HBXGP60	42	566892	AC026942	323		1-110 1503-2708
HBXGP60	42	566892	AC026942	324		1-512
HCE5B20	43	544507	AC018883	325		1-1064
HCE5B20	43	544507	AC025779	326		1-1064
HE2DY70	49	722217	AC009818	327		1-1408
HE2DY70	49	722217	AP001849	328		1-1408
HETBR16	51	703243	AC021617	329		1-1562
HETBR16	51	703243	AC069254	330		1-1562

HETBR16	51	703243	AC021617	331	1-230
HETBR16	51	703243	AC069254	332	1-412 741-1237 2615-2845 3760-3864 4614-4679
HETBR16	51	703243	AC069254	333	1-230
HISAD54	55	740754	AL136293	334	1-2835
HISAD54	55	740754	AL136293	335	1-142
HISAD54	55	740754	AL136293	336	1-489
HKGDL36	58	704088	AF196971	337	1-187 772-1083 3254-3730 4140-4503
HLYBI15	61	645262	AL354914	338	1-959
HLYBI15	61	645262	AL354914	339	1-441
HNGIX55	63	695749	AC025897	340	1-780
HNGIX55	63	695749	AC046138	341	1-780
HNGIX55	63	695749	AC025897	342	1-127
HNGIX55	63	695749	AC046138	343	1-127
HNHEX30	64	634848	AC005488	344	1-1685
HNHEX30	64	634848	AC004980	345	1-1926
HNHEX30	64	634848	AC018720	346	1-1668
HNHEX30	64	634848	AC005236	347	1-1685
HNHEX30	64	634848	AC005488	348	1-730
HNHEX30	64	634848	AC005488	349	1-104 124-335
HNHEX30	64	634848	AC004980	350	1-319

HNHEX30	64	634848	AC004980	351	1-468
HNHEX30	64	634848	AC018720	352	1-468
HNHEX30	64	634848	AC018720	353	1-319
HNHEX30	64	634848	AC005236	354	1-104 124-335
HNHEX30	64	634848	AC005236	355	1-730
HPJBI33	65	685699	AP000571	356	1-1676
HPJBI33	65	685699	AP001447	357	1-1676
HPJBI33	65	685699	AC018610	358	1-1675
HPJBI33	65	685699	AP000571	359	1-468 867-1077 3786-6173 6421-6522 7397-8119 8339-8436 9118-9268
HPJBI33	65	685699	AP001447	360	1-468 864-1126 3783-6172 6420-6521 7397-8119 8339-8436 9116-9266
HPJBI33	65	685699	AC018610	361	1-468 867-1130 3784-6176 6424-6525 7401-8123

						8343-8440 9122-9160
HRABA80	66	588460	AL356740	362		1-1698
HRACD80	67	882163	AL354898	363		1-160 411-815 1781-1919 2210-2347 2443-2558 3115-3353 4742-4807 5790-5921 6988-7116 7715-8037 8798-8918 9861-9987 10681-11556
HRACD80	67	882163	AL354898	364		1-267
HSLCX03	68	889145	AC078898	365		1-640
HSLCX03	68	889145	AC074196	366		1-606
HSLCX03	68	889145	AC077693	367		1-628
HSLCX03	68	889145	AC027037	368		1-640
HSLCX03	68	889145	AC026757	369		1-513
HSLCX03	68	889145	AC027036	370		1-612
HSLCX03	68	889145	AC022305	371		1-686
HSLCX03	68	889145	AC074108	372		1-462
HSLCX03	68	889145	AC074226	373		1-640
HSLCX03	68	889145	AC073166	374		1-640
HSLCX03	68	889145	AC068667	375		1-654

HSLCX03	68	889145	AC024594	376	1-414
HSLCX03	68	889145	AC024261	377	1-647
HSLCX03	68	889145	AC078893	378	1-640
HSLCX03	68	889145	AC073555	379	1-640
HSLCX03	68	889145	AC069474	380	1-571
HSLCX03	68	889145	AC068924	381	1-640
HSLCX03	68	889145	AC066689	382	1-639
HSLCX03	68	889145	AC035249	383	1-397
HSLCX03	68	889145	AC034258	384	1-648
HSLCX03	68	889145	AC027135	385	1-434
HSLCX03	68	889145	AC027035	386	1-624
HSLCX03	68	889145	AC027034	387	1-509
HSLCX03	68	889145	AC026815	388	1-654
HSLCX03	68	889145	AC025815	389	1-380
HSLCX03	68	889145	AC025781	390	1-546
HSLCX03	68	889145	AC018903	391	1-631
HSLCX03	68	889145	AC078894	392	1-654
HT5GJ57	69	740767	AC005081	393	1-149 1029-1450 4881-5071 5302-5397 6004-6132 6888-6926 7229-7329 9066-9254 9805-9848 9852-10211 10276-10315

HTSGJ57	69	740767	AC016675	394	10619-10807 10855-11472 11695-11852 12358-12468 13770-13847 14053-14259 14695-14822 16101-16553 18233-18690 18750-19965
					1-149 1029-1450 1623-1790 4908-5098 5329-5424 6031-6159 6915-6953 7256-7356 9095-9306 9834-9877 9881-10239 10304-10343 10647-10835 10883-11500 11724-11881 13799-13876 14082-14288 14725-14852 16131-16583

					18262-18719 18757-19994 20161-20420
HTSGJ57	69	740767	AC005081	395	1-233
HTSGJ57	69	740767	AC016675	396	1-720 2099-2265 2776-3550 3946-4146 4976-5104 5781-6171 6476-7039 7384-7738 7837-8009 8434-8593 11644-11746
HTACS42	70	722253	AC010655	397	1-926 1359-3248
HTACS42	70	722253	AC010655	398	1-351
HTACS42	70	722253	AC010655	399	1-415
HTEKE40	71	740768	AC027430	400	1-1447
HTEKE40	71	740768	AL356216	401	1-1567
HTEKE40	71	740768	AC027430	402	1-101
HTEKE40	71	740768	AL356216	403	1-101
HUVEO77	73	740776	AC031977	404	1-169 5219-10427
H2CBU83	75	884134	AC022205	405	1-281 1126-1265 4567-4638



					4750-5149 5194-5262 6765-6837 8311-8375 9163-9234 11487-11558 11857-11984 13132-13251 13836-13920 16388-19859
H2CBU83	75	884134	AC022205	406	1-630
H2CBU83	75	884134	AC022205	407	1-387
HAPNY94	76	699770	AL133351	408	1-238 2679-2860 6204-6544 6911-7399 7795-7909 8430-8914 9187-9620 9744-10234 11159-11190 11310-11737 12408-16037
HAPNY94	76	699770	AC013339	409	1-238 2699-2880 6224-6564 6931-7419 7815-7929 8449-8932

						9205-9638 9762-10130 10144-10309 11380-11807 12478-16107
HAPNY94	76	699770	AL133351	410		1-466
HAPNY94	76	699770	AC013339	411		1-466
HBJHZ58	77	745372	AC022609	412		1-1817
HBJHZ58	77	745372	AC009925	413		1-1816
HBJHZ58	77	745372	AC022609	414		1-339
HBJHZ58	77	745372	AC009925	415		1-339
HDPBQ02	79	745403	AC020929	416		1-110 227-409 520-565 681-817 998-3175 3448-3612 3693-3784 3866-4063 5477-5596
HDPBQ02	79	745403	AC020929	417		1-384
HFIYI70	80	744906	AC023020	418		1-1656
HFIYI70	80	744906	AL353755	419		1-1656
HFIYI70	80	744906	AC023020	420		1-1152
HFIYI70	80	744906	AL353755	421		1-1152

Table 1E

Gene No.	cDNA Clone ID No.:Z	AA SEQ ID NO.: Y	Biological Activity	Exemplary Activity Assay	Preferred Indication
3	HHPGO40	106	Activation of transcription through serum response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the SRE that may be used or routinely modified to test SRE activity of the polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-	A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated

				<p>368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); and Black et al., Virus Genes 12(2):105-117 (1997), the content of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2 dependent suspension culture of T cells with cytotoxic activity.</p>	<p>immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly preferred indication is sepsis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid tumors, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic</p>
--	--	--	--	---	---

					conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
3	HHPGO40	106	Upregulation of CD69 and activation of T cells	CD69 FMAT. CD69 is an activation marker that is expressed on activated T cells,	A highly preferred embodiment of the invention includes a method for

				<p>B cells, and NK cells. CD69 is not expressed on resting T cells, B cells, or NK cells. CD69 has been found to be associated with inflammation. Assays for immunomodulatory proteins expressed in T cells, B cells, and leukocytes are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate the activation of T cells, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory proteins evaluate the upregulation of cell surface markers, such as CD69, and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of</p>	<p>activating T cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating T cells. A highly preferred embodiment of the invention includes a method for activation B cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating B cells. A highly preferred embodiment of the invention includes a method for activating NK cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting activation of and/or inactivation NK cells. Highly preferred indications include inflammation and inflammatory disorders (e.g., as described below under "Immune Activity").</p>
--	--	--	--	--	---

				<p>the invention) include, for example, the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Ferenczi et al., J Autoimmun 14(1):63-78 (2000); Werfel et al., Allergy 52(4):465-469 (1997); Taylor-Fishwick and Siegel, Eur J Immunol 25(12):3215-3221 (1995); and Afetra et al., Ann Rheum Dis 52(6):457-460 (1993), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-</p>	<p>Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response and alternatively suppressing a T cell-mediated immune response, and boosting a B cell-mediated immune response and alternatively suppressing a B cell-mediated immune response. An additional highly preferred indication includes infection (e.g., as described below under "Infectious Disease"). Preferred indications also include anemia, pancytopenia,</p>
--	--	--	--	--	---

					<p>mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, inflammation and inflammatory disorders, asthma, and allergies. Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Preferred indications include neoplasms, such as, for example, leukemia, lymphoma, and prostate, breast, lung, colon, pancreatic, esophageal,</p>
--	--	--	--	--	---	--



					stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.
4	HAMGG68	107	Activation of Endothelial Cell p38 or JNK Signaling Pathway.	<p>Kinase assay. JNK and p38 kinase assays for signal transduction that regulate cell proliferation, activation, or apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and apoptosis. Exemplary assays for JNK and p38 kinase activity that may be used or routinely modified to test JNK and p38 kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell growth. A highly preferred embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell proliferation. A highly preferred embodiment of the invention includes a method for stimulating apoptosis of endothelial cells. An</p>

				<p>assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Gupta et al., Exp Cell Res 247(2): 495-504 (1999); Kyriakis JM, Biochem Soc Symp 64:29-48 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which are herein incorporated by reference in its entirety.</p> <p>Endothelial cells that may be used according to these assays are publicly available (e.g., through the ATCC).</p> <p>Exemplary endothelial cells that may be used according to these assays include human umbilical vein endothelial cells (HUVEC), which are endothelial cells which line venous blood vessels, and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.</p>	<p>alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) apoptosis of endothelial cells.</p> <p>A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) endothelial cell activation. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) the activation of and/or inactivating endothelial cells.</p> <p>A highly preferred embodiment of the invention includes a method for stimulating angiogenesis. An alternative highly preferred embodiment of the invention includes a method for inhibiting angiogenesis. A highly preferred embodiment of the invention includes a method for reducing cardiac hypertrophy. An alternative highly preferred embodiment</p>
--	--	--	--	--	---

					of the invention includes a method for inducing cardiac hypertrophy. Highly preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the cardiovascular system (e.g., heart disease, congestive heart failure, hypertension, aortic stenosis, cardiomyopathy, valvular regurgitation, left ventricular dysfunction, atherosclerosis and atherosclerotic vascular disease, diabetic nephropathy, intracardiac shunt, cardiac hypertrophy, myocardial infarction, chronic hemodynamic overload, and/or as described below under "Cardiovascular Disorders"). Highly preferred indications include cardiovascular, endothelial and/or angiogenic disorders (e.g., systemic disorders that affect vessels such as diabetes mellitus, as

					well as diseases of the vessels themselves, such as of the arteries, capillaries, veins and/or lymphatics). Highly preferred are indications that stimulate angiogenesis and/or cardiovascularization. Highly preferred are indications that inhibit angiogenesis and/or cardiovascularization. Highly preferred indications include antiangiogenic activity to treat solid tumors, leukemias, and Kaposi's sarcoma, and retinal disorders. Highly preferred indications include neoplasms and cancer, such as, Kaposi's sarcoma, hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, lymphangioma, lymphangiosarcoma. Highly preferred indications also include cancers such as,
--	--	--	--	--	---

					prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease, such as, atherosclerosis, hypertension, coronary artery disease, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, and cancer. Highly preferred indications also include trauma such as wounds, burns, and injured tissue (e.g., vascular injury such as, injury resulting from

					balloon angioplasty, and atherosclerotic lesions), implant fixation, scarring, ischemia reperfusion injury, rheumatoid arthritis, cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. Additional highly preferred indications include stroke, graft rejection, diabetic or other retinopathies, thrombotic and coagulative disorders, vasculitis, lymph angiogenesis, sexual disorders, age-related macular degeneration, and treatment /prevention of endometriosis and related conditions. Additional highly preferred indications include fibromas, heart disease, cardiac arrest, heart valve disease, and vascular disease. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or

					<p>""Cardiovascular Disorders"").</p> <p>Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain management.</p>
5	HAPOM49	108	Regulation of viability and proliferation of pancreatic beta cells.	Assays for the regulation of viability and proliferation of cells in vitro are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate viability and proliferation of pancreatic beta cells. For example, the Cell	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the ""Renal Disorders"" section below),</p>

				<p>Titer-Glo luminescent cell viability assay measures the number of viable cells in culture based on quantitation of the ATP present which signals the presence of metabolically active cells. Exemplary assays that may be used or routinely modified to test regulation of viability and proliferation of pancreatic beta cells by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Friedrichsen BN, et al., Mol Endocrinol, 15(1):136-48 (2001); Huotari MA, et al., Endocrinology, 139(4):1494-9 (1998); Hugi SR, et al., J Biol Chem 1998 Jul 10;273(28):17771-9 (1998), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or</p>	<p>diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section</p>
--	--	--	--	--	---



				<p>may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
6	HBGBA69	109	<p>Regulation of viability and proliferation of pancreatic beta cells.</p>	<p>Assays for the regulation of viability and proliferation of cells in vitro are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate viability and proliferation of pancreatic beta cells. For example, the Cell Titer-Glo luminescent cell viability assay measures the</p>	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage</p>

				<p>number of viable cells in culture based on quantitation of the ATP present which signals the presence of metabolically active cells. Exemplary assays that may be used or routinely modified to test regulation of viability and proliferation of pancreatic beta cells by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Friedrichsen BN, et al., Mol Endocrinol, 15(1):136-48 (2001); Huotari MA, et al., Endocrinology, 139(4):1494-9 (1998); Hugl SR, et al., J Biol Chem 1998 Jul 10;273(28):17771-9 (1998), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that</p>	<p>(e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal</p>
--	--	--	--	--	--

				<p>may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
9	HDPOJ08	112	<p>Regulation of apoptosis in pancreatic beta cells.</p>	<p>Caspase Apoptosis. Assays for caspase apoptosis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote caspase protease-mediated apoptosis. Apoptosis in pancreatic beta is associated with induction and progression of diabetes. Exemplary assays for caspase apoptosis that may be used or routinely modified to test</p>	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel</p>

				<p>capase apoptosis activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in: Loweth, AC, et al., FEBS Lett, 400(3):285-8 (1997); Saini, KS, et al., Biochem Mol Biol Int, 39(6):1229-36 (1996); Krauthelm, A., et al., Br J Pharmacol, 129(4):687-94 (2000); Chandra J, et al., Diabetes, 50 Suppl 1:S44-7 (2001); Suk K, et al., J Immunol, 166(7):4481-9 (2001); Tejado J, et al., FEBS Lett, 459(2):238-43 (1999); Zhang, S., et al., FEBS Lett, 455(3):315-20 (1999); Lee et al., FEBS Lett 485(2-3): 122-126 (2000); Nor et al., J Vasc Res 37(3): 209-218 (2000); and Karsan and Harlan, J Atheroscler Thromb 3(2): 75-80 (1996); the contents of each of which are herein incorporated by reference in its entirety. Pancreatic cells that</p>	<p>blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture).</p>
--	--	--	--	---	---

				may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include RIN-m. RIN-m is a rat adherent pancreatic beta cell insulinoma cell line derived from a radiation induced transplantable rat islet cell tumor. The cells produce and secrete islet polypeptide hormones, and produce insulin, somatostatin, and possibly glucagon. ATTC: #CRL-2057 Chick et al. Proc. Natl. Acad. Sci. 1977 74:628; AF et al. Proc. Natl. Acad. Sci. 1980 77:3519.	An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.
11	HELK31	114	Production of IL-6	IL-6 FMT. IL-6 is produced by T cells and has strong effects on B cells. IL-6 participates in IL-4 induced IgE production and increases IgA production (IgA plays a role in mucosal immunity). IL-6 induces cytotoxic T cells.	A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) IL-6 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g.,

				<p>Deregulated expression of IL-6 has been linked to autoimmune disease, plasmacytomas, myelomas, and chronic hyperproliferative diseases. Assays for immunomodulatory and differentiation factor proteins produced by a large variety of cells where the expression level is strongly regulated by cytokines, growth factors, and hormones are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation and differentiation and modulate T cell proliferation and function. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as IL-6, and the stimulation and upregulation of T cell proliferation and functional</p>	<p>reducing) IL-6 production. A highly preferred indication is the stimulation or enhancement of mucosal immunity. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or ""Cardiovascular Disorders""), and infection (e.g., as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Highly preferred indications also include boosting a B cell-mediated immune response and alternatively suppressing a B cell-mediated immune response. Highly preferred indications include</p>
--	--	--	--	---	--

				<p>activities. Such assays that may be used or routinely modified to test immunomodulatory and differentiation activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); and Verhasselt et al., J Immunol 158:2919-2925 (1997), the contents of each of which are herein incorporated by reference in its entirety. Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and</p>	<p>inflammation and inflammatory disorders. Additional highly preferred indications include asthma and allergy. Highly preferred indications include neoplastic diseases (e.g., myeloma, plasmacytoma, leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, myeloma, plasmacytoma, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia,</p>
--	--	--	--	--	--

				upregulate T cell proliferation and functional activities.	Hodgkin's disease, acute lymphocytic anemia (ALL), multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease. An additional preferred indication is infection (e.g., an infectious disease as described below under "'Infectious Disease'").
11	HEL GK31	114	Production of IFNgamma using a T cells	IFNgamma FMAT. IFNg plays a central role in the immune system and is considered to be a proinflammatory cytokine. IFNg promotes TH1 and inhibits TH2 differentiation; promotes IgG2a and inhibits IgE secretion; induces macrophage activation; and increases MHC expression.	<p>A highly preferred embodiment of the invention includes a method for stimulating the production of IFNg. An alternative highly preferred embodiment of the invention includes a method for inhibiting the production of IFNg. Highly preferred indications include blood</p>



				<p>Assays for immunomodulatory proteins produced by T cells and NK cells that regulate a variety of inflammatory activities and inhibit TH2 helper cell functions are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, regulate inflammatory activities, modulate TH2 helper cell function, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as Interferon gamma (IFNg), and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention</p>	<p>disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or as described below under "Infectious Disease"). Highly preferred indications include autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiency (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders. Additional preferred indications include idiopathic</p>
--	--	--	--	---	--

				<p>(including antibodies and agonists or antagonists of the invention) include the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Gonzalez et al., J Clin Lab Anal 8(5):225-233 (1995); Billiau et al., Ann NY Acad Sci 856:22-32 (1998); Boehm et al., Annu Rev Immunol 15:749-795 (1997), and Rheumatology (Oxford) 38(3):214-20 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These</p>	<p>pulmonary fibrosis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous</p>
--	--	--	--	---	---

12	HFPCX64	115	Production of IL-5	<p>cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p> <p>IL-5 FMAT. Assays for immunomodulatory proteins secreted by TH2 cells, mast cells, basophils, and eosinophils that stimulate eosinophil function and B cell Ig production and promote polarization of CD4+ cells into TH2 cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, stimulate immune cell function, modulate B cell Ig production, modulate immune</p>	<p>disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.</p> <p>A highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) IL-5 production. An alternative highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) IL-5 production.</p> <p>A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) immunoglobulin production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) immunoglobulin production.</p>
----	---------	-----	--------------------	---	--

				<p>cell polarization, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as IL-5, and the stimulation of eosinophil function and B cell Ig production. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Ohshima et al., Blood 92(9):3338-3345 (1998); Jung et al., Eur J Immunol 25(8):2413-2416 (1995); Mori et al., J Allergy Clin Immunol 106(1 Pt 2):558-564 (2000); and Koning et al., Cytokine</p>	<p>A highly preferred indication includes allergy. A highly preferred indication includes asthma. A highly preferred indication includes rhinitis. An additional highly preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"), and inflammation and inflammatory disorders. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, melanoma, and/or as described below under</p>
--	--	--	--	--	--

				<p>9(6):427-436 (1997), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>"Hyperproliferative Disorders"). Preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, leukemias, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, hemophilia,</p>
--	--	--	--	--	--

16	HMIAP86	119	Production of TNF alpha by dendritic cells	<p>TNF<math>\alpha</math> FMAT. Assays for immunomodulatory proteins produced by activated macrophages, T cells, fibroblasts, smooth muscle, and other cell types that exert a wide variety of inflammatory and cytotoxic effects on a variety of cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, modulate inflammation and cytotoxicity. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines such as tumor necrosis factor alpha (TNF<math>\alpha</math>), and the induction or inhibition of an inflammatory or cytotoxic response. Such</p>	<p>hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.</p> <p>A highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) TNF alpha production. An alternative highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and</p>
----	---------	-----	--	--	--

				<p>assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Verhasselt et al., Eur J Immunol 28(11):3886-3890 (1998); Dahlen et al., J Immunol 160(7):3585-3593 (1998); Verhasselt et al., J Immunol 158:2919-2925 (1997); and Nardelli et al., J Leukoc Biol 65:822-828 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human dendritic cells are</p>	<p>suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly preferred indication is sepsis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid tumors, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia,</p>
--	--	--	--	---	--

				antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities.	metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
16	HMIAP86	119	Production of MIP1alpha	MIP-1alpha FMAT. Assays for immunomodulatory proteins produced by activated dendritic cells that upregulate monocyte/macrophage and T	A highly preferred embodiment of the invention includes a method for stimulating MIP1a production. An alternative highly preferred



				<p>cell chemotaxis are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, modulate chemotaxis, and modulate T cell differentiation. Exemplary assays that test for immunomodulatory proteins evaluate the production of chemokines, such as macrophage inflammatory protein 1 alpha (MIP-1a), and the activation of monocytes/macrophages and T cells. Such assays that may be used or routinely modified to test immunomodulatory and chemotaxis activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-</p>	<p>embodiment of the invention includes a method for inhibiting (e.g., reducing) MIP1a production. A highly preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"). Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications include inflammation and inflammatory disorders. Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute</p>
--	--	--	--	---	--

				<p>204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Sathaporn and Eremic, J R Coll Surg Ednb 45(1):9-19 (2001); Drakes et al., Transp Immunol 8(1):17-29 (2000); Verhasselt et al., J Immunol 158:2919-2925 (1997); and Nardelli et al., J Leukoc Biol 65:822-828 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities.</p>	<p>lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma, and allergy. Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic</p>
--	--	--	--	--	--

16	HMIAP86	119	Production of MCP-1	<p>MCP-1 FMAT. Assays for immunomodulatory proteins that are produced by a large variety of cells and act to induce chemotaxis and activation of monocytes and T cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, induce chemotaxis, and modulate immune cell activation. Exemplary assays that test for immunomodulatory proteins evaluate the production of cell surface markers, such as monocyte chemoattractant protein (MCP), and the activation of monocytes and T cells. Such assays that may be used or routinely modified to test immunomodulatory and</p>	<p>conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.</p> <p>A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) MCP-1 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) MCP-1 production. A highly preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"). Additional highly preferred indications include inflammation and inflammatory disorders. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications include autoimmune diseases</p>
----	---------	-----	---------------------	---	--

				<p>differentiation activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Sathaporn and Eremin, J R Coll Surg Ednb 45(1):9-19 (2001); and Verhasselt et al., J Immunol 158:2919-2925 (1997), the contents of each of which are herein incorporated by reference in its entirety.</p> <p>Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art.</p> <p>Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation</p>	<p>(e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis (bacterial and viral), Lyme Disease, asthma, and allergy Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under</p>
--	--	--	--	--	--

					and functional activities.	<p>"Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.</p>
17	HMUAP70	120	Activation of transcription through serum response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the	<p>A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or</p>	

				<p>SRE that may be used or routinely modified to test SRE activity of the polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); and Black et al., Virus Genes 12(2):105-117 (1997), the content of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2 dependent suspension culture of T cells with cytotoxic activity.</p>	<p>""Cardiovascular Disorders""), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly preferred indication is sepsis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, for example,</p>
--	--	--	--	--	---

					leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid tumors, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis,
--	--	--	--	--	--

					meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").
18	HRACJ35	121	Regulation of transcription of Malic Enzyme in hepatocytes	Assays for the regulation of transcription of Malic Enzyme are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate transcription of Malic Enzyme, a key enzyme in lipogenesis. Malic enzyme is involved in lipogenesis and its expression is stimulated by insulin. ME promoter contains two direct repeat (DR1)-like elements MEp and ME <sub>d</sub> identified as putative PPAR response elements. ME promoter may also responds to AP1 and other transcription factors. Exemplary assays that may be	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-</p>



				<p>used or routinely modified to test for regulation of transcription of Malic Enzyme (in hepatocytes) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Streeter, R.S., et al., Mol Endocrinol, 12(11):1778-91 (1998); Garcia-Jimenez, C., et al., Mol Endocrinol, 8(10):1361-9 (1994); Barroso, I., et al., J Biol Chem, 274(25):17997-8004 (1999); Ijpenberg, A., et al., J Biol Chem, 272(32):20108-20117 (1997); Berger, et al., Gene 66:1-10 (1988); and, Cullen, B., et al., Methods in Enzymol. 216:362-368 (1992), the contents of each of which is herein incorporated by reference in its entirety. Hepatocytes that may be used according to these assays are publicly available (e.g., through the ATCC) and/or</p>	<p>hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively,</p>
--	--	--	--	--	---

				may be routinely generated. Exemplary hepatocytes that may be used according to these assays includes the mouse 3T3-L1 cell line. 3T3-L1 is a mouse preadipocyte cell line (adherent). It is a continuous substrain of 3T3 fibroblasts developed through clonal isolation. Cells undergo a pre-adipocyte to adipose-like conversion under appropriate differentiation culture conditions.	weight gain. Additional highly preferred indications are complications associated with insulin resistance.
25	HDPBQ71	128	IL-2 in Human T cells		
25	HDPBQ71	128	Production of IFNgamma using a T cells	IFNgamma FMAT. IFNg plays a central role in the immune system and is considered to be a proinflammatory cytokine. IFNg promotes TH1 and inhibits TH2 differentiation; promotes IgG2a and inhibits IgE secretion; induces macrophage activation; and increases MHC expression. Assays for immunomodulatory proteins produced by T cells and NK cells that regulate a	A highly preferred embodiment of the invention includes a method for stimulating the production of IFNg. An alternative highly preferred embodiment of the invention includes a method for inhibiting the production of IFNg. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related

				<p>variety of inflammatory activities and inhibit TH2 helper cell functions are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, regulate inflammatory activities, modulate TH2 helper cell function, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as Interferon gamma (IFNg), and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays</p>	<p>Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or as described below under "Infectious Disease"). Highly preferred indications include autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiency (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders. Additional preferred indications include idiopathic pulmonary fibrosis. Highly preferred indications include neoplastic diseases (e.g.,</p>
--	--	--	--	--	--

				<p>disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Gonzalez et al., J Clin Lab Anal 8(5):225-233 (1995); Billiau et al., Ann NY Acad Sci 856:22-32 (1998); Boehm et al., Annu Rev Immunol 15:749-795 (1997), and Rheumatology (Oxford) 38(3):214-20 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance</p>	<p>leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis,</p>
--	--	--	--	---	--

					responsiveness to immunomodulatory factors.	suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.
27	HELHL48	130	Upregulation of CD152 and activation of T cells	CD152 FMAT. CD152 (a.k.a. CTLA-4) expression is restricted to activated T cells. CD152 is a negative regulator of T cell proliferation. Reduced CD152 expression has been linked to hyperproliferative and autoimmune diseases. Overexpression of CD152 may lead to impaired immunoresponses. Assays for immunomodulatory proteins important in the maintenance of T cell homeostasis and expressed almost exclusively on CD4+ and CD8+ T cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and	A highly preferred embodiment of the invention includes a method for activating T cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating T cells. A highly preferred embodiment of the invention includes a method for inhibiting T cell proliferation. An alternative highly preferred embodiment of the invention includes a method for stimulating T cell proliferation. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or	

				<p>agonists or antagonists of the invention) to modulate the activation of T cells, maintain T cell homeostasis, and/or mediate humoral or cell-mediated immunity.</p> <p>Exemplary assays that test for immunomodulatory proteins evaluate the upregulation of cell surface markers, such as CD152, and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include, for example, the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); McCoy et al., Immunol Cell Biol 77(1):1-10 (1999); Oostervegal et al., Curr Opin Immunol 11(3):294-300 (1999); and Saito T, Curr Opin</p>	<p>"Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative</p>
--	--	--	--	---	--

			<p>Immunol 10(3):313-321 (1998), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, inflammation and inflammatory disorders, and asthma and allergy. An additional preferred indication is infection (e.g., as described below under "Infectious Disease").</p>
HTECC05	133	Regulation of	Assays for the regulation of	A highly preferred

30	viability and proliferation of pancreatic beta cells.	viability and proliferation of cells in vitro are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate viability and proliferation of pancreatic beta cells. For example, the Cell Titer-Glo luminescent cell viability assay measures the number of viable cells in culture based on quantitation of the ATP present which signals the presence of metabolically active cells. Exemplary assays that may be used or routinely modified to test regulation of viability and proliferation of pancreatic beta cells by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Friedrichsen BN, et al., Mol Endocrinol, 15(1):136-48 (2001); Huotari	<p>indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hypermolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders"</p>
----	---	--	--



31	HBJLF01	134	Activation of transcription through AP1	<p>MA, et al., Endocrinology, 139(4):1494-9 (1998); Hugi SR, et al., J Biol Chem 1998 Jul 10;273(28):17771-9.</p> <p>(1998), the contents of each of which is herein incorporated by reference in its entirety.</p> <p>Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated.</p> <p>Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture).</p> <p>An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
				<p>Assays for the activation of transcription through the AP1 response element are known in</p>	<p>Preferred indications include neoplastic diseases (e.g., as described below under</p>

			<p>response element in immune cells (such as T-cells).</p>	<p>the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate growth and other cell functions. Exemplary assays for transcription through the AP1 response element that may be used or routinely modified to test AP1-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1988); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Rellahan et al., J Biol Chem 272(49):30806-30811 (1997); Chang et al., Mol Cell Biol 18(9):4986-4993 (1998); and Fraser et al., Eur J Immunol 29(3):838-844 (1999), the</p>	<p>"Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications include inflammation and inflammatory disorders. Highly preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms</p>
--	--	--	--	---	---

				<p>contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2 dependent suspension-culture cell line with cytotoxic activity.</p>	<p>and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include arthritis, asthma, AIDS, allergy, anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, granulomatous disease, inflammatory bowel disease, sepsis, psoriasis, suppression of immune reactions to transplanted organs and tissues, endocarditis, meningitis, and Lyme Disease.</p>
34	HCMSQ56	137	Production of ICAM-1	Assays for measuring expression of ICAM-1 are well-known in the art and may	Preferred embodiments of the invention include using polypeptides of the invention

37	HDPCJ91	140	Activation of Skeletal Muscle Cell PI3 Kinase	<p>be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate ICAM-1 expression. Exemplary assays that may be used or routinely modified to measure ICAM-1 expression include assays disclosed in: Takacs P, et al, FASEB J, 15(2):279-281 (2001); and, Miyamoto K, et al., Am J Pathol, 156(5):1733-1739 (2000), the contents of each of which is herein incorporated by reference in its entirety. Cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary cells that may be used according to these assays include microvascular endothelial cells (MVEC).</p>	<p>(or antibodies, agonists, or antagonists thereof) in detection, diagnosis, prevention, and/or treatment of Inflammation, Vascular Disease, Atherosclerosis, Restenosis, and Stroke</p>
				<p>Kinase assay. Kinase assays, for example an GSK-3 kinase assay, for PI3 kinase signal</p>	<p>A highly preferred embodiment of the invention includes a method for</p>

			<p>transduction that regulate glucose metabolism and cell survival are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit glucose metabolism and cell survival. Exemplary assays for PI3 kinase activity that may be used or routinely modified to test PI3 kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Nikoulina et al., Diabetes 49(2):263-271 (2000); and Schreyer et al., Diabetes 48(8):1662-1666 (1999), the contents of each of which are herein incorporated by reference in its entirety. Rat myoblast cells that may be</p>	<p>increasing muscle cell survival An alternative highly preferred embodiment of the invention includes a method for decreasing muscle cell survival. A preferred embodiment of the invention includes a method for stimulating muscle cell proliferation. In a specific embodiment, skeletal muscle cell proliferation is stimulated. An alternative highly preferred embodiment of the invention includes a method for inhibiting muscle cell proliferation. In a specific embodiment, skeletal muscle cell proliferation is inhibited. A preferred embodiment of the invention includes a method for stimulating muscle cell differentiation. In a specific embodiment, skeletal muscle cell differentiation is stimulated. An alternative highly preferred embodiment of the invention includes a method for inhibiting muscle</p>
--	--	--	--	--

				<p>used according to these assays are publicly available (e.g., through the ATCC). Exemplary rat myoblast cells that may be used according to these assays include L6 cells. L6 is an adherent rat myoblast cell line, isolated from primary cultures of rat thigh muscle, that fuses to form multinucleated myotubes and striated fibers after culture in differentiation media.</p>	<p>cell differentiation. In a specific embodiment, skeletal muscle cell differentiation is inhibited. Highly preferred indications include disorders of the musculoskeletal system. Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), endocrine disorders (e.g., as described below under "Endocrine Disorders"), neural disorders (e.g., as described below under "Neural Activity and Neurological Diseases"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), immune disorders (e.g., as described below under "Immune Activity"), and infection (e.g., as described below under "Infectious Disease"). A highly preferred indication is diabetes</p>
--	--	--	--	---	---

					<p>mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hypermolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders"</p>
--	--	--	--	--	---

					section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance. Additional highly preferred indications are disorders of the musculoskeletal system including myopathies,
--	--	--	--	--	--



					muscular dystrophy, and/or as described herein. Additional highly preferred indications include: myopathy, atrophy, congestive heart failure, cachexia, myxomas, fibromas, congenital cardiovascular abnormalities, heart disease, cardiac arrest, heart valve disease, and vascular disease. Highly preferred indications include neoplasms and cancer, such as, rhabdomyoma, rhabdosarcoma, stomach, esophageal, prostate, and urinary cancer. Preferred indications also include breast, lung, colon, pancreatic, brain, and liver cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, hyperplasia, metaplasia, and/or dysplasia.
38	HDPGK25	141	Production of MCP-1	MCP-1 FMAT. Assays for immunomodulatory proteins that are produced by a large	A highly preferred embodiment of the invention includes a method for

				<p>variety of cells and act to induce chemotaxis and activation of monocytes and T cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, induce chemotaxis, and modulate immune cell activation. Exemplary assays that test for immunomodulatory proteins evaluate the production of cell surface markers, such as monocyte chemoattractant protein (MCP), and the activation of monocytes and T cells. Such assays that may be used or routinely modified to test immunomodulatory and differentiation activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J</p>	<p>stimulating (e.g., increasing) MCP-1 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) MCP-1 production. A highly preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"). Additional highly preferred indications include inflammation and inflammatory disorders. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Preferred</p>
--	--	--	--	--	---

			<p>Biomolecular Screening 4:193-204(1999); Rowland et al., "T Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Sathaporn and Eremin, J R Coll Surg Ednb 45(1):9-19 (2001); and Verhasselt et al., J Immunol 158:2919-2925 (1997), the contents of each of which are herein incorporated by reference in its entirety. Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities.</p>	<p>indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis (bacterial and viral), Lyme Disease, asthma, and allergy Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic,</p>
--	--	--	--	---

					<p>esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.</p>
39	HE2DY70	142	Production of IFNgamma using a T cells	<p>IFNgamma FMAT. IFNγ plays a central role in the immune system and is considered to be a proinflammatory cytokine. IFNγ promotes TH1 and inhibits TH2 differentiation; promotes IgG2a and inhibits IgE secretion; induces macrophage activation; and increases MHC expression. Assays for immunomodulatory proteins produced by T cells and NK cells that regulate a variety of inflammatory activities and inhibit TH2 helper cell functions are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating the production of IFNγ. An alternative highly preferred embodiment of the invention includes a method for inhibiting the production of IFNγ. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or as</p>

				<p>agonists or antagonists of the invention) to mediate immunomodulation, regulate inflammatory activities, modulate TH2 helper cell function, and/or mediate humoral or cell-mediated immunity. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as Interferon gamma (IFNg), and the activation of T-cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., ""Lymphocytes: a practical approach"" Chapter 6:138-160 (2000); Gonzalez et al., J Clin Lab Anal 8(5):225-233 (1995); Billiau et al., Ann NY Acad</p>	<p>described below under "Infectious Disease"). Highly preferred indications include autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiency (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders. Additional preferred indications include idiopathic pulmonary fibrosis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma,</p>
--	--	--	--	---	---

				<p>Sci 856:22-32 (1998); Boehm et al., Annu Rev Immunol 15:749-795 (1997), and Rheumatology (Oxford) 38(3):214-20 (1999), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.</p>
HF2NV57	143	ATF-2 in CTI I-2	final assay desc	final assay embodiment	

40	HE2NV57	143	<p>Activation of transcription through AP1 response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the AP1 response element are known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate growth and other cell functions. Exemplary assays for transcription through the AP1 response element that may be used or routinely modified to test AP1-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1988); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Rellahan et al., J Biol Chem 272(49):30806-30811 (1997);</p>	<p>Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications include inflammation and inflammatory disorders. Highly preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described</p>
40					

				<p>Chang et al., Mol Cell Biol 18(9):4986-4993 (1998); and Fraser et al., Eur J Immunol 29(3):838-844 (1999), the contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2 dependent suspension-culture cell line with cytotoxic activity.</p>	<p>below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include arthritis, asthma, AIDS, allergy, anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, granulomatous disease, inflammatory bowel disease, sepsis, psoriasis, suppression of immune reactions to transplanted organs and tissues, endocarditis,</p>
--	--	--	--	---	--



40	HE2NV57	143	<p>Activation of transcription through cAMP response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the cAMP response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to increase cAMP and regulate CREB transcription factors, and modulate expression of genes involved in a wide variety of cell functions. Exemplary assays for transcription through the cAMP response element that may be used or routinely modified to test cAMP-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn</p>	<p>meningitis, and Lyme Disease. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional preferred indications include inflammation and inflammatory disorders. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below</p>
----	---------	-----	---	--	---

				<p>et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Black et al., Virus Genes 15(2):105-117 (1997); and Belkowski et al., J Immunol 161(2):659-665 (1998), the contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTL cell line, which is a suspension culture of IL-2 dependent cytotoxic T cells.</p>	<p>under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma (e.g., T cell lymphoma, Burkitt's lymphoma, non-Hodgkin's lymphoma, Hodgkin's disease), melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune</p>
--	--	--	--	--	--

40	HE2NV57	143	Activation of transcription through GAS response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Gamma Interferon Activation Site (GAS) response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate STAT transcription factors and modulate gene expression involved in a wide variety of cell functions. Exemplary assays for transcription through the GAS response element that may be used or routinely modified to test GAS-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of	reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy.
				Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma (e.g., T cell lymphoma, Burkitt's lymphoma, non-Hodgkins lymphoma, Hodgkin's disease), melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include	

				<p>the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Matikainen et al., Blood 93(6):1980-1991 (1999); and Henttinen et al., J Immunol 155(10):4582-4587 (1995), the contents of each of which are herein incorporated by reference in its entirety. Exemplary mouse T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary T cells that may be used according to these assays include the CTLL cell line, which is a suspension culture of IL-2 dependent cytotoxic T cells.</p>	<p>autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional preferred indications include inflammation and inflammatory disorders. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or an infectious disease as described below under "Infectious Disease"). An additional preferred indication is</p>
--	--	--	--	---	--

					<p>idiopathic pulmonary fibrosis. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy.</p>
40	HE2NV57	143	<p>Activation of transcription through serum response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the Serum Response Element (SRE) are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate the serum response</p>	<p>A preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) TNF alpha production. An alternative preferred embodiment of the invention includes a method for stimulating (e.g., increasing) TNF alpha production. Preferred indications include blood</p>

				<p>factors and modulate the expression of genes involved in growth. Exemplary assays for transcription through the SRE that may be used or routinely modified to test SRE activity of the polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); and Black et al., Virus Genes 12(2):105-117 (1997), the content of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTL cell</p>	<p>disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional highly preferred indications include inflammation and inflammatory disorders, and treating joint damage in patients with rheumatoid arthritis. An additional highly preferred indication is sepsis. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative</p>
--	--	--	--	---	---

					<p>line, which is an IL-2 dependent suspension culture of T cells with cytotoxic activity.</p>	<p>Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma, melanoma, glioma (e.g., malignant glioma), solid tumors, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, neutropenia, neutrophilia, psoriasis, suppression of immune</p>
--	--	--	--	--	--	---

					<p>reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, cardiac reperfusion injury, and asthma and allergy. An additional preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease").</p> <p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic</p>
40	HE2NV/57	143	Insulin Secretion	<p>Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and <u>disregulation is a key</u></p>	



				<p>component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr J, 47(3):261-9 (2000); Salapatek, A.M., et al., Mol Endocrinol, 13(8):1305-17 (1999); Filipsson, K., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J Biol Chem, 271(28):16544-52 (1996); and, Miraglia S et al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that</p>	<p>neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or</p>
--	--	--	--	---	---

				<p>may be used according to these assays include HIT T15 Cells. HIT T15 are an adherent epithelial cell line established from Syrian hamster islet cells transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.</p>	<p>complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
40	HE2NV57	143	<p>Activation of transcription through CD28 response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the CD28 response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate IL-2</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating T cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting T cell proliferation. A highly preferred embodiment of the invention</p>

				<p>expression in T cells. Exemplary assays for transcription through the CD28 response element that may be used or routinely modified to test CD28-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); McGuire and Iacobelli, J Immunol 159(3):1319-1327 (1997); Parra et al., J Immunol 166(4):2437-2443 (2001); and Butscher et al., J Biol Chem 3(1):552-560 (1998), the contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC).</p>	<p>includes a method for activating T cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating T cells. A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) IL-2 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) IL-2 production. Additional highly preferred indications include inflammation and inflammatory disorders. Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune</p>
--	--	--	--	---	---

				<p>Exemplary human T cells that may be used according to these assays include the JURKAT cell line, which is a suspension culture of leukemia cells that produce IL-2 when stimulated.</p>	<p>response, and suppressing a T cell-mediated immune response. An additional highly preferred indication includes infection (e.g., AIDS, and/or as described below under "Infectious Disease").</p> <p>Highly preferred indications include neoplastic diseases (e.g., melanoma, renal cell carcinoma, leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, melanoma (e.g., metastatic melanoma), renal cell carcinoma (e.g., metastatic renal cell carcinoma), leukemia, lymphoma (e.g., T cell lymphoma), and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic</p>
--	--	--	--	--	--

					conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. A highly preferred indication is infection (e.g., tuberculosis, infections associated with granulomatous disease, and osteoporosis, and/or an infectious disease as described below under "Infectious Disease"). A highly preferred indication is AIDS. Additional highly preferred indications include suppression of immune reactions to transplanted organs and/or tissues, uveitis, psoriasis, and tropical spastic paraparesis. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL),
--	--	--	--	--	---

41	HETBR16	144				<p>plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, asthma and allergy.</p> <p>Preferred embodiments of the invention include using polypeptides of the invention (or antibodies, agonists, or antagonists thereof) in detection, diagnosis, prevention, and/or treatment of Inflammation, Vascular Disease, Atherosclerosis, Restenosis, and Stroke</p>
						<p>Assays for measuring expression of ICAM-1 are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate ICAM-1 expression. Exemplary assays that may be used or routinely modified to measure ICAM-1 expression include assays disclosed in: Takacs P, et al, FASEB J, 15(2):279-281 (2001); and, Miyamoto K, et al., Am J Pathol, 156(5):1733-1739 (2000), the contents of each of which is herein</p>

43	HFXKY27	146	Activation of Adipocyte ERK Signaling Pathway	<p>incorporated by reference in its entirety. Cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary cells that may be used according to these assays include microvascular endothelial cells (MVEC).</p> <p>Kinase assay. Kinase assays, for example an Elk-1 kinase assay, for ERK signal transduction that regulate cell proliferation or differentiation are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and differentiation. Exemplary assays for ERK kinase activity that may be used or routinely modified to test ERK kinase-induced activity of polypeptides of the</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating adipocyte proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting adipocyte proliferation. A highly preferred embodiment of the invention includes a method for stimulating adipocyte differentiation. An alternative highly preferred embodiment of the invention includes a method for inhibiting adipocyte differentiation. A highly preferred embodiment of the</p>
----	---------	-----	---	--	---

				<p>invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Le Marchand-Brustel Y, Exp Clin Endocrinol Diabetes 107(2):126-132 (1999); Kyriakis JM, Biochem Soc Symp 64:29-48 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which are herein incorporated by reference in its entirety.</p> <p>Mouse adipocyte cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse adipocyte cells that may be used according to these assays include 3T3-L1 cells. 3T3-L1 is an adherent mouse preadipocyte cell line that is a continuous substrain of 3T3</p>	<p>invention includes a method for stimulating (e.g., increasing) adipocyte activation. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of (e.g., decreasing) and/or inactivating adipocytes. Highly preferred indications include endocrine disorders (e.g., as described below under "Endocrine Disorders"). Highly preferred indications also include neoplastic diseases (e.g., lipomas, liposarcomas, and/or as described below under "Hyperproliferative Disorders"). Preferred indications include blood disorders (e.g., hypertension, congestive heart failure, blood vessel blockage, heart disease, stroke, impotence and/or as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related</p>
--	--	--	--	--	---



				fibroblast cells developed through clonal isolation and undergo a pre-adipocyte to adipose-like conversion under appropriate differentiation conditions known in the art.	Disorders"), immune disorders (e.g., as described below under "Immune Activity"), neural disorders (e.g., as described below under "Neural Activity and Neurological Diseases"), and infection (e.g., as described below under "Infectious Disease"). A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental
--	--	--	--	---	--

					confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below (particularly of the urinary tract and skin). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively,
--	--	--	--	--	---

					<p>weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p> <p>Additional highly preferred indications are disorders of the musculoskeletal systems including myopathies, muscular dystrophy, and/or as described herein.</p> <p>Additional highly preferred indications include, hypertension, coronary artery disease, dyslipidemia, gallstones, osteoarthritis, degenerative arthritis, eating disorders, fibrosis, cachexia, and kidney diseases or disorders. Preferred indications include neoplasms and cancer, such as, lymphoma, leukemia and breast, colon, and kidney cancer. Additional preferred indications include melanoma, prostate, lung, pancreatic, esophageal, stomach, brain, liver, and urinary cancer.</p> <p>Highly preferred indications</p>
--	--	--	--	--	--

43	HFXKY27	146	Activation of transcription through GAS response element in immune cells (such as T-cells).	Assays for the activation of transcription through the Gamma Interferon Activation Site (GAS) response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate STAT transcription factors and modulate gene expression involved in a wide variety of cell functions. Exemplary assays for transcription through the GAS response element that may be used or routinely modified to test GAS-response element activity of polypeptides of the invention (including antibodies	include lipomas and liposarcomas. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.
				Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma (e.g., T cell lymphoma, Burkitt's lymphoma, non-Hodgkins lymphoma, Hodgkins disease), melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.	

				<p>and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Matikainen et al., Blood 93(6):1980-1991 (1999); and Hentinen et al., J Immunol 155(10):4582-4587 (1995), the contents of each of which are herein incorporated by reference in its entirety. Exemplary mouse T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary T cells that may be used according to these assays include the CTLL cell line, which is a suspension culture of IL-2 dependent cytotoxic T cells.</p>	<p>Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional preferred indications include inflammation and inflammatory disorders. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., viral infections, tuberculosis, infections associated with chronic granulomatous disease and malignant osteoporosis, and/or an infectious disease as described below under "Infectious Disease"). An additional</p>
--	--	--	--	---	--

					<p>preferred indication is idiopathic pulmonary fibrosis. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy.</p>
46	HJBCY35	149	Regulation of viability and proliferation of pancreatic beta cells.	Assays for the regulation of viability and proliferation of cells in vitro are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate viability and	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as</p>

				<p>proliferation of pancreatic beta cells. For example, the Cell Titer-Glo luminescent cell viability assay measures the number of viable cells in culture based on quantitation of the ATP present which signals the presence of metabolically active cells. Exemplary assays that may be used or routinely modified to test regulation of viability and proliferation of pancreatic beta cells by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Friedrichsen BN, et al., Mol Endocrinol, 15(1):136-48 (2001); Huotari MA, et al., Endocrinology, 139(4):1494-9 (1998); Hugl SR, et al., J Biol Chem 1998 Jul 10;273(28):17771-9 (1998), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays</p>	<p>described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and</p>
--	--	--	--	---	--

				are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.	disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.
46	HJBCY35	149	Activation of Skeletal Muscle Cell PI3 Kinase Signalling Pathway	Kinase assay. Kinase assays, for example an GSK-3 kinase assay, for PI3 kinase signal transduction that regulate glucose metabolism and cell survival are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to	<p>A highly preferred embodiment of the invention includes a method for increasing muscle cell survival</p> <p>An alternative highly preferred embodiment of the invention includes a method for decreasing muscle cell survival. A preferred embodiment of the invention includes a method for stimulating muscle cell</p>



				<p>promote or inhibit glucose metabolism and cell survival. Exemplary assays for PI3 kinase activity that may be used or routinely modified to test PI3 kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Nikoulina et al., Diabetes 49(2):263-271 (2000); and Schreyer et al., Diabetes 48(8):1662-1666 (1999), the contents of each of which are herein incorporated by reference in its entirety. Rat myoblast cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary rat myoblast cells that may be used according to these assays include L6 cells. L6 is an adherent rat myoblast cell line, isolated from primary cultures of rat thigh muscle,</p>	<p>proliferation. In a specific embodiment, skeletal muscle cell proliferation is stimulated. An alternative highly preferred embodiment of the invention includes a method for inhibiting muscle cell proliferation. In a specific embodiment, skeletal muscle cell proliferation is inhibited. A preferred embodiment of the invention includes a method for stimulating muscle cell differentiation. In a specific embodiment, skeletal muscle cell differentiation is stimulated. An alternative highly preferred embodiment of the invention includes a method for inhibiting muscle cell differentiation. In a specific embodiment, skeletal muscle cell differentiation is inhibited. Highly preferred indications include disorders of the musculoskeletal system. Preferred indications include neoplastic diseases (e.g., as described below under</p>
--	--	--	--	--	--

				that fuses to form multinucleated myotubes and striated fibers after culture in differentiation media.	<p>"Hyperproliferative Disorders"), endocrine disorders (e.g., as described below under "Endocrine Disorders"), neural disorders (e.g., as described below under "Neural Activity and Neurological Diseases"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), immune disorders (e.g., as described below under "Immune Activity"), and infection (e.g., as described below under "Infectious Disease"). A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as</p>
--	--	--	--	--	--

					described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hypermolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and
--	--	--	--	--	--

					disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance. Additional highly preferred indications are disorders of the musculoskeletal system including myopathies, muscular dystrophy, and/or as described herein. Additional highly preferred indications include: myopathy, atrophy, congestive heart failure, cachexia, myxomas, fibromas, congenital cardiovascular abnormalities, heart disease, cardiac arrest,
--	--	--	--	--	---

48	HKGDL36	151	Regulation of viability and proliferation of pancreatic beta cells.	Assays for the regulation of viability and proliferation of cells in vitro are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate viability and proliferation of pancreatic beta cells. For example, the Cell	<p>heart valve disease, and vascular disease. Highly preferred indications include neoplasms and cancer, such as, rhabdomyoma, rhabdosarcoma, stomach, esophageal, prostate, and urinary cancer. Preferred indications also include breast, lung, colon, pancreatic, brain, and liver cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, hyperplasia, metaplasia, and/or dysplasia.</p> <p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below),</p>
----	---------	-----	---	---	--

				<p>Titer-Glo luminescent cell viability assay measures the number of viable cells in culture based on quantitation of the ATP present which signals the presence of metabolically active cells. Exemplary assays that may be used or routinely modified to test regulation of viability and proliferation of pancreatic beta cells by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Friedrichsen BN, et al., Mol Endocrinol, 15(1):136-48 (2001); Huotari MA, et al., Endocrinology, 139(4):1494-9 (1998); Hugl SR, et al., J Biol Chem 1998 Jul 10;273(28):17771-9 (1998), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or</p>	<p>diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section</p>
--	--	--	--	--	---

				<p>may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
55	HPJB133	158	Stimulation of insulin secretion from pancreatic beta cells.	<p>Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is</p>	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the ""Renal Disorders"" section below), diabetic neuropathy, nerve disease and nerve damage</p>

				<p>upregulated by glucose and also by certain proteins/peptides, and dysregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Ahren, B., et al., Am J Physiol, 277(4 Pt 2):R959-66 (1999); Li, M., et al., Endocrinology, 138(9):3735-40 (1997); Kim, K.H., et al., FEBS Lett, 377(2):237-9 (1995); and, Miraglia S et. al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC)</p>	<p>(e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal</p>
--	--	--	--	--	--



56	HRABA80	159		<p>and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
			Insulin Secretion	<p>Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion. For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from</p>	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve</p>

				<p>pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and dysregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Shimizu, H., et al., Endocr J, 47(3):261-9 (2000); Salapatek, A.M., et al., Mol Endocrinol, 13(8):1305-17 (1999); Filipsson, K., et al., Ann N Y Acad Sci, 865:441-4 (1998); Olson, L.K., et al., J Biol Chem, 271(28):16544-52 (1996); and, Miraglia S et al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein incorporated by reference in its entirety. Pancreatic cells that may be</p>	<p>disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the ""Cardiovascular Disorders"" section below), dyslipidemia, endocrine disorders (as described in the ""Endocrine Disorders"" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection (e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the</p>
--	--	--	--	---	---

				<p>used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include HIT15 Cells. HIT15 are an adherent epithelial cell line established from Syrian hamster islet cells transformed with SV40. These cells express glucagon, somatostatin, and glucocorticoid receptors. The cells secrete insulin, which is stimulated by glucose and glucagon and suppressed by somatostatin or glucocorticoids. ATTC# CRL-1777 Refs: Lord and Ashcroft. Biochem. J. 219: 547-551; Santerre et al. Proc. Natl. Acad. Sci. USA 78: 4339-4343, 1981.</p>	<p>urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
56	HRABA80	159	Activation of Endothelial Cell ERK Signaling Pathway.	<p>Kinase assay. Kinase assays, for example an Elk-1 kinase assay, for ERK signal transduction that regulate cell proliferation or differentiation</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly</p>

				<p>are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and differentiation. Exemplary assays for ERK kinase activity that may be used or routinely modified to test ERK kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Berra et al., Biochem Pharmacol 60(8):1171-1178 (2000); Gupta et al., Exp Cell Res 247(2):495-504 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which</p>	<p>preferred embodiment of the invention includes a method for inhibiting endothelial cell growth. A highly preferred embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell proliferation. A highly preferred embodiment of the invention includes a method for stimulating apoptosis of endothelial cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) apoptosis of endothelial cells. A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) endothelial cell activation. An alternative highly preferred embodiment of the invention</p>
--	--	--	--	--	--

				are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary endothelial cells that may be used according to these assays include human umbilical vein endothelial cells (HUVEC), which are endothelial cells which line venous blood vessels, and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.	includes a method for inhibiting the activation of (e.g., decreasing) and/or inactivating endothelial cells. A highly preferred embodiment of the invention includes a method for stimulating endothelial cell differentiation. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell differentiation. A highly preferred embodiment of the invention includes a method for stimulating angiogenesis. An alternative highly preferred embodiment of the invention includes a method for inhibiting angiogenesis. A highly preferred embodiment of the invention includes a method for reducing cardiac hypertrophy. An alternative highly preferred embodiment of the invention includes a method for inducing cardiac hypertrophy. Highly
--	--	--	--	--	--

					preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the cardiovascular system (e.g., heart disease, congestive heart failure, hypertension, aortic stenosis, cardiomyopathy, valvular regurgitation, left ventricular dysfunction, atherosclerosis and atherosclerotic vascular disease, diabetic nephropathy, intracardiac shunt, cardiac hypertrophy, myocardial infarction, chronic hemodynamic overload, and/or as described below under "Cardiovascular Disorders"). Highly preferred indications include cardiovascular, endothelial and/or angiogenic disorders (e.g., systemic disorders that affect vessels such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins
--	--	--	--	--	--

					and/or lymphatics). Highly preferred are indications that stimulate angiogenesis and/or cardiovascularization. Highly preferred are indications that inhibit angiogenesis and/or cardiovascularization. Highly preferred indications include antiangiogenic activity to treat solid tumors, leukemias, and Kaposi's sarcoma, and retinal disorders. Highly preferred indications include neoplasms and cancer, such as, Kaposi's sarcoma, hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, lymphangioma, lymphangiosarcoma. Highly preferred indications also include cancers such as, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and
--	--	--	--	--	---

					urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease, such as, atherosclerosis, hypertension, coronary artery disease, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, and cancer. Highly preferred indications also include trauma such as wounds, burns, and injured tissue (e.g., vascular injury such as, injury resulting from balloon angioplasty, and atherosclerotic lesions), implant fixation, scarring,
--	--	--	--	--	---



					ischemia reperfusion injury, rheumatoid arthritis, cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. Additional highly preferred indications include stroke, graft rejection, diabetic or other retinopathies, thrombotic and coagulative disorders, vasculitis, lymph angiogenesis, sexual disorders, age-related macular degeneration, and treatment /prevention of endometriosis and related conditions. Additional highly preferred indications include fibromas, heart disease, cardiac arrest, heart valve disease, and vascular disease. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications include autoimmune diseases (e.g.,
--	--	--	--	--	---

56	HRABA80	159	Upregulation of CD152 and activation of T cells	<p>CD152 FMAT. CD152 (a.k.a. CTLA-4) expression is restricted to activated T cells. CD152 is a negative regulator of T cell proliferation. Reduced CD152 expression has been linked to hyperproliferative and autoimmune diseases. Overexpression of CD152 may lead to impaired immunoresponses. Assays for immunomodulatory proteins important in the maintenance of T cell homeostasis and</p>	<p>rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain management.</p> <p>A highly preferred embodiment of the invention includes a method for activating T cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating T cells. A highly preferred embodiment of the invention includes a method for inhibiting T cell proliferation. An alternative highly preferred embodiment of the invention</p>
----	---------	-----	---	--	--

				<p>expressed almost exclusively on CD4+ and CD8+ T cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate the activation of T cells, maintain T cell homeostasis, and/or mediate humoral or cell-mediated immunity.</p> <p>Exemplary assays that test for immunomodulatory proteins evaluate the upregulation of cell surface markers, such as CD152, and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include, for example, the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al.,</p>	<p>includes a method for stimulating T cell proliferation. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Additionally, highly preferred indications include neoplasms and cancers, such as, for example,</p>
--	--	--	--	--	---

				<p>""Lymphocytes: a practical approach"" Chapter 6:138-160 (2000); McCoy et al., Immunol Cell Biol 77(1):1-10 (1999); Oosterveal et al., Curr Opin Immunol 11(3):294-300 (1999); and Saito T, Curr Opin Immunol 10(3):313-321 (1998), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, inflammation and</p>
--	--	--	--	--	--

57	HRACD80	160	Production of IL-6	<p>IL-6 FMAT. IL-6 is produced by T cells and has strong effects on B cells. IL-6 participates in IL-4 induced IgE production and increases IgA production (IgA plays a role in mucosal immunity). IL-6 induces cytotoxic T cells. Deregulated expression of IL-6 has been linked to autoimmune disease, plasmacytomas, myelomas, and chronic hyperproliferative diseases. Assays for immunomodulatory and differentiation factor proteins produced by a large variety of cells where the expression level is strongly regulated by cytokines, growth factors, and hormones are well known in the art and may be used or routinely modified to assess the ability of</p>	<p>inflammatory disorders, and asthma and allergy. An additional preferred indication is infection (e.g., as described below under "Infectious Disease").</p> <p>A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) IL-6 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) IL-6 production. A highly preferred indication is the stimulation or enhancement of mucosal immunity. Highly preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., as described below under "Infectious Disease"). Highly preferred indications include</p>
----	---------	-----	--------------------	--	--

				<p>polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation and differentiation and modulate T cell proliferation and function. Exemplary assays that test for immunomodulatory proteins evaluate the production of cytokines, such as IL-6, and the stimulation and upregulation of T cell proliferation and functional activities. Such assays that may be used or routinely modified to test immunomodulatory and differentiation activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); and Verhasselt et al., J</p>	<p>autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Highly preferred indications also include boosting a B cell-mediated immune response and alternatively suppressing a B cell-mediated immune response. Highly preferred indications include inflammation and inflammatory disorders. Additional highly preferred indications include asthma and allergy. Highly preferred indications include neoplastic diseases (e.g., myeloma, plasmacytoma, leukemia, lymphoma, melanoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, myeloma,</p>
--	--	--	--	---	--

				<p>Immunol 158:2919-2925</p> <p>(1997), the contents of each of which are herein incorporated by reference in its entirety.</p> <p>Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art.</p> <p>Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and upregulate T cell proliferation and functional activities.</p>	<p>plasmacytoma, leukemia, lymphoma, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, and Lyme Disease.</p> <p>An additional preferred</p>
--	--	--	--	--	--

59	HT5GJ57	162	<p>Activation of transcription through API response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the API response element are known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate growth and other cell functions. Exemplary assays for transcription through the API response element that may be used or routinely modified to test API-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1988); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA</p>	<p>indication is infection (e.g., an infectious disease as described below under "Infectious Disease").</p> <p>Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications include inflammation and inflammatory disorders. Highly preferred indications</p>
----	---------	-----	--	---	---



				<p>85:6342-6346 (1988); Rellahan et al., J Biol Chem 272(49):30806-30811 (1997); Chang et al., Mol Cell Biol 18(9):4986-4993 (1998); and Fraser et al., Eur J Immunol 29(3):838-844 (1999), the contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the CTLL cell line, which is an IL-2 dependent suspension-culture cell line with cytotoxic activity.</p>	<p>also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include arthritis, asthma, AIDS, allergy, anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, granulomatous disease, inflammatory bowel disease, sepsis, psoriasis, suppression</p>
--	--	--	--	---	--

59	HTSGJ57	162	Production of MCP-1	<p>MCP-1 FMAT. Assays for immunomodulatory proteins that are produced by a large variety of cells and act to induce chemotaxis and activation of monocytes and T cells are well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to mediate immunomodulation, induce chemotaxis, and modulate immune cell activation. Exemplary assays that test for immunomodulatory proteins evaluate the production of cell surface markers, such as monocyte chemoattractant protein (MCP), and the activation of monocytes and T cells. Such assays that may be used or routinely modified to</p>	<p>of immune reactions to transplanted organs and tissues, endocarditis, meningitis, and Lyme Disease.</p> <p>A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) MCP-1 production. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., reducing) MCP-1 production. A highly preferred indication is infection (e.g., an infectious disease as described below under "Infectious Disease"). Additional highly preferred indications include inflammation and inflammatory disorders. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications</p>
----	---------	-----	---------------------	---	---

			<p>test immunomodulatory and differentiation activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204(1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Sathaporn and Eremin, J R Coll Surg Ednb 45(1):9-19 (2001); and Verhaselt et al., J Immunol 158:2919-2925 (1997), the contents of each of which are herein incorporated by reference in its entirety. Human dendritic cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human dendritic cells are antigen presenting cells in suspension culture, which, when activated by antigen and/or cytokines, initiate and</p>	<p>include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis (bacterial and viral), Lyme Disease, asthma, and allergy Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as</p>
--	--	--	---	--

64	H2CBG48	167	<p>Activation of transcription through AP1 response element in immune cells (such as T-cells).</p>	<p>Assays for the activation of transcription through the AP1 response element are known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate growth and other cell functions. Exemplary assays for transcription through the AP1 response element that may be used or routinely</p>	<p>upregulate T cell proliferation and functional activities.</p>	<p>described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.</p>	<p>Preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), blood disorders (e.g., as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Highly preferred indications include</p>
----	---------	-----	--	---	---	--	---

				<p>modified to test API-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1988); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Rellahan et al., J Biol Chem 272(49):30806-30811 (1997); Chang et al., Mol Cell Biol 18(9):4986-4993 (1998); and Fraser et al., Eur J Immunol 29(3):838-844 (1999), the contents of each of which are herein incorporated by reference in its entirety. Mouse T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the HT2 cell line, which is an IL-2</p>	<p>autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional highly preferred indications include inflammation and inflammatory disorders. Highly preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, leukemia, lymphoma, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.</p>
--	--	--	--	--	--

				dependent suspension culture cell line that also responds to IL-4.	Preferred indications include arthritis, asthma, AIDS, allergy, anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, granulomatous disease, inflammatory bowel disease, sepsis, psoriasis, suppression of immune reactions to transplanted organs and tissues, endocarditis, meningitis, and Lyme Disease.
64	H2CBG48	167	Activation of transcription through cAMP response element in immune cells (such as T-cells).	Assays for the activation of transcription through the cAMP response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to increase cAMP, regulate CREB transcription factors, and modulate expression of genes involved in a wide variety of cell	Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"), and infection (e.g., an infectious disease as described below under "Infectious Disease"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple

				<p>functions. Exemplary assays for transcription through the cAMP response element that may be used or routinely modified to test cAMP-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in Berger et al., Gene 66:1-10 (1998); Cullen and Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Black et al., Virus Genes 15(2):105-117 (1997); and Belkowski et al., J Immunol 161(2):659-665 (1998), the contents of each of which are herein incorporated by reference in its entirety. T cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse T cells that may be used according to these assays include the HT2 cell</p>	<p>sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response, and suppressing a T cell-mediated immune response. Additional preferred indications include inflammation and inflammatory disorders. Highly preferred indications include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, leukemia, lymphoma (e.g., T cell lymphoma, Burkitt's lymphoma, non-Hodgkins lymphoma, Hodgkin's disease), melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and</p>
--	--	--	--	---	--

				line, which is a suspension culture of IL-2 dependent T cells that also respond to IL-4.	pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include anemia, pancytopenia, leukopenia, thrombocytopenia, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia, neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, and asthma and allergy.
65	H2CBU83	168	Stimulation of insulin secretion from pancreatic beta cells.	Assays for measuring secretion of insulin are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to stimulate insulin secretion.	<p>A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other</p>



				<p>For example, insulin secretion is measured by FMAT using anti-rat insulin antibodies. Insulin secretion from pancreatic beta cells is upregulated by glucose and also by certain proteins/peptides, and dysregulation is a key component in diabetes. Exemplary assays that may be used or routinely modified to test for stimulation of insulin secretion (from pancreatic cells) by polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: Ahren, B., et al., Am J Physiol, 277(4 Pt 2):R959-66 (1999); Li, M., et al., Endocrinology, 138(9):3735-40 (1997); Kim, K.H., et al., FEBS Lett, 377(2):237-9 (1995); and, Miraglia S et. al., Journal of Biomolecular Screening, 4:193-204 (1999), the contents of each of which is herein</p>	<p>diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyperosmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, and infection</p>
--	--	--	--	---	---

				<p>incorporated by reference in its entirety. Pancreatic cells that may be used according to these assays are publicly available (e.g., through the ATCC) and/or may be routinely generated. Exemplary pancreatic cells that may be used according to these assays include rat INS-1 cells. INS-1 cells are a semi-adherent cell line established from cells isolated from an X-ray induced rat transplantable insulinoma. These cells retain characteristics typical of native pancreatic beta cells including glucose inducible insulin secretion. References: Asfari et al. Endocrinology 1992 130:167.</p>	<p>(e.g., infectious diseases and disorders as described in the ""Infectious Diseases"" section below, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance.</p>
66	HAPNY94	169	Activation of Adipocyte ERK Signaling Pathway	<p>Kinase assay. Kinase assays, for example an Elk-1 kinase assay, for ERK signal transduction that regulate cell proliferation or differentiation are well known in the art and may be used or routinely modified to assess the ability</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating adipocyte proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting</p>

				<p>of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and differentiation. Exemplary assays for ERK kinase activity that may be used or routinely modified to test ERK kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Le Marchand-Brustel Y, Exp Clin Endocrinol Diabetes 107(2):126-132 (1999); Kyriakis JM, Biochem Soc Symp 64:29-48 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which are herein incorporated by reference in its entirety.</p>	<p>adipocyte proliferation. A highly preferred embodiment of the invention includes a method for stimulating adipocyte differentiation. An alternative highly preferred embodiment of the invention includes a method for inhibiting adipocyte differentiation. A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) adipocyte activation. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of (e.g., decreasing) and/or inactivating adipocytes. Highly preferred indications include endocrine disorders (e.g., as described below under ""Endocrine Disorders"").</p> <p>Highly preferred indications also include neoplastic diseases (e.g., lipomas, liposarcomas, and/or as described below under</p>
--	--	--	--	--	---

				<p>Mouse adipocyte cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary mouse adipocyte cells that may be used according to these assays include 3T3-L1 cells. 3T3-L1 is an adherent mouse preadipocyte cell line that is a continuous substrain of 3T3 fibroblast cells developed through clonal isolation and undergo a pre-adipocyte to adipose-like conversion under appropriate differentiation conditions known in the art.</p>	<p>"Hyperproliferative Disorders"). Preferred indications include blood disorders (e.g., hypertension, congestive heart failure, blood vessel blockage, heart disease, stroke, impotence and/or as described below under "Immune Activity", "Cardiovascular Disorders", and/or "Blood-Related Disorders"), immune disorders (e.g., as described below under "Immune Activity"), neural disorders (e.g., as described below under "Neural Activity and Neurological Diseases"), and infection (e.g., as described below under "Infectious Disease"). A highly preferred indication is diabetes mellitus. An additional highly preferred indication is a complication associated with diabetes (e.g., diabetic retinopathy, diabetic nephropathy, kidney disease (e.g., renal failure, nephropathy and/or other</p>
--	--	--	--	--	---

					diseases and disorders as described in the "Renal Disorders" section below), diabetic neuropathy, nerve disease and nerve damage (e.g., due to diabetic neuropathy), blood vessel blockage, heart disease, stroke, impotence (e.g., due to diabetic neuropathy or blood vessel blockage), seizures, mental confusion, drowsiness, nonketotic hyperglycemic-hyposmolar coma, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section below), dyslipidemia, endocrine disorders (as described in the "Endocrine Disorders" section below), neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infection (e.g.,
--	--	--	--	--	---

					infectious diseases and disorders as described in the "Infectious Diseases" section below (particularly of the urinary tract and skin). An additional highly preferred indication is obesity and/or complications associated with obesity. Additional highly preferred indications include weight loss or alternatively, weight gain. Additional highly preferred indications are complications associated with insulin resistance. Additional highly preferred indications are disorders of the musculoskeletal systems including myopathies, muscular dystrophy, and/or as described herein. Additional highly preferred indications include, hypertension, coronary artery disease, dyslipidemia, gallstones, osteoarthritis, degenerative arthritis, eating disorders, fibrosis, cachexia, and kidney diseases or
--	--	--	--	--	---

				disorders. Preferred indications include neoplasms and cancer, such as, lymphoma, leukemia and breast, colon, and kidney cancer. Additional preferred indications include melanoma, prostate, lung, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Highly preferred indications include lipomas and liposarcomas. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.
69	HDPBQ02	172	Upregulation of CD69 and activation of T cells	<p>CD69 F/MAT. CD69 is an activation marker that is expressed on activated T cells, B cells, and NK cells. CD69 is not expressed on resting T cells, B cells, or NK cells. CD69 has been found to be associated with inflammation. Assays for immunomodulatory proteins expressed in T cells, B cells, and leukocytes are</p> <p>A highly preferred embodiment of the invention includes a method for activating T cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating T cells. A highly preferred embodiment of the invention</p>

				<p>well known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to modulate the activation of T cells, and/or mediate humoral or cell-mediated immunity.</p> <p>Exemplary assays that test for immunomodulatory proteins evaluate the upregulation of cell surface markers, such as CD69, and the activation of T cells. Such assays that may be used or routinely modified to test immunomodulatory activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include, for example, the assays disclosed in Miraglia et al., J Biomolecular Screening 4:193-204 (1999); Rowland et al., "Lymphocytes: a practical approach" Chapter 6:138-160 (2000); Ferenczi et al., J</p>	<p>includes a method for activation B cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting the activation of and/or inactivating B cells. A highly preferred embodiment of the invention includes a method for activating NK cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting activation of and/or inactivation NK cells. Highly preferred indications include inflammation and inflammatory disorders (e.g., as described below under "Immune Activity"). Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Highly preferred indications include autoimmune diseases</p>
--	--	--	--	---	---



				<p>Autoimmun 14(1):63-78 (200); Werfel et al., Allergy 52(4):465-469 (1997); Taylor-Fishwick and Siegel, Eur J Immunol 25(12):3215-3221 (1995); and Afetra et al., Ann Rheum Dis 52(6):457-460 (1993), the contents of each of which are herein incorporated by reference in its entirety. Human T cells that may be used according to these assays may be isolated using techniques disclosed herein or otherwise known in the art. Human T cells are primary human lymphocytes that mature in the thymus and express a T Cell receptor and CD3, CD4, or CD8. These cells mediate humoral or cell-mediated immunity and may be preactivated to enhance responsiveness to immunomodulatory factors.</p>	<p>(e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below), immunodeficiencies (e.g., as described below), boosting a T cell-mediated immune response and alternatively suppressing a T cell-mediated immune response, and boosting a B cell-mediated immune response and alternatively suppressing a B cell-mediated immune response. An additional highly preferred indication includes infection (e.g., as described below under "Infectious Disease"). Preferred indications also include anemia, pancytopenia, leukopenia, thrombocytopenia, Hodgkin's disease, acute lymphocytic anemia (ALL), plasmacytomas, multiple myeloma, Burkitt's lymphoma, arthritis, AIDS, granulomatous disease, inflammatory bowel disease, sepsis, neutropenia,</p>
--	--	--	--	---	---

					neutrophilia, psoriasis, suppression of immune reactions to transplanted organs and tissues, hemophilia, hypercoagulation, diabetes mellitus, endocarditis, meningitis, Lyme Disease, inflammation and inflammatory disorders, asthma, and allergies. Preferred indications also include neoplastic diseases (e.g., leukemia, lymphoma, and/or as described below under "Hyperproliferative Disorders"). Preferred indications include neoplasms, such as, for example, leukemia, lymphoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia.
					Preferred embodiments of the
					Assays for the activation of
					Activation of
					174
					HDPOZ56

71		transcription through GAS response element in epithelial cells (such as HELA cells).	transcription through the Gamma Interferon Activation Site (GAS) response element are well-known in the art and may be used or routinely modified to assess the ability of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) to regulate STAT transcription factors and modulate gene expression involved in a wide variety of cell functions. Exemplary assays for transcription through the GAS response element that may be used or routinely modified to test GAS-response element activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include assays disclosed in: You M, et al, J Biol Chem, 272(37):23376-23381(1997); Min W, et al., Circ Res, 83(8):815-823 (1998); Berger et al., Gene 66:1-10 (1998); Cullen and	invention include using polypeptides of the invention (or antibodies, agonists, or antagonists thereof) in detection, diagnosis, prevention, and/or treatment of Cancer, Wound Healing, and Inflammation. Highly preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"). Highly preferred indications include neoplasms and cancers, such as, for example, melanoma, and prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver and urinary cancer. Other preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Preferred indications include inflammation and inflammatory disorders.
----	--	--	---	---

71	HDPOZ56	174	Activation of Endothelial Cell p38 or JNK Signaling Pathway.	<p>Malm, Methods in Enzymol 216:362-368 (1992); Henthorn et al., Proc Natl Acad Sci USA 85:6342-6346 (1988); Matikainen et al., Blood 93(6):1980-1991 (1999); and Henttinen et al., J Immunol 155(10):4582-4587 (1995), the contents of each of which are herein incorporated by reference in its entirety. Epithelial cells that may be used according to these assays are publicly available (e.g., through the ATCC). Exemplary epithelial cells that may be used according to these assays include the HELA cell line.</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating endothelial cell growth. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell growth. A highly preferred</p>
----	---------	-----	--	--	---

				<p>antibodies and agonists or antagonists of the invention) to promote or inhibit cell proliferation, activation, and apoptosis. Exemplary assays for JNK and p38 kinase activity that may be used or routinely modified to test JNK and p38 kinase-induced activity of polypeptides of the invention (including antibodies and agonists or antagonists of the invention) include the assays disclosed in Forrer et al., Biol Chem 379(8-9):1101-1110 (1998); Gupta et al., Exp Cell Res 247(2): 495-504 (1999); Kyriakis JM, Biochem Soc Symp 64:29-48 (1999); Chang and Karin, Nature 410(6824):37-40 (2001); and Cobb MH, Prog Biophys Mol Biol 71(3-4):479-500 (1999); the contents of each of which are herein incorporated by reference in its entirety. Endothelial cells that may be used according to these assays are publicly available (e.g.,</p>	<p>embodiment of the invention includes a method for stimulating endothelial cell proliferation. An alternative highly preferred embodiment of the invention includes a method for inhibiting endothelial cell proliferation. A highly preferred embodiment of the invention includes a method for stimulating apoptosis of endothelial cells. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) apoptosis of endothelial cells. A highly preferred embodiment of the invention includes a method for stimulating (e.g., increasing) endothelial cell activation. An alternative highly preferred embodiment of the invention includes a method for inhibiting (e.g., decreasing) the activation of and/or inactivating endothelial cells.</p>
--	--	--	--	---	--

				<p>through the ATCC). Exemplary endothelial cells that may be used according to these assays include human umbilical vein endothelial cells (HUVEC), which are endothelial cells which line venous blood vessels, and are involved in functions that include, but are not limited to, angiogenesis, vascular permeability, vascular tone, and immune cell extravasation.</p>	<p>A highly preferred embodiment of the invention includes a method for stimulating angiogenesis. An alternative highly preferred embodiment of the invention includes a method for inhibiting angiogenesis. A highly preferred embodiment of the invention includes a method for reducing cardiac hypertrophy. An alternative highly preferred embodiment of the invention includes a method for inducing cardiac hypertrophy. Highly preferred indications include neoplastic diseases (e.g., as described below under "Hyperproliferative Disorders"), and disorders of the cardiovascular system (e.g., heart disease, congestive heart failure, hypertension, aortic stenosis, cardiomyopathy, valvular regurgitation, left ventricular dysfunction, atherosclerosis and atherosclerotic vascular</p>
--	--	--	--	--	--

					disease, diabetic nephropathy, intracardiac shunt, cardiac hypertrophy, myocardial infarction, chronic hemodynamic overload, and/or as described below under "Cardiovascular Disorders"). Highly preferred indications include cardiovascular, endothelial and/or angiogenic disorders (e.g., systemic disorders that affect vessels such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins and/or lymphatics). Highly preferred are indications that stimulate angiogenesis and/or cardiovascularization. Highly preferred are indications that inhibit angiogenesis and/or cardiovascularization. Highly preferred indications include antiangiogenic activity to treat solid tumors, leukemias, and Kaposi's sarcoma, and retinal disorders. Highly preferred indications
--	--	--	--	--	---

					include neoplasms and cancer, such as, Kaposi's sarcoma, hemangioma (capillary and cavernous), glomus tumors, telangiectasia, bacillary angiomatosis, hemangioendothelioma, angiosarcoma, haemangiopericytoma, lymphangioma, lymphangiosarcoma. Highly preferred indications also include cancers such as, prostate, breast, lung, colon, pancreatic, esophageal, stomach, brain, liver, and urinary cancer. Preferred indications include benign dysproliferative disorders and pre-neoplastic conditions, such as, for example, hyperplasia, metaplasia, and/or dysplasia. Highly preferred indications also include arterial disease, such as, atherosclerosis, hypertension, coronary artery disease, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon,



					aneurysms, restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, and cancer. Highly preferred indications also include trauma such as wounds, burns, and injured tissue (e.g., vascular injury such as, injury resulting from balloon angioplasty, and atherosclerotic lesions), implant fixation, scarring, ischemia reperfusion injury, rheumatoid arthritis, cerebrovascular disease, renal diseases such as acute renal failure, and osteoporosis. Additional highly preferred indications include stroke, graft rejection, diabetic or other retinopathies, thrombotic and coagulative disorders, vasculitis, lymph angiogenesis, sexual disorders, age-related macular
--	--	--	--	--	---

					<p>degeneration, and treatment /prevention of endometriosis and related conditions. Additional highly preferred indications include fibromas, heart disease, cardiac arrest, heart valve disease, and vascular disease. Preferred indications include blood disorders (e.g., as described below under "Immune Activity", "Blood-Related Disorders", and/or "Cardiovascular Disorders"). Preferred indications include autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and/or as described below) and immunodeficiencies (e.g., as described below). Additional preferred indications include inflammation and inflammatory disorders (such as acute and chronic inflammatory diseases, e.g., inflammatory bowel disease and Crohn's disease), and pain</p>
--	--	--	--	--	--



Table 2

Clone ID NO:Z	Contig ID:	SEQ ID NO:X	Analysis Method	PFam/NR Description	PFam/NR Accession Number	Score/ Percent Identity	NT From	NT To
HIISCN02	638033	11	WUblastx. 64	(AF116695) PRO2221 [Homo sapiens]	gb AAAF71115.1 AF 116721_95	56%	930	1109
HHPGO40	753270	13	HMMER 2.1.1	PFAM: Leucine Rich Repeat	PF00560	122	542	613
			WUblastx. 64	(AF196976) brain tumor associated protein NAG14 [Homo sapiens]	gb AAG28019.1 AF 196976_1	70%	233	967
HHPGO40	560969	82	HMMER 2.1.1	PFAM: Leucine Rich Repeat	PF00560	77	548	619
HAMGG68	731859	14	blastx.2	CDNA FLJ20378 FIS, CLONE KAlA0536.	sp Q9NX85 Q9NX 85	64% 71% 56% 44% 47% 57% 70%	857 984 726 1454 1454 1457 1458	636 859 658 1401 1392 1416 1429
HAPOM49	769555	15	WUblastx. 64	(AF306567) group XII secreted phospholipase A2 [Homo sapiens]	gb AAG50243.1 AF 306567_1	91%	305	817
HBJFJ26	772348	17	WUblastx. 64	(BC000168) Unknown (protein for MGC:5242) [Homo sapiens]	gb AAH00168.1 A AH00168	77%	1166	831
HDPOJ08	731863	19	blastx.2	CDNA FLJ14153 fis,	sp BAB14852 BAB	99%	12	524

					clone NT2RM1000092, weakly similar to 1	14852		85%	524	904
HIDPRX82	730518	20		blastx.2	(AF336887) FKSG60 [Homo sapiens]	gb AAK01738.1 AF 336887_1		46%	763	900
HELK31	681138	21		HMMER 2.1.1	PFAM: DHHC zinc finger domain	PF01529		30%	315	479
				blastx.2	CDNA FLJ10479 FIS, CLONE NT2RP2000120 (DC1).	sp Q9NPG8 Q9NP G8		68%	1521	1724
HCNUA40	340352	85		HMMER 2.1.1	PFAM: DHHC zinc finger domain	PF01529		95.1	659	820
				blastx.2	CDNA FLJ10479 FIS, CLONE NT2RP2000120 (DC1).	sp Q9NPG8 Q9NP G8		99%	209	1240
HFPCX64	877637	22		WUblastx. 64	(AK025047) unnamed protein product [Homo sapiens]	dbj BAB15056.1		95.1	-82	-243
HCEBW71	514187	87		blastx.2	(AF000996) ubiquitous TPR motif, Y isoform [Homo sapiens]	gb AAC51843.1		100%	845	69
HFEXO60	731869	23		WUblastx. 64	(AL035587) dJ475N16.1 (CTG4A) [Homo sapiens]	emb CAB75301.1		98%	1101	847
HHEPG41	714102	24		blastx.2	(AF059620) Myo06 protein [Homo sapiens]	gb AAG43119.1 AF 059620_1		36%	1307	1215
HUAUI83	639009	88		blastx.2	(AF059620) Myo06 protein [Homo sapiens]	gb AAG43119.1 AF 059620_1		54%	891	781
								56%	1064	870
								56%	1125	859
								68%	306	88
								86%	1176	1024
								83%	771	643
								100%	406	723
								88%	160	399
								100%	489	557

HJPAZ83	383592	89		blastx.2	(AF059620) Myo06 protein [Homo sapiens]	gb AAG43119.1 AF059620_1	90%	25	84
HMIAP86	726831	26		HMMER 2.1.1	PFAM: Mitochondrial carrier proteins	PF00153	262	329	1180
				blastx.2	BRAIN MITOCHONDRIAL CARRIER PROTEIN-1 (BMCP-1) (SOLUTE CARRIER FAMILY 25, MEMBER 14).	sp O95258 BMCP_HUMAN	97%	182	1183
HMUAP70	872208	27		blastx.2	(AF220209) Nedd4 WW domain-binding protein 5 [Mus musculus]	gb AAG44248.1	89%	69	845
HAGFY16	778820	91		blastx.2	(AF220209) Nedd4 WW domain-binding protein 5 [Mus musculus]	gb AAG44248.1	69% 45%	56 31	844 402
HAGFY16	381964	94		blastx.2	(AF220209) Nedd4 WW domain-binding protein 5 [Mus musculus]	gb AAG44248.1	86%	1830	1111
HRACJ35	730504	28		WUblastx.64	(AF119386) blood plasma glutamate carboxypeptidase 1	gb AAD31418.1 AF119386_1	65% 99%	1486 99	1722 1439
HAWAZ34	470546	95		blastx.2	AMINOPEPTIDASE.	sp Q9Y646 Q9Y646	100% 96%	1134 628	616 350
HTWDE26	668265	29		blastx.2	C11ORF15 PROTEIN.	sp Q9NQ34 Q9NQ34	100% 100%	173 68	568 151
HMHBN40	638249	96		blastx.2	C11ORF15 PROTEIN.	sp Q9NQ34 Q9NQ	89%	129	650

						34			100%	652	693
HUSTB13	580885	30	blastx.2		DYSFERLIN.	sp O75923 O75923			73%	680	724
H2CBT75	703079	32	blastx.2		CDNA: FLJ21463 fis, clone COL04765.	sp BAB15071 BAB 15071			100%	25	309
HAGDQ42	702035	33	blastx.2		HSPC327 (FRAGMENT).	sp Q9P055 Q9P055			72%	318	611
HBMCI42	713345	34	HMMER 2.1.1		PFAM: Lectin C-type domain	PF00059			99%	33	869
			WUblastx. 64		(AK016908) putative [Mus musculus]	dbj BAB30491.1			100%	10	33
HDPBQ71	1160316	35	blastx.2		CDA08.	sp AAG41782 AA G41782			19.4	-297	-566
HDPBQ71	727200	97	blastx.2		CDA08.	sp AAG41782 AA G41782			28%	1545	775
									95%	114	1928
									65%	97	192
									44%	110	250
									95%	45	1859
									65%	28	123
									44%	41	181
HDPFQ90	886067	98	blastx		predicted using Genefinder; cDNA EST yk281d4.5 comes from this 1 comes from this gene [Caenorhabditis elegans]	emb CAA77450.1			38%	1790	1999
									29%	1658	1945
									31%	921	1091
									52%	306	362
									58%	1356	1406
									47%	480	536
									25%	1158	1241
									52%	639	701
									45%	1464	1523
									38%	783	860
									34%	321	398

								38%	1173	1265
								30%	1104	1211
								26%	798	875
								38%	1170	1223
								36%	897	995
								29%	903	995
								40%	1341	1415
								30%	324	392
								31%	2258	2305
HCEJG71	715592	36	HMMER 2.1.1	PFAM: WD domain, G- beta repeat	PF00400			79.1	265	381
			WUblastx. 64	(AF097484) transducin beta-like 2 [Homo sapiens]	gb AAF06823.1 AF 097484_1			89%	28	1368
HELHL48	696945	37	HMMER 2.1.1	PFAM: DHHC zinc finger domain	PF01529			124.3	797	991
			blastx.2	hypothetical protein DKFZp761E1347.1 - human (fragment)	pir T47144 T47144			100%	359	1501
HSKCT36	610025	99	HMMER 2.1.1	PFAM: DHHC zinc finger domain	PF01529			124.3	199	393
			blastx.2	hypothetical protein DKFZp761E1347.1 - human (fragment)	pir T47144 T47144			100%	10	471
								99%	585	905
								100%	470	586
HISAQ04	589960	38	blastx.2	CDNA FLJ20378 FIS, CLONE KAlA0536.	sp Q9NX85 Q9NX 85			56%	1159	968
								65%	972	850
								46%	1157	1086
								70%	1161	1132



HIACB89	689899	39	WUblastx. 64	(AK011230) putative [Mus musculus]	dbj BAB27480.1	93%	92	1093
HBJLF01	732111	41	HMMER 2.1.1	PFAM: Transmembrane 4 family	PF00335	131.8	223	891
			blastx.2	TETRASPANIN 5 (TSPAN-5) (TETRASPAN NET-4).	sp O60628 TSN5_ HUMAN	43%	151	894
HBXGP60	566892	42	blastx.2	hypothetical protein AAB71662.1 - human (fragment)	pir T03307 T03307	40%	10	549
HCE5B20	544507	43	blastx.2	retrovirus-related pol polyprotein pseudogene - human 1	pir A26718 A26718	33%	610	23
HCNAH57	694610	45	blastx.2	LINE-1 ELEMENT ORF2.	sp O62658 O62658	41% 44%	255 362	16 261
HDPCJ91	740748	47	blastx.2	CDNA FLJ20489 FIS, CLONE KAT08285.	sp Q9NX17 Q9NX 17	74% 68% 42%	2372 2545 1570	2548 2685 1674
HDPGK25	704067	48	blastx.2	CDNA: FLJ22233 fis, clone HRC02016.	sp BAB15271 BAB 15271	98%	3	701
HE2DY70	722217	49	blastx.2	SIMILAR TO RING-H2 FINGER PROTEIN RHA1A.	sp Q9SNH1 Q9SN H1	75%	638	543
HE2NV57	740750	50	blastx.2	BK445C9.3 (HIGH- MOBILITY GROUP (NONHISTONE CHROMOSOMAL) 1	sp Q9UGV6 Q9UG V6	31% 66%	321 71	866 106
HETBR16	703243	51	blastx.2	(AB055298) hypothetical	dbj BAB21923.1	75%	99	1

HFYDGI3	657390	52	blastx.2	protein [Macaca fascicularis] HYPOTHETICAL 149.0 KDA PROTEIN.	sp Q15606 Q15606	75% 64% 70% 80% 76% 58% 24% 81%	368 1097 832 552 1144 617 823 40	15 768 575 364 1094 552 677 8
HFYKY27	634161	53	blastx.2	CDNA: FLJ21394 fis, clone COL03536.	sp BAB15056 BAB15056	46% 63% 87%	936 821 763	814 765 716
HISAD54	740754	55	blastx.2	spliceosome-associated protein SAP-49 - human	pir A54964 A54964	46% 35% 52%	1331 1750 1938	1095 1472 1876
HJBCY35	719729	56	blastx.2	hypothetical protein DKFZp586J0619.1 - human (fragment)	pir T08758 T08758	100%	1	1212
HKAEA19	721489	57	blastx.2	SEVEN TRANSMEMBRANE PROTEIN TM7SF3.	sp Q9NS93 Q9NS93	99% 97%	321 83	1520 328
HKGDL36	704088	58	blastx.2	PROSAAS PRECURSOR.	sp Q9UHG2 Q9UHG2	82% 49%	99 55	830 555
HLDBS43	722228	59	WUblastx.64	(AF225417) 88.8 kDa protein [Homo sapiens]	gb AAG09719.1 AF225417_1	82% 99% 35% 96%	1163 1512 597 13	1438 1967 656 1161

HLWAD92	695736	60	blastx.2	SH3-CONTAINING PROTEIN SH3GLB2.	sp Q9NR46 Q9NR46	100%	1	351
HL YBI15	645262	61	blastx.2	PRO0483 PROTEIN.	sp Q9UI58 Q9UI58	55% 75%	144 71	64 24
HMEJE05	722231	62	WUblastx. 64	(AF168711) x 010 protein [Homo sapiens]	gb AAF87313.1 AF 168711.1	96%	25	816
HNGIX55	695749	63	blastx.2	CDNA FLJ11736 fis, clone HEMBA1005468.	sp BAB13899 BAB 13899	66%	379	717
HPJBI33	685699	65	blastx.2	NEURONAL THREAD PROTEIN AD7C-NTP.	sp O60448 O60448	49% 50% 53% 52% 42% 59% 34% 51% 56% 52% 35% 37% 47% 90% 33% 85%	617 3 701 137 750 154 633 24 877 155 41 659 886 805 1317 904	934 146 817 256 899 234 890 122 945 256 256 925 942 834 1415 924
HRABA80	588460	66	WUblastx. 64	(AK022184) unnamed protein product [Homo sapiens]	dbj BAB13980.1	50% 68%	237 311	296 445
	882163	67	HMMER	PFAM: EGF-like domain	PF00008	64.3	1337	1441

HRACD80			2.1.1	(AJ306906) fibulin-6 [Homo sapiens]	emb CAC37630.1		44% 37% 45% 42% 47%	695 32 1277 1286 1286	1861 1441 1915 1579 1525
HRACD80	740762	100	blastx.2	(AF135253) fibulin-2 [Mus musculus]	gb AAD34456.1		33% 31% 45% 49% 44% 30% 43% 31% 43% 35% 41% 42% 41% 48% 43% 33% 36% 30% 33% 37% 43% 46% 28%	898 1279 1279 681 898 901 928 802 699 690 928 699 699 699 1339 898 540 699 699 777 925 898	1581 1893 1608 911 1125 1605 1149 1137 899 998 1119 911 908 890 914 1533 1137 995 893 890 899 1002 1065

HSLCX03	889145	68	blastx.2	CDNA: FLJ21792 fis, clone HEP00441.	sp BAB15133 BAB 15133	33%	493	609 890 1125 1061 1041 869 1218 1095 1053
HSLCX03	740788	101	blastx.2	(AL132954) putative protein [Arabidopsis thaliana]	emb CAB75750.1	37%	65	637
HT5GJ57	740767	69	WUblastx. 64	(AX083396) unnamed protein product [Homo sapiens]	emb CAC33299.1	23%	1578	2102
HTACS42	722253	70	blastx.2	HYPOXIA-INDUCIBLE PROTEIN 2.	sp Q9Y5L2 HIG2_ HUMAN	32%	1389	1631
HTOBX69	722255	72	blastx.2	CGI-90 PROTEIN.	sp Q9Y398 Q9Y39 8	84%	122	856
HUVEO77	740776	73	blastx.2	MSTP032.	sp AAG39283 AA G39283	100%	213	401
H2CBU83	884134	75	WUblastx. 64	(AF257182) G-protein- coupled receptor 48 [Homo sapiens]	gb AAF68989.1 AF 257182_1	94%	9	122
HCE2B33	745399	78	blastx.2	CDNA: FLJ22160 fis, clone HRC00266.	sp BAB15242 BAB 15242	98%	1834	2082
						89%	10	777
						91%	9	443

HDPBQ02	745403	79	WUblastx. 64	(AK025047) unnamed protein product [Homo sapiens]	dbj BAB15056.1	60% 70% 38% 40% 67%	1759 2149 1828 1652 2022	1646 2021 1652 1548 1858
HFYI70	744906	80	blastx.2	UNNAMED PROTEIN PRODUCT.	sp Q9N0E1 Q9N0E 1	97%	74	208
HDPOZ56	815653	81	HMMER 2.1.1	PFAM: Flavin containing amine oxidase	PF01593	431.1	307	1614
			blastx.2	Fig-1 protein [Mus musculus]	gb AAB51353.1	69%	169	1740
HDPOZ56	743479	103	HMMER 2.1.1	PFAM: Flavin containing amine oxidase	PF01593	185.2	200	949

Table 3

Clone ID NO: Z	SEQ ID NO: X	Contig ID:	EST Disclaimer Range of a Range of b	Accession #'s
HISCN02	11	638033	1 - 1099 15 - 1113	BE791374, AU119289, AU140348, AU138078, AU136503, AV731936, AW840410, AL043065, AW840411, AW840407, AW840402, AW840408, AW840465, AW840466, AW840412, AW840471, AW840475, AW840473, AW814395, BF940866, BF056457, AA180278, AW840474, AA584866, BG005346, AW840406, AA569180, AV745684, AW270592, AA584638, AA976391, AV745320, AI820994, AA641592, BF195071, AI868368, BF931499, AA640504, BE797641, AV730261, AA258511, AW273171, AA457653, AA593381, AA584801, AW273229, AI052560, AV706319, AI800268, AA121904, AA664366, AA657354, BF954682, AI922061, BF513924, BE019309, AW939910, BE062393, T62761, AL044254, BF949385, AV701925, AA084302, AA601152, BF125684, AA121903, BF945554, AV652861, AW840551, BF946623, AV655231, AA584437, AW238615, AI061445, AA333509, F33455, BE439566, T66926, AL135706, AL044209, BE159332, AI349954, AA487808, AA481809, AW231969, AA720764, BE304382, AL359715, AL161627,

					AL390146, AL354833, AC068323, Z77249, AL139279, AL353633, AC010180, AC000055, AC010251, AL050401, AC006566, AL022157, AC074191, AL157830, AC006481, Z82211, AL136308, Z73913, AC004894, AC004470, AC007970, AL121755, AL160413, AC002454, AF003530, AC006120, AC007690, AC002449, AC025920, AC007286, AC024162, AC026197, AL136164, AC008250, AL121984, AL359641, AL109920, AL109761, AL023875, AL109764, AC011294, U69730, AC016626, AC004415, AL161804, AL133417, AC022143, AC016572, Y10196, AC005094, AC007032, AP001671, AL049859, AL132633, AC004842, AL359457, AC019058, AL360272, AC024084, AL359924, AL133412, AC012611, AC005230, AK002154, AC008550, AL157384, AC004677, AC012472, AC007683, AC008179, AC004959, AL031286, Z95124, AC007065, AC000378, AC004908, AL121782, AC005076, AL022345, U82828, AC005490, AL121983, AL445466, AC005034, AC005201, AC008664, AL359846, AK002104, AL133547, AL080275, AL133500, AC017092, AL033521, AL121825, AL023806, AC063976, AK023417, AL121575, AC027663, AP002532, AL138816, AC005386, AL121977, U40455, AL133516, AK024354, AC008462, AF235097, AL137022, AC003658, Z98255, AL161621, AC009230, AF101874, AC023478, AL031663, AL391691, AC026188, AL078597, AL034377, AC000119, AC034195, Z82899,



				AP001818, AL031274, AL157765, AL353999, AC011299, AP000692, AL136520, AL445472, AL359755, AL022241, AL357141, AL136147, AC016689, AL158841, AL121717, AC008009, AL121916, AF241732, AL161422, AK023839, AL139123, AL031114, AC002463, AC010282, AP001725, AC007327, AL139233, AL139375, AC008266, AL035252, AL035671, AC005823, AC006249, AC010596, AL359833, AL365400, AL161751, AC004628, AC006461, AL133325, AF044083, AC006265, Z83848, AC007745, Z68280, AC005064, AC016831, AC008583, AL031116, AL031347, AL390759, AL109915, AL138759, AL031673, AC009487, AC010369, AL033517, AL158206, AL049778, AL035699, AC005029, AC004852, AC006042, AC024576, AC004454, AL121867, AC006043, AP002023, AC008176, AC005019, AP002026, AC007748, AC003075, AL035563, AC004535, AC004948, U01882, AC005922, AL049794, AL121999, AC000125, AC013412, AB020861, AC006364, AB037817, AL355792, AK021968, AC016678, AL354793, AC016623, Z82210, AC021998, AC003986, AC008162, AL138478, AC006994, Z83745, AC005859, AC012312, AC008496, AL096803, AL133162, AF265340, AC009503, AL355294, AL021068, AL353614, Z80774, AE000659, AC008436, AC008394, AC073607, Z84720, AC009506, AC007253, AL356438, AC008897, AL359715, AL359715, AC012267, and AC012267.

HHGDM70	12	623416	1 - 969	15 - 983	AC019291, AC019291, AL157996, and AL157996.
HHPGO40	13	753270	1 - 959	15 - 973	BF936014, BF926087, BF849807, BG059559, AA663575, BE464797, and AL137451.
HAMGG68	14	731859	1 - 1444	15 - 1458	AW973341, AW974201, AL041477, AW471262, AV696883, AI799683, AI983869, AA579632, AI763280, AI962918, AW962479, AA919175, BE467860, AI694808, BE671481, BE670142, H97854, AA190313, AW608357, AV763623, AI656460, AI218288, AA057842, N39132, AA977897, AI907444, AI819548, AI698748, AI221889, AI300453, AA554290, BE327102, BF510243, AI366844, AI208651, AW341424, AW517375, AI092422, AI458704, AW770918, AA322568, H97652, AW058433, BG055320, T84069, AA587633, AI699024, BF881447, AW873347, AA397560, W46809, AI969771, AA807704, AA367835, R61770, AI819419, BF812696, BE882869, AL121039, AI702049, AA557945, AW148821, AA569220, AW118842, BF790866, AI567676, AW021674, AV683406, AI884404, BE875478, AW043803, AA935827, BG180320, BG059139, AI636422, AW265468, AW243817, AW162314, AW157128, AI439525, AI890283, AV743869, AW979200, AA805879, AW072963, AW162332, AI434103, H86399, AL134524, AA112864, AW576388, H47461, AW410844, AW192930, AL138262, AI445699, AI572680, BE049409, AV758849, AW029626, AW675677, AW575808, AU146789, BF725436, AI828721, BE045167, AW995605, AI860423, BG250794, AI888050, AI064968, BE065048, AV756809, AI547110, AV759204,

				AA084320, AA280886, AI028148, BF882222, AW662484, AA021061, AA349923, AW473160, AI732690, AW152451, BG059924, AA330549, AW328185, AW839858, AA604601, AW338376, AA171400, AW970856, BE747923, BF882223, AA218684, AI889177, AA661583, AW510403, AI150934, AI312614, BF901147, AI754926, AI620666, AI254267, AW275432, AW151848, AA101744, AI114494, AL031009, AB037847, AL035455, AC002430, AC007384, AC004765, AC005330, AC005399, AL121601, AP000952, AP001670, AC006039, AC024563, AL354751, AC006329, U85195, AC008008, AL138756, AL024498, AE000658, AC005003, AC011510, AC005519, AL050318, AC009506, AC005000, AP000349, AK000471, AC010328, AC007050, AC004400, AL121928, AC004067, AC010724, Z73979, AL118520, AL035684, AC008736, AL035420, AC005833, AP000503, AL354696, AC005253, AL109952, AC005837, L78833, AF134726, AC027689, AC007011, AC004890, AC007620, AC006137, AC005696, AC007736, AC002070, AC022432, AL137800, AC005913, AC008264, AP000257, AC004883, AC003041, AL122020, AB028893, L44140, AL021391, AC006449, AC005994, AC004383, AC003043, AL031281, AC002350, AC008795, AL034420, AC010271, AC006241, AP000098, AP001745, AL161757, AC020956, AC006145, AC011464, AC004975, AC006385,

				AC009330, AC007240, AL121652, AL022315, AF130089, AC011480, AL109935, AC002400, AC010553, AC034235, AC004166, AB025285, AL133448, AC020916, AL136228, AC005209, AC008649, AL008582, AL356747, AC007151, AC005553, AC007421, AC010326, AC011450, AC012627, AL031575, AL133174, AP000356, AC005822, AL109797, Z93928, AP001681, AC005031, Z82206, AL121890, AC005182, Z73900, AC002477, AC008952, AL031286, AC008897, AJ011930, AL163300, AF317635, AC004634, AC005365, AP001621, AL031311, AC004051, AC006064, AL031670, AC005585, AC003999, AC007272, AC006345, Z95703, AL022721, AC068993, AJ295844, AC006038, AL049778, AL354829, U18270, AF205588, AC011477, AF023268, AC002351, AC008764, AF207550, AL445263, AL161901, AC020934, AC004922, AL079342, AL031847, AC003098, AL121881, AC005726, AP001712, AL080317, AL035705, AC010725, AC004814, AL049759, AC020904, AL096865, AC016026, AL138759, AL033529, AC011475, AL034395, U80017, AC008123, AC022407, AL096775, AC004150, Z86090, AL109984, AL121886, AC005225, AL158830, AP000510, AL033378, AL354948, AC007957, AL050335, AC006071, AC004003, AJ400877, AC002299, AC007597, AJ009616, AL121845, AL121653, AC018641, AC004703, AP001630, AC007066, AC073175, AC004812, AC007934, AC004840, AL121897,

					AC008753, AC011442, AP001717, AC004913, AL080243, AC002316, AC005911, AL009181, AC005829, AC007546, AC006130, AL391114, AC005098, AC009542, AC006139, AL049569, AC010422, AC007845, AL133215, Z97876, AC004880, U07561, AB035196, AL109758, AF053356, AL163279, AC004797, AC011444, Z83840, AL136305, Z83844, Z93015, AC007098, AL022163, AC016144, AC005520, AC003013, Z98948, AL138752, T50763, R53008, AA054732, AL031009, and AL031009.
HAPOM49	15	769555	1 - 1991	15 - 2005	AL520731, AL520732, BE271092, BE271295, BF111901, AV650049, BF686278, BE840511, BF111645, AI809801, AW168904, AI809806, AW103024, AA933973, AI744944, AI588991, AI033486, AI096548, AA662523, AW468813, AI950317, AI279302, AI096696, BF239172, AW662564, AA417671, AI189300, AI753808, AA235373, AW960081, AI095057, W86920, AW189373, AI361321, BF061913, AI366754, AI218487, AI824959, AI348339, AI032926, AV659024, AA889791, BE243641, AA626261, AI338100, AA417558, W24077, AW974720, N72014, AA894657, N59290, R01247, AA235784, BE929365, BE929364, BE244396, AI275184, AI810247, W24089, R36924, AA356938, N91904, AA508411, AA649828, N91912, N99466, Z24931, H68902, BE782571, BF840140, and AC004067.
HBGBA69	16	709658	1 - 929	15 - 943	AL520551, AL521649, AL520900, AL520550, BG029889, AV704088, AW372721, AA779652, BE782595, AI037829, BE906201,

					BE264987, AL037830, AW372704, BG104612, AA722880, BF724791, N21569, AA447813, AI168324, BE349318, AA478642, BE047392, AW131642, AI590628, AA410845, AL520901, AI829611, AA447814, BF508776, BG254734, AI142945, AI359892, AI142943, AI085888, AA252189, AA974206, AI190425, AA861454, BE350039, D59872, AI446645, AI335769, AI268764, AI077663, AA776515, R66420, BG164250, AI806892, AW083118, AA554318, AI439022, AI373036, W73952, N42730, AA302641, AA594115, AA156886, AI249488, AV683614, AA936827, AI367631, AI917956, AW511599, AW151261, AA235619, D59873, W77995, W73178, W73457, AA678939, BF767379, AA447665, W93317, AI050013, AW960535, AI433148, AI693776, H43132, BE907089, AI868651, H42365, BF872750, AI215882, AA383684, AA843578, AA479185, AA325207, AA421010, AA766077, C21518, AI015576, F21903, AI274524, AA625709, AA535245, AW265759, AA927039, AA303411, AI684069, AA356903, AA339998, AW372719, AA811142, AA401731, AA742390, AL044300, AA336082, AW081250, AA433985, AA603705, H84185, AA157195, AI910669, AI682063, AL044011, AW273621, AA827896, AW170714, AI028476, AA496243, AI582763, AA916824, AI057210, AA768150, BG170969, AI440289, AI721078, AA634528, AA621271, AA776421, AI051711, AI287476, AW303838, AI636557, AA961201, AA815460, R06079, AI076520, AA773592, BF736165, BE171275, T24558,

HBJF126	17	772348	1 - 1489	15 - 1503	AI222486, and AI521648. AL522907, AL526811, AL528580, BE619639, BE798341, BE785683, BF036910, AI816714, AW410741, AW675663, AA226255, AI077876, AA813934, AI354477, AW410740, AL522908, AA906037, BF038884, BG030252, N53061, AW440434, AA134769, AA037624, AL526841, AA641954, AI302550, AA424016, AA134768, AW074122, AA709434, AA424082, AI206461, AW074284, AI813620, BF824919, AI241581, W93593, AW814771, AA911289, BE898093, AI218492, AW504945, AI612865, BE869464, BE732878, BE734483, AI277607, AI187313, AI350811, AI434025, AW275190, AW276616, AA954030, BE731318, AW439574, BE731332, AI202853, AI004585, BE396498, AI265804, BF353710, N73248, AI244408, BE731484, AI241127, AA226533, R02524, BG110816, BE619122, AA037625, BE711537, HI4806, AI954356, BF972886, AW193200, BE513950, BE300852, AA973778, AA876151, AA872499, AA010653, R29049, AA873196, AW629350, BF903325, BE280013, AA216115, BE177689, BF755890, BF756605, BF335325, BF088300, C02093, AA609581, AW016529, AA580145, AA760741, AI283813, AI096744, AU156247, N26872, AA057074, AI678948, N20594, AA486563, AA948624, AA535449, AA917667, AW015508, BE383689, BE877188, AW148479, AW802992, AI823982, F29139, F26541, F37068, BF526777, T96318, AI817412, BG255083, AK026103, AC009542, AC083862,
---------	----	--------	----------	-----------	---

HCEDH38	18	730529	1 - 1498	15 - 1512	AC009330, AK001862, AC009330, AC009330, AC009330, AC009542, AC009542, and AC009542.
					AI632101, RI5913, BG056741, AI880223, R43424, BF512075, BF515216, AW020619, Z99716, AK026597, AF126247, T66539, Z99716, and Z99716.
HDPOJ08	19	731863	1 - 1641	15 - 1655	BF968799, BF791555, AL513581, BE879926, AI949941, BE827843, BF968555, AI765763, BE875907, AW959968, AW382167, BF692458, BE876162, BF106234, AV713629, AV699640, AW382174, AU136532, BF692025, AA449500, AW902068, AW583040, BF212019, AW382170, AI768711, AI918137, AW235520, AI199832, AI074542, AA243341, AA071031, AL513582, AI308913, BE150978, AW609396, AA604828, AA831297, AI304674, BE151243, AW391610, AA704776, BE150919, AU155999, AW389522, AA878385, BF979062, BE150848, BE150932, AA554171, AI086256, AI285140, W48831, AW379916, BF215357, AW389518, AI361484, AI290204, BE150880, AA679730, AA285176, AI367820, BF570762, AA287652, AI028778, AI342266, AI332795, BE501465, AW609661, AA564884, AA497006, BF432681, BF438907, AA496929, AI742352, BF572848, AA824372, AW582335, AA286805, AA809400, AA101705, BE150881, H50009, AI356809, AI863722, AA449072, AW394227, N64570, BE614989, H66597, BE465872, AU157281, BF792958, AW394207, BE702178, AI860155, BE702109, T96603, BF792810, AW802638, H47883, BE702071, AW391634, AA425753,



					BE149864, BF766698, BF766705, T96711, R59882, AW816178, AI301234, AA524763, AW582392, AW609367, AA427806, AA243537, H89251, AA297709, BE892299, AI703471, AA284029, W49812, AI458780, AW075621, H89250, AI867621, AW380564, BF912063, H66596, AW380556, AW814225, AW380562, AA730264, R59881, AI433332, AA210752, AA863154, BF513435, H47884, AA211712, C00853, AU137710, AI269992, AW337692, AA489590, AA070527, AA101704, AW391666, AA296965, AA296966, AA497092, AI570809, BE673630, T25724, AW582435, BE150974, AW391617, AI954461, BF999751, AW152174, BE876251, AI587112, BF764712, AW816180, AW102931, AK024215, and AK023478.
HDPX82	20	730518	1 - 2511	15 - 2525	AL049055, BF684025, BF685956, BF683783, BF684251, BF683860, BF213335, AW816387, BF684265, AW857593, AW963304, AU123401, AA708837, BF991664, BG260606, BE542196, BF984668, AW857605, W52520, BG171880, AW968995, AW811248, AA573159, BF918605, AW857610, BF106301, AI066622, AW861480, BE160856, AA703380, BF959941, AA393030, AW852367, AW835723, BF952274, BG255269, AW835647, AA489237, AA452329, BE160656, BE161095, N35802, AW867362, AA808909, BF904041, AV764658, AW867431, AA730994, AA465244, AA158019, BF947338, AI086954, AI536854, AI291714, AL041488, AI792502, AI792459, AI741024, H94823, W61198, AW838260,

				AA772777, BE778292, AA218723, AA609811, AI356504, AV714369, AI025243, BF340632, N24969, BF911934, AV653343, AI254995, H80802, BG118138, AW167885, BE857554, AA465431, BE676520, AA069566, BE784550, AA461161, W07841, AI122688, AI079211, AI031714, AA452106, BE149694, AV726988, AA069789, AI627469, AW028732, AA771925, AI371162, BF737628, AA983155, AW867633, AA397928, AW867488, AW995456, AI814562, AW130022, AW968376, AV748165, BE069844, AI565122, AA570192, AW102909, BE855522, AW817786, AA126066, AI053500, AA157510, BE047103, AA490126, BE562112, AI580739, Z32766, BE349054, AI718353, BG025100, AI677976, AA069839, AI053809, AI356534, AI446523, AI580884, BE221572, AI803385, AW273309, AI037129, AI371783, BF947438, AW167442, AW316580, AI608666, AI581694, AI499665, N55579, AW001954, AA621666, AW248582, AI961876, AI923356, T48377, BF057354, AI829095, AW857607, AA679739, AI830606, R82294, BE515186, AI285371, AI114801, AI684007, W69718, BG025250, AI635165, AI559675, BF448522, BE046432, AA046268, AA629812, AW082099, AA609804, AA160713, BG057664, AI831826, W61150, N69868, R27973, AI821623, N47802, AI979218, AI475683, AW857604, AW513833, AI198692, AA173256, BG222362, AW303837, AA569404, AI752142, AW504640, AA721567, BF106068, H80803, AW131064, AI361711, BF435554,

					H66830, AW849724, T05809, AW851424, AI378096, CI7983, N63450, BG256189, W23004, BF897271, AA077016, AA070631, AW850283, AU147446, AA573136, AA813458, BE143805, AW861483, BE079784, AI025704, AI681955, AI969514, R85355, N49747, AI568377, AA400644, AA719453, N67689, BG002673, AI187296, AW966351, BF475456, AI708945, AA720992, AV705419, AW880945, AA393732, AI129305, AA046379, AI951358, AW117835, AW806389, AA972251, BE162110, AI951746, AV727699, N49709, AW966604, AI805112, AI760380, AW295592, AC008062, AC005833, AL121772, AL121928, Z84814, AC002103, AC023281, AC002400, AL034407, AP001748, AP001631, AL139421, AC000387, AC005562, U47924, AC007390, AC019155, AC010267, I47334, AL109653, AL353728, AC005799, AF240627, AC016577, AC007227, AC000389, AC006366, M12851, AC011811, AL163218, AL353807, AL121753, AC002350, AC008372, AL138889, AC073539, AL160008, AC004876, AC008733, AL009179, AC008996, AC009194, AL031283, AC005524, AL133448, AL139045, AL163285, AP001609, AL442167, AC005612, AL021879, AL049570, AC006432, AP000353, AL359703, AC019210, AC004617, AC007283, AL359218, AP001660, AL078615, AF130358, AC005091, AC008044, AC011460, X54171, AC007684, AC022150, AL450422, AC016816, AC007842, AC016968, AK023713, AL121969, AL121653, AC010889, AC004924,

				AC005531, AC006039, AC009408, AC004448, AL078594, AL049742, AC003976, AC026424, AP000350, AC005829, Z82901, AC008753, AC026431, AL359457, AC022148, AC004840, AL121985, X87344, AL356379, AC006327, AC008784, AC007325, U73641, AL135927, AL031654, AL163152, AL035405, AL390865, AC000401, AC006035, AC073898, AC007326, AC008103, AC005820, AC008995, AC006029, AC006556, AC013412, AC016728, U91328, AR036572, AJ009610, AF165175, AC006359, AC008649, AP001671, AF164621, AL122001, AL354857, M57950, AC000051, D87002, AF134576, AC008554, M12854, AC010104, M33841, AP000432, AL354872, AC008443, AB006684, AC009424, AF172459, AC006001, AP001060, AC002308, AC021999, AC012331, AF172458, AC008553, AC020754, AL139008, AF172457, M33842, AC022127, AF260248, AL355485, AF164618, AF164616, AP001670, AC046129, AP000345, M12852, AC016995, AF172456, M12853, AL109763, AF164617, AC004979, AX015915, AC010197, AF307337, AL133466, M57949, AC011500, AF172455, AF261945, AF164614, AL135901, AF172454, AC022209, AP000356, AL031774, AF164619, AF042089, AF001550, AF074086, Z80898, AF164611, AC002508, AF164609, AC007228, L35659, AC006057, AP000550, AF164613, M14123, AF164615, AC010632, AC011718, AC002507, AF260253, AF164610, AC008018, AL139090, AB014607, AF164612, AF148679, AP000346, AC008648, AC016698,

					AC008555, AC007539, AC012330, AC007981, AC012309, AC023491, AL096700, AC002992, AX000338, AL009176, AC008132, AC006539, AB000381, AC023490, AL445217, AL109918, AC008804, AC007690, AL163204, AL020995, AL109748, AC010451, AL133350, AC012078, AF260249, AC011494, Z21852, AP001753, Z82975, AC019173, AF078838, AC008639, AC008176, AC064878, AF205860, Z95704, AL078614, AL121873, AC007717, AC010645, AF260251, AC010506, AC024709, AC024709, and AC024709.
HELK31	21	681138	1 - 1382	15 - 1396	AL519840, AL519839, BE379142, BE786389, BE796190, BG117991, AL524590, BE744597, BE909841, BE907873, AL043167, BE544763, BE740216, AL518390, AL529705, AW592682, AW874363, AI085412, AW958434, AU126873, BF132076, AA604374, BF541758, BF794982, BE545432, AA936378, AA161264, AA531252, BE563799, AW072533, AA639981, AA677594, AI138280, AA218539, N94446, AI363012, BF114843, AI083837, D51047, BF343738, AW499697, AA437204, AA132746, AV712240, AI086913, AA889889, AA161263, AA916429, AA142878, AL518389, AA810233, AA613892, AA424834, AA143152, AA603133, AA132651, H11615, AW367012, AI268931, AI955333, AA948407, AW327686, AA856621, AA227183, AA524602, BE537412, W30793, AA969047, BE875215, AU149648, R54573, H18393, AW080718,

				AI082408, AA354603, BG024936, AA807409, BE762990, AA225683, AA745633, R09626, W22670, AA296971, N79058, AW131898, AA283047, R09625, AA974359, AA216343, AW352289, AI014772, AA426455, AA335199, AW352287, AA876045, AA569616, AA426587, AA365881, BE645623, AW352294, AA218538, AA225708, AW149303, Z45742, AA298844, AA693654, Z41394, AJ740665, BE142815, R09514, AW263934, BF515182, AA652379, W24000, AI400292, BF893436, AA281197, AI376646, AV703989, AV725633, AV656373, AV702372, AV702417, AV704217, AV702280, AW954248, AV702998, AW950443, AV725991, AW960601, AW952403, AW952410, AW952183, AW954237, AW952751, AW956075, AV645936, AV709587, AW955723, AV658084, AV692600, AV650315, AV659389, AV697880, AV727613, AV726010, AV660258, AW959521, AV647789, AV708109, AW956474, AV659294, AV727787, AV703146, AV725745, AV686060, AV660608, AW951239, AV728148, AV726590, AV656478, AV709314, AV653353, AV654070, AV691080, AW951281, AV702385, AV702772, AW949802, AV658275, AV652001, AW955662, AV703669, AV707979, AV725208, AV727003, AV709580, AV725582, AV708786, AW957517, AV659547, AV727526, AV651920, AV725618, AW954439, AV706734, AV729076,

					AV702266, AV725577, AV725033, AV706223, AV728924, AV725617, AW954206, AV707863, AV696931, AV707798, AV703062, AV727822, AV707572, AV699089, AV705135, AV701874, AV703501, AW962444, AV707401, AV701183, AV709660, AV704585, AV654035, AV709935, AV707652, AV728721, AV707654, AV707663, AV683994, AV704042, AV654282, AV697288, AV729220, AV709880, AV687035, AV698290, AV704847, AV694836, AV706882, AV697498, AV702954, AV727238, AV686420, AV694812, AV682997, AV696866, AV727126, AV707656, AV655890, AV728997, AV706162, AV705635, AV686390, AV702794, AV656256, AV686417, AV686083, AV698429, AV656240, AV655577, AV694871, AF201931, AK001341, AL137878, AX047063, AR050070, AF217994, Y08991, A62298, S68736, AX047062, A82595, A82593, Z30183, Y11505, AX047064, U94592, AX009343, AX009341, AX009337, AX009335, AX009345, AX009342, AX009344, AX009340, AX009339, AX009336, AX009338, AX009334, A62300, A91160, AX040577, AX040581, U45328, AF006072, AR025466, and AX046743.
HFPCX64	22	877637	1 - 1055	15 - 1069	AW969544, AW972136, AA503871, AI272041, AW515225, H65747, BF935424, AC016025, AC016026, AC007845, AC005562, AC020904, AF165926,

AC020917, AL162615, AL121655, AL135818, AC004797, AC007845, AC007845, AC007845, AC016025, AC016025, AC016025, AC016026, AC016026, and AC016026.					
BE390699, BF346226, AL520941, BG253282, BG032571, BE790095, AF150177, AI912465, AL520942, BG170667, AA292739, AA419155, BE250877, BF924799, BF901807, BE271697, BE891650, AL534026, AA639468, BF975546, BE790646, BF899941, BF973383, BF093166, BF093157, AL524222, AW889390, AI992170, BF903129, D63172, BE891409, W52850, BE250104, BE795572, BF882870, BE257602, BF093158, BF093167, BF744666, AA772406, AI040051, AI469599, AA527588, AI369580, AI870444, BG029528, AW515437, AA081727, AI499954, AW270771, BG222564, BG222326, AW780108, AA664604, AI962030, AI633168, BF992556, AA502991, AA720774, AW275971, T69638, AW188742, AA613624, AW979295, AW086291, AI754293, AL035587, AF161347, AL096791, AL118506, AL357497, AC011895, AC011465, AF196969, Z83822, AC005288, AL022237, AL109952, Z95115, AP000355, AC007386, AP000501, AC008745, AP000347, AC006057, AC007114, AC005399, AC020552, U85195, AC007225, AP000228, AC004961, AF038458, AL390738, AL109797, AP000512, AC010526, AL021707, AE000658, AC004882, AC005329, AL031658, AC006511, AC005522, AL138741, AC004149, AP000140, AL031672, AC006261, AC027319, Z97053,	23	731869	1 - 1644	15 - 1658	
HFXDO60					



					AL022313, AF207550, AL031276, AC018641, AF000967, AC005568, AC006312, AC005781, AL121890, AL020997, AL109825, AL162615, AL049839, AF000088, AL049766, AF156673, AP001745, AL136296, AL022336, AF200465, AC007655, U95742, AL139120, AL136418, AC006084, AC004655, AC005089, AC004647, AL136112, AC007201, AL034429, Z85986, AC005520, AC005529, AC002314, AC007216, AC011495, AL031848, AC006013, Z99127, AC022392, AC002115, AC013434, AC007731, AC004084, AC018719, AF190464, AC005500, AL135746, AC010422, AC020955, AL031228, AC005953, AL137059, AC005914, AL161731, AF030453, AC005484, AL137039, AC005822, AC004089, AC006538, AL133340, AC018755, AC016395, Z84484, AC010203, AC000118, AC005668, AC004890, AC011491, AC008403, AF243527, AC022596, AC005971, AC005088, AC063976, AL133163, AC006537, AC018758, AL136124, AC005098, AL117348, AC011464, AL031846, AC004867, AC005920, AC006141, AC011545, AC003982, AC004611, AC003109, AC005049, AL353596, U37450, AC009001, AP001619, AL121658, Z93783, AL009181, AL049760, AC009505, AC010627, AP001439, AC004826, AC025594, AC004933, AL022165, AL096840, AL121926, AC007969, AC007220, AP001670, AC012309, AL035659, U95090, AL136139, AC004893, AC004971,

					AL121825, AC010605, AL450224, AL136137, AP000558, AC008873, AC004834, AF111168, AL031291, AC007383, AC008536, AP000143, AC005052, AC005911, AC000075, AC009955, AC004843, AL031255, AC007690, AL031985, AL139095, AC008687, AC007160, Z82244, AL117336, AC008083, AC005067, AB023051, AL121771, AK025114, AC011475, AC004771, AC005231, AC004167, AL137853, AL034548, AL109798, AP000504, AL121774, AC011510, AP001711, AL121585, AL355385, AC004491, AL157372, AL117382, AK025338, AL139396, AC019209, AP000090, AL035400, Z98946, AL122020, U07563, AC005011, AC005225, AL096700, AC007051, AL121888, AC007546, AC018812, AC005800, AC005081, AC020629, AL023553, AL161670, AL354864, AL035387, and AL035587.
HHEPG41	24	714102	1 - 1063	15 - 1077	BE439675, BE903592, BF984328, BF337207, BF978147, AW955502, BE743902, BE272543, AV757236, BF212880, AW405217, AA889969, AI991315, AV701663, BE270100, BG178791, BF681301, BE222645, BG167626, BF238307, AW069149, BF680700, BF132414, BF698492, AV736544, BF130460, BG255905, AI493727, AV745093, BF102497, BE254068, AA934591, AI147316, BE543668, BG231583, BE256074, N24442, BE734398, AV754408, AW014782, AI198642, BE646408, AI709288, AA877730, AW135010, AI720901, AA496681, AA995328, AI032868, AI186312, AW579254, AI606672, AI969715, N23673, AI188938,

				AA420567, AA427691, AI191317, AI332586, AW000829, BF102532, AI219152, AI125390, H93124, AI470155, AA843102, AA471213, AW182893, BE312355, AI141484, BG117664, AW000718, AV706639, AA815421, AA708211, AI268069, AI023128, AA159902, AI147588, AI129253, AA129884, AI127280, AA290635, AV724436, AI142324, AI673417, AI186000, AI587141, AI128437, AA723220, AA315771, AI335350, AA995933, AI087415, AA552070, AW300769, BE349483, AA862543, AW008043, AI241459, N58266, AI355685, AW304225, AW083014, AI277068, R68241, AI160884, BF687940, AA774420, AV705947, AA810159, AI828898, AI093015, AI038096, AV707544, AA732834, AI934627, AA026633, AA844949, AV735174, H84951, AI279658, AI096712, AI969153, AA419151, BE407927, BF665006, AI798245, N95063, AA149944, AA653091, N69652, AA159798, AW104010, AA771923, N71609, H20023, R99610, N33986, W37128, W04866, AV729015, H20143, AW130386, W01678, D55334, AI125700, BE091971, AA572869, H40779, H50207, AA157561, AV743438, AA531221, AV736793, AA969778, N70496, H95780, AI159958, AI744165, BF977248, AI275921, AA037790, AI680770, N77862, N92248, N38815, AA305332, R71518, AI752109, H20098, AA937128, AA478395, AV738026, AA962124, AV743648, AV740102, R94908, BE621803, H99652, R77435, H18782, AA641831, H21165, H19070, AV741494, AA694460, W40195, AW511932, AI184349, AA844297, H46188,

					W38900, R71470, W58208, N94261, R70469, H01343, T31343, BE909620, N25251, BE620993, H20238, AA165011, AI752110, H23656, N72206, R77524, AA037789, R70556, AA643896, R92265, H67121, AV741554, T30654, H71491, W32075, W00449, H38970, AA326924, W37143, H69010, R91937, H50206, C01763, H60231, H18688, R09629, H27857, H75393, BF436567, R94992, AA558120, AA305400, R99715, H23612, H39170, R09517, AA326929, H46187, AA026672, H01135, N54428, T32463, AA339137, H59520, AA186949, N33887, H22402, AI709334, AF078861, AF151898, AC010422, A74952, A75027, A75031, A74945, AX047063, AR050070, A62298, AX047062, A82595, A82593, Z30183, T52716, T61025, T61577, R24626, R26656, R68534, R79694, H01394, H03302, H03303, H03402, H18972, H22368, H40075, H46478, R86746, R87112, H60187, H60393, H71551, H71623, H81427, H84494, H84495, H93252, N24542, N58289, N71651, N76257, N77644, N77658, W04664, W31583, AA150561, AA157861, AA164972, AA188345, AA419096, AA427690, AC010422, AC010422, AC010422, AC018761, AC018761, and AC018761.
HKGAH42	25	731871	1 - 1191	15 - 1205	BE840860.
HMIAP86	26	726831	1 - 1660	15 - 1674	AL533220, BF967956, AL533253, AL520510, BE735407, BF972030, BE735149, BE615619, BE616472, AI873527, BF347687, BE383692, BF967233, BE385645, AW593348, AW381588, BF541528, AI032869, BE294015, AA404241, AI564151, BE294088, AA401224,

				AI682367, BF694848, BE255192, AA910774, AI367739, AW976142, BE15232, BE389860, BF029472, BE615138, BE645680, AI131262, AA054608, AI479085, BE728074, BF672705, AI241428, AA021119, AA142931, BG108596, AI039086, BF348256, AV748480, AA021118, AA056945, N48177, AI202193, AI491859, N53324, AI364707, R44688, AA015735, AW015622, AA905989, AA813639, AA057005, AA035652, AA917010, AI952221, AA054548, AA015832, AA505774, AI697106, R19440, BE707409, BF841914, BE677828, AW954134, AW950006, AW954211, AI968179, AW960629, AW964070, AV728721, AV656478, AW953797, AV696931, AV683994, AV703878, AV702019, AV705014, AV728733, AV727510, AV706741, AV726026, AW952460, AV709596, AV709273, AV725633, AV706417, AW950443, AW959983, AW960655, AW960601, AW952403, AV702164, AV661704, AW952751, AW956075, AV645936, AV709587, AW955723, AV638084, AV692600, AV650315, AV659389, AV697880, AV727613, AV656373, AV726010, AV726091, AV660258, AV708109, AV647789, AW959521, AW956474, AV727787, AV659294, AV703146, AV726789, AV686060, AV692345, AV725745, AV660608, AV728148, AV726156, AV726590, AV709314, AV703790, AV653353, AV654070, AW964585, AV691080, AW951281, AV702385, AW949802,

AV658275, AV652001, AW955662, AV707979, AV703669, AV727003, AV709580, AV725208, AV658751, AV725582, AV708786, AV659547, AV727526, AV651920, AV725618, AW954439, AV684762, AV650283, AV702266, AV707088, AW963768, AV725776, AV650591, AV725577, AV725033, AV706223, AV728924, AV725617, AW954206, AW955900, AV707863, AV725991, AV650691, AV707304, AW952410, AV703062, AV726619, AV727822, AW951536, AV650768, AV699089, AV705135, AV701874, AW964410, AW962444, AV703501, AV661286, AV702772, AW962978, AW964440, AV702137, AW954237, AV707401, AV701183, AW955696, AV709660, AV704585, AV654035, AV709935, AV707652, AV707663, AV707654, AV704042, AV654282, AV709880, AV729220, AV697288, AV698290, AV694836, AV706882, AV704847, AV697498, AV702954, AV686420, AV727238, AV682997, AV696866, AV727126, AV707656, AV655890, AV701946, AV728997, AV706162, AV686390, AV705635, AV702794, AV686417, AV656256, AV695700, AV686083, AV698429, AV656240, AV655577, AV692972, AV694871, AV704217, AV727459, AV655901, AV689410, AV702790, AV705246, AV695545, AV687946, AV704924, AV728546,					
---	--	--	--	--	--

					AV703762, AV706734, AV702854, AF078544, AF155811, AF155809, AF076981, AF155813, AF300424, AF155812, AF155810, AL035423, AB028879, AB011068, AJ010966, AX047063, AR050070, A62298, AX047062, A82595, A82593, AX047064, U94592, AX009343, AX009341, AX009337, AX009335, AX009345, AX009342, AX009344, AX009340, AX009339, AX009336, AX009338, AX009334, Z30183, A62300, AF006072, AX040581, AF217994, Y08991, U45328, AX046743, S68736, and AR025466.
HMUAP70	27	872208	1 - 1951	15 - 1965	BE613319, AV687447, AV725712, AV687625, BG166531, BE612728, BG114876, AV686519, AW952404, AV725638, AI061630, BE877777, BF055022, BF439548, BF692350, BF732575, BF967994, BG054984, AW372569, BE866270, AW160677, AV706186, BF690981, AA813278, BF206792, BE876393, BE645016, AV728247, BF195583, AI612729, BF446480, BF210620, AW167859, AW167862, AA521082, BF445077, BF698977, BE348758, AW753532, AA161332, BF665995, BF195330, AI806813, AI887683, AA843967, AA525839, AI869290, AA447934, AW068627, BE881059, AI912708, AA843171, AW206294, BF673423, AA402367, AA910679, AA037122, AI091239, AI422091, AA287736, AI816253, AI802199, BE042949, W56256, AW156905, AA779099, AI057601, BG168894, BE327200, AA781082, AA496466, AW022886, AW275342, AI091181, BE218417, AA873496, AI290167,

					AA92894, AI168731, N35917, BF028133, AI929639, AW003760, AA287895, AA774263, N22752, AA843277, BF001600, AI685261, AA283859, AI678620, AW403982, AA984140, AA056053, AA907413, AI361356, BF572327, AW157133, N94537, AI816334, H15827, BE383297, BE218532, AA931689, W17196, BE538941, AI027113, W33009, AA293343, AI079727, AW161562, AV749347, N92441, BE673987, W23456, AA410485, D81853, AA935683, D58802, N27027, H99819, AI004733, N30220, AW516664, BE702242, AA452710, N94329, BF692523, AW470953, BF681161, AI566161, AA258458, BE077323, AA910558, AI128706, AA664059, AI446094, AA872758, AA725042, AW160789, AV684142, BF762393, AA861311, BE167341, N34534, AA846407, AA918516, BF762409, AA973796, AW073424, AA448868, N59261, AA857543, AA399445, AA515285, R90917, AA399423, AA911982, AA995135, BF036554, AW513259, AA577338, AA872812, T63367, AI423456, AA643728, AI027067, AA293329, AW162091, AA085090, R56184, AI245725, BF436213, BG109166, H23642, AI973249, AV650608, AV686647, BE928331, N68929, R64440, AA029562, H13310, W46630, AA114922, H41386, N57112, AA258388, AA744562, AA993782, AI499779, AI571822, AA744564, N40152, AA029728, Z43644, AA837702, Z45519, AV689458, AA620561, AI093848, AA602387, AA421573, AA922986, BE564509, C14582, R12614, AA410303, AA782100, AW083148, N36220, R32391,



					AA055763, AI570545, AA939289, R90813, AA112870, AI207050, H16135, N89859, F06244, AW162345, W92571, AI027262, AI149386, AW023549, R63828, AA311835, AW517389, H38655, AI348632, AW015099, T54934, AI826301, BE464247, AI360861, W30811, AI028088, AI768693, AI307614, AI343572, R32390, AI744258, AW276195, AA055962, AA724357, R42373, AW206298, AI167826, N78834, AC004752, AK025312, AL353956, AF061981, AL122045, AK025209, AF153205, I89947, AK026480, AF130100, AL389935, AK026542, AF116631, AF111851, AF159615, AF106657, AL122050, A08913, AF125948, AF217982, AL049382, A08912, AL162002, I48978, AL080163, AJ299431, AF058921, S78214, AF119909, A08916, D16301, AK000450, E12747, AR038854, Y16645, AK025414, AF321617, AL353940, A08910, AK000718, AL137429, A08909, AL442082, AF061573, AK027193, AL122123, AK000618, AF217966, A08908, AF030513, AL137537, E05822, AK025375, AB047904, AL133665, AF118094, AF119875, AL080159, AK026885, AL117460, AL050116, AL389939, AK025465, AJ012755, AF155148, AK026550, I89931, AF017437, AL133557, AL049452, AL137533, AL133113, AF106862, AK027204, AR087170, AK000418, AK026642, AL049314, S79832, AF022363, S76508, AF314091, A18777, AF143723, X67813, A15345, AK026865, AK025378, I33392, AB052191, AK025541, AL137550, I09499, AL137547, AF090901, Y07905, AL110222, AL389982, AF032666, AF026816,

					SG1953, AF067728, AX042059, AB048953, AF118090, AL137271, X57961, AB050431, AL110158, AF130077, AL096744, AF185576, AL117432, AK024538, AF271350, AK026408, AB047248, AK026583, AX045627, AB048975, AF155827, A12297, AL137294, AF242525, AF090934, AF090943, A77033, A77035, AF087943, Z72491, AK026744, AX045159, AF090903, L31396, I66342, AF090896, AF139986, L31397, D83032, AB049848, X53587, AR029490, AF116654, AK026532, AK026591, I89934, AK00652, AL122110, I17544, A65341, AJ000937, AB048913, AB048919, AL050172, AX017991, AK026746, AL133075, AK025524, AF208850, AL133072, AF113013, AF116682, AK026462, A08911, AL133560, AK024992, AX019230, AK025967, AF118070, AK026855, AB047623, AL117583, AL117416, AK025435, AL137711, AL162062, AK026627, AF274348, AK026927, AL023657, AF274347, AL157431, AL137488, AL050155, AF056191, AL137292, AJ005690, I00734, AF267991, I89944, X06146, AF119894, AK027114, AK026504, AL049300, AL049938, AB047878, AK026630, AK027144, AF130082, AL137558, E00617, E00717, E00778, AF130110, X93495, AL050024, AK024594, X63410, A08907, I48979, AL137705, AF119878, AB041801, AK026959, E06743, AF202636, AB048974, AL162006, AF130105, E08631, AX027129, AL133014, AL359618, AX019229, AF102578, AF207829, AF116644, AF078844, AF119883, AK027113, AL049460,

					AK000247, U95114, AF130055, AF119896, AL137478, AR000496, AK000323, U39656, AK026762, AK026784, AL133077, AF116602, AL359601, AX020124, T54768, T63693, T91023, T84597, R13763, R18327, R20519, R25031, R43789, R53025, R20519, R43789, R55911, R81848, R81849, R90812, R90918, H53640, H53684, H86289, H97448, N25711, N43983, N59141, N75178, N76730, W31472, W31935, W35396, N89770, AA018416, AA019585, AA122341, AA565211, AA583521, AA613126, AA767024, AA807259, AA829478, AA831898, AA876196, AA906972, AA932624, AA953784, AA953789, AA975996, AI028021, N56132, C00677, R29165, AA092968, AA679878, AA782815, AA890689, AI042642, AI041151, AI093012, T24514, F02527, F04381, F04532, F08307, AI244846, AI276792, AI279043, AI298862, AI334644, AI348509, AI364763, AI202774, AI453449, AI400913, AI401566, AI417788, AI418178, AI498899, AI419614, AI582814, AI423417, AI127285, AI147786, AI148738, AI167754, AI187434, AI652739, and AI219638.
HRACJ35	28	730504	1 - 1849	15 - 1863	BE906771, BE218907, AI912661, BE670671, BG166321, AW167740, AI698131, AI796048, BF476110, AW952474, AW149683, AW474992, AI814137, BF436724, AI635719, AA452391, AI422285, AI675301, AW301634, AI800309, AI023300, AA054467, AI269915, BF062213, AI220479, AA991181, AI159765, AI623293, W88683, AI205308, AA043330, AA461136, BE669608, AI032982, AA634903,

					AI361429, AI800329, AI042583, AA877688, AI094869, BF681677, AW868366, AI683625, AI040482, AA460833, AI268543, H40189, AA041196, AI420048, AA127006, AA045134, AI023081, T96696, AI161385, M79132, AI984382, W23483, BF000996, BF476853, AI521085, AA492294, N95081, AI146307, AA016124, R13864, W28330, AI022619, BF573582, T19296, AA126627, AA410735, BF056915, T30952, AI971069, AA043329, AA977851, AA215786, R07660, BE833878, BE833866, AA329616, AA226105, BE833882, BE833868, AA126801, Z41866, AA216384, AA056673, AW244035, AV693019, R18560, AA041433, R05716, AA868767, BF222351, H40140, AW589719, AV686312, BF207973, AA226035, AA228673, AI817777, AI248289, AI420271, AV747189, R05717, AA879250, T30818, R37006, BF847400, Z38161, D57208, AA319785, AA225132, AI699205, T96591, AW945698, AA333327, AA045610, D57177, AA226695, AA045355, BE905736, BE670421, AW469919, BF000980, AW152062, AW771589, BF871391, F19153, R41427, AW069103, AW964837, BE242459, BF445505, AW373047, W88670, AA761464, BF844537, AX006440, AF107834, AF119386, AF097723, AF131077, AF107835, AF009513, AF107833, and AF107832.
HTWDE26	29	668265	1 - 1612	15 - 1626	AL537331, BE883562, AI763238, BF111600, BF057137, AL537330, AI188389, AI188787, AA479523, AW338995, AW005918, BG033018, BE875058, AW583488, BG253636, AI346520, BF063112, AI423154,

					BG056218, AW291338, AJ682996, AA781395, AA778127, AI700522, AI348157, AI061441, N40533, AI139369, AI928073, AV713186, AW591208, AA858416, AA771952, AA835017, AA479526, BF001492, AI276159, AA576421, BE501616, AA418766, AI394520, T34153, AI272728, AA563878, AA433929, AA528124, AI050707, AW960832, BF960141, AI422109, AI218374, AA150587, BE169762, AI338694, AA662690, AW469376, BF956326, AA418722, AA505360, BF974922, BF923711, AA304971, AA969029, AW798447, AA782389, AI743240, AI075212, AI348193, BF853173, AI908134, AA904379, AI126395, N64614, AW604828, AI090901, AA505543, AI248295, AA465703, AW195236, BF924107, AA430584, BE855703, R52412, AA215970, AI811574, AI917748, AW271730, BF678074, AA771799, AA971867, AW194812, AI333671, T85033, BF964158, BF959989, BF089572, AI380868, AA574396, AI280563, R16040, R02608, D45470, BF954040, R16039, AA725308, AW798950, R42978, W30758, R35114, AW859933, R79672, R24139, Z45240, AA761523, AI926895, N98221, R18084, N71980, Z40957, BE163749, AW089148, AW891427, T30798, AA618381, BF947576, N79943, N99709, AL525321, AA650492, AA320674, BF856751, R79861, AI630495, AI365169, BE867898, AI886691, R01668, AI589880, R49502, N33899, R24146, AA705913, AI864209, AI247102, AI569369, T91981, F02495, AW604842, BF963172, BF959011,

HUSIB13	30	58085	1 - 591	15 - 605	BG150654, BF086695, BF960801, AA248224, BF958058, T25009, AA150513, AA115561, BE962584, AI687854, AJ400877, AJ400878, AB032249, AK000323, AF267747, and AF090886.
					AW291051, AI862657, AI652465, AI310142, BE179051, BE463912, BE857013, BF966849, AW411174, R21727, AI888432, R76464, R63695, H25920, BF512300, H96393, BF512297, AI678103, AI918447, AI583737, BE161834, AI651879, AI493554, BF966293, AI650333, BF350444, BG251367, BE152158, BE152167, AW606124, R62744, AA968638, AW606135, AI193492, AW393675, H96036, BG013610, R76778, BE164321, BF090384, BF087510, AI262782, BE179223, BF993885, BE707209, BF090383, AF075575, and AJ007670.
HBAFA02	31	679555	1 - 917	15 - 931	BG028424, BF852127, AJ084750, AU153708, AA398992, AA399627, AA402622, AI564897, AI083955, T03567, AI439461, AA729487, AI536788, AW364235, AW275187, AA999869, AI055824, AW364297, BF059669, W46460, AI198134, BG248314, BF814886, BE504806, AW274911, AW074663, AI652737, AU159564, BF738662, AI635013, AW364306, AL514829, AL513961, AL514773, AL515043, AL514757, AL514869, AL515375, AL514819, AL515035, AL514939, BF970652, AL515225, BG030750, AL514843, AI269580, AI538885, AI514885, AI648684, AL514763, AI632408, AL513977, BF815930, AW129106, BG036520, AL513817, AL513643, AI539153, AI783861, BF913616, AW054931, AI922561, AI355008, AL514357,

				AI497733, AW169604, BG179099, BF725463, AI582932, AI433976, BF795712, AI828574, BG257535, BE963035, AI815232, BG110517, BG029667, AI688858, AI433157, AI554821, AW858243, BG252929, AW151136, AI539771, BE897632, AI473451, AI537677, AI889189, AI500659, AI866461, BE541267, AI801325, AI500523, BF812438, BE885490, AI923989, AI284517, AI500706, AI513999, AI445237, AI491776, AI513911, AW151138, AI513991, AI521560, AI500662, BG113712, AI284509, AI889168, AI866573, AI633493, AI434256, AI805769, AI888661, AI284513, AI888118, AI514579, AI436429, AI440252, AW006046, AI514473, AI513723, BG112879, AI514089, AI513553, AI514219, BF814504, AI620284, AI568138, AW075484, BG181066, BE011885, AA833760, AI039086, AI514983, BE905408, AI514409, AI537261, AI514541, AI513985, AI514823, AI047187, AI514359, AI515019, AI513693, AA908294, AI889147, BE789764, AI513863, AI513687, AI514929, AI817244, AI554186, BE966990, AI514457, AI045500, AI514093, AI610557, BE883591, AI541056, BG122481, BE886728, AI514437, AI513779, AI514793, AW089350, AI494201, AW081298, AI514025, AI633125, BF816037, AI866510, AI513755, AI047422, BF032868, AI514015, AI274759, AI045626, AI039390, AI630928, AI627988, BG260144, AI120853, AI539800, AI648567, AI637584, AI514871, AI514085, BF971016, AI038605, BE965067, AI513631, BF726207, AI371228, AI491710, BF812963, AI513867, AW172723, AI569975, AI513577,

					BG110518, AL121007, AI866465, BF812961, BF812960, AI671642, BE895585, AI500714, AI538850, AI539707, BE875407, AI872423, AI491775, BF811804, AI860003, AI440263, AI514887, BG179993, AI887499, AI866469, BE968711, BF726237, AI434242, AI515413, AI468872, BG163618, AI859991, AI355779, AI581033, AI514101, AI670009, AI866786, AI242736, BG249582, AI513901, AI514035, AI655932, AI539781, AI572021, AI513865, BF934149, AI559957, AI521571, BG180295, AI570884, AI269862, AI048323, BF527014, AI133293, AF077754, AK024281, AF090901, AK026627, AI050116, AI359615, AK026784, AI137429, AB041801, I48978, AX040958, E05822, AC004883, I48979, AF119896, AK025431, AK024538, AB047623, AI110221, AK000323, AF090903, AF116631, I89947, A08913, AI157360, U35846, AI353940, A08916, AF079765, A08910, A08909, AF208850, AB034701, AI031984, AF217987, AX040974, AF138861, AP001346, AF090934, AK025254, A77033, A77035, AF119871, AF116654, AC024247, AX019230, AK026744, AF113019, AF130077, AK000718, AK025967, I89931, AF111851, AI137521, AF314091, AR087170, AF119875, AI034417, AK027164, AX019229, AI122049, Y16645, AI445220, AK026592, AF116602, AI162062, AF271350, AK026855, AF116691, AF218014, AK026741, AI389978, A7000937, AI049382, AI122111, AI117583, AK026452, AI133072, A03736, AI050277, AC007383, AK026533, AK026480,



					AK000432, AK026045, AF130075, AF130082, AF177401, AK025383, AK027116, X63574, AC023880, AF113677, AL137560, AF132676, AF061836, AL122093, AK026630, AL133258, AK026086, AF067728, AX042059, AB047615, AK025958, AL137550, AL353625, AL133075, AB051158, AF158248, AK026659, AF109906, AC004227, AF177336, AK026408, AC004213, AF113690, AF116688, AL049466, AL137271, AK026947, AL117460, A93350, S78214, AX010492, AL353956, S68736, U42766, U72620, AL080124, AF130066, AL080060, AF119899, AB052191, Y11254, AL049452, I33392, AF119865, AL162006, AF090900, AL050146, AF146568, AF111112, AL359620, AL122110, AK024588, AK027096, AL133080, AL049430, AK000137, E02349, AL353957, AL359583, AK000083, AF130105, AF116646, AL050149, AL133568, AK026593, E07361, AL359941, X82434, AF113689, AK000618, AL137533, A18777, A65341, U67958, AK026642, AL133640, Z82022, AF183393, AB048975, AR079032, AB052200, AL359618, AF111847, AF185576, AL117435, X65873, AF106862, AF081197, AF081195, AX026824, AX026823, A58524, A58523, AF078844, AK024524, E03348, AR011880, E03349, AR000496, U39656, AK026526, AF017152, AF026124, AF116649, AK000486, AF113013, AL080137, AF175983, AP001666, AL389935, AK025772, AR038854, AL031656, AF017437, AF118094, I09360, AB048953, E07108, AC006313, AL137658,

					A08912, AF091084, AL133104, AR038969, AL359622, AF113699, AK026959, AK025092, AF130087, AK026927, AL096744, AF056191, AL050393, AF116682, AL133565, X83508, AL133560, X72889, AF116639, AL389939, AL049300, AL137557, AL050024, AK000445, AB047887, AF087943, AL356278, AL133293, and AL133293.
H2CBT75	32	703079	1 - 1393	15 - 1407	BF308801, BF796401, AL120822, AA313583, AW772051, BF216725, BF769591, AA618422, BF769586, AA340511, BE138594, AV756809, AI754653, AA331298, AA410788, AI267356, AL041375, AW969743, AI267450, AV764259, BF925617, AA700014, AI040051, AU147162, AW968341, AA503298, AW575605, AW873061, AW976024, AI755202, AI066646, AV730824, BE676915, AW502796, AA570740, AA483606, AA578621, BG222875, AV763026, AV763058, AA228778, AV762633, AA468505, BF854244, AW268329, AA568204, BG250286, H38769, AI754170, AW271904, BF809041, AI537020, AA935409, AA455483, AI601229, BF997771, AA230025, AW069412, AW081303, AI251576, AI917132, AI798493, AW572159, AI732911, AA302812, AI306232, AW873261, AI056177, AA504818, AI821714, AF163573, AF168787, AL031584, AP002015, AC005913, AL050349, AC004962, AP000692, AL096801, AL138914, AC023510, AL031670, AC005971, AC020916, AC006270, AC004796, AC006515, Y10196, AC004966, AL035405, AL031427, AC008925, Z74739, AL008627.

				AL021939, AC008039, Z98884, AC003080, L78810, AC004671, AL138759, AL021367, AL035249, AP000009, AC004887, AC005297, AL136501, AC006600, Z98200, AC009245, AC002476, AL022332, AP001698, Z98304, AC007000, AL355094, AC003049, AC006460, AC007391, AC006162, AC005873, AL445669, AL133332, AC004526, AC037193, AP001603, AC009032, AL138707, S42653, AC003093, AC008041, AL031577, Z98751, AC018758, AC006449, AC011904, AL163207, AL031295, AC005228, AC007312, AP001435, AC005146, AL121574, AL118525, AL050328, AP001711, AP001697, AC004802, AL158159, AC016395, AC003029, AL137179, AC006960, AC008626, AC004977, AC004867, AC007681, AC078889, AL079304, Z73417, AL035071, AP000496, AL138958, AL031774, AP001686, AP000704, AC006115, AL136109, AC004782, AC007850, AF152364, AC024561, AC006559, AL021917, AC007114, AC008180, AP000008, AC000117, AC004491, AL049832, AL031053, AC008519, U52112, M87914, AL136962, I34294, AC002091, AL031575, AL133245, AL078581, AP000212, AP000134, AC009179, AC009286, AP000252, AL136980, AC004973, AC005666, AL356057, AL442167, D87009, AP000030, AP001705, AC018633, AC004849, AP001049, Z85997, AL034449, AL163285, AC005098, AC007157, AL096761, AC004166, Z83840, AP001751, AP001727, AC005722, AC004685, AC003962,

					AL356782, AL049870, AB020858, AC005183, AL163210, AL008629, AC004856, AC004662, AC007622, AL031319, AC016642, AL353734, AC003695, AL117348, AL133294, AC022407, AC009756, AC006241, AC006477, AC068799, AL121601, AC006251, AC005840, AC004890, AC008567, AL162414, Z95114, AL132765, AL391986, AC006983, AF111169, Z93020, AC026179, AP001712, AC005527, AC006023, AC004752, AC007790, U85195, AC006390, AC007327, AF235093, AC011742, AC008569, AC005488, AC007225, AL137060, AC010092, AL034420, AC020906, AC008716, AC010748, AC007690, AP000505, Z83843, AC005065, AL022315, AC008474, AL049761, AC005484, AL049636, AL118520, AC006077, AC005192, AE000658, AL356020, AC021016, AL136223, AB016897, AC023472, AP000210, AP000132, AL139383, AC004032, AC040163, AC007242, AC006061, AP000261, AP000949, AL353643, AC002045, Z85987, AF217413, AC027040, AC027040, AC027796, and AC027796.
HAGDQ42	33	702035	1 - 1512	15 - 1526	BE877473, BF970684, BE748570, BF980024, BF983256, AU118684, AL035740, BF035136, BF790498, AL572580, AV728273, BE620517, N21200, BE620914, BF590374, BG104800, AU151320, AA447823, AA864616, AA813354, BF033632, AA805669, BE748156, AI755042, AV717005, AW021089, AW105200, BF575231, AU145187,

					AV718330, AA829371, BE139070, BF435910, AI041821, AV734854, BE878737, AA767094, AA447639, AW029239, AA872365, BF691687, AA496973, AI886506, AA932874, W20261, BF979733, AA826930, AI672696, AL038768, AI038532, AI358553, BE568917, AA447189, T78200, AW002234, N27471, AA813928, AI281898, AL035739, N35061, AI750582, HI7763, AW768372, BE738971, AI250180, AA861319, AA084554, N45076, BF246715, AA625491, Z43102, BF351545, BF904068, R40807, BE765971, AV738720, BE765651, R42583, R43277, BE766126, BE785069, BE765418, BE765613, BE765879, BE765878, BE766511, R52491, BE766444, HI7648, BF791871, AV736862, AV717056, R52492, AI886983, AA490571, AA902899, BE708531, BF734574, AI580476, BF734672, AI866103, BE087028, N90685, Z46107, R34412, AA447673, AW196077, HI6532, T26419, AV726438, AI750581, AI149874, Z38263, BE769154, BF949574, AA448043, AI567344, AI903894, N75590, BE828025, BE172329, AI540450, F01910, BF241139, AA203320, R21494, AI344951, Z41981, AA461375, AI903843, AA322574, R13337, BG113643, AA092518, AW020381, AF161445, AK021683, AF151047, AF212245, and AL121694.
HBM/CJ42	34	713345	1 - 1723	15 - 1737	AV763804, AV700851, AV717615, AV700552, AI765451, AW467530, AV718709, BF510555, AW468273, AI674587, AI420431, AV682780, AW006869, AW192137, AI190626, AV646802, AI954636, AI655043, AI695965, BE242761, R19189,

HDPBQ71	35	116031 6	1 - 2298	15 - 2312	AA946590, AV689578, AV690953, AV684430, BF846122, BF904808, AU151003, BF432937, AI300427, AW860724, H66639, H69191, AR022348, AL137062, AC019060, U66083, AC003119, U91325, AC009134, AC004448, AC005544, AK022953, AF155912, AP000075, AL356739, AL121578, AB019441, AF011889, and AC010283. AL517702, AL535136, AL517701, BF966919, AW712906, BF310001, BE785105, BG023779, AW608043, AW959115, AW571652, BE546297, AV733133, BG164317, BF965688, AA910337, AW070547, AA630221, AA936329, AI077660, N66596, AA233825, BF769251, AW169158, BE896148, AW966447, AI092899, AI804163, BF966148, AI184325, AI400074, AW105140, AI038519, BE178803, AI243767, AI803580, AA49258, AI089365, AI969422, AI292304, AA971310, AV753091, AA233729, AI289889, AI335939, AI275621, AV748056, BF828492, AA451735, AA973548, HI9041, AW129980, BF791539, AW472838, H65681, AA478196, AA666224, BF940460, AI002830, AI374721, AI264277, H29405, BE930289, AA446666, R52737, N99048, F06358, AA233772, H11875, H65682, BF725919, R64291, R59440, AA812450, Z44951, BF825554, BE711465, F07390, AA093749, AI080343, R24935, R64256, AA878276, BF248328, AA081567, AA081513, R20695, D11945, AA249453, AW630557, AA331924, F07956, AI672272, AA383930, AA385881, R63983, AA865796, AI078076, AW964475, AA448551, BF878091, BF091153, T97552, AA453075, BE937893,
---------	----	-------------	----------	-----------	--

					<p>N98627, T53666, BF836787, R64175, R63901, AA319203, AA424168, BF791814, BG001790, H11513, BF376043, W30696, BE739183, BF086020, BF376012, AW189731, BF769066, AA383577, AW388471, AW388477, AW810765, AW388507, BF247577, AW810647, AW810736, AA092943, T97598, AW810677, AW627523, AW810964, AJ261898, BF216270, BF855391, AW810687, AJ221448, AI147974, AI611624, AA730133, AI377784, AI672529, BE551587, AI936568, BF115500, BE466653, AW303619, AW388498, BF382656, BF751597, AJ962331, AW006254, AI351767, AI655026, AA884783, AL119457, AL119324, AL134524, AW971745, BE161864, AW149892, AL119396, AL119443, AW804686, AW392670, AF212247, AC007533, AX030435, AJ251859, AX046357, AB026436, AR060234, AR080280, AR069079, A81671, AR054110, AR066494, and AJ279014.</p>
HCEJG71	36	715592	1 - 2221	15 - 2235	<p>AL516212, AL516213, BE277026, BE874995, BG254851, BF337522, BE782438, AW957186, BE908068, BG111021, BE313308, BE304728, BE791759, BG165174, BE276912, BE294077, BE390036, AI608789, BE387937, BE391028, AW845399, BG036397, BF593816, AW952842, BG032631, AA411541, AW150272, BE389434, AI991149, BF939786, BF205750, BF725012, AW962210, AW473868, AI934755, AI763268, AI090866, AA464314, AI277953, AI624414, AW514028, AI954973, BE908223, AI167471, BE390099, W96217, BG027342, AI675874, AA604659,</p>

					<p>AW501761, W93790, AW016493, AA813712, AW082293, AV746836, AI159950, AI038163, AW957189, AA834939, BF766716, AI279359, AW845401, BE700939, AA297727, AW004853, AA297726, AA550765, H91883, AA456486, W96311, BE818916, T16058, BE772045, T36190, AA412342, AA382771, AA412452, AA781072, AA377166, AA344749, Z38920, AA369026, AA326408, AA341054, R41523, AI435982, AW016126, R18534, AA477934, AA664345, AI144001, AA722624, AA628669, W93789, Z42768, D45660, BF095971, T52089, BE777658, BE714008, H06991, BE844048, AL080162, AF097484, AF056183, AK000536, AC005089, AF097485, AK026529, AF097523, AC005089, and AC005089.</p>
HELHL48	37	696945	1 - 2957	15 - 2971	<p>AL529435, AL524123, AL524122, BF312538, AU129727, BG164871, BF348048, AU120482, BG167168, BE733600, BE876571, BE875645, BE296592, BE901138, BF343028, BF308771, BF345199, BF308189, BE336871, BG028125, BF115264, BG116986, BG249650, BE903726, AV728373, AW007132, BG121227, BF206051, AW963600, BF347698, AU151806, BE294229, AW303548, AW411067, AW967356, AW411066, AU128086, AA100522, AI867409, AU137055, AI378902, W28880, AW752755, BF308950, AW751506, AI421175, BG180673, AW590377, BF001722, AI872412, BF924126, AA180518, AI373035, AW179322, AI401197, R24305, AW178945, AW150193, AA209515, AA564224, AI370802, AI984047, BF438508, AA293441,</p>



				AA088551, AI758667, AI275100, AW996404, AW007984, AI800710, AU150189, AI361596, AU150403, AA669849, BF432420, AI559326, AU146534, AA514455, AW513096, N31325, BF754347, AW896670, BE789836, AI299591, AI272929, AI089779, BE008621, AI912569, AI276235, AI283742, BF939706, AA508685, AA180517, AW169281, AI688823, AI310354, AW007978, AI359948, AA148446, AA292742, AA478976, AI041725, BE790438, AA292741, AI221864, AA157827, AA552023, AA112746, AA513477, AA232508, AA148445, AI493536, BE206110, N26490, BE147464, AA293508, T84545, BE093924, BF884193, AU157002, F12444, AI348568, D31225, N47540, AI269318, BE147790, AA088385, T74066, AA053180, H30187, AA654655, BE154572, AW579667, T88004, T35342, AI074255, AW571550, BG055222, AW579684, Z39831, BF434566, AW390755, AV698355, Z43770, AV685886, BE463536, AW270979, AW378596, AW514887, T31997, AA863225, BE296813, H04167, AI246176, AA363514, AA513359, AA477913, T34879, BF347090, BF438580, AA151938, AV684774, AA336395, AA492462, AW009840, AA053627, BF906710, T87910, AI470954, BF814719, BF593969, T64888, AA136495, AA179793, H08606, AA907036, F10066, AA503814, R22025, AW577064, BF749344, AA298224, AA339096, AA079476, T35287, AA936508, AI620090, AA079475, AW378971, T39180, F08643, H08605, AA372556, AA995437, BE294737, AW300420, AA496416, R01535, BE311798,

					AA345134, R44902, R22078, F02150, R49987, BE840622, T35182, AA369833, AI244019, BF947140, R00876, BE840609, BE294732, H04166, AA887342, BE143234, N47539, AW374684, T31964, AW178632, AA635427, AA188708, AW582129, R47850, AA152055, BF476766, AW291610, AA369871, AW451289, BE467357, AI630981, AW134630, BE763447, AI383035, BG255592, T58576, AA248989, AK001112, AL161962, AK001524, AF151847, AK001424, AL034405, T58537, and AA232607.
HISAQ04	38	589960	1 - 1149	15 - 1163	AV694051, BG178802, AV700042, AI635871, AW105519, AV763026, AV763058, AW502949, AI568849, AI368745, AI049709, AI090377, BG029528, AW962006, AA551390, AI683131, AW151541, AA525331, BF673854, AL079734, AV738383, BF821955, AA598443, AW275432, AV761486, AA515728, AA502532, AA831426, AV764383, AI804519, AI912401, AV759632, AI821467, AA736557, AW973992, AW833047, AL022324, AC003982, AL359382, AC016637, AL160313, AC011495, AC005695, AC009004, AL022327, AC005089, AL031281, AF109907, Z85987, AC004644, Z86090, AL138787, AL139095, AC003029, AC004596, AL049795, AC005081, AL035461, AC006111, AI295844, AP000553, AL161646, AL139343, AC003002, Z84480, AL022326, AL034548, AL121753, AC004846, AC006536, AC008521, AL359828, AC005726, AC004590, AC005004,

				AC011465, AC004531, AC009228, AC012076, Z82172, AP001207, AC024239, AL159997, AP000544, AC015968, AL133163, AC006530, AL121751, AL035455, U62293, AL391684, AC005064, U63721, AL021391, AC011479, AL021937, AC004583, AC004542, AC008474, AC009403, AC008543, AF111168, AC004983, AC022206, AL137853, AL079340, AL031589, AL132773, AC005378, AC020550, AL021394, AL138725, AC002302, AL031295, AC008623, AL135978, AC011510, AC073316, AP002085, AL133453, AC016543, AC011484, AC005620, AC009333, AL121601, AC004890, AC004938, AL158040, AL158841, AC006160, AC004797, AL049829, AL034372, AC005280, Z98036, AC010363, AC011811, AL118501, AP001717, Z99716, AC003043, AL023553, AC004674, AC004224, AC007919, AC027319, AC020913, Z98742, U47924, AL049761, AL022313, AD000813, AC005512, AL030998, AC004685, AF305941, AL358777, AC004840, AC016898, AC002365, AC005480, AL136139, AL031311, AC004921, AC005274, L40817, AP001679, AC004383, AC006023, Z93023, AC020904, AL136418, AC006251, AL050309, AL031431, AC002425, AC007384, AC005049, AC006449, AF001548, AC005052, AL022323, AC007029, AC008764, AC004447, AL139100, AL137783, AC004824, AC005531, AC020552, AC004854, AL033529, AC005091, D83989, AC009464, U07562,

					AC004777, AC005874, AF134471, AL137100, AC009516, AC007954, AC006312, AL136097, AL021918, AL049780, Z85996, AC009892, AC005701, AL357497, AC005924, AC011500, AC007200, Z98044, AL137012, AC005778, AJ400877, AC021863, AL121890, AC011444, AP000244, AC005058, AL035699, AP002898, AC008687, AL121774, AP001694, AL160231, AC020916, AC009314, AC005913, AC011462, AL031005, AC004000, AC004876, AC087094, Z97989, AC009244, AC007739, AL031727, AC018644, AC004922, AL109935, AC000085, AL137797, AL136304, AL080243, AC005484, AC005921, AJ251973, AL133244, AL121891, AL096712, AL136109, U91323, AL163279, AC008685, AC017006, AC005566, AL022324, AL022324, and AL022324.
HJACB89	39	689899	1 - 1918	15 - 1932	BE902912, BE902594, BG105130, BE908526, BG113157, AW361313, BE328831, AL040909, BF130137, AW043726, AI871093, W94722, AI654017, AI857485, AA609172, AI610359, AW019869, AA922082, AI363492, AA833529, R35261, AA737909, AA826460, AI497959, BF881634, W24732, AA039350, BF248109, AI536808, R50932, AA039240, AA331160, AI686320, AA310841, N57831, AW088881, AA588757, AI364550, BE902668, AI685789, AA337988, BF090955, BF109505, AI184432, AJ914850, AI217275, AI468096, AW401412, BG001512, BE936756, AC019054, and AC013356.
HTECC05	40	666743	1 - 867	15 - 881	AI040972, AI806582, AA437009, AA442839, AA759268, AI214390, AI799076, AA918443,

HBJLF01	41	732111	1 - 1918	15 - 1932	AW195596, AA910234, and AC040950. BG261130, BG121213, BF347966, BF796462, BE899286, R17115, AI123525, AI697325, BE783654, AW402585, AA032055, BF724098, AA031919, AW402594, AW402872, AW026287, W89010, AI926967, W95778, BF887406, AI376419, BF381332, BF507805, BF888120, AA233002, AI669291, AI963299, BF744292, BF907549, BF907541, AA954836, BF888127, AI768850, AA768759, BF888128, AA232951, BF744299, AW090314, AI571824, BF888074, N73038, AA480645, N53675, AA886377, BF888119, AA535561, AI864506, BF799491, AI217778, N51612, BF381336, N53906, BE819619, AI806785, BF744934, W95735, BG251027, BF381311, AI674508, AA016130, AA743705, AA917873, AA649797, BF887394, AA631017, BF907590, AI480218, AW302053, BE139664, Z39059, H86222, AA954334, AA456896, AI244571, AA015836, AI341715, AA485019, AI078627, AI015866, AA827439, BF745018, AW271993, AA954612, AW001670, AK000208, and AC083866.
HBXGP60	42	566892	1 - 1150	15 - 1164	BF671784, BE336052, AI913628, AU149885, AI680075, AW054875, BF512779, BF509344, AI373323, AW473443, AI953258, AW662614, BF038439, AI565458, AI651053, AA643721, AI224511, AI950680, H16805, F02963, AI697019, AI698350, AI934370, AW007591, AI700400, AA992991, AI917570, H16915, BF447312, AI912227, AA601933, BE019300, F03939, R93327, BE774158, T09346, BE563281, T09490, BE161378, BE161373, AK001383, AB046846,

HCE5B20	43	544507	1 - 1091	15 - 1105	AC026942, and AC026942. AW275464, AW079718, AW275556, AC025779, and AC018883.
HCMSQ56	44	740781	1 - 1248	15 - 1262	AI243049, AA778231, and AI248811.
HCNAH57	45	694610	1 - 503	15 - 517	AA327204, BF764474, BF764476, AW847311, AW847327, AW847328, AW847319, AA613739, AW022897, AA548890, AA433996, AA284871, BF676981, AI267161, AV705299, BF874758, AI369580, AI254913, AA659232, AI311684, AL042853, AW843301, AL134242, AA766310, AW963750, AI433008, BG029528, BG222337, AV756491, BG222576, AW369785, AA219018, AI873990, AA478355, BE907585, AW084246, BG115537, BF974349, BE175939, BF347740, BF347791, AI311234, BF030591, BF343686, AA449997, AW303196, AA584733, BE154678, BF874773, BF854223, BF675251, AA719292, AI924948, BF965290, AI673336, AA577824, AW858127, BE277210, AA631517, AW022655, AV711465, BE276480, BF725029, AI343233, AI249880, BF846505, AA469400, AA100718, AV701507, AA601202, AW301350, AL038606, BE159616, AV733830, AA601125, BF857083, AI732677, AI732710, AA584125, BE066105, AA167055, AA279421, BE066002, AW796784, AV764255, BE409047, AV733029, BF342223, AL048135, BF828577, BE902562, BF337291, AC006333, U82670, AP001672, AC087225, AC005999, AC004552, AL161663, AF042091, AC020750, AL096699, AL163282, AC018833,

				AC010223, AC087092, AL355916, AP001671, A1400877, AL162414, AL121601, AC022404, AC011450, AC002404, AC004972, AL161804, AL021026, AL035423, AC009086, AC008474, AC018764, AP001675, AL159977, AC007919, AC008162, AL121657, AF117829, AL163201, AC008739, AL031681, AC007253, AL352979, Z76735, AL022574, AB020862, AC006464, AL390738, AL137016, AL133480, AC026881, AC008738, D84394, AL096770, AP001666, AC002464, AC007040, AC027644, AL031311, AC010201, AF088219, Z98046, AC008008, AP001607, AC004895, Z95114, AC006039, AL356108, AL353700, AC009530, AC005341, AC004933, AL138956, AC007486, AF067844, AL353573, AL357752, Z95126, AC009481, AP002529, AL391354, Z93019, AC006028, AC007021, AC004066, AL360227, AC020550, AL049629, AL031274, AC008892, AC062020, AC004675, AC005000, Z94801, AC024167, AC004087, AC006525, AC005670, AL391259, AP001669, AC003950, AC007097, AC006121, AL135926, AL121774, AL135932, AC004159, AL049641, AL008629, AC005680, AL391595, AC002407, AL136418, AC002457, AC000119, AC022596, AF111167, AC005820, AC009155, AL160231, AC023798, AC003029, AC008772, AP001699, AC023511, AC005216, AC007312, AC010200, AC008115, AC006374, AC005028, AL161905, AL135936, AL354653, AC004125,

					AC009247, and AC022432.
HCUEP91	46	610610	1 - 844	15 - 858	
HDPCJ91	47	740748	1 - 6093	15 - 6107	AU119059, AW959367, BF792861, BF672087, BE439439, BE717153, BE770928, BE718895, AW971539, AL079949, BE770941, BF687684, BF132755, BF727151, BG009815, AI703121, AI066742, BE968461, BE717019, AW444843, W61007, AI949993, AW502324, AI150343, AI859085, AA393478, AW467411, BF515251, BF063545, BE717046, BE042969, BE673935, AU154204, AA292253, AA838717, AU145486, AI273190, AW512776, BF727150, AI084372, AI597583, AI457829, H99255, AW474793, BE327577, AI697937, AI167388, AI684736, W69563, W31042, AW753588, N98496, AI307397, AW613687, AW241267, BF198110, W60918, AA291214, AW316965, BF090819, AA988341, AA908177, AA043254, AA651802, AA502341, BE536255, AA043612, BF431421, AI261626, BF214133, AA972952, AI334810, R80993, AI539739, D62886, AI611313, N28297, H99484, AI825223, AW938439, T65655, AI221607, AA169878, AA435697, AA262010, W69419, F11961, T34633, AI873428, AI457907, BF103809, T65584, AI695552, AA126467, AA641749, AW882312, N52582, BG149944, BE669976, D57676, AA169566, AA126647, F09610, AA446424, R78978, AA291524, D62733, T15751, AA169579, AA628830, AI796712, C18687, AA649257, AI431924, BE763704, AW374026, AV746759, AA091017, RI3144, D79785, BF589508, R40624, R78884, AA250810, T20017,



				AA747613, BF725884, BF806370, AI733856, BF832074, AI635440, BF827469, AW504299, AI683131, AI291823, AI732789, AA236703, AI251034, AI355587, BE139139, AI336054, AI312790, AI250552, AW963463, BG222875, AI039809, AI223626, BF725844, AI284543, AI251284, AI251203, AW268329, AI254770, AA602906, AW673941, AV764259, AV647070, AI569086, AW303098, AA524800, AI249886, AI251241, AW474921, AV737641, BE042006, AI082510, AW971342, AW088049, AW068007, AK001067, AX018002, AX017863, AF162853, AC007688, AP001718, AL163281, AC009134, AL117336, AL359382, AL121890, AC007540, AC008651, AL031388, AC006013, AC018764, AC005747, AC002072, AC007792, Z82203, AC004593, AC068799, AL121656, AF020503, Z83822, AC005874, AF134471, AC004752, AL023575, AC006021, AC004638, AL161670, AL117377, AL050335, AC002287, AL139187, AL137061, AL031132, AP001726, AC007225, AC004953, AL137783, AP000696, AP001712, AC019187, AL355365, AL021395, AP001706, AL031273, AC017100, AP001694, AC020917, AC007639, AC009333, AC015541, AC005538, Z82244, Z83845, AC016831, AC009505, AC004949, AC004965, AC005358, AC007388, AC007462, AC006483, AL356244, AC002368, AC026162, AC020741, AL096814, AL390755, AC005514, AC008474, AC007151, AC008066, AC004032, AL034405, AL442064, AC019046.

				AC006115, AL138725, AL163209, AP001705, AL138755, AC003950, AC011331, AC002367, AC022308, AL137780, AL035415, AL035697, AP001729, AP001674, AL034549, AF134726, AF130342, AL163249, AC004905, AC004891, AC008812, AC005274, AL133255, AC010271, Z83826, AC006211, AL031228, AF001549, AC003012, AC004383, AL354680, AC004913, AC009263, AC002476, Z97353, AL445472, AC008738, AP000014, AC016673, AC005803, AC022336, AL158206, AC006430, AC006345, AC011464, AC016716, AC005703, AF168787, AP000563, AP001688, AC004885, AP001619, AP000236, AC005939, AL133355, AC012000, AL133387, AP001666, AF124730, AC012502, AC002365, AL133391, AC006120, AL138997, AL133215, AB023048, AC005988, AL360078, AC018731, AC009044, AL138836, AL031846, Z73417, AL133551, AC010722, AC004673, AC006288, AC004491, AL136979, AL022334, AL031658, AL031776, AL445189, AC006239, AC006334, AC002565, AC004382, AC009518, AC022206, AC020906, AC002331, AC006327, AF243527, AL157818, AC007542, AC006450, AF064858, AC002299, AC005751, AL022329, AP000697, AL121653, AC003670, AC008551, AC006333, AC017002, AC002073, AL133246, AC069298, AJ229041, AC004605, AL023807, AL121754, Z97055, AC005821, AL161938, AL163303, AC006960, AC005146, Z77249, AC007685, AL138976,

					AC004895, AF003626, AP001745, AC004929, AC005562, AP000133, AP000211, AC022311, AC005011, Z98949, Z98304, AC018755, AL135924, AC004388, AC004882, AC078899, AC004967, AC004867, AC003010, U91321, AL079342, AC004263, AC005049, AC006236, and AC003667.
HDPGK25	48	704067	1 - 689	15 - 703	AW976171, BG258661, AA427627, AA811193, AI275905, H20137, AI384044, AI339568, AI739227, AI923644, AI970737, H39189, H45408, AW130654, BF059008, AI659951, AI739226, AI142039, AI394459, AA968938, AI269770, AI392978, AA969916, AI364323, AI378436, AW137018, H46909, AW615186, AI356177, BE747585, BE898748, AA714852, AI934509, BF763404, AV745344, AI000835, BF877861, and AK025886.
HE2DY70	49	722217	1 - 625	15 - 639	AI983739, AI093491, BE464707, AA169811, AA232650, AA609946, AW023590, AW163464, BG260037, AW087445, AL515047, BE785868, BF680131, BE045182, BG257535, AI344817, AV712673, AW071417, BG179993, BG110517, AI345746, AI251205, AA830821, AV725055, BF726237, BF342070, BF792961, AI308032, BF344652, AL514129, AV711509, AV715560, AI802542, BE964614, AL079963, BG163618, BF726183, AI969641, BF970731, BG164371, BE910703, BF037097, BG104782, AW827289, AW103371, AL120853, AL110306, BF885081, AI929108, BE964876, AI815855, BF904180, BF856052, BE965432, BF792469, AI340603, AL514529, AL514357, BG035511, AI521012, AL036802, AI344785, AV681719, AI590120, BE966643,

					AW935969, BF793309, AV682051, BE047852, BE620084, AI620517, BF341801, BF969494, AA225339, AI909666, AL043981, AL037454, BG109221, BG109270, BE874133, BG110684, BG120816, BF904258, AA427700, BE018334, AV654624, AV764282, BE965014, BG036846, BE048071, AI364788, BE789764, AI619502, BE964497, BF816811, AV706744, BF970768, AV703585, AL119863, BF526407, BF037484, AV660662, AI537677, BG168549, AW082594, BG180996, AI627880, AI471361, AV764180, AL080046, AI569583, AI400725, AW999049, BG261093, BF526020, BG121222, BF133418, AW026882, AI866741, AI536685, BF527014, BF812938, AL036804, AV682289, AI623682, AW268220, AV714485, BE964593, AI349645, BE905394, BE619280, AI433976, AL119791, AV686346, AI497733, AI433157, BE964460, AI619716, AW167222, AI702073, BF910810, BG180046, AV764059, BF812961, BF812960, AA640779, BF344691, AW978080, BG179633, AI348897, AL045500, AI699865, AA572758, BE964636, BG114104, BF921291, AW075305, AI612913, AL041772, AI513943, BE965621, AI340519, BG058398, AI921248, BE965481, BE904902, BE891101, AL121270, AI922901, AI282326, BF904265, BG249582, BG252914, BG105099, BF885675, AI783504, AA814407, BE879906, AI620284, AV681647, AI358701, BE965067, BG168185, AW087901, AW238730, BG168696, AV733470, AL036274, AL041150, BG109857, BG114432, AW827103, BF753056, F37471, BE963035.

				BG254754, BF970449, BF343172, BE964700, BF882343, BE621256, AW084219, AI952920, AW103886, AI500077, BE781369, AV758087, AI933785, AI628217, AI697324, BF038804, AI812015, N80094, AI633419, AV746964, BG170430, AI554218, AW151785, AI498579, BF968558, AI866002, AI431909, BF914091, BF970990, AI828731, AW079159, BE875442, AI696626, AI274759, AI628833, AI514935, BE964512, AI269862, BF795712, AI432736, BF817402, AW168031, AI687065, AI514075, AI612759, AW089179, AI249962, AI815232, AV703042, AI610645, BF816785, AW151729, BE881155, BF816455, AI867042, AI049452, AI122050, AF113694, S78214, AF116631, I89947, AL050393, AF104032, AF090903, A08916, AF130104, AB041801, I48979, AI110221, AF130082, AF100931, AB047615, Y09972, AI133606, AI133080, AI117460, AF111851, I48978, AL080137, AF090934, AK024588, AK026086, AK026927, AF116691, I89931, X84990, AL359618, AL080124, AF078844, AF116688, AK027096, AF119875, AF113691, AF090896, AF113690, AF113677, AI133075, S68736, AI133565, AR038969, E03348, AL049430, AK025084, AK026600, AK026592, AL359601, AL049382, E05822, AX019230, AI137459, AK026784, AF116654, AI162006, AF130105, AI133557, AL050149, AF116646, AF119899, AK026528, AK000083, AF119878, AK026045, AI359596, AK026608, AF116602, AI117435, AI122121, AI137526, AK024538, AF175983, AL050277, A08913, AI137557, Y11587,

					AFI13013, AL442082, AL122093, AL389982, AX019229, AF116644, AF017437, AF118070, AL157431, AF090901, AL122110, Y11254, AL133640, AK026744, AF183393, AL117457, AB048953, AK026480, AL122111, AK026741, AK026452, AR079032, AF125949, AL050146, AF097996, AJ000937, AL049314, AF242189, AF130059, AF146568, U42766, AL117432, AF113019, AF113689, AK025339, AK025491, AR059958, AF130075, AF116649, AL133016, AF158248, AL389939, AB034701, A08910, AL162083, AJ299431, A08909, AL110197, AK025414, AK026630, AK025632, AF017152, AF116682, AL050116, AF130077, A03736, AF106862, AL389978, AB047887, Z72491, AF119909, Z82022, AL137538, AF207829, AB049758, AL050108, AF111847, AL133113, AR011880, AK000618, Y16645, AR087170, AL390154, E02349, AR070212, AF138861, AK026865, AB019565, AF090943, A65341, AL110196, AL080074, AK025958, L31396, AL096744, AK000323, L31397, AR013797, AK026597, AL359583, AL117583, AF130092, AF130087, AF113676, AL442072, AL353940, X63574, AK000652, AK027113, AB052191, AF218014, AB048954, AJ242859, AK025092, AL122098, AF219137, AK025383, AK026855, AF116639, AL050138, AK026534, AF111112, AL162002, AX026824, AX026823, A58524, A58523, AL049466, I03321, AL133093, AF132205, X87582, AL049283, Y07905, AF113699, AK027116, AX006092, U00763, AL080060, AL080127, AF090900, AK025772, AL133072,

					AF314091, AK024524, AF091084, AR038854, AX046603, AK000445, AK000432, AK026506, AK027164, E07108, AL162062, AF057300, AF057299, AF081197, AF119337, AL359941, AL137429, AL137556, AL137283, AF130100, AB052200, U96683, AK025708, AL133014, AL137527, A12297, AL390167, S61953, AL133104, AK027114, AF118064, AL049938, AB048964, AL050024, AK025484, U67958, AF116610, AF119871, AP001849, and AC009818.
HE2NV57	50	740750	1 - 853	15 - 867	C05927, R72949, AA327984, AC016673, AC004929, AC058786, AC016716, AC008066, AC003969, AC024082, AC002302, AC013246, AC011490, AL158064, Z98743, AC020610, AF195953, AC016910, AF110520, AL359394, AC005227, AC003692, AC002300, AL157838, AL031737, AL050335, AC007690, AF220294, AC004541, AL022401, AL008583, AC005868, AL133383, AC006070, AC006211, AC012526, AC009424, AL391686, AP001684, AC006013, AL158817, AL035685, AC006134, AC020906, AC015983, AF188024, AL357519, AC005081, AC005886, AB020875, AJ011930, AL163300, AP000952, AL133387, AP000953, AC025765, AC004891, AC003060, AL355792, AL163280, AL109662, AC010206, AC012302, AL049843, AC009362, AC005015, AL096791, AC007942, AC002487, AC005835, AC010726, AC005344, AC022363, AC009498, AP001699, AC008064, AL357507, AP001670, AC012147, AL137061, AC004585,

HEIBR16	51	703243	1 - 1555	15 - 1569	AC004963, AL445243, AL109618, Z97195, AC005146, AC007151, AF130342, AL138976, AL023513, and AX015907. AW661837, AA127395, D62246, BF838051, AA363498, BF673053, BF838050, N68223, AA608520, BF878696, AW238127, AA570224, AI635819, W45298, AW949001, BF932686, BE063025, W45283, BE063030, BF815072, F31654, AI610607, AI640411, AA568947, BE049229, BF856556, AI679442, AI679952, BF857619, AA665645, AV656064, AW949012, AA653612, F27410, AV740009, AI889440, AI540408, AV720211, BF850690, AA605266, BF844769, AW261996, AI885488, AA494090, AA626402, AW020088, AA486970, AW167154, AI809818, AA745356, AI634601, BE162124, AW271917, BE179216, AI859280, AU158549, AW148386, AW971243, BE674880, AA661948, AA665330, AA649148, D82461, F31619, AI565245, AI932902, AA708213, AL021807, AL132718, AL132653, AP001417, AP000160, AL122023, AP000018, AC008122, AP001730, AL078475, AL050302, AC006026, AC004964, AC008745, AL163203, AC002115, AL118524, AC004098, AC006387, AL033529, AL163210, AC011455, Z98048, AC007637, AL021408, AC021019, AC005668, AC011497, AC010150, U85195, AL135839, AL445490, AL033378, AF258547, AE000658, AL133545, AL031666, AC011540, AC002350, AC007881, AC007954, AC022407, AP001746, AB020878, AC007055, AC003029, AL158089,
---------	----	--------	----------	-----------	---



					AL391384, AL352979, X87344, AL445466, AC083875, AL161938, AF084941, AL008723, AC011604, AL359238, AC018448, AC004066, AC068948, AL035671, AL050335, AC003954, AC010620, AC021016, AC005666, AL135927, AC007227, AC008636, AC008521, AL022717, AC019171, AL356782, AC003106, AL034349, AL035587, AC007263, AC010422, AC004671, AC005899, AC005406, AC004686, AF008243, Z94801, AL031734, AF015416, AL158040, AL354993, AC005670, AL121891, AC005000, AC005971, AL137230, AC009086, AL137853, AC006211, AC002985, AC005209, AL445196, AL109946, AC011494, AC006500, AC015968, AC006353, Z85999, AC006017, AC018832, AC005399, AC010267, U80017, AC005411, AC000385, AC003041, AC011479, Z97630, AC004881, AC008770, AF111168, AL133406, AL139188, AC008733, AL357519, AP001624, AC010326, AC006050, AC005479, AL136969, AC010598, AC008831, AC027319, AL022320, AC024561, AC020906, AP001728, AL121886, AL035361, Z99128, AL031681, AC007057, AL049872, AC004491, AL031662, AC005324, AC004859, AL357150, AP001732, AC006045, AC022137, AL049840, AP001037, AC010457, AC069254, AC069254, AC069254, AC021617, and AC021617.
HFXDG13	52	657390	1 - 1182	15 - 1196	BF338151, BG120864, BF869369, AW893984, AV649111, AW967373, AV648643, AV731739, BE063143,

					AV732052, BE150807, BF875669, AW964353, AA847690, AW992839, AW391396, AA931987, AV648844, BE169205, AW969095, AI026925, AA831680, BF749712, AW975190, AW207719, BF433821, BF883025, BE065321, AI860789, AI198511, AL120314, AA595827, AA205322, AA147639, BE972284, AU156961, BF951370, N29555, BE674204, AI114511, AA565909, AA504616, AW896115, AA632808, BF735857, AA435704, BE080185, BF223671, AA613886, BF923208, AI805822, AI080461, AA398802, AW962969, AI660010, AA847407, BF110238, BE083044, BE644710, AC021058, AK001116, AL024507, AC023480, AC024167, AP002023, AL158050, AL117339, AL163210, AF235093, AL356098, AC016673, AC005399, AC007317, AL122057, AL049821, AC011310, AF280107, AC004026, AL109662, AC002385, AL023875, AL161666, AC010395, AC027329, AC007444, AL133417, AC010202, AC022268, AL022401, AL034347, AC004745, AC003686, AL022144, AC061958, AC009332, AC009264, AC074191, AL023713, AL121757, AL031772, AC083875, AC006120, AC079844, AL035427, AC018360, AC005019, AC004051, AC006479, AL133214, AC002454, AL355345, AC009301, AC002065, AL353667, AC011088, AC004823, AL035661, AC024094, AL354750, AL157830, AL356022, AC017004, AL355871, AL035089, AJ271735, AL445068, AC073539, AC006239,

AL136295, AL096801, AP002531, AB042235, AF002997, AC020550, AL035397, AL136296, AL138900, AL109800, AC000119, AL136520, AL035695, AL360272, AL135936, AL135902, AL359846, AC003106, AC004083, AP001671, AC010176, AC000125, AC010369, AL109761, AL109764, AF013593, AC007239, AP000379, AF088219, AL353788, AL355390, AL157384, AL132639, AL031116, AC005050, AL035401, AF235098, AC009506, AC007567, AL161743, AL157791, AL356115, AC009232, AL021307, AC068770, AC005588, U82828, AL356057, AL139123, AC009480, AC012611, AL079303, AL022345, AL353582, Z82899, AL354977, AC008407, AC005101, AL137026, AC009405, AC005176, AC004842, AL117191, AL035262, Z68871, AC005201, AC000389, AL133284, AC004931, AL121652, AC016689, AL133325, AC004010, AL136308, AL357153, AP001346, AC005191, AF241733, AF282856, AL121927, AL138702, AL391666, AL158832, AL356244, AL121582, AC078937, AL031599, AC007090, AC073323, AC002357, AC019183, AL121694, AC009517, AC012558, AC021070, AL121977, AC008070, AC024576, AC006265, AC002079, AC007690, AF188025, AF196972, AC008430, AP001674, AP001538, AF245226, AC007158, AC005509, AL096800, AC069313, AC008174, AC022224, AC006427, AL132774, AC003687, AC016716, Z71182, and AL109942.					
AA483223, AA552843, AV762050, BF991286, AA623002, BF827410,	53	634161	1 - 931	15 - 945	
HFXY27					

					AW193265, AI434706, AV759204, BE350475, AI270117, AV760937, BF217299, AV710066, AA610493, AI350211, AL041690, BF475381, AV764241, AV764307, AW673241, AV762139, AI192631, AA552856, AV763540, BF676536, AA468131, AV682003, AI368256, AI345157, AA649705, AI345518, AV760774, AA480772, AA521323, AI338433, AA644538, AL037683, AA577906, AA613227, AA503475, AW270382, AI355206, AW021583, AV759274, AA521399, AV761155, AA492166, AV735495, AI431303, AA490183, AW088846, AF330238, AA857486, AA493621, AV759382, AW438643, AA579362, AI610159, AA525790, AA507824, AV742057, AV763255, W60061, AV761786, AA644551, AI254615, AV735370, AW872676, AA649642, AA652057, AA984708, AA579736, AA682912, AA525824, AW238583, AW977303, AA470969, AI963720, AV734666, AV760624, AV762826, AA970213, AA908422, AI613280, BG150790, AV760777, AA834755, AW513362, BF668217, AA657535, AV761925, AA357937, AV730301, AV763971, AA491831, AI688846, AW731867, BE502107, AW517737, AV762558, AW238542, AA766151, AA862173, AA350859, AI619997, AA501418, AV702857, AA601355, AI634384, AF001552, AL122015, AL034405, AL035699, AL365315, AC010269, AL022163, AL031661, AC005084, D83989, X55926, X54181, U57007, X54178, U18391, U18392, U57006,

					U18394, X55925, U57005, X54179, I51997, X75335, X55932, AC020728, U18390, AC004887, M37551, X54175, U57009, U18395, AC006511, U18393, X54176, U57008, AC005521, AC004662, AC004525, X55923, AL136090, Z22650, X54177, AL13332, AP001677, U18400, AC009481, U18396, AL121891, U18399, U57004, AP001696, AC002529, AC005740, AL049745, AC006287, AC009498, AC008168, AC004972, AL031275, AL139350, AL050325, AC005913, AC010748, AL132777, AL109755, AL157830, AC002303, AC009508, L47228, Z77249, AP000501, AC006376, AL049563, X55927, U18398, AC005274, U18387, AL049539, AL138721, X55930, AL023281, AC009802, AC027345, AC002115, AC007272, AC008109, AL355578, AC018637, AL049713, AC004622, AP001700, AC005158, AF117829, AL132639, AL163278, X74558, AC007934, U67831, AC022335, AC022407, AL133415, AC008134, AL354751, AC011310, AC005544, AC005297, AC003010, AC004491, AC002128, AC009311, AP001727, AL163248, AL359012, AL022162, AJ011930, AL050333, AC002091, AJ006995, AC006128, AP002532, AC007970, AP000555, AL138759, AC012315, AC007179, AF149773, AL049613, AC008071, AC007132, Z72001, AC004806, AL133344, AF195953, AC004865, Z92844, AC004047, AC006375, AL133472, AL031390, AC008268, AP001683, AC008482, AC003983, AC017004, U67829, AL109823, AD000090, AP000472, AP002026, AC016716,

					AL135786, AC005399, AL020994, AC020698, AF246928, Z94044, AF227510, AC008543, AF077058, AP000567, AL357141, AC024094, AC005250, AC008534, AC004066, AC005342, AC015971, AL355835, AL024507, AC002402, AP001680, AC008770, AL022726, AC009408, AC026398, AL161450, AL445465, Z98051, AC006036, AL022323, AL136980, AC007380, AC005400, AL121934, AP002898, AJ006996, U67827, AC004526, AL133417, U67828, AL034348, AL163202, AL354750, AC083861, AL158040, AC011890, AF015153, AL031431, AC073900, AC002412, AC006002, AL122020, AJ006998, AL031000, AC063976, AL034420, AC068713, AJ010598, Z75407, L29252, AL157903, AL356379, AC003962, AC006367, AL049762, AL355352, AC004223, AL109810, AF029308, and AL078582.
HHPEC09	54	695726	1 - 474	15 - 488	
HISAD54	55	740754	1 - 2846	15 - 2860	BE387604, BE386701, AW138815, AW170555, AA402189, AW964645, AA402043, AA426655, AA402659, H08552, AW025318, AI275121, AI760500, H09223, AW204890, AA132741, AI362705, H08551, AA631662, BF431834, H09165, R69556, BF379963, R85615, AA132648, AA402676, BE549179, H52666, R69424, AW779499, AI869911, H52667, AI557584, AA322657, T09320, BF756532, R58145, AL136293, AL136293, and AL136293.
HJBCY35	56	719729	1 - 1545	15 - 1559	AL518865, AL526445, AL518864, BF690211, BE795952, BG261247, BG122941, BE871131, BF342499, BF797882, BG034854, BE874386,

					BF684303, AW958340, BF055513, BE265238, BF055496, AL042954, AL044311, AW393087, BF590235, BE251517, BF688851, AW500006, BF750912, BF436031, BE207255, AI523943, AI809559, AW615714, AI088845, AI199469, AI088821, BE792741, AA707004, AI393362, AI859578, AA864359, AI359119, AI963339, AA259086, AW027379, AA186786, AA703021, AA305929, AA393356, BE729570, AI961726, AW274049, AI216448, AW503180, AW505339, AI015694, AA291342, AI049539, AW873566, AI092749, BE410341, AI817912, AI870620, H44330, AI366215, AA258242, R46300, R16949, AI744596, R54656, BE386449, BE410337, AI807057, AW081887, AL041401, H15972, BE710574, BE410414, BE535502, BE222788, AA398688, AW273864, AA404987, D59795, AA077661, BE047327, T10451, AI871075, D59810, AI368575, BF526818, AA962247, AA335735, AW000813, BF435172, AA188015, R75708, AA329264, BE713106, AI218840, AA329538, AA291343, AA826970, T35806, R10855, D59833, D59821, BE547124, D80231, AI080034, AA299767, BF203222, AI908002, AA973311, AW087244, BF920764, AI648592, D80329, BE537114, BF511965, D59677, W93021, AI919083, AA749327, R16895, R55419, AA354448, AA136776, R54853, R46205, D59561, AI969256, W51754, AW273865, R10856, AI452772, BF765954, R10335, BF858687, AA076725, BF955782, BF206768, BF310354, BF032473, C01203, AL050110, AB037861, and AL137358.

HKAEA19	57	721489	1 - 2050	15 - 2064	AU120021, BF982844, BG169037, BG034578, BF036852, BG257906, BF568991, BF034397, BF905903, BE873247, BE893899, BE871129, AW957258, BG171337, BF036222, AA746226, AA573750, BF241654, AA236296, AW161827, AU150270, AA100812, AI809272, BF572758, AV713641, AI814417, AA600756, AI435028, BF679650, AI952058, BG253263, BE565828, AI669150, BE565013, AW471028, BF439102, BF569093, AA812943, AU128660, AU157320, AI300864, AW026387, BF906228, AI459100, AW072665, AW007290, AI346638, AA664274, AW157692, AI499354, AU151173, AA126954, W94441, AI984523, AI243221, AW243843, AA127163, AW157153, AI686902, AA903712, AI301646, BE746831, AU135873, AA877280, BF905975, BF185758, AI377065, AI680057, AA721330, AA194102, AW084970, AI022296, AA693624, AI538995, T82203, AA722895, AI803272, AI827881, AU137800, AA219348, AI244836, BF855557, T57283, R53227, AU131888, AI445306, R85862, R84465, AA455731, AA447739, AI808020, AI079234, AI240429, AI270490, AA683509, BF196711, AW135701, AV654872, AA172009, BE280022, R52411, AU130432, BE75994, AI758507, BE870395, AW135133, BF568465, AW340772, BE311979, R53228, AA236230, BE893096, T90533, AW163123, AI282353, BF568684, AI364022, BF513976, BE928347, AA504085, BE780164, BF206624, AW339342, BE698049, AW467264, AA370946, AW967026, AA306000, R34900,
---------	----	--------	----------	-----------	--



HKGDL36	58	704088	1 - 1036	15 - 1050	<p>AI903187, R87773, AA931878, AI627596, T56598, AI632989, BF316539, T82202, AW207618, R49289, AA328743, AA453671, T83068, AW376775, BE312569, BF983061, N23184, AU146213, AI873742, F02007, AW376774, BE898186, BF818799, BF905385, Z38683, BG030212, AI047822, Z42488, W94256, U25896, AI694590, AW892280, AI376246, AW161261, AA081761, AW161371, AA081750, BF893952, F05758, AU152388, BF905361, BF905369, BF906220, BF808687, BF905827, BF905829, BF905826, BF906173, AI769338, BF366557, BF366575, BF908288, BF366406, BF366419, BF366620, AW947032, BF366436, BF366548, BF366507, BF366535, BF366659, BF366625, BE766445, BF366593, BF366600, BF366545, BF366657, BF366481, BF366415, BF908287, AW192397, AW059667, AK023085, AK002031, and AB032470.</p> <p>BF966686, BF969262, BE798423, BE383172, BG108317, BF438085, BF967072, BF724971, BF437374, BF525713, BE327726, BF725537, BF983368, BE045542, AI261620, AI628667, AI955247, BF966496, AI796185, AW024651, BE392518, AI365220, AI767645, BE551437, AW051507, AI199503, AI418919, BF724666, BF310167, BF310234, BF724972, AI039610, AW162506, AW138191, AI955309, BE673721, AI969138, AW583447, AI373491, AI696987, AW583390, AI952012, AW341037, BF526596, AI758216, BF438130, AW013963, AI955147, BE669440, AI768473, D61105, BF592013, AI355910, AI969092, AI423438, AI968975, AI479582, AI913491,</p>
---------	----	--------	----------	-----------	---

					AW027769, AW090177, H41372, AI927970, AW300071, AI400855, AI348277, AW771649, AI672352, AI991536, AI421291, BF739771, AW103643, AA894790, BE312863, BF197448, BF197412, AW000953, AW299323, BF724667, AA199635, D59847, AV748923, AI560270, AI498193, AI625846, AI493832, AW590037, AW583609, AW955700, AI702136, AA877175, AA757536, AW583672, D59877, AA706516, AW393735, D60795, D80419, AI302316, AI248555, D80214, D80684, AI927667, AI627691, AA989221, BE464388, D59878, BE218723, BF346124, AI985164, AW000934, AW001692, AI701771, D59848, D59725, AA873392, AA364835, BF431598, H92678, AW135417, AI589246, AW072965, AI916619, BF752892, BE964512, AL515163, AW022102, AI783861, AL513839, AA600801, BE621073, BE544111, BF815196, BF910849, BE963809, BF814409, BE784387, BF840099, BE963918, BG170109, BE613727, BE80341, BF814360, AW005029, BF921092, AV712606, AV681927, BE967251, BE964621, AI866741, AW059713, BG108334, BE536377, BF929585, AI254754, BF764538, AA824513, AW083804, AI539462, BF129016, AI446605, AL513741, AA830821, BE966699, AI924035, AI445976, BE875966, AI242248, BE885353, BE538466, AI620093, AI537643, AI358042, BE880697, AI683255, AI591412, AI591081, W81248, AI536910, BE964962, AW834325, AI864827, BE048026, AI872159, BE061389, BE964767, AI591057, AW073868, AI863256, AI690449, BE907440, AI884574,

					F35927, BE878032, BE965121, N95566, AV743128, AV706465, AI445588, BE899377, AI934000, AI280670, AI583578, AI627714, AI500039, AV708075, BE900603, BF752858, AW265004, AI623682, BF341610, AW079032, AI925736, AI252077, AI590787, AW025533, AI267185, BG105895, AL513789, F26535, AL048377, BE965527, BE967255, BE964799, AW946864, AI514167, AI627880, BE621140, AV710267, AI678302, AI926878, BE878028, AI633300, BF817402, BF753053, BE875407, BF752999, AI689614, AI624668, BE966390, AI811192, AI866002, F28295, BG260275, BE963286, BF753056, AI686631, AF181562, AF196971, AF181560, AF293356, AF181561, AK000212, AJ012582, AF185576, AF113690, AX014095, AK024601, AK026865, AK025491, U77594, AF200416, M27260, L13297, AL137557, U90884, AK000598, AL121656, AK025906, AF194030, AJ010277, AL157464, X95876, I30339, I30334, AF155148, AL080162, AF026008, AK027113, AF036941, AK026600, AL137556, AF065135, AK026164, AK026613, AF077051, I48978, AF087943, AF028823, AF112208, AL137665, A08910, AB031064, A08909, AL137547, AR075041, AF218034, AB049629, I17544, A08908, AK026590, AK026603, AL049347, E15569, AL389978, AF116644, AL049460, X06146, S77771, E04257, AX019230, AF225424, X93495, AB047904, I00734, AF022813, Y16645, A65340, AL137459, E00617, E00717, E00778, AF111847, AL333935, AX019229, AR011880,

				AF266204, AF244915, AL359622, AL049314, AB047941, AK025119, AF205861, AF158248, AL133568, AB029065, AK000432, M92439, AF010191, AL117648, AL137657, AF069506, AF119894, AL133081, A08913, AL080137, M79462, AK025410, AL390167, A18777, I89931, AF119337, AK026533, Y16258, AF090934, Y16257, E02756, Y16256, E15582, M96857, AL162062, AL136842, A93016, AR087170, AB019565, AF031903, AK024594, E03671, AL122050, AF132676, AF166267, AX005848, AX005804, AF061836, U87620, AR059883, AF113676, AF217991, AL389935, I08319, AR038854, M84133, AF260436, AL353625, X66975, AK024570, AK000450, AB016226, AK024533, AB048888, U00763, AL133645, AL359596, AK026741, AL117585, AB044547, U96683, AK000310, AF036268, AB049758, AL080074, AL442082, U42766, X72387, AL049339, AK026086, AB047897, U53505, I26207, AK025239, AL359623, A08912, AF116610, AL110225, AL122118, AF321617, A08911, AC025226, AK026649, AF271350, U01145, AK026045, AK000652, AF151076, AF188698, AL133062, AK000445, A08916, AF089818, AL137648, AL157483, AK027142, AF130082, AK000323, AK025517, AX027129, AL353956, AL050092, AL096751, U91329, AF081197, AF081195, U49908, AK025383, A08907, AL080060, A07588, AB049849, AL162008, AK024538, E04233, AF119896, AB047887, AB047623, AK027081, AK027164, AL122098, AK000655, AK000421, S69510,

					AFI30068, AL137284, AL049466, AL080148, S76508, AB034701, I89934, S78214, AK026591, AL137539, Y10655, AL122110, AK026542, AF130066, AF017437, AK027116, AL049300, AF097996, AL137298, AX046603, AL049283, AK026522, AF143723, AF118090, AL353957, AL122111, AL110197, AF110640, AK027146, U68233, I92592, AK025782, AF130077, I66342, AL133077, S79832, and AF196971.
HLDBS43	59	722228	1 - 2519	15 - 2533	BE622991, AW963656, BG119873, BE877983, BG165586, BE540985, BF799495, AW384813, AW303432, AW364609, AA806218, AW364624, BE350826, AW364630, AW341530, AW027611, AI805297, AI337288, BF515285, AA843910, BE880133, BF841931, AU151830, BE350822, AW273064, AW298520, AW190250, AW418697, AI342360, AI803510, N41607, N30632, AA424201, AA451978, AA769583, AI949818, N29607, AA054360, AI807818, AI291337, AI818369, AU149416, AI740886, BF792293, AW117975, AW090291, AU126858, AI625006, AA056298, AA056251, BF769886, BF928449, BF956332, AI962665, AW304814, AA282124, AA054279, N41848, BF907600, AA446752, N30604, AA001856, AA227696, AU150222, W81474, BF935958, AI189506, N66649, BE620497, BE965154, N30620, W02645, AI800851, BF111474, AW182011, AI829418, AA995105, AI271773, AA554274, BE762482, AI632180, AU149636, H70705, N39917, BE161874, H50951, BE762487, AW977059, W30945, AA995103, AW176652, N41877, AW384822, BF841753,

HLWAD92	60	695736	1 - 885	15 - 899	<p> AI167563, BF888788, R98741, AA909396,  AI933933, BE762486, AW366588, AI468596,  R98740, AI784629, AW888548, AA373411,  AA432068, AW138399, H96404, AA760985,  N27172, D81521, H70704, AW805828,  C18685, AA424177, AW196470, T48542,  AI918473, AI869870, Z19078, N29687,  BF824815, AA366193, AA227557, C17395,  T27525, R27150, AW819642, H51610,  BF090148, AA705887, AW364641,  AA478490, BE697462, R26908, AW364628,  AW385624, AW860035, AA282125,  AI799369, AA825692, F33903, BF326595,  AA905767, BF931460, AW475022,  BG009907, BF761670, AA187106,  AA721174, AL137497, AF216644, AF225417,  AF277625, AL133113, AK001338, and  AC005046.  BF346613, AW084463, AW170356,  AI762784, AI684513, AI992037, AI423926,  BG116279, BE548119, BE857056, BF686616,  BF112165, BG109119, W72376, AW960392,  BG179066, AI149833, AW025395, AI660214,  AA521138, BE045815, AI860646,  AW190103, AI799279, AW469213,  AA612928, AI079941, AI090661, AW150153,  AI151095, AI147889, AI090989, AI991036,  AI680208, AI279071, N90763, AI349504,  AI122692, AI760878, AI160816, BE262067,  AI141126, BF112061, AI252763, AI150238,  AI042160, AI814304, W67964, AI936761,  AI581187, AI042090, AA455783, AI140818,  BE646616, AW149828, AI333625, AI955672,  BE046116, AA398208, AI051058, AA481262,  AI189920, AI808806, AI498841, AA776472, </p>
---------	----	--------	---------	----------	--

				AA977692, AI926685, AA934728, AI266480, AI391679, N25910, AW473959, R85555, AI274499, BE502692, BE675866, AW954644, AI453811, AI043626, AI285057, AI200064, AA025402, AI061408, AI015608, W22174, AI200490, W72998, BE349958, AI221384, W4965, R64181, AI262728, AI935879, AI200164, AA770211, H00220, AI200212, AI015055, AI148686, AI122816, AW292442, AA806026, AW182515, AW468941, AA946623, AA281083, AI024474, AW104815, AA908206, BF037752, AI569420, R82204, AA588152, AI278716, AI568295, AI125585, T33608, AI383159, R73475, BG231876, AA524768, AW087900, AA953876, AA811083, R77814, AW264307, R79384, BG011965, AA456606, AA565569, W74086, AA022667, AI356156, BG033627, H41673, AA864339, AA703088, R64093, AW081075, AI264517, BE672848, AA399384, AA831635, AA455244, AA437314, H40235, R86852, R82765, AA308193, T33861, AI138975, R68595, H00614, AI025694, W67142, R33018, W80786, AI472895, R80918, AI183287, R69007, W44805, AA350061, F36345, BF718520, BF197930, BE675867, R80917, H85560, AI692850, AI203702, AA807227, W67385, AA831118, H03453, R68390, AA465624, BF961260, BE819178, R69008, R89632, AI826281, R81222, T07999, H43702, R78182, R87944, AA831315, R46331, AA045502, AI351258, H00173, AA007650, AI372636, BE675626, AA514478, AI685955, R31036, AI686215, H40234, R27714,

					W80893, AI215166, AA722459, BE261763, BE259600, AA040607, AA766842, T33436, AW148921, T33664, AI696556, BE856135, AA683541, AI220680, H03537, H66462, R37563, BE259417, H94445, R36720, W88021, AA767709, AA627884, BF823469, AA603453, AI984877, R73474, R46418, BG056248, R27113, AA437045, H26978, T03626, AI914606, AA022766, AI076842, AA865073, T33964, AI371308, R82259, AW079562, R31520, F21470, BF951552, AA807858, R31525, AI372635, R31030, N93814, and AF257319.
HL7BI15	61	645262	1 - 1065	15 - 1079	AW972599, AW972743, AW975048, AW970887, AW970588, AW971379, AW970992, AW979200, AW975259, AW971949, AW974094, AW971374, AW979241, AW970981, AW971073, AW979102, AW974354, AW972754, AW972751, AW971960, AW972828, AW971167, AW971037, AW971983, AW968339, AW975675, AW975135, AW968194, AW970980, AW972752, AW975634, AW972358, AW972744, AW970929, AW970964, AW972858, AW971113, AW975086, AW975012, AW975655, AW970967, AW979156, AW971192, AW976034, AW973808, AW975113, AW975409, AW969672, AW972367, AW975573, AW975902, AW970909, AW979096, AW970064, AW976008, AW969856, AW971987, AW972802, AW975664, AW979245, AW975094, AW970914, AW970036, AW971163, AW968167, AW979272,



				AW979050, AW970922, AW973952, AW974283, AW975694, AW969946, AW971071, AW979193, AW979229, AW970564, AW979000, AW973218, AW973176, AW968340, AW974076, AW971360, AW974824, AW974997, AW979292, AW969941, AW972621, AW971131, AW979240, AW972846, AW973828, AW972741, AW975985, AW974344, AW973376, AW971263, AW975072, AW974110, AW975146, AW972282, AW971249, AW975894, AW972271, AW973116, AW971237, AW970058, AW971020, AW976030, AW971203, AW968191, AW970078, AW971124, AW975578, AW971215, AW975571, AW968178, AW975006, AW979100, AW972302, AW972417, AW974371, AW973160, AW970932, AW975176, AW973996, AW969751, AW973183, AW970574, AW970971, AW973771, AW975213, AW973757, AW973995, AW970962, AW971115, AW971051, AW972659, AA443390, AW973204, AW971214, AW969753, AW971097, AW971981, AW968150, AW979148, AW975117, AW974117, AW969966, AW975987, AW974813, AW979184, AW972727, AW979101, AW971333, AW975663, AW971189, AL134524, AW973998, AW971985, AW972790, AW971033, AW974389, AW971045, AW972897, AW971942, AW970911, AW974890, AW971257, AW970921, AW971135, AW970024,

					AW974933, AW979129, AW975035, AW972699, AW975222, AW772696, AW979139, AW975348, AW973720, AW975425, AW971204, AW970606, AW973746, AW974370, AW979220, AW972864, AW979219, AW971416, AW970958, AW969784, H15295, AW975645, AW970896, AL031289, AC011462, AC005622, AC006146, AC011495, AC004686, AC006449, AC004383, AC005914, AL136504, AC009362, AL035495, AL138807, AC010527, AL139286, AC002316, AC027319, AC008892, AL139100, AC005566, AC006530, AC004805, AC006241, AL023553, AC005250, AL353602, AP000355, AL033529, AC005899, AP001753, AC074331, AC004867, AC003047, AC020626, AL080243, AC000085, Z83840, AC005632, Z98036, AC010412, AL008718, M26434, AC008569, AC004139, AC004477, AC003957, AL022318, AC004858, AP001685, AC011451, AL035072, AC004895, AL021155, AF109907, AC008753, AL133230, AL035458, AL050318, AC004583, AC005694, AC005098, AL121658, AC005031, AC006080, AC004832, AL117258, AC005049, AC005081, AC005522, AC004971, AC004167, AC007917, AF053356, AL163249, AC008623, AC005781, AC004166, AL022323, AC005544, AL356354, AL118520, U91318, AC004777, AC004996, AC004408, AC005225, U80017, AL355476, AL021393, AL022320, AC005015, Z98200, Z81314,

					AC004019, AP000140, AC008760, Z83838, AC005527, AL109825, AL121928, AL354750, AC007666, AC012309, AC004534, AL162430, Z93015, AC010519, AL035659, AL158832, AL132653, AP001727, AP001711, Z82188, AC016637, AC004491, AC004980, AC004033, AL354914, and AL354914.
HMEJE05	62	722231	1 - 1914	15 - 1928	BE292961, BE300470, BE298159, AV701105, BF791212, AV717352, AV693678, AV717186, AW962353, AI814288, AV763685, AL522728, AW9666815, AA442919, BF962776, AW401801, AW962349, AI376871, AA305112, AI380212, AI683132, AI860202, BE743268, AA099733, AA099732, BF956120, AW627633, AI754022, AV764521, AI630537, BE206347, BF837353, AW966817, AI439469, AW630915, AA724473, AW183349, AV742743, BE019157, BF835349, BF960834, BF962781, BE874961, AA249097, BF961479, AI378222, BF110710, BE762832, AK027012, and AF168711.
HNGIX55	63	695749	1 - 767	15 - 781	AU140348, AU138078, AU136503, AV731936, AW814395, AL043065, AI868368, AI922061, AA569180, AA613221, AA501775, AA584099, AA664366, T62761, AA489896, D59168, BF985200, H54464, AA504977, BE304382, AA720764, AL044254, N86026, BF945554, T02940, AA376315, AC006249, AC007690, AC002449, AL121782, AC005034, AL136307, U69730, AC000125, AC005029, AL035695, AL353999, AK002154, AL136520, AL138478, AL121575, AK023773, AL136133, AK002104,

					AK023417, AC007286, AL158193, AC005064, AK024354, AL109920, AL023875, AC023478, AC005076, AC026188, AF235097, AC034195, AL359924, AC008162, AC000378, AC083875, AC024086, AC008664, AL049710, AC005378, AC016626, AL121916, AL356865, AL031663, AF241732, AC009503, AC003685, AL135879, AL121790, AL133325, AL133516, AC004908, AC005386, AC008462, AC084732, AC073980, AC016831, AC010369, AC004842, AP000460, AL136164, AL034410, AL049794, AL157830, AC024576, AC019330, AK023839, Z93019, AC008394, AC016956, AP000692, AC005230, AC016925, AP001331, AC013410, AL132988, AC022143, AL356652, AP001680, AP001964, AC007032, AP001725, Z82899, AC004852, AC008266, AB037817, AC019179, AC016751, AL355792, AL441964, AC007327, AP000083, AL033521, AL365440, AC007745, AL049838, AC024084, AC005273, AL121825, AB045359, AC066590, AC007567, AC004894, AL354793, AC022335, AC002070, AP002532, AC019173, AC005019, AC011666, AC006461, AL390759, AL031074, AL359755, AC016623, AC011288, AL161621, AL133412, AL049565, AC003099, AC004083, AP001821, Z83848, AL121999, AL138759, AC012082, AF049895, AC027663, AC005794, AL109915, AC004677, AC006840, AC016572, AC018897, AC006364, AC007683, AL133379, AL109659, AL022345, AC010395,

HNHEX30	64	634848	1 - 1180	15 - 1194	AL390836, AL391691, AC005201, AC005498, AL030996, AC016689, AC007319, AL023806, AC063976, AK002066, AL359457, AL158206, AC005199, AC046138, AC046138, ... AC025897, and AC025897.
					BF869510, BF870168, BF868734, BF379935, AI245870, AW843982, AA628010, BF743745, AA076920, BF081565, AW854413, AW854493, AW854488, AC005488, AC018720, AC004980, AB014518, AC005236, AC005236, AC005236, AC004980, AC004980, AC004980, AC005488, AC005488, AC005488, AC018720, AC018720, and AC018720.
HPJBI33	65	685699	1 - 1663	15 - 1677	AI679782, BE796439, AV763892, BE387734, AW303196, AW301350, AW274349, AL046409, AI204304, AU148742, AL048142, F36273, BF475381, BE156019, AL041690, BE872393, N94311, BG236735, AA599480, AW630298, AW473163, AI754955, BF683672, AI281881, AW276827, AI341548, BF806176, AW467362, BF805094, BF940837, AV762050, BE350475, AA631507, AV652936, AW963497, BF965007, AV681599, BE042649, AV762139, AW080939, AW276435, AI291268, AI291124, AW339568, AU154961, AA426277, AI133164, AW088616, AI951863, AW873530, BF816072, AL038785, AW148792, AW338086, BE869857, AW408717, BE042475, AI580652, AA525190, AL044940, AV760466, AV713243, AW969694, AI537955, AC005527, AL050318, AC000025, AF134726,

				AC008736, AC004983, AC004965, AL162458, AC020552, U91321, AL136179, AC011455, AC020916, AC009244, AL133332, AC005755, U95740, AP001725, AC008068, AC011497, AL021546, AL121586, AC004971, AL021391, AC007055, AC011464, AC010422, AC006430, AL1390738, AL109805, AC006483, AL033528, AP001716, AF053356, AP000112, AL022323, AC018751, AL121900, AL356354, AL121897, AC027689, AC004878, AL121903, AL121890, AP000044, AP000513, AC004662, AC027319, AC008738, AL136980, AC020904, AC009516, AJ400877, AC003003, AC004847, AP000555, AC018719, AC003029, Z93241, AC004797, AL031281, AP001741, AL033529, AC011479, AJ003147, AL163248, AC022148, AP001727, AL031602, AC008403, AC005488, AC006329, AC005736, AC004841, AL022316, AC003684, U47924, AL031733, AL050349, AC005231, AC004707, AL121585, AC005015, AL137800, AC016025, AP001726, AC027644, AC005295, AC007956, AC006050, AC013434, AC004382, AC010553, AC006581, AC004638, AC007739, AC007011, AL049537, AL049760, AC006211, AF109907, Z93015, AC011462, AC005844, AC006312, AC002990, AC008474, AC011489, AC007272, AL136418, AL136137, AL139352, AL109936, AC002365, AC005080, AP001710, AC009298, AC004858, AL035404, AC005531, AC008812, AC011491,

					AC004089, AL033659, AC005529, AC007226, AC006452, AC005837, AF111168, AL109797, AL355392, AL021155, AC005512, AL009181, AC004491, AC018720, Z97054, AC007686, AC023344, AC007597, AC005562, AC010618, AP000347, AC002369, AC004953, AC005081, AC011495, AP001748, Z86090, AC002470, AC005840, AC008760, AJ009611, AC008985, AC011484, AC002133, AC011444, Z98200, AL121652, AC008372, AL022320, AL109965, AL096701, AL031584, AC008616, AL034405, AC008649, AP000045, AL355305, AP001610, AC005225, AC020908, AC023510, AC006538, AC008764, Z85996, AC003070, AC005778, AC005037, AC020550, AC004859, AC005899, AC018801, AC007619, AC002996, AC008569, AL160175, AC002565, AC025593, AC005409, AL049569, AC021999, AC002044, AL031283, AL049712, AC004967, AC004166, AL161731, AL109825, AC007845, AC068799, AL136300, AL031284, AC009953, AC005523, AP001714, AC004019, AL133294, AC007731, U95090, AC007685, AC002394, AC084732, AL157938, AC020906, AL121601, AC012467, AC018663, AC005500, AC007021, AC005740, AC004150, AC006160, AC008745, AF128525, AC007679, AC006449, AC005696, AC006480, AP000065, AF131216, AL136981, AC005098, AC005057, AC019227, AC006241, AL049843, AC006071, Z99716,

HRABA80	66	588460	1 - 1223	15 - 1237	AC018637, AC008752, AC018639, Z84484, AL161892, AC018610, AC018610, AP001447, AP001447, AP000571, and AP000571. AU147250, F24079, AI791459, AI732503, AA523577, AI791342, AU121439, BF309840, BF308519, AI659402, AA719317, AA602233, AI752815, AW967109, AV694013, AA470486, AI218622, AA644545, AK022184, AC005777, AL031431, AC007406, AC004143, AC006131, AC005760, AC005529, AL354766, AC005544, AL035079, AL356299, AL031297, AC005778, AC011666, AL035071, AL136529, and AL356740.
HRACD80	67	882163	1 - 1920	15 - 1934	BF001770, AI431600, AI332903, AW778829, BF197765, AI814110, BF509841, BF875981, AI983390, AI741104, AI263763, AA719400, AL354898, and AL354898.
HSLCX03	68	889145	1 - 3286	15 - 3300	BF205433, BG025867, BF206942, AV729983, AV706183, AV732002, AV706746, AV752043, AV731759, BE867291, AV725927, AV723449, AV731977, AV702427, AV730711, AV751573, AV730171, AV731694, AV731043, AV751921, AV731744, AV731313, AV752443, AV728270, AV732653, AV706724, AV726505, AV752447, AV758481, AV730781, AV753374, AV732149, AV730288, AV711496, AV730816, AV730165, AV710938, AV731708, AV710534, AV732353, AV730547, AV731275, AV659189, AW247024, AI814360, AV757088, AW665404, AV702798, AV701611, AV726674, AV707783, AV702409,



				AV731915, AV758133, AV727932, AV710375, AV723452, AV662191, AV710495, AV732155, AV752993, AV751555, AV758003, AV730859, AV65240, AV707088, AV727103, AV710906, AV710417, AV710825, AV711240, AV757887, AV710562, AV756895, AV732200, AV733303, AA971547, AV745415, AV702869, AV730778, AV755874, AV755473, AV704592, AV761002, AV728844, AV706357, AV746276, AV760693, AV729129, AV763440, AV704974, AV725369, AV705263, AV737377, AV658362, AV756053, AV702637, AV732089, AW250225, AV707686, BF701516, AV761270, AV711567, AV752684, AV732255, AV745906, AV729568, AV704916, AV701237, AV728872, AV706035, AV721645, AV701320, AV702354, AV739275, AV704611, AV728777, AV732746, AV707117, AV711274, AV737379, AV707171, AV709897, AV737380, AV726067, AV740829, AV710941, AV705020, AV731653, AV652156, AV713945, AV710935, AV710622, AV711413, AA781889, AV723195, AV706104, BF185575, AV710394, AV738275, AV710086, AV711344, AV702498, AV725568, AV711571, AV757553, AV726738, AV713377, AV647654, AV714368, AV710909, AV763171, AV731884, AV757823, AV729357, AV759183, AV743303,

					AV730449, AV712324, AV707685, AV703591, AV736429, AV703012, AV756386, AV705234, AI932216, AV711475, BE858661, AI144206, AV705280, AV755714, AI146546, AV718341, AV727355, AV710146, AV707882, AV757171, AV737413, AV706910, AV724987, AV709407, AA436490, AI494424, AV687176, AV706234, AV701783, AI951048, AI123552, AV763669, AV706899, AV710090, AV728249, AV755335, AV728715, AV730866, AV757864, AV726480, AV712326, AV727189, AV746382, AV757673, AV732242, AV703862, AV748952, AV701728, AV693117, AV721318, AV730456, AV702787, AV704924, AV757686, AV718086, AV709935, AV757281, AV702958, AV705504, AV703417, AV740404, AV702954, AV702671, AV731862, AV726830, AV707948, AV726520, AV745756, AV650367, AV722093, AV652808, AV707589, AV725281, AV706290, AV726624, AV699148, AV726392, AV755783, AV709969, AV706814, AV732145, AV702026, AV721993, AV702537, AV706683, AV702581, AV705662, AV656004, AV725386, AV725387, AV705047, AV709356, AK025530, AK025445, AX020190, AR017907, AX035462, AX009712, AX035980, I13349, A91965, A38214, I56772, I95540, AX026821, AR031374, AR031375, AX001325, AX001326, AX001323, AX001324, A58521, AR020969, A49700,

				AR088705, AR091393, AR079804, AX008555, AR062871, AX026824, AX032758, AR062872, AR062873, AX026823, A63067, A51047, A63064, A63072, AR068507, AR068506, A20702, A20700, A43189, A43188, AR069362, AR069364, AR028564, A84772, AR067731, A84776, A84773, A84775, AR067732, A84774, A58522, A91750, I66481, A60985, I66488, AX006816, I66489, A60990, I66485, I66490, I66491, I66492, I66493, I66482, I66483, I66484, A91754, I66498, A18053, A95051, I66495, I66494, I66487, AR080470, AR077142, AR095492, A23334, A18050, A60111, A23633, AR007512, AX046332, AR089207, AR089206, AR089208, AR089205, A83642, A83643, AX012337, A75888, I70384, AR043601, I66497, I66496, I66486, A83151, AR083151, I06859, I60241, I60242, E12615, AX018504, AR035193, AX023553, AX023548, AR027100, A92133, I28266, AX003207, AR085082, AR085089, AR085091, AR085079, AR085083, AX001322, E13740, AR093385, A10361, AX009487, A02712, AR073846, AX011024, AX021518, A25909, A91752, A35537, A35536, A11245, A02136, A04664, A02135, A04663, A02710, A07700, AX027811, AX027809, A13393, A13392, AX027813, AX030369, AX030368, AX027812, AX027810, AX027816, AX027817, AX027818, AX027814, I21869, AR025207, AR074365, A70040, A85396, I08051, AR075286, I05488, A60977, A32110, X68127, I08196, AX008865, AX008867, AX027908,

					<p>             AX027904, AX027906, AX008868, A68112,              A68104, AX006823, AR027319, A91751,              A06419, A21892, AR027318, AX033247,              A23997, AX033249, A68114, AX006821,              AR037157, AR054109, AX008265, A05160,              A08030, A20502, A86792, AX042372,              A60961, A64973, A47368, I19516, I19517,              A89633, A89634, AR080280, I63560,              AR009152, AR009151, I63561, I63563,              AX006825, AX006826, AX006822,              AX001082, A58524, A58523, AR091716,              A60987, AR002333, A21895, E14304, I08776,              A81878, A76773, A22413, AR069374, I25027,              AR069426, AR069375, I26929, I44515,              I26928, I26930, I26927, I44516, E16678,              I25041, AR093392, A85477, AX027815,              A95096, A95106, A95105, A98767, I15353,              A93963, A93964, A44171, AX006030,              A29109, A32111, I07249, AR068508,              AR068510, AR068509, A63954, AR091571,              AR085090, I58322, T91232, R11114, T86015,              R61399, R61444, N25312, N71736,              AA463999, AA464700, AA515534,              AA770594, AA436445, AI005130, T20250,              T20249, AI350837, AI569246, AI580715,              AI240523, AI286226, AI610364, AC078894,              AC018903, AC025781, AC025815,              AC026815, AC027034, AC027035,              AC027135, AC034258, AC035249,              AC066689, AC068924, AC069474,              AC073555, AC078893, AC024261,              AC024594, AC068667, AC073166,              AC074226, AC074108, AC022305,              AC027036, AC026757, AC027037,              AC077693, AC074196, and AC078898.           </p>
--	--	--	--	--	--

HTSGJ57	69	740767	1 - 1783	15 - 1797	<p>AW574516, BG259057, BF975647, AW575080, BF795582, BE559713, BE396519, AI521311, BE397179, AW237047, AI446257, BF238156, BF663664, AI862389, AI573063, BE513368, AW296989, AU157608, BF128855, AA811488, AA827120, AW338778, AI439638, BE560794, AI250231, BG120258, AI312540, AA633095, AV742373, AI343438, AA604586, BE269253, AI669176, AI149413, AA723128, AW403042, AA722908, W57991, AI826124, BE246032, AU138425, BE513265, AI865336, AI219708, AI589599, AW732709, H23560, AA765412, AI589912, BE560732, T61448, AW444827, AA594614, AA648496, AA361096, N34423, W58075, AV742389, N48728, AA975334, AA731435, AA166766, BE247378, AA810638, AW298682, AI919140, AW402333, AI341517, BE245894, AV743440, AI962720, BF062274, T30849, AI982795, AW405561, T25945, AA810222, AA807717, Z39117, AV756294, AV724221, BG120887, AA593214, N48658, AW083122, AA639378, H23535, AI492348, AI656821, AF045555, AK002099, AF257135, AF161531, AC005081, AF086239, AC016675, AC016675, AC005081, and AC005081.</p>
HTACS42	70	722253	1 - 1359	15 - 1373	<p>AL338414, BF526452, BF526536, BF526493, BF973770, BE312752, BF311801, BG110390, BF338594, BE781152, BE879539, BG168442, BE264360, BF686397, BE545473, BF684020, BF340262, AL537916, BF245363, BE737756, BF697202, AW130967, AI310162, BE301024, BF700864, AA054583, BF381567, AI422243, AI800437, AL537915, AA461187.</p>

					AW151696, AI744870, BF828530, AI309121, AI343669, AA054543, AI769640, AI800457, AW134900, AI277620, BF381685, AV705487, AW381329, BF828532, AW674287, AW079667, AI696966, AI347821, AI591134, BF477370, AW514880, AI744879, BE734947, AA035341, AW381298, AA670144, AA244181, AW105694, AI760462, BF726610, AI954915, AI678476, BE908144, AI948588, AA320807, AW105695, BF881639, BF738279, AI139137, AA381807, AW083071, AA977994, AW082974, BE549300, BG259268, BF933137, AW236191, AI862078, BF934977, AW089950, AI864500, AW338021, AA856866, AI950309, AA587516, AV764001, BE077105, AI973173, BF197206, AA601230, AI499941, AA491423, AW083934, BF725844, BF931073, AF144755, AK024729, AL096701, AC009470, AC011510, AC021016, AL136369, Z85986, AC005229, AC005052, Z75407, AC009178, AC006530, AC007792, AF243527, AC004674, AC004148, AL136365, AC007395, AC005629, AC007880, AC002126, AC002073, AC006208, AC006160, AC016898, AL121926, AL157372, AC027319, AC004851, AC007956, AC005620, AL357560, AC006327, AP001695, AC007191, AC008764, AC005606, AL121943, AC005736, AC011742, AC010326, AL049872, AC004999, AC005570, AC005971, AL049569, D87675, AC002483, AP000114, AP000046, AC008392, AC008969, AL031984, AC005004, AC004166,

				AL021391, AC005261, AC005841, AC008521, AP001753, AC005098, AC005041, AC011895, AL138756, AP001728, Z98941, AL133545, AC005839, AL023553, AC005899, AF235098, AD000812, AC005914, Z94801, AC011811, AL353807, AL049776, AL391114, AC007376, AC005103, AC018751, AC005225, AP001711, U91323, AL136303, AF047825, AL121868, AC009086, X55448, AC006006, AC005274, AC000159, AL158830, AC009464, Z93096, AP001748, AL163201, AC009073, AC009362, AC004867, AP000152, AC002470, AC008762, AC011455, U85195, AF165926, AC015550, AC003006, AL117332, AL049537, AL121658, AP001708, AF196969, AC006120, AC005476, AL022323, AC018682, AC004150, AL035404, AF238375, AL031291, AL109984, AC008753, AP000031, AE000658, AC024561, AC005200, AL049759, AC004985, AC002984, Z97985, AC009302, AC005619, AP000694, AC011452, Z93930, AC008567, AC004854, AC004883, U95090, AC002430, AP001717, AC004033, AL117334, AP000143, AC020898, AC010526, AC009743, AC005632, AL031447, AL121601, AC005412, AL031282, AC020916, L44140, AF017104, AC006449, AC006312, AL139009, AC005080, AL157713, AP000212, AP000134, AP000030, AC002316, AL158828, AC007731, AC010412, AL354720, AC008687, AL358777, AC026729, AC016831, AP001670, AL136139, AL096703, AL137012, AC005500, AB023049, AC007384, AC010458,

					AC011453, AL136170, U91326, AC008277, AC005746, AC007546, AC025435, AC004826, AL050335, AL031577, AC004477, AL034379, AP000113, AP000045, AC007308, AC008079, AC005231, AC004024, AC005779, AL078472, AL109965, AC008085, AL023876, AL096791, AL109963, AC005081, AL161445, AC005015, AC008812, AC009244, U81031, AC010655, AC010655, and AC010655.
HTEKE40	71	740768	1 - 1565	15 - 1579	BF940114, AJ361316, BG223420, AA876320, AL356216, AL356216, AC027430, and AC027430.
HTOBX69	72	722255	1 - 1014	15 - 1028	AW273804, AA488861, AW968924, AA488938, AI093600, BE173122, AW206450, AA635743, BF222008, AI288448, AJ344556, AI800674, AA284257, AA505427, AA588588, N30779, AI149444, AL523271, AA886990, AI015520, AI248194, BE965684, AA458483, BE544421, AA004285, AK000672, AX026129, AF151848, AC004997, and AC005585.
HUVEO77	73	740776	1 - 3660	15 - 3674	AL523087, AL523086, AV727906, BF511581, AV707732, BE883906, AV727224, AW964463, AW003008, AV702158, AV705108, BE887170, AA928698, AA436935, AL041085, BE048631, BF515047, BE884186, BF672714, AJ888610, BE549984, BF105274, AI627792, BE138759, BE876805, AW954912, AW959529, BF693086, AI446742, AI332607, W60846, BE674526, BF790798, AA824382, BF694509, BF901184, AI610338, BF433383, W37870, W56436, BE677261, AA486366, AI936599, AI925670, AW451948, AV728172, AA548758,



					AW008465, AW964458, AW020326, AW964456, AI687914, AV751035, AJ285178, AI301813, BF060779, AI684201, AI631323, AI446630, BF677197, AI889300, N89591, N53349, BF366766, BF365281, W60845, BF477924, AI799331, AW071513, BE504880, AV746722, AW663212, AI273240, BE326810, AW193456, AA644626, D57704, AI273238, BF693868, W32116, AI299147, AI537189, BF370036, W37862, AI679619, AA974387, AI690324, AI027167, D57511, AW365615, AI452890, BF355506, F17744, C16075, D57477, R61474, D56708, Z26971, AI468266, W32174, AI032409, AA319718, AI819646, W16944, BF224107, AA496021, R20236, AI201552, AW020638, D56560, C16103, AA488074, AW292226, AW269215, AI924860, W07649, D56804, AI301979, AI044509, N22377, AA319464, C16524, Z25907, AA402177, C16119, AA319477, D58272, D57388, AI580712, D57553, AA879437, AA319566, AI291886, AW008087, R61475, C16280, D58225, C16504, C16476, C16386, AA770696, D57769, D56590, D58217, D57795, C16066, C16090, C16098, N81149, AA318536, D38097, C16454, D79751, D58174, R43691, H24485, D57329, C16155, D57529, C16171, D56609, D56853, AW897420, D56811, Z28838, D56587, D57507, C16233, AI918528, D57314, AW897469, D63091, D57280, D56884, C16422, AA319769, D58237, AA411986, BF373775, C16204, D56977, Z25194, AI473574, D56740, D57888, D57048, D58307, D56672, D57101, C16381, C16122,

					W21184, C16508, AA324951, D57147, D56955, C04302, D57564, AA319039, D57049, C16563, C16132, D57027, D57877, AV706572, D57429, BF820498, AA318959, H71596, D58354, AA089589, N87600, H71467, D79501, BF820859, D58238, BF060943, C16561, Z26989, AA248764, AA249046, BE439700, D63064, D62689, AI801634, D79277, AL514665, D63005, BE327838, AI307232, AI308207, BE463793, D79973, AI655757, AI962082, AI283005, AI291579, AA845454, D61820, AW263075, AA081209, D63101, AW300081, AU146937, AX017611, AX017512, AK026775, AF113212, AL157502, AB008109, and AC031977.
H2CBG48	74	745365	1 - 2783	15 - 2797	AL536879, AL536880, AW974652, BF978951, AI761251, AI655763, AA307225, AA628063, AW043567, AW376300, AI693827, BE047125, AI129587, AI701013, AA651730, AW172361, AW339506, AW085916, AA457150, AA052951, AI582629, AV688972, BF820514, AI590194, AW085909, AA916242, AI000008, AA962570, NS2070, AA293021, AI371342, BF891108, AA058439, BF946218, BF891008, AV689991, AV690900, AI458885, AI962506, H40784, AI364207, AA464514, AW994164, BF946219, AV656660, BF891112, AA336322, AA337109, AI824603, AA336509, AA336407, BF036975, AA337222, N46906, AA464515, AA319240, AA765507, AW361203, AA053434, AI928199, AW299270, AV713792, NS0282, AA056762, BE708029, AW361192, W07762, AL513817, BE965014,

				AI866082, AL513723, AI689470, AI684244, AI866624, BF970652, AW024594, AL514691, BF525392, AL047100, AL513687, AI963763, AI925404, AL514473, BE966388, AI634249, AI241901, AA580663, AL513553, AI584130, AV727963, BF868489, AI973288, AI499570, AI638644, AI745684, AI765323, AI583065, AI909697, BG058398, BE964967, AL514085, BE966547, AI889818, AI890223, AI473536, AL036187, AI521799, BE892325, AL514145, AL046466, AI636811, AI540179, AW262983, AL513779, AI345415, BG110192, AV761267, AL514493, BG030785, BE879336, AI590043, AV696866, AI417790, AI698391, AW088628, AL514359, AI916419, AI433647, AI690536, AI690748, AW081383, AL514497, AL513755, BE965732, AL514455, AW129264, AI382670, AI689557, AI357940, AI277008, AA761608, AW079334, AI884318, AL514047, AI493576, AI421903, BE967005, AI590227, AW105460, AI719817, AL037582, AL037602, AV682533, BF766531, AW161202, AI469505, AI491775, AW020397, AI744243, BE540578, AI953765, AW834282, BE966577, AL514867, AI635851, AW075382, BE962903, AL514871, AL514469, AL515195, BF309444, AV747571, AI873638, AI524724, AI440239, AL514899, BE967070, AI679550, AI345612, AL514457, BF039003, AA743354, BF792961, AL513911, AA631120, AW083374, AI284060, AI623179, BF791791, AL036705, AW827289, AI363741, BE966927, AI288305, BF895218, AL514155, BE966579, AW088899, AI345416, AI267185, BE964999, AI359787, AW189415, AI538850, AI301710, AW008226, AI341690, AI611743,

				AW198090, AI620302, AI683606, AL513951, AW078712, AL046618, BE964726, BG164558, AI540674, AI884469, AI539771, BF724420, BF970436, AI567846, AI862024, AI627866, AI696570, AW073677, AI362522, AI679891, AI678446, AL513781, BF981785, AL079799, BF727091, AI567625, BE888257, BG104845, AL515235, AI627893, AI559619, BG036506, AW500379, AI089970, AI270039, BG031894, AI932739, AI539042, AW007309, AI367210, AI933783, AI434731, AL445590, I48978, AL050155, AL390154, AF015958, AK025435, AF119875, Z97214, AF218000, X82434, AK026885, AF232009, AL389935, I89947, AB007812, AF115410, AF061981, AL137476, AF126247, AB048964, AL080154, AK026762, AL137648, AK027102, AL137533, AF119899, AL117587, AL117460, AK025350, AL157482, AL137488, AF155827, AL137268, AF314091, A77033, A77035, AL080159, AF047716, AL133062, AL354776, AK026518, AL050149, U49434, AR038854, AF218005, AL049460, S82852, Z82022, AF159615, U96683, AF116646, AL110218, AF090900, A07588, AF267849, AK026592, I48979, A08907, AP001343, AF215669, AL122100, AL049452, AP000697, U49908, AC026431, AF067790, AK025092, AF100931, AC004383, AK025099, X80340, AL122106, AF116609, AF119909, AK025407, AB049880, AC007298, AL359601, AL133075, AF119843, AL133113, AL133619, AL117435, AR034821, AL389982, AL121916, AF102578, I17544, AB040710, S77771, AL137550, AF106657, AF208026, AF183393, AK024588, AF130055,

					AJ299431, AL080148, AL034400, E02221, AP001666, AL389983, AL122104, X62580, AK026626, AL121828, I03321, AL133016, AK026462, E07108, AF119883, AK026504, AL137271, AB052191, X84990, AF106697, AL137558, AC003032, AL137555, AC016652, A17115, A18079, AF175983, AF030513, AL080118, AP001346, AL137463, A18777, AK027113, A65340, X99257, AL133640, A76335, AL080234, AB047631, U57352, D16301, AJ005690, AL050366, AL162008, AK025113, AF200464, AC012502, AL122098, AL110221, A58545, AF146568, A08910, A08909, AK027116, AL133010, AF038562, AL442082, AL080126, AK000257, AK026534, AK026542, AL050277, AK000418, AP000020, A08908, Y11254, AL357195, AB050421, A08913, AB052176, AB046642, AJ010277, AL389939, AF116631, AL117440, AF106945, AF116698, A21103, AK026408, Y11587, AL080060, S75997, AC005902, AF116688, AF130056, AF192401, AK026597, AK025798, AF130082, AL162003, AR029490, AF143723, AK000636, AX017991, AK027182, AL078630, Z98949, AF254119, X57084, AF192402, A08912, AL389947, AF205861, AF199027, AL353956, AF139986, AL133049, AL080163, AK024538, A08911, AC020956, AF285167, AL137537, I89931, Y10823, AL117649, A93350, AB048913, AL353802, AL023657, AX010492, A52563, AL137273, AL137480, X72889, AK000137, AC010137, AK026793, A18788, I89934, AC004200, AC004883, AL050309, AR087170, AF162270,

H2CBU83	75	884134	1 - 2689	15 - 2703	<p>Y10080, X66871, S36676, AL133558, AF166267, Z13966, AK027173, U53505, AK026746, M86826, AL157483, AK027144, AK024944, AF262032, AL133565, S76508, and AF000145.</p> <p>BE613316, BE739453, AW961199, AV658769, BE785673, AW963999, BF037119, BG030580, BF036149, BF699154, BF033837, BF697524, BF695458, BF036638, BF701778, BG030507, AW377122, BF665913, BF699078, AW377125, BF665294, AV658829, BF667082, BG166746, AW851261, BF241480, AW850925, AI978809, BF695890, AA845339, BF668201, BF699860, BF085620, AA405940, BE612726, BF666583, BF667787, BE739116, BF665805, AW752845, BF701466, AI800939, BG121547, AI620357, BF700054, AW851052, AI924880, AW752835, AI800807, BF697582, BF700919, BF667321, AI139396, BE958619, AV692286, AI955392, AW752844, BE042841, BF698625, BF244588, AW440250, BF698345, AW152584, AW955901, AI671911, AA535832, AW850982, AI935579, BE089877, AW752868, AI683119, BF130660, D61864, AW630835, AI621153, BF514638, BF697211, AW192136, AI286255, AA403153, D62117, AW028833, N78154, BF154792, BF665821, AI538061, N64201, AW851056, AW938593, BE093579, AW938596, AA928873, AV651183, BE817020, AV657915, AV657131, BF666276, AV660141, AI699025, AI016115, R66206, N45586, D61708, BE868472, AA403241, AV657914, AA313513, AV682813, H88565,</p>
---------	----	--------	----------	-----------	---

					AA531589, R58698, AA857811, H42631, AA307010, R67084, BF334107, AW971385, R68027, AW021104, AW296538, BG166828, AI887214, AW468968, R64487, H88521, BF697149, R94825, R68028, R92884, R65584, AA377208, AI050980, AA318641, D62093, BF813323, N78160, T73957, D61982, D62303, D62026, AI806100, AA095925, N56560, T73925, AA507092, BF750358, BE148612, BF750357, BE867141, T73948, N88292, T73916, BE044052, H95089, H73281, AV660091, AF257182, AR028555, AF061443, AX016195, AX016184, AR028556, AC022205, AC022205, and AC022205.
HAPNY94	76	699770	1 - 728	15 - 742	BG029349, AW384082, AI653230, AW384103, AW590965, AI952047, AW474522, BF514114, AI952951, AI138532, AI199860, AW474480, AI655852, AI656352, AV727834, AI424794, AA909918, AI377297, AA632416, AA205078, BG150070, BE243783, AA709293, AW016441, AA906134, AI350684, AI825691, AW770135, AA971473, U51144, BE867482, AA770535, AA873641, BE160147, BF772564, BE184408, AC013339, AC013339, AL133351, and AL133351.
HBJHZ58	77	745372	1 - 1811	15 - 1825	AA370047, AA370019, AL041562, AA581433, BF851009, AL041521, AA843874, AA985136, AA111953, BF935428, AI126075, W25952, AU146079, AI299358, BE671252, BE867935, BE379085, AA176997, AA773359, AW166737, AU150602, AA219042, R89180, AI909852, L11910, AL390035, AL450169, AC009228,

					<p>Z83843, AC004788, AL157792, AL163267, AL354720, AL079352, AC016642, AL121694, AP001686, AP000426, AL355365, AC007091, AC007327, AL354942, AL031387, AL117339, AC007671, AC004682, AC007514, AC013358, AL109963, AC007717, AC013737, AC007012, AC006511, AL033521, AC004860, AC007364, AC060834, AC012081, AC007282, AL358532, AL035608, U95743, AC005273, L09709, AC026189, AC008282, AC018503, AL358975, AC023480, AL031183, AC006371, AP000949, AC013357, AC004706, AL049734, AC012099, AL118510, AL163194, AL109931, AL035091, AL117693, AJ225782, AC011815, AC004673, Z72001, AC006578, AL022161, AC019187, AC016617, AL023583, AP002533, AL138894, AL021937, AC007972, Z97198, AP001713, AL022726, AL137839, Z81001, Z80107, AC022103, AL449163, AL035698, AL009173, AC007429, AC005725, AP001347, AL390027, AL359854, AC027663, AC002430, AC009925, AC009925, AC022609, and AC022609.</p>
HCE2B33	78	745399	1 - 1660	15 - 1674	<p>BE250543, BE250657, AL520610, AW955817, BE409837, BE886243, BF033602, AI826453, BE393689, BE378093, AI804861, BE743664, AW250030, AI971716, BE552024, AI140361, AI659632, AW452114, AI479198, AW779955, AW197198, AW590289, BF002997, N79585, AI144134, AI799889, BG032437, AI203257, AI358934, N64394, W16574, AL520611, H12263, BF509683, BE856425, AI351628, R14214,</p>



						H12264, AI817266, AA332565, R40631, AI650967, R54427, R40632, AW450259, AI523692, BG104378, F10829, R87336, R14215, BE385368, BE890335, AF150132, BF345824, AV739421, AW955816, AW081695, AA235053, BF125714, and AK025813.
HDPBQ02	79	745403	1 - 2177	15 - 2191		BF346320, AW972888, BE796439, AL048969, AV722075, BF673911, AU118837, AV720115, BF828714, AV763305, BE155132, AA525174, AV728369, BF826830, AI694178, AI653525, AV761562, AL044340, AU145476, BE908602, AW089861, BF901147, AU147226, BG110480, BG028665, BG034591, AL037632, AA527963, AI457389, AW970987, AV699393, AL044339, AW965008, AA577824, AU148007, AU146981, AV700663, AW504011, BE973855, AI831816, AW850396, AU120100, AA572983, BF529925, AL042310, AL119331, AI925665, AV700545, AW970588, BF347042, AA525807, AA631638, AV759046, AI251024, BE541237, BF892846, AW188427, AF074667, AA224525, AA551204, BG026818, AA601230, AV719084, AU151751, AV722030, AL042906, AA129272, AA807556, BF345114, AA557457, AV754399, AI983645, AU155359, BF968610, T57096, AV762002, BF694054, AV760497, AW502873, BF882222, AW510513, AA019966, AL532829, AA836811, AU155104, BG032943, AL042905, AA904211, AI251696, AI254508, AW962006,

				AA713829, AU157011, AV700498, AL048901, AV725627, AA297145, AV762838, AA507526, AA838140, AA578832, AA856817, BF345228, AA626632, AL044489, BE538259, BF240672, BG026977, AW089625, BE675240, BF882223, AW440545, BF346854, AC010412, AC005081, AC008753, AC009516, AF111168, AC018751, AF109907, AL034405, AP001760, AP000501, AL109614, AC004813, AC002470, AC013429, AC002563, AC004166, Z98200, AF134726, AP000688, AL132713, AC011500, AL158198, AC007216, AC004832, AL136137, AC009032, AL1358372, AC006285, AC005180, AL049776, AL137230, U91326, AC002544, AC004686, AC004383, AL133163, AC004655, AL049709, AL035249, AC009060, AL109743, AC004089, AC005484, AL136179, AC005920, AC004216, AP001724, AC008543, AC006345, AC005049, AF001549, AC006441, AL157838, AC016395, AC005052, AC006141, U85195, Z84487, AC007546, AC005412, AC005323, AC007371, AL138783, AP001728, AL022316, AC008569, AP001714, AC008752, AP001711, AC004638, AC005913, AC005736, AP001713, AC006511, AP001053, AE000658, AL135924, AC005694, AC002477, AC008738, AL031680, AL161670, AC006480, AL035659, AC005015, AP000065, AC025588, AC005488, AL163249, AC015853, Z99716, AL034429, AC011477, AF088219, AL109963, AC011464, AC009228.

					Z84466, AC005102, AC012442, AL078593, AL353807, AC005972, AL136300, Z98946, AC005520, AC007993, AC011484, AC010605, AC019227, AL049760, AF111167, AC007249, AC020908, AC027319, AC006026, U95742, AL132653, AC010311, AC005874, AF134471, AL008718, AC004965, AL109935, AL096791, AL162272, AF243527, U47924, AL117258, AL049870, AC007685, AL109825, AC008687, AC018719, AL031291, AC004967, AC005280, AL021407, AC007055, AL137918, AL049830, AC009247, AL445483, AC004477, AL080249, AC006028, AF067844, AC006011, AP000503, AF168787, AF047825, AC002554, AL391122, AL079342, AC007308, AC011489, Y10196, AC005098, AL050318, AC007225, AC004125, AC011455, AL158830, AC002316, AF001548, AL020997, AL137818, AC006013, AC005020, AC006006, AL109758, AC006211, AC005562, AC005103, AL162430, AC007957, AP001718, AC007057, AF312915, AL354889, AL033529, AC005080, AC018758, AL354864, AC011895, AL135749, AC007969, AC016898, AC008018, AL031733, AC005531, AC006038, AC003101, AL022398, AC008155, AC024082, AP001717, AC004966, AC006241, AC008395, AC005971, AC004797, AC008555, AC008747, AL009181, AC003104, AC000052, AL353777, U91323, AL356801, Z93015, AC008750, AC006077, AL031228, AC003982, AC007365, AC016543,

					AL109984, AP000697, AL135818, AC008760, AL161936, AP001716, AC005037, AC008616, AL136305, Z93017, AC006965, AC008733, AL034548, AL139100, AL031587, AC020663, AC010618, AL133467, AL049715, AL031848, AC008403, AL135928, AP001670, AC008626, AC024075, AC020629, AL031666, AC005740, AC005317, AL109804, AC006571, AC002288, AL133246, AC020929, and AC020929.
HFYI70	80	744906	1 - 1321	15 - 1335	BF345869, AV726707, BE301105, BG034889, AW360850, W19606, BF446277, AU148126, BE250349, AU149480, AU152860, AU148657, AU148883, AW418817, AW862152, AW003619, BE672523, BF350928, BE909817, BE208094, BE159456, AI697801, BF108425, AI969149, AW301720, BE073395, AA132979, BF111388, BF690067, AW612712, BF540929, N23638, AA889907, T87882, BF373283, H25796, AW606625, R51344, AW082596, AI910259, AA349693, AA860167, AI668892, T87971, BF593061, R48370, BF807501, AI364176, R39999, BE740663, AA640793, BF210703, N71593, AW016249, R48270, BE258960, R59020, BE819678, AA360038, AI700434, BE077265, AI076309, AI783692, BE742022, BF476374, AI798645, BE747651, BE730294, H05971, R51451, AI825888, N94965, BF773032, BE839417, U90730, U90731, AK024760, AK022451, AK024036, AK022740, AB045989, T63351, T63674, R49212, R59159, R64065, R66441, R76632, R80386, R80492, H03457, H03542, H20303, H20987, R89247, R89248, R98830, R99313, H48284,

						H50118, H56131, H64163, H78393, H93783, H93875, N26313, N29711, N32029, N33057, N34497, N39756, N42121, N42238, N47780, N57738, N58187, N58647, N64442, N67758, N70951, W48757, AA024815, AA024921, AA031973, AA053392, AA085909, AA129251, AA132937, AA133081, AA146728, AA147067, AA147069, AA258537, AA424525, AA428935, AA429150, AA429385, AL353755, AL353755, AC023020, and AC023020. AI859620, AI830021, AI949469, AI887204, AI218392, AW511272, AW194364, AA970014, AI307671, AW582666, AI873619, AW609988, AA693331, AI868204, AW079432, AI540674, AI537643, AV753074, AI800179, AI245748, AW193467, AA580663, AI537677, AI499913, AI560545, BG029829, AI564448, AI345688, AW162194, AW083572, BF680133, AA575874, AI540606, AI584130, AI564234, AI690887, BG107995, AW834282, AI358209, AA056265, AW050578, AI473451, AA485953, AW129589, AA641818, AA939199, BF871314, AI819663, AI525669, AI623941, AW827206, AW051088, AI758309, AI225000, AI961278, AW195253, AI621341, AI561356, AI690748, AW075382, AI783821, AI470648, AI927233, AI589428, AI860027, BE397784, BF572734, F28295, AW021373, AI859991, AI700159, AI635038, N27632, AW161202, BF836332, AI352326, AI619723, AI612885, AI814087, AW163834, AI636619, AI932739, AV682575, BF753053, BF997967, BF699668, AI956086, AW022636, BE907440,
HDPOZ56	81	815653	1 - 1853	15 - 1867		

					N98597, AW191844, AI524654, AI473536, AW075484, BG113299, AW089233, AI590043, AI620866, AI628325, AI678446, AI53885, AW073721, AL040241, AW081606, W60514, AW168768, AI802372, AI922812, AW168296, AI587156, AI581033, AI932458, BF339548, AI336634, AL037463, AI741158, AW022682, AI887389, AW081383, AI247193, AA070889, AW151136, AI349622, AI270295, AW193344, AI471282, AI933992, AI499131, AA847199, AI045413, AI627714, AW117675, AI888621, AI890907, AI926669, AI630876, AA835966, BF921291, AI784219, AV758339, AI281757, AI627988, AI432644, BG167393, AI582932, AW090393, AI872423, AV747571, AI500061, BG254284, AI434731, BF103211, BG001293, AI659043, AI758270, AI479292, AA502794, AI620037, AI569367, AI469801, AI573167, BE874133, AW082532, AW238753, AI570056, AI686749, BF895218, AW020592, AI440238, BF814072, F37419, AL048871, N75779, AW102902, AI478123, AW087199, AW161098, AW022494, AV750565, AW020288, BF811808, BE963159, AI702527, AI446823, AI688848, BG114724, AW089572, AI494201, BF872670, AW263804, AI289791, AI804505, AI885512, AW080076, AI582912, N29277, AI631216, BE540578, AI366959, AI697157, AA761557, AL048323, AI287476, AI431323, AI961414, AI335476, BF032768, AW073907, AW438793, AL048340, AI282346, N25033, AI826225, AW08226, BE393784, AI349937, AI805598, BG261310, AI334884, AI307543,

	AI918408, AI491710, AI345114, AI434134, AI911648, BE138712, AI345251, BF811804, AW071412, AI349957, AI254226, AW088560, AI568061, BF341908, BG169738, AI307210, AI307708, AI336513, BE885353, AI312325, AW071395, AI336662, AV738918, AI500659, AV717389, AI702301, AI564765, BG167986, AI784233, U70429, U70430, AC011452, AL389935, AK027116, I48978, AL137665, AF111112, AJ250403, AK025099, AF210052, AL050149, AR083266, AL157480, AK026541, AK027146, I89947, A18777, AF087943, AR038854, A07647, AL110218, AF111849, U86379, AF116646, AK025015, AL137558, L13297, AL355701, AF116691, AL049339, E07108, AF260566, AB048994, AX006386, AF260436, I00734, AK024524, AK026389, AK000603, A77033, A77035, X83544, AK000137, AF109155, AF132730, AF026124, AF205861, E00617, E00717, E00778, AF177401, AL442082, AL133054, A08913, AK000655, I48979, AF130066, AK026534, AF115392, I89931, AF159141, A08912, S77771, A08910, A08911, AR087170, A08909, AI049464, A52563, AL357195, AR073709, X76228, A08907, A21103, A08908, AJ299431, AB044547, AL137574, S79832, S76508, AL110222, AF022363, I89934, AJ005690, AF314091, AL136884, AL359622, E05822, AK026057, AF130054, AF119860, AF130075, A18788, AC004200, AF022813, Y10655, A07588, AK025391, AL162004, AK026744, AK025119, AF227198, AL049347, AF113691, AC006451, AK026647, S78453, AF162782,

				AB047941, AK025084, AB050421, AL157479, S82852, AL137488, AF230496, AK026542, AF130055, AF215669, AL080159, I33392, D44497, AL355719, I52013, AK025350, AF155221, AF017790, AB038698, AB040710, E01314, A58545, Y14314, AX015425, AJ003118, AF061981, AF321617, AL050155, AL096751, U79523, AL137550, AF055917, AK024538, AF130059, U75932, S75997, AK024588, AK024992, S36676, AK024533, AK026480, AL137478, I80064, AL359596, AF116609, Z82022, AF116650, AF079763, AK026762, AF183393, AF113222, AK027164, X59812, AL122098, AF106697, AF151109, AL137529, AF026008, AK027142, I09499, AF130082, A45787, AF217991, AL096720, AL080126, AL050138, U35846, AL137480, AL110280, AL359618, D55641, AL133067, A57389, AF116676, AF131773, AF218031, AL050277, E04233, AB048919, AF111851, AK000257, AF090903, AL096744, AB047609, X65873, AJ006417, AF061573, D83032, AL137537, E02914, AF036941, AK027095, AB050410, AK025906, AX005848, AL049314, AX005804, AF143957, M85165, AK026844, AF126488, U00686, AF040751, AF199027, X72387, I89944, A15345, AL137463, AF119899, Y11587, AL137530, AK024601, AF225424, AL122106, E12579, Z13966, AK024974, AK027144, AF061795, AF151685, AL133016, AK025113, L31396, AK024545, U57352, AF267849, AB032264, AF004162, AL359620, AR068466, L31397, AL389939, AF115410, AK026462, E12747, AL080124, and



[illegible]

Table 4

Code	Description	Tissue	Organ	Cell Line	Disease	Vector
AR022	a Heart	a Heart				
AR023	a Liver	a Liver				
AR024	a mammary gland	a mammary gland				
AR025	a Prostate	a Prostate				
AR026	a small intestine	a small intestine				
AR027	a Stomach	a Stomach				
AR028	Blood B cells	Blood B cells				
AR029	Blood B cells activated	Blood B cells activated				
AR030	Blood B cells resting	Blood B cells resting				
AR031	Blood T cells activated	Blood T cells activated				
AR032	Blood T cells resting	Blood T cells resting				
AR033	brain	brain				
AR034	breast	breast				
AR035	breast cancer	breast cancer				
AR036	Cell Line CAOV3	Cell Line CAOV3				
AR037	cell line PA-1	cell line PA-1				
AR038	cell line transformed	cell line transformed				
AR039	colon	colon				
AR040	colon (9808co65R)	colon (9808co65R)				
AR041	colon (9809co15)	colon (9809co15)				
AR042	colon cancer	colon cancer				
AR043	colon cancer (9808co64R)	colon cancer (9808co64R)				
AR044	colon cancer 9809co14	colon cancer 9809co14				
AR045	corn clone 5	corn clone 5				
AR046	corn clone 6	corn clone 6				
AR047	corn clone2	corn clone2				
AR048	corn clone3	corn clone3				
AR049	Corn Clone4	Corn Clone4				

AR050	Donor II B Cells 24hrs	Donor II B Cells 24hrs							
AR051	Donor II B Cells 72hrs	Donor II B Cells 72hrs							
AR052	Donor II B-Cells 24 hrs.	Donor II B-Cells 24 hrs.							
AR053	Donor II B-Cells 72hrs	Donor II B-Cells 72hrs							
AR054	Donor II Resting B Cells	Donor II Resting B Cells							
AR055	Heart	Heart							
AR056	Human Lung (clonotech)	Human Lung (clonotech)							
AR057	Human Mammary (clonotech)	Human Mammary (clonotech)							
AR058	Human Thymus (clonotech)	Human Thymus (clonotech)							
AR059	Jurkat (unstimulated)	Jurkat (unstimulated)							
AR060	Kidney	Kidney							
AR061	Liver	Liver							
AR062	Liver (Clontech)	Liver (Clontech)							
AR063	Lymphocytes chronic lymphocytic leukaemia	Lymphocytes chronic lymphocytic leukaemia							
AR064	Lymphocytes diffuse large B cell lymphoma	Lymphocytes diffuse large B cell lymphoma							
AR065	Lymphocytes follicular lymphoma	Lymphocytes follicular lymphoma							
AR066	normal breast	normal breast							
AR067	Normal Ovarian (4004901)	Normal Ovarian (4004901)							
AR068	Normal Ovary 9508G045	Normal Ovary 9508G045							
AR069	Normal Ovary 9701G208	Normal Ovary 9701G208							

AR070	Normal Ovary 9806G005	Normal Ovary 9806G005					
AR071	Ovarian Cancer	Ovarian Cancer					
AR072	Ovarian Cancer (9702G001)	Ovarian Cancer (9702G001)					
AR073	Ovarian Cancer (9707G029)	Ovarian Cancer (9707G029)					
AR074	Ovarian Cancer (9804G011)	Ovarian Cancer (9804G011)					
AR075	Ovarian Cancer (9806G019)	Ovarian Cancer (9806G019)					
AR076	Ovarian Cancer (9807G017)	Ovarian Cancer (9807G017)					
AR077	Ovarian Cancer (9809G001)	Ovarian Cancer (9809G001)					
AR078	ovarian cancer 15799	ovarian cancer 15799					
AR079	Ovarian Cancer 17717AID	Ovarian Cancer 17717AID					
AR080	Ovarian Cancer 4004664B1	Ovarian Cancer 4004664B1					
AR081	Ovarian Cancer 4005315A1	Ovarian Cancer 4005315A1					
AR082	ovarian cancer 94127303	ovarian cancer 94127303					
AR083	Ovarian Cancer 96069304	Ovarian Cancer 96069304					
AR084	Ovarian Cancer 9707G029	Ovarian Cancer 9707G029					
AR085	Ovarian Cancer 9807G045	Ovarian Cancer 9807G045					
AR086	ovarian cancer 9809G001	ovarian cancer 9809G001					
AR087	Ovarian Cancer 9905C032RC	Ovarian Cancer 9905C032RC					
AR088	Ovarian cancer 9907 C00 3rd	Ovarian cancer 9907 C00 3rd					

AR089	Prostate	Prostate			
AR090	Prostate (clonotech)	Prostate (clonotech)			
AR091	prostate cancer	prostate cancer			
AR092	prostate cancer #15176	prostate cancer #15176			
AR093	prostate cancer #15509	prostate cancer #15509			
AR094	prostate cancer #15673	prostate cancer #15673			
AR095	Small Intestine (Clonotech)	Small Intestine (Clonotech)			
AR096	Spleen	Spleen			
AR097	Thymus T cells activated	Thymus T cells activated			
AR098	Thymus T cells resting	Thymus T cells resting			
AR099	Tonsil	Tonsil			
AR100	Tonsil germinal center centroblast	Tonsil germinal center centroblast			
AR101	Tonsil germinal center B cell	Tonsil germinal center B cell			
AR102	Tonsil lymph node	Tonsil lymph node			
AR103	Tonsil memory B cell	Tonsil memory B cell			
AR104	Whole Brain	Whole Brain			
AR105	Xenograft ES-2	Xenograft ES-2			
AR106	Xenograft SW626	Xenograft SW626			
AR119	001: IL-2	001: IL-2			
AR120	001: IL-2.1	001: IL-2.1			
AR121	001: IL-2_b	001: IL-2_b			
AR124	002 : Monocytes untreated (1hr)	002 : Monocytes untreated (1hr)			
AR125	002 : Monocytes untreated (5hrs)	002 : Monocytes untreated (5hrs)			
AR126	002: Control.1C	002: Control.1C			
AR127	002: IL2.1C	002: IL2.1C			
AR130	003 : Placebo-treated Rat	003 : Placebo-			

	Lacrimal Gland	treated Rat Lacrimal Gland					
AR131	003 : Placebo-treated Rat Submandibular Gland	003 : Placebo-treated Rat Submandibular Gland					
AR135	004 : Monocytes untreated (5hrs)	004 : Monocytes untreated (5hrs)					
AR136	004 : Monocytes untreated 1hr	004 : Monocytes untreated 1hr					
AR139	005: Placebo (48hrs)	005: Placebo (48hrs)					
AR140	006: pC4 (24hrs)	006: pC4 (24hrs)					
AR141	006: pC4 (48hrs)	006: pC4 (48hrs)					
AR152	007: PHA (1hr)	007: PHA (1hr)					
AR153	007: PHA (6HRS)	007: PHA (6HRS)					
AR154	007: PMA (6hrs)	007: PMA (6hrs)					
AR155	008: 1449 #2	008: 1449 #2					
AR161	01: A - max 24	01: A - max 24					
AR162	01: A - max 26	01: A - max 26					
AR163	01: A - max 30	01: A - max 30					
AR164	01: B - max 24	01: B - max 24					
AR165	01: B - max 26	01: B - max 26					
AR166	01: B - max 30	01: B - max 30					
AR167	1449 Sample	1449 Sample					
AR168	3T3P10 1.0uM insulin	3T3P10 1.0uM insulin					
AR169	3T3P10 10nM Insulin	3T3P10 10nM Insulin					
AR170	3T3P10 10uM insulin	3T3P10 10uM insulin					
AR171	3T3P10 No Insulin	3T3P10 No Insulin					
AR172	3T3P4	3T3P4					
AR173	Adipose (41892)	Adipose (41892)					
AR174	Adipose Diabetic (41611)	Adipose Diabetic (41611)					
AR175	Adipose Diabetic (41661)	Adipose Diabetic (41661)					

AR176	Adipose Diabetic (41689)	Adipose Diabetic (41689)							
AR177	Adipose Diabetic (41706)	Adipose Diabetic (41706)							
AR178	Adipose Diabetic (42352)	Adipose Diabetic (42352)							
AR179	Adipose Diabetic (42366)	Adipose Diabetic (42366)							
AR180	Adipose Diabetic (42452)	Adipose Diabetic (42452)							
AR181	Adipose Diabetic (42491)	Adipose Diabetic (42491)							
AR182	Adipose Normal (41843)	Adipose Normal (41843)							
AR183	Adipose Normal (41893)	Adipose Normal (41893)							
AR184	Adipose Normal (42452)	Adipose Normal (42452)							
AR185	Adrenal Gland	Adrenal Gland							
AR186	Adrenal Gland + Whole Brain	Adrenal Gland + Whole Brain							
AR187	B7(1hr)+ (inverted)	B7(1hr)+ (inverted)							
AR188	Breast (18275A2B)	Breast (18275A2B)							
AR189	Breast (4004199)	Breast (4004199)							
AR190	Breast (4004399)	Breast (4004399)							
AR191	Breast (4004943B7)	Breast (4004943B7)							
AR192	Breast (4005570B1)	Breast (4005570B1)							
AR193	Breast Cancer (4004127A30)	Breast Cancer (4004127A30)							
AR194	Breast Cancer (400443A21)	Breast Cancer (400443A21)							
AR195	Breast Cancer (4004643A2)	Breast Cancer (4004643A2)							
AR196	Breast Cancer (4004710A7)	Breast Cancer (4004710A7)							
AR197	Breast Cancer	Breast Cancer							

	(4004943A21)	(4004943A21)				
AR198	Breast Cancer (400553A2)	Breast Cancer (400553A2)				
AR199	Breast Cancer (9805C046R)	Breast Cancer (9805C046R)				
AR200	Breast Cancer (9806C012R)	Breast Cancer (9806C012R)				
AR201	Breast Cancer (ODQ 45913)	Breast Cancer (ODQ 45913)				
AR202	Breast Cancer (ODQ45913)	Breast Cancer (ODQ45913)				
AR203	Breast Cancer (ODQ4591B)	Breast Cancer (ODQ4591B)				
AR204	Colon Cancer (15663)	Colon Cancer (15663)				
AR205	Colon Cancer (4005144A4)	Colon Cancer (4005144A4)				
AR206	Colon Cancer (4005413A4)	Colon Cancer (4005413A4)				
AR207	Colon Cancer (4005570B1)	Colon Cancer (4005570B1)				
AR208	Control RNA #1	Control RNA #1				
AR209	Control RNA #2	Control RNA #2				
AR210	Cultured Preadipocyte (blue)	Cultured Preadipocyte (blue)				
AR211	Cultured Preadipocyte (Red)	Cultured Preadipocyte (Red)				
AR212	Donor II B-Cells 24hrs	Donor II B-Cells 24hrs				
AR213	Donor II Resting B-Cells	Donor II Resting B-Cells				
AR214	H114EP12 10nM Insulin	H114EP12 10nM Insulin				
AR215	H114EP12 (10nM insulin)	H114EP12 (10nM insulin)				
AR216	H114EP12 (2.6ug/ui)	H114EP12 (2.6ug/ui)				



AR217	H114EP12 (3.6ug/ul)	H114EP12 (3.6ug/ul)				
AR218	HUVEC #1	HUVEC #1				
AR219	HUVEC #2	HUVEC #2				
AR221	L6 undiff.	L6 undiff.				
AR222	L6 Undifferentiated	L6 Undifferentiated				
AR223	L6P8 + 10nM Insulin	L6P8 + 10nM Insulin				
AR224	L6P8 + HS	L6P8 + HS				
AR225	L6P8 10nM Insulin	L6P8 10nM Insulin				
AR226	Liver (00-06-A007B)	Liver (00-06-A007B)				
AR227	Liver (96-02-A075)	Liver (96-02-A075)				
AR228	Liver (96-03-A144)	Liver (96-03-A144)				
AR229	Liver (96-04-A138)	Liver (96-04-A138)				
AR230	Liver (97-10-A074B)	Liver (97-10-A074B)				
AR231	Liver (98-09-A242A)	Liver (98-09-A242A)				
AR232	Liver Diabetic (1042)	Liver Diabetic (1042)				
AR233	Liver Diabetic (41616)	Liver Diabetic (41616)				
AR234	Liver Diabetic (41955)	Liver Diabetic (41955)				
AR235	Liver Diabetic (42352R)	Liver Diabetic (42352R)				
AR236	Liver Diabetic (42366)	Liver Diabetic (42366)				
AR237	Liver Diabetic (42483)	Liver Diabetic (42483)				
AR238	Liver Diabetic (42491)	Liver Diabetic (42491)				
AR239	Liver Diabetic (99-09-A281A)	Liver Diabetic (99-09-A281A)				
AR240	Lung	Lung				
AR241	Lung (27270)	Lung (27270)				

AR242	Lung (2727Q)	Lung (2727Q)							
AR243	Lung Cancer (4005116A1)	Lung Cancer (4005116A1)							
AR244	Lung Cancer (4005121A5)	Lung Cancer (4005121A5)							
AR245	Lung Cancer (4005121A5))	Lung Cancer (4005121A5))							
AR246	Lung Cancer (4005340A4)	Lung Cancer (4005340A4)							
AR247	Mammary Gland	Mammary Gland							
AR248	Monocyte (CT)	Monocyte (CT)							
AR249	Monocyte (OCT)	Monocyte (OCT)							
AR250	Monocytes (CT)	Monocytes (CT)							
AR251	Monocytes (INFG 18 hr)	Monocytes (INFG 18 hr)							
AR252	Monocytes (INFG 18hr)	Monocytes (INFG 18hr)							
AR253	Monocytes (INFG 8-11)	Monocytes (INFG 8-11)							
AR254	Monocytes (O CT)	Monocytes (O CT)							
AR255	Muscle (91-01-A105)	Muscle (91-01-A105)							
AR256	Muscle (92-04-A059)	Muscle (92-04-A059)							
AR257	Muscle (97-11-A056d)	Muscle (97-11-A056d)							
AR258	Muscle (99-06-A210A)	Muscle (99-06-A210A)							
AR259	Muscle (99-07-A203B)	Muscle (99-07-A203B)							
AR260	Muscle (99-7-A203B)	Muscle (99-7-A203B)							
AR261	Muscle Diabetic (42352R)	Muscle Diabetic (42352R)							
AR262	Muscle Diabetic (42366)	Muscle Diabetic (42366)							
AR263	NK-19 Control	NK-19 Control							

AR264	NK-19 IL Treated 72hrs	NK-19 IL Treated 72hrs					
AR265	NK-19 UK Treated 72 hrs.	NK-19 UK Treated 72 hrs.					
AR266	Omentum Normal (94-08-B009)	Omentum Normal (94-08-B009)					
AR267	Omentum Normal (97-01-A039A)	Omentum Normal (97-01-A039A)					
AR268	Omentum Normal (97-04-A114C)	Omentum Normal (97-04-A114C)					
AR269	Omentum Normal (97-06-A117C)	Omentum Normal (97-06-A117C)					
AR270	Omentum Normal (97-09-B004C)	Omentum Normal (97-09-B004C)					
AR271	Ovarian Cancer (17717AID)	Ovarian Cancer (17717AID)					
AR272	Ovarian Cancer (9905C023RC)	Ovarian Cancer (9905C023RC)					
AR273	Ovarian Cancer (9905C032RC)	Ovarian Cancer (9905C032RC)					
AR274	Ovary (9508G045)	Ovary (9508G045)					
AR275	Ovary (9701G208)	Ovary (9701G208)					
AR276	Ovary 9806G005	Ovary 9806G005					
AR277	Pancreas	Pancreas					
AR278	Placebo	Placebo					
AR279	rIL2 Control	rIL2 Control					
AR280	RSS288L	RSS288L					
AR281	RSS288LC	RSS288LC					
AR282	Salivary Gland	Salivary Gland					
AR283	Skeletal Muscle	Skeletal Muscle					
AR284	Skeletal Muscle (91-01-A105)	Skeletal Muscle (91-01-A105)					
AR285	Skeletal Muscle (42180)	Skeletal Muscle (42180)					
AR286	Skeletal Muscle (42386)	Skeletal Muscle (42386)					
AR287	Skeletal Muscle (42461)	Skeletal Muscle (42461)					

AR288	Skeletal Muscle (91-01-A105)	(42461) Skeletal Muscle (91-01-A105)					
AR289	Skeletal Muscle (92-04-A059)	Skeletal Muscle (92-04-A059)					
AR290	Skeletal Muscle (96-08-A171)	Skeletal Muscle (96-08-A171)					
AR291	Skeletal Muscle (97-07-A190A)	Skeletal Muscle (97-07-A190A)					
AR292	Skeletal Muscle Diabetic (42352)	Skeletal Muscle Diabetic (42352)					
AR293	Skeletal Muscle Diabetic (42366)	Skeletal Muscle Diabetic (42366)					
AR294	Skeletal Muscle Diabetic (42395)	Skeletal Muscle Diabetic (42395)					
AR295	Skeletal Muscle Diabetic (42483)	Skeletal Muscle Diabetic (42483)					
AR296	Skeletal Muscle Diabetic (42491)	Skeletal Muscle Diabetic (42491)					
AR297	Skeletal Muscle Diabetic 42352	Skeletal Muscle Diabetic 42352					
AR298	Skeletal Muscle (42461)	Skeletal Muscle (42461)					
AR299	Small Intestine	Small Intestine					
AR300	Stomach	Stomach					
AR301	T-Cell + HDPBQ71.fc 1449 16hrs	T-Cell + HDPBQ71.fc 1449 16hrs					
AR302	T-Cell + HDPBQ71.fc 1449 6hrs	T-Cell + HDPBQ71.fc 1449 6hrs					
AR303	T-Cell + IL2 16hrs	T-Cell + IL2 16hrs					
AR304	T-Cell + IL2 6hrs	T-Cell + IL2 6hrs					
AR306	T-Cell Untreated 16hrs	T-Cell Untreated 16hrs					
AR307	T-Cell Untreated 6hrs	T-Cell Untreated 6hrs					

AR308	T-Cells 24 hours	T-Cells 24 hours				
AR309	T-Cells 24 hrs	T-Cells 24 hrs				
AR310	T-Cells 24 hrs.	T-Cells 24 hrs.				
AR311	T-Cells 24hrs	T-Cells 24hrs				
AR312	T-Cells 4 days	T-Cells 4 days				
AR313	Thymus	Thymus				
AR314	TRE	TRE				
AR315	TREC	TREC				
AR316	Virtual Mixture	Virtual Mixture				
H0004	Human Adult Spleen	Human Adult Spleen		Spleen		Uni-ZAP XR
H0008	Whole 6 Week Old Embryo					Uni-ZAP XR
H0009	Human Fetal Brain					Uni-ZAP XR
H0012	Human Fetal Kidney	Human Fetal Kidney		Kidney		Uni-ZAP XR
H0013	Human 8 Week Whole Embryo	Human 8 Week Old Embryo		Embryo		Uni-ZAP XR
H0014	Human Gall Bladder	Human Gall Bladder		Gall Bladder		Uni-ZAP XR
H0015	Human Gall Bladder, fraction II	Human Gall Bladder		Gall Bladder		Uni-ZAP XR
H0024	Human Fetal Lung III	Human Fetal Lung		Lung		Uni-ZAP XR
H0028	Human Old Ovary	Human Old Ovary		Ovary		pBluescript
H0030	Human Placenta					Uni-ZAP XR
H0031	Human Placenta	Human Placenta		Placenta		Uni-ZAP XR
H0032	Human Prostate	Human Prostate		Prostate		Uni-ZAP XR
H0033	Human Pituitary	Human Pituitary				Uni-ZAP XR
H0036	Human Adult Small Intestine	Human Adult Small Intestine		Small Int.		Uni-ZAP XR
H0038	Human Testes	Human Testes		Testis		Uni-ZAP XR
H0039	Human Pancreas Tumor	Human Pancreas Tumor		Pancreas	disease	Uni-ZAP XR
H0040	Human Testes Tumor	Human Testes Tumor		Testis	disease	Uni-ZAP XR
H0041	Human Fetal Bone	Human Fetal Bone		Bone		Uni-ZAP XR
H0042	Human Adult Pulmonary	Human Adult Pulmonary		Lung		Uni-ZAP XR

H0046	Human Endometrial Tumor	Human Endometrial Tumor	Uterus		disease	Uni-ZAP XR
H0050	Human Fetal Heart	Human Fetal Heart	Heart			Uni-ZAP XR
H0051	Human Hippocampus	Human Hippocampus	Brain			Uni-ZAP XR
H0052	Human Cerebellum	Human Cerebellum	Brain			Uni-ZAP XR
H0053	Human Adult Kidney	Human Adult Kidney	Kidney			Uni-ZAP XR
H0056	Human Umbilical Vein, Endo. remake	Human Umbilical Vein Endothelial Cells	Umbilical vein			Uni-ZAP XR
H0059	Human Uterine Cancer	Human Uterine Cancer	Uterus		disease	Lambda ZAP II
H0060	Human Macrophage	Human Macrophage	Blood	Cell Line		pBluescript
H0063	Human Thymus	Human Thymus	Thymus			Uni-ZAP XR
H0065	Human Esophagus, Normal	Human Esophagus, normal	Esophagus			Uni-ZAP XR
H0068	Human Skin Tumor	Human Skin Tumor	Skin		disease	Uni-ZAP XR
H0069	Human Activated T-Cells	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0071	Human Infant Adrenal Gland	Human Infant Adrenal Gland	Adrenal gland			Uni-ZAP XR
H0081	Human Fetal Epithelium (Skin)	Human Fetal Skin	Skin			Uni-ZAP XR
H0083	HUMAN JURKAT MEMBRANE BOUND POLYSOMES	Jurkat Cells				Uni-ZAP XR
H0085	Human Colon	Human Colon				Lambda ZAP II
H0086	Human epithelioid sarcoma	Epithelioid Sarcoma, muscle	Sk Muscle		disease	Uni-ZAP XR
H0087	Human Thymus	Human Thymus				pBluescript
H0090	Human T-Cell Lymphoma	T-Cell Lymphoma	T-Cell		disease	Uni-ZAP XR
H0097	Human Adult Heart, subtracted	Human Adult Heart	Heart			pBluescript
H0100	Human Whole Six Week Old Embryo	Human Whole Six Week Old Embryo	Embryo			Uni-ZAP XR
H0105	Human Fetal Heart, subtracted	Human Fetal Heart	Heart			pBluescript

H0107	Human Infant Adrenal Gland, subtracted	Human Infant Adrenal Gland	Adrenal gland			pBluescript
H0110	Human Old Ovary, subtracted	Human Old Ovary	Ovary			pBluescript
H0118	Human Adult Kidney	Human Adult Kidney	Kidney			Uni-ZAP XR
H0123	Human Fetal Dura Mater	Human Fetal Dura Mater	Brain			Uni-ZAP XR
H0124	Human Rhabdomyosarcoma	Human Rhabdomyosarcoma	Sk Muscle	disease		Uni-ZAP XR
H0125	Cem cells cyclohexamide treated	Cyclohexamide Treated Cem, Jurkat, Raji, and Supt	Blood	Cell Line		Uni-ZAP XR
H0134	Raji Cells, cyclohexamide treated	Cyclohexamide Treated Cem, Jurkat, Raji, and Supt	Blood	Cell Line		Uni-ZAP XR
H0135	Human Synovial Sarcoma	Human Synovial Sarcoma	Synovium			Uni-ZAP XR
H0136	Supt Cells, cyclohexamide treated	Cyclohexamide Treated Cem, Jurkat, Raji, and Supt	Blood	Cell Line		Uni-ZAP XR
H0144	Nine Week Old Early Stage Human	9 Wk Old Early Stage Human	Embryo			Uni-ZAP XR
H0150	Human Epididymus	Epididymis	Testis			Uni-ZAP XR
H0156	Human Adrenal Gland Tumor	Human Adrenal Gland Tumor	Adrenal Gland	disease		Uni-ZAP XR
H0159	Activated T-Cells, 8 hrs., ligation 2	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0160	Activated T-Cells, 12 hrs., ligation 2	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0163	Human Synovium	Human Synovium	Synovium			Uni-ZAP XR
H0165	Human Prostate Cancer, Stage B2	Human Prostate Cancer, stage B2	Prostate	disease		Uni-ZAP XR
H0166	Human Prostate Cancer, Stage B2 fraction	Human Prostate Cancer, stage B2	Prostate	disease		Uni-ZAP XR
H0169	Human Prostate Cancer, Stage C fraction	Human Prostate Cancer, stage C	Prostate	disease		Uni-ZAP XR

H0170	12 Week Old Early Stage Human	Twelve Week Old Early Stage Human	Embryo			Uni-ZAP XR
H0171	12 Week Old Early Stage Human, II	Twelve Week Old Early Stage Human	Embryo			Uni-ZAP XR
H0176	CAMA1Ee Cell Line	CAMA1Ee Cell Line	Breast	Cell Line		Uni-ZAP XR
H0179	Human Neutrophil	Human Neutrophil	Blood	Cell Line		Uni-ZAP XR
H0181	Human Primary Breast Cancer	Human Primary Breast Cancer	Breast		disease	Uni-ZAP XR
H0182	Human Primary Breast Cancer	Human Primary Breast Cancer	Breast		disease	Uni-ZAP XR
H0185	Activated T-Cell labeled with 4-thioluri	T-Cells	Blood	Cell Line		Lambda ZAP II
H0188	Human Normal Breast	Human Normal Breast	Breast			Uni-ZAP XR
H0196	Human Cardiomyopathy, subtracted	Human Cardiomyopathy	Heart			Uni-ZAP XR
H0208	Early Stage Human Lung, subtracted	Human Fetal Lung	Lung			pBluescript
H0212	Human Prostate, subtracted	Human Prostate	Prostate			pBluescript
H0213	Human Pituitary, subtracted	Human Pituitary				Uni-ZAP XR
H0214	Raji cells, cyclohexamide treated, subtracted	Cyclohexamide Treated Cem, Jurkat, Raji, and Supt	Blood	Cell Line		pBluescript
H0224	Activated T-Cells, 12 hrs, subtracted	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0225	Activated T-Cells, 12hrs, differentially expressed	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0231	Human Colon, subtraction	Human Colon				pBluescript
H0232	Human Colon, differential expression	Human Colon				pBluescript
H0234	human colon cancer, metastatic to liver, differentially expressed	Human Colon Cancer, metastatic to liver	Liver			pBluescript
H0242	Human Fetal Heart,	Human Fetal Heart	Heart			pBluescript



	Differential (Fetal-Specific)						
H0244	Human 8 Week Whole Embryo, subtraced	Human 8 Week Old Embryo	Embryo				Uni-ZAP XR
H0250	Human Activated Monocytes	Human Monocytes					Uni-ZAP XR
H0251	Human Chondrosarcoma	Human Chondrosarcoma	Cartilage			disease	Uni-ZAP XR
H0252	Human Osteosarcoma	Human Osteosarcoma	Bone			disease	Uni-ZAP XR
H0253	Human adult testis, large inserts	Human Adult Testis	Testis				Uni-ZAP XR
H0254	Breast Lymph node cDNA library	Breast Lymph Node	Lymph Node				Uni-ZAP XR
H0255	breast lymph node CDNA library	Breast Lymph Node	Lymph Node				Lambda ZAP II
H0256	HL-60, unstimulated	Human HL-60 Cells, unstimulated	Blood	Cell Line			Uni-ZAP XR
H0257	HL-60, PMA 4H	HL-60 Cells, PMA stimulated 4H	Blood	Cell Line			Uni-ZAP XR
H0261	H. cerebellum, Enzyme subtraced	Human Cerebellum	Brain				Uni-ZAP XR
H0263	human colon cancer	Human Colon Cancer	Colon			disease	Lambda ZAP II
H0264	human tonsils	Human Tonsil	Tonsil				Uni-ZAP XR
H0265	Activated T-Cell (12hs)/Thiouridine labelledEco	T-Cells	Blood	Cell Line			Uni-ZAP XR
H0266	Human Microvascular Endothelial Cells, fract. A	HMEC	Vein	Cell Line			Lambda ZAP II
H0268	Human Umbilical Vein Endothelial Cells, fract. A	HUVE Cells	Umbilical vein	Cell Line			Lambda ZAP II
H0269	Human Umbilical Vein Endothelial Cells, fract. B	HUVE Cells	Umbilical vein	Cell Line			Lambda ZAP II
H0270	HPAS (human pancreas, subtraced)	Human Pancreas	Pancreas				Uni-ZAP XR
H0271	Human Neutrophil,	Human Neutrophil -	Blood	Cell Line			Uni-ZAP XR

	Activated	Activated	Activated				
H0272	HUMAN TONSILS, FRACTION 2	Human Tonsil	Tonsil				Uni-ZAP XR
H0275	Human Infant Adrenal Gland, Subtracted	Human Infant Adrenal Gland	Adrenal gland				pBluescript
H0280	K562 + PMA (36 hrs)	K562 Cell line	cell line	Cell Line			ZAP Express
H0284	Human OB MG63 control fraction I	Human Osteoblastoma MG63 cell line	Bone	Cell Line			Uni-ZAP XR
H0286	Human OB MG63 treated (10 nM E2) fraction I	Human Osteoblastoma MG63 cell line	Bone	Cell Line			Uni-ZAP XR
H0292	Human OB HOS treated (10 nM E2) fraction I	Human Osteoblastoma HOS cell line	Bone	Cell Line			Uni-ZAP XR
H0294	Amniotic Cells - TNF induced	Amniotic Cells - TNF induced	Placenta	Cell Line			Uni-ZAP XR
H0295	Amniotic Cells - Primary Culture	Amniotic Cells - Primary Culture	Placenta	Cell Line			Uni-ZAP XR
H0298	HCBB's differential consolidation	CAMA1Ee Cell Line	Breast	Cell Line			Uni-ZAP XR
H0300	CD34 positive cells (Cord Blood)	CD34 Positive Cells	Cord Blood				ZAP Express
H0305	CD34 positive cells (Cord Blood)	CD34 Positive Cells	Cord Blood				ZAP Express
H0306	CD34 depleted Buffy Coat (Cord Blood)	CD34 Depleted Buffy Coat (Cord Blood)	Cord Blood				ZAP Express
H0309	Human Chronic Synovitis	Synovium, Chronic Synovitis/ Osteoarthritis	Synovium		disease		Uni-ZAP XR
H0318	HUMAN B CELL LYMPHOMA	Human B Cell Lymphoma	Lymph Node		disease		Uni-ZAP XR
H0320	Human frontal cortex	Human Frontal Cortex	Brain				Uni-ZAP XR
H0327	human corpus colosum	Human Corpus Callosum	Brain				Uni-ZAP XR

H0328	human ovarian cancer	Ovarian Cancer	Ovary		disease	Uni-ZAP XR
H0331	Hepatocellular Tumor	Hepatocellular Tumor	Liver		disease	Lambda ZAP II
H0333	Hemangiopericytoma	Hemangiopericytoma	Blood vessel		disease	Lambda ZAP II
H0341	Bone Marrow Cell Line (RS4;11)	Bone Marrow Cell Line RS4;11	Bone Marrow	Cell Line		Uni-ZAP XR
H0343	stomach cancer (human)	Stomach Cancer - 5383A (human)			disease	Uni-ZAP XR
H0351	Glioblastoma	Glioblastoma	Brain		disease	Uni-ZAP XR
H0352	wilm's tumor	Wilm's Tumor			disease	Uni-ZAP XR
H0355	Human Liver	Human Liver, normal Adult				pCMVSPORT 1
H0359	KMH2 cell line	KMH2				ZAP Express
H0365	Osteoclastoma-normalized B	Human Osteoclastoma			disease	Uni-ZAP XR
H0370	H. Lymph node breast Cancer	Lymph node with Met. Breast Cancer			disease	Uni-ZAP XR
H0372	Human Testes	Human Testes	Testis			pCMVSPORT 1
H0373	Human Heart	Human Adult Heart	Heart			pCMVSPORT 1
H0375	Human Lung	Human Lung				pCMVSPORT 1
H0376	Human Spleen	Human Adult Spleen	Spleen			pCMVSPORT 1
H0383	Human Prostate BPH, re-excision	Human Prostate BPH				Uni-ZAP XR
H0388	Human Rejected Kidney, 704 re-excision	Human Rejected Kidney			disease	pBluescript
H0391	H. Meningioma, M6	Human Meningioma	brain			pSport1
H0393	Fetal Liver, subtraction II	Human Fetal Liver	Liver			pBluescript
H0399	Human Kidney Cortex, re-rescue	Human Kidney Cortex				Lambda ZAP II
H0402	CD34 depleted Buffy Coat (Cord Blood), re-excision	CD34 Depleted Buffy Coat (Cord Blood)	Cord Blood			ZAP Express
H0405	Human Pituitary, subtracted VI	Human Pituitary				pBluescript
H0409	H. Striatum Depression,	Human Brain,	Brain			pBluescript

	subtracted	Striatum Depression				
H0410	H. Male bladder, adult	H Male Bladder, Adult	Bladder			pSportl
H0411	H Female Bladder, Adult	Human Female Adult Bladder	Bladder			pSportl
H0412	Human umbilical vein endothelial cells, IL-4 induced	HUVE Cells	Umbilical vein	Cell Line		pSportl
H0413	Human Umbilical Vein Endothelial Cells, uninduced	HUVE Cells	Umbilical vein	Cell Line		pSportl
H0415	H. Ovarian Tumor, II, OV5232	Ovarian Tumor, OV5232	Ovary		disease	pCMVSPORT 2.0
H0417	Human Pituitary, subtracted VIII	Human Pituitary				pBluescript
H0418	Human Pituitary, subtracted VII	Human Pituitary				pBluescript
H0421	Human Bone Marrow, re-excision	Bone Marrow				pBluescript
H0422	T-Cell PHA 16 hrs	T-Cells	Blood	Cell Line		pSportl
H0423	T-Cell PHA 24 hrs	T-Cells	Blood	Cell Line		pSportl
H0424	Human Pituitary, sub IX	Human Pituitary				pBluescript
H0427	Human Adipose	Human Adipose, left hipipoma				pSportl
H0428	Human Ovary	Human Ovary	Ovary			pSportl
H0431	H. Kidney Medulla, re-excision	Kidney medulla	Kidney			pBluescript
H0433	Human Umbilical Vein Endothelial cells, frac B, re-excision	HUVE Cells	Umbilical vein	Cell Line		pBluescript
H0435	Ovarian Tumor 10-3-95	Ovarian Tumor, OV350721	Ovary			pCMVSPORT 2.0
H0436	Resting T-Cell Library, II	T-Cells	Blood	Cell Line		pSportl
H0437	H Umbilical Vein Endothelial Cells, frac A, re-excision	HUVE Cells	Umbilical vein	Cell Line		Lambda ZAP II

H0438	H. Whole Brain #2, re-excision	Human Whole Brain #2				ZAP Express
H0439	Human Eosinophils	Eosinophils				pBluescript
H0440	FGF enriched mixed library	Mixed libraries				pCMVSPORT 1
H0441	H. Kidney Cortex, subtracted	Kidney cortex	Kidney			pBluescript
H0442	H. Striatum Depression, sub II	Human Brain, Striatum Depression	Brain			pBluescript
H0444	Spleen metastatic melanoma	Spleen, Metastatic malignant melanoma	Spleen	disease		pSport1
H0445	Spleen, Chronic Lymphocytic leukemia	Human Spleen, CLL	Spleen	disease		pSport1
H0453	H. Kidney Pyramid, subtracted	Kidney pyramids	Kidney			pBluescript
H0455	H. Striatum Depression, sub	Human Brain, Striatum Depression	Brain			pBluescript
H0457	Human Eosinophils	Human Eosinophils				pSport1
H0461	H. Kidney Medulla, subtracted	Kidney medulla	Kidney			pBluescript
H0478	Salivary Gland, Lib 2	Human Salivary Gland	Salivary gland			pSport1
H0483	Breast Cancer cell line, MDA 36	Breast Cancer Cell line, MDA 36				pSport1
H0484	Breast Cancer Cell line, angiogenic	Breast Cancer Cell line, Angiogenic, 36T3				pSport1
H0485	Hodgkin's Lymphoma I	Hodgkin's Lymphoma I		disease		pCMVSPORT 2.0
H0486	Hodgkin's Lymphoma II	Hodgkin's Lymphoma II		disease		pCMVSPORT 2.0
H0488	Human Tonsils, Lib 2	Human Tonsils				pCMVSPORT 2.0
H0490	HL-60, untreated, subtracted	Human HL-60 Cells, unstimulated	Blood	Cell Line		Uni-ZAP XR
H0494	Keratinocyte	Keratinocyte				pCMVSPORT 2.0
H0497	HEL cell line	HEL cell line		HEL		pSport1

				92.1.7		
H0506	Ulcerative Colitis	Colon				pSport1
H0509	Liver, Hepatoma	Human Liver, Hepatoma, patient 8	Liver		disease	pCMV/Sport 3.0
H0510	Human Liver, normal	Human Liver, normal, Patient # 8	Liver			pCMV/Sport 3.0
H0518	pBMC stimulated w/ poly I/C	pBMC stimulated with poly I/C				pCMV/Sport 3.0
H0519	NTERA2, control	NTERA2, Teratocarcinoma cell line				pCMV/Sport 3.0
H0520	NTERA2 + retinoic acid, 14 days	NTERA2, Teratocarcinoma cell line				pSport1
H0521	Primary Dendritic Cells, lib 1	Primary Dendritic cells				pCMV/Sport 3.0
H0522	Primary Dendritic cells, frac 2	Primary Dendritic cells				pCMV/Sport 3.0
H0525	PCR, pBMC I/C treated	pBMC stimulated with poly I/C				PCRII
H0529	Myeloid Progenitor Cell Line	TF-1 Cell Line; Myeloid progenitor cell line				pCMV/Sport 3.0
H0530	Human Dermal Endothelial Cells, untreated	Human Dermal Endothelial Cells; untreated				pSport1
H0537	H. Primary Dendritic Cells, lib 3	Primary Dendritic cells				pCMV/Sport 2.0
H0538	Merkel Cells	Merkel cells	Lymph node			pSport1
H0539	Pancreas Islet Cell Tumor	Pancreas Islet Cell Tumour	Pancreas		disease	pSport1
H0540	Skin, burned	Skin, leg burned	Skin			pSport1
H0542	T Cell helper I	Helper T cell				pCMV/Sport 3.0
H0543	T cell helper II	Helper T cell				pCMV/Sport 3.0
H0544	Human endometrial stromal cells	Human endometrial stromal cells				pCMV/Sport 3.0
H0545	Human endometrial	Human endometrial				pCMV/Sport 3.0

	stromal cells-treated with progesterone	stromal cells-treated with proge					
H0546	Human endometrial stromal cells-treated with estradiol	Human endometrial stromal cells-treated with estradiol					pCMVSPORT 3.0
H0547	NTERA2 teratocarcinoma cell line+retinoic acid (14 days)	NTERA2, Teratocarcinoma cell line					pSport1
H0549	H. Epididymus, caput & corpus	Human Epididymus, caput and corpus					Uni-ZAP XR
H0550	H. Epididymus, cauda	Human Epididymus, cauda					Uni-ZAP XR
H0551	Human Thymus Stromal Cells	Human Thymus Stromal Cells					pCMVSPORT 3.0
H0553	Human Placenta	Human Placenta					pCMVSPORT 3.0
H0555	Rejected Kidney, lib 4	Human Rejected Kidney	Kidney			disease	pCMVSPORT 3.0
H0556	Activated T-cell(12h)/Thiouridine-re-excision	T-Cells	Blood		Cell Line		Uni-ZAP XR
H0559	HL-60, PMA 4H, re-excision	HL-60 Cells, PMA stimulated 4H	Blood		Cell Line		Uni-ZAP XR
H0560	KMH2	KMH2					pCMVSPORT 3.0
H0561	L428	L428					pCMVSPORT 3.0
H0563	Human Fetal Brain, normalized 50021F	Human Fetal Brain					pCMVSPORT 2.0
H0566	Human Fetal Brain, normalized c50F	Human Fetal Brain					pCMVSPORT 2.0
H0569	Human Fetal Brain, normalized CO	Human Fetal Brain					pCMVSPORT 2.0
H0570	Human Fetal Brain, normalized C500H	Human Fetal Brain					pCMVSPORT 2.0
H0571	Human Fetal Brain, normalized C500HE	Human Fetal Brain					pCMVSPORT 2.0
H0574	Hepatocellular Tumor, re-excision	Hepatocellular Tumor	Liver			disease	Lambda ZAP II

H0575	Human Adult Pulmonary;re-excision	Human Adult Pulmonary	Lung			Uni-ZAP XR
H0576	Resting T-Cell; re- excision	T-Cells	Blood	Cell Line		Lambda ZAP II
H0578	Human Fetal Thymus	Fetal Thymus	Thymus			pSport1
H0579	Pericardium	Pericardium	Heart			pSport1
H0580	Dendritic cells, pooled	Pooled dendritic cells				pCMVSPORT 3.0
H0581	Human Bone Marrow, treated	Human Bone Marrow	Bone Marrow			pCMVSPORT 3.0
H0583	B Cell lymphoma	B Cell Lymphoma	B Cell	disease		pCMVSPORT 3.0
H0584	Activated T-cells, 24 hrs;re-excision	Activated T-Cells	Blood	Cell Line		Uni-ZAP XR
H0586	Healing groin wound, 6.5 hours post incision	healing groin wound, 6.5 hours post incision - 2/ Groin-2/19/97	groin	disease		pCMVSPORT 3.0
H0587	Healing groin wound; 7.5 hours post incision	Groin-2/19/97	groin	disease		pCMVSPORT 3.0
H0590	Human adult small intestine;re-excision	Human Adult Small Intestine	Small Int.			Uni-ZAP XR
H0591	Human T-cell lymphoma;re-excision	T-Cell Lymphoma	T-Cell	disease		Uni-ZAP XR
H0592	Healing groin wound - zero hr post-incision (control)	HGS wound healing project; abdomen		disease		pCMVSPORT 3.0
H0593	Olfactory epithelium;nasalcavity	Olfactory epithelium from roof of left nasal cavit				pCMVSPORT 3.0
H0594	Human Lung Cancer;re- excision	Human Lung Cancer	Lung	disease		Lambda ZAP II
H0595	Stomach cancer (human);re-excision	Stomach Cancer - 5383A (human)		disease		Uni-ZAP XR
H0596	Human Colon Cancer;re- excision	Human Colon Cancer	Colon			Lambda ZAP II
H0597	Human Colon; re-excision	Human Colon				Lambda ZAP II
H0599	Human Adult Heart;re- excision	Human Adult Heart	Heart			Uni-ZAP XR



H0600	Healing Abdomen wound; 70&90 min post incision	Abdomen				disease	pCMVSPORT 3.0
H0604	Human Pituitary, re-excision	Human Pituitary					pBluescript
H0606	Human Primary Breast Cancer; re-excision	Human Primary Breast Cancer		Breast		disease	Uni-ZAP XR
H0607	H. Leukocytes, normalized cot 50A3	H. Leukocytes					pCMVSPORT 1
H0613	H. Leukocytes, normalized cot 5B	H. Leukocytes					pCMVSPORT 1
H0615	Human Ovarian Cancer Reexcision	Ovarian Cancer		Ovary		disease	Uni-ZAP XR
H0616	Human Testes, Reexcision	Human Testes		Testis			Uni-ZAP XR
H0617	Human Primary Breast Cancer Reexcision	Human Primary Breast Cancer		Breast		disease	Uni-ZAP XR
H0618	Human Adult Testes, Large Inserts, Reexcision.	Human Adult Testis		Testis			Uni-ZAP XR
H0619	Fetal Heart	Human Fetal Heart		Heart			Uni-ZAP XR
H0620	Human Fetal Kidney; Reexcision	Human Fetal Kidney		Kidney			Uni-ZAP XR
H0622	Human Pancreas Tumor; Reexcision	Human Pancreas Tumor		Pancreas		disease	Uni-ZAP XR
H0623	Human Umbilical Vein; Reexcision	Human Umbilical Vein Endothelial Cells		Umbilical vein			Uni-ZAP XR
H0624	12 Week Early Stage Human II; Reexcision	Twelve Week Old Early Stage Human		Embryo			Uni-ZAP XR
H0625	Ku 812F Basophils Line	Ku 812F Basophils					pSPORT1
H0628	Human Pre-Differentiated Adipocytes	Human Pre-Differentiated Adipocytes					Uni-ZAP XR
H0631	Saos2, Dexamethosone Treated	Saos2 Cell Line; Dexamethosone Treated					pSPORT1
H0632	Hepatocellular Tumor; re-excision	Hepatocellular Tumor		Liver			Lambda ZAP II

H0633	Lung Carcinoma A549 TNFalpha activated	TNFalpha activated A549-- Lung Carcinoma				disease	pSport1
H0634	Human Testes Tumor, re- excision	Human Testes Tumor	Testis			disease	Uni-ZAP XR
H0635	Human Activated T-Cells, re-excision	Activated T-Cells	Blood	Cell Line			Uni-ZAP XR
H0637	Dendritic Cells From CD34 Cells	Dendritic cells from CD34 cells					pSport1
H0638	CD40 activated monocyte dendritic cells	CD40 activated monocyte dendritic cells					pSport1
H0640	Ficoll Human Stromal Cells, Untreated	Ficoll Human Stromal Cells, Untreated					Other
H0641	LPS activated derived dendritic cells	LPS activated monocyte derived dendritic cells					pSport1
H0643	Hep G2 Cells, PCR library	Hep G2 Cells					Other
H0644	Human Placenta (re- excision)	Human Placenta	Placenta				Uni-ZAP XR
H0645	Fetal Heart, re-excision	Human Fetal Heart	Heart				Uni-ZAP XR
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,	Metastatic squamous cell lung carcinoma, poorly di					pSport1
H0647	Lung, Cancer (4005163 B7): Invasive, Poorly Diff. Adenocarcinoma, Metastatic	Invasive poorly differentiated lung adenocarcinoma				disease	pSport1
H0648	Ovary, Cancer: (4004562 B6) Papillary Serous Cystic Neoplasm, Low Malignant Pot	Papillary Cstic neoplasm of low malignant potentia				disease	pSport1
H0649	Lung, Normal: (4005313 B1)	Normal Lung					pSport1
H0650	B-Cells	B-Cells					pCMVSPORT 3.0

H0651	Ovary, Normal: (9805C040R)	Normal Ovary				pSportl
H0652	Lung, Normal: (4005313 B1)	Normal Lung				pSportl
H0653	Stromal Cells	Stromal Cells				pSportl
H0656	B-cells (unstimulated)	B-cells (unstimulated)				pSportl
H0657	B-cells (stimulated)	B-cells (stimulated)				pSportl
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	9809C332- Poorly differentiate	Ovary & Fallopian Tubes	disease		pSportl
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	Grade II Papillary Carcinoma, Ovary	Ovary	disease		pSportl
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	Poorly differentiated carcinoma, ovary		disease		pSportl
H0661	Breast, Cancer: (4004943 A5)	Breast cancer		disease		pSportl
H0662	Breast, Normal: (4005522B2)	Normal Breast - #4005522(B2)	Breast			pSportl
H0663	Breast, Cancer: (4005522 A2)	Breast Cancer - #4005522(A2)	Breast	disease		pSportl
H0664	Breast, Cancer: (9806C012R)	Breast Cancer	Breast	disease		pSportl
H0665	Stromal cells 3.88	Stromal cells 3.88				pSportl
H0667	Stromal cells(HBM3.18)	Stromal cell(HBM 3.18)				pSportl
H0668	stromal cell clone 2.5	stromal cell clone 2.5				pSportl
H0670	Ovary, Cancer(4004650 A3): Well-Differentiated Micropapillary Serous Carcinoma	Ovarian Cancer - 4004650A3				pSportl
H0672	Ovary, Cancer: (4004576 A8)	Ovarian Cancer(4004576A8)	Ovary			pSportl

H0673	Human Prostate Cancer, Stage B2; re-excision	Human Prostate Cancer, stage B2	Prostate			Uni-ZAP XR
H0674	Human Prostate Cancer, Stage C; re-excision	Human Prostate Cancer, stage C	Prostate			Uni-ZAP XR
H0682	Serous Papillary Adenocarcinoma	serous papillary adenocarcinoma (9606G304SPA3B)				pCMVSPORT 3.0
H0683	Ovarian Serous Papillary Adenocarcinoma	Serous papillary adenocarcinoma, stage 3C (9804G01)				pCMVSPORT 3.0
H0684	Serous Papillary Adenocarcinoma	Ovarian Cancer-9810G606	Ovaries			pCMVSPORT 3.0
H0685	Adenocarcinoma of Ovary, Human Cell Line, # OVCAR-3	Adenocarcinoma of Ovary, Human Cell Line, # OVCAR-3				pCMVSPORT 3.0
H0686	Adenocarcinoma of Ovary, Human Cell Line	Adenocarcinoma of Ovary, Human Cell Line, # SW-626				pCMVSPORT 3.0
H0687	Human normal ovary(#9610G215)	Human normal ovary(#9610G215)	Ovary			pCMVSPORT 3.0
H0688	Human Ovarian Cancer(#9807G017)	Human Ovarian cancer(#9807G017), mRNA from Maura Ru				pCMVSPORT 3.0
H0689	Ovarian Cancer	Ovarian Cancer, #9806G019				pCMVSPORT 3.0
H0690	Ovarian Cancer, #9702G001	Ovarian Cancer, #9702G001				pCMVSPORT 3.0
H0694	Prostate gland adenocarcinoma	Prostate gland, adenocarcinoma, mod/diff, gleason	prostate gland			pCMVSPORT 3.0
H0695	mononucleocytes from patient	mononucleocytes from patient at Shady Grove Hospit				pCMVSPORT 3.0
N0006	Human Fetal Brain	Human Fetal Brain				
S0001	Brain frontal cortex	Brain frontal cortex	Brain			Lambda ZAP II
S0002	Monocyte activated	Monocyte-activated	blood	Cell Line		Uni-ZAP XR

S0003	Human Osteoclastoma	Osteoclastoma	bone		disease	Uni-ZAP XR
S0007	Early Stage Human Brain	Human Fetal Brain				Uni-ZAP XR
S0010	Human Amygdala	Amygdala				Uni-ZAP XR
S0011	STROMAL - OSTEOCLASTOMA	Osteoclastoma	bone		disease	Uni-ZAP XR
S0013	Prostate	Prostate	prostate			Uni-ZAP XR
S0015	Kidney medulla	Kidney medulla	Kidney			Uni-ZAP XR
S0016	Kidney Pyramids	Kidney pyramids	Kidney			Uni-ZAP XR
S0022	Human Osteoclastoma Stromal Cells - unamplified	Osteoclastoma Stromal Cells				Uni-ZAP XR
S0026	Stromal cell TF274	stromal cell	Bone marrow	Cell Line		Uni-ZAP XR
S0027	Smooth muscle, serum treated	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0028	Smooth muscle, control	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0029	brain stem	Brain stem	brain			Uni-ZAP XR
S0031	Spinal cord	Spinal cord	spinal cord			Uni-ZAP XR
S0032	Smooth muscle-ILb induced	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0036	Human Substantia Nigra	Human Substantia Nigra				Uni-ZAP XR
S0037	Smooth muscle, IL1b induced	Smooth muscle	Pulmonary artery	Cell Line		Uni-ZAP XR
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	Human Whole Brain #2				ZAP Express
S0040	Adipocytes	Human Adipocytes from Osteoclastoma				Uni-ZAP XR
S0044	Prostate BPH	prostate BPH	Prostate		disease	Uni-ZAP XR
S0045	Endothelial cells-control	Endothelial cell	endothelial cell-lung	Cell Line		Uni-ZAP XR
S0046	Endothelial-induced	Endothelial cell	endothelial cell-lung	Cell Line		Uni-ZAP XR
S0049	Human Brain, Striatum	Human Brain, Striatum				Uni-ZAP XR
S0050	Human Frontal Cortex, Schizophrenia	Human Frontal Cortex,			disease	Uni-ZAP XR

	Human Hypothalamus, Schizophrenia	Schizophrenia Human Hypothalamus, Schizophrenia		disease	Uni-ZAP XR
S0051					
S0052	neutrophils control	human neutrophils	blood	Cell Line	Uni-ZAP XR
S0053	Neutrophils IL-1 and LPS induced	human neutrophil induced	blood	Cell Line	Uni-ZAP XR
S0112	Hypothalamus		Brain		Uni-ZAP XR
S0114	Anergic T-cell	Anergic T-cell		Cell Line	Uni-ZAP XR
S0116	Bone marrow	Bone marrow	Bone marrow		Uni-ZAP XR
S0126	Osteoblasts	Osteoblasts	Knee	Cell Line	Uni-ZAP XR
S0132	Epithelial-TNF $\alpha$ and INF induced	Airway Epithelial			Uni-ZAP XR
S0134	Apoptotic T-cell	apoptotic cells		Cell Line	Uni-ZAP XR
S0140	eosinophil-IL5 induced	eosinophil	lung	Cell Line	Uni-ZAP XR
S0142	Macrophage-oxLDL	macrophage-oxidized LDL treated	blood	Cell Line	Uni-ZAP XR
S0144	Macrophage (GM-CSF treated)	Macrophage (GM-CSF treated)			Uni-ZAP XR
S0146	prostate-edited	prostate BPH	Prostate		Uni-ZAP XR
S0150	LNCAP prostate cell line	LNCAP Cell Line	Prostate	Cell Line	Uni-ZAP XR
S0152	PC3 Prostate cell line	PC3 prostate cell line			Uni-ZAP XR
S0182	Human B Cell 8866	Human B- Cell 8866			Uni-ZAP XR
S0190	Prostate BPH, Lib 2, subtracted	Human Prostate BPH			pSport1
S0192	Synovial Fibroblasts (control)	Synovial Fibroblasts			pSport1
S0194	Synovial hypoxia	Synovial Fibroblasts			pSport1
S0196	Synovial IL-1/TNF stimulated	Synovial Fibroblasts			pSport1
S0206	Smooth Muscle- HASTE normalized	Smooth muscle	Pulmonary artery	Cell Line	pBluescript
S0208	Mesangial cell, frac 1	Mesangial cell			pSport1
S0210	Mesangial cell, frac 2	Mesangial cell			pSport1
S0212	Bone Marrow Stromal	Bone Marrow			pSport1

	Cell, untreated	Stromal Cell, untreated					
S0214	Human Osteoclastoma, re-excision	Osteoclastoma	bone		disease		Uni-ZAP XR
S0216	Neutrophils IL-1 and LPS induced	human neutrophil induced	blood	Cell Line			Uni-ZAP XR
S0218	Apoptotic T-cell, re-excision	apoptotic cells		Cell Line			Uni-ZAP XR
S0222	H. Frontal cortex, epileptic, re-excision	H. Brain, Frontal Cortex, Epileptic	Brain		disease		Uni-ZAP XR
S0242	Synovial Fibroblasts (III/TNF), subt	Synovial Fibroblasts					pSport1
S0250	Human Osteoblasts II	Human Osteoblasts	Femur		disease		pCMVSPORT 2.0
S0260	Spinal Cord, re-excision	Spinal cord	spinal cord				Uni-ZAP XR
S0276	Synovial hypoxia-RSF subtracted	Synovial fobroblasts (rheumatoid)	Synovial tissue				pSport1
S0278	H Macrophage (GM-CSF treated), re-excision	Macrophage (GM-CSF treated)					Uni-ZAP XR
S0282	Brain Frontal Cortex, re-excision	Brain frontal cortex	Brain				Lambda ZAP II
S0292	Osteoarthritis (OA-4)	Human Osteoarthritic Cartilage	Bone		disease		pSport1
S0298	Bone marrow stroma, treated	Bone marrow stroma, treated SB	Bone marrow				pSport1
S0300	Frontal lobe, dementia, re-excision	Frontal Lobe dementia/Alzheimer's	Brain				Uni-ZAP XR
S0308	Spleen/normal	Spleen normal					pSport1
S0318	Human Normal Cartilage Fraction II	Human Normal Cartilage					pSport1
S0328	Palate carcinoma	Palate carcinoma	Uvula		disease		pSport1
S0330	Palate normal	Palate normal	Uvula				pSport1
S0332	Pharynx carcinoma	Pharynx carcinoma	Hypopharynx				pSport1
S0334	Human Normal Cartilage Fraction III	Human Normal Cartilage					pSport1

S0338	Human Osteoarthritic Cartilage Fraction III	Human Osteoarthritic cartilage				disease	pSport1
S0342	Adipocytes; re-excision	Human Adipocytes from Osteoclastoma					Uni-ZAP XR
S0344	Macrophage-oxLDL; re-excision	macrophage-oxidized LDL treated	blood	Cell Line			Uni-ZAP XR
S0346	Human Amygdala; re-excision	Amygdala					Uni-ZAP XR
S0350	Pharynx Carcinoma	Pharynx carcinoma	Hypopharynx			disease	pSport1
S0352	Larynx Carcinoma	Larynx carcinoma				disease	pSport1
S0354	Colon Normal II	Colon Normal	Colon				pSport1
S0356	Colon Carcinoma	Colon Carcinoma	Colon			disease	pSport1
S0358	Colon Normal III	Colon Normal	Colon				pSport1
S0360	Colon Tumor II	Colon Tumor	Colon			disease	pSport1
S0364	Human Quadriceps	Quadriceps muscle					pSport1
S0366	Human Soleus	Soleus Muscle					pSport1
S0370	Larynx carcinoma II	Larynx carcinoma				disease	pSport1
S0374	Normal colon	Normal colon					pSport1
S0376	Colon Tumor	Colon Tumor				disease	pSport1
S0378	Pancreas normal PCA4	Pancreas Normal PCA4 No					pSport1
S0380	Pancreas Tumor PCA4 Tu	Pancreas Tumor PCA4 Tu				disease	pSport1
S0384	Tongue carcinoma	Tongue carcinoma				disease	pSport1
S0386	Human Whole Brain, re-excision	Whole brain	Brain				ZAP Express
S0388	Human Hypothalamus, schizophrenia, re-excision	Human Hypothalamus, Schizophrenia				disease	Uni-ZAP XR
S0390	Smooth muscle, control; re-excision	Smooth muscle	Pulmonary artery	Cell Line			Uni-ZAP XR
S0392	Salivary Gland	Salivary gland; normal					pSport1
S0404	Rectum normal	Rectum, normal					pSport1
S0406	Rectum tumour	Rectum tumour					pSport1



S0408	Colon, normal	Colon, normal					pSportl
S0410	Colon, tumour	Colon, tumour					pSportl
S0412	Temporal cortex - Alzheimer; subtracted	Temporal cortex, Alzheimer				disease	Other
S0414	Hippocampus, Alzheimer Subtracted	Hippocampus, Alzheimer Subtracted					Other
S0418	CHME Cell Line; treated 5 hrs	CHME Cell Line; treated					pCMVSPORT 3.0
S0420	CHME Cell Line, untreated	CHME Cell line, untreated					pSportl
S0422	Mo7e Cell Line GM-CSF treated (1ng/ml)	Mo7e Cell Line GM-CSF treated (1ng/ml)					pCMVSPORT 3.0
S0424	TF-1 Cell Line GM-CSF Treated	TF-1 Cell Line GM-CSF Treated					pSportl
S0426	Monocyte activated; re-excision	Monocyte-activated	blood		Cell Line		Uni-ZAP XR
S0428	Neutrophils control; re-excision	human neutrophils	blood		Cell Line		Uni-ZAP XR
S0430	Aryepiglottis Normal	Aryepiglottis Normal					pSportl
S0432	Sinus piniformis Tumour	Sinus piniformis Tumour					pSportl
S0434	Stomach Normal	Stomach Normal				disease	pSportl
S0436	Stomach Tumour	Stomach Tumour				disease	pSportl
S0438	Liver Normal Met5No	Liver Normal Met5No					pSportl
S0440	Liver Tumour Met 5 Tu	Liver Tumour					pSportl
S0442	Colon Normal	Colon Normal					pSportl
S0444	Colon Tumour	Colon Tumour				disease	pSportl
S0448	Larynx Normal	Larynx Normal					pSportl
S0458	Thyroid Normal (SDCA2 No)	Thyroid normal					pSportl
S0460	Thyroid Tumour	Thyroid Tumour					pSportl
S0462	Thyroid Thyroiditis	Thyroid Thyroiditis					pSportl
S0474	Human blood platelets	Platelets	Blood				Other

S3012	Smooth Muscle Serum			platelets	Cell Line		pBluescript
	Treated, Norm			Pulmonary artery			
S3014	Smooth muscle, serum			Pulmonary artery	Cell Line		pBluescript
S6014	H. hypothalamus, frac A			Brain			ZAP Express
S6016	H. Frontal Cortex, Epileptic			Brain		disease	Uni-ZAP XR
S6022	H. Adipose Tissue						Uni-ZAP XR
S6024	Alzheimer's, spongy change			Brain		disease	Uni-ZAP XR
S6026	Frontal Lobe, Dementia			Brain			Uni-ZAP XR
S6028	Human Manic Depression Tissue			Brain		disease	Uni-ZAP XR
T0002	Activated T-cells			Blood	Cell Line		pBluescript SK-
T0004	Human White Fat			Human White Fat			pBluescript SK-
T0006	Human Pineal Gland			Human Pineal Gland			pBluescript SK-
T0008	Colorectal Tumor			Colorectal Tumor		disease	pBluescript SK-
T0010	Human Infant Brain			Human Infant Brain			Other
T0023	Human Pancreatic Carcinoma			Human Pancreatic Carcinoma		disease	pBluescript SK-
T0039	HSA 172 Cells			Human HSA 172 cell line			pBluescript SK-
T0040	HSC172 cells			SA172 Cells			pBluescript SK-
T0041	Jurkat T-cell G1 phase			Jurkat T-cell			pBluescript SK-
T0042	Jurkat T-cell, S phase			Jurkat T-Cell Line			pBluescript SK-
T0048	Human Aortic Endothelium			Human Aortic Endothelium			pBluescript SK-
T0049	Aorta endothelial cells + TNF- $\alpha$			Aorta endothelial cells			pBluescript SK-
T0060	Human White Adipose			Human White Fat			pBluescript SK-
T0067	Human Thyroid			Human Thyroid			pBluescript SK-

T0069	Human Uterus, normal	Human Uterus, normal				pBluescript SK-
T0071	Human Bone Marrow	Human Bone Marrow				pBluescript SK-
T0082	Human Adult Retina	Human Adult Retina				pBluescript SK-
T0103	Human colon carcinoma (HCC) cell line					pBluescript SK-
T0109	Human (HCC) cell line liver (mouse) metastasis, remake					pBluescript SK-
T0110	Human colon carcinoma (HCC) cell line, remake					pBluescript SK-
T0112	Human (Caco-2) cell line, adenocarcinoma, colon					pBluescript SK-
T0114	Human (Caco-2) cell line, adenocarcinoma, colon, remake					pBluescript SK-
T0115	Human Colon Carcinoma (HCC) cell line					pBluescript SK-
L0002	Atrium cDNA library Human heart					
L0005	Clontech human aorta polyA+ mRNA (#6572)					
L0021	Human adult (K. Okubo)					
L0022	Human adult lung 3" directed Mbol cDNA					
L0045	Human keratinocyte differential display (B.Lin)					
L0055	Human promyelocyte					
L0065	Liver HepG2 cell line.					
L0105	Human aorta polyA+ (TFujiwara)	aorta				
L0142	Human placenta cDNA (TFujiwara)	placenta				
L0157	Human fetal brain (TFujiwara)		brain			

L0163	Human heart cDNA (YNakamura)		heart			
L0185	Human immortalized fibroblasts (H.L. Ozer)			HS74 and its SV40- transform ed sublines		
L0194	Human pancreatic cancer cell line Patu 8988t	pancreatic cancer		Patu 8988t		
L0351	Infant brain, Bento Soares					BA, M13-derived
L0352	Normalized infant brain, Bento Soares					BA, M13-derived
L0361	Stratagene ovary (#937217)		ovary			Bluescript SK
L0362	Stratagene ovarian cancer (#937219)					Bluescript SK-
L0363	NCI CGAP GC2	germ cell tumor				Bluescript SK-
L0364	NCI CGAP GC5	germ cell tumor				Bluescript SK-
L0366	Stratagene schizo brain S11	schizophrenic brain S-11 frontal lobe				Bluescript SK-
L0367	NCI CGAP Schl	Schwannoma tumor				Bluescript SK-
L0369	NCI CGAP AA1	adrenal adenoma	adrenal gland			Bluescript SK-
L0371	NCI CGAP Br3	breast tumor	breast			Bluescript SK-
L0372	NCI CGAP Co12	colon tumor	colon			Bluescript SK-
L0373	NCI CGAP Co11	tumor	colon			Bluescript SK-
L0374	NCI CGAP Co2	tumor	colon			Bluescript SK-
L0375	NCI CGAP Kid6	kidney tumor	kidney			Bluescript SK-
L0378	NCI CGAP Lu1	lung tumor	lung			Bluescript SK-
L0379	NCI CGAP Lym3	lymphoma	lymph node			Bluescript SK-
L0381	NCI CGAP_HN4	squamous cell carcinoma	pharynx			Bluescript SK-
L0382	NCI CGAP Pr25	epithelium (cell line)	prostate			Bluescript SK-
L0384	NCI CGAP Pr23	prostate tumor	prostate			Bluescript SK-
L0388	NCI CGAP_HN6	normal gingiva (cell line from immortalized kerati				Bluescript SK-
L0435	Infant brain, LLNL array					lafrmid BA

L0438	of Dr. M. Soares INIB normalized infant brain cDNA	total brain	brain			lafmid BA
L0439	Soares infant brain INIB		whole brain			Lafmid BA
L0448	3HFLSK20					Lafmid K
L0455	Human retina cDNA randomly primed sublibrary	retina	eye			lambda gt10
L0456	Human retina cDNA Tsp509I-cleaved sublibrary	retina	eye			lambda gt10
L0470	BL29 Burkitt's lymphoma, Pascalis Sideras					lambda ZAP 2
L0471	Human fetal heart, Lambda ZAP Express					Lambda ZAP Express
L0481	CD34+DIRECTIONAL					Lambda ZAPII
L0483	Human pancreatic islet					Lambda ZAPII
L0485	STRATAGENE Human skeletal muscle cDNA library, cat. #936215.	skeletal muscle	leg muscle			Lambda ZAPII
L0493	NCI_CGAP_Ov26	papillary serous carcinoma	ovary			pAMP1
L0506	NCI_CGAP_Br16	lobullar carcinoma in situ	breast			pAMP1
L0512	NCI_CGAP_Ov36	borderline ovarian carcinoma	ovary			pAMP1
L0515	NCI_CGAP_Ov32	papillary serous carcinoma	ovary			pAMP1
L0517	NCI_CGAP_Pr1					pAMP10
L0518	NCI_CGAP_Pr2					pAMP10
L0519	NCI_CGAP_Pr3					pAMP10
L0520	NCI_CGAP_Alvi	alveolar rhabdomyosarcoma				pAMP10
L0521	NCI_CGAP_Ew1	Ewing's sarcoma				pAMP10
L0526	NCI_CGAP_Pr12	metastatic prostate bone lesion				pAMP10

L0527	NCI CGAP Ov2	ovary				pAMP10
L0528	NCI CGAP Pr5	prostate				pAMP10
L0529	NCI CGAP Pr6	prostate				pAMP10
L0530	NCI CGAP Pr8	prostate				pAMP10
L0532	NCI CGAP Thy1	thyroid				pAMP10
L0534	Chromosome 7 Fetal Brain cDNA Library	brain		brain		pAMP10
L0536	NCI CGAP Br4	normal ductal tissue		breast		pAMP10
L0540	NCI CGAP Pr10	invasive prostate tumor		prostate		pAMP10
L0542	NCI CGAP Pr11	normal prostatic epithelial cells		prostate		pAMP10
L0545	NCI CGAP Pr4.1	prostatic intraepithelial neoplasia - high grade		prostate		pAMP10
L0561	NCI CGAP HN11	normal squamous epithelium		tongue		pAMP10
L0564	Jim bone marrow stroma	bone marrow stroma				pBluescript
L0565	Normal Human Trabecular Bone Cells	Bone		Hip		pBluescript
L0581	Stratagene liver (#937224)			liver		pBluescript SK
L0584	Stratagene cDNA library Human heart, cat#936208					pBluescript SK(+)
L0587	Stratagene colon HT29 (#937221)					pBluescript SK-
L0588	Stratagene endothelial cell 937223					pBluescript SK-
L0590	Stratagene fibroblast (#937212)					pBluescript SK-
L0591	Stratagene HeLa cell s3 937216					pBluescript SK-
L0592	Stratagene hNT neuron (#937233)					pBluescript SK-
L0593	Stratagene neuroepithelium (#937231)					pBluescript SK-

L0595	Stratagene NT2 neuronal precursor 937230	neuroepithelial cells	brain		pBluescript SK-
L0596	Stratagene colon (#937204)		colon		pBluescript SK-
L0597	Stratagene corneal stroma (#937222)		cornea		pBluescript SK-
L0598	Morton Fetal Cochlea	cochlea	ear		pBluescript SK-
L0599	Stratagene lung (#937210)		lung		pBluescript SK-
L0600	Weizmann Olfactory Epithelium	olfactory epithelium	nose		pBluescript SK-
L0601	Stratagene pancreas (#937208)		pancreas		pBluescript SK-
L0603	Stratagene placenta (#937225)		placenta		pBluescript SK-
L0605	Stratagene fetal spleen (#937205)	fetal spleen	spleen		pBluescript SK-
L0606	NCI_CGAP_Lym5	follicular lymphoma	lymph node		pBluescript SK-
L0607	NCI_CGAP_Lym6	mantle cell lymphoma	lymph node		pBluescript SK-
L0608	Stratagene lung carcinoma 937218	lung carcinoma	lung	NCI-H69	pBluescript SK-
L0611	Schiller meningioma	meningioma	brain		pBluescript SK- (Stratagene)
L0615	22 week old human fetal liver cDNA library				pBluescriptII SK(-)
L0622	HM1				pcDNAII (Invitrogen)
L0623	HM3	pectoral muscle (after mastectomy)			pcDNAII (Invitrogen)
L0631	NCI_CGAP_Br7		breast		pCMV-SPORT4
L0635	NCI_CGAP_PNS1	dorsal root ganglion	peripheral nervous system		pCMV-SPORT4
L0636	NCI_CGAP_Pit1	four pooled pituitary adenomas	brain		pCMV-SPORT6
L0637	NCI_CGAP_Bm53	three pooled meningiomas	brain		pCMV-SPORT6

L0638	NCI_CGAP_Brm35	tumor, 5 pooled (see description)	brain			pCMV-SPORT6
L0640	NCI_CGAP_Br18	four pooled high-grade tumors, including two <i>prima</i> juvenile granulosa tumor	breast			pCMV-SPORT6
L0641	NCI_CGAP_Co17	moderately differentiated adenocarcinoma	colon			pCMV-SPORT6
L0643	NCI_CGAP_Co19	moderately differentiated adenocarcinoma	colon			pCMV-SPORT6
L0645	NCI_CGAP_Co21	moderately differentiated adenocarcinoma	colon			pCMV-SPORT6
L0646	NCI_CGAP_Co14	moderately-differentiated adenocarcinoma	colon			pCMV-SPORT6
L0647	NCI_CGAP_Sar4	five pooled sarcomas, including myxoid liposarcoma	connective tissue			pCMV-SPORT6
L0648	NCI_CGAP_Eso2	squamous cell carcinoma	esophagus			pCMV-SPORT6
L0649	NCI_CGAP_GUI	2 pooled high-grade transitional cell tumors	genitourinary tract			pCMV-SPORT6
L0650	NCI_CGAP_Kid13	2 pooled Wilms' tumors, one primary and one metast	kidney			pCMV-SPORT6
L0651	NCI_CGAP_Kid8	renal cell tumor	kidney			pCMV-SPORT6
L0652	NCI_CGAP_Lu27	four pooled poorly-differentiated adenocarcinomas	lung			pCMV-SPORT6
L0653	NCI_CGAP_Lu28	two pooled squamous cell carcinomas	lung			pCMV-SPORT6
L0654	NCI_CGAP_Lu31	lymphoma, follicular mixed small and large cell	lung, cell line			pCMV-SPORT6
L0655	NCI_CGAP_Lym12		lymph node			pCMV-SPORT6



L0656	NCI_CGAP_Ov38	normal epithelium	ovary			pCMV-SPORT6
L0657	NCI_CGAP_Ov23	tumor, 5 pooled (see description)	ovary			pCMV-SPORT6
L0658	NCI_CGAP_Ov35	tumor, 5 pooled (see description)	ovary			pCMV-SPORT6
L0659	NCI_CGAP_Pan1	adenocarcinoma	pancreas			pCMV-SPORT6
L0661	NCI_CGAP_Mel15	malignant melanoma, metastatic to lymph node	skin			pCMV-SPORT6
L0662	NCI_CGAP_Gas4	poorly differentiated adenocarcinoma with signet r	stomach			pCMV-SPORT6
L0663	NCI_CGAP_Ur2	moderately-differentiated endometrial adenocarcinoma	uterus			pCMV-SPORT6
L0664	NCI_CGAP_Ur3	poorly-differentiated endometrial adenocarcinoma	uterus			pCMV-SPORT6
L0665	NCI_CGAP_Ur4	serous papillary carcinoma, high grade, 2 pooled t	uterus			pCMV-SPORT6
L0666	NCI_CGAP_Ur1	well-differentiated endometrial adenocarcinoma, 7	uterus			pCMV-SPORT6
L0667	NCI_CGAP_CML1	myeloid cells, 18 pooled CML cases, BCR/ABL rearra	whole blood			pCMV-SPORT6
L0698	Testis 2					PGEM 5zf(+)
L0717	Gessler Wilms tumor					pSPORT1
L0731	Soares_pregnant_uterus_NbHPU		uterus			pT7T3-Pac
L0738	Human colorectal cancer					pT7T3D
L0740	Soares melanocyte 2NbHM	melanocyte				pT7T3D (Pharmacia) with a modified

L0741	Soares adult brain N2b4HB5Y			brain				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0742	Soares adult brain N2b5HB5Y			brain				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0743	Soares breast 2NbHBst			breast				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0744	Soares breast 3NbHBst			breast				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0745	Soares retina N2b4HR		retina	eye				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0746	Soares retina N2b5HR		retina	eye				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0747	Soares_fetal_heart_NbHH 19W			heart				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0748	Soares fetal liver spleen 1NFLS			Liver and Spleen				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0749	Soares_fetal_liver_spleen _1NFLS_S1			Liver and Spleen				polylinker pT7T3D (Pharmacia) with a modified polylinker
L0750	Soares fetal lung NbHL1			lung				polylinker pT7T3D

	9W						(Pharmacia) with a modified polylinker
L0751	Soares ovary tumor NbHOT	ovarian tumor	ovary				pT7T3D (Pharmacia) with a modified polylinker
L0752	Soares parathyroid tumor _NbHPA	parathyroid tumor	parathyroid gland				pT7T3D (Pharmacia) with a modified polylinker
L0753	Soares pineal gland_N3H PG		pineal gland				pT7T3D (Pharmacia) with a modified polylinker
L0754	Soares placenta Nb2HP		placenta				pT7T3D (Pharmacia) with a modified polylinker
L0755	Soares placenta_8to9weeks_2NbHP8to9W		placenta				pT7T3D (Pharmacia) with a modified polylinker
L0756	Soares multiple_sclerosis_2NbHMSP	multiple sclerosis lesions					pT7T3D (Pharmacia) with a modified polylinker V TYPE
L0757	Soares senescent_fibroblasts_NbHSF	senescent fibroblast					pT7T3D (Pharmacia) with a modified polylinker V TYPE
L0758	Soares testis_NHT						pT7T3D-Pac (Pharmacia) with a modified polylinker
L0759	Soares total fetus Nb2H						pT7T3D-Pac

	F8_9w						(Pharmacia) with a modified polylinker
L0761	NCI_CGAP_CLL1	B-cell, chronic lymphocytic leukemia					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0762	NCI_CGAP_Br1.1	breast					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0763	NCI_CGAP_Br2	breast					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0764	NCI_CGAP_Co3	colon					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0765	NCI_CGAP_Co4	colon					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0766	NCI_CGAP_GCB1	germinal center B cell					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0767	NCI_CGAP_GC3	pooled germ cell tumors					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0768	NCI_CGAP_GC4	pooled germ cell tumors					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0769	NCI_CGAP_Bm25	anaplastic oligodendroglioma	brain				pT7T3D-Pac (Pharmacia) with a modified polylinker

L0770	NCI_CGAP_Bm23	glioblastoma (pooled)	brain				polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0771	NCI_CGAP_Co8	adenocarcinoma	colon				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0772	NCI_CGAP_Co10	colon tumor RER+	colon				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0773	NCI_CGAP_Co9	colon tumor RER+	colon				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0774	NCI_CGAP_Kid3		kidney				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0775	NCI_CGAP_Kid5	2 pooled tumors (clear cell type)	kidney				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0776	NCI_CGAP_Lu5	carcinoid	lung				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0777	Soares_NhHMPu_S1	Pooled human melanocyte, fetal heart, and pregnant	mixed (see below)				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0779	Soares_NFL_T_GBC_S1		pooled				pT7T3D-Pac (Pharmacia) with a modified polylinker
L0780	Soares_NSF_F8_9W_OT		pooled				pT7T3D-Pac

	_PA_P_S1					(Pharmacia) with a modified polylinker
L0782	NCI_CGAP_Pc21	normal prostate	prostate			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0783	NCI_CGAP_Pc22	normal prostate	prostate			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0785	Barstead spleen HPLRB2		spleen			pT7T3D-Pac (Pharmacia) with a modified polylinker
L0787	NCI_CGAP_Sub1					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0788	NCI_CGAP_Sub2					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0789	NCI_CGAP_Sub3					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0790	NCI_CGAP_Sub4					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0791	NCI_CGAP_Sub5					pT7T3D-Pac (Pharmacia) with a modified polylinker
L0792	NCI_CGAP_Sub6					pT7T3D-Pac (Pharmacia) with a modified polylinker

L0793	NCI_CGAP_Sub7							polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0794	NCI_CGAP_GC6							polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0796	NCI_CGAP_Bm50				brain			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0800	NCI_CGAP_Co16				colon			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0803	NCI_CGAP_Kid11				kidney			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0804	NCI_CGAP_Kid12				kidney			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0805	NCI_CGAP_Lu24				lung			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0806	NCI_CGAP_Lu19				lung			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0807	NCI_CGAP_Ov18				ovary			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker
L0809	NCI_CGAP_Pr28				prostate			polylinker pT7T3D-Pac (Pharmacia) with a modified polylinker

									(Pharmacia) with a modified polylinker
L2251	Human fetal lung		Fetal lung						
L3904	NCI_CGAP_Bm64		glioblastoma with EGFR amplification	brain					pCMV-SPORT6
L4501	NCI_CGAP_Sub8								pT7T3D-Pac (Pharmacia) with a modified polylinker
L5564	NCI_CGAP_HN20			normal head/neck tissue					pAMP1
L5565	NCI_CGAP_Bm66		glioblastoma with probably TP53 mutation and witho	brain					pCMV-SPORT6
L5622	NCI_CGAP_Skn3			skin					pCMV-SPORT6



Table 5

OMIM Reference	Description
102772	[AMP deaminase deficiency, erythrocytic]
106210	Peters anomaly
106210	Cataract, congenital, with late-onset corneal dystrophy
106210	Foveal hypoplasia, isolated, 136520
106210	Aniridia
107271	CD59 deficiency
112262	Fibrodysplasia ossificans progressiva, 135100
114290	Campomelic dysplasia with autosomal sex reversal
114550	Hepatocellular carcinoma
115500	Acatalasemia
116860	Cavernous angiomatous malformations
121050	Contractural arachnodactyly, congenital
125270	Porphyrria, acute hepatic
125270	Lead poisoning, susceptibility to
128100	Dystonia-1, torsion
129900	EEC syndrome-1
131400	Eosinophilia, familial
134570	Factor XIII A deficiency
136530	Male infertility, familial
137350	Amyloidosis, Finnish type, 105120
138033	Diabetes mellitus, type II
138040	Cortisol resistance
148900	Klippel-Feil syndrome with laryngeal malformation

151390	Leukemia, acute T-cell
153455	Cutis laxa, recessive, type I, 219100
156845	Tietz syndrome, 103500
156845	Wardenburg syndrome, type IIA, 193510
156845	Wardenburg syndrome/ocular albinism, digenic, 103470
159000	Muscular dystrophy, limb-girdle, type 1A
162100	Neuralgic amyotrophy with predilection for brachial plexus
164500	Spinocerebellar ataxia-7
168450	Hypoparathyroidism, autosomal dominant
168450	Hypoparathyroidism, autosomal recessive
170500	Myotonia congenita, atypical acetazolamide-responsive
170500	Paramyotonia congenita, 168300
170500	Hyperkalemic periodic paralysis
179095	Male infertility
179615	Reticulosis, familial histiocytic, 267700
179615	Severe combined immunodeficiency, B cell-negative, 601457
179616	Severe combined immunodeficiency, B cell-negative, 601457
180385	Leukemia, acute T-cell
180860	Russell-Silver syndrome
181460	Schistosoma mansoni, susceptibility/resistance to
182600	Spastic paraplegia-3A
182870	Spherocytosis-1
182870	Elliptocytosis-3
182870	Anemia, neonatal hemolytic, fatal and near-fatal
191100	Tuberous sclerosis-1
192974	Neonatal alloimmune thrombocytopenia
192974	Glycoprotein Ia deficiency

194070	Wilms tumor, type 1
194070	Denys-Drash syndrome
194070	Frasier syndrome, 136680
203800	Alstrom syndrome
215700	Citrullinemia
216550	Cohen syndrome
223360	Dopamine-beta-hydroxylase deficiency
227646	Fanconi anemia, type D
233700	Chronic granulomatous disease due to deficiency of NCF-1
245349	Lacticacidemia due to PDX1 deficiency
253601	Miyoshi myopathy, 254130
253601	Muscular dystrophy, limb-girdle, type 2B
257200	Niemann-Pick disease, type A
257200	Niemann-Pick disease, type B
264470	Adrenoleukodystrophy, pseudoneonatal
268900	[Sarcosinemia]
300046	Mental retardation, X-linked 23, nonspecific
300047	Mental retardation, X-linked 20
300071	Night blindness, congenital stationary, type 2
300110	Night blindness, congenital stationary, X-linked incomplete, 300071
300123	Mental retardation with isolated growth hormone deficiency
300600	Ocular albinism, Forsius-Eriksson type
301000	Thrombocytopenia, X-linked, 313900
301000	Wiskott-Aldrich syndrome
301201	Amelogenesis imperfecta-3, hypoplastic type
301830	Arthrogryposis, X-linked (spinal muscular atrophy, infantile, X-linked)
301835	Arts syndrome

301845	Bazex syndrome
307150	Hypertrichosis, congenital generalized
309470	Mental retardation, X-linked, syndromic-3, with spastic diplegia
309500	Renpenning syndrome-1
309610	Mental retardation, X-linked, syndromic-2, with dysmorphism and cerebral atrophy
309850	Brunner syndrome
310490	Cowchock syndrome
311050	Optic atrophy, X-linked
311850	Phosphoribosyl pyrophosphate synthetase-related gout
312060	Properdin deficiency, X-linked
600079	Colon cancer
600151	Bardet-Biedl syndrome 3
600163	Long QT syndrome-3
600194	Ichthyosis bullosa of Siemens, 146800
600225	Phenylketonuria, atypical, due to GCH1 deficiency, 233910
600225	Dystonia, DOPA-responsive, 128230
600231	Palmoplantar keratoderma, Bothnia type
600281	Non-insulin-dependent diabetes mellitus, 125853
600281	MODY, type 1, 125850
600807	Bronchial asthma
601090	Iridogoniodysgenesis, 601631
601154	Cardiomyopathy, dilated, 1E
601284	Hereditary hemorrhagic telangiectasia-2, 600376
601596	Charcot-Marie-Tooth neuropathy, demyelinating
601692	Reis-Bucklers corneal dystrophy
601692	Corneal dystrophy, Avellino type

601692	Corneal dystrophy, Groenouw type I, 121900
601692	Corneal dystrophy, lattice type I, 122200
601769	Osteoporosis, involutional
601769	Rickets, vitamin D-resistant, 277440
601850	Retinitis pigmentosa-deafness syndrome
602028	Multiple myeloma
602089	Hemangioma, capillary, hereditary
602092	Deafness, autosomal recessive 18
602121	Deafness, autosomal dominant nonsyndromic sensorineural, 1, 124900
602460	Deafness, autosomal dominant 15, 602459

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as,

for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra.*) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., *Protein Engineering* 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1A.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence

shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

#### **Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the



complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

- 5 Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 10 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95% 15 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95% 20 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1A, the ORF (open reading frame), or any fragment 25 specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best 30 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp.

App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the

deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence  
5 are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence  
10 except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.  
15 These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%,  
20 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1A (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject  
25 sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a  
30 FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window

Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not

matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing  
5 alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced  
10 for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an  
15 organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA  
20 technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after  
25 deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological  
30 activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over

3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

- As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

- Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification or (v) fusion of the polypeptide with another compound, such as albumin (including, but not limited to, recombinant albumin (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

#### **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,



and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40,

41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5           In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10   of the invention.

#### **Epitopes and Antibodies**

          The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15   NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20   polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25   stringency hybridization conditions defined supra.

          The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide  
30   encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies

described *infra*. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays  
5 described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985),  
10 further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30  
15 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,  
20 that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

25 Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985)). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any  
30 combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to

an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the polypeptides of the present invention (e.g., those comprising an immunogenic or antigenic epitope) can be fused to heterologous polypeptide sequences. For example, polypeptides of the present invention (including fragments or variants thereof), may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof,

resulting in chimeric polypeptides. By way of another non-limiting example, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused with albumin (including but not limited to recombinant human serum albumin or fragments or variants thereof (see, e.g., U.S. Patent No. 5,876,969, issued March 2, 1999, EP Patent 0 413 622, and U.S. Patent No. 5,766,883, issued June 16, 1998, herein incorporated by reference in their entirety)). In a preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with the mature form of human serum albumin (i.e., amino acids 1 – 585 of human serum albumin as shown in Figures 1 and 2 of EP Patent 0 322 094) which is herein incorporated by reference in its entirety. In another preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-x of human serum albumin, where x is an integer from 1 to 585 and the albumin fragment has human serum albumin activity. In another preferred embodiment, polypeptides and/or antibodies of the present invention (including fragments or variants thereof) are fused with polypeptide fragments comprising, or alternatively consisting of, amino acid residues 1-z of human serum albumin, where z is an integer from 369 to 419, as described in U.S. Patent 5,766,883 herein incorporated by reference in its entirety. Polypeptides and/or antibodies of the present invention (including fragments or variants thereof) may be fused to either the N- or C-terminal end of the heterologous protein (e.g., immunoglobulin Fc polypeptide or human serum albumin polypeptide). Polynucleotides encoding fusion proteins of the invention are also encompassed by the invention.

Such fusion proteins as those described above may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO 96/22024 and WO 99/04813). IgG

Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., *J. Biochem.*, 270:3958-3964 (1995). Nucleic acids encoding the  
5 above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8972- 897). In this  
10 system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose column and histidine-tagged  
15 proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to modulate the activities of polypeptides of the invention, such methods can be used to  
20 generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo and Blasco, *Biotechniques* 24(2):308- 13  
25 (1998) (each of these patents and publications are hereby incorporated by reference in its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the  
30 polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior



to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

5

### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as  
10 determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id  
15 antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM,  
20 IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule. In preferred embodiments, the immunoglobulin molecules of the invention are IgG1. In other preferred embodiments, the immunoglobulin molecules of the invention are IgG4.

Most preferably the antibodies are human antigen-binding antibody fragments  
25 of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region,  
30 CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any

animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from

5 human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for

10 different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920;

15 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in

20 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in

25 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described

30 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding

epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For

example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998); Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including

both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not

limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably,

the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

5        Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the  
10    CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such  
15    phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid  
20    surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods  
25    184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717;  
30    5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,



Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human

immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., *Bio/technology* 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, *FASEB J.* 7(5):437-444; (1989) and Nissinoff, *J. Immunol.* 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

*Polynucleotides Encoding Antibodies*

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that  
5 encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the  
10 polynucleotides determined, by any method known in the art. For example, if the nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence  
15 encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is  
20 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable  
25 to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

30 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences,

e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entirety), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., *J. Mol. Biol.* 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci.* 81:851-855 (1984); Neuberger et al., *Nature* 312:604-608 (1984); Takeda et al., *Nature* 314:452-454 (1985)) by splicing genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used.

As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

5           Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region  
10 via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

#### *Methods of Producing Antibodies*

15           The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the  
20 invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the  
25 antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and  
30 appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a

nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT  
5 Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an  
10 antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell  
15 for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with  
20 the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast  
25 expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid)  
30 containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein

promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., *EMBO J.* 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, *Nucleic Acids Res.* 13:3101-3109 (1985); Van Heeke & Schuster, *J. Biol. Chem.* 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric  
5 gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for  
10 efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The  
15 efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific  
20 fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and  
25 processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for  
30 example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell line such as, for example, CRL7030 and Hs578Bst.



For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>r</sup>t- or ap<sup>r</sup>t- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, 1993, TIB TECH 11(5):155-215); and hyg<sup>r</sup>, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993);

Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), which are incorporated by reference herein in their entireties.

5       The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in  
10       culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

      The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second  
15       vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic  
20       free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler, Proc. Natl. Acad. Sci. USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

      Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any  
25       method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or  
30       fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g., Harbor et al., *supra*, and PCT publication WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.* 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., *PNAS* 89:1428-1432 (1992); Fell et al., *J. Immunol.* 146:2446-2452(1991), which are incorporated by reference in their entireties.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., *Proc. Natl. Acad. Sci. USA* 88:10535-10539 (1991);

Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entireties).

As discussed, supra, the polypeptides corresponding to a polypeptide,  
5 polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins  
10 consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having disulfide- linked dimeric structures (due to the IgG) may also be more efficient in  
15 binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A 232,262). Alternatively, deleting the Fc part after the fusion protein has been  
20 expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58  
25 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA,  
30 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags

useful for purification include, but are not limited to, the "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof  
5 conjugated to a diagnostic or therapeutic agent. The antibodies can be used  
diagnostically to, for example, monitor the development or progression of a tumor as  
part of a clinical testing procedure to, e.g., determine the efficacy of a given  
treatment regimen. Detection can be facilitated by coupling the antibody to a  
detectable substance. Examples of detectable substances include various enzymes,  
10 prosthetic groups, fluorescent materials, luminescent materials, bioluminescent  
materials, radioactive materials, positron emitting metals using various positron  
emission tomographies, and nonradioactive paramagnetic metal ions. The detectable  
substance may be coupled or conjugated either directly to the antibody (or fragment  
thereof) or indirectly, through an intermediate (such as, for example, a linker known  
15 in the art) using techniques known in the art. See, for example, U.S. Patent No.  
4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics  
according to the present invention. Examples of suitable enzymes include horseradish  
peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase;  
examples of suitable prosthetic group complexes include streptavidin/biotin and  
20 avidin/biotin; examples of suitable fluorescent materials include umbelliferone,  
fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine  
fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material  
includes luminol; examples of bioluminescent materials include luciferase, luciferin,  
and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$   
25 or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic  
moiety such as a cytotoxin, e.g., a cytostatic or cytotoxic agent, a therapeutic agent or  
a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin  
or cytotoxic agent includes any agent that is detrimental to cells. Examples include  
30 paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,  
etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,  
dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-

dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld

et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

### *Immunophenotyping*

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to

prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

5    *Assays For Antibody Binding*

          The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent  
10    assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular  
15    Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

          Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium  
20    deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1% Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or  
25    more at 4° C, washing the beads in lysis buffer and resuspending the beads in SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing  
30    the cell lysate with sepharose beads). For further discussion regarding immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.



Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

#### *Therapeutic Uses*

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the

antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).  
Some of these approaches are described in more detail below. Armed with the  
teachings provided herein, one of ordinary skill in the art will know how to use the  
antibodies of the present invention for diagnostic, monitoring or therapeutic purposes  
5 without undue experimentation.

The antibodies of this invention may be advantageously utilized in  
combination with other monoclonal or chimeric antibodies, or with lymphokines or  
hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which  
serve to increase the number or activity of effector cells which interact with the  
10 antibodies.

The antibodies of the invention may be administered alone or in combination  
with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal  
therapy, immunotherapy and anti-tumor agents). Generally, administration of  
products of a species origin or species reactivity (in the case of antibodies) that is the  
15 same species as that of the patient is preferred. Thus, in a preferred embodiment,  
human antibodies, fragments derivatives, analogs, or nucleic acids, are administered  
to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or  
neutralizing antibodies against polypeptides or polynucleotides of the present  
20 invention, fragments or regions thereof, for both immunoassays directed to and  
therapy of disorders related to polynucleotides or polypeptides, including fragments  
thereof, of the present invention. Such antibodies, fragments, or regions, will  
preferably have an affinity for polynucleotides or polypeptides of the invention,  
including fragments thereof. Preferred binding affinities include those with a  
25 dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$   
M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  
 $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  
 $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

### 30 *Gene Therapy*

In a specific embodiment, nucleic acids comprising sequences encoding  
antibodies or functional derivatives thereof, are administered to treat, inhibit or

prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or

indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

In a specific embodiment, the nucleic acid sequences are directly administered  
5 in vivo, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct  
10 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,  
15 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for  
20 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,  
25 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral  
30 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can

be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy.

Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be

carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth. Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted.

10 The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

25 In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of

the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

5 In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

#### *Demonstration of Therapeutic or Prophylactic Activity*

10 The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect  
15 of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient  
20 tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

#### *Therapeutic/Prophylactic Administration and Composition*

The invention provides methods of treatment, inhibition and prophylaxis by  
25 administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses,  
30 chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above;



additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g., Joliot et al., *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term

"pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry

lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval  
5 by the agency of manufacture, use or sale for human administration.

### *Diagnosis and Imaging*

Labeled antibodies, and derivatives and analogs thereof, which specifically  
10 bind to a polypeptide of interest can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body  
15 fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder,  
20 comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With  
25 respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier  
30 thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art

(e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell . Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody  
5 assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

One aspect of the invention is the detection and diagnosis of a disease or  
10 disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which specifically binds to the polypeptide of interest; b) waiting for a time interval  
15 following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that detection of labeled molecule above the background level indicates that the subject  
20 has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

It will be understood in the art that the size of the subject and the imaging  
25 system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor  
30 imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode  
of administration, the time interval following the administration for permitting the  
5 labeled molecule to preferentially concentrate at sites in the subject and for unbound  
labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or  
6 to 12 hours. In another embodiment the time interval following administration is 5  
to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by  
10 repeating the method for diagnosing the disease or disease, for example, one month  
after initial diagnosis, six months after initial diagnosis, one year after initial  
diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods  
known in the art for in vivo scanning. These methods depend upon the type of label  
15 used. Skilled artisans will be able to determine the appropriate method for detecting a  
particular label. Methods and devices that may be used in the diagnostic methods of  
the invention include, but are not limited to, computed tomography (CT), whole body  
scan such as position emission tomography (PET), magnetic resonance imaging  
(MRI), and sonography.

20 In a specific embodiment, the molecule is labeled with a radioisotope and is  
detected in the patient using a radiation responsive surgical instrument (Thurston et  
al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with  
a fluorescent compound and is detected in the patient using a fluorescence responsive  
scanning instrument. In another embodiment, the molecule is labeled with a positron  
25 emitting metal and is detected in the patient using positron emission-tomography. In  
yet another embodiment, the molecule is labeled with a paramagnetic label and is  
detected in a patient using magnetic resonance imaging (MRI).

#### *Kits*

30 The present invention provides kits that can be used in the above methods. In  
one embodiment, a kit comprises an antibody of the invention, preferably a purified  
antibody, in one or more containers. In a specific embodiment, the kits of the present

invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled



monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting surface-bound anti-antigen antibody.

25

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target

30

cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).) Polynucleotides comprising or alternatively consisting of nucleic acids which encode these fusion proteins are also encompassed by the invention.

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a

fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the

vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic  
5 Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or  
10 ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

15 Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,  
20 insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine  
25 encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

30 In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A

main step in the methanol metabolization pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an

expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and  
5 immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example,  
10 techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411,  
15 published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using  
20 techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid  
25 analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Abx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine,  
30 norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, Ca-methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used,



depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog). For example, the polyethylene glycol may have an  
5 average molecular weight of about 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000,  
10 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

As noted above, the polyethylene glycol may have a branched structure. Branched polyethylene glycols are described, for example, in U.S. Patent No. 5,643,575; Morpurgo *et al.*, *Appl. Biochem. Biotechnol.* 56:59-72 (1996); Vorobjev *et al.*, *Nucleosides Nucleotides* 18:2745-2750 (1999); and Caliceti *et al.*, *Bioconjug. Chem.* 10:638-646 (1999), the disclosures of each of which are incorporated herein by  
15 reference.

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those  
20 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik *et al.*, *Exp. Hematol.* 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated  
25 polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for  
30 therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

As suggested above, polyethylene glycol may be attached to proteins via linkage to any of a number of amino acid residues. For example, polyethylene glycol can be linked to a proteins via covalent bonds to lysine, histidine, aspartic acid, glutamic acid, or cysteine residues. One or more reaction chemistries may be employed to attach polyethylene glycol to specific amino acid residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or cysteine) of the protein or to more than one type of amino acid residue (e.g., lysine, histidine, aspartic acid, glutamic acid, cysteine and combinations thereof) of the protein.

One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.

As indicated above, pegylation of the proteins of the invention may be accomplished by any number of means. For example, polyethylene glycol may be attached to the protein either directly or by an intervening linker. Linkerless systems for attaching polyethylene glycol to proteins are described in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992); Francis *et al.*, *Intern. J. of Hematol.* 68:1-18 (1998); U.S. Patent No. 4,002,531; U.S. Patent No. 5,349,052; WO 95/06058; and WO 98/32466, the disclosures of each of which are incorporated herein by reference.

One system for attaching polyethylene glycol directly to amino acid residues of proteins without an intervening linker employs tresylated MPEG, which is produced by the modification of monmethoxy polyethylene glycol (MPEG) using tresylchloride ( $\text{ClSO}_2\text{CH}_2\text{CF}_3$ ). Upon reaction of protein with tresylated MPEG, polyethylene glycol is directly attached to amine groups of the protein. Thus, the invention includes protein-polyethylene glycol conjugates produced by reacting proteins of the invention with a polyethylene glycol molecule having a 2,2,2-trifluoroethane sulphonyl group.

Polyethylene glycol can also be attached to proteins using a number of different intervening linkers. For example, U.S. Patent No. 5,612,460, the entire disclosure of which is incorporated herein by reference, discloses urethane linkers for connecting polyethylene glycol to proteins. Protein-polyethylene glycol conjugates wherein the polyethylene glycol is attached to the protein by a linker can also be produced by reaction of proteins with compounds such as MPEG-succinimidylsuccinate, MPEG activated with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate, MPEG-p-nitrophenolcarbonate, and various MPEG-succinate derivatives. A number additional polyethylene glycol derivatives and reaction chemistries for attaching polyethylene glycol to proteins are described in WO 98/32466, the entire disclosure of which is incorporated herein by reference. Pegylated protein products produced using the reaction chemistries set out herein are included within the scope of the invention.

The number of polyethylene glycol moieties attached to each protein of the invention (*i.e.*, the degree of substitution) may also vary. For example, the pegylated proteins of the invention may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, or more polyethylene glycol molecules. Similarly, the average degree of substitution within ranges such as 1-3, 2-4, 3-5, 4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16, 15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per protein molecule. Methods for determining the degree of substitution are discussed, for example, in Delgado *et al.*, *Crit. Rev. Thera. Drug Carrier Sys.* 9:249-304 (1992).

The polypeptides of the invention may be in monomers or multimers (*i.e.*, dimers, trimers, tetramers and higher multimers). Accordingly, the present invention

relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least  
5 dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and  
10 fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing  
15 polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at  
20 least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional  
25 embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as,  
30 for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed

when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the invention are formed by covalent associations with and/or between the polypeptides  
5 of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence (e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally  
10 occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence  
15 contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from  
20 another protein that is capable of forming covalently associated multimers, such as for example, osteopontin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627  
25 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper  
30 polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al.,

Science 240:1759, (1988)), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described  
5 in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

10 Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by  
15 reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations  
20 proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers  
25 of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues  
30 located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely

modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers,

since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers  
5 (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the SEQ ID NO:X will yield an  
10 amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping  
15 strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, preselection by hybridization to construct chromosome specific-cDNA libraries and computer mapping techniques (See, e.g., Shuler, Trends Biotechnol 16:456-459 (1998) which is hereby incorporated by reference in its entirety)..

Precise chromosomal location of the polynucleotides can also be achieved  
20 using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon  
25 Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes).

The polynucleotides of the present invention would likewise be useful for  
30 radiation hybrid mapping, HAPPY mapping, and long range restriction mapping. For a review of these techniques and others known in the art, see, e.g., Dear, "Genome Mapping: A Practical Approach," IRL Press at Oxford University Press, London



(1997); Aydin, J. Mol. Med. 77:691-694 (1999); Hacia et al., Mol. Psychiatry 3:483-492 (1998); Herrick et al., Chromosome Res. 7:409-423 (1999); Hamilton et al., Methods Cell Biol. 62:265-280 (2000); and/or Ott, J. Hered. 90:68-70 (1999) each of which is hereby incorporated by reference in its entirety.

5        Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins  
10 University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

      Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.  
15 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide  
20 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

      Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using  
25 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

      Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the  
30 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression

level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand containing a 31'-mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the polypeptide of the present invention or mRNA. As indicated, biological samples

include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art.

5 Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a  
10 "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying  
15 disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or  
20 according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain  
25 components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, Science 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, Nature 365, 666 (1993), PNAs bind specifically and  
30 tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide

backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)). Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of

5 HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl.

10 Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

15 In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al.,

20 Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan et al., Science 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix -

25 see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while

30 antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information

disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective  
5 gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute  
10 biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of  
15 "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions  
20 of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from  
25 extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or  
30 surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR

Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be  
5 used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the  
10 present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a  
15 specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a  
25 biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay  
30 (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and

technetium ( $^{99m}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo  
5 imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for  
10 the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99m}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or  
15 intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99m}\text{Tc}$ . The labeled antibody or antibody fragment will then  
20 preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

25 Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is  
30 indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for



detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

5           Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair  
10   proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune  
15   response to proliferative cells or tissues).

          Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can  
20   activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

          At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also  
25   be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

### Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldgrun et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations,

lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and  
5 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; pSVK3,  
10 pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters  
15 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoAI promoter; human globin promoters; viral thymidine kinase promoters,  
20 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the  
25 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver,  
30 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular,

fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph  
5 fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated  
10 cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20  
15 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

20 The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the  
25 procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

30 The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP

starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC),  
dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine  
5 (DOPE) can be used in various combinations to make conventional liposomes, with or  
without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be  
prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas  
into a sonication vial. The sample is placed under a vacuum pump overnight and is  
hydrated the following day with deionized water. The sample is then sonicated for 2  
10 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an  
inverted cup (bath type) probe at the maximum setting while the bath is circulated at  
15EC. Alternatively, negatively charged vesicles can be prepared without sonication  
to produce multilamellar vesicles or by extrusion through nucleopore membranes to  
produce unilamellar vesicles of discrete size. Other methods are known and available  
15 to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar  
vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.  
The various liposome-nucleic acid complexes are prepared using methods well known  
in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983),  
20 which is herein incorporated by reference. For example, MLVs containing nucleic  
acid can be prepared by depositing a thin film of phospholipid on the walls of a glass  
tube and subsequently hydrating with a solution of the material to be encapsulated.  
SUVs are prepared by extended sonication of MLVs to produce a homogeneous  
population of unilamellar liposomes. The material to be entrapped is added to a  
25 suspension of preformed MLVs and then sonicated. When using liposomes containing  
cationic lipids, the dried lipid film is resuspended in an appropriate solution such as  
sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and  
then the preformed liposomes are mixed directly with the DNA. The liposome and  
DNA form a very stable complex due to binding of the positively charged liposomes  
30 to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are  
prepared by a number of methods, well known in the art. Commonly used methods  
include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*,

394:483 (1975); Wilson et al., Cell , 17:77 (1979)); ether injection (Deamer et al., Biochim. Biophys. Acta, 443:629 (1976); Ostro et al., Biochem. Biophys. Res. Commun., 76:836 (1977); Fraley et al., Proc. Natl. Acad. Sci. USA, 76:3348 (1979)); detergent dialysis (Enoch et al., Proc. Natl. Acad. Sci. USA , 76:145 (1979)); and  
5 reverse-phase evaporation (REV) (Fraley et al., J. Biol. Chem., 255:10431 (1980); Szoka et al., Proc. Natl. Acad. Sci. USA , 75:145 (1978); Schaefer-Ridder et al., Science, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the  
10 ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469  
15 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

20 In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis  
25 virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-  
30 19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by reference in its entirety. The vector may transduce the packaging cells through any

means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

5           The producer cell line generates infectious retroviral vector particles which include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

          In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with  
10   polynucleotides of the invention contained in an adenovirus vector. Adenovirus can be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional  
15   mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991);  
20   Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

          Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993);  
25   Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther., 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and  
30   constitutively express Ela and Elb, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other



varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting sequence will be sufficiently near the 5' end of the desired endogenous polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The promoter then drives the expression of the endogenous sequence.

5       The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth  
10 factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

15       Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

20       Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available  
25 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
30 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is

administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide  
5 construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue inside the wound.

Therapeutic compositions useful in systemic administration, include  
10 recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a particular site.

Preferred methods of systemic administration, include intravenous injection,  
15 aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA, 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present  
20 invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

25 Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of  
30 polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of

the present invention can be administered to any animal, preferably to mammals and birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

## 5 **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological  
10 activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

Polynucleotides, translation products and antibodies corresponding to this gene may be useful for the diagnosis, prognosis, prevention, and/or treatment of diseases and/or disorders associated with the following systems.

15

## **Immune Activity**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing  
20 diseases, disorders, and/or conditions of the immune system, by, for example, activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of  
25 these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

30 In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to treat diseases and disorders of the immune system and/or to inhibit or enhance an

immune response generated by cells associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 8 (Tissue Distribution Library Code).

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing, and/or prognosing immunodeficiencies, including both congenital and acquired immunodeficiencies. Examples of B cell immunodeficiencies in which immunoglobulin levels B cell function and/or B cell numbers are decreased include: X-linked agammaglobulinemia (Bruton's disease), X-linked infantile agammaglobulinemia, X-linked immunodeficiency with hyper IgM, non X-linked immunodeficiency with hyper IgM, X-linked lymphoproliferative syndrome (XLP), agammaglobulinemia including congenital and acquired agammaglobulinemia, adult onset agammaglobulinemia, late-onset agammaglobulinemia, dysgammaglobulinemia, hypogammaglobulinemia, unspecified hypogammaglobulinemia, recessive agammaglobulinemia (Swiss type), Selective IgM deficiency, selective IgA deficiency, selective IgG subclass deficiencies, IgG subclass deficiency (with or without IgA deficiency), Ig deficiency with increased IgM, IgG and IgA deficiency with increased IgM, antibody deficiency with normal or elevated Igs, Ig heavy chain deletions, kappa chain deficiency, B cell lymphoproliferative disorder (BLPD), common variable immunodeficiency (CVID), common variable immunodeficiency (CVI) (acquired), and transient hypogammaglobulinemia of infancy.

In specific embodiments, ataxia-telangiectasia or conditions associated with ataxia-telangiectasia are treated, prevented, diagnosed, and/or prognosing using the polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof.

Examples of congenital immunodeficiencies in which T cell and/or B cell function and/or number is decreased include, but are not limited to: DiGeorge anomaly, severe combined immunodeficiencies (SCID) (including, but not limited to, X-linked SCID, autosomal recessive SCID, adenosine deaminase deficiency, purine nucleoside phosphorylase (PNP) deficiency, Class II MHC deficiency (Bare lymphocyte syndrome), Wiskott-Aldrich syndrome, and ataxia telangiectasia), thymic hypoplasia, third and fourth pharyngeal pouch syndrome, 22q11.2 deletion, chronic

mucocutaneous candidiasis, natural killer cell deficiency (NK), idiopathic CD4+ T-lymphocytopenia, immunodeficiency with predominant T cell defect (unspecified), and unspecified immunodeficiency of cell mediated immunity.

In specific embodiments, DiGeorge anomaly or conditions associated with  
5 DiGeorge anomaly are treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, or antagonists or agonists thereof.

Other immunodeficiencies that may be treated, prevented, diagnosed, and/or prognosed using polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, include, but are not limited to, chronic granulomatous disease,  
10 Chédiak-Higashi syndrome, myeloperoxidase deficiency, leukocyte glucose-6-phosphate dehydrogenase deficiency, X-linked lymphoproliferative syndrome (XLP); leukocyte adhesion deficiency, complement component deficiencies (including C1, C2, C3, C4, C5, C6, C7, C8 and/or C9 deficiencies), reticular dysgenesis, thymic aplasia, immunodeficiency with thymoma, severe congenital  
15 leukopenia, dysplasia with immunodeficiency, neonatal neutropenia, short limbed dwarfism, and Nezelof syndrome-combined immunodeficiency with Igs.

In a preferred embodiment, the immunodeficiencies and/or conditions associated with the immunodeficiencies recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or  
20 agonists or antagonists of the present invention.

In a preferred embodiment polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among immunodeficient individuals. In specific  
25 embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used as an agent to boost immunoresponsiveness among B cell and/or T cell immunodeficient individuals.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, diagnosing and/or prognosing autoimmune disorders. Many autoimmune disorders result from  
30 inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of polynucleotides and polypeptides of

the invention that can inhibit an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Autoimmune diseases or disorders that may be treated, prevented, diagnosed  
5 and/or prognosed by polynucleotides, polypeptides, antibodies, and/or agonists or  
antagonists of the present invention include, but are not limited to, one or more of the  
following: systemic lupus erythematosus, rheumatoid arthritis, ankylosing  
spondylitis, multiple sclerosis, autoimmune thyroiditis, Hashimoto's thyroiditis,  
autoimmune hemolytic anemia, hemolytic anemia, thrombocytopenia, autoimmune  
10 thrombocytopenia purpura, autoimmune neonatal thrombocytopenia, idiopathic  
thrombocytopenia purpura, purpura (e.g., Henloch-Scoenlein purpura),  
autoimmunocytopenia, Goodpasture's syndrome, Pemphigus vulgaris, myasthenia  
gravis, Grave's disease (hyperthyroidism), and insulin-resistant diabetes mellitus.

Additional disorders that are likely to have an autoimmune component that  
15 may be treated, prevented, and/or diagnosed with the compositions of the invention  
include, but are not limited to, type II collagen-induced arthritis, antiphospholipid  
syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing  
polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia,  
polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary  
20 inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus,  
and autoimmune inflammatory eye disorders.

Additional disorders that are likely to have an autoimmune component that  
may be treated, prevented, diagnosed and/or prognosed with the compositions of the  
invention include, but are not limited to, scleroderma with anti-collagen antibodies  
25 (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed  
connective tissue disease (often characterized, e.g., by antibodies to extractable  
nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by  
nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell,  
microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often  
30 characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility  
(often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often  
characterized, e.g., by glomerular basement membrane antibodies or immune



complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic  
5 drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized,  
10 e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by  
15 myocardial antibodies), cardiomyopathy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

20 In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed  
25 using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred  
30 embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

In a preferred embodiment, the autoimmune diseases and disorders and/or  
5 conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention

In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive  
10 agent(s).

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could  
15 be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or  
20 agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

25 Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic  
30 molecule, or blood group incompatibility.

Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose

IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations in vitro or in vivo.

5           Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells  
10 involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection,  
15 nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1.), respiratory disorders (e.g., asthma and allergy); gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain  
20 injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma,  
25 pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides,  
30 polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis,

balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

10 In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in  
15 this case, the foreign transplanted immune cells destroy the host tissues.

Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides,  
20 antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

In other embodiments, polypeptides, antibodies, or polynucleotides of the  
25 invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the  
30 invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected,

and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune

response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and

immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B  
5 cell responsiveness to pathogens.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.

In another specific embodiment, polypeptides, antibodies, polynucleotides  
10 and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce  
15 higher affinity antibodies.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

In another specific embodiment, polypeptides, antibodies, polynucleotides  
20 and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

25 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to,  
30 concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment,

compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

In another specific embodiment, polypeptides, antibodies, polynucleotides  
5 and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone  
10 marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or  
15 treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one  
20 embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to  
25 modulate the immune system.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct  
30 an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.



In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to  
5 virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or  
10 Common Variable Immunodeficiency.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies,  
15 polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-  
20 incompetence/immunodeficiency such as observed among SCID patients.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

25 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the  
30 applications described herein, as they may apply to veterinary medicine.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of

blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and  
5 diseases/disorders associated with pathogens.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus  
10 and multiple sclerosis.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and  
15 blocking sepsis.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related  
20 idiopathic monoclonal gammopathies, and plasmacytomas.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated  
25 and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic  
30 syndrome by, for example, preventing eosinophil production and migration.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

In another specific embodiment, polypeptides, antibodies, polynucleotides  
5 and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery  
10 wall.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

In another specific embodiment, polypeptides, antibodies, polynucleotides  
15 and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

In a specific embodiment, polynucleotides or polypeptides, and/or agonists  
20 thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne  
25 infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent bronchitis, sinusitis, otitis media,  
30 conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carinii. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or

polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

5 In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

10 In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute  
15 myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

20 In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of  
25 decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete  
30 splenectomy.

Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of

the present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention  
5 may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic  
10 animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741).  
15 Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention in an organ system listed above.

## 20 **Blood-Related Disorders**

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists  
25 or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or  
30 antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be

important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 8 (Tissue Distribution Library Code).

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis

and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g.,  
5 basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytoses, such as, for example eosinophilia.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists  
10 of the present invention may be used to prevent, treat, or diagnose blood dyscrasia.

Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies,  
15 and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic  
20 acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may  
25 be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias  
30 arising from drug treatments such as anemias associated with methyldopa, dapson, and/or sulfadru. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing,

and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists  
5 of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating  
10 thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited  
15 to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A2 dysfunction, thromboasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophelias such as hemophilia A or Factor  
20 VII deficiency and Christmas disease or Factor IX deficiency, Hereditary Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored  
25 using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in  
30 a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction



accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

5           In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias  
10 include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer.  
15 Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or  
20 antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists  
25 or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis,  
30 familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic

regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions  
5 in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating lymphocytopenias (decreased numbers of B and/or T lymphocytes),  
10 including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-  
15 Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick  
20 disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to,  
25 idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not  
30 limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and

Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or  
5 agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and  
10 Raynaud's phenomenon.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis,  
15 acute myelofibrosis, agnogenic myeloid metaplasia, thrombocythemia, (including both primary and secondary thrombocythemia) and chronic myelocytic leukemia.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

20 In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or  
25 agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

30 In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

## 5 **Hyperproliferative Disorders**

In certain embodiments, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder  
10 through direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating,  
15 differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

20 Examples of hyperproliferative disorders that can be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and  
25 peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute  
30 Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute

Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct  
5 Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer, Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia,  
10 Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease, Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma,  
15 Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer,  
20 Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational  
25 Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer,  
30 Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous

Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's  
5 Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic  
10 Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis Sarcomas, Sezary  
15 Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal  
20 Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

In another preferred embodiment, polynucleotides or polypeptides, or agonists  
25 or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia,  
30 metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolymphoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic

ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atridigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, 5 craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciodigitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, 10 florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, 15 oculovertebral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

Additional pre-neoplastic disorders which can be diagnosed, prognosed, 20 prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

25 In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 8 (Tissue Distribution Library Code).

30 In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including,



but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

5        Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated  
10    by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma,  
15    lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related  
20    glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

      In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis  
25    of cancers, in particular those listed above.

      Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such  
30    as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic

(granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, emangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstrom's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Another preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells.

In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention

inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for

polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some

of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

5           In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

10           The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example., which serve to increase the number or activity of effector cells which interact with the antibodies.

          It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or  
15       neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments  
20       thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

          Moreover, polypeptides of the present invention are useful in inhibiting the  
25       angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl  
30       Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,

Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, anti-inflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide

antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

10

### **Renal Disorders**

Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the renal system. Renal disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

Kidney diseases which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, acute kidney failure, chronic kidney failure, atheroembolic renal failure, end-stage renal disease, inflammatory diseases of the kidney (e.g., acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis), blood vessel disorders of the kidneys (e.g., kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal retinopathy, renal ischemia-reperfusion, renal

30



artery embolism, and renal artery stenosis), and kidney disorders resulting from urinary tract disease (e.g., pyelonephritis, hydronephrosis, urolithiasis (renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.)

5           In addition, compositions of the invention can be used to diagnose, prognose, prevent, and/or treat metabolic and congenital disorders of the kidney (e.g., uremia, renal amyloidosis, renal osteodystrophy, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, renal fibrocystic osteosis (renal rickets), Hartnup disease, Bartter's syndrome, Liddle's syndrome, 10 polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy), and autoimmune disorders of the kidney (e.g., systemic lupus erythematosus (SLE), 15 Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis).

          Compositions of the invention can also be used to diagnose, prognose, prevent, and/or treat sclerotic or necrotic disorders of the kidney (e.g., glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis 20 (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis), cancers of the kidney (e.g., nephroma, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, renal adenocarcinoma, squamous cell cancer, and Wilm's tumor), and electrolyte imbalances (e.g., nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, 25 hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia).

          Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle 30 accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the

art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

## 5 **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

10 Cardiovascular disorders include, but are not limited to, cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include, but are not limited to, aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia,  
15 patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

20 Cardiovascular disorders also include, but are not limited to, heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy,  
25 right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar  
30 Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-

branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular  
5 rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve diseases include, but are not limited to, aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse,  
10 tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular  
15 stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis,  
20 coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive  
25 diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena  
30 cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

- Arterial occlusive diseases include, but are not limited to, arteriosclerosis, 5. intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

- Cerebrovascular disorders include, but are not limited to, carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral 10 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, 15 vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

- Embolisms include, but are not limited to, air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include, but are not limited to, coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery 20 thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

- Ischemic disorders include, but are not limited to, cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes, but is not limited to, aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, 25 mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

- Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous 30 injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or

topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

5

### **Respiratory Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

10 Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and  
15 bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngoceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic  
20 interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and  
25 *Pseudomonas spp.*), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral  
30 infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal

infections in people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia* spp.), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestosis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

#### **Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization

including solid tumor growth and metastases, arthritis, some types of eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and

Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists  
5 may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in  
10 treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular  
15 glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations;  
20 ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a  
25 polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This  
30 therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress



(approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and

administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the

compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or antagonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, disorders and/or states, which can be treated, prevented, diagnosed, and/or prognosed with the the polynucleotides, polypeptides, agonists and/or antagonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals,

arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation

5 controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and  
10 fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

15 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present  
20 invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat  
25 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized  
30 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or antagonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or antagonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or antagonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl

complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten  
5 oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its  
10 hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and  
15 sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan  
20 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;  
25 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;  
30 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-

316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxyaminolimidazole; and metalloproteinase inhibitors such as BB94.

#### **Diseases at the Cellular Level**

5 Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors,  
10 pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's  
15 syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

20 In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or  
25 antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic  
30 lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and

carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

#### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to



stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical

5 wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications  
10 associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

Polynucleotides or polypeptides, as well as agonists or antagonists of the  
15 present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown  
20 grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentopial graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or  
25 antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach,  
30 small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes,

mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

5 Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides,  
10 as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat  
15 glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides,  
20 as well as agonists or antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large  
25 intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the  
30 production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and brochiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary displasia, in premature infants.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetraholoride and other hepatotoxins known in the art).

In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

**Neural Activity and Neurological Diseases**

The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be

5 treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian

10 patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including

15 lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of

20 the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration

25 associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia,

30 Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy),

systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human

5 immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects

10 of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the

15 polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

20 In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

25 In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

30 The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of

limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists

or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such  
5 neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition,  
10 compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage,  
15 disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus  
20 thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

25 In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides, polypeptides, agonists and/or antagonists of the invention may be  
30 used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dyssynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral



encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, 5 encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden- 10 Spatz Syndrome.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral 15 malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine 20 Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis 25 which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uveomeningoencephalitic syndrome, myelitis such as 30 transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as

Creutzfeldt-Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention

5 include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral

10 scleritis which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue

15 Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's

20 Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucopolysaccharidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett

25 Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydranencephaly, Arnold-Chiari Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

30 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie

Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, 5 apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, 10 broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, 15 myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic 20 Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, 25 spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, 30 Myasthenia Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia,

- amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes
- 5 Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis,
- 10 Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.
- 15 Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial
- 20 neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculities such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraplegia and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies
- 25 which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

### **Endocrine Disorders**

- Polynucleotides or polypeptides, or agonists or antagonists of the present
- 30 invention, may be used to treat, prevent, diagnose, and/or prognose disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine

system.

Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues  
5 to respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular  
10 disease or disorder related to the endocrine system and/or hormone imbalance.

Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual  
15 cycle (e.g., dysmenorrhea and endometriosis).

Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma--islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example,  
20 Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism,  
25 hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid  
30 carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

In specific embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides, agonists and antagonists, may be used to diagnose, prognose, treat, prevent, or ameliorate diseases and disorders associated with aberrant glucose metabolism or glucose uptake into cells.

In a specific embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type I diabetes mellitus (insulin dependent diabetes mellitus, IDDM).

In another embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type II diabetes mellitus (insulin resistant diabetes mellitus).

Additionally, in other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or antagonists thereof (especially neutralizing or antagonistic antibodies) may be used to diagnose, prognose, treat, prevent, and/or ameliorate conditions associated with (type I or type II) diabetes mellitus, including, but not limited to, diabetic ketoacidosis, diabetic coma, nonketotic hyperglycemic-hyperosmolar coma, seizures, mental confusion, drowsiness, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section), dyslipidemia, kidney disease (e.g., renal failure, nephropathy other diseases and disorders as described in the "Renal Disorders" section), nerve damage, neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture.

In other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to regulate the animal's weight. In specific embodiments the polynucleotides and/or polypeptides

corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin. In still other embodiments the polynucleotides and/or polypeptides corresponding to this gene  
5 and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin-like growth factor.

In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including  
10 cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

Moreover, endocrine system and/or hormone imbalance disorders and/or  
15 diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

In another embodiment, a polypeptide of the invention, or polynucleotides,  
20 antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 1A, column 8 (Tissue Distribution Library Code).

25

### **Reproductive System Disorders**

The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be  
30 treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and

diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocoele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

Reproductive system disorders also include disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid papulosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.



Moreover, diseases and/or disorders of the vas deferens include vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

Other disorders and/or diseases of the male reproductive system include, for example, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenosis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

Disorders and/or diseases of the uterus include dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitary rudimentary horn, unicornuate uterus with a

non-communicating cavitory rudimentary horn, unicornuate uterus with a communicating cavitory horn, arcuate uterus, uterine didelfus, and T-shaped uterus.

Ovarian diseases and/or disorders include anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometriod carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

Cervical diseases and/or disorders include cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

Additionally, diseases and/or disorders of the reproductive system include disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus eryematosus, rheumatoid arthritis, myasthenia

gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

Complications associated with labor and parturition include premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that  
5 progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

Further, diseases and/or disorders of the postdelivery period, including endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis,  
10 pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, for example, Turner's  
15 syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

### **Infectious Disease**

20 Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by  
25 initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or  
30 agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae,

Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., Norcardia), Acinetobacter, *Cryptococcus neoformans*, Aspergillus, Bacillaceae (e.g., *Bacillus anthracis*), Bacteroides (e.g., *Bacteroides fragilis*), Blastomycosis, Bordetella, Borrelia (e.g., *Borrelia burgdorferi*), Brucella, Candida, Campylobacter, Chlamydia, Clostridium (e.g., *Clostridium botulinum*, *Clostridium difficile*,

*Clostridium perfringens*, *Clostridium tetani*), *Coccidioides*, *Corynebacterium* (e.g., *Corynebacterium diphtheriae*), *Cryptococcus*, *Dermatocycoses*, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), *Enterobacter* (e.g. *Enterobacter aerogenes*), *Enterobacteriaceae* (*Klebsiella*, *Salmonella* (e.g., *Salmonella typhi*, *Salmonella enteritidis*, *Salmonella typhi*), *Serratia*, *Yersinia*, *Shigella*), *Erysipelothrix*, *Haemophilus* (e.g., *Haemophilus influenza* type B), *Helicobacter*, *Legionella* (e.g., *Legionella pneumophila*), *Leptospira*, *Listeria* (e.g., *Listeria monocytogenes*), *Mycoplasma*, *Mycobacterium* (e.g., *Mycobacterium leprae* and *Mycobacterium tuberculosis*), *Vibrio* (e.g., *Vibrio cholerae*), *Neisseriaceae* (e.g., *Neisseria gonorrhea*, *Neisseria meningitidis*), *Pasteurellaceae*, *Proteus*, *Pseudomonas* (e.g., *Pseudomonas aeruginosa*), *Rickettsiaceae*, *Spirochetes* (e.g., *Treponema* spp., *Leptospira* spp., *Borrelia* spp.), *Shigella* spp., *Staphylococcus* (e.g., *Staphylococcus aureus*), *Meningioccoccus*, *Pneumococcus* and *Streptococcus* (e.g., *Streptococcus pneumoniae* and Groups A, B, and C *Streptococci*), and *Ureaplasmas*. These

15 bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, dental caries, Reiter's Disease, respiratory tract infections, such as

20 Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, *Legionella* disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., meningitis types A and B), chlamydia, syphilis, diphtheria, leprosy, brucellosis, peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung

25 infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections,

30 noscomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In

specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Schistosoma, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*, *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997)). The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis,

osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

### **Gastrointestinal Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal

disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic ulcers.

5           Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric  
10 stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess,).

15           Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum, Meckel's diverticulum, multiple diverticula, failure of  
20 complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascariasis lumbricoides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).

25           Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolenticular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic,  
30 biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis), parasitic (hepatic echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver



enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic

5 encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma,

10 hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile

15 hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma,

20 cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Kaposi's sarcoma, hemangioendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger

25 syndrome).

Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, pancreoblastoma), and other

30 pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

Diseases and/or disorders of the large intestine include antibiotic-associated  
5 colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases  
10 [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases  
15 (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal  
20 volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms), malabsorption syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal  
25 lymphagiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia,  
30 gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach

rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)).

### **Chemotaxis**

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotaxic activity of particular cells. These

chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

#### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)). Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

5       Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a  
10       standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

15       Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides,  
20       for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The  
25       polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually  
30       yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express

the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would  
5 be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention  
10 thereby effectively generating agonists and antagonists of the polypeptide of the present invention. *See generally*, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., *et al.*, *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., *et al.*, *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R.  
15 *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides  
20 and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains,  
25 fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-  
30 beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation

factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity  
5 similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention.  
10 An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and  $^3\text{H}$  thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the  
15 compound to determine if the compound stimulates proliferation by determining the uptake of  $^3\text{H}$  thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of  $^3\text{H}$  thymidine. Both agonist and antagonist compounds may be identified by this procedure.

20 In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following  
25 interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

30 All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring

about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

5           Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate  
10   compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

#### **Targeted Delivery**

15           In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or  
20   prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic  
25   protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

30           In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.



By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation

of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

### **Polypeptides of the Invention Binding Peptides and Other Molecules**

The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the

polypeptide of the invention binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

5           This method comprises the steps of: contacting a polypeptide of the invention with a plurality of molecules; and identifying a molecule that binds the polypeptide of the invention.

          The step of contacting the polypeptide of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate  
10   immobilizing the polypeptide of the invention on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptide of the invention. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptide of the invention. The molecules having a selective affinity for the polypeptide of the  
15   invention can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptide of the invention to the solid support, solvent, and conditions of the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

          Alternatively, one may also separate a plurality of polypeptides into  
20   substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant  
25   phage). Individual isolates can then be "probed" by the polypeptide of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptide of the invention and the individual clone. Prior to contacting the polypeptide of the invention with each fraction comprising individual polypeptides, the polypeptides  
30   could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of

transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for a polypeptide of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptide of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

In certain situations, it may be desirable to wash away any unbound polypeptide of the invention, or alternatively, unbound polypeptides, from a mixture of the polypeptide of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptide of the invention or the plurality of polypeptides is bound to a solid support.

The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind to a polypeptide of the invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157;

Kay et al., 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis  
5 et al., 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide  
10 functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, Bio/Technology 13:351-360 list  
15 benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

Non-peptide libraries can be classified broadly into two types: decorated  
20 monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are  
25 assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer  
30 libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992, BioTechniques 13:422-427; Oldenburg et al., 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and CT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a molecule that binds a polypeptide of the invention can be carried out by contacting the library members with a polypeptide of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptide of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify molecules that specifically bind to a polypeptide of the invention.

Where the polypeptide of the invention binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine.

Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

5       As mentioned above, in the case of a polypeptide of the invention binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a polypeptide of the invention binding polypeptide has in the range of 15-100 amino acids, or 20-50  
10   amino acids.

The selected polypeptide of the invention binding polypeptide can be obtained by chemical synthesis or recombinant expression.

#### **Antisense And Ribozyme (Antagonists)**

15       In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered  
20   (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense  
25   Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., Nucleic Acids Research, 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

30       For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These

experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980)), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.



The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a  
5 sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the  
10 hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*,  
15 the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' -  
20 non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but  
25 could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

30 The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or

phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited

to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 10 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. 15 (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated 20 region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990)). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs 25 corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3'. The construction and production of hammerhead ribozymes is well 30 known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably,

the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

5       As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A  
10       preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular  
15       concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation  
20       or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon  
25       angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

30       Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of

a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present  
5 invention

### **Other Activities**

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as  
10 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells  
15 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's  
20 disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

25 The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be  
30 employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

5       The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

      The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as  
10   body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

15       A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to treat weight disorders, including but not limited to, obesity, cachexia, wasting disease, anorexia, and bulimia.

      Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by  
20   influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

      Polypeptide or polynucleotides and/or agonist or antagonists of the present invention  
25   may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### **Other Preferred Embodiments**

30       Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95%

identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A. Also preferred is the above nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1A. Further preferred is the above nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1A. Similarly preferred is the above nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1A.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1A.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
5 stringent hybridization conditions to a nucleic acid molecule, wherein said isolated nucleic acid molecule does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which  
10 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1A, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1A for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of the cDNA of a human cDNA clone identified by a cDNA Clone Identifier in Table 1A, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1A.  
Further preferred is the above nucleic acid molecule, wherein said sequence of at least  
20 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone. In addition, an isolated nucleic acid molecule of the invention may comprise a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence of the cDNA in said human cDNA clone. A further preferred  
25 embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence of the cDNA in said human cDNA clone. A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of the cDNA in  
30 said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least



95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and  
5 contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A; which method comprises: (a) a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group; and (b) determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence. The step of comparing  
10 sequences in the above method may further comprise determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, the step of comparing sequences in the above method may be performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said  
15 sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least  
20 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone  
25 in Table 1A. This method described above may further comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

30 Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1A, which method comprises a step of detecting in a

biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. This method described above may further comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1A; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A. Further preferred is the above isolated polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1A.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone  
10 identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. Further preferred is the above isolated polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone  
15 Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA  
20 clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human  
25 cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A  
30 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A; which method comprises: (a) a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group; and (b) determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids. The step in the above method of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group may further comprise determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. Further, the step of comparing sequences in the above method may be performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. This method may further comprise a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1A, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence

of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A. Further preferred is the above isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has  
5 been optimized for expression of said polypeptide in a prokaryotic host. Similarly preferred is the above isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1A; and a complete amino acid sequence of a secreted protein encoded by a human cDNA  
10 clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1A.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecules into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a  
15 method of making a recombinant host cell comprising introducing the vector of the invention into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is  
20 expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of  
25 the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1A and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1A; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1A and contained in the deposit with the ATCC Deposit Number shown for said cDNA  
30 clone in Table 1A. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to  
5 increase the level of said protein activity in said individual.

Additional preferred embodiments include the following:

- I. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide  
10 fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded  
15 by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X; (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit  
20 No:Z, which is hybridizable to SEQ ID NO:X, having biological activity; (f) a polynucleotide which is a variant of SEQ ID NO:X; (g) a polynucleotide which is an allelic variant of SEQ ID NO:X; (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y; and (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h),  
25 wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

Also preferred is the isolated nucleic acid molecule as described in preferred embodiment I, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein. The nucleotide sequence encoding a secreted protein  
30 may further comprise sequential nucleotide deletions from either the C-terminus or the N-terminus.

Also preferred is the isolated nucleic acid molecule as described in preferred embodiment I, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the

cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X. The nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z may further comprise sequential nucleotide deletions from either the C-terminus or the N-terminus.

Also preferred is the isolated nucleic acid molecule as described in preferred embodiment I, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

Also preferred is a recombinant vector comprising the isolated nucleic acid molecule described in preferred embodiment I.

Also preferred is a recombinant host cell comprising the isolated nucleic acid molecule described in preferred embodiment I and the method of making the recombinant host cell. The recombinant host cell may further comprise vector sequences.

Also preferred is a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising determining the presence or absence of a mutation in the polynucleotide described in preferred embodiment I and diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of the mutation.

II. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity; (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z; (g) a variant of SEQ ID NO:Y; (h) an allelic variant of SEQ ID NO:Y; and (i) a species homologue of SEQ ID NO:Y.

Also preferred is the isolated polypeptide as described in preferred embodiment II, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.



Also preferred is an isolated antibody that binds specifically to the isolated polypeptide described in preferred embodiment II.

Also preferred is a recombinant host cell that expresses the isolated polypeptide described in preferred embodiment II.

5        Also preferred is a method of making an isolated polypeptide that comprises culturing the recombinant host cells that expresses the isolated polypeptide described in preferred embodiment II and recovering said polypeptide. Further envisioned is the polypeptide produced by this method.

10       Also preferred is a method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or amount of expression of the polypeptide described in preferred embodiment II in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

15       Also preferred is a method for identifying a binding partner to the polypeptide described in preferred embodiment II comprising: (a) contacting the polypeptide with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide

III.     The gene corresponding to the cDNA sequence of SEQ ID NO:X.

20       IV.     A method of identifying an activity in a biological assay, wherein the method comprises: (a) expressing SEQ ID NO:X in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity. Preferred embodiment IV may further include the product produced by the method.

25       Also preferred is a method for preventing, treating, or ameliorating a medical condition comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide described in preferred embodiment I or the polypeptide described in preferred embodiment II.

30       Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, 5 goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of 10 illustration and are not intended as limiting.

ExamplesExample 1: Isolation of a Selected cDNA Clone From the Deposited Sample

5 Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1A identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA

10 library. For example, where a particular clone is identified in Table 1A as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
	Lambda Zap	pBluescript (pBS)
15	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
20	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos.

25 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and

30 pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK<sup>+</sup>, SK<sup>-</sup>, KS<sup>+</sup> and KS. The S and K refers to the orientation of the polylinker to the T7 and T3

primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the fl origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the fl ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lacmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1A, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1A for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1A. Typically, each ATCC deposit sample cited in Table 1A comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1A. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1A) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is 1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well

known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A<sup>+</sup> RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

#### **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

#### **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by,

among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

#### 15 **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C.

20 This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100  
25 bp PCR fragment in the particular somatic cell hybrid.

#### **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA  
30 sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product

into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a  
5 ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain  
10 M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

15 Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1  
20 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris  
25 is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

30 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then



washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.

5 Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250  
10 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements  
15 operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:  
1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The  
20 origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA  
25 insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to  
30 express protein in a bacterial system.

**Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 5        Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution
- 10    containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

- The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by
- 15    centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

- The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree
- 20    C overnight to allow further GuHCl extraction.

- Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C
- 25    without mixing for 12 hours prior to further purification steps.

- To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive
- 30    Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a

stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of  
5 tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using  
10 a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be  
15 observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

#### 20 **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear  
25 polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal  
30 of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1A, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™

baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 uCi of <sup>35</sup>S-methionine and 5 uCi <sup>35</sup>S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation.

The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV1, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J.

L. and Ma, C., *Biochem. et Biophys. Acta*, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., *Biotechnology* 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.* 227:277-279 (1991); Bebbington et al., *Bio/Technology* 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell* 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then

transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 a pC4 is cotransfected with 0.5  
5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in  
10 alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing  
15 even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### 20 **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see  
25 also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create  
30 chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by



modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These  
5 primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with  
10 BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted  
15 protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

20 GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCACC  
GTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCC  
AAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCG  
TGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAC  
GTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGC  
25 AGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG  
GACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCT  
CCCAACCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGA  
GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAA  
CCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCG  
30 CCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCAC  
GCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCAC  
CGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGA

TGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT  
CCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

5       The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it  
10       substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

          In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al.,  
15       Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in  
20       any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

          The splenocytes of such mice are extracted and fused with a suitable myeloma  
25       cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma  
30       cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

#### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

##### **Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described herein.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130

mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person

B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
5 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
10 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and  
15 proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors  
20 called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at  
25 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,  
30 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, *Ann. Rev. Biochem.* 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN- $\alpha$ , IFN- $\gamma$ , and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

	<u>JAKs</u>					<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN- $\alpha$ /B	+	-	-	1,2,3		ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	IL-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	IL-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)?	+	+	?	1,3		
	CNIF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
20	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
25	IL-15	?	+	?	+	5	GAS
	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
30	GM-CSF (myeloid)	-	-	+	-	5	GAS
	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
35	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)



To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10        5':GCGCCTCGAGATTTCCTCCCGAAATCTAGATTTCCTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGTCAAAGCCTAGGC:3'

15 (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following

20 sequence:

5':CTCGAGATTTCCTCCCGAAATCTAGATTTCCTCCCGAAATGATTTCCTCCCGAAATGATTTCCTCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCCTAACTCCGCCCATCCCGCCCCCTAACTCCGCCCAGTTCGCCCAATCTCCGCCCATGGCTGACTAATTTTATTTATGCAGAGGCCGAGGC  
25 CGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAGAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol

acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

#### **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152),

although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-  
5 SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is  
10 demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life  
15 Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25  
20 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing polypeptides of the invention and/or induced polypeptides of  
25 the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100  
30 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred  
5 directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed  
10 in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
15 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
20 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.

25 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
30 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing

10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM  
5 KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400  
10 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in  
15 the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the  
20 supernatant according to the protocol described in Example 17.

#### **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,  
25 EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or  
30 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor). The EGR1 gene expression is activated during this treatment. Thus, by stably

transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 5 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified 10 product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 15 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat- 20 inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine 25 protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% 30 confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

- 5           Add 200  $\mu$ l of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50  $\mu$ l supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ $\mu$ l of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the  
10           supernatant according to Example 17.

**Example 16: High-Throughput Screening Assay for T-cell Activity**

- NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and  
15           CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

- 20           In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded, causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

- 25           Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid  
30           arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-

KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCC  
5 GGGACTTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in  
10 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

15 5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTC  
CGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATG  
GCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCTCTG  
AGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGC  
20 AAAAAGCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-  
promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and  
HindIII. However, this vector does not contain a neomycin resistance gene, and  
25 therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP  
cassette is removed from the above NF-KB/SEAP vector using restriction enzymes  
SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,  
the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the  
30 GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are  
created and maintained according to the protocol described in Example 13. Similarly,



the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### 5 **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

10 Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser  
15 and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at  
20 each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

#### **Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5

21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small

molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star  
5 black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate  
10 is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension.  
15 The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

20 For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4  
25 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca<sup>++</sup> concentration.

30 **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies.

5 In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation  
10 of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

15 Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

20 Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or  
25 polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar  
30 Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen

Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium.

- 5 Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from
- 10 Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on
- 15 ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

- Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described
- 20 here.

- Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and
- 25 PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

- The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride,
- 30 pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the

components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

- 5 Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish
- 10 peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

- Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound
- 15 peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

#### **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

- 20 As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other
- 25 molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

- Specifically, assay plates are made by coating the wells of a 96-well ELISA
- 30 plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

5           A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

10           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
15           procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

20           **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
25           is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

          PCR products are then sequenced using primers labeled at their 5' end with T4  
30           polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring

suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

#### **Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.



For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in

5 Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled  
10 water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

15 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).  
20 Interpolate the concentration of the polypeptide in the sample using the standard curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention of  
25 diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type  
30 (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual

patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

5           As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1 ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for  
10 the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears  
15 to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid  
20 filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-  
25 release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or  
30 formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

In a preferred embodiment, Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions of the invention are formulated in a biodegradable, polymeric drug delivery system, for example as described in U.S. Patent Nos. 4,938,763; 5,278,201; 5,278,202; 5,324,519; 5,340,849; and 5,487,897 and in International Publication Numbers WO01/35929, WO00/24374, and WO00/06117 which are hereby incorporated by reference in their entirety. In specific preferred embodiments the Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions of the invention are formulated using the ATRIGEL® Biodegradable System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

Examples of biodegradable polymers which can be used in the formulation of Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions, include but are not limited to, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), poly(methyl vinyl ether), poly(maleic anhydride), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials. The preferred polymers are those that have a lower degree of crystallization and are more hydrophobic. These polymers and copolymers are more soluble in the

biocompatible solvents than the highly crystalline polymers such as polyglycolide and chitin which also have a high degree of hydrogen-bonding. Preferred materials with the desired solubility parameters are the polylactides, polycaprolactones, and copolymers of these with glycolide in which there are more amorphous regions to enhance solubility. In specific preferred embodiments, the biodegradable polymers which can be used in the formulation of Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions are poly(lactide-co-glycolides). Polymer properties such as molecular weight, hydrophobicity, and lactide/glycolide ratio may be modified to obtain the desired drug Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV release profile (See, e.g., Ravivarapu et al., Journal of Pharmaceutical Sciences 89:732-741 (2000), which is hereby incorporated by reference in its entirety).

It is also preferred that the solvent for the biodegradable polymer be non-toxic, water miscible, and otherwise biocompatible. Examples of such solvents include, but are not limited to, N-methyl-2-pyrrolidone, 2-pyrrolidone, C2 to C6 alkanols, C1 to C15 alcohols, diols, triols, and tetraols such as ethanol, glycerine propylene glycol, butanol; C3 to C15 alkyl ketones such as acetone, diethyl ketone and methyl ethyl ketone; C3 to C15 esters such as methyl acetate, ethyl acetate, ethyl lactate; alkyl ketones such as methyl ethyl ketone, C1 to C15 amides such as dimethylformamide, dimethylacetamide and caprolactam; C3 to C20 ethers such as tetrahydrofuran, or solketal; tweens, triacetin, propylene carbonate, decylmethylsulfoxide, dimethyl sulfoxide, oleic acid, 1-dodecylazacycloheptan-2-one, Other preferred solvents are benzyl alcohol, benzyl benzoate, dipropylene glycol, tributyrin, ethyl oleate, glycerin, glycofural, isopropyl myristate, isopropyl palmitate, oleic acid, polyethylene glycol, propylene carbonate, and triethyl citrate. The most preferred solvents are N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, triacetin, and propylene carbonate because of the solvating ability and their compatibility.

Additionally, formulations comprising Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions and a biodegradable polymer may also include release-rate modification agents and/or pore-forming agents. Examples of release-rate modification agents include, but are not limited to, fatty acids, triglycerides, other like hydrophobic compounds, organic solvents, plasticizing compounds and hydrophilic compounds. Suitable release rate modification agents include, for example, esters of

mono-, di-, and tricarboxylic acids, such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, diethyl phthalate, dimethyl phthalate, dibutyl phthalate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, glycerol triacetate, di(n-butyl) sebacate, and the like; polyhydroxy alcohols, such as propylene glycol, polyethylene glycol, glycerin, sorbitol, and the like; fatty acids; triesters of glycerol, such as triglycerides, epoxidized soybean oil, and other epoxidized vegetable oils; sterols, such as cholesterol; alcohols, such as C.sub.6 -C.sub.12 alkanols, 2-ethoxyethanol, and the like. The release rate modification agent may be used singly or in combination with other such agents. Suitable combinations of release rate modification agents include, but are not limited to, glycerin/propylene glycol, sorbitol/glycerine, ethylene oxide/propylene oxide, butylene glycol/adipic acid, and the like. Preferred release rate modification agents include, but are not limited to, dimethyl citrate, triethyl citrate, ethyl heptanoate, glycerin, and hexanediol. Suitable pore-forming agents that may be used in the polymer composition include, but are not limited to, sugars such as sucrose and dextrose, salts such as sodium chloride and sodium carbonate, polymers such as hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone. Solid crystals that will provide a defined pore size, such as salt or sugar, are preferred.

In specific preferred embodiments the Neutrokin- $\alpha$  and/or Neutrokin- $\alpha$ SV compositions of the invention are formulated using the BEMA<sup>TM</sup> BioErodible Mucoadhesive System, MCA<sup>TM</sup> MucoCutaneous Absorption System, SMP<sup>TM</sup> Solvent MicroParticle System, or BCP<sup>TM</sup> BioCompatible Polymer System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. (USA)* 77:4030-4034 (1980); E P 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos.

4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

5 In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer  
10 (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and  
15 concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.  
20 Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

25 The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten  
30 residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or

arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

5       The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile.

10       Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for  
15       example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

20       The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use  
25       or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus  
30       deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in

combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase



inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'-azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of  $\beta$ -L-FD4C and  $\beta$ -L-FddC (WO 98/17281).

Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N

mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™ (PNU-140690, a non-peptic dihydropyrene; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrene; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Wellcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , etc., may also inhibit fusion.

Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 $\alpha$ , MIP-1 $\beta$ , SDF-1 $\alpha$ , IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN- $\alpha$ 2a; antagonists of TNFs, NF $\kappa$ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as Remune™ (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targeted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, *PNAS* 94:11567-72 (1997); Chen *et al.*, *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the

anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- $\alpha$  antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and  $\alpha$ -naphthoflavone (WO 98/30213); and antioxidants such as  $\gamma$ -L-glutamyl-L-cysteine ethyl ester ( $\gamma$ -GCE; WO 99/56764).

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICLOVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or

prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific  
5 embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an  
10 opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™  
15 and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin,  
20 beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

25 In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other  
30 immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the

Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ<sup>TM</sup>), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT<sup>®</sup> 3 (muromonab-CD3), SANDIMMUNE<sup>TM</sup>, NEORAL<sup>TM</sup>, 5 SANGDYA<sup>TM</sup> (cyclosporine), PROGRAF<sup>®</sup> (FK506, tacrolimus), CELLCEPT<sup>®</sup> (mycophenolate mofetil, of which the active metabolite is mycophenolic acid), IMURAN<sup>TM</sup> (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE<sup>TM</sup> (prednisone) and HYDELTRASOL<sup>TM</sup> (prednisolone), FOLEX<sup>TM</sup> and MEXATE<sup>TM</sup> (methotrxate), OXSORALEN-ULTRA<sup>TM</sup> (methoxsalen) and 10 RAPAMUNE<sup>TM</sup> (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the 15 Therapeutics of the invention include, but not limited to, GAMMAR<sup>TM</sup>, IVEEGAM<sup>TM</sup>, SANDOGLOBULIN<sup>TM</sup>, GAMMAGARD S/D<sup>TM</sup>, ATGAM<sup>TM</sup> (antithymocyte globulin), and GAMIMUNE<sup>TM</sup>. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow 20 transplant).

In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, 25 dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, floctafenine, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as 30 well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid

derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, MD), Troponin-1 (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum

(VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

5           A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., *Cancer Res.* 51:22-26, (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may  
10 be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3  
15 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.*  
20 262(4):1659-1664, (1987)); Bisantrone (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

          Additional anti-angiogenic factors that may also be utilized within the context  
25 of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Storgard et al., *J Clin. Invest.* 103:47-54 (1999)); carboxynaminolimidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA);  
30 Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101;



Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopridiol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and  
5 5-Fluorouracil.

Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing  
10 the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven,  
15 CT), BMS-275291 (Bristol Myers Squibb, Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are  
20 not limited to, EMD-121974 (Merck KgaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/Medimmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody  
25 (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include,  
30 but are not limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

5 In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid  
10 arthritis.

In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not  
15 limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide  
20 synthase.

In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine,  
25 cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcolysin), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazenes (for example,  
30 Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouacil (5-fluorouracil; 5-FU), Floxuridine (fluorodeoxyuridine; FudR), and

Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2'-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate)) and Vincristine (vincristine sulfate)),  
5 epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for  
10 example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; MIH), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate),  
15 estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethinyl estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example, methyltestosterone, estramustine,  
20 estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dicarbazine, glutamic acid, and mitotane).

In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as Remicade™ Centocor, Inc.), Trocade (Roche, RO-32-3555), Leflunomide (also  
25 known as Arava™ from Hoechst Marion Roussel), Kineret™ (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.)

In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one  
30 embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with

anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

In another specific embodiment, the compositions of the invention are administered in combination Zevalin™. In a further embodiment, compositions of the invention are administered with Zevalin™ and CHOP, or Zevalin™ and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. Zevalin™ may be associated with one or more radisotopes. Particularly preferred isotopes are <sup>90</sup>Y and <sup>111</sup>In.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma

(International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2  
5 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms  
10 CD154, CD70, and CD153.

In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number  
15 EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993);  
20 Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth  
25 Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent  
30 Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, 5 FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor 10 (GM-CSF) (sargramostim, LEUKINE™, PROKINE™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, 15 especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, 20 oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amiodarone, bretylium, digitalis, digoxin, digitoxin, diltiazem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, 25 propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit  $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$  symport 30 (e.g., furosemide, bumetanide, azosemide, piretanide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide,

hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

5 In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to,  $^{127}\text{I}$ , radioactive isotopes of iodine such as  $^{131}\text{I}$  and  $^{123}\text{I}$ ; recombinant growth hormone, such as HUMATROPE™ (recombinant somatropin); growth  
10 hormone analogs such as PROTROPIN™ (somatrem); dopamine agonists such as PARLODEL™ (bromocriptine); somatostatin analogs such as SANDOSTATIN™ (octreotide); gonadotropin preparations such as PREGNYL™, A.P.L.™ and PROFASI™ (chorionic gonadotropin (CG)), PERGONAL™ (menotropins), and METRODIN™ (urofollitropin (uFSH)); synthetic human gonadotropin releasing  
15 hormone preparations such as FACTREL™ and LUTREPULSE™ (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRON™ (leuprolide acetate), SUPPRELIN™ (histrelin acetate), SYNAREL™ (nafarelin acetate), and ZOLADEX™ (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRH™ and THYPINONE™ (protirelin); recombinant  
20 human TSH such as THYROGEN™; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T<sub>4</sub>™, SYNTHROID™ and LEVOTHROID™ (levothyroxine sodium), L-T<sub>3</sub>™, CYTOMEL™ and TRIOSTAT™ (liothyroine sodium), and THYROLAR™ (liotrix); antithyroid compounds such as 6-*n*-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and  
25 TAPAZOLE™ (methimazole), NEO-MERCAZOLE™ (carbimazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca<sup>2+</sup> channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate).

Additional treatments for endocrine and/or hormone imbalance disorders  
30 include, but are not limited to, estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™,

ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIST™ (quínestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGEN™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen),

5 SEROPHENE™ and CLOMID™ (clomiphene); progestins such as DURALUTIN™ (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERA™ (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTIN™ (norethindrone), and NORLUTATE™ and AYGESTIN™ (norethindrone acetate); progesterone implants such as NORPLANT

10 SYSTEM™ (subdermal implants of norgestrel); antiproggestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENOVID™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRIN™, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYL™, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone),

15 LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIL-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULEN™ (ethinyl estradiol/ethynodiol diacetate), NORINYL™, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVA™ (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-

20 CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel).

Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™

25 (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone enanthate), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTIN™ (fluoxymesterone), ORETON METHYL™, TESTRED™ and VIRLON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor

30 antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (cyproterone



acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotrophic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (alclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate), CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate),

10 CLODERM™ (clocortolone pivalate), CORTEF™ and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEF™ (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and

20 MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-

25 MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate), HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A.™

30 (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and

KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetonide),  
ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and  
ARISTOSPAN™ (triamcinolone hexacetonide); inhibitors of biosynthesis and action  
of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™  
5 (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone).

Additional treatments for endocrine and/or hormone imbalance disorders  
include, but are not limited to bovine, porcine or human insulin or mixtures thereof;  
insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™;  
oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide),  
10 DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide),  
DYMELOR™ (acetoexamide), glibenclamide, MICRONASE™, DIBETA™ and  
GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™  
(gliclazide), GLUCOPHAGE™ (metformin), PRECOSE™ (acarbose), AMARYL™  
(glimepiride), and ciglitazone; thiazolidinediones (TZDs) such as rosiglitazone,  
15 AVANDIA™ (rosiglitazone maleate) ACTOS™ (pioglitazone), and troglitazone;  
alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as  
SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™  
(diazoxide). In still other embodiments, Therapeutics of the invention are  
administered in combination with one or more of the following: a biguanide  
20 antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic  
agent.

In one embodiment, the Therapeutics of the invention are administered in  
combination with treatments for uterine motility disorders. Treatments for uterine  
motility disorders include, but are not limited to, estrogen drugs such as conjugated  
25 estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and  
ALORA®), estropipate, and chlorotrianisene; progestin drugs (e.g., AMEN®  
(medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM®  
progesterone, and megestrol acetate); and estrogen/progesterone combination  
therapies such as, for example, conjugated estrogens/medroxyprogesterone (e.g.,  
30 PREMPRO™ and PREMPHASE®) and norethindrone acetate/ethinyl estradiol (e.g.,  
FEMHRT™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOL™), ferrous fumarate (e.g., FEOSTAT™), ferrous gluconate (e.g., FERGON™), polysaccharide-iron complex (e.g., NIFEREX™), iron dextran injection (e.g., INFED™), cupric sulfate, pyroxidine, riboflavin, Vitamin B<sub>12</sub>, cyanocobalamin injection (e.g., REDISOL™, RUBRAMIN PC™), hydroxocobalamin, folic acid (e.g., FOLVITE™), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

10 In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, 15 perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, 20 mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

25 In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, 30 gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa, selegiline, amantidine, bromocriptine, pergolide, ropinirole,

pramipexole, benztropine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents.

5 Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and  
10 nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nifedipine, nimodipine, and verapamil.

In additional embodiments, the Therapeutics of the invention are administered  
15 in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

#### **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of  
20 an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be  
25 treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

30 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the

polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

5           The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

10           In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense  
15 polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

20           One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is  
25 turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

30           At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

5        The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine  
10   sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene  
15   of interest properly inserted.

      The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.  
20   The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

      Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove  
25   detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral  
30   vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To**  
**Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are  
5 known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or  
10 any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
15 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
20 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
25 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the  
30 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The



resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 µg/ml. 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 µF and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al.,

Pharmacol. Res. 35(6):517-522 (1997); Wolff, Neuromuscul. Disord. 7(5):314-318 (1997); Schwartz et al., Gene Ther. 3(5):405-411 (1996); Tsurumi et al., Circulation 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers  
5 injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are  
10 free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al.  
15 (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in  
20 the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of  
25 tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid,  
30 mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It

is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and  
5 expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

10 For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the  
15 tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an  
20 aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for  
25 polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by  
30 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over

one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the

polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of  
5 such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to  
10 quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single  
15 transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the  
20 particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous  
25 recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific  
30 inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

#### **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-

512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e.g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The

engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

### **Example 31: Production of an Antibody**

#### **Hybridoma Technology**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler



et al., *Eur. J. Immunol.* 6:511 (1976); Kohler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention, or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies.

Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the polypeptide(s) of the invention protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the polypeptide(s) of the invention protein-specific antibody and are used to immunize an animal to induce formation of further polypeptide(s) of the invention protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing

chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

*Isolation Of Antibody Fragments Directed polypeptide(s) of the invention From A Library Of scFvs*

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in

300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

5           Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been  
10 found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

          One of the best studied classes of B-cell co-stimulatory proteins is the TNF-  
15 superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of  
20 proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or  
25 inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or  
30 immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be

readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$  M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peria-  
arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 33: T Cell Proliferation Assay****Proliferation assay for Resting PBLs.**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100 microliters per well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 °C (1 microgram/ml in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4$ /well) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of TNF Delta and/or TNF Epsilon protein (total volume 200 microliters). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 °C, plates are spun for 2 min. at 1000 rpm and 100 microliters of supernatant is removed and stored -20 °C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100 microliters of medium containing 0.5 microcuries of  $^3\text{H}$ -thymidine and cultured at 37 °C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of TNF Delta and/or TNF Epsilon proteins.

Alternatively, a proliferation assay on resting PBL (peripheral blood lymphocytes) is measured by the up-take of  $^3\text{H}$ -thymidine. The assay is performed as follows. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% (Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non-adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200 microliters. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control

supernatants are used at the same final dilution and express the following proteins:  
vector (negative control), IL-2 (\*), IFN , TNF , IL-10 and TR2. In addition to the  
control supernatants, recombinant human IL-2 (R & D Systems, Minneapolis, MN)  
at a final concentration of 100ng/ml is also used. After 24 hours of culture, each well  
5 is pulsed with 1uCi of <sup>3</sup>H-thymidine (Nen, Boston, MA). Cells are then harvested 20  
hours following pulsing and incorporation of <sup>3</sup>H-thymidine is used as a measure of  
proliferation. Results are expressed as an average of triplicate samples plus or minus  
standard error.

(\*) The amount of the control cytokines IL-2, IFN , TNF and IL-10 produced in each  
10 transfection varies between 300pg to 5ng/ml.

#### **Costimulation assay.**

A costimulation assay on resting PBL (peripheral blood lymphocytes) is  
performed in the presence of immobilized antibodies to CD3 and CD28. The use of  
15 antibodies specific for the invariant regions of CD3 mimic the induction of T cell  
activation that would occur through stimulation of the T cell receptor by an antigen.  
Cross-linking of the TCR (first signal) in the absence of a costimulatory signal  
(second signal) causes very low induction of proliferation and will eventually result in  
a state of "anergy", which is characterized by the absence of growth and inability to  
20 produce cytokines. The addition of a costimulatory signal such as an antibody to  
CD28, which mimics the action of the costimulatory molecule. B7-1 expressed on  
activated APCs, results in enhancement of T cell responses including cell survival and  
production of IL-2. Therefore this type of assay allows to detect both positive and  
negative effects caused by addition of supernatants expressing the proteins of interest  
25 on T cell proliferation.

The assay is performed as follows. Ninety-six well plates are coated with  
100ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final  
volume of 100ul and incubated overnight at 4C. Plates are washed twice with PBS  
before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio)  
30 gradient centrifugation from human peripheral blood, and are cultured overnight in  
10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL,  
Gaithersburg, MD). This overnight incubation period allows the adherent cells to

attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the proliferation assay. The assay is performed in a 96 well plate using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins: vector only (negative control), IL-2, IFN  $\gamma$ , TNF  $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 (R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are expressed as an average of triplicate samples plus or minus standard error.

#### **Costimulation assay: IFN $\gamma$ and IL-2 ELISA.**

The assay is performed as follows. Twenty-four well plates are coated with either 300ng/ml or 600ng/ml anti-CD3 and 5ug/ml anti-CD28 (Pharmingen, San Diego, CA) in a final volume of 500ul and incubated overnight at 4C. Plates are washed twice with PBS before use. PBMC are isolated by Ficoll (LSM, ICN Biotechnologies, Aurora, Ohio) gradient centrifugation from human peripheral blood, and are cultured overnight in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD). This overnight incubation period allows the adherent cells to attach to the plastic, which results in a lower background in the assay as there are fewer cells that can act as antigen presenting cells or that might be producing growth factors. The following day the non adherent cells are collected, washed and used in the costimulation assay. The assay is performed in the pre-coated twenty-four well plate using  $1 \times 10^5$  cells/well in a final volume of 900ul. The supernatants (293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 300ul are added to 600ul of 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the



following proteins: vector only(negative control), IL-2, IFN , IL-12 and IL-18. In addition to the control supernatants recombinant human IL-2 (all cytokines were purchased from R & D Systems, Minneapolis, MN) at a final concentration of 10ng/ml, IL-12 at a final concentration of 1ng/ml and IL-18 at a final concentration of 50ng/ml are also used. Controls and unknown samples are tested in duplicate. Supernatant samples (250ul) are collected 2 days and 5 days after the beginning of the assay. ELISAs to test for IFN and IL-2 secretion are performed using kits purchased from R & D Systems, (Minneapolis, MN). Results are expressed as an average of duplicate samples plus or minus standard error.

#### **Proliferation assay for preactivated-resting T cells.**

A proliferation assay on preactivated-resting T cells is performed on cells that are previously activated with the lectin phytohemagglutinin (PHA). Lectins are polymeric plant proteins that can bind to residues on T cell surface glycoproteins including the TCR and act as polyclonal activators. PBLs treated with PHA and then cultured in the presence of low doses of IL-2 resemble effector T cells. These cells are generally more sensitive to further activation induced by growth factors such as IL-2. This is due to the expression of high affinity IL-2 receptors that allows this population to respond to amounts of IL-2 that are 100 fold lower than what would have an effect on a naïve T cell. Therefore the use of this type of cells might enable to detect the effect of very low doses of an unknown growth factor, that would not be sufficient to induce proliferation on resting (naïve ) T cells.

The assay is performed as follows. PBMC are isolated by F/H gradient centrifugation from human peripheral blood, and are cultured in 10% FCS(Fetal Calf Serum, Biofluids, Rockville, MD)/RPMI (Gibco BRL, Gaithersburg, MD) in the presence of 2ug/ml PHA (Sigma, Saint Louis, MO) for three days. The cells are then washed in PBS and cultured in 10% FCS/RPMI in the presence of 5ng/ml of human recombinant IL-2 (R & D Systems, Minneapolis, MN) for 3 days. The cells are washed and rested in starvation medium (1%FCS/RPMI) for 16 hours prior to the beginning of the proliferation assay. An aliquot of the cells is analyzed by FACS to determine the percentage of T cells (CD3 positive cells) present; this usually ranges between 93-97% depending on the donor. The assay is performed in a 96 well plate

using  $2 \times 10^4$  cells/well in a final volume of 200ul. The supernatants (e.g., CHO or 293T supernatants) expressing the protein of interest are tested at a 30% final dilution, therefore 60ul are added to 140ul of in 10% FCS/RPMI containing the cells. Control supernatants are used at the same final dilution and express the following proteins:

5 vector (negative control), IL-2, IFN  $\gamma$ , TNF  $\alpha$ , IL-10 and TR2. In addition to the control supernatants recombinant human IL-2 at a final concentration of 10ng/ml is also used. After 24 hours of culture, each well is pulsed with 1uCi of  $^3\text{H}$ -thymidine (Nen, Boston, MA). Cells are then harvested 20 hours following pulsing and incorporation of  $^3\text{H}$ -thymidine is used as a measure of proliferation. Results are  
10 expressed as an average of triplicate samples plus or minus standard error.

The studies described in this example test activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

15

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

20 Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid  
25 change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3  
30 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies

for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA kit (e.g, R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or alternatively, decrease monocyte survival) are known in the art and may routinely be

applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks  
5 (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively  
10 lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free  
15 medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5 µg/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA  
20 fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is  
25 performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h  
30 and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g, R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays**

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl.*

*Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth

of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

5       The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized  
10 by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and  
15 eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic  
20 neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic  
25 neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips.  
30 The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for

dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2-5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.



**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of

the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 10   **Example 39: Stimulation of Endothelial Migration**

          This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

          Endothelial cell migration assays are performed using a 48 well microchemotaxis  
15   chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8  
          um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours  
          at room temperature and dried under sterile air. Test substances are diluted to appropriate  
          concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25  
20   ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus.  
          Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized  
          for the minimum time required to achieve cell detachment. After placing the filter  
          between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1%  
          FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at  
25   37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation  
          period, the filter is removed and the upper side of the filter with the non-migrated cells is  
          scraped with a rubber policeman. The filters are fixed with methanol and stained with a  
          Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by  
          counting cells of three random high-power fields (40x) in each well, and all groups are  
30   performed in quadruplicate.

          The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

5

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.


10

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

15

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:

20



25

The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C. The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions.

30

S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are

means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758

(1993); Leclerc *et al. J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean  $\pm$  SEM. Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ hybridization.

The study in this model is divided into three parts as follows:

Ischemic skin

Ischemic skin wounds

Normal wounds

The experimental protocol includes:

Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.

A polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.



The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

A polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

Making a 1-1.5 mm long incision from the center of cornea into the stromal layer. Inserting a spatula below the lip of the incision facing the outer corner of the eye. Making

a pocket (its base is 1-1.5 mm from the edge of the eye). Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

5       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 10   **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

##### ***Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process,  
15   the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*,  
20   *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.  
25   Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and  
30   microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,

*Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model  
5 may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study.  
10 Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

15 Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and  
20 iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to  
25 treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is  
30 no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

#### ***Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahl *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and

histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital.

- 5 Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's
- 10 Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

- Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the
- 15 lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

- Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are
- 20 then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

- Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving
- 25 a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

- To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To
- 30 evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing



perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules

(CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>.

HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are

aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$ ) is added to each well. Plates are held at 4°C for 30 min.

Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of  
5 diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to  
10 each well and incubated at 37°C for 30 min. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  
15  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The  
20 template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell**

#### **Proliferation**

30 This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL-3, and then contacted with the compound that is being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The

experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60 µl Microscint is added to each well and the plate sealed with TopSeal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

#### **Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM.

Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin  
5 receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with  
10 fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in  
15 the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$ ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA.  
20 Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACSscan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
25 antagonists and fragments and variants thereof.

If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and  
30 "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

**Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin,

2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5 µg/ml hEGF, 5mg/ml insulin, 1µg/ml hFGF, 50mg/ml gentamycin, 50 µg/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains  
5 fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50µg/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls.

- 10 For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNFa is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or supernatants and incubate at 37C/5% CO<sub>2</sub> until day 5.

- 15 Transfer 60µl from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100 µl in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10µl). Return plates to incubator for 3 to 4 hours. Then measure fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

- 20 On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100 µl/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

- On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200 µl/well of  
25 Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50 µl/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.



Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100  $\mu$ l/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

5 Add 100  $\mu$ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or smooth muscle cell proliferation. A positive result also suggests many potential uses  
10 of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vascularogenesis, both of the blood  
15 vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in  
20 the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the  
25 eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb  
30 angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the

gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

**Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are

incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20 µl of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with  
5 PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100 µl of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5 µl of each dilution is added to triplicate wells and the resulting AP content in  
10 each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100 µl of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50 µl of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-  
15 conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated  
20 inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a  
25 source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration. Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

30 Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37-C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with

GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days.

- 5 After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

- Alamar blue is an oxidation-reduction indicator that both fluoresces and  
10 changes color in response to chemical reduction of growth medium resulting from cell growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and  
15 inhibited proliferation will produce a weaker signal and the total signal is proportional to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

20

**Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

- This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability,  
25 modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

- 30 Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These include, but are not limited to, diseases such as asthma, arthritis, diabetes,

inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

5 Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM<sup>®</sup>, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is  
10 adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhuIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1  $\mu$ g/ml; anti-CD4 mAb (R&D  
15 Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10  $\mu$ g/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1  $\mu$ C of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

20 Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the  
25 activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above  
30 teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entirety. Additionally, the specifications and sequence listings of U.S. Patent Application Serial No. 09/482,273, filed January 13, 2000; International Patent Application Serial Nos: PCT/US99/15849 and PCT/US01/00911, filed July 14, 1999 and January 12, 2001, respectively; U.S. Provisional Patent Application Serial No. 60/234,925, filed September 25, 2000; and U.S. Provisional Patent Applications Serial Nos. 60/092,921, 60/092,922, and 60/092,956, filed July 15, 1998 are hereby incorporated by reference in their entirety.

Table 6

	Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
5	Met	1	A	A	.	.	.	.	.	-0.77	0.40	*	*	.	-0.60	0.38
	Ala	2	A	A	.	.	.	.	.	-0.27	0.40	*	*	.	-0.60	0.30
	Ala	3	A	A	.	.	.	.	.	-0.69	-0.03	*	*	.	0.30	0.45
	Ala	4	A	A	.	.	.	.	.	-0.51	0.23	*	*	.	-0.30	0.38
10	Gly	5	A	.	.	.	.	.	.	-0.42	0.04	*	*	.	0.03	0.58
	Arg	6	.	.	.	.	.	.	C	-0.12	-0.07	*	*	F	1.11	0.77
	Leu	7	.	.	.	.	.	.	C	0.18	-0.19	*	*	F	1.39	1.02
	Pro	8	.	.	.	.	.	T	C	0.18	0.23	*	*	F	1.12	1.08
15	Ser	9	.	.	.	.	T	T	.	-0.04	0.30	*	*	F	1.30	0.56
	Ser	10	.	.	B	.	.	T	.	-0.40	0.99	*	*	F	0.47	0.56
	Trp	11	.	.	B	.	.	T	.	-0.81	1.09	*	*	.	0.19	0.31
	Ala	12	.	.	B	B	.	.	.	-0.21	1.04	.	.	.	-0.34	0.31
20	Leu	13	.	.	B	B	.	.	.	-0.81	1.09	.	.	.	-0.47	0.36
	Phe	14	.	.	B	B	.	.	.	-1.32	1.39	.	.	.	-0.60	0.28
	Ser	15	.	.	B	.	.	T	.	-1.61	1.16	.	.	.	-0.20	0.23
	Pro	16	.	.	B	.	.	T	.	-1.67	1.16	*	.	.	-0.20	0.28
25	Leu	17	A	.	.	.	.	T	.	-1.89	0.90	.	.	.	-0.20	0.32
	Leu	18	A	.	.	.	.	T	.	-1.67	0.80	.	.	.	-0.20	0.20
	Ala	19	A	A	.	.	.	.	.	-1.78	0.91	.	.	.	-0.60	0.13
	Gly	20	A	A	.	.	.	.	.	-2.29	1.17	.	.	.	-0.60	0.13
30	Leu	21	A	A	.	.	.	.	.	-2.42	1.17	.	.	.	-0.60	0.13
	Ala	22	.	A	B	.	.	.	.	-2.47	0.91	.	.	.	-0.60	0.13
	Leu	23	.	A	B	.	.	.	.	-2.00	1.06	.	.	.	-0.60	0.10
	Leu	24	.	A	B	.	.	.	.	-1.62	1.06	.	.	.	-0.60	0.11
35	Gly	25	.	A	B	.	.	.	.	-2.13	0.80	.	.	.	-0.60	0.18
	Val	26	.	.	B	.	.	.	.	-1.53	0.94	.	.	.	-0.40	0.16
	Gly	27	.	.	B	.	.	.	.	-1.53	0.69	*	*	F	-0.25	0.30
	Pro	28	.	.	B	.	.	.	.	-0.61	0.50	*	*	F	-0.25	0.30
40	Val	29	.	.	B	.	.	.	.	-0.39	0.07	*	*	F	0.05	0.80
	Pro	30	.	A	B	.	.	.	.	-0.86	-0.07	*	*	.	0.30	0.81
	Ala	31	A	A	B	.	.	.	.	-0.03	0.19	*	*	.	-0.30	0.43
	Arg	32	A	A	.	.	.	.	.	0.31	0.26	*	*	.	-0.30	0.80
45	Ala	33	A	A	.	.	.	.	.	-0.33	0.01	*	*	.	-0.30	0.83
	Leu	34	A	A	.	.	.	.	.	0.21	0.23	*	*	.	-0.30	0.61
	His	35	A	A	.	.	.	.	.	-0.17	0.21	*	*	.	-0.30	0.45
	Asn	36	A	A	B	.	.	.	.	0.42	0.71	*	*	.	-0.60	0.45
50	Val	37	A	A	.	.	.	.	.	-0.50	0.21	*	*	.	-0.30	0.94
	Thr	38	A	A	.	.	.	.	.	-0.61	0.21	*	.	.	-0.30	0.57
	Ala	39	A	A	.	.	.	.	.	-0.14	0.50	*	.	.	-0.60	0.31
	Glu	40	A	A	.	.	.	.	.	-0.70	0.53	.	*	.	-0.60	0.41
55	Leu	41	A	A	.	.	.	.	.	-0.70	0.39	.	*	.	-0.30	0.29
	Phe	42	A	A	.	.	.	.	.	-0.43	-0.10	.	.	.	0.30	0.49
	Gly	43	A	A	.	.	.	.	.	-0.41	-0.10	.	.	.	0.30	0.29
	Ala	44	A	A	.	.	.	.	.	-0.17	0.81	.	.	.	-0.60	0.37
60	Glu	45	A	A	.	.	.	.	.	-0.48	0.56	.	.	.	-0.60	0.42
	Ala	46	A	A	.	.	.	.	.	-0.48	0.26	.	.	.	-0.30	0.61
	Trp	47	A	A	.	.	.	.	.	-0.37	0.51	.	*	.	-0.60	0.50
	Gly	48	A	A	.	.	.	.	.	-0.61	0.51	.	.	.	-0.60	0.29
65	Thr	49	A	A	.	.	.	.	.	-0.72	1.01	.	.	.	-0.60	0.29
	Leu	50	A	A	.	.	.	.	.	-1.07	1.30	*	.	.	-0.60	0.24
	Ala	51	A	A	.	.	.	.	.	-0.48	0.81	.	.	.	-0.60	0.24
	Ala	52	A	A	.	.	.	.	.	-1.00	0.39	.	*	.	-0.30	0.28
70	Phe	53	A	A	.	.	.	.	.	-0.66	0.59	.	*	.	-0.60	0.28
	Gly	54	A	.	.	.	.	.	.	-0.64	0.30	.	*	.	-0.10	0.44
	Asp	55	A	.	.	.	.	.	.	0.17	0.19	.	.	F	0.39	0.58
	Leu	56	.	.	.	.	.	.	C	0.80	-0.31	.	.	F	1.68	1.12
75	Asn	57	.	.	.	.	.	T	C	1.39	-1.10	.	.	F	2.52	2.27
	Ser	58	.	.	.	.	.	T	C	1.78	-1.13	.	*	F	2.86	2.36
	Asp	59	.	.	.	.	T	T	.	2.12	-0.64	.	*	F	3.40	4.12

1088

	Lys	60	A	.	.	.	.	T	.	1.31	-1.33	.	*	F	2.66	4.28
	Gln	61	A	.	.	B	.	.	.	1.42	-1.04	.	*	F	1.92	2.64
	Thr	62	A	.	.	B	.	.	.	0.57	-0.64	.	.	F	1.58	1.37
5	Asp	63	.	.	B	B	.	.	.	0.06	0.00	.	.	F	0.19	0.51
	Leu	64	.	.	B	B	.	.	.	0.17	0.69	.	.	.	-0.60	0.24
	Phe	65	.	.	B	B	.	.	.	0.12	0.29	.	*	.	-0.30	0.33
	Val	66	.	.	B	B	.	.	.	0.23	-0.20	.	*	.	0.30	0.34
	Leu	67	A	.	.	B	.	.	.	0.54	-0.20	.	*	.	0.30	0.81
10	Arg	68	A	.	.	B	.	.	.	0.54	-0.49	.	*	F	0.60	1.50
	Glu	69	A	.	.	.	.	T	.	0.54	-1.27	.	*	F	1.30	3.37
	Arg	70	A	.	.	.	.	T	.	0.36	-1.23	.	*	F	1.30	3.37
	Asn	71	A	.	.	.	.	T	.	0.36	-1.23	*	*	F	1.30	1.21
	Asp	72	A	.	.	.	.	T	.	0.47	-0.59	*	*	F	1.15	0.52
15	Leu	73	A	.	.	B	.	.	.	-0.46	0.20	.	*	.	-0.30	0.23
	Ile	74	.	.	B	B	.	.	.	-1.04	0.89	.	.	.	-0.60	0.12
	Val	75	.	.	B	B	.	.	.	-1.16	0.99	.	.	.	-0.60	0.07
	Phe	76	.	.	B	B	.	.	.	-1.16	0.99	.	.	.	-0.60	0.14
	Leu	77	.	.	B	B	.	.	.	-1.16	0.70	.	.	.	-0.36	0.35
20	Ala	78	A	.	.	B	.	.	.	-0.93	0.41	.	.	.	-0.12	0.77
	Asp	79	A	.	.	.	.	T	.	-0.26	0.27	.	.	F	0.97	0.90
	Gln	80	.	.	.	.	.	T	T	0.36	-0.09	.	.	F	2.36	1.68
	Asn	81	.	.	.	.	.	T	C	0.36	-0.01	.	.	F	2.40	2.61
	Ala	82	.	.	.	.	.	T	C	1.21	0.27	*	.	F	1.56	1.35
25	Pro	83	A	.	.	.	.	.	.	1.59	0.27	.	*	.	0.77	1.56
	Tyr	84	.	.	.	.	.	T	.	1.63	0.30	.	*	.	0.93	1.50
	Phe	85	.	.	B	.	.	.	.	0.78	-0.10	*	*	.	0.89	2.97
	Lys	86	.	.	B	.	.	.	.	0.82	0.04	.	*	F	0.20	1.43
	Pro	87	.	.	B	.	.	.	.	0.56	-0.39	.	*	F	0.80	1.82
30	Lys	88	A	.	.	B	.	.	.	0.47	-0.50	.	*	F	0.60	1.56
	Val	89	A	.	.	B	.	.	.	0.01	-0.90	*	*	F	0.90	1.05
	Lys	90	A	.	.	B	.	.	.	0.76	-0.11	*	*	F	0.45	0.59
	Val	91	A	.	.	B	.	.	.	0.71	-0.54	.	*	.	0.60	0.59
	Ser	92	A	.	.	.	.	.	.	0.89	-0.14	.	*	.	0.65	1.27
35	Phe	93	A	.	.	.	.	.	.	0.54	-0.29	.	*	.	0.50	0.86
	Lys	94	A	.	.	.	.	.	.	0.81	0.10	*	*	.	0.05	1.56
	Asn	95	A	.	.	.	.	.	.	-0.04	-0.04	*	*	.	0.65	1.18
	His	96	A	.	.	.	.	.	.	-0.08	0.26	.	*	.	0.05	1.12
	Ser	97	A	.	.	B	.	.	.	-0.09	0.16	*	.	.	-0.30	0.39
40	Ala	98	.	.	B	B	.	.	.	0.31	0.64	*	.	.	-0.60	0.35
	Leu	99	.	.	B	B	.	.	.	-0.59	0.63	*	.	.	-0.60	0.35
	Ile	100	.	.	B	B	.	.	.	-1.44	0.77	.	.	.	-0.60	0.19
	Thr	101	.	.	B	B	.	.	.	-1.62	1.03	.	.	.	-0.60	0.14
	Ser	102	.	.	B	B	.	.	.	-1.67	0.96	.	.	.	-0.60	0.26
45	Val	103	.	.	B	B	.	.	.	-1.08	0.70	.	.	.	-0.60	0.37
	Val	104	.	.	B	.	.	T	.	-0.51	0.01	*	.	F	0.25	0.43
	Pro	105	.	.	B	.	.	T	.	0.38	0.29	*	*	F	0.59	0.51
	Gly	106	.	.	.	.	.	T	T	0.34	-0.10	.	*	F	2.08	1.14
	Asp	107	.	.	.	.	.	T	T	0.64	-0.31	.	*	F	2.42	1.52
50	Tyr	108	.	.	.	.	.	T	.	1.20	-0.96	.	*	F	2.86	1.64
	Asp	109	.	.	.	.	.	T	T	2.06	-1.00	.	*	F	3.40	2.22
	Gly	110	.	.	.	.	.	T	T	1.67	-1.03	.	*	F	3.06	2.30
	Asp	111	.	.	.	.	.	T	T	2.01	-0.41	.	*	F	2.42	1.45
	Ser	112	.	.	B	.	.	T	.	1.16	-1.17	.	*	F	1.98	1.45
55	Gln	113	.	.	B	B	.	.	.	0.59	-0.53	.	*	F	1.24	1.09
	Met	114	.	.	B	B	.	.	.	-0.22	-0.27	.	*	.	0.30	0.54
	Asp	115	.	.	B	B	.	.	.	-0.19	0.41	.	*	.	-0.60	0.33
	Val	116	.	.	B	B	.	.	.	-0.43	0.51	*	*	.	-0.60	0.28
	Leu	117	.	.	B	B	.	.	.	-0.94	0.87	*	*	.	-0.60	0.44
60	Leu	118	.	.	B	B	.	.	.	-1.16	0.94	*	*	.	-0.60	0.22
	Thr	119	.	.	B	B	.	.	.	-0.51	1.37	*	.	.	-0.60	0.45
	Tyr	120	.	.	B	.	.	.	.	-0.51	0.73	*	.	.	-0.25	1.09
	Leu	121	.	.	B	.	.	.	.	0.10	0.44	*	.	.	-0.25	2.13
	Pro	122	A	.	.	.	.	T	.	0.32	0.51	*	.	F	0.10	2.31



1089

	Lys	123	.	.	.	.	T	T	.	1.18	0.53	*	.	F	0.50	1.49
	Asn	124	.	.	.	.	.	T	C	1.19	-0.23	*	.	F	1.20	3.61
	Tyr	125	A	.	.	.	.	T	.	1.43	-0.53	.	*	F	1.30	3.13
5	Ala	126	A	A	.	.	.	.	.	1.43	-0.96	.	*	F	0.90	2.71
	Lys	127	A	A	.	.	.	.	.	1.30	-0.27	.	*	F	0.60	1.39
	Ser	128	A	A	.	.	.	.	.	0.67	-0.24	*	*	F	0.45	0.88
	Glu	129	A	A	.	.	.	.	.	-0.19	-0.50	*	*	F	0.75	0.88
	Leu	130	A	.	.	B	.	.	.	-0.83	-0.36	.	*	.	0.30	0.33
	Gly	131	.	.	B	B	.	.	.	-0.94	0.33	.	*	.	-0.30	0.17
10	Ala	132	.	.	B	B	.	.	.	-1.28	0.73	.	*	.	-0.60	0.09
	Val	133	.	.	B	B	.	.	.	-1.32	1.64	.	.	.	-0.60	0.11
	Ile	134	.	.	B	B	.	.	.	-1.32	1.39	.	.	.	-0.60	0.11
	Phe	135	.	.	B	B	.	.	.	-0.51	1.36	.	.	.	-0.60	0.19
	Trp	136	.	.	B	B	.	.	.	-0.17	1.26	.	.	.	-0.60	0.40
15	Gly	137	.	.	.	.	.	T	C	0.11	1.01	.	.	F	0.15	1.00
	Gln	138	.	.	.	.	T	T	.	0.16	0.81	.	.	F	0.50	1.66
	Asn	139	.	.	.	.	.	T	C	1.04	0.71	.	.	F	0.54	1.30
	Gln	140	.	.	.	.	.	T	C	1.53	-0.20	.	.	F	1.68	2.20
20	Thr	141	.	.	.	.	.	.	C	1.82	-0.20	.	.	F	1.72	1.96
	Leu	142	.	.	.	.	.	.	C	2.17	-0.20	.	.	F	1.96	1.96
	Asp	143	.	.	.	.	.	T	C	1.57	-0.20	.	.	F	2.40	1.82
	Pro	144	.	.	.	.	.	T	C	1.26	0.01	.	.	F	1.56	1.25
	Asn	145	.	.	.	.	T	T	.	0.37	0.01	.	.	F	1.52	2.19
25	Asn	146	.	.	B	.	.	T	.	-0.13	0.01	.	.	F	0.73	0.92
	Met	147	.	.	B	B	.	.	.	0.68	0.70	*	*	.	-0.36	0.49
	Thr	148	.	.	B	B	.	.	.	0.79	0.67	*	.	.	-0.60	0.49
	Ile	149	.	.	B	B	.	.	.	0.69	0.27	*	.	.	-0.30	0.60
	Leu	150	.	.	B	B	.	.	.	-0.01	0.36	*	.	.	-0.30	0.87
30	Asn	151	.	.	B	B	.	.	.	-0.01	0.53	*	.	.	-0.38	0.52
	Arg	152	.	.	B	B	.	.	.	0.59	0.44	*	.	F	0.14	1.29
	Thr	153	.	.	.	B	.	.	C	0.90	-0.24	*	.	F	1.46	2.61
	Phe	154	.	.	.	B	.	.	C	1.58	-0.93	*	.	F	1.98	2.81
	Gln	155	.	.	.	B	.	.	C	1.58	-0.90	*	.	F	2.20	2.22
35	Asp	156	.	.	.	B	.	.	C	0.69	-0.21	*	.	F	1.68	1.27
	Glu	157	.	.	B	.	.	.	.	-0.02	-0.01	*	.	F	1.46	1.03
	Pro	158	.	.	B	.	.	.	.	0.29	-0.19	.	.	F	1.09	0.59
	Leu	159	.	.	B	.	.	.	.	0.29	-0.59	.	*	.	1.02	0.59
	Ile	160	A	.	.	.	.	.	.	0.29	0.20	.	*	.	-0.10	0.29
40	Met	161	A	.	.	.	.	.	.	-0.06	0.60	.	*	.	-0.15	0.30
	Asp	162	A	.	.	.	.	T	.	-0.06	0.60	*	*	.	0.30	0.37
	Phe	163	.	.	B	.	.	T	.	-0.66	-0.09	*	*	.	1.45	0.87
	Asn	164	.	.	.	.	T	T	.	-0.73	-0.09	*	*	F	2.25	0.73
	Gly	165	.	.	.	.	T	T	.	-0.06	-0.01	*	*	F	2.50	0.30
45	Asp	166	.	.	.	B	T	.	.	0.54	0.41	*	*	F	0.95	0.54
	Leu	167	.	.	.	B	.	.	C	-0.34	-0.37	*	*	F	1.40	0.57
	Ile	168	.	.	B	B	.	.	.	-0.34	-0.09	*	*	F	0.95	0.40
	Pro	169	.	.	B	B	.	.	.	-0.69	0.27	*	*	.	-0.05	0.21
	Asp	170	.	.	B	B	.	.	.	-1.23	0.70	*	.	.	-0.60	0.25
50	Ile	171	.	.	B	B	.	.	.	-1.54	0.70	*	.	.	-0.60	0.25
	Phe	172	.	.	B	B	.	.	.	-0.73	0.50	*	.	.	-0.60	0.23
	Gly	173	.	.	B	B	.	.	.	0.16	0.47	*	.	.	-0.60	0.22
	Ile	174	.	.	B	B	.	.	.	0.07	0.47	.	.	.	-0.60	0.55
	Thr	175	.	.	.	B	.	.	C	0.07	0.17	*	.	F	0.35	0.86
55	Asn	176	.	.	.	B	.	.	C	0.96	-0.21	*	.	F	1.40	1.39
	Glu	177	.	.	.	.	T	T	.	1.44	-0.24	.	.	F	2.30	3.44
	Ser	178	.	.	.	.	T	T	.	1.79	-0.50	.	.	F	2.60	3.68
	Asn	179	.	.	.	.	.	T	C	1.79	-0.59	.	.	F	3.00	3.97
	Gln	180	.	.	.	.	.	T	C	1.29	-0.30	.	.	F	2.40	1.61
60	Pro	181	.	.	B	B	.	.	.	0.48	0.39	.	.	F	0.75	0.99
	Gln	182	.	.	B	B	.	.	.	0.13	0.69	.	.	F	0.15	0.51
	Ile	183	.	.	B	B	.	.	.	0.09	0.71	.	*	.	-0.30	0.29
	Leu	184	.	.	B	B	.	.	.	0.09	0.74	.	*	.	-0.60	0.19
	Leu	185	.	.	B	B	.	.	.	-0.72	0.71	.	*	.	-0.60	0.17

1090

5	Gly	186	.	.	.	.	T	T	.	-0.81	1.00	.	*	F	0.35	0.20
	Gly	187	.	.	.	.	T	T	.	-1.10	0.70	.	*	F	0.35	0.33
	Asn	188	.	.	.	.	.	T	C	-0.24	0.93	.	*	F	0.15	0.42
	Leu	189	.	.	.	.	.	T	C	0.36	0.74	.	*	.	0.00	0.58
	Ser	190	.	.	.	.	T	.	.	0.58	0.74	.	*	.	0.00	0.90
10	Trp	191	.	.	B	.	.	.	.	0.11	0.81	.	*	.	-0.40	0.57
	His	192	.	.	B	.	.	.	.	0.14	1.10	.	*	.	-0.40	0.57
	Pro	193	.	.	B	.	.	.	.	-0.17	0.90	.	*	.	-0.40	0.61
	Ala	194	.	.	B	B	.	.	.	0.33	1.00	.	*	.	-0.60	0.84
	Leu	195	A	.	.	B	.	.	.	0.33	0.57	*	.	.	-0.60	0.89
15	Thr	196	A	.	.	B	.	.	.	0.67	0.46	*	*	F	-0.25	0.77
	Thr	197	A	.	.	.	.	T	C	0.10	0.03	.	*	F	1.00	1.52
	Thr	198	A	.	.	.	.	T	.	0.42	0.14	.	*	F	1.00	1.83
	Ser	199	A	.	.	.	.	T	.	0.12	-0.54	.	*	F	2.10	2.48
	Lys	200	.	.	B	.	.	T	.	0.72	-0.34	.	*	F	2.00	1.20
20	Met	201	.	.	B	.	.	.	.	1.00	-0.40	.	*	F	1.60	1.29
	Arg	202	.	.	B	.	.	.	.	1.01	-0.39	.	*	.	1.25	1.31
	Ile	203	.	.	B	.	.	T	.	1.29	-0.39	.	*	.	1.10	0.88
	Pro	204	.	.	B	.	.	T	.	1.00	0.11	.	*	.	0.45	1.21
	His	205	A	.	.	.	.	T	.	0.26	0.00	.	*	.	0.10	0.62
25	Ser	206	.	.	.	.	.	T	C	-0.03	0.79	.	*	.	0.00	0.77
	His	207	A	A	.	.	.	.	.	-0.14	0.79	.	*	.	-0.60	0.35
	Ala	208	.	A	B	.	.	.	.	-0.07	0.36	.	*	.	-0.30	0.43
	Phe	209	.	A	B	.	.	.	.	-0.17	0.54	*	.	.	-0.60	0.26
	Ile	210	.	A	B	.	.	.	.	-0.13	0.64	*	*	.	-0.60	0.28
30	Asp	211	A	A	.	.	.	.	.	0.17	0.14	*	*	.	-0.30	0.48
	Leu	212	A	A	.	.	.	.	.	-0.50	-0.36	*	*	.	0.30	0.92
	Thr	213	A	A	.	.	.	.	.	-0.22	-0.36	*	*	F	0.60	1.14
	Glu	214	A	A	.	.	.	.	.	-0.11	-0.56	*	*	F	0.75	0.99
	Asp	215	A	A	.	.	.	.	.	0.78	-0.06	*	*	F	0.60	1.21
35	Phe	216	A	A	.	.	.	.	.	-0.03	-0.74	*	*	F	0.90	1.40
	Thr	217	A	A	.	.	.	.	.	0.08	-0.54	.	*	.	0.60	0.67
	Ala	218	A	A	.	.	.	.	.	-0.42	0.24	.	*	.	-0.30	0.35
	Asp	219	A	.	.	B	.	.	.	-0.73	0.93	.	*	.	-0.60	0.33
	Leu	220	A	.	.	B	.	.	.	-1.04	0.63	.	*	.	-0.60	0.33
40	Phe	221	A	.	.	B	.	.	.	-1.16	0.63	.	*	.	-0.60	0.47
	Leu	222	A	.	.	B	.	.	.	-0.84	0.81	*	.	.	-0.60	0.23
	Thr	223	A	.	.	B	.	.	.	-0.84	1.21	*	.	.	-0.60	0.45
	Thr	224	.	.	B	B	.	.	.	-1.16	1.03	*	.	.	-0.60	0.53
	Leu	225	.	.	.	B	.	.	C	-0.66	0.73	.	.	F	-0.25	0.92
45	Asn	226	.	.	.	B	.	.	C	-0.26	0.53	.	.	F	-0.25	0.92
	Ala	227	.	.	.	B	.	.	C	0.24	0.43	.	.	F	-0.25	0.86
	Thr	228	.	.	.	B	.	.	C	-0.14	0.43	*	.	F	-0.10	1.50
	Thr	229	.	.	.	B	.	.	C	0.17	0.53	.	*	F	-0.25	0.81
	Ser	230	.	.	.	B	.	.	C	0.28	0.53	.	*	F	-0.10	1.38
50	Thr	231	.	.	B	B	.	.	.	0.28	0.81	.	*	F	-0.45	0.83
	Phe	232	.	.	B	B	.	.	.	-0.02	0.33	.	*	.	-0.30	1.00
	Gln	233	.	.	B	B	.	.	.	0.00	0.53	.	*	.	-0.60	0.52
	Phe	234	.	.	B	B	.	.	.	0.31	1.06	.	*	.	-0.60	0.38
	Glu	235	.	.	B	B	.	.	.	0.61	0.57	*	*	.	-0.60	0.76
55	Ile	236	A	A	.	.	.	.	.	0.11	0.19	*	*	.	-0.30	0.71
	Trp	237	A	A	.	.	.	.	.	0.81	0.47	.	*	.	-0.60	0.67
	Glu	238	A	A	.	.	.	.	.	0.47	-0.31	.	*	.	0.43	0.65
	Asn	239	.	A	.	.	T	.	.	1.17	0.11	*	*	F	0.51	0.91
	Leu	240	.	A	.	.	.	.	C	0.47	-0.17	*	*	F	1.19	1.40
60	Asp	241	.	.	.	.	T	T	.	1.06	-0.30	*	*	F	1.77	0.70
	Gly	242	.	.	.	.	T	T	.	0.49	0.09	.	*	F	1.30	0.58
	Asn	243	.	.	.	.	.	T	C	0.19	0.33	.	*	F	0.97	0.52
	Phe	244	.	.	.	.	.	T	C	-0.12	0.03	.	*	.	0.69	0.42
	Ser	245	.	.	B	B	.	.	.	-0.20	0.51	.	*	.	-0.34	0.61
	Val	246	.	.	B	B	.	.	.	-1.01	0.77	*	*	.	-0.47	0.27
	Ser	247	.	.	B	B	.	.	.	-0.67	1.06	*	*	.	-0.60	0.25
	Thr	248	.	.	B	B	.	.	.	-0.62	0.27	*	*	.	-0.30	0.33

1091

	Ile	249	.	.	B	B	.	.	.	-0.13	-0.11	*	.	.	0.30	0.89
	Leu	250	A	.	.	B	.	.	.	0.17	-0.33	*	.	F	0.60	1.02
	Glu	251	A	.	.	B	.	.	.	1.02	-0.31	*	.	F	0.60	1.23
5	Lys	252	A	.	.	.	.	.	.	0.72	-0.40	*	.	F	0.80	2.82
	Pro	253	A	.	.	.	.	T	.	0.43	-0.47	*	.	F	1.00	3.38
	Gln	254	A	.	.	.	.	T	.	0.47	-0.54	*	.	F	1.30	1.93
	Asn	255	A	.	.	.	.	T	.	0.42	0.10	.	.	.	0.10	0.72
	Met	256	.	.	B	.	.	T	.	0.08	0.74	.	.	.	-0.20	0.34
	Met	257	.	.	B	B	.	.	.	0.03	0.74	.	.	.	-0.60	0.20
10	Val	258	.	.	B	B	.	.	.	-0.06	0.74	*	.	.	-0.60	0.21
	Val	259	.	.	B	B	.	.	.	-0.64	0.73	*	.	.	-0.60	0.29
	Gly	260	.	.	B	.	.	.	.	-1.34	0.61	.	.	F	-0.25	0.29
	Gln	261	.	A	B	.	.	.	.	-1.33	0.79	.	.	F	-0.45	0.34
	Ser	262	.	A	B	.	.	.	.	-0.73	0.64	.	.	F	-0.45	0.47
15	Ala	263	.	A	B	.	.	.	.	-0.58	0.00	.	*	.	-0.30	0.79
	Phe	264	.	A	B	.	.	.	.	0.28	0.36	*	*	.	-0.30	0.39
	Ala	265	.	A	B	.	.	.	.	0.28	-0.04	.	*	.	0.61	0.49
	Asp	266	A	A	.	.	.	.	.	0.28	0.00	.	*	.	0.32	0.48
	Phe	267	A	A	.	.	.	.	.	0.23	-0.50	.	*	.	1.23	0.92
20	Asp	268	.	.	.	.	T	T	.	0.79	-0.86	.	*	F	2.79	0.91
	Gly	269	.	.	.	.	T	T	.	0.89	-0.86	.	*	F	3.10	0.74
	Asp	270	A	.	.	.	.	T	.	1.48	-0.24	.	*	F	2.09	0.84
	Gly	271	A	.	.	.	.	T	.	1.44	-1.03	.	*	F	2.08	0.84
	His	272	A	A	.	.	.	.	.	1.33	-0.53	.	*	.	1.37	1.16
25	Met	273	A	A	.	.	.	.	.	0.52	-0.27	*	*	.	0.61	0.57
	Asp	274	.	A	B	.	.	.	.	0.66	0.41	.	*	.	-0.60	0.48
	His	275	.	A	B	.	.	.	.	0.31	0.41	.	.	.	-0.60	0.54
	Leu	276	.	A	B	.	.	.	.	-0.01	0.34	.	.	.	-0.30	0.54
	Leu	277	.	.	B	.	.	T	.	0.02	0.30	*	.	.	0.10	0.17
30	Pro	278	.	.	.	.	T	T	.	0.62	0.30	*	.	F	0.65	0.22
	Gly	279	.	.	.	.	T	T	.	0.67	-0.20	.	.	F	1.25	0.45
	Cys	280	A	.	.	.	.	T	.	0.70	-0.89	.	.	F	1.64	1.09
	Glu	281	A	.	.	.	.	.	.	0.84	-1.17	.	.	F	1.78	1.13
	Asp	282	A	.	.	.	.	T	.	1.66	-1.03	.	.	F	2.17	0.61
35	Lys	283	A	.	.	.	.	T	.	1.91	-1.06	.	.	F	2.66	1.98
	Asn	284	.	.	.	.	T	T	.	1.96	-1.63	.	.	F	3.40	2.29
	Cys	285	A	.	.	.	.	T	.	2.31	-1.24	.	.	F	2.66	1.83
	Gln	286	A	.	.	.	.	T	.	1.42	-0.76	.	.	F	2.32	1.32
	Lys	287	.	.	.	.	T	T	.	1.18	-0.07	*	.	F	1.93	0.58
40	Ser	288	.	.	B	.	.	T	.	0.32	0.29	*	.	F	0.74	1.69
	Thr	289	.	.	B	.	.	T	.	-0.53	0.40	*	.	F	0.25	0.80
	Ile	290	.	.	B	B	.	.	.	0.24	0.64	*	.	.	-0.60	0.30
	Tyr	291	.	.	B	B	.	.	.	-0.06	0.64	*	.	.	-0.60	0.44
	Leu	292	.	.	B	B	.	.	.	-0.44	0.64	*	.	.	-0.26	0.40
45	Val	293	.	.	B	.	.	T	.	-0.74	0.59	*	*	.	0.48	0.57
	Arg	294	.	.	B	.	.	T	.	-0.39	0.51	*	.	F	0.97	0.36
	Ser	295	.	.	.	.	T	T	.	0.50	-0.24	*	.	F	2.61	0.87
	Gly	296	.	.	.	.	T	T	.	0.46	-0.53	*	*	F	3.40	2.04
	Met	297	.	.	.	.	T	.	.	0.41	-0.26	*	*	F	2.56	1.10
50	Lys	298	.	.	.	B	T	.	.	1.06	0.39	*	*	F	1.27	0.61
	Gln	299	.	.	B	B	.	.	.	0.09	0.43	*	*	.	0.08	0.95
	Trp	300	.	.	B	B	.	.	.	-0.42	0.64	*	.	.	-0.26	0.71
	Val	301	.	.	B	B	.	.	.	-0.08	0.71	*	.	.	-0.60	0.29
	Pro	302	.	.	B	B	.	.	.	0.52	1.11	*	.	.	-0.60	0.29
55	Val	303	.	.	B	B	.	.	.	-0.22	0.71	*	.	.	-0.60	0.47
	Leu	304	.	.	B	B	.	.	.	-0.52	0.59	*	.	.	-0.60	0.54
	Gln	305	.	.	B	B	.	.	.	-0.23	0.33	*	.	.	0.04	0.47
	Asp	306	.	.	.	B	T	.	.	0.67	0.30	*	.	F	1.08	1.02
	Phe	307	.	.	.	.	T	.	.	0.53	-0.34	*	.	F	2.22	2.47
60	Ser	308	.	.	.	.	.	.	C	1.08	-0.60	*	*	F	2.66	1.41
	Asn	309	.	.	.	.	T	T	.	1.08	-0.51	*	.	F	3.40	1.22
	Lys	310	.	.	.	.	T	T	.	0.79	0.17	*	*	F	2.16	1.16
	Gly	311	.	.	.	.	T	T	.	0.44	0.30	.	*	F	1.67	0.91

1092

	Thr	312	.	.	.	.	.	T	C	0.44	0.34	.	*	F	1.13	0.56
	Leu	313	.	.	.	B	T	.	.	-0.11	0.73	.	.	.	0.14	0.24
	Trp	314	.	.	B	B	.	.	.	-0.32	1.37	.	.	.	-0.60	0.18
5	Gly	315	.	.	B	B	.	.	.	-1.07	1.37	.	.	.	-0.60	0.20
	Phe	316	.	.	B	B	.	.	.	-1.58	1.67	.	.	.	-0.60	0.21
	Val	317	.	.	B	B	.	.	.	-1.27	1.63	*	.	.	-0.60	0.14
	Pro	318	.	.	B	B	.	.	.	-0.46	0.71	*	.	.	-0.60	0.24
	Phe	319	.	.	B	B	.	.	.	-0.17	0.29	.	.	.	-0.30	0.49
	Val	320	.	.	.	B	.	.	C	0.18	-0.10	.	.	.	0.95	1.14
10	Asp	321	.	.	.	B	.	.	C	0.67	-0.34	.	.	F	1.40	1.28
	Glu	322	.	.	.	.	T	.	.	1.21	-0.34	.	.	F	2.10	2.28
	Gln	323	.	.	.	.	.	.	C	1.42	-0.64	.	.	F	2.50	4.44
	Gln	324	.	.	.	.	.	T	C	1.23	-1.29	.	.	F	3.00	4.60
	Pro	325	.	.	.	.	.	T	C	1.88	-0.60	.	*	F	2.70	1.86
15	Thr	326	.	.	.	.	T	T	.	0.99	-0.17	.	*	F	2.30	1.66
	Glu	327	.	.	B	.	.	T	.	0.78	0.11	.	*	F	0.85	0.67
	Ile	328	.	.	B	B	.	.	.	-0.11	0.14	*	*	F	0.15	0.67
	Pro	329	.	.	B	B	.	.	.	-0.42	0.40	.	*	.	-0.60	0.33
	Ile	330	.	.	B	B	.	.	.	-1.02	0.40	.	*	.	-0.60	0.27
20	Pro	331	.	.	B	B	.	.	.	-0.74	1.09	.	*	.	-0.60	0.32
	Ile	332	.	.	B	B	.	.	.	-1.63	0.90	.	*	.	-0.60	0.28
	Thr	333	.	.	B	B	.	.	.	-1.09	1.16	.	*	.	-0.60	0.28
	Leu	334	.	.	B	B	.	.	.	-0.88	0.90	.	*	.	-0.60	0.18
25	His	335	.	.	B	B	.	.	.	-0.23	0.47	.	*	.	-0.60	0.43
	Ile	336	.	.	B	.	.	T	.	-0.02	0.54	.	*	.	-0.20	0.47
	Gly	337	.	.	B	.	.	T	.	0.27	0.46	.	*	.	0.05	0.91
	Asp	338	.	.	.	.	T	T	.	0.58	0.39	.	*	.	1.00	0.66
	Tyr	339	.	.	B	.	.	T	.	1.04	-0.11	.	*	.	1.60	1.58
	Asn	340	.	.	.	.	T	T	.	0.83	-0.37	*	*	.	2.25	1.58
30	Met	341	.	.	.	.	T	T	.	1.51	-0.04	*	*	.	2.50	1.48
	Asp	342	.	.	.	.	T	T	.	1.86	0.39	*	*	F	1.80	1.46
	Gly	343	.	.	.	.	.	T	C	1.27	-0.37	*	*	F	1.95	1.52
	Tyr	344	.	.	.	.	.	T	C	0.70	-0.27	.	*	F	1.70	1.55
	Pro	345	A	.	.	.	.	T	.	-0.16	-0.20	.	*	F	1.10	0.76
35	Asp	346	A	.	.	.	.	T	.	-0.44	0.44	*	.	F	-0.05	0.57
	Ala	347	A	.	.	.	.	T	.	-1.26	0.70	*	*	.	-0.20	0.26
	Leu	348	.	.	B	B	.	.	.	-0.87	0.63	*	.	.	-0.60	0.14
	Val	349	.	.	B	B	.	.	.	-0.62	0.20	*	.	.	-0.30	0.16
40	Ile	350	.	.	B	B	.	.	.	-0.72	0.60	.	.	.	-0.60	0.26
	Leu	351	.	.	B	B	.	.	.	-1.02	0.59	.	.	.	-0.30	0.46
	Lys	352	.	.	B	B	.	.	.	-0.78	0.29	.	.	F	0.45	0.82
	Asn	353	.	.	.	.	.	T	C	-0.27	0.07	.	.	F	1.50	1.16
	Thr	354	.	.	.	.	.	T	C	0.59	-0.23	.	.	F	2.40	1.89
	Ser	355	.	.	.	.	.	T	C	1.48	-0.51	*	.	F	3.00	1.52
45	Gly	356	.	.	.	.	.	T	C	2.29	-0.11	*	.	F	2.40	1.64
	Ser	357	.	.	.	.	.	.	C	1.66	-0.11	.	.	F	1.90	1.97
	Asn	358	.	A	.	.	.	.	C	0.96	-0.10	.	.	F	1.40	1.48
	Gln	359	.	A	B	.	.	.	.	0.46	0.30	.	.	F	0.30	1.30
50	Gln	360	.	A	B	.	.	.	.	-0.06	0.56	.	.	F	-0.45	0.80
	Ala	361	.	A	B	.	.	.	.	0.29	0.86	.	.	.	-0.60	0.41
	Phe	362	.	A	B	.	.	.	.	0.59	0.46	.	.	.	-0.60	0.41
	Leu	363	.	A	B	.	.	.	.	-0.27	0.46	.	.	.	-0.60	0.38
	Leu	364	.	A	B	.	.	.	.	-0.48	0.70	.	.	.	-0.60	0.28
	Glu	365	.	A	B	.	.	.	.	-1.14	0.63	.	.	.	-0.60	0.50
55	Asn	366	.	A	.	.	.	T	.	-0.56	0.41	.	.	.	-0.20	0.32
	Val	367	.	.	.	.	.	T	C	0.14	0.13	.	.	.	0.30	0.63
	Pro	368	.	.	.	.	.	T	.	0.37	-0.16	.	.	.	1.10	0.59
	Cys	369	.	.	.	.	.	T	.	0.88	0.34	.	.	.	0.50	0.37
60	Asn	370	.	.	.	.	.	T	.	0.21	0.33	.	.	.	0.50	0.67
	Asn	371	.	.	.	.	.	T	C	0.21	0.26	.	.	.	0.30	0.23
	Ala	372	.	.	.	.	.	T	C	1.07	-0.17	.	.	.	0.90	0.75
	Ser	373	A	.	.	.	.	T	.	0.69	-0.74	*	.	.	1.00	0.80
	Cys	374	A	.	.	.	.	T	.	1.47	-0.64	*	.	.	1.00	0.50

1093

	Glu	375	A	A	.	.	.	.	.	1.58	-1.04	*	.	F	0.75	0.98
	Glu	376	A	A	.	.	.	.	.	0.98	-1.54	*	.	F	0.90	1.43
	Ala	377	A	A	.	.	.	.	.	0.87	-1.31	*	.	F	0.90	2.64
5	Arg	378	A	A	.	.	.	.	.	1.21	-1.10	*	*	F	0.90	1.32
	Arg	379	A	A	.	.	.	.	.	1.02	-1.10	*	*	.	0.75	1.52
	Met	380	A	A	.	.	.	.	.	0.78	-0.46	*	*	.	0.45	1.12
	Phe	381	A	A	.	.	.	.	.	0.49	-0.20	*	*	.	0.30	0.89
	Lys	382	A	A	.	.	.	.	.	1.08	0.71	*	*	.	-0.60	0.48
	Val	383	A	A	.	.	.	.	.	0.16	0.71	*	*	.	-0.60	0.84
10	Tyr	384	.	A	B	.	.	.	.	-0.27	0.79	*	*	.	-0.60	0.80
	Trp	385	.	A	B	.	.	.	.	0.33	0.49	*	*	.	-0.60	0.58
	Glu	386	A	A	.	.	.	.	.	0.22	0.49	*	*	.	-0.45	1.30
	Leu	387	A	A	.	.	.	.	.	0.18	0.53	*	*	.	-0.60	0.68
	Thr	388	A	A	.	.	.	.	.	1.03	0.17	*	.	F	0.00	1.05
15	Asp	389	A	A	.	.	.	.	.	0.39	-0.34	.	.	F	0.60	1.05
	Leu	390	A	A	.	.	.	.	.	0.72	0.34	.	.	F	-0.15	0.89
	Asn	391	A	A	.	.	.	.	.	0.72	-0.34	*	.	F	0.60	1.23
	Gln	392	A	A	.	.	.	.	.	0.94	-0.83	*	.	F	0.90	1.23
	Ile	393	A	A	.	.	.	.	.	0.66	-0.33	*	.	F	0.60	1.51
20	Lys	394	A	A	.	.	.	.	.	-0.20	-0.40	*	.	F	0.45	0.93
	Asp	395	A	A	.	.	.	.	.	0.02	-0.16	*	.	.	0.30	0.40
	Ala	396	A	A	.	.	.	.	.	-0.29	-0.06	*	.	.	0.30	0.57
	Met	397	.	A	B	.	.	.	.	-0.99	-0.26	.	.	.	0.30	0.41
	Val	398	A	A	.	.	.	.	.	-0.80	0.53	.	.	.	-0.60	0.21
25	Ala	399	A	A	.	.	.	.	.	-0.84	1.31	.	.	.	-0.60	0.18
	Thr	400	A	A	.	.	.	.	.	-1.73	0.81	*	.	.	-0.60	0.31
	Phe	401	A	A	.	.	.	.	.	-1.39	0.89	*	.	.	-0.60	0.29
	Phe	402	A	A	.	.	.	.	.	-0.79	1.00	*	.	.	-0.60	0.46
	Asp	403	A	A	.	.	.	.	.	0.07	0.50	*	.	.	-0.60	0.55
30	Ile	404	A	A	.	.	.	.	.	0.31	0.01	*	.	.	-0.15	1.05
	Tyr	405	A	.	.	.	.	T	.	-0.27	-0.34	*	.	.	0.85	1.20
	Glu	406	A	.	.	.	.	T	.	-0.38	-0.44	*	*	.	0.70	0.51
	Asp	407	A	.	.	.	.	T	.	0.32	0.24	*	*	.	0.10	0.59
	Gly	408	A	.	.	.	.	T	.	-0.57	-0.44	*	*	.	0.70	0.63
35	Ile	409	A	.	.	B	.	.	.	-0.53	-0.51	.	*	.	0.60	0.26
	Leu	410	A	.	.	B	.	.	.	-1.14	0.13	*	.	.	-0.30	0.11
	Asp	411	.	.	B	B	.	.	.	-1.96	0.77	.	.	.	-0.60	0.09
	Ile	412	.	.	B	B	.	.	.	-2.26	1.03	*	*	.	-0.60	0.10
40	Val	413	.	.	B	B	.	.	.	-1.87	0.73	.	.	.	-0.60	0.16
	Val	414	.	.	B	B	.	.	.	-1.32	0.04	.	.	.	-0.30	0.20
	Leu	415	.	.	B	B	.	.	.	-0.76	0.47	.	*	.	-0.26	0.28
	Ser	416	.	.	B	.	.	T	.	-1.07	0.54	*	*	F	0.63	0.58
	Lys	417	.	.	.	.	T	T	.	-0.13	0.39	*	.	F	1.82	1.13
45	Gly	418	.	.	.	.	T	T	.	0.72	-0.26	.	.	F	2.76	2.75
	Tyr	419	.	.	.	.	T	T	.	1.58	-0.54	.	*	F	3.40	3.30
	Thr	420	.	.	.	.	.	T	C	1.69	-0.93	.	.	F	2.86	2.76
	Lys	421	.	.	.	.	.	T	C	1.40	-0.14	.	*	F	2.22	2.41
	Asn	422	.	.	B	.	.	T	.	0.47	-0.07	.	*	F	1.68	1.55
50	Asp	423	A	.	.	.	.	T	.	0.78	-0.14	.	*	F	1.19	0.75
	Phe	424	A	A	.	.	.	.	.	0.71	-0.13	.	*	.	0.30	0.51
	Ala	425	A	A	B	.	.	.	.	0.21	0.36	.	*	.	-0.30	0.46
	Ile	426	A	A	.	.	.	.	.	0.21	0.64	.	*	.	-0.60	0.23
	His	427	A	A	.	.	.	.	.	0.21	0.64	*	.	.	-0.60	0.53
55	Thr	428	A	A	.	.	.	.	.	0.21	0.26	*	*	.	-0.06	0.84
	Leu	429	A	.	.	.	.	T	C	0.21	0.16	*	*	.	0.93	1.92
	Lys	430	.	.	.	.	.	T	C	0.80	0.26	*	*	F	1.32	1.22
	Asn	431	.	.	.	.	.	T	C	1.10	-0.24	*	*	F	2.16	1.47
	Asn	432	.	.	.	.	.	T	C	1.13	-0.23	.	*	F	2.40	1.80
60	Phe	433	A	A	.	.	.	.	.	0.86	-0.91	.	*	.	1.71	1.50
	Glu	434	A	A	.	.	.	.	.	1.42	-0.41	.	*	.	1.02	0.94
	Ala	435	A	A	.	.	.	.	.	0.68	-0.06	.	*	.	0.78	0.92
	Asp	436	A	A	.	.	.	.	.	-0.18	0.33	.	*	.	-0.06	0.92
	Ala	437	A	.	B	.	.	.	.	-0.13	0.19	.	*	.	-0.30	0.39

1094

	Tyr	438	A	.	.	B	.	.	.	-0.29	0.19	*	*	.	-0.30	0.78
	Phe	439	A	.	.	B	.	.	.	-1.18	0.33	*	*	.	-0.30	0.35
	Val	440	A	.	.	B	.	.	.	-1.44	1.01	.	.	.	-0.60	0.24
5	Lys	441	.	.	B	B	.	.	.	-2.26	1.16	.	.	.	-0.60	0.11
	Val	442	.	.	B	B	.	.	.	-1.97	1.09	*	.	.	-0.60	0.11
	Ile	443	.	.	B	B	.	.	.	-2.07	0.69	.	.	.	-0.60	0.20
	Val	444	.	.	B	B	.	.	.	-2.18	0.47	.	.	.	-0.60	0.10
	Leu	445	.	.	B	.	.	T	.	-1.99	1.16	.	.	.	-0.20	0.11
10	Ser	446	.	.	B	.	.	T	.	-2.33	1.09	.	.	.	-0.20	0.08
	Gly	447	.	.	.	.	T	T	.	-1.48	0.79	.	.	.	0.20	0.15
	Leu	448	.	.	.	.	T	T	.	-0.59	0.54	.	.	.	0.54	0.29
	Cys	449	.	.	.	.	T	T	.	-0.40	-0.14	.	.	.	1.78	0.36
	Ser	450	.	.	.	.	T	T	.	0.20	0.04	.	.	F	1.67	0.20
15	Asn	451	.	.	.	.	T	T	.	0.61	0.04	*	.	F	2.01	0.37
	Asp	452	.	.	.	.	T	T	.	1.00	-0.64	*	.	F	3.40	1.34
	Cys	453	.	.	B	.	.	T	.	0.92	-1.21	*	.	F	2.66	2.00
	Pro	454	.	.	.	.	T	T	.	1.28	-0.91	*	.	F	2.57	0.87
	Arg	455	.	.	.	.	T	T	.	1.37	-0.83	*	.	F	2.23	0.75
20	Lys	456	.	.	B	.	.	T	.	0.67	-0.40	*	.	F	1.34	2.17
	Ile	457	.	.	B	.	.	.	.	0.32	-0.19	*	.	F	0.80	1.22
	Thr	458	.	.	B	.	.	T	.	0.13	-0.19	*	.	F	0.85	0.61
	Pro	459	.	.	B	.	.	T	.	0.34	0.46	*	.	F	-0.05	0.23
	Phe	460	.	.	B	.	.	T	.	0.23	0.86	*	.	.	-0.20	0.52
25	Gly	461	.	.	B	.	.	T	.	-0.02	0.57	.	.	.	-0.20	0.63
	Val	462	.	.	B	.	.	.	.	0.52	0.51	.	.	F	-0.25	0.63
	Asn	463	.	.	.	.	.	.	C	0.62	0.51	.	.	F	-0.05	0.72
	Gln	464	.	.	.	.	.	T	C	0.59	0.16	.	.	F	0.60	1.12
	Pro	465	.	.	.	.	.	T	C	0.40	0.49	.	.	F	0.30	2.37
30	Gly	466	.	.	.	.	.	T	C	0.14	0.53	*	.	F	0.30	1.03
	Pro	467	.	.	.	.	.	T	C	0.76	0.74	*	.	F	0.15	0.59
	Tyr	468	.	.	B	B	.	.	.	0.44	1.10	.	.	.	-0.60	0.60
	Ile	469	.	.	B	B	.	.	.	0.13	1.16	.	.	.	-0.60	0.87
35	Met	470	.	.	B	B	.	.	.	-0.51	1.21	.	.	.	-0.60	0.81
	Tyr	471	.	.	B	B	.	.	.	-0.17	1.43	.	.	.	-0.60	0.39
	Thr	472	.	.	B	B	.	.	.	-0.54	0.67	.	*	.	-0.60	0.92
	Thr	473	.	.	B	B	.	.	.	-0.30	0.49	.	*	.	-0.60	0.94
	Val	474	.	.	B	B	.	.	.	0.24	0.27	.	*	.	-0.30	0.96
40	Asp	475	.	.	B	.	.	T	.	0.60	-0.06	.	*	F	0.85	0.66
	Ala	476	.	.	B	.	.	T	.	0.03	0.21	.	*	F	0.25	0.72
	Asn	477	.	.	B	.	.	T	.	0.39	0.41	.	*	.	-0.20	0.80
	Gly	478	.	.	B	.	.	T	.	0.70	-0.23	.	*	.	0.70	0.95
	Tyr	479	.	.	B	.	.	.	.	1.21	0.17	.	*	F	0.20	1.52
45	Leu	480	.	.	B	.	.	T	.	0.91	0.10	*	*	F	0.46	0.93
	Lys	481	.	.	B	.	T	T	.	0.91	0.09	*	*	F	1.22	1.26
	Asn	482	.	.	.	.	T	T	.	0.57	0.16	.	.	F	1.28	0.81
	Gly	483	.	.	.	.	T	T	.	0.91	-0.17	.	.	F	2.09	0.98
	Ser	484	.	.	.	.	.	T	C	0.34	-0.46	.	.	F	2.10	0.85
50	Ala	485	.	.	B	.	.	T	.	0.86	0.23	.	.	F	1.09	0.43
	Gly	486	.	.	B	.	.	T	.	0.81	0.21	.	.	F	0.88	0.59
	Gln	487	.	.	B	.	.	T	.	0.51	0.19	.	.	F	0.67	0.76
	Leu	488	.	.	B	.	.	.	.	0.27	0.19	*	.	F	0.41	1.01
	Ser	489	.	.	B	.	.	T	.	0.53	0.19	.	*	F	0.40	1.03
55	Gln	490	.	.	B	.	.	T	.	0.31	0.26	*	.	F	0.25	0.81
	Ser	491	A	.	.	.	.	T	.	0.07	0.54	*	*	F	-0.05	0.81
	Ala	492	A	.	.	.	.	T	.	-0.74	0.36	*	*	.	0.10	0.61
	His	493	.	A	B	.	.	.	.	0.07	0.66	*	*	.	-0.60	0.29
60	Leu	494	.	A	B	.	.	.	.	-0.44	0.66	*	*	.	-0.60	0.37
	Ala	495	.	A	B	.	.	.	.	-0.66	0.96	*	*	.	-0.60	0.31
	Leu	496	.	A	B	.	.	.	.	-0.60	0.89	.	*	.	-0.60	0.35
	Gln	497	.	A	B	.	.	.	.	-0.01	1.14	*	*	.	-0.60	0.66
	Leu	498	.	.	B	.	.	T	.	-0.83	0.86	*	*	.	-0.05	1.05
	Pro	499	.	.	B	.	.	T	.	-0.83	1.00	*	*	.	-0.20	0.95
	Tyr	500	.	.	B	.	.	T	.	-0.59	1.00	*	*	.	-0.20	0.45

1095

5	Asn	501	.	.	B	.	.	T	.	-0.59	1.03	*	*	.	-0.20	0.54
	Val	502	.	.	B	.	.	.	.	-0.93	1.03	*	*	.	-0.40	0.29
	Leu	503	.	.	B	.	.	.	.	-0.01	1.03	*	*	.	-0.40	0.18
	Gly	504	.	.	B	.	.	.	.	-0.10	0.27	*	.	.	-0.10	0.22
	Leu	505	.	.	B	.	.	.	.	-0.44	0.26	*	.	.	-0.10	0.40
10	Gly	506	.	.	B	.	.	.	.	-0.44	0.11	*	.	F	0.05	0.49
	Arg	507	.	.	B	.	.	.	.	-0.29	-0.17	*	.	F	0.65	0.80
	Ser	508	.	.	.	.	.	T	C	-0.29	0.19	*	.	F	0.45	0.84
	Ala	509	.	.	B	.	.	T	.	0.06	0.19	*	.	F	0.25	0.70
	Asn	510	.	.	B	.	.	T	.	0.83	-0.24	*	.	.	0.70	0.60
15	Phe	511	.	.	B	.	.	T	.	0.37	0.26	*	.	.	0.10	0.60
	Leu	512	.	.	B	.	.	.	.	0.01	0.56	*	.	.	-0.40	0.49
	Asp	513	.	.	B	.	.	.	.	-0.54	0.81	*	.	.	-0.40	0.48
	His	514	.	.	B	B	.	.	.	-0.30	1.06	*	*	.	-0.60	0.41
	Leu	515	.	.	B	B	.	.	.	-1.19	0.70	*	.	.	-0.60	0.49
20	Tyr	516	.	.	B	B	.	.	.	-0.70	0.70	*	.	.	-0.60	0.21
	Val	517	.	.	B	B	.	.	.	0.22	1.13	*	.	.	-0.60	0.24
	Gly	518	.	.	B	B	.	.	.	0.01	0.63	*	.	.	-0.60	0.56
	Ile	519	.	.	B	B	.	.	.	-0.26	0.37	*	.	.	0.04	0.55
	Pro	520	.	.	B	B	.	.	.	0.21	0.00	*	*	F	0.53	1.00
25	Arg	521	.	.	.	.	.	T	C	0.46	-0.21	*	.	F	2.07	1.00
	Pro	522	.	.	.	.	.	T	C	1.36	-0.64	.	.	F	2.86	2.47
	Ser	523	.	.	.	.	T	T	.	1.40	-1.33	.	*	F	3.40	3.19
	Gly	524	.	.	.	.	.	T	C	1.40	-1.37	*	*	F	2.86	2.18
	Glu	525	.	.	.	.	T	.	.	1.72	-0.69	*	*	F	2.37	0.99
30	Lys	526	.	.	.	.	.	.	C	1.66	-1.11	*	*	F	1.98	1.45
	Ser	527	.	.	B	.	.	.	.	1.87	-1.50	*	.	F	1.44	2.92
	Ile	528	.	A	B	.	.	.	.	2.17	-1.53	*	.	F	0.90	2.92
	Arg	529	A	A	.	.	.	.	.	2.22	-1.53	*	.	F	0.90	2.53
	Lys	530	A	A	.	.	.	.	.	1.91	-0.61	*	.	F	0.90	1.98
35	Gln	531	A	A	.	.	.	.	.	1.28	-0.51	*	.	F	0.90	4.09
	Glu	532	A	A	.	.	.	.	.	0.69	-0.70	.	.	F	0.90	2.11
	Trp	533	.	A	B	B	.	.	.	0.69	-0.01	.	.	.	0.30	0.74
	Thr	534	.	A	B	B	.	.	.	0.37	0.67	.	.	.	-0.60	0.30
	Ala	535	.	A	B	B	.	.	.	0.32	0.70	.	.	.	-0.60	0.27
40	Ile	536	.	A	B	B	.	.	.	0.02	1.10	*	.	.	-0.60	0.41
	Ile	537	.	.	B	.	.	T	.	0.02	0.57	.	.	.	-0.20	0.38
	Pro	538	.	.	.	.	.	T	C	-0.50	0.49	.	.	F	0.15	0.65
	Asn	539	.	.	.	.	T	T	.	-1.08	0.67	.	.	F	0.35	0.76
	Ser	540	.	.	.	.	T	T	.	-1.34	0.67	.	.	F	0.35	0.76
45	Gln	541	.	.	B	B	.	.	.	-1.34	0.63	.	.	F	-0.45	0.37
	Leu	542	.	.	B	B	.	.	.	-0.67	0.89	.	.	.	-0.60	0.16
	Ile	543	.	.	B	B	.	.	.	-0.70	0.91	.	.	.	-0.60	0.18
	Val	544	.	.	B	B	.	.	.	-0.91	1.29	.	.	.	-0.60	0.17
	Ile	545	.	.	B	B	.	.	.	-0.64	1.31	.	.	.	-0.60	0.31
50	Pro	546	.	.	B	.	.	.	.	-0.64	1.13	.	.	.	-0.40	0.61
	Tyr	547	.	.	B	.	.	T	.	-0.69	0.84	.	.	.	-0.05	1.32
	Pro	548	.	.	.	.	T	T	.	-0.01	0.84	*	.	.	0.35	1.39
	His	549	.	.	.	.	T	T	.	0.96	0.59	*	.	.	0.35	1.39
	Asn	550	.	.	.	.	.	T	C	1.54	0.16	*	.	.	0.45	1.74
55	Val	551	.	.	B	.	.	.	.	1.47	-0.21	*	.	.	0.65	1.51
	Pro	552	.	.	.	.	.	T	C	1.41	0.27	*	.	F	0.60	1.17
	Arg	553	.	.	.	.	T	T	.	1.03	0.16	*	.	F	0.65	0.97
	Ser	554	.	.	.	.	T	T	.	1.11	0.26	*	*	F	0.80	1.32
	Trp	555	.	.	.	.	T	T	.	0.30	-0.39	*	*	.	1.25	1.71
60	Ser	556	.	A	B	.	.	.	.	0.91	-0.13	*	*	.	0.30	0.72
	Ala	557	.	A	B	.	.	.	.	0.31	0.63	.	*	.	-0.60	0.84
	Lys	558	.	A	B	.	.	.	.	-0.11	0.93	.	*	.	-0.60	0.66
	Leu	559	.	A	B	.	.	.	.	-0.02	0.50	.	*	.	-0.60	0.71
	Tyr	560	.	.	B	.	.	.	.	-0.03	0.54	.	*	.	-0.25	1.09
60	Leu	561	.	.	B	.	.	.	.	0.27	0.43	.	*	.	-0.40	0.73
	Thr	562	.	.	B	.	.	T	.	-0.03	0.83	*	*	F	0.10	1.42
	Pro	563	.	.	B	.	.	T	.	-0.93	0.83	*	*	F	-0.05	0.64

1096

	Ser	564	.	.	B	.	.	T	.	-0.93	0.71	.	.	F	-0.05	0.57
	Asn	565	.	.	B	.	.	T	.	-1.50	0.71	.	.	F	-0.05	0.33
	Ile	566	.	.	B	B	.	.	.	-1.00	0.91	.	.	.	-0.60	0.17
5	Val	567	.	.	B	B	.	.	.	-1.28	0.97	.	.	.	-0.60	0.19
	Leu	568	.	.	B	B	.	.	.	-1.96	1.09	.	.	.	-0.60	0.12
	Leu	569	.	.	B	B	.	.	.	-2.24	1.37	.	.	.	-0.60	0.12
	Thr	570	.	.	B	B	.	.	.	-3.06	1.19	.	.	.	-0.60	0.16
	Ala	571	.	.	B	B	.	.	.	-3.06	1.23	.	.	.	-0.60	0.16
10	Ile	572	A	.	.	B	.	.	.	-2.54	1.23	.	.	.	-0.60	0.14
	Ala	573	A	.	.	B	.	.	.	-2.59	0.97	.	.	.	-0.60	0.09
	Leu	574	.	.	B	B	.	.	.	-2.44	1.13	.	.	.	-0.60	0.07
	Ile	575	.	.	B	B	.	.	.	-2.99	1.20	.	.	.	-0.60	0.05
	Gly	576	.	.	B	B	.	.	.	-3.10	1.16	.	.	.	-0.60	0.04
	Val	577	.	.	B	B	.	.	.	-3.10	1.44	.	.	.	-0.60	0.04
15	Cys	578	.	.	B	B	.	.	.	-3.32	1.44	.	.	.	-0.60	0.04
	Val	579	.	.	B	B	.	.	.	-3.10	1.44	.	.	.	-0.60	0.03
	Phe	580	.	.	B	B	.	.	.	-3.10	1.51	.	.	.	-0.60	0.05
	Ile	581	.	.	B	B	.	.	.	-3.64	1.56	.	.	.	-0.60	0.06
	Leu	582	.	.	B	B	.	.	.	-3.13	1.67	.	.	.	-0.60	0.06
20	Ala	583	A	.	B	B	.	.	.	-3.36	1.46	.	.	.	-0.60	0.07
	Ile	584	A	.	.	B	.	.	.	-3.31	1.36	.	.	.	-0.60	0.07
	Ile	585	A	.	.	B	.	.	.	-2.64	1.36	*	.	.	-0.60	0.07
	Gly	586	A	.	.	B	.	.	.	-2.04	1.17	.	.	.	-0.60	0.09
	Ile	587	A	.	.	B	.	.	.	-1.23	1.59	.	.	.	-0.60	0.13
25	Leu	588	A	.	.	B	.	.	.	-0.64	1.30	*	.	.	-0.60	0.32
	His	589	A	.	.	B	.	.	.	0.29	0.61	.	.	.	-0.60	0.57
	Trp	590	A	.	.	B	.	.	.	1.22	0.19	.	.	.	-0.15	1.62
	Gln	591	A	.	.	B	.	.	.	0.98	-0.50	*	.	F	0.60	3.93
	Glu	592	A	.	.	B	.	.	.	1.87	-0.69	*	.	F	0.90	2.92
30	Lys	593	A	.	.	.	.	.	.	2.68	-1.19	.	*	F	1.10	4.64
	Lys	594	A	.	.	.	.	.	.	2.82	-2.10	.	.	F	1.10	4.47
	Ala	595	A	.	.	.	.	.	.	3.11	-2.50	.	*	F	1.10	5.06
	Asp	596	A	.	.	.	.	.	T	3.16	-2.50	*	.	F	1.30	4.38
35	Asp	597	A	.	.	.	.	.	T	3.27	-2.50	*	*	F	1.30	4.38
	Arg	598	A	.	.	.	.	.	T	3.22	-2.50	*	.	F	1.30	8.49
	Glu	599	A	.	.	.	.	.	T	3.18	-2.60	*	*	F	1.30	8.81
	Lys	600	A	A	.	.	.	.	.	3.18	-2.60	.	.	F	0.90	9.13
	Arg	601	A	A	.	.	.	.	.	3.14	-2.10	*	.	F	0.90	4.71
40	Gln	602	A	A	.	.	.	.	.	3.26	-1.60	*	.	F	0.90	3.70
	Glu	603	A	A	.	.	.	.	.	2.44	-1.60	*	.	F	0.90	3.63
	Ala	604	A	A	.	.	.	.	.	2.41	-0.81	.	*	.	0.75	1.60
	His	605	A	A	.	.	.	.	.	1.67	-0.31	.	*	.	0.45	1.26
	Arg	606	A	A	.	.	.	.	.	1.56	0.07	*	*	.	-0.30	0.63
45	Phe	607	A	A	.	.	.	.	.	0.97	0.07	*	*	.	-0.15	1.04
	His	608	A	A	.	.	.	.	.	0.37	0.07	*	*	.	-0.30	0.77
	Phe	609	A	A	.	.	.	.	.	0.57	0.19	*	*	.	-0.30	0.39
	Asp	610	A	A	.	.	.	.	.	0.21	0.61	*	*	.	-0.60	0.58
	Ala	611	A	A	.	.	.	.	.	-0.29	0.26	*	*	.	-0.30	0.54
50	Met	612	A	A	.	.	.	.	.	0.02	0.19	.	*	.	-0.30	0.80



Table 7

	Res	Position	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII	XIII	XIV
5	Met	1	.	.	.	.	.	.	C	0.09	0.10	.	.	.	0.46	0.66
	Ser	2	.	.	.	.	.	T	C	0.48	0.16	.	.	.	0.84	0.74
	Ser	3	.	.	.	.	.	T	C	0.06	-0.27	*	.	.	1.77	1.01
	Gly	4	.	.	.	.	.	T	C	-0.37	-0.01	.	.	.	1.80	0.84
10	Thr	5	.	.	.	.	.	T	C	-0.27	0.06	.	.	F	1.17	0.52
	Glu	6	A	.	.	.	.	.	.	0.12	0.59	*	.	F	0.29	0.41
	Leu	7	A	.	.	.	.	.	.	0.08	0.63	.	.	.	-0.04	0.63
	Leu	8	A	.	.	.	.	.	.	-0.21	0.63	.	.	.	-0.22	0.43
15	Trp	9	A	.	.	.	.	T	.	-0.46	0.64	.	.	.	-0.20	0.25
	Pro	10	A	.	.	.	.	T	.	-0.96	1.14	.	.	.	-0.20	0.31
	Gly	11	A	.	.	.	.	T	.	-1.77	1.14	.	.	.	-0.20	0.31
	Ala	12	A	.	.	.	.	T	.	-1.81	1.14	.	.	.	-0.20	0.24
20	Ala	13	A	.	.	B	.	.	.	-1.81	0.87	.	.	.	-0.60	0.12
	Leu	14	A	.	.	B	.	.	.	-2.33	1.13	.	.	.	-0.60	0.10
	Leu	15	A	.	.	B	.	.	.	-2.47	1.39	.	.	.	-0.60	0.08
	Val	16	A	.	.	B	.	.	.	-2.98	1.31	.	.	.	-0.60	0.08
25	Leu	17	A	.	.	B	.	.	.	-2.98	1.46	.	.	.	-0.60	0.07
	Leu	18	A	.	.	B	.	.	.	-2.98	1.27	.	.	.	-0.60	0.09
	Gly	19	A	.	.	B	.	.	.	-2.47	1.09	.	*	.	-0.60	0.12
	Val	20	A	.	.	B	.	.	.	-2.47	0.83	.	.	.	-0.60	0.19
30	Ala	21	A	.	.	B	.	.	.	-2.28	0.83	.	*	.	-0.60	0.19
	Ala	22	A	.	.	B	.	.	.	-2.32	0.71	*	*	.	-0.60	0.10
	Ser	23	A	.	.	B	.	.	.	-1.40	0.93	*	*	.	-0.60	0.10
	Leu	24	A	.	.	B	.	.	.	-1.72	0.29	.	*	.	-0.30	0.20
35	Cys	25	.	.	B	B	.	.	.	-1.17	0.36	*	*	.	-0.30	0.11
	Val	26	.	.	B	B	.	.	.	-0.47	0.24	*	*	.	-0.30	0.11
	Arg	27	.	.	.	B	T	.	.	-0.09	-0.14	*	*	.	1.04	0.25
	Cys	28	.	.	.	B	T	.	.	-0.13	-0.40	*	*	.	1.38	0.73
40	Ser	29	.	.	.	B	T	.	.	0.09	-0.54	*	*	F	2.17	0.97
	Arg	30	.	.	.	.	.	T	C	0.80	-0.69	*	.	F	2.71	0.50
	Pro	31	.	.	.	.	T	T	.	1.77	-0.69	*	.	F	3.40	1.86
	Gly	32	.	.	.	.	T	T	.	1.36	-1.26	*	.	F	3.06	2.72
45	Ala	33	.	.	.	.	.	T	C	2.02	-1.26	*	.	F	2.52	1.86
	Lys	34	.	A	.	.	.	.	C	2.37	-1.26	*	*	F	1.78	2.08
	Arg	35	A	A	.	.	.	.	.	1.37	-1.69	*	*	F	1.24	4.21
	Ser	36	A	A	.	.	.	.	.	1.33	-1.43	*	.	F	0.90	2.92
50	Glu	37	A	A	.	.	.	.	.	1.68	-1.17	*	.	F	0.90	2.29
	Lys	38	A	A	.	.	.	.	.	2.27	-0.77	*	.	F	0.90	2.02
	Ile	39	A	A	.	.	.	.	.	2.33	-0.37	*	.	F	0.60	2.62
	Tyr	40	A	.	.	.	.	.	.	1.92	-0.76	.	.	F	1.40	2.96
55	Gln	41	A	.	.	.	.	T	.	1.41	-0.37	.	*	F	1.60	1.98
	Gln	42	A	.	.	.	.	T	.	1.52	0.31	.	.	F	1.30	2.33
	Arg	43	.	.	.	.	.	T	C	1.48	-0.37	.	*	F	2.40	2.91
	Ser	44	.	.	.	.	.	T	C	2.37	-1.13	.	.	F	3.00	2.91
60	Leu	45	.	A	.	.	.	.	C	2.61	-1.53	*	*	F	2.30	2.81
	Arg	46	.	A	.	.	T	.	.	2.61	-1.53	*	.	F	2.20	2.49
	Glu	47	.	A	.	.	T	.	.	2.31	-1.13	*	.	F	1.90	3.21
	Asp	48	.	A	.	.	T	.	.	1.50	-1.13	*	.	F	1.60	5.22
55	Gln	49	.	A	.	.	T	.	.	1.49	-1.03	*	*	F	1.30	2.31
	Gln	50	.	A	.	.	T	.	.	1.96	-0.54	*	*	F	1.58	1.92
	Ser	51	.	A	.	.	.	.	C	1.54	-0.11	*	.	F	1.36	1.14
	Phe	52	.	.	.	.	T	T	.	1.66	0.27	.	.	F	1.49	0.88
60	Thr	53	.	.	.	.	T	T	.	1.34	-0.13	.	.	F	2.37	1.00
	Gly	54	.	.	.	.	T	T	.	1.10	-0.04	*	.	F	2.80	1.07
	Ser	55	.	.	.	.	T	T	.	0.80	0.33	.	.	F	1.92	1.94
	Arg	56	.	.	.	B	T	.	.	0.29	-0.07	.	.	F	1.84	1.80
60	Thr	57	.	.	.	B	T	.	.	0.13	0.13	.	.	F	0.96	1.50
	Tyr	58	.	.	.	B	T	.	.	0.10	0.34	*	.	.	0.38	0.83
	Ser	59	.	.	.	B	.	.	C	0.44	0.39	*	.	.	-0.10	0.42

1098

	Leu	60	.	.	B	B	.	.	.	0.16	0.79	*	.	.	-0.60	0.50
	Val	61	.	.	B	B	.	.	.	-0.24	0.80	*	.	.	-0.60	0.33
	Gly	62	.	.	.	.	T	.	.	-0.14	0.96	.	.	.	0.00	0.26
	Gln	63	.	.	.	.	T	.	.	-0.24	1.00	.	.	.	0.00	0.48
5	Ala	64	.	.	.	.	.	.	C	-0.16	0.74	.	.	.	-0.20	0.64
	Trp	65	.	.	.	.	.	T	C	-0.16	0.53	.	.	F	0.15	1.00
	Pro	66	.	.	.	.	.	T	C	0.11	0.79	*	.	F	0.15	0.48
	Gly	67	.	.	.	.	.	T	C	0.46	0.89	*	.	F	0.15	0.48
	Pro	68	.	.	.	.	.	T	C	-0.14	0.39	*	.	F	0.45	0.75
10	Leu	69	.	A	.	.	.	.	C	-0.14	0.09	.	.	F	0.05	0.48
	Ala	70	.	A	.	.	.	.	C	-0.07	0.16	.	.	.	-0.10	0.49
	Asp	71	A	A	.	.	.	.	.	-0.17	0.16	.	.	.	-0.30	0.49
	Met	72	A	A	.	.	.	.	.	0.29	0.21	.	.	.	-0.30	0.86
	Ala	73	A	A	.	.	.	.	.	0.54	-0.47	.	.	.	0.45	1.67
15	Pro	74	A	.	.	.	.	T	.	1.36	-0.97	.	.	F	1.30	2.00
	Thr	75	A	.	.	.	.	T	.	1.99	-0.97	.	.	F	1.30	3.38
	Arg	76	A	.	.	.	.	T	.	1.18	-1.59	.	.	F	1.30	6.69
	Lys	77	A	.	.	.	.	T	.	0.97	-1.40	.	.	F	1.30	3.57
	Asp	78	A	A	.	.	.	.	.	1.56	-1.14	.	.	F	0.90	2.04
20	Lys	79	A	A	.	.	.	.	.	1.07	-1.23	.	.	F	0.90	1.80
	Leu	80	A	A	.	.	.	.	.	1.13	-0.44	.	.	.	0.30	0.78
	Leu	81	.	A	B	.	.	.	.	0.81	0.31	.	.	.	-0.30	0.73
	Gln	82	.	A	B	.	.	.	.	0.47	0.74	*	*	.	-0.60	0.57
25	Phe	83	.	A	B	.	.	.	.	-0.34	1.13	*	*	.	-0.60	0.92
	Tyr	84	.	.	.	.	.	T	C	-0.39	1.13	*	*	.	0.00	0.92
	Pro	85	.	.	.	.	.	T	C	0.42	0.44	*	*	.	0.00	0.92
	Ser	86	.	.	.	.	.	T	C	1.02	0.04	*	*	F	0.60	1.78
	Leu	87	.	.	.	.	.	T	C	0.43	-0.31	*	*	F	1.50	1.75
	Glu	88	.	.	.	.	.	.	C	0.83	-0.57	*	*	F	1.90	1.14
30	Asp	89	.	.	.	.	.	.	C	0.78	-0.61	.	*	F	2.20	1.14
	Pro	90	.	.	.	.	.	.	C	1.10	-0.61	.	*	F	2.50	1.86
	Ala	91	.	.	.	.	T	.	.	1.16	-1.30	.	*	F	3.00	2.10
	Ser	92	A	.	.	.	.	T	.	1.97	-0.54	.	*	F	2.50	1.97
	Ser	93	A	.	.	.	.	T	.	1.97	-0.14	.	*	F	1.90	2.21
35	Arg	94	A	.	.	.	.	T	.	1.27	-0.17	*	.	F	1.60	3.52
	Tyr	95	.	.	.	.	T	T	.	1.18	0.11	*	*	F	1.10	2.27
	Gln	96	.	.	.	.	T	.	.	1.81	0.11	*	*	F	0.94	2.27
	Asn	97	.	.	.	.	T	.	.	1.77	-0.27	*	*	F	1.88	2.32
	Phe	98	.	.	.	.	T	.	.	1.77	0.16	*	*	F	1.62	1.47
40	Ser	99	.	.	.	.	T	T	.	1.77	-0.21	*	*	F	2.76	1.13
	Lys	100	.	.	.	.	T	T	.	1.98	-0.61	*	.	F	3.40	1.38
	Gly	101	.	.	.	.	.	T	C	1.63	-0.51	*	.	F	2.86	2.17
	Ser	102	.	.	.	.	.	T	C	1.33	-0.87	*	.	F	2.82	1.60
	Arg	103	.	.	.	.	.	.	C	2.03	-0.87	*	.	F	2.58	1.07
45	His	104	.	.	.	.	.	T	C	2.33	-0.87	*	.	F	2.74	1.88
	Gly	105	.	.	.	.	.	T	C	1.70	-1.30	*	.	F	2.70	2.43
	Ser	106	.	.	.	.	.	T	C	1.80	-1.19	*	.	F	3.00	1.25
	Glu	107	A	.	.	.	.	T	.	1.21	-0.43	.	*	F	2.20	1.44
50	Glu	108	A	.	.	.	.	.	.	1.10	-0.24	.	*	F	1.70	1.02
	Ala	109	A	.	.	.	.	.	.	0.92	-0.67	.	*	.	1.55	1.27
	Tyr	110	A	.	.	.	.	.	.	0.38	-0.63	.	*	.	1.25	1.14
	Ile	111	A	.	.	.	.	.	.	0.09	0.06	.	.	.	-0.10	0.46
	Asp	112	A	.	.	.	.	.	.	-0.51	0.56	.	.	.	-0.40	0.46
55	Pro	113	A	A	.	.	.	.	.	-0.51	0.67	.	*	.	-0.60	0.29
	Ile	114	A	A	.	.	.	.	.	-0.17	-0.09	.	.	.	0.30	0.72
	Ala	115	A	A	.	.	.	.	.	-0.17	-0.01	*	.	.	0.30	0.67
	Met	116	A	A	.	.	.	.	.	0.72	0.74	*	.	.	-0.60	0.68
	Glu	117	A	A	.	.	.	.	.	0.43	0.71	*	.	.	-0.45	1.57
60	Tyr	118	A	.	.	.	.	T	.	0.30	0.94	*	*	.	-0.05	1.63
	Tyr	119	.	.	.	.	T	T	.	1.30	0.87	*	*	.	0.35	1.63
	Asn	120	.	.	.	.	T	T	.	1.19	0.26	*	*	.	0.65	1.84
	Trp	121	.	.	.	.	T	T	.	1.49	1.04	*	*	.	0.35	1.02
	Gly	122	.	.	.	.	T	.	.	1.53	0.67	*	.	.	0.00	0.87

1099

	Arg	123	.	.	.	.	T	.	.	1.57	-0.09	*	.	.	1.05	1.08
	Phe	124	.	.	.	.	T	.	.	1.60	-0.06	*	.	F	1.20	1.59
	Ser	125	.	.	.	.	.	.	C	1.60	-0.54	*	.	F	1.64	2.49
5	Lys	126	.	.	.	.	.	.	C	1.89	-0.97	*	*	F	1.98	2.20
	Pro	127	.	.	.	.	.	T	C	2.23	-0.97	*	*	F	2.52	4.25
	Pro	128	.	.	.	.	.	T	C	2.12	-1.76	*	*	F	2.86	5.29
	Glu	129	.	.	.	.	T	T	.	2.23	-2.14	.	.	F	3.40	4.42
	Asp	130	A	.	.	.	.	T	.	2.53	-1.64	.	*	F	2.66	2.89
10	Asp	131	A	.	.	.	.	.	.	2.19	-1.67	.	*	F	2.12	3.00
	Asp	132	A	.	.	.	.	T	.	2.16	-1.71	.	.	F	1.98	2.32
	Ala	133	A	.	.	.	.	T	.	2.37	-0.96	.	.	F	1.64	2.18
	Asn	134	A	.	.	.	.	T	.	2.37	-0.96	.	.	F	1.30	2.26
	Ser	135	A	.	.	.	.	T	.	1.51	-0.56	*	.	F	1.30	2.18
15	Tyr	136	A	.	.	.	.	.	.	0.70	0.09	*	.	F	0.20	1.60
	Glu	137	A	.	.	.	.	.	.	-0.19	0.27	.	*	.	-0.10	0.82
	Asn	138	A	.	.	B	.	.	.	-0.27	0.56	.	.	.	-0.60	0.43
	Val	139	A	.	.	B	.	.	.	-0.22	0.74	.	.	.	-0.60	0.15
	Leu	140	A	.	.	B	.	.	.	0.08	-0.01	.	.	.	0.30	0.17
20	Ile	141	A	.	.	B	.	.	.	0.37	0.39	.	.	.	-0.30	0.18
	Cys	142	A	.	.	B	.	.	.	0.06	-0.01	.	.	.	0.56	0.49
	Lys	143	A	.	.	B	.	.	.	-0.26	-0.17	.	.	F	0.97	0.86
	Gln	144	A	.	.	.	.	.	.	0.60	-0.37	.	.	F	1.58	1.77
	Lys	145	.	.	.	.	.	.	C	1.10	-1.06	.	.	F	2.34	5.73
25	Thr	146	.	.	.	.	.	.	C	1.64	-1.14	.	.	F	2.60	4.13
	Thr	147	.	.	.	.	.	.	C	1.72	-0.71	.	*	F	2.34	2.36
	Glu	148	.	.	.	.	.	.	C	1.68	-0.61	.	.	F	2.08	1.19
	Thr	149	.	.	.	.	.	.	C	1.68	-0.21	.	.	F	1.52	1.43
	Gly	150	.	A	.	.	.	.	C	1.63	-0.30	.	.	F	1.06	1.72
30	Ala	151	A	A	.	.	.	.	.	1.60	-0.79	.	.	F	0.90	1.72
	Gln	152	A	A	.	.	.	.	.	1.02	-0.36	.	.	F	0.60	1.18
	Gln	153	A	A	.	.	.	.	.	0.68	-0.16	.	.	F	0.45	0.83
	Glu	154	.	A	.	.	.	T	.	0.64	-0.16	.	.	F	0.85	0.82
	Gly	155	.	.	.	.	T	T	.	0.18	-0.23	.	.	F	1.25	0.47
35	Ile	156	.	.	.	.	T	T	.	0.10	0.06	*	*	F	0.65	0.22
	Gly	157	.	.	.	.	T	T	.	0.21	0.23	*	*	F	0.90	0.07
	Gly	158	.	.	.	.	T	T	.	-0.13	0.23	*	*	F	1.15	0.14
	Leu	159	.	.	.	.	.	.	C	-0.13	0.23	*	*	.	0.85	0.19
	Cys	160	.	.	B	.	.	T	.	-0.60	-0.46	*	*	.	1.70	0.32
40	Arg	161	.	.	.	.	T	T	.	-0.01	-0.20	*	*	F	2.50	0.27
	Gly	162	.	.	.	.	T	T	.	-0.48	-0.24	.	*	F	2.25	0.44
	Asp	163	.	.	.	.	T	T	.	-0.43	-0.24	.	*	F	2.00	0.68
	Leu	164	A	A	.	.	.	.	.	-0.43	-0.43	.	*	F	0.95	0.46
	Ser	165	A	A	.	.	.	.	.	-0.36	0.26	.	*	.	-0.05	0.39
45	Leu	166	A	A	.	.	.	.	.	-1.28	0.33	*	*	.	-0.30	0.23
	Ser	167	A	A	.	.	.	.	.	-0.89	1.01	.	*	.	-0.60	0.23
	Leu	168	A	A	.	.	.	.	.	-1.20	0.33	.	*	.	-0.30	0.35
	Ala	169	A	A	.	.	.	.	.	-0.73	0.43	.	*	.	-0.60	0.61
	Leu	170	A	A	.	.	.	.	.	-0.64	0.17	*	*	.	-0.05	0.45
50	Lys	171	.	A	.	.	T	.	.	-0.14	0.21	*	*	F	0.75	0.84
	Thr	172	.	A	.	.	T	.	.	-0.14	0.01	.	*	F	1.15	1.20
	Gly	173	.	.	.	.	.	T	C	0.32	-0.10	.	*	F	2.20	1.96
	Pro	174	.	.	.	.	T	T	.	0.10	-0.36	.	.	F	2.50	0.97
	Thr	175	.	.	.	.	T	T	.	0.24	0.33	.	*	F	1.65	0.55
55	Ser	176	.	.	.	.	T	T	.	-0.01	0.41	.	.	F	1.10	0.30
	Gly	177	.	.	.	.	T	.	.	0.00	0.41	.	.	F	0.65	0.30
	Leu	178	.	.	.	.	.	.	C	-0.24	0.37	.	.	F	0.50	0.28
	Cys	179	.	.	.	.	.	T	C	-0.33	0.39	.	.	F	0.75	0.21
	Pro	180	.	.	.	.	.	T	C	-0.23	0.39	.	.	F	1.05	0.28
60	Ser	181	.	.	.	.	.	T	C	0.07	0.39	.	.	F	1.35	0.53
	Ala	182	.	.	.	.	.	T	C	0.41	-0.30	.	*	F	2.40	1.72
	Ser	183	.	.	.	.	.	T	C	1.22	-0.87	.	*	F	3.00	1.93
	Pro	184	.	.	.	.	.	T	C	1.89	-1.30	.	.	F	2.70	2.40
	Glu	185	A	.	.	.	.	T	.	1.76	-1.69	.	.	F	2.20	4.12

1100

5	Glu	186	A	.	.	.	.	T	.	1.17	-1.76	.	.	F	1.90	3.04
	Asp	187	A	.	.	.	.	T	.	1.37	-1.46	.	.	F	1.60	1.38
	Glu	188	A	.	.	.	.	T	.	1.28	-1.46	.	.	.	1.15	1.02
	Gly	189	A	.	.	.	.	T	.	1.10	-1.03	.	.	.	1.00	0.75
	Ile	190	A	.	.	.	.	T	.	0.71	-0.60	.	.	.	1.00	0.58

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

1101

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 231.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit

18 May 1998

Accession Number

209878

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209878****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209878**

## **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

## **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 233.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit

February 12, 1998

Accession Number

209626

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (If the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		



**ATCC Deposit No. 209626****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209626**

### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 233.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit

20 March 1998

Accession Number

209683

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209683**

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209683**

### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1110

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 233.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
25 February 1998

Accession Number  
209641

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209641  
CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209641**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.



**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 234.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*  
10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
09 July 1997

Accession Number  
209141

**C. ADDITIONAL INDICATIONS** *(leave blank if not applicable)*

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** *(if the indications are not for all designated States)*

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** *(leave blank if not applicable)*

The indications listed below will be submitted to the international Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209141****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209141**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1116

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 234.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)  
10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
26 February 1997

Accession Number  
97901

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 97901****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 97901**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 234.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
18 May 1998

Accession Number  
209877

**C. ADDITIONAL INDICATIONS** *(leave blank if not applicable)*

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** *(if the indications are not for all designated States)*

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** *(leave blank if not applicable)*

The indications listed below will be submitted to the international Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209877  
CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.



**ATCC Deposit No.: 209877**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)			
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 234.			
<b>B. IDENTIFICATION OF DEPOSIT</b>		Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>	
Name of depositary institution: American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit 11 August 1999		Accession Number PTA-499	
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)			
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>			
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)			
The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			
	For receiving Office use only		For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer		Authorized officer	

**ATCC Deposit No. PTA-499****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: PTA-499****UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1125

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 235.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
14 January 1998

Accession Number  
209580

**C. ADDITIONAL INDICATIONS** *(leave blank if not applicable)*

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** *(if the indications are not for all designated States)*

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** *(leave blank if not applicable)*

The indications listed below will be submitted to the international Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209580****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209580****UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 237.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
22 May 1998

Accession Number  
209889

**C. ADDITIONAL INDICATIONS** *(leave blank if not applicable)*

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** *(if the indications are not for all designated States)*

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** *(leave blank if not applicable)*

The indications listed below will be submitted to the international Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		



**ATCC Deposit No. 209889****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209889**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1131

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 232.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
15 May 1997

Accession Number  
209044

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer			Authorized officer	

**ATCC Deposit No. 209044**

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209044**

## **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

## **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1134

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 233.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)

10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit

13 March 1997

Accession Number

97958

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 97958****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 97958**

#### **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

#### **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

#### **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

#### **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.



1137

<b>INDICATIONS RELATING TO A DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL</b>  (PCT Rule 13bis)					
<b>A.</b> The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 233.					
<b>B. IDENTIFICATION OF DEPOSIT</b>			Further deposits are identified on an additional sheet <input checked="" type="checkbox"/>		
Name of depositary institution: American Type Culture Collection					
Address of depositary institution <i>(including postal code and country)</i> 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America					
Date of deposit 07 March 1997			Accession Number 97923		
<b>C. ADDITIONAL INDICATIONS</b> <i>(leave blank if not applicable)</i>			This information is continued on an additional sheet <input type="checkbox"/>		
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> <i>(if the indications are not for all designated States)</i>					
Europe In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). <div style="text-align: right;">Continued on additional sheets</div>					
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> <i>(leave blank if not applicable)</i>					
The indications listed below will be submitted to the international Bureau later <i>(specify the general nature of the indications e.g., "Accession Number of Deposit")</i>					
For receiving Office use only		For International Bureau use only			
<input type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:			
Authorized officer		Authorized officer			

**ATCC Deposit No. 97923****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 97923**

## **UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

## **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

1140

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

**A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description in Table 1 on page 234.

**B. IDENTIFICATION OF DEPOSIT**

Further deposits are identified on an additional sheet ☒

Name of depositary institution: American Type Culture Collection

Address of depositary institution (including postal code and country)  
10801 University Boulevard  
Manassas, Virginia 20110-2209  
United States of America

Date of deposit  
15 May 1997

Accession Number  
209047

**C. ADDITIONAL INDICATIONS** (leave blank if not applicable)

This information is continued on an additional sheet ☐

**D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE** (if the indications are not for all designated States)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

**E. SEPARATE FURNISHING OF INDICATIONS** (leave blank if not applicable)

The indications listed below will be submitted to the international Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

	For receiving Office use only			For International Bureau use only	
<input type="checkbox"/> This sheet was received with the international application			<input type="checkbox"/> This sheet was received by the International Bureau on:		
Authorized officer			Authorized officer		

**ATCC Deposit No. 209047  
CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ATCC Deposit No.: 209047**

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit
- 10 No:Z, which is hybridizable to SEQ ID NO:X;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
- 20 having biological activity;
- (f) a polynucleotide which is a variant of SEQ ID NO:X;
- (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;
- 25 (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

5 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

10 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

20 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

25

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

30

10. The recombinant host cell of claim 9 comprising vector sequences.



11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

5 (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

10 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

15 (g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

25 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

30 (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount  
5 of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of  
10 claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to  
15 a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.  
20

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the  
25 polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:X.

22. A method of identifying an activity in a biological assay, wherein the  
30 method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

1 ATGGCGGCGG CGGGCCGGCT CCCGAGCTCC TGGGCCCTCT TCTCGCCGCT 50  
M A A A G R L P S S W A L F S P L

51 CCTCGCAGGG CTTGCACTAC TGGGAGTCGG GCCGGTCCCA GCGCGGGCGC 100  
L A G L A L L G V G P V P A R A

101 TGCACAACGT CACGGCCGAG CTCTTTGGGG CCGAGGCCTG GGCACCCCTT 150  
L H N V T A E L F G A E A W G T L

151 GCGGCTTTCG GGGACCTCAA CTCCGACAAG CAGACGGATC TCTTCGTGCT 200  
A A F G D L N S D K Q T D L F V L

201 GCGGGAAAGA AATGACTTAA TCGTCTTTT GGCAGACCAG AATGCACCCT 250  
R E R N D L I V F L A D Q N A P

251 ATTTTAAACC CAAAGTAAAG GTATCTTTCA AGAATCAGAG TGCATTGATA 300  
Y F K P K V K V S F K N H S A L I

301 ACAAGTGTAG TCCCTGGGGA TTATGATGGA GATTCTCAAA TGGATGTCCT 350  
T S V V P G D Y D G D S Q M D V L

351 TCTGACATAT CTTCCCAAAA ATTATGCCAA GAGTGAATTA GGAGCTGTTA 400  
L T Y L P K N Y A K S E L G A V

401 TCTTCTGGGG ACAAATCAA ACATTAGATC CTAACAATAT GACCATACTC 450  
I F W G Q N Q T L D P N N M T I L

451 AATAGGACTT TTCAAGATGA GCCACTAATT ATGGATTTC AATGGTGATCT 500  
N R T F Q D E P L I M D F N G D L

501 AATTCCTGAT ATTTTGGTA TCACAAATGA ATCCAACCAG CCACAGATAC 550  
I P D I F G I T N E S N Q P Q I

551 TATTAGGAGG GAATTATCA TGGCATCCAG CATTGACCAC TACAAGTAAA 600  
L L G G N L S W H P A L T T T S K

Figure 1A

601 ATGCGAATTC CACATTCTCA TGCATTTATT GATCTGACTG AAGATTTTAC 650  
M R I P H S H A F I D L T E D F T

651 AGCAGATTTA TTCCTGACGA CATTGAATGC CACCACTAGT ACCTTCCAGT 700  
A D L F L T T L N A T T S T F Q

701 TTGAAATATG GGAAAATTG GATGGAACT TCTCTGTCAG TACTATATTG 750  
F E I W E N L D G N F S V S T I L

751 GAAAAACCTC AAAATATGAT GGTGGTTGGA CAGTCAGCAT TTGCAGACTT 800  
E K P Q N M M V V G Q S A F A D F

801 TGATGGAGAT GGACACATGG ATCATTTACT GCCAGGCTGT GAAGATAAAA 850  
D G D G H M D H L L P G C E D K

851 ATTGCCAAAA GAGTACCATC TACTTAGTGA GATCTGGGAT GAAGCAGTGG 900  
N C Q K S T I Y L V R S G M K Q W

901 GTTCCAGTCC TACAAGATT T CAGCAATAAG GGCACACTCT GGGGCTTTGT 950  
V P V L Q D F S N K G T L W G F V

951 GCCATTTGTG GATGAACAGC AACCAACTGA AATACCAATT CCAATTACCC 1000  
P F V D E Q Q P T E I P I P I T

1001 TTCATATTGG AGACTACAAT ATGGATGGCT ATCCAGACGC TCTGGTCATA 1050  
L H I G D Y N M D G Y P D A L V I

1051 CTAAAGAACA CATCTGGAAG CAACCAGCAG GCCTTTTAC TGGAGAACGT 1100  
L K N T S G S N Q Q A F L L E N V

1101 CCCTTGTAAT AATGCAAGCT GTGAAGAGGC GCGTCGAATG TTTAAAGTCT 1150  
P C N N A S C E E A R R M F K V

1151 ACTGGGAGCT GACAGACCTA AATCAAATTA AGGATGCCAT GGTGCCACC 1200  
Y W E L T D L N Q I K D A M V A T

**Figure 1B**

1201 TTCTTTGACA TTTACGAAGA TGAATCTTG GACATTGTAG TGCTAAGTAA 1250  
F F D I Y E D G I L D I V V L S K

1251 AGGATATACA AAGAATGATT TTGCCATTCA TACTACTAAA AATAACTTTG 1300  
G Y T K N D F A I H T L K N N F

1301 AAGCAGATGC TTATTTTGTT AAAGTTATTG TTCTTAGTGG TCTGTGTTCT 1350  
E A D A Y F V K V I V L S G L C S

1351 AATGACTGTC CTCGTAAGAT AACACCCTTT GGAGTGAATC AACCTGGACC 1400  
N D C P R K I T P F G V N Q P G P

1401 TTATATCATG TATACAACTG TAGATGCAAA TGGGTATCTG AAAAATGGAT 1450  
Y I M Y T T V D A N G Y L K N G

1451 CAGCTGGCCA ACTCAGCCAA TCCGCACATT TAGCTCTCCA ACTACCATAC 1500  
S A G Q L S Q S A H L A L Q L P Y

1501 AACGTGCTTG GTTTAGGTCG GAGCGCAAAT TTTCTTGACC ATCTCTACGT 1550  
N V L G L G R S A N F L D H L Y V

1551 TGGTATTTCC CGTCCATCTG GAGAAAAATC TATACGAAAA CAAGAGTGGA 1600  
G I P R P S G E K S I R K Q E W

1601 CTGCAATCAT TCCAAATTCC CAGCTAATTG TCATTCCATA CCCTCACAAT 1650  
T A I I P N S Q L I V I P Y P H N

1651 GTCCCTCGAA GTTGGAGTGC CAAACTGTAT CTTACACCAA GTAATATTGT 1700  
V P R S W S A K L Y L T P S N I V

1701 TCTGCTTACT GCTATAGCTC TCATCGGTGT CTGTGTTTTC ATCTTGCCAA 1750  
L L T A I A L I G V C V F I L A

1751 TAATTGGCAT TTTACATTGG CAGGAAAAGA AAGCAGATGA TAGAGAAAAA 1800  
I I G I L H W Q E K K A D D R E K

1801 CGACAAGAAG CCCACCGGTT TCATTTTGAT GCTATGTGA 1839  
R Q E A H R F H F D A M \*

**Figure 1C**

Figure 2




Figure 3A

1 GGTGACGGTATCGATAAGCTTGATATCGAATTCCTGCAACAGTTCTTGAAACCCACTC 60

61 GAGAGGGCCACGCCTCCATTACCCAGGCCACGCATCACAAGAGGCAACACCAGGAGCCAA 120

121 CATGAGCTCGGGGACTGAACTGCTGTGGCCCGGAGCAGCGCTGCTGGTGTCTGTTGGGGT 180  
1 M S S G T E L L W P G A A L L V L L G V 20

181 GGCAGCCAGTCTGTGTGTGCGCTGCTCAGCCCCAGGTGCAAAGAGGTCAGAGAAAATCTA 240  
21 A A S L C V R C S R P G A K R S E K I Y 40

241 CCAGCAGAGAAGTCTGCGTGAGGACCAACAGAGCTTTACGGGGTCCCGGACCTACTCCTT 300  
41 Q Q R S L R E D Q Q S F T G S R T Y S L 60

301 GGTGCGGCAGGCATGGCCAGGACCCCTGGCGGACATGGCACCCACAAGGAAGGACAAGCT 360  
61 V G Q A W P G P L A D M A P T R K D K L 80

361 GTTGCAATTCTACCCCAGCCTGGAGGATCCAGCATCTTCCAGGTACCAGAACTTCAGCAA 420  
81 L Q F Y P S L E D P A S S R Y Q N F S K 100

421 AGGAAGCAGACACGGGTGCGGAGGAAGCCTACATAGACCCATTGCCATGGAGTATTACAA 480  
101 G S R H G S E E A Y I D P I A M E Y Y N 120

481 CTGGGGGCGGTTCTCGAAGCCCCAGAAGATGATGATGCCAATTCTACGAGAATGTGCT 540  
121 W G R F S K P P E D D D A N S Y E N V L 140

541 CATTTCGAAGCAGAAAACACAGAGACAGGTGCCAGCAGGAGGGCATAGGTGGCCTCTG 600  
141 I C K Q K T T E T G A Q Q E G I G G L C 160

601 CAGAGGGGACCTCAGCCTGTCACTGGCCCTGAAGACTGGCCCCACTTCTGGTCTCTGTCC 660  
161 R G D L S L S L A L K T G P T S G L C P 180

661 CTCTGCCTCCCCGAAGAAGATGAAGGAATCTGAGGATTATCAGAACTTCAGCATTCAT 720  
181 S A S P E E D E G I \* 191

721 CCATTCACTGGCGCGAGTCCAGGAAGGTCAATGGGGCAACTCCAGAGAAGAAAGCATCCCC 780

781 TGGCCCGGTGGGAAGCCAGACGAGGAGGACGGGGAACCGGATTACGTGAATGGGGAGGT 840


841 GGCAGCCACAGAAGCCTAGGGCAGACCAAGAAGAAAGGAGCCAAGGCAAGAGGGACCAC 900



Figure 3B

901 TGTGCTCATGGACCCATCGCTGCCTTCCAAGGACCATTTCAGAGCTACTCAACTTTTA 960  
961 AGCCCCCTGCCATGGTTGCTCCTGGAAGGAGAACCAGCCACCCTGAGGACCACCTGGCCAT 1020  
1021 GCGTGACAGCCTGGGAAAAGACAGTTACTCACGGGAGCTGCAGGCCCGTCACCAAGCC 1080  
1081 CTCTCCCGACCCAGGCTTTGTGGGGCAGGCACCTGGTACCAAGGGTAACCCGGCTCCTGG 1140  
1141 TATGGACGGATGCGCAGGATTTAGGATAAGCTGTCACCCAGTCCCATAACAAAACCACT 1200  
1201 GTCCAACACTGGTATCTGTGTTCTTTTGTGCTATGAATTGGATTCTTAATTGCTATTGT 1260  
1261 TGGTTGCTGGGGTTTTAAATGATTGATAAGCTTGTACAGTTAACTTATAGAGGGGGAGCC 1320  
1321 ATATTTAACATTCTGGATTTAGAGTAGAGATTTCTGTGTTGTCTCCTAGAAAGCATTAC 1380  
1381 ATGTAGTTTATTTAGCATCCTTGTGGGTGGGGCCCTGGCTCTCTCCCTTTGGTGGG 1440  
1441 ACCTCCCTTTCTTTGGGCTTCAGTTCAGTTCAGGAAGAAATGAGGCTGTCGCCATCTTTA 1500  
1501 TGTGCTTCCAGTGGAAATGTCACTTGCTACAGACAATAGTGCATGAGAGTCTAGAGAAGT 1560  
1561 AGTGACCAGAACAGGGCAGAGTAGGTCCCTCCATGGCCCTGAATCCTCCTCTGCTCCAG 1620  
1621 GGCTGGCCTCTGCAGAGCTGATTAAACAGTGTGTGACTGTCTCATGGGAAGAGCTGGGG 1680  
1681 CCCAGAGGGACCTTGAGTCAGAAATGTTGCCAGAAAAAGTATCTCCTCCAACCAAAACAT 1740  
1741 CTCAATAAAACCATTTTAGTTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1797

Figure 4



1

&lt;110&gt; Human Genome Sciences, Inc. et al.

&lt;120&gt; 71 Human Secreted Proteins

&lt;130&gt; PZ030PCT3

&lt;140&gt; Unassigned

&lt;141&gt; 2001-09-19

&lt;150&gt; PCT/US01/00911

&lt;151&gt; 2001-01-12

&lt;150&gt; 60/234,925

&lt;151&gt; 2000-09-25

&lt;150&gt; 09/482,273

&lt;151&gt; 2000-01-13

&lt;150&gt; PCT/US99/15849

&lt;151&gt; 1999-07-14

&lt;150&gt; 60/092,921

&lt;151&gt; 1998-07-15

&lt;150&gt; 60/092,922

&lt;151&gt; 1998-07-15

&lt;150&gt; 60/092,956

&lt;151&gt; 1998-07-15

&lt;160&gt; 417

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 733

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttctctt	tccccccaaa	acccaaggac	accctcatga	120
tctcccggac	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	accccatcgc	360
agaaaaccat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgaggaga	gcaatgggca	gccggagaac	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctt	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

&lt;210&gt; 2

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; Site

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 2

Trp Ser Xaa Trp Ser

1

5

&lt;210&gt; 3

&lt;211&gt; 86

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; Primer\_Bind

<223> Synthetic sequence with 4 tandem copies of the GAS binding site found in the IRF1 promoter (Rothman et al., Immunity 1:457-468 (1994)), 18 nucleotides complementary to the SV40 early promoter, and a Xho I restriction site.

&lt;400&gt; 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60

cccgaatat ctgccatctc aattag 86

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; Primer\_Bind

<223> Synthetic sequence complementary to the SV40 promoter; includes a Hind III restriction site.

&lt;400&gt; 4

gcggcaagct ttttgcaaag cctaggc 27

&lt;210&gt; 5

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; Protein\_Bind

<223> Synthetic promoter for use in biological assays; includes GAS binding sites found in the IRF1 promoter (Rothman et al., Immunity 1:457-468 (1994)).

&lt;400&gt; 5

ctcgagattt ccccgaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60

aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120

gccctaact ccgccagtt ccgccattc tccgccccat ggctgactaa ttttttttat 180

ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240

ttttggaggc ctaggctttt gcaaaaagct t 271

&lt;210&gt; 6

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>  
 <221> Primer\_Bind  
 <223> Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6:867-871 (1991)); includes a Xho I restriction site.

<400> 6  
 gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> Primer\_Bind  
 <223> Synthetic primer complementary to human genomic EGR-1 promoter sequence (Sakamoto et al., Oncogene 6:867-871 (1991)); includes a Hind III restriction site.

<400> 7  
 gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
 <211> 12  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 ggggactttc cc 12

<210> 9  
 <211> 73  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> Primer\_Bind  
 <223> Synthetic primer with 4 tandem copies of the NF-KB binding site (GGGGACTTCCCC), 18 nucleotides complementary to the 5' end of the SV40 early promoter sequence, and a XhoI restriction site.

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> Protein\_Bind  
 <223> Synthetic promoter for use in biological assays; includes NF-KB binding sites.

<400> 10  
 ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccgcacct aactccgccc atcccgcgcc taactccgcc 120

4

```

cagttccgcc cattctccgc cccatggctg actaatTTTT tttatttatg cagaggccga 180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

```

```

<210> 11
<211> 1113
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<222> (393)..(393)
<223> n equals a,t,g, or c

```

```

<400> 11
gatgctcctt tagcttggag gagtttgta ttaccacct tctgaagcct acttctgtca 60
attcatccaa ctcatctca gtccagtttt gtttccttgc tggtgaggag ttgtgatcct 120
ttggaggaga agaggcattc tggtttttgg aatttttagc cattttgtctc tggtttcttc 180
ccatctttgt ggattttatct acctttcatc ttcaatgtta gtgacctatg gatgggggtct 240
ctgagtggat gtgctcttcc tttctgtttg twagttttct ttctaacagt tagccctctc 300
gctgtaggtc tgctggaktt tgctggaggt ccaactccaga ccctgtttgc ctgggtatca 360
ccagtggagg ctgcagaaca gcaaagattg ctncctgttc tttcctctgg aagcttcgtc 420
tcagagggca cctgccagat gccagccaga gctctcctgt atgaggtgtc tgttggccca 480
tactgggaga ttctccccag tcaggatata aggaggtcag ggacctactt gaggaggcag 540
tctgaccctt agcagaggtt gaacactgtg ctaggaggtc ctctgctctt ttcagagctg 600
tcaggcgggg cgtataagtc tgctgaatct gtgtccgcag ccacccttc cccaggtgc 660
tctgtccag ggagatgggg gttttatttt taagtcccca actggggctg ctgccttttt 720
ttcagagatg ccctgccag agaggagaaa tctggcagtc tggcctcaga ggccttgctg 780
agctgccgtt ggctccacc agttcaaact tcccaagggg ctttgtttat actgtaaggg 840
gaaaaccgcc tactcgagcc tcataatgg cagacacccc tccccgcgcc aagcttaagt 900
gtcccaggtt gatctcagac tgctgctgtg ctggcagtga gaatttcaag ccagtggatc 960
ttagtttgct gtgctctgtg ggggtgggac ccattgaacc agactactcg gctccctggc 1020
ttcagcccc tttccaggag agtgaagggt tctgtctcat tggcattcca ggagtcactg 1080
gtgtatggaa aaaaaaaaaa aaagggcggc cgc 1113

```

```

<210> 12
<211> 983
<212> DNA
<213> Homo sapiens

```

```

<400> 12
ggcacgaggg cagctgcaga gctccaggtt tctctgccc caagggcagg ggctgcccct 60
cgcccaggat gactctgcct tccagagcct tggcctccct ggggggtggga gtgtggggga 120
tgctaagggtt aaatcagggtc acagtaagtt gtgggggcag cagggtggagc agcagagtgg 180
cactgggagc tttctcttgg gtgtgcggtg tggccttggg tctgcagcca tcaggtgggg 240
gcttgggact gacttctcct tctgaaggat gctgggaagg tgagctggct ttggcagtgc 300
ttagagctcc ggggggttcc cctcctaga acatgcaagc tctcacaccg gtgcgtcatc 360
atcacacca tcatcaagcc cacagtggta tactgaacac ctgccccaca aagacggtgg 420
actgctctca gaggagcccc atgaaccacc gatggttaca actatccaat gcctgatggc 480
agacagccag gccaacctcg gcttccactc tctcttctc accctacaat cagccaaagt 540
gacctgagtc atgtagtgtg aagttgctt ctgcttctc ttgtttgtgc ttttgcgtgt 600
tcttctgccc catactttgt taactccatg agttaaagtgc taccatttt cccagacaag 660
tgctgcttct gcaaggaaac ccttcttgat cccccacct tctgaaaagt acctctccag 720
cttgcttctt cagggtgctg agcgctcctt cccagcctgt catcaccttc ctccatcgc 780
tatggtgtgt tctgtcttct tctagtcttg tctcttttt tctgttagat tgtagctcct 840
tgctgacagg aaccacgctt gctccagctt catacctccc actgctacag cacagaacct 900
gcttctcaga cttacagcaa atgtttgttt gctgaatgaa ttaattaaag ataaagcaaa 960
aaaaaaaaa aaaaaaactc gag 983

```

```

<210> 13

```

&lt;211&gt; 973

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

ggcagcagcc	cagcggaagc	caagccacca	ggccccccag	cgtccacgcg	gagcatgaac	60
attgaggatg	gcgcgtgcc	gcggctcccc	gtgccccccg	ctgccgcccg	gtaggatgtc	120
ctggccccac	ggggcattgc	tcttcctctg	gctcttctcc	ccacccctgg	gggccgggtg	180
aggtggagtg	gccgtgacgt	ctgccgcccg	aggggggtcc	ccgccggcca	cctcctgccc	240
cgtggcctgc	tcttcagca	accaggccag	ccgggtgac	tgcacacgga	gagacctggc	300
cgaggtccca	gccagcatcc	cggccaacac	gcggtacctg	aacctgcaag	agaacggcat	360
ccaggtgatc	cggacggaca	cgttcaagca	cctgcggcac	ctggagattc	tgcagctgag	420
caagaacctg	gtgcgcaaga	tcgaggtggg	gcgcttcaac	gggctgcccc	gcctcaacac	480
gctggagctt	tttgacaacc	ggctgaccac	ggtgcccacg	caggccttcg	agtacctgtc	540
caagctgcgg	gagctctggc	tgcggaacaa	ccccatcgag	agcatccctc	cctacgcctt	600
caaccgcgtg	ccctcgctgc	ggcgccctga	cctgggcgag	ctcaagcggc	tggaatacat	660
ctcggaggcg	gccttcgagg	ggctgggtcaa	cctgcgcctac	ctcaacctgg	gcatgtgcaa	720
cctcaaggac	atcccccaac	tgacggccct	ggtgcgcctg	gaggagctgg	agctgtcggg	780
caaccggctg	gacctgatcc	gcccgggctc	cttccagggt	ctcaccagcc	tgcgcaagct	840
gtggctcatg	caagcccagg	tagccaccat	cgagcgcaac	gccttcgacg	acctcaagtc	900
gctggaggag	ctcaacctgt	cccacaacaa	cctgatgtcg	ctgccccacg	acctcttcac	960
gcccctgcac	cgc					973

&lt;210&gt; 14

&lt;211&gt; 1458

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

ccacgcgtcc	gggaattttc	aaaagatcca	aacagagact	tcttgcattc	tctgcctttc	60
caacagaagc	ggtgatcgtc	taagtatgag	cctgtggcct	cctttgtgca	tttgagcatg	120
ctgtaattaa	gatgagatca	gtttcttaga	aaaagctttc	ctgaatccct	ctgacgttgc	180
ctgggatctt	tctgttgatt	cgtcttttct	ggagattggg	acagagcatc	tgtggtccag	240
ggaagttagt	cctctggcct	caattctggt	gtggatgtgc	agtataagc	gggcattgct	300
tgcctcgggg	gatgcctagt	tcgtggcttc	ctggctgttt	tgtccttctg	tgtctttag	360
ctgtagggtg	ccagctcagg	gagtggggtg	ttggcgccgt	ttccgcgggt	ggcctccttg	420
ctttgccgca	cctccagggt	ctgggcatga	gaggccgtgg	cctcatttct	ggtggataac	480
cttttttagt	taatagcatc	tttaattaga	tcacagcatt	gaattcaaaa	tttcttctgc	540
aaagaaagtt	gtggggcata	agacaccggg	aatgaggagg	gaggaagaca	gttgtgtttt	600
ctcttttaac	cttgagctct	agccgatgca	tttgtcagga	aatacagcac	tttgtcttaa	660
gaaaacaagg	aaggaggccg	ggcgcagtgg	ctcacgcctg	taatcccagc	actttgggag	720
gccgaggcgg	gcggatcacc	tgagggtggg	agtatgagac	cacctgact	aacatggaga	780
gacctgtct	ctactaaaag	tacagaatta	gccgggcgtg	gttgcgcatt	cccataatcc	840
cagctactga	ggagacttga	ggtaggagaa	tcacttgaac	ctcagcggcg	gaggttgacg	900
tgagtcgaga	tcgcgccagt	gcactccagc	ctgggcaaga	agagcgaaac	tgggtctcaa	960
gttaaaaaaa	gaaagcaagg	aaagagtaat	ttacaacgaa	ggaaaaaaac	ccacagcaca	1020
cccttcgcgg	ctgtcagcgc	tctcctgatg	tcacagtggc	tgcgtgtcct	tggggtgggt	1080
gaggtgtggg	gagcccagcc	cctggccctg	cctccgcgc	cccgtcccc	ttctctctct	1140
tactcggtta	agccatagcg	aggcctccgc	tcgtttcaga	tatgaatttg	ttttatagat	1200
tataaatatg	catatacagt	gtatgtataa	agcagaatgc	ctgcctttcc	tggttatttt	1260
ttgtaccata	ttgtaaatta	tattatttat	tctttaccaa	ttttgggaat	aaaaggtgtt	1320
ttggttattt	aataataata	gagctgttaa	acttctgttt	aaatttccag	ttcaacttgt	1380
aaatgttttt	attgtgcata	aatacatact	aatgttgatc	taaaaaaaaa	aaaaaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa					1458

&lt;210&gt; 15

&lt;211&gt; 2005

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ggttgctggc	ccaggtgagc	gggcgcgctg	gtccaggtga	gcgggcgcg	ccccgcgacg	60
gcgctgcctg	cccagggcgg	ttcacgtaaa	gacagcgaga	tcctgagggc	cagccgggaa	120
ggagggcgtg	atatggagct	ggctgctgcc	aagtccgggg	cccgcgcgcg	tgccctagcgc	180
gtcctgggga	ctctgtgggg	acgcgccccg	cgcgcgggct	cggggaccgg	tagagcccg	240
cgtgcgcgcg	atggccctgc	tctcgcgccc	cgcgctcacc	ctcctgctcc	tcctcatggc	300
cgtgtttgtc	agggtgccag	agcaggccca	gaccaccgac	tggagagcca	ccctgaagac	360
catccggaac	ggcggttcata	agatagacac	gtacctgaac	gccgccttgg	acctcctggg	420
aggcgaggac	ggctctctgcc	agtataaatg	cagtgcggga	tctaagcctt	tcccacgtta	480
tggttataaa	ccctccccac	cgaatggatg	tggctctcca	ctgtttgggtg	ktcatcttaa	540
cattgggtatc	ccttccctga	caaagtgttg	caaccaacac	gacaggtgct	atgaracctg	600
tggcaaaagc	agaatgact	gtgatgaaga	attccagtat	tgctctctcca	agatctgccg	660
agatgtacag	aaaactag	gactaactca	gcattgttcag	gcattgtgaaa	caacagtggg	720
gctcttgttt	gacagtgtta	tacatttagg	ttgtaaacca	tatctggaca	gcccaacgagc	780
cgcattgcagg	tgctcattatg	aagaaaaaac	tgatcttttaa	aggagatgcc	gacagctagt	840
gacagatgaa	gatggaagaa	cataaccttt	gacaaataac	taatgttttt	acaacataaa	900
actgtcttat	ttttgtgaaa	ggattatttt	gagaccttaa	aataatttat	atcttgatgt	960
taaaacctca	aagcaaaaaa	agtggaggag	atagtggagg	gagggcacgc	ttgtcttctc	1020
aggtatcttc	cccagcattg	ctcccttact	tagtatgcca	aatgtcttga	ccaatatcaa	1080
aaacaagtgc	ttgttttagcg	gagaattttg	aaaagaggaa	tatataactc	aattttcaca	1140
accacattta	ccaaaaaaaag	agatcaaata	taaaattcat	cataatgtct	gttcaacatt	1200
atcttatttg	gaaaatgggg	aaattatcac	ttacaagtat	ttgtttacta	tgaaatttta	1260
aatacacatt	tatgcctaga	aggaacggac	tttttttttc	tattttaatt	acacataata	1320
tgtaattaaa	gtmcaacata	atatgttggt	tctctgtagc	ccgttgagca	tatgagtaag	1380
tcacatttct	attaggacta	cttmcaagga	caagggtttcc	atttttccag	ttgtaaaatt	1440
ggaaccatca	gctgataacc	tcgtaggagg	caaccccagg	atagctaagt	gttatgtaat	1500
atgcctagaa	ggtagatgta	atgcgattca	gaagcatagc	cactccatt	ttatgagcta	1560
ctcacatgac	aaatgtcatc	ttttgctata	acctttgcca	agttagagaa	aagatggatt	1620
taatgagata	aatgaaaaga	tatttamcct	aatatatcaa	ggcactatct	gctgttatgc	1680
tttgttatct	atttcccagc	acttgctcct	tattgtagat	tttttaaaga	ctgtaacctt	1740
ttactaactg	tggtcttact	aaaatttggt	cttgatactg	cttttcaaaa	agcctttaat	1800
tagagccaaa	aggatggaaa	aggcaagata	taaattgcctt	ttatagatct	cttatttaca	1860
ttgaaaatta	ttaccatatg	tttagagcaa	atccaagaaa	acttcaacag	cttctgaaga	1920
tgtctatgaa	tgttgaaaac	tttcaatst	cttggratgc	tcakttaatt	cgcagaccgg	1980
cttaacggat	taaacgcccc	cccc				2005

&lt;210&gt; 16

&lt;211&gt; 943

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

ggcacgagct	ccgcccggcc	ccgaggggct	ctccccggag	gctcagcccc	ctctgctccc	60
catgggcaac	tgccaggcag	ggcacaacct	gcacctgtgt	ctggcccacc	accacacct	120
ggctctgtgc	actttgatcc	tgtgtgctct	tggcctctct	ggcctgggcc	ttggcagctt	180
cctcctcacc	cacaggactg	gcctgcgcac	cctgacatcc	cccaggactg	ggtctctttt	240
ttgagatctt	ttggccagct	gacctgtgt	cccaggaatg	ggacagtcac	agggaagtgg	300
cgaagggtctc	acgtcgtagg	cttgctgacc	accttgaact	tcggagacgg	tccagacagg	360
aacaagacc	ggacattcca	ggccacagtc	ctgggaagtc	agatgggatt	gaaaggatct	420
tctgcaggac	aactggctct	tatcacagcc	agggtgacca	cagaaaggac	tgcaaggacc	480
tgcttatatt	ttagtgtgt	tccaggaatc	ctaccctcca	gccagccacc	catatcctgc	540
tcagaggagg	gggctggaaa	tgccaccctg	agccctagaa	tgggtgagga	atgtgttagt	600
gtctggagcc	atgaaggcct	tgtgctgacc	aagctgctca	cctcggagga	gctggctctg	660
tgtggctcca	ggctgtctgt	cttgggctcc	ttcctgtctc	tcttctgtgg	ccttctctgc	720
tgtgtcactg	ctatgtgctt	ccaccgcgcg	cgggagtcct	actggtctag	aaccggctc	780
tgagggcact	ggcctagtct	ccgacttggt	tctcaggtgt	gaatcaactt	cttgggcctt	840
ggctctgagt	tggaaaagg	tttagaaaaa	gtgaagagct	ggaatgtggg	ggaaaataaa	900
aagctttttt	gccccaaaaa	aaaaaaaaa	aaaaaaaaa	aaa		943

&lt;210&gt; 17



&lt;211&gt; 1503

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

cagggttcctc	tcagtamarc	ctcarsccga	ggttcccttc	ctcttgcatc	catgtgtgtg	60
tttcaraggc	ggccatcctt	ccctacttcc	agatccttgt	agggcagttg	gtggagggtg	120
ggaggcaccc	cgggtgtgcc	tccatgaagc	cctgtgccag	tcactgggct	gcaaggctga	180
ggaaattgtg	tccgtgtcag	aaagctcctc	agctcagagg	tgctggtagc	tcctgcgtgg	240
taggaaggca	gggggaagag	gccctgcttc	tcctgttctc	tttgccctta	tgagacttga	300
gagtctgtgt	catctgtgcc	ttgcatgtct	ttttttcaga	ctccctgcga	caaggactgt	360
gtactgcatg	aatgaggctg	agatagttga	tgttgctctg	ggaatcctga	ttgagagccg	420
yaaacaggam	aaggcctgcg	agcagccggc	cctggcgggg	gctgataacc	cagagcactc	480
ccctccctgc	tccgtgtcgc	ctcacacaag	ttctgggagc	agcagtgagg	aagaggacag	540
tgggaaacag	gcactgrctc	caggcctcag	cccttcccag	aggccggggg	gttccagctc	600
tgctgttagc	aggagccctg	aggaggagga	ggaagaggat	gtgctgaaat	acgtccggga	660
gatctttttc	agctagggca	taaactgtgc	actgaactgt	ctgccgagag	cagctggagg	720
acagctgagc	ttccactggg	gctgctgggc	cgcccgcctg	tgggaatggg	gctctctgtg	780
ctcctacctt	tgtgccttct	tgggcctggc	agattcacct	caggccagaa	gcccctggag	840
actccggggc	ttggggctgc	cgttctgagt	gtgcggaagg	caggactcaa	aatgagatcc	900
catttgactc	cctctgtatg	tactgtgccc	tctcctggct	cttgaggctc	tggagtccca	960
attgtctgtg	ttagtcatgt	accaggttcc	agggaaaatg	atgtcatgtg	gtggtccaac	1020
ttactggaac	caaagagaca	gtactttgca	aagaaaagga	tcactgccag	gtgactgga	1080
attgctacag	tttagtccgc	atgatctctc	ctgaaggagg	aagcctgttt	caaaaatagt	1140
ttccatcatg	agtctatcaa	tgagctccca	cctctccagc	cagcctagaa	agcaaacgag	1200
ctgcccacag	ttctctgccc	tgtctgggag	ggtgaggcca	cagtgtatag	actggtaagc	1260
cagacaggcc	tcctcccgca	agctgctacc	ttgctttcac	ctgtaccttg	gtccccgggc	1320
agctagctat	aaagcaagag	ggacaggagc	ccagaagaga	cactgaggac	aagagatcac	1380
accagagtac	atgtctctgc	ctctgttttc	agtgtggctt	tggacaggaa	tatatgaata	1440
aatcactgcc	atacaggttt	tccaatacac	aagtgtctaga	aaatacacac	aattccccaa	1500
tga						1503

&lt;210&gt; 18

&lt;211&gt; 1512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (207)..(207)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (209)..(209)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (521)..(521)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 18

gcagagcccc	tgggtgtgag	aagctcgtct	cccgtggggt	gcattggctc	tgccctatct	60
ctgctccag	cacccagggc	ggccgcagat	ggcagtgtct	ctggggacag	cagctgcgaa	120
tgagtccacg	ggccaacgct	gagctgctca	ggctgaggcg	gtgtgctcag	cacagagccc	180
ccggaactgg	catctgcagg	gcgtgancna	aggccgcccgc	gatgccgcac	ttcctggact	240
ggttcgtgcc	ggtctacttg	gtcatctcgg	tcctcattct	ggtgggcttc	ggcgccctgca	300
tctactactt	cgagccgggc	ctgcaggagg	cgcacaagtg	gcgcatgcag	cgccccctgg	360
tggaccgcsa	cctccgcaag	acgctaattg	tgcgcgacaa	cctggccttc	ggcgggcccg	420

8

aggtctgagc	cgacttgcaa	aggggatagc	csggcggcac	cgggcgcctc	ccccagccc	480
gccccgccc	cccagccc	agaccccaa	ggcagaggga	ngccggcctg	ttggccctcc	540
acgtatccc	tctgcagcct	gggcccctcc	gacagaggcc	ccaggtgcgc	tgscagtgra	600
ggtggggcac	ttaggtgcct	ggctggccca	gggttgctc	tccgtgtcaa	gccgactcac	660
ccagagccca	ccctcccaag	ctcaggggca	tctccgctg	ggccccagtg	cctttgcrct	720
gcgcagcact	ctgccctcca	ctggactcag	gcattgtctat	ggctgcctgt	cctgaggctc	780
cggagccctc	atttcttcgt	gaagtcccca	gctcccctgc	ctccactcaa	tggcaccggc	840
cctgcaactt	taggcaggtc	gaagccaacc	caaggaaaga	acctaagaac	ctcgttttga	900
gggatgtcag	cttgggccag	mccagccgca	ccccgcgggg	ctcaggcttg	gaactgggtga	960
gggtgtgtgg	tgggggtatg	cagaggggata	agaccgtggt	agaggagagg	gttgggtgagg	1020
agagagagag	agagagagag	agagagagtc	tggggggagc	gggcaagcat	ggggagatga	1080
gagtgtgata	tgtgagagag	agtgtggggg	ccccaggcag	ggcaggaggt	ggtggaaacg	1140
gggtgaactc	cgtgggctgt	gtgaggactg	tccatagtgg	gtccmaacc	cctccctctg	1200
ctggagtttc	ctagcccttc	cccctcccy	agactgwggc	agcaggcagg	agccccctgc	1260
ctccctccct	gtcctgtgcc	acactttctg	ggccaaaccc	agcccccttg	agccaggccc	1320
tgccagactc	caagcccacc	ctagaaccct	cctcctgtgt	ggagactctg	ttgccccact	1380
ttggacacag	attggcaacc	tgcctcaccc	ckccccctw	cgtcggggct	tccatcttaa	1440
tttattctca	ataataaaga	cttcatgatg	amaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1500
aaaaaaaaaa	aa					1512

&lt;210&gt; 19

&lt;211&gt; 1655

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ccacgcgtcc	gggcaaagaa	ttaaaccctg	tgtttgact	tcaacttagc	atggctagaa	60
ttggaagtac	agtaaacatg	aacctcatgg	gatggctgta	ttctaagatt	gaagctttgt	120
taggtttctg	tggtcacaca	accctcgga	tcacacttat	gattgggggt	ataacgtgta	180
ttctttcact	aatctgtgcc	ttggctcttg	cctacttgga	tcagagagca	gagagaatcc	240
ttcataaaga	acaaggaaaa	acaggtgaag	ttattaaatt	aactgatgta	aaggactttc	300
ccttaccctc	gtggcttata	ttatcatct	gtgtctgcta	ttatgttgct	gtgttccctt	360
ttattggact	tgggaaagtt	ttctttacag	agaaatttgg	attttcttcc	caggcagcaa	420
gtgcaattaa	cagtggtgta	tatgtcatat	cagctcccat	gtccccgggtg	tttgggctcc	480
tggtggataa	aacagggaag	aacatcatct	gggttctttg	cgcatagcag	ccactcttgt	540
gtcccacatg	atgctggcct	ttacgatgtg	gaacccttgg	attgctatgt	gtcttctggg	600
actctoctac	tcatgtgctg	cctgtgcatt	gtggccaatg	gtggcatttg	tagttcctga	660
acatcagctg	ggaactgcat	atggcttcat	gcagtccatt	cagaatcttg	ggttggccat	720
catttccact	attgctggta	tgatactgga	ttctcggggg	tatttgtttt	tggaagtgtt	780
cttcattgcc	tgtgtttctt	tgtcactttt	atctgtggte	ttactctatt	ggtgaatcgt	840
gccaggggtg	ggaacctaaa	ttattctgca	agacaaagga	agaaataaaa	tttcccatat	900
tgaatgagaa	gttaaaatga	atgtgtcaga	gaatgggctt	aacacatcgt	tggtttgaaa	960
acttccattt	taaaaattta	gagtttagtc	attagaaaaa	ataatggact	ggaaagttaa	1020
atttatatcc	aaatatacct	atttcaaagt	gtattttgtg	ggcctgtttt	agcctgtgtc	1080
ttttgtattg	tgtgttgcta	aagaattcta	cttttagtag	gctaataaac	aatgaaaggg	1140
ttagaaaatt	gctgtggaac	atccagggtga	acttcaggaa	agacagtga	aaatggaaaa	1200
cgttgagct	tctgttgaga	taatcttcat	taggtatata	tcttagggat	acagcctttt	1260
ctttatctta	tagcaggaaa	aaaaaacttt	tgagggaat	agaagggtg	cgttacacaa	1320
aataaacaat	ggcattgtca	taggccttcc	ttttactagt	agggcataat	gctagggaa	1380
atgtgaagat	gtttttttga	agtctcttcc	tgatcacgaa	caatagcttg	cgtctacttc	1440
tgtagttatg	tggattgccg	agcaatgacc	cttttcaatt	tcttatttct	gtgttactga	1500
ggacccta	cacttaggga	tgtaatttta	tagtataaac	tttctgtaca	gtttttctta	1560
tagtctaata	agtaaaaagt	gtccttcaaa	ttatgataat	tgcttatgta	catggataaa	1620
ttaaaacact	gcacacggaa	aaaaaaaaaa	aaaaa			1655

&lt;210&gt; 20

&lt;211&gt; 2525

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (5)..(5)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (10)..(10)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (1354)..(1354)  
 <223> n equals a,t,g, or c

<400> 20  
 tgacnctatn gtaagggtacg cctgcaggta ccggtccgga attcccgggt cgacccacgc 60  
 gtccgggtctg ccaacaagggt cgttcatgaa agtggttttc tctttaagggt aattaaaaaa 120  
 cagtggaaatg gaaaaacagt gctgtagtca tctctgaata tgctccttgt caacaatgta 180  
 tacattccctg ctagggtgcca tattcattgc tttaagctca agtcgcatct tactagttaa 240  
 gtattctgccc aatgaaggta agttaagact tggatatatgc atggagcact tccatctaata 300  
 cacacatctc tctcttgccct ttggttctgt tatatataac atggaaataa taatgccttt 360  
 tgcttcatgt gtagtataaa gcatatttaa atttgattat ttaaccttgc attcctcaac 420  
 aagaaaaaat gtttgataat ggatgaaatg tgagtcaatc agatacaaaa atcaaacctt 480  
 ttggtgaaga accagtcgta acatttgact gttaattcaa tcaacagggtg tttctggacc 540  
 tatagcaaaa tgtgtaattg cgccttattt tgaagtagaa ggatatattt gtttggtcac 600  
 ttggcatttg ttaggtgactt actattgttaa ttattgtatc aatggtaagg tgtcagcatt 660  
 atattgtgcg gtcataattgt atcaacagta taaattataa gctttgataa gtatgtattt 720  
 aagaaatctt tttttatgta gggatttaag caaacacttt aattccacca aactgtattg 780  
 agtacttctt actagttatt gagtgaagggt gtgggttgcc cctccacatc tgtgggtggt 840  
 tctcgtagg tggaacgaga gacttggaag agaaagggac atagacaaag tatagagaaa 900  
 gaaaaaagggt ggcccagggt accggcgctc agcacacgga ggatctctgc cagcctctga 960  
 gtccmcttag tatttattga tcattattgg gtgtttctcg gagagtggga tgtggcagga 1020  
 tcataggata gttagtgaga gagggtcaac aggtaaacac gtgaacaaag gtctttgcat 1080  
 cataracaak gtaaaagrat aagtgtcttg cttttagata tgcatacaca taaacatctc 1140  
 aatgctttac aaagcagtat tgctgcccgc akgtcccacc tccagcccta aggcgggttt 1200  
 ycctatctc agtagatgga gcatacaatc gggttttata ccgagacatt ccattgcca 1260  
 gggacrggca ggagacagat gccttctctt tgtctcaact gcaagagggr ttccttctc 1320  
 ttttactaat cctcctcagc acagaccctt tacnnggtgt cgggctgggg gacggtcagg 1380  
 tctttccctt cccacgaggt catatttcag actatcacat ggggagaaac cttggacaat 1440  
 acctggcttt cctaggcaga ggtcscgtgc gcyttccrea gtgttttggtg tccctgsgta 1500  
 cttgagatta gggagtgggt atgactctta asgagcatgc tgccttcaag catctgttta 1560  
 acaaagcaca tcttgaccg cccttaatcc atttaacct gagtkgacac agcacatggt 1620  
 tcagagagca crgggttggt ggtaagggtta cagattgcag aacaaaatgg agtctcctat 1680  
 gtctacttct tctamacag acacagtaac aatctgatct ctcttttccc cacaattgag 1740  
 gacacataca atcatgatat gacctttaat ggtctactac ttggagagtc agatgtgtac 1800  
 ccaagtctct actgcagtta acatttacct gccaggcact aggctaagta ttagcagcag 1860  
 gttcaaagtg cataagatat agacctgtgc ctcaagactt agtttattag gagagacatg 1920  
 aatgtaaaaca catcatgaaa atccattata ataactgcaa taattgatata atcctgaaga 1980  
 tgcagagatt gtctagagga taaagttata tattctgttt ggtaggggat gatgtggagt 2040  
 tcaaatggat cagagaacac ttcgctgatt agaagtcagt tgatccacta gaagtcaagg 2100  
 tgaacaagggt gattcaaaac agaggcaaca gcctgtaaaa gggaaacagag gcataaaaaa 2160  
 gcaggatatg ttgtgagaac atgtagtttg aaattacca gcaaaaagtt taaggactcg 2220  
 tagccaggca cagtggctca tgctgtaact ccagactttt aggaggccaa ggccggcgga 2280  
 tcaactgagg tcagggaattt gagaccaggc tggccaacat ggtgaaaccc atctctacta 2340  
 gaaatacaaa aaattagctg ggtttgttgg cgtgtgcctg taatcccagc tatgagggag 2400  
 actgaagcag gagaatgaac ccgggaggca gagattgcag tgagccgaga tcatgccact 2460  
 gcactccagc ctgggcaaca gagcaaaact gtctcaagaa aaaaaaaaaa aaaaagggcg 2520  
 gccgc 2525

10

<210> 21  
 <211> 1396  
 <212> DNA  
 <213> Homo sapiens

<400> 21  
 aagtctcgtgta tgcgccccgg gaggcgcgcg agcccagcgg ctggcgccag atccaggctc 60  
 ctggaagaac catgtccggc agctactggt catgccaggc acacactgct gcccagagg 120  
 agctgctgtt tgaattatct gtgaatgttg ggaagaggaa tgccagagct gccggctgaa 180  
 aattacccaa ccaagagaaa tctgcaggat ggactttctg gtccctcttct tgttctacct 240  
 ggcttcggtg ctgatgggtc ttgttcttat ctgcgctctgc tcgaaaaccc atagcttgaa 300  
 aggcctggcc aggggaggag cacagatatt ttccctgtata attccagaat gtcttcagag 360  
 agccttgcac ggattgcttc attacctttt ccatacgaga aaccacacct tcattgtcct 420  
 gcacctggtc ttgcaaggga tggtttatac tgagtacacc tgggaagtat ttggctactg 480  
 tcaggagctg gagttgtcct tgcattacct tcttctgccc tatctgctgc taggtgtaaa 540  
 cctgtttttt ttcacctga cttgtggaac caatcctggc attataacaa aagcaaataga 600  
 attattattt cttcatgttt atgaatttga tgaagtgatg tttccaaaga acgtgagggtg 660  
 ctctactgtg gatttaagga aaccagctcg atccaagcac tgcagtgtgt gtaactgggtg 720  
 tgtccaccgt ttcgaccatc actgtgtttg ggtgaacaac tgcacgggg cctggaacat 780  
 caggtaacct ctcactctacg tcttgacctt gacggcctcg gctgccaccg tcgccattgt 840  
 gagcaccact tttctggtcc acttgggtgt gatgtcagat ttataccagg agacttacat 900  
 cgatgacctt ggacacctcc atgttatgga cagggtcttt cttattcagt acctgttctt 960  
 gacttttcca cggattgtct tcatgtctgg ctttgtcgtg gttctgagct tcctcctggg 1020  
 tggctacctg ttgtttgtcc tgtatctggc ggccaccaac cagactacta acgagtggta 1080  
 cagaggtgac tgggctgggt gccagcgttg tcccttgtg gcctggcctc cgtcagcaga 1140  
 gcccgaagtc caccggaaca ttcactccca tgggcttcgg agcaaccttc aagagatctt 1200  
 tctacctgcc tttccatgtc atgagaggaa gaaacaagaa tgacaagtgt atgactgcct 1260  
 ttgagctgta gttcccggtt atttacacat gtggatcctc gttttccaaa aaaaaaaaaa 1320  
 aaaaaaaaaa aaaaaaaaaa aaaactcgag ggggggcccg gtaccaaat gcacctggag 1380  
 ttcaagtaga catcaa 1396

<210> 22  
 <211> 1069  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (508)..(508)  
 <223> n equals a,t,g, or c

<400> 22  
 ggcacgagca cagcctcagg ccctgcccga gacctgcaga atcagaaact ctggggtgag 60  
 gcctggttat ctgctgtaac agaccttcca gtgggttctg atgccctcta gagcaggaga 120  
 accactagct tagaggttgc agtatgtttg gcatcttgcc atttgtgtta gttcagagga 180  
 atggctgacc cccatgtctc atttctaagc ttcaggcagc ttttctcctg gccagctgtc 240  
 attctgttga ggggaatcct ggggactgtg gctcctcctc cctgtccgtg tgtccttgat 300  
 ctggcagctc acccccttca tctccccgtg gaggtccat gcctagagggt ggtcttcaaa 360  
 cagaagaatg gcaaagataa ttgtctcgtg ttttaccctg accccattcc ttttaagagg 420  
 tcaactcttg gccattcat taaaaaccaa tgtcatagtt ctgtgattcc actatcagac 480  
 agtgccacgt ccaaggcgcg ggctcttnac ctccctggaa gagagactgt gctgtctgtg 540  
 ctctctgtgt tctccagtcc caogctccca cggacccacg cccttgagga ctccctcggt 600  
 gtcccaggc tcttggtgtg ttcagagacc tccacactca acgaccactg gtgtgcgaga 660  
 agggccgggtg cttacattcc aattaacaga cgcttttccc atctaattgcc tcttgccctc 720  
 tctaacacc acctcgggag tgtttatgtc tattctaagt gaatttcact gtgtgaaaaa 780  
 attcacacct gttgtcccag cgatttgga ggccggggcg ggtgtatcat ttgagcccag 840  
 gagtttgagg ctagcctggg caggatgggt aaaccccgtc tctataaaga aattttaaaa 900  
 attagctggg catagtggca cgtgcctgta gttccatcta ctggggaggc tggggtgga 960  
 ggatcgcatg agcccgggag tttgaggctg cagtgaagct tgatcgagc actgcactcc 1020  
 agtctgggca acagagcaag accctgtctc ttaaaaaaaaa aaaaaaaaaa 1069

<210> 23  
 <211> 1658  
 <212> DNA  
 <213> Homo sapiens

<400> 23  
 ggcacgagcc ggcctgccag agccatgccc ctgactcctc agcttcaaaa tcaggggtct 60  
 caggacagag gatgctgggt gggctcagag ctcatcaggg gggctgtgtg tgagagggga 120  
 tgccttcttg atgcctcat cctcctcggg gctggggctt cctcaaggc caccagctc 180  
 cttcctttgt ttgctgctgc tactcctgcc gectgctgcc ttggccctgc tgctcttctt 240  
 cttggacttc ttccctccca gggcagctgt gtctcccttc ttgccggacc actgctctgc 300  
 caggcaacct aggggtgtga ggagagagac cctcaacaga agtgccctcag ggctggggtg 360  
 ctgggcaagg agcactgagc agggagccgt gggagtagca actgggactg tgcttgacat 420  
 cagcctccct gcctcctgcc tctcgtgtg gccaccaggc cctcctgggg gcactctgact 480  
 tgtctgcccc tcattctgca cctggtttca gtgactctta cttcaccatg tcttgccaat 540  
 caagcctttc aagggcagag atcctacaat gccctctggt gccctctgtt tctcctccta 600  
 cccacctccc ccaagggaga gcaaacaaat catccagagc cagcctgcc ttgettcccc 660  
 aaactcactg gtgtcttttc ccttcagcac gtggtggcg cagaggaatt cagtcaggtc 720  
 ttctcctggg tggatcctgt accagtcctc gatcacctcc tcaaaactct caccagcaca 780  
 tcacacttgt taatcataat acctcatatt ggcaaagccc cagcacctga ctcgctccta 840  
 gaggagctca gcctaagcct cgcaaccac tgcaaggtag cagtggcacg gttcacctaa 900  
 ggaaactgag gccagagagg tgaaatgacc tgaccaaagc caccgcggcc tgggtggact 960  
 tctcagagc agaccaatc cccaccagcc cttactggg cacagcaacc cttccaaggg 1020  
 ctgaagggcc tgtacctgt tcttgaggtc agccacttct gcagaagtct cgttcaacag 1080  
 ctcatagggg atgtccatca ccacctgac ccctttgtgt accaggttgt gtaatgtctc 1140  
 aaaggctctt gacatgccct ggaagaagcg accagatatg gcaggcggag ctcccttctc 1200  
 tccctccac cctcgtctcc cagtgggtgc taagaaccca gctataagac caatgctcaa 1260  
 cgccctctaa ggatcctcat cctttttttt ttgagaagga gtctcactct gtcgcccagg 1320  
 ttggagcgct tcagctcact gcaacctctg cctcccagg tcaagcgatt ttcctgcctc 1380  
 agcctcccaa gcagctggga ctacaaaggc gtgccaccat acccggttaa tttttgtaga 1440  
 gttggggttt tgtcatgttg gtcaggctgg tctcgaactc ctagcatcaa gttttccact 1500  
 cactcagcc tcccaaagtg ctgagattac aggcgtgagc caccgcacct ggcctcatcc 1560  
 ttgacctgac cttcctcttc cctcttttag gccgtcttc cacaaccctt gcacatatac 1620  
 cccctgatct gcctctgcac acctcatcgc ttcaaaaa 1658

<210> 24  
 <211> 1077  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (1036)..(1036)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (1038)..(1038)  
 <223> n equals a,t,g, or c

<400> 24  
 ggcacgaggg gaaagccatg ctcccaggac tccttctctg cagccttaaa tcggtctgta 60  
 cggaaaaattc cgcgccttag aaaccacgc ttgggtgtaa cttattattg ttcttctgta 120  
 cctacttctt gtttatcact tccgggttca tcattttggc atttcggtga tcgggttggga 180  
 actattgaag cccgctttca ggttcttttc ccatttttcc ctttgaaagg aagacttctg 240  
 gcttctccta aatctccgtt ctctgggtaa ggggagtcca agcctctgtc atgaggaacg 300  
 gaaatgcgag ggcctcgggt gttactctaa aatccgacct cagcttgac gccggaagct 360  
 gcgattcctg cagcgggaaga ggcgtgatct ggccttcgac tcgctatgtc cactaacaat 420  
 atgtcggacc cacggaggcc gaacaaagtg ctgaggtaca agccccgcgc gagcgaatgt 480

12

aacccggcct	tggacgaccc	gacgccggac	tacatgaacc	tgctgggcat	gatcttcagc	540
atgtgcggcc	tcatgcttaa	gctgaagtgg	tgtgcttggg	tcgctgtcta	ctgctccttc	600
atcagctttg	ccaactctcg	gagctcggag	gacacgaagc	aaatgatgag	tagcttcctg	660
ctgtccatct	ctgccgtggg	gatgtcctat	ctgcagaatc	ctcagcccat	gacgccccca	720
tggtgatacc	agcctagaag	ggtcacattt	tggaccctgt	ctatccacta	ggcctgggct	780
ttggctgcta	aacctgctgc	cttcagctgc	catcctggac	ttccctgaat	gaggccgtct	840
cggtgcccc	agctggatag	agggaacctg	gccctttcct	agggaacacc	ctaggcttac	900
ccctcctgcc	tcccttcccc	tgctgtctgc	tgggggagat	gctgtccatg	tttctagggg	960
tattcatttg	ctttctcggt	gaaacctgtt	gttaataaag	tttttcactc	tgaaaaaaaa	1020
aaaaaaaaaa	aaaanancng	agggggggcc	cggaacccaa	ttcscgggat	agtgagt	1077

&lt;210&gt; 25

&lt;211&gt; 1205

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

cccacgcgtc	cgcagaggca	gggcaatagt	ggagtctctg	cttggccaag	cagcctagaa	60
ctcaaagtcc	atggcccctt	ctgggcctgg	agaaattgga	tggttatagc	accaggcagc	120
ccttgtgggt	gggggacagc	aaatgaggga	cctctctttt	ctctacactc	tcctttggct	180
cccgagatc	tggcaggccc	tggtggagg	cataagatta	gatgagggtg	agctgttgga	240
gaatgaagct	gtgttgggag	aagaaatgag	gttgaccgg	aagatcaacg	aggttgtgct	300
gtcagggaa	gaggtgggtac	ttgggggcaa	gtgaggctgc	attattagat	aaatgagggt	360
gtactgtcag	gggatgaagt	gtactttag	tagagatgac	gtcctgctgg	atcagtcggc	420
ttttgctcca	tcagagaaca	cagccacacc	acaggaggaa	ggagagtgtc	cgactcagag	480
gataaatgag	ggtgtcctgc	tgataaatg	agggggcccg	tcagggtgaat	ggagtgtctg	540
tagcaaatga	ggttgtactt	gctggataaa	tgggactggg	gtgctggata	aatgggggtg	600
tgctgtcagg	tgaatgcatt	actgtcctg	ggtgaagggc	atcctgggaa	taatgagggt	660
gtcctgctgg	atagatgagc	tgccaccacc	aaatggatca	gaccctgtcc	atgaaggagg	720
caccatcagc	aacgacgagg	ttatcctggt	cccactgggg	ctcctggagc	gtcttctggc	780
ccaggggaaa	ctcgggtgtg	gccaccctgg	gttatccaag	tctctctggg	gagcagggtg	840
gggggctggg	gagggcaggg	agctgcattg	tgaccctggg	gacctctcct	tcacccccaa	900
tggtatgccct	actcctctcc	ctggcacccc	tcagtgggtc	agactgcttc	ggacattctc	960
accccaactgc	ctgcttctca	tcctgcctgt	gtcttctttc	tgcccagttt	ggaaaagccc	1020
ctattatgtg	tcagccactc	tgcccagtct	tatttaatct	ccctataaca	cagtattact	1080
cctccttgca	catcacact	ttctcttatt	cattcatcca	ttcattcatt	tgacaaacat	1140
ttaagtgtct	agtatgtacc	aaacacatga	ggtacagttt	taaaaagaat	aaaaaaaaaa	1200
aaaaa						1205

&lt;210&gt; 26

&lt;211&gt; 1674

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc feature

&lt;222&gt; (1663)..(1663)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 26

cccgagcagc	tgagtccctt	ccctgtcttt	cactcttctg	gcacgggtgg	ttttacttct	60
tcgaattgaac	cctgcttctt	cgacccccct	gggaggccgc	cttcttcagg	cgctcccttc	120
ctctccacga	gctcgctctg	acagctgagg	aaactggcaa	atcctgctac	ccagagggtg	180
aatgggtatc	tttcccgga	taatccta	ttttctaagg	gtgaagtttg	caacggcggc	240
cgtgattgta	agcggagtaa	gcaaacacct	ccattgtatt	agtcaccaga	aaagtaccac	300
tgtaagtcat	gagatgtctg	gtctgaattg	gaaccccttt	gtatatggcg	gccttgccctc	360
tatcgtggct	gagtttggga	ctttccctgt	ggaccttacc	aaaacacgac	ttcagggttca	420
aggccaaagc	attgatgccc	gtttcaaaga	gataaaatat	agagggatgt	tccatgcgct	480
gtttcgcatc	tgtaaagagg	aaggtgtatt	ggctctctat	tcaggaattg	ctcctgcggt	540
gctaagacaa	gcacatcatg	gcaccattaa	aattgggatt	taccaaagct	tgaagcgctt	600

13

atccgtagaa	cgtttagaag	atgaaactct	tttaattaat	atgatctgtg	gggtagtgtc	660
aggagtata	tcttccacta	tagccaatcc	caccgatgtt	ctaaagattc	gaatgcaggc	720
tcaaggaagc	ttgttccaag	ggagcatgat	tggaagcttt	atcgatatat	accaacaaga	780
aggcaccagg	ggctctgtga	gggggtgtgt	tccaactgct	cagcgtgctg	ccatcgttgt	840
aggagtagag	ctaccagtct	atgatattac	taagaagcat	ttaatatatt	caggaatgat	900
gggcgataca	attttaactc	acttcgtttc	cagctttaca	tgtggtttgg	ctggggctct	960
ggcctccaac	ccggttgatg	tggttcgaac	tcgcatgatg	aaccagaggg	caatcgtggg	1020
acatgtggat	ctctataaag	gcactgttga	tggatattta	aagatgtgga	aacatgaggg	1080
ctttttttgca	ctctataaag	gatttttgcc	aaactggcct	cggcttgga	cctggaacat	1140
cattttttttt	attacatacg	agcagctaaa	gaggcttcaa	atctaagaac	tgaattatat	1200
gtgagcccag	ccctgccagc	ctttctactc	ctttgccctt	ttcccgtgtt	ctaattgtatt	1260
ttgacaatgt	tgtaagtgtt	taccaagccg	tgggtctcct	aagggcctcc	tgatggaaga	1320
acagtggggt	ggttcaaagt	tatttctatg	tttggtttac	catgttaact	tttcccagag	1380
agaaagtgtt	aacattgaga	ctctggcccc	agattgggtat	cttctatgaa	gatggatact	1440
gatgggtgac	attgaaaacg	gcctgctttc	caaatgtggt	taaatgtaat	tggttagccc	1500
cagacttggtg	ctagagcaga	aggcataggc	cagggtgggt	attgctatat	gtgttacaga	1560
cctcggttct	cattaaagta	tttattggca	gaatcaaaaa	aaaaaaaaaa	aaaaaaaaaa	1620
aaactcgagg	ggggggcccg	tacccaattc	gccctatggt	gantcgaatg	ggct	1674

&lt;210&gt; 27

&lt;211&gt; 1965

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (333)..(333)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1961)..(1961)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 27

ggatcctcgc	ggcggcggcg	gtgcttacag	cctgagaaga	gcgtctcgcc	cgaggagcggc	60
ggcggccatc	gagacccacc	caaggcgcgt	ccccctcgcc	ctcccagcgc	tcccagcccg	120
cagcggccgc	gccccttcag	ctagctcgct	cgctcgctct	gcttccctgc	tgccggctgc	180
gcatggcggt	ggcgttggcg	gcgctggcgg	cggctgcagc	ggcctgcggc	agccggtacc	240
agcagttgca	gaatgaagaa	gagctcggag	aacctgaaca	ggctgcaggt	gatgctcctc	300
caccttacag	cagcatttct	gcagagagcg	cancatattt	tgactacaag	gatgagctctg	360
ggtttccaaa	gcccccatct	tacaatgtag	ctacaacact	gcccagttat	gatgaagcgg	420
agaggaccaa	ggctgaagct	actatccctt	tggttcctgg	gagagatgag	gattttgtgg	480
gtcgggatga	ttttgatgat	gctgaccagc	tgaggatagg	aaatgatggg	attttcatgt	540
taactttttt	catggcattc	ctcttttaact	ggattggggt	tttctgtctt	ttttgcctga	600
ccacttcagc	tcaggaagg	tatggggcca	tttcaggatt	tggctctctt	ctaattaaat	660
ggatcctgat	tgtcagggtt	tccacctatt	tccctggata	ttttgatggg	cagtactggc	720
tctggtgggt	gttccttggt	ttaggccttc	tcctgtttct	cagaggattt	atcaattatg	780
caaaagtctg	gaagatgcc	gaaactttct	caaactctcc	caggaccaga	gttctcttta	840
tttattaaag	atgttttctg	gcaaaggcct	tcctgcattt	atgaattctc	tctcaagaag	900
caagagaaca	cctgcaggaa	gtgaatcaag	atgcagaaca	cagaggaata	atcacctgct	960
ttaaaaaaat	aaagtactgt	tgaaaagatc	atttctctct	atttggtcct	aggtgtaaaa	1020
ttttaatagt	taatgcagaa	ttctgtaatc	attgaatcat	tagtgggttaa	tgtttgaaaa	1080
agctcttgca	atcaagtctg	tgatgtatta	ataatgcctt	atatattggt	tgtagtcatt	1140
ttaaagtagca	tgagccatgt	ccctgtagtc	ggtagggggc	agtccttgct	tattcatcct	1200
ccatctcaaa	atgaacttgg	aattaaatat	tgtaagatat	gtataatgct	ggccatttta	1260
aaggggtttt	ctcaaaagtt	aaacttttgt	tatgactgtg	tttttgcaca	taatccatat	1320
ttgctgttca	agttaatcta	gaaatttatt	caattctgta	tgaacacctg	gaagcaaaat	1380
catagtgc	aaatacattt	aagggtgtgt	caaaaataag	tctttaattg	gtaaataata	1440
agcattaatt	ttttatagcc	tgtattcaca	attctgcggc	accttattgt	acctaagggg	1500

14

ttctaaaggt	gttgctactg	tataaaacag	aaagcactag	gatacaaatg	aagcttaatt	1560
actaaaatgt	aattcttgac	actcttttcta	taattagcgt	tcttcacccc	cacccccacc	1620
cccaccccc	ttattttctt	tttgtctcct	ggtgattagg	ccaaagtctg	ggagtaagga	1680
gaggattagg	tacttaggag	caaagaaaga	agtagcttgg	aacttttgag	atgatcccta	1740
acatactgta	ctacttgctt	ttacaatgtg	ttagcagaaa	ccagtgggtt	ataatgtaga	1800
atgatgtgct	ttctgcccac	gtggtaattc	atcttggttt	gctatgttaa	aactgtaaat	1860
acaacagaac	attaataaat	atctcttggtg	tagcaccttt	aaaaaaaaaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	naaaa		1965

&lt;210&gt; 28

&lt;211&gt; 1863

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

gactaggccg	cgagcttagt	cctgggagcc	gcctccgtcg	cgcgcgtcag	agccgcctta	60
tcagattatc	ttaacaagaa	aaccaactgg	aaaaaaaaat	gaaattcctt	atcttcgcat	120
ttttcggttg	tgttcacctt	ttatccctgt	gctctgggaa	agctatatgc	aagaatggca	180
ttcttaagag	gacttttgaa	gaaataaaag	aagaaatagc	cagctgtgga	gatgttgcta	240
aagcaatcat	caacctagct	gtttatggta	aagcccagaa	cagatcctat	gagcgattgg	300
cacttctggt	tgatactggt	ggaccagac	tgagtggctc	caagaacctt	gaaaaagcca	360
tccaaattat	gtacccaaac	ctgcagcaag	atgggctgga	gaaagttcac	ctggagccag	420
tgagaatacc	ccactgggag	aggggagaa	aatcagctgt	gatgctggag	ccaagaattc	480
ataagatagc	catcctgggt	cttggcagca	gcattgggac	tcctccagaa	ggcattacag	540
cagaagttct	ggtggtgacc	tctttcgatg	aactgcagag	aagggcctca	gaagcaagag	600
ggaagattgt	tgtttataac	caaccttaca	tcaactactc	aaggacggtg	caataccgaa	660
cgcagggggc	ggtggaagct	gccaaaggtg	gggctttggc	atctctcatt	cgatccgtgg	720
cctccttctc	catctacagt	cctcacacag	gtattcagga	ataccaggat	ggcgtgcccc	780
agattccaac	agcctgtatt	acggtggaag	atgcagaaat	gatgtcaaga	atggcttctc	840
atgggatcaa	aattgtcatt	cagctaaaga	tgggggcaaa	gacctaccca	gatactgatt	900
ccttcaacac	tgtagcagag	atcactggga	gcaaatatcc	agaacagggt	gtactggtca	960
gtggacattc	ggacagctgg	gatgttgggc	agggtgccat	ggatgatggc	ggtggagcct	1020
ttatatcatg	ggaagcactc	tcacttatta	aagatcttgg	gctgcgtcca	aagaggactc	1080
tgcggtggtg	gctctggact	gcagaagaac	aaggtggagt	tgggtgcctc	cagtattatc	1140
agttacacaa	ggtaaatatt	tccaaactaca	gtctggtgat	ggagtctgac	gcaggaacct	1200
tcttaccac	tgggctgcaa	ttcactggca	gtgaaaaggc	cagggccatc	atggaggagg	1260
ttatgagcct	gctgcagccc	ctcaatatca	ctcaggctct	gagccatgga	gaagggacag	1320
acatcaactt	ttggatccaa	gctggagtgc	ctggagccag	tctacttgat	gacttataca	1380
agtatttctt	cttccatcac	tcccacggag	acaccatgac	tgtcatggat	ccaaagcaga	1440
tgaatgttgc	tgctgctggt	tgggctggtg	tttcttatgt	tgttgagac	atggaagaaa	1500
tgctgcctag	gtcctagaaa	cagtaagaaa	gaaacgtttt	catgcttctg	gccaggaatc	1560
ctgggtctgc	aacttttgaa	aactcctctt	cacataacaa	tttcatccaa	ttcatcttca	1620
aagcacaact	ctatttcatg	ctttctgtta	ttatctttct	tgatactttc	caaattctct	1680
gattctagaa	aaaggaatca	ttctcccctc	cctcccacca	catagaatca	acatatggta	1740
gggattacag	tgggggcatt	tctttatatc	acctcttaaa	aacattgttt	ccacttttaa	1800
agtaaacact	taataaattt	ttggaagatc	tctgaaaaaa	aaaaaaaaaa	aaaggcgggc	1860
cgc						1863

&lt;210&gt; 29

&lt;211&gt; 1626

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

cccacgcgtc	cggagccggg	agccgggtcg	gggggctccg	ggctgtggga	ccgctggggc	60
cccagcgatg	gcgaccctgt	ggggaggcct	tcttcggctt	ggctccttgc	tcagcctgtc	120
gtgcctggcg	ctttccgtgc	tgtgtctggc	gcactgtcag	acgccgccaa	gtgattgcct	180
tcatgttgtg	gagcccatgc	ctgtgcgggg	gcctgatgta	gaagcatact	gtctacgctg	240
tgaatgcaaa	tatgaagaaa	gaagctctgt	cacaatcaag	gttaccatta	taatttatct	300
ctccattttg	ggccttctac	ttctgtacat	ggtatatctt	actctgggtg	agcccatact	360



15

gaagaggcgc	ctctttggac	atgcacagtt	gatacagagt	gatgatgata	ttggggatca	420
ccagccctttt	gcaaattgcac	acgatgtgct	agcccgcctcc	cgcagtcgag	ccaacgtgct	480
gaacaaggta	gaatatgcac	agcagcgctg	gaagcttcaa	gtccaagagc	agcgaaagtc	540
tgtctttgac	eggcatgttg	tcctcagcta	attgggaatt	gaattcaagg	tgactagaaa	600
gaaacaggca	gacaactgga	aagaactgac	tgggttttgc	tgggtttcat	tttaatacct	660
tgttgatttc	accaactggt	gctggaaatt	caaaactgga	agcaaaaact	tgcttgattt	720
ttttttcttg	ttaacgtaat	aatagagaca	tttttaaaag	cacacagctc	aaatcagcca	780
ataatctttt	cctattgtga	cttttactaa	taaaaataaa	tctgcctgta	aattatcttg	840
aagtccttta	cctggaacaa	gcactctctt	tttcaccaca	tagttttaac	ttgactttca	900
agataatttt	caggggtttt	gttggtgttg	ttttttgttt	gtttgttttg	gtgggagagg	960
ggaggggatgc	ctgggaagtg	gttaacaagt	tttttcaagt	cactttacta	aacaaacttt	1020
tgtaaatgta	ccttaccttc	tattttcgag	tttcatttat	attttgcagt	gtagccagcc	1080
tcatacaaga	gctgacttac	tcatttgact	tttgcactga	ctgtattatc	tgggtatctg	1140
ctgtgtctgc	acttcatggt	aaacgggatc	taaaatgcct	ggtggccttt	cacaaaaagc	1200
agattttctt	catgtactgt	gatgtctgat	gcaatgcac	ctagaacaaa	ctggccattt	1260
gctagtttac	tctaaagact	aaacatagtc	ttgggtgtgtg	tggctttact	catcttctag	1320
tacctttaag	gacaaatcct	aaggacttgg	acacttgcaa	taaagaaatt	ttatttttaa	1380
cccaagcctc	cctggattga	taatatatac	acatttgtca	gcatttcctg	tcgtgggtgag	1440
aggcagctgt	ttgagctcca	atgtgtgcac	ctttgaacta	gggctggggg	tgtgggtgcc	1500
tcttctgaaa	gggttaacca	ttattggata	actggccttt	ttcttcctct	ttggaatgta	1560
acaataaaaa	taatttttga	aacatcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1620
aaaaaa						1626

&lt;210&gt; 30

&lt;211&gt; 605

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

ccacgcgtcc	gcccacgcgt	ccgggaaatg	accttgagga	ttgtagcaga	gagtgagcat	60
gaggagcggc	ctgctggcca	gggcccggat	gagcccaaca	tgaaccctaa	gcttgaggac	120
ccaaggcgcc	ccgacacctc	cttcctgtgg	tttacctccc	catacaagac	catgaagtgc	180
atcctgtggc	ggcggtttccg	gtgggccatc	atcctcttca	tcactctctt	catcctgctg	240
ctgttcctgg	cctacttcat	ctacgccttc	ccgaactatg	ctgccatgaa	gctgggtgaag	300
cccttcagct	gaggactctc	ctgccctgta	gaagggggccg	tgggggtccc	tccagcatgg	360
gactggcctg	cctcctccgc	ccagctcggc	gagctcctcc	agacctccta	ggcctgattg	420
tcctgccagg	gtgggcagac	agacagatgg	accggccac	actcccagag	ttgctaacat	480
ggagctctga	gatcacccca	cttccatcat	ttccttctcc	cccaacccaa	cgttttttgg	540
gatcagctca	gacatatctt	agtataaaac	agttggaacc	acaaaaaaaa	aaaaaaaaaa	600
aaaaa						605

&lt;210&gt; 31

&lt;211&gt; 931

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

gagagtgcct	aagcgggggt	gaaagaggac	gtgttaccca	ctgccatgca	ccaggactgg	60
ctgtgtaacc	ttgggtggcc	cctgctgtct	ctctgggctg	cagagtctgc	cccacatgtg	120
gccatggcct	ctgcaactgc	tcagctctgg	tccaggccct	gtggcaggac	acacatgggtg	180
agcctagccc	tgggacatca	ggagactggg	ctctggctct	gttcggcctt	tgggtgtgtg	240
gtggattctc	cctgggcctc	agtgtgcccc	tctgtaaagg	ggcagctgac	agtttgtggc	300
atcttgccaa	gggtccctgt	gtgtgtgtat	gtgtgtgcat	gtgtgcgtgt	ctccatgtgc	360
gtccatattt	aacatgtaaa	aatgtccsc	crckcgctcg	cccaaactatg	ttgtacattt	420
caccatggcc	ccctcatcat	agcaataaca	ttcccaactgc	caggggttct	tgagccagcc	480
aggccctgcc	agtggggaag	gaggccaagc	agtgcctgcc	tatgaaattt	caacttttcc	540
tttcatacgt	ctttattacc	caagtcttct	cccgtccatt	ccagtcaaat	ctgggctcac	600
tcacccagc	gagctctcaa	atccctctcc	aactgcctaa	ggccctttgt	gtaagggtgtc	660
ttaatactgt	cctttttttt	tttttaacag	tgtttttag	atttcagatg	actatgcaga	720
ggcctggggg	accctgggct	ctgggcccgg	cctggggctc	cgaaattoca	aggcccagac	780

16

ttgcgggggg	tgggggggta	tccagaattg	gttgtaaata	ctttgcatat	tgtctgatta	840
aacacaaaaca	gacctcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900
aaaaaaaaaa	aaaaaaaaaa	aaaggcgccg	c			931

&lt;210&gt; 32

&lt;211&gt; 1407

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

gaattcggca	cgagggcagg	ctcagaagac	gatgcggggc	tgtgtgccgg	ccttcttgct	60
gcatgtactc	agcctcagga	gagcttgctg	caccagggcc	gcccaggtct	tcacagcaca	120
actgccttga	aggcagggtg	cgagaaggag	aggcggtatg	catgagcagc	aagggggacc	180
gatgctgtgc	agctcacacc	actccagaac	ctgacaaggc	accagcagga	ccccttgcca	240
ggagcatgtc	tgtgcagcag	tggttttgcc	cctgcacatt	ccagaagccc	tcattgggaag	300
ggatgcagcc	aggcagactc	ctgccagatg	gggcaggtag	tttattcaaa	gagaactctg	360
tatcccatag	gcccaggtcc	tcctttcgtc	tggcggtggc	tttgcctggc	cagtgtgtgc	420
tcctggctca	gcagaaacat	ccatttgagt	tggcatccct	gtagggatcc	cagagcggtg	480
taagccttct	tgtgatctgt	agggatggct	gtgggggtgg	ttccaggagg	gggccaccat	540
tgcgcgatct	acttctagac	tcccaaaagg	gcccaggctc	aggcaggcct	ggcccagagt	600
cacgctggca	accacgagtt	tgggaagcag	tcgtattctc	tctctctctc	tctctctctc	660
agtatccatg	acaggatga	aacatattgt	ctctttataa	atgtcatttt	acaaattatg	720
tgattatctg	gaagctctaa	gatgagagca	aatgcctgat	cactctggcc	aaatgtcaga	780
tactaaagcc	cattcttggc	cgggcattgt	ggctcccgcc	kgtaatccca	gcactttggg	840
aagcccaagt	gggtgaatca	cctgaggtca	ggagttcaag	accagcctga	ccaacatggg	900
gataccccgt	ctctactaaa	aatacaagcc	gggcgtgggt	gcgcatgcct	gtaatccagg	960
ctactcagga	ggctgaggca	ggaaaatcac	ttgaactcgg	gaggcagagg	ttgcagtgag	1020
ctgagatcgc	gccattgcac	tccagcctgg	gtgacagagc	aagactctgt	ctcataaata	1080
aatacaaaagc	ccattcttcc	agagtcctgt	gccttaaata	aaacacacct	ctctgctgtg	1140
ggaagactgt	gcaatggcac	agccgcagag	cttggttttg	gagggtgaag	tgctctgggg	1200
agaattcgta	gatcatcctc	agaaaagcct	tgccctgggt	ttctaccaga	aaaacgtctc	1260
ccaatcacc	aggaaagctg	tccacagtag	tcccccttta	tccacggtgt	cactttccat	1320
gggttcagtt	atctgcgggc	aaccacggtc	tgacaatatt	aaatggaaaa	ttcttcaaac	1380
agttaaaaaa	aaaaaaaaaa	aactcga				1407

&lt;210&gt; 33

&lt;211&gt; 1526

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

ggcacgagaa	aaaaccttca	ggcggcccat	gggtatgccc	aagaggacag	agaacgaatg	60
cacagaaata	ttgtcagcct	tgcacagaat	ctcctgaact	ttatgattgg	ctctatcttg	120
gatttatggc	aatgcttcc	ctgggtttac	attgggttct	cattgaatgg	tactcgggga	180
aaaagagttc	cagcgcactt	ttccaacaca	tcaactgcatt	atttgaatgc	agcatggcag	240
ctattatcac	cttacttgtg	agtgatccag	ttgggtgtct	ttatattcgt	tcattgtcag	300
tattgatgct	ttctgactgg	tacacgatgc	tttacaacct	aagtccagat	tacgttacca	360
cagtacactg	tactcatgaa	gccgtctacc	cactatatac	cattgtattt	atctattacg	420
cattctgctt	ggtattaatg	atgctgctcc	gacctcttct	ggtgaagaag	attgcatgtg	480
ggttagggaa	atctgatcga	ttttaaagta	tttatgctgc	actttacttc	ttcccaattt	540
taaccgtgct	tcaggcagtt	ggtggaggcc	ttttatatta	cgcttccca	tacattatat	600
tagtgttatc	tttggttact	ctggctgtgt	acatgtctgc	ttctgaaata	gagaactgct	660
atgatcttct	ggtcagaaag	aaaagactta	ttgttctctt	cagccactgg	ttacttcatg	720
ccatgggaat	aatctccatt	tccagagtgg	ataaacttga	gcaagatttg	ccccctttgg	780
ctttgggtacc	tacaccagcc	cttttttact	tggttactgc	aaaatttacc	gaaccttcaa	840
ggatactctc	agaaggagcc	aatggacact	gagtgtagac	atgtgaaatg	ccaaaaacct	900
gagaagtgtc	cctaataaaa	aagtaaatca	atcttaacag	tgatgagaa	ctattctatc	960
atatatggga	acaagattgt	cagtatatct	taatgtttgg	gtttgtcttt	gttttgttta	1020
tggttagact	tacagacttg	gaaaatgcaa	aactctgtaa	tactctgtta	cacagggtaa	1080
tattatctgc	tacactggaa	ggccgctagg	aagcccttgc	ttctctcaac	agttcagctg	1140

17

ttcttttaggg	caaaatcatg	tttctgtgta	cctagcaatg	tggtccatt	ttattaagaa	1200
aagctttaac	acgtgtaatc	tgcagtcctt	aacagtggcg	taattgtacg	tacctgttgt	1260
gtttcagttt	gtttttcacc	tataatgaat	tgtaaaaaca	aacatacttg	tggggtctga	1320
tagcaaacat	agaaatgatg	tatatgtttt	tttgttatct	atattatttc	atcaatacag	1380
tattttgatg	tattgcaaaa	atagataata	atttatataa	caggttttct	gtttatagat	1440
tggttcaaga	tttgtttgga	ttattgttcc	tgtaaagaaa	acaataataa	aaagcttacc	1500
tacataaaaa	aaaaaaaaaa	aaaaaa				1526

&lt;210&gt; 34

&lt;211&gt; 1737

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1674)..(1674)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1731)..(1731)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 34

gtcgacccac	gcgtccgccc	acgcgtccgc	ccacgcgtcc	ggtttataaa	cagaagttta	60
aaacttgtaag	cttaagcttc	cgtttataaa	cagaagttta	aaattatagg	tcctgtttaa	120
cattcagctc	tggttaactca	ctcatctttt	tgtgttttta	cactttgtca	agatttcttt	180
acatattcat	caatgtctga	agaagttact	tatgcagatc	ttcaattcca	gaactccagt	240
gagatggaaa	aaatcccaga	aattggcaaa	tttggggaaa	aagcacctcc	agctccctct	300
catgtatggc	gtccagcagc	cttgtttctg	actcttctgt	gccttctgtt	gctcattgga	360
ttgggagctc	tggaagcat	gtttcatgta	actttgaaga	tagaaatgaa	aaaaatgaac	420
aaactacaaa	acatcagtg	agagctccag	agaaatattt	ctctacaact	gatgagtaac	480
atgaatatct	ccaacaagat	caggaacctc	tccaccacac	tgcaaacat	agccaccaa	540
ttatgtcgtg	agctatatag	caaagaacaa	gagcacaaat	gtaagccttg	tccaaggaga	600
tggaattggc	ataaggacag	ctgttatttc	ctaagtgatg	atgtccaaac	atggcaggag	660
agtaaaatgg	cctgtgctgc	tcagaatgcc	agcctgttga	agataaaca	caaaaatgca	720
ttggaattta	taaaatccca	gagtagatca	tatgactatt	ggctgggatt	atctcctgaa	780
gaagattcca	ctcgtgggtat	gagagtggat	aatataatca	actcctctgc	ctgggttata	840
agaaacgcac	ctgacttaaa	taacatgtat	tgtggatata	taaatagact	atatgttcaa	900
tattatcact	gcacttataa	acaaagaatg	atatgtgaga	agatggccaa	tccagtgcag	960
cttggttcta	catattttag	ggaggcatga	ggcatcaatc	aaatacattg	aaggagtgtg	1020
kggggtgggg	gttctaggct	ataggtaaat	ttaaatattt	tctggttgac	aattagttga	1080
gtttgtctga	agacctggga	ttttatcatg	cagatgaaac	atccaggtag	caagcttcag	1140
agagaataga	ctgtgaatgt	taatgccaga	gagggtataat	gaagcatgtc	ccacctccca	1200
ctttccatca	tggcctgaac	cctggaggaa	gaggaagtcc	atccagatag	tgtggggggc	1260
cttcgaattt	tcattttcat	ttacgttctt	ccccttctgg	ccaagatttg	ccagaggcaa	1320
catcaaaaac	cagcaaatat	taattttgtc	ccacagcggt	gctaggggtg	catggctccc	1380
catctcgggt	ccatcctata	cttccatggg	actccctatg	gctgaaggcc	ttatgagtca	1440
aaggacttat	agccaattga	ttgttctagg	ccaggtaaga	atggatatgg	acatgcattt	1500
attacctctt	aaaattatta	ttttaagtaa	aagccaataa	acaaaaacga	aaaggcaagt	1560
tacgagactg	acttattttt	aacttctgtg	tgttgagcta	ctgtaagctt	ggctttttgt	1620
aaagacatac	agcaattagc	tatgcaaaac	taagcattgt	tctgaaaaaa	aatntataga	1680
tagatatgtt	tatctcccat	aactcataac	tggggagtat	tataccccgg	nggcttt	1737

&lt;210&gt; 35

&lt;211&gt; 2312

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> misc\_feature  
 <222> (2312)..(2312)  
 <223> n equals a,t,g, or c

<400> 35

gcccttgtag	gtgacactat	agaaggtag	cctgcaggta	ccggtccgga	attccccggg	60
cgacccacgc	gkscgggggc	tgaggggctg	ccatggcggc	ggcgggccgg	ctccccgagc	120
cctggggccct	cttctcgccg	ctcctcgag	ggcttgca	actgggagtc	gggcccgtcc	180
cagcgcgggc	gctgcacaac	gtcacggccg	agctctttgg	ggccgaggcc	tggggcacc	240
ttgcggttt	cggggacctc	aactccgaca	agcagacgga	tctcttcgtg	ctgcgggaaa	300
gaaatgactt	aatcgtcttt	ttggcagacc	agaatgcacc	ctatttttaa	cccaaagtaa	360
aggatatctt	caagaatcac	agtgcattga	taacaagtgt	agtcctggg	gattatgatg	420
gagattctca	aatggatgtc	cttctgacat	atcttcccaa	aaattatgcc	aagagtgaat	480
taggagctgt	tatcttctgg	ggacaaaatc	aaacattaga	tcctaacaat	atgaccatac	540
tcaataggac	ttttcaagat	gagccactaa	ttatggattt	caatggatgat	ctaattcctg	600
atatttttgg	tatcacaaat	gaatccaacc	agccacagat	actattagga	gggaatttat	660
catggcatcc	agcattgacc	actacaagta	aatgcggaat	tccacattct	catgcattta	720
ttgatctgac	tgaagatttt	acagcagatt	tattcctgac	gacattgaat	gccaccacta	780
gtaccttcca	ctgtgaaata	tgggaaaatt	tggatggaaa	cttctctgtc	agtactatat	840
tggaaaaacc	tcaaaatatg	atgggtggtg	gacagtcagc	atttgcagac	tttgatggag	900
atggacacat	ggatcattta	ctgccaggct	gtgaagataa	aaattgccaa	aagagtacca	960
tctacttagt	gagatctggg	atgaagcagt	gggttccagt	cctacaagat	ttcagcaata	1020
agggcacact	ctggggcttt	gtgccatttg	tggatgaaca	gcaaccaact	gaaataccaa	1080
ttccaattac	ccttcatatt	ggagactaca	atatggatgg	ctatccagac	gctctggtca	1140
tactaaagaa	cacatctgga	agcaaccagc	aggccttttt	actggagaac	gtcccttgta	1200
ataatgcaag	ctgtgaagag	gcgcgtcgaa	tgtttaaagt	ctactgggag	ctgacagacc	1260
taaatcaaat	taaggatgcc	atgggttgcca	ccttctttga	catttacgaa	gatggaatct	1320
tggacattgt	agtgctaagt	aaaggatata	caaagaatga	ttttgccatt	catacactaa	1380
aaaataactt	tgaagcagat	gcttattttg	ttaaagttat	tgttcttagt	ggctgtgtgt	1440
ctaattgactg	tcctcgtaag	ataacaccct	ttggagtga	tcaacctgga	ccttatatca	1500
tgtatacaac	tgtagatgca	aatgggtatc	tgaaaaatgg	atcagctggc	caactcagcc	1560
aatccgcaca	tttagctctc	caactaccat	acaacgtgct	tggtttaggt	cggagcgcaa	1620
atatttctga	ccatctctac	gttggtattc	cccgctcatc	tggagaaaaa	tctatacgaa	1680
aacaagagt	gactgcaatc	attccaaatt	cccagcta	tgtcattcca	taccctcaca	1740
atgtccctcg	aagttggagt	gccaaactgt	atcttacacc	aagtaataat	gttctgctta	1800
ctgctatagc	tctcatcggt	gtctgtgttt	tcactctggc	aataattggc	attttacatt	1860
ggcaggaaaa	gaaagcagat	gatagagaaa	aacgcacaaga	agcccaccgg	tttcattttg	1920
atgctatgtg	acttgccctt	aatattacat	aatggaatgg	ctgttcactt	gattagtgtg	1980
aacacaaatt	ctggcttgaa	aaaatagggg	agattaaata	ttatttataa	atgatgtatc	2040
ccatggtaat	tattggaaa	tattcaaata	aatatgggtt	gaatatgtca	caaggtcttt	2100
ttttttaaag	cactttgtat	ataaaaaatt	gggttctcta	ttctgtagt	ctgtacattt	2160
ttgttccttt	gtggaatgtg	ttgcatgtac	tccagtgttt	gtgtatttat	aatcttattt	2220
gcatcatgat	gatggaaaaa	gttgtgtaaa	taaaaataat	taaatgagca	ggaaaaaaa	2280
aaaaaaaaa	aaaaaaaaa	aaaacaaaaa	an			2312

<210> 36

<211> 2235

<212> DNA

<213> Homo sapiens

<400> 36

gtaattcggc	acgaggggtc	caccaacatg	gagctctcgc	agatgtcgga	gctcatgggg	60
ctgtcggtgt	tgcttgggct	gctggccctg	atggcgacgg	cggcggtasc	gcgggggtgg	120
ctgcgcgcgg	gggaggagag	gagcgcccg	ccgcctgcc	aaaaagcaaa	tggatttcca	180
cctgacaaat	cttcgggatc	caagaagcag	aaacaataatc	agcggattcg	gaaggagaag	240
cctcaacaac	acaacttcac	ccaccgcctc	ctggctgcag	ctctgaagag	ccacagcggg	300
aacatatctt	gcatggactt	tagcagcaat	ggcaaatacc	tggctacctg	tgcatgat	360
cgcaccatcc	gcatctggag	caccaaggac	ttcctgcagc	gagagcaccg	cagcatgaga	420
gccaacgtgg	agctggacca	cgccaccctg	gtgcgcttca	gccctgactg	cagagccttc	480
atcgtctggc	tggccaacgg	ggacaccctc	cgtgtcttca	agatgaccaa	gcgggaggat	540

19

gggggctaca	ccttcacagc	cacccagag	gacttcctta	aaaagcacia	ggcgctgtc	600
atcgacattg	gcattgctaa	cacaggaag	tttatcatga	ctgcctccag	tgacaccact	660
gtcctcatct	ggagcctgaa	gggtcaagt	ctgtctacca	tcaacaccaa	ccagatgaac	720
aacacacacg	ctgctgtatc	tcctgtggc	agattttag	cctcgtgtgg	cttcacccca	780
gatgtgaagg	tttgggaagt	ctgctttgga	aagaaggggg	agttccagga	ggtggtgcga	840
gccttcgaac	taaagggcca	ctccgcggct	gtgcactcgt	ttgctttctc	caacgactca	900
cggaggatgg	cttctgtctc	caaggatgg	acatggaaac	tgtgggacac	aratgtggaa	960
tacaagaaga	agcaggaccc	ctacttgctg	aagacaggcc	gctttgaaga	ggcggcggt	1020
gccgmccgt	gccgcctggc	cctctcccc	aacgcccagg	tcttggcctt	ggccagtggc	1080
agtagtattc	atctctacaa	tacccggcgg	ggcgagaagg	aggagtgtt	tgagcgggtc	1140
catggcgagt	gtatcgccaa	cttgtccttt	gacatcactg	gccgctttct	ggcctcctgt	1200
ggggaccggg	cgtgctggct	gtttcacaa	actcctggcc	accgagccat	ggtggaggag	1260
atgcagggcc	acctgaagcg	ggcctccaac	gagagcacc	gccagaggct	gcagcagcag	1320
ctgacccagg	cccaagagac	cctgaagagc	ctgggtgccc	tgaagaagt	actctgggag	1380
ggcccggcgc	agaggattga	ggaggaggga	tctggcctcc	tcatggcact	gctgccatct	1440
ttctcccgag	gtggaagcct	ttcagaagga	gtctcctgg	tttyttactg	gtggccctgc	1500
ttcttcccat	tgaactact	cttgtctact	taggtctctc	tcttcttget	ggctgtgact	1560
cctccctgac	tagtgccaa	ggtgcttttc	ttcctccag	gccagtggtg	tggaatctgt	1620
cccacctgg	cactgaggag	aatggtagag	aggagaggag	agagagagag	aatgtgattt	1680
ttggccttgt	ggcagcacat	cctcacacc	aaagaagttt	gtaaatgttc	cagaacaacc	1740
tagagaacac	ctgagtacta	agcagcagtt	ttgcaaggat	gggagactgg	gatagcttcc	1800
catcacagaa	ctgtgttcca	tcaaaaagac	actaagggat	ttccttctgg	gcctcagttc	1860
tatttgtaag	atggagaata	atcctctctg	tgaactcctt	gcaaagatga	tatgaggcta	1920
agagaatatc	aagtccccag	gtctggaaga	aaagtagaaa	agagtagtac	tattgtccaa	1980
tgtcatgaaa	gtggtaaaag	tgggaaccag	tgtgctttga	aaccaaatta	gaaacacatt	2040
ccttgggaag	gcaaagtttt	ctgggacttg	atcatacatt	ttatatgggt	gggacttctc	2100
tcttcgggag	atgatattctt	gtttaaggag	acctcttttc	agttcatcaa	gttcatcaga	2160
tatttgagtg	cccactctgt	gccccaaata	atatgagctg	gggattaaaa	aaaaaaaaaa	2220
aaaaaaaaaa	ctcga					2235

&lt;210&gt; 37

&lt;211&gt; 2971

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

gacgtgagga	gcgttccatt	tggccagtgg	tgggcgggtg	ccacagctgg	tttagggccc	60
cgaccactgg	ggccccttgt	caggaggaga	cagcctccc	gcccggggag	gacaagtcgc	120
tggcaccttt	ggctgccgac	gtgattccct	gggacgggtc	gtttcctgcc	gtcagctgcc	180
ggccgagttg	ggtctccgtg	gttcaggccg	gtcccccctt	cctgggtctc	cttctccgc	240
tgggcgggtt	tatcggggag	agattgtctt	ccagggctag	caattggact	tttgatgatg	300
tttgaccag	cggcaggaat	agcaggcaac	gtgatttcaa	agctgggctc	agcctctgtt	360
tcttctctcg	tgtaatcgca	aaaccattt	tggagcagga	attccaatca	tgtctgtgat	420
ggtggtgaga	aagaagggtga	cacggaaatg	ggagaaactc	ccaggcagga	acaccttttg	480
ctgtgatggc	cgcgtcatga	tggcccggca	aaagggcatt	ttctacctga	cccttttctt	540
catcctgggg	acatgtacac	tcttcttcgc	ctttgagtgc	cgctacctgg	ctgttcagct	600
gtctcctgcc	atccctgtat	ttgtgcccat	gctcttctt	ttctccatgg	ctacactgtt	660
gaggaccagc	ttcagtgacc	ctggagtgat	tcctcgggcg	ctaccagatg	aagcagcttt	720
catagaaatg	gagatagaag	ctaccaatgg	tgcggtgccc	caggggccagc	gaccaccgcc	780
tcgtatcaag	aatttccaga	taaacaacca	gattgtgaaa	ctgaaatact	gttacacatg	840
caagatcttc	cggcctcccc	gggcctccca	ttgcagcatc	tgtgacaact	gtgtggagcg	900
cttcgaccat	cactgcccc	gggtggggaa	tgtgttgga	aagagggaact	accgctactt	960
ctacctcttc	atcctttctc	tctccctct	cacaactctat	gtcttcgcct	tcaaacctgt	1020
ctatgtggcc	ctcaaatctt	tgaaaattgg	cttcttggag	acattgaaag	aaactcctgg	1080
aactgtttta	gaagtcttca	tttgcctctt	tacactctgg	tccgtcgtgg	gactgactgg	1140
atttcatact	ttcctcgtgg	ctctcaacca	gacaaccaat	gaagacatca	aaggatcatg	1200
gacaggggaag	aatcgcgctc	agaatcccta	cagccatggc	aatattgtga	agaactgctg	1260
tgaagtgtctg	tgtggccctt	tgccccccag	tgtgtcggat	cgaaggggta	ttttgccact	1320
ggaggaaagt	ggaagtgcgac	ctcccagtac	tcaagagacc	agtagcagcc	tcttgccaca	1380
gagcccgacc	cccacagaac	acctgaactc	aaatgagatg	ccggaggaca	gcagcactcc	1440

20

cgaagagatg	ccacctccag	agcccccaga	gccaccacag	gaggcagctg	aagctgagaa	1500
gtagcctatc	tatggaagag	acttttgttt	gtgtttaatt	agggctatga	gagatttcag	1560
gtgagaagtt	aaacctgaga	cagagagcaa	gtaagctgtc	ccttttaact	gtttttcttt	1620
ggctcttagt	cacccagttg	cacactggca	ttttcttgct	gcaagctttt	ttaaatttct	1680
gaactcaagg	cagtggcaga	agatgtcagt	cacctctgat	aactggaaaa	atgggtctct	1740
tgggccctgg	cactggttct	ccatggcctc	agccacaggg	tccccctgga	ccccctctct	1800
tccctccaga	tcccagccct	cctgcttggg	gtcactggtc	tcattctggg	gctaaaagt	1860
tttgagactg	gctcaaattc	tccaagctg	ctgcacgtgc	tgagtccaga	ggcagtcaca	1920
gagacctctg	gccaggggat	cctaactggg	ttcttgggg	cttcaggact	gaagaggagg	1980
gagagtgggg	tcagaagatt	ctcctggcca	ccaagtgcc	gcattgccca	caaatccttt	2040
taggaatggg	acaggtacct	tccacttggt	gtatttatta	gtgtagcttc	tcctttgtct	2100
cccatccacc	ctgacaccta	agccccactc	ttttccatt	agatatatgt	aagtagttgt	2160
agtagagata	ataattgaca	tttctcgtag	actaccaga	aactttttta	atacctgtgc	2220
cattctcaat	aagaatttat	gagatgccag	cggcatagcc	cttcacactc	tctgtctcat	2280
ctctcctcct	ttctcattag	ccccttttaa	tttgtttttc	cttttgactc	ctgctcccat	2340
taggagcagg	aatggcagta	ataaaagtct	gcactttgg	catttctttt	cctcagagga	2400
agcctgagtg	ctcacttaaa	cactatcccc	tcagactccc	tgtgtgaggc	ctgcagaggc	2460
cctgaatgca	caaattggaa	accaaggcac	agagaggctc	tcctctcttc	tcctctcccc	2520
cgatgtacc	tcaaaaaaaaa	aaaaaatgct	aaccagttct	tcattaagc	ctcggctgag	2580
tgagggaaag	cccagcactg	ctgccctctc	gggtaactca	ccctaaggcc	tcggcccacc	2640
tctggctatg	gtaaccacac	tgggggcttc	ctccaagccc	cgtctttcca	gcacttccac	2700
cggcagagtc	ccagagccac	ttcaccttgg	gggtgggctg	tggccccag	tcagctctgc	2760
tcaggacctg	ctctatttca	gggaagaaga	tttatgtatt	atatgtggct	atatttccta	2820
gagcacctgt	gttttctctc	ttctaagcca	gggtcctgtc	tggatgactt	atgcgggtggg	2880
ggagtgtaaa	ccggaacttt	tcatctattt	gaaggcgatt	aaactgtgtc	taatgcaaaa	2940
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a			2971

&lt;210&gt; 38

&lt;211&gt; 1163

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

ccacgcgtcc	gccaaagggtg	ctgattaggg	aatgggttatg	gactaggagt	atcagtaaca	60
atgggttagaa	agtggctaac	atttgttgag	cacctgctgt	gtgcctggcc	ccggctggga	120
gcttctgtgc	ccagagtgc	ccgtctgaa	tgcagttctt	tgcctcattc	aaactgggga	180
gtgggaggca	gagctgcaca	actcacaggt	gccagactca	agactcactc	ctgggtctgc	240
ctgggctggg	ctgtgcttgt	tggccctgtg	gccaacacac	gcgcaccttt	cacctgaaag	300
ccaggatccg	cagaacgttc	cccaggagg	tcatgttttg	gcactatgat	ttgtctcttc	360
ctaaaaaggt	gatagagtta	cactggagag	agcagcatcc	aggtgcagca	gggatgggcc	420
tggggctcac	gggcaggggc	tctgtgtccg	gctggggcct	ggggtcctgc	gctgcacctg	480
tgtgtcagaa	gcactcagta	aatctttgct	gatgaaggat	gacaggatat	aggacatgat	540
gcttgctgct	gcattgcctg	caatcctgga	tgaatgccca	ggttggcttt	gctccccgtc	600
gggtggatgt	gacgttagct	gtgatgttag	gtccctggct	ttaaaatacg	acggaactgg	660
gaattgaggg	agcagttggg	gcagaaagga	cagccccgca	gaggcctgga	gctgagcagt	720
gcgggcgacc	caggagcagt	gagtgttcc	gtcacagcct	tcacgcacc	ctgtggctct	780
cataaagggg	atgggaatcta	cgaatttagt	tttccagcc	tccttaaaaa	ctcattcatg	840
ccaggggag	tggctcacac	ctgaaatccc	accacttttg	gaggctgagg	caggctgatt	900
acttgaggtc	aggagtgtga	gaccagccta	gccaacatgg	tgaaaccccg	tgtctactca	960
aagtacaaaa	aaaaaaaaatta	gtcagacgtg	gtgtcacgca	cctgtaatcc	cagctctttg	1020
ggaggctgag	gcaggagaat	cacttgaacc	caggaggcag	aggttatagt	gagccagtat	1080
tgcgccactg	acctccatct	gggcaataga	gtgagaccct	gtctcaaaaa	aaaaaaaaaa	1140
aaaaaaaaaa	aaaaaaaaaa	aaa				1163

&lt;210&gt; 39

&lt;211&gt; 1932

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

<221> misc\_feature  
 <222> (1624) .. (1624)  
 <223> n equals a,t,g, or c

<400> 39

ggcacgagcc	aggccctcgg	gccggggcgt	gaggcgggcc	cctctgggca	gggcccgggc	60
ggggctgggt	gggcccgcgc	tgctgctgcc	gtccatgctg	atgtttgcgg	tgatcgtggc	120
ctccagcggg	ctgctgctca	tgatcgagcg	gggcatcctg	gccgaratga	agcccctgcc	180
cctgcaccgc	cccggccgcg	arggcacagc	ctggcgcggg	aaagcccca	agcctggggg	240
cctgtccctc	agggctgggg	acgcggactt	gcaagtgcgg	caggacgtcc	ggaacaggac	300
cctgcgggcg	gtgtgcgggc	agccaggcat	gccccgggac	ccctgggact	tgccgggtggg	360
gcagcggcgc	accctgctgc	gccamatcct	cgtaagtgcg	cgttaccgct	tcctctactg	420
ctacgtcccc	aagggtggcct	gctctaactg	gaagcgggtg	atgaagggtg	tggcaggcgt	480
cctggacagc	gtggacgtcc	gcctcaagat	ggaccaccgc	agtgcactgg	tgctcctggc	540
cgacctgcgg	cctgaggaga	ttcgctaccg	cctgcagcac	tactttaagt	tcctgtttgt	600
gcgggagccc	ttggaacgcc	tcctctctgc	ctaccgcaac	aagtttgccg	agatccgaga	660
gtaccagcaa	cgctatgggg	ctgagatagt	gaggcggtac	agggctggag	cggggcccag	720
ccctgcaggc	gacgatgtca	cattccccga	gttcctgaga	tacctggtgg	atgaggaccc	780
tgagcgcatt	aatgagcatt	ggatgcccgt	gtaccacctg	tgccagcctt	gtgccgtgca	840
ctagtacttt	gtgggctcct	atgagaggct	ggaggctgat	gcaaatcagg	tgctggagtg	900
ggtagcggca	ccacctcacg	tcggatttcc	agctcgccag	gcctgggtacc	ggccagccag	960
ccccgaaagc	ctgcattacc	acttgtgcag	tgccccccgg	gccctgctgc	aggatgtgct	1020
gcctaagtat	atcctggayt	tytccctctt	tgctacccca	ctgcctaagt	tcaccaagga	1080
ggcgtgtcag	cagtgaccat	gggtgtgggg	ccagcagctg	gtggggactg	gtttcaacgc	1140
cagctttctg	tgtttctgcc	tgctattcgg	agaaactctg	gctctggggc	ttggggcttc	1200
tcaggatcct	ggatggcaga	gactgccctc	agaarttcc	tgccagggt	gggcacccac	1260
agtgactcag	aggacagggc	taggcaggag	acctgctgct	cctcattggg	gggatctctt	1320
ggggggcaga	caccagtttg	ccaatgaagc	aacacatctg	atctaagac	tggtccaga	1380
ccccgggctg	ccaggattat	gcagtccact	tggtctacct	taatttaacc	tgtggccaaa	1440
ctcagagatg	gtaccagcca	ggggcaagca	tgaccagagc	cagggaccct	gtggctctga	1500
tcccccatth	atccacccca	tgtgcctcag	gactagagtg	agcaatcata	ccttataaat	1560
gacttttgtg	cctttctgct	ccagtctcaa	aatttctctc	acctgccagt	tcctttacatt	1620
tttnccaagg	aaaggaacac	ggaagcaggg	ttcttgccctg	gtagctccag	gaccagctc	1680
tgagggcacc	caaagaccct	ctgtgcccag	cctcttccct	gagttctcgg	aacctcctcc	1740
ctaattctcc	cttctctccc	cacaaggcmt	ttgaggttgt	gactgtggct	ggtatatctg	1800
gctgccatth	ttctgatgca	tttatttaaa	atttgtactt	tttgatagaa	cccttgtaag	1860
ggctttgttt	tcctaatagc	tgacttttta	ataaagcagt	tttatataaa	aaaaaaaaaa	1920
aaaaaaaaaa	aa					1932

<210> 40

<211> 881

<212> DNA

<213> Homo sapiens

<400> 40

gaattcggca	cgagggaacc	cagaagatgc	tgcctctcct	gatcatctgt	ctcctgcctg	60
ccattgaagg	gaagaactgc	ctccgctgct	ggccagaact	gtctgccttg	atagactatg	120
acctgcagat	cctctgggtg	accccagggc	cacccacaga	actttctcaa	agtattcact	180
ccttgctcct	agaggataat	aattttctca	aaccttggtg	ccttgatcgt	gaccatttgg	240
aagaagaaac	agccaaattc	ttcactcaag	tacaccaagc	cattaaaacg	ttacgagatg	300
ataaaacagt	acttctggaa	gagatctaca	cgcacaagaa	tctctttact	gagaggctga	360
ataagatata	tgatgggctg	aaggagaagg	gagccccacc	cytctccatg	aatgccttcc	420
cggctccatc	tcctacttgc	accccagaac	cccttggtct	tgtctgcctc	cccagcacct	480
cagtttctct	accttctcac	ctccctggca	gcttgcaatg	agtcctgtgc	caggaaaccg	540
cggacctccc	tgtgggctgt	gagtctcagc	agtgtcttac	tcctggccat	agctggagat	600
gtttctttta	ctggcacaagg	aagaaggagg	cagtaaagga	acagggcagc	ccgcatgtct	660
tcagaagtg	aacagaggcc	gcagctacca	ccgtcacaaa	gttcaactcat	ctctgggtcc	720
cggtgacccc	atccccccat	accctccatc	ctgggtcctg	gggccccaaa	gctctgaggc	780
ctaggagact	gcgctgtctc	gtgggtttgc	tactcctaca	cctttgtaaa	gagtcctctc	840
attaaaacc	ctcttcataa	aaaaaaaaaa	aaaaaactcg	a		881

<210> 41  
 <211> 1932  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (2)..(2)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (1022)..(1022)  
 <223> n equals a,t,g, or c

<400> 41  
 cncggcgcg ctcggctcat gcccccgggc gcggggcaca caggccggcc ggcagccgct 60  
 gggaaatagg cccccggggg cgggtggcggc ggcggggcca tggcgcgag accccgggcg 120  
 ccggccgcct ccggggagga gttctccttc gtcagccgc tggtgaaata cctgctcttc 180  
 ttcttcaaca tgctcttctg ggtgatttcc atggtgatgg tggctgtggg tgtctacgt 240  
 cggctaataga agcatgcaga agcagcccta gcctgcctgg cagtggaccc tgccatcctg 300  
 ctgatcgtag tgggtgtcct catgttctct ctcaccttct gtggctgcat tgggtccctc 360  
 cgcgagaaca tctgcctcct gcagacgttc tccctctgcc tcaccgctgt gttcctgctg 420  
 cagctggccg ctggggtcct gggcttcgtc ttctcagaca aggctcgagg gaaagtgagt 480  
 gagatcatca acaatgccat tgtgcactac cgagatgact tggatctgca gaacctcatt 540  
 gattttggcc agaaaaagtt tagctgctgt ggagggattt cctacaagga ctggtctcag 600  
 aacatgtatt tcaactgctc agaagacaac ccagtcgag agcgtgctc tgtgccttac 660  
 tcctgttgct tgccctactcc tgaccaggca gtgatcaaca ctatgtgtgg ccaaggatatg 720  
 caggcctttg actacttgga agctagcaaa gtcactctaca ccaatggctg tattgacaag 780  
 ttggccaact ggatacacag caacctattc ttacttggtg gtgtggctct aggcctggcc 840  
 atccccagc tgggtgggaat tctgctgtcc cagatcctag tgaatcagat caaagatcag 900  
 atcaagctac agctctacaa ccagcagcac cgggctgacc catggtagt agaatccatc 960  
 ctgcacctcc tcaccatgga aactggcaag cctcataaac gaacagcagt ggggtgctgaa 1020  
 ancagcacca aatggagatt tggattccag cccccagtg acagcccagt gggaagaagc 1080  
 aaactccaga tgggcagaag gcagggtgca cagggtggctc cagtctcagg aggatgcgcc 1140  
 tcctctcccc catcccagcc ctcagcattg tgccagagt atacccttaa gtgtttgggt 1200  
 ttatgttttc agttttgttt gggaaacagc agttgcacag agagttgggg gtactgctgc 1260  
 tgccctttca ccgaggcact gccaccacca gctctascag ggatgctcct gagcttggcg 1320  
 gacatactta gatcctaacg tgccagttag acctggctgt ggagagtagc actggcagcc 1380  
 ctgcttgagc tccacttgga atgataccag ctccagaagg gaagggagtg gagcaggcag 1440  
 tgaggagaga gcctgggggt cggctgggga cagccgtatg tgctaggtag gagtggaggg 1500  
 agatatgttt accaaatgcc tgtcctgcc tctcccagg tagtcagagt gagctacatc 1560  
 ctgccccgcc ttcattttcca tggaaacatg gcagctagga cacggggtac aacagcagcc 1620  
 aaattcttcc ccacctccct tacttcgaaa aaaagtttgg aacctgggtc cctatactct 1680  
 gcagtcagaa gtgggactga gccatacatg cccttgaatt cctccctgtc tggccctccc 1740  
 tctccagcaa gcagggtttt ctttaacttg gcagtgtgca gaggagaagt ggtaacaccc 1800  
 ccacccatt cccctgcacg ggagctcagt attcctacag ggtaagaggt aggaatcttg 1860  
 ctgggacgag gggagccaga agtggcaata aaagcgtgtt gacctggaaa aaaaaaaaaa 1920  
 aagggcggcc gc 1932

<210> 42  
 <211> 1164  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (582)..(582)  
 <223> n equals a,t,g, or c



<220>  
 <221> misc\_feature  
 <222> (592)..(592)  
 <223> n equals a,t,g, or c

<400> 42

ggcagcagct	tgtgtgtcac	cagcctcctg	atctgccagg	gtctgtctctg	ggttggcaact	60
gaccaggggtg	tcatcgtcct	gctgcccggtg	cctcggctgg	aaggcatccc	caagatcaca	120
gggaaaggca	tgggtctcact	caatggggcac	tgtgggcctg	tggccttccct	ggctgtgggt	180
accagcatcc	tggccctga	catcctgcgg	agtgaccagg	aggaggtga	ggggccccgg	240
gctgaggagg	acaagccaga	cgggcaggca	cacgagccca	tggccgacag	ccacgtgggc	300
cgagagctga	cccgcaagaa	gggcatcctc	ttgcagtacc	gcctgcgctc	caccgcacac	360
ctcccgggcc	cgctgtctctc	catgcgggag	ccggcgccctg	ctgatggcgc	agctttggag	420
cacagcgagg	aggacggctc	catttacgag	atggccgacg	accccgacgt	ctgggtgcgc	480
agccggccct	gcgcccgcga	cgccaccgc	aaggagattt	gctctgtggc	catcatctcg	540
gcgggcaggg	ctaccgcgaac	tttggcagcg	ctctgggcac	antgggaagc	angccccgtg	600
tggggagacg	gacagcacc	tcctcatctg	gcagtgccct	tgatgtctata	gcgcctcccc	660
tctcccctca	gagggcacag	ctgcaggcct	gaccaaggcc	acgcccggct	ctcgtgtct	720
aggacctgca	cgggacttgt	ggatgggcct	ggactctcca	gaaactactt	gggcccagagc	780
aaaggaaaaac	ctcttggtttt	aaaaaaat	ttttcagagt	gttttgggga	ggagttttag	840
ggcttgggga	gagggaggac	acatctggag	gaaatggcct	tctttttaaa	agcaaaaaac	900
acaaaacctc	acaactgcct	ggcaagccca	gtatcacttg	tttgggccct	agcgggactc	960
caaggcagcc	acacgccccct	cctggaaggg	tgtgtgcgtg	tgagtgtgtg	cgagtgtgtg	1020
ggctggtgtg	tgaatatcta	taaataagta	tatatggtgt	atattatatg	tgtataaata	1080
aagtctgtac	atattggagc	tctgggagat	gctggaataa	aagacaagag	ttacatctgg	1140
acttggaaaa	aaaaaaaaaa	aaaa				1164

<210> 43

<211> 1105

<212> DNA

<213> Homo sapiens

<400> 43

gaattcggca	cgagaacaaa	ttgaaacat	ctggatcatga	acttttattt	gttaagaggt	60
tttctaatat	tgattcaatc	tctttgctta	ttctaataatgt	gttcagattt	tccacttctt	120
gagtcaattt	ggtaatttat	ttgtttctag	gaattttgtcc	atttcatcta	gtttacctaa	180
tttttgacat	ataaaattat	atatggaaat	ttctaaaata	tttaaaaatt	tctgtaaatgt	240
caatagtaat	gtccccctct	ttgttaccac	tttgttattt	gaatcttctc	cttttttttg	300
tcaatctagc	taaaaatttg	tcaattttgt	tcgtctcttc	aaaaaaatat	acgtttgtct	360
tcatgatttc	tctawtgttt	ttccatcyat	atttcatttg	aatacatttt	taaaacyttay	420
ctttattatt	tcattccttc	tgggagcttt	gggtctcatt	tttttttccct	gataatctag	480
ttgtttattg	tataagatta	agtattttatt	tgaaatctgt	atgttcttta	atgtaggcat	540
tcactactat	aaattttactt	ctcaggagca	tctctgccgc	attccatggt	ttagtatggt	600
gtgttttaat	ttgtattcat	aactagaggg	aaacagaggt	gacggagaaa	aagacgtaca	660
aatatcatcc	acttgcaaag	tatagatttg	tttgatttgk	ratatgaatr	aaaatattac	720
gagacagata	agaaaatttg	aacactgacc	attgatgcag	ttacagttaa	ttttaaaatc	780
aagggttaata	acatttttagt	tatttttaaag	aatgatagta	atttagagat	gtattctgaa	840
tgttttttaa	tgaaaagata	tgcttgggat	ttcttccaaa	atgaatcttg	taggttggga	900
agaaaatgag	aacatagtgg	aaacaagact	gacaatgagt	tgttgaggtt	gggcaatgcg	960
tacactaaag	cttatttttat	cttatttttac	tgtatatact	gttaaagctt	gcattatttt	1020
cataaatgca	tttgctaagt	gcaactgtta	tcaataaaag	tggattgggc	tctaaaaaaa	1080
aaaaaaaaaa	aaactcgagg	ggggg				1105

<210> 44

<211> 1262

<212> DNA

<213> Homo sapiens

<400> 44

24

cagcatgtac	ccagttgttc	tttctcctga	gaaagcaaaa	tgcctgatat	ttcttataat	60
ccaggctgcc	acgtttacct	tgtaaaatca	atacttaatt	tttagatttt	tatattatct	120
tttctcgtga	agcaagacct	ctaaattatg	gctataatat	cttttgaatt	gttggtctta	180
atgaatcttc	caactgtaaa	ctcatctaata	ttcaaactta	tcataacctga	ggatgtaaca	240
ttgtcccttg	tttctcatct	tgatattacc	gtcaatcatt	ttgtatttct	gagtacattt	300
gaacttgctg	gagtaataga	gggaaaacct	ctgcctgatt	ctaaatcaga	tctttgtcct	360
atactcggac	aattatggtt	tcataatttta	ttatttttta	ttttctgggt	ttaacaaatg	420
agataacatt	ttagacataa	tatttgtaaa	catcttgact	tatttcagca	ttttcctttt	480
ttgtgtatct	tcagagaggt	tgttgaaagt	agcaatttcc	aagtaatttt	aaattattga	540
agtctactag	cacgaaaggt	caaattctta	ggatatttta	aaaatgttgt	ttaataatca	600
aactcatctt	aaaaaatggt	catcagactc	tgtctttgat	gcacattttg	ccaaaagaga	660
gccttatttc	tgtgaaagaa	atacagtatg	tactttggga	tttactaaag	taaaactggt	720
accttaaggc	acagagcaga	tatagaatcc	ccctctctcc	ccactcctag	tgactgggtat	780
tctacattaa	tatttatctt	ccatgcatag	tgtacttgag	ggaaaaaac	aataactctt	840
aattgtttta	tatcaaacaa	taaaatcctg	tgtatcagtg	actgtcaata	gatggctttc	900
tgtttaaaaa	ctgaagctac	tccagaagta	ggaattaatt	tatttagtaa	acaaagtcag	960
tcaaaccaga	gccatgtcct	ggggaactgt	caaaagaatg	gttcctaagg	gccagaggcc	1020
acatccactg	gtagatgaca	gaacaacat	acttcagatg	gcaaaaccgg	tcagtttggt	1080
ttgcgtttgt	tgcctatctc	tttctgtgtg	gcttcagctg	aattaagtgc	ttggagagct	1140
caaatagttc	aagatagcca	agatgaccaa	ttctgccagg	tggcaagcct	gatcttgcaa	1200
ttttgattaa	aataaagaac	attccccaag	aacagtttgt	tgcaaaaaaa	aaaaaaaaaa	1260
aa						1262

&lt;210&gt; 45

&lt;211&gt; 517

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

gaattcggca	cgagtgcact	tccaccagct	atgtatgaga	cttcccattg	ctccacatct	60
ccagtatctt	atgtggctcag	tctttttggt	tttggtcatt	ttgggtggata	tgaaatggca	120
tctcagtggt	gcttttcaat	atatttccct	gatgactaat	ggtattcttt	caccttttca	180
gtgcttattg	gccattcatg	tatctttggt	ttttgtgtag	cacttcagggt	cttttgccca	240
tagatttagt	gggttgattg	ctctttatta	atgatttgta	gggatgttat	atatattctg	300
gacacaagat	tattgttaga	gatacgtact	tcagatattt	tctcccagtc	tgtagcttgc	360
ctaattatta	ttattattat	tatttgagat	gaagtctcac	tctgtcgccc	aggcagagggt	420
tgacgtgggc	cgagatagca	ccactacact	caagcctggc	tgacagagtg	agactctgtc	480
tcaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aactcga			517

&lt;210&gt; 46

&lt;211&gt; 858

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

agaaaaaatc	ctacatggat	attggttagga	aagagagaaa	ggaagtggcc	agtgtcccgt	60
ggcctcttcc	accttctgga	ttgttgaagc	tggggcctgg	aggggatgggt	cctgccactc	120
agcagggggc	actaatggga	ccaagctaac	ctgtccagtg	agaatcctgc	agggagacct	180
gagggtagca	ggaaagtgca	ggggaaggcc	cgggaaatgg	agagagctgg	tctggagggg	240
aggagcaagc	cgcgtggggc	aggccatgtg	ccttttgcc	gggggagtat	tactattttg	300
gagctgtgcg	tctggaacgc	ctgcctcaca	cacaaaggac	tggggcagat	gtaagtcttc	360
tgacgcaacg	aagcgcacag	ctgagagtaa	cttagaaagc	accagctaa	tgctggcatc	420
ccagatcgac	cccctcctcg	ctgaatgttg	gcactctctg	gcctcagttt	cctcatctgt	480
aaatgggggt	gataagaaat	gtgtacacac	ctcccgggca	gtggggagga	ttaaactgtg	540
ctctgacacg	atccgggcat	gttcagggtg	gtatctgcag	taaaccgcgc	tcggaaaatg	600
gcggcgcacg	agggccagcg	gtgggagctc	tccgtgcttg	gcttgacgcc	attgtggagg	660
tggaggaggg	gctgcaagac	tctgagcagg	aagacccgcg	aaagcaggaa	agcagagcca	720
gagttggggg	ccagccgcag	aaacgagagc	ccccgtgact	ttgaggcacc	ctttggagag	780
ggcaggaagc	aggaagggtg	aattttctcc	aaaacccaag	aggcagagtg	acccacatg	840
ataactgagt	ttctcgag					858

<210> 47  
 <211> 6107  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (5749)..(5749)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (5892)..(5892)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (5896)..(5896)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (5906)..(5906)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (5957)..(5957)  
 <223> n equals a,t,g, or c

<220>  
 <221> misc\_feature  
 <222> (5966)..(5966)  
 <223> n equals a,t,g, or c

<400> 47  
 gcagttagtt ccttgatgtc agtagtgggc taaaggcagc ttactgtgtg tttgctggag 60  
 ctttcactca gccaaagtgtt agagtcagga aaccatttga ggcaatggcg tcaaagtgtg 120  
 tttcacaga atgagccatt cagtctttgc tcactatata tttaatattt tattattgtt 180  
 gttattgtta ttattaattg gctttctgta ttctatgcct tttatttata aagacactaa 240  
 gaaaacccat gtttgtaatt ttaataacat ttttcccatc ttgtaatatc cagagctact 300  
 ttataaattc tctgaaccaa aagtattttc ctcaagtgtat ctcttctccc ccagccccta 360  
 ttgggaaaaa ttaccagga tagttcaggt tatgaggagg atcagccaca caatccagtg 420  
 cttcagtttg aaaatgtaaa attctaacc taaagtaggg ttggttgaaa tttcagacaa 480  
 agcaaaccga gcaggtataa aaagtagtat aaatacaaat ctgtaagtta tttttgaatt 540  
 ttctgaactt ttttctaaga gattacatag gagactaaag aaatctatct gttcaagttc 600  
 taattaggat gattgttaat actgcactgt ggatgaagtg gcgactggct tgtgtgctga 660  
 cttctgtggt ttagcaagag gtttattgtt atcaaagtct aattggcaat gccaaagtcac 720  
 tgggaccaat tttctgtttt ataatatcta agtttagaac agaatatata cctgaactgt 780  
 agtgggttga tcggatggag acagaaaacc cgatttttat tctcataaat tttgtgggta 840  
 tttatacaag ggctgtgcta tgctaccata ttcttgttca ataataatag gtttgttgtt 900  
 ttttttacct tgttaaatgt tccttaccct taaagggtcaa tggttaagtac aacattctga 960  
 aaatacaatt tggctacgaa gagtattcat cttctttgaa gctcagtggt tgatatttgt 1020  
 gctaataatg caatttcctg attcctgtta caagttatag ctacatatgg gagagactca 1080  
 gtgagccagc aaaggccata gaaacaacaa tttattaaat gtatttatgg cagaaggacc 1140  
 taaataaact gtgagccacc ttttcttctt tatattgtta catttaagtgt ttcttgcttt 1200  
 cagcaactca cattaatgct tggagcttat ctcttctctc ctctctctct ctctctctct 1260  
 ctgtgtgtgt gtgtgtatgt gtgtgtgtgt gtgtgtgtgt ttccttattg tcattccatt 1320  
 atatatccac accaacaatgg gtgacgataa ttcaaagtca tattttgcct ctaagcttga 1380

tcatgttacc	tttatgatta	aagtatcatg	ttattttagcc	aatgcaaata	tgttttaaaa	1440
caaatagttt	aaaaaaagaa	caagtttttta	agggttttat	tatagaagaa	gtattaatga	1500
aggactttcc	ttcctccctc	cctttccctc	cctccctgcc	tcccttcttc	ccttccatct	1560
ccccctctc	cctgccttct	ttgtttctcc	ttcccttatt	cctccctccc	tcctttctcc	1620
cttccttctt	ttcttccatt	catccttccct	tgccctttat	ttttattttt	tgtaatatca	1680
catgtgctgt	agtttggaat	tttattctag	tgcatttctt	gctcatcaga	acctcagcta	1740
atctacctag	gaaaaatagt	atcaaaggaa	atgagaaagt	tgtatctgag	tccttccaga	1800
actaagataa	ttctttttga	ccatttaagc	ctttataaat	gcgttttgac	catttaagcc	1860
tttataaatg	cttgtttttag	gaaagtgaat	ctgttagatg	catcaacaaa	taatgaccag	1920
gacaaaacga	tttaataaatt	aaagtctcaa	atcaccatgg	ttatacatat	tcaccagaaa	1980
tagtaattctt	acaatttttc	atttttctga	tgaagatttc	tgttccaata	tctgtttcct	2040
aatagatttt	ttaaattaat	tagctttccct	ctgcctttatg	accacagggt	ttatccctaa	2100
ccgagacagc	tgtcttatat	ctgcatgcct	tagactgtgt	ggaggggactc	catgaagaaa	2160
gaccataggt	tagaaaaata	actcatagta	tataccctag	taagtgggtt	agtagaatct	2220
cataacatgt	attaaaaaga	ggttttcttc	tctgcttggt	tgtgtcacta	gagcaaaatt	2280
gtagagataa	tgctcataat	gcagtaaata	tcagaataat	ctacaatatc	atttgtggat	2340
ggteccaggt	cccagtgtct	tagttacttt	acttcttttt	ttttttttga	gatggagtct	2400
tgctctgtct	ctcaggctag	agcagtgtgc	gatctcagct	cactgcagcc	tcacacctcc	2460
aggttcaagc	gatttctctg	cctcagcctc	ccaagttagcc	aggattacag	gcacctccca	2520
ctaggcccg	ctaatttttt	ttgtattttt	ttagttagaga	tggggttttg	ccatgttggc	2580
caggctgggt	tcgaactcct	aacctccagt	gatccacctg	cctcggcgtc	ccaaagtgtc	2640
aggattacag	gcatgagcca	ccacatccgg	cctaattact	tctttaatcc	ccatttattt	2700
ttatgccatt	ctagcctcat	ttattaataa	aattatgttt	ttactttctc	tttcaggaaa	2760
ttttttaaat	taatatttta	tatctagatc	taatgctatg	gaaaagtgcc	tttttatcat	2820
ttataatttc	atttttcact	atttccaaaa	acacataaac	aaatagtttc	agtaggtccc	2880
agcttttact	ttttccattt	aaaccttctt	ttctccattt	cttccctttg	gcttaagaat	2940
aaaagaaaag	gtacattgct	agaattgttt	ctttgggaga	gggtaaaaga	ttacagaatt	3000
agactgttca	gcctttatat	aaactaaatt	tgtcttcctc	tcaaccagct	aatggtaggt	3060
cttatctgaa	tactcatgag	aatttttagca	tctgtgaaac	tccatgcacc	agatgtgtgt	3120
aaatttcagg	aagaaagtgt	tgaaagcatt	ttctctgatg	ttaattagat	ggaaataaat	3180
cactaaaaca	tagtttaggt	aaagcctgat	tatgccactt	tttttttaact	agacagggca	3240
aagttgttta	tgtagtgta	cttcttgtct	atcctcagtt	aatttaccta	gacaaaaagt	3300
gtcaaaggaa	atgagaaaaa	ggttatatct	gactccctcc	agacctaaaga	taattccttt	3360
tgatcagata	cagtcagatg	gagtgccttg	gtttttgtta	attttgcctc	tattccagct	3420
ccttaccaca	gcggtgggtc	ttaaagaaag	gatcatcagc	aacaggtcag	gatagttcta	3480
cctttgggat	agggtctgct	tcccgctgct	agtatttctg	tgactgttag	tggcactgag	3540
gactgcaaac	ttttatgcaa	tattcttaat	acctatttga	tattatgcac	tttaatcatt	3600
caaagaagc	caagaatgct	gtatagtgat	gattccttcc	taatgaattc	atcttaacta	3660
tttagaattgt	tatgtccctt	ttcttttgga	tagccaactt	ggtataaatg	ttatatggat	3720
ttttctaaaa	tgactatata	ggacttaaga	ctttgaaatg	taatttactt	ataaggggaa	3780
ataattatgc	tttagcacat	catttttagaa	acgtcacatt	ttagaacat	tcagcttgct	3840
aacctacatg	tttgggaatt	cattaaaacc	agttgtctat	atattttgtg	ccatgtatat	3900
aagaacatta	caatatatct	ttttctacat	atgtagtatg	tgcaaccagt	ggttctcaga	3960
gtatggttct	cagcccacca	gctagtatca	gtatcacctg	ggaactagtt	agaaatgtaa	4020
attctttggc	cccattcccag	acatactgag	tcagaaattc	tggaataggg	cccccgcaat	4080
ctgttttcac	aagccctcca	ggtgattctg	atgcacactt	taaagttag	gaaccactgg	4140
gctaagactc	tgttgagata	tagagttttt	cttccactca	gactgatata	gttatacatt	4200
gttcttcatg	taaattcagc	ttaacctggg	tatctataat	ctttttattgg	caaaagttaa	4260
ttctcagtag	tgcttataga	gatacagtag	attttatgta	catacacaat	tagtctaatt	4320
cttgataaatt	cagttaattt	agtttggcat	tttctacca	cttactaaaa	ggtttacatt	4380
aaatgactga	tttaaatata	taggtgcaat	gttctatggt	tatttttaatt	gttatgacat	4440
ttaagtagct	aatataattg	accggtgcta	aagtctcctg	tttatccata	aaatgggtac	4500
attatgggca	gtgtaataca	agctttcttt	tcattgcta	gtactttacc	agcagaccac	4560
agttttgccc	tggctagacc	aacctcaga	acaaaatcat	cattccttgt	atttatattt	4620
gtatctgaga	tagtaaacaa	gatggctggc	caggtaacaa	tggaacctta	acttattttt	4680
ttaataggta	aaacttcttc	aaaagtagct	tgctttgtat	aagaactaag	ctatcagtat	4740
agatatagct	atccttggag	cttatgtttc	agacaagaat	tatttactaa	aatataaat	4800
aaacaagata	atgcattata	caatttgggc	atttctcgtt	tctcaagtgt	atgcacatg	4860
gtaaatataa	actaaccaca	agataggtag	attgattcat	ttcattttta	tctccttgtg	4920
taattcagta	cctccataat	tgttctaata	ttcttccac	tgtttacaaa	ttaccagtta	4980

27

attaactcgt	gaaagaaaaa	ttcacatatc	agaataaaaa	taaatgtata	ctcactttat	5040
aaaaatcacc	actgctgtct	ttccttaata	ctagcagtgg	aaatgtaagt	ggcttactct	5100
acaaattttg	gtgctggcaa	atacataggc	aaactgttgg	gagctgctct	agttacattc	5160
ctcccttctt	attccctttt	tctcttcctc	actttattgc	ataacatatt	cctgtaccca	5220
aagcattcta	ccacagttct	atttgactcc	cacttgtaat	aactccttta	aaaaattcca	5280
tgtttaacca	tatgaccctg	cttgcttaact	catattctcc	ctccctctcc	ccttcctttc	5340
tctctcttcc	agaagtcatt	tgcttggttt	gaaatatatt	gtagggtatt	cttattatat	5400
tatttttagct	gatgaacctc	aggacaacgt	ctacacacac	acacatacat	acacgcacac	5460
aaaatctcag	ctggttgaga	gtgggcttgg	aatcagactt	ctgtgtccag	taaaaaactc	5520
ctgcactgaa	gtcattgtga	cttgagtagt	tacagactga	ttccagtga	cttgatctaa	5580
tttcttttga	tctaataaat	gtgtctgctt	accttggttc	cttttaattg	ataagctcca	5640
agtagttgct	aattttttga	caactttaaa	tgagtttcat	tcacttcttt	tacttaatgt	5700
tttaagtata	gtaccaataa	tttcattaac	ctgttctcaa	gtggtttanc	taccattctg	5760
ccatttttaa	ttttttattt	atttttattt	cttgagcaca	ctgatcaacc	actgaactgc	5820
cttcttccat	tgctctgcaa	tgatataagg	gttacatttt	tgtgtatatg	gctttcatag	5880
ttgggatttc	anagcncatg	taccanatat	tttcagtttg	ttctctgggg	gaatttcatt	5940
tgcatctatg	ttttttancta	tctgtnataa	cttggttaaat	attaaaaaga	tattttgctt	6000
ctattggaac	atttgtatac	tcgcaactat	atttctgtaa	acagctgcag	tcaaaaaata	6060
aacactgaaa	gtttttcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa		6107

&lt;210&gt; 48

&lt;211&gt; 703

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

ccacgcgtcc	gcaggacatc	gttttctaca	tggtggctgt	gttcctgacc	ttcctcatgc	60
tcttcctgtg	cagggtcacc	ctggcatggg	ctctgggtta	cctgggcttg	tatgtgttct	120
atgtggctac	tgtgattctc	tgacactgga	tctaccaacg	gcaacggaga	ggatctctgt	180
tctgccccat	gccagttact	ccagagatcc	tctcagactc	cgaggaggac	cgggtatctt	240
ctaataccaa	cagctatgac	tacggtgatg	agtaccggcc	gctgttcttc	taccaggaga	300
ccacggctca	gatcctggtc	cgggccctca	atcccctgga	ttacatgaag	tggagaagga	360
aatcagcata	ctggaaagcc	ctcaagggtg	tcaagctgcc	tgtggagtgc	ctgctgctcc	420
tcacagctcc	cgtcgtggac	ccggacaagg	atgaccagaa	ctggaaacgg	cccctcaact	480
gtctgcatct	ggttatcagc	cccttggttg	tggtcctgac	cctgcagtcg	gggacctatg	540
gtgtctatga	gataggcggc	ctcgttcccg	tctgggtcgt	ggtggtgatc	gcaggcacag	600
ccttggtctt	agtgcacttt	tttgccacat	ctgacagcca	gccccccagg	cttactggtc	660
tctttgcttt	cctgggcttt	ctgaccagcg	cctgtgggat	caa		703

&lt;210&gt; 49

&lt;211&gt; 639

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ggcacgagca	ttcacagggt	acaaatgctg	ctgccaaactg	tcctggccaa	atgactctgc	60
atcacaaacc	tttccttgca	tgtggagggg	atggattttac	tcagtccaac	tttgatggct	120
gcataccttc	tgccctatgt	gttctggaag	ctttaaagaa	ttatatattag	tgccctatct	180
cttattctct	acatgtgtat	tgggttttta	ttttcacaa	tttctgttat	tgattatttt	240
gttttctatt	ttgctaagaa	aaattactgg	aaaattgttc	ttcacttatt	atcatttttc	300
atgtggagta	taaaaatcaat	tttgtaattt	tgatagttac	aacccatgct	agaatggaaa	360
ttcctcacac	cttgacactt	ccctactttt	ctgaattgct	atgactactc	cttggtggag	420
gaaaagtggg	acttaaaaaa	taacaaacga	ctctctcaaa	aaaattacat	taaatcacaa	480
taacagtttg	tatgccaaaa	acttgattat	ccttatgaaa	atttcaattc	tgaataaaga	540
ataatcacat	tatcaaagcc	ccaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	600
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa			639

&lt;210&gt; 50

&lt;211&gt; 867

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

ggcagcagca	ggtactgggt	gactgcctgg	ctgaggaaaa	gttaactaga	cacttgggga	60
aaggagatcc	aagggagtaa	gaggcaaaat	gcctttgcat	gcttttcttc	ctatctcttt	120
ttctttctct	ctttctcact	ctctcccttc	cttctttctt	tcctttctct	ttcttttttt	180
tttctctttt	ccccacctc	tctgcctgcc	tccttctctc	cctccctcc	cctcccttcc	240
ccctccctcc	ctccctccct	tccttctctc	cttctctctc	tccttctctc	cttccctccc	300
tcctctctcc	ctccttccct	gccttctttc	cttcgttctg	ccaacttgcc	agaaggagcc	360
caagaaaaag	caccagatg	cttcagtcaa	cttcttagaa	ttctttcttt	ttttatgttc	420
agaaaagatg	gaaattcatt	tctgctaaag	agaaagaaaa	aattggaaga	cagggtgaag	480
gtgaacaggc	ccattataag	aaagaaacaa	aaatctatat	tctgtctaca	aggaagcgag	540
agagagaaag	agagagaaga	aagaagtctc	aggattctaa	tgtaccaaag	ggatctcctt	600
tttcttggtt	tggtctgaaa	atttcaccaa	aagagcacag	gagaacatct	tggttaattc	660
attggcgatg	atgtaagaaa	actgagagaa	atgaaagaaa	tgaagaatta	ctgctgcaga	720
taatatacag	ccttgaggaa	agaaaggctt	ttaagattat	agatataaag	gctattgctg	780
tattctggga	taaaagaaa	tctgatgtca	gggaaagggg	aagttggaaa	aactggaaaa	840
agaaaaaaga	aaaaaaaaaa	aaaaaaa				867

&lt;210&gt; 51

&lt;211&gt; 1569

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (341)..(341)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 51

gtattggcca	ggctgggtctc	aaactcctga	cctcgtgatc	cacccacctt	ggcctcccaa	60
agtgcagaga	ttacaggcat	gagccactgc	acctggcctc	aagaaaaatt	atatatcacg	120
tggaaatagga	tagtagtctc	tgcaactgatt	ttcgttgata	atggctgttc	ttcttatcac	180
catttttgcta	tttctttgtc	tgggctatta	cagggttatt	acagaaattt	ccagaaagac	240
ccctgcctgt	cgaatgttta	cttcaagctt	gagctcctgg	tatattatga	ggaaattata	300
tgatacccca	ggagaggtct	tcctttccca	tgccattgta	naattcctaa	agtaaaatta	360
atttgccttc	ttgtcaaaga	aggagccaat	gttggtttta	aatttttagct	tgagagatag	420
gtggggaaga	aattaaatag	acaagtaatc	mtatttcaga	agagaaggga	gagtcattgt	480
acgaggccca	agatacttgc	ccaaaaatat	cgcagagaaa	aactagtctt	tggggctcta	540
tttttttgagt	ggaacatttg	agttatttaa	aattagaatt	ttattttggg	cagattagaa	600
tttctagggg	atgtcatatg	tggtttttaa	ttgaaagctc	ttaaaactcc	tattgtagtt	660
taatgtcatt	atccattaat	ttacataaat	ctgatttgga	tctctatttt	catcgtagac	720
tgtgtagggg	caatttttcc	taaaggttct	gtgacatagt	gctacctttt	ttttaaacc	780
tgtcttgccc	aggcattatt	gagtgccccc	tggtgccagc	atgtgtatatt	cacgactgta	840
tcaacaaatc	atgatcatct	tctctggcca	ttgtgccctt	tcagattcca	aacttgttac	900
ctctcagctc	ttcctacaaa	cttagaaagt	ctaatactct	aatgtttact	tatgtagcaa	960
cctccctttc	tcccctccct	aaatcctctt	gtaattaat	attttccttt	ggaacttttt	1020
aaatctacaa	tttctttata	atatggtaac	caatattaat	tttcttggtc	tgcgccaagt	1080
ttgattttat	acaaattggt	tccagtttgg	gtcatgagca	caaaaccagg	tattttttaa	1140
aatctatata	acccttcaat	gaggcagtat	taattttatt	aactcattaa	ttcaaccaat	1200
aattcttgat	tgtttactgt	gttagatatt	ggggtatccc	caatacctga	cagctgtgag	1260
caaaacaaat	gccctacaca	catgaggtgt	acagtccagt	agaaaagata	aacaataagc	1320
aaattaatag	ataatgat	gtccaataag	gacttcaaag	gaaaataaag	cagagtaaag	1380
agccagagaa	tgacagtgag	ctgtttttca	catgagtcac	cagaaaaggc	ctctttaaag	1440
aattgacatt	tgaacagaaa	aacgaatcaa	gggcgtcaac	tgtttattgc	ttttattgct	1500
taccatttga	ccaagcaatt	ctacacatag	gattcacctc	aaaaaaaaaa	aaaaaaaaaa	1560
aaactcgag						1569

&lt;210&gt; 52

&lt;211&gt; 1196

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (590)..(590)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 52

gattggttct	gtttatgtga	tagattactt	ttattgattt	gtatgttgaa	ccagccttgc	60
atcctagggg	tgaagccgac	ttggttgtgg	tggataagct	ttttgatgtg	ctgctggggt	120
tggccttgcca	gtgtttttatt	agggattttt	gcgtcaatat	tcatcagggg	tattggcctg	180
gaatttttctt	tttttgttat	gtgtctgccca	ggttttggta	tcaggggtgat	gctggcctca	240
taaaataagt	tagggagggc	tccctctttt	tctttcattt	ggaagaattt	cagaaggaat	300
ggtaccagat	ccycttttga	cctctggttag	aatttggctg	tgaatccatc	tggtcckgag	360
cttttttttt	gttggttaggc	tattaattac	tgccctcaatt	tcagaacttg	ttattgggtct	420
attcagggat	ttgacttctt	cctgggttag	tcttgggagg	ttgtatgtgt	gcaggaattt	480
attcatttct	tctagatttt	ctcgtttatt	tgtgtagagg	tgtttatagc	atyctctgat	540
ggtagtttgt	attctgtggg	atcagtggtg	atctcccctt	tatcattttt	attgtgtcta	600
tttgatttct	ctctcttktc	ttctttatta	ttctygttaa	tggtctatgt	attttgttaa	660
tctyttacaa	aaacagggtt	ctagattcat	ggatgttttg	aaagggttyt	cgtgtctcta	720
tctccttcag	ttcttccctg	atcttagcta	tttcttgtct	tctgctagct	tttgaaattg	780
tttgcttttg	cttctctagt	tcttttaacc	gtgatgtcca	gtgtgtcaat	ttcagatctt	840
tccagccttc	tgatatgggc	atttaatgct	ataaaatttc	ctcttaacac	tgcttttagct	900
gtgtcctaga	gattctggta	cgttgtctct	ttgttctcat	tggtttcaaa	taacttcatt	960
atttctgcct	taatttttgt	atttaccag	cagtcattca	agagcagggt	gttcaatttc	1020
catgtagtgt	tgtgggtttg	agtgaatttc	ttaatcttga	gttctaattt	gattgcactg	1080
tggtctgaga	gacgggtaca	atttccattc	ttttgcattt	gctgagaagt	gttttacttc	1140
caattgtgtc	tcgtgccgaa	ttcgatatca	agcttatcga	taccgtcgac	ctcgag	1196

&lt;210&gt; 53

&lt;211&gt; 945

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (295)..(295)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (875)..(875)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (914)..(914)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 53

gaatggtgaa	atattaagtg	ctttctcccc	cagggttcagg	attatgacag	ctatgtccat	60
tcacctcttc	tgtacagcat	tgtcctgtgg	aagttctggc	cagtgcataa	aggcaattaa	120
aagaaataaa	atatcaaacg	attggaaaga	tgttaatgtg	tcatcattca	tagaaaacat	180
gattcataga	tatacataca	cgaatgcttt	gaattcataa	gtagattcag	ccagttgctg	240
gatataaagt	caatatacaa	aaactatttt	tatagacatg	aaacacgcaa	tgagnaaaaa	300
aatttaacca	tttttagtag	catcaaaaaa	cccccatacc	taggaatatg	aattttagtg	360
actatttggg	atatgttgat	ggatatttat	catttccagt	ttgggattat	tataaagaaa	420
atagccctga	acatttgtaa	tatatgactt	ttggtgaatg	tagcattcat	ttctgttgat	480

30

tacaaactca	ggggtgaaat	tgttgagtc	taagggagct	atagatgtat	tcaacttcag	540
ctgatatggc	taaataaatt	tgcgaaaaag	attgcatcaa	gttatgtctc	catcagcaat	600
atgagagttc	ctgtttttcc	acattgtcag	caacactttg	tactgttact	ccttttaatt	660
ttagccgatt	tggctgaagg	tgtggtaata	tctcattgta	gtggccaggc	gtggtgctca	720
cgcttgaat	cccagcactg	tgggaagcca	aggtgggccg	atcacgaggt	caggagatcc	780
agaccatcct	ggctaaccatg	atgaaacct	gttgccctgta	gtcccaacta	cttgggagggc	840
tgaggcagga	gaatggcatg	aactcgggag	gcggngcttg	cagtgaagcct	ccagcctggg	900
caacagagtg	agantctctc	aaaaaaaaaa	aaaaaaaaac	tcgag		945

&lt;210&gt; 54

&lt;211&gt; 488

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

ggcacgagga	gagtagaggc	tattcatgta	atgtctataa	aaaaataaca	ccaaggctgg	60
gattacaggc	atgagccact	gcacctggcc	agtttgctta	ttttgtttgg	tgccctcctc	120
catgggagac	ctcaaggagg	tatgcctgcc	ccacagatgc	cctggaagga	cagcttgctg	180
ctcctactca	gaaccacacc	tgacagacaga	ggaggacaga	cggacactca	tttgctgagc	240
acccatgtaa	catgaactaa	gagctgggtg	gagacaatga	acgggtggagc	catcgttccc	300
gatgtggagg	gagaacagct	caagaccacg	gaacagcctg	ctctcccgc	tcctggcttc	360
cgtgcgcttt	tgtccaatca	ggctttttga	ccaatcgcc	aggcgcgcta	tgtaaatttc	420
tgacattttc	aaagctgtct	ttttaataaa	cctttcagtg	taaaaataaa	aaaaaaaaaa	480
aaaaaaaa						488

&lt;210&gt; 55

&lt;211&gt; 2860

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (753)..(753)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 55

ggcacacagg	gctggcaggc	ccgcgggtggc	tggtgttgag	gcatgaacaa	attgtaccgg	60
gtatccccca	ccccactctg	accaccagtt	cctccttgga	tatcactccc	cctgacaggc	120
agcccaccca	ggcctggatt	tgtccctgtc	tccccctttt	gcttttcccc	catgactaat	180
gggcaccagg	tcttgctgct	cctgcttctc	acctctgcag	tggcagcagg	cccctggccc	240
caggtgcatg	ccggctcagtg	gggttggtatg	tgcccttctc	caggcctgcc	ctctgtccaa	300
gcccgagtg	ggcttggtgg	gctccctggt	ggccccagtg	gggtgccagg	tggtgcccgg	360
ggttattgag	gggtgggtgt	atcactgtag	ggacaggctt	cttgccccag	cctggagagc	420
tgttttcttc	aggaagggtc	tggagatgga	gacttgtttg	cgaattcacc	acaactccag	480
gctgggaggc	tgggtctctg	ctctcagagc	cgagacacca	gggaggatag	ccaggctgcc	540
ctgcctggga	attctgctgg	gccgtcaaat	tcaaccgcga	ccaacgtggg	caggaggcca	600
cagtgtcctg	ccaggagcag	agggctgaag	gtctgcagga	ggaagaccct	atcctgggtg	660
ggggcacctg	ctgcccaccc	tgccccagc	gtgcctgggg	ggagcacacc	tgggcatgga	720
ggagtccagg	gtgctggggc	acacaagaga	ggngggggag	aggcctggac	agttaggaaga	780
tcttgcccag	ggtcctggat	ccgccactct	gggggtgacc	ttggacaaac	ctctgccttg	840
gccctcagtc	tccccatcaa	ggtttttcca	ttcaggaggg	tttgggccat	cttcagccac	900
cctaccagcc	ctgaaaagga	tgtgactcct	gtttctggga	agtgtgtggt	gtgttaggtg	960
ggcctacagc	cctgggtgtg	gggagggaga	gatggagaga	cagcacagtg	acagagccca	1020
gactgcaggc	tggagtggag	gttccacttc	ccgcgtgctg	tgtgtcctgg	accagtgcct	1080
ctgaaccttg	gcacttgggg	cagtggatat	taacatcttt	ccaagcccaa	ttcttggggc	1140
atcagggcct	ccggtcctct	gggaggtggc	aggtcctcag	attggagatg	ccatgggggg	1200
gggaggtgcc	tctccttttg	agggtatgga	agtggagaca	ggagtggcct	ggcgcagctg	1260
ccgtggttct	taggggcttg	gcccggggag	cccatggggc	ttgtgcctag	aaagcctggg	1320
ctcctcactg	gggtctagat	gtgcagactt	catgtctccc	cagctccagc	tctgttctct	1380
ataggtcaag	cctccacaat	gccagaggcc	cagggctagc	cccctccacg	tccctcctag	1440



31

atctacagct	gcccccttga	tgacagcgcc	attgagtcce	ctgggctggg	ggggtcatgc	1500
aggggtgagg	cagctgcctg	ccgcccgtac	tcattgcctg	gccaggcagg	acacaggctg	1560
gcgggcactg	agagtgggcc	ccacgaaatc	cattgtcagg	ttaccaggat	gaagaaccca	1620
ggctggctcg	ggagtgcagg	gcggggcctg	ccggaagaat	tatgggcaat	gcagcaggag	1680
ggcagcctgg	gccattagct	cctgatgtca	tcgatttggg	tgaggggaca	gggaagtcag	1740
aggaagctgg	ccagtggctc	tcacgcagac	ttacagcagt	ggagtgggtg	ctgattcctg	1800
gtacagctgc	tccactgag	tctccaggga	tctgtggttc	aggaccccc	gcaaccccc	1860
cccagacccc	tgtactgggt	ggaggagagg	acctagagga	aaggtgctgg	gcagataagc	1920
agctgaggga	ggccctgggt	ttagcttatc	agtcttctgg	gccctcctgc	cccaggaagg	1980
gcagcgagga	ccatgggtgt	gccccctgtc	tcgttatcgt	cctggccatg	agcttgcagg	2040
actgggagg	ccggagtcag	ccaggcagac	ggcagcacag	catttgcctg	ttggcagggt	2100
gccttgggtg	cttcccaaag	gcaatcgctc	cacgcagaac	aaaactcact	tttttggggg	2160
gtgaagcacc	ttggttcatt	tgtttagttc	gttaattcca	gcagtctgtt	tctaaggga	2220
acatggctgc	agccggctct	gcgcctccca	ccctcccacc	aggtgcccag	tggtcccaag	2280
ggccccgaat	cccaacctta	ttcaggcgctc	agcatctctg	caccccaaat	gcctgttagg	2340
gaggatagtg	aaggctgagc	cctcctgggc	ccatcaaaag	ccagcagtga	gagaacaccc	2400
ccatctctct	gaggtgacct	tgtagggcag	tcctgtgctg	ctggctggcc	tggtgagggt	2460
gggcagggac	caaggcctgg	cgccctgggc	tcgctggcct	tgctctgcgt	gctgacttca	2520
tcttgatagt	accttgattt	tcctactgtg	acttcccctt	ctgtcgactt	cctcaccaac	2580
tttaaaattc	cgtattgaga	gcagtttcc	aagttacctc	aaatcctatt	cagaagaagg	2640
ttcttcctgg	aagttgggag	ggcggaaaac	aagtttagtc	acagaagact	actccatgtt	2700
tgagcttctg	tttcaaggga	agtgaagta	tgccggagga	gccctgcccc	tctgcagtg	2760
gtggtgttgc	cctgatactt	ttcagattga	ggtgttactt	acatgtaata	aaatgcacag	2820
acttaagtgt	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa			2860

&lt;210&gt; 56

&lt;211&gt; 1559

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1445) .. (1445)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1551) .. (1551)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 56

atccagcagt	ggggagacag	cgtgctgggc	aggcgtgcc	gagaccttct	cctgcagctc	60
tacctacagc	ggccggagct	gcgggtgccc	gtgcctgagg	tcctactgca	cagcgaagg	120
gctgccagca	gcagcgtctg	caagctggac	ggactcatcc	accgcttcat	cacgctcctt	180
gcggacacca	gcgactccc	ggcgttggag	aaccgagggg	cggatgccag	catggcctgc	240
cggaagctgg	cgggtggcgca	cccgtgctg	ctgctcaggc	acctgccc	gatcgcggcg	300
ctcctgcacg	gccgcaccca	cctcaacttc	caggagtctc	ggcagcagaa	ccacctgagc	360
tgcttcctgc	acgtgctggg	cctgctggag	ctgctgcagc	cgacgtgtt	ccgcagcgag	420
caccaggggg	cgctgtggga	ctgccttctg	tccttcaccc	gcctgctgct	gaattacagg	480
aagtcctccc	gccatctggc	tgccctcacc	aacaagtttg	tgagttcat	ccataagtac	540
attacctaca	atgccccagc	agccatctcc	ttcctgcaga	agcacgccga	cccgtccac	600
gacctgtcct	tcgacaacag	tgacctgggt	atgctgaaat	ccctccttgc	agggtcagc	660
ctgccagca	gggacgacag	gaccgaccga	ggcctggacg	aagagggcga	ggaggagagc	720
tcagccggct	ccttgcctcc	ggtcagcgct	tcctgttcca	cccctctgac	cgcgcccgag	780
atggccccc	acatgaaacg	gcttcccggg	ggccaaacgg	tggaggatct	gctggagggt	840
ctgagtgcga	tagacgagat	gtcccggcgg	agaccggaga	tcctgagctt	cttctcgacc	900
aacctgcagc	ggctgatgag	ctcggccgag	gagtgctgcc	gcaacctcgc	cttcagcctg	960
gccctgcgct	ccatgcagaa	cagccccagc	attgcagccg	ctttcctgcc	cacgttcatg	1020
tactgcctgg	gcagccagga	ctttgagggt	gtgcagacgg	ccctccggaa	cctgcctgag	1080
tacgctctcc	tgtgccaaga	gcacgcggct	gtgctgctcc	accgggcctt	cctggtgggc	1140

32

atgtacggcc	agatggaccc	cagcgcgcag	atctccgagg	ccctgaggat	cctgcatatg	1200
gaggccgtga	tgtgagcctg	tggcagccga	ccccctcca	agccccggcc	cgtcccgtcc	1260
ccggggatcc	tcgaggcaaa	gccaggaag	cgtgggcgtt	gctgggtctg	ccgaggaggt	1320
gagggcgccg	agccctgagg	ccaggcaggc	ccaggagcaa	tactccgagc	cctgggggtg	1380
ctccggggccg	gccgctggca	tcagggggccg	tccagcaagc	cctcattcac	cttctggggc	1440
acagncctgc	gcggagcgcc	ggatcccccc	gggcatggcc	tgggctgggt	ttgaatgaaa	1500
cgacctgaac	tgtcaaaaaa	aaaaaaaaaa	aaacccgrrg	ggggggcccg	nacccaatt	1559

&lt;210&gt; 57

&lt;211&gt; 2064

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2001)..(2001)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2024)..(2024)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2049)..(2049)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 57

atgggcgagg	ctgcggggcc	ccggcgcgca	cgcccgacc	tctcccage	cctggcgagg	60
gccagcccc	gccagggcag	caatgggggt	cctgcagctg	ctggctgtar	cgggtgctgy	120
atccgaacac	cgggtggctg	gtgcagccga	ggtcttcggg	aattccagcg	arggtcttat	180
tgaattttct	gtgggggaaat	ttagatactt	cgagctcaat	aggccctttc	cagagggaagc	240
tattttgcat	gataatttcaa	gcaatgtgac	ttttcttatt	ttccaaatac	actcacagta	300
tcagaataca	actgtttcct	tttctccgag	gcgtagatcc	cccaccatgt	gacgctggga	360
cagaccagga	ctccaggtgg	aggttgcagt	atgatgtcta	tcagtatttt	ctgcctgaga	420
atgacctcac	tgaggagatg	ttgctgaagc	atctgcagag	gatggtcagt	gtgccccagg	480
tgaaggccag	tgctctcaag	gtggttaccc	taacagctaa	tgataagaca	agtgtttcct	540
tctcctccct	cccgggacaa	ggtgtcatat	acaatgtcat	tgtttgggac	ccgtttctaa	600
atacatctgc	tgctacatt	cctgctcaca	catacgcttg	cagctttgag	gcaggagagg	660
gtagttgtgc	ttccctagga	agagtgtctt	ccaaagtgtt	cttcaactct	tttgccctgc	720
ttggtttctt	catttgtttc	tttggaacac	gattctggaa	aacagaatta	ttcttcatag	780
gctttatcat	catgggattc	ttcttttata	tactgattac	aagactgaca	cctatcaagt	840
atgatgtgaa	tctgattctg	acagctgtca	ctggaagcgt	cggtggaatg	ttcttggtag	900
ctgtgtgggt	gcgatttgga	atcctctcga	tctgcatgct	ctgtgttgga	ctagtgtctg	960
ggttcctcat	ctcgtcagtg	actttcttta	ctccactggg	aaacctaaag	atttttcatg	1020
atgatgggtg	attctgggtc	actttctctt	gcatagctat	cctcattcca	gtagttttca	1080
tgggctgcct	aagaatactg	aacatactga	cttgtggagt	cattggctcc	tattcggtgg	1140
ttttagccat	tgacagttac	tggtccacaa	gcctttccta	catcactttg	aacgtactca	1200
agagagcgct	caacaaggat	ttccacagag	ctttcacaaa	tgtgcctttt	caaactaatg	1260
acttcattat	cctggcagta	tggggcatgc	tggctgtaag	tggaattacg	ttacagattc	1320
gaagagagag	aggacgaccg	ttcttcctcc	cccaccata	caagttatgg	aagcaagaga	1380
gagagcgccg	agtgcacaa	attctggacc	cattctacca	cattcctcca	ttgagagaga	1440
ggctctatgg	ccgattaacc	cagattaaag	ggctcttcca	gaaggagcag	ccagctggag	1500
agagaacgcc	tttgcttctg	tagatgcccc	ggggcttggg	cagtgtgcct	cagctttgga	1560
gttcatgcct	ggagtgggtc	aacagtctct	ggtgcaagtc	taataagaga	tcaggcatat	1620
atatctgttc	tttgcataat	attatgggtc	ccttattgat	atatggtaag	ggtgtactag	1680
gggattagga	tgattgtaag	agaatgagaa	agatgaccaa	aaggttggtg	gtagggaggc	1740
ttttctttat	ttccaaatac	ttgagaaatt	accttttggg	ttacaaatct	atgatcaact	1800
tattccatta	aatagataca	ttaaaaaaat	taaaaactga	ttcttctgca	gagcactggt	1860

33

gtttcttttt	ataacccctt	gaaacaagtc	tctcacctga	gcctgtctaa	acttttcggag	1920
ggagttttatt	attgagtcctt	tatctgtgac	agtattttgga	gatttaggga	tttgatactt	1980
aggcctttga	atttttagaat	ncaaaaaggg	gagccagcca	gacngggggg	ccaacccgga	2040
tccccaacng	ggaccagggg	ggtc				2064

&lt;210&gt; 58

&lt;211&gt; 1050

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

ccacgcgtcc	ggccagccag	tccgcccgtc	cggagcccgg	ctcgctgggg	cagcatggcg	60
gggtcgccgc	tgtcttgggg	gccgcggggc	gggggcgtcg	gccttttggg	gctgctgctg	120
ctcggcctgt	ttcggccgcc	ccccgcgtc	tgcgcgcggc	cggtaaagga	gccccgcggc	180
ctaagcgag	cgtctccgcc	cttggtctaga	ctggcgctcc	tcgcccgttc	cggcggtcag	240
tgccccgag	tgaggcgcg	ggggcggtgc	agacctggcg	cgggcgctgg	cgcatctgct	300
ggagccgaac	gtcaggagcg	ggcgcgggcc	gaggcgacga	ggctgaggat	cagcaggcgc	360
gcgtcctggc	gcagctgctg	cgcgctctgg	gcgccccccg	caactctgat	ccggctctgg	420
gcctggagca	cgacccccg	gcgcctgcag	cgcagctcgc	tcgcgctctg	ctccgcgccc	480
gccttgaccc	tgccgcctca	gcagcccagc	ttgtccccgc	gcccgtcccc	gccgcggcgc	540
tccgaccccc	gcccccggtc	tacgacgacg	gccccgcggg	cccggatgct	gaggaggcag	600
gcgacgagac	acccgacgtg	gacccccgagc	tggttaggta	cttgctggga	cggattcttg	660
cgggaagcgc	ggactccgag	gggggtggcag	ccccgcgcgc	cctccgcctg	gccgcgacc	720
acgatgtggg	ctctgagctg	ccccctgagg	gcgtgctggg	ggcgctgctg	cgtgtgaaac	780
gcctagagac	ccggcgcccc	cagggtgctg	cacgcgcgct	cttgccaccc	tgagcactgc	840
ccggatcccc	tgacccctgg	gacccagaag	tgcccccgcc	atccccgccac	caggactgct	900
ccccgccagc	acgtccagag	caacttaccc	cggccagcca	gcctctctac	ccgaggatcc	960
ctacccccctg	gccccacaat	aaacatgatc	tgaagcagca	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1050

&lt;210&gt; 59

&lt;211&gt; 2533

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 59

ccacgcgtcc	gcctggcaac	ccctaataatt	tgggatctct	caatgctatt	tgccctcatt	60
agcttgctcg	ttatgcttcc	cacttggtgg	attgtgtctt	cctggctggt	atggggagtg	120
attctatttt	tgtatctggt	cataagagct	ttgagattat	ggaggacagc	caaaactacaa	180
gtgaccttaa	aaaaatacag	cgttcatttt	gaagatatgg	ccacaaacag	ccgagctttt	240
actaacctcg	tgagaaaagc	tttacgtctc	attcaagaaa	ccgaagtgat	ttccagagga	300
tttacctggg	tcagtgtctg	ttgcccattt	aataaagctg	gacagcatcc	aagtcagcat	360
ctcatcggtc	ttcggaaaagc	tgtctaccga	actctaagag	ccaacttcca	agcagcaagg	420
ctagctaccc	tatatatgct	gaaaaactac	ccctgaact	ctgagagtga	caatgtaacc	480
aactacatct	gtgtggtgcc	ttttaagag	ctgggccttg	gacttagtga	agagcagatt	540
tcagaagagg	aagcacataa	ctttacagat	ggcttcagcc	tgcttgcat	gaagggtttg	600
ttccaactct	gggtggcaca	gagttcagag	ttcttcagac	ggttagccct	attactttct	660
acagccaatt	cacctcctgg	gcccttactt	actccagcac	ttctgcctca	tcgtatctta	720
tctgatgtga	ctcaagggtc	acctcatgct	cattctgcct	gtttggaaga	gcttaagcgc	780
agctatgagt	tctatcggtg	ctttgaaact	cagcaccagt	cagtaccgca	gtgtttatcc	840
aaaactcaac	agaagtcaag	agaactgaat	aatgttcaca	cagcagtgcg	tagcttgtag	900
gtccatctga	aagcattact	gaatgaggta	ataattcttg	aagatgaact	tgaaaagcct	960
gtttgtacta	aagaaacaca	agaactagtg	tcagaggctt	atcccatcct	agaacagaaa	1020
ttaaagttga	ttcagcccca	cgttcaagca	agcaacaatt	gctgggaaga	ggccattttc	1080
cagggtcgaca	aactgctacg	aagaaataca	gataaaaaag	gcaagcctga	aatagcatgt	1140
gaaaacccac	attgtacagt	aagtaccttt	gaagcagcct	actctacaca	ttgcagacaa	1200
agatccaatc	ccagaggagc	aggaattaga	agcttatgta	gatgatatag	atattgatag	1260
tgatttcaga	aaggatgatt	tttattactt	gtctcaagaa	gacaaagaga	gacagaagcg	1320
tgagcatgaa	gaatccaaga	gggtgctcca	agaattaaaa	tctgtgctgg	gatttaagc	1380
ttcagaggca	gaaaggcaga	agtggaagca	acttctattt	agtgatcatg	tgtttcttca	1440

tatagcttta	aaattatgct	attgacatta	tgggaaagat	ttatcaatga	gagaaatgtg	1500
tctctttttc	agccgtgttg	aaatccttgt	ctcctgtaga	cccagtggaa	cccataagta	1560
attcagaacc	atcaatgaat	tcagatatgg	gaaaagtcag	taaaaatgat	actgaagagg	1620
aaagtaataa	atccgccaca	acagacaatg	aaataagtag	gactgagtat	ttatgtgaaa	1680
actctctaga	aggtaaaaaat	aaagataaatt	cttcaaataga	agtcttcccc	caaggagcag	1740
aagaaagaat	gtgtttaccaa	tgtgagagtg	aagatgaacc	acaagcagat	ggaagtgggtc	1800
tgaccactgc	ccctccaact	cccagggact	cattacagcc	ctccattaag	cagaggctgg	1860
cacggctaca	gctgtcacca	gattttacct	tcactgctgg	ccttgctgca	gaagtggctg	1920
ctagatctct	ctccttttacc	accatgcagg	aacagacttt	tggatgatgag	gaggaagaac	1980
aaataataga	agaaaataaaa	aatgagatag	aagaaaagta	agaaccaaga	ttcatatgaa	2040
gtgatattag	attgttcctt	ttacaaaagt	gtttagcttc	aagactggaa	agggaaatatg	2100
agtgtaaagt	tactatataat	aaagctaaga	tgtggattta	caggaagaac	cctgggtttga	2160
ataactgate	tgaattagtg	agttacctgt	aaatggcaga	tcttttagga	aaataagaga	2220
aaggtaaggg	ctcttttgaa	taaactgctg	ttttatttgt	ggcacactg	atcaatcttg	2280
gaaattcttt	aagtattttt	aataagaaat	gaattatcat	ttcttgccag	aatttgctac	2340
cttaaggtga	ttgggaaaaat	tctgttgcaa	gaacattaac	atttagtatg	actccttttt	2400
actgtattct	tgcagttaat	aactgcagct	attatgttaa	taacaagttg	tttgtatttt	2460
atttttgttt	ataccagctc	taaagatcca	ggttctgaat	aaaaaaatta	attgatacaa	2520
aaaaaaaaaa	aaa					2533

&lt;210&gt; 60

&lt;211&gt; 899

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 60

ggcagatttc	ccggcacctt	cgtgggcacc	acagagcccg	cctccccacc	cctgagcagc	60
acctcaccce	ccactgctgc	ggccactatg	cctgtggtgc	cctctgtggc	cagcctggcc	120
cctccggggg	aggcctcgct	ctgcctggaa	gaggtggccc	cccctgccag	tgggaccgcg	180
aaagctcggg	tgtctataga	ctacgaggca	gccgacagca	gtgagctggc	cctgctggct	240
gatgagctca	tcactgtcta	cagcctgcct	ggcatggacc	ctgactggct	cattggcgag	300
agaggcaaca	agaagggcaa	ggtccctgtc	acctacttgg	aactgctcag	ctaggcaggt	360
gcccccatcc	ccccgcattt	ctggcctagg	caggagagga	tgggcgcact	gccacttaac	420
ttgtttgttg	gtgacacagt	tggtcagagt	ggggagaatt	caccccatte	tgtccctgcc	480
cctagtcacc	tagctgtgag	ggtgcctgag	gctgaatggc	tccaccctcc	cccagccctg	540
cttctgacct	gtggetctgg	agccctgccc	cctgcctgca	tccccgagca	ccccaccctc	600
caggctccac	taaggaggga	ggggtgtgtc	gcagcagctg	cactcagcac	ctaggccagg	660
gtggggccgc	cgcagatggg	ctcaggaagc	cccagggtga	ctcagcgaga	gccctgcttt	720
tcagttgccca	aaagctgcat	caggggaatg	cggcaaggca	cacagggtct	tggcagcccc	780
tggggactgg	gcgctgcccc	tgggagggga	gagcctggcc	agggtgtgtg	ttggggcccg	840
agcagcatct	tccggtgcta	tcctcccttc	ccaccctca	cagctcaagc	caagtccag	899

&lt;210&gt; 61

&lt;211&gt; 1079

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 61

tcgacccacg	cgtccggggt	tcaccacggt	ggccaggctg	gtctcaaact	cctgacttca	60
gttggcctcc	caaagtgtct	ggattaaagg	catgagccac	tgcgcccggc	ctacctttct	120
aactctactt	ctagcttctt	gcttctgggc	tgctgctata	ccaaacagga	atgtaatact	180
ttctgtcagc	ttcaggcctt	tgacatgca	gttcactttg	tctatcttgg	tttttattct	240
taggattttta	attctcctaa	gaagctttct	ctgaccagcc	taaaacttac	gtaagccctg	300
gggttaggtgc	tatgcttatg	tcctcccata	gcattttgca	tttgcatgtg	ttgtaactct	360
taatgtacag	catcatgatt	gcctattttta	actttcctgt	ttgttacagt	agactttta	420
ctctttaagg	acaggaactg	tgtcttgttt	agaatcccca	gagcttattt	agtacaatgg	480
ctatgcttat	aatttaagta	tttattgaac	aaatgaaatt	ttcctaagcc	ctaaaacctt	540
gcaagatggt	ttagtgcagg	aaactggcct	cggtggagtt	gaataactag	cacgaggtca	600
ctcacctaaa	aagtgggtgag	gagggattaa	aatctaaatc	tgttttagctg	taaaagattgg	660
gcttttttyc	ttgctgctgc	acatgactgc	yctctctcat	gttgctgtga	cacatccctg	720

35

tcaagtgttc	aaacagcccc	tgcctaacaa	ccccatccat	agcttctgag	gaaagttgtg	780
tcatcttttg	acagctctga	gagctgaagc	gagtccttgc	agaataattt	cccatctatt	840
ggtcttaatt	tatgcttttg	agaatataac	ttattttcaa	aaaacaaatg	attcagaatt	900
tgctcatctc	ttaaggtccg	tttattagtt	tattttcattc	cttcattcac	tgataaccat	960
ttactgagca	ccagcctggg	caacatgggtg	agaacccatc	tctaccaatt	taaaaaaaaa	1020
aaaaaagggc	ggccgctcta	gaggatccaa	gcttacgtac	gcgtgcatgc	gacgtcata	1079

&lt;210&gt; 62

&lt;211&gt; 1928

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

ggcacgagag	taggtctgcc	ggcgatggag	tggtgggcta	gctcgccgct	tcggctctgg	60
ctgctgttgt	tctctctgcc	ctcagcgag	ggccgccaga	aggagtcagg	ttcaaatagg	120
aaagtattta	ttgaccaa	taacaggtct	ttggagaatt	acgaaccatg	ttcaagtcaa	180
aactgcagct	gctaccatgg	tgctcatagaa	gaggatctaa	ctcctttccg	aggaggcatc	240
tccaggaaga	tgatggcaga	ggtagtcaga	cggaagctag	ggacccacta	tcagatcact	300
aagaacagac	tgtaccggga	aaatgactgc	atgttccctt	caaggtgtag	tggtgttgag	360
cactttat	tggaagtgat	cgggcgctct	cctgacatgg	agatgggtgat	caatgtacga	420
gattatcctc	aggttcctaa	atggatggag	cctgccatcc	cagtcttctc	cttcagtaag	480
acatcagagt	accatgat	catgtatcct	gcttgacat	tttgggaagg	gggacctgct	540
gtttggccaa	tttatcctac	aggtcttgga	cggtgggacc	tcttcagaga	agatctggta	600
aggtcagcag	cacagtggcc	atggaaaaag	aaaaactcta	cagcatat	ccgaggatca	660
aggacaagtc	cagaacgaga	tcctctcatt	cttctgtctc	ggaaaaaccc	aaaacttggt	720
gatgcagaat	acaccaaaaa	ccaggcctgg	aaatctatga	aagatacctt	aggaaagcca	780
gctgctaagg	atgtccatct	tgtaggcac	tgcaaataca	agtatctggt	taattttcga	840
ggcgtagctg	caagtttccg	gtttaaacc	ctcttctgt	gtggctcact	tgttttccat	900
gttgggtgat	agtggctaga	attcttctat	ccacagctga	agccatgggt	tcactatctc	960
ccagtcaaaa	cagatctctc	caatgtccaa	gagctgttac	aatttgtaaa	agcaaatgat	1020
gatgtagctc	aagagattgc	tgaaagggga	agccagttta	ttaggaacca	tttgcatgat	1080
gatgacatca	cctgttactg	ggagaacctc	ttgagtgaat	actctaaatt	cctgtcttat	1140
aatgtaacga	gaaggaaagg	ttatgatcaa	attattccca	aaatggtgaa	aactgaacta	1200
tagtagtcat	cataggacca	tagtcctctt	tgtaggcaaca	gatctcagat	atcctacggt	1260
gagaagctta	ccataagctt	ggcacctata	ccttgaatat	ctgctatcaa	gccaaatacc	1320
tggttttctt	tatcatgctg	caccagagc	aactcttgag	aaagatttaa	aatgtgtcta	1380
atacactgat	atgaagcagt	tcaacttttt	ggatgaataa	ggaccagaaa	tcgtgagatg	1440
tggattttga	acccaactct	acctttcatt	ttcttaagac	caatcacagc	ttgtgcctca	1500
gatcatccac	ctgtgtgagt	ccatcactgt	gaaattgact	gtgtccatgt	gatgatgccc	1560
tttgtcccac	tatttggagc	agaaaattcg	tcatttggaa	gtagtacaac	tcattgctgg	1620
aattgtgaaa	ttattcaagg	cgtgatctct	gtcactttat	tttaatgtag	gaaaccttat	1680
ggggtttatg	aaaaatactt	ggggatcatt	ctctgaatgg	tctaaggaag	cggtagccat	1740
gccatgcaat	gatgtaggag	ttctcttttg	taaaaccata	aactctgtta	ctcaggagggt	1800
ttctataatg	ccacatagaa	agaggccaat	tgcatgagta	attattgcaa	ttggatttca	1860
ggttcccttt	ttgtgccttc	atgccctact	tcttaatgcc	tctctaaagc	caaaaaaaaa	1920
aaaaaaaa						1928

&lt;210&gt; 63

&lt;211&gt; 781

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 63

ggcacgagat	tttcagcctt	tttggactgg	tttctccaca	tcttcgtgga	tttatctaac	60
tttgggtctt	gatgttgggt	accttcagat	tggtgtctct	agtgaacatc	ctttttgttg	120
atgttgatac	tattcctttc	tggttgtttg	tttgttttcc	ttctaacagt	cagggccctc	180
tgctgcaggt	ctgctggagt	ttggttgagg	tccactccag	accctgtttg	tctgggtttt	240
gccagaggag	gctgcagaat	agcaatgatt	gctgcctggt	tttctctctg	aagctttgtc	300
ccagaggggc	accaccaga	tgccagccag	agctctcctg	tatgaggtgt	ctgttggccc	360
atacttggag	gtgccttcca	gtcaggatag	acaggtgtca	ggtaccact	tgaggaggca	420

36

ctctgtcccc	tatcagagct	cgaacactgt	gctgggagat	ccactgttct	cttcagagct	480
gtcagacagg	gacgtttaag	tctgctgaag	ctatgccac	agctgccct	ttccccagat	540
gctctgtccc	agggagaagg	gagttttatc	tataagtctc	tgactggggc	tgctgccttt	600
tcttcagaga	tgccctgccc	caagacgggg	actctagaga	ggcagctctg	ctgcagtggc	660
cttgctgaac	tgtggtgggc	ttcaccaggt	tggaccttcc	ctgagccttt	ttttttaccc	720
tgtgagggtg	aaaatgccta	atcaagcctc	agcaatgggtg	gatgcccttc	ccccaccaa	780
g						781

&lt;210&gt; 64

&lt;211&gt; 1194

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1172)..(1172)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 64

ggcagcagaa	gacatggagt	cttaagtgtg	atcagtggga	gggggctgga	atcatttaga	60
ggcatcttca	ttcacaaaac	caggagctga	tactggctgt	cagccaggac	ttcaactgac	120
ctatgtagaa	cctgtccatg	tggccctcc	ttgcagtctc	cccatttggg	ctggtttggg	180
cttcatacaca	gtccggcagc	ttactttctaa	gggcaagcat	tccacgacaa	cacagcagaa	240
gggcatggca	tttttacagt	gaagtttggc	aatctcatag	cgctcgcttct	gtcctacttt	300
atattattggt	cagggcaatc	acaaagatgt	gcataggctc	aaagaaaaga	gacataaccc	360
cgaccacgcg	atggaagaag	tgacacggtc	atgttatgag	aggagtgtgt	gggatgggag	420
atagggctgt	ggccacctgc	agaaaacagc	atctgctata	ggctgtcatg	gaagcgcagg	480
atggggattt	agcctacctg	aggggtcagt	cagcaaaggc	ctctgggagg	aagtgagatc	540
ttcggctgag	gatgtgaagg	gctaaaagga	gaatgaggaa	gagtttcagg	gagaggaatc	600
aatgaaacga	gtccagagac	gctggtgagt	tggatggttt	gcttcagtat	gatgacaata	660
cagaggggca	aggagactgg	tgacaggagaa	gagagaagg	gccatgtgct	ctgggtcgtg	720
tcttctatgc	cagactccct	tagaagagga	gcagcctcca	gtcagcgggtg	tcccaggaac	780
acggaggcta	gacaggacaa	tggcagccaa	tcctgtctcc	caaactgggtg	acagtgggga	840
aaagctgcat	ggtctagatc	caccctgctc	cctggcccca	gtatagaaga	tcaaattcaa	900
tctgcccatt	cttatccaga	taaagtaaa	gaagactgga	aaaaagaact	aatccacggc	960
tccatctgcc	catgactttc	tctgctgatg	cgggaggcag	ctatggataa	agagacggca	1020
cacggcatgt	cccgcagctg	tggaggtggg	gagaccccgc	aagtccacag	gaaaagagtt	1080
aagttgctgc	cacctgggca	tccgctattc	tctgctcttc	tgctctatcc	tcaattcaga	1140
ccatgatgga	gctgattgtc	tccattttta	tncccttggat	tgaatggtct	cgag	1194

&lt;210&gt; 65

&lt;211&gt; 1677

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1012)..(1012)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 65

ggtgcagtgg	tgccatcaca	gttcaactgca	gccttgacct	cccgggctca	agcaatcctc	60
ccacctcagc	cacttgagta	gctgagacct	cagatatgtg	ccatcacacc	cagctgattt	120
tttaaaatta	attttttgtg	gagataggg	ctcatatgtt	gccccatgctg	gtctcaaact	180
actgggttca	aatgatcctc	ctgcctcagc	cttccaaagt	actgggatta	caggcatgag	240
ccaccatgcc	gggctgggag	gcggaatttt	gttcagtcta	aagataagct	ttttcatagc	300
tctggctgta	gtgggaggga	gcagaggagt	gaatgattgt	cagttgggag	ggtgcagagt	360
gggctcctgc	cctagggtgr	aggtragggt	ggcttaggtg	asmcamcaca	gaggccctgt	420
tcagccccac	gtccctcccc	tgtgctccct	cctctctctc	cctctcctgc	aggcgtggga	480
ggtatcatca	ttcagcagat	ttcaccagag	gcagtggagg	aggcaggtag	ctgagccaga	540

37

attcagaatg	tcttattctc	cacttgactc	tgccactaac	ttgttgtgca	actttgggcc	600
tttccccagg	ccttcatttt	cttttctttt	cttttctttt	yttttttttt	gaggcgaggt	660
ctcgtatgt	tgcccaggct	ggagtgcagt	ggcgagcat	catctcggt	cactgcaagc	720
tccaccttct	gagttcacgc	cattctactg	cctcagcctc	ccgagtagcc	gggactgcag	780
gcrccacca	ccacgcccgg	cttatttttt	gtatttttag	tagagacagg	gtttcaccac	840
gttagccaag	atgggtctcg	tctcctgacc	tctgtatcca	cccgctggg	cttcccaaa	900
tgctgggatt	acaggcgtga	gccactgcgc	ccggccattt	tcttaaatat	ctaataaaaa	960
atatatagca	aatgcagttt	ttaaactacg	acaatatgac	cacgcaaaa	antattatct	1020
tccaagactg	ctgggtccaag	gaaaagtcag	taataaagt	gaagcattgt	agcttatgga	1080
atgactgggt	asatttggga	gaagccttag	caataatcta	gaatctgcat	agataatata	1140
tctgaggatt	gggctttgtg	gtttacaaag	catttttttt	tcttcttttg	atcccagccg	1200
tttgtctgga	ctgatacaaa	gcatttttat	tagtttgtct	tattcaatcc	tcacaccacc	1260
tcaaatttac	agaggatatg	gatctggtta	atttgtatga	ctatgtaacc	tcagtgcagt	1320
ccacagcact	gcctggagggt	gggtagagggt	ggctcctggg	tggaatccca	gccccagtg	1380
gaccttgagc	aagttacttt	agctgtctgc	acctaaattt	cctcactggc	aaaacaggaa	1440
tactgggtgt	tcacacctgc	aattccagca	ctttgggagg	ctgagggtgg	aggattgctt	1500
gagtccagaa	gttcaaaacc	agactgggca	acatagcaag	accatctcta	caaaaattaa	1560
ataaataaaa	catttacaag	ggttgtgggt	aagattaaat	gagatcactc	acgaaaaagc	1620
tcagcagacc	ctgatgtgca	gtaggtgctc	aataaatgtt	agccagcaaa	aaaaaag	1677

&lt;210&gt; 66

&lt;211&gt; 1237

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 66

agcaaacc	ggaaggtgtg	gcgtccccgc	ttcgcgccaa	gatgggtgctg	gtgctgcgcc	60
atcctttgtg	tgcccgggaa	agggcggtcc	gggagcgggg	tcgggggctc	ctgactcgca	120
ctgggcagca	tgacgggtgc	ccggctgtca	ctgctgtgcc	gggacctctg	ggcgtgtgg	180
ctgctgtgta	agggccggcg	agtgcgtggg	gcgcggggcg	gtcctcgcc	ccccggaagg	240
tggtgtgggg	cgacatgcgg	ggacgcccgg	cggggggtgga	cgttctgggc	ccagccctgt	300
cctcagaagc	tgctggggca	gaagccccgg	gctgggggat	gccggggatg	ggtgttgggg	360
tggtgtgctc	cgagaccaga	ggagccctgt	tccttggcag	ggaaggtgtg	cacgggcctt	420
gcccgaattg	tgggttaggg	ccatggccct	ggggctccctg	gtgagcagtg	gggcccgcct	480
tgcccttggc	ctgtgaggga	ctgtctgtgc	tggtcccaga	aggctgggat	cacctttcca	540
ctggctcctt	tgttcgaggt	ttttcataga	caggctatgt	ggacaaatga	gggcagcgcc	600
cacgtctggc	tgggtggagg	gctgcggctc	ctccttggag	gggacgcctg	gccactgctg	660
tccccacaat	ggggccaccc	gtggtgcaag	gcgtgacaag	ctgccctctc	taggtaagca	720
ggacttggga	ggccccctgg	caagcctgtg	gacccggctg	ggcggccctc	gtggtctcag	780
gtttgggtgt	gtttgggtctg	gtcagggtct	aggggtgctg	ggtccacact	ggccccatcc	840
tgacaatttg	agctttgggg	caaggctccct	ggagaagggg	tcacgtcggg	aggaaacagc	900
ctgggttttg	ttgatgcttt	tctaagaatg	gagtactcgt	tttcaagaga	tttgtcctaa	960
ttatatatttc	cagcgggtac	ttatgccaa	tattgatgaa	taattcataa	aataagcatc	1020
tttgtgaatt	ttagtgaatc	agaccttaac	tatcaacggc	aatgaatgaa	catctaaagt	1080
ttccaatttt	aaagtaaaga	actggctggg	tacagcagtt	cacgcctgta	atcccagcac	1140
tttgggaggc	caaggctaga	ggatcgcttg	agcccaggag	tttgagatca	gcctggggca	1200
cataccaaga	cctcatctgt	taaaaaaaaa	aaaaaaa			1237

&lt;210&gt; 67

&lt;211&gt; 1934

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 67

ccacgcgtcc	ggggcggtcc	tggtcgtgag	aggggagccc	caggggagct	ggggcagcat	60
gactgggggtg	ataaatggcc	ggaaatttgg	cgtggccaca	ctcaacacca	gcgtgatgca	120
ggaggcacac	tccgggtgca	gcagcatcca	cagcagcatc	cgccatgtcc	cagcaaacgt	180
ggggcctctg	atgcgggtgc	tcgtggtcac	catcgccccc	atctactggg	ccctggccag	240
agagagtggg	gaagccctga	atggccactc	tctgactggg	ggcaagtcc	ggcaggagtc	300
acacgtggag	tttgctacag	gggagctgct	cacgatgacc	cagtggcccc	gggtctggat	360

38

```

ccccgatggcc tccctgctcct cgacgtgggtg gtcaatggcg ttgtccccgg acagcctggc 420
tgacgcagat cttcaagtgc aggactttga ggagcactac gtgcaaacag ggcctggcca 480
gctgttcgtg gggtccacac agcgcttctt ccaggggcgc cccccctcgt tcctacgctg 540
caaccacagc atccagtaca acgcggcccc gggtccccag ccccgactgg tgcagcacct 600
gcgggcctca gctatcagct cggcctttga tccagaggcc gaggcctgc gcttccagct 660
cgctacagcc ctgcaggcgg aggagaacga ggtcggctgc cccgagggct ttgagctgga 720
ctcccaggga gcgtttttgtg tggatgtgga cgagtgtgcg tgggatgctc acctctgccg 780
agagggacag cgctgtgtga acctgtcgcg gtccctaccg tgccctcccc actgtgggcc 840
tggcttccgg gtggctgatg gggccggctg tgaagatgtg gacgaatgcc tggaggggtt 900
ggacgactgt cactacaacc agctctgcga gaacacccca ggcggtcacc gctgcagctg 960
ccccagggtt taccggatgc agggccccag cctgcccctgc ctagatgtca atgagtgcct 1020
gcagctgccc aaggcctgcg cctaccagtg ccacaacctc cagggcagct accgctgcct 1080
gtgcccccca ggccagctacc tccttcgcga cggcaaggcc tgcacctcac tggagcgga 1140
tggacaaaat gtgaccaccg tcagccaccg agggcctcta ttgccctggc tgcggccctg 1200
ggcctcgatc cccggtacct cctaccacgc ctgggtctct ctccgtccgg gtcccatggc 1260
cctgagcagt gtgggcccgg cctggtgcc tcttggtttc atcaggcaga acggagtctg 1320
cacagacctt gacgagtgcc gcgtgaggaa cctgtgtcag cacgcctgcc gcaacactga 1380
gggcagctac cagtgcctgt gccccgcgg ctaccgtctg ctccccagcg ggaagaactg 1440
ccaggacatc aacgagtgcg agggaggagag catcgagtgt ggaccggcc agatgtgctt 1500
caacacctcg ggcagctacc agtgtgtgga cacacctgt cctgccacct accggcaggg 1560
ccccagccct gggacgtgct tcgggcgctg ctgcgaggac tgcggcacgg gcggcccttc 1620
tacgtgcag taccggctgc tgccgctgcc cctgggcgtg cgcgcccacc acgacgtggc 1680
ccgcctcacc gccttctccg aggtcggcgt ccccgccaac cgcaccgagc tcagcatgct 1740
ggagccccgac ccccgcagcc ccttcgcgt gcgtccgctg cgcgcgggcc ttggcgcggt 1800
ctacacctcg cgcgcgctca cccgcgcgg cctctaccgg ctccacctgc gtgctggggc 1860
accgcgccac caaagcgtct tcgtcttgcg catcgccgtg tccccctacc cctactaaac 1920
gggagagggc attg 1934

```

&lt;210&gt; 68

&lt;211&gt; 3300

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (3)..(3)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (15)..(15)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 68

```

nncgcagccg gacgnccgag cgcagcgagt cagtgagcga ggaagcggaa gagcgcccaa 60
tacgcaaacc gcctctcccc gcgcgttggc cgattcatta atgcagctgg cagcagaggt 120
ttcccgactg gaaagcgggc agtgagcgca acgcaattaa tgtgagttag ctactcatt 180
aggcacccca ggctttacac tttatgcttc cggctcgatg gttgtgtgga attgtgagcg 240
gataacaatt tcacacagga aacagctatg accatgatta cgccaagctc gaaattaaacc 300
ctcactaaag ggaacaaaag ctggagctcc accgcggtgg cgcccgctct agaactagt 360
gatcccccg gctgcaggaa ttcggcacga gaacacatct taagggaacc aagtctcaag 420
agaaatcaag taattatgaa tgaacagctc taaaaaagag agagagaata ttttcttaa 480
tcaacttagt tgctgttatg accaaagaac agatgttgtg gtgttcaccc cagagaagca 540
agagattttc ccttaaacct cagcttataa tgaatggaag tgaatgacag ggagagagtt 600
tttctctcgt ttcccagaac tctatccttt tcttctcaaa cagttggaaa ctgtagccaa 660

```



39

tacagtagac	agtgatatgg	gagaacccaaa	tcgtcatcca	agcatgtttc	tcttactttt	720
ggtgttggag	agactctacg	cttccccgat	ggatgggtact	tcttctgtct	tcagcatggg	780
accttttgtt	cccttcatta	tgaggtgtgg	tcactcacct	gtctaccact	cccgtgaaat	840
ggcagctcgt	gccttggtcc	catttggtat	gatagatcac	attcctaata	ccattcgaac	900
tctgttgtcc	acactcccca	gctgcactga	ccagtgtttc	cggcaaaacc	acattcatgg	960
gacacttctc	caggtttttc	atttgttgca	agcctactca	gactccaaac	acggaacgaa	1020
ttcagacttc	cagcacgagc	tgactgacat	cactgtttgt	accaaagcca	aactctggct	1080
ggccaagagg	caaaatccat	gtttggtgac	cagagctgta	tatatgtata	ttctcttctt	1140
attgacttgc	tgcctcaaca	gatctgcaaa	ggacaaccag	ccagtctctg	agagtcttgg	1200
cttctggggag	gaagtccagag	ggattatctc	aggatcagag	ctgataacgg	gattcccttg	1260
ggccttcaag	gtgccaggcc	tgcccagta	cctccagagc	ctcaccagac	tagccattgc	1320
tgcaagtgtg	gccgcggcag	ccaagagtgg	agagcgggag	acgaatgtcc	ccatctcttt	1380
ctctcagctg	ttagaatctg	ccttccctga	agtgcgtcca	ctaactctgg	aagccctctt	1440
ggaaaagtgc	ttagcagcag	cctctggact	tggagagaag	ggcgtgccac	ccttgcgttg	1500
caacatggga	gagaagtctt	tattgttggc	catgaaggaa	aatcacccag	aatgcttctg	1560
caagatactg	aaaattctcc	actgcatgga	ccctgggtgag	tggcttcccc	agacggagca	1620
ctgtgtccat	ctgaccccaa	aggagtctct	gatctggacg	atggatattg	cttccaatga	1680
aagatctgaa	attcagagtg	tagctctgag	acttgccttc	aaagtcatth	cccaccacat	1740
gcagacatgt	gtggagaaca	gggaattgat	agctgctgag	ctgaagcagt	gggttcagct	1800
ggtcatcttg	tcatgtgaag	accatcttcc	tacagagtct	aggctggccg	tcgttgaagt	1860
cctcaccagt	actacaccac	ttttctcac	caaccccat	cctattcttg	agttgcagga	1920
tacacttgct	ctctggaagt	gtgtccttac	ccttctgcag	agtgaggagc	aagctgttag	1980
agatgcagcc	acggaaaccg	tgacaactgc	catgtcaca	gaaaatacct	gccagtcaac	2040
agagtttgcc	ttctgccagg	tggatgcctc	catcgtctg	gccctggccc	tggcgtctct	2100
gtgtgatctg	ctccagcagt	gggaccagtt	ggcccttgga	ctgcccattcc	tgctgggatg	2160
gctgttggga	gagagtgatg	acctcgtggc	ctgtgtggag	agcatgcac	aggtgggaaga	2220
agactacctg	tttgaaaaag	cagaagtcaa	cttttgggccc	gagaccctga	tctttgtgaa	2280
atacctctgc	aagcacctct	tctgtctcct	ctcaaagtcc	ggctggcgtc	ccccagccc	2340
tgagatgctc	tgtcaccttc	aaaggatggt	gtcagagcag	tgccacctcc	tgtctcagtt	2400
cttcagagag	cttccaccag	ctgctgagtt	tgtgaagaca	gtggagtcca	caagactacg	2460
cattcaagag	gaaaggactt	tggcttgctt	gaggctgctg	gccttttttg	aaggaaagga	2520
aggggaagac	acctagttc	tcagtgtttg	ggactcttat	gcagaatcga	ggcagttaac	2580
tcttccaaga	acagaagcgg	catgttgaag	aaaatctggg	ggattgggat	gggggtatgt	2640
tgggattttt	cctccactaa	atctgcagga	aactgttga	acataaattc	aaaaatttta	2700
tcccaaaaaa	aaaaaaaaaa	aaactcgagg	gggggcccgg	taccaaatcc	gccctatagt	2760
gagtcgtatt	acaattcact	ggcgtcggtt	ttacaacgtc	gtgactggga	aaacctgggc	2820
gttaccacac	ttaatcgctt	tgcagcacat	ccccctttcg	ccagctggcg	taatagcgaa	2880
gaggcccgca	cagatcgccc	ttccaacag	ttgcgcagcc	tgaatggcga	atggcaaatt	2940
gtaagcggtta	atattttgtt	aaaattcgcg	ttaaattttt	gttaaatcag	ctcatttttt	3000
aaccaatagg	ccgaaatcgg	caaaatccct	tataaatcaa	aagaatagac	cgagataggg	3060
ttgagtgttg	ttccagtttg	gaacaagagt	ccactattaa	agaacgtgga	ctccaacgtc	3120
aaagggcgaa	aaacggtcta	tcaggcgcat	ggccactac	gtgaaccatc	accctaatac	3180
agtttttttg	ggtcgaggtg	ccgtaaagca	ctaaatcgga	accctaaggg	gagccccgga	3240
tttagagctt	gacggggaaa	gccggcgaac	gtggcgagaa	aggaagggaa	gctgtctctt	3300

&lt;210&gt; 69

&lt;211&gt; 1797

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 69

ggtcgacggt	atcgataagc	ttgatatcga	attcctgcaa	cagttcttgg	aaaccactc	60
gagagggcc	cgctccatt	caccaggcca	cgcacacaa	gaggcaacac	caggagccaa	120
catgagctcg	gggactgaac	tgtgtgggccc	cggagcagcg	ctgctgggtgc	tgttgggggt	180
ggcagccagt	ctgtgtgtgc	ctgtgtcacg	ccaggtgca	aagaggtcag	agaaaatcta	240
ccagcagaga	agtctgcgtg	aggaccaaca	gagctttacg	gggtcccggga	cctactcctt	300
ggtcgggcag	gcatggccag	gacccctggc	ggacatggca	cccacaaggga	aggacaagct	360
gttgcaattc	tacccagcc	tggaggatcc	agcatcttcc	aggtaccaga	acttcagcaa	420
aggaagcaga	cacgggtcgg	aggaagccta	catagacccc	attgccatgg	agtattacaa	480
ctggggggcg	ttctcgaagc	ccccagaaga	tgatgatgcc	aattccctacg	agaatgtgct	540

40

catttgcaag	cagaaaacca	cagagacagg	tgcccagcag	gagggcatag	gtggcctctg	600
cagaggggac	ctcagcctgt	cactggccct	gaagactggc	cccacttctg	gtctctgtcc	660
ctctgcctcc	ccggaagaag	atgaaggaat	ctgaggatta	tcagaacttc	agcattccat	720
ccattcagtg	gcgcgagtc	aggaaggta	tggggcaact	ccagagaaga	aagcatcccc	780
tggcccggtg	ggaagcccag	acgaggagga	cggggaaccg	gattacgtga	atggggaggt	840
ggcagccaca	gaagcctagg	gcagaccaag	aagaaaggag	ccaaggcaaa	gagggaccac	900
tgtgctcatg	gacccatcgc	tgccctccaa	ggaccatttc	ccagagctac	tcaactttta	960
agcccctgcc	atgggttgctc	ctggaaggag	aaccagccac	cctgaggacc	acctggccat	1020
gcgtgcacag	cctgggaaaa	gacagttact	cacgggagct	gcaggccccc	tcaccaagcc	1080
ctctcccgc	ccaggctttg	tggggcaggc	acctgggtacc	aagggtaacc	cggctcctgg	1140
tatggacgga	tgccgaggat	ttaggataag	ctgtcaccca	gtccccataa	caaaaccact	1200
gtccaacact	ggtatctgtg	ttcttttgtg	ctatgaattt	ggattcctaa	ttgctattgt	1260
tggttgtcgg	ggtttttaaat	gattgataag	cttgtagagt	taacttatag	agggggagcc	1320
atatttaaca	ttctggattt	cagagtagag	atttctgtgt	tgtctcctag	aaagcattac	1380
atgtagttta	tttcagcatc	cttggtgggt	ggggccctgg	ctctcttccc	ctttgggtggg	1440
acctcccctt	tctttgggct	tcagttcact	caggaagaaa	tgaggctgtc	gccatcttta	1500
tgtgcttcca	gtggaaatgt	cacttgctac	agacaatagt	gcatgagagt	ctagagaagt	1560
agtgaccaga	acagggcaga	gtagggtccc	tccatggccc	tgaatcctcc	tctgctccag	1620
ggctggcctc	tgcagagctg	attaaacagt	gttgtagactg	tctcatggga	agagctgggg	1680
cccagaggga	ccttgagtcg	gaaatgttgc	cagaaaaagt	atctcctcca	acaaaaacat	1740
ctcaataaaa	ccatttttagt	tgaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaa	1797

&lt;210&gt; 70

&lt;211&gt; 1373

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 70

ggcagcaggg	ctgacggcgc	ttttgtctcc	ggtgagtttt	gtggcgggaa	gcttctgcgc	60
tgggtgcttag	taaccgactt	tcctccggac	tcctgcacga	cctgctccta	cagccggcga	120
tccactcccg	gctgttcccc	cggagggtcca	gaggcccttc	agaaggagaa	ggcagctctg	180
tttctctgca	gaggagtagg	gtcctttcag	ccatgaagca	tgtgttgaac	ctctacctgt	240
taggtgtggt	actgacccta	ctctccatct	tcgttagagt	gatggagtcc	ctagagggct	300
tactagaggg	cccatacgct	gggacctcct	ggaccaccag	aagccaacta	gccaacacag	360
agcccaccaa	gggccttcca	gaccatccat	ccagaagcat	gtgataagac	ctccttccat	420
actggccata	ttttggaaca	ctgacctaga	catgtccaga	tgggagtccc	attcctagca	480
gacaagctga	gcaccgttgt	aaccagagaa	ctattactag	gccttgaaaa	acctgtctaa	540
ctggatgctc	attgcctggg	caaggcctgt	ttaggccggt	tcgggtggct	catgcctgta	600
atcctagcac	tttgggaggc	tgatgtgggt	ggatcacctg	aggtcaggag	ttcagaccag	660
cctcgccaac	atggcgaaac	cccactctcta	ctaaaaatac	aaaagttagc	tgggtgtggt	720
ggcagagggc	tgtaatccca	gctccttggg	aggctgaggg	gggagaattg	cttgaaccgg	780
gggacggagg	ttgcagttag	ccgagatcgc	actgctgtac	ccagcctggg	ccacagtgca	840
agactccatc	tcaaaaaaaa	aagaaaagaa	aaagcctgtt	taatgcacag	gtgtgagtgg	900
attgcttatg	gctatgagat	aggttgatct	cgcccttacc	ccgggggtctg	gtgtatgctg	960
tgttttcctc	agcagtatgg	ctctgacatc	tcttagatgt	cccaacttca	gctgttggga	1020
gatggtgata	ttttcaaccc	tacttccata	acatctgtct	gggggttcctt	tagtcttgaa	1080
tgtcttatgc	tcaattattt	ggtgttgagc	ctctcttcca	caagagctcc	tccatgtttg	1140
gatagcagtt	gaagagtgtg	tgggtgggct	gttgggatga	gatggagtgt	tcagtgcoca	1200
tttctcattt	tacattttta	agtcgttcc	ccaacatagt	gtgtattggg	ctgaaggggg	1260
tgggtgggatg	ccaagcctg	ctcaagttat	ggacattgtg	gccaccatgt	ggcttaaagt	1320
attttttcta	actaataaag	tgggatatat	atttaaaaaa	aaaaaaaaa	aaa	1373

&lt;210&gt; 71

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 71

ggcagcagga	tttggagggg	acaaacatcc	aaaccattta	agtcacagca	ctttactccg	60
cagtgtgaat	aacacaggca	ttctcctaca	taatcacagt	acagttatca	tactctggaa	120

41

attgaatata	atctaata	ctttccata	ccagattttc	ttagattttc	caatgatatt	180
tcttactgtc	ctccctttag	ccttcctctt	tctccattca	ggattctacc	attacatttc	240
atthttcatgt	ctcttcagtc	tctcttttagc	tttggttttc	tttcttgatg	ttgccacttt	300
taggaggcca	ggccagttgt	tttgtgaaag	atctgttctc	tttgatatgt	ttcatttttg	360
atthgtttca	ttgtttttgc	atgaatggat	tcaggctaaa	cattttttggg	caggactgtt	420
tattgtatta	cctagtgatg	tgttcttttc	agtccatcat	ctggaggcac	ctgatggcag	480
ttttcccaat	attgcgaaat	taagtttgat	tatttttgta	aggtagtgtc	caccagatct	540
ctccatttta	aagacatcct	tttctcta	tactcagtg	actgtagagt	gatgctttga	600
aactgaataa	ctaactctcc	ctaactcagt	gatttagcac	ccgttgattt	tttttttttg	660
cctgaatcaa	atattattat	agtagtttta	aatgggtgatt	ttccattttc	attcttttgt	720
tagctgccat	tcttctataa	ttttgtcttt	atattttact	gggtgttaag	attgctattc	780
cagctttcct	ttgtctttta	caccttttcc	cattctttta	tttttttcca	tccctttttg	840
tcctgttttc	caatagatgg	atagaatttt	ctttctctgg	tttaaagggt	atacatttgt	900
gtgtgtgtgt	gtatttctaa	ccattttgcc	ttaaaacata	gagatgggta	ttcctgttga	960
ttaaaaaaa	ctcagtaatg	ttactatctt	ctctttaata	agataggtac	tttatttcat	1020
tctgtgttct	tgggtgaggt	ctcccctcac	ccagtcaagt	tgatgttaat	ctagaatttt	1080
tagtttttta	aattatcgat	atactttctg	tcttttctct	tttttttcac	tctctctgta	1140
tttgtgtctt	ccccctttac	tctctttccc	ttcattcctt	ctttctcact	ttcttctctt	1200
atthtttca	cttgggtaga	ttatctttta	gaaaacagca	agatattata	taatttactt	1260
tatattctct	ttccaaatga	ttaaagtaat	aattaaaaat	tttgatatg	tgtgtatgca	1320
aggataggaa	tcctcttgta	agtggaaaga	ctctaccaca	tgcatgagtc	attagtgtgt	1380
taaacactgg	gaagtggctt	taggtccagc	tgggtgctct	gaagaaggta	ggtttcttca	1440
gttctttatg	ttactgtct	ccttacctta	aaaaaggagt	gaagaatact	gactgcagag	1500
gttttgtgag	gattccggta	acacagaagc	atagaactgg	aaaagaatat	taatatttgc	1560
caaaaaaaaa	aaaaaaaaa					1579

&lt;210&gt; 72

&lt;211&gt; 1028

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 72

gcacgacaat	tgaactgaac	cctaaaaatg	ctacttcaat	tcaccttatg	ggattttggg	60
gctatacatt	tcccgaatg	ccttggtatc	aaagaagaat	tgctaaaatg	ctgtttgcaa	120
ctgcctccta	gttccaccta	tgagaaggta	gtatgatgtc	ctttgttaag	ttagtacgga	180
tttcttgaac	cacagcgccc	attctaccat	gtgttccaca	cattgtggag	ctctggattc	240
agtgaagggg	acttgaggca	atttccttaa	cgatccaatt	caactgtgtt	atcacaaggc	300
ttaacactta	ttatccttga	ctggtgagtg	gttttctttt	tccccgttag	gtgagtggct	360
ggtaattctg	gaatactgtc	atctaaaatg	gctcgtggct	aaaatctacc	ttcattttct	420
gtttgaaatc	taaactatat	tgaagtcata	aaatagaaca	agaaatacag	catctgttac	480
ccagcatggt	ttactgtgat	tacacacaat	aacagaaaag	taaagcagat	gcttaagtgt	540
ataaaagaag	aacactcatt	ataacttcta	ttttaaaaag	catatgaaag	gttcatattc	600
tctcatattt	tcaaggcctt	ttgcttttct	tgtaaaaaat	aagatttgag	aggaatttct	660
ggttaaactt	tgggtttact	catcacaagc	ttttcagagt	aagaaaacag	gcaatcgaaa	720
aagctgtact	tgtattattt	acattataac	aaggagcctt	tttttctttc	tgggaagcta	780
tagtgtagaa	attgatgtaa	aaaatactta	gttgatttct	ttacacacag	ttgagaaata	840
ttattaaaa	aatgcaccaa	tattttataa	tggattattt	aaaataatgc	ccatttgctg	900
gacacgggtg	ctcatgcctg	taatgccagc	atthtgggaag	gccaagggtg	gtggatcagt	960
tgagcctggg	agtttgagac	cagcctgggc	aacgtggcaa	aacctctgca	aaaaaaaaa	1020
aaaaaaaaa						1028

&lt;210&gt; 73

&lt;211&gt; 3674

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 73

ggcagcagct	caaaagaaat	agggtgattt	ttaaaggatt	aataaaaattc	tgaaatgtta	60
agtagaagat	tacattgtct	agtcttgat	ttcctccttc	tggtgctctc	tttcattcac	120
acactctcag	tttctcatat	ttgtagctca	tttatttggg	tatttcctaa	gaatattgaa	180

agtgaagcaa	ctatgtgact	gtatttettca	ggtaaacact	gactgcgctt	gttggatttt	240
ccctattttt	gtgacttcaa	gaataatatg	ccctgctgaa	tacatgccat	ttcacattct	300
gaaactgggt	agagtgggtg	gggtgtctgc	caacaattgc	tagtgggtgtg	aattcattca	360
tatttgccag	tattgtctac	ttcaaagaaa	ctccttcac	aagcagtcga	gagctaggcc	420
agatcaatgc	tacaatcatg	aagttctcat	tgcattgcaat	tgtgtaggat	tgacaaggaa	480
ctcagataaa	aatttccagg	gtgcacttcc	agaaccagct	tcaacatatg	tctacattgc	540
ccccaggtta	ataaagtgcc	aaccttttac	tctctcatac	agccagaaat	gttagaatac	600
caaaatcttg	gtgcattatt	ttttcataaa	cgctaaaaaca	tttgaagaaa	caattttaatt	660
attttaaatt	caagtatttt	attcacatta	tttgcaatat	ccaaatgttt	aaaaattccc	720
agataaattaa	ctagctatta	cagatctcac	ctagagggtt	gatgttatga	agactccagt	780
ggactgtact	cacaaattga	ctggacaccc	tatgaaagtg	ggtagacctc	tcagcggaaa	840
ataagaaggg	cttttaccta	cagggcagga	caggggtccca	tgagagcagt	tctgtggaga	900
tataaaaaaga	atggaagaag	gaatgcctta	tagtgatatt	gtgacattat	atctatatat	960
ctacatatat	ctatctatct	atatctacat	ctatataatc	ttacatttaa	aattgtattc	1020
ctacacatat	tagaaaactct	tctaataaat	gaagtaaaaa	aattaaaaag	aatacaataa	1080
ttccagcccc	aaatgagaaa	tcaaacatat	taaaattgtt	caagaaaatt	tctttgaaca	1140
cttctgaaag	tttttggaag	cttagaaaag	agggaaaaaa	atccagtgtt	actagtaatt	1200
tccatggtaa	tacagataaa	atacattctt	ttaattctgg	gaaattagaa	aaagtggggg	1260
gatctttcca	ggaaaaacat	gtgtaacatc	tgccttatcac	tccagctccc	tctctctctt	1320
cctctccacc	ttcccttgag	taaattgtctg	ggaaagcatg	aagcttgatg	caagaacctt	1380
gttgtactgg	cgttttctct	ccctgtgaaa	acgtaactac	tgttgggagt	gaattgagga	1440
tgtagaaagg	tgggtggaacc	aaattgtggt	caattggaat	aggagaatat	ggttctcact	1500
cttgagaaaa	aaacctaaga	ttagcccagg	tagttgcctg	taacttcagt	ttttctgcct	1560
gggtttgata	tagtttaggg	ttggggttag	attaagatct	aaattacatc	aggacaaaga	1620
gacagactat	taactccaca	gttaattaag	gacgtatggt	ccatgtttat	ttgttaaagc	1680
agtgtgaata	gccttcaagc	atgtgaataa	tcttccatct	tccccgccac	acatacacac	1740
acacactttt	tgtttctttc	aggtagacac	cttttaaaat	gcagaactaa	ctgaggcatt	1800
tcagtaactt	tgtcttcaaa	tcaataaagt	caaatgtatg	gaaacatttt	gtgccctact	1860
ctccataccc	cgtgtactca	aattctctac	tgtatgaatt	atgctttaag	tagaattcag	1920
tgccaaggag	aacttggtga	aataaattat	tttaattttt	tttttatcct	ttacaaagcc	1980
atggatttta	tttggttgat	gtgtgctctg	tacacaagcc	atttcaatag	gatggagctg	2040
ttaattattt	tccaaagagt	aatagacatg	caaaagtttc	aataaaaaact	gggccattaa	2100
caagtaaatt	aataaaactaa	taagcattcc	cttctagggt	tttgccaaac	tgccctatcca	2160
ataacaaatt	tgagaatcgt	tgtaaaagct	agttatatatt	cagagaaatg	attttcatta	2220
ttgaaaactgt	tctccctagc	aggccatttt	ccctttttcc	tgggagttta	gcaagtttag	2280
gagagaatag	tcatgaaaag	aaagggaaga	aaggggagaa	gggaagaggt	taaaaagtaa	2340
gtgctcagac	ctatgaacgt	aatccctttg	ctacaaatat	ttaagagcag	ctcagcttgg	2400
ttgaaactga	gttttgtcat	cttccatatt	tgcaggaagg	tattttctga	cttgcaatgc	2460
agctagatgt	aaaattttat	tttatcatcc	tagaaagcct	tgactagaaa	aatgaataaa	2520
tattgagggg	ttcctgtcca	tatctggctt	gcattgtgcca	gaaagcagag	aatagaaaaa	2580
gtaatctcca	acatccaagc	atcgaaacct	aaggggtagg	caattctatg	taggttttgg	2640
acatgaagtt	tgggtgcatct	tgggttatgc	tggctcaact	gctattaaac	ctctctggct	2700
tatagtctct	tcattctatt	agacaagcac	gtatcgaaca	cttgcttcgc	acaaggctct	2760
ttagttaaca	atttagcagc	tactgtttgt	gttaaacaca	cttttcacca	aataggttct	2820
gaggcaaacg	agagcaatga	ctattttaag	aaaggctttc	ccagcatcac	ttacacatcc	2880
caaaactaaa	aagatcaact	cttccaactg	agaaaagact	cctggctttg	aatggaaact	2940
tacagcagag	agtcacaggc	cacggcaaca	acaacgacaa	caacaaacat	ttggaatatt	3000
attctcaact	cacgttttaa	taatacatct	tattattttt	ctagtagaga	aactacaaat	3060
cagcctcttc	aacattttata	tacagttaa	taagcctctt	gcaagttact	tgttctctca	3120
cctgaggtat	ttttttctct	cccaccttgc	ccctgttctt	cccttctctt	tctccctttg	3180
caagaggaaa	tatttaacat	atttgggtcc	aacttcaata	atgtaataat	taatacatta	3240
aaagcattta	acttcctttc	tagaaaaatg	cacaggctaa	ggcatagaca	aaacaaagag	3300
aaatgctgag	aaatttgcca	ctggagacaa	gcaatctgaa	taaatatattg	ccaaaagtct	3360
tttttatgtc	atatagtgtc	aggatttgaa	ggagctattt	ttttttaatg	ttgcaactag	3420
caactcatct	tcggaagaca	cagccaggag	aatgaaagtag	aagtgaagg	tttataaatc	3480
catttgtaag	catttatccc	atataattta	aattcaagaa	aaattgtgtt	tatctttaga	3540
attttgattt	caatacttta	tgtactatgt	gactcatgct	tctggataaa	taaagcacca	3600
aatatgtatc	tgttaaccaca	atcacacata	ttatatttaa	tatatatcta	tataacaaaa	3660
aaaaaaaaaa	aaaa					3674

<210> 74  
<211> 2797  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (853)..(853)  
<223> n equals a,t,g, or c

<400> 74  
ggcacgagag agcagacaga attatatgta gaggacacag gagatattta cattgtggat 60  
ggagatggag gattgaataa cagattgatc aaactgtccc aagatttcat gatcctttgg 120  
ctgcatggag aaaatgggac agggcctgct aagttcaaca tacctcacag tgttacactt 180  
gattcagctg gtcgggtgtg ggttgctgac cgaggaaata aaagaatcca agtatttgat 240  
aaagacactg gggagtgggt aggagcatgg aataattggt tcacagaaga ggaccttctt 300  
cagtcagttt actcctgatg ggaagtactt gattgtggcc cagctgaatc ttagcaggct 360  
ctcagtcgta gcagcacccc cagtgggaag cattggggag tgttctgtga tcagcacaat 420  
ccaactagca gatcaagttt tgccacatct cctagaagtc gacagaaaag actggagcag 480  
tctatgtagc agaaattgga gcaaaacaag tacaaaaata tgtccctttg aatagctatg 540  
ttccttcatt tggttcataa tgtttctttc ccgggaatat ttcaagtggc agttcagatt 600  
ctcaattcac taagtgttta aaaatgatgt tcaagcaca gaatttattt ttctagtata 660  
aaagatctag tatcagaaag atttgttttt gtatcattaa gaatcttata ttttgttgcc 720  
ctcttgggac ttagttttat ttgtaagtgc ataaggatat tttaatgaaa ggaaagtaac 780  
taaaaaatgg ggttgggaag agggactaag gtggtaacct cattatttgc cctggtagac 840  
tgattctccc tgngtaaaaa aaatgggaat aaaaatgagc ttgcatgata atttattaaa 900  
tttcatgtga agaactccag acctccagat tgtgcaacta acataaagtg agctgcttga 960  
gagattgtta ataagatgaa ctattgatta atttgagtag ccacagagtg ctgtgtcttg 1020  
acgacttaaa aatgaaaaag catgattgcc ttttgagtag cttgcagctc agtggggaga 1080  
caagcaggca aacagtcaca acacagcaaa agcgaccttg gagcatagtg ggacttttgg 1140  
agtaggagtg ctgcatttga ctgagggaat catggatact tcgcaggaga agtgaatttg 1200  
agctcagact tgaaaactga ggaggagctt accaaggagc aaggaggaga aaacaataat 1260  
ttccaagtaa agaaggtata aaaagttaga agtgtactgt aaactttgat aggcttttag 1320  
gcctttttta aagcccaact tggcttctgt ccattaccta taagatattt aatgtcagtc 1380  
agccttttaa tgtaggaata aaatggctgg cacttaagca ctttagtaaa agaggttttt 1440  
acaaataact aaggattgta gagcttcctt ctcttttttt ttctttttct ttcttttgtt 1500  
ttacatgaac tcaacttatt cctaactatt gtctacctca aagaaatttc aagattattt 1560  
agataacatg gatattgtgc aaatcctttg agctgttaag atgataattt cctgctttcc 1620  
tcctacatct tctcctccca ctccctcctt tgggtgtgaat attggcttcc caattaagac 1680  
cttttttttt tccagtttgt tttagcttat tataggtttt ggaggaaact tgccattttg 1740  
taatctttca aatcattctt cacccttctt cacatcagct tcctgctttt ccagtggtt 1800  
tactgtaaat tgtgtagcat atgacaaatc ttgagctgac tttcctcttc acctgttatg 1860  
gctggagtat tttccagacc tgaagggact cacacttggt ttgatacttg gatcacatct 1920  
ccgtgagggt aggaaggtaa atctaccaac aggaagccct gtactctgta ttccaaggcc 1980  
attggtaaat gtgttggtgc cactgatcgg actgtatgac cttaaacaag tcaccttagt 2040  
tttcagtga atgggaatat cattgtctcc tctttcatga atgctgtgag aatcagatgt 2100  
gcaacaggta catacttgcc ctttggaat ctaataacct tgggatacca ttaagaggca 2160  
ttttaattaa acaaaagggc ccttctaatt gtgctattta tttgacaata actatcagat 2220  
ttgccttaat tttgtgttta tagcatttat caaaacgtat cctcatagac tttatgcaga 2280  
ttaatatggt caattgattt ggataaaaga aagtaatttc agggtttgtt ttttaagccag 2340  
gacaagaagt gcaaatgcct ctttgaagca atttaggcta aactgatttt gaaatttcaa 2400  
aatgttttat tttactttgt tttattaagc caggacaaga agtgcaaatg cctctttgaa 2460  
gcaattcagg ctaggtaaac cgattttgcc atttcaaaac gttttatttt actttgwttt 2520  
rtrtcagagt yttawaarvc ctgctgcaaa tatttctgaa tgtctttgta aaagtgtttg 2580  
ttagtgtacc tgtgattata tcttctcact ttttctcttt ggatttaattg gttaaatgaa 2640  
tgagaaatgt gttatgtttt ttactaaaaa gtataaatta aaattttgga aagaaaaggc 2700  
aatattatct ggctcccaa ttaaagtttg attttattgt cacaaaaaaa aaaaaaaaaa 2760  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 2797

<210> 75

&lt;211&gt; 2703

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

```

ggcacgagat ttcctacagg tgaacgcca tcattaggat tcactgtaac gttagtgtta 60
ttaaactcac tagcattttt attaatggcc gttatctaca ctaagctata ctgcaacttg 120
gaaaaagagg acctctcaga aaactcacia tctagcatga ttaagcatgt cgcttggtta 180
atcttcacca attgcatctt tttctgccct gtggcggttt tttcatttgc accattgata 240
actgcaatct ctatcagccc cgaataatg aagctgttta ctctgatatt tttccattg 300
cctgcttgcc tgaatccagt cctgtatggt ttcttcaacc caaagtttaa agaagactgg 360
aagttactga agcgacgtgt taccaagaaa agtggatcag tttcagtttc catcagtagc 420
caagggtggt gtctggaaca ggatttctac tacgactgtg gcatgtactc acatttgcag 480
ggcaacctga ctggtttgca ctgctgcgaa tcgtttcttt taacaaagcc agtatcatgc 540
aaacacttga taaaatcaca cagctgtcct gcattggcag tggcttcttg ccaaagacct 600
gagggctact ggtccgactg tggcacacag tcggccactc ctgattatgc agatgaagaa 660
gattcctttg tctcagacag ttctgaccag gtgcaggcct gtggacgagc ctgcttctac 720
cagagtagag gattcccttt ggtgcgctat gcttacaatc taccaagagt taaagactga 780
actactgtgt gtgtaaccgt tcccccgctc aacaaaaatc agtgtttata gagtgaacc 840
tattctcatt tttcatctgg gaagcacttc tgtaatcact gcctgggtgc acttagaaga 900
aggagaggtg gcagtttatt tctcaaacca gtcattttta aagaacagggt gcctaaatta 960
taaattggtg aaaaatgcaa tgtccaagca atgtatgata tgtttgaaac aaatatatga 1020
cttgaaaagg atcttaggtg tagtagagca atataatgtt agttttttct gatccataag 1080
aagcaaatat atacctatct gtgtattaag cacaagataa agaacagctg ttaatatatt 1140
ttaaaaatct atttttaaat gtgattttct ataactgaag aaaatatctt gctaatttta 1200
cctaattggt catccttaat ctacaggaca ctactgcag ggccaaaaaa gggactgtcc 1260
cagctagaac tgtgagagta tacataggca ttactttatt atgttttcac ttgccatcct 1320
tgacataaga gaactataaa ttttgtttaa gcaattttta aatctaaaac ctgaagatgt 1380
ttttaaaaca atattaacag ctgttaggtt aaaaaaatag ctggacattt gttttcagtc 1440
attatacatt gctttggtcc aatcagtaat tttttcttaa gtgttttggtg attacactac 1500
tagaaaaaaa gtaaaaggct aattgctgtg tgggtttagt cgatttggct aaactactaa 1560
ctaattgtgg ggtttaatag tatctgaggg atttgggtggc ttcatgtaat gttctcatta 1620
atgaatactt cctaatatcg ttggctctac taatattttc caatttgctg ggatgtcacc 1680
tagcaatagc ttggattata tagaaagtaa actgtgggtc atacttgcac ttaattagac 1740
gaaacgggga gtaattatga cacgaagtac ttatgtttat ttcttagtga gctggattat 1800
cttgaacctg tgctattaaa tggaaatttc catacatctt cccatacta ttttttataa 1860
aagagcctat tcaatagctc agagggtgaa ctctgggttaa acaagataat atgttattaa 1920
taaaaataga agaagaaaga ataaagctta gtctgtgtc tttaaaaatt aaaaatttta 1980
cttgattccc atctatgggc tttagacctt ttactgggtg gagtcttaaa gttataattg 2040
ttcaatatgt tttttgaaca gtgtgctaaa tcaatagcaa acccactgcc atattagtta 2100
ttctgaatat actaaaaaaa tccagctaga ttgcagttta ataattaaac tgtacatact 2160
gtgcataata tgaattttta tcttatgtaa attattttta gaacacaagt tgggaaatgt 2220
ggcttctgtt catttcgttt aattaaagct acctcctaaa ctatagtggc tgccagtagc 2280
agactgttaa attgtggttt atatactttt tgcattgtaa atagtctttg ttgtacattg 2340
tcagtgtaat aaaaacagaa tctttgtata tcaaatcat gtagtttgta taaaatgtgg 2400
gaaggattta tttacagtgt gttgtaattt tgtaaggcca actattttaca agttttaaaa 2460
attgctatca tgtatattta cacatctgat aaatattaaa tcataacttg gtaagaaact 2520
cctaattaaa aggttttttc caaaattcag gttattgaaa atttttcatt ttattcattt 2580
aaaaactaga ataacagata tataaaagtg ttaattcttg tgctatatgg tatgaaatac 2640
aatattgtac tcagtgtttt gaattattaa agtttctaga aagcaaaaaa aaaaaaaaaa 2700
aaa 2703

```

&lt;210&gt; 76

&lt;211&gt; 742

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (707)..(707)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (724)..(724)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (726)..(726)

<223> n equals a,t,g, or c

<400> 76

gcgctcgaga	atagtgggtc	ccccgggctg	caggattcgg	cacgagctca	cttcaatyct	60
tctttgagaa	gtttttcctt	tctccgcaac	cagatgtaca	tatttgaact	ctctttgtac	120
ttggagggca	cttctttcgt	ggtagttcct	ttatttttat	taatctctgt	atccttagat	180
agtcctccaa	caaccaaagg	ttgggactct	gtcttacata	tctgggtgcc	cctcatagt	240
cagtaataag	taagttgatt	atatacgagc	tatgtaacct	atatttttta	atggttggat	300
atcactgagt	tttttttttt	aagaattttt	ttattgaggt	aaacttcaca	taacataaaa	360
ttaactattt	taaagtgaga	agttcagtcg	cacttagtat	tgtaacaat	gttgcataac	420
caccaccttt	atttaaagtt	ccaaaaaaaa	tgttctcctc	taaaaggaaa	cccatccca	480
ttaagcagat	actctccatt	ccttcccttc	tccagcccc	agcaaccacc	aatctgcttt	540
ctgtctctat	ggatttatct	attcttgcta	ttttatataa	atcgaattgt	atgagacctt	600
ttgtgtctgg	cttctttcac	ttagtacaag	tttttgagat	ttattttacat	agtagcatgt	660
atcaacactt	catttttatg	gccaaataaa	attgtattat	gtgtttntag	cacaaaaaaa	720
aaananaaaa	atgaccctcg	ag				742

<210> 77

<211> 1825

<212> DNA

<213> Homo sapiens

<400> 77

ggcacgagca	tgtcacatgt	ataacctatgt	aacacacctg	cacattctgc	acatgtatcc	60
cagaacttaa	attataataa	taaaaaaaga	ataattgggt	gatggcacat	ccaggtttgc	120
caaaagacagt	cccagtttat	gctgttgtcc	tggcattatt	aataatgaca	ctgcctttaa	180
ctctcacaat	taatttggat	gataacttat	atggtaactc	tgctaaataa	aaaaaataaa	240
aattaccata	gtaacaggaa	cctacttgaa	atgatgcctc	tgtttctatt	ctggcttgaa	300
ttctgcattc	tttgaggatt	tgtagcctca	tgacagaatc	ctatctacag	gtgatgtatt	360
tcatatgatt	tttggtctatt	tttttaacaa	tctcaagccc	aataatagcc	agtgtataaa	420
ggaatgtagt	tactttctcc	ccactttctg	gcaagttaag	tttagccacc	tgattacaag	480
aaggggacatt	cagaggttagg	atggcacaaa	gacacagggg	ccactggaga	tcactggaag	540
cagctgcagc	agggttaaga	gaaggggagtc	ccagcgagtc	ttcagtcacc	acacactaac	600
atcatcagtg	aaaagttcct	gggcctgaag	atccagctat	gttggttcta	gttgactatt	660
ttaagtgaac	gaacttggcc	caagcattga	ccattttggg	tcctcaataa	gcctgattca	720
accaggggtca	cctttgaatc	tgtcctccac	ctttccaata	aacctatttt	atgcatcatt	780
cagtgaagtta	tttatattat	tacttttttg	ctgagaaaca	tgactagatt	taggaaaaat	840
gtagaatttt	actttttttt	caatattttc	tgggttttcc	agagttttca	cgtgtttcac	900
accttccctt	gcttcccacc	attccccctt	ctatttggaa	ctagagagac	atgagtttga	960
attctagctg	tgtaacctga	gtcagttatt	taacctcttt	ttgtttctgt	ttctttgtct	1020
gtaaaatgca	aaaactacaa	ttaacttttag	tccctgctgt	acaccaaagt	ttatcttgaa	1080
atattatata	tattatatgt	aattactact	gaaatgctct	aagatgccta	tgtgtgaatg	1140
gcattgttgt	aaagattaaa	taataataagg	gaagtgtctg	cttcagtgtc	tggcatataa	1200
taaaaagctat	tattttttacg	attattttcc	atccttataga	agaattatcg	ttcttccctt	1260
ccaaagctaa	ttaattggaca	tgtgtttatc	agacagaacg	taagagctgc	caaataaata	1320
gggaatagggt	gctttcggga	gtctagggaa	ataaaaggtca	gggaattgtt	cataaaattt	1380
agtaccataa	aatagcctat	aagtagattc	cctagtttat	tctatgcagg	aaaataaagt	1440
tctacggagc	acagattcca	aaactaattg	gtcataaata	tcacctgaaa	gtttagaaaa	1500
tgtagcatca	tggacctctt	ttcatagggt	ctaaatctta	atatctgtgg	gatggtgcag	1560
gaatctagct	ttgctaagtg	ccctcagatg	actcttgctg	ttctaggcta	aaatacatgt	1620

46

ggtttggcctt	caatggacat	gttcctgaag	aatgtttgga	tgtcacacat	tcatatttag	1680
tatgagagat	gaggtcctcc	tctcatcatt	ttcttaggtt	ctcttctctc	cactccttac	1740
cctcccatca	cttacaataa	atctttttaga	aaattagcta	tacatttggt	tcattataaa	1800
aaagaaagaa	gataaaaaaa	aaaaa				1825

&lt;210&gt; 78

&lt;211&gt; 1674

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 78

ggccacgaga	gtatctgcgg	cagctgcagg	tcctggattt	atctctcgat	tcgctgtcgg	60
aggagaatga	gacctgggtg	gagtttgcta	ttggaggcct	gtgcaacctg	tgcccagaca	120
gggccaacaa	ggagcacatc	ctgcacgcag	gaggtgtccc	actcatcatc	aactgcctat	180
ccagcccaaa	tgaggagacg	gtgctgtctg	ccatcaccac	gctcatgcac	ctgagcccg	240
cgggcgcgag	ctttctccca	gagctgaccg	ccacgcccgt	ggtgcagtgc	atgcttcgct	300
tctccctctc	ggccagcgcc	aggttccgga	acctggcaca	gatcttcctg	gaggacttct	360
gtcccccccg	ccaagtggcc	gaggcccgcg	gccggcaggc	gcaattttgc	cctgggtatc	420
ccactgccga	ggagcgtggc	cccacggcag	cgctgatcca	tggagactgc	gagaccgtgg	480
caccctact	gctggggacc	acagtccctga	tgtggacgca	gggaacgggg	agcacatact	540
gccccattgg	tgccctttca	gccatctgaa	aggcgggttc	tttcagcagg	acaggcattt	600
acactgatga	aacgccactg	ggagtgagga	agccagactc	cagagacacg	gagaagatca	660
aactggagct	gcgttcatag	gctggcactc	tcaatcctac	atcagggtgc	accaccacca	720
gactcaggcc	ctggtgtaag	aagcggccaa	gtgcctggac	ccagaggctt	tgaggagacg	780
tgttctcagg	agctgggcct	gaggcttagg	agagctgcct	tcgctgcagg	aaatcaggga	840
ttatccctta	acagaagtgt	ctggagtagt	tttcagggtat	aggaatgaga	tgccctcgtg	900
tgaaggatgc	tcaccctggg	aagatgtggg	gccccctcca	gggctctgga	ggatggatgc	960
ctccccccag	ggctctccaa	gctgggcatt	tgggcctggg	ggatgccaac	ctggataacc	1020
tgtggccag	catgtactgt	ccaccagccc	ttgctgttag	gcaccatgac	tccaaagatg	1080
aagatgtggg	ccctgccctt	gagtgcacgc	cccagggact	taatgtggcc	atcgggcac	1140
aagcacaagg	ccatgcagg	gatgatacgt	cggaaatagag	gcaccagccc	tggttaactgc	1200
atcttctccc	cttgccaccc	catggccccc	gctgaaagct	tcggccctcc	tctgctgtca	1260
ctcaatgatg	gggagcccta	ccccagaagt	gtatcccacg	agggcatcag	ggacgcagtg	1320
agtgttgctc	aagggagtc	ggaagagacg	gcaacgtaaa	ggatgtggct	ccatgtccat	1380
ggtgccccct	ggccaacata	aggagcgtgg	gatccgatgg	aaagggtggag	ctcagggaaa	1440
atgggggttc	ttgcctctcg	tgtaccccc	caaggctgac	cccttagatg	gcccagggaat	1500
ggcagggtgct	acaaaaatgg	tacccacgtg	ggcatggaaa	tggggcagat	taggggacca	1560
ctggactcag	aggggaggga	agggtcatc	agcaccgcgt	cagggagcct	gtccctttat	1620
gttcccaaat	aaagggtcct	agaagactaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa	1674

&lt;210&gt; 79

&lt;211&gt; 2191

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1327)..(1327)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1334)..(1334)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 79

ccttctctaa	aaaagcaaac	aggcaaaact	tcatgagaat	cttgatcatg	ttaaaatttt	60
atgtccttcg	attttccct	acacacacac	acacacacac	acacacacac	acacacacac	120
tcaacatttc	ctccacccat	atcatcactc	cttagcatct	ttattccatc	aaaactttct	180
accccttgac	attctctgtg	cagttttgaa	aattaccctc	tcagcattct	ctgttcaccc	240



47

ccacacctag	accctgacct	ctagtcaatt	ctactaccca	ggggtgtcca	cggttccage	300
ctcctccatg	aagcccagtt	ctatgggctc	actcctctgg	gtaagtggga	gccccagct	360
atcatcctca	ttgtatagaa	aaccaactct	gtgatgctac	ctgccccctc	tccccctctc	420
tcttgaaaga	gggctgggg	agagggtggga	ggactgggta	tggccctggc	cggtctctgta	480
ttcgctactgg	gaggagtatt	ggtactctgt	gtagaaagaa	atgggggagg	ggaaatgggg	540
tggcctcagc	atctccctaa	gtcccagcct	ttaagtcctc	ctgttgagc	tcgtcgctgc	600
agcttcgaga	ggagttggat	cgatcttctt	gtggaaacgt	cctcttcaat	ggttacctgc	660
cgccaacag	taggcactcc	caatggaatg	gaggggcgcg	gaggtggggc	aaagactaca	720
tttcccataa	ggctgcagct	ctcgggtgcc	tgtgctgtgc	gtcctgagat	acagtgaggaa	780
gtgtagtctc	ctatcagatg	cttgggctga	tgttggaata	ggaagttgga	cacagcattt	840
cccatgaaac	aatgggcca	ctaactcttg	aagctcaaaa	agatgtcctt	ggaaccccat	900
ggggaatttg	ttatcccggg	tttgggtttc	ttttgttagg	gggggctttg	ggaaaaactg	960
gggattcctc	cgtatggaag	gggaaaaaat	attaaatagg	aagttattga	cattaatgcc	1020
catgatagcc	accccactgg	gccatggaag	gtatgcccc	gtgggtattg	gaactaggct	1080
tttctgattg	gtagaaagta	caagtagggg	aaatttcatc	tacagcttta	tttccctaac	1140
tgcagtcagc	acctgtacct	tcatgaaagt	tgccagatat	aaagatctgt	agtagtactt	1200
ttccaactta	gttttatcct	gttttccga	aaaacaatca	tttatttatt	tattttattta	1260
tttaatttta	tgagacaggg	tctggccttg	tcaccagggc	tggagtgcag	tggtgcgac	1320
ttggctncac	tgcnacctct	gcctctcaga	ttcaagccat	ccttccacct	cagctctgcc	1380
actgagtagc	tgagactaca	agcactcgcc	accatgcccc	gctaattaaa	aaaataataa	1440
tcatttttaa	tgcaagcttt	atattataaa	tacaaagtaa	acatgaaaat	aaaacccaaa	1500
catagcagtg	ttattaaact	ctggcctgta	gcagtggctc	acacctgtaa	tcctagcagt	1560
ttggaggcgg	agacaggtgg	attacttgag	acctggagtt	tgagaccagc	ccagggtgaca	1620
cagcaagacc	tcatctctac	taaaaataaa	aaaaaattag	ccagggtgtg	tggtatgcac	1680
ctgtggctcc	agctacttag	gatgctggag	tgcgaggatc	gcttgagccc	aggagggtcaa	1740
ggctgcagtg	aactatgatc	actcattaca	ccccagcctg	ggtgacagag	cgagatgctg	1800
tctcaaaaaca	aaacaaaacg	aaaaacaact	ctggctagat	gctattgctt	gccaagggtg	1860
cagtcttcca	tttattaaaa	gtgaaaatta	gggccaggca	cattggctca	tgctgtgaat	1920
cccagcactt	tgggaggctg	aggtgggtgg	atcacctgag	gtcaggagtt	cgagaccagc	1980
ctggccaaca	tgggtgaaacc	ttatctctgc	caaaaatata	aaagattagc	catgtgtcgt	2040
ggtgggtgct	tgtaatctca	gctacttggg	aggctgaggc	aggagaatca	cttgaaccca	2100
ggaggcagag	gttgcagtg	gccaagattg	tgccattgca	ctccagcctg	tgcaacgagc	2160
gaaactccaa	ctcaaaaaaa	aaaaaaaaaa	a			2191

&lt;210&gt; 80

&lt;211&gt; 1335

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1287)..(1287)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 80

ggatatatcc	agggtgcgg	attttccccc	cttcagggtt	aaatgttctt	gtttttctac	60
ctttccctcg	cagtatacgc	tcaacggcaa	gawagtggaa	gttgccgtca	aacagatcat	120
cgctggaaaa	gccgtggagc	aaggagggtgc	tttctcgaac	cccagagacc	tggtatctgta	180
ccgggacatc	cctgagctgc	agggtctctg	agtcagactg	gctggcgtgt	cactcagccg	240
caccggtgtg	cactgttaact	tttgtgtgct	caagaaatta	tacagaaacc	tacagctggt	300
gtaaaaggat	gctcgcacca	agtgttctgt	aggcttgggg	agggatcggt	tctctgtttt	360
gttaaactctg	gtgggtacct	ggatcttcca	cacgagtggg	attctggcct	tcagagacca	420
ggaggggagt	tctgggcccgc	agtgtggcac	tgtggtgaga	gtgtgtgtct	ttgcacacac	480
agtgcagcgg	gaacgggtggg	gctggctggg	gctgaagaca	gacacactcc	tgagccaagg	540
tcttgtcttc	aacctccccg	tcccgttgtc	ccattttgct	ctgtgaagg	gcaaatccct	600
ttcttccctt	cccatctcag	gctctcctgt	tttccctcag	ggtccagtat	gcctttgagc	660
tttagctggt	agaaagggaac	ccccgtgact	tgacacagct	ttcacagctg	gctgctagga	720
ccggcgggct	gggtgttcac	gtgtgtctgt	gtcatggatg	caatgcaggc	cctggaggac	780
tgtgcgtcac	ccgtcaacca	gagcgtgcct	ccgggccagc	ttccctccaa	ggaatgagtg	840
gatttcatat	aggatctctt	tattgcacag	actgaatggc	tttacatggt	tctaattgtga	900

48

attagggcatg	tgaagcagtg	ggtgtccacc	cgtgtccctc	atgggtgagc	cctccagctg	960
tgagcccagg	cagtgtgggc	accgagttag	gacctcctc	accaggaacc	gcacccctgt	1020
gctgcctcca	cctgagagtt	gctagggggg	tcttgtcgag	atcatgtcat	cagcaccctt	1080
aagtcaagtc	acgggtttcc	atagccaggc	agttgggtatg	tacaattcag	ttcagcgtat	1140
gaacttgtat	ctctaattctg	atgtccattt	ttatatTTTT	tgaaactgag	cacaatgaaa	1200
tcctttcttg	aatcattttc	cttttggatt	ataaaaaatat	gggggaaagt	gctatgatga	1260
attttatgca	ataaatgtat	acatgtntgc	acatgcaccc	atgctgaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaa					1335

&lt;210&gt; 81

&lt;211&gt; 1867

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 81

cccacgcgtc	cgggccacag	cagagacagt	ggagggcagt	ggagaggacc	gcgctgtcct	60
gctgtcacca	agagctggag	acaccatctc	ccaccgagag	tcattggcccc	attggccctg	120
cacctcctcg	tcctcgtccc	catcctcctc	agcctgggtg	cctcccagga	ctggaaggct	180
gaacgcagcc	aagacccctt	cgagaaatgc	atgcaggatc	ctgactatga	gcagctgtct	240
aagggtggga	cctggggggc	caatcggacc	ctgaagcccc	agaggggtgat	tgtggttggc	300
gctgggtgtg	cggggctggg	ggccgccaag	gtgctcagcg	atgctggaca	caaggtcacc	360
atcctggagg	cagataacag	gatcgggggc	cgcatcttca	cctaccggga	ccagaacacg	420
ggctggattg	gggagctggg	agccatgcgc	atgccagctc	ctcacaggat	cctccacaag	480
ctctgccagg	gctgggggct	caacctgacc	aagttcaccc	agtacgacaa	gaacacgtgg	540
acggaggtgc	acgaagtga	gctgcgcaac	tatgtggtgg	agaaggtgcc	cgagaagctg	600
ggctacgcct	tgcgtcccca	ggaaaagggc	cactcgcccc	aagacatcta	ccagatggct	660
ctcaaccaga	ccctcaaaga	cctcaaggca	ctgggctgca	gaaaggcgat	gaagaagtgt	720
gaaaggcaca	cgtctcttga	atatcttctc	ggggaggggg	acctgagccg	gccggccgtg	780
cagcttctcg	gagacgtgat	gtccgaggat	ggcttcttct	atctcagctt	cgccgaggcc	840
ctccggggcc	acagctgcct	cagcgacaga	ctccagtaca	gccgcacgtt	gggtggctgg	900
gacctgctgc	cgcgcgcgct	gctgagctcg	ctgtccgggc	ttgtgctgtt	gaacgcgccc	960
gtggtggcga	tgacccaggg	accgcacgat	gtgcacgtgc	agatcgagac	ctctcccccg	1020
gcgcggaatc	tgaagggtgc	gaaggccgac	gtggtgctgc	tgacggcgag	cggaccggcg	1080
gtgaactgca	tcaccttctc	gccgcgctg	ccccgccaca	tgacggaggc	gctgcggagg	1140
ctgcactacg	tgccggccac	caagggtgtt	ctaagcttcc	gcaggccctt	ctggcgcgag	1200
gagcacattg	aaggcggcca	ctcaaacacc	gatecgccgt	cgcgcacgat	tttctacccg	1260
ccgcgcgcgc	agggcgcgct	gctgctggcc	tcgtacacgt	ggtcggacgc	ggcggcagcg	1320
ttcgccggct	tgagccggga	agaggcggtg	cgcttgggcg	tcgacgacgt	ggcggcattg	1380
cacgggcctg	tcgtgcgcga	gctctgggac	ggcaccggcg	tcgtcaagcg	ttgggcggag	1440
gaccagcaca	gccagggtgg	ctttgtggta	cagccgcggg	cgctctggca	aaccgaaaag	1500
gatgactggc	cggctccctt	tggccgcac	tactttgccg	gcgagcacac	cgcctacccg	1560
cacggctggg	tggagacggc	ggtcaagttg	ctgcgcgcgc	ccatcaagat	caacagcccg	1620
aaggggcctg	catcggacac	ggccagcccc	gaggggcacg	catctgacat	ggaggggcag	1680
gggcatgtgc	atgggggtgg	cagcagcccc	tcgcatgacc	tggcaaagga	agaaggcagc	1740
cacctccag	tccaaggcca	gttatctctc	caaaacacga	cccacacgag	gacctcgcat	1800
taaagtattt	tcggaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1860
aaaaaaa						1867

&lt;210&gt; 82

&lt;211&gt; 984

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 82

gaattcggca	cgagcccagc	ggaagccaag	ccaccaggcc	ccccagcgtc	cacgcggagc	60
atgaacattg	aggatggcgc	gtgcccgcgg	ctccccgtgc	cccccgctgc	cgcccggtag	120
gatgtcctgg	ccccacgggg	cattgtctct	cctctggctc	ttctccccac	ccctgggggc	180
cgggtggagg	ggagtggccg	tgacgtctgc	cgcggagggg	ggctccccgc	cggccacctc	240
ctgccccgtg	gcctgtctct	gcagcaacca	ggccagccgg	gtgatctgca	cacggagaga	300

mctggccgag	gtcccagcca	gcatcccggg	caacacgcgg	tacctgaacc	tgcaagagaa	360
cggcatccag	gtgatccgga	cggacacgtt	caagcacctg	cggcacctgg	agattctgca	420
gctgagcaag	aacctggtgc	gcaagatcga	ggtgggcgcc	ttcaacgggc	tgcccagcct	480
caacacgctg	gagctttttg	acaaccggct	gaccacgggtg	cccacgcagg	ccttcgagta	540
cctgtccaag	ctgcggggagc	tctggctgcg	gaacaacccc	atcgagagca	tcccctccta	600
cgcttcaac	cgctgcccct	cgctgcggcg	cctggacctg	ggcgagctca	agcggctgga	660
atacatctcg	gagggcgccct	tcgargggct	ggccaacctg	cgctacctca	acctgggcat	720
gtgcaacctc	aaggacatcc	ccaactgacg	ggcctggtgc	gcctggagga	gctggagctg	780
tcgggcaacc	ggctggacct	gatccgcccc	ggctccttcc	agggctctac	cagcctgcgc	840
aagctgtggc	tcatgcacgc	ccaggtagcc	accatcgagc	gcaacgcctt	cgacgacctc	900
aagtcgctgg	aggagctcaa	cctgtcccac	aacaacctga	tgctgctgcc	ccacgacctc	960
ttcacgcccc	tgcaccgcct	cgta				984

&lt;210&gt; 83

&lt;211&gt; 2664

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 83

ggttgctggc	ccaggtgagc	gggcgcgctg	gtccagggtga	gcggggcgct	ccccgcgacg	60
gcgctgcctg	cccgaggcgg	ttcacgtaaa	gacagcgaga	tcctgagggc	cagccgggaa	120
ggaggcgctg	atatggagct	ggctgctgcc	aagtccgggg	cccgcgccgc	tgcttagcgc	180
gtcctgggga	ctctgtgggg	acgcgccccg	cgccgcggct	cggggacccg	tagagcccg	240
cgctgcgcgc	atggccctgc	tctcgcgccc	cgcgctcacc	ctcctgctcc	tcctcatggc	300
cgctgttgct	aggtgccagg	agcaggccca	gaccaccgac	tgagagagca	ccctgaagac	360
catccggaac	ggcggttcata	agatagacac	gtacctgaac	gccgccttgg	acctcctggg	420
aggcgaggac	ggtctctgccc	agtataaatg	catgacggat	ctaagccttt	cccacgttat	480
ggttataaac	cctccccacc	gaatggatgt	ggctctccac	tgtttggtgt	tcctcttaac	540
attggtatcc	cttccctgac	aaagtgttgc	aaccaacacg	acagggtgcta	tgaracctgt	600
ggcaaaagca	agaatgactg	tgatgaagaa	ttccagttat	gcctctccaa	gatctgccga	660
gatgtacaga	aaacactagg	actaactcag	catgttcagg	catgtgaaac	aacagtggag	720
ctcttgtttg	acagtgttat	acatttaggt	tgtaaaccat	atctggacag	ccaacgagcc	780
gcatgcaggt	gtcattatga	agaaaaaact	gatctttaa	ggagatgccg	acagctagt	840
acagatgaag	atggaagaac	ataacctttg	acaaataact	aatgttttta	caacataaaa	900
ctgtcttatt	tttgtgaaag	gattattttg	agaccttaaa	ataatttata	tcttgatgtt	960
aaaacctcaa	agcaaaaaaa	gtgagggaga	tagtgagggg	agggcacgct	tgtcttctca	1020
ggatatcttc	ccagcattgc	tccttactt	agtatgccaa	atgtcttgac	caatatcaaa	1080
aacaagtgtc	tgtttagcgg	agaattttga	aaagaggaat	atataactca	attttcacaa	1140
ccacattttac	caaaaaaaga	gatcaaatat	aaaattcatc	ataatgtctg	ttcaacatta	1200
tcttattttg	aaaatgggga	aattatcact	tacaagtatt	tgtttactat	gaaattttta	1260
atacacattt	atgcctagaa	ggaacggact	ttttttttct	attttaatta	cacataaat	1320
gtaattaaag	tacaacataa	tatgttggtt	ctctgtagcc	cgttgagcat	atgagtaagt	1380
cacattttcta	ttaggactac	ttmcaaggac	aagggtttcca	tttttccagt	tgtaaaattg	1440
gaaccatcag	ctgataacct	cgtaggggagc	aaccccgagga	tagctaagt	ttatgtaata	1500
tgccatagaag	gtgatgtgaa	tgcgattcag	aagcatagcc	actcccattt	tatgagctac	1560
tcacatgaca	aatgtcatct	tttgctataa	cctttgccaa	gttagagaaa	agatggattt	1620
aatgagataa	atgaaaagat	atltamccta	atatatcaag	gcactatttg	ctgttatgct	1680
ttgttattta	tttcccagca	cttgttcctt	attgtagatt	ttttaagac	tgtaaccttt	1740
tactaactgt	ggtcttacta	aaatttgtgc	ttgatactgc	ttttcaaaaa	gcctttaatt	1800
agagccaaaa	ggatggaaaa	ggcaagatat	aaatgccttt	tatagatctc	ttattttacat	1860
tgaaaattat	taccatatgt	ttagagcaaa	tccaagaaaa	cttcaacagc	ttctgaagat	1920
gtctatgaat	gttgaaaact	tttcaatctc	ttggaatgct	cagttatgtt	cctagaccgg	1980
tctttgctga	ctactgggtg	ttaacctttc	cctagcctgg	gacctcaagc	catatatatc	2040
ctttgggtga	cccatggcca	aagttattaa	gatgaactga	ctttcaaagt	cagagaagga	2100
cagcataggg	agaggcggtt	atttgtaagt	cattacaggt	agaacagggc	agaaggaaaa	2160
gtatgttctg	gagaaagggc	catgttccta	actttggaga	tatgtcattg	ccgggaacct	2220
agtatcttcc	aacttgaatt	gggtggcagct	gttccagtga	gacaaggcac	atgtatgcct	2280
tgtaggctaag	tgagcaaaact	gggtttccac	ttaaatgttt	gggacctca	attgattctt	2340
tattttcaaac	ctttataaaa	ggtacagttt	tgtaagccat	tattaataat	taatgcttat	2400
cggctgggca	cagtggctca	cacctataat	cccagcactt	gggaggctga	ggcgggttga	2460

50

tcacttgagg	tcaggagttt	gagaccagct	ggccaacatg	gtgaaacagc	gtctctacta	2520
aaaatacaaa	aattttgccg	gcgtgggtgg	gcatgcttat	agtctcagct	actcaggaag	2580
ctgaggtacg	agaatcactt	gaacccagga	ggtggaggtt	gcagtgagct	gagattgtgc	2640
cactgcactg	cagcctggct	cgag				2664

&lt;210&gt; 84

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

cccacgcgtc	cggggccagt	gaggtccgca	gagtttgggc	gccaggcgag	acggcagggc	60
ttaaagttcc	gggaatcaaa	gatcaactcc	cactgaggac	aaatggacct	gtaattccgg	120
gtgtgacgag	agaacgagat	ttaccttcct	gaattaaaaa	wcwgactccc	tgcgacaagg	180
actgtgtact	gcatgaatga	ggctgagata	gttgatgttg	ctctgggaat	cctgattgag	240
agccgcaaac	aggaaaaggc	ctgcgagcag	ccggccctgg	cgggggctga	taaccagar	300
cactcccctc	cctgctccgt	gtgcctcac	acaagttctg	ggagcagcag	tgaggaagag	360
gacagtggga	aacaggcact	grctccaggc	ctcagccctt	cccagaggcc	ggggggttcc	420
agctctgcct	gtagcaggag	ccctgaggag	gaggaggaag	aggatgtgct	gaaatacgct	480
cgggagatct	ttttcagcta	gggcataaac	tgtgactga	actgtctgcc	gagagcagct	540
ggaggttcca	tgagctttcca	ctggtgctgc	tgggccgccc	gcctgtggga	atggggctct	600
ctgtgctcct	acctttgtgc	cttcttgggc	ctggcagatt	cacctcaggc	cagaagcccc	660
tggacactcc	gggccttggg	gctgccgttc	tgagtgtgcg	gaaggcagga	ctcaaatga	720
gatcccattt	gactccctct	gtatgtactg	tgccctctcc	tggctcttga	ggctctggag	780
tcccaattgt	ctgtgttagt	cagtgaccag	gttccaggga	aaatgatgtc	atgtggtggt	840
ccaacttact	ggaaccaaag	agacagtact	ttgcaaagaa	aaggatcact	gccagggtga	900
ctggaattgc	tacagtttag	tccgcagtgt	ctctcctgaa	ggaggaagcc	tgtttcaaaa	960
atagtttcca	tcattgagct	atcaatgagc	tcccacctct	ccagccagcc	tagaaagcaa	1020
acgagctgcc	cacagttctc	tgccctgtct	gggaggttga	ggccacagtg	tatagactgg	1080
taagccagac	aggcctctct	ccgcaagctg	ctaccttgct	ttcacctgta	ccttgggtccc	1140
cgggcagcta	gctataaagc	aagagggaca	ggagcccaga	agagacactg	aggacaagag	1200
atcacaccag	agtacatgtc	tctgcctctg	ttttcagtgt	ggctttggac	aggaatatat	1260
gaataaatca	ctgccataca	ggtttttcaa	tacacaagtg	ctagaaaata	cacacaattc	1320
cccaatga						1328

&lt;210&gt; 85

&lt;211&gt; 1342

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 85

ggcccgcctc	ggagggtattc	tgcccttgac	tgcaactctt	gtcgtcttat	gtgggtgttg	60
aattgatctg	tctctgcagc	cagatccagg	ctcctggaag	aacctgtcc	ggcagctact	120
ggatcatgcca	ggcacacact	gctgcccagg	aggagctgct	gtttgaatta	tctgtgaatg	180
ttgggaagag	gaatgccaga	gctgccggct	gaaaattacc	caaccaagag	aaatctgcag	240
gatggacttt	ctggctcctct	tcttgttcta	cctggcttcg	gtgctgatgg	gtcttgttct	300
tatctgcgtc	tgctcgaaaa	cccatagctt	gaaaggcctg	gccaggggag	gagcacagat	360
attttctgtg	ataattccag	aatgtcttca	gagagccrtg	catggattgc	ttcattacct	420
tttccatacg	agaaaaccaca	ccttcattgt	cctgcacctg	gtcttgcaag	ggatggttta	480
tactgagtac	acctggggaa	gtatttggct	actgtcagga	gctggagttg	tccttgcat	540
accttcttct	gccctatctg	ctgctagggtg	taaacctgtt	ttttttcacc	ctgactgtg	600
gaaccaatcc	tggcattata	acaaaagcaa	atgaattatt	atttcttcat	gtttatgaat	660
ttgatgaagt	gatgtttcca	aagaacgtga	ggtgctctac	ttgtgattta	aggaaaccag	720
ctcgatccaa	gcactgcagt	gtgtgtaact	ggtgtgtgca	ccgtttcgac	catcactgtg	780
tttgggtgaa	caactgcac	ggggcctgga	acatcaggta	cttcctcacc	tacgtcttga	840
ccttgacggc	ctcggctgcc	accgtcgcca	ttgtgagcac	cacttttctg	gtccacttgg	900
tgggtgatgtc	agattttatac	caggagactt	acatcgatga	ccttggacac	ctccatgtta	960
tggacacggt	ctttcttatt	cagtacctgt	tcctgacttt	tccacggatt	gtcttcatgc	1020
tgggctttgt	cgtgggtctg	agcttcctcc	tgggtggcta	cctgttgttt	gtcctgtatc	1080
tggcggccac	caaccagact	actaacagagt	ggtacagagg	tgactgggcc	tgggtgccagc	1140

51

gttgtccct	tgtggcctgg	cctccgtcag	cagagcccca	agtccaccgg	aacattcact	1200
cccatgggct	tcgaggaac	cttcaagaga	tctttctacc	tgcctttcca	tgtcatgaga	1260
ggaagaaaca	agaatgacaa	gtgtatgact	gcctttgagc	tgtagtcccc	gtttatttac	1320
acatgtggat	cctcgttttc	ca				1342

&lt;210&gt; 86

&lt;211&gt; 1154

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

aagacaggaa	aagctccagg	ccgtggttct	caaagtgtgg	tccctggaca	gcagcaacat	60
cacctaggag	cctgttaggg	aaggcacagc	ctcaggccct	gccccagacc	tgcagaatca	120
gaaactctgg	ggtgaggcct	ggttatctgc	tgtaacagac	cttccagtgg	gttctgatgc	180
cctctagagc	aggagaacca	ctagcttaga	ggttgcaagta	tgtttgccat	cttgccatct	240
gtgttagttc	agaggaatgg	ctgaccccca	tgtctcattt	ctaagcttca	ggcagctttt	300
ctcctgggca	gctgtcattc	tgttgagggg	aatcctgggg	actgtggctc	ctcctccctg	360
tccgtgtgtc	cttgatctgg	cagtctaccc	ccttcattct	cccgtggagg	ctccatgcct	420
agaggtggtc	ttcaaacaga	agaatggcaa	agataattgt	ctcgtgtttt	accctgaccc	480
cattccttta	agaggggtcac	ttcttgcccc	attcatttaa	aaaccaatgt	catagtctct	540
tgattccacc	tatcagacag	tgccacgtcc	aaaggcgggg	ctctyacctc	cctggraaga	600
gagactgttg	ctgtctgtgc	ttcctgtgtt	ctccagtccc	acgctcccac	ggacccacgc	660
ccttgaggac	tccctcrgtg	tcccagggct	tctggtgtgt	tcagagacct	ccacactcaa	720
cgaccactgg	tgctgcagaa	gggcccgtgc	ttacattcca	attaacagac	gcttttccca	780
tctaattgcct	cttgccctct	cctaacacca	cctcgggagt	gtttatgtct	attctaagtg	840
aatttcactg	tgtgaaaaaa	ttcacacctg	ttgtcccagc	gatttgggag	gccggggcgg	900
gtgtatcatt	tgagcccagg	agtttgaggc	tagcctgggc	aggatgggtg	aaccccgctc	960
ctataaagaa	attttaaaaa	ttagctgggc	atagtggcac	gtgcctgtag	ttccatctac	1020
tggggaggct	gggggtgggag	gatcgcatga	gcccgggagt	ttgaggctgc	agtgagctgt	1080
gatcgagca	ctgcactcca	gtctgggcaa	cagagcaaga	ccctgtctct	taaaaaaaaa	1140
aaaaaaaaact	cgag					1154

&lt;210&gt; 87

&lt;211&gt; 1197

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (573)..(573)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1177)..(1177)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1185)..(1185)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 87

aagacaggaa	aagctccagg	ccgtggttct	caaagtgtgg	tccctggaca	gcagcaacat	60
cacctaggag	cctgttaggg	aaggcacagc	ctcaggccct	gccccagacc	tgcagaatca	120
gaaactctgg	ggtgaggcct	ggttatctgc	tgtaacagac	cttccagtgg	gttctgatgc	180
cctctagagc	aggagaacca	ctagcttaga	ggttgcaagta	tgtttgccat	cttgccatct	240
gtgttagttc	agaggaatgg	ctgaccccca	tgtctcattt	ctaagcttca	ggcagctttt	300
ctcctgggca	gctgtcattc	tgttgagggg	aatcctgggg	actgtggctc	ctcctccctg	360
tccgtgtgtc	cttgatctgg	cagtctaccc	ccttcattct	cccgtggagg	ctccatgcct	420

52

```

agaggtgggtc ttcaaacaga agaatggcaa arataattgt ctctgtgtttt accctgaccc 480
cattccttta agaggggtcac ttcttggccc attcatttaa aaaccaatgt catagtctctg 540
tgattccacc tatcagacag tgccacgtcc aangcggggc tctcacctcc ctgggaagag 600
agactgtttgc tgtctgtgct tctgtgttcc tccagtccca cgtcccccacg gacccacgcc 660
cttggagact ccctcagtggt cccagggcctt ctgggtgtgtt cagagacctc cacctcaac 720
gaccactgggt gctgcagaag ggccgggtgct tacattccaa ttaacagacg cttttcccat 780
ctaatacctc ttgcctttctc ctaacaccac ctccggagtg tttatgtcta ttctaagtga 840
atttcactgt gtgaaaaaat tcacacctgt tatcccagca atttgggagg ccgaggcggg 900
tgtatcattt gggcccagga gtttgagact agcctgggca agatggtgaa accccgtctc 960
tataaagaaa ttttaaaaat tggctgggca tagtggcgcg tgctgtagt tccatctgct 1020
ggggaggctg ggggtgggagg atcgcagtag cccgggagtt tgaggctgca gtgagctgtg 1080
atcgcggcac tgcactccag tctgggcaac agagcaaaac cctgtctctt aaaaaaaaaa 1140
aaaactcgag gggggggccc gtacccaatt cgcctnats agtgnagtgc tattaca 1197

```

&lt;210&gt; 88

&lt;211&gt; 910

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 88

```

ggcagagctg gccttcgact cgctatgtcc actaacaata tgtcggaccc acggaggccg 60
aacaaagtgc tgaggtgagg accccagcgt cgtgggcacg gggtcgggtt gtgggtgtgg 120
atcggggccc tgggaagcgc ctgtctatcc cgggggcagg acctgagcgc cctgacctt 180
cgagcctgtc gcaggtacaa gccccgcgcg agcgaatgta acccggcctt ggacgacctg 240
acgccggact acatgaacct gctgggcatg atcttcagca tgtcggcctt catgcttaag 300
ctgaagtgggt gtgcttgggt cgctgtctac tgctccttca tcagctttgc caactctcgg 360
agctcggagg acacgaagca aatgatgagt agcttcagtg gagacttgcc ctacagaaca 420
agtgaactctt gagtaagggg tggggggacc ccagcctggc catcctagac tgacacctct 480
ctcctgtctt catgctgtcc atctctgccg tggatgatgt ctatctgcag aatcctcagc 540
ccatgacgcc cccatggtga taccagccta gaagggtcac attttggacc ctgtctatcc 600
actaggcctg ggccttgggt gctaaacctg ctgccttcag ctgccatcct ggacttccct 660
gaatgaggcc gtctcgggtc cccagctgg atagagggaa cctggccctt tcctagggaa 720
caccctaggc ttacctctcc tgctcctctt cccctgctg ctgctggggg agatgctgtc 780
catgtttcta ggggtattca tttgctttct cgttgaaacc tgttgttaat aaagtttttc 840
actctgaaaa aaaaaaaaaa aaaaaaaaaa tyrggggggg gcccggaacc caattccscg 900
gatagtgagt                                     910

```

&lt;210&gt; 89

&lt;211&gt; 1076

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1029)..(1029)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1037)..(1037)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1040)..(1040)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 89

```

ggcacgaggg gaaagccatg ctcccaggac tcttctcttg cagccttaaa tcggtctgta 60
cggaaaattc cgcgccttag aaaccacgcg ttgggtgtaa cttattattg ttcttctgta 120

```

53

cctacttccct	gtttatcact	tccgggttca	tcattttggc	atttcgggtga	tcgggttgga	180
actattgaag	cccgttttca	ggttcttttc	cccattttcc	ctttgaaagg	aagacttctg	240
gcttctccta	aatctccggt	ctctgggtaa	ggggagtcca	agcctctgtc	atgaggaacg	300
gaaatgcgag	ggcctcggtt	gttactctaa	aatccgccct	cagcttgac	gccggaagct	360
gcgattcctg	cagcgggaaga	ggcgtgatct	ggccttcgac	tcgctatgtc	actaacaat	420
atgtcggacc	cacggaggcc	gaacaaagtg	ctgagggtaca	agcccccgcc	gagcgaatgt	480
aaccggcct	tggacgacc	gacgccggac	tacatgaacc	tgctgggcat	gatcttcagc	540
atgtgcggcc	tcatgcttaa	gctgaagtgg	tgtgcttggg	tcgctgtcta	ctgctccttc	600
atcagctttg	ccaactctcg	gagctcggag	gacacgaagc	aaatgatgag	tagcttcatg	660
ctgtccatct	ctgccgtggt	gatgtcctat	ctgcagaatc	ctcagcccat	gacgccccca	720
tggtgatacc	agcctagaag	ggtcacattt	tggaccctgt	ctatccacta	ggcctgggct	780
ttggctgcta	aacctgctgc	cttcagctgc	catcctggac	ttccctgaat	gaggccgtct	840
cgtgcgcccc	agctggatag	agggaaacctg	gccctttcct	agggaaacacc	ctagggttac	900
ccctcctgcc	tcccttcccc	tgctgtctgc	tgggggagat	gctgtccatg	tttctagggg	960
tattcatttg	ctttctcggt	gaaacctggt	gttaataaag	tttttcactc	tgaaaaaaa	1020
aaaaaaaana	raaaacncgn	ggggggggccc	ggaacccaat	tcscgggata	gtgagt	1076

&lt;210&gt; 90

&lt;211&gt; 1842

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (67)..(67)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (98)..(98)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (212)..(212)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1838)..(1838)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 90

gcgaccgcgc	ccttcagcta	gctcgtctgc	tcgctctgct	tccttgcctgc	cggctgcgca	60
tggcttnggc	gttggcggcg	ctggcggcgg	ctcgagcngc	ctgcgsagcc	ggtaccagca	120
gttgacgaat	gaagaagagt	ctggagaacc	tgaacaggct	gcagggtgatg	ctcctccacc	180
ttacagcagc	atttctgcag	agagcgacac	tnattttgac	tacaaggatg	agtctggggt	240
tccaaagccc	ccatcttaca	atgtagctac	aacactgccc	agttatgatg	aagcggagag	300
gaccaaggct	gaagctacta	tccttttggg	tcctgggaga	gatgaggatt	ttgtgggtcg	360
ggatgatttt	gatgatgctg	accagctgag	gataggaaat	gatgggattt	tcatgttaac	420
ttttttcatg	gcattcctct	ttaactggat	tgggtttttc	ctgtcttttt	gcctgaccac	480
ttcagctgca	ggaaggatat	gggccatttc	aggatttggg	ctctctctaa	ttaaatggat	540
cctgattgtc	aggttttcca	cctatttccc	tggatatttt	gatgggtcagt	actggctctg	600
gtgggtgttc	cttgttttag	gctttctcct	gtttctcaga	ggatttatca	attatgcaaa	660
agttcgggaag	atgccagaaa	ctttctcaaa	tctccccagg	accagagttc	tctttattta	720
ttaaagatgt	tttctggcaa	aggccttccc	gcattttatga	attctctctc	aagaagcaag	780
agaacacctg	cagggaagtga	atcaagatgc	agaacacaga	ggaataatca	cctgctttta	840
aaaaataaag	tactgttgaa	aagatcattt	ctctctatatt	gttcctaggt	gtaaaaattt	900
aatagttaat	gcagaattct	gtaatcattg	aatcattagt	ggttaatgtt	tgaaaaagct	960
cttgcaatca	agtctgtgat	gtattaataa	tgccttatat	attgtttgta	gtcattttta	1020

54

gtagcatgag	ccatgtccct	gtagtcggta	gggggcagtc	ttgctttatt	catcctccat	1080
ctcaaaatga	acttgggaatt	aaatatgtga	agatatgtat	aatgctggcc	attttaaagg	1140
ggttttctca	aaagttaaac	ttttgttatg	actgtgtttt	tgcacataat	ccatatttgc	1200
tggtcaagtt	aatctagaaa	tttattcaat	tctgtatgaa	cacctggaag	caaaatcata	1260
gtgcaaaaat	acattttaagg	tgtgggtcaaa	aataagtctt	taattggtaa	ataataagca	1320
ttaatttttt	atagcctgta	ttcacaattc	tgcggtacct	tattgtacct	aagggattct	1380
aaagggtgtg	tcactgtata	aaacagaaaag	cactaggata	caaatgaagc	ttaattacta	1440
aaatgtaatt	cttgacactc	tttctataat	tagcgttctt	cacccccacc	cccccccca	1500
ccccccctat	tttccctttg	tctcctgggtg	attaggccaa	agtctgggag	taaggagagg	1560
attaggtact	taggagcaaa	gaaagaagta	gcttggaact	tttgagatga	tccctaacat	1620
actgtactac	ttgcttttac	aatgtgttag	cagaaaccag	tgggttataa	tgtagaatga	1680
tgtgctttct	gcccaagtgg	taattcatct	tggtttgcta	tgtaaaaact	gtaaatataa	1740
cagaacatta	ataaatatct	cttgtgtagc	acctttttaa	aaaaaaaaaa	aaaaaaaaaa	1800
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaanaa	aa		1842

&lt;210&gt; 91

&lt;211&gt; 1963

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (335)..(335)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1959)..(1959)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 91

ggatcctcgc	ggcggcgggc	gtgcttacag	cctgagaaga	gcgtctcgcc	cgggagcggc	60
ggcggccatc	gagacccacc	caaggcgcg	ccccctcgcc	ctcccagcgc	tcccagccg	120
cagcggccgc	gccccttcag	ctagctcgct	cgctcgctct	gcttccctgc	tgccggctgc	180
gcatggcktt	ggcgttggcg	gcgctggcg	cggtcggagcc	gcctgcgcag	ccggtaccag	240
cagttgcaga	atgaagaaga	gtctggagaa	cctgaacagg	ctgcagggtga	tgctcctcca	300
ccttacagca	gcattttctgc	agagagcgca	gcatnatttt	gactacaagg	atgagtctgg	360
gtttccaaag	cccccatctt	acaatgtagc	tacaacactg	cccagttatg	atgaagcggga	420
gaggaccaag	gctgaagcta	ctatcccttt	ggttcctggg	agagatgagg	attttgtggg	480
tcgggatgat	tttgatgatg	ctgaccagct	gaggatagga	aatgatggga	ttttcatggt	540
aacttttttc	atggcatttc	tctttaactg	gattgggttt	ttcctgtctt	tttgctgac	600
cacttcagct	gcaggaaggt	atggggccat	ttcaggattt	ggtctctctc	taattaaatg	660
gatectgatt	gtcagggttt	ccacctattt	ccctggatat	tttgatggtc	agtactggct	720
ctgggtgggtg	ttccttggtt	taggctttct	cctgtttctc	agaggattta	tcaattatgc	780
aaaagttcgg	aagatgccag	aaactttctc	aaatctcccc	aggaccagag	ttctctttat	840
ttattaaaga	tgttttctgg	caaaggcctt	cctgcattta	tgaattctct	ctcaagaagc	900
aagagaacac	ctgcaggaag	tgaatcaaga	tgacagaacac	agaggaataa	tcacctgctt	960
taaaaaaata	aagtactgtt	gaaaagatca	tttctctcta	tttgttccta	ggtgtaaaaa	1020
tttaatatgt	aatgcagaat	tctgtaataa	ttgaatcatt	agtggttaat	gtttgaaaaa	1080
gctcttgcaa	tcaagtctgt	gatgtattaa	taatgcctta	tatattgttt	gtagtcattt	1140
taagtagcat	gagccatgtc	cctgtagtcg	gtagggggca	gtcttgcttt	attcatcctc	1200
catctcaaaa	tgaacttgga	attaaatatt	gtaagatatg	tataatgctg	gccattttta	1260
aggggttttc	tcaaaaagtt	aacttttgtt	atgactgtgt	ttttgcacat	aatccatatt	1320
tgctgttcaa	gttaatctag	aaatttattc	aattctgtat	gaacacctgg	aagcaaaatc	1380
atagtgcaaa	aatacattta	aggtgtggtc	aaaaataagt	ctttaattgg	taataataaa	1440
gcatttaatt	tttatagcct	gtattcacaa	ttctgcggta	ccttattgta	cctaagggat	1500
tctaaagggtg	ttgtcactgt	ataaaacaga	aagcactagg	atacaaatga	agcttaatta	1560
ctaaaatgta	attcttgaca	ctctttctat	aattagcggt	cttcaccccc	acccccaccc	1620
ccacccccct	tattttcctt	ttgtctcctg	gtgattaggc	caaagtctgg	gagtaaggag	1680
aggattaggt	acttaggagc	aaagaaagaa	gtagcttgga	acttttgaga	tgatccctaa	1740



55

catactgtac	tacttgcttt	tacaatgtgt	tagcagaaac	cagtgggtta	taatgtagaa	1800
tgatgtgctt	tctgccccag	tggttaattca	tcttggtttg	ctatgttaaa	actgtaaata	1860
caacagaaca	ttaataaata	tctcttgtgt	agcaccttta	aaaaaaaaaa	aaaaaaaaaa	1920
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa		1963

&lt;210&gt; 92

&lt;211&gt; 1487

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1470)..(1470)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1487)..(1487)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 92

gcgaccgcgc	ccctttcagc	tagctcgctc	gctcgctctg	cttccctgct	gccggctgcg	60
catggckwtg	gcgttggcgg	cgctggcgcc	ggctcgagccg	gcctgcgcag	ccggtaccag	120
cagttgcaga	atgaagaaga	gtctggagaa	cctgaacagg	ctgcagggtga	tgctcctcca	180
ccttacagca	gcattttctg	agagagcgca	gttttccacc	tatttccctg	gatattttga	240
tggtcagtag	tggtctctgt	gggtgttcct	tggttttaggc	ttctcctgt	ttctcagagg	300
atttatcaat	tatgcaaaaag	ttcggaagat	gccagaaaact	ttctcaaate	tccccaggac	360
cagagttctc	tttattttatt	aaagatgttt	tctggcaaaag	gccttccctg	atttatgaat	420
tctctctcaa	gaagcaagag	aacacctgca	ggaagtgaat	caagatgcag	aacacagagg	480
aataatcacc	tgcttttaaaa	aaataaagta	ctgttgaaaa	gatcattttct	ctctattttgt	540
tcctaggtgt	aaaatttttaa	tagttaatgc	agaattctgt	aatcattgaa	tcattagtgg	600
ttaatgtttg	aaaaagctct	tgcaatcaag	tctgtgatgt	attaataatg	ccttatatat	660
tggtttgtagt	catttttaagt	agcatgagcc	atgtccctgt	agtcggtagg	gggcagtcct	720
gcctttattca	tcctccatct	caaaatgaac	ttggaattaa	atattgtaag	atatgtataa	780
tgctggccat	tttaaagggg	ttttctcaaa	agttaaactt	ttgttatgac	tggtgtttttg	840
cacataatcc	atatttgctg	ttcaagttaa	tctagaaatt	tattcaattc	tgtatgaaca	900
cctggaagca	aaatcatagt	gcaaaaatac	atttaagggtg	tggtcaaaaa	taagtcttta	960
atttggtaaat	aataagcatt	aattttttat	agcctgtatt	cacaattctg	cggtagctta	1020
ttgtacctaa	gggattctaa	agggtgtgtc	actgtataaa	acagaaagca	ctaggataca	1080
aatgaagctt	aattactaaa	atgtaatctt	tgacactctt	tctataatta	gcgttcttca	1140
ccccaccctc	cacccccacc	ccccttattt	tccttttgct	tcctggtgat	taggccaaag	1200
tctgggagta	aggagaggat	taggtactta	ggagcaaaaga	aagaagtagc	ttggaacttt	1260
tgagatgata	cctaacatac	tgtactactt	gcttttacia	tgtgttagca	gaaaccagtg	1320
ggttataatg	tagaatgatg	tgctttctgc	ccaagtggta	attcatcttg	gtttgctatg	1380
ttaaaactgt	aaatacaaca	gaacattaat	aaatatctct	tgtgtagcac	ctttaaaaaa	1440
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ccccggggggg	ggccccn		1487

&lt;210&gt; 93

&lt;211&gt; 1653

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (67)..(67)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (212)..(212)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (1636)..(1636)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (1653)..(1653)

<223> n equals a,t,g, or c

<400> 93

gcgaccgcgc	ccttcagcta	gctcgcgcgc	tcgctctgct	tccctgctgc	cggtgcgcga	60
tggcttnggc	gttggcggcg	ctggcggcgg	ctcgagccgc	ctgcgsagcc	ggtaccagca	120
gttgacagaat	gaagaagagt	ctggagaacc	tgaacaggct	gcaggatgatg	ctcctccacc	180
ttacagcagc	atttctgcag	agagcgcaca	tnattttgac	tacaaggatg	agtctgggtt	240
tccaaagccc	ccatcttaca	atgtagctac	aacactgccc	agttatgatg	aagcggagag	300
gaccaaggct	gaagctacta	tccctttggt	tccctgggaga	gatgaggatt	ttgtgggtcg	360
ggatgatttt	gatgatgctg	accagctgag	gataggaaat	gatgggattt	tcatgttaac	420
ttttttcatg	gcatttcctct	ttaactggat	tgggtttttc	ctgtcttttt	gcctgaccac	480
ttcagctgca	ggaaggatg	gggccatttc	aggatttggt	ctctctctaa	ttaaatggat	540
cctgattgtc	aggttttcca	cctatttccc	tgcatttatg	aattctctct	caagaagcaa	600
gagaacacct	gcaggaagtg	aatcaagatg	cagaacacag	aggaataatc	acctgcttta	660
aaaaaataaa	gtactgttga	aaagatcatt	tctctctatt	tgttcctagg	tgtaaaattt	720
taatagttaa	tgcagaattc	tgtaatcatt	gaatcattag	tggttaatgt	ttgaaaaagc	780
tcttgcaatc	aagtctgtga	tgtattaata	atgccttata	tattgtttgt	agtcatttta	840
agtagcatga	gccatgtccc	tgtagtcggt	agggggcagt	cttgctttat	tcctcctcca	900
tctcaaaatg	aacttggaat	taaatattgt	aagatatgta	taatgctggc	catttttaaag	960
gggttttctc	aaaagttaaa	cttttgttat	gactgtgttt	ttgcacataa	tccatatttg	1020
ctgttcaagt	taatctagaa	atttattcaa	ttctgtatga	acacctggaa	gcaaaatcat	1080
agtgcaaaaa	tacatttaag	gtgtgggtcaa	aaataagtct	ttaattggta	aataataagc	1140
attaattttt	tatagcctgt	attcacaatt	ctgcggtacc	ttattgtacc	taagggtacc	1200
taagggtggt	gtcactgtat	aaaacagaaa	gcactaggat	acaaatgaag	cttaattact	1260
aaaatgtaat	tcttgacact	ctttctataa	ttagcgttct	tcacccccac	ccccaccccc	1320
acccccctta	ttttcctttt	gtctcctggt	gattaggcca	aagtctggga	gtaaggagag	1380
gattagggtac	ttaggagcaa	agaaagaagt	agcttggaac	ttttgagatg	atccctaaca	1440
tactgtacta	cttgctttta	caatgtgtta	gcagaaacca	gtgggttata	atgtagaatg	1500
atgtgctttc	tgcccaagtg	gtaattcatc	ttggtttgct	atgttaaaac	tgtaaataca	1560
acagaacatt	aataaatatc	tcttgtgtag	caccttttaw	aaaaaaaaaa	aaaaaaaaaa	1620
aaaaaaaaaa	aaaancccg	ggggggggcc	ccn			1653

<210> 94

<211> 1830

<212> DNA

<213> Homo sapiens

<220>

<221> misc\_feature

<222> (67)..(67)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (97)..(97)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (211)..(211)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (1813)..(1813)

<223> n equals a,t,g, or c

<220>

<221> misc\_feature

<222> (1830)..(1830)

<223> n equals a,t,g, or c

<400> 94

gcgaccgcgc	ccttcagcta	gctcgcgcgc	tcgctctgct	tccctgctgc	cggtcgcgca	60
tggcttnggc	gttggcggcg	ctggcggcgg	tcgagcngcc	tgcgsagccg	gtaccagcag	120
ttgcagaatg	aagaagagtc	tggagaacct	gaacaggctg	caggtgatgc	tcctccacct	180
tacagcagca	tttctgcaga	gagcgcacat	nattttgact	acaaggatga	gtctgggttt	240
ccaaagcccc	catcttacaa	tgtagctaca	acactgccca	gttatgatga	agcggagagg	300
accaaggctg	aagctactat	ccctttgggt	cctgggagag	atgaggattt	tgtgggtcgg	360
gatgattttg	atgatgctga	ccagctgagg	ataggaaaatg	atgggatttt	catgttaact	420
tttttcatgg	cattcctcct	taactggatt	gggtttttcc	tgtctttttg	cctgaccact	480
tcagctgcag	gaaggatagg	ggccatttca	ggatttgggt	tctctctaata	taaatggatc	540
ctgattgtca	ggttttccac	ctatttccct	ggatattttg	atggtcagta	ctggctctgg	600
tgggtgtttc	ttgttttagg	ctttctcctg	tttctcagag	gatttatcaa	ttatgcaaaa	660
gttcggaaga	tgccagaaac	tttctcaaat	ctccccagga	ccagagttct	ctttatttat	720
taaagatggt	ttctggcaaa	ggccttccct	catttatgaa	ttctctctca	agaagcaaga	780
gaacacctgc	aggaagtga	tcaagatgca	gaacacagag	gaataatcac	ctgctttaa	840
aaaataaagt	actgttgaaa	agatcatttc	tctctatttg	ttcctagggtg	taaaatttta	900
atagttaagt	cagaattctg	taatcattga	atcatttagtg	gttaatgttt	gaaaaagctc	960
ttgcaatcaa	gtctgtgatg	tattaataat	gccttatata	ttgtttgtag	tcattttaag	1020
tagcatgagc	catgtocctg	tagtcggtag	ggggcagctc	tgcctttattc	atcctccatc	1080
tcaaaatgaa	cttgggaatta	aatattgtaa	gatatgtata	atgctggcca	ttttaagggg	1140
gttttctcaa	aagttaaact	ttgtttatga	ctgtgttttt	gcacataatc	catatttgct	1200
gttcaagtta	atctagaaat	ttattcaatt	ctgtatgaac	acctggaagc	aaaatcatag	1260
tgcaaaaata	catttaagggt	gtggtcaaaa	ataagtcctt	aattggtaaa	taataagcat	1320
taatttttta	tagcctgtat	tcacaattct	gcggtacctt	attgtacctt	agggattcta	1380
aagggtgtgt	cactgtataa	aacagaaagc	actaggatac	aaatgaagct	taattactaa	1440
aatgtaattc	ttgacactct	ttctataatt	agcgttcttc	acccccaccc	ccacccccac	1500
cccccttatt	ttccttttgt	ctcctgggtg	ttaggccaaa	gtctgggagt	aaggagagga	1560
ttagggtact	aggagcaaag	aaagaagtag	cttggaactt	ttgagatgat	ccctaacata	1620
ctgtactact	tgtctttaca	atgtgttagc	agaaaccagt	gggttataat	gtagaatgat	1680
gtgctttctg	cccaagtggg	aattcatctt	ggtttgctat	gttaaaactg	taaaataaac	1740
agaacattaa	taaatatctc	ttgtgtagca	ccttttaaaa	aaaaaaaaaa	aaaaaaaaaa	1800
aaaaaaaaaa	aancccgggg	gggggccccn				1830

<210> 95

<211> 1134

<212> DNA

<213> Homo sapiens

<400> 95

tccatctaca	gtcctcacac	aggatttcag	gaataccagg	atggcgtgcc	caagattcca	60
acagcctgta	ttacgggtga	agatgcagaa	atgatgtcaa	gaatggcttc	tcatgggatc	120
aaaattgtca	ttcagctaaa	gatgggggca	aagacctacc	cagatactga	ttccttcaac	180
actgtagcag	agatcactgg	gagcaaatat	ccagaacagg	ttgtactggg	cagtggaacat	240
ctggacagct	gggatgttgg	gcagggtgcc	atggatgatg	gcggtggagc	ctttatatca	300
tgggaagcac	tctcacttat	taaagatctt	gggctgcgtc	caaagaggac	tctgcggctg	360
gtgctctgga	ctgcagaaga	acaagggtga	gttggtgcct	tccagtatta	tcagttaaac	420
aaggtaaata	tttccaacta	cagtctgggtg	atggagtcctg	acgcaggaac	cttcttacc	480
actgggctgc	aattcactgg	cagtgaagaag	gccagggcac	catggaggag	gttatgagcc	540

58

tgctgcagcc	cctcaatatc	actcaggtcc	tgagccatgg	agaagggaca	gacatcaact	600
tttggatcca	agctggagt	cctggagcca	gtctacttga	tgacttatac	aagtatttct	660
tcttccatca	ctcccacgga	gacaccatga	ctgtcatgga	tccaaagcag	atgaatgttg	720
ctgtgctgt	ttgggctgtt	gtttcttatg	ttgttgacga	catggaagaa	atgctgccta	780
ggctctagaa	acagtaagaa	agaaacgttt	tcatgcttct	ggccaggaat	cctgggtctg	840
caactttgga	aaactcctct	tcacataaca	atttcatcca	attcatcttc	aaagcacaac	900
tctatttcat	gctttctgtt	attatctttc	ttgatacttt	ccaaattctc	tgcatcttag	960
aaaaaggaat	cattctcccc	tccctcccac	cacatagaat	caacatatgg	tagggattac	1020
agtgggggca	tttctttata	tcacctctta	aaaacattgt	ttccacttta	aaagtaaaca	1080
cttaataaat	ttttggaaga	tctctgaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa	1134

&lt;210&gt; 96

&lt;211&gt; 1772

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 96

tcgacccacg	cgtccgggag	gatccccagc	cgggtcccaa	gcctgtgcct	gagcctgagc	60
ctgagcctga	gccgagccg	gagccggtcg	cgggggctcc	gggctgtggg	accgctgggc	120
cccagcgat	ggcgaccctg	tggggaggcc	ttcttcggct	tggctccttg	ctcagcctgt	180
cgtgcctggc	gctttccgtg	ctgctgctgg	cgcactgtca	gacgccgcca	agaatttcga	240
ggatgtcaga	tgtaaatgta	tctgccctcc	ctataaagaa	aaattctggg	catattttata	300
ataagaacat	atctcagaaa	gattgtgatt	gccttcatgt	tgtggagccc	atgcctgtgc	360
gggggcctga	tgtagaagca	tactgtctac	gctgtgaatg	caaatatgaa	gaaagaagct	420
ctgtcacaca	caagggttacc	attataattt	atctctccat	tttgggcctt	ctacttctgt	480
acatggata	tcttactctg	gttgagccca	tactgaagag	gcgcctcttt	ggacatgcac	540
agttgataca	gagtgatgat	gatattgggg	atcaccagcc	ttttgcaaat	gcacacgatg	600
tgttagcccg	ctccgcagct	cgagccaacg	tgtgaacaa	ggtagaatat	ggcacagcag	660
cgttggaagc	ttcaagtcca	agagcagcga	aaagtctgtc	tttgaccggc	atgttgtcct	720
cagctaattg	gggaattgaa	ttcaaggtga	ctagaaagaa	acaggcagac	aactggaaag	780
gaactgactg	ggttttgctg	ggtttcatat	taataccttg	ttgatttcac	caactgttgc	840
tggaagattc	aaaactggaa	gkaaaaactt	gcttgatttt	tttttcttgt	taacgtaata	900
atagagacat	ttttaaaagc	acacagctca	aagtcagcca	ataagtcttt	tcctatttgt	960
gacttttact	aataaaaaata	aatctgcctg	taaaaataat	taaaaaatcc	tttacctgga	1020
acaagcactc	tctttttcac	cacatagttt	taacttgact	ttccaagata	attttcaggg	1080
tttttgttgt	tggttgtttt	tggttgtttt	ttttgggtgg	agaggggagg	gatgcctggg	1140
aagtgggttaa	caactttttt	caagtcactt	tactaaacaa	actttttgta	atagacctta	1200
ccttctattt	tcgagtttca	tttatatttt	gcagtgtagc	cagcctcctc	aaagagctga	1260
cttactcatt	tgactttttg	actgactgta	ttatctgggt	atctgctgtg	tctgcacttc	1320
atggtaaacg	ggatctaaaa	tgccctgggtg	cttttcacaa	aaagcagatt	ttcttcatgt	1380
actgtgatgt	ctgatgcaat	gcacccctaga	acaaactggc	catttgctag	tttactctaa	1440
agactaaaca	tagtcttggt	gtgtgtgggc	ttactcatct	tctagtacct	ttaaggacaa	1500
atcctaagga	cttggaacact	tgcaataaag	aaattttatt	ttaaacccaa	gcctccctgg	1560
attgataata	tatacacatt	tgtcagcatt	tccggtcgtg	gtgagaggca	gctgttttag	1620
ctccaatgtg	tgcagctttg	aactagggct	ggggttggtg	gtgcctcttc	tgaaaggctc	1680
aaccattatt	ggataaactg	ctttttttct	tccctcttgg	aatgtaacaa	taaaaataat	1740
ttttgaaaca	tcaaaaaaaaa	aaaaaaaaaaa	aa			1772

&lt;210&gt; 97

&lt;211&gt; 2242

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 97

tcgacccacg	cgtccgggct	gcatggcg	cggcgggcg	gctcccgagc	tcctgggccc	60
tcttctcgcc	gctcctcgca	gggcttgcac	tactgggagt	cgggcccggc	ccagcgcg	120
cgtgcacaa	cgtcacggcc	gagctctttg	gggcccaggc	ctggggcacc	cttgccgctt	180
tgggggacct	caactccgac	aagcagacgg	atctcttcgt	gctgcgggaa	agaaatgact	240
taatcgtctt	tttggcagac	cagaatgcac	cctattttta	acccaaagta	aagggtatctt	300
tcaagaatca	cagtgcattg	ataacaagtg	tagtccctgg	ggattatgat	ggagattctc	360

aaatggatgt	ccttctgaca	tatcttccca	aaaattatgc	caagagtga	ttaggagctg	420
ttatcttctg	gggacaaaat	caaacattag	atcctaacia	tatgaccata	ctcaatagga	480
cttttcaaga	tgagccacta	attatggatt	tcaatgggtga	tctaattcct	gatatttttg	540
gtatcacaaa	tgaatccaac	cagccacaga	tactattagg	agggaaattta	tcatggcatc	600
cagcattgac	cactacaagt	aaaatgcgaa	ttccacattc	tcatgcattt	attgatctga	660
ctgaagattt	tacagcagat	ttattcctga	cgacattgaa	tgccaccact	agtaccttcc	720
agtttgaaat	atgggaaaaat	ttggatggaa	acttytstgw	magtacymta	ttggaaaaac	780
ctcaaaatat	gatgggtggt	ggacagtcag	catttgcaga	ctttgatgga	gatggacaca	840
tggaatcattt	actgccaggc	tgtgaagata	aaaattgccca	aaagagtacc	atctacttag	900
tgagatctgg	gatgaagcag	tgggttccag	tcctacaaga	tttcagcaat	aagggcacac	960
tctggggcctt	tgtgccattt	gtggatgaac	agcaaccaac	tgaaatacca	attccaatta	1020
cccttcatat	tggagactac	aatatggatg	gctatccaga	cgctctggtc	ataactaaga	1080
acacatcttg	agcaaccag	caggcctttt	tactggagaa	cgctccttgt	aataatgcaa	1140
gctgtgaaga	ggcgctcga	atgtttaaag	tctactggga	gctgacagac	ctaaatcaaa	1200
ttaaggatgc	catggttgcc	accttctttg	acatttacga	agatggaatc	ttggacattg	1260
tagtgctaag	taaaggatat	acaaagaatg	attttgccat	tcatacacta	aaaaataact	1320
ttgaagcaga	tgcttatttt	gttaaagtta	ttgttcttag	tggtctgtgt	tctaatagact	1380
gtcctcgtaa	gataacaccc	tttggagtga	atcaacctgg	accttatatc	atgtatacaa	1440
ctgtagatgc	aaatgggtat	ctgaaaaatg	gatcagctgg	ccaactcagc	caatccgcac	1500
attagtctct	ccaactacca	tacaacgtgc	ttggtttagg	tcggagcgca	aattttcttg	1560
accatctcta	cgttgggtatt	ccccgtccat	ctggagaaaa	atctatacga	aaacaagagt	1620
ggactgcaat	cattccaaat	tcccagctaa	ttgtcattcc	ataccctcac	aatgtccctc	1680
gaagttggag	tgccaaactg	tatcttacac	caagtaatat	tgttctgctt	actgctatag	1740
ctctcatcgg	tgtctgtggt	ttcatcttgg	caataattgg	cattttacat	tggcaggaaa	1800
agaaagcaga	tgatagagaa	aaacgacaag	aagccaccgg	gtttcatttt	gatgctatgt	1860
gacttgccctt	taataattaca	taatggaatg	gctgttcact	tgattagttg	aaacacaaat	1920
tctggcttga	aaaaataggg	gagattaaat	attatttata	aatgatgtat	cccatggtaa	1980
ttattggaaa	gtattcaaat	aaatatgggt	tgaatatgtc	acaaggtcct	tttttttaaa	2040
gcactttgta	tataaaaaat	tgggttctct	attctgtagt	gctgtacatt	tttgttccct	2100
tgtggaatgt	gttgcatgta	ctccagtgtt	tgtgtattta	taatcttatt	tgcacatga	2160
tgatggaaaa	agttgtgtaa	ataaaaaata	ttaaatgagc	aggaaaaaaa	aaaaaaaaaa	2220
aaaaaaaaaa	aagggcgggc	gc				2242

&lt;210&gt; 98

&lt;211&gt; 2381

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 98

ccacgcgtcc	cgcaaggcca	gttctagtgt	agagagaaaa	aggagccggc	agcggctctt	60
acgcgtcccc	gggtgcgcg	ccactctctc	ggcgggtaac	gcggtgcttt	gcggctgtcg	120
tcaagcgcgg	cgttgggccc	gcgggcgggg	gctgaggggc	tgccatggcg	gcggcgggcc	180
ggctcccag	ctcctgggcc	ctcttctcgc	cgctcctcgc	agggcttgca	ctactgggag	240
tcgggcccgt	cccagcgcgg	gcgctgcaca	acgtcacggc	cgagctcttt	ggggccgagg	300
cctggggcac	ccttgcggct	ttcggggacc	tcaactccga	caagcagacg	gatctcttcg	360
tgtgcggga	aagaaatgac	ttaatcgtct	ttttggcaga	ccagaatgca	ccctatttta	420
aacccaaagt	aaaggtatct	ttcaagaatc	acagtgcatt	gataacaagt	gtagtccctg	480
gggattatga	tggagattct	caaatggatg	tccttctgac	atatcttccc	aaaaattatg	540
ccaagagtga	attaggagct	gttatcttct	ggggacaaaa	tcaaacatta	gacctaaca	600
atatgaccat	actcaatagg	acttttcaag	atgagccact	aattatggat	ttcaatgggtg	660
atctaattcc	tgataatttt	ggtatcacaa	atgaatccaa	ccagccacag	atactattag	720
gagggaaatt	atcatggcat	ccagcattga	ccactacaag	taaaaatgcga	attccacatt	780
ctcatgcatt	tattgatctg	actgaagatt	ttacagcaga	tttattcctg	acgacattga	840
atgccaccac	tagtaccttc	cagtttgaaa	tatgggaaaa	tttggatgga	aacttctctg	900
tcagttatct	attggaaaaa	cctcaaaaata	tgttgggtgt	tggacagtca	gcatttgcag	960
actttgatgg	agatggacac	atggatcatt	tactgccagg	ctgtgaagat	aaaaattgcc	1020
aaaagagtac	catctactta	gtgagatctg	ggatgaagca	gtgggttcca	gtcctacaag	1080
atttcagcaa	taagggcaca	ctctggggct	ttgtgccatt	tgtggatgaa	cagcaaccaa	1140
ctgaaatacc	aattccaatt	acccttcata	ttggagacta	caatatggat	ggctatccag	1200
acgctctggt	cataactaaag	aacacatctg	gaagcaacca	gcaggccttt	ttactggaga	1260

acgtcccttg	taataatgca	agctgtgaag	aggcgctcg	aatgttttaa	gtctactggg	1320
agctgacaga	cctaaatcaa	attaaggatg	ccatgggtgc	caccttcttt	gacattttacg	1380
aagatggaat	cttggacatt	gtagtgctaa	gtaaaggata	tacaaagaat	gatttttgcca	1440
ttcatacact	aaaaaataac	tttgaagcag	atgcttattt	tgtaaaggtt	attgttctta	1500
gtggctctgtg	ttctaagac	tgctctcgta	gataacaccc	tttggagtga	atcaacctgg	1560
accttatatc	atgtatacaa	ctgtagatgc	aaatgggtat	ctgaaaaatg	gatcagctgg	1620
ccaactcagc	caatccgcac	atttagctct	ccaactacca	tacaacgtgc	ttgggttagg	1680
tcggagcgca	aattttcttg	accatctcta	cgttgggtatt	ccccgtccat	ctggagaaaa	1740
atctatacga	aaacaagagt	ggactgcaat	cattccaaat	tcccagctaa	ttgtcattcc	1800
ataccctcac	aatgtccctc	gaagttggag	tgccaaactg	tatcttacac	caagtaatat	1860
tgttctgctt	actgctatag	ctctcatcgg	tgtctgtggt	ttcatcttgg	caataattgg	1920
cattttacat	tggcaggaaa	agaaagcaga	tgatagagaa	aaacgacaag	aagcccaccg	1980
gtttcatttt	gatgctatgt	gacttgcctt	taatattaca	taatggaatg	gctgttcact	2040
tgattagttg	aaacacaaat	tctggcttga	aaaaataggg	gagattaaat	attatttata	2100
aatgatgtat	cccatggtaa	ttattggaaa	gtattcaaat	aaatatgggt	tgaatatgtc	2160
acaaggtctt	ttttttttaa	gcactttgta	tataaaaatt	tgggttctct	attctgtagt	2220
gctgtacatt	tttgttcctt	tgtggaatgt	gttgcatgta	ctccagtgtt	tgtgtattta	2280
taatcttatt	tgcacatga	tgatggaaaa	agtgtgttaa	ataaaaaata	ttaaatgagc	2340
aggaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a		2381

&lt;210&gt; 99

&lt;211&gt; 1955

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 99

ggcacgagtg	ccatccctgt	atttgcctgc	atgctcttcc	ttttctccat	ggctacactg	60
ttgaggacca	gcttcagtga	ccctggagtg	attcctcggtg	cgctaccaga	tgaagcagct	120
ttcatagaaa	tggagataga	agctaccaat	ggtgcggtgc	cccagggcca	gcgaccaccg	180
cctcgatca	agaatttcca	gataaacaac	cagattgtga	aactgaaata	ctgttacaca	240
tgcaagatct	tccggcctcc	ccgggcctcc	cattgcagca	tctgtgacaa	ctgtgtggag	300
cgcttcgacc	atcactgccc	ctgggtgggg	aattgtgttg	gaaagaggaa	ctaccgctac	360
ttctacctct	tcctccttct	tctctccctc	ctcacaatct	atgtcttcgc	cttcaacatc	420
gtctatgtgg	ccctcaaate	tttgaaaatt	ggctctcttg	agacattgaa	aggaactcc	480
tggaaactgtt	ctagaagtcc	tcatttgctt	ctttacactc	tggctcgtcg	tgggactgac	540
tggatttcat	actttcctcg	tggctctcaa	ccagacaacc	aatgaaagac	atcaaaggat	600
catggacagg	gaagaatcgc	gtccagaatc	cctacagcca	tggcaatatt	gtgaagaact	660
gctgtgaagt	gctgtgtggc	cccttgcccc	ccagtgtgct	ggatcgaagg	ggtattttgc	720
cactggagga	aagtgggaagt	cgacctccca	gtactcaaga	gaccagtagc	agcctcttgc	780
cacagagccc	agccccccca	gaacacctga	actcaaata	gatgccggag	gacagcagca	840
ctcccgaaga	gatgccacct	ccagagcccc	caggccacc	acaggaggca	gctgaagctg	900
agaagtagcc	tatctatgga	agagactttt	gtttgtgttt	aattagggct	atgagagatt	960
tcaggtgaga	agttaaacct	gagacagaga	gcaagtaagc	tgtccctttt	aactgttttt	1020
ctttgggtctt	tagtcaccca	gttgcacact	ggcattttct	tgctgcaagc	ttttttaaat	1080
ttctgaactc	aaggcagtg	cagaagatgt	cagtcacctc	tgataactgg	aaaaatgggt	1140
ctcttggggc	ctggcactgg	ttctccatgg	cctcagccac	agggtccctt	tggacccctt	1200
ctcttccctc	cagatcccag	ccctcctgct	tggggtcact	ggtctcattc	tggggctaaa	1260
agttttctgag	actggctcaa	atcctcccaa	gtgctgagtc	gtgctgagtc	cagaggcagt	1320
cacagagacc	tctggccagg	ggatccctaac	tgggttcttg	gggtcttcag	gactgaagag	1380
gagggagagt	ggggctcagaa	gattctcctg	gccaccaagt	gccagcattg	cccacaaatc	1440
cttttaggaa	tgggacaggt	accttccact	agttgtattt	attagtgtag	cttctccttt	1500
gtctcccatc	cactctgaca	ccttaagccc	cactcttttc	ccattagata	tatgtaagta	1560
gttgtagtag	agataataat	tgacatttct	cgtagactac	ccagaaactt	ttttaataacc	1620
tgtgccattc	tcaataagaa	tttatgagat	gccagcggca	tagcccttca	cactctctgt	1680
ctcactctctc	ctcctttctc	attagccctt	tttaatttgt	tttctctttt	gactcctgct	1740
cccattagga	gcaggaatgg	cagtaataaa	agtctgcact	ttggctcattt	cttttctctca	1800
gaggaagcct	gagtgtctac	ttaaacacta	tccctcaga	ctccctgtgt	gaggcctgca	1860
gaggccctga	atgcacaaat	gggaaaccaa	ggcacagaga	ggctctcctc	tcctctcctc	1920
tccccgatg	taccctcaaa	aaaaaaaaaa	aaaaa			1955

61

<210> 100  
 <211> 1958  
 <212> DNA  
 <213> Homo sapiens

<400> 100  
 ccacgcgtcc ggggcgttcc tggtcgtgag aggggagccc caggggagct ggggcagcat 60  
 gactgggggtg ataaatggcc ggaaatttgg cgtggccaca ctcaacacca gcgtgatgca 120  
 ggaggcacac tccgggggtca gcagcatcca cagcagcatc cggcatgtcc cagcaaactgt 180  
 ggggcctctg atgcgggtgc tctgtgtcac catcgcccc atctactggg ccttgccag 240  
 agagagtggg gaagccctga atggccactc tctgactggg ggcaagtcc ggcaagtca 300  
 cagctggagt ttgtctacagg gagctgtca cgtgaccca gtggccggg gtctggatcc 360  
 cgatggcctc ctgctcctcg aacgtgtgtt caatggcgtt gtccccggac gagcctggct 420  
 gacgcagatc ttcaagtga ggactttgaa gaagcactac gtgcaaaaaa gggcctggcc 480  
 agctgttctg gggctccaca cagcgttctc tccagggcgg cctccccctg ttcctacgt 540  
 gcaaccacag catccagtac aacgcggccc ggggccccca gcccagctg gtgcagcacc 600  
 tgcgggcctc agctatcagc tccgcccctt atccagaggg cgaggccctg cgcttccagc 660  
 tctgtacagc cctgcaggcg gaggagaacg aggtcggctg ccccgagggc tttgagctgg 720  
 actcccaggg agcgttttgg gtggatgtgg acgagtgtgc gtgggatgct cacctctgcc 780  
 gacagggaca ctgctgtgtg aacctgtctg ggtcctacgg ctgcctcccc gactgtgggc 840  
 ctggcttccg ggtggctgat ggggcgggct gtgaaaatgt ggacgaatgc ctggaagggg 900  
 ttggacgact gtcactacaa ccagctctgc gagaacaccc caggcgggtca ccgctgcagc 960  
 tgccccaggg gttaccggat gcagggcccc agcctgccct gcctagatgt caatgagtgc 1020  
 ctgcagctgc ccaaggcctg cgcttaccag tgccacaacc tccagggcag ctaccgctgc 1080  
 ctgtgcccc caggccagac cctccttcgc gacggcaagg cctgcacctc actggagcgg 1140  
 aatggacaaa atgtgaccac cgtcagccac cgaggccctc tattgccctg gctgcggccc 1200  
 tgggcctcga tccccggtag ctcttaccac gcctgggtct ctctccgtcc ggggtcccatg 1260  
 gccctgagca gtgtggggcg ggcttgggtc cctcctgggt tcatcaggca gaacggagtc 1320  
 tgcacagacc ttgacgagtg ccgcgtgagg aacctgtgtc agcacgcctg ccgcaacact 1380  
 gagggcagct accagtgctt gtgccccgcc ggctaccgtc tgctccccag cgggaagaac 1440  
 tgccaggaca tcaacgagtg cgaggaggag agcatcgagt gtggacccgg ccagatgtgc 1500  
 ttcaacaccc gtggcagcta ccagtggtgt gacacaccct gtccctgccac ctaccggcag 1560  
 ggccccagct ctgggacgtg cttccggcgc tgcctgcagg actgcggcac gggcgccct 1620  
 tctacgtgc agtacgggtg gctgcgctg cccctgggcg tgcgcgccc ccacgacgtg 1680  
 gccgcctca ccgccttctc cgaggtcggc gtccccgcca accgcaccga gctcagcatg 1740  
 ctggagcccc acccccgcag ccccttcgcg ctgcgtccgc tgcgcgagg ccttggcgcg 1800  
 gtctacaccc gtcgcgcgtc caccgcgcgc ggctctacc ggctcaccgt gcgtgctgcg 1860  
 gcaccgcgc accaaagcgt cttcgtcttg ctcatcgccg tgtcccccta cccctactaa 1920  
 acgggagagg gcattggcgg ccgctctaga ggatccct 1958

<210> 101  
 <211> 2444  
 <212> DNA  
 <213> Homo sapiens

<400> 101  
 ttacgccaaag ctggcacgag caatgaaaga gttaatctct ttggctgggc ctacagatga 60  
 catacagagt acagtcccc aggttcatgc tttaaatata cttagagcat tgttcagaga 120  
 tacgcgcctg ggagaaaata ttattcctta tgttgtgat ggagctaagg ctgcaattct 180  
 gggttttaca tcaccggtct gggcagtgcg aaattcatcc acacttctct ttagtcctt 240  
 gatcacaaga atttttggag ttaaaagggc aaaggatgaa cattccaaaa caaatagaat 300  
 gacagggaga gagtttttct ctcgtttccc agaactctat ccttttcttc tcaaacagtt 360  
 ggaaactgta gccaatacag tagacagtga tatgggagaa ccaaatcgtc atccaagcat 420  
 gtttctctta cttttgggtg ttgagagact ctacgcttcc ccgatggatg gtacttcttc 480  
 tgcctcagc atgggacctt ttgttccctt cattatgagg tgtggtcact cacctgtcta 540  
 ccactccctg gaaatggcag ctcgtgcctt ggtcccatat gttatgatag atcacattcc 600  
 taataccatt cgaactctgt tgtccacact cccagctgc actgaccagt gtttccgggc 660  
 aaaaccacat tcatggggac acttctccag gtttttccat ttgttgcaag cctactcaga 720  
 ctccaaaaca cgggaacgaat tcagacttcc agcacgagct gactgacatc actgtttgta 780  
 ccaaagccaa actctggctg gccaaagggc aaaatccatg tttggtgacc agagctgtat 840

62

atattgatat	tctcttccta	ttgacttgct	gcctcaacag	atctgcaaag	gacaaccagc	900
cagttctgga	gagtcctggc	ttctgggaag	aaattcaaag	ggaattatct	caggatcaga	960
agctgataac	gggattccct	tgggccttca	aggtgccagg	cctgccccag	tacctccaga	1020
gcctcaccag	actagccatt	gctgcagtg	gggccgcggc	agccaagagt	ggagagcggg	1080
agacgaatgt	ccccatctct	ttctctcagc	tgtagaatc	tgcttccct	gaagtgcgt	1140
cactaacact	ggaagccctc	ttggaaaagt	tcttagcagc	agactctgga	cttggagaga	1200
agggcgtgcc	acccttgctg	tgcaacatgg	gagagaagtt	cttattgttg	gccatgaagg	1260
aaaatcacc	agaatgcttc	tgcaagatac	tgaaaattct	acactgcatg	gacctgggtg	1320
agtggcttcc	ccagacggag	cactgtgtcc	atctgacccc	aaaggagtcc	ttgatctgga	1380
cgatggatat	tgcttccaat	gaaagatctg	aaattcagag	tgtagctctg	agacttgctt	1440
ccaaagtcac	ttcccaccac	atgcagacat	gtgtggagaa	caggggaattg	atagctgctg	1500
agctgaagca	gtgggttcag	ctggctcatct	tgctcatgtga	agaccatctt	cctacagagt	1560
ctaggctggc	cgatcttgaa	gtcctcacca	gtactacacc	acttttctct	accaaccccc	1620
atcctattct	tgagttgcag	gatacacttg	ctctctggaa	gtgtgtcctt	acccttctgc	1680
agagtgaagga	gcaagctggt	agagatgcag	ccacggaaac	cgtgacaact	gccatgtcac	1740
aagaaaatac	ctgccagtc	acagagtttg	ccttctgcc	ggtggatgcc	tccatcgctc	1800
tggccctggc	cctggcgcgc	ctgtgtgatc	tgctccagca	gtgggaccag	ttggccctg	1860
gactgcccac	cctgctggga	tggctgttgg	gagagagtga	tgacctcgctg	gcctgtgtgg	1920
agagcatgca	tcaggtggaa	gaagactacc	tgtttgaaaa	agcagaagtc	aacttttggg	1980
ccgagaccct	gatctttgtg	aaatacctct	gcaagcacct	cttctgtctc	ctctcaaagt	2040
ccgctggcgc	tcccccaagc	cctgagatgc	gtgtcacct	tcaaaggatg	gtgtcagagc	2100
agtgccacct	cctgtctcag	ttcttcagag	agcttccacc	agctgctgag	tttgtgaaga	2160
cagtggagtt	cacaagacta	cgcattcaag	aggaaaggac	tttggcttgc	ttgaggtgc	2220
tggccttttt	ggaaggaaag	gaaggggaag	acaccctagt	tctcagtgtt	tgggactctt	2280
atgcagaatc	gaggcagtta	actcttccaa	gaacagaagc	ggcatgttga	agaaaatctg	2340
ggggattggg	atgggggtat	gtgtggattt	ttcctccact	aaatctgcag	gaaacatggt	2400
gaacataaat	tcaaaaattt	tatcccaaaa	aaaaaaaaaa	aaaa		2444

&lt;210&gt; 102

&lt;211&gt; 2709

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 102

ggcacgagat	ttcctacagg	tgaaacgcca	tcattaggat	tcactgtaac	gttagtgcta	60
ttaaactcac	tagcattttt	attaatggcc	gttatctaca	ctaagctata	ctgcaacttg	120
gaaaaagagg	acctctcaga	aaactcacia	tctagcatga	ttaagcatgt	cgcttggtcta	180
atcttcacca	attgcatctt	ttctctgccct	gtggcggtttt	tttcatattgc	accattgatac	240
actgcaatct	ctatcagccc	cgaaataatg	aagtctgtta	ctctgatatt	ttttccatgc	300
ctgcttgctc	gaatccagtc	ctgtatgttt	tcttcaaccc	aaagttttaa	gaagactgga	360
agttactgaa	gcgacgtggt	accaagaaaa	gtggatcagt	ttcagtttcc	atcagtagcc	420
aagggtggtg	tctggaacag	gatttctact	acgactgtgg	catgtactca	catttgccagg	480
gcaacctgac	tgtttgccag	tgctgcgaat	cgtttctttt	aacaaagcca	gtatcatgca	540
aacacttgat	aaaatcacac	agctgtcctg	cattggcagt	ggcttcttgc	caaagacctg	600
agggctactg	gtccgactgt	ggcacacatt	cggcccactc	tgattatgca	gatgaagaag	660
attcctttgt	ctcagacagt	tctgaccagg	tgccaggcctg	tggacgagcc	tgcttctacc	720
agagttagagg	attccctttg	gtgcgctatg	cttacaatct	accaagagtt	aaagactgaa	780
ctactgtgtg	tgtaaacggt	tcccccgta	accaaaaatca	gtgtttatag	agtgaacctc	840
attctcatct	ttcatctggg	aagcaactct	gtaatcactg	cctgggtgtca	cttagaagaa	900
ggagaggtgg	cagtttattt	ctcaaaccag	tcattttcaa	agaacagggtg	cctaaattat	960
aaattgggtga	aaaatgcaat	gtccaagcaa	tgtatgatct	gtttgaaaca	aatatatgac	1020
ttgaaaagga	tcttaggtgt	agtagagcaa	tataatgtta	gttttttctg	atccataaga	1080
agcaaattta	tacctatttg	tgtattaagc	acaagataaa	gaacagctgt	taatattttt	1140
taaaaattct	atttttaaaa	tgtgattttc	tataactgaa	gaaaaatata	ttgctaattt	1200
tacctaatgt	ttcatctctt	aatctcagga	caacttactg	cagggccaaa	aaagggactg	1260
tcccagctag	acctgtgaga	gtatacatag	gcattacttt	attatgtttt	cacttgccat	1320
ccttgacata	agagaactat	aaattttgtt	taagcaattt	ataaatctaa	aacctgaaga	1380
tgtttttaaa	acaatatata	cagctgttag	gttaaaaaaa	tagctggaca	tttgttttca	1440
gtcattatac	attgcttttg	tccaatcagt	aattttttct	taagtgtttt	gtgattacac	1500
tactagaaaa	aaagtaaaag	gctaattgct	gtgtgggttt	agtcgatttg	gctaaactac	1560



63

taactaatgt	ggggggttaa	tagtatctga	gggatttggg	ggcttcatgt	aatgttctca	1620
ttaatgaata	cttcctaata	tcgttggctc	tactaatatt	ttccaatttg	ctgggatgtc	1680
acctagcaat	agcttggatt	atatagaaag	taaactgtgg	tcaatacttg	catttaatta	1740
gacgaaacgg	ggagtaatta	tgacacgaag	tacttaatgt	ttatttctta	gtgagctgga	1800
ttatcttgaa	cctgtgctat	taaatggaaa	ttccataca	tcttcccat	actatttttt	1860
ataaaagagc	ctattcaata	gctcagaggt	tgaactctgg	ttaaacaaga	taatatgtta	1920
ttaataaaaa	tagaagaaga	aagaataaag	cttagtcctg	tgtcttttaa	aaattaaaaa	1980
ttttacttga	ttccccatct	atgggcttta	gacctattac	tgggtggagt	cttaaagtta	2040
taattgttca	atatgttttt	tgaacagtgt	gctaaatcaa	tagcaaacc	actgccatat	2100
tagttattct	gaatatacta	aaaaaatcca	gctaagattgc	agtttaataa	ttaaactgta	2160
catactgtgc	atataatgaa	tttttatctt	atgtaaatga	tttttagaac	acaagttggg	2220
aaatgtggct	tctgttcatt	tcgtttaatt	aaagctacct	cctaaactat	agtggctgcc	2280
agtagcagac	tggttaaattg	tggtttatat	actttttgca	ttgtaaatag	tctttgttgt	2340
acattgtcag	tgtaataaaa	acagaatctt	tgtatatcaa	aatcatgtag	tttgtataaa	2400
atgtgggaag	gatttattta	cagtgtgttg	taattttgta	aggccaacta	tttacaagtt	2460
ttaaaaattg	ctatcatgta	tatttacaca	tctgataaat	attaaatcat	aacttggtta	2520
gaaactccta	attaaaagggt	tttttccaaa	attcagggtta	ttgaaaactt	ttcattttat	2580
tcatttaaaa	actagaataa	cagatatata	aaagtgttaa	tctttgtgct	atatggtatg	2640
aaatacaata	ttgtactcag	tgttttgaat	tattaaagtt	tctagaaagc	aaaaaaaaaa	2700
aaaaaaaaaa						2709

&lt;210&gt; 103

&lt;211&gt; 1722

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (401)..(401)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (695)..(695)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 103

gggaccgcgc	tgtcctgctg	tcaccaagag	ctggagacac	catctccac	cgagagtcac	60
ggccccattg	gccttgcaac	tcctcgctct	cgtcccatc	ctctcagcc	tgggtggcctc	120
ccaggactgg	aaggctgaac	gcagccaaga	ccccttcgag	aaatgcatgc	aggatcctga	180
ctatgagcag	ctgctcaagg	tcaccatcct	ggaggcagat	aacaggatcg	ggggccgcat	240
cttcacctac	cgggaccaga	wyacgggctg	gattggggag	ctgggagcca	tgcgcatgcc	300
cagctctcac	aggatcctcc	acaagctctg	ccagggcctg	gggctcaacc	tgaccaagtt	360
caccagctac	gacaagaaca	cgtggacgga	ggtgcacgaa	ntgaagctgc	gcaactatgt	420
ggtggagaag	gtgcccgaga	agctgggcta	cgccttgctg	ccccaggaaa	agggccactc	480
gcccgaaagc	atctaccaga	tggctctcaa	ccaggccctc	aaagacctca	aggcactggg	540
ctgcagaaag	gcgatgaaga	agtttgaaag	gcacacgctc	ttggaatata	ttctcgggga	600
ggggaacctg	agccggcccg	ccgtgcagct	tctgggagac	gtgatgtccg	aggatggctt	660
cttctatctc	agcttcgccc	aggccctccg	ggccnacagc	tgcctcagcg	acagactcca	720
gtacagccgc	atcgtgggtg	gctgggacct	gctgccgcgc	gcgctgctga	gctcgtgtgc	780
cgggcttggt	ctgttgaaag	cgcctgtggt	ggcgatgacc	cagggaccgc	acgatgtgca	840
cgtgcagatc	gagacctctc	ccccggcgcg	gaatctgaag	gtgctgaagg	ccgacgtggg	900
gctgctgacg	gcgagcggac	cggcggtgaa	gcgcacacac	ttctcgccgc	gctgccccgc	960
cacatgcagg	aggcgctgcg	gaggctgcac	tacgtgccgg	ccaccaaggt	gttcctaagc	1020
ttccgcaggc	ccttctggcg	cgaggagcac	attgaaggcg	gccactcaaa	caccgatcgc	1080
ccgtcgcgca	tgattttcta	cccgcgcgcg	cgcgagggcg	cgtgctgctg	ggcctcgtae	1140
acgtggctcg	acgcggcggc	agcgttcgcc	ggcttgagcc	gggaagaggc	ggtgcgcttg	1200
gcgctcgacg	acgtggcggc	attgcacggg	cctgtcgtgc	gccagctctg	ggacggcacc	1260
ggcgctcgta	agcgttgggc	ggaggaccag	cacagccagg	gtggctttgt	ggtacagmcg	1320
ccggcgctct	ggcaaaccga	aaaggatgac	tggacggtcc	cttatggccg	catctacttt	1380

64

```

gccggcgagc acaccgccta cccgcacggc tgggtggaga cggcgggtcaa gtcggcgctg 1440
cgcgcccgcca tcaagatcaa cagccggaag gggcctgcat cggacacggc cagccccgag 1500
gggcacgcat ctgacatgga ggggcagggg catgtgcatg gggtgccag cagccccctg 1560
catgacctgg caaaggaaga aggcagccac cctccagtc aagggcagtt atctctccaa 1620
aacacgaccc acacgaggac ctgcattaa agtattttcg gaaaaaaaaa aaaaaaaaaa 1680
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaagggcgg cc 1722

```

&lt;210&gt; 104

&lt;211&gt; 106

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (14)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 104

```

Met Gly Ser Leu Ser Gly Cys Ala Leu Pro Phe Cys Leu Xaa Val Phe
  1             5             10             15

```

```

Phe Leu Thr Val Ser Pro Ser Ala Val Gly Leu Leu Xaa Phe Ala Gly
          20             25             30

```

```

Gly Pro Leu Gln Thr Leu Phe Ala Trp Val Ser Pro Val Glu Ala Ala
          35             40             45

```

```

Glu Gln Gln Arg Leu Leu Pro Val Leu Ser Ser Gly Ser Phe Val Ser
          50             55             60

```

```

Glu Gly Thr Cys Gln Met Pro Ala Arg Ala Leu Leu Tyr Glu Val Ser
          65             70             75             80

```

```

Val Gly Pro Tyr Trp Glu Ile Pro Pro Ser Gln Asp Thr Arg Arg Ser
          85             90             95

```

```

Gly Thr Tyr Leu Arg Arg Gln Ser Asp Pro
          100             105

```

&lt;210&gt; 105

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 105

```

Met Thr Leu Pro Ser Arg Ala Leu Ala Ser Leu Gly Val Gly Val Trp
  1             5             10             15

```

```

Gly Met Leu Arg Leu Asn Gln Val Thr Val Ser Cys Gly Gly Ser Arg
          20             25             30

```

```

Trp Ser Ser Arg Val Ala Leu Gly Ala Phe Ser Trp Val Cys Gly Val
          35             40             45

```

65

Ala Leu Val Leu Gln Pro Ser Gly Gly Gly Leu Gly Leu Thr Ser Pro  
 50 55 60

Ser Glu Gly Cys Trp Glu Gly Glu Leu Ala Leu Ala Val Leu Arg Ala  
 65 70 75 80

Pro Gly Gly Ser Pro Ser  
 85

<210> 106  
 <211> 302  
 <212> PRT  
 <213> Homo sapiens

<400> 106  
 Met Ala Arg Ala Arg Gly Ser Pro Cys Pro Pro Leu Pro Pro Gly Arg  
 1 5 10 15

Met Ser Trp Pro His Gly Ala Leu Leu Phe Leu Trp Leu Phe Ser Pro  
 20 25 30

Pro Leu Gly Ala Gly Gly Gly Gly Val Ala Val Thr Ser Ala Ala Gly  
 35 40 45

Gly Gly Ser Pro Pro Ala Thr Ser Cys Pro Val Ala Cys Ser Cys Ser  
 50 55 60

Asn Gln Ala Ser Arg Val Ile Cys Thr Arg Arg Asp Leu Ala Glu Val  
 65 70 75 80

Pro Ala Ser Ile Pro Val Asn Thr Arg Tyr Leu Asn Leu Gln Glu Asn  
 85 90 95

Gly Ile Gln Val Ile Arg Thr Asp Thr Phe Lys His Leu Arg His Leu  
 100 105 110

Glu Ile Leu Gln Leu Ser Lys Asn Leu Val Arg Lys Ile Glu Val Gly  
 115 120 125

Ala Phe Asn Gly Leu Pro Ser Leu Asn Thr Leu Glu Leu Phe Asp Asn  
 130 135 140

Arg Leu Thr Thr Val Pro Thr Gln Ala Phe Glu Tyr Leu Ser Lys Leu  
 145 150 155 160

Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu Ser Ile Pro Ser Tyr  
 165 170 175

Ala Phe Asn Arg Val Pro Ser Leu Arg Arg Leu Asp Leu Gly Glu Leu  
 180 185 190

Lys Arg Leu Glu Tyr Ile Ser Glu Ala Ala Phe Glu Gly Leu Val Asn  
 195 200 205

Leu Arg Tyr Leu Asn Leu Gly Met Cys Asn Leu Lys Asp Ile Pro Asn  
 210 215 220

66

Leu Thr Ala Leu Val Arg Leu Glu Glu Leu Glu Leu Ser Gly Asn Arg  
 225 230 235 240

Leu Asp Leu Ile Arg Pro Gly Ser Phe Gln Gly Leu Thr Ser Leu Arg  
 245 250 255

Lys Leu Trp Leu Met His Ala Gln Val Ala Thr Ile Glu Arg Asn Ala  
 260 265 270

Phe Asp Asp Leu Lys Ser Leu Glu Glu Leu Asn Leu Ser His Asn Asn  
 275 280 285

Leu Met Ser Leu Pro His Asp Leu Phe Thr Pro Leu His Arg  
 290 295 300

&lt;210&gt; 107

&lt;211&gt; 55

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 107

Met Pro Ser Ser Trp Leu Pro Gly Cys Phe Val Leu Leu Cys Leu Val  
 1 5 10 15

Ala Val Gly Cys Gln Leu Arg Glu Trp Gly Val Gly Gly Val Ser Ala  
 20 25 30

Val Gly Leu Leu Ala Leu Pro His Leu Gln Val Leu Gly Met Arg Gly  
 35 40 45

Arg Gly Leu Ile Ser Gly Gly  
 50 55

&lt;210&gt; 108

&lt;211&gt; 189

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (94)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 108

Met Ala Leu Leu Ser Arg Pro Ala Leu Thr Leu Leu Leu Leu Met  
 1 5 10 15

Ala Ala Val Val Arg Cys Gln Glu Gln Ala Gln Thr Thr Asp Trp Arg  
 20 25 30

Ala Thr Leu Lys Thr Ile Arg Asn Gly Val His Lys Ile Asp Thr Tyr  
 35 40 45

Leu Asn Ala Ala Leu Asp Leu Gly Gly Glu Asp Gly Leu Cys Gln  
 50 55 60

67

Tyr Lys Cys Ser Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys  
 65 70 75 80  
 Pro Ser Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Xaa His Leu  
 85 90 95  
 Asn Ile Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg  
 100 105 110  
 Cys Tyr Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe  
 115 120 125  
 Gln Tyr Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly  
 130 135 140  
 Leu Thr Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe  
 145 150 155 160  
 Asp Ser Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg  
 165 170 175  
 Ala Ala Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu  
 180 185

&lt;210&gt; 109

&lt;211&gt; 60

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

Met Gly Asn Cys Gln Ala Gly His Asn Leu His Leu Cys Leu Ala His  
 1 5 10 15  
 His Pro Pro Leu Val Cys Ala Thr Leu Ile Leu Leu Leu Leu Gly Leu  
 20 25 30  
 Ser Gly Leu Gly Leu Gly Ser Phe Leu Leu Thr His Arg Thr Gly Leu  
 35 40 45  
 Arg Thr Leu Thr Ser Pro Arg Thr Gly Ser Leu Phe  
 50 55 60

&lt;210&gt; 110

&lt;211&gt; 128

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (90)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

68

&lt;400&gt; 110

```

Met Arg Leu Glu Ser Leu Cys His Leu Cys Leu Ala Cys Leu Phe Phe
 1           5           10           15

Arg Leu Pro Ala Thr Arg Thr Val Tyr Cys Met Asn Glu Ala Glu Ile
          20           25           30

Val Asp Val Ala Leu Gly Ile Leu Ile Glu Ser Arg Lys Gln Xaa Lys
          35           40           45

Ala Cys Glu Gln Pro Ala Leu Ala Gly Ala Asp Asn Pro Glu His Ser
          50           55           60

Pro Pro Cys Ser Val Ser Pro His Thr Ser Ser Gly Ser Ser Ser Glu
 65           70           75           80

Glu Glu Asp Ser Gly Lys Gln Ala Leu Xaa Pro Gly Leu Ser Pro Ser
          85           90           95

Gln Arg Pro Gly Gly Ser Ser Ser Ala Cys Ser Arg Ser Pro Glu Glu
          100          105          110

Glu Glu Glu Glu Asp Val Leu Lys Tyr Val Arg Glu Ile Phe Phe Ser
 115          120          125

```

&lt;210&gt; 111

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (50)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 111

```

Met Pro His Phe Leu Asp Trp Phe Val Pro Val Tyr Leu Val Ile Ser
 1           5           10           15

Val Leu Ile Leu Val Gly Phe Gly Ala Cys Ile Tyr Tyr Phe Glu Pro
          20           25           30

Gly Leu Gln Glu Ala His Lys Trp Arg Met Gln Arg Pro Leu Val Asp
          35           40           45

Arg Xaa Leu Arg Lys Thr Leu Met Val Arg Asp Asn Leu Ala Phe Gly
          50           55           60

Gly Pro Glu Val
 65

```

&lt;210&gt; 112

69

&lt;211&gt; 122

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 112

Met Ile Gly Gly Ile Thr Cys Ile Leu Ser Leu Ile Cys Ala Leu Ala  
 1 5 10 15

Leu Ala Tyr Leu Asp Gln Arg Ala Glu Arg Ile Leu His Lys Glu Gln  
 20 25 30

Gly Lys Thr Gly Glu Val Ile Lys Leu Thr Asp Val Lys Asp Phe Ser  
 35 40 45

Leu Pro Leu Trp Leu Ile Phe Ile Ile Cys Val Cys Tyr Tyr Val Ala  
 50 55 60

Val Phe Pro Phe Ile Gly Leu Gly Lys Val Phe Phe Thr Glu Lys Phe  
 65 70 75 80

Gly Phe Ser Ser Gln Ala Ala Ser Ala Ile Asn Ser Val Val Tyr Val  
 85 90 95

Ile Ser Ala Pro Met Ser Pro Val Phe Gly Leu Leu Val Asp Lys Thr  
 100 105 110

Gly Lys Asn Ile Ile Trp Val Leu Cys Ala  
 115 120

&lt;210&gt; 113

&lt;211&gt; 82

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Met Glu Lys Gln Cys Cys Ser His Pro Val Ile Cys Ser Leu Ser Thr  
 1 5 10 15

Met Tyr Thr Phe Leu Leu Gly Ala Ile Phe Ile Ala Leu Ser Ser Ser  
 20 25 30

Arg Ile Leu Leu Val Lys Tyr Ser Ala Asn Glu Gly Lys Leu Arg Leu  
 35 40 45

Gly Ile Cys Met Glu His Phe His Leu Ile Thr His Leu Ser Leu Ala  
 50 55 60

Phe Gly Ser Val Ile Tyr Asn Met Glu Ile Ile Met Pro Phe Ala Ser  
 65 70 75 80

Cys Glu

&lt;210&gt; 114

&lt;211&gt; 344

&lt;212&gt; PRT

70

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (53)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 114

Met	Asp	Phe	Leu	Val	Leu	Phe	Leu	Phe	Tyr	Leu	Ala	Ser	Val	Leu	Met
1				5					10					15	

Gly	Leu	Val	Leu	Ile	Cys	Val	Cys	Ser	Lys	Thr	His	Ser	Leu	Lys	Gly
		20						25					30		

Leu	Ala	Arg	Gly	Gly	Ala	Gln	Ile	Phe	Ser	Cys	Ile	Ile	Pro	Glu	Cys
		35				40						45			

Leu	Gln	Arg	Ala	Xaa	His	Gly	Leu	Leu	His	Tyr	Leu	Phe	His	Thr	Arg
	50					55					60				

Asn	His	Thr	Phe	Ile	Val	Leu	His	Leu	Val	Leu	Gln	Gly	Met	Val	Tyr
65					70					75					80

Thr	Glu	Tyr	Thr	Trp	Glu	Val	Phe	Gly	Tyr	Cys	Gln	Glu	Leu	Glu	Leu
				85					90					95	

Ser	Leu	His	Tyr	Leu	Leu	Leu	Pro	Tyr	Leu	Leu	Leu	Gly	Val	Asn	Leu
			100					105						110	

Phe	Phe	Phe	Thr	Leu	Thr	Cys	Gly	Thr	Asn	Pro	Gly	Ile	Ile	Thr	Lys
		115					120					125			

Ala	Asn	Glu	Leu	Leu	Phe	Leu	His	Val	Tyr	Glu	Phe	Asp	Glu	Val	Met
	130					135					140				

Phe	Pro	Lys	Asn	Val	Arg	Cys	Ser	Thr	Cys	Asp	Leu	Arg	Lys	Pro	Ala
145					150					155					160

Arg	Ser	Lys	His	Cys	Ser	Val	Cys	Asn	Trp	Cys	Val	His	Arg	Phe	Asp
				165					170					175	

His	His	Cys	Val	Trp	Val	Asn	Asn	Cys	Ile	Gly	Ala	Trp	Asn	Ile	Arg
			180					185					190		

Tyr	Phe	Leu	Ile	Tyr	Val	Leu	Thr	Leu	Thr	Ala	Ser	Ala	Ala	Thr	Val
		195					200					205			

Ala	Ile	Val	Ser	Thr	Thr	Phe	Leu	Val	His	Leu	Val	Val	Met	Ser	Asp
	210					215					220				

Leu	Tyr	Gln	Glu	Thr	Tyr	Ile	Asp	Asp	Leu	Gly	His	Leu	His	Val	Met
225					230					235					240

Asp	Thr	Val	Phe	Leu	Ile	Gln	Tyr	Leu	Phe	Leu	Thr	Phe	Pro	Arg	Ile
			245						250					255	

Val	Phe	Met	Leu	Gly	Phe	Val	Val	Val	Leu	Ser	Phe	Leu	Leu	Gly	Gly
		260						265						270	

Tyr	Leu	Leu	Phe	Val	Leu	Tyr	Leu	Ala	Ala	Thr	Asn	Gln	Thr	Thr	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----



71

275                      280                      285  
 Glu Trp Tyr Arg Gly Asp Trp Ala Trp Cys Gln Arg Cys Pro Leu Val  
     290                      295                      300  
 Ala Trp Pro Pro Ser Ala Glu Pro Gln Val His Arg Asn Ile His Ser  
     305                      310                      315                      320  
 His Gly Leu Arg Ser Asn Leu Gln Glu Ile Phe Leu Pro Ala Phe Pro  
                     325                      330                      335  
 Cys His Glu Arg Lys Lys Gln Glu  
                     340

&lt;210&gt; 115

&lt;211&gt; 181

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (110)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 115

Met Ala Asp Pro His Val Ser Phe Leu Ser Phe Arg Gln Leu Phe Ser  
     1                      5                      10                      15  
 Trp Ala Ala Val Ile Leu Leu Arg Gly Ile Leu Gly Thr Val Ala Pro  
                     20                      25                      30  
 Pro Pro Cys Pro Cys Val Leu Asp Leu Ala Val Tyr Pro Leu His Leu  
                     35                      40                      45  
 Pro Val Glu Ala Pro Cys Leu Glu Val Val Phe Lys Gln Lys Asn Gly  
     50                      55                      60  
 Lys Asp Asn Cys Leu Val Phe Tyr Pro Asp Pro Ile Pro Leu Arg Gly  
     65                      70                      75                      80  
 Ser Leu Leu Gly Pro Phe Ile Lys Asn Gln Cys His Ser Ser Val Ile  
                     85                      90                      95  
 Pro Leu Ser Asp Ser Ala Thr Ser Lys Ala Arg Ala Leu Xaa Leu Pro  
                     100                      105                      110  
 Gly Arg Glu Thr Val Leu Ser Val Leu Pro Val Phe Ser Ser Pro Thr  
     115                      120                      125  
 Leu Pro Arg Thr His Ala Leu Gly Asp Ser Leu Gly Val Pro Gly Leu  
     130                      135                      140  
 Leu Val Cys Ser Glu Thr Ser Thr Leu Asn Asp His Trp Cys Cys Arg  
     145                      150                      155                      160  
 Arg Ala Gly Ala Tyr Ile Pro Ile Asn Arg Arg Phe Ser His Leu Met  
                     165                      170                      175

72

Pro Leu Ala Phe Ser  
180

&lt;210&gt; 116

&lt;211&gt; 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 116

Met Pro Ser Ser Ser Ser Gly Leu Gly Ser Pro Ser Arg Pro Pro Ser  
1 5 10 15

Ser Phe Leu Cys Leu Leu Leu Leu Leu Leu Pro Pro Ala Ala Leu Ala  
20 25 30

Leu Leu Leu Phe Phe Leu Asp Phe Phe Pro Pro Arg Ala Ala Val Ser  
35 40 45

Pro Phe Leu Pro Asp His Cys Ser Ala Arg Gln Pro Arg Val Trp Arg  
50 55 60

Arg Glu Thr Leu Asn Arg Ser Ala Ser Gly Leu Gly Cys Trp Ala Arg  
65 70 75 80

Ser Thr Glu Gln Gly Ala Val Gly Val Ala Thr Gly Thr Val Leu Asp  
85 90 95

Ile Ser Leu Pro Ala Ser Cys Leu Ser Leu Trp Pro Pro Gly Pro Ser  
100 105 110

Gly Gly Ile  
115

&lt;210&gt; 117

&lt;211&gt; 70

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

Met Asn Leu Leu Gly Met Ile Phe Ser Met Cys Gly Leu Met Leu Lys  
1 5 10 15

Leu Lys Trp Cys Ala Trp Val Ala Val Tyr Cys Ser Phe Ile Ser Phe  
20 25 30

Ala Asn Ser Arg Ser Ser Glu Asp Thr Lys Gln Met Met Ser Ser Phe  
35 40 45

Met Leu Ser Ile Ser Ala Val Val Met Ser Tyr Leu Gln Asn Pro Gln  
50 55 60

Pro Met Thr Pro Pro Trp  
65 70

73

&lt;210&gt; 118

&lt;211&gt; 63

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 118

Met Arg Asp Leu Ser Phe Leu Tyr Thr Leu Leu Trp Leu Pro Glu Ile  
 1 5 10 15

Trp Gln Ala Leu Ala Gly Gly Ile Arg Leu Asp Glu Val Glu Leu Leu  
 20 25 30

Glu Asn Glu Ala Val Leu Gly Glu Glu Met Arg Leu Tyr Arg Lys Ile  
 35 40 45

Asn Glu Val Val Leu Ser Gly Asn Glu Val Val Leu Gly Gly Lys  
 50 55 60

&lt;210&gt; 119

&lt;211&gt; 334

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe  
 1 5 10 15

Ala Thr Ala Ala Val Ile Val Ser Gly Val Ser Lys His Leu His Cys  
 20 25 30

Ile Ser His Gln Lys Ser Thr Thr Val Ser His Glu Met Ser Gly Leu  
 35 40 45

Asn Trp Lys Pro Phe Val Tyr Gly Gly Leu Ala Ser Ile Val Ala Glu  
 50 55 60

Phe Gly Thr Phe Pro Val Asp Leu Thr Lys Thr Arg Leu Gln Val Gln  
 65 70 75 80

Gly Gln Ser Ile Asp Ala Arg Phe Lys Glu Ile Lys Tyr Arg Gly Met  
 85 90 95

Phe His Ala Leu Phe Arg Ile Cys Lys Glu Glu Gly Val Leu Ala Leu  
 100 105 110

Tyr Ser Gly Ile Ala Pro Ala Leu Leu Arg Gln Ala Ser Tyr Gly Thr  
 115 120 125

Ile Lys Ile Gly Ile Tyr Gln Ser Leu Lys Arg Leu Phe Val Glu Arg  
 130 135 140

Leu Glu Asp Glu Thr Leu Leu Ile Asn Met Ile Cys Gly Val Val Ser  
 145 150 155 160

Gly Val Ile Ser Ser Thr Ile Ala Asn Pro Thr Asp Val Leu Lys Ile  
 165 170 175

Arg Met Gln Ala Gln Gly Ser Leu Phe Gln Gly Ser Met Ile Gly Ser

74

180	185	190
Phe Ile Asp Ile Tyr Gln Gln Glu Gly Thr Arg Gly Leu Trp Arg Gly		
195	200	205
Val Val Pro Thr Ala Gln Arg Ala Ala Ile Val Val Gly Val Glu Leu		
210	215	220
Pro Val Tyr Asp Ile Thr Lys Lys His Leu Ile Leu Ser Gly Met Met		
225	230	235
Gly Asp Thr Ile Leu Thr His Phe Val Ser Ser Phe Thr Cys Gly Leu		
245	250	255
Ala Gly Ala Leu Ala Ser Asn Pro Val Asp Val Val Arg Thr Arg Met		
260	265	270
Met Asn Gln Arg Ala Ile Val Gly His Val Asp Leu Tyr Lys Gly Thr		
275	280	285
Val Asp Gly Ile Leu Lys Met Trp Lys His Glu Gly Phe Phe Ala Leu		
290	295	300
Tyr Lys Gly Phe Trp Pro Asn Trp Leu Arg Leu Gly Pro Trp Asn Ile		
305	310	315
Ile Phe Phe Ile Thr Tyr Glu Gln Leu Lys Arg Leu Gln Ile		
325	330	

&lt;210&gt; 120

&lt;211&gt; 221

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 120

Met Ala Leu Ala Leu Ala Ala Leu Ala Ala Val Glu Pro Ala Cys Gly		
1	5	10
Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly Glu Pro Glu		
20	25	30
Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile Ser Ala Glu		
35	40	45
Ser Ala Xaa Tyr Phe Asp Tyr Lys Asp Glu Ser Gly Phe Pro Lys Pro		
50	55	60
Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser Tyr Asp Glu Ala Glu		
65	70	75
Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu Val Pro Gly Arg Asp Glu		
85	90	95

75

Asp Phe Val Gly Arg Asp Asp Phe Asp Asp Ala Asp Gln Leu Arg Ile  
 100 105 110  
 Gly Asn Asp Gly Ile Phe Met Leu Thr Phe Phe Met Ala Phe Leu Phe  
 115 120 125  
 Asn Trp Ile Gly Phe Phe Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala  
 130 135 140  
 Gly Arg Tyr Gly Ala Ile Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp  
 145 150 155 160  
 Ile Leu Ile Val Arg Phe Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly  
 165 170 175  
 Gln Tyr Trp Leu Trp Trp Val Phe Leu Val Leu Gly Phe Leu Leu Phe  
 180 185 190  
 Leu Arg Gly Phe Ile Asn Tyr Ala Lys Val Arg Lys Met Pro Glu Thr  
 195 200 205  
 Phe Ser Asn Leu Pro Arg Thr Arg Val Leu Phe Ile Tyr  
 210 215 220

&lt;210&gt; 121

&lt;211&gt; 472

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 121

Met Lys Phe Leu Ile Phe Ala Phe Phe Gly Gly Val His Leu Leu Ser  
 1 5 10 15  
 Leu Cys Ser Gly Lys Ala Ile Cys Lys Asn Gly Ile Ser Lys Arg Thr  
 20 25 30  
 Phe Glu Glu Ile Lys Glu Glu Ile Ala Ser Cys Gly Asp Val Ala Lys  
 35 40 45  
 Ala Ile Ile Asn Leu Ala Val Tyr Gly Lys Ala Gln Asn Arg Ser Tyr  
 50 55 60  
 Glu Arg Leu Ala Leu Leu Val Asp Thr Val Gly Pro Arg Leu Ser Gly  
 65 70 75 80  
 Ser Lys Asn Leu Glu Lys Ala Ile Gln Ile Met Tyr Gln Asn Leu Gln  
 85 90 95  
 Gln Asp Gly Leu Glu Lys Val His Leu Glu Pro Val Arg Ile Pro His  
 100 105 110  
 Trp Glu Arg Gly Glu Glu Ser Ala Val Met Leu Glu Pro Arg Ile His  
 115 120 125  
 Lys Ile Ala Ile Leu Gly Leu Gly Ser Ser Ile Gly Thr Pro Pro Glu  
 130 135 140  
 Gly Ile Thr Ala Glu Val Leu Val Val Thr Ser Phe Asp Glu Leu Gln

76

145		150		155		160
Arg Arg Ala Ser Glu Ala Arg Gly Lys Ile Val Val Tyr Asn Gln Pro						
		165		170		175
Tyr Ile Asn Tyr Ser Arg Thr Val Gln Tyr Arg Thr Gln Gly Ala Val						
		180		185		190
Glu Ala Ala Lys Val Gly Ala Leu Ala Ser Leu Ile Arg Ser Val Ala						
		195		200		205
Ser Phe Ser Ile Tyr Ser Pro His Thr Gly Ile Gln Glu Tyr Gln Asp						
		210		215		220
Gly Val Pro Lys Ile Pro Thr Ala Cys Ile Thr Val Glu Asp Ala Glu						
		225		230		235
Met Met Ser Arg Met Ala Ser His Gly Ile Lys Ile Val Ile Gln Leu						
		245		250		255
Lys Met Gly Ala Lys Thr Tyr Pro Asp Thr Asp Ser Phe Asn Thr Val						
		260		265		270
Ala Glu Ile Thr Gly Ser Lys Tyr Pro Glu Gln Val Val Leu Val Ser						
		275		280		285
Gly His Leu Asp Ser Trp Asp Val Gly Gln Gly Ala Met Asp Asp Gly						
		290		295		300
Gly Gly Ala Phe Ile Ser Trp Glu Ala Leu Ser Leu Ile Lys Asp Leu						
		305		310		315
Gly Leu Arg Pro Lys Arg Thr Leu Arg Leu Val Leu Trp Thr Ala Glu						
		325		330		335
Glu Gln Gly Gly Val Gly Ala Phe Gln Tyr Tyr Gln Leu His Lys Val						
		340		345		350
Asn Ile Ser Asn Tyr Ser Leu Val Met Glu Ser Asp Ala Gly Thr Phe						
		355		360		365
Leu Pro Thr Gly Leu Gln Phe Thr Gly Ser Glu Lys Ala Arg Ala Ile						
		370		375		380
Met Glu Glu Val Met Ser Leu Leu Gln Pro Leu Asn Ile Thr Gln Val						
		385		390		395
Leu Ser His Gly Glu Gly Thr Asp Ile Asn Phe Trp Ile Gln Ala Gly						
		405		410		415
Val Pro Gly Ala Ser Leu Leu Asp Asp Leu Tyr Lys Tyr Phe Phe Phe						
		420		425		430
His His Ser His Gly Asp Thr Met Thr Val Met Asp Pro Lys Gln Met						
		435		440		445
Asn Val Ala Ala Ala Val Trp Ala Val Val Ser Tyr Val Val Ala Asp						
		450		455		460
Met Glu Glu Met Leu Pro Arg Ser						

77

465

470

&lt;210&gt; 122

&lt;211&gt; 167

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser  
 1 5 10 15

Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr  
 20 25 30

Pro Pro Ser Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly  
 35 40 45

Pro Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu  
 50 55 60

Arg Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile  
 65 70 75 80

Leu Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro  
 85 90 95

Ile Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp  
 100 105 110

Asp Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu  
 115 120 125

Ala Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Ala  
 130 135 140

Gln Gln Arg Trp Lys Leu Gln Val Gln Glu Gln Arg Lys Ser Val Phe  
 145 150 155 160

Asp Arg His Val Val Leu Ser  
 165

&lt;210&gt; 123

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Met Lys Phe Ile Leu Trp Arg Arg Phe Arg Trp Ala Ile Ile Leu Phe  
 1 5 10 15

Ile Ile Leu Phe Ile Leu Leu Leu Phe Leu Ala Ile Phe Ile Tyr Ala  
 20 25 30

Phe Pro Asn Tyr Ala Ala Met Lys Leu Val Lys Pro Phe Ser  
 35 40 45

<210> 124  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<400> 124  
 Met His Gln Asp Trp Leu Cys Asn Leu Gly Trp Pro Leu Leu Ser Leu  
     1                    5                    10                    15  
 Trp Ala Ala Glu Ser Ala Pro His Val Ala Met Ala Ser Ala Thr Ala  
                     20                    25                    30  
 Gln Leu Trp Ser Arg Pro Cys Gly Arg Thr His Met Val Ser Leu Ala  
                     35                    40                    45  
 Leu Gly His Gln Glu Thr Gly Leu Trp Leu Cys Ser Ala Phe Gly Cys  
                     50                    55                    60  
 Val Val Asp Ser Pro Trp Ala Ser Val Cys Pro Ser Val Lys Gly Gln  
                     65                    70                    75                    80  
 Leu Thr Val Cys Gly Ile Leu Pro Arg Val Pro Val Cys Val Tyr Val  
                     85                    90                    95  
 Cys Ala Cys Val Arg Val Ser Met Cys Val His Ile  
                     100                    105

<210> 125  
 <211> 60  
 <212> PRT  
 <213> Homo sapiens

<400> 125  
 Met Arg Gly Cys Val Pro Ala Phe Leu Leu His Val Leu Ser Leu Arg  
     1                    5                    10                    15  
 Arg Ala Cys Cys Thr Gln Ala Ala Gln Val Phe Thr Ala Gln Leu Pro  
                     20                    25                    30  
 Gly Arg Gln Val Ala Arg Arg Arg Gly Gly Trp His Glu Gln Gln Gly  
                     35                    40                    45  
 Gly Pro Met Leu Cys Ser Ser His His Ser Arg Thr  
                     50                    55                    60

<210> 126  
 <211> 248  
 <212> PRT  
 <213> Homo sapiens

<400> 126  
 Met Ala Met Leu Pro Leu Val Leu His Trp Phe Phe Ile Glu Trp Tyr  
     1                    5                    10                    15



79

Ser Gly Lys Lys Ser Ser Ser Ala Leu Phe Gln His Ile Thr Ala Leu  
                     20                    25                    30  
 Phe Glu Cys Ser Met Ala Ala Ile Ile Thr Leu Leu Val Ser Asp Pro  
                     35                    40                    45  
 Val Gly Val Leu Tyr Ile Arg Ser Cys Arg Val Leu Met Leu Ser Asp  
                     50                    55                    60  
 Trp Tyr Thr Met Leu Tyr Asn Pro Ser Pro Asp Tyr Val Thr Thr Val  
                     65                    70                    75                    80  
 His Cys Thr His Glu Ala Val Tyr Pro Leu Tyr Thr Ile Val Phe Ile  
                     85                    90                    95  
 Tyr Tyr Ala Phe Cys Leu Val Leu Met Met Leu Leu Arg Pro Leu Leu  
                     100                    105                    110  
 Val Lys Lys Ile Ala Cys Gly Leu Gly Lys Ser Asp Arg Phe Lys Ser  
                     115                    120                    125  
 Ile Tyr Ala Ala Leu Tyr Phe Phe Pro Ile Leu Thr Val Leu Gln Ala  
                     130                    135                    140  
 Val Gly Gly Gly Leu Leu Tyr Tyr Ala Phe Pro Tyr Ile Ile Leu Val  
                     145                    150                    155                    160  
 Leu Ser Leu Val Thr Leu Ala Val Tyr Met Ser Ala Ser Glu Ile Glu  
                     165                    170                    175  
 Asn Cys Tyr Asp Leu Leu Val Arg Lys Lys Arg Leu Ile Val Leu Phe  
                     180                    185                    190  
 Ser His Trp Leu Leu His Ala Tyr Gly Ile Ile Ser Ile Ser Arg Val  
                     195                    200                    205  
 Asp Lys Leu Glu Gln Asp Leu Pro Pro Leu Ala Leu Val Pro Thr Pro  
                     210                    215                    220  
 Ala Leu Phe Tyr Leu Phe Thr Ala Lys Phe Thr Glu Pro Ser Arg Ile  
                     225                    230                    235                    240  
 Leu Ser Glu Gly Ala Asn Gly His  
                     245

&lt;210&gt; 127

&lt;211&gt; 248

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 127

Met Glu Lys Ile Pro Glu Ile Gly Lys Phe Gly Glu Lys Ala Pro Pro  
                     1                    5                    10                    15  
 Ala Pro Ser His Val Trp Arg Pro Ala Ala Leu Phe Leu Thr Leu Leu  
                     20                    25                    30  
 Cys Leu Leu Leu Leu Ile Gly Leu Gly Val Leu Ala Ser Met Phe His

80

35	40	45
Val Thr Leu Lys Ile Glu Met Lys Lys Met Asn Lys Leu Gln Asn Ile		
50	55	60
Ser Glu Glu Leu Gln Arg Asn Ile Ser Leu Gln Leu Met Ser Asn Met		
65	70	75
Asn Ile Ser Asn Lys Ile Arg Asn Leu Ser Thr Thr Leu Gln Thr Ile		
85	90	95
Ala Thr Lys Leu Cys Arg Glu Leu Tyr Ser Lys Glu Gln Glu His Lys		
100	105	110
Cys Lys Pro Cys Pro Arg Arg Trp Ile Trp His Lys Asp Ser Cys Tyr		
115	120	125
Phe Leu Ser Asp Asp Val Gln Thr Trp Gln Glu Ser Lys Met Ala Cys		
130	135	140
Ala Ala Gln Asn Ala Ser Leu Leu Lys Ile Asn Asn Lys Asn Ala Leu		
145	150	155
Glu Phe Ile Lys Ser Gln Ser Arg Ser Tyr Asp Tyr Trp Leu Gly Leu		
165	170	175
Ser Pro Glu Glu Asp Ser Thr Arg Gly Met Arg Val Asp Asn Ile Ile		
180	185	190
Asn Ser Ser Ala Trp Val Ile Arg Asn Ala Pro Asp Leu Asn Asn Met		
195	200	205
Tyr Cys Gly Tyr Ile Asn Arg Leu Tyr Val Gln Tyr Tyr His Cys Thr		
210	215	220
Tyr Lys Gln Arg Met Ile Cys Glu Lys Met Ala Asn Pro Val Gln Leu		
225	230	235
Gly Ser Thr Tyr Phe Arg Glu Ala		
245		

&lt;210&gt; 128

&lt;211&gt; 612

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro		
1	5	10
Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg		
20	25	30
Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly		
35	40	45
Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu		
50	55	60

Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
 65 70 75 80  
 Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
 85 90 95  
 Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
 100 105 110  
 Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser  
 115 120 125  
 Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro  
 130 135 140  
 Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile  
 145 150 155 160  
 Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn  
 165 170 175  
 Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His  
 180 185 190  
 Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala  
 195 200 205  
 Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr  
 210 215 220  
 Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu  
 225 230 235 240  
 Asp Gly Asn Phe Ser Val Ser Thr Ile Leu Glu Lys Pro Gln Asn Met  
 245 250 255  
 Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His  
 260 265 270  
 Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser  
 275 280 285  
 Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu  
 290 295 300  
 Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val  
 305 310 315 320  
 Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile  
 325 330 335  
 Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys  
 340 345 350  
 Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro  
 355 360 365  
 Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr  
 370 375 380

82

Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr  
 385 390 395 400  
 Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser  
 405 410 415  
 Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn  
 420 425 430  
 Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu  
 435 440 445  
 Cys Ser Asn Asp Cys Pro Arg Lys Ile Thr Pro Phe Gly Val Asn Gln  
 450 455 460  
 Pro Gly Pro Tyr Ile Met Tyr Thr Thr Val Asp Ala Asn Gly Tyr Leu  
 465 470 475 480  
 Lys Asn Gly Ser Ala Gly Gln Leu Ser Gln Ser Ala His Leu Ala Leu  
 485 490 495  
 Gln Leu Pro Tyr Asn Val Leu Gly Leu Gly Arg Ser Ala Asn Phe Leu  
 500 505 510  
 Asp His Leu Tyr Val Gly Ile Pro Arg Pro Ser Gly Glu Lys Ser Ile  
 515 520 525  
 Arg Lys Gln Glu Trp Thr Ala Ile Ile Pro Asn Ser Gln Leu Ile Val  
 530 535 540  
 Ile Pro Tyr Pro His Asn Val Pro Arg Ser Trp Ser Ala Lys Leu Tyr  
 545 550 555 560  
 Leu Thr Pro Ser Asn Ile Val Leu Leu Thr Ala Ile Ala Leu Ile Gly  
 565 570 575  
 Val Cys Val Phe Ile Leu Ala Ile Ile Gly Ile Leu His Trp Gln Glu  
 580 585 590  
 Lys Lys Ala Asp Asp Arg Glu Lys Arg Gln Glu Ala His Arg Phe His  
 595 600 605  
 Phe Asp Ala Met  
 610

&lt;210&gt; 129

&lt;211&gt; 447

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (309)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (333)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 129

Met	Glu	Leu	Ser	Gln	Met	Ser	Xaa	Leu	Met	Gly	Leu	Ser	Val	Leu	Leu
1				5					10					15	

Gly	Leu	Leu	Ala	Leu	Met	Ala	Thr	Ala	Ala	Val	Xaa	Arg	Gly	Trp	Leu
			20					25					30		

Arg	Ala	Gly	Glu	Glu	Arg	Ser	Gly	Arg	Pro	Ala	Cys	Gln	Lys	Ala	Asn
		35					40					45			

Gly	Phe	Pro	Pro	Asp	Lys	Ser	Ser	Gly	Ser	Lys	Lys	Gln	Lys	Gln	Tyr
	50					55					60				

Gln	Arg	Ile	Arg	Lys	Glu	Lys	Pro	Gln	Gln	His	Asn	Phe	Thr	His	Arg
65					70					75					80

Leu	Leu	Ala	Ala	Ala	Leu	Lys	Ser	His	Ser	Gly	Asn	Ile	Ser	Cys	Met
				85					90					95	

Asp	Phe	Ser	Ser	Asn	Gly	Lys	Tyr	Leu	Ala	Thr	Cys	Ala	Asp	Asp	Arg
			100					105					110		

Thr	Ile	Arg	Ile	Trp	Ser	Thr	Lys	Asp	Phe	Leu	Gln	Arg	Glu	His	Arg
	115						120					125			

Ser	Met	Arg	Ala	Asn	Val	Glu	Leu	Asp	His	Ala	Thr	Leu	Val	Arg	Phe
	130					135					140				

Ser	Pro	Asp	Cys	Arg	Ala	Phe	Ile	Val	Trp	Leu	Ala	Asn	Gly	Asp	Thr
145					150					155				160	

Leu	Arg	Val	Phe	Lys	Met	Thr	Lys	Arg	Glu	Asp	Gly	Gly	Tyr	Thr	Phe
			165						170					175	

Thr	Ala	Thr	Pro	Glu	Asp	Phe	Pro	Lys	Lys	His	Lys	Ala	Pro	Val	Ile
			180					185					190		

Asp	Ile	Gly	Ile	Ala	Asn	Thr	Gly	Lys	Phe	Ile	Met	Thr	Ala	Ser	Ser
	195						200					205			

Asp	Thr	Thr	Val	Leu	Ile	Trp	Ser	Leu	Lys	Gly	Gln	Val	Leu	Ser	Thr
	210					215					220				

Ile	Asn	Thr	Asn	Gln	Met	Asn	Asn	Thr	His	Ala	Ala	Val	Ser	Pro	Cys
225					230					235					240

Gly	Arg	Phe	Val	Ala	Ser	Cys	Gly	Phe	Thr	Pro	Asp	Val	Lys	Val	Trp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

84

245	250	255
Glu Val Cys Phe Gly Lys Lys Gly Glu Phe Gln Glu Val Val Arg Ala		
260	265	270
Phe Glu Leu Lys Gly His Ser Ala Ala Val His Ser Phe Ala Phe Ser		
275	280	285
Asn Asp Ser Arg Arg Met Ala Ser Val Ser Lys Asp Gly Thr Trp Lys		
290	295	300
Leu Trp Asp Thr Xaa Val Glu Tyr Lys Lys Lys Gln Asp Pro Tyr Leu		
305	310	315
Leu Lys Thr Gly Arg Phe Glu Glu Ala Ala Gly Ala Xaa Pro Cys Arg		
325	330	335
Leu Ala Leu Ser Pro Asn Ala Gln Val Leu Ala Leu Ala Ser Gly Ser		
340	345	350
Ser Ile His Leu Tyr Asn Thr Arg Arg Gly Glu Lys Glu Glu Cys Phe		
355	360	365
Glu Arg Val His Gly Glu Cys Ile Ala Asn Leu Ser Phe Asp Ile Thr		
370	375	380
Gly Arg Phe Leu Ala Ser Cys Gly Asp Arg Ala Val Arg Leu Phe His		
385	390	395
Asn Thr Pro Gly His Arg Ala Met Val Glu Glu Met Gln Gly His Leu		
405	410	415
Lys Arg Ala Ser Asn Glu Ser Thr Arg Gln Arg Leu Gln Gln Gln Leu		
420	425	430
Thr Gln Ala Gln Glu Thr Leu Lys Ser Leu Gly Ala Leu Lys Lys		
435	440	445

&lt;210&gt; 130

&lt;211&gt; 291

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

Met Leu Phe Leu Phe Ser Met Ala Thr Leu Leu Arg Thr Ser Phe Ser		
1	5	10
Asp Pro Gly Val Ile Pro Arg Ala Leu Pro Asp Glu Ala Ala Phe Ile		
20	25	30
Glu Met Glu Ile Glu Ala Thr Asn Gly Ala Val Pro Gln Gly Gln Arg		
35	40	45
Pro Pro Pro Arg Ile Lys Asn Phe Gln Ile Asn Asn Gln Ile Val Lys		
50	55	60
Leu Lys Tyr Cys Tyr Thr Cys Lys Ile Phe Arg Pro Pro Arg Ala Ser		
65	70	75
		80

85

[illegible]

<210> 131

<211> 78

<212> PRT

<213> Homo sapiens

<400> 131

Met Val Arg Lys Trp Leu Thr Phe Val Glu His Leu Leu Cys Ala Trp  
1 5 10 15

Pro Arg Leu Gly Ala Phe Val Pro Arg Val Thr Pro Ser Glu Cys Ser  
20 25 30

Ser Leu Pro His Ser Asn Trp Gly Val Gly Gly Arg Ala Ala Gln Leu  
35 40 45

86

Thr Gly Ala Glu Leu Lys Thr His Ser Trp Val Cys Leu Gly Trp Ala  
 50 55 60

Val Leu Val Ala Pro Val Ala Asn Thr Arg Ala Pro Phe Thr  
 65 70 75

&lt;210&gt; 132

&lt;211&gt; 333

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (97)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 132

Met Leu Met Phe Ala Val Ile Val Ala Ser Ser Gly Leu Leu Leu Met  
 1 5 10 15

Ile Glu Arg Gly Ile Leu Ala Glu Met Lys Pro Leu Pro Leu His Pro  
 20 25 30

Pro Gly Arg Glu Gly Thr Ala Trp Arg Gly Lys Ala Pro Lys Pro Gly  
 35 40 45

Gly Leu Ser Leu Arg Ala Gly Asp Ala Asp Leu Gln Val Arg Gln Asp  
 50 55 60

Val Arg Asn Arg Thr Leu Arg Ala Val Cys Gly Gln Pro Gly Met Pro  
 65 70 75 80

Arg Asp Pro Trp Asp Leu Pro Val Gly Gln Arg Arg Thr Leu Leu Arg  
 85 90 95

Xaa Ile Leu Val Ser Asp Arg Tyr Arg Phe Leu Tyr Cys Tyr Val Pro  
 100 105 110

Lys Val Ala Cys Ser Asn Trp Lys Arg Val Met Lys Val Leu Ala Gly  
 115 120 125

Val Leu Asp Ser Val Asp Val Arg Leu Lys Met Asp His Arg Ser Asp  
 130 135 140

Leu Val Phe Leu Ala Asp Leu Arg Pro Glu Glu Ile Arg Tyr Arg Leu  
 145 150 155 160

Gln His Tyr Phe Lys Phe Leu Phe Val Arg Glu Pro Leu Glu Arg Leu  
 165 170 175

Leu Ser Ala Tyr Arg Asn Lys Phe Gly Glu Ile Arg Glu Tyr Gln Gln  
 180 185 190

Arg Tyr Gly Ala Glu Ile Val Arg Arg Tyr Arg Ala Gly Ala Gly Pro  
 195 200 205

Ser Pro Ala Gly Asp Asp Val Thr Phe Pro Glu Phe Leu Arg Tyr Leu  
 210 215 220



87

Val Asp Glu Asp Pro Glu Arg Met Asn Glu His Trp Met Pro Val Tyr  
 225 230 235 240

His Leu Cys Gln Pro Cys Ala Val His Tyr Asp Phe Val Gly Ser Tyr  
 245 250 255

Glu Arg Leu Glu Ala Asp Ala Asn Gln Val Leu Glu Trp Val Arg Ala  
 260 265 270

Pro Pro His Val Arg Phe Pro Ala Arg Gln Ala Trp Tyr Arg Pro Ala  
 275 280 285

Ser Pro Glu Ser Leu His Tyr His Leu Cys Ser Ala Pro Arg Ala Leu  
 290 295 300

Leu Gln Asp Val Leu Pro Lys Tyr Ile Leu Asp Phe Ser Leu Phe Ala  
 305 310 315 320

Tyr Pro Leu Pro Asn Val Thr Lys Glu Ala Cys Gln Gln  
 325 330

&lt;210&gt; 133

&lt;211&gt; 164

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (126)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 133

Met Leu Pro Leu Leu Ile Ile Cys Leu Leu Pro Ala Ile Glu Gly Lys  
 1 5 10 15

Asn Cys Leu Arg Cys Trp Pro Glu Leu Ser Ala Leu Ile Asp Tyr Asp  
 20 25 30

Leu Gln Ile Leu Trp Val Thr Pro Gly Pro Pro Thr Glu Leu Ser Gln  
 35 40 45

Ser Ile His Ser Leu Phe Leu Glu Asp Asn Asn Phe Leu Lys Pro Trp  
 50 55 60

Tyr Leu Asp Arg Asp His Leu Glu Glu Glu Thr Ala Lys Phe Phe Thr  
 65 70 75 80

Gln Val His Gln Ala Ile Lys Thr Leu Arg Asp Asp Lys Thr Val Leu  
 85 90 95

Leu Glu Glu Ile Tyr Thr His Lys Asn Leu Phe Thr Glu Arg Leu Asn  
 100 105 110

Lys Ile Ser Asp Gly Leu Lys Glu Lys Gly Ala Pro Pro Xaa Ser Met  
 115 120 125

Asn Ala Phe Pro Ala Pro Ser Pro Thr Cys Thr Pro Glu Pro Leu Gly

88

130 135 140

Ser Val Cys Leu Pro Ser Thr Ser Val Ser Leu Pro Ser His Leu Pro  
 145 150 155 160

Gly Ser Leu Gln

<210> 134  
 <211> 244  
 <212> PRT  
 <213> Homo sapiens

<400> 134  
 Met Val Ala Val Gly Val Tyr Ala Arg Leu Met Lys His Ala Glu Ala  
 1 5 10 15

Ala Leu Ala Cys Leu Ala Val Asp Pro Ala Ile Leu Leu Ile Val Val  
 20 25 30

Gly Val Leu Met Phe Leu Leu Thr Phe Cys Gly Cys Ile Gly Ser Leu  
 35 40 45

Arg Glu Asn Ile Cys Leu Leu Gln Thr Phe Ser Leu Cys Leu Thr Ala  
 50 55 60

Val Phe Leu Leu Gln Leu Ala Ala Gly Ile Leu Gly Phe Val Phe Ser  
 65 70 75 80

Asp Lys Ala Arg Gly Lys Val Ser Glu Ile Ile Asn Asn Ala Ile Val  
 85 90 95

His Tyr Arg Asp Asp Leu Asp Leu Gln Asn Leu Ile Asp Phe Gly Gln  
 100 105 110

Lys Lys Phe Ser Cys Cys Gly Gly Ile Ser Tyr Lys Asp Trp Ser Gln  
 115 120 125

Asn Met Tyr Phe Asn Cys Ser Glu Asp Asn Pro Ser Arg Glu Arg Cys  
 130 135 140

Ser Val Pro Tyr Ser Cys Cys Leu Pro Thr Pro Asp Gln Ala Val Ile  
 145 150 155 160

Asn Thr Met Cys Gly Gln Gly Met Gln Ala Phe Asp Tyr Leu Glu Ala  
 165 170 175

Ser Lys Val Ile Tyr Thr Asn Gly Cys Ile Asp Lys Leu Val Asn Trp  
 180 185 190

Ile His Ser Asn Leu Phe Leu Leu Gly Gly Val Ala Leu Gly Leu Ala  
 195 200 205

Ile Pro Gln Leu Val Gly Ile Leu Leu Ser Gln Ile Leu Val Asn Gln  
 210 215 220

Ile Lys Asp Gln Ile Lys Leu Gln Leu Tyr Asn Gln Gln His Arg Ala  
 225 230 235 240

Asp Pro Trp Tyr

<210> 135  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<400> 135  
 Met Gly Thr Val Gly Leu Trp Pro Ser Trp Leu Trp Leu Pro Ala Ser  
           1                  5                  10                  15  
 Trp Pro Leu Thr Ser Cys Gly Val Thr Arg Arg Arg Leu Arg Gly Pro  
                   20                  25                  30  
 Gly Leu Arg Arg Thr Ser Gln Thr Gly Arg His Thr Ser Pro Cys Pro  
                   35                  40                  45  
 Thr Ala Thr Trp Ala Glu Ser  
           50                  55

<210> 136  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (47)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (51)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 136  
 Met Ser Ile Val Met Ser Pro Leu Leu Leu Pro Ile Cys Tyr Leu Asn  
           1                  5                  10                  15  
 Leu Leu Leu Phe Phe Val Asn Leu Ala Lys Asn Leu Ser Ile Leu Phe  
                   20                  25                  30  
 Val Ser Ser Lys Lys Tyr Thr Phe Val Phe Met Ile Ser Leu Xaa Phe  
                   35                  40                  45  
 Phe His Xaa Tyr Phe Ile  
           50

<210> 137  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens

90

&lt;400&gt; 137

Met Ala Ile Ile Ser Phe Glu Leu Leu Phe Leu Met Asn Leu Pro Thr  
 1 5 10 15

Val Asn Ser Ser Asn Phe Lys Leu Ile Ile Pro Glu Asp Val Thr Leu  
 20 25 30

Ser Phe Val Ser His Leu Asp Ile Thr Val Asn His Phe Val Phe Leu  
 35 40 45

Ser Thr Phe Glu Leu Ala Gly Val Ile Glu Gly Lys Pro Leu Pro Asp  
 50 55 60

Ser Lys Ser Asp Leu Cys Pro Ile Leu Gly Gln Leu Trp Phe His Ile  
 65 70 75 80

Leu Leu Phe Phe Ile Phe Trp Val  
 85

&lt;210&gt; 138

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 138

Met Arg Leu Pro Ile Ala Pro His Leu Gln Tyr Phe Met Trp Ser Val  
 1 5 10 15

Leu Leu Phe Leu Val Ile Leu Val Asp Met Lys Trp His Leu Ser Val  
 20 25 30

Ala Phe His Tyr Ile Ser Leu Met Thr Asn Gly Ile Leu Ser Pro Phe  
 35 40 45

Gln Cys Leu Leu Ala Ile His Val Ser Leu Phe Phe Val  
 50 55 60

&lt;210&gt; 139

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 139

Met Cys Leu Leu Pro Gly Gly Val Leu Leu Ile Trp Ser Cys Ala Ser  
 1 5 10 15

Gly Thr Pro Ala Ser His Thr Lys Asp Trp Gly Arg Cys Lys Phe Ser  
 20 25 30

Ala Ala Thr Lys Arg Thr Ala Glu Ser Asn Leu Glu Ser Thr Gln Leu  
 35 40 45

Met Leu Ala Ser Gln Ile Asp Pro Leu Leu Ala Glu Cys Trp His Leu  
 50 55 60

91

Cys Ala Ser Val Ser Ser Ser Val Asn Gly Gly Asp Lys Lys Cys Val  
 65 70 75 80

His Thr Ser Arg Ala Val Gly Arg Ile Lys Leu Cys Ser Asp Thr Ile  
 85 90 95

Arg Ala Cys Ser Gly Trp Tyr Leu Gln  
 100 105

&lt;210&gt; 140

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 140

Met Ser His Ser Val Phe Ala His Tyr Ile Phe Asn Ile Leu Leu Leu  
 1 5 10 15

Leu Leu Leu Leu Leu Leu Ile Gly Phe Leu Tyr Ser Met Pro Phe Ile  
 20 25 30

Tyr Lys Asp Thr Lys Lys Thr His Val Cys Asn Phe Asn Asn Ile Phe  
 35 40 45

Pro Ile Leu  
 50

&lt;210&gt; 141

&lt;211&gt; 119

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 141

Met Lys Trp Arg Arg Lys Ser Ala Tyr Trp Lys Ala Leu Lys Val Phe  
 1 5 10 15

Lys Leu Pro Val Glu Phe Leu Leu Leu Leu Thr Val Pro Val Val Asp  
 20 25 30

Pro Asp Lys Asp Asp Gln Asn Trp Lys Arg Pro Leu Asn Cys Leu His  
 35 40 45

Leu Val Ile Ser Pro Leu Val Val Val Leu Thr Leu Gln Ser Gly Thr  
 50 55 60

Tyr Gly Val Tyr Glu Ile Gly Gly Leu Val Pro Val Trp Val Val Val  
 65 70 75 80

Val Ile Ala Gly Thr Ala Leu Ala Ser Val Thr Phe Phe Ala Thr Ser  
 85 90 95

Asp Ser Gln Pro Pro Arg Leu His Trp Leu Phe Ala Phe Leu Gly Phe  
 100 105 110

Leu Thr Ser Ala Leu Trp Ile  
 115

<210> 142  
 <211> 58  
 <212> PRT  
 <213> Homo sapiens

<400> 142  
 Met Cys Ser Gly Ser Phe Lys Glu Leu Tyr Leu Val Pro Ile Ser Leu  
           1                          5                          10                          15  
 Phe Ser Thr Cys Val Leu Gly Phe Tyr Phe His Asn Phe Leu Leu Leu  
                           20                          25                          30  
 Ile Ile Leu Phe Ser Ile Leu Leu Arg Lys Ile Thr Gly Lys Leu Phe  
                           35                          40                          45  
 Phe Thr Tyr Tyr His Phe Ser Cys Gly Val  
           50                          55

<210> 143  
 <211> 99  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Met Leu Phe Phe Leu Ser Leu Phe Leu Ser Leu Leu Leu Thr Leu Ser  
           1                          5                          10                          15  
 Leu Pro Ser Phe Leu Pro Phe Ser Phe Phe Phe Ser Leu Phe Pro  
                           20                          25                          30  
 His Leu Ser Ala Cys Leu Leu Pro Ser Leu Pro Ser Pro Pro Phe Pro  
                           35                          40                          45  
 Leu Pro Pro Ser Leu Pro Ser Phe Leu Pro Ser Phe Leu Pro Ser Phe  
           50                          55                          60  
 Leu Pro Ser Leu Leu Ser Pro Ser Phe Pro Ala Phe Phe Pro Ser Phe  
           65                          70                          75                          80  
 Cys Gln Leu Ala Arg Arg Ser Pro Arg Lys Ser Thr Gln Met Leu Gln  
                           85                          90                          95  
 Ser Thr Ser

<210> 144  
 <211> 64  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 144

```

Met Ala Val Leu Leu Ile Thr Ile Leu Leu Phe Leu Cys Leu Gly Tyr
 1             5             10             15

Tyr Arg Val Ile Thr Glu Ile Ser Arg Lys Thr Pro Ala Cys Arg Met
             20             25             30

Phe Thr Ser Ser Leu Ser Ser Trp Tyr Ile Met Arg Lys Leu Tyr Asp
             35             40             45

Thr Pro Gly Glu Val Phe Leu Ser His Ala Ile Val Xaa Phe Leu Lys
 50             55             60

```

&lt;210&gt; 145

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

```

Met Leu Asn Gln Pro Cys Ile Leu Gly Met Lys Pro Thr Trp Leu Trp
 1             5             10             15

Trp Ile Ser Phe Leu Met Cys Cys Trp Val Trp Leu Ala Ser Val Leu
             20             25             30

Leu Gly Ile Phe Ala Ser Ile Phe Ile Arg Asp Ile Gly Leu Glu Phe
 35             40             45

Ser Phe Phe Val Met Cys Leu Pro Gly Phe Gly Ile Arg Val Met Leu
 50             55             60

Ala Ser
 65

```

&lt;210&gt; 146

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

```

Met Thr Ala Met Ser Ile His Leu Phe Cys Thr Ala Leu Ser Cys Gly
 1             5             10             15

Ser Ser Gly Gln Cys Asn Lys Ala Ile Lys Arg Asn Lys Ile Ser Asn
 20             25             30

Asp Trp Lys Asp Val Asn Val Ser Ser Phe Ile Glu Asn Met Ile His
 35             40             45

Arg Tyr Thr Tyr Thr Asn Ala Leu Asn Ser

```

94

50

55

<210> 147  
<211> 55  
<212> PRT  
<213> Homo sapiens

<400> 147  
Met Ser His Cys Thr Trp Pro Val Cys Leu Phe Cys Leu Val Pro Pro  
1 5 10 15  
Pro Met Gly Asp Leu Lys Glu Val Cys Leu Pro His Arg Cys Pro Gly  
20 25 30  
Arg Thr Ala Cys Cys Ser Tyr Ser Glu Pro His Leu Gln Thr Glu Glu  
35 40 45  
Asp Arg Arg Thr Leu Ile Cys  
50 55

<210> 148  
<211> 65  
<212> PRT  
<213> Homo sapiens

<400> 148  
Met Thr Asn Gly His Gln Val Leu Leu Leu Leu Leu Thr Ser Ala  
1 5 10 15  
Val Ala Ala Gly Pro Trp Pro Gln Val His Ala Gly Gln Trp Gly Trp  
20 25 30  
Met Cys Leu Pro Pro Gly Leu Pro Ser Val Gln Ala Arg Ser Gly Leu  
35 40 45  
Gly Gly Leu Pro Gly Gly Pro Gln Trp Val Pro Gly Gly Ala Arg Gly  
50 55 60  
Tyr  
65

<210> 149  
<211> 327  
<212> PRT  
<213> Homo sapiens

<400> 149  
Met Ala Cys Arg Lys Leu Ala Val Ala His Pro Leu Leu Leu Leu Arg  
1 5 10 15  
His Leu Pro Met Ile Ala Ala Leu Leu His Gly Arg Thr His Leu Asn  
20 25 30  
Phe Gln Glu Phe Arg Gln Gln Asn His Leu Ser Cys Phe Leu His Val



35 40 95 45  
 Leu Gly Leu Leu Glu Leu Leu Gln Pro His Val Phe Arg Ser Glu His  
 50 55 60  
 Gln Gly Ala Leu Trp Asp Cys Leu Leu Ser Phe Ile Arg Leu Leu Leu  
 65 70 75 80  
 Asn Tyr Arg Lys Ser Ser Arg His Leu Ala Ala Phe Ile Asn Lys Phe  
 85 90 95  
 Val Gln Phe Ile His Lys Tyr Ile Thr Tyr Asn Ala Pro Ala Ala Ile  
 100 105 110  
 Ser Phe Leu Gln Lys His Ala Asp Pro Leu His Asp Leu Ser Phe Asp  
 115 120 125  
 Asn Ser Asp Leu Val Met Leu Lys Ser Leu Leu Ala Gly Leu Ser Leu  
 130 135 140  
 Pro Ser Arg Asp Asp Arg Thr Asp Arg Gly Leu Asp Glu Glu Gly Glu  
 145 150 155 160  
 Glu Glu Ser Ser Ala Gly Ser Leu Pro Leu Val Ser Val Ser Leu Phe  
 165 170 175  
 Thr Pro Leu Thr Ala Ala Glu Met Ala Pro Tyr Met Lys Arg Leu Ser  
 180 185 190  
 Arg Gly Gln Thr Val Glu Asp Leu Leu Glu Val Leu Ser Asp Ile Asp  
 195 200 205  
 Glu Met Ser Arg Arg Arg Pro Glu Ile Leu Ser Phe Phe Ser Thr Asn  
 210 215 220  
 Leu Gln Arg Leu Met Ser Ser Ala Glu Glu Cys Cys Arg Asn Leu Ala  
 225 230 235 240  
 Phe Ser Leu Ala Leu Arg Ser Met Gln Asn Ser Pro Ser Ile Ala Ala  
 245 250 255  
 Ala Phe Leu Pro Thr Phe Met Tyr Cys Leu Gly Ser Gln Asp Phe Glu  
 260 265 270  
 Val Val Gln Thr Ala Leu Arg Asn Leu Pro Glu Tyr Ala Leu Leu Cys  
 275 280 285  
 Gln Glu His Ala Ala Val Leu Leu His Arg Ala Phe Leu Val Gly Met  
 290 295 300  
 Tyr Gly Gln Met Asp Pro Ser Ala Gln Ile Ser Glu Ala Leu Arg Ile  
 305 310 315 320  
 Leu His Met Glu Ala Val Met  
 325

&lt;210&gt; 150

&lt;211&gt; 89

96

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 150

Met Gly Phe Leu Gln Leu Leu Val Val Xaa Val Leu Xaa Ser Glu His  
 1 5 10 15

Arg Val Ala Gly Ala Ala Glu Val Phe Gly Asn Ser Ser Glu Gly Leu  
 20 25 30

Ile Glu Phe Ser Val Gly Lys Phe Arg Tyr Phe Glu Leu Asn Arg Pro  
 35 40 45

Phe Pro Glu Glu Ala Ile Leu His Asp Ile Ser Ser Asn Val Thr Phe  
 50 55 60

Leu Ile Phe Gln Ile His Ser Gln Tyr Gln Asn Thr Thr Val Ser Phe  
 65 70 75 80

Ser Pro Arg Arg Arg Ser Pro Thr Met  
 85

&lt;210&gt; 151

&lt;211&gt; 148

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

Met Ala Gly Ser Pro Leu Leu Trp Gly Pro Arg Ala Gly Gly Val Gly  
 1 5 10 15

Leu Leu Val Leu Leu Leu Leu Gly Leu Phe Arg Pro Pro Pro Ala Leu  
 20 25 30

Cys Ala Arg Pro Val Lys Glu Pro Arg Gly Leu Ser Ala Ala Ser Pro  
 35 40 45

Pro Leu Ala Arg Leu Ala Leu Leu Ala Ala Ser Gly Gly Gln Cys Pro  
 50 55 60

Glu Val Arg Arg Arg Gly Arg Cys Arg Pro Gly Ala Gly Ala Gly Ala  
 65 70 75 80

Ser Ala Gly Ala Glu Arg Gln Glu Arg Ala Arg Ala Glu Ala Gln Arg  
 85 90 95

Leu Arg Ile Ser Arg Arg Ala Ser Trp Arg Ser Cys Cys Ala Ser Gly  
 100 105 110

Ala Pro Pro Ala Thr Leu Ile Arg Leu Trp Ala Trp Thr Thr Thr Pro  
 115 120 125

Thr Arg Leu Gln Arg Ser Ser Leu Ala Leu Cys Ser Ala Pro Ala Leu  
 130 135 140

Thr Leu Pro Pro  
 145

<210> 152

<211> 390

<212> PRT

<213> Homo sapiens

<400> 152

Met Leu Pro Thr Trp Trp Ile Val Ser Ser Trp Leu Val Trp Gly Val  
 1 5 10 15

Ile Leu Phe Val Tyr Leu Val Ile Arg Ala Leu Arg Leu Trp Arg Thr  
 20 25 30

Ala Lys Leu Gln Val Thr Leu Lys Lys Tyr Ser Val His Leu Glu Asp  
 35 40 45

Met Ala Thr Asn Ser Arg Ala Phe Thr Asn Leu Val Arg Lys Ala Leu  
 50 55 60

Arg Leu Ile Gln Glu Thr Glu Val Ile Ser Arg Gly Phe Thr Leu Val  
 65 70 75 80

Ser Ala Ala Cys Pro Phe Asn Lys Ala Gly Gln His Pro Ser Gln His  
 85 90 95

Leu Ile Gly Leu Arg Lys Ala Val Tyr Arg Thr Leu Arg Ala Asn Phe  
 100 105 110

Gln Ala Ala Arg Leu Ala Thr Leu Tyr Met Leu Lys Asn Tyr Pro Leu  
 115 120 125

Asn Ser Glu Ser Asp Asn Val Thr Asn Tyr Ile Cys Val Val Pro Phe  
 130 135 140

Lys Glu Leu Gly Leu Gly Leu Ser Glu Glu Gln Ile Ser Glu Glu Glu  
 145 150 155 160

Ala His Asn Phe Thr Asp Gly Phe Ser Leu Pro Ala Leu Lys Val Leu  
 165 170 175

Phe Gln Leu Trp Val Ala Gln Ser Ser Glu Phe Phe Arg Arg Leu Ala  
 180 185 190

Leu Leu Leu Ser Thr Ala Asn Ser Pro Pro Gly Pro Leu Leu Thr Pro  
 195 200 205

Ala Leu Leu Pro His Arg Ile Leu Ser Asp Val Thr Gln Gly Leu Pro  
 210 215 220

98

His Ala His Ser Ala Cys Leu Glu Glu Leu Lys Arg Ser Tyr Glu Phe  
 225 230 235 240  
 Tyr Arg Tyr Phe Glu Thr Gln His Gln Ser Val Pro Gln Cys Leu Ser  
 245 250 255  
 Lys Thr Gln Gln Lys Ser Arg Glu Leu Asn Asn Val His Thr Ala Val  
 260 265 270  
 Arg Ser Leu Gln Leu His Leu Lys Ala Leu Leu Asn Glu Val Ile Ile  
 275 280 285  
 Leu Glu Asp Glu Leu Glu Lys Leu Val Cys Thr Lys Glu Thr Gln Glu  
 290 295 300  
 Leu Val Ser Glu Ala Tyr Pro Ile Leu Glu Gln Lys Leu Lys Leu Ile  
 305 310 315 320  
 Gln Pro His Val Gln Ala Ser Asn Asn Cys Trp Glu Glu Ala Ile Ser  
 325 330 335  
 Gln Val Asp Lys Leu Leu Arg Arg Asn Thr Asp Lys Lys Gly Lys Pro  
 340 345 350  
 Glu Ile Ala Cys Glu Asn Pro His Cys Thr Val Ser Thr Phe Glu Ala  
 355 360 365  
 Ala Tyr Ser Thr His Cys Arg Gln Arg Ser Asn Pro Arg Gly Ala Gly  
 370 375 380  
 Ile Arg Ser Leu Cys Arg  
 385 390

&lt;210&gt; 153

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Met Thr Thr Arg Gln Pro Thr Ala Val Ser Trp Pro Cys Trp Leu Met  
 1 5 10 15  
 Ser Ser Ser Leu Ser Thr Ala Cys Leu Ala Trp Thr Leu Thr Gly Ser  
 20 25 30  
 Leu Ala Arg Glu Ala Thr Arg Arg Ala Arg Ser Leu Ser Pro Thr Trp  
 35 40 45  
 Asn Cys Ser Ala Arg Gln Val Pro Pro Ser Pro Pro His Ser Gly Leu  
 50 55 60  
 Gly Arg Arg Gly Trp Ala His Cys His Leu Thr Cys Leu Leu Val Thr  
 65 70 75 80  
 Gln Leu Phe Arg Val Gly Arg Ile His Pro Ile Leu Ser Leu Pro Leu  
 85 90 95

Val Thr

&lt;210&gt; 154

&lt;211&gt; 60

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Met	Ser	His	Cys	Ala	Arg	Pro	Thr	Phe	Leu	Thr	Leu	Leu	Leu	Ala	Ser
1				5					10					15	

Cys	Phe	Trp	Ala	Ala	Ala	Ile	Pro	Asn	Arg	Asn	Val	Ile	Leu	Ser	Val
			20					25					30		

Ser	Phe	Arg	Pro	Leu	His	Met	Gln	Phe	Thr	Leu	Ser	Ile	Leu	Val	Phe
		35					40					45			

Ile	Leu	Arg	Ile	Leu	Ile	Leu	Leu	Arg	Ser	Phe	Leu
	50					55					60

&lt;210&gt; 155

&lt;211&gt; 392

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Met	Glu	Trp	Trp	Ala	Ser	Ser	Pro	Leu	Arg	Leu	Trp	Leu	Leu	Leu	Phe
1				5					10					15	

Leu	Leu	Pro	Ser	Ala	Gln	Gly	Arg	Gln	Lys	Glu	Ser	Gly	Ser	Lys	Trp
			20					25					30		

Lys	Val	Phe	Ile	Asp	Gln	Ile	Asn	Arg	Ser	Leu	Glu	Asn	Tyr	Glu	Pro
		35					40					45			

Cys	Ser	Ser	Gln	Asn	Cys	Ser	Cys	Tyr	His	Gly	Val	Ile	Glu	Glu	Asp
	50					55					60				

Leu	Thr	Pro	Phe	Arg	Gly	Gly	Ile	Ser	Arg	Lys	Met	Met	Ala	Glu	Val
	65				70					75					80

Val	Arg	Arg	Lys	Leu	Gly	Thr	His	Tyr	Gln	Ile	Thr	Lys	Asn	Arg	Leu
				85					90					95	

Tyr	Arg	Glu	Asn	Asp	Cys	Met	Phe	Pro	Ser	Arg	Cys	Ser	Gly	Val	Glu
			100					105					110		

His	Phe	Ile	Leu	Glu	Val	Ile	Gly	Arg	Leu	Pro	Asp	Met	Glu	Met	Val
		115					120					125			

Ile	Asn	Val	Arg	Asp	Tyr	Pro	Gln	Val	Pro	Lys	Trp	Met	Glu	Pro	Ala
	130					135					140				

Ile	Pro	Val	Phe	Ser	Phe	Ser	Lys	Thr	Ser	Glu	Tyr	His	Asp	Ile	Met
145					150					155					160

100

Tyr	Pro	Ala	Trp	Thr	Phe	Trp	Glu	Gly	Gly	Pro	Ala	Val	Trp	Pro	Ile		
165							170									175	
Tyr	Pro	Thr	Gly	Leu	Gly	Arg	Trp	Asp	Leu	Phe	Arg	Glu	Asp	Leu	Val		
180							185					190					
Arg	Ser	Ala	Ala	Gln	Trp	Pro	Trp	Lys	Lys	Lys	Asn	Ser	Thr	Ala	Tyr		
195							200			205							
Phe	Arg	Gly	Ser	Arg	Thr	Ser	Pro	Glu	Arg	Asp	Pro	Leu	Ile	Leu	Leu		
210							215			220							
Ser	Arg	Lys	Asn	Pro	Lys	Leu	Val	Asp	Ala	Glu	Tyr	Thr	Lys	Asn	Gln		
225							230			235						240	
Ala	Trp	Lys	Ser	Met	Lys	Asp	Thr	Leu	Gly	Lys	Pro	Ala	Ala	Lys	Asp		
245							250									255	
Val	His	Leu	Val	Asp	His	Cys	Lys	Tyr	Lys	Tyr	Leu	Phe	Asn	Phe	Arg		
260							265					270					
Gly	Val	Ala	Ala	Ser	Phe	Arg	Phe	Lys	His	Leu	Phe	Leu	Cys	Gly	Ser		
275							280			285							
Leu	Val	Phe	His	Val	Gly	Asp	Glu	Trp	Leu	Glu	Phe	Phe	Tyr	Pro	Gln		
290							295			300							
Leu	Lys	Pro	Trp	Val	His	Tyr	Ile	Pro	Val	Lys	Thr	Asp	Leu	Ser	Asn		
305							310			315						320	
Val	Gln	Glu	Leu	Leu	Gln	Phe	Val	Lys	Ala	Asn	Asp	Asp	Val	Ala	Gln		
325							330									335	
Glu	Ile	Ala	Glu	Arg	Gly	Ser	Gln	Phe	Ile	Arg	Asn	His	Leu	Gln	Met		
340							345					350					
Asp	Asp	Ile	Thr	Cys	Tyr	Trp	Glu	Asn	Leu	Leu	Ser	Glu	Tyr	Ser	Lys		
355							360			365							
Phe	Leu	Ser	Tyr	Asn	Val	Thr	Arg	Arg	Lys	Gly	Tyr	Asp	Gln	Ile	Ile		
370							375			380							
Pro	Lys	Met	Leu	Lys	Thr	Glu	Leu										
385							390										

```
<210> 156
<211> 74
<212> PRT
<213> Homo sapiens
```

<400> 156  
Met Leu Ile Leu Phe Leu Ser Val Cys Leu Phe Val Phe Leu Leu Thr  
1 5 10 15  
Val Arg Ala Leu Cys Cys Arg Ser Ala Gly Val Trp Leu Arg Ser Thr  
20 25 30

101

Pro Asp Pro Val Cys Leu Gly Phe Ala Arg Gly Gly Cys Arg Ile Ala  
           35                          40                          45

Met Ile Ala Ala Cys Phe Ser Ser Gly Ser Phe Val Pro Glu Gly His  
       50                          55                          60

Pro Pro Asp Ala Ser Gln Ser Ser Pro Val  
       65                          70

&lt;210&gt; 157

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 157

Met Trp Pro Leu Leu Ala Val Ser Pro Phe Gly Leu Val Trp Ala Ser  
       1                          5                          10                          15

Ser Gln Ser Gly Ser Leu Leu Leu Arg Ala Ser Ile Pro Arg Gln His  
           20                          25                          30

Ser Arg Arg Ala Trp His Phe Tyr Ser Glu Val Trp Gln Ser His Ser  
           35                          40                          45

Val Ala Ser Val Leu Leu Tyr Leu Leu Val Arg Ala Ile Thr Lys Met  
       50                          55                          60

Cys Ile Gly Ser Lys Lys Arg Asp Ile Thr Pro Thr Thr Arg Trp Lys  
       65                          70                          75                          80

Lys

&lt;210&gt; 158

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (49)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 158

Met Ser His His Ala Gly Leu Gly Gly Gly Ile Leu Phe Ser Leu Lys  
       1                          5                          10                          15

Ile Ser Phe Phe Ile Ala Leu Ala Val Val Gly Gly Ser Arg Gly Val  
           20                          25                          30

Asn Asp Cys Gln Leu Gly Gly Cys Arg Val Gly Ser Cys Pro Arg Val  
       35                          40                          45

Xaa Val Arg Val Ala  
       50

102

<210> 159  
 <211> 102  
 <212> PRT  
 <213> Homo sapiens

<400> 159  
 Met Thr Val Arg Arg Leu Ser Leu Leu Cys Arg Asp Leu Trp Ala Leu  
     1                    5                    10                    15  
 Trp Leu Leu Leu Lys Ala Gly Ala Val Arg Gly Ala Arg Ala Gly Pro  
                     20                    25                    30  
 Arg Leu Pro Gly Arg Cys Cys Gly Ala Thr Cys Gly Asp Ala Gly Arg  
                     35                    40                    45  
 Gly Trp Thr Phe Trp Ala Gln Pro Cys Pro Gln Lys Leu Leu Gly Gln  
                     50                    55                    60  
 Lys Pro Gly Ala Gly Gly Cys Arg Gly Trp Val Leu Gly Trp Val Pro  
                     65                    70                    75                    80  
 Pro Arg Pro Glu Glu Pro Cys Ser Leu Ala Gly Lys Val Cys Thr Gly  
                     85                    90                    95  
 Leu Ala Arg Trp Met Val  
                     100

<210> 160  
 <211> 575  
 <212> PRT  
 <213> Homo sapiens

<400> 160  
 Met Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala  
     1                    5                    10                    15  
 Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys  
                     20                    25                    30  
 Phe Arg Gln Glu Ser His Val Glu Phe Ala Thr Gly Glu Leu Leu Thr  
                     35                    40                    45  
 Met Thr Gln Trp Pro Gly Val Trp Ile Pro Met Ala Ser Cys Ser Ser  
                     50                    55                    60  
 Thr Trp Trp Ser Met Ala Leu Ser Pro Asp Ser Leu Ala Asp Ala Asp  
                     65                    70                    75                    80  
 Leu Gln Val Gln Asp Phe Glu Glu His Tyr Val Gln Thr Gly Pro Gly  
                     85                    90                    95  
 Gln Leu Phe Val Gly Ser Thr Gln Arg Phe Phe Gln Gly Gly Leu Pro  
                     100                    105                    110  
 Ser Phe Leu Arg Cys Asn His Ser Ile Gln Tyr Asn Ala Ala Arg Gly  
                     115                    120                    125



103

Pro Gln Pro Gln Leu Val Gln His Leu Arg Ala Ser Ala Ile Ser Ser  
 130 135 140  
 Ala Phe Asp Pro Glu Ala Glu Ala Leu Arg Phe Gln Leu Ala Thr Ala  
 145 150 155 160  
 Leu Gln Ala Glu Glu Asn Glu Val Gly Cys Pro Glu Gly Phe Glu Leu  
 165 170 175  
 Asp Ser Gln Gly Ala Phe Cys Val Asp Val Asp Glu Cys Ala Trp Asp  
 180 185 190  
 Ala His Leu Cys Arg Glu Gly Gln Arg Cys Val Asn Leu Leu Gly Ser  
 195 200 205  
 Tyr Arg Cys Leu Pro Asp Cys Gly Pro Gly Phe Arg Val Ala Asp Gly  
 210 215 220  
 Ala Gly Cys Glu Asp Val Asp Glu Cys Leu Glu Gly Leu Asp Asp Cys  
 225 230 235 240  
 His Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg Cys Ser  
 245 250 255  
 Cys Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys Leu Asp  
 260 265 270  
 Val Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln Cys His  
 275 280 285  
 Asn Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln Thr Leu  
 290 295 300  
 Leu Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly Gln Asn  
 305 310 315 320  
 Val Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu Arg Pro  
 325 330 335  
 Trp Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser Leu Arg  
 340 345 350  
 Pro Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys Pro Pro  
 355 360 365  
 Gly Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu Cys Arg  
 370 375 380  
 Val Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly Ser Tyr  
 385 390 395 400  
 Gln Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly Lys Asn  
 405 410 415  
 Cys Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys Gly Pro  
 420 425 430  
 Gly Gln Met Cys Phe Asn Thr Arg Gly Ser Tyr Gln Cys Val Asp Thr  
 435 440 445

104

Pro Cys Pro Ala Thr Tyr Arg Gln Gly Pro Ser Pro Gly Thr Cys Phe  
 450 455 460  
 Arg Arg Cys Ser Gln Asp Cys Gly Thr Gly Gly Pro Ser Thr Leu Gln  
 465 470 475 480  
 Tyr Arg Leu Leu Pro Leu Pro Leu Gly Val Arg Ala His His Asp Val  
 485 490 495  
 Ala Arg Leu Thr Ala Phe Ser Glu Val Gly Val Pro Ala Asn Arg Thr  
 500 505 510  
 Glu Leu Ser Met Leu Glu Pro Asp Pro Arg Ser Pro Phe Ala Leu Arg  
 515 520 525  
 Pro Leu Arg Ala Gly Leu Gly Ala Val Tyr Thr Arg Arg Ala Leu Thr  
 530 535 540  
 Arg Ala Gly Leu Tyr Arg Leu Thr Val Arg Ala Ala Pro Arg His  
 545 550 555 560  
 Gln Ser Val Phe Val Leu Leu Ile Ala Val Ser Pro Tyr Pro Tyr  
 565 570 575

&lt;210&gt; 161

&lt;211&gt; 643

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 161

Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val  
 1 5 10 15  
 Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu  
 20 25 30  
 Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro  
 35 40 45  
 Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val  
 50 55 60  
 Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu  
 65 70 75 80  
 Pro Ser Cys Thr Asp Gln Cys Phe Arg Gln Asn His Ile His Gly Thr  
 85 90 95  
 Leu Leu Gln Val Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys His  
 100 105 110  
 Gly Thr Asn Ser Asp Phe Gln His Glu Leu Thr Asp Ile Thr Val Cys  
 115 120 125  
 Thr Lys Ala Lys Leu Trp Leu Ala Lys Arg Gln Asn Pro Cys Leu Val  
 130 135 140

105

Thr	Arg	Ala	Val	Tyr	Ile	Asp	Ile	Leu	Phe	Leu	Leu	Thr	Cys	Cys	Leu	145	150	155	160
Asn	Arg	Ser	Ala	Lys	Asp	Asn	Gln	Pro	Val	Leu	Glu	Ser	Leu	Gly	Phe	165	170	175	
Trp	Glu	Glu	Val	Arg	Gly	Ile	Ile	Ser	Gly	Ser	Glu	Leu	Ile	Thr	Gly	180	185	190	
Phe	Pro	Trp	Ala	Phe	Lys	Val	Pro	Gly	Leu	Pro	Gln	Tyr	Leu	Gln	Ser	195	200	205	
Leu	Thr	Arg	Leu	Ala	Ile	Ala	Ala	Val	Trp	Ala	Ala	Ala	Ala	Lys	Ser	210	215	220	
Gly	Glu	Arg	Glu	Thr	Asn	Val	Pro	Ile	Ser	Phe	Ser	Gln	Leu	Leu	Glu	225	230	235	240
Ser	Ala	Phe	Pro	Glu	Val	Arg	Ser	Leu	Thr	Leu	Glu	Ala	Leu	Leu	Glu	245	250	255	
Lys	Phe	Leu	Ala	Ala	Ala	Ser	Gly	Leu	Gly	Glu	Lys	Gly	Val	Pro	Pro	260	265	270	
Leu	Leu	Cys	Asn	Met	Gly	Glu	Lys	Phe	Leu	Leu	Leu	Ala	Met	Lys	Glu	275	280	285	
Asn	His	Pro	Glu	Cys	Phe	Cys	Lys	Ile	Leu	Lys	Ile	Leu	His	Cys	Met	290	295	300	
Asp	Pro	Gly	Glu	Trp	Leu	Pro	Gln	Thr	Glu	His	Cys	Val	His	Leu	Thr	305	310	315	320
Pro	Lys	Glu	Phe	Leu	Ile	Trp	Thr	Met	Asp	Ile	Ala	Ser	Asn	Glu	Arg	325	330	335	
Ser	Glu	Ile	Gln	Ser	Val	Ala	Leu	Arg	Leu	Ala	Ser	Lys	Val	Ile	Ser	340	345	350	
His	His	Met	Gln	Thr	Cys	Val	Glu	Asn	Arg	Glu	Leu	Ile	Ala	Ala	Glu	355	360	365	
Leu	Lys	Gln	Trp	Val	Gln	Leu	Val	Ile	Leu	Ser	Cys	Glu	Asp	His	Leu	370	375	380	
Pro	Thr	Glu	Ser	Arg	Leu	Ala	Val	Val	Glu	Val	Leu	Thr	Ser	Thr	Thr	385	390	395	400
Pro	Leu	Phe	Leu	Thr	Asn	Pro	His	Pro	Ile	Leu	Glu	Leu	Gln	Asp	Thr	405	410	415	
Leu	Ala	Leu	Trp	Lys	Cys	Val	Leu	Thr	Leu	Leu	Gln	Ser	Glu	Glu	Gln	420	425	430	
Ala	Val	Arg	Asp	Ala	Ala	Thr	Glu	Thr	Val	Thr	Thr	Ala	Met	Ser	Gln	435	440	445	
Glu	Asn	Thr	Cys	Gln	Ser	Thr	Glu	Phe	Ala	Phe	Cys	Gln	Val	Asp	Ala	450	455	460	

106

Ser Ile Ala Leu Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln  
 465 470 475 480  
 Gln Trp Asp Gln Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu  
 485 490 495  
 Leu Gly Glu Ser Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln  
 500 505 510  
 Val Glu Glu Asp Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala  
 515 520 525  
 Glu Thr Leu Ile Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu  
 530 535 540  
 Leu Ser Lys Ser Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His  
 545 550 555 560  
 Leu Gln Arg Met Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe  
 565 570 575  
 Arg Glu Leu Pro Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr  
 580 585 590  
 Arg Leu Arg Ile Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu  
 595 600 605  
 Ala Phe Leu Glu Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val  
 610 615 620  
 Trp Asp Ser Tyr Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu  
 625 630 635 640  
 Ala Ala Cys

&lt;210&gt; 162

&lt;211&gt; 190

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 162

Met Ser Ser Gly Thr Glu Leu Leu Trp Pro Gly Ala Ala Leu Leu Val  
 1 5 10 15  
 Leu Leu Gly Val Ala Ala Ser Leu Cys Val Arg Cys Ser Arg Pro Gly  
 20 25 30  
 Ala Lys Arg Ser Glu Lys Ile Tyr Gln Gln Arg Ser Leu Arg Glu Asp  
 35 40 45  
 Gln Gln Ser Phe Thr Gly Ser Arg Thr Tyr Ser Leu Val Gly Gln Ala  
 50 55 60  
 Trp Pro Gly Pro Leu Ala Asp Met Ala Pro Thr Arg Lys Asp Lys Leu  
 65 70 75 80  
 Leu Gln Phe Tyr Pro Ser Leu Glu Asp Pro Ala Ser Ser Arg Tyr Gln

107

	85	90	95
Asn Phe Ser Lys Gly Ser Arg His Gly Ser Glu Glu Ala Tyr Ile Asp	100	105	110
Pro Ile Ala Met Glu Tyr Tyr Asn Trp Gly Arg Phe Ser Lys Pro Pro	115	120	125
Glu Asp Asp Asp Ala Asn Ser Tyr Glu Asn Val Leu Ile Cys Lys Gln	130	135	140
Lys Thr Thr Glu Thr Gly Ala Gln Gln Glu Gly Ile Gly Gly Leu Cys	145	150	155
Arg Gly Asp Leu Ser Leu Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser	165	170	175
Gly Leu Cys Pro Ser Ala Ser Pro Glu Glu Asp Glu Gly Ile	180	185	190

<210> 163  
 <211> 63  
 <212> PRT  
 <213> Homo sapiens

<400> 163  
 Met Lys His Val Leu Asn Leu Tyr Leu Leu Gly Val Val Leu Thr Leu  
   1                  5                  10                  15  
 Leu Ser Ile Phe Val Arg Val Met Glu Ser Leu Glu Gly Leu Leu Glu  
                   20                  25                  30  
 Ser Pro Ser Pro Gly Thr Ser Trp Thr Thr Arg Ser Gln Leu Ala Asn  
                   35                  40                  45  
 Thr Glu Pro Thr Lys Gly Leu Pro Asp His Pro Ser Arg Ser Met  
   50                  55                  60

<210> 164  
 <211> 117  
 <212> PRT  
 <213> Homo sapiens

<400> 164  
 Met Ile Phe Leu Thr Val Leu Pro Leu Ala Phe Leu Phe Leu His Ser  
   1                  5                  10                  15  
 Gly Phe Tyr His Tyr Ile Ser Phe Ser Cys Leu Phe Ser Leu Ser Leu  
                   20                  25                  30  
 Ala Leu Phe Phe Phe Leu Asp Val Ala Thr Phe Arg Arg Pro Gly Gln  
                   35                  40                  45  
 Leu Phe Cys Glu Arg Ser Val Leu Phe Asp Met Phe His Phe Gly Phe  
   50                  55                  60

108

Val Ser Leu Phe Leu His Glu Trp Ile Gln Ala Lys His Phe Trp Ala  
 65 70 75 80

Gly Leu Phe Ile Val Leu Pro Ser Asp Val Phe Phe Ser Val His His  
 85 90 95

Leu Glu Ala Pro Asp Gly Ser Phe Pro Asn Ile Ala Lys Leu Ser Leu  
 100 105 110

Ile Ile Leu Leu Arg  
 115

&lt;210&gt; 165

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 165

Met Leu Leu Gln Phe Thr Leu Trp Val Phe Gly Ala Ile His Phe Pro  
 1 5 10 15

Lys Cys Leu Gly Ile Lys Glu Glu Leu Leu Lys Cys Cys Leu Gln Leu  
 20 25 30

Pro Pro Ser Ser Thr Tyr Glu Lys Val Val  
 35 40

&lt;210&gt; 166

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 166

Met Leu Ser Arg Arg Leu His Cys Leu Val Leu Tyr Phe Leu Leu Leu  
 1 5 10 15

Leu Leu Ser Phe Ile His Thr Leu Ser Val Ser His Ile Cys Ser Ser  
 20 25 30

Phe Ile Trp Leu Phe Pro Lys Asn Ile Glu Ser Glu Ala Thr Met  
 35 40 45

&lt;210&gt; 167

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 167

Met Glu Lys Met Gly Gln Gly Leu Leu Ser Ser Thr Tyr Leu Thr Val  
 1 5 10 15

Leu His Leu Ile Gln Leu Val Gly Cys Gly Leu Leu Thr Glu Glu Ile  
 20 25 30

109

Lys Glu Ser Lys Tyr Leu Ile Lys Thr Leu Gly Ser Gly  
                   35                  40                  45

&lt;210&gt; 168

&lt;211&gt; 207

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 168

Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
   1                  5                  10                  15

Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
                   20                  25                  30

Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Leu  
                   35                  40                  45

Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe Phe Asn Pro Lys Phe  
                   50                  55                  60

Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val Thr Lys Lys Ser Gly  
   65                  70                  75                  80

Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly Cys Leu Glu Gln Asp  
                   85                  90                  95

Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu Gln Gly Asn Leu Thr  
                   100                  105                  110

Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys Pro Val Ser Cys  
                   115                  120                  125

Lys His Leu Ile Lys Ser His Ser Cys Pro Ala Leu Ala Val Ala Ser  
                   130                  135                  140

Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys Gly Thr Gln Ser Ala  
   145                  150                  155                  160

His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe Val Ser Asp Ser Ser  
                   165                  170                  175

Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe Tyr Gln Ser Arg Gly  
                   180                  185                  190

Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro Arg Val Lys Asp  
                   195                  200                  205

&lt;210&gt; 169

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 169

Met Tyr Ile Phe Glu Leu Ser Leu Tyr Leu Glu Gly Thr Ser Phe Val  
   1                  5                  10                  15

110

Val Val Leu Leu Phe Leu Leu Ile Ser Val Ser Leu Asp Ser Pro Pro  
                   20                  25                  30

Thr Thr Lys Gly Trp Asp Ser Val Leu His Ile Trp Val Pro Leu Ile  
           35                  40                  45

Val Gln  
       50

&lt;210&gt; 170

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 170

Met Ala His Pro Gly Leu Pro Lys Thr Val Pro Val Tyr Ala Val Val  
   1                  5                  10                  15

Leu Ala Leu Leu Ile Met Thr Leu Pro Leu Thr Leu Thr Ile Asn Leu  
                   20                  25                  30

Asp Asp Asn Leu Tyr Gly Asn Ser Ala Lys  
           35                  40

&lt;210&gt; 171

&lt;211&gt; 55

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 171

Met Arg Pro Trp Trp Ser Leu Leu Leu Glu Ala Cys Ala Thr Cys Ala  
   1                  5                  10                  15

Gln Thr Gly Pro Thr Arg Ser Thr Ser Cys Thr Gln Glu Val Ser His  
           20                  25                  30

Ser Ser Ser Thr Ala Tyr Pro Ala Pro Met Arg Arg Arg Cys Cys Leu  
           35                  40                  45

Pro Ser Pro Arg Ser Cys Thr  
       50                  55

&lt;210&gt; 172

&lt;211&gt; 108

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 172

Met Ala Leu Ala Gly Ser Val Phe Val Leu Gly Gly Val Leu Val Leu  
   1                  5                  10                  15

Cys Val Glu Arg Asn Gly Glu Gly Glu Met Gly Trp Pro Gln His Leu  
           20                  25                  30



111

C

Pro Lys Ser Gln Pro Leu Ser Pro Pro Val Ala Val Arg Arg Cys Ser  
35 40 45

Phe Glu Arg Ser Trp Ile Asp Leu Leu Val Glu Thr Ser Ser Ser Met  
50 55 60

Val Thr Cys Arg Gln Gln Val Gly Thr Pro Asn Gly Met Glu Gly Arg  
65 70 75 80

Gly Gly Gly Pro Lys Thr Thr Phe Pro Ile Arg Leu Gln Leu Ser Gly  
85 90 95

Ala Cys Ala Val Arg Pro Glu Ile Gln Trp Glu Val  
100 105

<210> 173

<211> 50

<212> PRT

<213> Homo sapiens

**<220>**

&lt;221&gt; SITE

<222> (17)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 173

Met Phe Leu Phe Phe Tyr Leu Ser Leu Ala Val Tyr Ala Gln Arg Gln  
1 5 10 15

Xaa Ser Gly Ser Cys Arg Gln Thr Asp His Arg Trp Lys Ser Arg Gly  
20 25 30

Ala Arg Arg Cys Phe Leu Glu Pro Arg Asp Pro Gly Ser Val Pro Gly  
35 40 45

His Pro  
50

<210> 174

<211> 566

<212> PRT

<213> Homo sapiens

<400> 174

Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu  
1 5 10 15

Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
20 25 30

Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
35 40 45

Val Thr Trp Gly Leu Asn Arg Thr Leu Lys Pro Gln Arg Val Ile Val  
50 55 60

112

Val Gly Ala Gly Val Ala Gly Leu Val Ala Ala Lys Val Leu Ser Asp  
 65 70 75 80  
 Ala Gly His Lys Val Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly  
 85 90 95  
 Arg Ile Phe Thr Tyr Arg Asp Gln Asn Thr Gly Trp Ile Gly Glu Leu  
 100 105 110  
 Gly Ala Met Arg Met Pro Ser Ser His Arg Ile Leu His Lys Leu Cys  
 115 120 125  
 Gln Gly Leu Gly Leu Asn Leu Thr Lys Phe Thr Gln Tyr Asp Lys Asn  
 130 135 140  
 Thr Trp Thr Glu Val His Glu Val Lys Leu Arg Asn Tyr Val Val Glu  
 145 150 155 160  
 Lys Val Pro Glu Lys Leu Gly Tyr Ala Leu Arg Pro Gln Glu Lys Gly  
 165 170 175  
 His Ser Pro Glu Asp Ile Tyr Gln Met Ala Leu Asn Gln Ala Leu Lys  
 180 185 190  
 Asp Leu Lys Ala Leu Gly Cys Arg Lys Ala Met Lys Lys Phe Glu Arg  
 195 200 205  
 His Thr Leu Leu Glu Tyr Leu Leu Gly Glu Gly Asn Leu Ser Arg Pro  
 210 215 220  
 Ala Val Gln Leu Leu Gly Asp Val Met Ser Glu Asp Gly Phe Phe Tyr  
 225 230 235 240  
 Leu Ser Phe Ala Glu Ala Leu Arg Ala His Ser Cys Leu Ser Asp Arg  
 245 250 255  
 Leu Gln Tyr Ser Arg Ile Val Gly Gly Trp Asp Leu Leu Pro Arg Ala  
 260 265 270  
 Leu Leu Ser Ser Leu Ser Gly Leu Val Leu Leu Asn Ala Pro Val Val  
 275 280 285  
 Ala Met Thr Gln Gly Pro His Asp Val His Val Gln Ile Glu Thr Ser  
 290 295 300  
 Pro Pro Ala Arg Asn Leu Lys Val Leu Lys Ala Asp Val Val Leu Leu  
 305 310 315 320  
 Thr Ala Ser Gly Pro Ala Val Lys Arg Ile Thr Phe Ser Pro Pro Leu  
 325 330 335  
 Pro Arg His Met Gln Glu Ala Leu Arg Arg Leu His Tyr Val Pro Ala  
 340 345 350  
 Thr Lys Val Phe Leu Ser Phe Arg Arg Pro Phe Trp Arg Glu Glu His  
 355 360 365  
 Ile Glu Gly Gly His Ser Asn Thr Asp Arg Pro Ser Arg Met Ile Phe  
 370 375 380

113

Tyr Pro Pro Pro Arg Glu Gly Ala Leu Leu Leu Ala Ser Tyr Thr Trp  
 385 390 395 400  
 Ser Asp Ala Ala Ala Ala Phe Ala Gly Leu Ser Arg Glu Glu Ala Leu  
 405 410 415  
 Arg Leu Ala Leu Asp Asp Val Ala Ala Leu His Gly Pro Val Val Arg  
 420 425 430  
 Gln Leu Trp Asp Gly Thr Gly Val Val Lys Arg Trp Ala Glu Asp Gln  
 435 440 445  
 His Ser Gln Gly Gly Phe Val Val Gln Pro Pro Ala Leu Trp Gln Thr  
 450 455 460  
 Glu Lys Asp Asp Trp Thr Val Pro Tyr Gly Arg Ile Tyr Phe Ala Gly  
 465 470 475 480  
 Glu His Thr Ala Tyr Pro His Gly Trp Val Glu Thr Ala Val Lys Leu  
 485 490 495  
 Leu Arg Ala Ala Ile Lys Ile Asn Ser Arg Lys Gly Pro Ala Ser Asp  
 500 505 510  
 Thr Ala Ser Pro Glu Gly His Ala Ser Asp Met Glu Gly Gln Gly His  
 515 520 525  
 Val His Gly Val Ala Ser Ser Pro Ser His Asp Leu Ala Lys Glu Glu  
 530 535 540  
 Gly Ser His Pro Pro Val Gln Gly Gln Leu Ser Leu Gln Asn Thr Thr  
 545 550 555 560  
 His Thr Arg Thr Ser His  
 565

&lt;210&gt; 175

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (76)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 175

Met Ala Arg Ala Arg Gly Ser Pro Cys Pro Pro Leu Pro Pro Gly Arg  
 1 5 10 15

Met Ser Trp Pro His Gly Ala Leu Leu Phe Leu Trp Leu Phe Ser Pro  
 20 25 30

Pro Leu Gly Ala Gly Gly Gly Gly Val Ala Val Thr Ser Ala Ala Gly  
 35 40 45

Gly Gly Ser Pro Pro Ala Thr Ser Cys Pro Val Ala Cys Ser Cys Ser

114

50	55	60
Asn Gln Ala Ser Arg Val Ile Cys Thr Arg Arg Xaa Leu Ala Glu Val		
65	70	75 80
Pro Ala Ser Ile Pro Val Asn Thr Arg Tyr Leu Asn Leu Gln Glu Asn		
85	90	95
Gly Ile Gln Val Ile Arg Thr Asp Thr Phe Lys His Leu Arg His Leu		
100	105	110
Glu Ile Leu Gln Leu Ser Lys Asn Leu Val Arg Lys Ile Glu Val Gly		
115	120	125
Ala Phe Asn Gly Leu Pro Ser Leu Asn Thr Leu Glu Leu Phe Asp Asn		
130	135	140
Arg Leu Thr Thr Val Pro Thr Gln Ala Phe Glu Tyr Leu Ser Lys Leu		
145	150	155 160
Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu Ser Ile Pro Ser Tyr		
165	170	175
Ala Phe Asn Arg Val Pro Ser Leu Arg Arg Leu Asp Leu Gly Glu Leu		
180	185	190
Lys Arg Leu Glu Tyr Ile Ser Glu Ala Ala Phe Glu Gly Leu Val Asn		
195	200	205
Leu Arg Tyr Leu Asn Leu Gly Met Cys Asn Leu Lys Asp Ile Pro Asn		
210	215	220

<210> 176  
 <211> 123  
 <212> PRT  
 <213> Homo sapiens

<400> 176

Met His Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys Pro Ser		
1	5	10 15
Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Val His Leu Asn Ile		
20	25	30
Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr		
35	40	45
Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe Gln Tyr		
50	55	60
Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly Leu Thr		
65	70	75 80
Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe Asp Ser		
85	90	95

115

Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg Ala Ala  
                   100                                  105                                  110

Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu  
                   115                                  120

&lt;210&gt; 177

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 177

Met Gly Leu Ser Val Leu Leu Pro Leu Cys Leu Leu Gly Pro Gly Arg  
   1                                  5                                  10                                  15

Phe Thr Ser Gly Gln Lys Pro Leu Asp Thr Pro Gly Leu Gly Ala Ala  
                   20                                  25                                  30

Val Leu Ser Val Arg Lys Ala Gly Leu Lys Met Arg Ser His Leu Thr  
                   35                                  40                                  45

Pro Ser Val Cys Thr Val Pro Ser Pro Gly Ser  
                   50                                  55

&lt;210&gt; 178

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 178

Met Asp Thr Val Phe Leu Ile Gln Tyr Leu Phe Leu Thr Phe Pro Arg  
   1                                  5                                  10                                  15

Ile Val Phe Met Leu Gly Phe Val Val Val Leu Ser Phe Leu Leu Gly  
                   20                                  25                                  30

Gly Tyr Leu Leu Phe Val Leu Tyr Leu Ala Ala Thr Asn Gln Thr Thr  
                   35                                  40                                  45

Asn Glu Trp Tyr Arg Gly Asp Trp Ala Trp Cys Gln Arg Cys Pro Leu  
                   50                                  55                                  60

Val Ala Trp Pro Pro Ser Ala Glu Pro Gln Val His Arg Asn Ile His  
   65                                  70                                  75                                  80

Ser His Gly Leu Arg Ser Asn Leu Gln Glu Ile Phe Leu Pro Ala Phe  
                                   85                                  90                                  95

Pro Cys His Glu Arg Lys Lys Gln Glu  
                   100                                  105

&lt;210&gt; 179

116

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 179

Met Ala Asp Pro His Val Ser Phe Leu Ser Phe Arg Gln Leu Phe Ser  
 1 5 10 15

Trp Ala Ala Val Ile Leu Leu Arg Gly Ile Leu Gly Thr Val Ala Pro  
 20 25 30

Pro Pro Cys Pro Cys Val Leu Asp Leu Ala Val Tyr Pro Leu His Leu  
 35 40 45

Pro Val Glu Ala Pro Cys Leu Glu Val Val Phe Lys Gln Lys Asn Gly  
 50 55 60

Lys Asp Asn Cys Leu Val Phe Tyr Pro Asp Pro Ile Pro Leu Arg Gly  
 65 70 75 80

Ser Leu Leu Gly Pro Phe Ile  
 85

&lt;210&gt; 180

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (55)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (66)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 180

Met Ala Asp Pro His Val Ser Phe Leu Ser Phe Arg Gln Leu Phe Ser  
 1 5 10 15

Trp Ala Ala Val Ile Leu Leu Arg Gly Ile Leu Gly Thr Val Ala Pro  
 20 25 30

Pro Pro Cys Pro Cys Val Leu Asp Leu Ala Val Tyr Pro Leu His Leu  
 35 40 45

Pro Val Glu Ala Pro Cys Xaa Glu Val Val Phe Lys Gln Lys Asn Gly  
 50 55 60

Lys Xaa Asn Cys Leu Val Phe Tyr Pro Asp Pro Ile Pro Leu Arg Gly  
 65 70 75 80

Ser Leu Leu Gly Pro Phe Ile  
 85

117

<210> 181  
<211> 49  
<212> PRT  
<213> Homo sapiens

<400> 181  
Met Asn Leu Leu Gly Met Ile Phe Ser Met Cys Gly Leu Met Leu Lys  
1 5 10 15  
Leu Lys Trp Cys Ala Trp Val Ala Val Tyr Cys Ser Phe Ile Ser Phe  
20 25 30  
Ala Asn Ser Arg Ser Ser Glu Asp Thr Lys Gln Met Met Ser Ser Phe  
35 40 45  
Met

<210> 182  
<211> 23  
<212> PRT  
<213> Homo sapiens

<400> 182  
Leu Gly Ser Leu Ser Thr Ala Pro Ser Ser Ala Leu Pro Thr Leu Gly  
1 5 10 15  
Ala Arg Arg Thr Arg Ser Lys  
20

<210> 183  
<211> 103  
<212> PRT  
<213> Homo sapiens

<400> 183  
Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
1 5 10 15  
Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
20 25 30  
Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
35 40 45  
Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp  
50 55 60  
Val Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn  
65 70 75 80  
Tyr Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg  
85 90 95  
Thr Arg Val Leu Phe Ile Tyr

118

100

<210> 184  
 <211> 198  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (29)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 184  
 Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
       1                  5                  10                  15  
 His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln His Xaa Phe Asp Tyr  
                   20                  25                  30  
 Lys Asp Glu Ser Gly Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr  
           35                  40                  45  
 Thr Leu Pro Ser Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr  
       50                  55                  60  
 Ile Pro Leu Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp  
       65                  70                  75                  80  
 Phe Asp Asp Ala Asp Gln Leu Arg Ile Gly Asn Asp Gly Ile Phe Met  
                   85                  90                  95  
 Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe Leu  
           100                  105                  110  
 Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile Ser  
           115                  120                  125  
 Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe Ser  
       130                  135                  140  
 Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val  
       145                  150                  155                  160  
 Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr  
           165                  170                  175  
 Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr  
           180                  185                  190  
 Arg Val Leu Phe Ile Tyr  
       195

<210> 185  
 <211> 70  
 <212> PRT  
 <213> Homo sapiens



119

&lt;400&gt; 185

```

Met Leu Leu His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln Phe Ser
 1             5             10             15

Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val
          20             25             30

Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr
          35             40             45

Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr
          50             55             60

Arg Val Leu Phe Ile Tyr
 65             70

```

&lt;210&gt; 186

&lt;211&gt; 82

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 186

```

Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe
 1             5             10             15

Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile
          20             25             30

Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe
          35             40             45

Ser Thr Tyr Phe Pro Ala Phe Met Asn Ser Leu Ser Arg Ser Lys Arg
          50             55             60

Thr Pro Ala Gly Ser Glu Ser Arg Cys Arg Thr Gln Arg Asn Asn His
 65             70             75             80

Leu Leu

```

&lt;210&gt; 187

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 187

```

Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu
 1             5             10             15

His Leu Thr Ala Ala Phe Leu Gln Arg Ala His Xaa Ile Leu Thr Thr

```

120

20                      25                      30

Arg Met Ser Leu Gly Phe Gln Ser Pro His Leu Thr Met  
                  35                      40                      45

<210> 188  
 <211> 33  
 <212> PRT  
 <213> Homo sapiens

<400> 188  
 Met Thr Val Met Asp Pro Lys Gln Met Asn Val Ala Ala Ala Val Trp  
          1                      5                      10                      15

Ala Val Val Ser Tyr Val Val Ala Asp Met Glu Glu Met Leu Pro Arg  
                  20                      25                      30

Ser

<210> 189  
 <211> 231  
 <212> PRT  
 <213> Homo sapiens

<400> 189  
 Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser  
          1                      5                      10                      15

Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr  
                  20                      25                      30

Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro  
                  35                      40                      45

Ile Lys Lys Asn Ser Gly His Ile Tyr Asn Lys Asn Ile Ser Gln Lys  
          50                      55                      60

Asp Cys Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly Pro  
          65                      70                      75                      80

Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu Arg  
                  85                      90                      95

Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile Leu  
                  100                      105                      110

Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro Ile  
          115                      120                      125

Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp Asp  
          130                      135                      140

Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu Ala  
          145                      150                      155                      160

121

Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Gly Thr  
                   165                  170                  175

Ala Ala Leu Glu Ala Ser Ser Pro Arg Ala Ala Lys Ser Leu Ser Leu  
                   180                  185                  190

Thr Gly Met Leu Ser Ser Ala Asn Trp Gly Ile Glu Phe Lys Val Thr  
                   195                  200                  205

Arg Lys Lys Gln Ala Asp Asn Trp Lys Gly Thr Asp Trp Val Leu Leu  
                   210                  215                  220

Gly Phe Ile Leu Ile Pro Cys  
 225                  230

&lt;210&gt; 190

&lt;211&gt; 612

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (245)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (246)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (249)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 190

Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
   1                  5                  10                  15

Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
                   20                  25                  30

Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
                   35                  40                  45

Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
   50                  55                  60

Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
   65                  70                  75                  80

Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
                   85                  90                  95

Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
                   100                  105                  110

Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser

122

115	120	125
Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro		
130	135	140
Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile		
145	150	155
Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn		
	165	170
		175
Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His		
	180	185
		190
Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala		
	195	200
		205
Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr		
210	215	220
Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu		
225	230	235
		240
Asp Gly Asn Phe Xaa Xaa Ser Thr Xaa Leu Glu Lys Pro Gln Asn Met		
	245	250
		255
Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His		
	260	265
		270
Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser		
	275	280
		285
Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu		
290	295	300
Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val		
305	310	315
		320
Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile		
	325	330
		335
Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys		
	340	345
		350
Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro		
	355	360
		365
Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr		
370	375	380
Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr		
385	390	395
		400
Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser		
	405	410
		415
Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn		
	420	425
		430
Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu		

123

435                      440                      445  
 Cys Ser Asn Asp Cys Pro Arg Lys Ile Thr Pro Phe Gly Val Asn Gln  
 450                      455                      460  
 Pro Gly Pro Tyr Ile Met Tyr Thr Thr Val Asp Ala Asn Gly Tyr Leu  
 465                      470                      475                      480  
 Lys Asn Gly Ser Ala Gly Gln Leu Ser Gln Ser Ala His Leu Ala Leu  
 485                      490                      495  
 Gln Leu Pro Tyr Asn Val Leu Gly Leu Gly Arg Ser Ala Asn Phe Leu  
 500                      505                      510  
 Asp His Leu Tyr Val Gly Ile Pro Arg Pro Ser Gly Glu Lys Ser Ile  
 515                      520                      525  
 Arg Lys Gln Glu Trp Thr Ala Ile Ile Pro Asn Ser Gln Leu Ile Val  
 530                      535                      540  
 Ile Pro Tyr Pro His Asn Val Pro Arg Ser Trp Ser Ala Lys Leu Tyr  
 545                      550                      555                      560  
 Leu Thr Pro Ser Asn Ile Val Leu Leu Thr Ala Ile Ala Leu Ile Gly  
 565                      570                      575  
 Val Cys Val Phe Ile Leu Ala Ile Ile Gly Ile Leu His Trp Gln Glu  
 580                      585                      590  
 Lys Lys Ala Asp Asp Arg Glu Lys Arg Gln Glu Ala His Arg Phe His  
 595                      600                      605  
 Phe Asp Ala Met  
 610

&lt;210&gt; 191

&lt;211&gt; 456

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
 1                      5                      10                      15  
 Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
 20                      25                      30  
 Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
 35                      40                      45  
 Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
 50                      55                      60  
 Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
 65                      70                      75                      80  
 Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
 85                      90                      95

124

Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
 100 105 110  
 Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser  
 115 120 125  
 Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro  
 130 135 140  
 Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile  
 145 150 155 160  
 Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn  
 165 170 175  
 Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His  
 180 185 190  
 Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala  
 195 200 205  
 Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr  
 210 215 220  
 Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu  
 225 230 235 240  
 Asp Gly Asn Phe Ser Val Ser Thr Ile Leu Glu Lys Pro Gln Asn Met  
 245 250 255  
 Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His  
 260 265 270  
 Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser  
 275 280 285  
 Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu  
 290 295 300  
 Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val  
 305 310 315 320  
 Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile  
 325 330 335  
 Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys  
 340 345 350  
 Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro  
 355 360 365  
 Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr  
 370 375 380  
 Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr  
 385 390 395 400  
 Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser  
 405 410 415

125

Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn  
 420 425 430

Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu  
 435 440 445

Cys Ser Asn Asp Cys Pro Arg Arg  
 450 455

&lt;210&gt; 192

&lt;211&gt; 184

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 192

Met Leu Phe Leu Phe Ser Met Ala Thr Leu Leu Arg Thr Ser Phe Ser  
 1 5 10 15

Asp Pro Gly Val Ile Pro Arg Ala Leu Pro Asp Glu Ala Ala Phe Ile  
 20 25 30

Glu Met Glu Ile Glu Ala Thr Asn Gly Ala Val Pro Gln Gly Gln Arg  
 35 40 45

Pro Pro Pro Arg Ile Lys Asn Phe Gln Ile Asn Asn Gln Ile Val Lys  
 50 55 60

Leu Lys Tyr Cys Tyr Thr Cys Lys Ile Phe Arg Pro Pro Arg Ala Ser  
 65 70 75 80

His Cys Ser Ile Cys Asp Asn Cys Val Glu Arg Phe Asp His His Cys  
 85 90 95

Pro Trp Val Gly Asn Cys Val Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr  
 100 105 110

Leu Phe Ile Leu Ser Leu Ser Leu Leu Thr Ile Tyr Val Phe Ala Phe  
 115 120 125

Asn Ile Val Tyr Val Ala Leu Lys Ser Leu Lys Ile Gly Phe Leu Glu  
 130 135 140

Thr Leu Lys Gly Asn Ser Trp Asn Cys Ser Arg Ser Pro His Leu Leu  
 145 150 155 160

Leu Tyr Thr Leu Val Arg Arg Gly Thr Asp Trp Ile Ser Tyr Phe Pro  
 165 170 175

Arg Gly Ser Gln Pro Asp Asn Gln  
 180

&lt;210&gt; 193

&lt;211&gt; 146

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

126

&lt;400&gt; 193

```

Met Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala
 1           5           10           15

Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys
      20           25           30

Phe Arg Gln Ser His Thr Trp Ser Leu Leu Gln Gly Ala Ala His Asp
      35           40           45

Asp Pro Val Ala Arg Gly Leu Asp Pro Asp Gly Leu Leu Leu Asp
      50           55           60

Val Val Val Asn Gly Val Val Pro Gly Arg Ala Trp Leu Thr Gln Ile
 65           70           75           80

Phe Lys Cys Arg Thr Leu Lys Lys His Tyr Val Gln Thr Arg Ala Trp
      85           90           95

Pro Ala Val Arg Gly Leu His Thr Ala Leu Leu Pro Gly Arg Pro Pro
      100          105          110

Leu Val Pro Thr Leu Gln Pro Gln His Pro Val Gln Arg Gly Pro Gly
      115          120          125

Pro Pro Ala Pro Ala Gly Ala Ala Pro Ala Gly Leu Ser Tyr Gln Leu
      130          135          140

Gly Leu
145

```

&lt;210&gt; 194

&lt;211&gt; 124

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 194

```

Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Val
 1           5           10           15

Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu
      20           25           30

Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro
      35           40           45

Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val
      50           55           60

Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu
      65           70           75           80

Pro Ser Cys Thr Asp Gln Cys Phe Arg Ala Lys Pro His Ser Trp Gly
      85           90           95

His Phe Ser Arg Phe Phe His Leu Leu Gln Ala Tyr Ser Asp Ser Lys
      100          105          110

```



127

Thr Arg Asn Glu Phe Arg Leu Pro Ala Arg Ala Asp  
115 120

<210> 195  
<211> 51  
<212> PRT  
<213> Homo sapiens

<400> 195  
Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
1 5 10 15  
Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
20 25 30  
Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Cys  
35 40 45  
Leu Leu Ala  
50

<210> 196  
<211> 319  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (68)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (115)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (213)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 196  
Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu  
1 5 10 15  
Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
20 25 30  
Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
35 40 45  
Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly Arg Ile Phe Thr Tyr  
50 55 60  
Arg Asp Gln Xaa Thr Gly Trp Ile Gly Glu Leu Gly Ala Met Arg Met

128

65					70					75					80
Pro	Ser	Ser	His	Arg	Ile	Leu	His	Lys	Leu	Cys	Gln	Gly	Leu	Gly	Leu
				85					90					95	
Asn	Leu	Thr	Lys	Phe	Thr	Gln	Tyr	Asp	Lys	Asn	Thr	Trp	Thr	Glu	Val
			100					105					110		
His	Glu	Xaa	Lys	Leu	Arg	Asn	Tyr	Val	Val	Glu	Lys	Val	Pro	Glu	Lys
		115					120					125			
Leu	Gly	Tyr	Ala	Leu	Arg	Pro	Gln	Glu	Lys	Gly	His	Ser	Pro	Glu	Asp
	130					135					140				
Ile	Tyr	Gln	Met	Ala	Leu	Asn	Gln	Ala	Leu	Lys	Asp	Leu	Lys	Ala	Leu
145					150					155					160
Gly	Cys	Arg	Lys	Ala	Met	Lys	Lys	Phe	Glu	Arg	His	Thr	Leu	Leu	Glu
				165					170					175	
Tyr	Leu	Leu	Gly	Glu	Gly	Asn	Leu	Ser	Arg	Pro	Ala	Val	Gln	Leu	Leu
			180					185					190		
Gly	Asp	Val	Met	Ser	Glu	Asp	Gly	Phe	Phe	Tyr	Leu	Ser	Phe	Ala	Glu
		195					200					205			
Ala	Leu	Arg	Ala	Xaa	Ser	Cys	Leu	Ser	Asp	Arg	Leu	Gln	Tyr	Ser	Arg
	210					215					220				
Ile	Val	Gly	Gly	Trp	Asp	Leu	Leu	Pro	Arg	Ala	Leu	Leu	Ser	Ser	Leu
225					230					235					240
Ser	Gly	Leu	Val	Leu	Leu	Asn	Ala	Pro	Val	Val	Ala	Met	Thr	Gln	Gly
				245					250					255	
Pro	His	Asp	Val	His	Val	Gln	Ile	Glu	Thr	Ser	Pro	Pro	Ala	Arg	Asn
			260					265						270	
Leu	Lys	Val	Leu	Lys	Ala	Asp	Val	Val	Leu	Leu	Thr	Ala	Ser	Gly	Pro
		275					280					285			
Ala	Val	Lys	Arg	Ile	Thr	Phe	Ser	Pro	Arg	Cys	Pro	Ala	Thr	Cys	Arg
	290					295					300				
Arg	Arg	Cys	Gly	Gly	Cys	Thr	Thr	Cys	Arg	Pro	Pro	Arg	Cys	Ser	
305					310					315					

&lt;210&gt; 197

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

129

&lt;221&gt; SITE

&lt;222&gt; (53)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 197

Pro Phe Cys Ser Gly Phe Phe Pro Ser Leu Trp Ile Tyr Leu Pro Phe  
 1 5 10 15

Ile Phe Asn Val Ser Asp Leu Trp Met Gly Ser Leu Ser Gly Cys Ala  
 20 25 30

Leu Pro Phe Cys Leu Xaa Val Phe Phe Leu Thr Val Ser Pro Ser Ala  
 35 40 45

Val Gly Leu Leu Xaa Phe Ala Gly Gly Pro Leu Gln Thr Leu Phe Ala  
 50 55 60

Trp Val Ser Pro Val Glu Ala Ala Glu Gln Gln Arg Leu Leu Pro Val  
 65 70 75 80

Leu Ser Ser Gly Ser Phe Val Ser Glu Gly Thr Cys Gln Met Pro Ala  
 85 90 95

Arg Ala Leu Leu Tyr Glu Val Ser Val Gly Pro Tyr Trp Glu Ile Pro  
 100 105 110

Pro Ser Gln Asp Thr Arg Arg Ser Gly Thr Tyr Leu Arg Arg Gln Ser  
 115 120 125

Asp Pro  
 130

&lt;210&gt; 198

&lt;211&gt; 108

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 198

His Glu Gly Ser Cys Arg Ala Pro Gly Phe Ser Ala His Lys Gly Arg  
 1 5 10 15

Gly Cys Pro Ser Pro Arg Met Thr Leu Pro Ser Arg Ala Leu Ala Ser  
 20 25 30

Leu Gly Val Gly Val Trp Gly Met Leu Arg Leu Asn Gln Val Thr Val  
 35 40 45

Ser Cys Gly Gly Ser Arg Trp Ser Ser Arg Val Ala Leu Gly Ala Phe  
 50 55 60

Ser Trp Val Cys Gly Val Ala Leu Val Leu Gln Pro Ser Gly Gly Gly  
 65 70 75 80

Leu Gly Leu Thr Ser Pro Ser Glu Gly Cys Trp Glu Gly Glu Leu Ala  
 85 90 95

Leu Ala Val Leu Arg Ala Pro Gly Gly Ser Pro Ser  
 100 105

```
<210> 199
<211> 104
<212> PRT
<213> Homo sapiens
```

```

<400> 199
Ile Pro Leu Thr Leu Pro Gly Ile Phe Leu Leu Ile Arg Leu Phe Trp
  1             5             10             15

Arg Leu Gly Gln Ser Ile Cys Gly Pro Gly Lys Leu Val Leu Trp Pro
          20             25             30

Gln Phe Cys Cys Gly Cys Ala Val Ile Ser Gly His Cys Val Pro Arg
          35             40             45

Gly Met Pro Ser Ser Trp Leu Pro Gly Cys Phe Val Leu Leu Cys Leu
  50             55             60

Val Ala Val Gly Cys Gln Leu Arg Glu Trp Gly Val Gly Gly Val Ser
  65             70             75             80

Ala Val Gly Leu Leu Ala Leu Pro His Leu Gln Val Leu Gly Met Arg
          85             90             95

Gly Arg Gly Leu Ile Ser Gly Gly
          100

```

```
<210> 200
<211> 237
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (142)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 200
Gly Pro Ala Gly Lys Glu Ala Trp Ile Trp Ser Trp Leu Leu Pro Ser
  1             5             10             15

Pro Gly Pro Ala Pro Leu Pro Ser Ala Ser Trp Gly Leu Cys Gly Asp
      20             25             30

Ala Pro Arg Ala Ala Ala Arg Gly Pro Val Glu Pro Gly Ala Ala Arg
      35             40             45

Met Ala Leu Leu Ser Arg Pro Ala Leu Thr Leu Leu Leu Leu Met
  50             55             60

Ala Ala Val Val Arg Cys Gln Glu Gln Ala Gln Thr Thr Asp Trp Arg
  65             70             75             80

Ala Thr Leu Lys Thr Ile Arg Asn Gly Val His Lys Ile Asp Thr Tyr
      85             90             95

```

131

Leu Asn Ala Ala Leu Asp Leu Leu Gly Gly Glu Asp Gly Leu Cys Gln  
 100 105 110  
 Tyr Lys Cys Ser Asp Gly Ser Lys Pro Phe Pro Arg Tyr Gly Tyr Lys  
 115 120 125  
 Pro Ser Pro Pro Asn Gly Cys Gly Ser Pro Leu Phe Gly Xaa His Leu  
 130 135 140  
 Asn Ile Gly Ile Pro Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg  
 145 150 155 160  
 Cys Tyr Glu Thr Cys Gly Lys Ser Lys Asn Asp Cys Asp Glu Glu Phe  
 165 170 175  
 Gln Tyr Cys Leu Ser Lys Ile Cys Arg Asp Val Gln Lys Thr Leu Gly  
 180 185 190  
 Leu Thr Gln His Val Gln Ala Cys Glu Thr Thr Val Glu Leu Leu Phe  
 195 200 205  
 Asp Ser Val Ile His Leu Gly Cys Lys Pro Tyr Leu Asp Ser Gln Arg  
 210 215 220  
 Ala Ala Cys Arg Cys His Tyr Glu Glu Lys Thr Asp Leu  
 225 230 235

&lt;210&gt; 201

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 201

Cys Cys Asn Gln His Asp Arg Cys  
 1 5

&lt;210&gt; 202

&lt;211&gt; 15

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 202

Ser Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr Glu Thr  
 1 5 10 15

&lt;210&gt; 203

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 203

Leu Thr Lys Cys Cys Asn Gln His Asp Arg Cys Tyr Glu Thr Cys Gly  
 1 5 10 15

&lt;210&gt; 204

&lt;211&gt; 260

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 204

Gly Thr Ser Ser Ala Arg Pro Arg Gly Ala Leu Pro Gly Gly Ser Ala  
 1 5 10 15

Pro Ser Ala Pro His Gly Gln Leu Pro Gly Arg Ala Gln Pro Ala Pro  
 20 25 30

Val Ser Gly Pro Pro Pro Thr Ser Gly Leu Cys His Phe Asp Pro Ala  
 35 40 45

Ala Pro Trp Pro Leu Trp Pro Gly Pro Trp Gln Leu Pro Pro His Pro  
 50 55 60

Gln Asp Trp Pro Ala His Pro Asp Ile Pro Gln Asp Trp Val Ser Phe  
 65 70 75 80

Leu Arg Ser Phe Gly Gln Leu Thr Leu Cys Pro Arg Asn Gly Thr Val  
 85 90 95

Thr Gly Lys Trp Arg Gly Ser His Val Val Gly Leu Leu Thr Thr Leu  
 100 105 110

Asn Phe Gly Asp Gly Pro Asp Arg Asn Lys Thr Arg Thr Phe Gln Ala  
 115 120 125

Thr Val Leu Gly Ser Gln Met Gly Leu Lys Gly Ser Ser Ala Gly Gln  
 130 135 140

Leu Val Leu Ile Thr Ala Arg Val Thr Thr Glu Arg Thr Ala Gly Thr  
 145 150 155 160

Cys Leu Tyr Phe Ser Ala Val Pro Gly Ile Leu Pro Ser Ser Gln Pro  
 165 170 175

Pro Ile Ser Cys Ser Glu Glu Gly Ala Gly Asn Ala Thr Leu Ser Pro  
 180 185 190

Arg Met Gly Glu Glu Cys Val Ser Val Trp Ser His Glu Gly Leu Val  
 195 200 205

Leu Thr Lys Leu Leu Thr Ser Glu Glu Leu Ala Leu Cys Gly Ser Arg  
 210 215 220

Leu Leu Val Leu Gly Ser Phe Leu Leu Leu Phe Cys Gly Leu Leu Cys  
 225 230 235 240

Cys Val Thr Ala Met Cys Phe His Pro Arg Arg Glu Ser His Trp Ser  
 245 250 255

133

Arg Thr Arg Leu  
260

<210> 205  
<211> 80  
<212> PRT  
<213> Homo sapiens

<400> 205

Ala Arg Ala Pro Pro Gly Pro Glu Gly Leu Ser Pro Glu Ala Gln Pro  
1 5 10 15

Pro Leu Leu Pro Met Gly Asn Cys Gln Ala Gly His Asn Leu His Leu  
20 25 30

Cys Leu Ala His His Pro Pro Leu Val Cys Ala Thr Leu Ile Leu Leu  
35 40 45

Leu Leu Gly Leu Ser Gly Leu Gly Leu Gly Ser Phe Leu Leu Thr His  
50 55 60

Arg Thr Gly Leu Arg Thr Leu Thr Ser Pro Arg Thr Gly Ser Leu Phe  
65 70 75 80

<210> 206  
<211> 224  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (6)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (9)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (22)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (143)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (186)  
<223> Xaa equals any of the naturally occurring L-amino acids

134

&lt;400&gt; 206

```

Arg Phe Leu Ser Val Xaa Pro Gln Xaa Glu Val Pro Phe Leu Leu His
  1           5           10           15

Pro Cys Val Cys Phe Xaa Gly Gly His Pro Ser Leu Leu Pro Asp Pro
      20           25           30

Cys Arg Ala Val Gly Gly Gly Trp Glu Ala Pro Arg Cys Cys Leu His
      35           40           45

Glu Ala Leu Cys Gln Ser Leu Gly Cys Lys Ala Glu Glu Ile Val Ser
      50           55           60

Val Ser Glu Ser Ser Ser Ala Gln Arg Cys Trp Tyr Leu Leu Arg Gly
      65           70           75           80

Arg Lys Ala Gly Gly Arg Gly Pro Ala Ser Pro Val Leu Phe Ala Leu
      85           90           95

Met Arg Leu Glu Ser Leu Cys His Leu Cys Leu Ala Cys Leu Phe Phe
      100          105          110

Arg Leu Pro Ala Thr Arg Thr Val Tyr Cys Met Asn Glu Ala Glu Ile
      115          120          125

Val Asp Val Ala Leu Gly Ile Leu Ile Glu Ser Arg Lys Gln Xaa Lys
      130          135          140

Ala Cys Glu Gln Pro Ala Leu Ala Gly Ala Asp Asn Pro Glu His Ser
      145          150          155          160

Pro Pro Cys Ser Val Ser Pro His Thr Ser Ser Gly Ser Ser Ser Glu
      165          170          175

Glu Glu Asp Ser Gly Lys Gln Ala Leu Xaa Pro Gly Leu Ser Pro Ser
      180          185          190

Gln Arg Pro Gly Gly Ser Ser Ser Ala Cys Ser Arg Ser Pro Glu Glu
      195          200          205

Glu Glu Glu Glu Asp Val Leu Lys Tyr Val Arg Glu Ile Phe Phe Ser
      210          215          220

```

&lt;210&gt; 207

&lt;211&gt; 199

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;



135

&lt;221&gt; SITE

&lt;222&gt; (103)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (191)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 207

Val Pro Gly Trp Pro Arg Ala Cys Ser Pro Cys Gln Ala Asp Ser Pro  
 1 5 10 15

Arg Ala His Pro Pro Lys Leu Arg Gly Ile Leu Arg Trp Ala Pro Val  
 20 25 30

Pro Leu Xaa Cys Ala Ala Leu Cys Pro Pro Leu Asp Ser Gly Met Ser  
 35 40 45

Met Ala Ala Cys Pro Glu Ala Pro Glu Pro Ser Phe Leu Arg Glu Val  
 50 55 60

Pro Ser Ser Pro Ala Ser Thr Gln Trp His Arg Pro Cys Asn Phe Arg  
 65 70 75 80

Gln Val Glu Ala Asn Pro Arg Lys Glu Pro Lys Asn Leu Val Trp Arg  
 85 90 95

Asp Val Ser Leu Gly Gln Xaa Ser Arg Thr Pro Arg Gly Ser Gly Leu  
 100 105 110

Glu Leu Val Arg Val Cys Gly Gly Gly Met Gln Arg Asp Lys Thr Val  
 115 120 125

Val Glu Glu Arg Val Gly Glu Glu Arg Glu Arg Glu Arg Glu Arg Glu  
 130 135 140

Ser Leu Gly Gly Ala Gly Lys His Gly Glu Met Arg Cys Val Tyr Val  
 145 150 155 160

Arg Glu Ser Val Gly Ala Pro Gly Arg Ala Gly Gly Gly Gly Asn Gly  
 165 170 175

Val Asn Ser Val Gly Cys Val Arg Thr Val His Ser Gly Ser Xaa Pro  
 180 185 190

Pro Pro Ser Ala Gly Val Ser  
 195

&lt;210&gt; 208

&lt;211&gt; 174

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 208

Thr Arg Pro Gly Lys Glu Leu Asn Leu Val Phe Gly Leu Gln Leu Ser  
 1 5 10 15

136

Met Ala Arg Ile Gly Ser Thr Val Asn Met Asn Leu Met Gly Trp Leu  
                   20                  25                  30

Tyr Ser Lys Ile Glu Ala Leu Leu Gly Ser Ala Gly His Thr Thr Leu  
           35                  40                  45

Gly Ile Thr Leu Met Ile Gly Gly Ile Thr Cys Ile Leu Ser Leu Ile  
       50                  55                  60

Cys Ala Leu Ala Leu Ala Tyr Leu Asp Gln Arg Ala Glu Arg Ile Leu  
       65                  70                  75                  80

His Lys Glu Gln Gly Lys Thr Gly Glu Val Ile Lys Leu Thr Asp Val  
           85                  90                  95

Lys Asp Phe Ser Leu Pro Leu Trp Leu Ile Phe Ile Ile Cys Val Cys  
           100                  105                  110

Tyr Tyr Val Ala Val Phe Pro Phe Ile Gly Leu Gly Lys Val Phe Phe  
           115                  120                  125

Thr Glu Lys Phe Gly Phe Ser Ser Gln Ala Ala Ser Ala Ile Asn Ser  
       130                  135                  140

Val Val Tyr Val Ile Ser Ala Pro Met Ser Pro Val Phe Gly Leu Leu  
       145                  150                  155                  160

Val Asp Lys Thr Gly Lys Asn Ile Ile Trp Val Leu Cys Ala  
           165                  170

&lt;210&gt; 209

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 209

Cys Lys Asp Leu Cys Ser Arg Val Tyr Leu Leu Thr Leu Ser Pro Leu  
       1                  5                  10                  15

Leu Ser Tyr Asp Pro Ala Thr Ser His Ser Pro Arg Asn Thr Gln  
           20                  25                  30

&lt;210&gt; 210

&lt;211&gt; 369

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (78)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 210

Ile Ile Cys Glu Cys Trp Glu Glu Glu Cys Gln Ser Cys Arg Leu Lys  
       1                  5                  10                  15

137

Ile Thr Gln Pro Arg Glu Ile Cys Arg Met Asp Phe Leu Val Leu Phe  
                     20                    25                    30  
 Leu Phe Tyr Leu Ala Ser Val Leu Met Gly Leu Val Leu Ile Cys Val  
                     35                    40                    45  
 Cys Ser Lys Thr His Ser Leu Lys Gly Leu Ala Arg Gly Gly Ala Gln  
                     50                    55                    60  
 Ile Phe Ser Cys Ile Ile Pro Glu Cys Leu Gln Arg Ala Xaa His Gly  
                     65                    70                    75                    80  
 Leu Leu His Tyr Leu Phe His Thr Arg Asn His Thr Phe Ile Val Leu  
                     85                    90                    95  
 His Leu Val Leu Gln Gly Met Val Tyr Thr Glu Tyr Thr Trp Glu Val  
                     100                    105                    110  
 Phe Gly Tyr Cys Gln Glu Leu Glu Leu Ser Leu His Tyr Leu Leu Leu  
                     115                    120                    125  
 Pro Tyr Leu Leu Leu Gly Val Asn Leu Phe Phe Phe Thr Leu Thr Cys  
                     130                    135                    140  
 Gly Thr Asn Pro Gly Ile Ile Thr Lys Ala Asn Glu Leu Leu Phe Leu  
                     145                    150                    155                    160  
 His Val Tyr Glu Phe Asp Glu Val Met Phe Pro Lys Asn Val Arg Cys  
                     165                    170                    175  
 Ser Thr Cys Asp Leu Arg Lys Pro Ala Arg Ser Lys His Cys Ser Val  
                     180                    185                    190  
 Cys Asn Trp Cys Val His Arg Phe Asp His His Cys Val Trp Val Asn  
                     195                    200                    205  
 Asn Cys Ile Gly Ala Trp Asn Ile Arg Tyr Phe Leu Ile Tyr Val Leu  
                     210                    215                    220  
 Thr Leu Thr Ala Ser Ala Ala Thr Val Ala Ile Val Ser Thr Thr Phe  
                     225                    230                    235                    240  
 Leu Val His Leu Val Val Met Ser Asp Leu Tyr Gln Glu Thr Tyr Ile  
                     245                    250                    255  
 Asp Asp Leu Gly His Leu His Val Met Asp Thr Val Phe Leu Ile Gln  
                     260                    265                    270  
 Tyr Leu Phe Leu Thr Phe Pro Arg Ile Val Phe Met Leu Gly Phe Val  
                     275                    280                    285  
 Val Val Leu Ser Phe Leu Leu Gly Gly Tyr Leu Leu Phe Val Leu Tyr  
                     290                    295                    300  
 Leu Ala Ala Thr Asn Gln Thr Thr Asn Glu Trp Tyr Arg Gly Asp Trp  
                     305                    310                    315                    320  
 Ala Trp Cys Gln Arg Cys Pro Leu Val Ala Trp Pro Pro Ser Ala Glu  
                     325                    330                    335

138

Pro Gln Val His Arg Asn Ile His Ser His Gly Leu Arg Ser Asn Leu  
 340 345 350

Gln Glu Ile Phe Leu Pro Ala Phe Pro Cys His Glu Arg Lys Lys Gln  
 355 360 365

Glu

<210> 211

<211> 147

<212> PRT

<213> Homo sapiens

<400> 211

Leu Leu Ser Phe Lys Ile Arg Gly Leu Arg Thr Glu Asp Ala Gly Trp  
 1 5 10 15

Ala Gln Ser Ser Ser Gly Gly Leu Cys Val Arg Gly Asp Ala Phe Trp  
 20 25 30

Met Pro Ser Ser Ser Gly Leu Gly Ser Pro Ser Arg Pro Pro Ser  
 35 40 45

Ser Phe Leu Cys Leu Leu Leu Leu Leu Leu Pro Pro Ala Ala Leu Ala  
 50 55 60

Leu Leu Leu Phe Phe Leu Asp Phe Phe Pro Pro Arg Ala Ala Val Ser  
 65 70 75 80

Pro Phe Leu Pro Asp His Cys Ser Ala Arg Gln Pro Arg Val Trp Arg  
 85 90 95

Arg Glu Thr Leu Asn Arg Ser Ala Ser Gly Leu Gly Cys Trp Ala Arg  
 100 105 110

Ser Thr Glu Gln Gly Ala Val Gly Val Ala Thr Gly Thr Val Leu Asp  
 115 120 125

Ile Ser Leu Pro Ala Ser Cys Leu Ser Leu Trp Pro Pro Gly Pro Ser  
 130 135 140

Gly Gly Ile  
 145

<210> 212

<211> 143

<212> PRT

<213> Homo sapiens

<400> 212

Gln Leu Gly Leu Cys Leu Thr Ser Ala Ser Leu Pro Pro Ala Ser Arg  
 1 5 10 15

Cys Gly His Gln Ala Pro Leu Gly Ala Ser Asp Leu Ser Ala His His  
 20 25 30

```
<210> 213
<211> 160
<212> PRT
<213> Homo sapiens
```

```

<400> 213
His Gln Pro Pro Cys Leu Leu Pro Leu Ala Val Ala Thr Arg Pro Leu
  1              5              10              15

Trp Gly His Leu Thr Cys Leu Pro Ile Ile Leu His Leu Val Ser Val
      20              25              30

Thr Leu Thr Ser Pro Cys Leu Ala Asn Gln Ala Phe Gln Gly Gln Arg
      35              40              45

Ser Tyr Asn Ala Leu Trp Cys Pro Leu Phe Leu Leu Leu Pro Thr Ser
      50              55              60

Pro Lys Gly Glu Gln Thr Asn His Pro Glu Pro Ala Cys Pro Cys Phe
  65              70              75              80

Pro Lys Leu Thr Gly Val Phe Ser Leu Gln His Val Val Gly Ala Glu
      85              90              95

Glu Phe Ser Gln Val Phe Leu Leu Val Asp Pro Val Pro Val Leu Asp
      100              105              110

His Leu Leu Lys Leu Phe Thr Ser Thr Ser His Leu Leu Ile Ile Ile
      115              120              125

Pro His Ile Gly Lys Ala Pro Ala Pro Asp Ser Leu Leu Glu Glu Leu
      130              135              140

Ser Leu Ser Leu Ala Thr His Cys Lys Val Ala Val Ala Arg Phe Thr
  145              150              155              160

```

140

&lt;210&gt; 214

&lt;211&gt; 157

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 214

Met Ala Ala Glu Gly Ser Arg Phe Ser Ser Gln Ser Pro Gly Leu Val  
 1 5 10 15

Asp Arg Gln Gly Pro Lys Cys Asp Pro Ser Arg Leu Val Ser Pro Trp  
 20 25 30

Gly Arg His Gly Leu Arg Ile Leu Gln Ile Gly His His His Gly Arg  
 35 40 45

Asp Gly Gln His Glu Ala Thr His His Leu Leu Arg Val Leu Arg Ala  
 50 55 60

Pro Arg Val Gly Lys Ala Asp Glu Gly Ala Val Asp Ser Asp Pro Ser  
 65 70 75 80

Thr Pro Leu Gln Leu Lys His Glu Ala Ala His Ala Glu Asp His Ala  
 85 90 95

Gln Gln Val His Val Val Arg Arg Arg Val Val Gln Gly Arg Val Thr  
 100 105 110

Phe Ala Arg Arg Gly Leu Val Pro Gln His Phe Val Arg Pro Pro Trp  
 115 120 125

Val Arg His Ile Val Ser Gly His Ser Glu Ser Lys Ala Arg Ser Arg  
 130 135 140

Leu Phe Arg Cys Arg Asn Arg Ser Phe Arg Arg Ala Ser  
 145 150 155

&lt;210&gt; 215

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 215

Arg Leu Val Ser Pro Trp Gly Arg His Gly Leu Arg Ile Leu Gln Ile  
 1 5 10 15

Gly His His His Gly Arg Asp Gly Gln His Glu Ala Thr His His Leu  
 20 25 30

Leu Arg Val Leu Arg Ala  
 35

141

<210> 216  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 216  
Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln  
1 5 10

<210> 217  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 217  
Thr Tyr Glu Gln Leu Lys Arg  
1 5

<210> 218  
<211> 137  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (22)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (33)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (71)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 218  
Arg Pro Arg Pro Ser Ala Ser Ser Leu Ala Arg Ser Ala Ser Leu Leu  
1 5 10 15

Pro Ala Ala His Gly Xaa Gly Val Gly Gly Ala Gly Gly Gly Ser Ser  
20 25 30

Xaa Leu Arg Ser Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly  
35 40 45

Glu Pro Glu Gln Ala Ala Gly Asp Ala Pro Pro Pro Tyr Ser Ser Ile  
50 55 60

Ser Ala Glu Ser Ala His Xaa Phe Asp Tyr Lys Asp Glu Ser Gly Phe  
65 70 75 80

Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr Thr Leu Pro Ser Tyr Asp  
85 90 95

142

Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr Ile Pro Leu Val Pro Gly  
100 105 110

Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp Asp Ala Asp Gln  
115 120 125

Leu Arg Ile Gly Asn Asp Gly Ile Phe  
130 135

&lt;210&gt; 219

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 219

Arg Tyr Gln Gln Leu Gln Asn Glu Glu Glu Ser Gly Glu Pro Glu Gln  
1 5 10 15

Ala Ala Gly Asp  
20

&lt;210&gt; 220

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 220

Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp Phe Asp Asp Ala  
1 5 10 15

Asp Gln Leu Arg Ile Gly  
20

&lt;210&gt; 221

&lt;211&gt; 103

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 221

Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
1 5 10 15

Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
20 25 30

Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
35 40 45

Ser Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp  
50 55 60

Val Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn  
65 70 75 80



143

Tyr Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg  
                                   85                                  90                                  95

Thr Arg Val Leu Phe Ile Tyr  
                                   100

&lt;210&gt; 222

&lt;211&gt; 198

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 222

Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
   1                                  5                                  10                                  15

His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln His Xaa Phe Asp Tyr  
                                   20                                  25                                  30

Lys Asp Glu Ser Gly Phe Pro Lys Pro Pro Ser Tyr Asn Val Ala Thr  
                                   35                                  40                                  45

Thr Leu Pro Ser Tyr Asp Glu Ala Glu Arg Thr Lys Ala Glu Ala Thr  
                                   50                                  55                                  60

Ile Pro Leu Val Pro Gly Arg Asp Glu Asp Phe Val Gly Arg Asp Asp  
   65                                  70                                  75                                  80

Phe Asp Asp Ala Asp Gln Leu Arg Ile Gly Asn Asp Gly Ile Phe Met  
                                   85                                  90                                  95

Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe Leu  
                                   100                                  105                                  110

Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile Ser  
                                   115                                  120                                  125

Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe Ser  
                                   130                                  135                                  140

Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val  
   145                                  150                                  155                                  160

Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr  
                                   165                                  170                                  175

Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr  
                                   180                                  185                                  190

Arg Val Leu Phe Ile Tyr  
                                   195

144

<210> 223  
 <211> 70  
 <212> PRT  
 <213> Homo sapiens

<400> 223  
 Met Leu Leu His Leu Thr Ala Ala Phe Leu Gln Arg Ala Gln Phe Ser  
     1                    5                    10                    15  
 Thr Tyr Phe Pro Gly Tyr Phe Asp Gly Gln Tyr Trp Leu Trp Trp Val  
                     20                    25                    30  
 Phe Leu Val Leu Gly Phe Leu Leu Phe Leu Arg Gly Phe Ile Asn Tyr  
                     35                    40                    45  
 Ala Lys Val Arg Lys Met Pro Glu Thr Phe Ser Asn Leu Pro Arg Thr  
                     50                    55                    60  
 Arg Val Leu Phe Ile Tyr  
     65                    70

<210> 224  
 <211> 82  
 <212> PRT  
 <213> Homo sapiens

<400> 224  
 Met Leu Thr Phe Phe Met Ala Phe Leu Phe Asn Trp Ile Gly Phe Phe  
     1                    5                    10                    15  
 Leu Ser Phe Cys Leu Thr Thr Ser Ala Ala Gly Arg Tyr Gly Ala Ile  
                     20                    25                    30  
 Ser Gly Phe Gly Leu Ser Leu Ile Lys Trp Ile Leu Ile Val Arg Phe  
                     35                    40                    45  
 Ser Thr Tyr Phe Pro Ala Phe Met Asn Ser Leu Ser Arg Ser Lys Arg  
                     50                    55                    60  
 Thr Pro Ala Gly Ser Glu Ser Arg Cys Arg Thr Gln Arg Asn Asn His  
     65                    70                    75                    80  
 Leu Leu

<210> 225  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (28)  
 <223> Xaa equals any of the naturally occurring L-amino acids

145

&lt;400&gt; 225

Met Lys Lys Ser Leu Glu Asn Leu Asn Arg Leu Gln Val Met Leu Leu  
 1 5 10 15

His Leu Thr Ala Ala Phe Leu Gln Arg Ala His Xaa Ile Leu Thr Thr  
 20 25 30

Arg Met Ser Leu Gly Phe Gln Ser Pro His Leu Thr Met  
 35 40 45

&lt;210&gt; 226

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 226

Met Thr Val Met Asp Pro Lys Gln Met Asn Val Ala Ala Ala Val Trp  
 1 5 10 15

Ala Val Val Ser Tyr Val Val Ala Asp Met Glu Glu Met Leu Pro Arg  
 20 25 30

Ser

&lt;210&gt; 227

&lt;211&gt; 189

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 227

Pro Arg Val Arg Ser Arg Glu Pro Val Ala Gly Ala Pro Gly Cys Gly  
 1 5 10 15

Thr Ala Gly Pro Pro Ala Met Ala Thr Leu Trp Gly Gly Leu Leu Arg  
 20 25 30

Leu Gly Ser Leu Leu Ser Leu Ser Cys Leu Ala Leu Ser Val Leu Leu  
 35 40 45

Leu Ala His Cys Gln Thr Pro Pro Ser Asp Cys Leu His Val Val Glu  
 50 55 60

Pro Met Pro Val Arg Gly Pro Asp Val Glu Ala Tyr Cys Leu Arg Cys  
 65 70 75 80

Glu Cys Lys Tyr Glu Glu Arg Ser Ser Val Thr Ile Lys Val Thr Ile  
 85 90 95

Ile Ile Tyr Leu Ser Ile Leu Gly Leu Leu Leu Leu Tyr Met Val Tyr  
 100 105 110

Leu Thr Leu Val Glu Pro Ile Leu Lys Arg Arg Leu Phe Gly His Ala  
 115 120 125

Gln Leu Ile Gln Ser Asp Asp Asp Ile Gly Asp His Gln Pro Phe Ala

146

130	135	140
Asn Ala His Asp Val Leu Ala Arg Ser Arg Ser Arg Ala Asn Val Leu		
145	150	155 160
Asn Lys Val Glu Tyr Ala Gln Gln Arg Trp Lys Leu Gln Val Gln Glu		
	165	170 175
Gln Arg Lys Ser Val Phe Asp Arg His Val Val Leu Ser		
	180	185

<210> 228  
 <211> 231  
 <212> PRT  
 <213> Homo sapiens

<400> 228

Met Ala Thr Leu Trp Gly Gly Leu Leu Arg Leu Gly Ser Leu Leu Ser		
1	5	10 15
Leu Ser Cys Leu Ala Leu Ser Val Leu Leu Leu Ala His Cys Gln Thr		
	20	25 30
Pro Pro Arg Ile Ser Arg Met Ser Asp Val Asn Val Ser Ala Leu Pro		
	35	40 45
Ile Lys Lys Asn Ser Gly His Ile Tyr Asn Lys Asn Ile Ser Gln Lys		
	50	55 60
Asp Cys Asp Cys Leu His Val Val Glu Pro Met Pro Val Arg Gly Pro		
	65	70 75 80
Asp Val Glu Ala Tyr Cys Leu Arg Cys Glu Cys Lys Tyr Glu Glu Arg		
	85	90 95
Ser Ser Val Thr Ile Lys Val Thr Ile Ile Ile Tyr Leu Ser Ile Leu		
	100	105 110
Gly Leu Leu Leu Leu Tyr Met Val Tyr Leu Thr Leu Val Glu Pro Ile		
	115	120 125
Leu Lys Arg Arg Leu Phe Gly His Ala Gln Leu Ile Gln Ser Asp Asp		
	130	135 140
Asp Ile Gly Asp His Gln Pro Phe Ala Asn Ala His Asp Val Leu Ala		
	145	150 155 160
Arg Ser Arg Ser Arg Ala Asn Val Leu Asn Lys Val Glu Tyr Gly Thr		
	165	170 175
Ala Ala Leu Glu Ala Ser Ser Pro Arg Ala Ala Lys Ser Leu Ser Leu		
	180	185 190
Thr Gly Met Leu Ser Ser Ala Asn Trp Gly Ile Glu Phe Lys Val Thr		
	195	200 205
Arg Lys Lys Gln Ala Asp Asn Trp Lys Gly Thr Asp Trp Val Leu Leu		
	210	215 220

147

Gly Phe Ile Leu Ile Pro Cys  
 225 230

&lt;210&gt; 229

&lt;211&gt; 456

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 229

Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
 1 5 10 15

Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
 20 25 30

Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
 35 40 45

Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
 50 55 60

Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln  
 65 70 75 80

Asn Ala Pro Tyr Phe Lys Pro Lys Val Lys Val Ser Phe Lys Asn His  
 85 90 95

Ser Ala Leu Ile Thr Ser Val Val Pro Gly Asp Tyr Asp Gly Asp Ser  
 100 105 110

Gln Met Asp Val Leu Leu Thr Tyr Leu Pro Lys Asn Tyr Ala Lys Ser  
 115 120 125

Glu Leu Gly Ala Val Ile Phe Trp Gly Gln Asn Gln Thr Leu Asp Pro  
 130 135 140

Asn Asn Met Thr Ile Leu Asn Arg Thr Phe Gln Asp Glu Pro Leu Ile  
 145 150 155 160

Met Asp Phe Asn Gly Asp Leu Ile Pro Asp Ile Phe Gly Ile Thr Asn  
 165 170 175

Glu Ser Asn Gln Pro Gln Ile Leu Leu Gly Gly Asn Leu Ser Trp His  
 180 185 190

Pro Ala Leu Thr Thr Thr Ser Lys Met Arg Ile Pro His Ser His Ala  
 195 200 205

Phe Ile Asp Leu Thr Glu Asp Phe Thr Ala Asp Leu Phe Leu Thr Thr  
 210 215 220

Leu Asn Ala Thr Thr Ser Thr Phe Gln Phe Glu Ile Trp Glu Asn Leu  
 225 230 235 240

Asp Gly Asn Phe Ser Val Ser Thr Ile Leu Glu Lys Pro Gln Asn Met  
 245 250 255

148

Met Val Val Gly Gln Ser Ala Phe Ala Asp Phe Asp Gly Asp Gly His  
 260 265 270

Met Asp His Leu Leu Pro Gly Cys Glu Asp Lys Asn Cys Gln Lys Ser  
 275 280 285

Thr Ile Tyr Leu Val Arg Ser Gly Met Lys Gln Trp Val Pro Val Leu  
 290 295 300

Gln Asp Phe Ser Asn Lys Gly Thr Leu Trp Gly Phe Val Pro Phe Val  
 305 310 315 320

Asp Glu Gln Gln Pro Thr Glu Ile Pro Ile Pro Ile Thr Leu His Ile  
 325 330 335

Gly Asp Tyr Asn Met Asp Gly Tyr Pro Asp Ala Leu Val Ile Leu Lys  
 340 345 350

Asn Thr Ser Gly Ser Asn Gln Gln Ala Phe Leu Leu Glu Asn Val Pro  
 355 360 365

Cys Asn Asn Ala Ser Cys Glu Glu Ala Arg Arg Met Phe Lys Val Tyr  
 370 375 380

Trp Glu Leu Thr Asp Leu Asn Gln Ile Lys Asp Ala Met Val Ala Thr  
 385 390 395 400

Phe Phe Asp Ile Tyr Glu Asp Gly Ile Leu Asp Ile Val Val Leu Ser  
 405 410 415

Lys Gly Tyr Thr Lys Asn Asp Phe Ala Ile His Thr Leu Lys Asn Asn  
 420 425 430

Phe Glu Ala Asp Ala Tyr Phe Val Lys Val Ile Val Leu Ser Gly Leu  
 435 440 445

Cys Ser Asn Asp Cys Pro Arg Arg  
 450 455

&lt;210&gt; 230

&lt;211&gt; 558

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 230

Met Ala Ala Ala Gly Arg Leu Pro Ser Ser Trp Ala Leu Phe Ser Pro  
 1 5 10 15

Leu Leu Ala Gly Leu Ala Leu Leu Gly Val Gly Pro Val Pro Ala Arg  
 20 25 30

Ala Leu His Asn Val Thr Ala Glu Leu Phe Gly Ala Glu Ala Trp Gly  
 35 40 45

Thr Leu Ala Ala Phe Gly Asp Leu Asn Ser Asp Lys Gln Thr Asp Leu  
 50 55 60

Phe Val Leu Arg Glu Arg Asn Asp Leu Ile Val Phe Leu Ala Asp Gln

65				70				75				80				
Asn	Ala	Pro	Tyr	Phe	Lys	Pro	Lys	Val	Lys	Val	Ser	Phe	Lys	Asn	His	
				85					90				95			
Ser	Ala	Leu	Ile	Thr	Ser	Val	Val	Pro	Gly	Asp	Tyr	Asp	Gly	Asp	Ser	
				100					105				110			
Gln	Met	Asp	Val	Leu	Leu	Thr	Tyr	Leu	Pro	Lys	Asn	Tyr	Ala	Lys	Ser	
				115									125			
Glu	Leu	Gly	Ala	Val	Ile	Phe	Trp	Gly	Gln	Asn	Gln	Thr	Leu	Asp	Pro	
				130									140			
Asn	Asn	Met	Thr	Ile	Leu	Asn	Arg	Thr	Phe	Gln	Asp	Glu	Pro	Leu	Ile	
145				150				155				160				
Met	Asp	Phe	Asn	Gly	Asp	Leu	Ile	Pro	Asp	Ile	Phe	Gly	Ile	Thr	Asn	
				165					170				175			
Glu	Ser	Asn	Gln	Pro	Gln	Ile	Leu	Leu	Gly	Gly	Asn	Leu	Ser	Trp	His	
				180					185				190			
Pro	Ala	Leu	Thr	Thr	Thr	Ser	Lys	Met	Arg	Ile	Pro	His	Ser	His	Ala	
				195									205			
Phe	Ile	Asp	Leu	Thr	Glu	Asp	Phe	Thr	Ala	Asp	Leu	Phe	Leu	Thr	Thr	
				210	215								220			
Leu	Asn	Ala	Thr	Thr	Ser	Thr	Phe	Gln	Phe	Glu	Ile	Trp	Glu	Asn	Leu	
225				230				235				240				
Asp	Gly	Asn	Phe	Ser	Val	Ser	Thr	Ile	Leu	Glu	Lys	Pro	Gln	Asn	Met	
				245					250				255			
Met	Val	Val	Gly	Gln	Ser	Ala	Phe	Ala	Asp	Phe	Asp	Gly	Asp	Gly	His	
				260					265				270			
Met	Asp	His	Leu	Leu	Pro	Gly	Cys	Glu	Asp	Lys	Asn	Cys	Gln	Lys	Ser	
				275	280								285			
Thr	Ile	Tyr	Leu	Val	Arg	Ser	Gly	Met	Lys	Gln	Trp	Val	Pro	Val	Leu	
				290	295								300			
Gln	Asp	Phe	Ser	Asn	Lys	Gly	Thr	Leu	Trp	Gly	Phe	Val	Pro	Phe	Val	
305				310				315				320				
Asp	Glu	Gln	Gln	Pro	Thr	Glu	Ile	Pro	Ile	Pro	Ile	Thr	Leu	His	Ile	
				325					330				335			
Gly	Asp	Tyr	Asn	Met	Asp	Gly	Tyr	Pro	Asp	Ala	Leu	Val	Ile	Leu	Lys	
				340					345				350			
Asn	Thr	Ser	Gly	Ser	Asn	Gln	Gln	Ala	Phe	Leu	Leu	Glu	Asn	Val	Pro	
				355	360								365			
Cys	Asn	Asn	Ala	Ser	Cys	Glu	Glu	Ala	Arg	Arg	Met	Phe	Lys	Val	Tyr	
				370	375				380							
Trp	Glu	Leu	Thr	Asp	Leu	Asn	Gln	Ile	Lys	Asp	Ala	Met	Val	Ala	Thr	

										150											
385					390					395					400						
Phe	Phe	Asp	Ile	Tyr	Glu	Asp	Gly	Ile	Leu	Asp	Ile	Val	Val	Leu	Ser						
405					410					415											
Lys	Gly	Tyr	Thr	Lys	Asn	Asp	Phe	Ala	Ile	His	Thr	Leu	Lys	Asn	Asn						
420					425					430											
Phe	Glu	Ala	Asp	Ala	Tyr	Phe	Val	Lys	Val	Ile	Val	Leu	Ser	Gly	Leu						
435					440					445											
Cys	Ser	Asn	Asp	Cys	Pro	Arg	Lys	Ile	Thr	Pro	Phe	Gly	Val	Asn	Gln						
450					455					460											
Pro	Gly	Pro	Tyr	Ile	Met	Tyr	Thr	Thr	Val	Asp	Ala	Asn	Gly	Tyr	Leu						
465					470					475					480						
Lys	Asn	Gly	Ser	Ala	Gly	Gln	Leu	Ser	Gln	Ser	Ala	His	Leu	Ala	Leu						
485					490					495											
Gln	Leu	Pro	Tyr	Asn	Val	Leu	Gly	Leu	Gly	Arg	Ser	Ala	Asn	Phe	Leu						
500					505					510											
Asp	His	Leu	Tyr	Val	Gly	Ile	Pro	Arg	Pro	Ser	Gly	Glu	Lys	Ser	Ile						
515					520					525											
Arg	Lys	Gln	Glu	Trp	Thr	Ala	Ile	Ile	Pro	Asn	Ser	Gln	Leu	Ile	Val						
530					535					540											
Ile	Pro	Tyr	Pro	His	Asn	Val	Pro	Arg	Ser	Trp	Ser	Ala	Lys								
545					550					555											

```
<210> 231
<211> 282
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (144)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>  
<221> SITE  
<222> (168)  
<223> Xaa equals any of the naturally occurring L-amino acids
```

```

<400> 231
Met Thr Lys Arg Glu Asp Gly Gly Tyr Thr Phe Thr Ala Thr Pro Glu
  1             5             10             15

Asp Phe Pro Lys Lys His Lys Ala Pro Val Ile Asp Ile Gly Ile Ala
      20             25             30

Asn Thr Gly Lys Phe Ile Met Thr Ala Ser Ser Asp Thr Thr Val Leu
      35             40             45

Ile Trp Ser Leu Lys Gly Gln Val Leu Ser Thr Ile Asn Thr Asn Gln

```



151

50	55	60	
Met Asn Asn Thr His Ala Ala Val Ser Pro Cys Gly Arg Phe Val Ala			
65	70	75	80
Ser Cys Gly Phe Thr Pro Asp Val Lys Val Trp Glu Val Cys Phe Gly			
	85	90	95
Lys Lys Gly Glu Phe Gln Glu Val Val Arg Ala Phe Glu Leu Lys Gly			
	100	105	110
His Ser Ala Ala Val His Ser Phe Ala Phe Ser Asn Asp Ser Arg Arg			
	115	120	125
Met Ala Ser Val Ser Lys Asp Gly Thr Trp Lys Leu Trp Asp Thr Xaa			
	130	135	140
Val Glu Tyr Lys Lys Lys Gln Asp Pro Tyr Leu Leu Lys Thr Gly Arg			
	145	150	155
Phe Glu Glu Ala Ala Gly Ala Xaa Pro Cys Arg Leu Ala Leu Ser Pro			
	165	170	175
Asn Ala Gln Val Leu Ala Leu Ala Ser Gly Ser Ser Ile His Leu Tyr			
	180	185	190
Asn Thr Arg Arg Gly Glu Lys Glu Glu Cys Phe Glu Arg Val His Gly			
	195	200	205
Glu Cys Ile Ala Asn Leu Ser Phe Asp Ile Thr Gly Arg Phe Leu Ala			
	210	215	220
Ser Cys Gly Asp Arg Ala Val Arg Leu Phe His Asn Thr Pro Gly His			
	225	230	235
Arg Ala Met Val Glu Glu Met Gln Gly His Leu Lys Arg Ala Ser Asn			
	245	250	255
Glu Ser Thr Arg Gln Arg Leu Gln Gln Gln Leu Thr Gln Ala Gln Glu			
	260	265	270
Thr Leu Lys Ser Leu Gly Ala Leu Lys Lys			
	275	280	

&lt;210&gt; 232

&lt;211&gt; 456

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (17)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

152

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (318)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (342)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 232

Val	Ile	Arg	His	Glu	Gly	Ser	Thr	Asn	Met	Glu	Leu	Ser	Gln	Met	Ser
1				5					10					15	

Xaa	Leu	Met	Gly	Leu	Ser	Val	Leu	Leu	Gly	Leu	Leu	Ala	Leu	Met	Ala
			20					25					30		

Thr	Ala	Ala	Val	Xaa	Arg	Gly	Trp	Leu	Arg	Ala	Gly	Glu	Glu	Arg	Ser
			35				40					45			

Gly	Arg	Pro	Ala	Cys	Gln	Lys	Ala	Asn	Gly	Phe	Pro	Pro	Asp	Lys	Ser
	50					55					60				

Ser	Gly	Ser	Lys	Lys	Gln	Lys	Gln	Tyr	Gln	Arg	Ile	Arg	Lys	Glu	Lys
65					70					75					80

Pro	Gln	Gln	His	Asn	Phe	Thr	His	Arg	Leu	Leu	Ala	Ala	Ala	Leu	Lys
			85						90					95	

Ser	His	Ser	Gly	Asn	Ile	Ser	Cys	Met	Asp	Phe	Ser	Ser	Asn	Gly	Lys
			100					105					110		

Tyr	Leu	Ala	Thr	Cys	Ala	Asp	Asp	Arg	Thr	Ile	Arg	Ile	Trp	Ser	Thr
	115						120					125			

Lys	Asp	Phe	Leu	Gln	Arg	Glu	His	Arg	Ser	Met	Arg	Ala	Asn	Val	Glu
	130					135					140				

Leu	Asp	His	Ala	Thr	Leu	Val	Arg	Phe	Ser	Pro	Asp	Cys	Arg	Ala	Phe
145					150					155					160

Ile	Val	Trp	Leu	Ala	Asn	Gly	Asp	Thr	Leu	Arg	Val	Phe	Lys	Met	Thr
			165						170					175	

Lys	Arg	Glu	Asp	Gly	Gly	Tyr	Thr	Phe	Thr	Ala	Thr	Pro	Glu	Asp	Phe
		180						185					190		

Pro	Lys	Lys	His	Lys	Ala	Pro	Val	Ile	Asp	Ile	Gly	Ile	Ala	Asn	Thr
	195						200					205			

Gly	Lys	Phe	Ile	Met	Thr	Ala	Ser	Ser	Asp	Thr	Thr	Val	Leu	Ile	Trp
	210					215					220				

Ser	Leu	Lys	Gly	Gln	Val	Leu	Ser	Thr	Ile	Asn	Thr	Asn	Gln	Met	Asn
225					230					235					240

Asn	Thr	His	Ala	Ala	Val	Ser	Pro	Cys	Gly	Arg	Phe	Val	Ala	Ser	Cys
			245						250					255	

153

Gly Phe Thr Pro Asp Val Lys Val Trp Glu Val Cys Phe Gly Lys Lys  
                   260                  265                  270  
 Gly Glu Phe Gln Glu Val Val Arg Ala Phe Glu Leu Lys Gly His Ser  
                   275                  280                  285  
 Ala Ala Val His Ser Phe Ala Phe Ser Asn Asp Ser Arg Arg Met Ala  
                   290                  295                  300  
 Ser Val Ser Lys Asp Gly Thr Trp Lys Leu Trp Asp Thr Xaa Val Glu  
 305                  310                  315                  320  
 Tyr Lys Lys Lys Gln Asp Pro Tyr Leu Leu Lys Thr Gly Arg Phe Glu  
                   325                  330                  335  
 Glu Ala Ala Gly Ala Xaa Pro Cys Arg Leu Ala Leu Ser Pro Asn Ala  
                   340                  345                  350  
 Gln Val Leu Ala Leu Ala Ser Gly Ser Ser Ile His Leu Tyr Asn Thr  
                   355                  360                  365  
 Arg Arg Gly Glu Lys Glu Glu Cys Phe Glu Arg Val His Gly Glu Cys  
                   370                  375                  380  
 Ile Ala Asn Leu Ser Phe Asp Ile Thr Gly Arg Phe Leu Ala Ser Cys  
 385                  390                  395                  400  
 Gly Asp Arg Ala Val Arg Leu Phe His Asn Thr Pro Gly His Arg Ala  
                   405                  410                  415  
 Met Val Glu Glu Met Gln Gly His Leu Lys Arg Ala Ser Asn Glu Ser  
                   420                  425                  430  
 Thr Arg Gln Arg Leu Gln Gln Gln Leu Thr Gln Ala Gln Glu Thr Leu  
                   435                  440                  445  
 Lys Ser Leu Gly Ala Leu Lys Lys  
                   450                  455

&lt;210&gt; 233

&lt;211&gt; 363

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 233

Met Ser Val Met Val Val Arg Lys Lys Val Thr Arg Lys Trp Glu Lys  
   1                  5                  10                  15  
 Leu Pro Gly Arg Asn Thr Phe Cys Cys Asp Gly Arg Val Met Met Ala  
                   20                  25                  30  
 Arg Gln Lys Gly Ile Phe Tyr Leu Thr Leu Phe Leu Ile Leu Gly Thr  
                   35                  40                  45  
 Cys Thr Leu Phe Phe Ala Phe Glu Cys Arg Tyr Leu Ala Val Gln Leu  
                   50                  55                  60  
 Ser Pro Ala Ile Pro Val Phe Ala Ala Met Leu Phe Leu Phe Ser Met

154

65		70		75		80
Ala Thr Leu Leu Arg Thr Ser Phe Ser Asp Pro Gly Val Ile Pro Arg						
		85		90		95
Ala Leu Pro Asp Glu Ala Ala Phe Ile Glu Met Glu Ile Glu Ala Thr						
		100		105		110
Asn Gly Ala Val Pro Gln Gly Gln Arg Pro Pro Pro Arg Ile Lys Asn						
		115		120		125
Phe Gln Ile Asn Asn Gln Ile Val Lys Leu Lys Tyr Cys Tyr Thr Cys						
		130		135		140
Lys Ile Phe Arg Pro Pro Arg Ala Ser His Cys Ser Ile Cys Asp Asn						
		145		150		155
Cys Val Glu Arg Phe Asp His His Cys Pro Trp Val Gly Asn Cys Val						
		165		170		175
Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr Leu Phe Ile Leu Ser Leu Ser						
		180		185		190
Leu Leu Thr Ile Tyr Val Phe Ala Phe Asn Ile Val Tyr Val Ala Leu						
		195		200		205
Lys Ser Leu Lys Ile Gly Phe Leu Glu Thr Leu Lys Glu Thr Pro Gly						
		210		215		220
Thr Val Leu Glu Val Leu Ile Cys Phe Phe Thr Leu Trp Ser Val Val						
		225		230		235
Gly Leu Thr Gly Phe His Thr Phe Leu Val Ala Leu Asn Gln Thr Thr						
		245		250		255
Asn Glu Asp Ile Lys Gly Ser Trp Thr Gly Lys Asn Arg Val Gln Asn						
		260		265		270
Pro Tyr Ser His Gly Asn Ile Val Lys Asn Cys Cys Glu Val Leu Cys						
		275		280		285
Gly Pro Leu Pro Pro Ser Val Leu Asp Arg Arg Gly Ile Leu Pro Leu						
		290		295		300
Glu Glu Ser Gly Ser Arg Pro Pro Ser Thr Gln Glu Thr Ser Ser Ser						
		305		310		315
Leu Leu Pro Gln Ser Pro Ala Pro Thr Glu Leu Asn Ser Asn Glu Met						
		325		330		335
Pro Glu Asp Ser Ser Thr Pro Glu Glu Met Pro Pro Pro Glu Pro Pro						
		340		345		350
Glu Pro Pro Gln Glu Ala Ala Glu Ala Glu Lys						
		355		360		

&lt;210&gt; 234

&lt;211&gt; 184

155

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 234

```

Met Leu Phe Leu Phe Ser Met Ala Thr Leu Leu Arg Thr Ser Phe Ser
 1             5             10             15

Asp Pro Gly Val Ile Pro Arg Ala Leu Pro Asp Glu Ala Ala Phe Ile
      20             25             30

Glu Met Glu Ile Glu Ala Thr Asn Gly Ala Val Pro Gln Gly Gln Arg
      35             40             45

Pro Pro Pro Arg Ile Lys Asn Phe Gln Ile Asn Asn Gln Ile Val Lys
      50             55             60

Leu Lys Tyr Cys Tyr Thr Cys Lys Ile Phe Arg Pro Pro Arg Ala Ser
      65             70             75             80

His Cys Ser Ile Cys Asp Asn Cys Val Glu Arg Phe Asp His His Cys
      85             90             95

Pro Trp Val Gly Asn Cys Val Gly Lys Arg Asn Tyr Arg Tyr Phe Tyr
      100            105            110

Leu Phe Ile Leu Ser Leu Ser Leu Leu Thr Ile Tyr Val Phe Ala Phe
      115            120            125

Asn Ile Val Tyr Val Ala Leu Lys Ser Leu Lys Ile Gly Phe Leu Glu
      130            135            140

Thr Leu Lys Gly Asn Ser Trp Asn Cys Ser Arg Ser Pro His Leu Leu
      145            150            155            160

Leu Tyr Thr Leu Val Arg Arg Gly Thr Asp Trp Ile Ser Tyr Phe Pro
      165            170            175

Arg Gly Ser Gln Pro Asp Asn Gln
      180

```

&lt;210&gt; 235

&lt;211&gt; 52

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 235

```

Leu His Glu Cys Leu Pro Gly Ser Ile Ser Tyr Leu His Pro Arg Thr
 1             5             10             15

Pro Trp Leu Cys Leu Pro Pro Gln His Leu Ser Phe Ser Thr Phe Ser
      20             25             30

Pro Pro Trp Gln Pro Ala Met Ser Pro Val Pro Gly Thr Gly Gly Pro
      35             40             45

Pro Cys Gly Leu
      50

```

156

<210> 236  
 <211> 177  
 <212> PRT  
 <213> Homo sapiens

<400> 236  
 Met Leu Pro Leu Leu Ile Ile Cys Leu Leu Pro Ala Ile Glu Gly Lys  
           1                  5                  10                  15  
 Asn Cys Leu Arg Cys Trp Pro Glu Leu Ser Ala Leu Ile Asp Tyr Asp  
                   20                  25                  30  
 Leu Gln Ile Leu Trp Val Thr Pro Gly Pro Pro Thr Glu Leu Ser Gln  
           35                  40                  45  
 Ser Ile His Ser Leu Phe Leu Glu Asp Asn Asn Phe Leu Lys Pro Trp  
           50                  55                  60  
 Tyr Leu Asp Arg Asp His Leu Glu Glu Glu Thr Ala Lys Phe Phe Thr  
           65                  70                  75                  80  
 Gln Val His Gln Ala Ile Lys Thr Leu Arg Asp Asp Lys Thr Val Leu  
                   85                  90                  95  
 Leu Glu Glu Ile Tyr Thr His Lys Asn Leu Phe Thr Glu Arg Leu Asn  
                   100                  105                  110  
 Lys Ile Ser Asp Gly Leu Lys Glu Lys Gly Ala Pro Pro Leu His Glu  
           115                  120                  125  
 Cys Leu Pro Gly Ser Ile Ser Tyr Leu His Pro Arg Thr Pro Trp Leu  
           130                  135                  140  
 Cys Leu Pro Pro Gln His Leu Ser Phe Ser Thr Phe Ser Pro Pro Trp  
           145                  150                  155                  160  
 Gln Pro Ala Met Ser Pro Val Pro Gly Thr Gly Gly Pro Pro Cys Gly  
                   165                  170                  175  
 Leu

<210> 237  
 <211> 95  
 <212> PRT  
 <213> Homo sapiens

<400> 237  
 Pro Pro Val Pro Pro Trp Ile Ser Leu Pro Leu Thr Gly Ser Pro Pro  
           1                  5                  10                  15  
 Arg Pro Gly Phe Val Pro Val Ser Pro Phe Cys Phe Ser Pro Met Thr  
                   20                  25                  30  
 Asn Gly His Gln Val Leu Leu Leu Leu Leu Thr Ser Ala Val Ala  
           35                  40                  45

157

Ala Gly Pro Trp Pro Gln Val His Ala Gly Gln Trp Gly Trp Met Cys  
 50 55 60

Leu Pro Pro Gly Leu Pro Ser Val Gln Ala Arg Ser Gly Leu Gly Gly  
 65 70 75 80

Leu Pro Gly Gly Pro Gln Trp Val Pro Gly Gly Ala Arg Gly Tyr  
 85 90 95

&lt;210&gt; 238

&lt;211&gt; 404

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 238

Ile Gln Gln Trp Gly Asp Ser Val Leu Gly Arg Arg Cys Arg Asp Leu  
 1 5 10 15

Leu Leu Gln Leu Tyr Leu Gln Arg Pro Glu Leu Arg Val Pro Val Pro  
 20 25 30

Glu Val Leu Leu His Ser Glu Gly Ala Ala Ser Ser Ser Val Cys Lys  
 35 40 45

Leu Asp Gly Leu Ile His Arg Phe Ile Thr Leu Leu Ala Asp Thr Ser  
 50 55 60

Asp Ser Arg Ala Leu Glu Asn Arg Gly Ala Asp Ala Ser Met Ala Cys  
 65 70 75 80

Arg Lys Leu Ala Val Ala His Pro Leu Leu Leu Arg His Leu Pro  
 85 90 95

Met Ile Ala Ala Leu Leu His Gly Arg Thr His Leu Asn Phe Gln Glu  
 100 105 110

Phe Arg Gln Gln Asn His Leu Ser Cys Phe Leu His Val Leu Gly Leu  
 115 120 125

Leu Glu Leu Leu Gln Pro His Val Phe Arg Ser Glu His Gln Gly Ala  
 130 135 140

Leu Trp Asp Cys Leu Leu Ser Phe Ile Arg Leu Leu Leu Asn Tyr Arg  
 145 150 155 160

Lys Ser Ser Arg His Leu Ala Ala Phe Ile Asn Lys Phe Val Gln Phe  
 165 170 175

Ile His Lys Tyr Ile Thr Tyr Asn Ala Pro Ala Ala Ile Ser Phe Leu  
 180 185 190

Gln Lys His Ala Asp Pro Leu His Asp Leu Ser Phe Asp Asn Ser Asp  
 195 200 205

Leu Val Met Leu Lys Ser Leu Leu Ala Gly Leu Ser Leu Pro Ser Arg  
 210 215 220

158

Asp Asp Arg Thr Asp Arg Gly Leu Asp Glu Glu Gly Glu Glu Glu Ser  
 225 230 235 240  
 Ser Ala Gly Ser Leu Pro Leu Val Ser Val Ser Leu Phe Thr Pro Leu  
 245 250 255  
 Thr Ala Ala Glu Met Ala Pro Tyr Met Lys Arg Leu Ser Arg Gly Gln  
 260 265 270  
 Thr Val Glu Asp Leu Leu Glu Val Leu Ser Asp Ile Asp Glu Met Ser  
 275 280 285  
 Arg Arg Arg Pro Glu Ile Leu Ser Phe Phe Ser Thr Asn Leu Gln Arg  
 290 295 300  
 Leu Met Ser Ser Ala Glu Glu Cys Cys Arg Asn Leu Ala Phe Ser Leu  
 305 310 315 320  
 Ala Leu Arg Ser Met Gln Asn Ser Pro Ser Ile Ala Ala Ala Phe Leu  
 325 330 335  
 Pro Thr Phe Met Tyr Cys Leu Gly Ser Gln Asp Phe Glu Val Val Gln  
 340 345 350  
 Thr Ala Leu Arg Asn Leu Pro Glu Tyr Ala Leu Leu Cys Gln Glu His  
 355 360 365  
 Ala Ala Val Leu Leu His Arg Ala Phe Leu Val Gly Met Tyr Gly Gln  
 370 375 380  
 Met Asp Pro Ser Ala Gln Ile Ser Glu Ala Leu Arg Ile Leu His Met  
 385 390 395 400  
 Glu Ala Val Met

&lt;210&gt; 239

&lt;211&gt; 361

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 239

Met Leu Leu Lys His Leu Gln Arg Met Val Ser Val Pro Gln Val Lys  
 1 5 10 15  
 Ala Ser Ala Leu Lys Val Val Thr Leu Thr Ala Asn Asp Lys Thr Ser  
 20 25 30  
 Val Ser Phe Ser Ser Leu Pro Gly Gln Gly Val Ile Tyr Asn Val Ile  
 35 40 45  
 Val Trp Asp Pro Phe Leu Asn Thr Ser Ala Ala Tyr Ile Pro Ala His  
 50 55 60  
 Thr Tyr Ala Cys Ser Phe Glu Ala Gly Glu Gly Ser Cys Ala Ser Leu  
 65 70 75 80  
 Gly Arg Val Ser Ser Lys Val Phe Phe Thr Leu Phe Ala Leu Leu Gly



159

	85	90	95
Phe Phe Ile Cys Phe Phe Gly His Arg Phe Trp Lys Thr Glu Leu Phe	100	105	110
Phe Ile Gly Phe Ile Ile Met Gly Phe Phe Phe Tyr Ile Leu Ile Thr	115	120	125
Arg Leu Thr Pro Ile Lys Tyr Asp Val Asn Leu Ile Leu Thr Ala Val	130	135	140
Thr Gly Ser Val Gly Gly Met Phe Leu Val Ala Val Trp Trp Arg Phe	145	150	155
Gly Ile Leu Ser Ile Cys Met Leu Cys Val Gly Leu Val Leu Gly Phe	165	170	175
Leu Ile Ser Ser Val Thr Phe Phe Thr Pro Leu Gly Asn Leu Lys Ile	180	185	190
Phe His Asp Asp Gly Val Phe Trp Val Thr Phe Ser Cys Ile Ala Ile	195	200	205
Leu Ile Pro Val Val Phe Met Gly Cys Leu Arg Ile Leu Asn Ile Leu	210	215	220
Thr Cys Gly Val Ile Gly Ser Tyr Ser Val Val Leu Ala Ile Asp Ser	225	230	235
Tyr Trp Ser Thr Ser Leu Ser Tyr Ile Thr Leu Asn Val Leu Lys Arg	245	250	255
Ala Leu Asn Lys Asp Phe His Arg Ala Phe Thr Asn Val Pro Phe Gln	260	265	270
Thr Asn Asp Phe Ile Ile Leu Ala Val Trp Gly Met Leu Ala Val Ser	275	280	285
Gly Ile Thr Leu Gln Ile Arg Arg Glu Arg Gly Arg Pro Phe Phe Pro	290	295	300
Pro His Pro Tyr Lys Leu Trp Lys Gln Glu Arg Glu Arg Arg Val Thr	305	310	315
Asn Ile Leu Asp Pro Ser Tyr His Ile Pro Pro Leu Arg Glu Arg Leu	325	330	335
Tyr Gly Arg Leu Thr Gln Ile Lys Gly Leu Phe Gln Lys Glu Gln Pro	340	345	350
Ala Gly Glu Arg Thr Pro Leu Leu Leu	355	360	

&lt;210&gt; 240

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

160

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 240

Trp Ala Arg Leu Arg Gly Pro Gly Ala His Ala Arg Thr Ser Pro Gln  
 1 5 10 15

Pro Trp Arg Gly Pro Ser Pro Ala Gln Ala Ala Met Gly Phe Leu Gln  
 20 25 30

Leu Leu Val Val Xaa Val Leu Xaa Ser Glu His Arg Val Ala Gly Ala  
 35 40 45

Ala Glu Val Phe Gly Asn Ser Ser Glu Gly Leu Ile Glu Phe Ser Val  
 50 55 60

Gly Lys Phe Arg Tyr Phe Glu Leu Asn Arg Pro Phe Pro Glu Glu Ala  
 65 70 75 80

Ile Leu His Asp Ile Ser Ser Asn Val Thr Phe Leu Ile Phe Gln Ile  
 85 90 95

His Ser Gln Tyr Gln Asn Thr Thr Val Ser Phe Ser Pro Arg Arg Arg  
 100 105 110

Ser Pro Thr Met  
 115

&lt;210&gt; 241

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 241

Pro Arg Val Arg Pro Ala Ser Pro Pro Val Arg Ser Pro Ala Arg Trp  
 1 5 10 15

Gly Ser Met Ala Gly Ser Pro Leu Leu Trp Gly Pro Arg Ala Gly Gly  
 20 25 30

Val Gly Leu Leu Val Leu Leu Leu Leu Gly Leu Phe Arg Pro Pro Pro  
 35 40 45

Ala Leu Cys Ala Arg Pro Val Lys Glu Pro Arg Gly Leu Ser Ala Ala  
 50 55 60

Ser Pro Pro Leu Ala Arg Leu Ala Leu Leu Ala Ala Ser Gly Gly Gln  
 65 70 75 80

Cys Pro Glu Val Arg Arg Arg Gly Arg Cys Arg Pro Gly Ala Gly Ala  
 85 90 95

161

Gly Ala Ser Ala Gly Ala Glu Arg Gln Glu Arg Ala Arg Ala Glu Ala  
                   100                  105                  110

Gln Arg Leu Arg Ile Ser Arg Arg Ala Ser Trp Arg Ser Cys Cys Ala  
                   115                  120                  125

Ser Gly Ala Pro Pro Ala Thr Leu Ile Arg Leu Trp Ala Trp Thr Thr  
                   130                  135                  140

Thr Pro Thr Arg Leu Gln Arg Ser Ser Leu Ala Leu Cys Ser Ala Pro  
                   145                  150                  155                  160

Ala Leu Thr Leu Pro Pro  
                   165

&lt;210&gt; 242

&lt;211&gt; 414

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 242

Pro Arg Val Arg Leu Ala Thr Pro Asn Ile Trp Asp Leu Ser Met Leu  
   1                  5                  10                  15

Phe Ala Phe Ile Ser Leu Leu Val Met Leu Pro Thr Trp Trp Ile Val  
                   20                  25                  30

Ser Ser Trp Leu Val Trp Gly Val Ile Leu Phe Val Tyr Leu Val Ile  
                   35                  40                  45

Arg Ala Leu Arg Leu Trp Arg Thr Ala Lys Leu Gln Val Thr Leu Lys  
                   50                  55                  60

Lys Tyr Ser Val His Leu Glu Asp Met Ala Thr Asn Ser Arg Ala Phe  
   65                  70                  75                  80

Thr Asn Leu Val Arg Lys Ala Leu Arg Leu Ile Gln Glu Thr Glu Val  
                   85                  90                  95

Ile Ser Arg Gly Phe Thr Leu Val Ser Ala Ala Cys Pro Phe Asn Lys  
                   100                  105                  110

Ala Gly Gln His Pro Ser Gln His Leu Ile Gly Leu Arg Lys Ala Val  
                   115                  120                  125

Tyr Arg Thr Leu Arg Ala Asn Phe Gln Ala Ala Arg Leu Ala Thr Leu  
                   130                  135                  140

Tyr Met Leu Lys Asn Tyr Pro Leu Asn Ser Glu Ser Asp Asn Val Thr  
                   145                  150                  155                  160

Asn Tyr Ile Cys Val Val Pro Phe Lys Glu Leu Gly Leu Gly Leu Ser  
                   165                  170                  175

Glu Glu Gln Ile Ser Glu Glu Glu Ala His Asn Phe Thr Asp Gly Phe  
                   180                  185                  190

162

Ser Leu Pro Ala Leu Lys Val Leu Phe Gln Leu Trp Val Ala Gln Ser  
 195 200 205  
 Ser Glu Phe Phe Arg Arg Leu Ala Leu Leu Leu Ser Thr Ala Asn Ser  
 210 215 220  
 Pro Pro Gly Pro Leu Leu Thr Pro Ala Leu Leu Pro His Arg Ile Leu  
 225 230 235 240  
 Ser Asp Val Thr Gln Gly Leu Pro His Ala His Ser Ala Cys Leu Glu  
 245 250 255  
 Glu Leu Lys Arg Ser Tyr Glu Phe Tyr Arg Tyr Phe Glu Thr Gln His  
 260 265 270  
 Gln Ser Val Pro Gln Cys Leu Ser Lys Thr Gln Gln Lys Ser Arg Glu  
 275 280 285  
 Leu Asn Asn Val His Thr Ala Val Arg Ser Leu Gln Leu His Leu Lys  
 290 295 300  
 Ala Leu Leu Asn Glu Val Ile Ile Leu Glu Asp Glu Leu Glu Lys Leu  
 305 310 315 320  
 Val Cys Thr Lys Glu Thr Gln Glu Leu Val Ser Glu Ala Tyr Pro Ile  
 325 330 335  
 Leu Glu Gln Lys Leu Lys Leu Ile Gln Pro His Val Gln Ala Ser Asn  
 340 345 350  
 Asn Cys Trp Glu Glu Ala Ile Ser Gln Val Asp Lys Leu Leu Arg Arg  
 355 360 365  
 Asn Thr Asp Lys Lys Gly Lys Pro Glu Ile Ala Cys Glu Asn Pro His  
 370 375 380  
 Cys Thr Val Ser Thr Phe Glu Ala Ala Tyr Ser Thr His Cys Arg Gln  
 385 390 395 400  
 Arg Ser Asn Pro Arg Gly Ala Gly Ile Arg Ser Leu Cys Arg  
 405 410

&lt;210&gt; 243

&lt;211&gt; 145

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 243

Ala Ala Pro His Pro Leu Leu Arg Pro Leu Cys Leu Trp Cys Pro  
 1 5 10 15  
 Leu Trp Pro Ala Trp Pro Leu Arg Gly Arg Pro Arg Ser Ala Trp Lys  
 20 25 30  
 Arg Trp Pro Pro Leu Pro Val Gly Pro Ala Lys Leu Gly Cys Ser Met  
 35 40 45  
 Thr Thr Arg Gln Pro Thr Ala Val Ser Trp Pro Cys Trp Leu Met Ser

163

50                                      55                                      60  
 Ser Ser Leu Ser Thr Ala Cys Leu Ala Trp Thr Leu Thr Gly Ser Leu  
 65                                      70                                      75                                      80  
 Ala Arg Glu Ala Thr Arg Arg Ala Arg Ser Leu Ser Pro Thr Trp Asn  
 85                                      90                                      95  
 Cys Ser Ala Arg Gln Val Pro Pro Ser Pro Pro His Ser Gly Leu Gly  
 100                                      105                                      110  
 Arg Arg Gly Trp Ala His Cys His Leu Thr Cys Leu Leu Val Thr Gln  
 115                                      120                                      125  
 Leu Phe Arg Val Gly Arg Ile His Pro Ile Leu Ser Leu Pro Leu Val  
 130                                      135                                      140  
 Thr  
 145

<210> 244  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<400> 244  
 Leu Gln Leu Ala Ser Gln Ser Ala Gly Ile Lys Gly Met Ser His Cys  
 1                                      5                                      10                                      15  
 Ala Arg Pro Thr Phe Leu Thr Leu Leu Ala Ser Cys Phe Trp Ala  
 20                                      25                                      30  
 Ala Ala Ile Pro Asn Arg Asn Val Ile Leu Ser Val Ser Phe Arg Pro  
 35                                      40                                      45  
 Leu His Met Gln Phe Thr Leu Ser Ile Leu Val Phe Ile Leu Arg Ile  
 50                                      55                                      60  
 Leu Ile Leu Leu Arg Ser Phe Leu  
 65                                      70

<210> 245  
 <211> 140  
 <212> PRT  
 <213> Homo sapiens

<400> 245  
 Met Val Leu Val Leu Arg His Pro Leu Cys Ala Arg Glu Arg Ala Phe  
 1                                      5                                      10                                      15  
 Arg Glu Pro Gly Arg Gly Leu Leu Thr Arg Thr Gly Gln His Asp Gly  
 20                                      25                                      30  
 Ala Pro Ala Val Thr Ala Val Pro Gly Pro Leu Gly Ala Val Ala Ala  
 35                                      40                                      45

164

Ala Glu Gly Arg Arg Ser Ala Trp Gly Ala Gly Gly Ser Ser Pro Pro  
 50 55 60

Arg Lys Val Leu Trp Gly Asp Met Arg Gly Arg Arg Ala Gly Val Asp  
 65 70 75 80

Val Leu Gly Pro Ala Leu Ser Ser Glu Ala Ala Gly Ala Glu Ala Arg  
 85 90 95

Gly Trp Gly Met Pro Gly Met Gly Val Gly Val Gly Ala Ser Glu Thr  
 100 105 110

Arg Gly Ala Leu Phe Leu Gly Arg Glu Gly Val His Gly Pro Cys Pro  
 115 120 125

Met Asp Gly Leu Gly Pro Trp Pro Trp Gly Pro Trp  
 130 135 140

&lt;210&gt; 246

&lt;211&gt; 353

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 246

Met Gly Pro Ala Val Lys Met Trp Thr Asn Ala Trp Lys Gly Leu Asp  
 1 5 10 15

Asp Cys His Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg  
 20 25 30

Cys Ser Cys Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys  
 35 40 45

Leu Asp Val Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln  
 50 55 60

Cys His Asn Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln  
 65 70 75 80

Thr Leu Leu Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly  
 85 90 95

Gln Asn Val Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu  
 100 105 110

Arg Pro Trp Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser  
 115 120 125

Leu Arg Pro Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys  
 130 135 140

Pro Pro Gly Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu  
 145 150 155 160

Cys Arg Val Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly  
 165 170 175

165

Ser Tyr Gln Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly  
 180 185 190  
 Lys Asn Cys Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys  
 195 200 205  
 Gly Pro Gly Gln Met Cys Phe Asn Thr Arg Gly Ser Tyr Gln Cys Val  
 210 215 220  
 Asp Thr Pro Cys Pro Ala Thr Tyr Arg Gln Gly Pro Ser Pro Gly Thr  
 225 230 235 240  
 Cys Phe Arg Arg Cys Ser Gln Asp Cys Gly Thr Gly Gly Pro Ser Thr  
 245 250 255  
 Leu Gln Tyr Arg Leu Leu Pro Leu Pro Leu Gly Val Arg Ala His His  
 260 265 270  
 Asp Val Ala Arg Leu Thr Ala Phe Ser Glu Val Gly Val Pro Ala Asn  
 275 280 285  
 Arg Thr Glu Leu Ser Met Leu Glu Pro Asp Pro Arg Ser Pro Phe Ala  
 290 295 300  
 Leu Arg Pro Leu Arg Ala Gly Leu Gly Ala Val Tyr Thr Arg Arg Ala  
 305 310 315 320  
 Leu Thr Arg Ala Gly Leu Tyr Arg Leu Thr Val Arg Ala Ala Ala Pro  
 325 330 335  
 Arg His Gln Ser Val Phe Val Leu Leu Ile Ala Val Ser Pro Tyr Pro  
 340 345 350  
 Tyr

&lt;210&gt; 247

&lt;211&gt; 146

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 247

Met Arg Val Leu Val Val Thr Ile Ala Pro Ile Tyr Trp Ala Leu Ala  
 1 5 10 15  
 Arg Glu Ser Gly Glu Ala Leu Asn Gly His Ser Leu Thr Gly Gly Lys  
 20 25 30  
 Phe Arg Gln Ser His Thr Trp Ser Leu Leu Gln Gly Ala Ala His Asp  
 35 40 45  
 Asp Pro Val Ala Arg Gly Leu Asp Pro Asp Gly Leu Leu Leu Asp  
 50 55 60  
 Val Val Val Asn Gly Val Val Pro Gly Arg Ala Trp Leu Thr Gln Ile  
 65 70 75 80  
 Phe Lys Cys Arg Thr Leu Lys Lys His Tyr Val Gln Thr Arg Ala Trp

[illegible]

```
<210> 248
<211> 638
<212> PRT
<213> Homo sapiens
```

<400> 248																
His	Ala	Ser	Gly	Ala	Phe	Leu	Val	Val	Arg	Gly	Glu	Pro	Gln	Gly	Ser	
1				5					10					15		
Trp	Gly	Ser	Met	Thr	Gly	Val	Ile	Asn	Gly	Arg	Lys	Phe	Gly	Val	Ala	
			20					25					30			
Thr	Leu	Asn	Thr	Ser	Val	Met	Gln	Glu	Ala	His	Ser	Gly	Val	Ser	Ser	
		35					40					45				
Ile	His	Ser	Ser	Ile	Arg	His	Val	Pro	Ala	Asn	Val	Gly	Pro	Leu	Met	
	50					55					60					
Arg	Val	Leu	Val	Val	Thr	Ile	Ala	Pro	Ile	Tyr	Trp	Ala	Leu	Ala	Arg	
65					70					75					80	
Glu	Ser	Gly	Glu	Ala	Leu	Asn	Gly	His	Ser	Leu	Thr	Gly	Gly	Lys	Phe	
				85					90					95		
Arg	Gln	Glu	Ser	His	Val	Glu	Phe	Ala	Thr	Gly	Glu	Leu	Leu	Thr	Met	
			100					105					110			
Thr	Gln	Trp	Pro	Gly	Val	Trp	Ile	Pro	Met	Ala	Ser	Cys	Ser	Ser	Thr	
		115					120					125				
Trp	Trp	Ser	Met	Ala	Leu	Ser	Pro	Asp	Ser	Leu	Ala	Asp	Ala	Asp	Leu	
	130					135					140					
Gln	Val	Gln	Asp	Phe	Glu	Glu	His	Tyr	Val	Gln	Thr	Gly	Pro	Gly	Gln	
145					150					155					160	
Leu	Phe	Val	Gly	Ser	Thr	Gln	Arg	Phe	Phe	Gln	Gly	Gly	Leu	Pro	Ser	
				165					170					175		
Phe	Leu	Arg	Cys	Asn	His	Ser	Ile	Gln	Tyr	Asn	Ala	Ala	Arg	Gly	Pro	
			180					185					190			
Gln	Pro	Gln	Leu	Val	Gln	His	Leu	Arg	Ala	Ser	Ala	Ile	Ser	Ser	Ala	
		195					200					205				



167

Phe Asp Pro Glu Ala Glu Ala Leu Arg Phe Gln Leu Ala Thr Ala Leu  
 210 215 220  
 Gln Ala Glu Glu Asn Glu Val Gly Cys Pro Glu Gly Phe Glu Leu Asp  
 225 230 235 240  
 Ser Gln Gly Ala Phe Cys Val Asp Val Asp Glu Cys Ala Trp Asp Ala  
 245 250 255  
 His Leu Cys Arg Glu Gly Gln Arg Cys Val Asn Leu Leu Gly Ser Tyr  
 260 265 270  
 Arg Cys Leu Pro Asp Cys Gly Pro Gly Phe Arg Val Ala Asp Gly Ala  
 275 280 285  
 Gly Cys Glu Asp Val Asp Glu Cys Leu Glu Gly Leu Asp Asp Cys His  
 290 295 300  
 Tyr Asn Gln Leu Cys Glu Asn Thr Pro Gly Gly His Arg Cys Ser Cys  
 305 310 315 320  
 Pro Arg Gly Tyr Arg Met Gln Gly Pro Ser Leu Pro Cys Leu Asp Val  
 325 330 335  
 Asn Glu Cys Leu Gln Leu Pro Lys Ala Cys Ala Tyr Gln Cys His Asn  
 340 345 350  
 Leu Gln Gly Ser Tyr Arg Cys Leu Cys Pro Pro Gly Gln Thr Leu Leu  
 355 360 365  
 Arg Asp Gly Lys Ala Cys Thr Ser Leu Glu Arg Asn Gly Gln Asn Val  
 370 375 380  
 Thr Thr Val Ser His Arg Gly Pro Leu Leu Pro Trp Leu Arg Pro Trp  
 385 390 395 400  
 Ala Ser Ile Pro Gly Thr Ser Tyr His Ala Trp Val Ser Leu Arg Pro  
 405 410 415  
 Gly Pro Met Ala Leu Ser Ser Val Gly Arg Ala Trp Cys Pro Pro Gly  
 420 425 430  
 Phe Ile Arg Gln Asn Gly Val Cys Thr Asp Leu Asp Glu Cys Arg Val  
 435 440 445  
 Arg Asn Leu Cys Gln His Ala Cys Arg Asn Thr Glu Gly Ser Tyr Gln  
 450 455 460  
 Cys Leu Cys Pro Ala Gly Tyr Arg Leu Leu Pro Ser Gly Lys Asn Cys  
 465 470 475 480  
 Gln Asp Ile Asn Glu Cys Glu Glu Glu Ser Ile Glu Cys Gly Pro Gly  
 485 490 495  
 Gln Met Cys Phe Asn Thr Arg Gly Ser Tyr Gln Cys Val Asp Thr Pro  
 500 505 510  
 Cys Pro Ala Thr Tyr Arg Gln Gly Pro Ser Pro Gly Thr Cys Phe Arg  
 515 520 525

168

Arg Cys Ser Gln Asp Cys Gly Thr Gly Gly Pro Ser Thr Leu Gln Tyr  
 530 535 540  
 Arg Leu Leu Pro Leu Pro Leu Gly Val Arg Ala His His Asp Val Ala  
 545 550 555 560  
 Arg Leu Thr Ala Phe Ser Glu Val Gly Val Pro Ala Asn Arg Thr Glu  
 565 570 575  
 Leu Ser Met Leu Glu Pro Asp Pro Arg Ser Pro Phe Ala Leu Arg Pro  
 580 585 590  
 Leu Arg Ala Gly Leu Gly Ala Val Tyr Thr Arg Arg Ala Leu Thr Arg  
 595 600 605  
 Ala Gly Leu Tyr Arg Leu Thr Val Arg Ala Ala Ala Pro Arg His Gln  
 610 615 620  
 Ser Val Phe Val Leu Leu Ile Ala Val Ser Pro Tyr Pro Tyr  
 625 630 635

<210> 249  
 <211> 367  
 <212> PRT  
 <213> Homo sapiens

<400> 249  
 Met Gly Glu Lys Phe Leu Leu Leu Ala Met Lys Glu Asn His Pro Glu  
 1 5 10 15  
 Cys Phe Cys Lys Ile Leu Lys Ile Leu His Cys Met Asp Pro Gly Glu  
 20 25 30  
 Trp Leu Pro Gln Thr Glu His Cys Val His Leu Thr Pro Lys Glu Phe  
 35 40 45  
 Leu Ile Trp Thr Met Asp Ile Ala Ser Asn Glu Arg Ser Glu Ile Gln  
 50 55 60  
 Ser Val Ala Leu Arg Leu Ala Ser Lys Val Ile Ser His His Met Gln  
 65 70 75 80  
 Thr Cys Val Glu Asn Arg Glu Leu Ile Ala Ala Glu Leu Lys Gln Trp  
 85 90 95  
 Val Gln Leu Val Ile Leu Ser Cys Glu Asp His Leu Pro Thr Glu Ser  
 100 105 110  
 Arg Leu Ala Val Val Glu Val Leu Thr Ser Thr Thr Pro Leu Phe Leu  
 115 120 125  
 Thr Asn Pro His Pro Ile Leu Glu Leu Gln Asp Thr Leu Ala Leu Trp  
 130 135 140  
 Lys Cys Val Leu Thr Leu Leu Gln Ser Glu Glu Gln Ala Val Arg Asp  
 145 150 155 160

169

Ala Ala Thr Glu Thr Val Thr Thr Ala Met Ser Gln Glu Asn Thr Cys  
 165 170 175

Gln Ser Thr Glu Phe Ala Phe Cys Gln Val Asp Ala Ser Ile Ala Leu  
 180 185 190

Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln Gln Trp Asp Gln  
 195 200 205

Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu Leu Gly Glu Ser  
 210 215 220

Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln Val Glu Glu Asp  
 225 230 235 240

Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala Glu Thr Leu Ile  
 245 250 255

Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu Leu Ser Lys Ser  
 260 265 270

Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His Leu Gln Arg Met  
 275 280 285

Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe Arg Glu Leu Pro  
 290 295 300

Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr Arg Leu Arg Ile  
 305 310 315 320

Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu Ala Phe Leu Glu  
 325 330 335

Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val Trp Asp Ser Tyr  
 340 345 350

Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu Ala Ala Cys  
 355 360 365

&lt;210&gt; 250

&lt;211&gt; 124

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 250

Met Gly Glu Pro Asn Arg His Pro Ser Met Phe Leu Leu Leu Leu Val  
 1 5 10 15

Leu Glu Arg Leu Tyr Ala Ser Pro Met Asp Gly Thr Ser Ser Ala Leu  
 20 25 30

Ser Met Gly Pro Phe Val Pro Phe Ile Met Arg Cys Gly His Ser Pro  
 35 40 45

Val Tyr His Ser Arg Glu Met Ala Ala Arg Ala Leu Val Pro Phe Val  
 50 55 60

Met Ile Asp His Ile Pro Asn Thr Ile Arg Thr Leu Leu Ser Thr Leu

170

65		70		75		80									
Pro	Ser	Cys	Thr	Asp	Gln	Cys	Phe	Arg	Ala	Lys	Pro	His	Ser	Trp	Gly
				85					90					95	
His	Phe	Ser	Arg	Phe	Phe	His	Leu	Leu	Gln	Ala	Tyr	Ser	Asp	Ser	Lys
			100					105					110		
Thr	Arg	Asn	Glu	Phe	Arg	Leu	Pro	Ala	Arg	Ala	Asp				
		115					120								

&lt;210&gt; 251

&lt;211&gt; 674

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 251

Met	Thr	Gly	Arg	Glu	Phe	Phe	Ser	Arg	Phe	Pro	Glu	Leu	Tyr	Pro	Phe
1				5					10					15	
Leu	Leu	Lys	Gln	Leu	Glu	Thr	Val	Ala	Asn	Thr	Val	Asp	Ser	Asp	Met
			20					25					30		
Gly	Glu	Pro	Asn	Arg	His	Pro	Ser	Met	Phe	Leu	Leu	Leu	Leu	Val	Leu
		35					40					45			
Glu	Arg	Leu	Tyr	Ala	Ser	Pro	Met	Asp	Gly	Thr	Ser	Ser	Ala	Leu	Ser
	50					55					60				
Met	Gly	Pro	Phe	Val	Pro	Phe	Ile	Met	Arg	Cys	Gly	His	Ser	Pro	Val
65					70					75					80
Tyr	His	Ser	Arg	Glu	Met	Ala	Ala	Arg	Ala	Leu	Val	Pro	Phe	Val	Met
			85						90					95	
Ile	Asp	His	Ile	Pro	Asn	Thr	Ile	Arg	Thr	Leu	Leu	Ser	Thr	Leu	Pro
			100					105					110		
Ser	Cys	Thr	Asp	Gln	Cys	Phe	Arg	Gln	Asn	His	Ile	His	Gly	Thr	Leu
		115					120					125			
Leu	Gln	Val	Phe	His	Leu	Leu	Gln	Ala	Tyr	Ser	Asp	Ser	Lys	His	Gly
	130					135					140				
Thr	Asn	Ser	Asp	Phe	Gln	His	Glu	Leu	Thr	Asp	Ile	Thr	Val	Cys	Thr
145					150					155					160
Lys	Ala	Lys	Leu	Trp	Leu	Ala	Lys	Arg	Gln	Asn	Pro	Cys	Leu	Val	Thr
			165						170					175	
Arg	Ala	Val	Tyr	Ile	Asp	Ile	Leu	Phe	Leu	Leu	Thr	Cys	Cys	Leu	Asn
		180					185						190		
Arg	Ser	Ala	Lys	Asp	Asn	Gln	Pro	Val	Leu	Glu	Ser	Leu	Gly	Phe	Trp
		195					200					205			
Glu	Glu	Val	Arg	Gly	Ile	Ile	Ser	Gly	Ser	Glu	Leu	Ile	Thr	Gly	Phe
	210					215					220				

171

Pro Trp Ala Phe Lys Val Pro Gly Leu Pro Gln Tyr Leu Gln Ser Leu  
 225 230 235 240  
 Thr Arg Leu Ala Ile Ala Ala Val Trp Ala Ala Ala Lys Ser Gly  
 245 250 255  
 Glu Arg Glu Thr Asn Val Pro Ile Ser Phe Ser Gln Leu Leu Glu Ser  
 260 265 270  
 Ala Phe Pro Glu Val Arg Ser Leu Thr Leu Glu Ala Leu Leu Glu Lys  
 275 280 285  
 Phe Leu Ala Ala Ala Ser Gly Leu Gly Glu Lys Gly Val Pro Pro Leu  
 290 295 300  
 Leu Cys Asn Met Gly Glu Lys Phe Leu Leu Leu Ala Met Lys Glu Asn  
 305 310 315 320  
 His Pro Glu Cys Phe Cys Lys Ile Leu Lys Ile Leu His Cys Met Asp  
 325 330 335  
 Pro Gly Glu Trp Leu Pro Gln Thr Glu His Cys Val His Leu Thr Pro  
 340 345 350  
 Lys Glu Phe Leu Ile Trp Thr Met Asp Ile Ala Ser Asn Glu Arg Ser  
 355 360 365  
 Glu Ile Gln Ser Val Ala Leu Arg Leu Ala Ser Lys Val Ile Ser His  
 370 375 380  
 His Met Gln Thr Cys Val Glu Asn Arg Glu Leu Ile Ala Ala Glu Leu  
 385 390 395 400  
 Lys Gln Trp Val Gln Leu Val Ile Leu Ser Cys Glu Asp His Leu Pro  
 405 410 415  
 Thr Glu Ser Arg Leu Ala Val Val Glu Val Leu Thr Ser Thr Thr Pro  
 420 425 430  
 Leu Phe Leu Thr Asn Pro His Pro Ile Leu Glu Leu Gln Asp Thr Leu  
 435 440 445  
 Ala Leu Trp Lys Cys Val Leu Thr Leu Leu Gln Ser Glu Glu Gln Ala  
 450 455 460  
 Val Arg Asp Ala Ala Thr Glu Thr Val Thr Thr Ala Met Ser Gln Glu  
 465 470 475 480  
 Asn Thr Cys Gln Ser Thr Glu Phe Ala Phe Cys Gln Val Asp Ala Ser  
 485 490 495  
 Ile Ala Leu Ala Leu Ala Leu Ala Val Leu Cys Asp Leu Leu Gln Gln  
 500 505 510  
 Trp Asp Gln Leu Ala Pro Gly Leu Pro Ile Leu Leu Gly Trp Leu Leu  
 515 520 525  
 Gly Glu Ser Asp Asp Leu Val Ala Cys Val Glu Ser Met His Gln Val  
 530 535 540

172

Glu Glu Asp Tyr Leu Phe Glu Lys Ala Glu Val Asn Phe Trp Ala Glu  
 545 550 555 560  
 Thr Leu Ile Phe Val Lys Tyr Leu Cys Lys His Leu Phe Cys Leu Leu  
 565 570 575  
 Ser Lys Ser Gly Trp Arg Pro Pro Ser Pro Glu Met Leu Cys His Leu  
 580 585 590  
 Gln Arg Met Val Ser Glu Gln Cys His Leu Leu Ser Gln Phe Phe Arg  
 595 600 605  
 Glu Leu Pro Pro Ala Ala Glu Phe Val Lys Thr Val Glu Phe Thr Arg  
 610 615 620  
 Leu Arg Ile Gln Glu Glu Arg Thr Leu Ala Cys Leu Arg Leu Leu Ala  
 625 630 635 640  
 Phe Leu Glu Gly Lys Glu Gly Glu Asp Thr Leu Val Leu Ser Val Trp  
 645 650 655  
 Asp Ser Tyr Ala Glu Ser Arg Gln Leu Thr Leu Pro Arg Thr Glu Ala  
 660 665 670  
 Ala Cys

<210> 252  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 252  
 Ile Ile Ser Gly Ser Glu Leu Ile Thr Gly  
 1 5 10

<210> 253  
 <211> 230  
 <212> PRT  
 <213> Homo sapiens

<400> 253  
 Val Asp Gly Ile Asp Lys Leu Asp Ile Glu Phe Leu Gln Gln Phe Leu  
 1 5 10 15  
 Glu Thr His Ser Arg Gly Pro Arg Leu His Ser Pro Gly His Ala Ser  
 20 25 30  
 Gln Glu Ala Thr Pro Gly Ala Asn Met Ser Ser Gly Thr Glu Leu Leu  
 35 40 45  
 Trp Pro Gly Ala Ala Leu Leu Val Leu Leu Gly Val Ala Ala Ser Leu  
 50 55 60  
 Cys Val Arg Cys Ser Arg Pro Gly Ala Lys Arg Ser Glu Lys Ile Tyr

173

65		70		75		80
Gln Gln Arg Ser Leu Arg Glu Asp Gln Gln Ser Phe Thr Gly Ser Arg						
	85			90		95
Thr Tyr Ser Leu Val Gly Gln Ala Trp Pro Gly Pro Leu Ala Asp Met						
	100		105			110
Ala Pro Thr Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu Glu						
	115		120			125
Asp Pro Ala Ser Ser Arg Tyr Gln Asn Phe Ser Lys Gly Ser Arg His						
	130		135			140
Gly Ser Glu Glu Ala Tyr Ile Asp Pro Ile Ala Met Glu Tyr Tyr Asn						
145		150		155		160
Trp Gly Arg Phe Ser Lys Pro Pro Glu Asp Asp Asp Ala Asn Ser Tyr						
	165		170			175
Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly Ala Gln						
	180		185			190
Gln Glu Gly Ile Gly Gly Leu Cys Arg Gly Asp Leu Ser Leu Ser Leu						
	195		200			205
Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys Pro Ser Ala Ser Pro						
	210		215			220
Glu Glu Asp Glu Gly Ile						
225		230				

<210> 254  
 <211> 25  
 <212> PRT  
 <213> Homo sapiens

<400> 254  
 Ala Ser Ser Arg Tyr Gln Asn Phe Ser Lys Gly Ser Arg His Gly Ser  
 1 5 10 15  
 Glu Glu Ala Tyr Ile Asp Pro Ile Ala  
 20 25

<210> 255  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<400> 255  
 Met Glu Tyr Tyr Asn Trp Gly Arg Phe Ser Lys Pro Pro Glu Asp Asp  
 1 5 10 15  
 Asp Ala Asn Ser Tyr  
 20

174

<210> 256  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 256  
Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly Ala Gln  
1 5 10 15

Gln Glu Gly Ile Gly Gly Leu Cys Arg Gly Asp  
20 25

<210> 257  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 257  
Leu Ser Leu Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys  
1 5 10 15

Pro Ser Ala Ser Pro Glu Glu Asp Glu Gly Ile  
20 25

<210> 258  
<211> 68  
<212> PRT  
<213> Homo sapiens

<400> 258  
Val Arg Cys Ser Arg Pro Gly Ala Lys Arg Ser Glu Lys Ile Tyr Gln  
1 5 10 15

Gln Arg Ser Leu Arg Glu Asp Gln Gln Ser Phe Thr Gly Ser Arg Thr  
20 25 30

Tyr Ser Leu Val Gly Gln Ala Trp Pro Gly Pro Leu Ala Asp Met Ala  
35 40 45

Pro Thr Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu Glu Asp  
50 55 60

Pro Ala Ser Ser  
65

<210> 259  
<211> 122  
<212> PRT  
<213> Homo sapiens

<400> 259  
Val Leu Trp Arg Glu Ala Ser Ala Leu Val Leu Ser Asn Arg Leu Ser



175

1	5	10	15
Ser Gly Leu Leu His Asp Leu Leu Leu Gln Pro Ala Ile His Ser Arg	20	25	30
Leu Phe Pro Arg Arg Ser Arg Gly Leu Ser Glu Gly Glu Gly Ser Ser	35	40	45
Val Ser Leu Gln Arg Ser Arg Val Leu Ser Ala Met Lys His Val Leu	50	55	60
Asn Leu Tyr Leu Leu Gly Val Val Leu Thr Leu Leu Ser Ile Phe Val	65	70	75
Arg Val Met Glu Ser Leu Glu Gly Leu Leu Glu Ser Pro Ser Pro Gly	85	90	95
Thr Ser Trp Thr Thr Arg Ser Gln Leu Ala Asn Thr Glu Pro Thr Lys	100	105	110
Gly Leu Pro Asp His Pro Ser Arg Ser Met	115	120	

<210> 260  
 <211> 129  
 <212> PRT  
 <213> Homo sapiens

<400> 260

Tyr Thr Phe His Thr Gln Ile Phe Leu Asp Phe Pro Met Ile Phe Leu	1	5	10	15
Thr Val Leu Pro Leu Ala Phe Leu Phe Leu His Ser Gly Phe Tyr His	20	25	30	
Tyr Ile Ser Phe Ser Cys Leu Phe Ser Leu Ser Leu Ala Leu Phe Phe	35	40	45	
Phe Leu Asp Val Ala Thr Phe Arg Arg Pro Gly Gln Leu Phe Cys Glu	50	55	60	
Arg Ser Val Leu Phe Asp Met Phe His Phe Gly Phe Val Ser Leu Phe	65	70	75	80
Leu His Glu Trp Ile Gln Ala Lys His Phe Trp Ala Gly Leu Phe Ile	85	90	95	
Val Leu Pro Ser Asp Val Phe Phe Ser Val His His Leu Glu Ala Pro	100	105	110	
Asp Gly Ser Phe Pro Asn Ile Ala Lys Leu Ser Leu Ile Ile Leu Leu	115	120	125	

Arg

176

&lt;210&gt; 261

&lt;211&gt; 99

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 261

Gly Thr Arg Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr Val  
 1 5 10 15

Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val Ile  
 20 25 30

Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu Asn  
 35 40 45

Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn  
 50 55 60

Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile  
 65 70 75 80

Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile  
 85 90 95

Phe Phe Pro

&lt;210&gt; 262

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 262

Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn Cys Ile Phe Phe  
 1 5 10 15

Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile Thr Ala Ile Ser  
 20 25 30

Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile Phe Phe Pro Cys  
 35 40 45

Leu Leu Ala  
 50

&lt;210&gt; 263

&lt;211&gt; 259

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 263

Gly Thr Arg Phe Pro Thr Gly Glu Thr Pro Ser Leu Gly Phe Thr Val  
 1 5 10 15

Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu Met Ala Val Ile  
 20 25 30

177

Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp Leu Ser Glu Asn  
           35                                  40                                  45  
 Ser Gln Ser Ser Met Ile Lys His Val Ala Trp Leu Ile Phe Thr Asn  
           50                                  55                                  60  
 Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe Ala Pro Leu Ile  
           65                                  70                                  75                                  80  
 Thr Ala Ile Ser Ile Ser Pro Glu Ile Met Lys Ser Val Thr Leu Ile  
                                   85                                  90                                  95  
 Phe Phe Pro Leu Pro Ala Cys Leu Asn Pro Val Leu Tyr Val Phe Phe  
                                   100                                  105                                  110  
 Asn Pro Lys Phe Lys Glu Asp Trp Lys Leu Leu Lys Arg Arg Val Thr  
           115                                  120                                  125  
 Lys Lys Ser Gly Ser Val Ser Val Ser Ile Ser Ser Gln Gly Gly Cys  
           130                                  135                                  140  
 Leu Glu Gln Asp Phe Tyr Tyr Asp Cys Gly Met Tyr Ser His Leu Gln  
           145                                  150                                  155                                  160  
 Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys  
                                   165                                  170                                  175  
 Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser Cys Pro Ala Leu  
                                   180                                  185                                  190  
 Ala Val Ala Ser Cys Gln Arg Pro Glu Gly Tyr Trp Ser Asp Cys Gly  
           195                                  200                                  205  
 Thr Gln Ser Ala His Ser Asp Tyr Ala Asp Glu Glu Asp Ser Phe Val  
           210                                  215                                  220  
 Ser Asp Ser Ser Asp Gln Val Gln Ala Cys Gly Arg Ala Cys Phe Tyr  
           225                                  230                                  235                                  240  
 Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr Asn Leu Pro Arg  
                                   245                                  250                                  255  
 Val Lys Asp

&lt;210&gt; 264

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 264

Cys Asp Cys Cys Glu Ser Phe Leu Leu Thr Lys Pro Val Ser Cys Lys  
   1                                  5                                  10                                  15

His Leu Ile Lys Ser His  
                                   20

<210> 265  
<211> 81  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (20)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 265  
Ala Leu Glu Asn Ser Gly Ser Pro Gly Leu Gln Asp Ser Ala Arg Ala  
1 5 10 15  
His Phe Asn Xaa Ser Leu Arg Ser Phe Ser Phe Leu Arg Asn Gln Met  
20 25 30  
Tyr Ile Phe Glu Leu Ser Leu Tyr Leu Glu Gly Thr Ser Phe Val Val  
35 40 45  
Val Leu Leu Phe Leu Leu Ile Ser Val Ser Leu Asp Ser Pro Pro Thr  
50 55 60  
Thr Lys Gly Trp Asp Ser Val Leu His Ile Trp Val Pro Leu Ile Val  
65 70 75 80  
Gln

<210> 266  
<211> 77  
<212> PRT  
<213> Homo sapiens

<400> 266  
Gly His Glu Ser Ile Cys Gly Ser Cys Arg Ser Trp Ile Tyr Phe Ser  
1 5 10 15  
Ile Arg Cys Arg Arg Arg Met Arg Pro Trp Trp Ser Leu Leu Leu Glu  
20 25 30  
Ala Cys Ala Thr Cys Ala Gln Thr Gly Pro Thr Arg Ser Thr Ser Cys  
35 40 45  
Thr Gln Glu Val Ser His Ser Ser Ser Thr Ala Tyr Pro Ala Pro Met  
50 55 60  
Arg Arg Arg Cys Cys Leu Pro Ser Pro Arg Ser Cys Thr  
65 70 75

<210> 267  
<211> 119  
<212> PRT  
<213> Homo sapiens

179

&lt;400&gt; 267

Lys Arg Ala Gly Val Glu Val Gly Gly Leu Val Met Ala Leu Ala Gly  
 1 5 10 15  
 Ser Val Phe Val Leu Gly Gly Val Leu Val Leu Cys Val Glu Arg Asn  
 20 25 30  
 Gly Glu Gly Glu Met Gly Trp Pro Gln His Leu Pro Lys Ser Gln Pro  
 35 40 45  
 Leu Ser Pro Pro Val Ala Val Arg Arg Cys Ser Phe Glu Arg Ser Trp  
 50 55 60  
 Ile Asp Leu Leu Val Glu Thr Ser Ser Ser Met Val Thr Cys Arg Gln  
 65 70 75 80  
 Gln Val Gly Thr Pro Asn Gly Met Glu Gly Arg Gly Gly Gly Pro Lys  
 85 90 95  
 Thr Thr Phe Pro Ile Arg Leu Gln Leu Ser Gly Ala Cys Ala Val Arg  
 100 105 110  
 Pro Glu Ile Gln Trp Glu Val  
 115

&lt;210&gt; 268

&lt;211&gt; 275

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (94)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (192)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 268

Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro Phe Glu Lys Cys Met  
 1 5 10 15  
 Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val Thr Ile Leu Glu Ala  
 20 25 30  
 Asp Asn Arg Ile Gly Gly Arg Ile Phe Thr Tyr Arg Asp Gln Xaa Thr  
 35 40 45  
 Gly Trp Ile Gly Glu Leu Gly Ala Met Arg Met Pro Ser Ser His Arg  
 50 55 60

180

Ile Leu His Lys Leu Cys Gln Gly Leu Gly Leu Asn Leu Thr Lys Phe  
 65 70 75 80  
 Thr Gln Tyr Asp Lys Asn Thr Trp Thr Glu Val His Glu Xaa Lys Leu  
 85 90 95  
 Arg Asn Tyr Val Val Glu Lys Val Pro Glu Lys Leu Gly Tyr Ala Leu  
 100 105 110  
 Arg Pro Gln Glu Lys Gly His Ser Pro Glu Asp Ile Tyr Gln Met Ala  
 115 120 125  
 Leu Asn Gln Ala Leu Lys Asp Leu Lys Ala Leu Gly Cys Arg Lys Ala  
 130 135 140  
 Met Lys Lys Phe Glu Arg His Thr Leu Leu Glu Tyr Leu Leu Gly Glu  
 145 150 155 160  
 Gly Asn Leu Ser Arg Pro Ala Val Gln Leu Leu Gly Asp Val Met Ser  
 165 170 175  
 Glu Asp Gly Phe Phe Tyr Leu Ser Phe Ala Glu Ala Leu Arg Ala Xaa  
 180 185 190  
 Ser Cys Leu Ser Asp Arg Leu Gln Tyr Ser Arg Ile Val Gly Gly Trp  
 195 200 205  
 Asp Leu Leu Pro Arg Ala Leu Leu Ser Ser Leu Ser Gly Leu Val Leu  
 210 215 220  
 Leu Asn Ala Pro Val Val Ala Met Thr Gln Gly Pro His Asp Val His  
 225 230 235 240  
 Val Gln Ile Glu Thr Ser Pro Pro Ala Arg Asn Leu Lys Val Leu Lys  
 245 250 255  
 Ala Asp Val Val Leu Leu Thr Ala Ser Gly Pro Ala Val Lys Arg Ile  
 260 265 270  
 Thr Phe Ser  
 275

&lt;210&gt; 269

&lt;211&gt; 212

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (123)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 269

Leu Pro Arg His Met Gln Glu Ala Leu Arg Arg Leu His Tyr Val Pro  
 1 5 10 15

Ala Thr Lys Val Phe Leu Ser Phe Arg Arg Pro Phe Trp Arg Glu Glu

181

20	25	30
His Ile Glu Gly Gly His Ser Asn Thr Asp Arg Pro Ser Arg Met Ile		
35	40	45
Phe Tyr Pro Pro Pro Arg Glu Gly Ala Leu Leu Leu Ala Ser Tyr Thr		
50	55	60
Trp Ser Asp Ala Ala Ala Ala Phe Ala Gly Leu Ser Arg Glu Glu Ala		
65	70	75
Leu Arg Leu Ala Leu Asp Asp Val Ala Ala Leu His Gly Pro Val Val		
85	90	95
Arg Gln Leu Trp Asp Gly Thr Gly Val Val Lys Arg Trp Ala Glu Asp		
100	105	110
Gln His Ser Gln Gly Gly Phe Val Val Gln Xaa Pro Ala Leu Trp Gln		
115	120	125
Thr Glu Lys Asp Asp Trp Thr Val Pro Tyr Gly Arg Ile Tyr Phe Ala		
130	135	140
Gly Glu His Thr Ala Tyr Pro His Gly Trp Val Glu Thr Ala Val Lys		
145	150	155
Ser Ala Leu Arg Ala Ala Ile Lys Ile Asn Ser Arg Lys Gly Pro Ala		
165	170	175
Ser Asp Thr Ala Ser Pro Glu Gly His Ala Ser Asp Met Glu Gly Gln		
180	185	190
Gly His Val His Gly Val Ala Ser Ser Pro Ser His Asp Leu Ala Lys		
195	200	205
Glu Glu Gly Ser		
210		

&lt;210&gt; 270

&lt;211&gt; 319

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (68)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (115)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (213)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

182

&lt;400&gt; 270

Met Ala Pro Leu Ala Leu His Leu Leu Val Leu Val Pro Ile Leu Leu  
 1 5 10 15  
 Ser Leu Val Ala Ser Gln Asp Trp Lys Ala Glu Arg Ser Gln Asp Pro  
 20 25 30  
 Phe Glu Lys Cys Met Gln Asp Pro Asp Tyr Glu Gln Leu Leu Lys Val  
 35 40 45  
 Thr Ile Leu Glu Ala Asp Asn Arg Ile Gly Gly Arg Ile Phe Thr Tyr  
 50 55 60  
 Arg Asp Gln Xaa Thr Gly Trp Ile Gly Glu Leu Gly Ala Met Arg Met  
 65 70 75 80  
 Pro Ser Ser His Arg Ile Leu His Lys Leu Cys Gln Gly Leu Gly Leu  
 85 90 95  
 Asn Leu Thr Lys Phe Thr Gln Tyr Asp Lys Asn Thr Trp Thr Glu Val  
 100 105 110  
 His Glu Xaa Lys Leu Arg Asn Tyr Val Val Glu Lys Val Pro Glu Lys  
 115 120 125  
 Leu Gly Tyr Ala Leu Arg Pro Gln Glu Lys Gly His Ser Pro Glu Asp  
 130 135 140  
 Ile Tyr Gln Met Ala Leu Asn Gln Ala Leu Lys Asp Leu Lys Ala Leu  
 145 150 155 160  
 Gly Cys Arg Lys Ala Met Lys Lys Phe Glu Arg His Thr Leu Leu Glu  
 165 170 175  
 Tyr Leu Leu Gly Glu Gly Asn Leu Ser Arg Pro Ala Val Gln Leu Leu  
 180 185 190  
 Gly Asp Val Met Ser Glu Asp Gly Phe Phe Tyr Leu Ser Phe Ala Glu  
 195 200 205  
 Ala Leu Arg Ala Xaa Ser Cys Leu Ser Asp Arg Leu Gln Tyr Ser Arg  
 210 215 220  
 Ile Val Gly Gly Trp Asp Leu Leu Pro Arg Ala Leu Leu Ser Ser Leu  
 225 230 235 240  
 Ser Gly Leu Val Leu Leu Asn Ala Pro Val Val Ala Met Thr Gln Gly  
 245 250 255  
 Pro His Asp Val His Val Gln Ile Glu Thr Ser Pro Pro Ala Arg Asn  
 260 265 270  
 Leu Lys Val Leu Lys Ala Asp Val Val Leu Leu Thr Ala Ser Gly Pro  
 275 280 285  
 Ala Val Lys Arg Ile Thr Phe Ser Pro Arg Cys Pro Ala Thr Cys Arg  
 290 295 300  
 Arg Arg Cys Gly Gly Cys Thr Thr Cys Arg Pro Pro Arg Cys Ser  
 305 310 315



<210> 271  
 <211> 1102  
 <212> DNA  
 <213> Homo sapiens

<400> 271  
 atgctccttt agcttggagg agtttgttat taccacacct ctgaagccta cttctgtcaa 60  
 ttcattccaac tcattctcag tccagttttg tttccttgct ggtgaggagt tgtgatcctt 120  
 tggaggagaa gaggcattct gggttttggg atttttagcc attttgctct ggtttcttcc 180  
 catctttgtg gatttatcta cctttcatct tcaatgttag tgacctatgg atggggctctc 240  
 tgagtggatg tgctcttctt ttctgtttgt tagttttctt tctaacagtt agccctctcg 300  
 ctgtaggctt gctggagttt gctggaggct cactccagac cctgtttgcc tgggtatcac 360  
 cagtggaggc tgcagaacag caaagattgc ttctgtttct ttctctgga agcttcgtct 420  
 cagaggggca cctgccagat gccagccaga gctctcctgt atgagggtgc tgttggccca 480  
 tactgggaga ttctctccag tcaggataca aggaggctag ggacctactt gaggaggcag 540  
 tctgaccctt agcagagggt gaacactgtg ctaggaggct ctctgctctt ttcagagctg 600  
 tcaggcgggg acgtataagt ctgctgaatc tgtgtccgca gccaccctt cccccagggtg 660  
 ctctgtccca gggagatggg gggttttatt ttaagtcccc aactggggct gctgcctttt 720  
 tttcagagat gccctgcccc gagaggagaa atctggcagt ctggcctcag aggccttgct 780  
 gagctgccgt tggctccacc cagttcaaac ttcccaaggg gctttgttta tactgtaagg 840  
 ggaaaaccgc ctactcgagc ctcatcaatg gcagacacc ctccccgcgc caagcttaag 900  
 tgtcccagggt tgatctcaga ctgctgctgt gctggcagtg agaatttcaa gccagtggat 960  
 cttagtttgc tgtgctctgt ggggtgggga cccattgaac cagactactc ggctccctgg 1020  
 cttcagcccc ctttcagga gagtgaaggg ttctgtctca ttggcattcc aggagtcact 1080  
 ggtgtatgga aaaaaaaaaa aa 1102

<210> 272  
 <211> 1102  
 <212> DNA  
 <213> Homo sapiens

<400> 272  
 atgctccttt agcttggagg agtttgttat taccacacct ctgaagccta cttctgtcaa 60  
 ttcattccaac tcattctcag tccagttttg tttccttgct ggtgaggagt tgtgatcctt 120  
 tggaggagaa gaggcattct gggttttggg atttttagcc attttgctct ggtttcttcc 180  
 catctttgtg gatttatcta cctttcatct tcaatgttag tgacctatgg atggggctctc 240  
 tgagtggatg tgctcttctt ttctgtttgt tagttttctt tctaacagtt agccctctcg 300  
 ctgtaggctt ctggagttt gctggaggct cactccagac cctgtttgcc tgggtatcac 360  
 cagtggaggc tgcagaacag caaagattgc ttctgtttct ttctctgga agcttcgtct 420  
 cagaggggca cctgccagat gccagccaga gctctcctgt atgagggtgc tgttggccca 480  
 tactggcaga ttctctccag tcaggataca aggaggctag gtacctactt gaggaggcag 540  
 tctgaccctt agcagagggt gaacactgtg ctaggaggct ctctgctctt ttcagagctg 600  
 tcaggcgggg acgtataagt ctgctgaatc tgtgtccgca gccaccctt cccccagggtg 660  
 ctctgtccca gggagatggg gggttttatt ttaagtcccc aactggggct gctgcctttt 720  
 tttcagagat gccctgcccc gagaggagaa atctggcagt ctggcctcag aggccttgct 780  
 gagctgccgt tggctccacc cagttcaaac ttcccaaggg gctttgttta tactgtaagg 840  
 ggaaaaccgc ctactcgagc ctcatcaatg gcagacacc ctccccgcgc caagcttaag 900  
 tgtcccagggt tgatctcaga ctgctgctgt gctggcagtg agaatttcaa gccagtggat 960  
 cttagtttgc tgtgctctgt ggggtgggga cccattgaac cagactactc ggctccctgg 1020  
 cttcagcccc ctttcagga gagtgaaggg ttctgtctca ttggcattcc aggagtcact 1080  
 ggtgtatgga aaaaaaaaaa aa 1102

<210> 273  
 <211> 185  
 <212> DNA  
 <213> Homo sapiens

184

&lt;400&gt; 273

tctgtatttc	ctgaatttga	atgttggcct	gccttgctag	gttggggaag	ttctcctgga	60
taatatcctg	aagaatgttt	tccaacttgg	ttacattctg	cccatcaatt	tcaggtaacac	120
caaccaaagt	tagatttggg	cttttcacat	agtcccatat	ttcttgagg	ctttgctcat	180
tcctt						185

&lt;210&gt; 274

&lt;211&gt; 185

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 274

tctgtatttc	ctgaatttga	atgttggcct	gccttgctag	gttggggaag	ttctcctgga	60
taatatcctg	aagaatgttt	tccaacttgg	ttacattctg	cccatcaatt	tcaggtaacac	120
caaccaaagt	tagatttggg	cttttcacat	agtcccatat	ttcttgagg	ctttgctcat	180
tcctt						185

&lt;210&gt; 275

&lt;211&gt; 950

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 275

ggcagctgca	gagctccagg	tttctctgcc	cacaagggca	ggggtgcc	ctcgcccagg	60
atgactctgc	cttccagagc	cttggcctcc	ctgggggtgg	gagtgtggg	gatgctaagg	120
ttaaatacagg	tcacagtaag	ttgtgggggc	agcaggtgga	gcagcagagt	ggcactggga	180
gctttctctt	gggtgtgcgg	tgtggccttg	gttctgcagc	catcaggtgg	gggcttggga	240
ctgactttctc	cttctgaagg	atgctgggaa	ggtgagctgg	ctttggcagt	gcttagagct	300
ccgggggggtt	ccccctccta	gaacatgcaa	gctctcacac	cgggtgcgtca	tcatacacacc	360
catcatcaag	cccacagtgg	tatactgaac	acctgcccc	caaagacggg	ggaatgctct	420
cagaggagcc	ccatgaacca	ccgatgggta	caactatcca	atgcctgatg	gcagacagcc	480
aggccaacct	cggcttccac	tctctcttcc	tcacctaca	atcagccaaa	gtgacctgag	540
tcgtgtagt	cgaagtgtgt	ttctgcttcc	tcttgtttgt	gcttttctgc	tttcttctgc	600
cccatacttt	gttaactcca	tgagttaaat	gctacctatt	ttcccagaca	agtgtgtgctt	660
ctgcaaggaa	acccttctct	atccccacc	tgtctgaaaa	gtacctctcc	agcttgcctc	720
ttcagggtgc	tgagcgttcc	ttcccagcct	gtcatcacct	tcctccatac	gctatggtgt	780
gttctctgtc	tctctagtct	tgtcctcttt	tttctgttag	attgtagctc	cttgcctgaca	840
ggaaccacgc	ctgtctccagc	ttcatacctc	ccactgctac	agcacagaac	ctgcttctca	900
gacttacagc	aaatgtttgt	ttgctgaatg	aattaattaa	agataaagca		950

&lt;210&gt; 276

&lt;211&gt; 950

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 276

ggcagctgca	gagctccagg	tttctctgcc	cacaagggca	ggggtgcc	ctcgcccagg	60
atgactctgc	cttccagagc	cttggcctcc	ctgggggtgg	gagtgtggg	gatgctaagg	120
ttaaatacagg	tcacagtaag	ttgtgggggc	agcaggtgga	gcagcagagt	ggcactggga	180
gctttctctt	gggtgtgcgg	tgtggccttg	gttctgcagc	catcaggtgg	gggcttggga	240
ctgactttctc	cttctgaagg	atgctgggaa	ggtgagctgg	ctttggcagt	gcttagagct	300
ccgggggggtt	ccccctccta	gaacatgcaa	gctctcacac	cgggtgcgtca	tcatacacacc	360
catcatcaag	cccacagtgg	tatactgaac	acctgcccc	caaagacggg	ggaatgctct	420
cagaggagcc	ccatgaacca	ccgatgggta	caactatcca	atgcctgatg	gcagacagcc	480
aggccaacct	cggcttccac	tctctcttcc	tcacctaca	atcagccaaa	gtgacctgag	540
tcgtgtagt	cgaagtgtgt	ttctgcttcc	tcttgtttgt	gcttttctgc	tttcttctgc	600
cccatacttt	gttaactcca	tgagttaaat	gctacctatt	ttcccagaca	agtgtgtgctt	660
ctgcaaggaa	acccttctct	atccccacc	tgtctgaaaa	gtacctctcc	agcttgcctc	720
ttcagggtgc	tgagcgttcc	ttcccagcct	gtcatcacct	tcctccatac	gctatggtgt	780
gttctctgtc	tctctagtct	tgtcctcttt	tttctgttag	attgtagctc	cttgcctgaca	840

185

ggaaccacgc	ctgctccagc	ttcatacctc	ccactgctac	agcacagaac	ctgctttctca	900
gacttacagc	aaatgtttgt	ttgctgaatg	aattaattaa	agataaagca		950

&lt;210&gt; 277

&lt;211&gt; 297

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 277

tttttttttt	tttttttttg	agacagagtg	ttgctctgtc	acccaggctg	gagagcagtg	60
gcatgatctc	cacttactgc	aagctctgcc	tcctgggttc	acgccattct	cctgcctcag	120
cctcccagtg	agctgggact	acaggcgccc	accaccatgc	ccagctaatt	ttttttgtat	180
tttttagtaga	gacagggttt	caccgtgtta	cccaggatgg	tctccatctc	ctgacctcgt	240
gatccaccgc	cctcggcctc	ccaaagtgc	gggattacag	gcgtgagcca	ctgcgcc	297

&lt;210&gt; 278

&lt;211&gt; 297

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 278

tttttttttt	tttttttttg	agacagagtg	ttgctctgtc	acccaggctg	gagagcagtg	60
gcatgatctc	cacttactgc	aagctctgcc	tcctgggttc	acgccattct	cctgcctcag	120
cctcccagtg	agctgggact	acaggcgccc	accaccatgc	ccagctaatt	ttttttgtat	180
tttttagtaga	gacagggttt	caccgtgtta	cccaggatgg	tctccatctc	ctgacctcgt	240
gatccaccgc	cctcggcctc	ccaaagtgc	gggattacag	gcgtgagcca	ctgcgcc	297

&lt;210&gt; 279

&lt;211&gt; 4002

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 279

gatgaacgaa	aacagcattg	attacatttc	tcggttcaat	gacctggccc	aagagctgtc	60
catcgctgag	cctggccgcc	gagaagctct	gtttgatggg	ggtggaggcg	gccccgctgt	120
cagtgcctg	tcccagtgac	cacacgtcct	ggtggcggat	gaagccctct	tcgagctaga	180
gaaaaataga	taagcccagc	agcccagaa	gatggtctga	acagaggcat	ctccgcaccc	240
aagactgtgc	aacgggcagg	aacgtggtca	cagagctgct	tccccacgag	cagcaggcaa	300
cggcgtccaa	ggagactagg	atgagttcct	ggcaagggcc	agcgttagaa	atcactgtgg	360
tactagagcc	gtcttccacc	acgcctgggc	ccatgttagg	gtctgcataa	tgatcccatt	420
tcagcctgtg	ctctgcctcg	attgttgtgt	tggacattcc	ggtggcattt	ccttctgaga	480
caaggaggta	tgtgtgcctt	ggtgtagtgt	ctgtgcacta	ggagctgtga	tctccctctc	540
tgcagggagg	ccccagcccc	tgtctcttgc	tttctgccaa	acctgtgcta	tgcatacagt	600
gtgccctctg	tggactgtaa	cgggcaggac	agtgggtgtg	ggcctgggct	catgcctggg	660
ggtgtcacat	cccaaggcag	caagagcatg	gataccgatc	acagggtgc	tgccgagtcg	720
tggggccctg	ggctgggtgc	tcccctccct	agaggttttg	ttcgtactct	taacaggggag	780
tgggggcagg	aagagtccctg	tactatgcag	gttgtgtgga	ctttacatgg	gaccctgcta	840
agctggttga	aaatgttttt	cttgtgtttt	aagaattagg	agacatggaa	gaggaagaac	900
aaagtccctt	ctgtagtgtg	tttccctcct	gtgtcccttt	gcaagcttcc	aggcgatcta	960
aggtgtcatt	tctccctcct	ggggtgaccc	ttaggcgcta	atatgattac	agcgaagact	1020
ttcctgataa	gttctcaaac	tcgatgtgtg	actgtttggc	acttgagaca	aacctgcctt	1080
tgcagggaaa	gtgtctctca	cgggcatttg	tgtgggcgtg	cctgacatac	gtgttcagtc	1140
ccttgcatat	ccttgccctg	agacttctgt	gtctccttcc	catttgggac	acccagggtga	1200
gggcccagac	atctggatgt	ggtcagacct	cacaaatat	atgccttcgt	ggtggtctcc	1260
ctccttgccg	cctcttgggt	ggccagcggt	cctactgcag	acggcccaac	atccagtcct	1320
tccccaggac	agagctaaca	agggccctct	tgccctctca	tcctcaggag	ttccaggcac	1380
atgagtcacc	gtccatccac	atccagtgtg	gcctggagct	gctacagagg	tgttgggcag	1440
gccatgcctg	tgccgccatc	tctcccttcc	tgccctcattt	catccccgc	agcagccggg	1500
attgattgtg	ctttcctaac	ccccttggac	ctactctccc	tcctccccac	cattcctctt	1560
ccccacatg	tgtggcacgc	tgcagccctc	aaggccagcc	ctggccctcc	cactgcttct	1620

186

ctccccatcc	acaatggaga	aggtgaaaag	aggagggaaa	ggccttttgg	gtggacaagc	1680
atgtggacgc	cctccgctct	gcagtcttgc	cagcccacca	cagccactgt	agaccacagg	1740
caggccgtgt	actgcaccac	tgggaggacg	tggagaggac	agtgaacttc	caggcaagag	1800
cttcccttct	ttgtctcacg	agtttttctt	agagctcttg	cctgagctgg	cttccctcct	1860
tcagacattg	acatgagatc	ttaagcaaac	agtcccaaac	ctcttagggg	tgaaaaaaga	1920
aacatgccac	ttgattagga	gagagacagc	agtgtttgaa	ctacagcatc	tttacactag	1980
cttgtgtttt	gtgctacgta	taccagcttc	caaaattagc	atctcattga	gccagagaag	2040
acaaggagat	ctccctctgg	gcatctggct	ttgctgctgc	tctagagggt	taggatacca	2100
ggccgagttc	aggccactgc	tagctttctc	atactccac	aggctagacc	agagatgcca	2160
agtcccaaca	gcactgagct	gtgtgcaact	tgccagggac	aggaggggtt	gtgaactgcc	2220
tgtcagggtg	cctgttagcc	cctgacaact	cagtgggggt	aagttttgga	ggtcagagtc	2280
tgctttcgtg	ggctcttttag	acagcaccta	ccacttggtt	ctccagcgta	gactcctggg	2340
agcagccaac	tgcagccatt	gccatccagt	ggggagatgg	gttagggagg	aggacgggct	2400
gactcctctc	ctgtaataaa	gctgacaaga	gttctagagg	attctgcttc	tctagtaact	2460
agacagggtg	tacgcatttg	cttgccacat	taagggaata	tgggtgtcatt	tgttgcagaa	2520
aaacaatgga	tacattttct	tctggcctaa	atgaatatct	atgtgcaaac	ataggcaact	2580
gttaaaggct	ggaattttca	aaagatccaa	acagagactt	cctgcactct	ctgcctttcc	2640
aacagaagcg	gtgatcgtct	aagtatgagc	ctgtggcttc	ctttgtgcat	ttgagcatgc	2700
tgtaattaag	atgagatcag	tttcttagaa	aaagctttcc	tgaatccctc	tgacgttgcc	2760
tgggactctt	ctgttgattc	gtcttttctg	gagattggga	cagagcatct	gtggtccagg	2820
gaagttagtc	ctctggcctc	aattctgttg	tggatgtgca	gtgataagcg	ggcattgctg	2880
gcctcggggg	atgcctagtt	cgtggcttcc	tggctgtttt	gtccttctgt	gtcctgtagc	2940
tgtagggtgc	cagctcaggg	agtgggggtg	tggcggcggt	tccgcgggtg	gcctccttgc	3000
tttgccgcac	ctccagggtc	tgggcatgag	aggccgtggc	ctcatttctg	gtggataacc	3060
tttttagttt	aatagcatct	ttaattagat	cacagcattg	aattcaaaat	ttcttctgca	3120
aagaaagtgt	tggggcataa	gacaccggga	atgagggagg	aggaagacag	ttgtgttttc	3180
tctttaaacc	ttgagctcta	gccgatgcat	ttgtcaggaa	atacagcact	ttgtcttaag	3240
aaaacaagga	aggaggcccg	gcgcagtggc	tcacgcctgt	aatcccagca	ctttgggagg	3300
ccgaggcggg	cggatcacct	gaggtgggga	gtatgagacc	accctgacta	acatggagag	3360
accctgtctc	tactaaaagt	acagaattag	ccgggcgtgg	tggcgcagtc	ccataatccc	3420
agctactgag	gagacttgag	gtaggagaat	cacttgaacc	tcagcggcgg	aggttgagct	3480
gagtcgagat	cgcgccagtg	cactccagcc	tgggcaagaa	gagcgaaaact	gggtctcaag	3540
ttaaaaaaag	aaagcaagga	aagagtaatt	tacaacgaag	gaaaaaaacc	cacagcacac	3600
ccttcgcggc	tgtcagcgct	ctcctgatgt	cacagtggct	gcgtgtcctt	ggggtgggtg	3660
aggtgtgggg	agcccagccc	ctggccctgc	ctcccgccgc	ccgctccctt	tctctctctt	3720
actcggttaa	gccatagcga	ggcctccgct	cgtttcagat	atgaatttgt	tttatagatt	3780
ataaatatgc	atatacagtg	tatgtataaa	gcagaatgcc	tgcctttcct	ggttattttt	3840
tgtaccatat	tgtaaattat	attattttatt	ctttaccaat	tttgggaata	aaaggtgttt	3900
tggttattta	atataataag	agctgttaaa	cttctgttta	aatttccagt	tcaacttgta	3960
aatgttttta	ttgtgcataa	atacatacta	atgttgatct	aa		4002

&lt;210&gt; 280

&lt;211&gt; 106

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 280

atcccggcac	ttggggaggc	cgaggcaggt	ggaccacgag	atcaggagat	cgagaccatc	60
ctggccaaca	cggtgaaacc	cgtctctac	taaaaatacg	aaaaaa		106

&lt;210&gt; 281

&lt;211&gt; 7332

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 281

ccaaggactg	tagcaggaca	agccacagac	aaaacctctc	agacacggag	ctgtagaaga	60
aagggcttta	ttcagctggg	agcattggca	agctactgcc	ttaaaatccg	agctccccga	120
gtgcacaatt	tctgtcgctt	ttaagagctc	acaacactaa	aatttcacat	gaaagggctg	180
tgattgattt	gagcaagcaa	ggggtacgtg	acaggggctg	catgcaccga	tggtcaggga	240

gaaacagaac	agggcagggg	gtttcacaat	gttcttctat	agaatgtctg	gaatctatga	300
ataacatcgg	tttctaagtc	atgagttgat	ttttaactac	taggttttagg	ccaggcagggc	360
ccaggctccag	ttttgggcct	ggcgcctgggc	tgcctgtctt	tgatttcact	tccttttttt	420
tttaaaaaaa	aaaaaaaaaa	caggctactga	gtataaaaaca	atatgagagg	gtctctctct	480
tccctcgctt	taacttttcgg	agggctgaaa	ttctttctag	ccttggttaa	tacagcaatt	540
cattccattc	tagctattgt	tatttctctt	actataattt	tactattagt	acttacgcta	600
ttctattatt	ttcttaattt	tccacttaat	taggataaca	aaccgagggc	gggctcccat	660
cctcctcaag	cacacgaggg	gggcctggcc	cagcagggag	cttcgcctgg	tttctgaggg	720
aattcccggc	gggccttttc	aaaacatgcc	cgttcccttc	cgctaacttc	aggggccaaag	780
aattgaactt	tcaccctcct	caagccgggtg	gcgctgcctc	gctggcgctc	ccagcgcgca	840
gccaacccga	tgccagccgg	cggcattacc	actgccagca	tggggcgccc	gcggacctcc	900
gactgagcca	gctgccggga	gccggaagtg	tcccggggcg	cgggactgcg	agggggccgg	960
gagttcccca	agaccgggaag	tgtcccggag	ccgggagccc	gcgggacccc	ggagcgcgcg	1020
gggcccgaag	aggcggggcg	ccagtgagg	tccgcagagt	ttggggcgcca	ggcgagacgg	1080
cagggcctaa	agttccgggt	gaggcggtgg	tcccacaacc	gcttgggaatt	tgcctcccgg	1140
ctccgctctg	gaagctaaga	aggggcacga	gagccggaga	cgggaacctg	agagcagggg	1200
agccagtagc	cggccggagg	agcgcgcggc	cgctccagtc	ggaaggagcc	gttgacagccc	1260
tgcccggcgt	gtggcggggg	cagcgaggcc	cctgcgggtg	ttcgcccgcg	ccttcgcgtc	1320
cgcactcacc	cgccctctgg	gcctcccaca	ggtcggcgcc	gccagcggcg	ggtaccggcc	1380
cgcagaggga	gggcggggctg	tgaactggca	gcacatcgcg	ttcccgcggg	gccccatttc	1440
tgcccaggca	gggagcggct	gggatgggac	tgaggtcggt	ccgcgagcgc	ggtgccccag	1500
agaccgggct	tctggaagtt	gccgcggcct	gctctggggg	cccagaagta	gggcggggag	1560
gcgcggggtc	tggagtctgc	aggacctggc	tgcgaatcca	accagctgat	ttcaaacttt	1620
tctgtgatct	tctgcaagtt	aactaagtct	cagttcctcg	tttgcgaaat	gtacttaata	1680
ggcacccccag	ggtgaactaa	atttgtccgc	acagactgca	gcattgcgct	tgggaggcgc	1740
cttagggggg	aggagtcact	aatatcactg	agttttgaca	gaaatgaagg	tgcattggca	1800
aaggtgtgcc	ccatggccgg	gcaggttagg	aggagggcct	ggtaatat	tttcttaaat	1860
tgtaaacagc	catctggatg	agcaatgcat	tatcaaatta	tgattcagag	aggactatcg	1920
ctgactactc	tttttttttg	gcaaacctcc	gcttcaggag	cttctggctt	gattcctaag	1980
tggaaggtag	agacctaggc	cctctgagtc	acaactccat	ctctctgggt	gaggactgag	2040
ctccaggact	gctgagtgga	ggcagaacaa	ttgggatagg	gaaaagagag	gccaaactag	2100
atcagaggct	ggcgtgggct	tcagaatcta	cagactggca	cagttaatgc	ctccggggccc	2160
ctattgtctg	ttcaagtttg	accaatcaga	agtatcttta	gcttaagggc	ggcgtgttgg	2220
ccaatgagac	tttattgtga	aataaaaatgc	cctcagtttc	atttaactga	gccaccatag	2280
aagagtagag	aaatcgagtt	ggccagatga	gggagaggcc	attaagaggt	attttaggga	2340
ttgaatgggc	tgggcaccca	gaggacagtg	gcatttgggg	tggtaatgag	aagggaacatt	2400
aggggcctcc	gcctccttcc	gttctctctg	tgtcagtgca	gtcagcacag	aggctgcagg	2460
aggtatctct	ggttggcttt	ggctgcctgt	agggggcacc	agctttgggg	aggtcagagg	2520
gctctctcct	gagctgctgt	cctgcccaca	atcacacctg	cctgatgcct	gtgaatggcc	2580
gtctgagtc	cttgggcctt	ggtcacttct	ggcctgccct	gcaccgacca	gtaactgtgc	2640
ctgctgactg	gaggttatgg	aattcaocgg	actttattgt	tctttgtagg	aatacaagat	2700
caactcccac	tgaggacaaa	tggacctgta	attccgggtg	tgacgagaga	acgagattta	2760
ccttccctgaa	ttaaaaaaca	ggtcattaag	cttgggccc	gactcttctt	tgtgagaagg	2820
tacagagatg	gaaaccttac	aatccgagac	taaaacgagg	gtccttccct	catggctgac	2880
agcccagggtg	gctacaaaaga	atgtggcacc	aatgaaggcc	cccaagagga	tgagaatggc	2940
agcagtgcc	gtggcagcag	caagggtcga	cagctctggt	cagaagactc	ctgcgaatct	3000
ggcaagtgg	gcaggggcct	ccatgacctg	ggccaggtct	tccagcctag	gcagaacagc	3060
aagatggggc	ggtgtttcag	tctgatcatc	tcttgagctt	ttagaagggtg	gaggggctgt	3120
gggcggggagg	caaagcgggt	taaccctcga	ggacagggc	ccacttctgc	ctctgcactg	3180
gtgagtggcc	tgcctcagc	acacacagag	tgggttctcc	atgtcagcca	gtctctgatg	3240
ccagttgtcc	agaatgccag	tctcttccct	tacaacaaac	atggtaacat	cagatgggca	3300
agatcagtg	aagggctctgt	tctgagtggt	gcctgcccct	gtggacagac	ctttagggat	3360
ggacagatga	gcagcagctg	cagggccagc	aagagctaag	gagctgggga	gtgagttagt	3420
tgaatgacgg	taattgccgg	ggggggggcg	gggggggggtg	gtgagtcctc	aggctgcact	3480
gtgaagtggg	cggggcccca	gcactcgggtg	tttccctctc	tggctcctcc	tcctctaagg	3540
tttccctgact	gacagccttc	ccttgtgact	gctgccgtct	ttccctaagt	ctggctcctgc	3600
tttcaggttc	ctctcagtac	agcctcagcc	cgaggttccc	ttcctcttgc	atccatgtgt	3660
gtgtttcaga	ggcggccatc	cttccctact	tccagatcct	tgtaggggcag	ttggtggagg	3720
gtgggaggca	ccccgggtgt	gcctccatga	agcctctgtc	cagtcactgg	gctgcaaggc	3780
tgaggaaatt	gtgtccgtgt	cagaaagctc	ctcagctcag	aggtgctggt	acctcctgcg	3840

188

tggttaggaag	gcagggggaa	gaggccctgc	ttctcctggt	ctctttgccc	ttatgagact	3900
tgagagtctg	tgtcatctgt	gccttgcatg	tctttttttc	agactccctg	cgacaaggac	3960
tgtgtactgc	atgaatgagg	ctgagatagt	tgatgttgct	ctgggaatcc	tgattgagggt	4020
aaagtccagac	aagcctctta	ctcatgacca	gaaactctgc	atgggcagag	gctagaccct	4080
tggtcaccgt	cagtaagaga	gacgcctct	gccgtaggct	acctcttctt	cctcctgcca	4140
cttcccttgc	tcttatctcg	gccatgctgc	ccaggcctct	ccccatgtgg	gtgtgcgctc	4200
gtgggggtgtc	tttgaggcta	gaagcctggg	agggcatgcg	tgtgttaggg	agggcggtgtg	4260
tgtgttaggg	agagcgtgac	tgtgactgg	tgtgtatgtg	gatgggacat	gaagcgttta	4320
cctgtttgtg	ttcttggaag	ggttcccagt	tgggtagatg	acttcttagc	cattgcccct	4380
ctcctgagca	gaggatgctg	agcttccctg	cttccctgag	taataattgc	agtgcctcag	4440
agttgcacag	cattctacag	tttaccagggt	gccttgaaag	catgcgttat	gtcatttttag	4500
ccttgcaata	accctgtgggt	gtgggacttt	tcctagtgtc	aaggcatggg	cccacaccca	4560
ggttttgtat	cttgggttct	gtcacgggcc	ttcttagaca	tgtttcttcc	atttcttttt	4620
cctttccctc	cagctaatacc	tcctgccttt	gcttgcctct	ctcccgagtg	ggttctgggt	4680
tcttcaagag	ctgtgaagag	ggggtcaggg	gaaggagtgg	ggtgaagaga	gggtgggtgc	4740
tcaggatatg	ggtacattgc	ctggcctggt	cacattggct	ttgtagttgc	ttctagatac	4800
atcctgtgtt	actgacagat	cagcatgtta	gggaaataaa	acacgtatgt	tgagcctgcg	4860
ttttcccgta	ctccacagag	ccgcaaacag	gaaaaggcct	gcgagcagcc	ggccctggcg	4920
ggggctgata	accagagca	ctcccctccc	tgtccgtgtg	cgctcacac	aagttctggg	4980
agcagcagta	aggaagagga	cagtgggaaa	caggcactgg	ctccaggcct	cagcccttcc	5040
cagagggccg	ggggttccag	ctctgcctgt	agcaggagcc	ctgaggagga	ggaggaagag	5100
gatgtgctga	aatacgtccg	ggagatcttt	ttcagctagg	gcataaactg	tgcactgaac	5160
tgtctgccga	gagcagctgg	aggacagctg	agcttccact	ggtgctgctg	ggccgcccgc	5220
ctgtgggaat	ggggtctctc	gtgctcctac	cttctgtgct	tcttgggccc	ggcagattca	5280
cctcaggcca	gaagcccctg	gacactccgg	gccttggggc	tgcctgtctg	agtgtgcgga	5340
aggcaggact	caaaatgaga	tcccatttga	ctcccctctg	atgtactgtg	ccctctcctg	5400
gctcttgagg	ctctggagtc	ccaattgtct	gtgttagtca	gtgaccagggt	tccagggaaa	5460
atgatgtcat	gtggtgggtc	aacttactgg	aaccaaagag	acagtacttt	gcaaagaaaa	5520
ggatcactgc	caggtgcact	ggaattgcta	cagtttagtc	cgcatgatct	ctcctgaagg	5580
aggaagcctg	tttcaaaaat	agtttccatc	atgagtctat	caatgagctc	ccacctctcc	5640
agccagccta	gaaagcaaac	gagctgcccc	cagttctctg	ccctgtctgg	gaggttgagg	5700
ccacagtgtg	tagactggta	agccagacag	gcctcctccc	gcaagctgct	accttgcttt	5760
cacctgtacc	ttggtccccg	ggcagctagc	tataaagcaa	gagggacagg	agcccagaag	5820
agacactgag	gacaagagat	cacaccagag	tacatgtctc	tgcctctggt	ttcagtgtgg	5880
ctttggacag	gaatatatga	ataaatcact	gccatacagg	ttttccaata	cacaagtgtc	5940
agaaaataca	cacaattccc	caatgcgtaa	gttgtgctaa	tgtctttcca	agttctgggt	6000
tggaagtgg	aggggtggcag	cgtttgtttg	tgtgcagccg	tccagtcctg	ttcacagcga	6060
ggatttgagg	tcctccaggg	tctcatcatg	ggagtgtatt	gtcagcggac	gcctctgccc	6120
tgtctggctt	caggtccagg	gaagctttga	agcagtcaag	ccttgtcttt	gtaccccatg	6180
tgctctgtct	ttgttgagtc	actcagagat	cactcctgga	cctctggggg	tggagttcca	6240
gtgatggctt	atggcggccc	actcactatg	gtgggctgag	tggaaagctcc	ttaaccatgt	6300
ccccagagac	actgaggtgc	tcgctctttt	aatgtcctcg	tttgttgccg	taagttcttt	6360
gctaggtttc	atlttgat	ttggcaaatc	agcctggaag	tctggcccca	tgacagcaat	6420
cactccctcc	ccacctctct	gaagctagag	gaagatttgc	tcagatccat	taattaaagc	6480
aggaattggt	gtgacaatga	gctgcatggt	ttagggagtc	tttgggagcc	ttggaagtcc	6540
tgaaggacag	acaatcttgt	actaagaagt	cacagggtgcc	ctggctgccc	ttgctgcccc	6600
tcggcctctt	tgacacaggg	gccccacctc	ctctgtagtg	ggttccatcg	ctggagctgg	6660
agatcagcgt	tagctgtaaa	atgagatggc	tgagcagatg	tgccacctct	gaccatgggt	6720
ggaactgaac	ccttgcaatc	acgtaagcct	ttagcagctc	tcaagcttgc	tctcagccct	6780
ctcagccctc	agagggaaca	cagccatggc	tataagcaag	aggatgagta	aggcctgggc	6840
gctgcccaga	gctagaaacc	caggccccgg	gagggagagc	ctgacccact	tccacacata	6900
ggagaggaag	aggcccaggc	cgctgcccag	cagcacagag	gacacagcca	ggaagcccac	6960
tgccagccgc	cacgtctctc	catcactgtt	gcactgggct	aggaggagag	gctggggggc	7020
aaagaggggt	aggaccaggg	accgtacac	gccaaagcct	gccaggccca	ggccaacccg	7080
aggcaccccc	aggccttcca	gctcagggaa	ctgtgacac	tgtagggtgc	tggtgtcctc	7140
attccacagg	cagaagttat	agaagccgat	tctcaggttg	ggcaggtcag	tgaggttgcc	7200
agcctcccag	agaagagcgt	aaaacatcag	gcagatgacc	acaatcacga	ggactatgat	7260
gctcatgaac	agcagctggt	cgcgccaccg	aggccttggg	ccggccatct	ctactgcctc	7320
ctgccggggg	ac					7332

&lt;210&gt; 282

&lt;211&gt; 7334

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 282

ccaaggactg	tagcaggaca	agccacagac	aaaacctctc	agacacggag	ctgtagaaga	60
aagggcttta	ttcagctggg	agcattggca	agctactgcc	ttaaaatccg	agctccccga	120
gtgcacaatt	tctgtcgctt	ttaagagctc	acaacactaa	aatttcacat	gaaagggctc	180
tgattgattt	gagcaagcaa	gggtacgtg	acaggggctg	catgcaccga	tggtcagaga	240
gaaacagaac	agggcagggg	gtttcacaat	gttcttctat	agaatgtctg	gaatctatga	300
ataacatcgg	tttctaagtc	atgagttgat	ttttaactac	taggtttagg	ccaggcaggg	360
ccaggtccag	ttttgggcct	ggcgtgggc	tgctgtctct	tgatttcact	tccttttttt	420
aaaaaaaaaa	aaaaaaaaaa	ggtactgagc	ataaaacaat	atgagagggt	ctctctcttc	480
cctcgcttta	actttcggag	ggctgaaatt	ctttctagcc	ttggttaata	cagcaattca	540
ttccattcta	gctattgtta	tttctcttac	tataatttta	ctattagtac	ttacgctatt	600
ctattatftt	cttaattttc	cacttaatta	ggataacaaa	ccgaggccgg	gctcccatcc	660
tcctcaagca	cacgaggggg	gcctggccca	gcaggggagct	tcgcctgggt	tctgagggaa	720
ttcccggcgg	gcctttccaa	aacatgcccc	ttcccttcgg	ctaacttcag	gggccaagaa	780
ttgaactttc	acctcctca	agccggtggc	gtgcctcgc	tgccgttccc	agcgcgcagc	840
caaccggatg	ccagccggcg	gcattagcac	tgccagcatg	gggcgcccgc	ggacctccga	900
ctgaggcagc	tgccggggagc	cggaaagtgc	ccgggcgcgc	ggactgcgag	ggggccggga	960
gttccccaa	accggaagt	tcccaggcc	gggagcccgc	gggacctgg	agcgcgcggg	1020
gccggaagag	gcgggcggcc	agtggaggct	cgagaggtt	gggcgccagg	cgagacggca	1080
gggcttaaa	ttccgggtga	ggcgtgggtc	ccacaaccgc	ttggaatttg	cctcccggct	1140
ccgctctgga	agctaagaag	gggcacgaga	gccggagacg	ggaacctgag	agcagggaa	1200
ccagatcccg	gccgagggag	cgcgcggccg	gtccctcgg	aaggagccgt	tgacgctctg	1260
cccggcggtg	ggcgggggtca	gcgagggccc	tgccgtgctt	cgcccgccgc	ttccgctccg	1320
cactcaccgg	ccctctgggc	ctcccacagg	tcggcgccgc	cagcggcggg	taccggcccc	1380
cagagggagg	gcgggctgtg	aactggcagc	acatcgcggt	cccgcggggc	ccccattctg	1440
ccagggcagg	gagcggctgg	gatgggactg	aggtcgggtc	gcgagcgcgg	tgccccagag	1500
acccggtctc	tggaaagtgc	tgccgcctgc	tcttggggcc	cagaagtagg	gcggggaggc	1560
gcggggctct	gagctgcag	gacctggctg	cgaatccaac	cagctgattt	caaacttttc	1620
tgtgatcttc	tgcaagttaa	ctaagtctca	gttctcgtt	tgcaaatgt	acttaatagg	1680
cacccagggg	tgaactaaat	ttgtccgcac	agactgcagc	attgcgcttg	ggaggcgcct	1740
tagggggtag	gagtcactaa	tatcactgag	ttttgacaga	aatgaagggt	cattggcaaa	1800
ggtgtgcccc	atggccgggc	aggttagggg	gagggcctgg	taatatfttt	tcttaaatgt	1860
taaacagcca	tctggatgag	caatgcatta	tcaaattatg	attcagagag	gactatcgct	1920
gactactctt	ttttttgggc	aaacctccgc	ttcaggagct	tctggcttga	ttcctaagtg	1980
gaaggtagag	acctaggccc	tctgagtcac	aactccatct	ctctgggtga	ggactgagct	2040
ccaggactgc	tgagtggagg	cagaacaatt	gggtatggga	aaagagaggc	caaactagat	2100
cagaggctgg	cgtgggcttc	agaatctaca	gactggcaca	gttaatgcct	ccggggccct	2160
attgctgctt	caagtttgac	caatcagaag	tatctttagc	ttaagggcgg	cgtgttggcc	2220
aatgagactt	tattgtgaaa	taaaatgccc	tcagtttcat	ttaactgagc	caccatagaa	2280
gagtagagaa	atcgagttgg	ccagatgagg	gagaggccat	taagagggtat	tttagggatt	2340
gaatgggctg	ggcaccacga	ggacagtggc	atttgggggt	gtaatgagaa	ggaacattag	2400
gggcctccgc	ctccttcggt	tcctcctgtg	ctgagtcagt	cagcacagag	gctgcaggag	2460
gtatctctgg	ttggctttgg	ctgcctgtag	ggggcaccag	ctttggggag	gtcagagggc	2520
tctctcctga	gctgctgtcc	tgcccacaa	cacacctgcc	tgatgcctgt	gaatggccgt	2580
ctgagctctt	tgggccttgg	tcacttctgg	cctgccttgc	accgaccagt	aactgtgcct	2640
gatgactgga	ggtatgggaa	ttcaccggac	tttattgttc	ttttagggaa	tcaaagatca	2700
actcccactg	aggacaaatg	gacctgtaat	tccgggtgtg	acgagagaac	gagatttacc	2760
ttcctgaatt	aaaaaacagg	tcattaagct	tgggcccctga	ctcttctttg	tgagaaggta	2820
cagagatgga	aaccttaca	tccgagacta	aaacgagggt	ccttccttca	tggtgcagag	2880
ccaggtggc	tacaaagaat	gtggcaccaa	tgaaggcccc	caagaggatg	agaatggcag	2940
cagtgcaggt	ggcagcagca	aggtgcgaca	gctctggtca	gaagactcct	gcgaatctgg	3000
caagtggagc	aggggcctcc	atgacctggg	ccaggtcttc	cagcctaggc	agaacagcaa	3060
gatggggcgg	tgtttcagtc	tgatcatctc	ttgagctttt	agaaggtgga	ggggctgtgg	3120
gcgggaggca	aagcgggtta	acctcagagg	acaggcaccc	acttctgcct	ctgactgggt	3180
gagtgccttg	ccctcagcac	acacagagtg	ggttctccat	gtcagccagt	ctctgatgcc	3240

190

agttgtccag	aatgccagtc	tcttccttta	caacaaacat	ggtaacatca	gatgggcaag	3300
atcagtgga	gggtctgttc	tgagtgggtc	ctgcccctgt	ggacagacct	ttagggatgg	3360
acagatgagc	agcagctgca	gggccagcaa	gagctaagga	gctggggagt	gagttagttg	3420
aatgacggta	attgccgggg	gggggggggg	cggggggggg	tggtagtct	ccaggetgca	3480
ctgtgaagtg	ggcggggccc	cagcactcgg	tgtttccctc	tctggctcct	cctcctctaa	3540
ggtttctga	ctgacagcct	tcccttgtag	ctgctgccgt	ctttccctaa	gtctgggtcct	3600
gctttcaggt	tctctcagtc	acagcctcag	cccagggttc	ccttcctcct	gcatccatgt	3660
gtgtgtttca	gaggcggcca	tccttcccta	cttcagatc	ctttagggc	agttgggtgga	3720
gggtgggagg	caccccgggtg	ttgcctccat	gaagccctgt	gccagtcact	gggctgcaag	3780
gctgagga	ttgtgtccgt	gtcagaaagc	tcctcagctc	agaggtgctg	gtacctcctg	3840
cgtggtagga	aggcaggggg	aagaggccct	gcttctcctg	ttctctttgc	ccttatgaga	3900
cttgagagtc	tgtgtcatct	gtgccttgca	tgtctttttt	tcagactccc	tgcgacaagg	3960
actgtgtact	gcatgaatga	ggctgagata	tgtgatgttg	ctctgggaat	cctgattgag	4020
gtaaagtcag	acaagcctct	tactcatgac	cagaaactct	gcatgggcag	aagctagacc	4080
cttggtcacc	gtcagtaaga	gagacgccct	ctgccgtagg	ctacctcttc	ttcctcctgc	4140
cacttccctt	gctcttatct	cggccatgct	gccaggccct	ctccccatgt	gggtgtgcgc	4200
tcgtgggggtg	tctttgaggc	tagaagcctg	ggagggcctg	cgtgtgttag	ggagggcgtg	4260
tgtgtgttag	ggagagcgtg	actgtgcact	ggtgtgtatg	tggatgggac	atgaagcgtt	4320
tacctgtttg	tgttcttggg	aaggttccca	gttgggtaga	tgacttttta	gccattgccc	4380
ctctccttag	cagaggatgc	tgagcttccct	agcttccctg	agtaataatt	gcagtgccct	4440
agagttgcac	agcatttctac	agtttaccag	gtgccttgaa	agcatgcgtt	atgtcatttt	4500
agccttgcaa	taaccctgtg	gtgtgggact	tttcctagt	ctaaggcatg	ggcccacacc	4560
caggttttgt	atcctgggtt	ctgtcaccgg	cctttctaga	catgtttctt	ccattttctt	4620
ttcctttccc	ctcagcta	cctcatgcct	ttgcttgctt	ctctcccag	tgggttctgg	4680
tttcttcaag	agctgtgaag	agggggctcag	gggaaggagt	ggggtgaaga	gagggtgggt	4740
gctcaggata	tgggtacatt	gcctggcctg	gtcacattgg	ctttgtagtt	gcttctagat	4800
acatcctgtg	ttactgacag	atcagcatgt	tagggaaata	aaacacgtat	gttgagcctg	4860
cgttttccc	tactccacag	agccgcaaac	aggaaaaggc	ctgcgagcag	ccggccctgg	4920
cgggggctga	taaccacag	cactcccctc	cctgctccgt	gtcgcctcac	acaagttctg	4980
ggagcagcag	tgaggaagag	gacagtggga	aacaggcact	ggctccaggc	ctcagccctt	5040
cccagaggcc	gggggggttcc	agctctgcct	gtagcaggag	ccctgaggag	gaggaggaag	5100
aggatgtgct	gaaatacgtc	cgggagatct	ttttcagcta	gggcataaac	tgtgactga	5160
actgtctgcc	gagagcagct	ggaggacagc	tgagcttcca	ctggtgctgc	tgggcccggc	5220
gcctgtggga	atggggctct	ctgtgctcct	acctttgtgc	cttcttgggc	ctggcagatt	5280
cacctcaggc	cagaagcccc	tggacactcc	gggccttggg	gctgccgttc	tgagtgtgcg	5340
gaaggcagga	ctcaaatga	gatcccattt	gactccctct	gtatgtactg	tgccctctcc	5400
tggctcttga	ggctctggag	tcccaattgt	ctgtgttagt	cagtgaccag	gttccaggga	5460
aaatgatgtc	atgtgggtgg	ccaacttact	ggaaccaaag	agacagtact	atgcaaagaa	5520
aaggatcact	gccagggtgca	ctggaattgc	tacagttagt	tccgcatgat	ctctcctgaa	5580
ggaggaagcc	tgtttcaaaa	atagtttcca	tcagtgtct	atcaatgagc	tcccacctct	5640
ccagccagcc	tagaaagcaa	acgagctgcc	cacagttctc	tgccctgtct	gggagggtga	5700
ggccacagtg	tatagactgg	taagccagac	aggcctcctc	ccgcaagctg	ctaccttgct	5760
ttcacctgta	ccttgggtctc	cgggcagcta	gctataaagc	aagagggaca	ggagcccaga	5820
agagacactg	aggacaagag	atcacaccag	agtacatgtc	tctgcctctg	ttttcagtgt	5880
ggctttggac	aggaatatat	gaataaatca	ctgccataca	ggttttccaa	tacacaagtg	5940
ctagaaaaata	cacacaattc	cccaatgcgt	aagttgtgct	aatgtctttc	caagttctgg	6000
gttgggaagt	ggaggggtgg	agcgtttgtt	tgtgcgcaac	cgtccagtc	tgttcacagc	6060
gaggattttg	agtcctccag	ggtctcatca	tgggagtgat	ttgtcagcgg	acgcctctgc	6120
cctgtctggc	ttcaggtcca	gggaagcttt	gaagcagtea	agccttgtct	ttgtacccca	6180
tgtgtcctgt	ctttgttgag	tcactcagag	atcactcctg	gacctctggg	gttggagttc	6240
cagtgtatggc	ttatggcggc	ccactcacta	tgggtgggctg	agtggagct	ccttaaccat	6300
gtccccagag	acactgaggt	gctcgtctct	ttaatgtcct	cgtttgttgc	cgtaagttct	6360
ttgtcaggtt	tcattttggc	atttggcaaa	tcagcctgga	agtctggccc	catgacagca	6420
atcactccct	ccccaccctc	ctgaagctag	agggaagattt	gctcagatcc	attaattaaa	6480
gcaggaattg	gtgtgacaat	gagctgcatg	gtttaggagg	tctttgggag	ccttgggaagt	6540
cctgaaggac	agacaatctt	gtactaagaa	gtcacagggtg	ccctggctgc	ccttgctgcc	6600
cctcggcctc	tttgacacag	gggccccacc	tctctgttag	tgggttccat	cgctggagct	6660
ggagatcagc	gttagctgta	aatgagatg	gctgagcaga	tgtgccacct	ctgacctagg	6720
ttggaaactga	acccttgcaa	tcacgtaagc	cttttagcagc	tctcaagctt	gctctcagcc	6780
ctctcagccc	tcagagggaa	cacagccatg	gctataagca	agaggatgag	taaggcctgg	6840



191

gcgctgcccc	gagctagaaa	cccaggcccc	gggagggaga	gcctgaccca	cttccacaca	6900
taggagagga	agaggccag	gccgcctgcc	agcagcacag	aggacacagc	caggaagccc	6960
actgccagcc	gccacactct	ctcatcactg	ttgcactggg	ctaggaggag	aggctggggg	7020
gcaaagaggg	tgaggaccag	ggacccgtac	acgccaagcc	tggccaggcc	caggccaacc	7080
cgaggcacc	ccagggtctc	cagctcaggg	aactgggtgac	actgtagggt	gctgggtgcc	7140
tcattccaca	ggcagaagtt	atagaagccg	attctcaggt	tgggcagggtc	agtgagggtg	7200
ccagcctccc	agagaagagc	gtataacatc	aggcagatga	ccacaatcac	gaggactatg	7260
atgctcatga	acagcagctg	gtcgcgccac	cgagaccttg	ggccggccat	ctctactgcc	7320
ctctgcccgg	ggac					7334

&lt;210&gt; 283

&lt;211&gt; 5071

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 283

agctcatgtt	ctcccttttg	catttctttac	aaactcatgg	caagtttccc	tcctaccctg	60
ccctccacca	aggaccagaa	gtctgaggta	acctcctgcc	aggacctatt	tgcaaataag	120
tcattgtgga	ccctctgatt	tgaggtcagg	aggaaaagtc	tctcccaagc	agctttgaaa	180
gtgtgaaaca	tcttaaaactg	agtgaagtgc	tcttttagcca	aaggctttgc	tccagtccaa	240
atacaacaag	ccattggaaa	cattagttag	gggattttctc	agatcttttt	tgaagggtggg	300
ttttgactga	ggtgaagggc	aaggcccacc	cttaattggag	acctgaagggt	ggaggaagct	360
attgggttttc	accacagctg	ccaagacaac	cacctggggga	gctgtaagaa	ctaccatttg	420
ctggggccaca	gatcaatcag	agctcaactt	atgtgcttcg	ggctggggcac	tgggtgtgtt	480
ctgaagctct	gaagctcatt	cgaagggtgag	cctgggtcaa	ggaccactga	cacacccact	540
ctgatttttac	ctgcagtgtc	ctgggaactc	attactgggt	caagacaaga	tgtcacctgg	600
tgatgaaatc	ccatcatata	ctcattactt	taaaaactaa	tacataatct	ttcctgacaa	660
tggtagtatg	aattatagaa	aacttagacg	tttttggttg	tttggttgtt	tttgagatgg	720
agcctcactc	tgtcaccag	gctggagtgc	agtgggtcga	tcttggtcca	ctgcaatctc	780
tgctcccg	ggtcaagcaa	gtctcctgcc	tcagcctccc	gagtagctgg	gactacaggg	840
accgcccacc	atgcctgggt	aattttttgta	tttttggtag	agatgggttt	caccatgttg	900
gccaggcttg	tcttgattga	actcctgacc	tcaaatgac	caccacacct	ggcctcccaa	960
agtgtctggga	cttaactggc	gagccaccat	gcttggccag	aagataatct	aaaaataata	1020
ataaaaaaga	taacctttta	tccatcata	cacataaaac	cactgttaat	attctacca	1080
tattttcttc	ctgtactgat	gtatttttac	ataatcatga	tgttgaatgt	aatgtttttt	1140
cactagatgt	agtaaacatt	tttcaaagct	gttaaataat	cttcaaaaac	atgatcaatg	1200
gctgtgcaat	agttcatgtg	ggatcatcca	ttacactatt	actagacaaa	ttgtttccac	1260
ttttcaccat	tataagtga	gacgtgtgt	gaatcgtgtt	tggaaatctga	tttttctcag	1320
tgatctatcc	tataagtga	atcattggat	caagggtaga	aatatctttt	agtgatcttg	1380
ctaaataact	cctaactggc	ctacagaaaa	tttgcataat	atagtccctc	taattgtata	1440
taaaagtggc	cactttgtta	tactctttta	aaaaattctt	ttcactccgt	tttaaatcag	1500
aagggtcttg	tccagttggt	ctctgaaaca	gtgggtctga	cactgtattt	tacatatgtg	1560
tattttccag	tatgggataa	gtttcggtcg	atatgggttg	gctgtgtccc	tacccaaatc	1620
tcattcttgaa	ttatagctcc	cataatcccc	acattgtggg	agggacccag	tgggagggtaa	1680
ttggatcatg	ggggtgggtt	tcccccatc	tgtactcatg	gtagtgaagc	tcatgatatc	1740
tgtggtttt	ataaagggca	tttcccctgc	acatgttctc	ttgcctgctg	ccatgtaaga	1800
tgtgcttttg	ctcttccctt	gcctttccac	atgattgtga	ggcctcccta	accatgtgga	1860
actatgagtc	cattaaacct	ctttttcttt	tcaaatctct	gggtatctct	tcatagcagt	1920
atgaaaatgg	actaatata	cagcattcac	caggaaagtg	ctaggaacac	agagcttcaa	1980
gctttgtgag	gcacaaggta	ctggggccat	gataccaaat	ggcctcctgg	aagccccagc	2040
agggagtccc	agggtggtgt	cagcagcaaa	atgagtcgtg	gccctgggaa	gggacctgaa	2100
ggctacacag	ccctgatgat	cagttttctga	ggggacccct	ctgggggaac	agctccctcc	2160
tctttccag	agctgactgg	aaggtctgtc	tcattctaca	cactgcattt	gttacagaaa	2220
gggaccaagt	ggggaaaata	aagaacatgg	aacaggctga	gagagagggc	agctccattc	2280
aaaggacctg	ggtgtatgcc	aaaaatgaga	atgaagattg	accagcgact	tctttggcag	2340
agacctgggc	aggctggctg	atggagagct	ggggcctgtg	aatacagtaa	gggtgggggtc	2400
cacactgcca	ccgcctcccc	tcagatgccg	cttctctgga	ctcagcagca	ctgggcagtc	2460
tgcccagttc	tgcccgtggc	ttctgtctcca	gagaagccca	gtggggacag	tcagagtggg	2520
ggagtggagg	gctgtccag	cagaagccct	ggctgtctgc	ttgggtggca	ctgtcaaagg	2580
ctctggagggt	cccagagggc	caagggtctg	aagactcggg	tttgaatgta	gttgagagat	2640

192

tcttggagca	atgatgcttg	ttacggaagg	aattattggg	aattgaaaag	gtggcattag	2700
tctgggatga	taaggagttt	taaccatttg	agtccatggt	atgggaaaaa	ttgccgacgg	2760
gaacataattt	tgtatgggtt	tgtttattta	gtaaaatgtt	gtaaaagcct	atatctgtgc	2820
ttttaatggg	tttgggtatt	ttagggtgtg	gaatagattt	ccaggacttc	cctgatattat	2880
accatcatgc	tgtggaagag	aagggttgac	ctcctccatt	gttcaggacc	aactgggaag	2940
ggacttgggg	atgcctttgt	ttaaacactc	cctctcactt	ttcccatttg	aattctgtta	3000
cactgggggtt	ccaaaaaaaa	ttattaaacg	ttttgctttg	aaaacagctg	cctttttaaa	3060
aattaatgtg	gtcctcggg	gagattgcat	cagccacctt	gcggcagctc	ctgccagacg	3120
ccaggagcct	ttgttttgac	ttcctcattt	tctctcaact	gaccttttaa	tgtagagcaa	3180
aacaaaacga	gccaaagaagc	ccaggaccag	gcattgtggag	aagggtggtg	cctctcacct	3240
ttttatattc	agtcccagct	cttatgaggc	tcgccatcat	ctggtgcgac	ttggaacttg	3300
aacttgggaat	tctctggtga	ggcccagctt	cccctcttgc	cttgtgcagt	ccagcacctg	3360
ctcagctgct	caggctgtgt	atgaatacat	tccactctgc	ccatcctcag	ccacccccc	3420
gctcctagag	tcctactcta	ctttctgctt	ctctaaatct	gatccatgca	gcaagagcat	3480
tcctgggctc	cttcagccca	cactctgggt	tagctataaa	ttaggattta	ttctccactc	3540
tagtgtcatg	tctctgagga	acagtcctta	gttttggtat	tttgatacac	agtaggggct	3600
cttttttttg	tttttttttt	ttaaatgagc	gaatgaaaat	gctacatagg	ctccctgagt	3660
tctttcatgt	acgaatcctg	gttacacatc	ttaggacagc	agagctgcct	gagggagggt	3720
tgtgtttaat	gtcgtatgca	tgtcagcac	agtgtggca	tggcccatcc	atgctttctg	3780
ttgaactctg	gacagaattc	aggaacttgt	gtatggagag	ggtggaagtc	agtcctcgct	3840
tccttcctta	aacattttgc	agtgcagaca	tatggatcct	gggttggaaa	ccccatgaca	3900
ctcttctcta	cttcccatg	ggccttccct	ggtttttggt	tttcttttct	taaacaatcc	3960
tggtaatgac	acttccacca	caatgagctt	ttaaatgtcc	tttaatgata	agccagtgtt	4020
tccttcagag	ggcaaagggg	agactgctga	gtcactgtgg	ccatttttag	ataaaccttt	4080
tcctgtttat	aataacacat	gctgattgta	ggaaactaga	aaatacatga	aagtgcagag	4140
aaaagactaa	aagtcatcta	tacttcagggt	cgtagaaata	accactctga	acagcacact	4200
tcctttttaca	ctattgtttt	acactgttgg	gattacataa	atatatatgt	ttgtatccca	4260
ctttgtgaac	atcattctat	gtgaactaga	aatggttcct	aaacatttaag	ggctgcatat	4320
agctgtatca	tagtttatag	tttatacata	gatgctttgt	aacattattt	tataatgcta	4380
tgaatgctat	gggtgaatatt	tttgtgaatc	aacttatgtt	tccaccagca	gtttcagaga	4440
gtgcctgtct	catcccatcc	tcccagctat	tgcataattc	tgagtctttt	attctttgat	4500
aatgacaaat	gatgaatcat	tgatagtttt	tcttcataat	aagtaaagtt	taacattttc	4560
aagtgtttgt	tgacctctg	tatttcttct	tttgtgaagt	gctgtcagtt	cttttgcctat	4620
tttaaaaaata	attttgagtt	tcagtttttg	tttgttggtc	tgtatgaacc	ctttaaaaat	4680
aaaggctggt	agccttttgc	catcttagtt	gtgcagtaaa	agtataatgc	tttgcctcac	4740
taggtcctct	ggaacaagat	gcagatttag	attccaggtc	agcatgtaac	ttgaccactg	4800
tcactcaaga	gttacagcct	gagcagggcc	ttaggaggga	gatgatttct	gcttaagggc	4860
gatacaaaatt	cctagtttag	gaaatagaag	gaaagtattc	tcaggagatt	aatttaaggc	4920
agcttttttg	ttggtttaag	cacctctaac	attttcatac	taataaggga	gaatgggatg	4980
gcggctgaaa	gagacacaaa	tattgtatca	tttaattcta	aattatgtat	ttgtcagggt	5040
cttattgaaa	gagtaaaattt	tcgaaaggat	c			5071

&lt;210&gt; 284

&lt;211&gt; 512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 284

ttttttccag	acaaaatacc	acgtcacac	cacacatacc	acaagacaaa	gaacaggtaa	60
agagggcaca	cacactttta	ccgtttatac	caaaccacaa	tcacgaaatt	caaaatccga	120
gtacacaaaa	attcaagcca	agtcaaaacc	aaaaccacaa	tatccagcaa	ttcaagtcaa	180
gtcaaaaacca	gaacaagagt	gccatgcag	gcattgctgtg	gggtgacagg	ccacgtttcc	240
actcagatgg	agtggggcaa	gttccaaaga	ctagtcttac	caagtcaagc	caagtcaaaa	300
ccagaacaaa	agtgcacata	caggcacacc	gtgggtgac	aggccacgct	tccactcacg	360
tgagtgggg	caagttccaa	agactagctc	taccaagtca	agccaagtca	aaaccagaac	420
aaagatgtca	atacaggcac	accgtgggtg	atcaggccat	gcttccactc	acatggagtg	480
gggcaagttc	caaaaactag	tcttgacaag	ct			512

&lt;210&gt; 285

&lt;211&gt; 5072

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 285

agctcatgtt	ctccctttgg	catttcttac	aaactcatgg	caagtttccc	tcctaccctg	60
ccctccacca	aggaccagaa	gtctgaggta	acctcctgcc	aggacctatt	tgcaaataag	120
tcattagctg	ccctctgatt	tgaggtcagg	aggaaaagtc	tctcccaagc	agctttgaaa	180
gtgtgaaaca	tcttaaaactg	agtgaagtgc	tcttttagcca	aaggctttgc	tccagtccaa	240
atacaacaag	ccattggaaa	cattagttag	gggatttctc	agatcttttt	tgaaggtggg	300
ttttgactga	ggtgaagggc	aaggcccacc	cttaatggag	acctgaagggt	ggaggaagct	360
attgggttttc	accacagctg	ccaagacaac	cacctgggga	gctgtaagaa	ctaccatttg	420
ctggggccaca	gatcaatcag	agctcaactt	atgtgcttcg	ggctgggcac	tgggtgtgtt	480
ctgaagctct	gaagctcatt	cgaaggtag	cctgggtcaa	ggaccactga	cacaccact	540
ctgatttttac	ctgcagtgc	ctgggaactc	attactgggt	caagacaaga	tgtcacctgg	600
tgatgaaatc	ccatcatata	ctcattactt	taaaaactaa	tacatatatt	ttcctgacaa	660
tggtagtatg	aattatagaa	aacttagacg	ttttgtttg	ttgtttgtt	tttgagatgg	720
agcctcactc	tgtcacccag	gctggagtgc	agtggtagca	tcttggtcca	ctgcaatctc	780
tgctcccg	ggtcaagcaa	gtctcctgcc	tcagcctccc	gagttagctg	gactacaggg	840
accgcgccacc	atgcctggct	aatttttcta	tttttggtag	agatgggttt	caccatgttg	900
gccagggttg	tcttgattga	actcctgacc	cctaaatgatc	caccacactt	ggcctcccaa	960
agtgtctggga	ttacaggcat	gagccaccat	gcctggccag	aagatatatt	aaaaataata	1020
ataaaaaaga	taacctttta	tcccatcata	cacataaaac	cactgttaat	attctaccaa	1080
tattttcttc	ctgtactgat	gtatttttac	ataatcatga	tgttgatgt	aatgtttttt	1140
cactagatatt	agttaacatt	tttcaaagct	gttaaatatt	cttcaaaaac	atgatcaatg	1200
gctgtgcaat	agttcatgtg	ggatcatcca	ttacactatt	actagacaaa	ttgtttccac	1260
ttttcaccat	tataagtga	gacgctgtgt	gaatcgtgtt	tggaaatctga	tttttctcag	1320
gtgatctacc	tataagtga	atcattggat	caagggtaga	aatatctttt	agtgatcttg	1380
ctaaatactg	cctaactggc	ctacagaaaa	tttgctaate	atagtccctc	taattgtata	1440
taaaagtgcc	cactttgtta	tactctttta	aaaaattctt	ttcactccgt	tttaaatcag	1500
aagggtcttg	tccagtgtgt	ctctgaaaca	gtggctctga	cactgtattt	tacatatgtg	1560
tattttccag	tatgggataa	ggttcggctg	atatgggttg	gctgtgtccc	tacccaaatc	1620
tcactctgaa	ttatagctcc	cataatcccc	acattgtggg	agggaccag	tgggaggtaa	1680
ttggatcatg	ggggtgggtt	tccccatcac	tgtactcatg	gtagtgaagc	tcattgatatc	1740
tgatgtgttt	ataaaggcca	tttccctgc	acatgttctc	ttgcctgctg	ccatgttaaga	1800
tgtgtctttg	ctcttctctt	gcctttcacc	atgattgtga	ggcctcccta	accatgtgga	1860
actatgagtc	cattaaacct	ctttttcttt	tcaaattact	gggtatctct	tcatagcagt	1920
atgaaaatgg	actaatataa	cagcattcac	caggaaagta	ctaggaacac	agagcttcaa	1980
gctttgtgag	gcacaaggta	ctggggccat	gataccaaat	ggcctcctgg	aagccccagc	2040
agggagtccc	agggtgtgtt	cagcagcaaa	atgagtcgtg	gccctgggaa	gggacctgaa	2100
ggctacacag	ccctgatgat	cagtttctga	ggggaccctc	ctgggggaac	agctccctcc	2160
tctttccag	agctgactgg	aaggctgtgc	tcattctaca	cactgcattt	gttacagaaa	2220
gggaccaagt	ggggaaaata	aagaacatgg	aacaggctga	gagagagggc	agctccattc	2280
aaaggacct	ggtgtatgcc	aaaaatgaga	atgaagattg	accagcgact	tctttggcag	2340
agacctgggc	aggctggctg	atggagagct	ggggcctgtg	aatacagtaa	gggtggggtc	2400
cacactgcca	ccgcctcccc	tcagatgccg	cttctctgga	ctcagcagca	ctgggcagtc	2460
tgcccagttc	tgcccgtggc	ttctgtctca	gagaagccca	gtggggacag	tcagagtgga	2520
ggagtgaagg	gctgtcccag	cagaagccct	ggctgtgtgc	ttgggtggca	ctgtcaaagg	2580
ctctggaggt	cccagagggc	caagggtctg	aagactcggg	tttgaatgta	gttgagagat	2640
tcttgagca	atgatgcttg	ttacggaagg	aattattggg	aattgaaaag	gtggcattag	2700
tctgggatga	taaggagttt	taaccatttg	agtccatggg	atgggaaaaa	ttgccgacgg	2760
gaacataatt	tgtatggttt	tgcttattta	gtaaatgttt	gtaaaagcct	atatctgtgc	2820
ttttaatggg	tttgggtatt	ttaggtgtg	gaatagattt	ccaggacttc	cctgatttat	2880
accatcatgc	tgtggaaaag	aaggtttgac	ctctccatt	gttcaggacc	aactgggaag	2940
ggacttgggg	atgcctttgt	ttaaacactc	ctctcactt	ttcccatttg	aattctgtta	3000
cactgggggt	ccaaaaaaaa	ttattaaacg	ttttgctttg	aaaacagctg	cctttttaaa	3060
aattaatgtg	gctcctcggg	gagattgcat	cagccacctt	gcggcagctc	ctgccagacg	3120
ccaggagcct	ttgttttgac	ttctcatttt	tctctcaact	gaccttttaa	tgtagagcaa	3180
aacaaaacga	gccaagaagc	ccaggaccag	gcattgtggag	aagggtgggtg	cctctcacct	3240
ttttatatte	agtcccagct	cttatgaggc	tcgccatcat	ctggtgcgac	ttggaacttg	3300
aacttggaat	tctctggtga	ggcccagctt	cccctcttgc	cttgtgcagt	ccagcacctg	3360

194

ctcagctgct	caggctgtgt	atgaatacat	tcccatctgc	ccatcctcag	ccacccccca	3420
gctcctagag	tcctactcta	ctttctgctt	ctctaaatct	gatccatgca	gcaagagcat	3480
tcctgggctc	cttcagccca	cactctgggt	tagctataaa	ttaggattta	ttctccactc	3540
tagtgtcatg	tctctgagga	acagtcttca	gtttgtttat	tttgatacac	agtaggggct	3600
cttttttttg	tttttttttt	tttaaagtag	cgaatgaaaa	tgctacatag	gctccctgag	3660
ttctttcatg	tacgaatcct	ggttacacat	cttaggacag	cagagctgcc	tgagggaggg	3720
ttgtgtttaa	tgctgtatgc	atgctcagca	cagtgtctggc	atggcccatc	catgctttct	3780
gttgaaactat	ggacagaatt	caggaacttg	tgtatggaga	gggtggaagt	cagtcctcgc	3840
ttctttccct	aaacattttg	cagtgcacgc	atatggatct	ttgggttgaa	accccatgac	3900
actcttctct	acttccccat	gggccttccc	tggtttttgt	ttttcttttc	ttaaacaatc	3960
ctggtaatga	cacttccacc	acaatgagct	tttaaagtgc	ctttaatgat	aagccagtgt	4020
ttccttcaga	gggcaaaggg	gagactgctg	agtcactgtg	gccattttta	gataaacctt	4080
ttcctgttta	taataacaca	tgctgattgt	aggaaactag	aaaatacatg	aaagtgcaga	4140
gaaaagacta	aaagtcactc	atacttcagg	tcgtagaaat	aaccactctg	aacagcacac	4200
ttctttttac	actattgttt	tacactgttg	ggattacata	aatatatatg	tttgtatccc	4260
actttgtgaa	catcattcta	tgtgaactag	aaatggttcc	taaacattaa	gggctgcata	4320
tagctgtatc	atagtttata	gtttatacat	agatgctttg	taacattatt	ttataatgct	4380
atgaatgcta	tggtgaatat	ttttgtgaat	caacttatgt	ttccaccagc	agtttcagag	4440
agtgcctgtc	tcatcccac	ctccccagta	ttgcatattc	ttgagtcttt	tattctttga	4500
taactgacaa	tgatgaatca	ttgatagttt	ttcttcataa	taagtaaagt	ttaacatttt	4560
caagtgtttg	ttgaccatct	gtatttcttc	ttttgtgaag	tgctgtcagt	tcttttgcta	4620
ttttaaaaa	aattttgagt	ttcagttttt	gtttgttggt	ctgtatgaac	cctttaaaaa	4680
taaaggctgt	tagccttttg	ccatcttagt	tgtgcacagta	aagtataatg	ctttgctgca	4740
ctaggtcctc	tggaacaaga	tgcagattta	gattccaggt	cagcatgtaa	cttgaccact	4800
gtcactcaag	agttacagcc	tgagcagggc	cttaggaggg	agatgatttc	tgcttaaagg	4860
cgatacaaat	tcctagttag	ggaaatagaa	ggaaagtatt	ctcaggagat	taatttaagg	4920
cagctttttt	gttggtttta	gcacctctaa	cattttcata	ctaataaggg	agaatgggat	4980
ggcggctgaa	agagacacaa	atattgtatc	atttaattct	aaattatgta	tttgtcaggt	5040
tcttattgaa	agagtaaatt	ttcgaaagga	tc			5072

&lt;210&gt; 286

&lt;211&gt; 512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 286

ttttttccag	acaaaatacc	acgctcacac	cacacatacc	acaagacaaa	gaacaggtaa	60
agagggcaca	cacactttta	ccgttttatac	caaaccacaaa	tcacgaaatt	caaaaatccga	120
gtaccaaaaa	attcaagcca	agtcaaaacc	aaaaccacaa	tatccagcaa	ttcaagtcaa	180
gtcaaaaacca	gaacaagagt	gcccattgcag	gcagtctgtg	ggatgatcagg	ccacgtttcc	240
actcagatgg	agtgggggcaa	gttccaaaga	ctagtcttac	caagtcaagc	caagtcaaaa	300
ccagaacaaa	agtgccaata	caggcacacc	gtgggtgatc	aggccacgct	tccactcacg	360
tgagtgggg	caagttccaa	agactagtct	taccaagtca	agccaagtca	aaaccagaac	420
aaagatgtca	atacaggcac	accgtgggtg	atcaggccat	gcttccactc	acatggagtg	480
gggcaagttc	caaagactag	tcttgacaag	ct			512

&lt;210&gt; 287

&lt;211&gt; 6717

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 287

cagagcccct	gggtgtgaga	agctcgtctc	ccgtgggttg	cattggctct	gccctatctc	60
tgctccagc	accaggggcg	gccgcagatg	gcagtgtctc	tggggacagc	agctgcgaat	120
gagtcacgg	gccaatgctg	agctgctcag	gctgaggcgg	tgtgctcagc	acagagcccc	180
cggaactggc	atctgcaggg	cgtgaggtgg	gtctttgggc	acacggaggg	caccgagtg	240
tgccaatggc	ttgggaggtg	gggagagggg	ctctgcaaac	tcacactgtc	tcaggcagca	300
cattggctga	aatgaggctg	gaaaattcca	tatagatcat	ctggtaaccc	catccccacc	360
ctgtcacctg	gcacagggga	ccgtgaggcc	cagagagggg	gaagaagggg	ccaagataac	420
acaggaggcc	agtgagtgtg	ttgcttttcc	acctagggtca	gttccctgag	aatcaggaa	480

gagaccacgg	ggctcctcagt	cagcctcaga	atgcctggga	ttttgtgcac	agggctggag	540
aggttggggg	accttgatct	ctattccaca	ccccccagca	ttgcagctga	aatggcttct	600
gttctgcccc	agccctccat	tcgcatgttt	aagctggaag	gaaactgggg	gcctggctgg	660
gcctggatag	ggggcatgag	tcaccttgga	cacagttaag	tcacacaggg	agcagcctcc	720
ctgcctgagg	tgctccttcc	ctaccttcac	caaccctggc	agcaccagac	aatcctgcac	780
tctctccagc	tccccagaaa	ggcagctggg	taaaagggtg	tgggtcctac	acgctcccc	840
gcctggctg	cactagtcac	tttgataaat	cagtgcactc	ttcattttat	tccttcacaa	900
ataggggact	ttaatacaat	gtcgggtgct	cagaacagcc	agtgaggacc	tttggggtag	960
gagaggggct	ccggatggat	gcaggaccag	gaaacagcat	ctttccctcc	cctggggcca	1020
cagcttccct	cacaggccca	cctgggagta	gagagacaag	aggagctgga	gtttggagac	1080
ggaggtcaga	agagtggagg	cttctctccg	acctacctgg	agttctttcc	atccatcccc	1140
ctgctttcct	ccccagaagc	aagggtggga	tctgctcatt	tcacctgctc	caggtgcctt	1200
tccctccctt	ggaggacgca	agcctcaggg	catcgctggg	gtttggcgct	tagctctgcc	1260
actttccagt	tgggtaagcc	aaggcaagtt	agtgagcctg	tctgggcctc	agtttcttca	1320
tctgtaaaat	gtggatagtg	acacttgccc	cataggcctg	ttgtgaagtt	tgtggaggaa	1380
gtcaaaacag	tgctctacct	gccgggcagg	cagaggtggg	ctcctcacgt	cacccttttc	1440
ttataactag	ggaaggttgg	gggtgggttc	aataggccct	gcacatcctc	gtccctggag	1500
gagatgatct	gtgatctgtg	atctgttttt	tttttttttt	tttttttttt	tttgagatgg	1560
agtctcgctc	tgttgcccag	gctggagtgc	agtggcgccg	tctcggtcca	ctgcaagctc	1620
tgcctccggg	gttcacgcca	ttctcctgcc	tcagctcccc	aagtagctgg	gactacaggc	1680
acctgccacc	acgcctggct	aattttttgt	atttttaata	gagacggggg	ttcaccgtgt	1740
tagccaggat	ggtcttgatc	tcctgatcaa	gtctcaaaaa	aaaaaaaaaa	tagagaatgg	1800
taacaagtac	ccagggtgata	gagcttttgt	gtctgctgaa	tgagttaatt	tatgtaaaat	1860
attcagaacc	agtgcctggc	acataacaag	tgtacatag	taagtttgtt	cttattctct	1920
gagcctcagt	ttccttatct	gtaaaatggg	gataggaata	gcacccacgt	cctaagggtta	1980
ctttgaattt	tttttttttt	tttttttttt	agatggagtc	ttgctctgtc	acccaggctg	2040
gagtgcagtg	gcaccatctc	ggctcactgc	aaactccgcc	tcacaggctc	aagcgatttt	2100
cctggctcag	cctgttgagt	agctgggatt	acaggtgcct	gccaccaccc	ctggcttaatt	2160
tttgactctt	tagaagagac	gggggtttct	catgttggcc	aggctggtct	tgaactcctg	2220
gcctcaagtg	atccactgcc	ttggcctccc	aaaatgctgg	aattacaggg	gtgaccaccc	2280
acagccagac	agtgatctgg	cttttgaaat	atgagtagga	atgtgccaag	tgaacaagaa	2340
tgcataatgca	aaatgaaagc	atatgcaaag	atgaggactg	cataatgtgc	aggcgcatgt	2400
aggtgacgga	caggcagttc	catgtgaccc	cacatagtgt	gccatgtgag	gagggggagg	2460
ttggcaggga	gcagatgggc	acctttgggc	cattctaaag	agtctgggtg	ggccgagcac	2520
ggtggctcat	gcctgtaatc	ccagcacttt	gggagtcgga	ggttaggatc	acttgaggct	2580
aggagtttga	gaccagcctg	gccaaacatg	caaaaccccg	tctctactaa	aaaatacaaa	2640
aactacctgg	gcatgggtggc	agatgcctgt	aatcccagct	actcacaagg	gaggctgagg	2700
caggagaatc	gcttgaaggt	ggagcttgcc	gtgagccgag	atcatgccat	tgcactccag	2760
cctgggcaac	agaatgagac	tctgtctcaa	aaacaaaaac	aataaaaaag	agtctgggtg	2820
tatataaggt	ttgtgacgca	ccttacacct	gctaccttcc	actttcctgc	cttctccgcc	2880
tctcgctcag	tggaaataac	aatagctgat	attgaccaag	tgtgattctc	gtgccaggca	2940
gaatgggtgca	aaatgctttt	ttattttta	tttttttttt	ttgagacaga	gtttcactct	3000
tgttgcccag	gctggagtgc	agtggcacag	tcgtggctca	ctggaaactc	acctcctggg	3060
ttcaagcaac	tctcctgcct	cagcctgccg	agtagttggg	attacaagca	tgtgccacca	3120
cacctggcta	attttgtact	tttagtagag	acagggtttc	accatgttgg	tcaggctggg	3180
cttgaattcc	tgacctcagg	tgacccatcc	tccttggcct	cccaaagtgc	tgggatcata	3240
ggcatgagcc	attggcctgg	ttgcaaaatg	ctcttttaggc	attgtcttgt	taaaactgca	3300
aagtaccag	gctgcatgca	gtggctcacg	cctgtaatcc	cagcactttg	ggaggccgag	3360
gtggggcggt	cacgaggtca	ggagatcaag	accatcctgg	ctaaccagg	gaaacccggt	3420
ctctactaaa	aatacaaaaa	attagctggg	tgcagtggcg	gtcacctgca	gtcccagcta	3480
ctcaggaggg	tgaggcagga	gaatgggtgt	aacctgggag	gcggagcttg	cagtgagccg	3540
agatggcgcc	actgcattcc	agcctgggtg	acagagcaag	actccgtctc	aaaaaaaaaa	3600
aaaaaaaaaa	ttcaaagtac	ccttaggacg	tgggtgctat	ttctatcccc	attttacaga	3660
taaggaaact	gaggetcaga	gaataagaac	aaacttacta	tgtagcactt	gttatgtgcc	3720
aggcactggt	tctgaatatt	ttacataaat	taactcattc	agcagacaca	aaagctctat	3780
cacctgggta	cttggttacc	ttcccttttt	tttttttttt	agactggatc	ttgctccagg	3840
ctggagtgc	gtggcgggat	cacagctcac	tgcagcctcc	atctcccaga	cttaggtgat	3900
ccttccacct	cagcctcccc	ggtaactggg	attacaggta	tgtgccacca	tgcccagcta	3960
attttttgag	tttttagtag	agacgggggt	ttgccatgtt	gcccaggctg	gtctcgaagt	4020
cctgggctca	agcaatccac	ccgctttggc	ctcccaaaat	gcttggatta	caggcatgag	4080

196

ccaccacgctc	cagccccatt	cccatTTTTat	agatgtagaa	accaaaggctc	tgaatatctt	4140
gccaagtgt	tttgggtgcta	ggggccttgt	ccttacaact	atgaaactgg	gcttgtgtag	4200
actccattga	tatcaaccag	gtctccttca	atgggtgttt	gttcaactaca	ctttcaccag	4260
gccacacttg	gctagggcgt	gcagggtggct	gggagacctc	ctcatctcag	gggcagggtgc	4320
tggcaactgg	cagccatggc	agctgcagtc	agggctgggc	cccggggctc	aggggcacaa	4380
ggagaccaga	ggaggcatcg	cccaacctgt	cctttaccga	gtgccctgca	caggcccat	4440
ccagggatca	gtcaccaccac	tgaatcctca	ctaggaccag	tgtagagggtg	ttgccccctt	4500
ccccttccat	aggggaggaa	gctgaggccc	tgcgagggtta	ggcaacttgc	ccaagggcac	4560
acatcctggc	aagagactga	accagaactg	ctcatgggtta	agtcgctctg	ttgcccaggc	4620
tggagcacag	tggcgcgac	ttggctcact	gcaacctcca	cctcccagggt	tcaaacgatt	4680
ctcctgtctc	aagtagctag	gattacaggt	gcgtgccatc	atgcccggt	aatttttcta	4740
tttttagtag	agatgggggt	tcaccatatt	ggccaggctg	gtcttgaact	cctgacctca	4800
ggtgatctgc	ccacctcggc	cctccaaagt	gctgggatta	cagggtgtgag	ccactgtgcc	4860
cagcctaaga	ctccttaaag	ggtgaatagg	agctgggtgt	ccccatggcg	tggggatagc	4920
tctgtgcttg	cccacgaggc	ctgggcggct	gagtcaccac	gtggctcttt	tttttttttt	4980
tttttttttt	tttctgaga	cggagtatcg	ctctgtcacc	caggctggag	tgcagtggca	5040
cgatcttggc	ccactgcaag	ctctgcttcc	cagggtcacg	acattctcct	gcgtcagcct	5100
ccggagtagc	tgggactaca	ggcatgcgcc	accacgcccc	gctaattttt	tttttttttt	5160
gtatttttaa	tggagacggg	gtttcaccat	gttagccagg	atggctctga	tctcctgacc	5220
tcgtgatccg	ccgacttcgg	cctccaaagt	gctgggatta	caggcgtgag	ccaccgcgcc	5280
cggcctacca	cgtggtcttg	atcagccgct	tccccgccct	tgctctcctg	gacctcagtc	5340
tcccattttg	taaagtgatg	cttgggcctc	gggctctgtg	aagcctgaag	gtctccctct	5400
gggtgggcgg	gacagggagc	acctctgctg	gccctcacca	cgtgtgtctc	ccgcagccaa	5460
ggccgcccgg	atgccgcact	tcctggactg	gttcgtgccg	gtctacttgg	tcctctcggt	5520
cctcattctg	gtgggcttcg	gcgcctgcac	ctactacttc	gagccgggcc	tgcaggaggc	5580
gcacaagtgg	cgcctgcagc	gccccctggc	ggaccgcgac	ctccgcaaga	cgtaatggc	5640
gcgcgacaac	ctggccttcg	gcggcccgga	ggtctgagcc	gacttgcaaa	ggggataggc	5700
gggcggcacc	gggcgccttc	ccccagcccc	ccccgcccgc	ccagcccggg	gaccccccaag	5760
gcagagggag	gccggcctgt	tggccctcca	cgtatccctc	ctgcagcctg	ggccctcccg	5820
acagagggccc	cagggtgcgt	ggcagtggag	gtggggcact	taggtgcctg	gctggccag	5880
ggcttgctct	ccgtgtcaag	ccgactcacc	cagagcccac	cctcccagc	tcaggggcat	5940
cctccgctgg	gccccagtgc	ctttgcgctg	cgcagcactc	tgccctccac	tggactcagg	6000
catgtctatg	ctgagctgtc	ctgaggtctc	ggaccctca	tttcttcgtg	aagtccccag	6060
ctccccctgcc	tccactcaat	ggcaccggcc	ctgcaacttt	aggcaggctg	aagccaaacc	6120
aaggaaagaa	cctaagaacc	tcgtttggag	ggatgtcagc	ttgggcccaga	ccagccgcac	6180
cccgcggggc	tcaggcttgg	aactggtgag	ggtgtgtggt	gggggtatgc	agagggataa	6240
gaccgtggta	gaggagaggg	ttggtgagga	gagagagaga	gagagagaga	gagtctgggg	6300
ggagcgggca	agcatgggga	gatgagatgt	gtatatgtga	gagagagtgt	gggggccccca	6360
ggcagggcag	gaggtgggtg	aaacgggggtg	aactccgtgg	gctgtgtgag	gactgtccat	6420
agtgggtccc	aaccccctcc	ctctgctgga	gtttcctagc	ccttccccct	ccccaaagact	6480
gtggcagcag	gcaggagccc	ctgccctccc	tcctgtcctc	gtgccacact	tctggggcca	6540
aacccagccc	ccttgagcca	ggccctgcca	gactccaagc	ccaccctaga	accctcctcc	6600
tgtgtggaga	ctctgttgcc	ccactttgga	cacagattgg	caacctgcct	caccccgccc	6660
cccttcgctg	gggcttccat	cttaatttat	tctcaataat	aaagacttca	tgatgat	6717

&lt;210&gt; 288

&lt;211&gt; 141

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 288

ggctgggctc	agtggctcat	gcctgtaatc	ccagcacttt	gggaggctga	ggtgggcgga	60
tcacctgagg	tcaggagttt	gagaccagcc	tggccaacat	ggtgaaacct	cgtctctact	120
aaaaatacaa	aaattagcca	g				141

&lt;210&gt; 289

&lt;211&gt; 28046

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
<221> misc\_feature  
<222> (19882)..(19882)  
<223> n equals a,t,g, or c

<400> 289

ctcatcatag	ccaaacaacc	ataatcgtgg	agtctggtaa	tatttatcat	aagtgatgta	60
aagggtcataa	gttctgggtt	gcaaaatagc	atcttcaccg	ccagcatcag	ttttggcttt	120
acaagcttct	actattttcc	ttgtatctag	ggtagcctga	aaataataaa	agagaaaaat	180
ttacaaccat	taaactcggt	tgaatgtgac	attctagaaa	acttattttt	tccattctat	240
atthttgttt	cttaagagta	aatgaacttg	gaactcaaag	ctacgtttta	tatgctataa	300
tcaatatgaa	caaattagaa	tgtctttgaa	agatcaatat	attattagta	agaacatgca	360
tccccaggtt	catccattaa	aaattaacta	aagaaaactc	aatttacaaa	cctcatctgt	420
ttccaacaat	ccactctctt	catattctgt	tataaaaaaa	caacaaaaga	ttaatcaagt	480
tcaagttcaa	gaaaattccc	taaaccaatt	taagtattac	ttcatagtat	cattcaaaaa	540
ctgggggttt	gcctttgttt	ttaagtgaag	atattgaata	gatagatata	agtgaactaa	600
ttctatactt	ccaaaggcga	aagcccagag	aaagccagca	tgtttaaggc	ttgacataat	660
aatactgtag	agtcctcagt	ggctccacag	tgtacacaag	cctacttctg	taactgcgta	720
gtcatcggtg	gaactctctt	tgtgtaatcc	agtggttaaat	tcccagtttt	catcttaatt	780
gacctatcag	aacatgttgg	catgatttag	tcccttctcc	ttggaacata	ctttctttcc	840
ttggctttta	aaatatthtt	ctggctttcc	tccctcatca	ctgagtgtctg	tttcagtatc	900
ttctatgctg	gttctctctc	atcacctcta	ctttaaaaag	aaccataaaa	tcaaacgctg	960
cagtaaccaa	gggctcagtt	tctggacctt	gtctctctct	taaccacact	tatttctgta	1020
acgatttcat	ccagactcaa	tgacttcaaa	tactgatgac	tttcaaatth	attccctgcc	1080
tggggacttg	gattatthtt	tttacgtctc	tactaaataa	ctaatagaac	ctgcaaatat	1140
cacatgtctg	aaactgagtt	cctgactccc	tctccaaagc	taataccttt	tgatttttcc	1200
acatctcagt	taatgggtatc	tttctagaag	ctcagggtcaa	aaaccttggg	gtcacccttg	1260
actattccac	ttgtcacata	tgacatccaa	tccagcagca	aatctctttg	gctcaacctt	1320
caaagtattc	cagcattcta	ctgtttctca	tccctacca	tggtacgacc	ctagcccaag	1380
ccaccatcat	ttcttgccct	gattatcaaa	cagcctctctg	ttgtcccttt	ctcccttcag	1440
tctattctca	ccactgcaca	gtgattctgt	tgaatgtca	ctcctctact	tgaaaaacaa	1500
acaaacaaac	aaaacccctc	aatggcttgt	ctcactctga	gtaatgtcaa	gaccttatag	1560
aatctggctc	ctgggttacct	ctctgactcc	accctttact	actctccctt	ctctcctatc	1620
tggacataag	catacccttac	aatatthttac	ataagccaaa	cgtgttccca	cctcagttac	1680
tttgcaactc	tccctcaaat	acctagtttc	attcacttcc	ttccaggctt	tatttaaatg	1740
gggtgtactt	tcaattaggt	ttttcttgac	caatttatth	aaaaattgca	atactcattc	1800
ccaccccaag	attctctaac	ccctttcttc	ctthattthtt	tccttaacac	ttataactaa	1860
tactgtatat	atthttgctta	tctatthttt	gtctccactg	attagaatat	aaactccatg	1920
aaatcatgtc	tactgcttht	tctccaacac	caaggacaat	acctgataaa	tactgtactg	1980
cccaataaat	atthgttcaa	taaatgaaaa	ttactthtat	attagatacc	attaacacaa	2040
ctgttgagca	aaattacata	tatagcaatt	ctthtaactct	atctaggggg	aataataata	2100
acatactaaa	tgactatcag	atattthaagg	caatcccaca	gcttgtaact	tgaaaacagt	2160
gctthtactc	aagggttcta	tgctacccca	ccaccccaac	ttggtcaact	atgtcattca	2220
gagacagatg	aaattcagaa	acaatattht	tccaagaaag	tgatgtcagt	ttctgacaac	2280
tatgagacat	ccaggggggaa	atgaaactga	aatacatctg	aagttgagaa	tatctagggt	2340
acctctagat	atgggaagtcc	ctagcataca	gatgggtatg	gaggctgctg	tgatcaatth	2400
tggttacaag	taattcattc	agatttccct	aaggaacagc	agtttaccat	gaaaataagg	2460
acaagaatct	cactaaaatt	taggaacaga	catagctagg	tttcatgggg	aattgaaagt	2520
aatthttgaa	acaaacagaa	aggtacttht	gatctagcaa	gcatcacttg	ccattatggg	2580
gtthtcaact	tacttggcac	catcttctac	ttctgcatgc	tacaaaacac	aatctatctc	2640
actctaaagt	ctatgtatth	ttggcattca	gctgccttac	agccttcaat	gcctgcctth	2700
ttthtcatatt	ccthtccctt	ttccaacttc	ttcacatgc	accctattht	catatataaa	2760
tatatctata	thtcaactct	cacaaagtac	tggatgtaat	ttatactcta	ctthtcttgt	2820
tgacacaaatt	ttcatgcca	actacagaat	gcatttatag	aagaaaaaat	ctgggagtac	2880
agagagtaag	caagggggaa	aaaaaaagaa	acccacggaa	cagtaacatt	taatagctga	2940
gggaaagaaa	aagaatcata	gaagatgact	agaagaaaga	gtccaggaaa	gagtaagaaa	3000
accagtggtt	atagaaacca	agagagaaaa	aaaaaagagg	aagatatggg	taacagaatc	3060
aatgcagaaa	aggttaagtgt	aataaagata	aactgggattt	aacaaagagg	tcaccctggg	3120
gacagcaatt	thttcatcta	ctthttaaata	tctgaggtth	caaatgtatt	gaaaaagatt	3180
atcatgctca	tgaatacaaa	agctthtgaat	aacatgtgc	tcacagaccc	atactgctct	3240

gttctagtg	gtttctctct	cttttaagaa	tgattcacta	atgcagtgat	tctcaactgg	3300
caactctagg	aggaggactt	ttcagaatct	tgggaaactg	atgggattct	gtgtagttca	3360
aaaggcccca	ttagccaagc	acagtggtct	acacctgtaa	tcccagcact	ttggggaggc	3420
cgagggtggc	gatcatgagg	ttaagagatc	gagaccatcc	tggccaacat	ggtgaaatcc	3480
cgtctctact	aaaaatacca	aaatttagctg	ggtgtgggtg	catgcacctg	tagtcccagt	3540
tactcaggag	gcagaggcaa	gagaatcacc	tgaacctggg	agacggcgg	tgcagtgagc	3600
agagatcgca	ccactgcact	ccagcctggc	gagagtgaga	ctccgtctca	aaaaaagaaa	3660
aaaaaaaggc	cccattgaaa	ctcactatct	tcagggtttta	atagaaagat	gctatcaaag	3720
agggaaaaaga	aaatacaaaa	tgcataataa	gcaaactttg	ttctgctctg	aaataattca	3780
gttaggaatt	aatatcttgc	agccgtatcc	agtattaaat	atttatgact	aatagttatt	3840
ccaataaaaa	tgatattgtc	caagactatg	tttggagtaa	aatagaagag	tccaagatca	3900
agataagttt	tacactaatg	aaatttatga	actaaacata	tataaaacac	tcactaggct	3960
gctaaatgct	aaactttacaa	ctcaatgaag	aattctttaat	ccacataaat	tacaaatatt	4020
ctaaatcaat	attctagtg	aactgaagca	aatctagaac	aggaatacct	tccatatctg	4080
cagcttctcc	ttcatcttca	tcttcttcc	cttcacatag	tgctgagcaa	tcttgaagcc	4140
ttatattgtc	ctttgaaatt	aatttatatt	aaaatcactt	aagtatatat	attaatttga	4200
acactgaaca	cccatgtgct	agcacagtgg	taaccactgt	gaaaataaga	atgacaaggc	4260
agttcttgtc	cacaaaaacc	ttaaactcca	atgaagataa	tgaattcata	tatcagtcac	4320
taaaagtaac	gtgctaagt	ctgtgactga	aaaataacaa	aggttattat	gggagcagta	4380
agagtcactc	aagctatttta	aaaataattg	ccagttgcac	ttccaataaa	acagtatttt	4440
tggttaatca	attcattagt	attagaaaa	cagttcaaaa	ttatattaac	ttgtgcactt	4500
ataaggggaa	aaagtgcaca	tatctgtaaa	tcaaatataa	gctaaaatat	aaatcaaaca	4560
ctattacatt	ctaatttggt	aacaatatct	tagctgaatt	aggcaagtta	tcagacttta	4620
cagttattaa	aatgcacaag	atatcagttc	aatttcttaa	ctatattagc	tctaaagtga	4680
aagaatattg	atggacaggt	ttaacatctg	ggtatcgttt	tcacaaaatt	aatattctga	4740
aaatctgaag	tcaacataat	aagtggataa	actgaatatt	tagttttacc	taggttacat	4800
tttacttagg	ggtgggttaa	tttaacacta	gaaacttaag	tcatatgttt	aaaacttaaa	4860
tcattcttac	acccaaaatt	gaaaccacaa	aaccacaaaa	ccatcagtg	cggagtaatt	4920
attatatgag	ctaataattta	acaaattaat	cattaagaaa	aagtttcac	atattggtga	4980
tattttatact	tgataaagta	gaatagaaat	tgacaaccaa	gattaatact	tctgcttgga	5040
tggaaggtat	tctaagttac	aaaaaatact	aaaggaatta	ccataagccc	gtccaagaaa	5100
aacactacta	tctacactac	tgtgccattt	atcattccca	aagttctga	catatatagt	5160
aattgtcaga	gtaaacaaga	tcttctaaaa	cagcaaatga	atttgtgtta	tttctccgta	5220
agtcattcaa	acactccaaa	aagtcctaatt	tcaaaatgat	gaattctcag	gccaaagaac	5280
taaatcttaa	agcataaaac	tgtaaataaa	aaaacaaaa	aaacaaaaaa	aaaacttgct	5340
ttcgtttcta	tcactttctg	ttaagcccca	gtaacaaatc	tagaaagatc	caaagtacaa	5400
aaacacacaa	agaatatctt	tagtaactgt	tgtagcaaaa	gtgtcataag	actaggaaca	5460
caattattcc	attcaaatag	tctatcctct	aagtgatttg	atgggttaaa	aaataattaa	5520
gacaaggggt	aaagcatttt	atattatttt	ttcatatcat	ttcaaacaac	tacagggtata	5580
taaaacactg	aagacaactg	cggttgatct	ctctgagaaa	tgaaaagcta	atctaatacc	5640
tacaacagcc	taaaataact	caaaaatttc	aagcaaaaaa	actctaccca	attatgtttt	5700
acccccataa	atcatgcaat	aaaacttaac	agattaagct	tctattcatt	caaaatgtca	5760
tgaatttgaa	tgatgcaagc	taaagtttgc	tttcaaattt	tcaaaaacaa	ataaacccca	5820
aattaccagt	aattgaagaa	aatacagaga	gaatgattaa	attgcttatg	gcactattta	5880
agctataaaa	tttaaagtgt	aatatatcat	tagcatctac	tagtaagcaa	gtagtttaatt	5940
ccaccccaac	attctccact	tatatgacat	ttggtactaa	atacatttta	aaacaaaaaa	6000
gtcatctctt	ttaaactagc	ctagaagttg	ctccagtcag	tgaaaattag	tagtttgtac	6060
aagttacaat	ctaaaagctg	ttttacttaa	ccatactaca	aattaaggaa	aataagagat	6120
gcattaggca	gcagtagtgt	tttgggtgtg	tgagacagaa	aaatgaatgg	ggaagaaaac	6180
agctggaatt	taaaagagct	tgataataaa	aaaccagggt	ttttataaga	aagatatggg	6240
gattatata	gtgtgtgtat	agatagatag	ataggcaaat	aactactcat	taaatttaaa	6300
aatataacta	attaaccagt	accttatttt	ccagtggtgat	ctctttaacg	gcttccgtta	6360
ttctgtta	acctatgtaa	aattcggcag	aaaagaataa	ctaaaaattaa	actgtaaaaca	6420
ccctatttac	ttattaaagc	aatataaaaa	tgctgaaaa	tctcacaatt	tctctgaaat	6480
aaggaggcaa	ataatagtag	tatctttaca	aatgaactct	aatgagaata	gtcacaaatg	6540
cacctctca	aattttgaaa	aactcattaa	tattttacca	tgaattactt	tccttggttg	6600
aatctctatc	acaacacttt	ctgagaaaca	gaacagtttg	gccagggtgc	gtggatcacg	6660
cctgtaatcc	caatgctttg	ggaagctggg	gcgggtggat	catctgaggt	cggaagttca	6720
agaccagcct	agccaacatg	gtgaaaccgt	ttctactaaa	aatacaaaag	ttagctcagc	6780
gtggtggcgt	gtgcctgtag	tccccgctac	ttgggaggct	gagacaggag	aatcgcttgg	6840



acccggaagg	tggaggttgc	aatgagccga	aatcgaccca	ttgcactcca	gcctggggcga	6900
caagagcgaa	actccgtctc	agggaaaaaa	aaaaaaggaa	agacaagagt	ttaaaaaac	6960
tacaggactc	gtatgtacat	tttaattaaa	cttgcaccaa	aattttctca	aaaagctatt	7020
agttatctta	atataggctg	attatccctt	atctgaagtg	cttgggacca	gaagtatttc	7080
tgattttttt	agatttttga	atatttgcac	aaatacttac	tggtaagta	tccctaatac	7140
aaaaattcaa	aatgctctaa	tgagcatttt	atttgagcat	catatcagtg	ctcaaaaagt	7200
tttggctttt	ggaacatttc	atttggattt	ttggattagg	gatactcaat	ctgtttgtta	7260
tttgccttcag	aaatgtagga	tacccaaagg	tagtaatatc	atatcacatt	tatatgtggc	7320
tttctactat	ttccacatct	tatttaatcc	tcacaatgac	tatcttatga	ggacgttaca	7380
gtaataatgt	cttcctatga	agaaatgaag	tcactggaga	gatgacttgc	ttgagtgtta	7440
taccagtcga	aatgatgaaa	ttgggattaa	aatccataca	agctaacttt	tggttcaatt	7500
ctcttgcact	ctacggggca	aatacctcaa	aacctacttg	tctcaaagaa	agccttaaga	7560
aggtggcaga	accaccagtc	agctagataa	ctttctact	tcaaagtacc	tgtcaatggt	7620
aacaaaatag	tttaacaaga	ataagaaata	tagtaaaaaca	atagcatcta	aagttactaa	7680
agaaaaaacc	taagtacaga	atatgcttag	ctcctttgtt	aatcttctaa	aattttgaga	7740
tgtctgttca	acatgcctaa	acaaaataga	tagctcactt	tcacacataa	aataggtcaa	7800
aatccacagg	tctagcacaa	gcttttactt	cagtttttct	agaaattact	atataatagg	7860
tatgactatt	cataacagta	aacccaaatt	ttaacatacg	aattgactgc	ggaacataaa	7920
aacaaagcaa	atcaacctct	tttaatttgc	aaaataataa	aagtagtacg	ccattaaaaa	7980
actcttagaa	gtagcatata	gttgacaaa	aaaaagaaa	ctcaaagtac	tctaagtaga	8040
gtaatactct	aaagggttat	ggtaattaat	tttatgtcaa	cttggctagg	ttgtggcacc	8100
cagatgtttg	gtcaaaccac	attctagata	ttgctgaagg	tatttttgag	atgtgatgaa	8160
catttaagta	agtagactgg	ataaagcaga	ttaccctcta	caagataggg	ggatatcatc	8220
caattagttg	aaggccttgt	aagaaaaaga	ctgaggtcct	ccagaagaag	gaattcagcc	8280
tccagaacgc	tttaggacta	aagctgcaat	atcaacactc	cctgaatctc	tagtctgcc	8340
gtgtgcctcg	cagaattcag	acttgccagc	ccatataatc	agatgagtca	attcctctaa	8400
aaaaaacaca	aaaaaacaaa	aaacaacaac	aacaaacaaa	aaaaaaccta	tctacctata	8460
tctataccta	tacctatgca	atagtcctca	cttatctgtg	gggaatacat	tccaagacc	8520
ccagaggggtg	tctgaaagca	cagatagtag	caaaccctac	ctacgctgta	catgacagtc	8580
gacctgataa	tcgagttggc	tattaagtga	ctaattggctg	ggtagcatat	acagcatgca	8640
tacactagac	aatgggatga	ttcacctctt	gggcagaacg	gatcaggata	gcagatttta	8700
tcagtctact	cccaacagtg	gggacaaaaa	ttaaaactga	tgaattattt	ctggaatttg	8760
gcacttaata	tttttggacc	atgggtgact	acataactga	aaccacagaa	agcaaaacct	8820
actctgtata	catcctatgg	gttgtttctc	tagagaacca	tgactaatat	acaagctaat	8880
agaagaaaac	gcccaggaaa	agcaaggata	aagcaaggga	aactgagttg	aaaaaggaa	8940
cagtatctgg	cctcataagt	cactaacttg	acatcaaaaa	caatgcacaa	tcaatggatc	9000
cagtcagtcga	acagagaatt	tctactgat	gtgttgccaa	catcttccag	gcattggaaa	9060
gtcaaagcag	aagagttaaa	agactttcac	tactcagtg	ggcgggggga	aagaaggatg	9120
atttttgaaa	ttacttttaa	aagtttttca	atctgttatt	tcttttaggc	tttgatatag	9180
cactgcactc	attaataagc	caataaattt	cagatcaagg	agcccaagtc	ctgaatcttt	9240
gcctataact	ccataaggaa	agagatggca	gtatccttta	ttcagagtag	gggagaaact	9300
gacctaaagaa	ggaactttta	cctgggcaga	tacttagccc	tctgtctact	gcagtgaagtc	9360
tcaactgaag	gcagcaattt	ttcccccaac	agaacattca	gcaatttctg	gaggcatttt	9420
tggttgttaa	aactgaggga	tgtactgggt	atccagtggt	tacaggccag	agatactgg	9480
aagcattcta	caatgcacag	aaaataatta	tccattccaa	aaaacagtgc	caaggttgag	9540
aaaccctggt	ctattactac	taaggatata	cctcctaata	tctaggactc	gaaggggaga	9600
aaacataattt	agtatcatgg	acttaaacctt	agagcacatt	ttccattcca	aaaaacagtg	9660
ccaaggttga	gaaaccctgt	tttattacta	ctactaagga	tataactcct	aacctctagg	9720
actcaaaggg	agaaaaattt	gttttttagta	tcattggattt	aaacttagag	cacattttct	9780
tcatcaaaac	taagtaataa	atggtagtta	gcttcagcag	catatgataa	tatgcatgta	9840
catagttata	taaatatagt	ggcaaaacag	tgtttttagga	cttagaataa	aaaagtatat	9900
tcagggtttc	aaataactca	tagaaacact	tataaaaacc	ttgcattcaa	ctcatttaac	9960
aaatattttac	tgaacaactt	ctacatcata	cactgtgata	gatactgaga	attcaacaat	10020
gaactctttac	cttcattggag	cttcagtagc	tgaaaatttc	ttttagtcgt	tatttaacaa	10080
ataattatta	aatacttaat	agatgtcagt	tctctgggta	aatgtgaata	cagtatagtt	10140
cctgtcatag	aggagcacat	aatccagcaa	tggaaatgaca	atgacatgta	agcaagagac	10200
tgtaaagcaa	agtagtatgc	atattcagca	tctctgacgg	tctttttttt	ccctctctgt	10260
atttagaaac	taagaaaata	atattttcaa	attgcaatgg	aagtagcagg	tattatagaa	10320
atttggcata	ctctggccgg	gcgcagtggt	tcattgcctgt	aatcctagca	ctttgggagg	10380
ccgaggcagc	cagatgacga	ggtcaagaga	tggagaccat	catgaccaac	atggtgaaac	10440

200

cccctctcta	ctaaaaatac	aaaaattagc	tgggcgtggg	ggcgacacac	tgtagtccca	10500
gctactcggg	aggctgaggc	aggagaatcg	cttgaacccg	ggagggtggag	gttgacagtga	10560
gcaaagatcg	cactccagcc	tgggtgacaga	gcaagactct	tgtctcaaaa	aaagaaataa	10620
at ttggcata	ctctaaaggc	ttctttttta	aaat ttgtcc	tctgtctttt	ttcatgtaag	10680
tctattggga	caaaactatg	ccttatgtat	cctctttttt	aaatcaaggc	tattataaaa	10740
gattgtgaaa	gagtttaatt	taaactaaat	atatgtcatt	ttattctcct	cttacctgtg	10800
ttgtgatatg	tatctaccca	tccgcatca	ccatcatctt	cttcaatgat	agcttccaat	10860
tcatctgaat	attccatctg	tttgacccgc	ttatagcacg	gcactataaa	aaaaatggta	10920
aatacagtta	actagcacgt	aatctgctaa	ccataaatcc	attagaaaga	agagagctta	10980
gtccataaaa	taggggtgtt	ataccaccaa	agtactaagt	gaatatttca	cttttaaagg	11040
tgattaagag	ttacattcag	ctcatagaca	cataattatt	tggctacatt	taccttttcc	11100
taaatgtcct	tgtcagaaga	caagtagaaa	agctctattg	ggaatgttct	atgcattcct	11160
ttacctgat	ggctgtgaa	gaacagcagg	gtgatgtcag	agatacatat	catagtcca	11220
tttcagtcta	atgaataata	ataccttatt	ttaatggcct	tactttcaga	acatggagct	11280
accagctatc	atagtcagtg	gtggtaaagg	tgaactcttg	ttttcaaggc	taaaagtaact	11340
ttcaatataa	at ttttataat	tcataattta	gttccagtta	ttcacaatgg	ataaaacagt	11400
ttaaaattca	ccaaccttct	gatttttact	tctttatacc	acactagtaa	gttgttcata	11460
cagcaaatgt	gtcaattaac	aggtattatt	attcataagc	ctaagattgg	gtaattatat	11520
ggtaaaagca	ttatgggtata	aggtcaacaa	attgtctttt	aatctcctga	tttttttaaa	11580
acaatcagga	tataaattat	cagcctttgt	aaaaagaaat	atgctgtaga	aaagaaaaaa	11640
ctgctgttct	gttcacttta	ttttcccttt	ccataaatga	gtaaattgga	acagaaatca	11700
atgtattgtt	ttgtgattag	ttaggaacta	taacaacctt	ttgatgttgt	ttttaaat tt	11760
aacttcataa	ataaaacact	acctgtttca	gccaggcgcg	gtggctcaca	cctgtaatcc	11820
cagcactttg	ggaggccaag	gtgggcaggt	cacctgaggt	caggagggtcg	agaccagcct	11880
gaccaacatg	gcaaaacctt	gtctctacta	aaaatacaaa	aattagccgg	gcgtgggtggc	11940
aggcctgtaa	tcccaactac	ttgggaggct	gaggcaggag	aatcgcttga	acctgtgagc	12000
caaaatctgat	ccactgcact	ctagcctggg	caacaaagtg	agactctgtc	tcaaaacaac	12060
caaaaaaaaa	aaaaaaaaaa	ccactacctg	tttcaaaaata	ttttgtgtgc	cttcaatgac	12120
acaacggata	ataacatcgt	cagctctgag	cttttagatg	tcataggtag	tatgaatttc	12180
at ttgccatg	caaaatttca	gtctaaagaa	gattaaaatc	aaatacctag	aaagattatt	12240
atgaagccaa	cttcaaaaaa	atccacttag	aagtctaact	ttccttaggg	ccctcttct	12300
tcgtatcttg	acaactatat	gtttttggca	aaaagaaata	acagaaagag	gtgataaaac	12360
taaggaaaaa	at ttttcaagc	aatagaaaaa	ccgagagctt	catttttaata	tacctctacg	12420
caaaat ttat	tcatatatgc	aacataattc	ttacaaattt	tggttaccaa	aaattgtttg	12480
cctgtttgga	ggtatgcctt	cactttcaat	tcttcccctg	tagcccttta	aaaacagtga	12540
aaagcaccaa	aatacaaaac	atattttta	aggcaaatat	acagcagaaa	gtattgcata	12600
taaactctcaa	aatgatataa	tccataattc	tcagaaaatt	ggtttaaaat	tgattttggga	12660
aggactccat	taagtaatac	atgtcagggc	atggagaaaa	gcacaacaat	aatctaagtg	12720
aaacatacta	agagatgcag	atagacccaa	gagaattttg	attaaatatt	agacaaaaaa	12780
ggtagaataa	tatagaacta	ttaagcaact	attatgtttg	cctctaaca	acaataaaa	12840
tactgtctcc	gtactgagtt	gtagcccact	gtataatctc	tcacattttt	aatccataag	12900
tactgtctgt	catcttgaga	acaagaaaa	gcagaaaaaa	aagctgcatg	acattatgta	12960
acactgtagg	tggtgtggca	aatccctgtt	cctatcactg	gattaaaatc	agaattaaga	13020
gataaaagat	gtctctgaatc	ataaaatgac	aatattaata	attcttgaaa	acaaaaaac	13080
ttttatttgag	tgcttattga	gtatagaatt	taagtctcca	acatgttatt	ttcaattagt	13140
cttcataact	ctaaacagta	gaacatataa	atatcccat	ttatagttaa	gtaaaactaa	13200
gattaaacag	atcaagttgc	ttatgatcac	aaaacttggt	gggagagcaa	gggtcaaagc	13260
caagtgcact	cagggctcct	actcttaaac	actgctccct	ctgtgggtca	gagccaacta	13320
tctacaacat	ttctgagctg	ctctggcacc	tcttcttaag	aat ttgtggg	tcacttgaaa	13380
acgggtgagag	gtggagtggg	atgtgggtgcc	tttcacaaac	atatggccat	aaattttggag	13440
ttcagctgtc	ttttcaagct	tcagtctaaa	gttcaaaacca	tagatctggg	cacaaggtaa	13500
agtcaggaaa	tgccttaata	ttatttgacg	gccttctaga	cttcttttga	ctagtcccaa	13560
gtgtcaaatt	caacaatgtc	atggcaacac	ccgaagtctt	gaggaaagag	ttaaaataag	13620
gtcatgata	cacttggtgca	cgtgaaggca	taagcatgga	aataacctgg	ctctagtgtc	13680
gattttaaa	gaatttttcc	tttggcccg	gaattttagcc	aaaagtgtgg	acactgaagt	13740
gggttataat	tcagttctaa	gttacaataa	aagtatttaa	atcactctaa	ttcataaaat	13800
ggaataaaac	tactagtacc	tgctaaaaaa	agatcccgtc	catatataca	agcccctaca	13860
acaatgctat	aaatcaaata	cctaaactac	ttaattaaagc	tggtagaaca	aagaaatctc	13920
aatgaagaaa	atgcttatca	tatagaaaaa	aacctgaatc	agttattttc	acaaaatgaa	13980
tactactgta	aacctcattt	ccctatttga	cttgaaatac	atataaatta	tagaccagaa	14040

201

cctagctaaa	tatagtttta	acagaaaatc	tggaatacag	aaagaaaaaa	aaaccacctt	14100
tattaaatca	gagatcttct	atgacatgaa	tttaatttta	aatatggaac	aaaaaacaca	14160
tgtaggagag	aaaaatacat	aaaaacaaac	ttgaaacttt	agtcttttgg	tacataaata	14220
atgccctaca	aaataaagag	taattgaaaa	aagcagtgac	aactgtttca	gcgacacggt	14280
aagtattaaa	atgcaggaga	ataccaggcc	acagatgaaa	gagtttgaag	ctagaaaaac	14340
attatcaatt	ggaaacttat	taattataga	attcctatcc	ccagtcaaaa	ctgtaccttt	14400
caactacaat	tgaaaaacaa	tttttaagaa	aaaagatata	ttaagttgaa	gcacatatat	14460
acaacaagg	tgataattcc	aaacaatcct	agtttaaata	aaagttctgc	caatattggg	14520
atcatttttt	cagctaccaa	cagggagtct	ttatcgtgag	tacttggaag	taataaaaca	14580
ctgttattat	tcagaatatt	ttaaaatata	gattgtgaaa	actgctaaat	tgcttaaggt	14640
accttagtaa	ttaaaataaa	aggtattgaa	aaaaaataaa	aacttaaaag	ctcttaaaag	14700
cagattttata	atgaaggcct	taattgggtat	cataaacctt	tcttttagct	ttagccagtt	14760
tcctaaagat	ggagcatact	tttgaaccta	acagaaaacg	tttatgtttt	atatttttaa	14820
gaacataaaa	tgcaaaaatc	tctgcattta	ttaatgccac	aaacatgttc	agtaaatatt	14880
gttaattttaa	aaaaaaaaaa	cctgttcaaa	aatttttttt	tttttttgag	acgggagcct	14940
ctcactctgt	tgcccaggct	ggagtgcagt	ggcatcatct	ccggctcact	gcaagctcca	15000
cctcccagg	tcacaccatt	ctcctgcctc	agcctcccaa	gtagctggga	ccacagacgc	15060
ctgccaccat	gccagctaa	tattttgcat	ttttagagat	gggtttcacc	atgttagcca	15120
ggatgggtct	catctcctga	cctcgtgatc	tgcccgcctc	agcctcccaa	agtgtctggga	15180
ttacaggtgt	gagccaccgc	gccctgcca	aaactctgat	aaattttatt	aaactattta	15240
ttattcctaa	aaccagaagg	tcagacttag	acactataaa	gaaaagaagt	aatagttaag	15300
gaagtaaatg	cattttttct	aaattagtcc	atcatattgt	gctaacatag	ccaaataaca	15360
taggtataac	accacttgt	tcttccttta	ttttgaagg	gcattgttta	acagaagaat	15420
ctgctggggg	gaaagttaaa	ctggtcattc	taattttcat	ccattaacct	attttgcaaa	15480
ttgctataat	tctgaagcca	tgcattttac	taattttcta	ttctttactc	aatattactt	15540
accattgcca	tgttggacag	tggtggacta	ggtgatctcc	agctgccaca	aactattcag	15600
gatttaaaag	taatatgaaa	aaaaggaaaa	agaaaaatca	aacatcactg	aatgtgcaag	15660
gtggcaaaat	accaaaactga	tggcactagg	taacactgaa	atccagtaag	caataaaaaat	15720
ataaacagca	acaaagctgc	tctaccagcc	tcaagattta	tttttgatta	tgactaaact	15780
gcaatgtttt	ctaattgtcca	taaaaaaatt	caaattaatc	ttggaagaaa	aaacaagtgc	15840
tgttttttaa	aaattcagtt	tttataattg	gattaagtaa	tgccaaaagc	agtataatga	15900
aattgataaa	tgtaaggcta	tcagatttaa	attgtcaaaa	tccattttta	ggatacaaaa	15960
atgtagacac	attcttgcca	atgactgaaa	atacaataaa	aatctgaaaa	aaattactaa	16020
atagatacaa	gtctataatg	taagtctact	ttattatata	actgggcaca	cttcttcctc	16080
ttcctctttt	attattttta	aaaatttaag	tgattttgaa	agcttttttg	cacttctaaa	16140
agagaaatgc	agtgccaaaa	caatgggaaa	aagttagaag	ctttttgggt	tcactctgaa	16200
aacacctaca	aaattaacaa	attgaattct	ctctaaaaaa	ccttagactt	cctaagcggg	16260
ctgaatattg	tacaagtttt	tgtttttctt	cagaaataaa	aaccagattc	agggagataa	16320
actttaacca	tttgagaatt	atcagtttac	acgaacatga	gctgatctta	ctggcgaaac	16380
gaaatcctgc	ttattttctga	gggcagaaaa	tttaagtctg	ttaagcataa	ctgcagtgtc	16440
ccaaactcaag	caggtatgtc	attgtcaggc	ctctgagccc	aagctaagcc	atcatatacc	16500
ctgtgacctg	cacgtatata	tctagatgtg	ctgaagcaac	tgaagatcca	caaaagaagt	16560
gaaaatagcc	ttaattgatg	acactccacc	attgtgattt	gtttctgccc	caccctaact	16620
gatcaaggta	ctttgtaatc	tccccatcc	ttaagaaggt	tctttgtaat	tctccccatc	16680
cttgagaatg	tattttgtgc	catccacccc	ctgccacaaa	aacattgctc	ctaactccac	16740
tgctatcccc	aaaatctata	agaactaatg	ataatctcac	catcctttgc	tcttttcgga	16800
ctcagcccgc	ctgcaccag	gtgaaataaa	cagccttggt	gctcacacaa	agcctgtttg	16860
gtggtctcta	cacatggacg	catgtgacac	ccacatactt	gccaaattac	ttctattttg	16920
caacagctct	agcttaaaaat	cttgtattgt	tcatgggttt	actacacagc	aaaaaattac	16980
aaaatattta	atctctaata	cctttgagaa	agtatgccta	tataaaatac	tctagtttaa	17040
tttgagcata	taattctatc	aaataagaat	tctaagaata	acctctttta	agatgaacaa	17100
ttacaagat	atagcaactg	gattcctgat	agaaacttta	tgtttctggt	cttttacttc	17160
gaataacctt	attattttaa	cagcctaagt	aaagacaaaa	accaaataaa	aaacaatagt	17220
ctcttcccca	aattttgagc	acttcgagct	cattgcaacc	agatgctaca	tttagctctg	17280
tggttattcag	gaactaattt	attaccatta	aaagtaataa	tttaactaaa	tgaaagcaaa	17340
ataattaaaa	ataaaaaaatt	ctttcattgt	attgccttga	ggtaacaaga	ctaacatttt	17400
atctcatagt	ccctatagta	tcttctattt	aaaaacaaga	acactaggag	gcaagaaaaa	17460
cgaaaaacaa	aaaacaaaac	aaaaaaaaca	cagactcaca	ctgataatac	atgtgtacat	17520
ctgccctcat	tagcaatggc	catcataact	tgcttcacgt	gttcaaatga	tgcaagattc	17580
aaattttctaa	atgatcaata	ttgcttgcaa	tagctttctc	ttagagacta	aaaatgttct	17640

ottattatct	ttattatcag	tatataatac	tgaccaactc	caacaagaat	caatattttac	17700
accttgggtga	gcaattccat	tcctcaagct	aacctcaatt	aatagtatct	tacttaaaca	17760
agtcatacat	acatccaaca	ttagtttttt	ctttgttttt	tgacaataca	gtatcagata	17820
ctagctgccc	ctctttttta	gcacaatact	gccacacctc	tgaatgaaaa	caaaaagata	17880
gctgatgtct	ggcagaaact	cagaaacagc	aagatgaaac	aaatgaacaa	atcaactcag	17940
tatataatat	ttacacaaaag	caaattgatgc	cttcccattt	cctcctccag	gctcattcta	18000
ctctaactca	atcctgtaat	tgtgctctat	cccaaccctg	cattatgtaa	tagacagcca	18060
gctgggctaa	tttggccttg	gattttttta	gagaggaaaa	ttcataaatt	gattgatgtt	18120
gtaattaaagt	gtaacagtta	tttattctag	gatgaattcc	tgttttgaaa	ctgcttaatt	18180
ctatccaatg	accacagact	ttgcatctct	aactgcaact	atatattcaa	caattagtca	18240
tcttcacaga	ggaaataaaa	caaagagtg	caataagaac	agcatacttt	catctccgct	18300
cttgatttca	gataaagagc	catgttcaaa	ttacacctct	gtttggcaag	aatgttaatg	18360
atatccttaa	aatcaaaact	tagttttatt	tggtcattga	ggtaataaaa	cctaaggcag	18420
aataggatct	ttacagaatg	tctagcccac	aaccgttatt	ttatagatga	ggaaacatga	18480
agcctcgcca	gggatagttt	aactgatttc	ctcattagga	gaaattaccg	tcccgtccgg	18540
gaggtgaggg	gcgcctctgc	ctggccgccc	ctactgggaa	gtgaggagcc	cctctgcccg	18600
gccgccccta	ctgggaagag	aggagccctt	ctgcccggcc	agccgcccga	tccgggaggg	18660
aggtgggggg	gtcagccccc	cgcccgcag	cgcccgcgtc	cgggaggtga	ggggcacctc	18720
tgcccggccg	cccctactgg	gaagtgagga	gcccctctgc	ccggccacca	ccccgtctgg	18780
gaggtgtact	caacagctca	ttgagaacgg	gccatgatga	caatggcggt	tttgtggaat	18840
agaaaggggg	gaaaggtggg	gaaaagattg	agaaatcgga	tggttgccat	gtctgtgtag	18900
aaagaggtag	acattgtaga	cttttcattt	tggtctgtac	taagaaaaat	tcttctgcct	18960
tgggatcctg	ttgatctgtg	accttaccct	caaccctgtg	ctctctgaaa	catgtgctgt	19020
gtccactcag	ggttgaatgg	attaagggtg	gtgcaagatg	tgctttgtta	aacagatgct	19080
tgaaggcagc	atgctcgtaa	agagtcatca	ccactcccta	acctcaagta	cccagggaca	19140
caaacactgc	ggaaggccac	agggtcctct	gcctagggaa	accagagacc	tttgttccat	19200
tatctgtcta	ccttccctcc	actattgtcc	tgtgacctg	ccaaatcccc	ctctgcgaga	19260
aacacccaag	aatgatcaat	taaaaaaaaa	aaagaaatta	cagaaatagg	tctagaaggc	19320
aggtctccta	ggttattttc	atactaccat	gtgtcttcac	caaaaaacaa	agacaatttt	19380
agagaaaaaga	ttagttatgc	aaaccatttt	tttttttcag	acggagtctc	gttctgtcgc	19440
ccaggctgga	ctacaggcgc	ccaccatcac	gcccgcgtaa	ttttttatat	ttttagtaga	19500
gacgggggtt	cgccctgtta	gcctgtattc	cgctgcctc	tgccctccta	agtgttggga	19560
ttacagcgtg	agccaccacg	cccagcacag	aaaccattct	taaaactcac	aaggagccgg	19620
gcgcagctgc	tcaagcctgt	aatcccagg	caggcggatc	acgaggtaa	gaggtcagga	19680
ccattctggc	caacatggtg	aaaccccatc	tctactaaaa	gtacaaaact	tagctgggcg	19740
tggtggcgct	cacctgtatt	cccagctact	tgggaggctg	aggcaggaga	attgcttgaa	19800
cccaggaggc	agaggctgca	gtgagccaag	atcgcgccac	tgtgtccag	cctggtgaca	19860
gagggagact	ccgtctatct	anaaaaaatt	aaaaaaacca	caaagatttg	gaactagaca	19920
aattccatca	caactgaaaa	ttgaaagatc	agtttaattct	ctagctccac	accttgagac	19980
ttaacagcag	cagccttatt	ataaaaataag	gctttaaaccg	tttgtttcaa	aacagtgaat	20040
aaagtctcat	tgccaaaaaag	tggtgttttc	attggcagaa	aaaaaaaaaat	tcaagcttaa	20100
ataaattgtc	tcttattaag	aacaacctaa	gtctgataaa	accataatta	ttcataaaat	20160
tgagagcctga	aaagggtttt	agcccagtat	ttacttctcc	accgacaacg	aaatagaact	20220
cttaagagaa	aacaatatct	aagtagtaag	caaagttttc	caatgaaaag	catgaaaact	20280
cacatttgat	gtaaacagaa	ccaagacacc	acagacatta	cagagcttac	tgcacagctc	20340
aatataacac	caatacaagt	caaggataag	tgacatagga	ctcattttga	tcccttcttt	20400
caccttcatt	tctaataaaa	gaggaactac	agagaaatat	gagaagtggc	aaactgacgg	20460
ggaagttaca	tcttttcttc	tatgggaagt	agaaattccc	ataaatcaca	gtcataaaac	20520
ctaattttac	tcaaatcaaa	attaaagttc	aagatgtttt	cttatgaagc	agaaaagcca	20580
cctagtttag	tattattgta	aaataaaaag	acttcagtat	atcttcagca	ctcacctctt	20640
ctggggtaat	tacacctgtt	tccttaaact	ttgattccta	aaaaaagcag	aaagaaaaac	20700
aatattatat	catgtttcac	tatcaattaa	atatattttg	ggggcaatta	tttgctggt	20760
gcccttctag	gcaatagagc	acatacaaaa	aaaaattagt	ctatctatct	aatctataat	20820
ctatctaate	tacctatcta	cctacctcat	tggtatctat	ctatatctat	ctatctgttt	20880
cactcactgg	taatgaccac	aggaataaac	aagtctaattg	taggaaacag	acatgaaaat	20940
aattataata	ctatcagatc	agtgtataaa	tagagtaaag	ctctatgtag	aaacattctt	21000
tttttttttt	tttaagatgg	agtttcactc	ctgttgccca	ggctggagtg	cagtggcgcc	21060
atcttggtct	acggcaacct	ccacctcccg	ggttcaagcg	attctcctgc	ctcagcctcc	21120
tgctgtagc	tgggattaca	ggcatgtgcc	accatgcccg	gctaattttt	gcatttttag	21180
tagagacagg	gtttctccat	gtttgtcagg	ctggtctcga	actcctgacc	tcaggtgatc	21240

cacccgcctc	ggcctcccaa	tgtgctggga	ttacaggcgt	gagccactgc	gcccggccaa	21300
gctctatgta	caaacattct	aagatttaaa	taaaaataaa	gccttacagt	gattctgtga	21360
aatgaacaaa	tacctttatt	ttacagcaca	gcaaaaatgt	cttaaagatg	tttagacatc	21420
ttacaattca	gccagtcctta	tttaaaactga	ataatggttag	aaaccaaatc	tagaaaattat	21480
tttagcatttt	cctctaattc	tcactctccac	caagatactg	acacactatt	ctctaaattt	21540
ttctaaactt	taagttatat	gtaagatttt	ctggtagagt	ctacaaaaat	gaaaacactc	21600
atttataaac	attattcatt	caacaaatgt	ttactatgtg	ccagacacta	tttgaggcag	21660
tggggatatt	tgggggtgaa	taacataaat	acaaatttat	tcttgccctc	ataaggagtt	21720
tcaactccag	ttgaggaaga	aaagccaaat	ggtaatgaat	aacataccat	aaagaaaaat	21780
gaagctgaga	ggaatctgtg	gggtggctgg	ggagagatgg	ccatttaaaa	tagaatggta	21840
agagaacaaa	gacttcactg	aataatgact	taaaaacctt	aaggaaagga	acatgccata	21900
aggctgttaa	gtgcgaagcg	cgtttcagat	agagggaaga	gcacatgcaa	aaccccaaac	21960
caagagtgtg	cttaacagaa	taataaagag	atcagggttag	cttaagcaac	agcagtcagg	22020
ggatggagca	gatgagattg	gggcctctac	caattaagca	gaaccttaga	gatgattgta	22080
agaacttcag	tgtttactgc	atgtacatac	tccaaacaaa	acatgatttt	tcttaatttt	22140
tacttgctag	gagaaggcta	ttacttattt	cctgaggatt	ttgttctttc	tccttgccct	22200
ccctaagcag	gaaactgtaa	ggattctctc	tgtaaacac	agtttgcaca	ggagtatcaa	22260
ggagacggtc	attcattcct	tcctttttac	taaagacata	taccatacat	actgacatgc	22320
caacagttcc	ttttcagttt	ggtgagcaag	tatgatggac	tcctgaaaac	ataattctac	22380
atcatacatt	ttatatattca	tttgggcagt	ctcttgctcc	tctctcccg	aaactaaaaa	22440
ggtgtacaat	ggtgtattat	taaaatactg	tatacctagg	tagatatgat	attctgaaaa	22500
gttaacataa	ttatgtaaaa	gcatttgatt	caaattgtgaa	aattattttc	caatcttagt	22560
ttgactgaat	aatcttaaaa	tgactttcac	agtaaacaaa	tgtaagcaaa	gcaacagttg	22620
aaattctcat	ttataatcgc	tggtttattt	cttacttggc	caataagtta	ttctttttaa	22680
aggagcttta	caaaaacgta	ttttaaaaag	tatagaccta	gtactccct	ttgtcatgga	22740
aagggagcaa	agcaaaaactc	tccactattc	ttagcatatt	aaggtatttc	acccccacac	22800
tgagattggt	acatttctaac	tgaaaagctta	aaaacaacta	gaaaaaaaaa	acaaaaacta	22860
agcaagaact	tcccattaat	ttactattct	tgctcacttt	tcagaaagca	aaaatgaagt	22920
tacaacaaaa	cactccaaaa	gagttataaa	agaaaagctt	gaaggcagtt	gtagaaattt	22980
acctttaaaa	aaaaaatcag	tcactactgt	aacagcta	gtgtcacaat	tttttacttt	23040
aaaaatgctg	tactgttgcc	aatatatattt	taaaaattat	acagccagga	aggtcaaacc	23100
gtgccttggt	atcactaata	accagctacg	gctatctgaa	aagcttggga	aaaaggtttt	23160
gctcgtaga	tgggttcaag	gttactgaat	gagataatgt	tgccaatttc	acctccttcc	23220
tctgaaatct	aaacgagttg	ggatcgcagt	cacaacttcc	ccactacagc	ggactttcat	23280
gaaacttaaa	ggaaaagtga	cctcacctca	ggtctctttt	gacctctgtg	tgtcaaacac	23340
taaattcatt	ttttaagag	aagcaaaatc	cttgcttaaa	aaggctaaaa	gacttccagt	23400
gtttggattt	aacgtttctc	aatctactca	gcctccgaac	acccttccaa	cccagcgtac	23460
ccgaccgcgc	agagttatga	cgggagaagg	caggaaacacg	cagagctcgc	tccaagttaa	23520
cccctgagga	gtcagaaagc	cctaacgaac	agccgggttaa	gactacgggt	gggggctgca	23580
cacttccctg	tgtctcgagc	cctactgcct	tcctacacct	tgccccgcgc	gagaaagcgg	23640
ggactcctgc	ggcgcttggt	cctgaaaag	tcagagcatgt	gcctgacagc	tccgggcaac	23700
cctggcctgg	cttaccttga	ggaccggggt	caggtactca	gccacttcca	gtgcctttcc	23760
cttcacagta	ttaatcacat	tctgcacct	ggggccggag	tagcggccgg	ccccgcgacg	23820
ggatggaaa	tgcagccgtg	tcaggggcca	gggagtcaga	aaatgtcctc	gctgccaccg	23880
actcgcacat	gcacccggt	ggcagcacc	gaggggacgg	gacgcgacgc	gacgggacgg	23940
gcgggacgag	ggggcggggc	ggcaggcaca	gcgcgcgaag	acggggtgcg	cgatcctcgc	24000
accccaggca	gcccgcgacg	gaccggaccc	agctgtcacc	cagccgcgag	ggagggcagc	24060
ggggccgaag	ggagacctga	ggtgagaagc	ggacgcacac	gcaccctcgc	ccctctgcga	24120
gctgtctgtc	ctcgctttgc	ttcactcgcg	ccccctccgg	cttcccttcc	ttctcactct	24180
cttgccgtag	ctgcgcgcgc	accggggcct	cacgtgacac	tagactctcc	cggcacgtga	24240
cgtgagaaa	gggcccgggt	ggggcgggat	aagccgcttc	tcccctcctt	ccggaagcgt	24300
aacactgaac	gtgcctgcgc	aatgggtgtc	gggtccgctt	tttcccaatc	cggacgtaat	24360
cgtggttttt	gttctgcaat	aggcggttta	gagggagggg	ctttttcgcc	tatacctact	24420
gtagcttctc	cacgtatgga	ccctaaaggc	tactgctgct	actacggggc	tagacagtta	24480
ctgtctcagc	tctaggatgt	cgttcttcc	actagaagct	cttctgaggg	aggtaacgcg	24540
cccgcgggca	aggaattgcg	cctgcgtctg	aggggagggt	gcgccagtga	agagccctac	24600
tgcgcagtgt	tgactagaag	ggtagtccct	gactgtgaag	ggaaatctgg	ccccctctgt	24660
cggggaggcg	tcctgtatgc	gtgcgcccac	tgggctgtc	agtattggca	tttctcccca	24720
ctccccgcag	gctctatgct	ctatttctac	agtacgctgg	gaggctttgg	gcaagtact	24780
tacccaacct	ggggttttagt	gtcctcagcc	tatcaaaaga	gggccttaga	ttcattgatt	24840

tctacgatct	cctccatttc	aaacactaac	tagttcagta	aaactttaca	gcagtgtttc	24900
agatatttcc	attttggctg	ttattgtaat	gaagtctgtc	ctaataagct	ttttcctccg	24960
agggaaaaga	ggaggaaaat	acaattctga	aagccttatc	ttacagcaaa	attattttact	25020
aataagagta	aaagcgaggg	cgggcgcggt	ggctcacgcc	tgtaatccca	gcactttggg	25080
aggcagaggg	gggcggatca	cagtcaggag	ttcgagacca	gcctggccaa	catagtgaag	25140
ccccgtctct	actaaaaata	caaaaattag	ccgggcgtgg	tgccggggcg	ttgtagtccc	25200
agctattctg	gaggctgacg	caggagaatc	gactgagtc	ggtaggtagg	ggttgacagt	25260
agccaagacc	gcgcggttgc	actccagcct	gggtgacaga	gcgagactcc	gtctcaaaat	25320
acataaataa	ataaaattta	aaaataaaat	tcaaaattgc	tttgaagaat	tcttttctgc	25380
tggtgcaaag	tgatcatttc	tcacctgcta	cctttgtcag	cagggtcta	ctggttctac	25440
gttttctgtc	tccagagtac	tccctcttat	cagattttca	ctttcctttt	gtcatagtgt	25500
ctttatgcct	caactttctt	ggtgctgata	tagtcatagc	caaaattttt	taaaaattcc	25560
ttttttgtcc	tcacgatcaa	tggtatttgc	gtttagggtc	tgccaacaag	gtcgttcatg	25620
aaagtgtttt	tctctttaag	gtaattaaaa	aacagtggaa	tggaataaca	gtgctgtagt	25680
catcctgtaa	tatgctcctt	gtcaacaatg	tatacattcc	tgctagggtc	catattcatt	25740
gctttaagct	caagtcgcat	cttactagt	aagtattctg	ccaatgaagg	taagttaaga	25800
cttggtatat	gcattggagca	cttccatcta	atcacacatc	tctctcttgc	ctttggttct	25860
gttatatata	acattggaaat	aataatgcct	tttgcttcat	gtgagtgata	aagcatattt	25920
aaatttgatt	atttaacctt	gcattcctca	acaagaaaaa	atgtttgata	atggatgaaa	25980
tgtgagtcac	tcagatacaa	aaatcaaacc	ctttggtgaa	gaaccagtcg	taacatttga	26040
ctgttaattc	aatcaacagg	tggttctgga	cctatagcaa	aatgtgtaat	tgcccttat	26100
tttgaagtag	aaggatata	ttgtttgggc	acttggcatt	tgtaggttac	ttactattgt	26160
aattatttga	tcaatggtaa	ggtgtcagca	ttatattgtg	cggtcatatt	gtatcaacag	26220
tataaattat	aagctttgat	aagtattgat	tttaagaaatc	tttttttatg	tagggattta	26280
agcaaacact	ttaattccac	aaaactgtat	tgagtacttc	ttactagtta	ttgagtgaag	26340
gggtgggttg	ccccctccca	tctgtgggtg	tttctcgtaa	ggtggaacga	gagacttgga	26400
aaagaaaggg	acatagacaa	agtatagaga	aagaaaaaag	ggggcccagg	ggaccggcgc	26460
tcagcacacg	gaggatctct	gccagcctct	gagttccatt	agtatttatt	gatcattatt	26520
gggtgtttct	cggagagtgg	gatgtggcag	gatcatagga	tagtagtgga	gagagggtca	26580
acaggtaaac	acgtgaacaa	aggctctctg	atcataaaca	aggtaaagaa	ttaagtgtct	26640
tgcttttagat	atgtatacac	ataaacattt	caatgcctta	aagagcagta	ttgttgcccg	26700
catgtcccac	ctccagccct	aaggcgggtt	tcccttatct	cagtagatgg	aataatacaat	26760
cgggtttttc	tccgagacat	tccattgccc	agggacgagc	aggagacaga	tgcccttctc	26820
ttgtctcaac	tgcaaaaggg	cgttccttcc	tcttttacta	atcctcctca	gcacagaccc	26880
tttacagggt	tcgggctggg	ggacgggtcag	gtctttccct	tcccacgagg	ccatatttca	26940
gactatcaca	tggggagaaa	ccttggaaca	tacctggcct	tcctaggcag	aggctcgctg	27000
ggctttccac	agtgttttgt	gtccctgcgt	acttgagatt	agggagtggg	gatgactctt	27060
aacgagcatg	ctgccttcaa	gcatttggtt	aacaaagcac	atcttgacac	gcccttaatc	27120
catttaaccc	tgagttgaca	cagcacctgt	ttcagggagc	acaggggttg	gggtaagggt	27180
acagattgca	gaacaaaatg	gagtctccta	tgctacttcc	tttctacaca	gacacagtaa	27240
caatctgata	tctcttttcc	ccacaattga	ggacacatac	aatcatgata	tgacctttaa	27300
tggtctacta	cttgagaggt	cagatgtgta	cccaagtctc	tactgcagtt	aacattttacc	27360
tgccaggcac	taggctaagt	attagcagca	ggttcaaagt	gcataagata	tagaccttgt	27420
cctcaagact	tagtttatta	ggagagacat	gaatgtaaac	acatcatgaa	aatccattat	27480
aataactgca	ataattgata	tatcctgaag	atgcagagat	tgtctagagg	ataaagttat	27540
atattctggt	tggtagggga	tgatgtggag	ttcaaattgga	tcagagaaca	cttcgctgat	27600
tagaagttag	ttgatccact	agaagtcaag	gtgaacaagg	ggattcaaaa	cagaggcaac	27660
agcctgtaaa	agggaacaga	ggcataaaaa	agcaggatat	gttgtagagaa	tatgtagttt	27720
gaaattacca	agcaaaaagt	ttaaggactc	gtagccaggc	acagtggctc	atgctgtaat	27780
cccagcactt	taggagccaa	ggccggcgga	tcacttgagg	tcagggaatt	gagaccaggc	27840
tgcccaacat	ggtgaaaccc	atctctacta	gaaatacaaa	aaattagctg	ggtttgttgg	27900
cgtgtgcctg	taatcccagc	tatgagggag	actgaagcag	gagaatgaac	ccgggaggca	27960
gagattgcag	tgagccgaga	tcatgccact	gcactccagc	ctgggcaaca	gagcaaaact	28020
gtctcaagaa	aaaagaaaaa	aaaaag				28046

&lt;210&gt; 290

&lt;211&gt; 228

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

205

&lt;400&gt; 290

taatatcaag	ggagggacag	gaaggagtca	cagccaagct	ctgtgacagc	tacccccaat	60
gcagaaaaaa	aatctcacaa	aaagacaagt	ttgtggctat	caaacattt	tataactttg	120
tggtcatct	tttagactga	ctttattttc	ttgtttccca	tgtatagcca	taagaatgac	180
aggttaaaca	agttgatttc	ctgtcaatta	tcctttaatt	caattaag		228

&lt;210&gt; 291

&lt;211&gt; 156

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 291

tgggcagagt	ttgaaaagat	tgtagttgaa	gaggtcagga	gctatgtccc	tactgcagtt	60
ttctgcagta	tctggcatgt	catgcacatg	agggaataac	caattatatg	aataaatagg	120
aggtaggttt	tcgtttgat	atttatagtg	ggcaat			156

&lt;210&gt; 292

&lt;211&gt; 14304

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 292

ttctttttat	aatttcacac	tttattacga	gcagggtttt	tgtctcattt	tgttttttga	60
gacagggctc	cagtctgtta	ctcaggctgg	agtgcagtga	tgtgatcagc	ctaagtctcc	120
acacttaagt	ggagtgcata	tgggagacat	cctgggtgtt	ttgggtgttt	ttttgttttt	180
attcgctttt	tagagatgag	ggtctcactg	tgttgctcag	gctggactgg	aactcctggg	240
ctcaagtgat	cctctcaagc	cacctcccaa	gtagctggga	ctacaggcat	gcactgcaca	300
tggtttgtgt	tttgattcag	aacaggtaga	aattcatcta	tatgaatttc	tgtatatcag	360
gtagattaat	ttctgcctgt	tctgaatcaa	aacaaaaaca	agccatggat	gggaaggggt	420
ataggaaagt	gggaggcaac	gcccagttc	ggaaaggctt	gtgtgggtgg	gagaagaaaa	480
gaaaaacctg	ggctgggctg	taagccacac	acctgtaatt	ccaaaacttt	gggaggccga	540
ggtgggggga	ttgctggagc	ccagaagtgt	gagaccagcc	tgggcaaacac	agcaaaaccc	600
cgtctctacc	aaaaaaaaaa	aaaaagggaa	agaaaaaac	ccggaaaagcc	aggtttcctg	660
cattctgcct	ttctaggcag	ggccagagta	agctgctgct	gggtgggctg	cgtgaaagct	720
agtgagtatg	caacaagcct	ggcccttggg	aagcagtaac	cacaggtaac	agagcaaaag	780
agtgacaaca	ctgcctgccc	tcaagactgg	gccaggccct	gggattgggc	cactgggcca	840
acacctcagt	aaggagtttt	ttttattttt	ttttgagatg	gagtctccct	ctgtcgccca	900
ggctgacctc	aggatgaacc	cccctctcag	cctcccaaa	tgccgggatt	acagccgtga	960
gccaccacac	ctggcttggg	ggttagatct	ttaccttgct	ctactttaaa	aatcaatgag	1020
gccaggcatg	gtggctcaca	cgtgtaatcc	cagcaacttg	ggaggccgag	atgggaggat	1080
tgcttgagtc	caggagtttg	agaccagcct	ggccaacatg	tggagaccct	gttgctacaa	1140
attttttttt	tttttttggt	gcgggggatg	cgtctcactg	ctgtcaccca	ggctggagtg	1200
cagtgggtga	atctcggttc	actgcaacct	ccgcctcttg	gtttcaagca	attgtcctgc	1260
ctcagcctcc	caaataagag	gctgaaacca	ccccaggccc	aaaaaataaa	ttaaaaatta	1320
aaaaaattat	tggccgggta	cagtggctca	tacctataat	cctagcactc	tgagaggccg	1380
aggtgggtga	atcatctgag	gtgaggagtt	cgagaccagc	ctggccatca	tggtgaaacc	1440
ccgtctctat	taaaaataca	aaaattagcc	agacgtgggt	gtgtgtgggt	gtaatcccag	1500
ctactcggga	ggctgaagca	ggataatcac	ttgaaccag	gaggaagagg	ttgcagtga	1560
acaagattgt	gccagtgcac	tccagcctgg	gtgacagagt	gagactcttg	caaacaaaata	1620
aaaaagattt	taaataattt	tttctttttt	tagacacatg	gtctcactat	gttgccctagg	1680
ctagtctcga	actcctgggt	tcaagcgatc	ctccagcctt	ggctctccca	agtgttagga	1740
ttacagggtg	gagcctccac	acctgggtata	caaaaaataa	gatgtttaaa	ttagccagggt	1800
acagtgggtg	atacctatgg	tcccaactat	tcaggaggat	cacttgagcc	tgagagggtg	1860
aggcctgcag	tgagtcatga	tcacgccact	gcactccagc	ctgggtgaca	aaggagagtc	1920
ctgttccaaa	aaagaaagg	aggggaaagg	gttaggcag	gtagtccctg	cctgtaatcc	1980
cagcaacttg	ggaggccaag	gcagggtggat	cacttgaggt	caggagttcg	agaacagcct	2040
ggccaacatg	gggaaacccc	gtctctactg	aaaatacaaa	aattagctgg	gtgtgggtggc	2100
ggttgcctgt	aatcccagct	acttgggagg	ctgaagcaga	gaatcacttg	aaccagagg	2160
gcggagggtg	cagtgaagctg	agattgtgac	actgcactcc	agcctgggca	acagagtgag	2220
actctgtctc	aaaaaaaaaa	aaaaaaagac	tcaaaacaaa	acaaaaaaca	aaaaaaaaat	2280

caatgaagct	gtggggacag	aagtaagcca	ggccttgaag	tgctgttagt	gatagaatgg	2340
gggaatcaga	gggtggccac	caaatacctag	acagttcagg	gggcaggaaa	cacatccctg	2400
ccctgggtac	cagccccctc	acctcaccac	cagccatttt	ctatgctcag	aacaaagtcc	2460
aggacaagac	ctgcatctag	actgtaatct	cactgctcac	cagctccctt	aacaggggga	2520
acatcagtc	tggagatgca	gaggtggagg	ctggaccaag	acagtatcat	tttcccagga	2580
cctggcgta	tcctcaacag	cttaaggaga	gacagattcc	attctgttcc	actctctatg	2640
gccttggctg	ccctaacctg	gtagaggggg	agaggctggg	accaggctat	gagggggccc	2700
ctcactccca	gttcagcccc	cagagccgct	gcaatggacg	cagggaggct	tcagcagtgt	2760
atccctccta	cccactgggc	ctagcctgga	agtgtgaggt	agagttgcag	tgtgggtgct	2820
cacgggagat	ctgggtgctg	cacagctccc	ccaggacttg	ctgccattct	ttccttccaa	2880
taagccacag	ctgcttcccta	ttcgcccttt	aggaatcttg	gtgggtggtta	ggccaggcgc	2940
agtggctccc	acctgtaatc	ccaacacttt	gggaagccga	ggcagatgga	tcagtagggtc	3000
aggagttcaa	aactatcctg	gccaaagtgg	tgaaccctcg	tctctactac	aaatacaaaa	3060
aaattagctg	ggcgtggtgg	caggtgcctg	taatcccagc	tactcgggag	gctaaggcag	3120
agaattgctt	gaacccggga	ggcagacgat	gcagtggacc	aagatcacac	cactgcactc	3180
cagcctgggc	aacagagtga	gattccgcct	caaaaaaaca	aaacaaaaca	aaacaaaaca	3240
aaaagaatct	tgggtggtgt	gacaggttaa	ggccaagaaa	ctaaaccagt	tcgatacaac	3300
tcacactgtc	agtgccaggg	gttgggggaa	gaggccctgg	cagctgtgga	gagtgggaagt	3360
accatggatt	tgtaatctga	acgccagtgt	ctgcgtccca	gctataccac	tccttaacag	3420
caggaccttg	actccaaggt	cacctgactc	caagcatatc	acttgactct	agcctgtttt	3480
ctcctctaca	caatgaggtt	aacagcacac	ctcacaagag	tgtggtaata	gtaaaagtta	3540
aagcatacaa	tttgaataca	tacaattgtc	atcactactg	taccaattgc	cccgatccct	3600
gccttcagga	caaactggga	ggtgcctgag	cttccccacc	ccttctccct	agaggccagc	3660
ctctctgtct	ctcccttggc	cctgaggaac	atggtgtgac	cagatggtgt	tgggaaccgg	3720
gtgtccctccc	aactgcactc	caggtacaac	agctaggaac	ctcagagtga	tcaagtgttg	3780
tcatacagaa	acaaggttca	ggaccaacag	tcagagccag	gtggaaagtag	gaacaggggc	3840
gggagctggc	caggtaaaca	ctgcatttta	cacaacaaat	gggaggcctt	gggaagagga	3900
gcagcaggag	agagggaggg	agggaaacgg	agccaggtgt	ccaggacacg	agggagcagc	3960
gtaaggtcag	tgcactgccc	tgggcctcat	cctatgcccc	tgcctccctc	cacccaaga	4020
caaccctggg	ccttcccagc	acttgetgct	cccagagagt	ggtgggtttt	agccttcccc	4080
tcctcagccc	cacgggctgg	aaggcgaggg	gcaggaaaga	acaagaggct	ccagggcacc	4140
tttgagggct	gcagaggact	cagaaatcag	aaccagaaca	ttttactct	ttgggtcttg	4200
ggaagggcca	ggcagagtgc	aagggtgtcca	caggaggggt	aagcagagag	gagctacagg	4260
gggctgcagt	cctagtaccc	tgttggggag	gactgagga	tggtagtatt	ggtctccgga	4320
gggggctcca	gtcctggtgc	ccagttctga	cacctgcccc	tcctgagttc	acactggagt	4380
ccttgcagtc	ctgaaaccac	aaggcctgcc	tgaaccctgg	gtcaggagag	aaacacttgg	4440
ggaggggaaa	ggacggcggt	ggctaccat	gacggctctg	agttcttctc	ggggcttgtg	4500
tctttccttg	gcagaagagg	gcacagccaa	ggcaaggagg	ggctgaaggc	tgcggggcca	4560
tcocggcctg	ccagagccat	gcccctgact	cctcagcttc	aaaatcaggg	gtctcaggac	4620
agaggatgct	gggtggggctc	agagctcatc	aggggggctg	tgtgtgagag	gggatgcctt	4680
ctggatgccc	tcacctcctc	cggggctggg	gtctccctca	aggccaccca	gtccttctc	4740
ttgtttgctg	ctgctaactc	tgccgcctgc	tgccttggcc	ctgctgctct	tcttcttgga	4800
cttcttccct	cccagggcag	ctgtgtctcc	cttcttgcgc	gaccactgct	ctgccaggca	4860
acctagggtg	tggaggagag	agaccctcaa	cagaagtgcc	tcagggctgg	ggtgctgggc	4920
aaggagcact	gagcagggag	ccgtgggagt	agcaactggg	actgtgcttg	acatcagcct	4980
ccctgcctcc	tgctctcgc	tgtggccacc	agggccctct	gggggcatct	gacttgtctg	5040
cccatcatcc	tgcacctggt	ttcagtgact	cttacttcac	catgtcttgc	caatcaagcc	5100
tttcaagggc	agagatcccta	caatgccctc	tgggtgccctc	tgtttctcct	cctaccaccc	5160
tccccaaagg	gagagcaaac	aaatcatcca	gagccagcct	gcccttgctt	ccccaaactc	5220
actggtgtct	tttcccttca	gcacgtgggt	ggcgagagg	aattcagtea	ggtcttctct	5280
ctgggtggtc	ctgtaccagt	cctcgatcac	ctctccaaac	tcttccacca	gcacatcaca	5340
ctgttaatac	taatacctca	tattggcaaa	gccccagcac	ctgactcgct	cctagaggag	5400
ctcagctaag	cctcgcaacc	cactgcagag	taggcagtgg	cagcgggttca	cctaaggaaa	5460
ctgaggccag	agaggtgaaa	tgacctgacc	aaagccaccc	cggcctgggt	ggacttctct	5520
agagcagacc	caatccccac	cagccctcca	ctgggcacag	caacccttcc	aagggtgaa	5580
gggcctgtac	ctgtctcttg	aggtcagcca	cctctgcaga	agtctcgttc	cacagctcat	5640
aggggatgtc	catcaccacc	ttgacccctt	tgtgtaccag	gttgtgtaat	gtctcaaagg	5700
tctctgacat	gccttggag	aagcgaccag	atatggcagg	cggagctccc	ttctctccct	5760
cccaccctcg	tctcccagtg	gtggctaaga	accagctat	aagaccaatg	ctcaacgccc	5820



207

tctaaggatc	ctcatccttt	tttttttgag	aaggagtctc	actctgtcgc	ccagggttga	5880
gcgtctcagc	tcactgcaac	ctctgcctcc	cagggttcaag	cgatttttct	gcttcagcct	5940
cccaagcagc	tgggactaca	aaggcgtgcc	accatacccg	gctaattttt	gtagagttgg	6000
ggttttgtca	tgttggtcag	gctgggtctcg	aactcctagc	atcaagtttt	ccactcacct	6060
cagcctccca	aagtgtctgag	attacaggcg	tgagccaccg	cacctggcct	catccttgac	6120
ctgaccttcc	tcttccctct	tttaggcctg	cttcccacaa	ccctgcaca	tataccctct	6180
gatctgcctc	tgcacacctc	atcgcttcaa	aaagacctgc	ggctgccttc	aggccctttg	6240
gctttatgct	tcttttccag	gaaatagggt	tgtcttagct	ctttcccttc	actatggctg	6300
gaaacactcc	catatcatcc	agacctgctg	ttccgttctt	cctgggttgt	gtctttcctc	6360
agtgggaaaa	aggcatagct	gaggcaggta	gaccctttat	tctgtaaaaa	ctatctctgc	6420
tagctgccta	ggtcttatcc	ccagagaaaa	catactatcc	atttctctta	ttttcccaga	6480
gataactcat	acaaatacca	atatctaaat	atatcctccc	ccgcctttt	tacacaagca	6540
gtggtatagc	atacacacta	ttttgcactt	gcctttttta	cttatacctt	gaagggtctg	6600
gtgcagtggc	tcatgcctgt	aatcccagca	ctttgagagg	ccaagggtgg	ctgatcacct	6660
gaggtcagga	gttcgagacc	ccctggccag	catggtgaaa	ccccgtttct	actaaaaaac	6720
acaaaaatta	gtcgggcgtg	gtggtcgggt	cctgtaatcc	cagctactca	ggaggctgag	6780
gtggggagaat	agcttcaatc	tgggaagggtg	aggttgcaat	gaactgagat	cgcaccactg	6840
cgctccagct	tgggcaacag	agtgtgagac	tctgtctcca	aaacaaacaa	acacacaaaa	6900
accttgaaaa	tcaattgaat	tcagttccta	aagagcctcc	ccatgcttgc	tttccagccg	6960
catactagtc	caccaaacgg	ctggatcaac	gtattttaatc	ccctattggt	agagttagat	7020
tgtttctcat	ttttttcctg	ctatgaaaaa	taattcttaa	acacttttta	ttaaagcaaa	7080
cacagattta	ttactgagtg	caaaattcat	acaaatttct	gctgcttgag	actattccct	7140
taggtatccc	aggagtttat	gaatgggtatc	ctttgctaga	aggaaactta	ggtagaaaaa	7200
tgtgggtggc	aactatctta	ccctgtgcc	ggcactgaag	atgtagagag	taagaactat	7260
gggccttggt	gtaagcagct	cattctccag	agagaaaagc	actcgtacac	atactgagta	7320
catggggccat	cacaagggca	tcccagcggg	gltgtgggag	gtgctgtgtg	gacccagaga	7380
tgggactggg	cagtcactcc	caccgagggtg	tcctctgaca	cctcgccata	accccacct	7440
ttctgcacat	cgtggatctt	gctgagttct	ccccgttcta	gtgtctttag	gttcccacgg	7500
gggcagcaac	tgtggagcat	ttctgcctgt	gtctgagatt	gaagcaggac	cctcatgaac	7560
aggcccagac	cctcatgcat	gtgcctgaaa	aatgaggcca	ctcaagaggg	gaggagcaca	7620
aacggcaatc	aaagaatggg	aagaggcaat	gaagggaagat	cccagggtgg	catcttcaaa	7680
tcacactcac	accagcagac	acactaagat	acatgcaggc	ctgacccag	agcggatgaa	7740
ggacaatccc	gaatccaacc	ttggcaaatc	gattgctgcc	ggtcctctcc	ttgtgcaggc	7800
tataatccag	gagcctcttg	caaatgggtct	gattgacttc	gattaaccgc	aagtccttgc	7860
caagacagga	ggatgaggaa	ctgagttccc	ctcctagccg	cagtgggtta	gtggtctgtc	7920
cctccagccc	tgtgccccaa	cacctgcaca	tctcaccaat	gggaagtga	tcagagctgg	7980
aaggaagata	ggatcatctg	tctgggggat	ctgaaatgct	ggaacacaga	ccagagagac	8040
aaaatttttaa	cagctctaa	ggaagggaatt	ttttataaag	ctaaatgatt	cagtatttag	8100
attttttgat	aaagcaaaat	tattaaattt	tgatagtaaa	atatcattct	ctttgaaagg	8160
atgatcacag	ctgacagaat	tgggttttta	aaaactatat	ttgtacctag	caaaataaaa	8220
agctggtaat	cgtgttacta	atgtttttaa	aaattgcact	gtggccgggt	gtggtgtctc	8280
acacctgtaa	tcccagcact	ttgggaggcc	gaggcaggcg	gatcatctca	ggtcaggagt	8340
tcgagaccag	cctaaccaac	atggtgaaac	tccatctcta	ctaaaaaaat	acagaaaatt	8400
agctgggctg	gatggcacat	gcctgtaatc	ccagctactt	gggaggctga	ggcaggaaaa	8460
tctcttgaac	ccgggaggca	gaggttgcag	tgagcaaaaga	tcatgccatt	gcactccagc	8520
ctgggcaaca	agagtgaaac	tccgtcgcaa	aaaaaaactt	gcattgtctc	gtgaaatcca	8580
agcgtctgag	aatcaatgat	atagtccaac	agctcttgct	ttagagatga	gaaatctgct	8640
gaagcataaa	gaagttaaga	gatttatgca	cgtcacccaa	ttagctgggg	acagaatcag	8700
tgggcaaaact	caggctcttg	ttacaaatga	tgccttgta	gggggtttgc	ctagctagga	8760
gaagggaact	ccaaaccctt	gaagcctcca	gcagcaacgc	aggccaggcc	agtgagtccc	8820
cattcactta	cgacttggtg	tatttgactc	cagaggcctt	ctggtccagg	atgccatagc	8880
ccgtgccaat	cacctccttg	gtcttgccgg	tttctcaaaa	ggctgacttc	agctccacag	8940
caacatattt	acacactggg	ggaggggagt	agcacagccc	actgagtga	catgagtcta	9000
atgggaggcc	agctcccagc	aaaacagatc	caggtgggca	tcctttccta	gactggagga	9060
ccaaaatcag	catctaaggc	aggggaaggag	ttagaacctg	tggaggctaa	agcaactcca	9120
tcttggtatg	taatgtgcca	tgttgacttc	tgattaaacc	cagtttcagg	aatgcctcta	9180
ggatttctat	tttatctact	gtttcttggt	taagagcatg	tacttactgt	aaatcctgcc	9240
cttaagcaat	tgttcttcgt	attccttttt	tttttttgag	atggagtttc	gctcttggtg	9300
cccaggctag	agtacaatga	tgagatctca	gctcctgggt	tcaagcgatt	ctcctgcctc	9360
agcctcccaa	gtagctggga	ttacaggcat	gcaccacat	gcacggctaa	ttctgtattt	9420

ttagtagaga	cagggtttcat	cttggtgggt	aggctgggtct	tgaactcctg	acctcaagcg	9480
atccgcccac	ctcggcctca	caaagtgctg	ggattacagg	cgtgagccac	cacgcagggg	9540
tctatcattt	tacttttctaa	aattgcatac	atacagaaaa	gctgaaagaa	cacaatgaat	9600
accttccact	tgtattcaac	agttgttaat	agtttgccac	attctctctt	caatatataa	9660
ttataatatc	tcaacaatat	atacatttct	tttgctacac	catcttgaaa	gtaagtggca	9720
aacatgacct	tttgagataa	atataatcatc	atgtatctcc	tgagaaaaaa	gacctcctcc	9780
tacataacca	tagaacaatt	atgatacttg	gaaaaattaac	aattccaaca	tcacccagta	9840
gtccatatct	aaatttccct	aattgtcccc	aaaacatctt	ttatggttgt	tagattactt	9900
gatttccatat	gtgttccaac	atcagctcta	tttctaccaa	gttaatttgc	tccatgccct	9960
ccagagagct	cttggttccta	ctgtctccgc	acatttattt	cctcatttcc	tcttaccctt	10020
cctcaaatag	gtattaggca	actcctacgt	gtcagcctgg	ggatacacag	atgaaaaaaa	10080
ggccccctcc	cttccagata	ctcagtcctaa	tgcagcagat	aaagggtgtag	acaaataact	10140
accactgtat	agagtgtctac	agtgtctacca	ccgaggggtg	gaagtgcctg	aggccctagg	10200
aaaataactta	atgcctttcta	agggtctctc	tgcccatcct	gccccctcg	cattataagc	10260
ctctccccca	ggaagccatt	ctgcactaat	gccaatgtct	ctagatttca	ctctgggect	10320
ctgcaggatc	catgtctctcc	ctaaggaccc	tcagtcattt	gatgtgtctc	tccacataga	10380
ccacaaggg	ccccaaaatg	tgcattatgt	attagatttt	ttcgtatttc	cttagcctgg	10440
gacttgatat	atgctggacg	ctcgataaat	cttggtgata	gagaccgtct	tctgatgcct	10500
ctgaatggaa	taccagtcctg	aaggctaaat	gccatcagca	gttttaacac	tgacagcaca	10560
gtctgtgtag	ataccaattt	accacaaaaa	taaatacatc	ccctggaggc	ctgctgtgtg	10620
aaattaatca	atggcttgga	gaatttgaaa	cacatacaaa	ttccaagtaa	taagctgggtg	10680
atcttcaagt	ctgcaatgaa	ctggggatgt	ctcacctccc	cagctctcca	tccaggacca	10740
tctgggctcc	ctccccctct	ctgtcctgta	ctctgtgcag	gcacatcatt	tttctagcac	10800
cacttgcccc	tctctcccacg	ccctccccag	gagtggggaa	aggggagggt	tggaaacatcc	10860
tttctctctc	ataccatca	accacagcct	tgctttccag	ctcttccaaa	cattacctct	10920
tcaagacctc	ctctgcggt	cccaccaga	accagactca	caggagattc	acggcacaga	10980
caccagacct	tcaactgacat	ccaccactc	ttttttccg	ggcagggtct	ccttctctg	11040
tgccgaggcc	tgttccactc	aggctactga	gccaggaggc	aggcttggtg	ggctagacac	11100
agtcagcatt	taataacaaa	ggtgtaataa	taatacaaac	aaatatacta	ttaagatgaa	11160
cctaacgggt	ggagtttgcc	aagccatcct	gtgactgcaa	atcccttttc	aattaatctt	11220
catcagttac	caaatgaggg	tagactagaa	tgatctctag	atatagagat	atagagatcc	11280
tgggcatctc	tatgcttccg	tgagtctgtg	aatgttgctt	aaggagaata	aatgtgagct	11340
ccttaggcta	tgagaataat	aagagggaga	gtatgggtc	tttgatatca	gaataagaca	11400
gaatacaggg	tgggcaagg	ggctcatgcc	tgtaatccca	gcaatttggg	aggctgaggt	11460
gggaggatca	cctgagggtca	ggagttcaag	accaacctgg	ccaacatggt	gaaacccagt	11520
ctctacaaaa	atacaaaaat	taccgggcca	tgatggcagg	tgctgtaat	cccagctatt	11580
caggagggtg	aggcaggaga	atcacttgaa	ccctggaggc	agaggttgca	gtgagccgag	11640
gttggtgcat	tgcactccag	cctgggcaac	agagcaagac	tccgtctcaa	aaaaaaaaaa	11700
taataataat	aataagacag	aaaagaaaga	gaagagggaag	cgaacgctg	aaaggctatc	11760
agtgatgtgg	gtgggtgca	gtggctcacg	ctgtaatcc	cagcactttg	ggaggctaag	11820
gtgggtggat	caccgaggt	caggagtcca	agaccgcct	ggccaacatg	gtgaaaaacc	11880
gtctctacta	aaaatagccg	ggagtgggtg	cacacacctg	tagtcccacc	tactcgggag	11940
gctgaggtag	aagaatcctt	gaacctgggg	gacggagggt	gcagcgagtc	aaggctgcac	12000
cactgcactc	cagactgggc	agagcaagac	tccgtctcaa	aaaaaaaaaa	aaggccaggc	12060
acgggtggctc	atgcctgtaa	tcccaatact	ttgtaaggcc	gaggagggtg	ggtcactgga	12120
ggttgcggtg	agccaagatc	gcgccactgc	attccagcct	gggcaataag	agcgaacctc	12180
catctcaaaa	aaaaaaaaaa	aagctatcag	gactagagga	agagcgaaaa	gtgaaaaggc	12240
ggccaggagc	agaggctcac	gcctataaag	ccagcactgt	gggagcccaa	ggcagggtgga	12300
tcaattgagg	tcaggagtcc	aagaccagcc	tgaccaatat	gatgaaatcc	catctctact	12360
aaaaacacaa	aaattagctg	ggcatggtgg	catgcgcctg	taatcccagc	tactcaggag	12420
gctgagacag	gaaaaatcgt	tgaacctagg	aggcagagggt	tgcaataaag	cgagatctcg	12480
ccactgcact	ccagcctggg	caacagagcc	agacagtctc	ataaaaaaaa	aaaaggaaaa	12540
aaagaaaaa	atgtacgggg	gaaggcacag	gcttgaactc	atactgggtg	ccctaccagt	12600
gaagtcggct	tatctctaaa	gcctcctttt	aatctctcta	atggaaggat	tatgtgtccg	12660
aaacttacct	caaacccact	ttccagtgtt	tagggaacat	ctggcctgat	gtaggctttc	12720
aattcagatg	agagattcac	agccaacttt	ctgggggccc	tgggggttac	gggctaggaa	12780
ggcaggcatg	actgtaagggt	ctgaggagaa	aactaaggga	cggagttagg	gaaaaagaaa	12840
taggtccttt	atagtcctgg	ctcgctggta	gctccctctc	tctctctctc	tgtagtctct	12900
caacgcctat	gtctttggga	ctcacctttt	ctccaaagtc	ctaaaatctt	ctttcaagtt	12960
ccccataggg	tctattgttc	ccccaaaggg	ctcctcagat	ccagatcctc	ctcctcacac	13020

209

acacccacag	tctcccattt	aatcatctgt	attctcaaaa	catttattga	gtgcctacca	13080
gacactgtgt	gaatacgtat	ctaagacaaa	aattcctgcc	ttcgaggagt	tgttagtggg	13140
tgcaacagac	aactacacag	attgggttgc	agtgagggca	aaaggggaaa	gtcttagggt	13200
tttttcccc	aagatgagtc	atctggagct	tttcagttcc	tcaaaactcg	tcttagcttc	13260
tcagccggca	ggcctctgcc	tctgtagttt	cctgagtggg	cccctctctt	tccacttctc	13320
ttcatccggc	taactcctaa	tgctctctcg	tgcttctgt	atgaagccct	ctttgactcc	13380
cctctgcaca	cagccttcgc	ccacccctc	ccccactcca	ggctagacca	gatgctcctc	13440
gtccggcccc	caaaaggaag	ctctgtacct	cccctatcat	ggcatctact	actctgaatt	13500
atcattgctt	gtttctacca	atgtgtgaac	tccaggggta	ccgggaccag	atctctcgtc	13560
cgccgcagcg	tcccggcgca	agcctgttca	aggaaggaag	acaccctgca	gagctcggaa	13620
ccttgcaacc	cccgcagctg	ctccgcaagc	accaccgctg	gagccagccc	ctccggcagg	13680
atacgcccca	cgggccccgc	ctcctcacct	tcgcatttgc	tgggcaggcg	aaccagctcg	13740
ttctctccgc	ctccggcctg	gctcggggcc	agctccgggg	ccggcagcag	cagcagcagc	13800
agcagcagca	agggagaag	cagaagacag	cgggacgcgg	gctcaggcat	tgaatccatg	13860
gcccggccgg	gcccggacc	taaaggaccg	ggcggttctt	cctcccgcg	cgcgcgcgga	13920
gcagtttccc	ctcgccgctt	ccgggactgc	acacgtgcct	ccgagcaacc	acgacaacag	13980
ctagcctccc	gcccgccttc	ctctcgcagc	cgagcccgcc	cttcaaagcg	gaccaaggcc	14040
cgcgagcggc	gcagccaata	ggctttctcg	ggtttgcctt	ctagctaatt	ggaagactat	14100
ctttttacgc	ccttggccag	taagagagca	gatggtggcc	tcagcgacct	atggcaaagt	14160
cctttccccc	ccccaacgg	aggctctggg	agagagagga	tcaggacca	agaccgcaga	14220
agaagcctgc	gtctgggcct	gggtgggacg	gattcaggcg	cgcaggtgct	ggaagatgtg	14280
gggaaggccg	tcttcggcgc	tttc				14304

&lt;210&gt; 293

&lt;211&gt; 219

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 293

ctggctcatct	gtggttcttt	taatcattga	actggaacaa	actggccttg	tggtctgtcc	60
atcagccctc	gtggttctag	ttgatggaag	tcttcaacag	agatggagcc	attctgtctgt	120
ttgtgtttct	gaggacaaga	cattgaccca	ctgtaaattc	actgaagtcc	tgccccatct	180
taggacaaca	ccctgggttt	atcttgggtga	agtgaagttc			219

&lt;210&gt; 294

&lt;211&gt; 15090

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 294

acgttcccta	cttctctgtgc	tcttgccggag	acgcgcgcgt	cggggtttta	cgcgtttctg	60
ggccgcgcga	agcccgccct	aggggcagct	ttgactcgag	agccggctat	aggcgcatgg	120
aagggttccct	ggaacggggag	gcgccagcgg	ggcgctggc	cgccgtgcta	aagcacagct	180
cgacgttgcc	gcccgaagc	accaggtcc	ggggctacga	cttcaaccgc	ggtgtgaatt	240
accgcgcact	gctggaggcc	ttcggcacca	ccggcttcca	agcaaccaac	ttcgggcgcg	300
ctgtacagca	agtcaatgcc	atgggtgagga	ccgggcggaa	tttctagggg	cgcgaggggg	360
cgtggcttgt	agaaccaacg	cgttactaga	cgggggcagc	gtttccagt	gaggggatat	420
gtcttttatt	tgagttgccc	aatagttggg	ggaaggcggg	acctattctg	ggcgggagtt	480
tctgtcctgg	gaaggggatt	ttgcactctg	gtagttacat	gctggtacgg	taacctgagg	540
aggcgaggac	tgattcttgg	tgtggggcg	ggttctaggt	acatttaaag	ctttctggaa	600
tgggcggagc	ctggggcaag	acaaattaag	ggaggatatg	ggaggaggag	cctaagtctg	660
ggcggttctt	gaatttagat	ttgcttttcc	cagcggggaa	gggaccggat	ctgaaggag	720
atgctctctg	attcctaaaa	gggtgggggc	tggtggggcg	cggtggcgca	tgctataat	780
cccagacttt	tgggaagccg	aggcgggtg	atcaagagaa	gaggagttcg	agacaagcct	840
ggccaacatg	gtgaaaccct	gtctctacta	aaatgcacaaa	aattagccgg	gcatggtggt	900
gcgcgcctgt	agtccagct	actcgggagg	ctgaggcagg	agaatcgctt	gaaccgcgga	960
ggtggagggt	gcagttagct	gagattgcgc	cactgcactc	cagcctggtg	acagagcgat	1020
actctgtctc	aaaaaaaaaa	aaaaaaaaag	gccgggcacg	gtggctcatg	cctgtaatct	1080
cagcattttg	ggaggccgag	gcgggcggat	cacctgaggt	cgggagttcg	agaccagcct	1140
gaccaacatg	gagaaacccc	gtctctacta	aaatgcacaaa	aattagccgg	gcatggtggt	1200

gcgcgcctgt	agtcccagct	actcgggagg	ctgaggcagg	agaatcgctt	gaacccggga	1260
ggtggagctt	gcagtgcgac	gagatcgcg	cattgcactc	tagcctgggt	aacaagagt	1320
aaactccgtc	caaaaaaaaa	aaaaaaagg	tgggggcaaa	tccatgaacg	gtgtcttgag	1380
atctggctcg	ggaaggggca	gagtttacac	aggagatggt	ccttgggtccc	ctgtagaact	1440
ggtcctgtat	ccctgaatgt	gcagggcctg	gggtgaaatc	tgtttctgga	gcccacctgg	1500
agtcctgagt	ctgggattta	aggccagtgc	ttaacttgac	ttggccctta	ctcacagatc	1560
gagaagaagc	tggaaacct	gtcacaggat	gaagaccagc	acgcggacct	gaccagagc	1620
cgccgcccac	ttaccagctg	caccattttc	ctgggatata	catccaacct	catcagttca	1680
ggcatccgtg	agaccattcg	ctaccttggt	cagcacaaca	tgggtggggac	ctgggtgaggc	1740
cgtggccttg	gcctctgggt	caatgggcaa	tgcagttatt	gatcggttaa	gtgagatggg	1800
cagatagggg	tctgttataa	gcagaggaat	agaatcaagt	tttgttttgt	agcagagctc	1860
cctcataaga	gtcactggac	aaggatgagg	ttagaagttc	tgcccagaat	gagggcaggg	1920
ggtcccttct	tgggccaat	tcactgcctt	gtggctgcag	gtggacgtat	tgggtgaccac	1980
agctggcgcc	gtggaggaag	acctcatcaa	gtgcctggcg	cccacatact	tgggcgagtt	2040
tagcctcagg	gggaaggagc	tccgggagaa	cgggatcaat	aggtgagaac	cctgagtggt	2100
gttgggcagg	ggagctggac	caagggtcct	ggggcctgat	gcctacatgc	ctcctgttct	2160
caggatcggg	aacctgctgg	tgcccaatga	gaattactgc	aagtttgagg	actggctgat	2220
gcccattctg	gaccagatgg	tgatggagca	gaacacagag	gtggggctgg	ggcaacctgg	2280
agggggcagt	tcagtgggag	tcaggggagg	catggcctga	aggtcacatc	ctctcctagg	2340
gtgtcaagtg	gcagccttct	aagatgatcg	cccggctggg	caaggagatc	aacaaccag	2400
agtcctgtga	ttactgggcc	cagaagggtga	ggacctaaag	gggagcaaa	tagccagact	2460
ttggcatgtg	ttactttatt	tcatctttcc	agcctcctgg	ggattcagta	ctgttattct	2520
cagcatcctc	actcttagat	gaggagactc	aaacacagat	agggctggta	attttttttt	2580
tttttgagac	aggatcctgc	tctgtcacct	aggctggagt	gcagtgggtg	gatcacagct	2640
cattgcagcc	tcaacctcct	ggggccaagc	agtcctccca	cctcagcctc	tcgagtagct	2700
gggaccacag	gcacatgcca	tcatgcccag	ctaattttta	aaattttttg	tagagatggg	2760
ggtctccctg	gttttcccag	gctggctctg	aactcctggc	gtcaggcagt	cctcccacct	2820
tggcctccca	aagtgtctgg	attacaggcg	tgagccactg	tgcccagcca	ggctaggtaa	2880
ttttgtctga	agtcacacag	ataactagt	gggcctcagc	atccttatgc	tcctcccaga	2940
ctatctctgg	aacagtagag	gcaacactta	gcaactctcc	tggggcctgg	ctcagggctc	3000
cacactccca	gatgctataa	aataagagct	accactcccc	tttaattaga	gaatcagaac	3060
ctgaaaaaaa	aaaaaaaaaa	gctacatagt	cttttttttt	tttttttttt	ttttgagaca	3120
gagtcctgct	ctgtcgccca	ggctggagtg	taattgggtg	atttcagctc	actgcacctt	3180
ccacctccca	ggttcaagt	attctcccg	ctcacctccc	tgagttagctg	ggactatagg	3240
caccacccat	catgcccggc	caatttttgt	atttttctac	agatgggggt	tcaccatggt	3300
ggccaggctg	gtcttgaact	cctgacctca	agtgatccac	ccgccttggc	ctcccaaagt	3360
gctgggatta	caggggtgag	ccaccacacc	cagcctactt	actctttctt	ttttacgaga	3420
cagggctctc	ttctgtttcc	caggctggag	tgcaatggca	caataatggc	tcactgctgt	3480
cttgagcttc	tgggctcagt	cgattctcct	gcctcagcct	gctgagtagc	tgggactaca	3540
gagtcgctg	accatgcctg	gctaattggt	tttgtataga	tgggaactca	ccatgttgca	3600
caagctggct	cttttttttt	ttttgagacg	gagttttgct	cttggtacct	aggccagagt	3660
ccaatggcgc	aatcttggct	cacagcaacc	tctacctcct	gggttcaagc	aattctcctg	3720
cctcagcatc	aagttcccaa	gtagctggga	ttataggcat	gtgccaccac	ccctggctaa	3780
ttttgtattt	ttagtagagg	caggggttct	ccatgttggt	caggctgggtg	tcgagctcct	3840
gacctcaggt	gatccaccgg	cctcggcctc	ccaaagtgtc	gggattacaa	gcgtgagcca	3900
ccgcgcccgg	ccacaagctg	gctcttttaa	aaagaattag	acggccgggc	acgggtggctc	3960
atgcttghta	tcccagtagt	ttggggggctg	aggcgggtgg	atcacctgaa	gtcaggagtt	4020
caagaccagc	ctggccaaca	tgggtggaacc	ctgtctctac	taaaaaaaca	aatgcaaaa	4080
ttagctgggc	atagtggcat	gcgcctgtaa	tcctagctac	tcgggagggt	gaagcaggag	4140
aatcactgga	accaggagg	cagaggttgc	agttagctga	gatagtggca	ttgcaactca	4200
gcctgggcaa	cgagtgaac	tccgtctcag	ggaataaaaa	aaaagagaga	gaaacagctc	4260
agcaagctaa	gaataggctg	gttcttttatg	tgccaggcac	tatactaagt	gttttctgtg	4320
ggttttctca	tataggcctc	atctgtgaga	gggtgttctg	ttatgcttat	aattgaggaa	4380
acagtcctag	agaaatttag	caccccatcc	acagtcagat	agtcataatg	ccagcatgga	4440
gacgaggtcg	tgagctccag	ccactgtcct	gtcatgttct	ctgcagaacc	acatccctgt	4500
gttttagtccc	gcacttacag	acggctcgct	gggcgacatg	atcttcttcc	attcctacaa	4560
gaacccgggc	ctggctcctg	acatcggtga	gggtgaggcg	ctagggccac	agaggagagg	4620
ggaaggaggg	ctggctgagt	ccaaggcctg	acttcggcgc	tcttccccca	gacctgaggc	4680
tcatcaacac	acaggccatc	tttgccaagt	gcactgggat	gatcattctg	ggcgggggcg	4740
tggtaagca	ccacattgcc	aatgccaacc	tcatggtgag	tgggggtggc	gcttcggccc	4800

211

actctgcaga	catgctgtgt	ggtgggccta	tgccatgtgc	tgggtagaca	gcatgaacta	4860
gacaggccag	gatccctgct	cccgggact	gatgttctag	taggggagat	agcaaacaag	4920
tgacatccac	gtcagggggc	agtcaattgct	acggggaata	ctaaatgatg	gcatgagaag	4980
agaaaggggt	gctgtccaac	aagaggtttt	ggaaggaggc	ttctggaagt	gtgagctggg	5040
agcaggggtt	tggggaggca	tctcccagga	gctatgtggt	tgtctcccg	gccaggagtt	5100
tgtgctgctg	tactagcatt	gagcttctgg	attgcaaagt	tcccaggaga	gggaacagcc	5160
attgcaaagg	ctctggggcg	cctgaagtaa	tccaggaaca	gctgggtacc	tggtaggggg	5220
aaggtggagt	ggtgagggcc	aggaggtgat	gcagggaggt	gccacagga	gcctgctggg	5280
ccctgtgggc	tgaggcgggg	ctttggcttt	tgcactgaga	gaagtgggag	aggacttgac	5340
tggggttccc	atgctccccc	tggtaggecat	gtggtgaaca	gatggtggca	ggtgagttag	5400
aactccagtc	caggacagtg	gtgaccatgc	agggatcagg	aggcaggcgg	tggttggatt	5460
tggagggctt	ctgaagatag	agttgctggc	agctcctgcc	ttgcagatgg	ggcagggttg	5520
ttgacacctg	gctgttgggt	ctggggaaac	acagccatcg	ttgccagca	gctctagtga	5580
ccccagacat	tgacatgggc	cctgtctggg	aggcaatgtc	tgtgaagggc	ttccttcac	5640
tgggacacac	ctctcagcct	gtttggtctac	ggtgtcctcc	ctctgtgtct	gtctcctgtg	5700
actggctgac	tgggcccacc	gtgccccgc	ctccccacag	cggaaacggg	ccgactacgc	5760
tgtttacatc	aacacagccc	aggagtttga	tggctctgac	tcagggtgcc	gaccagacga	5820
ggctgtctcc	tggggcaaga	tccgggtgga	tgcacagccc	gtcaaggtaa	gcgctggctg	5880
ggtggggcat	agggtctctg	ggacgatgag	tgtgggtccc	atggcttacc	caggttcccc	5940
cctaccacag	tctatgctga	cgctccctg	gtcttcccc	tgcttgtggc	tgaacctttt	6000
gccagaaga	tggatgcctt	catgcatgag	aagaacgagg	actgagcggc	tgcggtccca	6060
ggaaggctct	acccctctct	ctatttatta	atttgcagac	ccagccctc	ccctactttt	6120
tggtcagcta	cgtctctaga	ataagatggt	atctgaagtc	cttccatgtc	tgtgtctcgg	6180
tccttggtcc	tgttgggtgg	tcccttggt	tcagcctgct	ccatcctctg	cctcataggg	6240
ctcctctcgc	cagcactgga	cgctgcctcc	catggcggtc	agcaggcagg	gctctgttgg	6300
gtggtaggcc	agcgactgca	ccacaccgga	accacaggc	agggccagag	ccagcgcacc	6360
ctgtggagcg	aggggtaggg	agtggttatc	tgtggctggg	ctgtaccctg	gtttctbgagg	6420
tccttgggca	cccccatct	cagtccctgc	tgaagccctc	agtcacctct	ccccgacctt	6480
cagccacctg	cctctaattg	cctcctagac	actgcaaaat	taatctacct	cagactgagc	6540
ccctcagtag	ctctgtccta	ccaggtgttc	aggccgcaag	tcttgggagc	ctcttattga	6600
ttttttatatt	tttaaaatag	cagagatggg	gtcttaccat	gttgcccagg	ctggtctcga	6660
actcctggcc	tcaagtgatc	ctcctgcctt	ggcctcccaa	agtgttagga	ctacaggtgt	6720
gagccaccat	gcctggcttt	gggagtcttt	ttctttttct	gttttttttt	gagatggagt	6780
ctgtgctctg	cgccaggctg	gagtgcagtg	gcgcactctg	ggctcactgc	aacctccgac	6840
tcctagtttc	aagcgattct	cctgcctcag	cctcccgagt	agggtgggatt	acaggcacgc	6900
gctaccatgc	ccagctaatt	tttgtatttt	tagtacagat	gggggtttcac	catgttggcc	6960
aggatgatct	ctatctcctg	acctcgtgat	ccacccccct	cggcctccca	aagtgtctggg	7020
attacagggtg	tgaaccacca	tgcctggccg	ggagtctttt	tcttgtacca	catgttccctc	7080
tatcagttat	tctctttggc	tctgcttcta	gaccatgtcc	agagactgct	gattttctgc	7140
cactaccatg	tttggagcat	gccttgtctc	atcttgcct	gttccctgcc	accagctggg	7200
ctccatcctg	tccatttggc	agcccaatg	atccccactt	cccctggtcc	caacacaatg	7260
taaacagttc	ctcaagcaag	ccatgcttcc	tctttccacc	ttgaaaatgt	cccttgatgt	7320
gcctgccctc	caaggcaact	tctgttctac	tgggcccata	agaaataggt	ggaacattct	7380
tgtacacctt	gttcctaaag	caagagcttg	tccgccaagt	cttcaggggc	cccccggttc	7440
cctccatcct	cttatgggccc	ttagtccccc	tggccaagcc	cagcgtgat	gtctcctttg	7500
ccgagattcc	cccggctctg	acccactac	accaggatgg	tctgtttctg	gcctgactcc	7560
ccaccaggct	gggacatgtc	aaggacaggg	ctcagggtct	gaaaccatgc	acagggatgc	7620
taagatgtag	ctccagtttc	ttgaatgact	gcagccctat	ctcaccacaag	gttagacatg	7680
gccgtcggct	cccccttggc	caggggtcag	tgccagttgc	tggcctggc	atctgcagcc	7740
cagcctgacc	ccggtctctg	ccgcacctgc	cgccaccctg	aagcctttgt	ttcctgactg	7800
atgcatgcgc	aggctacacc	tcttaacata	tgctgttccc	tttgccctgga	atgcccttcc	7860
tgcctcatct	tctctctagc	ccaagctggg	cacggtgtct	caggcctgta	atcccagcac	7920
tttgggaggc	cgaggcgggt	gaatcacttg	aggtcaggag	tttgagacca	gcctggccaa	7980
catggtgaaa	ccctgtctct	actaaaaata	caaaaattag	ccaggtatgg	tggtaggggc	8040
ctgtaatccc	agctactcag	gaggctgaga	cattgagaatc	acctgaaccc	tgggggggag	8100
aggttgcagt	gagctgagat	ggcgccactg	catttgcctg	ggcaatagtc	tcaaaaaaag	8160
aaaaaagggc	cgggtgtggt	ggcttacgcc	tgtaatccta	gcacttggga	aggctgagggt	8220
gggtggatca	tgaggtcagg	agtttaagac	cagcctgacc	aacatagtga	aacctgtct	8280
ctactaaaaa	tacaaaaatt	agctgggtgt	ggtggcacgc	acctataatc	ccaactactc	8340
aggagactga	ggcaggagaa	tcgcttgaac	ttgggaggcg	gagtttacag	tgagccaaga	8400

212

ttgcgccact	gcactctagc	ctgggcgaca	gagcaagact	tgtctcaaaa	aaaaaaaaaa	8460
aaaaaaaaaa	aagatcctag	ccttcaggcc	ctggagtgac	tgaggtaagg	acagggtcga	8520
gatggggcag	gcactctaggt	atgaagtagg	gctgggggca	cctcacctcc	accagggtccc	8580
agaagaacac	cttcccgtcc	tcagaacagc	tgaccacatg	tgtgtcacgc	tcgctcaggc	8640
agcagtcag	cttgattcc	tggttcttat	ggcccttgta	cctaagggtg	gacaggatcg	8700
gggggcttgg	tcctctccag	gggtgggaga	ggaagggaagg	ggatccccac	gaccacaagg	8760
actcactcgc	ccagcagctc	ccctgtgtct	ttgtccagga	gccgcaatgt	ggagtccagg	8820
ctggacacca	gggtgcactg	cccatcccgg	ctgaagcagg	tgagggtgat	ggggccttgg	8880
gggaagggtg	ggtagggtgag	tgagggtggg	gtgcccctgg	ttggccccc	atcttcctcg	8940
cctgtcccac	atccccagcc	acactcactg	cccacgtagt	ctgagaagag	ctgccccatc	9000
cttaggtcat	agcgtctcac	gcggccatcc	acggagctgc	aggagagggt	agatccagcg	9060
ggaaccttga	ctacactcac	atggctccag	gcagccctgt	gccttcccag	cccagtgggc	9120
ctgctcttcc	agtgcacagg	agtggaattc	gccttgagac	tcaggcccag	tcaggcccag	9180
ggccaattac	gtcctactcc	atcatttcca	agaccacac	cccctttcca	agcccttgga	9240
gtccttctga	ttcccccttt	tcttcctttt	gtttgagaca	gagttttgct	cttgtttgctc	9300
aggctggagt	gcaatggcat	gatcttggct	caccggaacc	tctgcctccc	gggttcaaga	9360
gattctcctt	cctcagcctc	ccgagtagat	gggaatacac	gcattgacca	ccacgcccctg	9420
ctaattttgt	atttttagta	gagacggggt	ttctccatgt	tggtcaggct	ggtctcgaac	9480
ttcccaacctc	aggtgacccg	cccacctcag	cctcccaaag	tgctgggatt	acagggtgta	9540
gccaccccac	ctggcccaat	tcctcccttt	cctgcattct	ccagctcctc	ctcctcagta	9600
ctcagtccca	ccactttccc	cactaccag	caccagcatc	tagactgttc	tggtctccct	9660
gcacccccca	cagccaccag	agggagcact	tttcaaagta	cagttgacct	atgaacaaca	9720
cgttttgaac	tgaacgcgtc	cacttatatg	tggattttct	tctgcctcta	tcagctgtga	9780
gacaccaaga	tcaatccctc	ctcttctctc	tctcttgctt	tctcaacacg	aagatcttta	9840
tgacgatctc	ttcacttcca	cttaatgaat	agaaaatata	ttttttccac	caggcgcggt	9900
ggctcacgcc	tgtgattcca	gctctttggg	agggcagggc	aggtggatca	cgaggccaag	9960
agatggagac	cctctggcc	aacatggcga	aaccctgtct	ctactaaaaa	tacaaaaatt	10020
agctgggcgt	ggtggcacgc	gactgtagtc	ccagctacta	gggaggctga	ggcaggagaa	10080
tcgctgaac	ctagaagtta	gaggttgacg	tgagccgaga	tcacgtcact	gcactccagc	10140
ctggcaacag	agcgagactg	cgtctcaaaa	aaaacaaaaa	ttcttcttta	tgattatttt	10200
tatgtattta	tttatttaat	ttatttactt	attttgagac	ggagtcttgc	tctatcgccc	10260
aggagtgtag	tggtgcgatg	tcggctcaca	gcaagctctg	cctcctgggt	tcactccatt	10320
ctcctgcctc	agcctcctga	gtagctggga	ctacaggcgc	ctgccactat	gcccggctaa	10380
ttttttgtat	ttttagttaga	gacggggttt	caccgtgtta	gccagaatga	tctcgatctc	10440
ctgacctcat	gatccgcctg	cctctgcctc	ccaaagtgtc	gggattacag	gcattgagcca	10500
cagcgcccg	cctattttta	tttattttta	gaaatcattt	tatctttttt	tttttgagat	10560
ggagtctcac	tttgtcgccc	aggctggagt	gcagtggcac	aatctcggct	cactgcaacc	10620
tccaactccc	gggttcaggc	gattctcctg	cctccgcctc	ccgagtggct	gggattacag	10680
gtcctcgta	ccacacctgg	ctaatttttg	catttttagt	agagacgggg	tttcaccatg	10740
ttggccaggc	ttgctcaac	cctctgacct	caagtgcact	gccacacctg	gcctcccaaa	10800
gtgtgtgggt	tacaggtgtg	agccaccgtg	cccgccagga	ttattattat	tttgtagaca	10860
gtctgtcttt	caccagcat	ggagtgcaat	ggtgcctcga	actcttgga	tcaagtgatc	10920
cttccacttc	agcctcccaa	gtagctggga	ttacagctgt	gtgccactgt	gccagctga	10980
gagtaggttt	taatctgagc	atgggggcag	ctatgattcc	ccgtagcacc	tgggtgaga	11040
ccaggctcctg	gctccactca	ccctgccagg	atctcgtggt	ctgacacctt	cacactggac	11100
acgccatctc	tggectcate	cagcgtctgc	actggctcag	gcctccgtga	gcggcaatcc	11160
caacagcgga	tactggaatc	aatagagcct	gtgaggccag	catgatgggtg	aggtcagggtt	11220
tggaggggga	gggcagcacc	ctgggcccc	gtgcttaggc	ccagactca	ccggacagga	11280
taactgtggc	ctcttcatta	aactgcaccg	tgttcacctt	ctgagaaagt	tattgccact	11340
cagaggaggc	tggactttgg	aggactggga	taaaggcagg	gttcccagtg	tcggttaaag	11400
caaggcgga	ggggaggtga	aaggttttgg	gggaacagca	aggacagggg	ttggtgactg	11460
cctagcctgg	catgcggagt	gggggatcgt	catctgggga	agggatcctt	acggtgtaat	11520
gggggtggcc	gtgtcaccac	ctatgcgcta	atacgggtcc	cctccactca	aatgagggtc	11580
ttcaggcttt	cactcacccc	tgcgtggccc	cggattttgc	gcacgacctg	ccctgatgcc	11640
acatcccaca	gaaccaccgc	cttgtccccg	cgccgggagc	agagactact	gttgtcaaa	11700
gagctggagt	aaaggaggag	gaggatcagc	atcgacctcg	gatcccagcc	tcagcgctcc	11760
catcccagcc	tggctcccgg	ctcaccgggc	cgcattccagc	acctcgtagc	cgtggccgct	11820
gtacgtccgc	agcagcgtcc	cccgaagcgg	gttcacacagc	ttcagcgtct	tgtcactgcc	11880
gcacgtcagg	cagtaattgc	catccactgg	ggaacaccag	gcgggggtta	ctgggcccgtc	11940
gatctcagga	ggcgggagga	ggaccgggaa	tgaagacgaa	ggcgctcacc	attaaatcgt	12000

213

acggctcgca	ctgccccctg	cccgcagtc	agcgtcttca	accgtttctg	cggcagctct	12060
ggaggccgcg	gctttggctc	agggaaagcc	atgctcccag	gactccttcc	ttgcagcctt	12120
aaatcgggtc	gtacggaaaa	ttccgcgcct	tagaaaccca	cgcttgggtg	taaccttatt	12180
attgttcttc	ctgacctact	tctgttttat	cacttccggg	ttcatcattt	tggcatttctg	12240
gtgatcgggt	tggaaactatt	gaagcccgc	ttcagggtct	tttccccatt	ttccctttga	12300
aaggaagact	tctggcttct	cctaaatctc	cgttctctgg	gtaaggggag	tccaagcctc	12360
tgtcatgagg	aacggaaaatg	cgagggcctc	gggtgttact	ctaaaaatccg	ccctcagctt	12420
gcacgccgga	agctgcgatt	cctgcagcgg	aagaggcgtg	atctggcctt	cgactcgcta	12480
tgtccactaa	caatatgtcg	gacccacgga	ggccgaacaa	agtgtgagg	tgaggacccc	12540
agcgtcgtg	gcacgggttc	gggttgtggg	tgtggatcgg	ggccctggga	agcgctgtc	12600
tatcccgggg	gcaggacctg	agcgcctctg	accctcgagc	ctgtcgcagg	tacaagcccc	12660
cgccgagcga	atgtaacccg	gccttggacg	acccgacgcc	ggactacatg	aacctgctgg	12720
gcatgatctt	cagcatgtgc	ggcctcatgc	ttaaggtggg	cggggttgag	cttctatggg	12780
tgtagttgga	cctgagaacg	aggccggggg	gcgggtttgg	aatgaagcgg	gggtgtctgt	12840
cattgctgat	ggggcgggac	ctgagatcgg	ccgggagtg	ggctgcgatg	acgtctgggc	12900
gagaaagccc	cagtcttttg	tgaagtcaag	gattcgagtc	aggttgggga	tgtggcagat	12960
tgtctcgca	gtggggccag	gctttgaagc	aacttggaga	ggagttgtgg	aaaaagggca	13020
gggtcttaag	catgtgggat	gtcagagtct	ctcttgggtc	tgagagacgc	aggccagaca	13080
gtaggactag	aaaccacgta	tctagagtat	gccatgagca	ggtgggactg	aggaattccg	13140
ggtggggcaa	ggtcccagct	gcatcagatg	gaatcagtg	gcatgatctg	gtgtctggaa	13200
aggtggcttc	ggggactcat	tgttgtgcct	ttcactaacc	tgccccacca	cttacctttc	13260
cctagctgaa	gtgggtgtgt	tgggtcgtc	tctactgctc	cttcatcagc	tttgccaact	13320
ctcggagctc	ggaggacacg	aagcaaatga	tgagtagctt	catgtgagac	ttgccctaca	13380
gaacaagtga	ctcttgagta	aggggtgggg	ggaccccagc	ctggccatcc	tagactgaca	13440
cctctctcct	gtctcaggct	gtccatctct	gccgtggtga	tgtcctatct	gcagaatcct	13500
cagcccatga	cgcccccatg	gtgataccag	cctagaagg	tcacattttg	gaccctgtct	13560
atccactagg	cttgggcttt	ggctgctaaa	cctgtgcct	tcagctgcc	tcctggactt	13620
cctgaatga	ggcgtctc	gtgccccag	ctgcatagag	ggaacctggc	ccttccctag	13680
ggaacacctt	aggcttacct	ctcctgcctc	ccttccctg	cctgtgctg	ggggagatgc	13740
tgtccatgtt	tctaggggta	ttcatttgtc	ttctcgttga	aacctgttgt	taataaagtt	13800
tttcaactctg	gctgtcagcc	tctctgttct	agtggggtgt	tcctcctacc	tggcgggaag	13860
ggctctagcc	ccataggcct	ggtgtggggc	ccagttctgg	aggcttctgg	ctgttcatct	13920
gcttacttca	taaaccttgt	gtcttaagtc	aggtgctagg	gacaagacag	tgacttctgc	13980
cctctggcaa	ctcaccagat	ggcctgctg	acctagataa	tctaggcttt	ggtttccctt	14040
tttttttttc	ctttttaaga	aagaaaaatg	tcttgatctg	tcatgcaggc	tgagtgcagt	14100
ggcacaatct	atgttcaactg	cagcctcaaa	ctcctgggct	caagcaatcc	tcccacctca	14160
gcctgccacg	taactgggac	cacaaatgcg	tgctaccatg	cccagttaat	tcttgttttt	14220
tttgagacag	agttttgtct	ttgttgccca	ggctggagg	caatggcatg	atcttgatct	14280
cggctcactg	caacctccgc	ctcccagggt	caagtgatct	tcctgcctca	gtctcccaag	14340
tagctgggat	tacaggcatg	tgccaccatg	ccagctaat	ttttgtattt	ttacattttg	14400
tgtaaaatta	caaattttgt	gttttcaaac	cgcgtctctac	aaaacaaccc	atgttgccca	14460
ggctgggtctc	aaactcccag	gcccagtgta	ttcaccagcc	tggccctccc	aaagtgtctg	14520
gattgcaggc	ttgagccact	gcgcctgccc	tgggctttgt	tttcttatca	gagaatgaac	14580
tggtaggaat	tgggaaaggc	atgaaagact	cggggtcctt	ccccacttgt	cagacctct	14640
tttctctccg	gaacaccacg	ggatccttct	caaccaggct	ggatcccatc	cctggtaactc	14700
caggggtatt	tacccaacgt	cccaatcccc	acagtatagg	actcttcac	agatcctcct	14760
cttaggcaag	ctaggtcctt	ccaggacctt	agcgtgaag	gtccatggga	cggacacctt	14820
ggattcccat	ggacacacta	caccggctag	gaaaacccgg	cccccttagg	aaaagcactt	14880
ctgctcctac	cggcatthaag	aggcatccg	tcttggaatt	ccggcattha	gaggcatcc	14940
gtcttcatag	cccgtgagac	gccagtgtca	cctttagccc	aaccagtgcc	ctgagggtgg	15000
cattttccta	ccttctgtga	acgacccccg	ggattgcccc	gggctacagc	ctctctcccg	15060
tgagcctcca	gaccgcgccc	tggccccgcc				15090

&lt;210&gt; 295

&lt;211&gt; 15090

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 295

acgttcccta cttcctgtgc tcttgccggag acgcgcgcgt cgggggtttaa cgcgtttctg

60

214

ggccgcccgt	agccccggcct	agggggcagct	ttgactcgag	agccggctat	aggcgcattg	120
aaggtttccct	ggaacgggag	gcgccagcgg	gggcgctggc	cgccgtgcta	aagcacagct	180
cgacgttgcc	gcccgaagc	accaggtcc	ggggctacga	cttcaaccgc	ggtgtgaatt	240
accgcgcact	gctggaggcc	ttcggcacca	ccggcttcca	agcaaccaac	ttcgggcgcg	300
ctgtacagca	agtcaatgcc	atggtgagga	ccgggcggaa	tttctaggga	cgccgagggg	360
cgtggcttgt	agaaccaacg	cgggtactaga	cgggggcagc	gtttccagtg	gaggggatat	420
gtcttttatt	tgagttgccc	aatagttgga	ggaaggcggg	acctattctg	ggcgggagtt	480
tctgtcctgg	gaaggggatt	ttgcactctg	gtagttacat	gctggtacgg	taacctgagg	540
aggcgaggac	tgattcttgg	tgtgggggcg	ggttctaggt	acattttaaag	ctttctggaa	600
tgggcggagc	ctggggcaag	acaaattaag	ggaggatatg	ggaggaggag	cctaagtctg	660
ggcggttctt	gaatttagat	ttgcttttcc	cagcggggaa	gggaccggat	ctgaaaggag	720
atgctctctg	attcctaata	gggtgggggc	tggctgggcg	cggtagcgca	tgctataat	780
cccagcattt	tgggaagccg	aggcgggtgg	atcaagagaa	gaggagttcg	agacaagcct	840
ggccaacatg	gtgaaaccct	gtctctacta	aaatgcaaaa	aattagccgg	gcatggtgtt	900
gcgcgcctgt	agtcccagct	actcgggagg	ctgaggcagg	agaatcgctt	gaaccgcga	960
ggtggagggt	gcagtgaact	gagattgcgc	cactgcactc	cagcctgggt	acagagcgat	1020
actctgtctc	aaaaaaaaaa	aaaaaaaaaa	gccgggcacg	gtggctcatg	cctgtaattct	1080
cagcattttg	ggaggccgag	gcgggcggat	cacctgaggt	cgggagttcg	agaccagcct	1140
gaccaatctg	gagaaacccc	gtctctacta	aaatgcaaaa	aattagccgg	gcatggtggt	1200
gcgcgcctgt	agtcccagct	actcgggagg	ctgaggcagg	agaatcgctt	gaaccgggga	1260
ggtggagctt	gcagtgaacc	gagatcgcg	cattgcactc	tagcctgggt	aacaagagtg	1320
aaactccgct	caaaaaaaaa	aaaaaaaaaa	tgggggcaaa	tcctgaacgt	gtgtcttgag	1380
atctggctct	ggaaggggca	gagtttacac	aggagatggt	ccttgggtccc	ctgtagaact	1440
ggtcctgtat	ccctgaatgt	gcagggcctg	gggtgaaatc	tgtttctgga	gcccacctgg	1500
agtcctagat	ctgggattta	aggccagtgc	ttactttgac	ttggccctta	ctcacagatc	1560
gagaagaagc	tggaaaccact	gtcacaggat	gaagaccagc	acgcggacct	gaccagagc	1620
cgccgcccac	ttaccagctg	caccattttc	ctgggatata	catccaacct	catcagttca	1680
ggcatccgtg	agaccattcg	ctaccttgtg	cagcacaca	tggtagggac	ctggtgaggc	1740
cgtggccttg	gcctctgggt	caatgggcaa	tgcagttatt	gatcgtttaa	gtgagatggg	1800
cagatagggg	tctgttataa	gcagaggaat	agaatcaagt	tttgttttgt	agcagagctc	1860
cctcataaga	gtcactggac	aaggatgagg	ttagaagttc	tgcccagaat	gagggcaggg	1920
gcttccctct	tgggcccatt	tcactgcctt	gtggctgcag	gtggacgtat	tggtagaccac	1980
agctggcgcc	gtggaggaag	acctcatcaa	gtgcctggcg	cccacatact	tgggcgagtt	2040
tagcctcagg	gggaaggagc	tcggggagaa	cgggatcaat	aggtgagaac	cctgagtggt	2100
gttgggcagg	ggagctggac	caagggtcct	ggggcctgat	gcctacatgc	ctcctgttct	2160
caggatcgga	aacctgctgg	tgcccaatga	gaattactgc	aagtttgagg	actggctgat	2220
gcccattctg	gaccagatgg	tgatggagca	gaacacagag	gtggggctgg	ggcaacctgg	2280
agggggccagt	tcagtgggag	tcaggggagg	catggcctga	aggtcacatc	ctctcctagg	2340
gtgtaaaagt	gacgccttct	aagatgatcg	cccggctggg	caaggagatc	aacaacccag	2400
agtccagtga	tactcgggcc	cagaagggtg	ggacctaaag	gggagcaaa	tagccagact	2460
ttggcagtgt	ttactttatt	tcattcttcc	agcctcctgg	ggattcagta	ctgttattct	2520
cagcatcctc	actcttagat	gaggagactc	aaacacagat	aggcgtggta	atTTTTTTTT	2580
TTTTTgagac	aggatcttgc	tctgtcacct	aggctggagt	gcagtgggtg	gatcacagct	2640
cattgcagcc	tcaacctcct	ggggccaagc	agtcctccca	cctcagcctc	tcgagtagct	2700
gggaccacag	gcacatgcc	tcatgccccg	ctaattttta	aaattttttg	tagagatggg	2760
ggtctccctg	tgtttcccag	gctgggtctg	aactcctggc	gtcaggcagt	cctcccacct	2820
tgccctccca	aagtgcctgg	attacaggcg	tgagccactg	tgcccagcca	ggctaggtaa	2880
TTTTTgtctg	agtcacacag	ataactagt	gggcctcagc	atccttatgc	tcctccagga	2940
ctatctcttg	aacagtagag	gcaacactta	gcaactctcc	tggggcctgg	ctcagggtcc	3000
cacactccca	gatgctataa	aataagagct	accactcccc	tttaattaga	gaatcagaac	3060
ctgaaaaaaaa	aaaaaaaaaa	gctacatagt	cttttttttt	tttttttttt	ttttgagaca	3120
gagtcttgct	ctgtgcgcc	ggctggagtg	taattggtgtg	atttcagctc	actgcacctc	3180
ccacctccca	ggttcaagt	attctcccg	ctcaccctcc	tgagttagctg	ggactatagg	3240
cacccacat	catgcccggc	caatttttgt	attttcttac	agatgggggt	tcaccatggt	3300
ggccaggctg	gtcttgaaat	cctgaacctc	agtgatccac	ccgccttggc	ctcccaaagt	3360
gctgggatta	caggggtgag	ccaccacacc	cagcctactt	actctttctt	ttttacgaga	3420
caggggtctc	ttctgtttcc	caggctggag	tgcaatggca	caataatggc	tcactgctgt	3480
cttgagcttc	tgggctcagt	cgtattctct	gcctcagcct	gctgagtagc	tgggactaca	3540
ggtgcgtgcc	accatgcctg	gctaattggt	ttttagtaga	tgggaactca	ccatgttgca	3600



215

caagctggct	cttttttttt	ttttgagacg	gagtttttgc	cttgttacc	aggccagagt	3660
ccaatggcgc	aatcttggct	cacagcaacc	tctacctcct	gggttcaagc	aattctcctg	3720
cctcagcatc	aagttcccaa	gtagctggga	ttataggcat	gtgccaccac	ccctggctaa	3780
ttttgtattt	ttagtagagg	cagggtttct	ccatgttggt	caggctgggtg	tcgagctcct	3840
gacctcaggt	gatccacccg	cctcggcctc	ccaaagtgtc	gggattacaa	gcgtgagcca	3900
ccgcgcccgc	ccacaagctg	gctctttaaa	aaagaattag	acggccgggc	atggtggctc	3960
atgcttgtaa	tcccagttact	ttgggggctg	aggcgggtgg	atcacctgaa	gtcaggagtt	4020
caagaccagc	ctggccaaca	tggtggaacc	ctgtctctac	taaaaaaaca	aaatgcaaaa	4080
ttagctgggc	atagtggcat	gcgcctgtaa	tcctagctac	tcgggaggct	gaagcaggag	4140
aatcactgga	accaggagg	cagagggttc	agtgaagctg	gatagtgcc	ttgcactcca	4200
gcctgggcaa	cgagtgaaac	tccgtctcag	ggaataaaaa	aaaagagaga	gaaacagctc	4260
agcaagctaa	gaataggctg	gttcttttatg	tgccaggcac	tatactaagt	gttttctgtg	4320
ggttttctca	ctataggctc	atctgtgaga	ggtgtttctg	ttatgcttat	aattgaggaa	4380
acagtcctag	agaaattagg	caccccatcc	acagtcagat	agtcatatag	ccagcatgga	4440
gacgaggctc	tgagctccag	ccactgtcct	gtcatgttct	ctgcagaacc	acatccctgt	4500
gttttagtccc	gcacttacag	acggctcgtc	ggcgacatg	atcttcttcc	attcctacaa	4560
gaacccgggc	ctggctcctg	acatcggtga	gggtgaggcg	ctagggccac	agaggagagg	4620
ggaaggagg	ctggctgagt	ccaaggcctg	acttcggcgc	tcttccccc	gacctgaggc	4680
tcatcaacac	acaggccatc	tttgccaagt	gcactgggat	gatcattctg	ggcggggggc	4740
ttgttctcga	ccacattgcc	aatgccaacc	tcttggtgag	tgggggtggc	gcttcggccc	4800
actctgcaga	catgctgtgt	ggtgggccta	tgccatgtgc	tggttagaca	gcatgaacta	4860
gacaggccag	gatccctgct	ccccgggact	gatgttctag	taggggagat	agcaaacaag	4920
tgacatccac	gtcagggggc	agtcattgct	acggggaata	ctaaatgatg	gcatgagaag	4980
agaaaggggt	gctgtccaac	aagaggtttt	ggaaggaggc	ttctggaagt	gtgagctggg	5040
agcaggggtt	tggggaggca	tctcccagga	gctatgtggt	tgtctcccg	gccaggagtt	5100
tgtgctgctg	tactagcatt	gagcttctgg	attgcaaagt	tcccaggaga	gggaacagcc	5160
attgcaaagg	ctctggggcg	cctgaagtaa	tcaggaaca	gctgggtacc	tggtgagggg	5220
aagggtggagt	ggtgagggcc	aggaggtgat	gcagggagg	gccacaggg	gcctgctggg	5280
ccctgtgggc	tgaggcgggg	ctttggcttt	tgactgaga	gaagtgggag	aggacttgac	5340
tcgggttccc	atgctcccc	tggtggccat	gtggtgaaca	gatggtggca	ggtgagtgag	5400
aactccagtc	caggacagtg	gtgaccatgc	agggatcagg	aggcaggcgg	tggttggtatt	5460
tgaggggctt	ctgaagatag	agttgctggc	agctcctgcc	ttgcagatgg	ggcagggttg	5520
ttgacacctg	gctgttgggt	ctggggaaac	acagccatcg	ttgccagca	gctctagtga	5580
cccagacat	tgacatgggc	cctgtctggg	agcgaatgtc	tgtagaaggc	ttccttcate	5640
tgggacacac	ctctcagcct	gtttggctac	ggtgtcctcc	ctctgtgtct	gtctcctgtg	5700
actggctgac	tgggcccacc	gtgccccgc	ctccccacag	cggaaacggg	ccgactacgc	5760
tgtttacatc	aacacagccc	aggagtttga	tggtctgac	tcaggtgccc	gaccagacga	5820
ggctgtctcc	tggggcaaga	tccgggtgga	tgacacagcc	gtcaaggtaa	gcgctggctg	5880
ggtggggcat	agggtctctg	ggacgatgag	tgtgggtccc	atggcttacc	cagggtcccc	5940
cctaccagcg	tctatgtctg	cgctccctg	gtcttcccc	tgcttgtggc	tgaaccttt	6000
cccagaaaga	tggatgcctt	catgcatgag	aagaaacgag	actgagcggc	tgcggtccca	6060
ggaaggctct	acccctctct	ctatttatta	atttgcagac	ccagccctc	ccctactttt	6120
tggtcagcta	cgtctctaga	ataagatggt	atctgaagtc	cttccatgtc	tgtgtctcgg	6180
tccttgggtc	tggttgggtg	tcccttggct	tcagcctgct	ccatcctctg	cctcataggc	6240
ctcctctcgc	cagcactgga	cgctgcctcc	catggcggtc	agcaggcagg	gctctgttgg	6300
gtggtagggc	agcgactgca	ccacaccgga	acccacaggc	agggccagag	ccagcgcacc	6360
ctgtggagca	aggggtaggg	agtgggttat	tggtgctggg	ctgtaccctg	gtttctgagg	6420
tccctgggca	cccccatct	cagtcctgcc	tgaagccctc	agtcacctct	ccccgacctt	6480
cagccacctg	cctctaattg	cctcctagac	actgcaaaat	taatctacct	cagactgagc	6540
ccctcagtag	ctctgtccta	ccagggtgtc	aggccgcaag	tcttggggagc	ctcttattga	6600
ttttttatatt	tttaaaatag	cagagatggg	gtcttaccat	gttgcccagg	ctggtctcga	6660
actcctggcc	tcaagtgatc	ctcctgcctt	ggcctcccaa	agtgttagga	ctacagggtg	6720
gagccaccat	gcctggcttt	gggagctctt	tcttttttct	gttttttttt	gagatggagt	6780
cttgcctctg	cgccaggctg	gagtgcagtg	gcgcctctg	ggctcactgc	aacctccgac	6840
tccctagttc	aagcgattct	cctgcctcag	cctcccagag	agggtgggatt	acaggcacgc	6900
gctaccatgc	ccagctaatt	tttgtatttt	tagtacagat	gggggtttcac	catgttggcc	6960
aggatgatct	ctatctcctg	acctcgtgat	ccacccccct	cggcctccca	aagtgtggg	7020
attacagggtg	tgaaccacca	tgcttggccg	ggagtctttt	tcttgtacca	catgttcctc	7080
tatcagttat	tctcttgggc	tctgtctcta	gaccatgtcc	agagactgct	gattttctgc	7140
cactaccatg	tttgagagcat	gccttgcctc	cagcttgctc	gttccctgcc	accagctggg	7200

216

ctccatcctg	tccatttggc	agccccaatg	atccccactt	cccctgggtc	caacacaatg	7260
taaacagttc	ctcaagcaag	ccatgcttcc	tctttccacc	ttgaaaatgt	cccttgatgt	7320
gcctgccctc	caaggcaact	tctgtttctac	tgggcccata	agaaataggt	ggaacattct	7380
tgctacctta	gttcctaaag	caagagcttg	tccgccaagt	cttcagggcc	cccccggttc	7440
cctccatcct	cttatgggcc	ttagttcccc	tggccaagcc	cagcgtgat	gtctcctttg	7500
ccgagattcc	cccggtctctg	acccccactac	accaggatgg	tctgtttctg	gcctgactcc	7560
ccaccaggct	gggacatgtc	aaggacaggg	ctcagggcct	gaaacctatg	acagggatgc	7620
taagatgtag	ctccagtttc	ttgaatgact	gcagccctat	ctcacccaag	gttagacatg	7680
gccgtcggtc	cccccttgcc	caggggtcag	tgcagttgc	tcggcctggc	atctgcagcc	7740
cagcctgacc	ccggatcttg	ccgcacctgc	cggccacctg	aagcctttgt	ttcctgactg	7800
atgcatgcgc	aggtacaccc	tcttaacata	tgtgtttccc	tttgcttga	atgcccttcc	7860
tgctctatgc	tctctctagc	ccaagctggg	cagcgtgtct	caggcctgta	atcccagcac	7920
tttgggaggg	cgaggcggtg	gaatcacttg	aggtcaggag	tttgagacca	gcctggccaa	7980
catggtgaaa	ccctgtctct	actaaaaata	caaaaattag	ccaggtatgg	tggtaggggc	8040
ctgtaatccc	agctactcag	gaggctgaga	catgagaatc	acctgaacct	tggggggaag	8100
aggttgagct	gagctgagat	ggcgccactg	catttgccctg	ggcaatagtc	tcaaaaaaag	8160
aaaaaagggc	cgggtgtggt	ggcttacgcc	tgtaatccta	gcacttggga	aggctgaggt	8220
gggtggatca	tgaggtcagg	agttaaagac	cagcctgacc	aacatagtga	aacctgtct	8280
ctactaaaaa	tacaaaaatt	agctgggtgt	ggtggcacgc	acctataatc	ccaactatc	8340
aggagactga	ggcaggagaa	tcgcttgaac	tgttcaggcg	gagtttacag	tgagccaaga	8400
ttgcgccact	gcactctagc	ctgggcgaca	gagcaagact	tgtctcaaaa	aaaaaaaaaa	8460
aaaaaaaaaa	aagatcctag	ccttcaggcc	ctggagtgc	tgaggtgaag	acagggctga	8520
gatggggcag	gcacttaggt	atgaagttag	gctgggggca	cctcacctcc	accaggtccc	8580
agaagaacac	cttcccgtcc	tcagaacagc	tgaccacatg	tgtgtcacgc	tcgctcaggc	8640
agcagtccag	cttgatttcc	tggttcttat	ggcccttgta	cctaagggtg	gacaggatcg	8700
gggggcttgc	tcctctccag	gggtgggaga	ggaggggaag	ggatccccac	gaccacaagg	8760
actcactcgc	ccagcagctc	ccctgtgtct	ttgtccagga	gccgcaatgt	ggagtccagg	8820
ctggacacca	gggtgcactg	cccatcccg	ctgaagcagg	tgcaggtgat	ggggccttgg	8880
gggaagggtg	ggtaggtgag	tgagggtggg	gtgcccttgg	ttggccccc	atcttccctg	8940
cctgtcccac	atccccagcc	acactcactg	cccacgtagt	ctgagaagag	ctgcccacac	9000
cttaggtcat	agcgtctcac	gcggccatcc	acggagctgc	aggagagggt	agatccagcg	9060
ggaaccttga	ctacactcac	atggctccag	gcagccctgt	gccttcccag	cccagtgggc	9120
tgctctcttc	agtgcacagg	agtgaattc	tgaagctctg	gccttgagac	tcaggcccag	9180
ggccaattac	gtcctactcc	atcatttcca	agaccacac	cccctttcca	agcccttggga	9240
gtccttctga	ttcccccttt	tcttcccttt	gtttgagaca	gagttttgct	cttgttgcct	9300
aggctggagt	gcaatggcat	gatcttggct	caccggaacc	tctgcctccc	gggttcaaga	9360
gattctcctt	cctcagcctc	ccgagtagat	gggaatacag	gcattgcacca	ccacgcccctg	9420
ctaattttgt	attttttagta	gagacggggt	ttctccatgt	tggctcaggt	ggtctcgaac	9480
ttcccaacctc	aggtgatccg	cccacctcag	cctcccaaag	tgctgggatt	acaggtgtga	9540
gccaccccac	ctggcccatt	ctcccctttt	cctgcattct	ccagctcctc	ctcctcagta	9600
ctcagtccca	ccactttccc	cactaccag	caccagcacc	tagactgttc	tggctcctcc	9660
gcacccccca	cagccaccag	agggagcact	tttcaaagta	cagttgacct	atgaacaaca	9720
cggtttgaac	tgaacgcgtc	cacttatatg	tggattttct	tctgcctcta	tcagctgtga	9780
gacaccaaga	tcaatccctc	ctcttccctc	tcctctgctt	tctcaacacg	aagatcttta	9840
tgaagatctc	ttcacttcca	cttaatgaat	agaaaatata	ttttttccac	caggcgcggt	9900
ggctcacgcc	tgtgattcca	gctctttggg	aggccagggc	aggtggatca	cgaggccaag	9960
agatggagac	cctcctggcc	aacatggcga	aaccccgtct	ctactaaaaa	tacaaaaatt	10020
agctgggggt	ggtggcacgc	gactgtagtc	ccagctacta	gggaggtga	ggcaggagaa	10080
tcgctgaac	ctagaagtta	gaggttgacg	tgagccgaga	tcacgtcact	gcactccagc	10140
ctggcaacag	agcgagactg	cgtctcaaaa	aaaacaaaaa	ttcttcttta	tgattatttt	10200
tatgtattta	ttattttaat	ttatttactt	attttgagac	ggagtcttgc	tctatcgccc	10260
aggagtgtag	tgggtcgatg	tcggctcaca	gcaagctctg	cctcctgggt	tcactccatt	10320
ctcctgcctc	agcctcctga	gtagctggga	ctacagggcg	ctgccactat	gcccggctaa	10380
ttttttgtat	ttttagtaga	gacgggggtt	caccgtgtta	gccagaatga	tctcgatctc	10440
ctgacctcat	gatccgcctg	cctctgcctc	ccaaagtgtc	gggattacag	gcattgagcca	10500
cagcgcccg	cctattttta	tttattttta	gaaatcattt	tatctttttt	tttttgagat	10560
ggagtctcac	tttgcgccc	aggctggagt	gcagtggcac	aatctcggct	cactgcaacc	10620
tccaactccc	gggttcaggc	gattctcctg	cctccgcctc	ccgagtgggt	gggattacag	10680
gctcccgta	ccacacctgg	ctaatttttg	catttttagt	agagacgggg	tttcaccatg	10740
ttggccaggc	tgatctcaac	ctcctgacct	caagtgtatc	gcccaccttg	gcctcccaaa	10800

gtgctgggat	tacaggtgtg	agccaccgtg	cccggccaga	ttattattat	tttgtagaca	10860
gtctgtcttt	caccagcat	ggagtgaat	ggtgcctcga	actcttgac	tcaagtgatc	10920
cttccacttc	agcctccaa	gtagctggga	ttacagctgt	gtgccactgt	gccagctga	10980
gagtaggttt	taatctgagc	atgggggag	ctatgattcc	ccgtagcacc	tggggtgaga	11040
ccaggtcctg	gctccactca	ccctgccagg	atctcgtggt	ctgacacctt	cacactggac	11100
acgccatctc	tggcctcatc	cagcgtctgc	actggctcag	gcctccgtga	gcggcaatcc	11160
caacagcgga	tactggaatc	aatagagcct	gtgaggccag	catgatggtg	aggtcaggtt	11220
tggaggggga	gggcagcacc	ctgggcccc	gtgcttaggc	cccagactca	ccggacagga	11280
taactgtggc	ctcttcatta	aactgcaccg	tgttcacctt	ctgagaaagt	tattgccact	11340
cagaggaggc	tggacttttg	aggactggga	taaaggcagg	gttcccagtg	tccggttaaag	11400
caagggcgaa	ggggagggtg	aaggttttgg	gggaacagca	aggacagggg	tgggtgactg	11460
cctagcctgg	catgaggagt	gggggacgt	catctgggga	agggatcctt	acggtgtaat	11520
gggggtggcc	gtgtcaccac	ctatgcgcta	ataagggtcc	cctccactca	aatgagggtc	11580
tccaggcttt	cactcaccac	tgcgtggccc	cggaaattgc	gcacgacctg	ccctgatgcc	11640
acatcccaca	gaaccaccgc	cttgtccccg	ccgcccggagc	agagactact	gttgtcaaaag	11700
gagctggagt	aaaggaggag	gaggatcagc	atcgacctcg	gatcccagcc	tcagcgctcc	11760
catcccagcc	tgggtccccg	ctcaccgggc	cgaatccagc	acctcgtagc	cgtggccgct	11820
gtacgtccgc	agcagcgtcc	cccgaagcgg	gttccacagc	ttcagcgtct	tgtcactgcc	11880
gcacgtcagg	cagtaattgc	catccactgg	ggaacaccag	gcgggggtta	ctgggcccgc	11940
gatctcagga	ggcggaggga	ggaccgggaa	tgaagacgaa	ggcgctcacc	attaaactcg	12000
acggctcgca	ctgccccctg	cccgcagtc	agcgtcttca	accgtttctg	cggcagctct	12060
ggaggccgcg	gctttggctc	agggaaagcc	atgctcccag	gactccttcc	ttgcagcctt	12120
aaatcgggtc	gtacggaaaa	ttccgcgcct	tagaaaccca	cgcttgggtg	taaccttatt	12180
attgttcttc	ctgacctact	tctgttttat	cacttccggg	ttcatcattt	tggcatttccg	12240
gtgatcgggt	tggaactatt	gaagcccgtc	ttcaggttct	tttccccatt	ttccctttga	12300
aaggaagact	tctggcttct	cctaaatctc	cgttctctgg	gtaaggggag	tccaagcctc	12360
tgtcatgagg	aacggaaaatg	cgagggccctc	gggtgttact	ctaaaatccg	ccctcagctt	12420
gcacgccgga	agctgcgatt	cctgcagcgg	aagaggcgtg	atctggcctt	cgactcgcta	12480
tgtccactaa	caatatgtcg	gacccacgga	ggccgaacaa	agtgtcgagg	tgaggacccc	12540
agcgtcgtgg	gcacgggttc	gggttgtggg	tgtggatcgg	ggccctggga	agcgctgtc	12600
tatcccgggg	gcaggacctg	agcggccctg	accctcgagc	ctgtcgcagg	tacaagcccc	12660
cgccgagcga	atgtaacccg	gccttgagcg	acccgacgcc	ggactacatg	aacctgctgg	12720
gcatgatctt	cagcatgtgc	ggcctcatgc	ttaaggtggg	cggggttgag	cttctatggg	12780
tgtagtggga	cctgagaacg	aggcccgggg	gcgggttttg	aatgaagcgg	ggtgtcttgt	12840
cattgctgat	ggggcgggac	ctgagatcgg	ccgggagtg	ggctgcgatg	acgctgggcc	12900
gagaaagccc	cagtcttttg	tgaagtcaag	gattcgagtc	aggttgggga	tgtggcagat	12960
tggctcgcga	gtggggccag	gctttgaagc	aacttggaga	ggagtgtgg	aaaaagggca	13020
gggtcttaag	catgtgggat	gtcagagtct	ctcttggtcc	tgagagacgc	aggccagaca	13080
gtaggactag	aaaccacgta	tctagagtat	gccatgagca	ggtgggactg	aggaattccg	13140
ggtggggcaa	gggtccagct	gcatcagatg	gaatcagtg	gcatgatctg	gtgtctggaa	13200
aggtggcttc	ggggactcat	tgttgtgctt	ttcatcaacc	tgccaccca	cttaccttcc	13260
cctagctgaa	gtgggtgtgt	tgggtcgctg	tctactgctc	cttcatcagc	tttgccaact	13320
ctcggagctc	ggaggacacg	aagcaaatga	tgagttagctt	catgtgagac	ttgccctaca	13380
gaacaagtga	ctcttgagta	aggggtgggg	ggaccccagc	ctggccatcc	tagactgaca	13440
cctctctcct	gtctcaggct	gtccatctct	gccgtggtga	tgtcctatct	gcagaatcct	13500
cagcccatga	cgcccccatg	gtgataccag	cctagaaggg	tcacattttg	gacctgtctc	13560
atccactagg	cctgggcttt	ggctgctaaa	cctgctgctt	tcagctgcca	tcctggactt	13620
ccctgaatga	ggccgtctcg	gtgccccag	ctggatagag	ggaacctggc	cctttcctag	13680
ggaacacctt	aggcttacc	ctcctgcctc	ccttccctg	cctgctgctg	ggggagatgc	13740
tgtccatggt	tctaggggta	ttcatttgct	ttctcgttga	aacctgttgt	taataaagt	13800
tttcaactctg	gctgtcagcc	tctctgttcc	agtggggtgt	tcctcctacc	tggcgggaag	13860
ggctctagcc	ccataggcct	ggtgtggggc	cccagctctg	aggcttctgg	ctgttcat	13920
gcttacttca	taaaccttgt	gtcttaagtc	aggtgctagg	gacaagacag	tgacttctgc	13980
cctctggcaa	ctcaccagat	ggcctgctg	acctagataa	tctaggcttt	ggtttccttt	14040
tttttttttc	ctttttaaga	aagaaaatgg	tcttgatctg	tcatgcaggc	tgagtgcagt	14100
ggcacaatct	atgttcaactg	cagcctcaaa	ctcctgggct	caagcaatcc	tcccacctca	14160
gcttgccacg	taactgggac	cacaaatgcg	tgctaccatg	cccagttaat	tcttggtttt	14220
tttgagacag	agttttgctc	ttgttgccca	ggctggaggg	caatggcatg	atcttgatct	14280
cggctcactg	caacctccgc	ctcccagggt	caagtgatcc	tcctgcctca	gtctcccaag	14340
tagctgggat	tacaggcatg	tgccaccatg	cccagcta	ttttgtattt	ttacattttg	14400

218

tgtaaaatta	caaattttgt	gttttcaaac	ccgtctctac	aaaacaaccc	atgttgccca	14460
ggctgggtctc	aaactcccag	gcccagtgga	ttcaccagcc	tggccctccc	aaagtgtctg	14520
gattgcaggc	ttgagccact	gcgcctgccc	tgggctttgt	tttcttatca	gagaatgaac	14580
tggtaggaat	tgggaaaggc	atgaaagact	cggggctcct	ccccacttgt	cagaccctct	14640
tttctctccg	gaacacccag	ggatccttct	caaccaggct	ggatcccatc	cctggtactc	14700
caggggtatt	taccaacgt	cccaatcccc	acagtatagg	actcttcate	agatcctcct	14760
cttaggcaag	ctaggctcct	ccaggaccct	agcgtgaag	gtccatggga	cggacaccct	14820
ggattcccat	ggacacacta	caccggctag	gaaaacccgg	cccccttagg	aaaagcactt	14880
ctgtcctac	cggcattaag	aggcattccg	tcttggaaat	ccggcattaa	gaggcattcc	14940
gtcttcatag	cccgtagagac	gccagtgtca	cctttagccc	aaccagtgcc	ctgaggggtg	15000
cattttccta	ccttcctgta	acgacccccg	ggattgcccc	gggctacagc	ctctctcccc	15060
tgagcctcca	gaccgcgccc	tggccccgcc				15090

&lt;210&gt; 296

&lt;211&gt; 3830

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 296

ctgggacacg	tggctcatgc	ctgtaatccc	agcacttttg	gaggctgagg	tgggcggatc	60
acgaggtcag	gagatcaaga	ccatcctggc	taacatggtg	aaaccccgtc	tctactaaaa	120
atacaaaaaa	ttagctgggc	gtgtggcggg	cgctgtagt	cccagctact	tgggaggctg	180
aggcaggaga	ctggcgtgaa	cccgggaggt	ggagcttgta	gtgagccgaa	atcacaccac	240
tacactccag	cctgggcgac	agagcaagac	tccgtctcaa	aaaaaaaaaa	aaaaaaaaaa	300
aagctctctg	attttagctg	ttaggtggga	gatgggttgg	aggataccaa	agccagcttg	360
caggctatgg	ggataaagaa	aacacctgga	tttcggacct	actttatagg	tagaggttgg	420
cagacatgtt	gagaaggatg	gatgtggggg	gtgagaaaag	gggagacagc	aagctgcgct	480
cctcattttt	aattttttatt	tatctatttt	tgagacggag	tttcgctctg	ttgcccaggc	540
tggagtgcag	tggcaccatc	tcagctcact	gcaacctcca	cctcccgggt	tcaagtgatt	600
ctcctgcctc	agcctcctga	gtagctggga	ttatgggtgt	gcgccaccac	acccggctaa	660
tttttgtatt	tttttagtaga	gacgggggtt	cgccatgttg	tccaggctgg	tctctaactc	720
ctaacctcag	gtgatctgcc	ctccttggca	tcccaaagtg	ctgggattac	aggtgtgagc	780
caccgcgccc	agccccaatc	cctatttttc	agtctagtgg	atgagtggag	ggtggggccg	840
tttgctgaga	tgcagaaaga	tcagggatag	gtggagaggg	agctgagggg	gcaactttga	900
ggccaagcag	aggatgtcaa	ggaggatgtc	tgtctcctcc	aacaaggtag	gctcattcca	960
gcctcacggc	ttttgctggt	ctgtcttccc	atgtgcagga	aatggcctct	ctgcatcttc	1020
acatacgggg	attttctcag	ccttctgggt	ttggctcaaa	tctcacctcc	ttggcgctct	1080
tcacccatcc	ctccaactaa	aatcccgaac	tctccacct	aaagactcaa	attatcctgt	1140
ttaaatcctg	attgcgctgg	gcgcgggtgg	tcacacctgt	aatcccagca	ctttgggagg	1200
ccgaggcagg	cagatcacct	gaggtcagga	gttcgagact	agcctgacca	acatagtga	1260
accccatctc	tactaaaaat	acaagaatta	gccggggcgt	atggctcatg	cctgtaatcc	1320
cagctactcg	ggaggctgag	gcaggagaat	tgcttgaaac	tgggaggcag	aggtttgcgat	1380
gagtggagat	cgcgccattg	cactccagcc	tgggcaacaa	gagcgaaact	ctgtctccaa	1440
aaaaaaca	aaacaaaaaa	ggcctgata	cactcaccac	tattgttaac	tttctatctt	1500
cccaatcaga	ttgtgggctc	cagtagggca	gggtccacat	cttggctctg	ttcaccacta	1560
aatccttagt	gcctagcacg	gagcccacca	tagagaatag	actacatgaa	ttgtagagt	1620
agtgaataat	cctgttggcc	gtatgcactg	ttaggagggt	gtgtttgaga	tacagatgac	1680
accagggtc	tcacattctt	gcaggaggga	aagagacgtc	agccctgggt	cccagaagag	1740
gccactgacc	cagtgggagt	tcagggaagg	cttcccagag	gaggtggagg	tgacagctgc	1800
agctataagg	gaaggagaa	cagagcggtt	tgcagcatgt	gaaggctttg	gagacttgtg	1860
agggcacgaa	ccgggctcac	tatcccat	gacaaaagt	gctgaggaag	gatgaaactg	1920
tgtctaactc	tgcttggtga	ccgaaatctt	gtccatgggt	gacgtttaag	aagtgaacct	1980
cggccggggc	cagtgggtca	cgctgtaat	cctggcactt	tgggaggcca	aggcggggcg	2040
gtcacgagtt	caggagatcg	agaccatcct	ggctaacacg	gtgaaacccc	atctctacta	2100
aaaacagaaa	aaattagccg	gggtgtgggt	cgggcacctg	tagtcccagt	tactcgggag	2160
gctgaggcag	gagaatggca	tgaacctggg	aggcagagct	tgcagtgagc	cgagattgctg	2220
ccactgcact	ccagcctggg	cgacagagcg	agactctgtc	tcaaaaaaaa	aaaaaaaaaa	2280
aaaagtgacc	ctcataaaaa	aattagctgg	gcacgatggt	gcacactagt	cggaatgctg	2340
gggtgggagg	atgacctgag	tccgggagtc	agaggttgca	gtgggccgag	atcgcgtcac	2400
agcactccag	cctggcgaca	gagtgagacc	ctatcaaaaa	atagcagcag	gccaggcgcg	2460

219

gtggctcatg	cctgtaatcc	cagcactttg	ggaggctgag	gcgggaggat	cacgaggtca	2520
ggagatcgag	actaccctgg	ctaacacggt	gaaaccccg	ctctactaaa	aatacaaaat	2580
attagccggg	cggtggtggc	ggcgccgtga	gtcccagtta	ctggggaggc	tgaggcagaa	2640
gaatggcgtg	aacctgggag	gcggagggtg	cagtgaagccg	agatcgtgcc	actgcactcc	2700
agcctgggag	acagcgcaag	actctagctc	aaacaaacaa	acaaacaaaa	cagcaacaac	2760
aacaacaaaa	ccatcctccc	ctcccagggg	gacagaacag	aaacgaatgg	gcgagtgcgc	2820
ggccaagcag	tgggtctcca	gcagggtggc	ttaaaatagg	aattttggct	ggggacgggtg	2880
gctcacacct	gtaatctcag	cactttggaa	agcccaggcg	ggcggtcacc	tgagggcaga	2940
accagcctcg	ccaacatggt	gaaatgccat	ctctactaaa	aataaaaaat	tagccaggcc	3000
tgggtgggtgg	tgtctgtaat	cccagcaact	cgggaggctg	aggcaggaga	atcgcttgaa	3060
ccagggggggc	agagggttgca	atgagtcagg	attgcaccac	cgcactccag	cctgcgtaac	3120
aagagcgtgt	aactcttgct	tcaaaaaata	attaaataaa	tataataata	aaataaaaaa	3180
gaatcttcac	atcctgggaag	tcgagaacac	atgaaaacaa	gtaaaggccg	aagcgcagtg	3240
gctcacgcct	gtaatcccg	cactttggga	ggctgaggcg	ggcggataac	ctgaggctcg	3300
aagtctcgaga	ccagcctgac	caacagggag	aaaccccgcc	tctactaaaa	atacaaaatt	3360
agccggggcat	ggcgggtgcat	gccagtagtc	ccagctactc	gggaggctga	ggcaggagaa	3420
tcgcttgaa	ccggaatgtg	gagggttggtg	tgagctgaga	tcgggcaatt	gcactccagc	3480
ctgggcaaca	agagcgaaac	cctgtatcaa	aaaaaaaaaa	aagaaaaaaa	aaggaagaaa	3540
agggcctaaag	gcccggggcg	cgggtgggtca	cgcctgtaat	cccagcactt	tgggaggccg	3600
agggcgggcga	atcacagggt	caggagatcg	agaccagggtg	aaaccccgctc	tctactaaaa	3660
atacaaaaaa	attagccggg	cggtggtggtg	ggcgccgtga	gtcccagcta	ctcgggaggc	3720
tgaggcagga	gaacagcgtg	aaccgggaaa	gcggagctgg	cagtgaagctg	agatcgcgcc	3780
actgcactcc	agcctgggtg	acagagcgag	actccgtctc	aaaaaaaaaa		3830

&lt;210&gt; 297

&lt;211&gt; 20245

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 297

gcctttccag	ggccgggggaa	ccccaggagg	aagctgctga	gccatggggc	cctacgcgcg	60
ggcttcgggg	gtctgcgtc	gcggctgcct	ggactcgaca	ggccccctga	ccatgtcccg	120
cgccctgcgg	ccaccgctcc	cgccctctctg	ctttttcctt	ttgttgctgg	cggctgccgg	180
tgctcggggc	gggggatacg	agggtgagtg	ggcctccgag	ctgaaacgta	caggaggcag	240
agtgaaccc	agaatacagt	ctagagggtg	gggtgggtct	gtcctgtggg	tgtctagtga	300
atggctgatg	atatgacagt	gtggtctgag	tgcgtgcttt	gtgtcattgc	gaggctctggc	360
tgtgcgcctc	tgagtatagg	actgtgtctg	attgtacctg	cctccgtgtc	tccgggatgc	420
ttgcctagac	tttgtctgca	cttaactgtg	ggattggagg	ggcaggagggt	ggcaggggggt	480
gagcagtgtg	tgtgtggggg	gagggtgctg	ctgagagctg	ggactctgga	gtctgcctga	540
aattccagcc	tagctcttac	acttccctgag	tgtgtgacgt	tgggcaagtc	acctatcctc	600
tctaagcctc	agtgccttca	tctggaaact	ggggataaca	tcacccacc	tcccacgggtg	660
gccgtctgct	gtcggcaaat	gctgaacaaa	catcagctac	ttctattatt	attttcccg	720
agtgtgaatg	agagctgccc	tgtgggggtg	tgcaaaagtgg	agttgtatct	atgagcacia	780
ctatgtatgt	gtgtgtcctg	cctggggagg	cctggccctc	tctgcacata	ggcgagatca	840
ggcctctctg	agtcactcac	ctctagatca	agacttactc	tgaagcccc	gacctcgggg	900
gttattgaca	aggtatgtgt	gtttgggggtc	cctgtgcaga	catgccccac	agtgcagccg	960
aacatgctga	acgtgcacct	gctgcctcac	acacatgatg	acgtgggctg	gctcaaaacc	1020
gtggaccagt	acttttatgg	aagtgaagtag	aggatgggga	ctgggtccctg	ggatccccat	1080
ggctccctgta	atccctctgg	gtcctggaca	ttagggtggg	gccagtgtca	ccctaataatc	1140
caggggtttg	gctcctctgt	ctaggaataa	cccccttggtc	tctgctgttc	cctgagagcc	1200
ttatccctgt	tatccacagt	caagaatgac	atccagcacg	ccgggtgtgca	gtacatcctg	1260
gactcgggtca	tctctgcctt	gctggcagat	cccacccgctc	gcttcattta	cgtggagatt	1320
gccttcttct	cccgttggtg	gcaccagcag	acaaatgcc	cacaggaagt	cgtgcgagac	1380
cttgtgcgcc	aggggtgagc	taccccaagg	agctgaaaag	aggaagccca	gccagcttc	1440
tgcttctgca	tctctggttt	ctgagatttg	tcatgccacg	tgcaagctgt	ataacatgcg	1500
tgtcgtcccg	cctgcctgga	ctctccattt	ggagacctcc	tatacatccc	acaaagcccc	1560
acctgctgtg	catcctctgg	gaagcctgcc	atgcaggggg	cctctttccc	atatctggga	1620
actatggcct	gggagcgacc	cctcttgtcc	ttccgccaga	aatgtgtaca	caggcaggct	1680
ttcacattcc	cagtatcacc	caccctactc	ccactcctgg	ctctgaccgc	tgaccctgac	1740
cttgccctgct	ctggcacagg	gcgcctggag	ttcgccaatg	gtggctgggt	gatgaacgat	1800

gaggcagcca	cccactacgg	tgccatcgtg	gaccagatga	cacttgggct	gcgctttctg	1860
gaggacacat	ttggcaatga	tgggagaccc	cgtgtggcct	ggcacattga	ccccttcggc	1920
cactctcggg	agcaggcctc	gctgtttgcg	caggtgcgac	ccgggacctc	tcttgggccc	1980
acttcttcac	tcaactctggc	tcctccctcg	cccagtcaaa	ccccgcctc	tccttgcaat	2040
ctcacaagga	ccaggcccag	gcctaggcct	gttgaagccc	tgccccctga	gtgagccgta	2100
aagccagtgg	cttttgagct	ctggcctcag	ccggctatgc	ccagcccagg	ctgaccceagc	2160
tcgggtggc	tcggccctct	ccctaataag	gccccctctg	gtgttctggc	cccacccact	2220
agctcgggtc	ctggctcctc	cctaaaccgg	gtggcaagtg	gatgcctagg	ctgccttaaa	2280
aacaggttca	ttacctgtgc	tcagacccca	tccatcctca	ggctgtggaa	gggggaacct	2340
cattcctgga	gtcaggcctg	ctctgcgctt	tgacagtgc	ggggaggtga	acctgggttc	2400
tgatgttgga	cccgcctct	ccctgctagc	ccaaggtggt	gagttctgaa	acttcccca	2460
gcttggaat	aagctggagg	cctctctgtt	tcagccctac	gtgtttttgt	ttttgttttt	2520
tgagacagtg	ctcaggctg	atccaggctg	gagtgcagtg	gtgcaatcct	aactcactat	2580
agcctcaatc	tcccggtatc	aagcgattct	cctgtctcag	ccccctagt	agatgagact	2640
acaagagcgc	accactacgc	ctggctaatt	tttaaatctt	ttgtagacag	tctgcccgtg	2700
ttgtgcaggc	tggtctcaaa	aactcctggg	tttaagtgat	cctcctgttt	tggcctccca	2760
gaaggctggg	atcataggca	agagccacca	catcgacct	gcactgcttt	ttaacctgtg	2820
ctctgacctg	cccctcccaa	gcagagggga	gtttgggtgt	gagagggctg	ggcactaatt	2880
cacactgcct	tttctcctct	catccccaga	tgggcttcga	cggtctcttc	tttggggcgc	2940
ttgattatca	agataagtgg	gtacggatgc	agaagctgga	gatggagcag	gtgtggcggg	3000
ccagcaccag	cctgaagccc	ccgaccggcg	acctcttcac	tggtaggggg	cttgggtgagg	3060
gcagggccag	ccatgggtgcc	acacactcag	aaggggcctg	ggcttgatat	ctgctctgtt	3120
gtcactgtcc	tggaaattcct	atagtctggg	aacaaaggcc	ctgcatttcc	ttttgcattg	3180
ggacacaaat	tctgaagccc	atcctgggtg	ggacatggcc	ggctttgaaa	ccagggaagg	3240
tctgggtgat	gggccacccc	ttgaacttgg	tgtgacctgc	aggtgtgctt	cccaatgggt	3300
acaaccgcgc	aaggaaatctg	tgtgggatg	tgtgtgtgt	cgatcagccg	ctgggtggagg	3360
accctcgagc	ccccgagtac	aacgccaagg	agctggctga	ttacttctca	aatgtggcca	3420
ctgcccagg	aacctgggtg	tcagaacct	tcgagtcgg	tatatacaat	acaatgagct	3480
ctttccatgg	tacaggcatc	ccctaacacg	ttctccttat	ttttaatttt	tttgagacag	3540
tcttactctg	tcacccaggc	tggagtgcag	tgggtgcgatc	tcggctcact	gcaacctctg	3600
cctcctgggt	tcaaaacaagc	acatccagct	aattttttgt	tttttgcaat	gggtctctcat	3660
catgttgtcc	aggctgggtct	caaactcctg	agctcaagtg	atctgcttgc	ctcggcctcc	3720
caaagtgccg	ggattacagg	catgagccac	cgcacctggc	ctctattttt	aacattttta	3780
tttattttatt	attatttttt	tttttttgag	acagagtctt	gctctgtcac	ccaggctgga	3840
gtgcagtggc	atgatctcag	ctcactgcaa	cctccgcctc	ccgggttcaa	gcgattctcc	3900
tgctcagcc	tcctaagaag	ctgggattag	aggcacctgc	caccacaccc	agctaatttt	3960
tgtattttta	gtagacaggg	tttcgtcatg	ttgaccaggc	tggctcttgac	ctcagggtgat	4020
ctgcccgcct	caacctccca	aagtgtctgg	attacagggtg	tgggccactg	tgcttagtct	4080
atttttaaca	tttttattga	gaattccttt	tttatttttt	ttagactcac	tctgtcgccc	4140
aggctggagt	gcagtggcac	gatctoggct	cactgcaacc	tccacctact	gggtccaagc	4200
gattctctctg	cctcagcctc	cgagtagct	gggattacag	gtgcccacca	ccatgctcgg	4260
ctaagtttta	tgtcttttta	gtagaaaggg	ggtttcacca	tattggccag	gctggtctcg	4320
aactcctaac	cttttgacc	acagccttgg	cctctcaaa	tgctgggatt	acaggcgtga	4380
gccaccgcgt	ccagccttta	acatttttat	aattaaaaaa	cattattttt	tcacagagat	4440
aaggctctcac	catgtggccc	aggctgggtct	caaactcctg	aactcaagtg	atcctcctgc	4500
cttggcctcc	caaagtgcta	ggatataggt	gtgagccacc	atgcctggca	taacacgttc	4560
tccttaaaaa	aatttttttt	tcctttcttt	aaaaattgat	ggctgggcat	ggtggctcac	4620
gcctataaat	ccagcatttt	gagagggcga	gatgggcaga	tcactctgaag	tcaggagttc	4680
aagaccagca	tagccaaaat	gacgaaaccc	tgtctctact	aaaaatacaa	aaattagtcg	4740
ggtgtggtgg	cgcacgcctg	taatcccagc	tacttgggag	gctaaggcaa	gagagtcgct	4800
tgaacctggc	agggtggagg	tgcagtgcgc	cgagatcacg	tcacttcact	ctagcttggg	4860
cagcagagtg	aaactctgtc	tcaaaaaaaa	aattgtttta	gattaatttt	tttttttttt	4920
cttgagacag	ggtcttgcctg	tgtggcccag	gttggcttta	aactcctaga	ctcaagcgat	4980
cctcctgcct	cagtcctcctg	agtagctggg	attacagggtg	tgagcccctg	taatcatggt	5040
ctcactgccc	ctggagggaag	atgctattct	attcaccatc	acaatgtccc	cctcctggat	5100
ttatgtgcat	tcctcattag	aagagatagc	ataggctggg	caagagatag	catggcatgg	5160
tgactggatg	ccctcttcta	ggtagtgggt	ccaagagaac	tgctcaacaa	ctgggtggcta	5220
cttttatctg	tgtcccccag	ctcccaagtg	ccataccccc	acccatgcct	gtgcacccaa	5280
catccttgac	cccatataca	tcaaaacaca	gctatacaca	gggatggccc	aggatcctct	5340
ggcttcagga	ctccccctct	gcctgcaggg	ccggtattac	cgcaccaacc	acactgtgat	5400

gaccatgggc	tgggacttcc	aatatgagaa	tgccaacatg	tggttcaaga	accttgacaa	5460
gctcatccgg	ctggtaaagt	cgcaggctcag	tgccgctacc	ctgtgggtacc	cttgtgcaca	5520
tgtgcgcttg	catccggggg	ccttgggtta	tgtgcatagc	tctcagtgct	gtcctttgttt	5580
tctattgttc	tattgtggtc	attctataac	aaatgaccac	acacttagca	gctcaaaaca	5640
acagaaatc	attgtcttac	agttctgtag	gtaaagaagtc	cagcatgagg	ccgggcgcaa	5700
tggtcatgc	ctgtaatccc	agcatgttgg	gaggctgagc	cgggcagatc	acgaggtcag	5760
gaattcgaga	ccagcctgac	caacatggtg	aaacgctgtc	tctactaaaa	atacagaaat	5820
tagctgggtg	tgatgggtgc	tgccgtgaat	cccagctact	cgggagcctg	aggcagggga	5880
atctcttgaa	tccgggaggc	ggagggttga	gtgagcggag	attgtaccac	tgactccag	5940
cctggggccac	agagaaagac	tctgtctcaa	aaaaaaaaaa	aaaaaaaaaa	aatccagcct	6000
gagtctcacc	aggtatataat	caagggtgtg	gcaaggctgt	gttccttctg	cagtctctag	6060
gagagaatc	aatttccctg	ctttttccaa	catctagaag	ttaccacat	tcaaaatcta	6120
ttcttggctc	catcttcaaa	gccagccaca	tagcatcttt	ctgaccctgt	ttctgtaatc	6180
acatcccttt	ctctcattct	cacctcttct	gctctctct	tccacatttt	atttatttac	6240
ttagagacgg	agtctcgctc	tgctgcccag	gctggagtgc	agtggcgtgc	tctcggtca	6300
ctgcaacctc	cgcctcctgg	gttcaagtga	ttcttctgtc	tcagcctccc	aagtagctgg	6360
gactacagtc	gcgtgccacc	acgcccagct	aatttttcta	tttttagtag	acagggtttc	6420
accatgttgg	ccaggatggt	ctcgatttct	tgacctcgtg	atccaccccc	ctcggcctcc	6480
caaggtgctg	ggatcacaga	tgtgagccac	tgtgtggcct	aatttcccta	ctttaagttt	6540
ggctgatgaa	caacctcaat	tccatctgca	accttaattc	cccttttgcc	atgtaactta	6600
atgtggtaat	aggttctggg	gatcaggaca	tggacacttt	tgggcagtta	tcattttacc	6660
caacacagat	gtgttagtgt	tttgactaa	gtggcctgtg	gctgtggtg	tgtgcacagt	6720
cagtcactct	catcagcaca	gaaacttgct	tccctctccc	catctcagac	accccttccc	6780
atcaatcttg	tcctcactac	ggtgcaatct	ccattcccac	cttccactcg	ctcccagcac	6840
tgctatttca	ccaaaacagc	tcttttatgt	catttatatt	tatttatatt	ttctttttta	6900
aattttattt	atttatttat	ttattgagac	aagagtcttg	ctttgtcacc	caggctggag	6960
tgcagtggca	tgatcttgcc	tcattggcaac	ctctgcctcc	tgggttctag	tgattctcct	7020
gcctcagcct	cccaagtagc	tgggactaca	ggcatgtgcc	accaaccctg	gctaattttt	7080
gtatttttag	tagaggcagg	gtttcactat	gttggccagg	ctggtctcaa	aactcctgac	7140
ctcaggtgat	ccgtccgcct	tggcctccca	aagtgttggg	attgtaactc	gagggtggcg	7200
gatcacttga	agacaggagt	tggagaccag	cctggccaac	atggtgaaac	cttgtctcta	7260
ctaaaaatc	tacaaattag	gtgggcgtga	tggcaactcat	ctgtaagacc	agctactcgg	7320
caggctcagg	caggagaatc	gctggaacct	gggaggcgga	gtttgcagcc	agctgagatc	7380
gtgccactgc	actccagctt	gggcgacaga	gtcagactca	gtctcaaaaa	aaaaaaaaaa	7440
aaaaaaagt	tattgagcac	ctactgtgta	cattggggga	cacagctcgt	gcaaaacaaa	7500
catccttttc	ctcacatagg	tcactttctt	gttcctccac	cttgctcagg	tgaaagtga	7560
cctccattca	ttataaaaa	tgtgtctagg	ccgggcacgg	tggctcatgc	ctgtaatccc	7620
agcacttttg	gaggctgagg	cgggcggatc	atgaggtcag	gagatcgaga	ccatcctggc	7680
taacacgggt	aaactccgtc	tctactaaaa	aatgcaaaaa	attagccggg	tgtggtggcg	7740
ggcacctgta	gtcccaggta	ctcatgaggc	tgaggctgga	gaatggcgtg	aaccaagag	7800
tgggagcttg	cagtgcagctg	agattgagcc	gtcgcactac	agcctgggca	acaaagtga	7860
actccgtccc	aaaaaaaaaa	agttgtgttt	tttggttaaca	atctgacagt	cctgcaaaac	7920
gattattcct	gccctataat	gtcacactta	gtttttccac	aaaagttttt	aataataaag	7980
ttggaattat	tgtaaaagt	tagtaaaatt	tcaggtttat	tcttgcatct	ctgaaatcct	8040
tttaaaaaag	gctagtggtc	atgtttgact	tcagccaaaa	ttcattttca	cacccaacca	8100
ttggcttgca	cgccaaatat	gtatttagag	aaactgaacc	tatgggatgc	atgaatgtgc	8160
acacatgtgt	ggaagtgtgg	gccccaggga	aggtgcggac	tcccaggggc	tcactccgtc	8220
gcctccccca	gcagcaggca	aaagggaagca	gtgtccatgt	tctctactcc	accccgcctt	8280
gttacctctg	ggagctgaac	aaggccaacc	tcacctggta	tttggggaaa	ctggggagct	8340
tgggggggtt	ggcatgcccc	gtgggtcatg	accctgccct	caatgcccc	gccgctgtag	8400
gtcagtgaat	catgacgact	tcttccctta	cgcggatggc	ccccaccagt	tctggaccgg	8460
ttacttttcc	agtccggccg	ccctcaaacg	ctacgagcgc	ctcagctaca	acttctgtca	8520
ggtgggtagg	agccgggcta	gagggggcat	gcagccccga	ggcccgacag	gctgggcgcc	8580
ccaacatacc	cctctgcctc	caggtgtgca	accagctgga	ggcgctggtg	ggcctggcgg	8640
ccaacgtggg	accctatggc	tccggagaca	gtgcacccct	cagtaagtgt	cgggcccaag	8700
aggggaagag	gtttgcggct	gaagtggaa	accaccctta	ggccgcccc	ctcaggtttc	8760
ttcttttttt	tttttttttt	tttttttttt	gagacggagt	ctcgatttgt	ctcccaggct	8820
ggagtgcagt	ggtgcgatct	cggctcactg	caagctccac	ctcccgtgtt	cacgccattc	8880
tcctgactca	gcctcccag	tagctgggac	tacaggcgcc	caccaccacg	cccggcta	8940
tttttgtatt	tttagtagag	acggggtttc	accatgttag	ccaggatggt	ctcgatctga	9000

222

cctcgtgac	cgcccgctc	ggtctctcaa	agtgtggtg	ttacaggcgt	gagccaccgc	9060
ccccagccgt	cctcgagttc	cttcttaaag	cctctaagaa	tcctgcccgc	cagcaccgga	9120
cctttcgctt	ccccttgggg	tctcagctga	gtcccacaga	acctcaccgg	actcattgtc	9180
tatgagcaga	tgaggcgatg	gctgtgctcc	agcatcacga	cgccgtcagc	ggcaccctccc	9240
gccagcacgt	ggccaacgac	tacgcgcgcc	agcttgccgc	aggctggggg	ccttgcgagg	9300
tgcgcggggc	gagacttggg	agacacgggg	gtggagacag	gaaggggcgg	ggccagggcc	9360
tgaggaaagg	gacagagaca	ggtgtgaggg	gtagccgaga	gccctgtggc	ggggctacaa	9420
gggctcgtgg	gggcggggct	tgtaggaggc	ggggaaagat	acaggaaacg	ggcggggcct	9480
tggagggggg	aaggaggcgg	ggcgtgggca	agaggaggcg	gagacagcta	tggggatatag	9540
tcaagggcag	cagggtgggg	ctagaagggg	ttttggggcg	actcttgagg	gaggcgggac	9600
agagaccgga	acggggcggg	gcctgaggag	aggggaggag	tcaggcctgg	cgctcctgaac	9660
ccaccggtcc	ctttgcgctc	ttccgcagg	tctcttgagc	aacgcgctgg	cgcggtctcag	9720
aggcttcaaa	gatcacttca	ccttttgcca	acagctaaac	atcagcatct	gcccgtctcag	9780
ccagacggcg	gcgcgcgtga	gccgggacgg	gaggggtgga	tctagggcag	atgggcttta	9840
gagggggtag	ttggaaaatg	tttttgagg	actatacagg	agtgaataa	cgtgggctgc	9900
gaagctgggt	cagcagagag	aacaacgcac	ctcgaggggg	cttggcctta	agtgccgtga	9960
ccacactagg	accagccagg	ggtgtttctg	tgcaaagtgg	gtgggtttgg	agaaggcctg	10020
ctgtgaccca	tgccctctct	gaccccgccc	tcccagttc	caggctcatcg	tttataatcc	10080
cctggggcgg	aaggtgaatt	ggatggtacg	gctgccgggc	agcgaaggcg	ttttcgttgt	10140
gaaggacccc	aatggcagga	cagtgtccag	cgatgtgagc	ccaaacaacg	aatattcccc	10200
cgctgggact	cctccccag	tgggcatttc	ctcatcgccc	ccatggatat	cgccgtcttc	10260
catgaatacc	tcccactcat	gcatactct	tccccctct	tgtatcttct	ccctctgccc	10320
cttaatatca	gtctccccct	gggaacatat	gcctcctgtg	agtgttcctc	cctttttttt	10380
ttttttttga	gacggagtct	cgctctgtca	cccaggctgg	agtgcagtgg	cgcgatcttg	10440
gctcacttca	aactccgcct	gctggattat	aggcatgagc	caccgtgcct	ggctggctct	10500
ccattttaat	accccgcttc	cccaggaaaa	tttattgctg	tttatggaca	tctccttcat	10560
tcagaaaaac	gtcctcccc	aaacctcttc	ctcccccgag	aacctgcctc	aagggtttct	10620
tcccactact	cctccttcac	tccccgact	ccatggtctc	tccaccctcc	cgggtgggtt	10680
ttttttccac	ctggtgaatc	ttctctgcaa	tcatttcctt	ggaatctgac	tgtcccccca	10740
ccacacacac	ctccatttcc	tttccccatc	tcaggactct	tttccttcc	tgagtttttt	10800
gtctccatgc	atgtatagct	ttccatgggt	actcttgact	cagtttccct	cctcctttat	10860
ccgaggtggt	aatatttccc	agctcagaca	gccaggcgca	ccctccggag	ctgctgttct	10920
cagctcact	gcccgcctcg	ggcttcagca	cctattcagt	agcccagggtg	cctcgctgga	10980
agcccagggc	ccgcgcacca	cagcccatcc	ccagaagatc	ctggtccctc	gctttaacca	11040
tcgaaaaatga	ggtgagaccc	catttcaatc	cccttctctg	ctcctgtgac	aaatttgaa	11100
tgtcatgggtg	agctgtgtgg	actctgggtc	agcaggctcc	taggcttatg	acctcctgtc	11160
acaactcccc	tcattgtgtg	tccttgagca	agtgcctttt	gtctgagcct	cagtgtcctt	11220
tcctgggact	gttatgagga	cccagtgtag	tcatgggtga	cacttgacag	acatgtcaga	11280
gttggtggga	gggtggtggt	cgcaattttg	gcagggacgt	ttcagggaag	gtgttcccga	11340
taaaggtgac	atttaagata	tgacctgagg	gagggagccg	tgtggctatt	tgaagggaag	11400
gagatccagg	tggggagaga	ataacaggca	taaaagcctt	cgagcaggag	agtgtgcaga	11460
attccaggag	ccacaaggag	ctcagtgtgg	ctgaacagg	gtgaacgggt	gacaggtcag	11520
accttgaggg	ccttgaggac	caacagggaag	actttggctt	ttgccagtca	ttgttgcctc	11580
tgtgtctact	cctagctctt	tgggaggctg	aagcgggagg	atcacttgag	cccaggagtt	11640
gtcccagcta	attgggaggc	ccagatggga	ggtttgtttg	agctggggag	ttcgagggtg	11700
cagtgaagtaa	tgattgtccc	actgtactcc	atcctggcaa	cagagtgaag	ccctgtctga	11760
aaagaataat	aataaaatag	gccaggcatc	gtggattata	cctgtaattc	tagcaccacg	11820
ggaggctgag	gtgggtggat	ctactgagct	caggagtgtg	agaccagctt	gggcaacatg	11880
gtgaaaccca	gtctctacaa	aaaattagct	gggggtgggtg	gtacacgtct	gtaatcccag	11940
ctacttgggg	gctgaggaag	gaggattgct	tgagcccagg	tggcagagg	tgcatgtgag	12000
cgagatcatg	ccactgcact	ccagcctggg	tgacaaaagt	agaccctgtc	tcaataaaat	12060
aaaataaaag	aagttctgca	gtaggactgt	tcattgttag	aagaaaacat	ctttttcata	12120
tttttattaa	aataaaataa	aagaagttaa	aacgttccca	caggccctta	aaagtcttgt	12180
gagttctggc	attgtggttc	acacatcaga	tgcccaagtt	ggccctgggtc	cgagcagag	12240
gagggctttg	atgggactta	gggtatcaca	ggtgtgctct	ggctgttgtg	gggaacagac	12300
tgtaggcagc	cagtggtgaa	gtgcagggac	ctggaagggg	ttgactgcac	tggccctgga	12360
aggccctggt	aagaggtggt	gaggttgaaa	ataaggttgg	gggggcccggg	cgcggtggct	12420
cacacctgta	atcccagcac	tttgggaggc	cgaggcaggc	agatcacgag	gtcaggagat	12480
ggagaccatc	ctggctaaca	cggtgaaacc	ctgactctac	aaaaatacaa	aaaatttagc	12540
caggcgtggt	ggcgagcatc	tgtagtccca	gttactcggt	aggctgaggc	aggagaatgg	12600



223

cgtgaacccg	gaaggcggag	cttgacgtga	cctgagatgg	cgccactgca	ttccagcctg	12660
ggcaacagag	tgagactccg	tctcaaaaaa	aaaaaaaaga	aaaaaaaaga	aaaaaagaaa	12720
aggctggggg	gggcacggtg	gctcatgcct	gtaatcccg	gactttggga	ggctgaggct	12780
ggcagggtcac	ctgaggtcag	gagtttgaga	ccagcctggc	caacacagtg	aaacctcgtc	12840
tgtacaaaaa	atacaaaaat	taactgggcg	tgggtgtaca	cacttgtagt	cctagctact	12900
cgggagggag	aggcaggaga	atcacttgaa	cccaggagg	ggaggttgca	gtgagccgag	12960
atcatgccac	tgcactccag	cctgggggac	agagcaagac	tctgtctcaa	aagcaaacaa	13020
aaaaaaaaatc	aggttgaatg	gctgggtgtg	gtggactgct	tgagcccagg	agttggacac	13080
tagccccagg	caacatagtg	ggacccccat	ctctagaaaa	caaatttaaa	tttttttttt	13140
tttaattttag	tagagatgga	gtttcactat	gttgccagg	ctggtatcaa	actcctcacc	13200
tcaggttatc	cacccaactt	ggtctcccaa	agttctggga	ttacagggtg	gagccaccac	13260
gctcgccctt	aaaaaaattt	taaattgaga	aaaaaagggg	ccaggcgtgt	tggctcatgc	13320
ctgtaatccc	agcacttttg	gaggctgagg	ggggggtgga	tcatgagggtc	aggagttcga	13380
gaccagcatg	gccaatattg	tgaaccctg	tctctaataa	aaatacaaaa	attagccagg	13440
tgtggtggca	tgtgcctgta	gtcccagcta	ttcaggaggc	tgagtcagga	gaattgcttg	13500
aaccggggag	gcgagggttg	cagtgaacca	agatcacgcc	actttctgca	ctccagcctg	13560
ggcgatagag	cgagactcag	tctcaaaaaa	aaaaaaaaaa	caaaaaaccc	aggccagggtg	13620
cagtggctca	cgctgtaat	cccagccctt	tgggaggcca	aggcgggtgg	attacctgag	13680
gtcaggaggt	ggagaccagc	ctgaccaaca	tggcgaaacc	ccgtctctac	taaaaatata	13740
aaaattagcc	aggcatgggt	gcattgacct	gtatcccgag	ctaccaggga	ggctgaggca	13800
ggagaattgc	tggaaacccag	gggcagaggc	tgtagtgaag	agagattgag	ccccctgact	13860
ccagcctggg	cgacacagca	agtttctgtc	tcaaaaaaaa	aaaataaaaa	tccggctggg	13920
cacagtggct	tatgtctgta	atcctagtac	tttgggaggc	caagtgagc	agatcacttg	13980
agttcagggg	tttgagacca	gcctggccaa	catggtgaaa	ccctgtctct	actaaaaata	14040
tgaaaattag	ccaggcgggg	tgggtggcac	ctgtaatccc	agctacttgg	atagctgagg	14100
cacgagaatc	acttgaaccc	gggaggtggg	gggtgcagtg	agccaagatt	gcaccactgt	14160
actctagcct	gggtacagca	gtgagactca	gtctcaaaaa	aaaaaaaaaga	aaaaagaaaa	14220
attaaaaaaaa	gaaaaacacac	acacatacac	acacaaaccc	atctgtggac	ccttttctgc	14280
ccagcacatc	cgggcaacgt	ttgatcctga	cacagggtcg	ttgatggaga	ttatgaacat	14340
gaatcagcaa	ctcctgctgc	ctgttcgcca	gaccttcttc	tggtaaggga	agatcaccag	14400
gcctgagggg	ggggtgggtg	tgctcgccat	ggagctaggg	ccccttacct	gactctcacc	14460
tgccccaact	ccaggtacaa	cgccagtata	ggtgacaacg	aaagtgaacca	ggcctcagggt	14520
gcctacatct	tcagacccaa	ccaacagaaa	ccgctgcctg	tgagccgctg	ggctcagatc	14580
cactctgggtga	aggtcagggg	ctaggaatga	tgagtgggca	gttgggaatg	gggaagttat	14640
ggagcccaag	aggggtgggtg	gccatgtgta	gagtgagggt	aggggaggat	ttacttttcc	14700
ttcagatcag	tgggctaaga	cccacagatc	agcgggggaa	atatttgagg	gtccttccat	14760
agaattgata	ttcatagctg	gtcgtatgag	agtctcccca	taggacacat	catacaaagc	14820
cattcacatc	tgctgtggac	gtttacatac	ttagttttgg	aaattggggg	tggggcatte	14880
ccacttggcc	catgaatcag	gagagccaaa	tatcactgct	tgaagaatte	accaaagtct	14940
gtagtaagag	gagcttctat	ctggagtga	tatttgagag	tccacccttg	gattgattgg	15000
gtttgggtga	gattcagggt	gaatgcctat	gggtgcatct	ggctagggaac	agtggtttcc	15060
cagggcctct	catgatgtt	tgactttcat	agatgacaaa	actcacattt	gtccacattc	15120
aagagcctcg	cgtttcatgt	gagtcctttt	gagatgaatg	tctgcatatc	tgtatatagt	15180
tttgctgtgt	ctaacagagt	tacccaaatt	aactgtgact	agaataagat	agaagattat	15240
tttcttctaa	caaaaagtct	ggctgttagt	ccagagaaaag	tggggtgggt	ccataatcac	15300
ccaggacctc	ctcttctatc	ttgttgcctc	gccttcccca	atattcagtt	tccacctcat	15360
ggtccaagat	agctgctgaa	gctccagccg	ccacatttgt	gtttgagtca	gtagcagagg	15420
gacagggggca	aggaacattg	ttgacaccac	ttggatcact	ttctatgggg	caaactgggtc	15480
actcagctac	tgatagcctc	aggggaagact	ggacaatata	gtctttatcc	caggtagcca	15540
tgtgccaaagc	tagaatccta	ttctatgggg	caatggtgaa	caggaggcgt	ttatgccacg	15600
ctcaagagtg	atgtggtgaa	ccagatgcag	tggctcatgc	ctgtaatcac	agcactttgg	15660
gagactgaag	caggaggatc	gctgagcata	ggagtccaag	accagggtggg	agcattttgct	15720
gattaggtgc	ctacatagtg	atgcctgtc	tcaaaaaaaa	aaaaaaaaaa	agaggccggg	15780
tgcagtgggt	cagcctgta	atccagcac	tttgcagggc	agaggcaggc	agatcatctg	15840
aggtcaggag	ttcaagacaa	gtctggccaa	cattggataga	aaccccgctc	ctactaaaaa	15900
tacaaaaatt	agccaggggg	ggtggcagg	acctgcaatc	cctctactcg	ggaggctgag	15960
gcaggagaat	tgcttgaacc	caggaggcgg	aggttgcagt	gaggcaagat	tgtgccactg	16020
cactccatcc	tgggcaacaa	gagcaaaact	ctgtctcaaa	aaaaaaaaaa	gaaaaaagaa	16080
ttatgtgggg	caggcgcggt	ggctcacgcc	tgtaatccca	gcactttggg	aggccgaggc	16140
gggctgatca	cgaggtcagg	agatcgagac	catccttgc	aacacggtga	aaccccatct	16200

ctactaaaaa	tacaaaaaat	tagccgggtg	tgggtggcggg	tgccctgtagt	cccagctact	16260
cgggaggctg	aggcaggaga	atgggtgtgaa	cccgggaggc	ggagcttgca	gtgagccgag	16320
atcgcgccac	tgcactccc	cctgggcaaa	agagcgagac	tccgtctcaa	aaaaaaaaaa	16380
aaaaaaagaa	ttatgtggcg	gtgactgaag	gttgaccttg	atgtaggcct	taatgggggtt	16440
tatggccagg	gttgggggac	atgtgttagga	ctcacctctg	ctcaggtaca	gactgacatc	16500
cacctcacc	gtgtgcccgc	agacaccctt	ggtgcaggag	gtgcaccaga	acttctcagc	16560
ttggtgttcc	caggtggttc	gcctgtaccc	aggacagcgg	cacctggagc	tagagtgggtc	16620
ggtggggccg	atacctgtgg	ggtgagtggc	acaggctggg	agaggggtgt	ggaagcaagg	16680
gcagaggggt	ttatccaagg	ctcacaacct	tgccatccca	ttgggtacag	cgacacctgg	16740
gggaaggagg	tcatacagcg	ttttgacaca	ccgctggaga	caaagggacg	cttctacaca	16800
gacagcaatg	gccggggagat	cctggagagg	aggtgggggg	tgactgagag	cactgagggg	16860
tgggtctgtg	gtgtgttggg	gcccaggggt	ggtgagggaa	atltgtctgat	tacatgagtg	16920
tgggagacag	aggacgaagg	gagagtgaag	ggcgggggag	ccaggcaggg	tgcatgtgct	16980
cacgcctgta	atcccagcac	tttgggaagc	cgaggcgggc	agatcacaa	gtcaggagat	17040
cgagactatc	ctggctaaca	tgggtgaaacc	ccgtctctac	taaaaataca	aaaaaatcag	17100
ccgggtgtgg	tggcgggcac	ctgtagtccc	agctactcgg	gaggctgagg	caggagaatg	17160
gcgtgaagcc	gggaggcgga	gcttgacagt	agccgagatc	gcgccactgc	actccagcct	17220
gggtgacaga	gcgagactcc	atctcaaaaa	aaaaaaaaaa	aaaaaaagag	ttggggagcc	17280
agatcccaag	cctgatcagc	tcaccccaaa	ccccaggcgg	gattatcgac	ccacctggaa	17340
actgaaccag	acggagccc	tggcaggaaa	ctactatcca	gtcaacaccc	ggatttacct	17400
cacggtagct	ctcccccatc	ctgcacctcc	ccacctcgat	agaaagggaa	tcacccctta	17460
tctgcagcat	ctcaaagctg	cctgggggtg	gggttgactg	ccctctactt	tcacccctca	17520
actcccagga	tggaaacatg	cagctgactg	tgctgactga	ccgctcccag	gggggcagca	17580
gcctgagaga	tggctcgctg	gagctcatgg	tgagtgggtc	agagccccat	ccgagccagg	17640
gtcctcccaa	cctggacccc	tgctggacct	tgaaggctgt	ttctggccca	gttctctgct	17700
ctcaggcccc	actaagctga	ggactccgtt	ctttcttttt	cttctctttg	agacggagtt	17760
ttgctcttgt	tgtccaagct	ggagtgcatt	agtactatct	cagctcactg	caacctctgc	17820
ctcctgggtt	caagtgtatt	tcttgctcca	gccttccgag	tagctgggct	tacaggcaca	17880
caccatcacg	cccggtctaat	tttgggtatt	ttagtagaga	tgggggtttca	ccatgttggc	17940
caggctgggtc	togaactcct	tacctcaggt	gatccactca	cctcggcctc	ccaaagtgtc	18000
gggattacag	gcgtgaacca	ccgctcccgg	ccaaggactc	catttctgtg	tgtggttttt	18060
cctctccgtt	tttctccatc	tcttgcccag	gctccctcca	cgctctggcg	tgccatatcc	18120
aggccccctc	gttaggcatt	tacctccttc	cggcctgggt	cccatgccta	cttgggacct	18180
gcctctgctg	gggttgccct	accagacctc	caccttcac	ctcatccgtt	cctcccaccc	18240
tttaattttct	tttgacattc	ccacacgccc	ttaccagtt	tctggcccaa	ggacacccac	18300
aaacccacga	ctctcaccac	ctcctggcca	ctctccccc	aggtgcaccg	aaggtgtctg	18360
aaggacgatg	gacgcggagt	atcggagcca	ctaattggaga	acgggtcggg	ggcgtgggtg	18420
cgaggcgcc	acctgggtgt	gctggacaca	gcccaggctg	cagccgcggg	acaccggctc	18480
ctggcgggagc	aggaggtcct	ggccccctcag	gtggtgctgg	ccccgggtgg	cggcgccgcc	18540
tacaatctcg	gggtcctcc	gcgcacgcag	gtgaggggca	gcggggtagg	cagagaggac	18600
cggattgaag	tctaccaggg	agccgggttt	gggtgcggag	tttcttaggc	tcagcgggga	18660
tccatttggc	cataattagc	cccaaaccct	cgggccaacc	ccatccctg	ggcagtcctc	18720
gccagtgcc	agcccagtc	caacccccct	ggactgtgta	gaggcacagc	cctagctcat	18780
gcccctaaac	caccaactca	cctccggccc	cgcccatttc	actttagccc	cgccctctca	18840
ccgccccag	gctctgtcct	gcctcaccca	gccccgcggc	ttcagccccg	ccgtaactcc	18900
caaagtctca	ggtcacatca	gttctgtctc	atcgggactc	gaaccctaag	cttgggaccg	18960
acccatctcc	ccattggctc	agtcctccct	gtcaccggcc	tggccgctcc	tctcggctga	19020
gccttgcccc	tctccggcga	aaacccgccc	ctacaacctc	gccttgctc	ctgacctggc	19080
tcggccccgc	ccttctccat	ccaggccccg	ccccctctca	actcagcccc	gcccctctct	19140
ccgcagttct	cagggctgcg	cagggacctg	ccgcccctcg	tgcacctgct	cacgctggcc	19200
agctggggcc	ccgaaatggt	gctgctgctc	ttggagcacc	agtttgccgt	aggagaggat	19260
tccggacgta	acctgagcgc	ccccgttacc	ttgaacttga	gggtgagaag	ggcaaaattg	19320
agaaggagat	cggagagagg	caagagagag	ggagagaaga	gaaacctggc	tttgcccca	19380
ctcatctggg	cccatccct	tccccgcagg	acctgttctc	caccttcacc	atcacccgcc	19440
tgcaggagac	cacgctgggt	gccaaaccagc	tccgcgaggc	agcctccagg	ctcaagtggg	19500
caacaaacac	aggtggggcc	ctgggtcagg	gtagggaagg	ggtggagtct	tacctggggc	19560
cggcaggtg	gggcaatgtg	tgaggcatgg	gatgttgccc	aggacccaaa	aaggtcatga	19620
gggtatgggg	cagagtccag	acccagggtta	ggggcttaaa	ggatctgaaa	tgggtgcgcc	19680
aaaccaggaa	tgggtcttga	ggtttgtggg	tgctgtttag	tcccaagaac	aagatttgaa	19740
aatccccatc	catgtctagt	tctgggaggg	tgttcatcac	ccctgggggtc	agattgaggg	19800

225

taaggaggaca	gtggccagat	tgagggtatg	aggacattgg	acctgggggt	ggtattcggg	19860
gccggggaag	cagggttaaga	gtctgggatt	gaggccctgg	agacagattc	ggggatatgc	19920
agctgtgtct	agaccaggg	gaggaagcat	cgtgggggtga	gtcagaggaa	gtctgcacct	19980
cctcactcct	ccttccccct	gcacctctcc	aggccccaca	ccccaccaa	ctccgtacca	20040
gctggaccgg	gccaacatca	cgctggaacc	catggaaatc	cgcaactttcc	tggcctcagt	20100
tcaatggaag	gaggtggatg	gttaggtctg	ctgggatggg	ccctccaagc	ccaagcctcc	20160
tgctccgggg	gcagaccaga	ctctgactct	cctcttgggg	ctgctgccat	taaaacgcta	20220
ctactaagac	tcaggctcgt	ctgtg				20245

&lt;210&gt; 298

&lt;211&gt; 9796

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 298

gcctttccag	ggccggggaa	ccccaggagg	aagctgctga	gccatgggcg	cctacgcgcg	60
ggcttcgggg	gtctgcgctc	gcggctgcct	ggactcagca	ggccccctga	ccatgtcccc	120
cgccctgcgg	ccaccgctcc	cgccctctctg	ctttttcctt	ttgttgctgg	cggctgcggg	180
tgtcggggcc	gggggatacg	aggtgagtg	ggcctccgag	ctgaaacgta	caggaggcag	240
agtgaaccc	agaatacagt	ctagaggtgt	gggtgggtct	gtcctgtggg	tgtctagtga	300
atggctgatg	atatgacagt	gtggtctgag	tgctgctttt	gtgtcattgc	gaggtctggc	360
tgtgcgcctc	tgagtatagg	actgtgtctg	attgtacctg	cctccgtgtc	tccgggatgc	420
ttgcctagac	tttgtctgca	cttaactgtg	ggattggagg	ggcaggagggt	ggcaggggggt	480
gagcagtgtg	tgtgtggggg	gaggtgctgg	ctgagagctg	ggactctgga	gtctgcctga	540
aattccagcc	tagctcttac	acttcctgag	tgtgtgacgt	tgggcaagtc	acctatcctc	600
tctaagcctc	agtgccttca	tctggaaact	ggggataaca	tcacccccacc	tccccagggtg	660
gccgtctgct	gtcggcaaat	gctgaacaaa	catcagctac	ttctattatt	attttcccgg	720
agtgtgaatg	agagctgccc	tgtgggggtg	tgcaaatggg	agttgtatct	atgagcacia	780
ctatgtatgt	gtgtgtcctg	cctgggaggg	cctggcctcc	tctgcacata	ggcgagatca	840
ggcctctctg	agtcactcac	ctctagatca	agacttaact	tgacagcccc	gacctcgggg	900
gttattgaca	aggtatgtgt	gtttgggggtc	cctgtgcaga	catgccccac	agtgcagccg	960
aacatgctga	acgtgcacct	gctgcctcac	acacatgatg	acgtgggctg	gctcaaaacc	1020
gtggaccagt	acttttatgg	aagtgagtag	aggatgggga	ctgggtccctg	ggatccccat	1080
gggtccctga	atccctctgg	gtcctggaca	ttaggggtggg	gccagtgtca	ccctaataac	1140
caggggttgg	gctcctctgt	ctaggaataa	cccccttggc	tctgctgttc	cctgagagcc	1200
ttatccctgt	tatccacagt	caagaatgac	atccagcacg	ccgggtgtgca	gtacatcctg	1260
gactcgggtc	tctctgcctt	gctggcagat	cccacccgtc	gcttcattta	cgtggagatt	1320
gccttcttct	cccggttggg	gcaccagcag	acaaatgcc	cacaggaagt	cgtgcgagac	1380
cttgtgcgcc	aggggtgagc	taccccaagg	aagtgaanaa	aggaagcccc	gcccagcttc	1440
tgcttctgca	tctctggttt	ctgagatttg	tcatgccacg	tgcaagctgt	ataacatgcg	1500
tgctgcctcg	ctctgcctga	ctctccattt	ggagacctcc	tatacatccc	acaaagcccc	1560
acctgctgtg	catcctctgg	gaagcctgcc	atgcaggggg	cctctttccc	atatctggga	1620
actatggcct	gggagcgacc	cctcttgtcc	ttccgccaga	aatgtgtaca	caggcaggct	1680
ttcacattcc	cagtatcacc	caccctactc	ccactcctgg	ctctgaccgc	tgaccctgac	1740
cttgccctgtc	ctggcacagg	gcgcctggag	ttcgccaatg	gtggctgggt	gatgaacgat	1800
gaggcagcca	cccactacgg	tgccatcgtg	gaccagatga	cacttgggct	gcgctttctg	1860
gaggacacat	ttggcaatga	tgggcgaccc	cgtgtggcct	ggcacattga	ccccttcggc	1920
cactctcggg	agcaggcctc	gctgtttgcg	caggtgcgac	ccgggacctc	tcttgggccc	1980
acttcttcac	tcactctggc	tcctccctcg	cccagtcaaa	ccccgccctc	tccttgcaat	2040
ctcacaagga	ccaggcccg	gcctaggcct	gttgaagccc	tgccccttga	gtgagccgta	2100
aagccagtg	cttttgagct	ctggcctcag	ccggctatgc	ccagcccagg	ctgacccagc	2160
tccggctggc	tccgcctct	cccctaatag	gcccctcttg	gtgttctggc	cccacccact	2220
agctcgggtc	ctggctcctc	cctaaaccgg	gtggcaagtg	gatgcctagg	ctgccttaaa	2280
aacaggttca	ttacctgtgc	tcagacccca	tccatcctca	ggctgtggaa	gggggaacct	2340
cattcctgga	gtcaggcctg	ctctgcctct	tgacagtgtc	ggggagggtga	acctgggttc	2400
tgatgttggg	cccgcctct	cctgtctagc	ccaaggtggg	gagttctgaa	acttcccca	2460
gcttggaaat	aagctggagg	cctctctgtt	tcagccctac	gtgtttttgt	ttttgttttt	2520
tgagacaggg	tcttgctgtc	atccaggctg	gagtgcagtg	gtgcaatcct	aactcactat	2580
agcctcaatc	tcccggattc	aagcgattct	cctgtctcag	cccccttagt	agatgagact	2640
acaagagcgc	accactacgc	ctggctaatt	tttaaatttt	ttgtagacag	tctgcccgtg	2700

226

ttgtgcaggc	tggctcctaaa	aactcctggg	tttaagtgat	cctcctgttt	tggcctccca	2760
gaaggctggg	atcataggca	agagccacca	catcgaccta	gcactgcttt	ttaacctgtg	2820
ctctgacctg	cccctcccaa	gcagagggga	gtttgggtgg	gagagggctg	ggcactaatt	2880
cacactgcct	tttccctccct	catccccaga	tgggcttcga	cggcttcttc	tttgggcgcc	2940
ttgattatca	agataagtgg	gtacggatgc	agaagctgga	gatggagcag	gtgtggcggg	3000
ccagcaccag	cctgaagccc	ccgaccgcgg	acctcttcac	tggtaggggg	cttgggtgag	3060
gcagggccag	ccatgggtgcc	acacactcag	aagggccctg	ggcttgatat	ctgctctgtt	3120
gtcactgtcc	tggaaattcct	atagtctggg	aacaaaggcc	ctgcatttcc	ttttgcattg	3180
ggacacaaat	tctgaagccc	atcctgggtg	ggacatggcc	ggctttgaaa	ccagggaagg	3240
tctgggtgat	gggccacccc	ttgaacttgg	tgtgacctgc	aggtgtgctt	cccaatgggt	3300
acaacccgcc	aaggaatctg	tgctgggatg	tgctgtgtgt	cgatcagccg	ctgggtggagg	3360
acctctgcag	ccccagtagc	aacgccaagg	agctgggtcga	ttacttccta	aatgtggcca	3420
ctgccagggt	aaccttgggtg	tccagaacct	tcgagtccgg	tatatácaat	acaatgagct	3480
ctttccatgg	tacaggcatc	ccctaacacg	ttctccttat	ttttaatttt	tttgagacag	3540
tcttactctg	tcacccaggc	tggagtgcag	tgggtgcgatc	tcggctcact	gcaacctctg	3600
cctcctgggt	tcaaacaaagc	acatccagct	aatttttgta	tttttgact	ggggtctcat	3660
catgttgtcc	aggctgggtct	caaactcctg	agctcaagtg	atctgcttgc	ctcggcctcc	3720
caaagtgcgg	ggattacagg	catgagccac	cgcacctggc	ctctattttt	aacattttta	3780
tttatttatt	attatttttt	tttttttgag	acagagtctt	gctctgtcac	ccaggctgga	3840
gtgcagtggc	atgatctcag	ctcactgcaa	cctcgccttc	ccgggttcaa	gcgattctcc	3900
tgctcagcc	tcctaagaag	ctgggattag	aggcacctgc	caccacaccc	agctaatttt	3960
tgtattttta	gtagacaggg	tttcgtcatg	ttgaccaggc	tggctctgac	ctcaggtgat	4020
ctgccgcct	caacctccca	aagtgtctgg	attacagggtg	tgggccactg	tgcttagtct	4080
atttttaaca	tttttattga	gaattccttt	tttatttttt	ttagactcac	tctgtcgcct	4140
aggctggagt	gcagtggcac	gatctcggtc	cactgcaacc	tccacctact	gggtccaagc	4200
gattcttctg	cctcagcctc	ccgagttagt	gggattacag	gtgccacca	ccatgtctcg	4260
ctaagtttta	tgtcttttta	gtagaaaggg	ggtttcacca	tattggccag	gctgggtctg	4320
aactcctaac	cttttgaccc	acagccttgg	cctctcaaa	tgctgggatt	acaggcgtga	4380
gccaccgcgt	ccagccttta	acatttttat	aattaaaaaa	cattattttt	tcacagagat	4440
aaggctctac	catgtggccc	aggctggtct	caaactcctg	aactcaagtg	atcctcctgc	4500
cttggcctcc	caaagtgtct	ggatatagg	gtgagccacc	atgcctggca	taacacgttc	4560
tccttaaaaa	aatttttttt	tcctttcttt	aaaaattgat	ggctgggcat	gggtggctcac	4620
gcctataatc	ccagcatttt	gagaggccga	tgtgggcaga	tcacttgaag	tcaggagttc	4680
aagaccagca	tagccaaaat	gacgaaaccc	tgtctctact	aaaaatacaa	aaattagtcg	4740
ggtgtggtgg	cgcacgcctg	taatcccagc	tacttgggag	gctaaggcaa	gagagtcgct	4800
tgaacctggc	aggtggagg	tgcatgtagc	cgagatcacg	tcacttcaact	ctagcttggg	4860
cagcagagtg	aaactctgtc	tcaaaaaaaa	aattgtttta	gattaatttt	tttttttttt	4920
cttgagacag	ggtcttgtct	tgtggcccag	gttggtctta	aactcctaga	ctcaagcgat	4980
cctcctgcct	cagtcctctg	agtagctggg	attacagggtg	tgagccctcg	taatcatggt	5040
ctcatgcccc	ctggagggaag	atgctattct	attaccatc	acaatgtccc	cctcctggat	5100
ttatgtgcat	tcctcattag	aagagatagc	ataggctggg	caagagatag	catggcatgg	5160
tgactggatg	ccctcttcta	ggtagtgggt	ccaagagaac	tgctcaacaa	ctgggtggcta	5220
cttttatctg	tgtcccccacg	ctcccaagtg	ccataccccc	acccatgcct	gtgcacccaa	5280
catccttgac	cccatataca	tcaaaaacaca	gctatacaca	gggatggccc	aggatcctct	5340
ggcttcagga	ctccctctct	gcctgcaggg	ccggtattac	cgcaccaacc	acactgtgat	5400
gaccatgggc	tcggacttcc	aatatgagaa	tgccaacatg	tggttcaaga	accttgacaa	5460
gctcatccgg	ctggtaaatg	cgcaggtcag	tgcgcctacc	ctgtggtacc	cttgtgcaca	5520
tgtgcgcttg	catccggggg	ccttgggtta	tgtgcatagc	tctcagtgtc	gtctttgttt	5580
tctattgttc	tattgtggtc	attctataac	aaatgaccac	acacttagca	gctcaaaaca	5640
acagaaatac	attgtcttac	agttctgtag	gtaagaagtc	cagcatgagg	ccgggcgcaa	5700
tggctcatgc	ctgtaatccc	agcatgttgg	gaggctgagc	cgggcagatc	acgaggctcag	5760
gaattcgaga	ccagcctgac	caacatgggtg	aaacgctgtc	tctactaaaa	atacagaaat	5820
tagctgggtg	tgtggtgctg	tgctgtaat	ccgactact	cgggagcctg	aggcagggga	5880
atctcttgaa	tccgggaggc	ggaggttgca	gtgagcggag	attgtaccac	tgactccag	5940
cctgggccac	agagaaagac	tctgtctcaa	aaaaaaaaaa	aaaaaaaaaa	aatccagcct	6000
gagctcacc	aggctataat	caaggtgttg	gcaaggctgt	gttctctctg	cagtctctag	6060
gagagaatat	aatttccttg	ctttttccaa	catctagaag	ttaccacat	tcaaaatcta	6120
ttcttggtct	catcttcaaa	gccagccaca	tagcatcttt	ctgacctgt	ttctgtaatc	6180
acatcccttt	ctctcattct	cacctctct	gcctctctct	tccacatttt	atttatttac	6240
ttagagacgg	agtctcgctc	tgtcgccag	gctggagtgc	agtggcgtgc	tctcggctca	6300

ctgcaacctc	cgctcctgg	gttcaagtga	ttcttctgtc	tcagcctccc	aagtagctgg	6360
gactacagtc	gcgtgccacc	acgcccagct	aatttttcta	tttttagtag	acagggtttc	6420
accatggttg	ccaggatggt	ctcgatttct	tgacctcgtg	atccaccccg	ctcggcctcc	6480
caaggtgctg	ggattacaga	tgtgagccac	tgtgtggcct	aatttcccta	ctttaagttt	6540
ggctgatgaa	caacctcaat	tccatctgca	accttaattc	cccttttgcc	atgtaatcta	6600
atgtggtaat	aggttctggg	gatcaggaca	tggacacttt	tgggcagtta	tcattttacc	6660
caacacagat	gtgttagtgt	tttgactaa	gtggcctgtg	gctgtggctg	tgtgcacagt	6720
cagtcactct	catcagcaca	gaaacttgtc	tccctctccc	catctcagac	accccttccc	6780
atcaatcttg	tctcactac	ggtgcaatct	ccattcccac	cttccactcg	ctcccagcac	6840
tgtattttca	ccaaaacagc	tcttttatgt	catttatttt	tatttatttt	ttctttttaa	6900
aattttattt	attttatttt	ttattgagac	aagagtcttg	ctttgtcacc	caggetggag	6960
tgcagtggca	tgatcttgcc	tcatggcaac	ctctgcctcc	tgggttctag	tgattctcct	7020
gcctcagcct	ccaagttagc	tgggactaga	ggcaltgtgc	accaaccctg	gctaattttt	7080
gtatttttag	tagaggcagg	gtttcactat	gttggccagg	ctgggtctca	aactcctgac	7140
ctcaggtgat	ccgtccgcct	tggcctccca	aagtgttggg	attgtaatct	gaggtgggag	7200
gatcacttga	agacaggagt	tggagaccag	ccgtggccaac	atggtgaaac	cttgtctcta	7260
ctaaaaatac	tacaaattag	gtgggcgtga	tggcactcat	ctgtaagacc	agctactcgg	7320
caggetgagg	caggagaatc	gctggaacct	gggaggcgga	gtttgcagcc	agctgagatc	7380
gtgccactgc	actccagctt	ggcgacaga	gtcagactca	gtctcaaaaa	aaaaaaaaaa	7440
aaaaaaagtt	tattgagcac	ctactgtgta	cattggggga	cacagctcgt	gcaaaacaaa	7500
catccttttc	ctcacatagg	tacttttctt	gttccctcac	cttgctcagg	tgaaagtgca	7560
cctccattca	ttataaaaa	tgtgtctagg	ccgggacagg	tggctcatgc	ctgtaatccc	7620
agcacttttg	gaggctgagg	cgggcgatc	atgaggctag	gagatcgaga	ccatcctggc	7680
taacacgggtg	aaactccgtc	tctactaaaa	aatgcaaaaa	attagccggg	tgtggtggcg	7740
ggcacctgta	gtcccaggta	ctcatgaggc	tgaggctgga	gaatggcgtg	aacccaagag	7800
gtggagcttg	cagtgcagctg	agattgagcc	actgcactac	agcctgggca	acaaagtaag	7860
actccgtccc	aaaaaaaaaa	agttgtgttt	tttggttaaca	atctgacagt	cctgcaaaac	7920
gattattcct	gccctataat	gtcacactta	gtttttccac	aaaagttttt	aataataaag	7980
ttggaattat	tgtaaaagtt	tagtaaaatt	tcagggtttat	tcttgcatct	ctgaaatcct	8040
tttaaaaaag	gctagtggtc	atgtttgact	tcagccaaaa	ttcattttca	cacccaacca	8100
ttggcttgca	cgccaaatat	gtatttagag	aaactgaacc	tatgggatgc	atgaatgtgc	8160
acacatgtgt	ggaagtgtgg	gccccagga	aggtgcggac	tcccaggggc	tactccgtc	8220
gcctccccc	gcagcaggca	aaaggaagca	gtgtccatgt	tctctactcc	accccgctt	8280
gttacctctg	ggagctgaac	aaggccaacc	tcacctggta	tttggggaaa	ctggggagct	8340
tgggggggtt	ggcatgcccc	gtgggtcatg	accctgccct	caatgcccc	gccgtgtag	8400
gtcagtgaat	catgacgact	tcttccctta	cgcgatggc	ccccaccagt	tctggaccgg	8460
ttacttttcc	agtccggccg	ccctcaaacg	ctacgagcgc	ctcagctaca	acttccctga	8520
ggtgggttag	agccgggcta	gagggggcat	gcagccccga	ggcccgacag	gctgggcgcc	8580
ccaacatacc	cctctgcctc	caggtgtgca	accagctgga	ggcgtggtg	ggcctggcgg	8640
ccaacgtggg	accctatggc	tccggagaca	gtgcaccct	cagtaagtgt	cgggcccagg	8700
aggggaagag	gtttgcggct	gaagtggaa	accaccccta	ggccgcccc	ctcaggtttc	8760
ttcttttttt	tttttttttt	tttttttttt	gagacggagt	ctcgatttgt	ctcccaggct	8820
ggagtgcagt	ggtgcgatct	cggctcactg	caagctccac	ctcccggtgt	cacgccattc	8880
tcttgactca	gcctcccag	tagctgggac	tacaggcgcc	caccaccacg	cccggctaat	8940
tttttgattt	tttagtagag	acgggggttt	accatgttag	ccaggatggt	ctcgatctga	9000
cctcgtgata	cgcccgctc	ggtctctcaa	agtgtggga	ttacaggcgt	gagccaccgc	9060
ccccagccgt	cctcgagtgc	cttcttaag	cctctaagaa	tctgcccgc	cagcaccgga	9120
cctttcgctt	ccccttgggg	tctcagctga	gtcccacaga	acctcaccgg	actcattgtc	9180
tatgagcaga	tgaggcgatg	gctgtgctcc	agcatcacga	cgccgtcagc	ggcacctccc	9240
gccagcacgt	ggccaacgac	tacgcgcgcc	agcttgccgc	aggctggggg	ccttgcgagg	9300
tgcgcggggc	gagacttggg	agacacgggg	gtggagacag	gaagggggcg	ggccaggggc	9360
tgggaaaggg	gacagagaca	ggtgtgaggc	gtagccgaga	gccctgtggc	ggggctacaa	9420
gggctcgtgg	gggcggggct	tgtaggaggc	ggggaaagat	acagggaacg	ggcggggctt	9480
tggagggggg	aaggaggcgg	ggcgtgggca	agaggaggcg	gagacagcta	tggggatatag	9540
tcaagggcag	caggggtggg	ctagaagggg	ttttggggcg	actcttgagg	gaggcgggac	9600
agagaccgga	acggggcggg	gcctgaggag	aggggaggag	tcaggcctgg	cgtcctgaac	9660
ccaccgggtc	ctttgcgctc	ttccgcaggt	tcttctgagc	aacgcgctgg	cgcggctcag	9720
aggcttcaaa	gatcacttca	ccttttgcca	acagctaaac	atcagcatct	gcccgctcag	9780
ccagacggcg	gcgcgc					9796

&lt;210&gt; 299

&lt;211&gt; 3844

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 299

tcatgcctgt	aatcccagca	ttttgggagg	ccgaggcgagg	cagatcacaa	ggtcaggaga	60
tcaagaccat	cctgggtaac	acgggtgaaac	cctgtctctta	tcttagtaat	actttattaa	120
ttagtctggt	cgtgtggcgg	gcgcctgtag	tccagctac	ttgggaggct	gaggcaggag	180
actggcgtag	acccggggagg	tggagcttgt	agtgcagcga	aatcacacca	ctacactcca	240
gcctgggcga	cagagcaaga	ctccgtctca	aaaaaaaaaa	aaaaaaaaaa	aaagctctct	300
gatttttagct	gttaggtggg	agatgggttg	gaggatacca	aagccagctt	gcaggctatg	360
gggataaaga	aaacacctgg	atttcggacc	tactttatag	gtagagggtg	gcagacatgc	420
tgagaaggat	ggatgtgggg	tgtgagaaaa	ggggagacag	caagctgcgc	tcctcatttt	480
taatttttat	ttatctattt	ttgagacgga	gtttcgctct	gttgcccagg	ctggagtgc	540
gtggcaccat	ctcagctcac	tgcaacctcc	acctcccggg	ttcaagtgat	tctcctgcct	600
cagcctcctg	agtagctggg	attatgggtg	tgcgccacca	caccgggcta	atttttgtat	660
tttttagtag	agacgggggt	tcgccatggt	gtccaggctg	gtctctaact	cctaacctca	720
ggtgatctgc	cctccttggc	atcccaaagt	gctgggatta	caggtgtgag	ccaccgcgcc	780
cagccccaat	ccctattttt	cagctctagt	gatgagtggg	gggtggggcc	gtttgctgag	840
atgcagaaag	atcagggata	gggtggagagg	gagctgaggg	ggcaactttg	aggtccaagc	900
gaggatgtca	aggaggatgt	ctgtctcttc	caacaaggta	ggctcattcc	agcctcacgg	960
cttttgcctg	tctgtcttcc	catgtgcaga	aatggcctct	ctgcatcttc	acatacgggg	1020
attttctcag	ccttctggct	ttggctcaaa	tctcacctcc	ttggcgctct	tcacccatcc	1080
ctccaactaa	aatcccgaac	tctccacct	aaagactcaa	attatcctgt	ttaaatcctg	1140
attgcgctcg	gcgcgggtgg	tcacacctgt	aatcccagca	ctttgggagg	ccgaggcagg	1200
cagatcacct	gaggtcagga	gttcgagact	agcctgacca	acatagtga	accccatctc	1260
tactaaaaat	acaagaatta	gccgggcgtg	atggctcatg	cctgtaatcc	cagctactcg	1320
ggaggctgag	gcaggagaat	tgcttgaaac	tgggaggcag	aggttgcgat	gagtggagat	1380
cgcgccattg	cactccagcc	tgggcaacaa	gagcgaaact	ctgtctccaa	aaaaaacaaa	1440
aaacaaaaaa	ggcctgatag	cactcaccac	tattgttaac	tttctatctt	cccaatcaga	1500
ttgtgggctc	cagtagggca	gggtccacat	cttggctctg	ttcaccacta	aatccttagt	1560
gcctagcacg	gagcccacca	tagagaatag	actacatgaa	ttgtagagt	agtgaataat	1620
cctgttggcc	gtatgcactg	ttaggagggt	gtgtttgaga	tacagatgac	accagggtc	1680
tcacattctt	gcaggaggga	aagagacgtc	agccctgggt	cccagaagag	gccactgacc	1740
cagtgggagt	tcagggaagg	ctcccagag	gaggtggagg	tgacagctgc	agctataagg	1800
gaaggaagaa	cagagcggtt	tgcagcatgt	gaaggttttg	gagacttgtg	agggcacgaa	1860
ccgggctcac	tatcccatta	gacaaaagt	gctgaggaag	gatgaaactg	tgtctaactc	1920
tgcttggtga	ccgaaatctt	gtccatgggt	gacgtttaag	aagtgacctt	cggccggggc	1980
cagtggctca	cgcctgtaat	ctgggcactt	tgggaggcca	aggcggggcg	gtcacgagtt	2040
caggagatcg	agaccatcct	ggctaacacg	gtgaaacccc	atctctacta	aaaacagaaa	2100
aaattagccg	ggtgtggtgg	cgggcacctg	tagtcccagt	tactcgggag	gctgaggcag	2160
gagaatggca	tgaacctggg	aggcagagct	tgcagtgcgc	cgagattgcg	ccactgcact	2220
ccagcctggg	gcacagagcg	agactctgtc	tcaaaaaaaa	aaaaaaaaaa	aaaagtgacc	2280
ctcataaaaa	aattagctgg	gcacgatggt	gcacactagt	cggaatgctg	gggtgggagg	2340
atgacctgag	tccgggagtc	agagggttgc	gtgggcccag	atcgcgtcac	agcactccag	2400
cctggcgaca	gagtgcagac	ctatcaaaaa	atagcagcag	gccaggcgcg	gtgggtcatg	2460
cctgtaatcc	cagcactttg	ggaggttcag	gcggggcgat	cacgagggtc	ggagatcgag	2520
actaccctgg	ctaaccacgg	gaaaccccgt	ctctactaaa	aatacaaaat	attagccggg	2580
cgtggtggcc	ggcgccctgt	gtcccagtta	ctggggaggc	tgaggcagaa	gaatggcggt	2640
aacctgggag	gcggagggtt	cagtgcagcg	agatcgtgcc	actgcactcc	agcctgggag	2700
acagcgcaag	actctagctc	aaacaaacaa	acaaacaaaa	cagcaacaac	aacaacaaaa	2760
ccatccctcc	ctcccagggg	gacagaacag	aaacgaatgg	gcgagtgccg	ggccaagcag	2820
tggtgtctcca	gcagggtggc	ttaaaatagg	aattttggct	ggggacgggt	gctcacacct	2880
gtaatctcag	cactttggaa	agcccaggcg	ggcggtcacc	tgagggcaga	accagcctcg	2940
ccaacatggt	gaaatgccat	ctctactaaa	aataaaaaat	tagccaggcc	tggtgggtgg	3000
tgtctgtaat	cccagcaact	cgggagggtg	aggcaggaga	atcgcttgaa	ccaggggggg	3060
agagggttgc	atgagtcaag	attgcaccac	cgcactccag	cctgcgtaac	aagagcggtg	3120
aactcttgct	tcaaaaataa	attaaaataa	taataataaa	aaataaaaaa	gaatcttcat	3180
tcatgggaag	tcgagaacac	atgaaaacaa	gtaaaaggcc	aagcgcagtg	gtcacgcct	3240

229

gtaatcccag	cactttggga	ggctgagggc	ggcggataac	ctgaggtcgg	aagttcgaga	3300
ccagcctgac	caacagggag	aaaccccgcc	tctactaaaa	atacaaaatt	agccgggcat	3360
ggcgggtgcat	gccagtagtc	ccagctactc	gggagggctga	ggcaggagaa	tcgcttgaac	3420
ccggaatgtg	gaggtttgtg	tgagctgaga	tcgggcaatt	gactccagc	ctgggcaaca	3480
agagcgaaac	cctgtatcaa	aaaaaaaaaa	aagaaaaaaa	aaggaagaaa	aggcctaaag	3540
gcgccggggc	cgtgggtca	cgctgtaat	cccagcactt	tgggagggcc	aggcgggcga	3600
atcacgaggt	caggagatcg	agaccaggtg	aaaccccgtc	tctactaaaa	atacaaaaaa	3660
attagccggg	cgtggtggtg	ggcgctgta	gtcccagcta	ctcgggaggg	tgaggcagga	3720
gaacagcgtg	aacccggaaa	gcggagctgg	cagtgaagctg	agatcgcgcc	actgcactcc	3780
agcctgggtg	acagagcgag	actccgtctc	aaaaaaaaaa	aaaaaaaaaa	aaagaaagaa	3840
aggg						3844

&lt;210&gt; 300

&lt;211&gt; 2368

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 300

tctgtccagc	tccccgtgtg	gccgcacgcc	tctccctgca	ctccctcctg	gagctctgtg	60
ggtctctgga	agaggaacca	ggagaagggc	tggggccggg	gctgaggggtg	cccttttcca	120
gctcagcct	actccgctca	ctgaactcct	tccccacttc	tgtgccaccc	ccggtctatg	180
tcgagagctg	gccaaagagc	ctttccaaag	aggagcgatg	ggcccttggc	cccgctgcc	240
tgccaccctg	ccccttgcca	tccattcttg	aaacacctgt	aggcagaggc	tgccgagaca	300
gacctctgc	cgctgcttcc	aggctgggca	gcacaaggcc	ttgcctggcc	tgatgatggt	360
gggtgggtgg	gatgagtacc	ccctcaaacc	ctgcctcctc	tagacctgag	ggacccttcg	420
agatcatcac	ttccttgccc	ccatttcacc	catggggaga	cagttgagag	cggggatgtg	480
acatttccaa	ggccacggag	cagttcagag	tggagggcgg	cttggaaacc	ggtgctccct	540
ctgtcatcct	caggaaccaa	caattcgtcg	gaggcatcat	ggaaagactg	ggacagccca	600
ggaaacaagg	ggtctgagga	tgcattcgag	atggcagatt	cccactgccg	ctgcccgctc	660
agcccagctg	ttgggaacag	catggaggca	gatgtggggc	tgagctgggg	aatcagggtg	720
aaaggtgcag	gtgtggagag	agaggcttca	atcggtttgt	gggtgatgtt	tgaccttcag	780
agccagccgg	ctatgaaagg	gagcgagccc	ctcggtctct	gaggcaatca	agcagacata	840
gaagagccaa	gagtcaggga	ggccctgggc	ctggcctcct	tccccgtact	ttgtcccgtg	900
gcatttcaat	tccctggcct	gttctcctcc	ccaagtcggc	accctttaac	tcatgaggag	960
ggaaaagagt	gcctaagcgg	gggtgaaaga	ggacgtgtta	cccactgcca	tgcaccagga	1020
ctggctgtgt	aaccttgggt	ggcccttgc	gtctctctgg	gctgcagagt	ctgccccaca	1080
tgtggccatg	gcctctgcaa	ctgctcagct	ctggtccagg	ccctgtggca	ggacacacat	1140
ggtgagccta	gccctgggac	atcaggagac	tgggtctctg	ctctgttcgg	cctttgggtg	1200
tgtggtggat	tctccctggg	cctcagtgtg	cccattctgt	aaggggcagc	tgacagtttg	1260
tggcatcttg	ccaagggtec	ctgtgtgtgt	gtatgtgtgt	gcattgtgtg	gtgtctccat	1320
gtgcgtccat	atttaacatg	taaaaatgtc	cccccgctc	cgtcccccaa	acatgttgta	1380
catttcacca	tggccccctc	atcatagcaa	taacattccc	actgccaggg	gttcttgagc	1440
cagccaggcc	ctgccagtgg	ggaaggaggc	caagcagtg	ctgcctatga	aattttcaact	1500
tttcttttca	tacgtcttta	ttacccaagt	cttctcccg	ccattccagt	caaactctggg	1560
ctcactcacc	ccagcgagct	ctcaaatccc	tctccaaactg	cctaaggccc	tttgtgtaag	1620
gtgtcttaat	actgtccttt	tttttttttt	aacagtgttt	tgtagatttc	agatgactat	1680
gcagaggcct	gggggacccc	tggctctggg	cgggcctgg	ggctccgaaa	ttccaaggcc	1740
cagacttgcg	gggggtgggg	gggtatccag	aattggttgt	aaatactttg	catattgtct	1800
gattaaacac	aaacagacct	cagaatctga	tcaacagtgt	attgaacatc	tactgtgtgc	1860
tggaaagcga	gatggggcgg	aatgcgagaa	caaactaccc	cttgaggggt	ctttgggcag	1920
cactagtagc	tggagggctt	caggccaagg	caggggtgac	atcagattgg	agacagctac	1980
ggcagaatgt	ggctgtttgt	gaacatctgc	acctgtgtta	gggggtgagc	acctgggaga	2040
aggacaaggc	acatcacagg	acttcctctga	gcattgacaag	ttcaggactc	aaatgtccgt	2100
ggtggatggt	agcagtga	ttggggagtg	ggtggggctg	tcaagcctgc	ctagaggaga	2160
tcacaaatac	acgacgagaa	taccgttgtg	tgtgtcttcc	gtgtgttcc	taggagtgca	2220
gggcaggggt	gctgggtcga	tccacaaaag	tcctgaaaac	gctgaagaaa	aatccaaaga	2280
ccctccctcc	cctccctcct	tccccaccac	cgaagcacac	agtcttgaag	gttgatttgc	2340
aaccgtctat	acaaacacat	ttatttta				2368

&lt;210&gt; 301

&lt;211&gt; 2996

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 301

aggagcccat	ttacatcgtc	acggagtaca	tgagcaaggg	tgagtcctgg	gcggccgggg	60
cagggggcag	gggcactccg	gacagggcag	ggagcatgag	cctcatttcc	tctcatgtct	120
agaatgggca	tcttcaaagg	tggaatgcag	tagagccaaa	ttctctgttg	cctggggcgg	180
agtgtggtgg	tgcaatcata	gctcacttca	gcctcaacct	tccaggetca	agcagttctc	240
ccacctcagc	cacccaagta	gctgggacca	caggtgtgtg	tcaccaggcc	cagctaattt	300
tttatttttt	gtagagatgg	gacctatgt	tgcccaggct	ggtctcgaac	tcttgggctc	360
aaggagtcct	cccacttcca	cctcccaaag	tgctgggatt	acaggtgtga	gccacagtaa	420
tttttaaact	aattagttat	ttttcaaaat	tccacttttt	ggaggtatag	tttacatatg	480
ataaaataca	ccctttttaa	gtgttcagtt	cagtggtgtt	taacaactgg	atttactgtg	540
tacccttaac	cataatgaag	atatataaca	tctccatcac	ccagaaagtt	cctcatgccc	600
tttgacagaca	gtaccctcca	gccccaaacc	caagcaccca	ctgatttgct	ttctgtcatt	660
ataaatttgt	tttgtttatt	ctagaatttc	atacatggaa	tcttttacat	ctgggatgca	720
ttgttttttt	actttttaca	tttcaatttt	ttattttttg	agatgagggt	ttgtatgttt	780
gcccaggctg	gagtgcagtg	gcgtgatcat	agctcactgc	agccttgacc	tcccaggctc	840
aattgatctt	ctcatctcag	cctctcaagt	agctgggact	acaggtgcac	aacatcctgc	900
ccagctactt	tttttttctg	tattttttgt	acagacagag	acttactgtg	tagctcaggc	960
tggtctcaaa	ctattgggct	caagcgatct	tcccacctcg	gcctcccaca	gtgctgggat	1020
tgcaggcagg	agccactgct	cccggcctga	gatgcacct	tgttgcatct	cccagcagtt	1080
tggtcctggt	gttgctgagc	gggactccgc	tgctctgcat	agcacagttt	acctgttcac	1140
ctggagggtg	acttctgctt	gtttcccatc	ctgcttgcc	tttgagtgc	aagcactgag	1200
tgagacttta	ttcagagatg	agtttacgta	aaatctgctg	tgctgggtta	agcaaggcca	1260
gccacctggg	aggatgggtt	ttgggaatca	ctgcacctg	gcagagggac	agggcaggag	1320
ctggagctgg	gtctctctct	gccaggggag	tttgctggac	tttctcaagg	gggagacagg	1380
caagtagctg	cggtctgctc	agctgggtga	catggctgct	caggtgagtc	agccctccc	1440
gcctccccac	acccttggtc	ctcaagcacc	cagacccatc	tggtgcagcc	agttctggcc	1500
tcttgagtgc	cccctccaag	aagcctgcct	tgattgcctc	cacactcact	gatcttgccg	1560
cacgtattta	ccaggctctg	ttacaggtgc	cctgaggggt	gattctgggc	agcagaaggc	1620
ccttacctgg	gcacagggg	tcactgactt	actgtgggac	ctcgggcctc	agttgtcgct	1680
tctgtaaagg	tcatttagtc	gcttagcaga	cgtgttcatg	cttgctgtag	gcagtggtca	1740
acaagccttt	ttttttttca	tttaatctct	atcacgacca	ggagtgcaga	ggattggctg	1800
ttattcccat	tggacggatg	agaaaactga	ggctcagaga	ggggacttgg	gcagcaggca	1860
ggacctggca	ctcatctgtg	tctgggtccg	ctggggcctc	tttccctggg	cacctcgctt	1920
tcttggtctg	atcggtatct	gtgcctcccc	tttgaccttt	gccttctgcc	ctctgctctg	1980
tgcctctgtc	tcctactctc	cgcagagcac	tgctcctgct	ttcgatgcca	acagcattta	2040
ctgtgaactg	acctcacttg	cctgaagaag	tggtgggagg	gtggggaagg	ggtggttggc	2100
tctccagccc	cagagtgtct	tggtggcctg	ggagggcatg	ggtggcacct	gagccaggct	2160
cccacgggtc	cgctgcaga	tcgcctcagg	catggcgtag	gtggagcggg	tgaactacgt	2220
ccaccgggac	cttcgtgcag	ccaacatcct	ggtgggagag	aacctggtgt	gcaaagtggc	2280
ggactttggg	ctggctcggc	tcattgaaga	caatgagtac	acggcgcggc	aaggtgggca	2340
ggggctgtgt	ggtatgtcgc	gcttggcctg	ggacaggtca	cgtcccgtct	tgagccccag	2400
ttttttcctc	agctgtcatt	cctcatgggt	cttatctaac	agagcgggtc	tgacaggagg	2460
tcagagctgc	cctgaccttt	ctcgttcctg	caggtgcca	attccccatc	aagtggacgg	2520
ctccagaagc	tgccctctat	ggcgcttca	ccatcaagtc	ggacgtgtgg	tccttcggga	2580
tctgtctgac	tgagctcacc	acaaagggac	gggtgcccta	ccctggtaag	aaggtcctca	2640
tggcctgtct	gtggtccctg	aatccctctg	ccttggtggc	cttgggcaag	tcatgactcc	2700
tgctgggcct	gtttccccac	ccgtaaaaca	aagaagtga	gcgtctgatg	ttaggctctc	2760
tcgatggtcc	atgctctcag	cttcggggac	aggacttatc	tatggtcact	cccaacctgt	2820
cctaggcagg	aagccctcgc	tgccctcccc	atcagcttcc	cccaccccc	tttctcacc	2880
ggagccgggc	tcccatgcc	tcgctctgcc	cacagggatg	gtgaaccgcg	aggtgctgga	2940
ccaggtggag	cggggctacc	ggatgccctg	cccgcgggag	tgtcccgagt	ccctgc	2996

&lt;210&gt; 302

&lt;211&gt; 2572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens



&lt;400&gt; 302

```

agctggcctc agtgaccaga atctcctcct cggacctctc cctggggcac gtgacccggg 60
ctctgtgccg aggcattggt cagaacctgc actccatgct tccgattcag cagctccagg 120
actggggcgt ggagaggggtg atgggcagtg ggagtgcgct gtccaggaat gacgtgctga 180
agcaggaggt gcagagggct tcccttttgc ccatgtcctt tgggcaggat gtggatgcag 240
ctgtcggggc agctctgggc atggtccgga gacacctcaa ccagaaggaa tcttagacag 300
caaactcttt cgccaaacga ctgctgtgaa ttttacctga ttaacattcc tgacaccatc 360
tgtgggtcat cctttccctg gaccgttcag tggacagctt tcaagcagtg cttgtgtgta 420
gggtcccatct cggccaagaa cttaccttca gaacatactc taataatgca gccaggagcc 480
gtcagccaga tcccaaatga gtgccttcgg aaattgaccc acctggggagc tatttacaaa 540
tgtccatgtg ggagagagag agcatgagag cacagtagcc cagcctgctg gtcagcaggg 600
gatctgtggg ttcacctgta gacagagagc agatcaatgt gtacttcaga caccagaaag 660
tctggtgggc ttggtcccaa gtgggaaaag agaactgccc catgcccagc ttgtgattat 720
cgtttttgga gacctgaagc ccacactcgg gtctgtatgga cttctggaaa agttcttgtc 780
tcctggactg aacctatgta ccggaggccc ctttcttagt ctcatctcc cctggctgca 840
gatgcttagc tgggcccaggg attgacccaa gcgcgatgca gcaggcaggc tcagaagacg 900
atgcggggct gtgtgccggc cttcttgctg catgtactca gcctcaggag agcttgctgc 960
accaggcccg cccaggtctt cacagcacia ctgcctggaa ggcagggtgc gagaaggaga 1020
ggcggatggc atgagcagca aggggagccg atgctgtgca gctcacacca ctccagaacc 1080
tgacaaggca ccagcaggac cccttgccag gagcatgtct gtgcagcagt gtttttgccc 1140
ctgcacattc cagaagccct catgggaagg gatgcagcca ggcagactcc tgccagatgg 1200
ggcaggtagt ttattcaaag agaactctgt atcccatagg cccaggctct cctttcgctt 1260
ggcgtgggct ttgctggccc agtgtgtgct cctggctcag cagaaacatc catttgagtt 1320
ggcatccctg tagggatccc agagcgttgt aagccttctt gtgattggta gggatggctg 1380
tggggtggct tccaggaggg ggccaccatt gccgcacta cttctagact cccaaaggag 1440
cccaggctca ggcaggcctg gccagagtc acgctggcaa ccacgagttt gggaagcagt 1500
cgtattctct ctctctctct ctctctctct ctacgtatcc atgacaggta tgaaacatat 1560
tgtctcttta taaatgtcat tttaaaatt atgtgattat ctggaagctc taagatgaga 1620
gcaaagtccct gatcactctg gccaaatgtc agatactaaa gccattctt ggccgggcat 1680
gttggtcccc gcctgtaate ccagcacttt gggaagccca agtgggtgaa tcacctgagg 1740
tcaggagttc aagaccagcc tgaccaacat ggggataccc cgtctctaot aaaaatacaa 1800
gccgggcgtg gtggcgcatg cctgtaatcc cagctactca ggaggctgag gcaggaaaat 1860
cacttgaact cgggagcgag aggttgcatg gagctgagat cgcgccattg cactccagcc 1920
tgggtgacag agcaagactc tgtctcataa ataaatacaa agccattct tccagagtct 1980
tgtgccttaa ataaacaca cctctctgct gtgggaagac tgtgcaatgg cacagccgca 2040
gagcttgggt tgggaggttg aagtgtcttg gggagaattc gtagatcatc ctcaaaaag 2100
ccttgccctg gtgttctacc agaaaaacgt ctccaatca cccaggaaag ctgtccacag 2160
tagtcccccc ttatccacgg tgtcacttct catgggttca gttatctgag gtcaaccacg 2220
gtctgacaat attaaatgga aaattcttca aacagttccc aagttttccc ttgtgcattg 2280
ttctgagcag tgtatggag agtctctgcc gctccatctg ggatgcaaac cgtccctgtg 2340
ttcccaagc ccaggccgta gatgtcccc gccggtcagt cacttagtcg tcagatcgcc 2400
cgtcctggta tcacagtgt tctgttcagg tcagtctttt ttacttcat tagggcccca 2460
aagcaccaga gtagtgatg tggtagtgat gctggctgtt cggatatgcc aaagagaaac 2520
cgtaagggtgc ttcctttaag tgaaaagagg gaagaaaaca gtcatatgct ga 2572

```

&lt;210&gt; 303

&lt;211&gt; 2238

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 303

```

acaccatctg tgggtcatcc tttccctgga cgttccagtg gacagctttc aagcagtgtc 60
tggtgtgagg tcccacttg gccaaagaact taccttcaga acatactcta ataatgcagc 120
caggagccgt cagccagatc ccaaagagat gccttccgaa attgaccacac ctgggagcta 180
tttacaatat tccatgtggg agagagagag catgagagca cagtagccca gcctgctggt 240
cagcaggctc atctgtggtt cacctgtaga cagagagcag atcaatgtgt acttcagaca 300
ccagaaaagtc tgggtggcttt ggtcccaagt gggaaaagag aactgcccc tgcccagctt 360
gtgattatcg tttttggaga cctgaagccc acactcgggt cgtatggact tctggaaaag 420
ttcttgtctc ctggactgaa ccatgtgacc ggaggccctt ttcttagtct cactctcccc 480

```

232

tggetgcaga	tgcttagctg	ggccagggat	tgacccaagc	gcgatgcagc	aggcaggctc	540
agaagacgat	gcggggctgt	gtgccggcct	tcttgctgca	tgtactcagc	ctcaggagag	600
cttgctgcac	ccaggccgcc	caggtcttca	cagcacaact	gcctggaagg	cagggtgcga	660
gaaggagagg	cggatggcat	gagcagcaag	ggggaccgat	gctgtgcagc	tcacaccact	720
ccagaacctg	acaaggcacc	agcaggaccc	cttgccagga	gcattgtctgt	gcagcagtgt	780
ttttgcccct	gcacattcca	gaagccctca	tgggaaggga	tgcagccagg	cagactcctg	840
ccagatgggg	caggtagttt	attcaaagag	aactctgtat	cccataggcc	caggctctcc	900
tttcgcttgg	cgtgggcttt	gctggcccag	tgtgtgctcc	tggctcagca	gaaacatcca	960
tttgagttgg	catccctgta	gggatcccag	agcgttgtaa	gccttcttgt	gattggtagg	1020
gatggctgtg	gggtggcttc	caggaggggg	ccaccattgc	cgcattctact	tctagactcc	1080
caaaggagcc	caggctcagg	caggcttggc	ccagagtcac	gctggcaacc	acgagtttgg	1140
gaagcagtcg	tattctctct	ctctctctct	ctctctcagt	atccatgaca	ggtatgaaac	1200
atattgtctc	tttataaatg	tcattttaca	aattatgtga	ttatctggaa	gctctaagat	1260
gagagcaaat	gcctgatcac	tctggccaaa	tgtcagatac	taaagcccat	tcttggccgg	1320
gcattgttgc	tcccgctgt	aatcccagca	ctttgggaag	cccaagtggg	tgaatcacct	1380
gaggtcagga	gttcaagacc	agcctgacca	acatggggat	accccgctct	tactaaaaat	1440
acaagccggg	cgtggtggcg	catgcctgta	atcccagcta	ctcaggaggc	tgaggcagga	1500
aaatcacttg	aactcgggag	gcagaggttg	cagtgcagctg	agatcgccgc	attgcactcc	1560
agcctgggtg	acagagcaag	actctgtctc	ataaataaat	acaaagccca	ttcttccaga	1620
gccttgtgct	ttaaataaaa	cacacctctc	tgtgtgggga	agactgtgca	atggcacagc	1680
cgcagagctt	ggtttgggag	gttgaagtgc	tatggggaga	attggtagat	catcctcaga	1740
aaagccttgc	cgtggtgttc	taccagaaaa	acgtctccca	atcaccagg	aaagctgtcc	1800
acagtagtcc	ccccttatcc	acggtgtcac	tttccatgag	ttcagttatc	tgcggtcaac	1860
cacggtctga	caatattaaa	tggaaaattc	ttcacacagt	tcccaagttt	tcccttgtgc	1920
attgttctga	gcagtgtgat	ggagagtctc	tgccgtgcca	tctgggatgc	aaaccgtccc	1980
tgtgtccccc	acgtccaggc	cgtagatgct	ccccgccggt	cagtcactta	gtcgtcagat	2040
cgcccgctct	ggtatcacag	tgcttctggt	caggtcagtc	tttttttact	tcattagggc	2100
cccaaagcac	cagagtagtg	atgctggtag	tgatgctggc	tggtcggata	tgccaaagag	2160
aaaccgtaag	gtgcttcctt	taagtgaaaa	gatgggaaga	aaacagtcac	atgctgaatc	2220
ttctatctgt	gaaattct					2238

&lt;210&gt; 304

&lt;211&gt; 108

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 304

ttcaccacgt	tggccaggct	ggtcttgaac	tcctgacctc	aggatgatctg	cccgcccttgg	60
cctcccaaag	tgctgggatt	acaggcgtga	gccaccacgc	ccagccaa		108

&lt;210&gt; 305

&lt;211&gt; 101

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 305

tttttttttt	ttttttgaga	catagtctca	ctgtgtcacc	caggctggag	tacagtgggtg	60
caatcttggc	tcactgcaac	ctccacctcc	cgggttcaag	c		101

&lt;210&gt; 306

&lt;211&gt; 9682

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 306

ggccccgcag	agccgtgcgg	gcgccccgct	actcactagc	tgaggtggca	gtggttccac	60
caacatggag	ctctcgcaga	tgctggagct	catggggctg	tcggtgttgc	ttgggctgct	120
ggccctgatg	gcgacggcgg	cggtagcgcg	gggggtggctg	cgcgcggggg	aggagaggag	180
cggccggccc	gcctgtaagt	ggggccgggt	cgggtggggg	cggccccggg	tgccccggct	240
cccggcctcc	tcgtggtccg	acctgcggtt	tgggccccgcg	gctggtgggg	cccggcgact	300

233

ccatgggect	cagttttctcc	tctggtaacg	tgagcttcgc	ttccagagac	ggggacccgc	360
cttgccgggt	taggcgcacc	tcctggggcg	ggactggctc	caacctgggc	cccttactgc	420
ggctttctct	gtggccgagg	ccaggccgct	cccgggggtg	ccaggagagc	accgtaaact	480
cttcagcctg	ctccgtggcc	gcgatctcgg	aaaaagcacc	aattctgtga	tgtgcagcag	540
cattttactgg	gcatctatga	ccctgtgata	ggctttgggg	tctttttctg	taaggagtc	600
agtaaaaggag	aagtacatct	gtattatgaa	cacctaaata	tgtaatgtaa	aaacacgggtg	660
aaataagttt	cactgaggcc	aggcgaagt	gctcacgcct	gtattcccag	cactttggga	720
ggccgaggca	gggagatcgc	ttgagcccag	gagtttggga	ccagcctgag	caacatagca	780
agaccccatc	tctacgcaaa	attagctggg	tgtggttgtg	cacgcccctg	tagtcccagc	840
tccatgggag	gccgaggcag	gagggtgtcg	tgagtccagg	aattcaaggc	tgcagtgagt	900
tgtgatagat	cgcgccactg	tacttcagcc	tgggtgacgg	caagagcctg	tctctgaaaa	960
gtttcataga	agaggttagt	actagaaatg	ggaacacca	gagagtcagt	gggcagccct	1020
gtctctttta	tttatttttc	agacagagtt	tcgctcttct	tgcccaggct	ggagtgcagt	1080
ggcacaatct	tggctcgttg	caacttccgc	ctgccagggt	caagcgattc	ttctgcctct	1140
gcctcccag	tagctgggac	tacaggcaca	caccaccacg	cctggcta	ttttgtatat	1200
ttagtagacg	gggtttcgcc	acgttggtea	ggctggctct	gaacgcctga	tctcaggtga	1260
tcactcgtc	ctggcctcca	aaagtgtcga	gattacaggg	gtgaaccact	gtgcccgcc	1320
agccctgcat	ttttttttt	tttttttttg	cagggggacg	gagttttgct	ctgtcgccca	1380
atctggagtc	tagtggcggg	atctcggtc	actgcaagct	ccgcctctgg	gttcacgcca	1440
ttctcttgcc	tgcctctct	gagtagctgg	gactacaggg	gtccgacacc	acaccggct	1500
aattttttgt	attttttgag	tagagacggg	gtttcactgt	gttagccagg	atggtctcaa	1560
tctcctaacc	tcttgtgac	cacctgcctc	ggcctcccaa	agtgtcggga	ttacaggcgt	1620
gagccaccct	gcctggccga	gtcctgttct	tttatggggg	aggtggttgt	tagggaaatc	1680
attactgaga	atagggggca	catgaggtag	tgtggggtct	caaaggatgg	ttctagaaga	1740
agagtttgcc	agaaggccaa	ggaaaaaaga	cattcctgcc	aatggcaata	cccagagaagg	1800
caaggagtc	caaacacgca	tttggtatga	cttaagtgtg	aggagggggg	cttgtagac	1860
atgctctggg	agaagggaagc	agaggacaga	ttgtggctgt	gtttgtttgc	agggccagg	1920
agcttttttc	ctgttggaat	tggggagcat	ctgcagtcac	ttaccacatg	ccagctttgt	1980
gactcaatta	agtatctttt	acaaaagtga	ctggctccac	tccccgcac	aggactcaac	2040
agatgttgac	ttctcatccc	cgagttcttt	caggtactgg	agtgcagtg	tgcgatcttg	2100
gcttactgca	acctctacct	cctgggttca	agtgtattct	ctgcctcagc	ctcctgagta	2160
gctgggatta	caggcgccctg	ccaccacgcc	cggctaattt	ttgtattttt	agtagagacg	2220
gggtttcacc	atgttgggca	gactgggtga	actcctgggc	atcaagatga	tccagctgcc	2280
gggcccggga	tgggtgactca	cgctgtaat	cccagcactt	tgggaggccg	aagcgggcag	2340
gtcacaagg	caggagatcg	agactgaggc	aacagagcga	gactctgtat	caaacaaaaa	2400
aaaaaaatga	tccagcagct	gcctcagcct	cccaaagcgc	tgggattaca	ggcatgagcc	2460
accgcacccg	gcctccatag	agcctttaat	gcttgtgttc	ggtacttttg	cttgtcactt	2520
tgtagatata	tcatccaatt	caatctccct	tatttttatt	tatttattta	tttatttatt	2580
ttgagacaga	atctcactct	gtcgcttagg	ctggaatata	gtggcacgat	cactgcattt	2640
gaactcctgg	gtccaagcaa	ttttccctcc	tacgcctccg	aatagctggg	accacaggcg	2700
cacaccacca	tgcctagcta	attaaagttt	tctgtagaga	tggggtgtca	ctatgttacc	2760
caggctgggtc	tcgaactcct	gagctcaagc	aatcctccca	tctcagccta	ccaaaatgct	2820
gggatcacag	gcatgagcca	ccgccccag	ttctcaacct	ctctttaaga	aaaccaaggc	2880
tgggcccggac	acagtggctc	acgcctataa	tcccagcact	ttgggaggcc	aaggcaggca	2940
gatcacttga	ggtgaggagt	tggagacaag	cctggcccac	atggtgaaac	cccatctcta	3000
ctaaaaaaac	aaaaaaattg	gggccagggt	ccatggctca	cgctgtaat	cctagcactt	3060
tgggaggccg	aggcggttgg	atcacaagg	caggagattg	agaccattct	ggctaattgt	3120
gtgaaacccc	acatctacta	aaaatacaaa	aaaaaattag	ccgggcattg	tggcgggcgc	3180
ctgtagtccc	agctacttgg	gaggctgagg	caggagaatg	gcgtgaaccc	gggaggcaga	3240
gcttgcagtg	agctgagatc	acgccactgc	actccagcct	gggtgacaga	gcgagactcc	3300
atctgaaaaa	aaaaaaaaaa	attagctgga	tatggtgggt	cacgcccattg	atcccagcta	3360
cttggaaggc	tgaggcacia	gaattgcttg	aacctgggag	gcagaggcta	cagtgcagcg	3420
agatcacgcc	actgcactcc	agcctggggc	acagagcaag	actctgtctc	caaaaaaaag	3480
aaagaaagaa	aagaaaaaaa	aaaccaagg	ccagagcaat	tactaaactt	acccaaagca	3540
gggcccgtag	agatggttgt	gcacattact	ccctacatag	ggatgtctgg	ccaaggatcc	3600
acactccact	ggccgtgctg	tgtaccgcgc	cagcagcatc	acccaaccca	gagagtgcgc	3660
cttttccact	ctacatgaag	gtgctctgtg	gacttactgt	aaacagcctc	ctcagtgtgc	3720
agtgcagtag	agagacagaa	tccaaaccca	ggctctgatt	caaagcctct	gttttgtttc	3780
tgttttctgt	ttgttttttt	ttgagacagg	gtcttgcctc	gtcactcagg	atggaatgca	3840
gtagtgttgt	gatcatagct	tactgcagcc	tcgaactcct	gggctcaaat	gatccaaagc	3900

attgggatta	caggcatgag	ccaccataacc	cagccagcca	aagcctctgt	ttttgcccatt	3960
atcacactca	ttctcctcca	gaagacaagg	gccatatctg	gttaatctcc	tgctgttcca	4020
ctcaatgcct	ggctcatcat	aggtgggcag	taaagtctta	tcagttagta	actggagaac	4080
aacatggccc	ttccttatag	gccaaaaagc	aaatggattt	ccacctgaca	aatcttcggg	4140
atccaagaag	cagaaacaat	atcagcggat	tcggaaggag	aagcctcaac	aacacaactt	4200
caccaccgc	ctcctggctg	cagctctgaa	ggtaoctggg	gtacctggca	cagcgtgcac	4260
cctgagactc	agccccacag	gcttttcctc	tggagtattc	catgcatgtt	acaggctctc	4320
ctgcctctga	tcagaatcag	cgggggtgct	taattctgtc	ccctctcctc	gcagcccaat	4380
ctcagcttgc	tgtaatacca	ggccacaggg	ccccatctcc	ccggtccag	gtttggcttc	4440
cccctctccc	ccaggagctc	ctattgacac	ttcctgccac	ccttccccta	gagccacagc	4500
gggaacatat	cttgcatgga	cttttagcagc	aatggcaaat	acctggctac	ctgtgcagat	4560
gatcgacca	tccgcatctg	gagcaccaag	gacttctctg	agcgagagca	ccgcagcatg	4620
agagccaacg	tggagctgga	ccacgccacc	ctgggtgcgt	tcagccctga	ctgcagggtg	4680
gacaagacgg	agcctcaggt	ttgcctgcag	aggcctagtc	ccaggctttg	gccttcccac	4740
atctgctttg	aggtagtgag	gagggacctg	gacccagggc	ctcccttggg	gtgccagaaa	4800
gagcatccac	atagtttgcg	cgctgcctgg	ggctccctgg	agatctgggc	tgctatacag	4860
caaggaaaca	gggggaggtc	tcttctctacc	tggaataacc	ttggcctggc	ttccagatga	4920
gccttagttt	ctaaacccta	gagagaaact	aaaggagcca	aagctatcag	aatcttacct	4980
tttgaggagt	tttatgagat	ttggaaccag	gggcttaagt	tttaaggcta	gactgtgggg	5040
catgaggaga	gatcttgact	tccccgagaa	cccagcacag	gacctggaac	acagagcctc	5100
tttgtccagt	gagagcgtga	cttgtctgct	gctgtctctc	agagccttca	tcgtctggct	5160
ggccaacggg	gacacccctc	gtgtcttcaa	gatgaccaag	cgggaggatg	ggggctacac	5220
cttcacagcc	accccagagg	acttccctaa	aaagcacaag	gcgcctgtca	tcgacattgg	5280
cattgctaac	acaggtaaga	ggcattcaga	gggtggcgcc	tgcccaaagc	atgaaggaaa	5340
gatccagttc	tatttctctc	atgagttaat	gctgcctgaa	agttctgtct	aacctgagag	5400
gaacaagggg	tccctggctc	tgaacagcct	ggctctgtgc	tccctgggag	tccttgggccc	5460
acaccaggtc	cctagggaag	gtggggaagg	gccacagtct	tcagcagagt	ccttatctgt	5520
agtgaccctt	ggcctgggag	gagacatgta	tacttcgggc	agcagaggcc	ttgtaagtgt	5580
ctttggagag	tgacagttgg	tcaggtcact	gcccgtagcc	cacatcactc	ccttcccgtc	5640
cagggaagtt	tatcatgact	gcctccagtg	acaccactgt	cctcatctgg	agcctgaagg	5700
gtcaagtgtc	gtctaccatc	aacaccaacc	agatgaacaa	cacacacgct	gctgtatctc	5760
cctgtggcag	gtgggcaagg	aggggtattg	gcgtctggga	ccacgagagg	ctggggctgg	5820
ggagcaggca	cagaacagag	agccagcttc	atcgctgggg	aagagcatac	gggggtgggg	5880
caggaacccg	agcttcaagt	ctcagctctc	cccacttgca	gtagtgggat	ttcatgcagg	5940
tcgccccatg	tccttagtcg	ctatttcttc	atcttcagtg	tttttgtttt	ttagaaaatt	6000
agtctcactc	tgtcaccag	gctggagcac	agtgggtcga	tcatagctca	ctgcagcctc	6060
aaactcctgg	gttgtagcta	ttctcccagc	tcagcctcct	gagtagtcag	gactataggc	6120
atgtgccact	gtactcagct	aatttttgtt	ttttgtttgt	ttgtttgttg	agacggtttc	6180
accctcgccc	aggcaggagt	gcagtggcgc	aatcacagct	cactgtagcc	ttgacttccc	6240
aggtcagac	catcctccca	ccttagcctc	ccgagttagt	gggactacag	gcgtgcacta	6300
ccacacctgg	ctaatttttg	tattttttgt	tgagatgggg	tcttactatg	ttgccaggcc	6360
tcgtctgtaa	ctcctggcct	caagtgatcc	tcttgccctg	acctcccaa	gtggtagaat	6420
tacaggcgtg	agccactgtg	ccaagccacc	tttgggcggg	gatgttacat	atcttagaac	6480
aaggctagaa	gataaaactga	ggtcacatac	ataaaagaac	ttttttgttg	tggttggttg	6540
tttgtttttt	gagatggagt	ttcgctcttg	ttgcttaggt	tgagtgcaa	tggcaggatc	6600
ttggctcacc	acaacctccg	tctcccggtt	tcaagcgatt	ctcctgcctc	agcctcccc	6660
aagtagctgg	gattacaggc	atgcaccacc	atgccagct	aattttttat	tttttagtaga	6720
ggtgaggttt	ctccatgttg	gtcaggctgg	tctcaaatcg	tcggacctta	ggtgagctgc	6780
cgcctggggc	ctcccaaagt	gctgggatta	caggtagtag	ccaccacacc	cggccttttt	6840
tttttttttt	ttctgagaca	gtctcactct	gttgcccagg	ctggagtga	gtggtgcaat	6900
ctcaatctca	gctcactgca	acctccacct	accaggttca	agtgattctc	ccacctcagc	6960
cttcccagta	ggtgggacta	caggcatgcg	ccaccacgcc	tggtctaattt	tgtattttta	7020
gtagagatga	ggtttcacca	tgttggccag	gctgggtctg	aactcctgac	ctcagggtgat	7080
ccaccacact	cggcctccca	aagtgtctgg	atgacaggcg	tgagccaccg	cgcctggcca	7140
aaataactct	ttaaagggtt	atatatatcca	gatattgagga	ttatcaactt	tctcaggaaa	7200
gagattgagg	ggtttttacag	gaacaacatg	ctccgaaaat	gaagttttta	aggcttctgg	7260
gttgtagtgc	agattttgag	cctcgtgtgg	cttcacccca	gatgtgaagg	tttgggaagt	7320
ctgctttgga	aagaaggggg	agttccagga	ggtgggtcga	gccttcgaac	taaagggcca	7380
ctccgcggct	gtgcactcgt	ttgctttctc	caacgactca	cggagggtgag	tgaatccgct	7440
ctgatgtctg	accagtggct	cttgggccct	cttgacaacc	agggtccttc	tgtctgtttg	7500

235

tgccatggct	ctgaagaggg	tgggggtgcct	ggccctcggc	aggaagctga	cttagcttcc	7560
tagctggagc	tgctcaagtt	gggcccagtc	ttaccctgcc	aggggtgtgt	ggggcttgag	7620
ctgtgatttt	ctgtgttgca	ggatggcttc	tgtctccaag	gatgggtacat	ggaaactgtg	7680
ggacacagat	gtggaataca	agaagaagca	ggaccacctac	ttgctgaaga	caggccgctt	7740
tgaagaggcg	gcgggtgccg	cgccgtgccg	cctggccctc	tcccccaacg	cccaggtcct	7800
ggccttggcc	agtggcagta	gtattcatct	ctacaatacc	cggcggggcg	agaaggagga	7860
gtgctttgag	cgggtccatg	gcgagtgtat	cgccaacttg	tcctttgaca	tcactggccg	7920
ctttctggcc	tcctgtgggg	accgggcggg	gcggctgttt	cacaacactc	ctggccaccg	7980
agccatgggt	gaggagatgc	agggccacct	gaagcggggc	tccaacgaga	gcaccgccca	8040
gaggctgcag	cagcagctga	cccaggccca	agagaccctg	aagagcctgg	gtgccctgaa	8100
gaagtgactc	tgggagggcc	cggcgccagag	gattgaggag	gagggatctg	gcctcctcat	8160
ggcactgctg	ccactcttcc	tcccagggtg	aagcctttca	gaaggagtct	cctgggtttc	8220
ttactggtgg	cctgcttctt	tccatttgaa	actactcttg	tctacttagg	tctctctctt	8280
cttgctggct	gtgactcctc	cctgactagt	ggccaagggtg	cttttcttcc	tcccaggccc	8340
agtgggtgga	atctgtcccc	acctggcact	gaggagaatg	gtagagagga	gaggagagag	8400
agagagaatg	tgatttttgg	ccttgtggca	gcacatcctc	acacccaaag	aagtttgtaa	8460
atgttccaga	acaacctaga	gaacacctga	gtactaagca	gcagttttgc	aaggatggga	8520
gactgggata	gcttccccatc	acagaactgt	gttccatcaa	aaagacacta	agggatttcc	8580
ttctgggcct	cagttctatt	tgtaagatgg	agaataatcc	tctctgtgaa	ctccttgcaa	8640
agatgatatg	aggctaagag	aatatcaagt	ccccaggctc	ggaagaaaag	tagaaaagag	8700
tagtactatt	gtccaatgtc	atgaaaagtg	taaaagtggtg	aaccagtgtg	ctttgaaacc	8760
aaattagaaa	cacattcctt	gggaaggcaa	agttttctgg	gacttgatca	tacattttat	8820
atggttggga	cttctctctt	cgggagatga	tatcttggtt	aaggagacct	cttttcagtt	8880
catcaagttc	atcagatatt	tgagtgccca	ctctgtgccc	aaataaatat	gagctgggga	8940
ttaaatacga	ataagacatg	gtttctgcca	tcaaagatgg	ctgggtgggag	agagagatac	9000
accctfatta	agtgtcttgt	gttagtttat	tcatagctat	tggtatatat	gtcaaggcaa	9060
gagaggacca	gagcaggaca	gaggcaatgg	gtattgaagt	tgaaggggta	catttgataa	9120
gagagtcggt	attgagaagt	ttaaatttgt	gaatttgaag	gctgcgtggg	tgtggcaggt	9180
aagggaaatg	aggatatctg	gaaggcttga	gtgtaggcaa	atttattcat	cccaagtcaa	9240
actcttgatc	tctctcacga	aaactatgac	ccccctgggt	tgccccctgac	ctctcaatgt	9300
tggacaacgc	cacaaccgtg	gagttatcct	tgatgactcc	ccattcatta	tcccttctgt	9360
cccaccacca	cagctgtcat	ctgttcacca	gaacgttctt	ttggttacac	tccatgtgac	9420
atcctgaggc	tgttgcttct	ctccagcttt	tctgttacca	tctgtgtcct	ggctactgtc	9480
acctagtggg	ccactataat	atggcttcc	aatggatctt	cctgcttcc	ctgttgctc	9540
attacttttc	tatatagcag	aatgatcttt	tgaaaatgtg	aaccagatca	cattattccc	9600
tagttaaaac	cccccaaggc	ttcccatcac	acttgaata	aaatccaaaa	gaatttttct	9660
aaacccaaaa	tagtaaaaaac	aa				9682

&lt;210&gt; 307

&lt;211&gt; 441

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 307

ccagctactc	tggaggctga	ggcaggagaa	tctcttgac	ccgggagacg	gaggttgacg	60
tgagccgaga	cgcgtcactg	cactccaacc	tgggcaaccg	tctcaaaagt	aaatacataa	120
ataaataaat	aaaataagtt	ttctattaaa	aattctccct	tttaactttc	gacttgccag	180
gccagcccca	aatccaggcc	ctcgtcacct	ccctctcgga	tccttgaagc	cactgcccgt	240
tttctgattt	tgggtctttt	acacaaaggt	ccatccaggg	aatcctcaga	cacagctttt	300
gccccacctc	tcctgttaat	gagcagcttg	ttggatggag	ccagcgctca	acgtccccc	360
gacctttccg	cccctctagc	catttcccac	atcccagctt	ctcagggtctt	tgcggaggtc	420
gttccactcc	acgcgcctgg	c				441

&lt;210&gt; 308

&lt;211&gt; 8790

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 308

ctgctgctgg	cccggtagac	ggaccaatgg	aggggtctcg	tggacacacc	ggacttcacc	60
------------	------------	------------	------------	------------	------------	----

gacatcgtgc	tgcagctgga	cgacatccag	catgccatcg	ccatcaacta	tgacccaatg	120
gagggccacg	tctactggac	ggatgacgag	gtgtggggcca	tccgcagggc	atacctggat	180
gggtctgggg	cgcagacgct	gatcaacacc	aagatcaacg	accccgatga	catcgagtc	240
aactgggtgg	cccgaagcct	ctattggacc	cacacaggca	ctgaacacat	cgagggtgacg	300
tgccatcaaca	gcacctccca	caagatcctg	gtgtcagagg	acatggacga	gccccgtgcc	360
attgcactgc	atccccgagat	ggggtaaagac	gggtggggcc	tggagccagg	gccaggccaa	420
gcagagggag	cttgacctgg	accagtcatt	ctggaaacact	gtcttgcatc	agaacctgga	480
ggaaggcttg	ttaaaacacc	agcggtctgg	ccccatcccc	agagtgetga	ttcaggagct	540
ccagggcagg	gctgaggact	tgggtttcta	acaagtaccc	aggtggctcg	gtgctgtgc	600
tgggtccatg	catagaaagc	cctggagacc	tggagtgagc	cctttcttcc	cctagcttca	660
gcttcctgat	ctgtagaatg	gaacagtcca	cctgggtgat	ttccaggacg	acagtagtgg	720
tagtaagggc	agcctctgtg	acactgacca	cagtacaggc	caggcctctt	tttttttttt	780
ttgagatggg	gtctcactct	gtcgcccaga	ctggaatgca	atggcacaa	cttggctcac	840
tgcaacctct	gccttccggg	ctcaagcaat	tctcctgcct	cagcctccca	agtagctggg	900
attacaggtg	cctgccaccg	tgtctggcta	atttttgtat	ttttgctaga	gatggggttt	960
ctccatgttg	gccaggctgg	tctcgaactc	ctgacctcag	gtgatccacc	tgcttggcc	1020
tcccaaagtg	ctgggattac	aggcatgagc	caccatgcct	ggccaggcca	ggcctctttt	1080
aacactttgc	acaccatggg	tcttttcatc	caggagggta	ggtagttata	cagttgagga	1140
cagtgaagcc	cagagatgct	cagggaactg	gccagggtca	cacagcagga	ggtggcaggt	1200
gtgtggctgg	ggctgacagc	atggctccag	ctttccagcg	tagaagtctg	tgaagcaga	1260
gagcttgtcg	gttgggttag	accccccca	cagcggctca	gattgctgta	gccaggggcc	1320
ttcctggggg	ctcataaccc	agaacactaa	atgggcagac	cctgagggag	gaggtgcagt	1380
ggagctgggg	gtgccgatgg	gaagtcccg	aggagctggg	aggtcagtcg	cagtgtgct	1440
ctctgtggag	cacttagtag	gcaccaggtg	tgtttccagg	ttcatggctc	tgggaccoga	1500
agctcaggtg	aagtgaactg	cccagggtag	ccagcgggca	gaggattttg	aggctatgaa	1560
gcctgcgctc	atggcctggc	cctgggggtt	gccagtgtgc	tggctgggga	gcttttctctg	1620
caagtggact	ggtgtctaga	agccagcatg	tcaggcagca	ggcagcggga	gcacagtagg	1680
cagatggtgg	ggcccaagca	gcctccatg	gacccaggg	catggcggca	cgtggaagag	1740
agctgtccca	tgtcgggtgg	tgacgggctg	ggttgtgccc	cgaggagggc	ggatgatggg	1800
aggaagtggg	gtcccccagg	gcttttagcaa	gaggaggcac	aggaaactgg	tgccagctgc	1860
agtgaagggg	acatggccct	gaggtcagga	gcttgggtcaa	gtcactgcct	ctatgggcct	1920
cagtgtcctc	atctgtgaaa	gaggaagggg	cggggaagcc	aactccaagg	tccctcctag	1980
ccctgggttc	atgagtctga	ggatcccagg	gaaatggggc	ttggcagctc	gacatgtgag	2040
gtcatggggg	ctagggaggg	gcaccgagct	ggaagtggga	ggcagagggg	ctggccggct	2100
gggtcagaca	cagctgaagc	agaggctgtg	acctgaggcc	ccagaacctc	cacctctgag	2160
ctgccacccc	aggatctggg	ttccctcctt	ggggggccac	agggaaacaag	tcacctgtcc	2220
tttgcacagg	ggagcccttc	agctgtatgc	agaagattgc	gctctgcccc	ttcctccctc	2280
tgggtgctga	gcttcttcag	cccaccagtc	agatgtgagg	ctgccctaga	ccctgggcag	2340
ggtcattgct	atccactgac	gtttgagatg	ggagatgagc	tcttgcccc	tcagagtcc	2400
aagggctggg	gcagtgaagc	ctgcacaggg	tggagtggg	caccactgtc	ccaggggagc	2460
cccaggggg	tctggtcact	gggcttgtgg	ctggcatgct	cagtctcca	gcacttactg	2520
acaccagcat	ctaccaacac	caacatttac	aaacactgac	attgaccaac	actgacaatt	2580
actgacaccg	acattttacca	acactgatat	tgaccgacgc	cgacatttac	ctacaccagc	2640
atttaccaat	gccgatattt	actgacccca	acatttagcc	atgtgatggg	ggccggctcg	2700
gggacggggc	ttgctcttag	cagtgggggt	gccacagaaa	ctagacagat	gcatgggggtc	2760
atggacttct	gcttcttctc	cagcctcacg	tactggatag	actggggaga	gaacctgaa	2820
atcaagcgtg	ccaacctgga	caggcaggag	ctgcgcgtgc	tggtaaatgc	ttccctcggg	2880
tggcccaacg	gcctggccct	ggacctgcag	gaaggggaagc	tctactgggg	agatgccaa	2940
acagacaaga	tcgaggtgag	gtcccatgg	aggtatttga	tcctggaggc	ctggccctgc	3000
ccggctgtcc	ctgggctcct	aagaggccag	gcccggccac	cccctgcagc	ctgacatacg	3060
tatcaccaag	gcaccaatgg	gtgcctgtgc	tctgctatatt	ggccaagcgg	aatgcttgat	3120
aaagttagtta	cagtaacttc	tgacaaaaac	gccttgagag	ggtagcgcta	tacaacgtcc	3180
tgtggttacg	taagatgtta	tcattggggc	aggcgcctgt	agtcacagct	acttgagagc	3240
tgaggtggga	ggatcactgg	agcccaagag	tttaaggcca	gcctgggtaa	aggggacacg	3300
ggaaacctct	gcactgcttt	tgccacttac	tgtgagcctt	aaactatttc	acaaacaata	3360
caaaatcaag	acaaaaaatt	aataacatat	ccactgcccc	cacttaagac	ataaaacatg	3420
agtgtcattg	aagccagagg	cagccattgg	cctgagtttg	ttgattcggt	cccaagcagt	3480
tgaagacagt	tttggttttc	tgtggatgtc	tgtctcttct	ccctatgctg	ggtgcagccc	3540
tgcattgccca	ctgtgggtgg	atttcagtgg	ccttgtcctg	tgggcgtgct	ttggcagctt	3600
gctttttgct	cacctgtgga	gcttctattg	agcttttgtt	gttgttgttg	ttgtagtgtg	3660

237

ccaggetgga	gtgcagtggc	acgatctcag	ctcactgcaa	tctccacctc	ctgggtttcta	3720
gcgattctcc	tgcctcagcc	tcccagtag	ctgggattac	aggcgcatgc	caccacactc	3780
ggctaatttt	tacattttta	gtagagacgg	ggtttcacca	tttgccagg	ctgttctgga	3840
actcctgacc	tcaagtgate	cacctgcctc	agcctcccaa	agtactggga	ttacaggcgt	3900
gagccaccgt	gccttgccctc	tattgagcag	tttttttgag	gtgctcttgg	tgccagtaat	3960
atgttacatg	tgtccccatt	gcacattgtc	accatcgag	gtgacattgg	tgcctctcct	4020
cggttagtgc	gcctcccttt	gttccagca	acttctgaag	gattttcctg	agcctcatca	4080
gtccttggtg	acgtcaccat	cggtgtcacc	tttgcctccc	tcagggtccc	caggggaggc	4140
ccgaaccagg	cagcttgcat	gggaggtgg	gatggagaac	acgagtgtgt	gtctgtgttg	4200
caggattttca	gacctgctt	ctgagcggga	ggagcctcag	caccttcagg	gtggggaaca	4260
cccagggatg	gaaagggctg	agtggatgcc	cctcccaaaa	aaactctaga	agctgcagat	4320
gtggccattt	cctgttggag	ctccttgtaa	atgttgtttt	tttttttttt	tttggcaagg	4380
cccatgtttc	tgggcgctg	aggatgattt	gccttcattg	atcccccta	cccatgggag	4440
caggctcagg	actcactcac	gtgtctgtgg	cacgccaggc	cacaggtgtt	gttccttgta	4500
ctgttgcatg	agtgttttcc	ttgagacagg	gtctcgtcca	gttgctcagg	ctggagtcca	4560
gtggcgcatg	cacggctccc	tgcagcctcc	atctccttgg	tctcaggtga	tccttctgcc	4620
tcagcttctg	agtactggg	actacagaca	cacaccacca	tatccagcta	gtttttgcat	4680
atttttttgt	agacatgggg	tttcgccatg	gtgcccgaagc	tgatctgaaa	ctcctgaggc	4740
acaagtgate	cacctgcctt	ggcctcccaa	agtgtctggga	tgactgacag	gcataagcca	4800
ccacaccaag	cccaatgatt	ttttttattg	tgataaaata	aacatagcac	aaaattgatg	4860
attttaacca	ttttaaagtg	aacaattcag	gccagggacg	gtgggtcaca	cctgtaatcc	4920
cagtactttg	ggaggtctgag	gcaggcggat	cacctgaggt	taggagtccc	aagaccagcc	4980
tggaccaaca	tgggtgaacc	cccctgtcta	ctaaaaatac	aaaaattcac	cgggtatggt	5040
ggcaggcacc	tgtagtccca	gctacttggg	aggctgaggc	aggagaatcg	cttgaaccca	5100
ggaggtggag	gttgacgtga	gccagatct	cacctgtgca	ctccagcctg	ggcaacaggg	5160
agagactctg	tctcagaatc	tcaaaaaaaa	gaaaaagaaa	aacgtcattt	atccagcacc	5220
ccgtgagacg	gctgacacct	ggcgttttat	ggtacctggc	aaggtgcagg	tgaagttgag	5280
gctcctgggt	gttgaacccg	tctcgttttg	ggcagctcag	gcccagggca	gggtcagggt	5340
tggctctcgt	tggcatggcc	ctggcccatc	cagacctgta	tctttgccat	tctgcaggcg	5400
atcagtgtcg	atgagacgaa	gaggcagacc	ctcctgaagg	acaagctccc	acacattttc	5460
aggttcaccc	tgtcggggga	cttcattctac	tggaccgcct	ggcagcacca	cagcatcaag	5520
cggttacaca	aggtcaaggc	caaccgggac	gtcatcattg	accagctgcc	cgacctgatg	5580
gggtctaaag	ctgtgaacgt	ggacaaggct	ctcggtgagt	ccaggggggt	gggcccgaag	5640
ccgttgctca	gctgcagact	tgcattgagga	agaagtgcga	gttccaaacc	tgggcataag	5700
tgttgagctg	gggtgccctg	ccctggggaa	gggcaggaca	ggaaagggtga	cagtatctgg	5760
ctaaggatag	atgggaaggg	accaagggtg	ctgattaggg	aatggttatg	gactaggagt	5820
atcagtaaca	atggttagaa	agtggctaac	atttgttgag	cacctgctgt	gtgcctggcc	5880
ccggtctggga	gccttcgtgc	ccagagtgc	cccgtctgaa	tgcagtctct	tgcctcatte	5940
aaactgggga	gtgggaggca	gagctgcaca	actcacaggt	gccgagctca	agactcactc	6000
ctgggtctgc	ctgggctggg	ctgtgcttgt	tgcccctgtg	gccaacacac	gcgcaccttt	6060
cacctgaagg	ccagtgccg	cagaacgttc	cccaggagg	tcgttgtttg	gcactatgat	6120
ttgtctcttc	ctaaaaagg	gatagagtta	cactggagag	agcagcatcc	aggtgcagca	6180
gggatgggcc	tggggctcac	gggcaggggc	tctgtgtccg	gctggggcct	ggggctctgc	6240
gctgcacctg	tgtgtcagaa	gcactcagta	aatctttgct	gatgaaggat	gagaggatag	6300
aggacatgat	gcttgctgct	gcattgcctg	caatcctgga	tgagatgccc	aggttggtct	6360
tgtccccctg	cgggtggatg	tgatgttagc	tgtgatgtta	ggtccctggc	tttaaaatac	6420
gagggagctg	ggaattgagg	gagcaggttg	gggcagaaag	gacagccccg	cagaggcctg	6480
gagctgaggc	agtgcggggc	acccaggag	cagtgaagtgc	ttccgtcaca	gccttcacgc	6540
cacctgtgg	tcctcataaa	gggatggaa	tctacgaatt	tagttttccc	agcctcctta	6600
aaaactcatt	catgccaggg	gcagtggctc	acacctgaaa	tcccaccact	ttgggaggct	6660
gaggcaggct	gattacttga	ggtcaggagt	ttgagaccag	cctagccaac	atggtgaaac	6720
cccgtgtcta	ctcaaagtac	aaaaaaaaaa	attagtcaga	cgtggtgtca	cgcacctgta	6780
atcccagctc	tttgggaggc	tgaggcagga	gaatcacttg	aacccaggag	gcagagggtta	6840
tagtgagcca	gtattgcgcc	actgacctcc	atctgggcaa	tagagtgaga	ccctgtctca	6900
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	catgaatgcc	aggtgcagtg	gctcacgcct	6960
gaaatcccag	cactttggaa	ggctgaggca	ggaggatcac	ttgagcccag	gaatttgaga	7020
gtgtctctcc	tgggcaacag	agacagacct	catctctact	aaaaaaataa	aaattacaaa	7080
caattagccg	ggcatagtgg	catgtgcctg	tgggtcccatc	tacttaggag	gctgaggtgg	7140
caggatccct	gagcctggag	gcagaggttg	cagtgcagag	agatcatgcc	actgcactcc	7200
agcctgggtg	acagagtgg	aacctgtctc	aaaaaaaaaa	aaaaaaaaagca	ttcactatcc	7260

238

accatggaag	gtgagactga	cccactgtga	gtgattgttc	aaagaacaaa	aaataatccc	7320
cagagataag	acaaaagggt	gcatccatgg	ggctgtgatt	taaatctgag	aaattgggct	7380
tctttccct	cccctctcac	cccatgggtt	actaaaggag	atgaacaaaa	ggattctttt	7440
tttggttaa	atatttaata	ctaaattaaa	gccagtttta	acagcacttc	ggttgatgag	7500
attaacagac	tggccaaaaa	taaatgaaca	cactctgtac	tgtgtgaaaa	agaggcagct	7560
ttggccatgc	tgggtgaatg	tgagttttca	gggttgctgg	gaatgtctgt	gaatcagaag	7620
aaggagcctag	gtgggagctc	caggagccga	gacccaagg	ggtgacttac	ccagtccctg	7680
ccccaaagccg	ttaccgtggt	cttcctgggt	cggagcacag	gccaggaggc	tggaccacca	7740
ggctggcatt	ctcgtgagc	tgctccctga	cttcctgacc	atgctccctt	cagcagcctc	7800
tgcactttag	tttcctcgaa	tgagaaatgg	ggatgagaat	agctcctaac	tccaagggtg	7860
atggagtaa	ttcgacacag	ttgaatccct	gggatcagcg	cctggagcct	gacaagggtcc	7920
agtcagagcc	agaactgctg	ttactgatac	tgacccttgg	ccgtaccagg	ggagaacttg	7980
gttgccattg	ccagggtgtc	tcccaccacg	cccagctact	gtccctgttt	gacatgtggc	8040
tggataaaag	ctgtgcacgt	tgacgctttt	ggcacatcct	ggctttgagg	taaaagggtac	8100
gtgtgtgttt	gaggggtgag	cctggccatg	ggaatgataa	tcacagccca	acccagccgt	8160
gaggtcgaac	cctacctagg	ggtgagtcct	gagcttgaca	cccctgagct	gtgcggttca	8220
cgggtggcatt	cattgtgtgg	cttggctgca	cccctttccc	tgctgggctg	ttggtgttta	8280
gatcggagcc	tgtgtgttca	cttcaggaa	ccaaccctca	tgcgagacag	aatgggggtg	8340
cagccacctg	tgcttcttca	cgccccacac	aaccgggttt	ggctgcccc	tctagggcct	8400
ggaactgctg	agtgcacatg	agacctgcac	catgcccaag	gccttcttgg	tcttcaccag	8460
tagagccgccc	atccacagga	tctccctcga	gaccaacaac	aacgatgtgg	ccatcctgct	8520
ctcggcgta	aggaggcctc	ggccctggac	tttgatgtgt	ccagcaacca	catctactgg	8580
acagacatca	gcctgaagg	agcgtgggcc	cgaacatgca	cacgtgcagc	ctatatggga	8640
aaaccttccc	tctgtacctg	cctcaaagg	ttcagacatt	tttcttaaag	cactataata	8700
tttattgtaa	cacaattcaa	gctaattaaa	tatgagcaag	cctatttcaa	aaaaaataga	8760
cgattataat	gagcaaatcc	ggtagacaca				8790

&lt;210&gt; 309

&lt;211&gt; 890

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 309

ggcggcagga	actggggctg	agctgtcccc	gctgcgtgcc	tgcgacagtg	accagccag	60
ccccggagca	cagtcgccga	aggatgataa	tgaagataat	tcaaatgatg	ggaccagcc	120
atccaaaagg	agggtgaatg	gctcaggagg	tagttctaat	agttatgaaa	cttcaagtca	180
agatcttggc	tttagtcact	atccagcaga	aaatttgata	gagtacaaaa	ggccacctga	240
tgaatatagga	gaatactata	tgcttcaata	acaagtcagt	gaatatttgg	gtgtgacctc	300
ctttaaaagg	aaatatccag	atttagagcg	agatttgtct	cacaaggaga	aactctacct	360
gagagagcta	aagtcattac	tgaaactcag	tgcatgctag	gtataacagc	attgcgagct	420
gatgaagtga	ttgatttaat	gataaaagaa	tatccagcca	aacatgctga	gtattctgtt	480
attctacaag	aaaatgaatg	tcagcgaatt	acagaccatt	ataaagagta	ttcccaaatg	540
caacaacaga	atactcagaa	agttgaagcc	agtaaagtg	ctgaggatat	taagaaagct	600
gccaaaaaag	cagctgaatt	taacagcaac	gtaaactggg	aacgcatgga	agaagagctt	660
atthtgactt	gcagacacat	gttatccagg	tgcttcaagg	gaattacaaa	gttttgccaa	720
cagagcaaac	aatgattagt	tcttaccacg	tgggtctcat	cccctgacag	ttcgacagtt	780
tgaggaatat	tataaaagg	actcaccaga	tgagctctgg	tacctgccat	taaacacagc	840
cctgtatgag	ccccctctg	gatcctgagc	tcctgctgt	agacagtgat		890

&lt;210&gt; 310

&lt;211&gt; 404

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 310

gagttactgg	gggtcatcgc	tacattctga	tggcctagct	gtgtggaggc	cacggtggag	60
ccccatccaa	ggagccagg	ccctgggtct	agcgtgacc	agaacgcatg	ccctggagg	120
gtttctcatc	ttgcacctgt	gttgcttggt	gtctcaagt	gccacaaaac	tgtgttagct	180
cttggtgccc	ctgggcttcg	gaaccagggt	ttcccttcat	ctcagtgcac	cgggagcatc	240
tgggcagtga	gtaaaagagg	tgatttactt	gatgggtacg	tttggtcctg	cctgggagcc	300



239

ccccaggca	cggtcctggg	acctgaagct	gccctcgttg	gtggagggga	gggagagagc	360
ttcagggatg	aggtggcggt	gagctgggag	ggaaggggtga	gccc		404

&lt;210&gt; 311

&lt;211&gt; 1908

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 311

gccgagcccc	tggggccgggc	gctgaggcgg	gccccctctgg	gcaggggccc	ggcggggctg	60
ggtggggccgc	ccctgctgct	gccgtccatg	ctgatgtttg	cggtgatcgt	ggcctccagc	120
gggctgctgc	tcatgatcga	gcggggcatc	ctggccgaga	tgaagccctt	gccccctgcac	180
ccgcccggcc	gcgagggcac	agcctggcgc	gggaaagccc	ccaagcctgg	gggcctgtcc	240
ctcagggctg	gggacgcgga	cttgcaagtg	cggcaggacg	tccggaacag	gacctgcgg	300
gcggtgtgcg	gacagccagg	catgccccgg	gacccctggg	acttgccggg	ggggcagcgg	360
cgcacctgc	tgcgccacat	cctcgtaagt	gaccgttacc	gcttcctcta	ctgctacgtc	420
cccaaggtgg	cctgctctaa	ctggaagcgg	gtgatgaagg	tgctggcagg	cgtcctggac	480
agcgtggacg	tccgcctcaa	gatggaccac	cgcagtgacc	tggtgttcct	ggccgacctg	540
cggcctgagg	agattcgcta	ccgcctgcag	cactacttta	agttcctggt	tgtgcgggag	600
cccttggaa	gcctcctctc	tgctaccgc	aacaagtttg	gcgagatccg	agagtaccag	660
caacgctatg	gggctgagat	agtgaaggcg	tacagggctg	gagcggggcc	cagccctgca	720
ggcgacgatg	tcacattccc	cgagtccctg	agatacctgg	tggtgagga	ccctgagcgc	780
atgaatgagc	attggatgcc	cgtgtaccac	ctgtgccagc	cttgtgccgt	gcactatgac	840
tttgtgggct	cctatgagag	gctggaggct	gatgcaaata	aggtgctgga	gtgggtacgg	900
gcaccacctc	acgtccgatt	tccagctcgc	caggccctggt	accggccagc	cagccccgaa	960
agcctgcatt	accacttgtg	cagtgcctcc	cgggcccctgc	tgccaggatgt	gctgcctaag	1020
tatatcctgg	acttctccct	ctttgcctac	ccactgccta	atgtcaccaa	ggaggcgtgt	1080
cagcagtac	catgggtgtg	gggccagcag	ctggtgggga	ctggtttcaa	cgcagctttt	1140
ctgtgcttct	gcctgtcatt	cggagaaact	ctggctctgg	ggcttggggc	ttctcaggat	1200
cctggatggc	agagactgcc	ctcagaagtt	ccttgtccag	ggtgggcacc	cacagtgact	1260
cagaggacag	ggctaggcag	gagacctgct	gtcctcattt	ggggggatct	cttggggggc	1320
agacaccagt	ttgccaatga	agcaacacat	ctgatctaaa	gactggctcc	agaccccggg	1380
ctgccaggat	tatgcagtc	acttggtcta	ccttaattta	acctgtggcc	aaactcagag	1440
atggtaccag	ccaggggcaa	gcatgaccag	agccagggac	cctgtggctc	tgatccccc	1500
tttatccacc	ccatgtgcct	caggactaga	gtgagcaatc	ataccttata	aatgactttt	1560
gtgcctttct	gctccagtct	caaaatttcc	tacacctgcc	agttctttac	atttttccaa	1620
ggaaaggaaa	acggaagcag	ggttcttgcc	tggtagctcc	aggacccagc	tctgcaggca	1680
cccaaagacc	ctctgtgccc	agcctcttcc	ttgagttctc	ggaacctcct	ccctaattct	1740
cccttccttc	cccacaaggc	ctttgaggtt	gtgactgtgg	ctggtatatc	tggctgccat	1800
ttttctgatg	catttattta	aaatttgtac	tttttgatag	aaccttgta	agggctttgt	1860
tttcctaata	gctgactttt	taataaagca	gttttatata	taaggcga		1908

&lt;210&gt; 312

&lt;211&gt; 2203

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 312

gtcactgcga	ggccgggggt	ggagagcggc	cgggcgggac	atccggccc	ggtccctcgc	60
cgcgcccgc	gcccgcgcgc	cgttcggcg	ccgcagccc	ggagccggcc	acccctacac	120
gcgccagggc	tgtccctgc	cctccctcc	ccaactaccc	ccgtcccag	accctcctcc	180
cgcgccagc	ccgagcccgc	cttccaggcc	gcctcggat	cggccggggc	cgcgcaggcc	240
cccacccctt	gagcaccatg	ttccccgcgc	cgtgacccc	gctggcggcc	ccaaatggcg	300
ccgagccctt	gggcccggcg	ctgaggcggg	ccctctggca	gggcccgggc	ggggctgggt	360
gggcccgcgc	tgctgtgcc	gtccatgctg	atgtttgcgg	tgatcgtggc	ctccagcggg	420
ctgctgctca	tgatcgagcg	gggcacccg	cccgagatga	agccctgcc	cctgcacccg	480
cccggccgcg	aggcacagcc	tggcgcggga	aagcccccaa	gcctgggggc	ctgtccctca	540
gggctgggga	cgcggacttg	caagtgcggc	aggacgtccg	gaacaggacc	tgccggcggg	600
gtgcggacag	ccaggcatgc	cccgggaccc	ctgggacttg	ccggtggggc	aggcgcgcac	660
cctgctgcgc	cacatcctcg	taagtgaccg	ttaccgcttc	ctctactgct	acgtccccaa	720

240

ggtggcctgc	tctaactgga	agcgggtgat	gaaggtgctg	gcaggcgtcc	tggacagcgt	780
ggacgtccgc	ctcaagatgg	accaccgcag	tgacctgggtg	ttcctggccg	acctgcggcc	840
tgaggagatt	cgctaccgcc	tgcagcacta	ctttaagtcc	ctgtttgtgc	gggagccctt	900
ggaacgcctc	ctctctgcct	accgcaacaa	gtttggcgag	atccgagagt	accagcaacg	960
ctatggggct	gagatagtga	ggcggtagag	ggctggagcg	gggcccagcc	ctgcaggcga	1020
cgatgtcaca	ttccccgagt	tcctgagata	cctgggtgat	gaggaccctg	agcgcatgaa	1080
tgagcattgg	atgcccgtgt	accacctgtg	ccagccttgt	gccgtgcact	atgactttgt	1140
gggctcctat	gagaggctgg	aggctgatgc	aaatcagggtg	ctggagtggg	tacgggcacc	1200
acctcacgtc	cgatttccag	ctcgccaggc	ctggtaccgg	ccagccagcc	ccgaaagcct	1260
gcattaccac	ttgtgcagtg	ccccccgggc	cctgctgcag	gatgtgctgc	ctaagtatat	1320
cctggacttc	tcctctcttg	cctacccact	gcctaagtgc	accaaggagg	cgtgtcagca	1380
gtgaccatga	gtgtggggcc	agcagctggt	ggggactggt	ttcaacgcc	gctttctgtg	1440
ttctcgctcg	tcattcggag	aaactctggc	tctggggctt	ggggcttctc	aggatcctgg	1500
atggcagaga	ctgccctcag	aagtcccttg	tccaggggtg	gcaccacacg	tgactcagag	1560
gacagggcta	ggcaggagac	ctgctgctcc	tcattggggg	gatctcttgg	ggggcagaca	1620
ccagtttgcc	aatgaagcaa	cacatctgat	ctaaagactg	gctccagacc	ccgggctgcc	1680
aggattatgc	agtccacttg	gtctacctta	atttaacctg	tggccaaact	cagagatggg	1740
accagccagg	ggcaagcatg	accagagcca	gggaccctgt	ggctctgata	ccccatttat	1800
ccacccccatg	tgcctcagga	ctagagttag	caatcatacc	ttataaatga	cttttgtgcc	1860
ttctcgctcc	agtctcaaaa	ttcctacac	ctggcagttc	tttacatttt	tccaaggaaa	1920
ggaaaaaggga	agcaggggtc	ttgcctggta	gctccaggac	ccagctctgc	aggcacccaa	1980
agaccctctg	tgcccagcct	cttccttgag	ttctcggaac	ctcctcccta	attctccctt	2040
ccttccccac	aaggcctttg	aggttgtgac	tgtggctggt	atactgggt	gccatttttc	2100
tgatgcattt	attttaaatt	tgtacttttt	gatagaacct	ttgtaagggt	tttgttttcc	2160
taatagctga	ctttttaata	aagcagtttt	atatataagg	tga		2203

&lt;210&gt; 313

&lt;211&gt; 3202

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 313

gcacagtagg	aggaaccag	aagatgctgc	ctctcctgat	catctgtctc	ctgcctgcc	60
ttgaaggga	gaactgcctc	cgctgctggc	cagaactgtc	tgccttgata	gactatgacc	120
tgcagatcct	ctgggtgacc	ccagggccac	ccacagaact	ttctcaaagt	attcactcct	180
tgttcctaga	ggataataat	tttctcaaac	cctggtacct	tggtaggca	cagccaggag	240
atcagggatt	ggatgtggcc	tctttacctg	acctgggatc	ttactccctt	gacttccttt	300
tgacctgtat	ctcatcctca	gatcgtgacc	atttggaaaa	agaaacagcc	aaattcttca	360
ctcaagtaca	ccaagccatt	aaaacgttac	gagatggtga	ggaagccaag	agccccaggg	420
ccttggggct	tgggttgaca	aaggcccacc	ctccaaggca	ttctcagagg	cccatgtggc	480
catgggtggg	aggtcttggt	aagggtggag	atgaatgcag	tctgtctccg	tgtgctcttt	540
ggaacttcca	tgtagaaaca	agggtctgaa	aacccaacct	tgagcaagtt	gtaaccctga	600
acaccccttc	cctcctgctc	taccagata	aaacagtact	tctggaagag	atctacacgc	660
acaagaatct	ctttactgag	aggctgaata	agatatctga	tgggtggaag	gagaagggtg	720
aggggtgggg	acgatccctg	cacacggcct	agccctccac	acctgccaa	acccaaggca	780
tgcagatttc	actctgcagc	cccctcgatc	atccccagga	gccccacccc	tctccatgaa	840
tgcttcccgc	gctccatctc	ctacttgac	cccagaacct	cttggctctg	tctgcctccc	900
cagcacctca	gtttctctac	cttctcacc	tccttggcag	cctgcaatga	gtcctgtggg	960
gagtatgcat	ggggactggg	cctgggggag	ggatgaaagg	cacctggcac	cccctagccc	1020
ctgtccctcc	cctcccatag	acatacagtc	cacactgaag	gtcaccagct	gtgctgactg	1080
caggactcac	ttcctctcct	gcaatgacct	cactttctgc	ccaggtcagt	ggccaccacc	1140
ctgtccagcc	tctccccctc	ctgcctgca	tttctggagc	cattgctgtc	tctgtcatte	1200
tcttttgccc	aactcaagct	tttcttgctc	tttatcctca	ccctgggtga	aggcagcacc	1260
ttctgggatt	tcttgatgtc	ctcatgtcaa	gtccagagc	cccttggagg	catctgcctg	1320
taggacatca	ctcatggagg	cctcttggtt	ctcagagatg	ccatgcctag	aaacatgtcc	1380
aatccttact	caggaggctg	aggcaggaga	gtcgttggga	cctgggagggt	ggagggttga	1440
gtgagccgag	atcatgacac	tgcactccag	gctgggcaac	agagcaagac	tttgtttcaa	1500
aaaaaaaaaa	aagaaagaaa	aaagaaaaga	aaaagaaaaa	tgcccaatcc	catcgaaacc	1560
ccaaacctgt	tcttctctca	gggcccgtct	caacaaatgg	ccccactcaa	gccctcagtc	1620
tcctaaacca	ggaatctccc	tccacttagc	acggagaatc	accatgtctt	gctaaataag	1680

241

tcttctatgt	gttcccatag	tttcattcta	acctccactc	tcaggcctcc	tcctctctca	1740
tctaacttac	agcaacattt	cccattagcc	tccctgtccc	tccaggccac	atcacactct	1800
gaacttcttc	tcaacgagca	agtctaccca	tgacactccc	tgcttataac	cagcagtggg	1860
tcccaaatgc	ccctagagaa	agcccaccct	cctcgggagc	cccctactcc	ccaggcacac	1920
taagtgcata	caggcagctc	catacctcta	tccttgagcg	tgctctgtgc	cggggacaca	1980
gccttgccct	tgaactgac	ccttatttgt	gtttccaagt	ccagctcaga	ctcctgtttt	2040
ctaagaagct	ttccctgac	agctcccacc	ccaggagctt	gtcagccatc	ctcactgtca	2100
cttccccctc	catgtcctgt	cctattttccc	ttgaacccca	caccatgatt	gtttgcttgt	2160
ctagatatga	gctgggcgca	cagcgtgctc	agtaagtgtt	tgcaaacaca	tcctgagtga	2220
acgaatcaaa	gaatgagagg	atggtggcct	tctctctgag	ttgaggtagc	cctgcctggc	2280
ctccaaacac	ctggcttcct	ctttcacacc	ccagccagga	accggcggac	ctccctgtgg	2340
gctgtgagtc	tcagcagctc	tctactcctg	gccatagctg	gaggtgggtg	agtgaacctc	2400
ccaagcccca	gcattcccc	ggaagacaca	cctattccct	gactgactcc	accctgtttc	2460
ttggcccgag	tggtttcttt	actggcaaa	gaagaaggag	gcagttaaagg	tactgggaaa	2520
ggagaccccg	acccaattct	agggtcccca	gagggaaaa	ctgggtgtgc	cctgggagtc	2580
tcagggcctg	gaacccccag	gctgaacctc	tggggtctgg	cgtgcagaac	agagtgggat	2640
cgaggggccag	gactctcagg	agtcccactc	atcagcctcc	atatatgcag	acatatggg	2700
gccagggggc	caggacacag	aaatggcaaa	gctccaggcc	tcccatcctc	actacagagt	2760
gctcttcttc	ccagctgtcc	ctgtccccctg	cacacccac	cttcaacctc	gctgccttgc	2820
cctgaccac	agggaccatt	agcatggctg	ccttgccctc	tgctctgggt	tgggtttggc	2880
cagggggagac	tcccaggagg	aagttagaga	gacagggagg	aggccagagt	agtgggaggt	2940
cagggtagaa	atgccagct	tcttctccct	cagcaggaac	agggcagccc	gcatgtcttc	3000
cagaagtga	cagaggccgc	agctaccacc	gtcacaaagt	tcactcatct	ctgggtcccg	3060
gtgaccccat	cccccatatc	cctccatcct	gggtcctggg	gccccaaagc	tctgaggcct	3120
aggagactgc	gctgtctcgt	ggtttgccta	ctcctacacc	tttgtaaaga	gtctcttcat	3180
taaaaccct	cttcatagcc	ta				3202

&lt;210&gt; 314

&lt;211&gt; 2708

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 314

cttgtgtgtc	accagcctcc	tgatctgcc	gggtctgtc	tgggtgggca	ctgaccagg	60
tgtcatcgct	ctgctgccc	tgctcggt	ggaaggcatc	ccaagatca	caggtgaggc	120
tttgggagct	ggtgttggca	ggaccaggg	gtcagctgca	ggtggccagt	ggggcttggc	180
ggggagggtg	tattatgccc	tcattggtat	agggatggg	ttccagtctc	cagcttcctc	240
tcatctcagg	tggtatggtg	gccagtagaa	ctgaatcgct	ctggccccag	tctcccacct	300
ttctgagtg	cagtttccct	atctggcaga	tggacacaag	agtggcttgg	ggcctggctg	360
agacacctgc	ctaattggcag	gggtccact	ggccctttct	gctgcttccc	atagcagttt	420
caagatgttc	aggtccaga	gaaagaaata	actgagtgtc	tctggggcca	ggcccgccct	480
gctcgtgggg	tccatgtgca	aatgaatgtg	ttcacataga	tcagaggaag	gtctgctctg	540
atctgcacta	ctgggcccag	gacaacaagg	gcaggatcag	agaagacccc	cacacttggg	600
tgcttgagc	tccgggtccc	cctccaccac	cctgagaatg	atgactgtgg	tcttttccag	660
caagggagca	gggccaatag	gaagccctgg	gggtgggctg	gctccctgcg	cagacctcaa	720
gtccttctga	taaagaagaa	ttgctttggc	tgggcgcggt	ggctcacacc	tgtaacctta	780
gcactttggg	aggccgaggt	gggtggattg	cctgagctca	ggagtttgag	accagcctgg	840
gcaacacagt	gaaaccccat	ctctactaaa	aaataaaaaa	aaataaaaaa	aaaaaattag	900
ctgggcatgg	cggtgtgcgc	ctgtaatccc	agttacttgg	gaagctgagg	caagagaatt	960
tcttgaaccc	gggaggtgga	ggttgacgtg	agccgagatt	gcgccattgc	actccagcct	1020
gggggacaga	gtgagacacc	atctcaaaaa	aaaaaaaaaa	agttgcttct	aaattctgag	1080
atthttctatt	ttcaagggtt	catcaaatag	ggcattttgt	ccatccaggg	ggcatttgtg	1140
gaggttctat	ttccaggtag	aatcctggga	tgcagggatg	aaatcgggca	gagaccttgc	1200
tctcaacaag	ctgatggtct	cctgggggtc	atcatagctc	gggtgacagg	tgctgggatg	1260
aggggtgctcc	gggggtctgg	gacacagaga	ctggggcgag	cagctcccca	tgcatgaatt	1320
caggagggat	tcacagttag	gagtgtagc	tgggccttgc	tgaaagagtt	gcagaatcaa	1380
gtagacagga	aaggatttct	aggcagagga	gctgcttggc	aaaggctcag	gaaattcttg	1440
gaatttcaca	ctgaggctcc	cccgtgtggt	gtataagggtg	gtttctgttc	cactcccttg	1500
aggaagttgt	gcaggagcac	gggtagacca	gagcctgtgg	ccttcggggg	aggtgccaac	1560
atagacagaa	gtgaccccc	caaataccca	cccagaatgt	tctccaggag	agagactcag	1620

242

gtgcttccct	taatgcgctg	ggcctttggg	cccccttctc	tctcgcccca	ttttctgcag	1680
ggaaaggcat	ggtctcactc	aacgggcact	gtgggcctgt	ggccttcctg	gctgtggcta	1740
ccagcatcct	ggccccctgac	atcctgcgga	gtgaccagga	ggaggctgag	gggccccggg	1800
ctgaggagga	caagccagac	gggcaggcac	acgagcccat	gcccgatagc	cacgtgggcc	1860
gagagctgac	ccgcaagaag	ggcatcctct	tgcagtaccg	cctgcgctcc	accgcacacc	1920
tcccggggccc	gctgctctcc	atgaggggagc	cggcgccctgc	tgatggcgca	gctttggagc	1980
acagcgagga	ggacggctcc	atttacgaga	tggccgacga	ccccgacatc	tgggtgcgca	2040
gccggccctg	cgcccgcgac	gcccaccgca	aggagatttg	ctctgtggcc	atcatctccg	2100
gcgggcaggg	ctaccgcaac	tttggcagcg	ctctgggcag	cagtgggagg	caggccccgt	2160
gtggggagac	ggacagcacc	ctcctcatct	ggcaggtgcc	cttgatgcta	tagcgccctc	2220
cctctccctc	cagagggcac	agctgcaggc	ctgaccaagg	ccacgcccgg	ctctcgtgct	2280
ctaaggacct	cacgggactt	gtggatgggc	ctggactctc	cagaaactac	ttgggcagag	2340
caaagggaaa	cctcttgttt	taaaaaaatt	tttttcagag	tgttttgggg	aggagtttta	2400
gggcttgggg	agagggagga	cacatctgga	ggaaatggcc	ttctttttta	aagcaaaaaa	2460
cacaaaacct	cacaactgcc	tggcaagccc	agtatcactt	gtttggggcc	tagcgggact	2520
ccaaggcagc	cacacgcccc	tcttgaaggg	gtgtgtgcgt	gtgagtgtgt	gcgagtgtgt	2580
gggctggtgt	gtgaatatct	ataaataagt	atatatggtg	tatattatat	gtgtataaat	2640
aaagtctgta	catattggag	ctctggggaga	tgttggaata	aaagacaaga	gttacatctg	2700
gacttgga						2708

&lt;210&gt; 315

&lt;211&gt; 512

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 315

ccagaggagt	ttaggatggg	ccccagggtca	tgtagctgga	gagtggcaga	gccaaagggtg	60
gaatcccgcga	cctggctctg	gagccctggt	ctcagccacc	gtgctgggca	gcccacacct	120
ggcatcctct	ctgttaggag	caggggcctg	ccccacgcc	ctctctgaca	ttgctattct	180
tgctaaaatg	aagagacaga	gctgagggga	gagctaaaaa	gaatgaatct	ggactggcat	240
cagaaacatg	ctgcttccca	ccagcgagtt	ttgtgcttca	ctcttgggcc	cagggcctgc	300
aggggtgtgct	gtgacctcat	ctgaagaagc	acccacacgg	gcaggccctg	aggggctgca	360
gcagagccac	ctcgagccct	acccggccct	acttatgcct	tccatctgca		420
ccaacaccga	tgagaagctt	gcacctcccc	agtcctccct	ggttttgctc	gtagctggct	480
ggctggatcc	ctgcatggat	tgccttggga	ca			512

&lt;210&gt; 316

&lt;211&gt; 1064

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 316

taacaaattg	aaaccatctg	gtcatgaact	tttattttgt	aagagggttt	ctaattattga	60
ttcaatctct	ttgcttattc	taaatgtgtt	cagattttcc	acttcttgag	tcaatttggt	120
aatttatttg	tttctaggaa	tttgtccatt	tcatctagtt	tacctaattt	ttgacatata	180
aaattatata	tggaaatttc	taaaatattt	aaaaatttct	gtaatgtcaa	tagtaatgtc	240
ccctcttttg	ttaccaattt	gttatttgaa	tcttctcctt	ttttttgtca	atctagctaa	300
aaatttgtca	attttgttcg	tctcttcaaa	aaaatatacg	tttgtcttca	ttgattttct	360
ctattgtttt	tccattctat	atttcatttg	aatacatttt	taaactttat	ctttattatt	420
tcatctcttc	tgggagcttt	gggtctcatt	tttttttcct	gataatctag	ttgtttattg	480
tataagatta	agtattttatt	tgaatctgt	atgttcttta	atgtaggcac	tactactat	540
aaatttactt	ctcaggagca	tctctgccgc	attccatggt	ttagtatggt	gtgttttaat	600
ttgtatttat	aactagaggg	aaacagaggt	gacggagaaa	aagacgtaca	aatatcatcc	660
acttgcaaag	tatagatttg	tttgtattgt	aatatgaata	aaaatattac	gagacagata	720
agaaaatttg	aacactgacc	attgatgcag	ttacagttta	ttttaaaatc	aaggtttaata	780
acatttttagt	tatttttaaag	aatgatagta	atttagagat	gtattctgaa	tgtttttaaa	840
tgaaaagata	tgcctgggat	ttcttccaaa	atgaatcttg	taggttgagg	agaaaatgag	900
aacatagtgg	aaacaagact	gacaatgagt	tgttgagggt	gggcaatgcg	tacactaaag	960
cttattttat	cttattttac	tgtatatact	gttaaagctt	gcattatttt	cataaatgca	1020
tttgctaagt	gcaactgtta	tcaataaag	tggattgggc	tcta		1064

<210> 317  
 <211> 1064  
 <212> DNA  
 <213> Homo sapiens

<400> 317  
 taacaaattg aaaccatctg gtcatgaact tttatttggt aagagggttt ctaatatattga 60  
 ttcaatctct ttgcttattc taaatgtgtt cagattttcc acttcttgag tcaatttggt 120  
 aatttatttg tttctaggaa tttgtccatt tcatctagtt tacctaattt ttgacatata 180  
 aaattatata tggaaatttc taaaatattt aaaaatttct gtaatgtcaa tagtaatgtc 240  
 ccctcttttg ttaccaattt gttatttgaa tcttctcctt ttttttgta atctagctaa 300  
 aaatttgta attttgttcg tctcttcaaa aaaatatagc tttgtcttca ttgattttct 360  
 ctattgtttt tccattctat atttcatttg aatacatttt taaactttat ctttattatt 420  
 tcattccttc tgggagcttt gggctcatt ttttttccct gataatctag ttgtttattg 480  
 tataagatta agtatttatt tgaatctgt atgttcttta atgtaggcat tcactactat 540  
 aaatttactt ctccaggagca tctctgccgc attccatggt ttagtatggt gtgttttaaat 600  
 ttgtattcat aactagaggg aaacagaggt gacggagaaa aagacgtaca aatatcatcc 660  
 acttgcaaag tatagatttg tttgtattgt aatatgaata aaaatattac gagacagata 720  
 agaaaatttg aacactgacc attgatgcag ttacagttta ttttaaaatc aaggtttaata 780  
 acatttttagt tatttttaaag aatgatagta atttagagat gtattctgaa tgtttttaa 840  
 tgaagagata tgcctgggat ttcttccaaa atgaatcttg taggttgga agaaaatgag 900  
 aacatagtgg aaacaagact gacaatgagt tgttgaggtt gggcaatgcg tacactaaag 960  
 cttattttat cttattttac tgtatatact gttaaagctt gcattatttt cataaatgca 1020  
 tttgctaagt gcaactgtta tcaataaaag tggattgggc tcta 1064

<210> 318  
 <211> 1408  
 <212> DNA  
 <213> Homo sapiens

<400> 318  
 caggttacaa atgctgctgc caactgtcct ggccaaatga ctctgcatca caaacctttc 60  
 cttgcatgtg gaggggatgg atttactcag tccaactttg atggctgcat cacttctgcc 120  
 ctatgtgttc tggaaacttt aaagaattat atttagtgcc tataatcctta ttctctacat 180  
 gtgtattggg tttttatttt cacaattttc tgttattgat tattttgttt tctattttgc 240  
 taagaaaaat tactggaaaa ttgttcttca cttattatca tttttcatgt ggagtataaa 300  
 atcaattttg taattttgat agttacaacc catgctagaa tggaaattcc tcacaccttg 360  
 cactttccct acttttctga attgctatga ctactccttg ttggaggaaa agtggtaact 420  
 aaaaaataac aaacgactct ctcaaaaaaa ttacattaaa tcacaataac agtttgtgtg 480  
 ccaaaaactt gattatcctt atgaaaattt caattctgaa taaagaataa tcacattatc 540  
 aaagcccat cttaagtctt cggatgtgtc cttgaatcaa tatttttgca aattatacaa 600  
 aacaagattt ttccaaaatg taggtaacag agtgaattc ttatttctca tttatcccc 660  
 aagttattaa gtgatcctga attgtaggtc atatatgtca tcatcttagt gtggagggca 720  
 acttgactga taaagagacc ttcttccaga ttttcagaaa gtataagatt ccacatgatt 780  
 ttcccagcca cacagtactt ttttaacttt aaacaaattc cagtcctaata atgaaagata 840  
 aaaattaaat agaaacagag agaaagtata tctatcctta ccttttgcta tattttatag 900  
 ctgttgctgt tactttatgg gttctccagt atgtgctgtg gcatttagac tgtgtcgagt 960  
 ttaatgaatt taacacaaca aaaaatttac tgaaccagaa aatagatgca cttaaaaatag 1020  
 ttcaatattt gccaaagtgg tggttcagca tatcccccac atgcttcagt gacctgacct 1080  
 cactgactgc tagctggaga gaaatcaatc tccagccttc caaacagct acctgttgc 1140  
 aatttgaaaa gcaaatgat gagttctatt tcagcatttt gaaaggagaa aaatcattgc 1200  
 agcctctcaa actaacaaaa gttcaacaaa agacttctta ctgtaatagt gtttaaaagt 1260  
 tcacacttac atgtccactg tcatacacag acatacacag gcacaggcag aacttgcttc 1320  
 tatagctgca aagtggtgtt tatgacccta tagcatatta ttatatgttt cctcttagca 1380  
 ataaattggt gaaaaactta aatgccaa 1408

<210> 319  
 <211> 1408  
 <212> DNA

244

&lt;213&gt; Homo sapiens

&lt;400&gt; 319

cagggttacaa	atgctgctgc	caactgtect	ggccaaatga	ctctgcatca	caaacctttc	60
cttgcatgtg	gaggggatgg	atttactcag	tccaactttg	atggctgcat	cacttctgcc	120
ctatgtgttc	tggaagcttt	aaagaattat	atttagtgcc	tatatcctta	ttctctacat	180
gtgtattggg	tttttatttt	cacaattttc	tgttattgat	tattttgttt	tctattttgc	240
taagaaaaat	tactggaaaa	ttgttcttca	cttattatca	tttttcatgt	ggagtataaa	300
atcaattttg	taattttgat	agttacaacc	catgctagaa	tggaaattcc	tcacaccttg	360
cactttccct	acttttctga	attgctatga	ctactccttg	ttggaggaaa	agtggtagctt	420
aaaaaataac	aaacgactct	ctcaaaaaaa	ttacattaaa	tcacaataac	agtttgtgtg	480
ccaaaaactt	gattatcctt	atgaaaattt	caattctgaa	taaagaataa	tcacattatc	540
aaagccccat	cttaagtcct	cggatgtgtc	cttgaatcaa	tatttttgca	aattatacaa	600
aacaagattt	ttccaaaatg	taggtaacag	agtgtaatcc	ttatttctca	tttatccccc	660
aagttattaa	gtgatcctga	attgtaggtc	atatatgtca	tcactcttagt	gtggagggca	720
acttgactga	taaagagacc	ttccttcaga	ttttcagaaa	gtataagatt	ccacatgatt	780
ttcccagcca	cacagtactt	tttaactttc	aaacaaattc	cagtcctaata	atgaaagata	840
aaaattaaat	agaaacagag	agaaagtata	tcgatcctta	ccttttgcta	tattttatag	900
ctgttgctgt	tactttatgg	gttctccagt	atgtgctgtg	gcatttagac	tgtgtcgagt	960
ttaatgaatt	tacacaaca	aaaaatttac	tgaaccagaa	aatagatgca	cttaaaatag	1020
ttcaatattt	gccaaagtgg	tggttcagca	tatcacccac	atgcttcagt	gacctgacct	1080
cacgacttgc	tagctggaga	gaaatcaatc	tccagccttc	caaaccagct	acctgttgct	1140
aatttgaaaa	gcaaaatgat	gagttctatt	tcagcatttt	gaaaggagaa	aatcatttgc	1200
agcctctcaa	actaacaana	gttcaacaaa	agacttctta	ctgtaatagt	gtttaaagtt	1260
tcacacttac	atgtccactg	tcatacatat	acatacacag	gcacaggcag	aacttgcttc	1320
tatagctgca	aagtgggttt	tatgacctta	tagcatatta	ttatatgttt	cctcttagca	1380
ataaattggg	gaaaaactta	aatgccaa				1408

&lt;210&gt; 320

&lt;211&gt; 1562

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 320

tattggccag	gctgggtctca	aactcctgac	ctcgtgatec	accacacctg	gcctcccaaa	60
gtgcagagat	tacaggcatg	agccactgca	cctggcctca	agaaaaatta	tatatcacgt	120
ggaataggat	agtagtctct	gcactgattt	tcgttgataa	tggctgttct	tcttatcacc	180
attttgctat	ttctttgtct	gggctattac	agggttatta	cagaaatttc	cagaaagacc	240
cctgcctgtc	gaatgtttac	ttcaagcttg	agctcctggt	atattatgag	gaaattatat	300
gatacccccag	gagaggctct	cctttcccat	gccattgtaa	aattcctaaa	gtaaaattaa	360
tttgctctct	tgtcaaagaa	ggagccaatg	ttgttttaaa	attttagctt	gagagatagg	420
tggggaagaa	attaaataga	caagtaatca	ctattcagaa	gagaaggagg	agtcattgta	480
cgaggcccaa	gatacttgcc	caaaaatata	gcagagaaaa	actagtcttt	ggggctctat	540
tttttgagtg	gaacatttga	gttattttaa	attagaattt	tattttgggc	agattagaat	600
ttctagggta	tgtcatatgt	gttttttaaa	tgaagctctt	taaaactcct	attgtagtgt	660
aatgtcatta	tccattaatt	tacataaaat	tgatttggat	ctctattttc	atcgtagact	720
gtgtaggggc	aatttttctt	aaaggttctg	tgacatagtg	ctaccttttt	tttaaaacct	780
gtcttgccca	ggcattattg	agtgcctcct	ggtgccagca	tgtgtatttc	acgactgtat	840
caacaaatca	tgatcatctt	ctctggccat	tgtgcctttt	cagattccaa	acttggtacc	900
tctcagtcct	tcctacaaac	ttagaaagtc	taatatctta	atgtttactt	atgtagcaac	960
ctccctttct	cccatcccta	aatcctcttg	taatttaatta	ttttcctttg	gaacttttta	1020
aatctacaat	ttccttataa	tatggtaacc	aatattaatt	ttcttgttct	gcgccaggtt	1080
tgattttata	caaattgttt	ccagtttggg	tcattgagcac	aaaaccagggt	atttttataa	1140
atctatatata	cccttcaatg	aggcagtatt	aattttatta	actcattaat	tcaaccaata	1200
attcttgatt	gtttactgtg	ttagatatgg	gggtatcccc	aatacctgac	agctgtgagc	1260
aaaacaaatg	ccctacacac	atgaggtgta	cagtcagta	gaaaagataa	acaataagca	1320
aattaataga	taatatgatg	tccaataagg	acttcaaagg	aaaataaagc	agagtaaaga	1380
gccagagaat	gacagtgagc	tgtttttcac	atgagtcata	agaaaaggcc	tcttttaaga	1440
attgacattt	gaacagaaaa	acgaatcaag	ggcgtcaact	gtttattgct	tttattgctt	1500
accatttgac	caagcaattt	tacacatagg	attcccccta	aaaaaaaaaa	aaaaaaaaaa	1560

245

aa

1562

&lt;210&gt; 321

&lt;211&gt; 1562

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 321

tattggccag	gctgggtctca	aactcctgac	ctcgtgatcc	acccaccttg	gcctcccaaa	60
gtgcagagat	tacaggcatg	agccactgca	cctggcctca	agaaaaatta	tatatcacgt	120
ggaataggat	agtagtctct	gcactgattt	tcgttgataa	tggctgttct	tcttatcacc	180
atthttgctat	ttctttgtct	gggctattac	agggttatta	cagaaatttc	cagaaagacc	240
cctgcctgtc	gaatgtttac	ttcaagcttg	agctcctggt	atattatgag	gaaattatat	300
gataccccag	gagaggctct	cctttcccat	gccattgtaa	aattcctaaa	gtaaaaattaa	360
tttgccttct	tgtcaaagaa	ggagccaatg	ttgttttaaa	atthttagctt	gagagatagg	420
tggggaagaa	attaaataga	caagtaatcg	ctattcagaa	gagaagggag	agtcattgta	480
cgaggcccaa	gatacttgcc	caaaaatata	gcagagaaaa	actagtcttt	ggggctctat	540
tttttgagtg	gaacatttga	gttatttaaa	attagaattt	tattttgggtc	agattagaat	600
ttctagggta	tgtcatatgt	gttttttaaa	tgaagctct	taaaactcct	attgtagttt	660
aatgtcatta	tccattaatt	tacataaatc	tgatttggat	ctctattttc	atcgtagact	720
gtgtaggggc	aatttttctt	aaagggtctg	tgacatagtg	ctaccttttt	tttaaaacct	780
gtcttgccca	ggcattattg	agtccccct	gggtccagca	tgtgtatttc	acgactgtat	840
caacaaatca	tgatcatctt	ctctggccat	tgtgcccttt	cagattccaa	acttgttacc	900
tctcagtcct	tctacaaaac	ttagaaagtc	taatatctta	atgtttactt	atgtagcaac	960
ctccctttct	cccatcccta	aatcctcttg	taattaatta	ttttcctttg	gaacttttta	1020
aatctacaat	ttccttataa	tatggtaacc	aatattaatt	ttcttgttct	gcgccaagtt	1080
tgattttata	caaattgttt	ccagtttggg	tcatgagcac	aaaaccagggt	atthtttaaaa	1140
atctatataa	cccttcaatg	aggcagtatt	aattttatta	actcattaat	tcaaccaata	1200
attcttgatt	gtttactgtg	ttagatattg	gggtatcccc	aatacctgac	agctgtgagc	1260
aaaacaaatg	ccctacacac	atgaggtgta	cagtccagta	gaaaagataa	acaataagca	1320
aattaataga	taatatgatg	tccaataagg	acttcaaagg	aaaataaagc	agagtaaaga	1380
gccagagaat	gacagtgagc	tgthttttcac	atgagtcata	agaaaaggcc	tcttttaaga	1440
attgacattt	gaacagaaaa	acgaatcaag	ggcgtcaact	gtttattgct	tttattgctt	1500
accatttgac	caagcaattc	tacacatagg	attcaccccta	aaaaaaaaaa	aaaaaaaaaa	1560
aa						1562

&lt;210&gt; 322

&lt;211&gt; 230

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 322

caggcatgcg	ccaccacacc	cagctaattt	tgtatthttta	gtagagatgg	ggthttctcca	60
tgthgggtcag	gctgatctca	aactcccaac	ctcagggtgat	ccaccaatct	tggcctccca	120
aagtgtctggg	attacagggtg	tgagccactg	cgcttgccct	atthttthttt	thttthtttaa	180
gaaaattcaa	gggaagattg	tccagtactc	tcgtattaga	cacttagaat		230

&lt;210&gt; 323

&lt;211&gt; 4679

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 323

aaccagggtt	atgcattagc	tacaatcctg	tatggattat	tctthttattc	taatggggcca	60
agaaaatgat	ggatatactt	ttgcagccca	attgcagagg	ttacacatcg	atactgagaa	120
tctccggggag	gagaaggaca	gtgaaatcac	aagtactaga	gatgaattgc	ttagtggccg	180
agatgaaatt	ttgtctcttc	atcaagcagc	agcaaagggt	gcctctgagc	gggacactga	240
cattgtcttct	ttacaagaag	agcttaagaa	ggtgagagct	gagcttgagc	ggtggcggaa	300
agcagcgtct	gaatatgaga	aagaaatcac	aagtctgcaa	aacagthttc	agcttagatg	360
tcaacagtgt	gaggaccagc	agagagaaga	agcaacaagg	ttgcaagggtg	aataaatgta	420

246

ttttacataa	agctgttaac	ttttgacaat	gataacttct	taacttgttt	aaaaaagaaa	480
catgcaggct	ttttttttct	ttgttagcta	tcagttgtat	aaaccaatgt	ttttaaatcg	540
gagctaaaaa	tgtattttca	ggtctgcaag	ttctacttaa	atztatattt	ttttacggtt	600
ttatatttta	ttttaaaatt	gttaaaaaatt	gcttgcttta	taaaagtga	gtggaaaaaa	660
atactattgt	tcaagtacaa	gctgatagca	gtccttgagg	tatacatgca	aagtaacagg	720
aatcatataa	ttaaccatgt	aaaatctact	tgcttttaag	ggggcaaaaa	gtatgttctc	780
ctctgaaatc	ttttccttta	tcctttgaag	tattatggaa	gttatatttc	tgtattaaca	840
aatatgtttt	gggactattt	taggtgaact	agagaagttg	agaaaggaat	ggaatgcatt	900
ggaaaccgaa	tgccattctc	taaaaaggga	aaatgttttg	ctatcatcag	aactgcaacg	960
gcaagaaaaa	gaattgcaca	agtatgcaag	aactactctg	tttttcagat	ataaaaatatt	1020
tctttatctt	aaattttcat	ctaaattaaa	tttaattttta	atacttaaat	attttacagg	1080
agcaaagtgt	cagcccatct	ctgtttggct	atltggcagg	ttaaccatac	tgaataaata	1140
cttcagcttt	tttttttctt	gccaccacca	ttctcttaca	tgctctttcc	ttgtactcat	1200
ggaatctga	tctcattaat	gtcccaaaga	aacctgaac	aaacaacaaa	agtctgtaat	1260
tcatagttga	acttgccctg	taaactaata	aatttc aaat	atcaactgct	tttctttcac	1320
accagtgtac	tcttctttta	gtaaacgtga	tcaggaagtg	actataatga	agaatttgta	1380
agactgggctg	tggtggttca	cgctgtgaat	gccatcactt	tgggaggctg	aggtgggagg	1440
atcgcttgag	cctgagagtc	caagatcagc	ctggacaatg	tggcaaaacc	ctgtctctac	1500
aaaaaaatc	aaaaatttac	cgggcatagt	gatgtgtgct	tgtagtcttg	gctacttgga	1560
aggctgaggt	ggggaattg	cttggggcca	ggaggtcaag	gctgcagtga	gccacgatca	1620
tgccactgca	ctccaacctg	ggtgacagag	ccaaacctta	tatcaaaaca	accaaaaaaa	1680
aaaatggaat	ttgtgctact	gaaagatata	aattaatctt	ctgaatttca	aatagggttg	1740
tatgaagggt	aataatata	aagaccaata	attctctgaa	accagttaaa	tctttctagt	1800
atctaatact	tgacaagcaa	atcagtgaat	gcattagatt	tattccagca	aatttaata	1860
agtcctatct	taccaccaca	gtttgccata	tttaagttta	aaatgggttt	attccggccg	1920
ggtgtggaca	ttatgaaaca	acatctctac	aaaaaataca	acaaattagc	ctggcctgta	1980
gtcccagcta	ctcaggaggc	tgaggtgaga	ggatcacttg	agcctaggag	gtggggactg	2040
caataagcca	tgatcacacc	actgtagtct	agcctgggca	acagagccag	tcccatgtct	2100
caagaaaaca	tgaataaaaa	taaaaacaaa	tgttttacat	tgttttataag	atgtaaaaaa	2160
ctttgtaaaa	gcaattccaa	aataggaatg	ggacaaaata	aaggtaaaaa	ctataaatat	2220
atgtatatga	tatatatcat	atatgaaata	catatgagat	ctatacatat	ctcatatata	2280
gctatatata	taaatttttt	ttttttgaga	cggagttttg	ctcttggtggc	ccaggctaga	2340
gatcagtggt	gcgatctcag	ctcatcacaa	cctccacccc	ctgggggtcaa	tcgattctcc	2400
tgcttcagcc	tcctgagtaa	cttggattac	agacatgtgc	caccatgccc	acctaatttt	2460
gtatttttag	tgatgacggg	gtttctccat	gttggttagg	ctgttctcaa	actcctgacc	2520
tcagggtgatc	tgcccatctt	ggcctcccaa	agtgtctggga	ttacaggcat	gagccactgc	2580
actcaactca	taattttttt	tttttttttt	gaggcagagt	cacattcagt	tgcccaggct	2640
ggagtgcagt	ggcatgatct	cggctcactg	cagcctccgc	ctcccagggt	caagcgattc	2700
tgctgcctca	gcctcctaag	tagctgggat	tataggtgtg	tgccaccatg	cctggctaata	2760
ttttgtatct	ctagtagaga	gggggtttca	ccatgttgat	caggctgggtc	tcaaaactcct	2820
gaccttggtc	tccttaagtg	ctgggattac	aggcgtaagc	cactgcccctc	ggccgaaagt	2880
attgatattt	taatgattca	ggctagatcc	cttattttta	agatgtgatt	aattggaatc	2940
tggcagattc	ttaaatactg	ttttcaatta	tttcaaat	taagtgttgg	gaagcaagcc	3000
tacaaactcc	tagtgagtag	aagcacatgg	tttaaaaaata	ttagggccca	gaaagggggc	3060
ctataagtca	ttggtcagat	catctgccta	aactcacata	aagtatttaa	gacagattaa	3120
ttctttttct	taaacttttc	tgtatgccta	aatttgcttg	ataagcctcc	ccagcattta	3180
agtagtatct	agaagctagt	cttcctttac	agggtcttat	gtgccattta	attcctagct	3240
gtatttggtt	gacaacatca	gaccacccc	aaagaatctg	tgaagtgtac	aatcaaaatg	3300
ggattcagac	tctgtagtag	ttcaattacc	atagtgagtc	tgagtcttga	atgatccatt	3360
ctgaaagatg	taaaactgtc	accttgaaaa	ccttatactc	ctttagctat	ttatggggagc	3420
caaattccct	aacacagcta	tactgtacag	accttttatt	ttctgttgtc	tgggctacgg	3480
aagaaggaat	tgaagaagga	atttctgttc	acacatatca	agctgttctc	cacatatggt	3540
gtaagtgcaga	ttttttttta	catccagtta	taaaagtgat	catagagact	gtggtgggtc	3600
acacctgtaa	ttccagcact	ttgggaggcc	gaagcaggca	gatcacctga	ggtcagaagt	3660
tcaacaccag	cctgaccaac	gtggagaac	ctcgtcacta	ctaaaaatat	aaaatgagcc	3720
aggcatgggt	gcgcatgcct	gttaatccac	ctactcagaa	ggctaaggca	ggagaatcac	3780
ttgaacccgg	gaggcagagg	ttgcagtgg	ccgagatcac	accattgcac	tccagcctgg	3840
gcaacaagag	cgaaactctg	tctcaaaaaa	aaaaaaaagt	gatcatagaa	tttattaacc	3900
ttgggaacag	cctcagaagt	taatgaattc	aatcctgtta	tttggcagtg	aagggcactg	3960
agactctgct	tgtgttagtt	atgtctgtat	tacgtgggtat	ctggtatagg	tctaagagct	4020



247

gaggaagtgt	ttactctgaa	aatgaaatgt	accagttaag	tgacttgctt	aatatcccc	4080
agctaaatag	tggcagagct	aggggtctag	aactcagcct	cctacttctt	tgtcttatgc	4140
tcttttctca	atttgggtgtg	tcttctcatt	tgaacagggt	tatctttact	tgaattgaca	4200
gtgactccta	agctttaagt	ttctgacccc	cattctatct	gtcaagtatt	taaacttaaa	4260
agaaattggt	gaaacatgtg	tgttcttttc	ctgtagaaga	cctacactga	gtcttttcat	4320
gatgaaatta	atacaatttg	atacaacaaa	atatacagtt	aattacctcc	tatttctggt	4380
tttaaaattt	caacctttgt	gtatatattga	tgggacacac	ctttaaaactt	gcattttttt	4440
agtgttttga	tggtttttgc	ttattgaatg	aaaatatttc	attctttttt	atacttttct	4500
tttttctct	gaaatccact	ctatcccttc	tagtgaaatg	tataagaaac	tggacttcc	4560
tctgtgtcca	gtttctacct	gtgaataact	atctgtcaat	atttatattg	cagttctcag	4620
aagcagagtt	tagagcttac	cagtgatctc	agcatccttc	aatgtctag	gaaagaact	4679

&lt;210&gt; 324

&lt;211&gt; 230

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 324

caggcatgcg	ccaccacacc	cagctaattt	tgtattttta	gtagagatgg	ggtttctcca	60
tgttggctag	gctgatctca	aactcccaac	ctcagggtgat	ccaccaatct	tggcctccca	120
aagtgtctggg	attacagggtg	tgagccactg	cgctggcct	attttttttt	tttttttaaa	180
gaaaattcaa	gggaagattg	tccagtactc	tcgtattaga	cacttagaat		230

&lt;210&gt; 325

&lt;211&gt; 2835

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 325

gggcacacag	ggctggcagg	cccgcggtgg	ctggtgttga	ggcatgaaca	aattgtaccg	60
ggatcccc	acccactct	gaccaccagt	tcctccttgg	atatcactcc	ccctgacagg	120
cagccacccc	aggcctggat	ttgtccctgt	ctcccccttt	tgcttttccc	ccatgactaa	180
tgggcaccag	gtcttgtctg	tcctgcttct	cacctctgca	gtggcagcag	gccctggcc	240
ccaggtgcat	gccggtcag	ggggttggat	gtgccttct	ccaggcctgc	cctctgtcca	300
agcccgaggt	gggcttgggtg	ggctccctgg	tggcccccag	tgggtgccag	gtggtgccc	360
gggttattga	ggggtggtt	tatcactgta	gggacaggct	tcctgcccc	gcctggagag	420
ctgttttctt	caggaagggt	ctggagatgg	agacttgttt	gcgaattcac	cacaactcca	480
ggctgggagg	ctgggtctcc	gctctcagag	ccgagacacc	agggaggata	gccaggctgc	540
cctgcctggg	aattctgctg	ggcgtcaaaa	ttcaacccgc	accaacgtgg	gcaggagggc	600
cacagtgtcc	tgccaggagc	agagggtcga	aggctcgcag	gaggaagaac	cactatcctg	660
gtggggggc	cctgctgccc	accctgcccc	cagcgtgcct	ggggggagca	cacctgggca	720
tggaggagtc	caggggtgctg	ggccacacaa	gagagggtggg	ggagaggcct	ggacagtagg	780
aagatcttgc	ccagggtcct	ggatccgcca	ctctgggggt	gaccttggac	aaacctctgc	840
cttgccctc	agtctcccca	tcaaggtttt	tccattcagg	aggttttggg	ccatcttcag	900
ccacctacc	agccctgaaa	aggatgtgac	tcctgtttct	gggaagtgtg	tgggtgtgta	960
ggtgggccta	cagccctggt	tgtggggagg	gaaggatgga	gagacagcac	agtgcacag	1020
cccagactgc	aggctggagt	gaggttcca	cttccccgct	gctgtgtgtc	ctggaccagt	1080
gcctctgaac	cttggcactt	ggggcagtg	atattaacat	ctttccaagc	ccaattcttg	1140
gggcatcagg	gcctccggct	ctctgggagg	tggcaggctc	tcagattgga	gatgccatgg	1200
gggggggagg	tgcctctct	ttggagggtta	tggaaagtga	gacaggagt	gcctggcgca	1260
gctgcctggg	ttcttagggg	ctgggcccgg	ggagcccatg	gggcttgtgc	ctagaaagcc	1320
tgggtcctc	actggggtct	agatgtgcag	acttcatgtc	tccccagctc	cagctctgtt	1380
ctctataggt	cagcctccac	aatgccagag	gccccagggt	agccccctcc	acgtccctcc	1440
tagatctaca	gctgcccctt	tgatgacagc	gccattgagt	cccctgggct	gggggggtca	1500
tgcaggggtg	agtcagctgc	ctgccgccc	tactcattgc	ctggccaggc	aggacacagg	1560
ctggcgggca	ctgagagtgg	gccccacgaa	atccattgtc	aggttaccag	gatgaagaac	1620
ccaggctggt	cgtggagtgc	agggcggggc	ctgccggaag	aattatgggc	actgcagcag	1680
gagggcagcc	tgggccaatta	gctcctgatg	tcattcgattt	gggtgagggg	acagggaagt	1740
cagaggaagc	tggccagtgg	ctctcacgaa	gacttacagc	agcggagtgg	tgcctgatcc	1800
ctagtacagc	tgctcccact	gagtcctcag	ggatctgtgg	ttcaggaccc	cctgcaaccc	1860

248

cctcccagac	ccctgtactg	gtgggaggag	aggacctaga	ggaaagggtgc	tgggcagata	1920
agcagccgag	ggaggccctg	ggtttagctt	atcagtcctc	tgggccctcc	tgccccagga	1980
agggcagcga	ggaccatggt	gttgcccctg	tcacgcgttat	cgctcctggcc	atgagcttgc	2040
aggactggga	gggcccggagt	cagccaggca	gaaggcagca	cagcatttgc	ctgttggcag	2100
gtggccttgg	tggcttccca	aaggcaatcg	ctccacgcag	aacaaaactc	acttttttgg	2160
ggggtgaagc	accttggttc	atttgtttag	ttcgtaatt	ccagcagtct	gtttctaagg	2220
gaaacatggc	tgcagccggt	cctgcccctc	cacccaccca	ccagggtgcc	agtgttccca	2280
agggccccga	atcccaacct	tattcaggcg	tcagcatctc	tgaccccaa	atgcctgtta	2340
gggaggatag	tgaaggctga	gccctcctgg	gctcatcaaa	agccagcagt	gagagaacac	2400
ccccatctct	ctgagggtgac	cttgtagggc	agtccgtgct	gtctggctgg	cctgggtgag	2460
gtgggcaggg	accaaggcct	ggcgccctggg	cctcgctggc	cttgctctgc	gtgctgactt	2520
catcctgata	gtaccttgat	tttcctactg	tgacttcccc	ttctgtcgac	ttcctcacca	2580
acttttaaat	tccgtattga	gagcagtttc	ctaagttacc	tcaaatccta	ttcagaagaa	2640
ggttcttctc	ggaagtggg	agggcgga	acaagtttag	tcacagaaga	ctactccatg	2700
tttgagcttc	tgtttcaagg	gaagtgaagta	actgccggag	gagccctgcc	cctctgcagt	2760
gtgtggtgtt	gccctgatac	ttttcagatt	gaggtgttac	ttacatgtaa	taaaatgcac	2820
agacttaagt	gtata					2835

&lt;210&gt; 326

&lt;211&gt; 142

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 326

cctgtactcc	cagctactca	ggaggctgag	gcaggagaat	tgcttgaacc	caggaggcgg	60
aggttgacgt	gagccaagat	tgcgccattg	cactccagcc	tgggcgacag	agcaagactc	120
catctcaaaa	aaaaaaaaaa	aa				142

&lt;210&gt; 327

&lt;211&gt; 489

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 327

tgcgggacgg	cggcgccctc	acgcctctcg	agctgctgct	gcgccagctg	ggccgcgacg	60
ccggggccac	tccctccgcc	gccggagccc	ccgcctcagc	tcccggggag	ccgcgccagc	120
gccgcctgct	gctgctggac	ctcctggcgc	tgtacacccc	cgtgggtgcc	gccggctcgg	180
cccgcagga	gctgctgggc	gaccggccgc	gctggcagcg	gctgctgggt	gaggacaagt	240
tccagtggct	ggcgggcctg	gcgcgcacct	cgtctctcgc	gcgcgccatg	cagggtgctgg	300
tcaccgccat	ctctccaggc	cgttcccccg	aggccctgga	cgagctgccg	ctgcccccat	360
tccctgcagc	gttggaacct	actggcaaaag	gctaggcccg	gagcaccta	ggcgtggat	420
tttgggacaa	aactatTTTT	cagagcggtg	taccggcact	ttatatatat	tgatctctgt	480
acggcacaa						489

&lt;210&gt; 328

&lt;211&gt; 4503

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 328

tcgccagctc	gccccggcac	tgcgcacttg	ccagccagtc	cgcccgctcg	gagcccggt	60
cgtgggggca	gcatggcggg	gtcgccgctg	ctctgggggc	cgcgggcccg	gggcgtcggc	120
cttttggtgc	tgtgctgct	cggcctgttt	cggccgcccc	ccgcgctctg	cgcgcggccg	180
gtaaaagggtc	gacccagtc	cggcgagggg	tgggggttgg	gggaggatgc	caccggcgag	240
ggttgggggt	ggggctgcgc	cgcctcacc	ccgcccgagc	cggctcccgg	gacgtgcgga	300
gagatcgacg	agggtggccc	gggctccggc	cgcgggtccg	cgcggggccc	acgcgggcac	360
acctgagacc	tgacttggtc	tctgcctgtg	cgggtggcgt	tgtccggggc	gccgccggta	420
accgtgccct	gccacacct	ccgtgcccgg	tgctgtgac	gctgtccacg	gactaaggc	480
gctttaagaa	agggcgcgcg	cgcacagtg	tgtgtgcgtg	tgatgtgagg	agagcgggtg	540
ggagggtgtc	tgtccttgaa	agtgtgtgtt	ctttgggttg	agcgttcca	agtgtcctag	600

aaaggtgccg	tgggtgcgtct	gggtgtgtag	tgtgtgtgat	accgggatac	ttctgtgcgc	660
gattcttttg	tgcgtccgat	tgttttctca	gtgacaccgt	gtggatattt	gtgaatcctt	720
attatgtgtg	ttggcttggc	ctatgggcgt	gtctctctct	ctctctctct	gtctctctct	780
ctctctgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgatt	tcgtttgtgt	ttgagagggga	840
atggctcttcg	catctccgtg	tgcacattcc	atagtggttc	tgttggaaca	agtgcctggg	900
atttcgtttg	cgtgttcctg	agactgtttc	tctccgtttc	tttgtggagc	tgtgtcatcc	960
tgaggagagg	agccatgatg	tctctctgct	gcatttgtgtc	tttaaggatg	gtgcatgtcc	1020
ttgcacctgg	gtggcttggc	gattgtaact	gcaggagcag	ctgcggatgt	gaacgtgtgc	1080
aggctccttgc	atgtggctgt	ggcagtgttg	ggctgtatat	gtgacatctc	caggcctgtc	1140
agtcctcatg	agtgtgtgtg	aggctgtgat	tgtctggtag	tgtgatcccc	cgggggtgact	1200
gaggagtggg	ggggcggcagc	aagggcactt	ggagaggcat	cctcctctag	ctcttcaata	1260
ctgtcttgcat	caaagatggg	aattaaaaaa	aactgttacc	ttatatccgt	gtaacaatgt	1320
gtttaatata	tatgtacaat	gtaaagaatg	agcagaaaaa	aactctctcg	tgtagcagtc	1380
actcagctta	ataaatagag	cctgaccaag	agttagaagc	ccctgcgtgc	ccctcgccat	1440
ggcagccctt	gtccccccac	agtccttatt	ctgtattttt	tgtccattga	tcccttactt	1500
ttgtttgtag	cttatcacat	atgtgtagct	ctcaaaaaaa	atccattggt	tagtttttcc	1560
tgtttttgaa	catcattgaa	acggaatcat	actgggtgac	tggttccctg	tagtcactag	1620
gggtcactag	gaagtccctca	gggtgtctag	tagtctcagg	cagtctgcag	tgaaattctg	1680
gaacttgacg	tttttttttc	ccttggctct	attctgggtca	cgagattcat	ccaagttgat	1740
gcatgtggct	gtaattcatt	tattttttatt	gctgcataat	attacatcct	atgaggacat	1800
catgatttat	atatgtattc	tcaatttgct	agtggacatt	ggactgtttc	caggcttttc	1860
tttctccccc	gcccttttat	gctattacga	acagtgtctg	tgtcatcttt	cacgaacttg	1920
tgaccagtag	cgtatgtgcc	aaagctgtct	tggggagtga	catcccagga	gtgggtcata	1980
ggatatgtgc	atcttttttag	atattgtcaa	accgctctgc	aaaattactt	tgccagttta	2040
attctcacca	gcatagtatg	agagttccca	tttttctgca	ttcatatcaa	cacttcatat	2100
tatcagactt	tttgatttgg	gtcaatcttt	tggttatatt	atgcatagta	tctccctggc	2160
attttaattt	gctttccctt	gattactaat	gagggttttta	attttatttt	atgtttgtta	2220
gagacagggg	cttctctctg	catgcacgct	ggagtgcagt	ggtgcgatct	gggtcactg	2280
caaccttgag	tttctggact	cagggtgatcc	tcccacctca	tcttcccaag	tagctgggac	2340
tatgggcttg	tgccccgctc	attttttttg	gttttatttt	ttgtagagac	aggggtctcg	2400
cattttgacc	aggetgggtc	caaactcctg	gcctcaagcg	atcttctctg	cttggcctcc	2460
caaagtgcgt	ggattacagg	catgaaccac	tacacctggc	ccaatttttc	atatgttttag	2520
taatcatttt	tgtgaaatag	gcgatcatgt	attttttcta	tttctgtatg	agtttggttt	2580
tctcttacta	cttttttagga	attctctgta	tcttctgtgt	actactcttt	cattgactat	2640
ttgtgttgca	ggcatcactc	cttttaaaca	tatttatatg	tggcctgtat	gtttcttttc	2700
caaaccttca	cagtcatttt	tatgatcttt	tattccttgc	tcagattatt	ggtaccctct	2760
tttatttctt	taaacttgtg	gaaattgttt	gaaaactgct	tgaaactgaa	atttgtcatt	2820
gggtaattta	ttctacagat	gaacttgtac	acatgccaaa	tgatataatga	acaagtttat	2880
tcataatatt	cctattgtcc	acaatattaa	atatggaaaa	atctataact	gtcatatcta	2940
ccatcactac	tcttatgaag	aaactcggct	tccaggagtg	gggggtggga	gggaggaaat	3000
atgagagtca	ccaagggatc	actggcgcgc	tgtgggggtg	gggtgggggg	tgtctggggg	3060
tcttttgggt	tcttaagtgc	gtctggagat	atttgggtgt	ttccagtggc	cttaggggtg	3120
tccgggtata	tttggatggt	cacgggtgct	ttgggtggcat	ctgggatgtt	tgaggcctac	3180
gaagcttccc	gggtcggggg	tccctgtctc	gacggacgct	gacaaaactc	tttccccccac	3240
ctcattttcc	cgcaggagcc	ccgcggccta	agcgcagcgt	ctccgcctct	ggctgagact	3300
ggcgtctctc	gccgcttccg	gcggtcagtg	ccccgaggtg	aggcggcggg	ggcgggtgcag	3360
gagctggcgc	gggcgctggc	gcactctgctg	gaggccgaac	gtcaggagcg	ggcgcggggc	3420
gaggcgcagg	aggctgagga	tcagcaggcg	cgcgtcctgg	cgcagctgct	gcgcgtctgg	3480
ggcgcctccc	gcaactctga	tccggctctg	ggcctggacg	acgaccccca	cgcgcctgca	3540
gcgcagctcg	ctcgcgctct	gctccgcgcc	cgccttgacc	ctgcgcctct	cgcagcccgag	3600
cttgtccccg	cgcccgctccc	cgcccgggcg	ctccgacccc	ggcccccggt	ctacgacgac	3660
ggccccgcgt	gcccggtatgc	tgaggaggca	ggcgacgaga	cacccgacgt	ggaccccgag	3720
ctgttgaggg	ggccgcaggg	gggtggggag	gggtcgggcg	cctgcgtccg	gagaggacga	3780
gggcgaggaa	ctgggaagcc	tgtttacccc	gtggagtgcg	aaaccctaag	tcttggggcc	3840
taagagggag	tgagggtcctg	gatccaggga	gtccaggcaa	ggatgcctgg	ctgactcagt	3900
gggggaagtg	gaccccgagg	cctgggaagg	ggagagggag	gcgggggaagc	cacagttttc	3960
tgggatgaaa	ggcgatgacg	gctgtctact	gaaagcagtg	ggctgaggac	gccttcttgg	4020
ggagggaacc	gtgtccccag	gcagtatgtg	gttgtggatc	ctgcgttctg	ggccccgagc	4080
gtggggcggg	ggaacgcccc	accgcggaca	cgcctcactc	gctttgcgct	cggccctgca	4140
ggtacttgct	gggacggatt	cttgccggaa	gcgcggactc	cgaagggggtg	gcagccccgc	4200

250

gccgcctccg	ccgtgccgcc	gaccacgatg	tgggctctga	gctgccccct	gagggcgtgc	4260
tgggggcgct	gctgcgtgtg	aaacgcctag	agaccccgcc	gcccaggtg	cctgcacgcc	4320
gcctcttgcc	accctgagca	ctgcccggat	cccgtgcacc	ctgggaccca	gaagtgcgcc	4380
cgccatcccg	ccaccaggac	tgtcccccgc	cagcacgtcc	agagcaactt	accccgccca	4440
gccagccctc	tcacccgagg	atccctaccc	cctggcccca	caataaacat	gatctgaagc	4500
agc						4503

&lt;210&gt; 329

&lt;211&gt; 959

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 329

gggtttcacc	acgttggcca	ggctgggtctc	aaactcctga	cttcagttgg	cctcccaaag	60
tgtctgggatt	aaaggcatga	gccactgcgc	ccggcctacc	tttctaactc	tacttctagc	120
ttcttgcttc	tgggctgctg	ctataccaaa	caggaatgta	atactttctg	tcagcttcag	180
gcctttgcac	atgcagttca	ctttgtctat	cttggttttt	attcttagga	ttttaattct	240
cctaagaagc	tttctctgac	cagcctaaaa	cttaocgtaag	ccctgggtta	ggtgctatgc	300
ttatgtcctc	ccatagcatt	ttgcatttgc	atgtgttgta	actcttaatg	tacagcatca	360
tgattgccta	ttttaacttt	cctgtttggt	acagtagact	ttaatctctt	taaggacagg	420
aactgtgtct	tgtttagaat	cccagagct	tatttagtac	aatggctatg	cttataattt	480
aagtatttat	tgaacaaatg	aaattttcct	aagccctaaa	accttgcaag	atgttttagt	540
gcaggaaact	ggcctcgggt	gagttgaata	actagcacga	ggtcactcac	ctaaaaagtg	600
gtgaggaggg	attaaaatct	aaatctgttt	agctgtaaag	attgggcttt	ttttcttgct	660
gctgcacatg	actgctctct	ctcatgttgc	ctttacacat	ccctgtcaag	tgttcaaaca	720
gcccgtgcct	aacaacccca	tccatagctt	ctgaggaaaag	ttgtgtcatc	tttgacagc	780
tctgagagct	gaagcgagtc	tttcagaaat	aatctcccat	ctattgggtc	taatttatgc	840
tttgagaaat	ataacttatt	ttcaaaaaac	aaataattca	gaatttgta	tctccttaag	900
gtccatttat	tagtttattt	cattccttca	ttcactgata	accatttact	gagcaccag	959

&lt;210&gt; 330

&lt;211&gt; 441

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 330

acattagttc	tgtgtagtgc	taatcagtgt	cctttgggga	taaaaagagg	atccttgaca	60
aaaaatggcc	aaagtgaat	gcctttcttt	actgcagaat	tattattcag	agccttggtg	120
cttatttgcc	tatgaccctt	caagagggaa	gatacattac	gcgggtgttac	tcagacttac	180
ttggtcatgg	accgctgttt	gtgagaacac	ctaataaacg	tttcatgcta	tgactgggtg	240
gtagtggagc	ccagttgagc	agttctgggt	tagtctatga	ataaaaaaat	gaatcatttt	300
gtataagata	gcttggtaat	cgtgggaaaag	gacttttctg	agaacaagat	acatcttcaa	360
ggtaacgtag	actcttaagg	atgaatgtga	tttcaaagg	catctaatac	aatgcccact	420
aacaataata	atagtagcag	g				441

&lt;210&gt; 331

&lt;211&gt; 780

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 331

aattttcagc	ctttttggac	tggtttctcc	acatcttcgt	ggatttatct	aactttggtc	60
tttgatgttg	gtgaccttca	gattgggtct	ctgagtgaac	atcctttttg	ttgatgttga	120
tactattcct	ttctgtttgt	ttgtttgttt	tccttctaac	agtcagggcc	ctctgtgtga	180
ggctctgctg	agtttggttg	aggtccactc	cagacctgt	ttgtctgggt	tttgccagag	240
gaggctgcag	aatagcaatg	attgctgcct	gtttttctct	tggaaagctt	gtcccagagg	300
ggcaccaccc	agatgccagc	cagagctctc	ctgtatgagg	tgtctgttgg	cccatacttg	360
gagggtgcct	ccagtcagga	tacacagggt	tcaggtaacc	acttgaggag	gcactctgtc	420
ccctatcaga	gctcgaacac	tgtgctggga	gatccactgt	tctcttcaga	gctgtcagac	480
agggacgttt	aagtctgctg	aagctatgcc	cacagctgcc	cctttcccca	gatgctctgt	540

251

cccagggaga	agggagtttt	atctataagt	ctctgactgg	ggctgctgcc	ttttcttcag	600
agatgccctg	ccccaaagacg	gggactctag	agaggcagtc	tggctgcagt	ggccttgctg	660
aactgtggtg	ggcttcaccc	agttggacct	tccctgagcc	ttttttttta	ccctgtgagg	720
gtaaaaaatgc	ctaatacaagc	ctcagcaatg	gtggatgccc	ttccccccac	caagctcgag	780

&lt;210&gt; 332

&lt;211&gt; 780

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 332

aatttttcagc	ctttttggac	tggtttctcc	acatcttcgt	ggattttatct	aacttttggtc	60
tttgatgttg	gtgaccttca	gattgggtct	ctgagtgaac	atcctttttg	ttgatgttga	120
tactattcct	ttctgtttgt	ttgtttgttt	tccttctaac	agtcagggcc	ctctgctgca	180
ggctctgctg	agtttggttg	aggctccactc	cagacctgt	ttgtctgggt	tttgccagag	240
gaggctgcag	aataagcaatg	attgctgcct	gtttttcctc	tggaaagcttt	gtcccagagg	300
ggcaccaccc	agatgccagc	cagagctctc	ctgtatgagg	tgtctgttgg	cccatacttg	360
gagggtgcctt	ccagtcagga	tacacaggtg	tcaggtagcc	acttgaggag	gcactctgtc	420
ccctatcaga	gctcgaacac	tgtgctggga	gatccactgt	tctcttcaga	gctgtcagac	480
agggagcgttt	aagtctgctg	aaagctatgcc	cacagctgcc	cctttcccca	gatgctctgt	540
cccagggaga	agggagtttt	atctataagt	ctctgactgg	ggctgctgcc	ttttcttcag	600
agatgccctg	ccccaaagacg	gggactctag	agaggcagtc	tggctgcagt	ggccttgctg	660
aactgtggtg	ggcttcaccc	agttggacct	tccctgagcc	ttttttttta	ccctgtgagg	720
gtaaaaaatgc	ctaatacaagc	ctcagcaatg	gtggatgccc	ttccccccac	caagctcgag	780

&lt;210&gt; 333

&lt;211&gt; 127

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 333

caggagctct	tgtaaggcac	acttggtggt	gacaaaatct	ctcagcattt	gcttatctgt	60
aaaggatttt	attttctcctt	cacttatgaa	gcttagtttg	gctggatgtg	aaattctggg	120
ttaaaaa						127

&lt;210&gt; 334

&lt;211&gt; 127

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 334

caggagctct	tgtaaggcac	acttggtggt	gacaaaatct	ctcagcattt	gcttatctgt	60
aaaggatttt	attttctcctt	cacttatgaa	gcttagtttg	gctggatgtg	aaattctggg	120
ttaaaaa						127

&lt;210&gt; 335

&lt;211&gt; 1685

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 335

ccgggattct	gtgattccaa	caggcctggc	ttgtctctgg	tccacgacat	gtggggcctc	60
agctgggaag	acatggagtc	ttaagtgtga	tcagtgggag	ggggctggaa	tcatttagag	120
gcatcttcat	tcacaaaacc	aggagctgat	actggctgtc	agccaggact	tcaactgacc	180
tatgtagaac	ctgtccatgt	ggccctcct	tcagctctcc	ccatttgggc	tggtttgggc	240
ttcatcacag	tccggcagct	tacttctaag	ggcaagcatt	ccacgacaac	acagcagaag	300
ggcatggcat	ttttacagtg	aagtttgga	atctcatagc	gtcgcttctg	tcctacttta	360
tttattggtc	agggcaatca	caaagatgtg	cataggctca	aagaaaagag	acataacccc	420
gaccacgcga	tggaaagaag	gacacggtca	tgttatgaga	ggagtgtgtg	ggatgggaga	480
tagggctgtg	gccacctgca	gaaaaacagca	tctgctacag	gctgtcatgg	aagcgcagga	540

252

tgaggattta	gcctacctga	ggggtcagtc	agcaaaggcc	tctgggagga	agtgagatct	600
tcggctgagg	atgtgaaggg	ctaaaaggag	aatgaggaag	agtttcaggg	agaggaatca	660
atgaaacgag	tccagagacg	ctgggtgagtt	ggatgggtttg	cttcagtatg	atgacaatac	720
agaggggcaa	ggagactggg	gcaggagaag	agagaagggtg	ccatgtgctc	tgggtcgtgt	780
cttctatgcc	agactccctt	agaagaggag	cagcctccag	tcagcgggtg	cccaggaaca	840
cggaggctag	acaggacaat	ggcagccaat	ccctgctccc	aaactgggtga	cagtggggaa	900
aaqctgcatg	gtctagatcc	accctgctcc	ctggccccag	tatagaagat	caaattcaat	960
ctgcccattc	ttatccagat	aaagtaaagg	aagactggaa	aaaagaacta	atccacggct	1020
ccatctgccc	atgactttct	ctgctgatgc	cggaggcagc	tatggataaa	gagacggcac	1080
acggcatgtc	ccgacgcagt	ggaggtgggg	agacccccga	agtccacagg	aaaagagtta	1140
agttgctgcc	acctgggcat	ccgctattct	ctgctcttct	gcctcatcct	caattcagac	1200
catgatggag	ctgattttct	cccattttat	accttggatt	gaatgggtctc	gagctgctgg	1260
tcttgctctc	agagtacat	ccaagaggtt	tatctttcaa	ataaatgctg	tgtatcaatg	1320
tacagtatat	ataattaatg	catgatatac	gactaaataa	tagataagac	aagagatgaa	1380
attagagtta	agttagggacc	tgatgatgaa	gagccttgta	aatcagggag	agtctgcgtc	1440
atgtgcttct	ccagacacaa	tttcgacatg	gctgtaggca	tgtaccactg	atgacgcgga	1500
cactgaatta	cccgcctgtc	tgggtctgtg	ctctcaagtt	ttgctcattc	tgcttctgcg	1560
ggaaatgccc	tgactcaact	tgggaaaacc	cacttagatc	ttgttttgaa	acggagtcct	1620
gctctgttgc	caggctggag	tacagtggcg	cgatctcggc	tcactgcaac	ctctgcctcc	1680
cgggt						1685

&lt;210&gt; 336

&lt;211&gt; 1926

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 336

ttgggaggct	gaggcaggag	aatcgcttga	acccgggagg	cagaggttgt	ggtgagccga	60
gatcatgcc	tcgcaactca	gcctgggcaa	caagagcaaa	actcggactc	aaaaaaaaaa	120
aaaaaaaaaa	aaagacacag	tctcattcct	taatgagtat	aaagaagtaa	agtgtttcag	180
ttactaattg	cataagaaac	caatctaaaa	catagtggca	aaaaacaatc	attatcatca	240
gggattctgt	gattccaaca	ggcctggctt	gtctctgggtc	cacacgacat	gtggggcctc	300
agctgggaag	acatggagtc	ttaagtgtga	tcaatgggag	ggggctggaa	tcatttagag	360
gcactcttcat	tcacaaaacc	aggagctgat	actggctgtc	agccaggact	tcaactgacc	420
tgtgggcttg	aacctgtcca	tgtggccctc	cgcaatctcc	ccatttgggc	tggtttgggc	480
ttcatcacag	tccagcagct	tacttctaag	tgcaagcatt	ccatgacaac	acagcagaaa	540
ggcatgacat	ttttacagtg	cagcctgggt	atctcatagc	gtcgttctctg	tcctacttta	600
tttattggct	agggcaatca	caaagatgtg	cataggctca	aggaaaagag	acataccccc	660
gaccacgcga	tggaagaagt	gacaagggtca	tgttatgaga	ggagtgtgtg	ggatggggaga	720
tagggctgtg	gccacctgca	gaaaatagca	tctgccacag	gctgtcatgg	aagcgcagga	780
tggggattta	gcctacctga	ggggtcagtc	agcaaaaggcc	tctgggacga	agtgagatct	840
tcggctgagg	atgtgagggg	ctaaaaggag	actgaggaag	agtttcaggg	agaggaatca	900
atgagactgg	attccagaga	gaggctgggtg	agttggatgg	tttgcttcaa	tatgatggca	960
atacagaggg	caaggagact	ggtgcaggag	gagagagaag	gtgccatgtg	ctctgggtgg	1020
cgtctgtgct	cggacccccct	tagaagagga	gcagcctcca	gtcagcgggtg	tcccaggaac	1080
acagaggctg	gagaggacaa	tggcagccaa	tcctgctctc	caatctgggtg	acagttagga	1140
aaagctgcat	ggtctagatc	cacctgtctc	cctggcccca	gtatagaaga	tcaaattcaa	1200
tctgcccatt	cttatccaga	taaagttaaag	gaagactgga	aaaaagaact	aatccaaagc	1260
tccatctgcc	catgattttc	tctgctgatg	ccggaggcag	ctatggataa	agagatggca	1320
cacggcatgt	cccgcgcag	tggaggtggg	gagaccctgc	aactccacag	ggaaggagtg	1380
aagttgctgc	cacctgggca	tcagctattc	tctgctcttc	tgctctatcc	tcaattcaga	1440
ccatgatgga	gctgattttc	ctccatttta	taccttggat	tgaatgggtc	cgagctgctg	1500
gtcttgtctc	cagagtcaca	tccaagaggt	ttgtctttca	aataaatgct	gtgtatcaat	1560
gtacagtgtg	tataattaat	gtatgatata	agactaaatt	atagataaga	caagagatga	1620
aattagagtt	aagtagggac	ccgatgacga	agagccttgt	aaatcagggg	gagctctgggt	1680
catgtgcttc	tccagacaca	atctcaacac	ggctgtgaagc	atgtaccact	gatgacacgg	1740
acactgaatt	accgcctgtg	ctggctctgtg	gctctcaagt	tttgctcatt	ctgcttctgc	1800
gggaaatgcc	ttgacgcacc	ttgggaaaac	tcacttagac	ctttttttga	gatggagtct	1860
cgtctgtctg	ccaggctgga	gtacagtggc	gcgactctgg	ctcactgcaa	cttctgcctc	1920
ccaggt						1926

<210> 337  
 <211> 1668  
 <212> DNA  
 <213> Homo sapiens

<400> 337  
 gaagacatgg agtcttaagt gtgatcaatg ggaggggggct ggaatcattt agaggcatct 60  
 tcattcacaa aaccaggagc tgatactggc tgtcagccag gacttcaact gacctgtggg 120  
 ctggaacctg tccatgtggc ccctcgcagt ctccccattt gggctgggtt gggcttcac 180  
 acagtcaggc agcttacttc taagggcaag cattccatga caacacagca gaaaggcatg 240  
 acatttttac agtgcagcct ggctatctca tagcgctcgt tctgtcctac tttattttatt 300  
 ggtcagggca atcacaaaga tgtgcacagg ctcaaggaaa agagacatac ccccgaccac 360  
 gcgatggaag aagtgcacag gtcatgttat gagaggagtg tgtgggatgg gagatagggc 420  
 tgtggccacc tgcagaaaat agcatctgcc acaggctgtc atggaagcgc aggatgggga 480  
 tttagcctac ctgaggggtc agtcagcaaa ggcctctggg acgaagttag atcttcggct 540  
 gaggatgtga ggggctaaaa ggagactgag gaagagtctc agggagagga atcaatgaga 600  
 ctggattcca gagagaggct ggtgagttgg atggtttgct tcagtatgat gacaatacag 660  
 agggcaagga gactgggtgca ggaggagaga gaagggtgcca tgtgctctgg gtggcgctct 720  
 gtgccgggacc cccttagaag aggagcagcc tccagtcagc ggtgtcccag gaacacagag 780  
 gctggagagg acaatggcag ccaatccctg ctcccaatct ggtgacagta gggaaaagct 840  
 gcattggtcta gatccactct gctccctggc ccagtatag aagatcaaat tcaatctgcc 900  
 caatcttatc cagataaagt aaaggaagac tggaaaaaag aactaatcca aagctccatc 960  
 tgcccatgac tttctctgct gatgccggag gcagctatgg ataaagagat ggcacacggc 1020  
 atgtcccgcac gcagtggagg tggggagacc ctgcaactcc acagggaaaag agtgaagttg 1080  
 ctgccacctg ggcacagct attctctgct ctctgcctc atcctcaatt cagaccatga 1140  
 tggagctgat tttctccat tttatacctt ggattgaatg gtctcgagct gctggctctg 1200  
 tctccatagt cacatccaag aggtctgtct ttcaaataaa tgcgtgtgtat caatgtacag 1260  
 tgtatataat taatgtatga tatcagacta aattatagat aagacaagag atgaaattag 1320  
 agttaagtag ggaccgatg acgaagagcc ttgtaaatca gggagagtct ggttcatgtg 1380  
 cttctccaga cacaatttca acacggctgt aggcattgtac cactgatgac acggacactg 1440  
 aattaccgcg cgtgctggct tgtggctctc aagttttgct cattctgctt ctgcgggaaa 1500  
 tgccttgatg caccttggga aaactcactt agatcttttt ttgagatgga gtctcgctct 1560  
 gtgccaggc tggagtcacag tggcgcgatc tcggctcact gcaacttctg cctcccagg 1620  
 tcaagcgatt ccctgcctc agtctcccaa gtgactggga ctacaggc 1668

<210> 338  
 <211> 1685  
 <212> DNA  
 <213> Homo sapiens

<400> 338  
 ccgggattct gtgattccaa caggcctggc ttgtctctgg tccacgacat gtggggcctc 60  
 agctgggaag acatggagtc ttaagtgtga tcagtgggag ggggctggaa tcatttagag 120  
 gcattctcat tcacaaaacc aggagctgat actggctgtc agccaggact tcaactgacc 180  
 tatgtagaac ctgtccatgt ggcctctcct tgcagctctc ccatttgggc tggtttgggc 240  
 ttcatacacag tccggcagct tacttctaag ggcaagcatt ccacgacaac acagcagaag 300  
 ggcattggcat ttttacagtg aagtttggca atctcatagc gtcgcttctg tcctacttta 360  
 tttattggctc agggcaatca caaagatgtg cataggctca aagaaaagag acataacccc 420  
 gaccacgcga tggaaagaag gacacggtca tgttatgaga ggagtgtgtg ggatgggaga 480  
 tagggctgtg gccacctgca gaaaacagca tctgtctacag gctgtcatgg aagcgcagga 540  
 tggggattta gcctacctga ggggtcagtc agcaaaaggcc tctgggagga agtgagatct 600  
 tcggctgagg atgtgaagg ctaaaaggag aatgaggaag agtttcaggg agaggaatca 660  
 atgaaacgag tccagagacg ctggtgagtt ggaatgggtt cttcagtatg atgacaatac 720  
 agaggggcaa ggagactggt gcaggagaag agagaagggt ccatgtgctc tgggtcgtgt 780  
 cttctatgcc agactccctt agaagaggag cagcctccag tcagcgggtg cccaggaaca 840  
 cggaggctag acaggacaat ggcagccaat ccctgctccc aaactgggtg cagtggggaa 900  
 aagctgcatg gtctagatcc accctgctcc ctggccccag tatagaagat caaattcaat 960  
 ctgcccaatc ttatccagat aaagtaaagg aagactggaa aaaagaacta atccacggct 1020  
 ccactgtccc atgactttct ctgctgatgc cggaggcagc tatggataaa gagacggcac 1080

254

acggcatgtc	ccgacgcagt	ggaggtgggg	agaccccgca	agtccacagg	aaaagagtta	1140
agttgctgcc	acctgggcat	ccgctattct	ctgctcttct	gcctcatcct	caattcagac	1200
catgatggag	ctgattttct	cccattttat	accttggatt	gaatgggtct	gagctgctgg	1260
tcttgtctcc	agagtcacat	ccaagagggt	tatctttcaa	ataaatgctg	tgtatcaatg	1320
tacagtatat	ataattaatg	catgatatca	gactaaataa	tagataagac	aagagatgaa	1380
attagagtta	agtagggacc	tgatgatgaa	gagccttgta	aatcagggag	agtctgcgtc	1440
atgtgcttct	ccagacacaa	tttcgacatg	gctgtaggca	tgtaccactg	atgacgcgga	1500
cactgaatta	cccgccgtgc	tggctctgtg	ctctcaagtt	ttgctcattc	tgcttctgcg	1560
ggaaatgccc	tgactcaact	tgggaaaacc	cacttagatc	ttgttttgaa	acggagtcct	1620
gctctgttgc	caggetggag	tacagtggcg	cgatctcggc	tcactgcaac	ctctgcctcc	1680
cggt						1685

&lt;210&gt; 339

&lt;211&gt; 730

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 339

agctaagatt	gcgctattgt	actccaacct	ggcggacata	gccagactat	ctcaattaaa	60
aacaaataaa	taaatacatg	aagcaacgat	ccaatcaatc	aaaccaacaa	attctggaaa	120
ggtagagaag	agaagggctg	accagtggt	gagttcctgg	ggtggtttga	tggttgttc	180
tttggcctcc	tataaccct	gtcttatctg	ttagagcaga	gtctacaacc	aggaaatccc	240
agtgcacctc	tcatccccta	acccccgcaa	aaggagcctc	atctttcgag	ccaaatgaca	300
gcgaagaggg	cgccctgcg	ggacagtgcc	cttttgacta	cacacacctc	actctaggaa	360
aacagcctga	aaaaagctgc	accttcccct	gccccagata	ctgtagacac	tgtggaacaa	420
agacctgttg	acctccccta	ccttgggcca	acacaagcag	aggtggcatc	tctcccctct	480
ccaccaagca	ctggaagac	tgtgtggaag	ggccctgctg	accatccaca	acctgcacaa	540
gactgaacca	cagtaacaag	gtggcaccct	atcctctctc	aaagacagtg	aggagctaga	600
agcaaggatt	ctccaaccca	tttcccgctc	cccgctccac	ccaccgcaga	atattcctct	660
ctaatacctaa	tataacgtcg	tgtacatttc	tgttacattc	ggattaaaga	caagttctgt	720
ttaataataa						730

&lt;210&gt; 340

&lt;211&gt; 335

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 340

ggatcaagct	gggaagcaca	gaactgcagg	ccagagacaa	ctctggaagc	agaaacaggt	60
gtgtgcttcc	aggcacacag	acaccaactg	tgtgacacct	acacgaaaag	gagaaacaca	120
caccttctac	tcacaaactc	actattgaca	gtgcacctac	caccacctgc	tttgtgcaac	180
acaggaaaca	ccaataaaca	ctggagacag	tgtcaggcca	ggcatggtgg	ctcagcctg	240
tgtctccagc	actttgggag	gctgaggtag	gaggatcgct	tgaggccaga	agttcaagac	300
catcctcagc	aatacggcga	gacctatct	ctaca			335

&lt;210&gt; 341

&lt;211&gt; 319

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 341

ggatcaagct	aggaagcaca	gaactgcagg	ccagagacaa	ctctggaagc	agaaacaggt	60
gtgtgcttcc	aggcgacacag	acaccaactg	tgtgacacct	acaccttcta	ctcacaaact	120
cactattgac	agtgcaccac	cacctgcttt	gtgcaacaca	ggaaacacca	ataaacactg	180
gagacagtgt	caggccaggc	atggtggctc	acacctgtgc	ttccagcact	ttgggaggct	240
gaggtaggag	gatcgcttga	ggccagaagt	tcaagacat	cctcagcaat	acagagagac	300
cctatctcta	caaaaagt					319

&lt;210&gt; 342

&lt;211&gt; 468



255

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 342

ccccacaaaa	ggagcctcat	ctttcgagcc	aatgacagc	gaagagggcg	gccctgcggg	60
acagtgcctt	tttgactaca	cacaccctac	tctaggaaaa	cagcctgaaa	aaagctgcac	120
cttccccctgc	cccagatact	gtagacactg	tggacaaaag	acctgttgac	cctccccacc	180
ttggggccaac	acaagcagag	gtggcatctc	tccccctctcc	accaagcact	ggcaagactg	240
tgtggaaggg	ccttgctgac	catccacaac	ctgcacaaga	ctgaaccaca	gtaacaaggt	300
ggcaccccat	cctctctcaa	agacagttag	gagctagaag	caaggattct	ccaacccatt	360
tcccgttccc	cgtcccaccc	accgcagaat	actcctctct	aatcctaata	taacgtcatg	420
tacattttctg	ttacattcgg	attaaagaca	agttctgttt	aataataa		468

&lt;210&gt; 343

&lt;211&gt; 468

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 343

ccccacaaaa	ggagcctcat	ctttcgagcc	aatgacagc	gaagagggcg	gccctgcggg	60
acagtgcctt	tttgactaca	cacaccctac	tctaggaaaa	cagcctgaaa	aaagctgcac	120
cttccccctgc	cccagatact	gtagacactg	tggacaaaag	acctgttgac	cctccccacc	180
ttggggccaac	acaagcagag	gtggcatctc	tccccctctcc	accaagcact	ggcaagactg	240
tgtggaaggg	ccttgctgac	catccacaac	ctgcacaaga	ctgaaccaca	gtaacaaggt	300
ggcaccccat	cctctctcaa	agacagttag	gagctagaag	caaggactct	ccaacccatt	360
tcccgttccc	cgtcccaccc	accgcagaat	actcctctct	aatcctaata	taacgtcgtg	420
tacattttctg	ttacattcgg	attaaagaca	agttctgttt	aataataa		468

&lt;210&gt; 344

&lt;211&gt; 319

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 344

ggatcaagct	aggaagcaca	gaactgcagg	ccagagacaa	ctctggaagc	agaaacaggt	60
gtgtgcttcc	aggcgcacag	acaccaactg	tatgacaccc	acaccttcta	ctcacaaact	120
cactattgac	ggtgcaccac	cacctgcttt	gtgcaacaca	ggaaacacca	ataaacactg	180
gagacagtgt	caggccaggc	atggtggctc	acacctgtgc	tcccagcact	ttggggaggct	240
gaggtaggag	gatcgcttga	ggccagaagt	tcaagaccat	cctcagcaat	acagagagac	300
cctatctcta	caaaaagtt					319

&lt;210&gt; 345

&lt;211&gt; 335

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 345

ggatcaagct	gggaagcaca	gaactgcagg	ccagagacaa	ctctggaagc	agaaacaggt	60
gtgtgcttcc	aggcacacag	acaccaactg	tgtgacaccc	acacgaaaag	gagaaacaca	120
caccttctac	tcacaaactc	actattgaca	gtgcacctac	caccacctgc	tttgtgcaac	180
acaggaaaca	ccaataaaca	ctggagacag	tgtcaggcca	ggcatggtgg	ctcacgcctg	240
tgtctccagc	actttgggag	gctgaggtag	gaggatcgct	tgaggccaga	agttcaagac	300
catcctcagc	aatacggcga	gaccctatct	ctaca			335

&lt;210&gt; 346

&lt;211&gt; 730

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 346

256

agctaagatt	gcgctattgt	actccaacct	ggcggacata	gccagactat	ctcaattaaa	60
aacaaataaa	taaatacatg	aagcaacgat	ccaatcaatc	aaaccaacaa	attctggaaa	120
ggtagagaag	agaagggctg	acccagtggt	gagttcctgg	ggtgggttga	tggtttggtc	180
tttggcctcc	tatataacct	gtcttatctg	ttagagcaga	gtctacaacc	aggaaatccc	240
agtgcacctc	tcatccccct	acccccgcaa	aaggagcctc	atctttcgag	ccaaatgaca	300
gcgaagagg	cggccctgcg	ggacagtgcc	cttttgacta	cacacacct	actctaggaa	360
aacagcctga	aaaaagctgc	accttcccc	gccccagata	ctgtagacac	tgtggaacaa	420
agacctgttg	accctcccca	ccttggggcca	acacaagcag	aggtggcatc	tctccccctc	480
ccaccaagca	ctggaaagac	tgtgtggaag	ggccctgctg	accatccaca	acctgcacaa	540
gactgaacca	cagtaacaag	gtggcaccac	atctctctct	aaagacagtg	aggagctaga	600
agcaaggatt	ctccaaccca	tttcccgctc	cccgtcccac	ccaccgcaga	atatctctct	660
ctaatacctaa	tataacgtcg	tgtacatttc	tgttacattc	ggattaaaga	caagttctgt	720
ttaataataa						730

&lt;210&gt; 347

&lt;211&gt; 1676

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 347

gtgcagtggt	gccatcacag	ttcactgcag	ccttgacctc	ccgggctcaa	gcaatcctcc	60
cacctcagcc	acttgagtag	ctgagacctc	agatatgtgc	catcacaccc	agctgatttt	120
ttaaaattaa	ttttttgtag	agatagggtc	tcatatgttg	cccatgctgg	tctcaaaacta	180
ctgggttcaa	atgatcctcc	tgccctcagcc	ttccaaagta	ctgggattac	aggcatgagc	240
caccatgccg	ggctgggagg	cggaaatttg	ttcagtctaa	agataagctt	tttcatagct	300
ctggctgtag	tgggaggagg	cagaggagtg	aatgattgtc	agttgggagg	gtgcagagtg	360
ggctcctgcc	caggggtgga	ggtgagggtg	gcttaggtga	gacaacacag	aggccctggt	420
cagccccacg	tccccctccc	gtgctccctc	ctctctctct	ctctcctgca	ggcgtgggag	480
gtatcatcat	tcagcagatt	tcaccagagg	cagtggagga	ggcagggtacc	tgagccagaa	540
ttcagaatgt	cttattctcc	acttgactct	gccactaact	tgttgtgcaa	ctttgggacct	600
ttccccaggc	cttcattttc	ttttcttttc	ttttcttttt	tttttttttg	aggcggagtc	660
tcgctatggt	gccagagctg	gagtgcagtg	gcgcagcatc	atctcggtct	actgcaagct	720
ccaccttctg	agttcacgcc	attctactgg	cctcagcctc	ccgagtagcc	gggactgcag	780
gcgcccacca	ccacgcccgg	cttatttttt	gatttttttag	tagagacagg	gtttcaccac	840
gttagccaag	atggtctcga	tctcctgacc	tctgatccca	cccgctggg	cttcccaaag	900
tgctgggatt	acaggcgtga	gccactgcgc	ccggccattt	tcttaaatat	ctaataaaaa	960
atataatagca	aatgcagttt	gtaaactacg	acaatatgac	cacgcaaag	attattatct	1020
tccaagactg	ctggtccaag	gaaaggctcag	taataaagtg	gaagcattgt	agcttatgga	1080
atgactgggt	agattttgga	gaagccttag	caataatcta	gaatctgcat	agataataca	1140
tctgaggatt	gggctttgtg	gtttacaaag	catttttttt	cctcttttga	tcccagccgc	1200
ttgtctggac	tgatacaaa	catttttatt	agtttgtctt	attcaatcct	cacaccacct	1260
caaatattaca	gaggatatgg	atctgggttaa	cttgtatgac	tatgtaacct	catgtcagtc	1320
cacagcactg	cctggagggtg	ggtagagggtg	gtcctgggct	ggaatcccag	ccccagtggtg	1380
accttgagca	agttacttta	gctgtctgca	cctaaatttc	ctcactggca	aaacagggaat	1440
actgggtggt	cacacctgca	attccagcac	tttgggaggc	tgagggtggga	ggattgcttg	1500
agtccagaag	ttcaaaaacca	gactgggcaa	catagcaaga	ccatctctac	aaaaattaaa	1560
taaaaaaac	atttacaagg	gttgtgggtga	agattaaatg	agatcactca	cgaaaaagct	1620
cagcagaccc	tgatgtgcag	taggtgctca	ataaatgtta	gccagcaaaa	aacaaa	1676

&lt;210&gt; 348

&lt;211&gt; 1676

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 348

gtgcagtggt	gccatcacag	ttcactgcag	ccttgacctc	ccgggctcaa	gcaatcctcc	60
cacctcagcc	acttgagtag	ctgagacctc	agatatgtgc	catcacaccc	agctgatttt	120
ttaaaattaa	ttttttgtag	agatagggtc	tcatatgttg	cccatgctgg	tctcaaaacta	180
ctgggttcaa	atgatcctcc	tgccctcagcc	ttccaaagta	ctgggattac	agacatgagc	240
caccatgccg	ggctgggagg	cggaaatttg	ttcagtctaa	agataagctt	tttcatagct	300

257

ctggctgtag	tgggagggag	cagaggagtg	aatgattgtc	agttgggagg	gtgcagagtg	360
ggctcctgcc	ctaggggtgga	ggtgaggggtg	gcttaggtga	gacaacacag	aggccctgtt	420
cagccccacg	tcccctccct	gtgctccctc	ctcctctctc	ctctcctgca	ggcgtgggag	480
gtatcatcat	tcagcagatt	tcaccagagg	cagtggagga	ggcaggtacc	tgagccagaa	540
ttcagaatgt	cttattctcc	acttgactct	gccactaact	tggtgtgcaa	ctttgggcct	600
ttccccaggc	cttcattttc	ttttcttttc	ttttcttttc	tttttttttg	aggcggagtc	660
tcgctatggt	gcccaggctg	gagtgcagtg	gcgcagtcac	catctcagct	cactgcaagc	720
tccaccttct	gagttcacgc	cattctactg	cctcagcctc	ccgagtagcc	gggactgcag	780
gcgcccacca	ccacgcccgg	cttatttttt	gtatttttag	tagagacagg	gtttcaccac	840
gtagccaag	atgggtctcga	tctcctgacc	tcgtgatcca	ccgcctggg	cttcccaaa	900
tgctgggatt	acaggcgtga	gccactgcgc	ccggccattt	tcttaaatat	ctaataaaaa	960
atatatagca	aatgcagttt	gtaaactatg	acaatatgac	cacgcaaaag	attattatct	1020
tccaagactg	ctgggtccaag	gaaagggtcag	taataaagtg	gaagcattgt	agcttatgga	1080
atgactgggt	agatttgga	gaagccttag	caataatcta	gaatctgcat	agataataca	1140
tctgaggatt	gggctttgtg	gtttacaaag	catttttttt	cctcttttga	tcccagccgc	1200
ttgtctggac	tgatacaaa	cattttttat	agtttgtctt	attcaatcct	cacaccacct	1260
caaattttaca	gaggatatgg	atctgggttaa	cttgtagtac	tatgtaacct	catgtcagtc	1320
cacagcactg	cctggagggtg	ggttagagggtg	gtcctgggct	ggaatcccg	ccccagtggtg	1380
accttgagca	agttacttta	gctgtctgca	cctaaatttc	ctcactggca	aaacaggaat	1440
actggtgggt	cacacctgca	attccagcac	tttgggaggc	tgaggtggga	ggattgcttg	1500
agtcagaaag	ttcaaaaacca	gactggggcaa	catagcaaga	ccatctctac	aaaaattaaa	1560
taaataaaac	atttacaagg	gttgtgggtga	agattaaatg	agatcactca	cgaaaaagct	1620
cagcagaccc	tgatgtgcag	taggtgctca	ataaatgtta	gccagcaaaa	aacaaa	1676

&lt;210&gt; 349

&lt;211&gt; 1675

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 349

gtgcagtggt	gccatcacag	ttcactgcag	ccttgacctc	ccggggtcaa	gcaatcctcc	60
cacctcagcc	acttgagtag	ctgagacctc	agatatgtgc	catcacaccc	agctgatttt	120
ttaaaattaa	ttttttgtag	agataggggtc	tcatatgttg	cccattgctg	tctcaaacta	180
ctgggttcaa	atgacctctc	tgccctcagcc	ttccaaagta	ctgggattac	aggcatgagc	240
caccatgccg	ggctgggagg	cggaaattttg	ttcagttctaa	agataagctt	tttcatagct	300
ctggctgtag	tgggagggag	cagaggagtg	aatgattgtc	agttgggagg	gtgcagagtg	360
ggctcctgcc	ctaggggtgga	ggtgaggggtg	gcttaggtga	gacaacacag	aggccctgtt	420
cagccccacg	tcccctccct	gtgctccctc	ctcctctctc	ctctcctgca	ggcgtgggag	480
gtatcatcat	tcagcagatt	tcaccagagg	cagtggagga	ggcaggtacc	tgagccagaa	540
ttcagaatgt	cttattctcc	acttgactct	gccactaact	tggtgtgcaa	ctttgggcct	600
ttccccaggc	cttcattttc	ttttcttttc	ttttcttttc	tttttttttg	aggcggagtc	660
tcgctatggt	gcccaggctg	gagtgcagtg	gtgcagcatc	atctcggctc	actgcaagct	720
ccaccttctg	agttcacgcc	attctactgc	ctcagcctcc	cgagtagccg	ggactgcagg	780
cgcccaccac	cacgcccggc	ttattttttg	tattttttagt	agagacaggg	tttcaccacg	840
ttagccaaga	tggtctcgat	ctcctgacct	cgtgatccac	ccgcctgggc	ttcccaaaag	900
gctgggatta	caggcgtgag	ccactgcgcc	cggccatttt	cttaaatatc	taataaaaaa	960
tatatagcaa	atgcagtttg	taaaactatga	caatatgacc	acgcaaaaaga	ttattatctt	1020
ccaagactgc	tggtccaagg	aaagggtcagt	aataaagtgg	aagcattgta	gcttatggaa	1080
tgactgggtta	gatttgggag	aagccttagc	aataatctag	aatctgcata	gataatacat	1140
ctgaggattg	ggctttgtgg	tttacaaga	attttttttc	ctcttttgat	cccagccgct	1200
tgtctggact	gatacaaaag	attttttatta	gtttgtctta	ttcaatcctc	acaccacctc	1260
aaattttacag	aggatatgga	tctgggttaac	ttgtatgact	atgtaacctc	atgtcagtc	1320
acagcactgc	ctggaggtgg	gtagaggtgg	tcctgggctg	gaatcccagc	cccagtgagg	1380
ccttgagcaa	gttactttag	ctgtctgcac	ctaaatttcc	tcactggcaa	aacaggaata	1440
ctgggtgggtc	acacctgcaa	ttccagcact	ttgggaggct	gaggtgggag	gattgcttga	1500
gtccagaagt	tcaaaaccag	actgggcaac	atagcaagac	catctctaca	aaaattaaat	1560
aaataaaaaca	tttacaaggg	ttgtgggtgaa	gattaaatga	gatcactcac	gaaaaagctc	1620
agcagaccct	gatgtgcagt	aggtgctcaa	taaatgttag	ccagcaaaaa	acaaa	1675

&lt;210&gt; 350

&lt;211&gt; 9268

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 350

aagcaacat	gcagggtgcta	accaagcgtt	accccaagaa	ctgcctgctg	accgtcatgg	60
accggtatgc	agccgaggtg	cacaacatgg	agcagggtgt	gatgatcccc	agccttctgc	120
gggacgtgca	gctgagtggt	cctggggggc	aggcccaggc	tgaggccctt	gatctctaca	180
cctacttcac	catgctcaag	gccatctgtg	tggatgtgga	ccatgggctg	ctgccgcggg	240
aggagtggca	ggccaaggtg	gcaggcagcg	aagagaatgg	aaccgcagag	acagaggaag	300
tcgaggacga	gagtgcctca	ggagagctgg	acctggaagc	ccagttccac	ctgcacttct	360
ccagcctcca	tcacatcctc	atgcacctca	ccgagaaagc	ccaggaggtg	acaaggaaat	420
accaggaaat	gacgggacaa	gtttggtaga	ccttggacac	tagggaaggt	aatggtggcc	480
atgctggtgg	gtgtgagtct	acaaagggtg	attccaggag	aggagagggg	gcagtgtgtc	540
aaccacgtgg	gagaggaaca	gcctgacttt	cagacagagc	cactcttggg	tcagggtatt	600
gggaccacaa	cctaggaggg	cctaagacta	ggcctgtgtt	actatccttc	tgacctcaaa	660
ttggcaattg	caatgaagtg	atatggaaac	agagggaaaa	gtggcctgtg	agggcataatc	720
tcatatgcac	atataatgtg	ttgtgcacgt	gtgcatttat	tagtatgtga	atgcttgtaa	780
atgtgtgaat	tgaatgagtg	tggtctcctc	agtgcatttg	ttaagaattt	aattgaagag	840
gggcccggga	cgggtggctca	caccaagcga	ccttgggagg	ccgaggcggg	cggatcatga	900
ggccaggaga	ttgagacat	cctgggtaac	atggtgaaac	ccaatctcta	ctaaaaatac	960
aaaaaattag	ctgggcgtgg	tggtgggtgc	ctgtagtccc	agctactcgg	gaggctgagg	1020
caggagaatg	gcatgaacct	gggaggcaga	ggttgagctg	agctgagatt	gtgccactgc	1080
actccagcct	aggtgacaga	aggagactcc	atctcaaaaa	aaaaaaaaaa	aacttaccta	1140
aggcatgcac	attgatattaa	gtgaacattg	tgaattccat	ttgtgtgaca	gtgtttccca	1200
acattttttc	aagtcacaga	acattgaaaa	ttattatatg	gcacatgggg	atacataggt	1260
gaggctgctt	gcagtactgc	tacaacaggc	tgggggtact	ctgacctacc	cagggttgaa	1320
cccaccaaac	gggaagccga	gggaccagtc	atggcactct	aatccattcc	aggcaactg	1380
gagtatgcag	acatgcctgt	tggaagccc	tggtgtatgt	acatatgaat	atgtgttcca	1440
gtctaagcct	acatgtctat	gcacagaggg	gctgggggtg	tgagtgtgga	tgagcagcaa	1500
gctagacaag	cagggtggtg	cagagggtag	gagggtggaa	ggggccctag	catggtcacc	1560
actagttcac	tcattggataa	agactagtat	taatagaaat	tggaaccacg	cacctgccag	1620
ttttgattct	gtgccacctg	ccagccctgc	tcccacaaac	tggtctcatt	agttgtaaac	1680
aacatccacg	tccattgcaa	tctcaaaacc	acctgatgca	gctatgtagg	aaaagattct	1740
catccccagt	ttactagtat	ggaaattgaa	gccagagagg	tgaagtgact	cacccaaagt	1800
cacacagtaa	ggagacaaaa	gtaagactgg	cctcaacttt	gagctgagtg	ttctttccat	1860
cgtacccact	gtctgccatt	ttgtgttatc	ttcataatct	gtgtgaaggc	tgctctgtaa	1920
ttatgcgga	taaacatggg	acccccaaac	acagagccta	tggaagagctc	tgctccaggc	1980
atcttctcag	ccgttttttc	ttctcccgtc	tcaaacccaa	actgtcaacc	tcaacccttc	2040
ttccctctcc	cgttgaggct	ccctgagttg	ccctcacagag	gttcttcttg	aattagacgg	2100
ggctgtgtca	acagctcttg	gttcacgttc	tgattctatc	actaatgagc	tgtggggcct	2160
tggaagagct	aattcatttc	tctgggtttc	agcttcttca	ctgaataata	acagtgggtg	2220
taaaactaac	aactggcatt	tgaatagttt	taagatcact	ttgcatatcc	attatctaata	2280
ggaattatca	tcccccccca	ccttttttaa	ttttgagagc	gagtctcacc	ctgtccccca	2340
ggttgagagt	caatgtgcaa	tctcagctca	ctgccacctc	cacctcccag	gttcaagaga	2400
ttttcctcag	cctcccaagt	agctgggatt	acaggcgtgt	gccaccacac	ccagctaatt	2460
ttttttaaat	cttttagtaga	gaccgggttt	caccatgttg	gccaggctgg	tcttgaactc	2520
ctgacctcgt	gateccacctg	cctcggcctc	ccgaagtgtc	gggattacag	gcatgagcca	2580
ccgcgcccag	cctatcatte	cctttttgcag	atgagaaaa	tggaaggcctg	agaagtaaaa	2640
tgagtccaag	tttactcagt	aaataacagc	caagatgtga	accctggcct	aattagtcta	2700
attctttttc	tctacagtgg	tggttccttag	agccttagac	ttttgcagag	tggtgtcaaa	2760
gtgggaacgt	ggcatggcag	agtgggtaga	aaccacactc	tgactcactc	agttgtctta	2820
aaggccagag	cagcaactct	acgccataac	gtttcaacac	accctaacct	gattttcatt	2880
cagaggcaat	atgggtatagc	aacagttaaa	aatctgggct	cttgttctgg	ctcttccatt	2940
gacttctgta	ttatcctaga	caactttttt	tttgagatgg	agtctcacc	tattgccagg	3000
ctggagtgca	gtggcgcgat	ctcagctcac	tgcaacctcc	acctcccgat	tcaagcaatt	3060
ctcctgcctc	agccacccga	gtagttggga	ctacaggtgc	acgccactac	accagctaa	3120
ttttttgtat	tttttagtaga	gatgggggtt	caccatgttg	gccaaagatg	tctcaatctc	3180
ctgaccttgt	gatectcccc	gctcggcttc	ccaaagtgtc	gggattacag	gcgtgagcca	3240
ccgcacccaa	cctttttttt	tttttttag	atggagtcct	gctgttgtca	cccaggctgg	3300

agtgcagtgg	cgccaccttg	gctcactaca	acctctgect	cccagattca	agcaagtctc	3360
ctgcctcagc	ctccccagta	gctgggatta	caggctcacg	ccaccatgcc	tggctaattt	3420
ttgtactttt	agtaaagaca	gggtttcacc	atgttggcca	ggctgatctc	gaactcctga	3480
cctcaaatga	tccacccacc	ttggcctccc	aaagtgtctg	gattacaggc	gtgagccacc	3540
acgcccggcc	ctagacaact	tatcttacct	ttctgtatct	gtttccctgt	tagtaaaata	3600
tagcagagaa	atcaaatgag	ttattccagc	tctgacaacc	taggattttc	cttacagtgc	3660
tgaggcactg	ccagttttcc	aacagcaaca	tcagcattgt	tcttcctgct	tcaatgggca	3720
tgtgacagta	tcttggttgt	ttgaattgat	actgacttgg	ccttttataa	atttcttcac	3780
tccacagatc	ccttcacatg	atagaagaca	gactctttga	tgaggtcggc	ggagcagttc	3840
actagccaat	gatgagagca	gaaaggccta	gacctgcagc	cagaagtga	ggcggctcag	3900
ttctccggga	tgcttctcta	cctcctgagc	accaattcct	ggattccagt	cactggctca	3960
ccttttagaat	gtctgttgct	attcactgct	ccctcgctc	ctcttaacag	cttggggagg	4020
tgaccatgg	ttcaggaggg	actagacaat	tacctgtcca	gtgtggtatg	gtaggaagag	4080
tgtaggtgtt	ggcacgtgac	caaaattcac	atccttcttc	atggcagtca	ttcagtatgt	4140
gtacttgtac	aagttattta	acccattgga	gctaaattc	cctcatctat	aaaatgggga	4200
taatattatc	tacctcaca	gcttatgaaa	actaaacatg	atgaatcaaa	agcacttggc	4260
atgtgagggc	tattaaaata	gcctgatttt	tttttctctc	ccctctcccc	aatgtatttg	4320
ctctggccct	tgctttttac	cctccagagc	taagaggtag	cagagtctct	ggggatgagt	4380
gattcacccct	cttacttggc	gaccactgat	gagatcaaca	acaggtgaac	tataaaccta	4440
ttattttattg	cagaactaat	aaaaaatcca	aagcctggta	tttgtacatc	tttattattt	4500
ctaaagcact	ttcctcaacc	taatttcagt	ttttacaatt	ggtagtcaag	aaaatagaga	4560
cagaaatcat	ttgattttgc	ccagaaacca	tctgcttata	tttataaggc	cacctaatth	4620
gaaatcacat	atagaccagg	cgcggtggct	cacgcctgta	attccaacac	tttggaaggc	4680
caaggcaggt	ggatcacaa	gtcaagagat	tgagaccatc	ttggccaaca	tgggtgaacc	4740
ccgtctctac	taaaaacaca	aaaatcagct	ggcgctcgtg	gcattgcacct	gtagtcccag	4800
ctactcggga	ggctgaggca	ggagaattgc	ttgaaccag	gaggtggagg	ttgcagttag	4860
ccgaaattgc	gccactgcac	tccagcctga	tgcagagca	agactgtctc	aaaaaaaaaa	4920
aaaaataacca	catatacttt	atctcccaaa	cctaactctga	ttataaaattc	taagctagga	4980
aaccaaaact	tttgggacaa	gtactttttt	ttttgacggg	gtctcctttg	tcaccagggc	5040
tggagtgtca	cccaggctgc	agtgaactgt	gacacaacca	caattaattg	catcctcgaa	5100
ttccagggtc	caatagatcc	tcccacctca	gccttatgag	tagctgggat	tgcaggaacg	5160
tgccaccacg	cccagctaat	ttttgtattt	tatgtagaga	cagtgtttca	ccatgttgcc	5220
caagttgggc	tcgaactcct	gggctcatgc	aatctgcctt	gcctcagcct	ctcaaagtgc	5280
tgggattaca	ggcactgagc	actgcatcgg	gccaggacaa	gcatttgata	agccataaaa	5340
agtaacctca	ttccagttag	gtacagtctt	ttgcttctaa	ttgcaccaag	ctccactgta	5400
gacagtatta	gctcctgagt	ccattttctc	caggataacc	cacctaaagag	caaagacaac	5460
ttggcaacat	aagatttctg	ttttccttgt	ctggagtctc	ctccttcgaa	accaccttct	5520
atatcattca	ttatagacag	ctcagaaata	caaacctgac	tgtatgattt	aaaacgcctt	5580
aatgacttaa	tacctacagg	atgaagtcaa	aattattttg	caagagtca	agaatcctcc	5640
ataatctggc	tactctctaa	ttcactttgc	actaggacag	gggcaggcaa	accttttctg	5700
aaagggctac	atatttaatta	ggctttgcag	gccataggtc	tctatcacaa	ctactcaatt	5760
ctgctcctgc	agcatggcag	tcgccataaa	acaatgtaa	acaaatgagc	atggctgtgt	5820
tccaatgaga	ctttattggc	agtgggccag	atttgggtag	tctgctaact	ctaaactaga	5880
attcaacctc	atcttaaaat	ctttcagatg	ggtgaatgga	aactgacct	tctctgatga	5940
tgaactattt	ttcttacaac	aataaagagt	cagagtactc	atggtacgta	ttttaattac	6000
aaggtgtcaa	catacagatt	agcataagct	tcaactgtca	taagaaacat	gttccatcaa	6060
attcagaaac	agcaggtatc	agtgaactg	gagcaagcat	tttgaagact	tcaacgtatt	6120
ggatggaatt	tttcaaaaat	ttcaccatat	gttttcttat	ctataaaaagg	aaagatcata	6180
aaagatttat	tttaaaaata	tgttttaaaa	attgtatttc	ctaaacgaaa	attaacactc	6240
actaatctta	cgattgaaat	cctgctgtgg	tctgaatggt	catgtccccc	caaagttcat	6300
aaattgaaat	gtaaccccca	agataatgat	attaagaggt	taggactttg	ggaggtgatt	6360
aggtcacaaa	ggctctgtcc	tcatgagggg	gatcggttta	ggggaccttg	tttgctctct	6420
ctaccatgtg	aggacacagc	aagatggcat	catctatgaa	gcagagtggg	ccctcagcag	6480
acaccaactg	tgtcgtgacc	ctgatcctgg	atttcccagc	ctccagaatt	gcaagcaata	6540
aatttctatt	acttatatat	taccagtcct	attctgcaat	tatacagggtg	gtaagaaaaa	6600
caaagttaaa	aaattttttt	taattaccca	gtttaaggca	ttttgttata	gtaggccaaa	6660
cggactaaga	caaaccctta	agaatttcct	tattttcttg	tccttgacta	tggcttggtg	6720
atcactgaag	gattttcttt	cattgactga	agaataactt	tggaggaatc	tgtgatgaca	6780
accaaagac	tgccaagagg	gacaaggtgc	tgccaggagt	atcctgactg	aagaggtgaa	6840
ggaagaaata	aacacagagg	ggcacaggtc	agctaggaga	ggccaacagc	caatgtggtc	6900

260

aagctctccg	ggctcccaact	gtctgtgcat	gaggctcttg	gcacaactgc	cactaatctg	6960
cagctcagaa	agagaatgag	ccctgaagct	atacacactc	ctgcagacac	agggaaactca	7020
tggaactatg	tctaggcaaa	gagccagagg	tctgagactg	aagactcctc	aagccactgg	7080
gcctcactcc	tagtaatcaa	tatatccaag	atgacttcca	gctctaacat	ttaacggttc	7140
tggttattat	gcattcccgga	tacatccact	attcatggct	ttgtgctagt	ctttatgctc	7200
ttctttggca	aaaaaagaaa	ctgtatcttt	ctgatccacc	ataaatatca	tatatgtgac	7260
tgaaggctgt	gggaatatta	aagagtaata	aaatttttaga	gctaaataag	accttagaga	7320
tcattcagtg	taatgaaatt	taaatgtttt	atatcacgca	tttacattaa	cagaagaatt	7380
tttttttttt	ttttttttga	gacagggtct	cgctctgtca	cctaggctgg	aatgcagtg	7440
tgtgatcacg	gctcacggca	ccttgtcctc	ccaggctcaa	gtaatcctcc	tgcctcagcc	7500
tccaagtca	ctgggtctat	aggcatgtgc	cacctcaccc	agctaatttt	ttaattttct	7560
gtagagatga	ggtctcacta	tgttgccgag	actggggaaa	atctattttat	gtttacaagt	7620
tcaaattttt	tctatactca	ttcattttaca	catttaataa	ggctatgtgt	gccaaccccc	7680
tggggaaacc	aaaaaaaact	gtcgtagtag	ttaaactccc	agcctacaga	tactcatata	7740
tgtgcacatc	tgtgttgtgt	atatgtgtgt	aaaacacagg	tgagaaaagt	tatattacaa	7800
ctattaatag	attcatagca	gactagagat	agagcaccct	gagggaatgc	ctgactgtag	7860
ctgggtgaaa	gcttcactga	gataataaaa	gcagaaattt	gctagggtgga	tggtgtgga	7920
acaggggcaa	gaggaagaat	aacatagcag	gaagaaggta	caacatgtat	aaagtaatat	7980
agggcaggtt	cgggacaaag	catttcacca	ggcaaatgat	gagtgtatgag	gaatgaggaa	8040
gtattccata	cggttcata	ccactattat	gcataagtaa	gtgcctgcta	tgtgtaggct	8100
ctatacaaga	ggctggggaa	acaaagacga	agctacaatc	catgaagaac	acacacatgt	8160
gtatatcata	tggtagataa	gaatgtgggt	aaagtgtttc	taccagagga	caggcaatta	8220
gctaacctgg	agtaaatgag	ccatcctaag	gagtctggat	tttatccact	aggcaatgga	8280
tggtctatatt	attttatttt	aattttattt	tattttttga	gacacagtct	tgctgtgaca	8340
cccaggctgg	agtgcaatgg	cgcgatctca	gctcactgca	acctccgact	cccaggttca	8400
agcgattctc	ctgcctcagc	ctcccaagta	gctgggctta	caggcaccgc	ccatcatgcc	8460
cggctaattt	ttgtatttct	aatagagaca	gggtttcacc	atgttgcca	ggctgggtctc	8520
aaactcctga	cctcagatga	tctgccccgc	tgggcccccc	aaagtgtctg	gattacaggc	8580
gtgagccact	gcgaccagcc	ggatgactat	tttaaacaga	tgtgatcaga	tttgctgtca	8640
ttggaaataa	gaccaaagca	agtgggtgag	taagaggcaa	gtgcaacagt	ccaagcaaga	8700
gattaacaag	gcctgaacca	gggtagtgg	agtgggagag	gagagttcaa	agttaagaaa	8760
tatttaggaa	gtagaactga	taagacctga	tgactaatgg	gaagtgaag	agaaagactt	8820
gatgattctc	aggcttctgg	cttgagtgtc	cagggtggaca	gtagtgccat	tctctgaage	8880
aggacacaga	ggagcaggag	gtttgggaag	gcagagggga	tatgagtttt	gtttgctgtc	8940
caaaggacac	ggaggtagtc	agaaactgga	tatatataat	caagagaatt	ttggtctata	9000
gactaagatg	tggtgagtc	cagaatttag	aaggtatcta	aagccataca	catggataag	9060
attaaccagg	gaaaataata	atacagtaaa	cacagattat	ctaaaattaa	cttgaaatac	9120
cttcttcagg	aaaatcctct	ggatgtaatt	tcatatatcc	aaacatttca	cgggtccctca	9180
cagcatacag	gtagtcttca	cgttttacaa	gataatatcc	agcaaaaaaa	aaggccgtaa	9240
tatatagaag	ctggcgatgc	aaacctga				9268

&lt;210&gt; 351

&lt;211&gt; 9266

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 351

aagcaaccat	gcagggtgcta	accaagcggtt	accccaagaa	ctgcctgctg	accgtcatgg	60
accggtatgc	agccgaggtg	cacaacatgg	agcagggtgg	gatgatcccc	agccttctgc	120
gggacgtgca	gctgagtggt	cctggggggcc	aggcccaggc	tgaggcccct	gatctctaca	180
cctacttcac	catgctcaag	gccatctgtg	tggatgtgga	ccatgggctg	ctgccgcggg	240
aggagtggca	ggccaagggtg	gcaggcagcg	aagagaatgg	aaccgcagag	acagaggaag	300
tcgaggacga	gagtgcctca	ggagagctgg	acctggaagc	ccagttccac	ctgcacttct	360
ccagcctcca	tcacatcctc	atgcacatca	ccgagaaagc	ccaggaggtg	acaaggaaat	420
accaggaaat	gacgggacaa	gtttggtaga	ccttggacac	tagggaaggt	aatgggtggc	480
atgctggtgg	gtgtgagtct	acaaagggtg	attccaggag	aggagagggg	gcagtgggtgc	540
aaccactcgg	gagaggaaca	gctgactttt	cagacagagc	cactcttggg	tcagggtatt	600
gggaccacaa	cctaggaggg	cctaagacta	ggcctgtgtt	actatccttc	tgacctcaaa	660
ttggcaattg	caatgaagtg	atatggaaac	agagggaaaa	gtggcctgtg	agggcatatc	720
tcatatgcac	atatatgtgt	ttgtgcatgt	gtgcattttat	tagtatgtga	atgcttgtaa	780

261

atgtgtgaat	tgaatgagtg	tggtctcatc	agtgaacttta	agaatttaaat	tgaagagggg	840
ccaggcgcg	tggtctcacac	caaagcactt	tgaggaggccg	aggcgggcg	atcatgaggc	900
caggagattg	agaccatcct	ggctaacatg	gtgaaaccca	atctctacta	aaaatacaaa	960
aaattagctg	ggcgtgggtg	tggttgccctg	tagtcccagc	tactcgggag	gctgaggcag	1020
gagaatggca	tgaacctggg	aggcagaggt	tgcagtgagc	tgagattgtg	ccactgcact	1080
ccagcctagg	tgacagaggg	agactccatc	tcaaaaaaaa	aaaaaagata	cttacctaag	1140
gcattgcacat	tgattttaagt	gaacattgtg	aattccattt	gtgtgacagt	gtttcccaac	1200
attttttcaa	gtcacagaac	atggaaaatt	attatatggc	acatggggat	acataggtga	1260
ggctgcttgc	agtactgcta	caacaggctg	gggttactct	gaccatccca	ggttggaacc	1320
caccaaacgg	gaagccgagg	gaccagtcac	ggcactctaa	tccattccag	gcaaactgga	1380
gtatgcagac	atgcctgttg	ggaagccctg	ttgtatgtac	atatgaatat	gtgttccagt	1440
ctaagcctac	atgtctatgc	acagaggggc	tggtgtggatg	agcagcaagc	1500	
tagacaagca	gggtgtggca	gagggtagga	ggccctagca	tggtccaccac	1560	
tagttcactc	atggataaag	actagtatta	atagaaaattg	gaccacagca	cctgccagtt	1620
ttgattctgt	gccacctgcc	agccctgtct	ccacaaactg	gtctcattac	ttgtaaaaaa	1680
catccacgtc	cattgcaatc	tcaaaaccac	ctgatgcagc	tatgtaggaa	aagattctca	1740
tccccagttt	actagtatgg	aaattgaagc	cagagaggtg	aagtgaactca	cccaaagtca	1800
cacagtaagg	agacaaaagt	aagactggcc	tcaactttga	gctgagtgtt	ctttccatcg	1860
taccactgtt	ctgccatttt	gtgttatctt	cataatctgt	gtgaaggctg	ctctgtaatt	1920
atgcggaagca	aaatgtggac	ccccaaacac	agagcctatg	gagagctctg	ctccaggcat	1980
tttctcagcc	atttttcctt	ctcccgcttc	aaacccaaac	tgtcaacctc	aaccttctt	2040
ccctctcccg	ttgaggtctc	ctgagttgcc	tcacagaggt	tcttcttgaa	ttagacgggg	2100
ctgtgtcaac	agctctgggt	tcacgttctg	attctatcac	taatgagctg	tggtggcctt	2160
ggcaagctaa	ttcattttct	tgggtttcag	cttcttcaact	gaataataac	agtgtgtgta	2220
aaactaacia	ctggcatttg	aatagtttta	agatcacttt	gcataatccat	tatctaattg	2280
aattatcctc	ccccccacc	tttttaaatt	ttgagacgga	gtctcaccct	gtcccccagg	2340
ttagagtgca	atgtgcaatc	tcagctcaact	gccacctcca	cctcccagggt	tcaagaagatt	2400
ttctctcagct	tccaaagtag	ctgggattac	aggcgtgtgc	caccacaccc	agctaatttt	2460
tttaaaatct	ttagtagaga	ccgggtttca	ccatgttggt	caggctgggt	ttgaactcct	2520
gacctcgtga	tccacctgcc	tcggcctccc	gaagtgtctg	gattacaggc	atgagccacc	2580
gcgcccagcc	tatcattccc	ttttgcagat	gagaaaaactg	gaggcctgag	aagtaaaatg	2640
agtccaagtt	tactcagtaa	ataacagcca	agatgtgaac	cctggcctaa	ttagtctaat	2700
tcttttctct	tacagtggta	ttccttagag	ccttagactt	ttgcagagtg	ggctcaaagt	2760
gggaactggg	catggcagag	tggttagaaa	ccacactctg	actcactcag	ttgtctcaaa	2820
ggccagagca	gcaactctac	gccataacgt	ttcaacacac	cctaacctga	ttttcattca	2880
gaggcaatat	ggtatagcaa	cagttaaaaa	tctgggctct	tgttctggct	cttccattga	2940
cttctgtatt	atcctagaca	actttttttt	tgagatggag	tctcacccta	ttgccaggct	3000
ggagtgcagt	ggcgcgactc	cagctcactg	caacctccac	ctcccgattc	aagcaattct	3060
cctgcctcag	ccacccgagt	agttgggact	acaggtgcac	gccactacac	ccagctaatt	3120
ttttgtattt	ttagttagaga	tggtgtttca	ccatgttggt	caagatgggt	tcaatctcct	3180
gacctgtgtga	tcctccccc	tcggcttccc	aaagtgtctg	gattacaggc	gtgagccacc	3240
gcaccaaac	cttttttttt	ttttgagatg	gagttctgtc	cttgtcaccc	aggctggagt	3300
gcagtggcgc	caccttggtc	cactacaacc	tctgcctccc	agattcaagc	aagtctcctg	3360
cctcagcctc	ccgagtagct	gggattacag	gctcacgcca	ccatgcctgg	ctaatttttg	3420
tacttttagt	agagacaggg	tttcaccatg	ttggccaggc	tgatctcgaa	ctcctgacct	3480
caaagtatcc	accacacttg	gcctcccaaa	gtgctgggat	tacaggcggt	agccaccacg	3540
cccgcccta	gacaacttat	cttacctttc	tgtatctgtt	tccctgttag	taaaaatatg	3600
cagagaaatc	aaatgagtta	ttccagctct	gacaacctag	gattctcctt	acagtgcctga	3660
ggcactacca	gttttccaac	agcaacatca	gcattgttct	tctgtcttca	atgggcatgt	3720
gacagtatct	tggtgtgttg	aattgatact	gacttgccct	tttaaaaatt	tcttcaactc	3780
acagatccct	tcacatgata	gaagacagac	tctttgatga	ggtcggcgga	gcagttcact	3840
agccaatgat	gagagcagaa	aggcctagac	ctgcagccag	aagtgaaggc	agctcagttc	3900
tccgggatgc	ttctctacct	cctgagcacc	aattcctgga	ttccagtcac	tggtcacctc	3960
ttagaatgtc	tggtgtctat	cactgctccc	ctgcctccc	ttaacagctt	ggggaggtga	4020
ccagtgggtc	aggagggact	agacaattac	ctgtccagtg	tggtatggta	ggaagagtg	4080
agggtgtggc	acgtgaccaa	aattcacatc	cctcctcatg	gcagtcattc	agtatgtgta	4140
cttgtagaag	ttatttaacc	cattggagcc	ttaattccct	catctataaa	atggggataa	4200
tattatctac	ctcacaaagt	tatgaaaact	aaacatgatg	aatcaaaagc	acttggcatg	4260
tgagggtctat	taaaaatagcc	tgattttttt	tttctccccc	tctccccaat	gtatttgcct	4320
tggcccttgc	tttttaccct	ccagagctaa	gaggtagcag	agtctcttgg	gatgagtgat	4380

262

tcaccctctt	acttggcgac	cactgatgag	atcaacaaca	ggtgaactat	aaacctatta	4440
tttattgcag	aactaataaa	aaatccaaag	ccttgatatt	gtacatcttt	attattttcta	4500
aagcactttc	ctcaacctaa	tttcagtttt	tacaattggg	actcaagaaa	atagagacag	4560
aaatcatttg	attttgccca	gaaaccatct	gcttatattt	ataaggccac	ctaatttgaa	4620
atcacatata	gaccaggcgc	ggtggctcac	gcctgtaatt	ccaacacttt	ggaaggccaa	4680
ggcagggtga	tcacaaggtc	aagagattga	gacctcttgg	gccaaactgg	tgaaaccccg	4740
tctttactaa	aaacacaaaa	atcagctggg	cgtgggtggc	tggaacctgt	agtcccagct	4800
actcgggagg	ctgaggcagg	agaattgctt	gaacccagga	ggtggagggt	gcagtgagcc	4860
gaaattgcgc	cactgcactc	cagcctgatg	acagagcaag	actgtctcaa	aaaaaaaaaa	4920
aaaataccac	atatacttta	tctccaaaac	ctaactctgat	tataaattct	aagctaggaa	4980
acaaaaactt	ttgggacaag	tacttttttt	tttgacgggg	tctcctttgt	caccaggt	5040
ggagtgtcac	ccaggctgca	gtgaactgtg	acacaaccac	aattaattgc	atcctcgaat	5100
tccaggtctc	aatagatcct	cccactcag	ccttatgagt	agctgggatt	gcaggacgt	5160
gccaccacgc	ccagctaatt	tttgtatttt	atgtagagac	agtgtttcac	catgttgccc	5220
aagttggtct	cgaactcctg	ggctcatgca	atctgccctg	cctcagcctc	tcaaagtgt	5280
gggattacag	gcattgagcca	ctgcacggg	ccaggacaag	catttgataa	gccataaaaa	5340
gtaacctcat	tccagttagg	tacagtcttt	tgcttctaata	tgaccaagc	tccactgtag	5400
acagtattag	ctcctgagtc	cattttctcc	aggataaacc	acctaagagc	aaagacaact	5460
tggcaacata	agattttctgt	tttccttgct	tggagtctcc	tccttcgaaa	ccaccttcta	5520
tatcattcat	tatagacagc	tcagaaatac	aaactcgact	gtatgattta	aaacgcctta	5580
atgacttaat	acctacagga	tgaagtcaaa	attatttggc	aagagtcaca	gaatcctcca	5640
taatctggct	cactctaaat	tcactttgca	ctaggacagg	ggcaggcaaa	ccttttctga	5700
aagggtctaca	tattaattag	gctttgcagg	ccataggtct	ctatcacac	tactcaattc	5760
tgctcttgca	gcattggcagt	cgccataaac	aacatgtaaa	caaagtacga	tggtctgtgt	5820
ccaatgagac	tttattggca	gtgggcccaga	tttgggtagt	ctgctaactc	taactagaa	5880
ttcaacctca	tctttaaatac	tttcagatgg	gtgaatggaa	actgaccatt	ctctgatgat	5940
gaactatttt	tcttacaaca	ataaagagtc	agagtactca	tggtacgtat	tttaattaca	6000
agggtgtcaac	atacagatta	gcataagctt	caactgtcat	aagaaacatg	ttccatcaaa	6060
ttcagaaaca	gcaggatatca	gtgaaactgg	agcaagcatt	ttgaagactt	caacgtattg	6120
gatggaattt	ttcaaaaatt	tcaccatatg	ttttcttata	tataaaagga	aagatcataa	6180
aagattttatt	ttaaaaatat	gttttaaaaa	ttgtatttcc	taaacgaaaa	ttaacactca	6240
ctaactcttac	gattgaaatc	ctgctgtggt	ctgaatgttc	atgtccccc	aaagttcata	6300
aattgaaatg	taaccccaa	gataatgata	ttaagaggtt	aggactttgg	gaggtgatta	6360
ggtcacaaag	gctctgtcct	catgaggggg	atcggcttag	gggacctgt	ttgcctcttc	6420
taccatgtga	ggacacagca	agatggcatc	atctatgaag	cagagtgggc	cctcagcaga	6480
caccaactgt	gctggtaccc	tgatcttgga	cttcccagcc	tccagaattg	caagcaataa	6540
atttctatta	cttatatatt	accagctcta	ttctgcaatt	atacaggtgg	taagaaaaac	6600
aaagttaaaa	aaattttttt	aattaccag	tttaaggcat	tttggtatag	taggccaaac	6660
ggactaagac	aaacccctaa	gaatttcctt	attttcttgt	ccttgactat	ggcttggtaa	6720
tcactgaagg	attttcttcc	attgactgaa	gataaacttt	ggaggaaatc	gtgatgacaa	6780
ccaaatgact	gccaagaggg	acaaggtgct	gcaggagta	tcctgactga	agagggtgaag	6840
gaagaaataa	acacagaggg	gcacaggtca	gctaggagag	gccaacagcc	aatgtggtca	6900
agctctccgg	gctcccactg	tctgtgcatg	aggctcttgg	cacaactgcc	actaatctgc	6960
agctcagaaa	gagaatgagc	cctgaagcta	tacacactcc	tgacagacaca	gggaactcat	7020
ggaactatgt	ctaggcaaa	agccagagg	ctgagactga	agactcctca	agccactggg	7080
cctcactcct	agtaatcaat	atatccaaga	tgacttccag	ctctaacatt	taacggttct	7140
gggtattatg	cattcccgat	acatccacta	ttcatggctt	tgtgctagtc	tttatgctct	7200
tctttggcaa	aaaaagaaac	tgtatctttc	tgatccacca	taaatatcat	atatgtgact	7260
gaaggctgtg	ggaatattaa	agagtaataa	aatttttagag	ctaaataaga	ccttagagat	7320
cattcagtgt	aatgaaattt	aatgttttta	tatcacgcat	ttacattaac	agaagaattt	7380
tttttttttt	ttttttttga	gacaggtct	cgctctgtca	cctaggctgg	aatgcagtgg	7440
tgtgatcacg	gctcacggca	ccttgtcctc	ccaggctcaa	gtaatcctcc	tgccctcagcc	7500
tcccaagtca	ctgggtctat	aggcatgtgc	cacctcacc	agctaatttt	ttaattttct	7560
gtagagatga	ggtctcacta	tggtgcccag	actggggaaa	atctattttat	gtttacaagt	7620
tcaaattttt	tctatactca	ttcatttaca	catttaataa	ggctatgtgt	gccaaccccc	7680
tggggaaacc	aaaaaaaaact	gtcgtagtag	ttaaactccc	agcctacaga	tactcatata	7740
tgtgcacatc	tgtgtgtgt	atatgtgtgt	aaaacacagg	tgagaaaagt	tatattacaa	7800
ctattaatag	attcatagca	gactagagat	agagcaccct	gagggaaatgc	ctgactgtag	7860
ctgggtgaaa	gcttcactga	gataataaaa	gcagaaattt	gctagggtgga	tggggtggaa	7920
acagggggcaa	gaggaagaat	aacatagcag	gaagaaggta	caacatgtat	aaagtaatat	7980



263

agggcagggtt	cgggacaaa	catttcacca	ggcaaatgat	gagtgatgag	gaatgaggaa	8040
gtattccata	cggttcatat	ccactattat	gcataagtaa	gtgcctgcta	tgtgtaggct	8100
ctatacaaga	ggctggggaa	acaaagacga	agctacaatc	catgaagaac	acacacatgt	8160
gtatatcata	tggtagataa	gaatgtgggt	aaagtgtttc	taccagagga	caggcaatta	8220
gctaacctgg	agtaaatgag	ccatccctaag	gagtcctggat	tttatccact	aggcaatgga	8280
tggtctatatt	attttatttt	aattttattt	tattttttga	gacacagtct	tgctgtgaca	8340
cccaggctgg	agtgcaatgg	cgcgatctca	gctcactgca	acctccgact	cccagggttca	8400
agcgattctc	ctgcctcagc	ctcccaagta	gctgggctta	caggcaccgc	ccatcatgcc	8460
cggtctaattt	ttgtattttc	aatagagaca	gggtttcacc	atgttggcca	ggctgggtctc	8520
aaactcctga	cctcagatga	tctgccccgc	tcggcccccc	aaagtgtctgg	gattacaggc	8580
gtgagccact	gcgaccagcc	ggatgactat	tttaaacaga	tgtgatcaga	tttgctgtca	8640
ttggaaacctg	gaccaaaagca	agtggtagt	taggaggcaa	gtgccacagt	ccaagcaaga	8700
gattaacaag	gcctgaacca	ggtagtggtta	gtgggagagg	agagtcaaaag	ttaaagaaata	8760
tttaggaagt	agaactgata	agacctgatg	actaatggga	agtgaagag	aaagacttga	8820
tgattctcag	gcttctggct	tgagtgtcca	ggtggacagt	agtgccattc	tctgaagcag	8880
gacacagagg	agcaggagggt	ttgggaaggg	agaggggata	tgagttttgt	ttgctgtcca	8940
aaggacacgg	aggtagtcag	aaactggata	tattaattca	agagaatttt	ggtctataga	9000
ctaagatgtg	ggagtcaaca	gaatttagaa	ggtatctaaa	gccatacaca	tggaataagat	9060
taaccaggga	aaataataat	acagtaaaaca	catattatct	aaaattaact	tgaaataacct	9120
tcttcaggaa	aatcctctgg	atgtaatctc	atatatccaa	acatttcacg	gtccctcaca	9180
gcatacaggt	agtcttcacg	ttttacaaga	taatatccag	caaaaaaaaa	ggccgttaata	9240
tatagaagct	ggcgtatgca	acctga				9266

&lt;210&gt; 352

&lt;211&gt; 9160

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 352

aagcaaccat	gcaggtgcta	accaagcggt	accccaagaa	ctgcctgctg	accgtcatgg	60
accggtatgc	agccgagggtg	cacaacatgg	agcagggtggt	gatgatcccc	agccttctgc	120
gggacgtgca	gctgagtggg	cctggggggc	aggcccaggc	tgaggccctt	gatctctaca	180
cctacttcac	catgctcaag	gccatctgtg	tgatgtgga	ccatgggctg	ctgccgcggg	240
aggagtggca	ggccaagggtg	gcaggcagcg	aagagaatgg	aaccgcagag	acagaggaaag	300
tcgaggacga	gagtgcctca	ggagagctgg	acctggaagc	ccagtccac	ctgcacttct	360
ccagcctcca	tcacatcctc	atgcacctca	ccgagaaagc	ccaggagggtg	acaaggaaat	420
accaggaaat	gacgggacaa	gtttggtaga	ccttggacac	tagggaagggt	aatggtggcc	480
atgctgggtg	gtgtgagtct	acaaagggac	attccaggag	aggagagggg	gcagtgggtgc	540
aaccactctg	gagaggaaca	gcctgacttt	cagacagagc	cactcttggg	tcagggtatt	600
gggaccacaa	cctaggaggg	ccaaagacta	ggcctgtggt	actatccttc	tgacctcaaa	660
ttggcaattg	caatgaagtg	atatggaaac	agagggaaaa	gtggcctgtg	agggcatatc	720
tcatatgcac	atatatgtgt	ttgtgcatgt	gtgcatttat	tagtatgtga	atgcttgtaa	780
atgtgtgaat	tgaatgagtg	tgttctcatc	agtgactttg	ttaagaattt	aattgaagag	840
gggccaggcg	cgttggctca	caccaaagca	ctttgggagg	ccgaggcggg	cggatcatga	900
ggccaggaga	ttgagaccat	cctggctaac	atggtgaaac	ccaatctcta	ctaaaaatac	960
aaaaaattag	ctgggcgtgg	tggtgggtgc	ctgtagtccc	agctactcgg	gaggctgagg	1020
caggagaatg	gcatgaacct	gggaggcaga	ggttgacgtg	agctgagatt	gtgccactgc	1080
actccagcct	aggtagacaga	gggagactcc	atctcaaaaa	aaaaaaaaaa	acttacctaa	1140
ggcatgcaca	ttgatttaag	tgaacattgt	gaattccatt	tgtgtgacag	tggttcccaa	1200
cattttttca	agtcacagaa	catggaaaat	tattatatgg	cacatgggga	tacatagggtg	1260
aggctgcttg	cagtactgct	acaacagggt	gggggtactc	tgaccatccc	aggttggaaac	1320
ccaccaaacg	ggaagccgag	ggaccagtca	tggcactcta	atccattcca	ggcaaactgg	1380
agtatgcaga	catgcctggt	gggaagccct	gtgtatgta	catatgaata	tgtgtccag	1440
tctaagccta	cagtctatg	cacagagggg	ctgggtgggt	gagtggtgat	gagcagcaag	1500
ctajacaagc	agggtggtgg	agagggtagg	agggtgggaag	gggccctagc	atggtcacca	1560
ctagttcact	catggataaa	gactagtatt	aatagaaatt	ggaccacagc	acctgccagt	1620
tttgattctg	tgccacctgc	cagccctgct	cccacaaact	ggtctcatta	gttgtaaaaa	1680
acatccacgt	ccattgcaat	ctcaaaaacca	cctgatgcag	ctatgtagga	aaagattctc	1740
atccccagtt	tactagtatg	gaaattgaag	ccagagaggt	gaagtgactc	acccaaagtc	1800
acacagtaag	gagacaaaag	taagactggc	ctcaactttg	agctgagtgt	tctttccatc	1860

264

gtaccactg	tctgccattt	tgtgttatct	tcataatctg	tgtgaaggct	gctctgtaat	1920
tatgcggaat	aaacatggga	ccccaaaaca	cagagcctat	ggagagctct	gctccaggca	1980
ttttctcagc	catttttctt	tctcccgtt	caaaccacaa	ctgtcaacct	caacccttct	2040
tccctctccc	gttgaggctc	cctgagttgc	ctcacagagg	ttcttcttga	attagatggg	2100
gctgtgtcaa	cagctctggg	ttcacgttct	gattctatca	ctaatagagc	gtggggcctt	2160
gggcaagcta	attcatttct	ctgggtttca	gcttcttcac	tgaataataa	cagtgggttg	2220
aaaactaaca	actggcattt	gaatagtttt	aagatcactt	tgcatatcca	ttatctaata	2280
gaattatcat	ccccccacac	cttttttaaa	tttgagacgg	agtctcacc	tgtccccag	2340
gttggagtg	aatgtgcaat	ctcagctcac	tgccacctcc	acctcccagg	ttcaagagat	2400
tttctcagc	ttccaaagta	gctgggatta	caggcgtgtg	ccaccacacc	cagctaattt	2460
ttttaaaatc	tttagtagag	accgggtttc	accatgttgg	ccaggctggg	cttgaactcc	2520
tgactctgtg	atccacctgc	ctcggcctcc	cgaagtgtcg	ggattacagg	catgagccac	2580
cgcgcccagc	ctatcattcc	cttttgcaga	tgagaaaact	ggaggcctga	gaagtataaa	2640
gagtccaagt	ttactcagta	aataacagcc	aagatgtgaa	ccctggccta	attagtctaa	2700
ttcttttctt	ctacagtggg	attccttaga	gccttagact	tttgcagagt	gggctcaaag	2760
tgggaactgg	gcatggcaga	gtgggtagaa	accacactct	gactcactca	gttgcttcaa	2820
aggccagagc	agcaactcta	cgcataacg	tttcaacaca	ccctaacctg	attttcattc	2880
agaggcaata	tggtatagca	acagttaaaa	atctgggctc	ttgttctggc	tcttccattg	2940
acttctgtat	tatcttagac	aacttttttt	ttgagatgga	gtctcaccct	attgccaggc	3000
tggagtgcag	tggcgcgatc	tcagctcact	gcacacctca	cctcccgatt	caagcaattc	3060
tcttgctcca	gccacccgag	tagttgggac	tacaggtgca	cgcactaca	cccagctaata	3120
tttttgtatt	tttagtagag	atggggtttc	accatgttgg	ccaagatggg	ctcaatctcc	3180
tgaccttgtg	atcctccccg	ctcggcttcc	caaagtgtcg	ggattacagg	cgtgagccac	3240
cgcacccaac	cttttttttt	tttttgagat	ggagtcttgc	tcttgtcacc	caggctggag	3300
tgcagtggcg	ccaccttggc	tactacaac	ctctgcctcc	cagattcaag	caagtctcct	3360
gctcagcct	cccagtagc	tgggattaca	ggctcacgcc	accatgcctg	gctaattttt	3420
gtacttttag	tagagacagg	gtttcaccat	gttggccagg	ctgatctcga	actcctgacc	3480
tcaaatgac	caccacacct	ggcctcccaa	agtgtcggga	ttacaggcgt	gagccaccac	3540
gcccgccct	agacaactta	tcttaccctt	ctgtatctgt	ttccctgtta	gtaaaatata	3600
gcagagaaat	caaatgagtt	attccagctc	tgacaaccta	ggattctcct	tacagtgtcg	3660
aggcactgcc	agttttccaa	cagcaacatc	agcattgttc	ttcctgtctc	aatgggcatg	3720
tgacagtatc	ttggttgttt	gaattgatac	tgacttggcc	ttttaaaaat	ttcttcactc	3780
cacagatccc	ttcacatgat	agaagacaga	ctctttgatg	aggtcggcgg	agcagttcac	3840
tagccaatga	tgagagcaga	aaggccctaga	cctgcagcca	gaagtgaagg	cggctcagtt	3900
ctccgggatg	cttctctacc	tcctgagcac	caattcctgg	attccagtea	ctggctcacc	3960
tttagaatgt	ctgttgctat	tcactgctcc	cctcgctcct	cttaacagct	tggggagggtg	4020
accagtgggt	caggagggac	tagacaatta	cctgtccagt	gtggtatggg	aggaagagtg	4080
taggtgttgg	cagtgacca	aaattccat	ccctcctcat	ggcagtcatt	cagtatgtgt	4140
acttgtacaa	gttatttaac	ccattggagc	ctaaattccc	tcactataaa	aatggggata	4200
atattatcta	cctaccaagc	ttatgaaaac	taaacatgat	gaatcaaaag	cacttggcat	4260
gtgagggcta	ttaaaatagc	ctgatttttt	ttttctcccc	ctctcccaaa	tgtatttgc	4320
ctggcccttg	ctttttacc	tccagagcta	agaggtagca	gagtctcttg	ggatgagtga	4380
ttcaccctct	tacttggcga	ccactgatga	gatcaacaac	aggtgaacta	taaacctatt	4440
atttattgca	gaactaataa	aaaatocaaa	gccttgattt	tgtacatctt	tattatttct	4500
aaagcacttt	cctcaacctt	atttcagttt	ttacaattgg	tactcaagaa	aatagagaca	4560
gaaatcattt	gattttgccc	agaaaccatc	tgcttatatt	tataaggcca	cctaatttga	4620
aatcacatat	agaccaggcg	cggtaggtca	cgctgtaat	tccaacactt	tggaaaggcca	4680
aggcagggtg	atcacaaagt	caagagattg	agaccatctt	ggccaacatg	gtgaaacccc	4740
gtctctacta	aaaacacaaa	aatcagctgg	gcgtcgtggc	atgcacctgt	agtcccagct	4800
actcgggagg	ctgaggcagg	agaattgctt	gaaccaggga	ggtagagggt	gcagtgagcc	4860
gaaattgcgc	cactgcactc	cagcctgatg	acagagcaag	actgtcgtct	caaaaaaaaa	4920
aaaaaaaaata	ccacatatat	tttatctcca	aaacctaatc	tgattataaa	ttctaagcta	4980
ggaaacaaaa	acttttggga	caagtacttt	tttttttgac	gggtctcctt	ttgtcaccca	5040
ggctggagtg	tcacccaggc	tgtagtgaa	tgtgacacaa	ccacaattaa	ttgcatcctc	5100
gaattccagg	gctcaataga	tcctccacc	tcagccttat	gagtagctgg	gattgcagga	5160
acgtgccacc	acgcccagct	aatttttgta	ttttatgtag	agacagtgtt	tcaccatgtt	5220
gcccaagttg	gtctcgaact	cctgggctca	tgcaatctgc	cctgcctcag	cctctcaaag	5280
tgctgggatt	acaggcatga	gccactgcat	cgggccaggga	caagcatttg	ataagccata	5340
aaaagtaacc	tcattccagt	taggtacagt	cttttgcctc	taattgcacc	aagctccact	5400
gtagacagta	ttagctcctg	agtcattttt	ctccaggata	accacaccaa	gagcaaagac	5460

265

aacttggcaa	cataagattt	ctgttttctt	tgtctggagt	ctcctccttc	gaaaccacct	5520
tctatatcat	t cattataga	cagctcagaa	atacaaacct	gactgtatga	ttttaaaccgc	5580
cttaatgact	taatacctac	aggatgaagt	caaaattatt	tggcaagagt	cacagaatcc	5640
tccataatct	ggctcactct	aaattcactt	tgcactagga	caggggcagg	caaaccctttt	5700
ctgaaagggc	tacataattaa	ttaggctttg	caggccatag	gtctctatca	caactactca	5760
attctgctct	tgcagcatgg	cagtcgccat	aaacaacatg	taaacaatg	agcatggctg	5820
tgttccaatg	agactttatt	ggcagtgggc	cagatttggg	tagtctgcta	actctaaact	5880
agaattcaac	ctcatcttaa	aatctttcag	atgggtgaat	ggaaactgac	cattctctga	5940
tgatgaacta	tttttcttac	aacaataaag	agtcagagta	ctcatggtac	gtattttaat	6000
tacaaggtgt	caacatacag	attagcataa	gcttcaactg	tcataagaaa	catgttccat	6060
caaattcaga	aacagcaggt	atcagtgaag	ctggagcaag	catttttgaag	acttcaacgt	6120
attggatgga	attttttcaa	aatttcacca	tatgttttct	tatctataaa	aggaaagatc	6180
ataaaaagatt	tatttttaaa	aatgttttta	aaaattgtat	ttcctaaacg	aaaattaaca	6240
ctcactaatc	ttatgattga	aatcctgctg	tggcttgaat	gttcatgtcc	ccccaaagtt	6300
cataaattga	aatgtaaccc	ccaagataac	gatattaaga	ggtaggact	ttgggaggtg	6360
attaggtcac	aaaggctctg	tcctcatgag	ggggatcggc	ttaggggacc	ttgtttgcct	6420
cttctacat	gtgaggacac	agcaagatgg	catcatctat	gaagcagagt	gggccctcag	6480
cagacaccaa	ctgtgctggt	accctgatct	tggacttccc	agcctccaga	attgcaagca	6540
ataaaattct	attacttata	tattaccag	tctattctgc	aattatacag	gtggtaagaa	6600
aaacaaagtt	aaaaaatttt	ttttaattac	ccagtttaag	gcattttggt	atagtaggcc	6660
aaacggacta	agacaaaccc	ctaagaattt	ccttatcttc	ttgtccttga	ctatggcttg	6720
gtaatcactg	aaggattttt	tttcattgac	tgaagaataa	ctttggagga	atctgtgatg	6780
acaaccaaat	gactgccaag	agggacaagg	tgtctgccagg	agtatcctga	ctgaagaggt	6840
gaaggaagaa	ataaacacag	aggggcacag	gtcagctagg	agaggccaac	agccaatgtg	6900
gtcaagctct	ccgggctccc	actgtctgtg	catgaggctc	tgggcacaac	tgccactaat	6960
ctgcagctca	gaaagagaat	gagccctgaa	gctatacaca	ctcctgcaga	cacagggaac	7020
tcatggaaact	atgtctaggg	aaagagccag	aggctctgaga	ctgaagactc	ctcaagccac	7080
tgggcctcac	tcctagtaat	caatatatcc	aagtagactt	ccagctctaa	catttaacgg	7140
ttctgggtat	tatgcattcc	cgatacatcc	actattcatg	gctttgtgct	agtctttaag	7200
ctcttctttg	gcaaaaaaag	aaactgtatc	tttctgatcc	accataaata	tcataatagt	7260
gactgaaggg	tgtgggaata	ttaaagagta	ataaaaatttt	agagctaaat	aagaccttag	7320
agatcattca	gtgtaatgaa	atttaaattgt	tttatatcac	gcattttacat	taacagaaga	7380
attttttttt	tttttttttt	ttgagacagg	gtctcgctct	gtcacctagg	ctggaatgca	7440
gtgggtgtgt	cacggctcac	ggcaccttgt	ctcccagggc	tcaagtaatc	ctcctgcctc	7500
agcctcccaa	gtcaatgggt	ctataggcat	gtgccacctc	acccagctaa	ttttttaatt	7560
ttctgtagag	atgaggtctc	actatgttgc	cgagactggg	gaaaatctat	ttatgtttac	7620
aagttcaaat	tttttctata	ctcattcatt	tacacattta	ataaggctat	gtgtgccaaa	7680
cccctgggga	aaccaaaaaa	aactgtcgta	gtagttaaac	tcccagccta	cagataactca	7740
tatatgtgca	catctgtggt	gtgtatatgt	gtgtaaaaca	caggtgagaa	aagtttatatt	7800
acaactatta	atagattcat	agcagactag	agatagagca	ccctgaggga	atgcctgact	7860
gtagtgagg	gaaagcttca	ctgagataat	aaaagcagaa	atttgcctagg	tggatggggt	7920
ggaaacaggg	gcaagaggaa	gaataacata	gcaggaagaa	ggtacaacat	gtataaagta	7980
atatagggca	ggttcgggac	aaagcatttc	accaggcaaa	tgatgagtga	tgaggaaatga	8040
ggaagtattc	catacgggtc	atatccacta	ttatgcataa	gtaagtgcct	gctatgtgta	8100
ggctctatac	aagaggctgg	ggaaacaaaag	acgaagctac	aatccatgaa	gaacacacac	8160
atgtgtatat	catatggtag	ataagaatgt	gggtaaagtg	tttctaccag	aggacaggca	8220
attagctaac	ctggagtaaa	tgagccatcc	taaggagtct	ggattttatc	cactaggcaa	8280
tggatgactt	atttatttta	ttttaatttt	attttatatt	ttgagacaca	gtcttgctgt	8340
gacacccagg	ctggagtgca	atggcgcgat	ctcagctcac	tgcaacctcc	gcctcccagg	8400
ttcaagcgat	tctcctgcct	cagcctccca	agtagctggg	cttacaggca	cccgcctatca	8460
tgcccgggcta	atttttgtat	ttctaataga	gacagggttt	cgccatgttg	gccaggctgg	8520
tctcaaaact	ctgacctcag	gtgatctgcc	ccgctcgccc	ccccaaagtg	ctgggattac	8580
aggcgtgagc	cactgcgacc	agccggatga	ctatttttaa	cagatgtgat	cagatttgct	8640
gtcattggaa	ataagaccaa	agcaagtggg	gagtttaagag	gcaagtgcaa	cagttccaagc	8700
aagagattaa	caaggcctga	accagggtag	tgttagtggg	agaggagagt	tcaaagttaa	8760
gaaatattta	ggaagtagaa	ctgataagac	ctgatgacta	atgggaagtg	aaagagaaag	8820
acttgatgat	tctcaggctt	ctggcttgag	tgtccagggtg	gacagtagtg	ccattctctg	8880
aagcaggaca	cagaggagca	ggagggtttg	gaaggcagag	gggatatgag	ttttgtttgc	8940
tgtccaaagg	acacggagggt	agtcagaaac	tggatatatt	aattcaagag	aatttttggtc	9000
tatagactaa	gatgtgggag	tcaacagaat	ttagaaggta	tctaaagcca	tacacatgga	9060

266

taagattaac	cagggaaaat	aataatacag	taaacacaga	ttatctaaaa	ttacttgaa	9120
ataccttctt	caggaaaatc	ctctggatgt	aatttcatat			9160

&lt;210&gt; 353

&lt;211&gt; 1698

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 353

gcactcaaag	gctcaactcc	ccacaggcgt	gtgttgccag	gggcagaagg	cttggccctt	60
gggtcagcat	actctccgga	cagctcatcc	ctgccagccc	aggtccctgc	agccctgggg	120
ctagcacagg	ggatgcgga	ctcggcctag	gtccccacag	ctgtggggct	ggctcggggg	180
acggatctct	gctaagcatg	gcccctgcc	gctcaggctc	ctgccactca	gtggatggga	240
ctttggcgga	gtgtggggcc	cctgcaggga	gggtctagac	aagcaacacc	aggaacctga	300
agcctccctg	gccggggctc	agctgtcgcc	aggatcgcaa	cagttaagct	gcctgcagca	360
ggataagtga	gccgatgctg	ctccttaatc	agggacatcg	aatcggaggc	cctgggagga	420
gcagccggct	ggctgccctg	cagaggccag	gtctgcccag	caaaccacag	aaggtgtggc	480
gtccccgctt	cgccggccaag	atgggtgctg	tgctgcgcca	tcctttgtgt	gcccgggaag	540
ggcgttccgg	gagccgggct	gggggctcct	gactcgcact	gggcagcatg	acggtgcgcc	600
ggctgtcact	gctgtgccgg	gacctctggg	cgctgtggct	gctgtggaag	gccggcgag	660
gtgcgtgggg	cgccggcggg	tcctcgccct	cccggaaagg	gttgtggggc	gacagtgcgg	720
ggacgcgggg	cggggggtgga	cgttctgggc	ccagccctgt	cctcagaggc	tgctggggca	780
gaagcccggg	gctgggggat	gccggggatg	gatgttgggg	tgggtgcctc	cgagaccaga	840
ggagccctgt	tccttggcag	ggaagggtgt	cacgggcctt	gcccgatgga	tggtttaggg	900
ccatggccct	gggggtccctg	gtgagcagtg	gggcccctc	tgcccttggt	ctgtgaggga	960
ctgtctgtgc	tggteccaga	aggctgggat	cacctttcca	ctggctcctt	tgttcgaggt	1020
ttttcataga	caggctatgt	ggacaaatga	gggcagcgcc	cacgtctggc	tgggtggagg	1080
gctgcggctc	ctccttggag	gggacgcctg	gccactgctg	tccccacaat	ggggccaccc	1140
gtgggtgcaag	gcgtgacaag	ctgcctctc	taggtaagca	ggacttggga	ggccctgggc	1200
caagcctgtg	gacccggctg	ggcgccctct	gtgggtctcag	gtttgggtgt	gtttggtctg	1260
gtcagggctc	aggggctgct	ggtccacact	ggccccatcc	tgacaatttg	agctttgggg	1320
caaggtccct	ggagaagggg	tcacgtgggg	aggaaacagc	ctgggttttg	ttgatgcttt	1380
tctaagaatg	gagtactcgt	tttcaagaga	tttgtcctaa	ttatattttc	cagcgggtac	1440
ttatgccaa	tattgatgaa	taattcataa	aataagcatc	tttgtgaatt	ttagtgaatc	1500
agaccttaac	tatcaacggc	aatgaatgaa	catctaaagt	ttccaatttt	aaagtaaaga	1560
actggctggg	tacagcagtt	cacgcctgta	atcccagcac	tttgggaggc	caaggctaga	1620
ggatcgcttg	agcccaggag	tttgagatca	gcctgggcaa	cataccaaga	cctcatctgt	1680
taaaaaaaaa	aaaaaaaa					1698

&lt;210&gt; 354

&lt;211&gt; 11556

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 354

tccttacagg	ggagccccag	gggagctggg	gcagcatgac	tggggtgata	aatggccgga	60
aatttggcgt	ggccacactc	aacaccagcg	tgatgcagga	ggcactctcc	ggggctagca	120
gcatccacag	cagcatccgc	catgtcccag	caaacgtggg	tgagtggaa	gcagagcatc	180
acctgcctct	gggttattgt	cacagcccag	cgagcatcct	ccagaacatg	ctggacctag	240
gaggcgagga	gcctgtgccc	cgagacttgc	tcaaggcctg	atgaccagag	cacgtctgac	300
catctctcaa	agctgagtgc	aatccaaagt	ggactcagat	gcaggcaact	tcctgtcccc	360
ctcacaacct	ccccaaaaca	aaggaaactg	atttacagtc	agaccaagag	tgtgtgaaac	420
ggtcagtggt	ctgggggtgc	gggcgctcag	attgtggttt	cccaagccac	cgatggctcc	480
ctgaggcttt	tccccattta	agttaaaagt	caggctgatg	gaagtggagg	gatctccagt	540
catgagttag	gggtgcaggc	tggaggtgac	gggaagcggg	aaacatggag	aattgaattg	600
cctagaaaac	ctagaggact	aagaagagtc	acctgcacac	agagctctca	tgtacggtgt	660
ctgagcgatg	aatgctctga	gagacttgca	gagcttgtga	cagtggacgt	caactgtctc	720
cccttcccaa	ggaatccctg	gcccctcgtg	ggggccagag	aggggcagta	ttcatggagt	780
cttcaactgaa	agtagctcct	ctgaagctgc	ccttggccat	ggtcccgcac	gagcagtggt	840
gggtcagggg	atthtgcctg	ggaagtcact	ctgagctggc	tgtcagcaga	cagcagatga	900

267

agcgagacgc	tgcccagaca	tggctgctta	ttctagctgc	aggagtgtga	ggcctggaga	960
agcatctggc	cccaagcccg	tggaccaggc	tttgttccat	gaaacagacg	cacagagagg	1020
ctgggaaggt	ggtgcccatg	cacaggggcc	tggccagctc	ctgtgaacct	tgcaaaagctg	1080
gcaccgtccc	tgactcagag	caagtgggga	gcgggtgtgt	tccccctgcc	cagtccatgg	1140
ccccacctgg	tcctgcgtgg	agggcggggc	atcacatgaa	gaagatctga	gaatccacgt	1200
ccagggccat	tttttggttc	ttttttcaaa	cggtttggaa	caaaccgggg	ctggtccaga	1260
agggatctgc	aagttagaaa	agttggttca	cttcaactca	gcaaatatat	aatgacagtc	1320
tgtggagtc	ctggtccgt	ggtgaccggg	ggccctcaat	cggatattgt	tgaactgagt	1380
taaatatcaa	caaggtacat	gcatttattt	cttctttttt	ttttcttttt	gagactgctt	1440
ctcgctttgt	tgcccaggct	ggagtgcagg	tggtcagctc	acagctcact	gcagcctcaa	1500
cctcccaggc	tcaagcgatc	ctcctacctt	agcctcccca	gtagctagga	ctataggtga	1560
atgccaccac	acctggctaa	tgtccatata	tatatatata	tatttttttt	ttttttaatt	1620
tttttttttg	agacggagtc	tcgctctgtc	accaggcta	gagtgcagtg	gcatgatctt	1680
ggctcactgc	aagctctgcc	ttccgggttc	acaccattat	cctgcctcag	cctcccaagt	1740
agctgggact	acagacgcct	gccacggcgc	ccggctaatt	tttttttttt	ttgtattttt	1800
agtagagaca	gggtttcacc	gtgttagcca	ggatggcttc	gatctcctga	cctcgtgatc	1860
tgactgcctc	ggcctcccaa	agtgtcggga	ttacaggcat	gagccaccgc	gcccggcctg	1920
tccttaatat	ttttattttt	tgtagagaca	gagtctcact	atgtcgccta	gcatttcctt	1980
gtataaattt	ttaaatttca	gttactccag	gaagtagatt	atttgcctcc	accagatccc	2040
tgattctggt	ataataattg	gcatggcagt	cacaaggctg	agtatggaca	tcaagggaag	2100
gggctgagct	ctcctggggg	cagtggggag	ccatgacggg	accttgaaca	ggaggtggct	2160
gccttgagga	tcagctctaa	cccggcctct	atgccctgcc	ccaccagggg	cctctgatgc	2220
gggtgctcgt	ggtcaccatc	gccccatct	actgggccct	ggccagagag	agtggggaag	2280
ccctgaatgg	ccactctctg	actgggggca	ggttccggca	ggagtccacac	gtggagtttg	2340
ctacaggtaa	acagggcctc	ccccaggtag	gccaggtagg	actaaagcct	gcgccaggga	2400
cctcccgtgg	tgactctggg	ctgggtgggg	atggtttgca	ggggagctgc	tcacgatgac	2460
ccaggtgggc	cggggtctgg	atcccgatgg	cctcctgctc	ctcgacgtgg	tggtcfaatg	2520
cgttgtcccc	gagagcctgg	ctgacgcaga	tcttcaagtg	caggtcgggg	gtcaagccct	2580
ggggtgtgca	gacagggtag	gtgagagaga	cgaagggtgc	cggctctcaa	ccaccctga	2640
gcagccaggc	ccactctccc	ttctgacagc	gctgcagggc	tgggtcacag	tctagccttg	2700
gacttagggg	aggatgagca	gttgaacag	gctcaagttc	aagcgcttga	agggatgctc	2760
tgagccctgc	gacttcagat	cagagtattc	ttgttcaaaa	gcacgagtc	tgaagagagg	2820
tgactgcct	agacagccc	agctgggttag	aagaggctct	gggaggctca	ccccatctcc	2880
tcccaaggct	caccccatct	cctcccaagg	ctcaccctat	ctcttcccaa	ggctcacccc	2940
atctcttccc	aaggctcacc	ccatcttctc	ccaagcctcc	tcaagccctc	gagttggggg	3000
aagggtctca	ggctgcttgg	gagttgaaat	ctcagcattt	tcctcctccc	cttccaaccc	3060
tgaccctttt	ctcctctctc	cccaccctcc	ctcctcctcc	cctcctcttc	atcctgcagg	3120
actttgagga	gcactacgtg	caaacagggc	ctggccagct	gttcgtgggg	tccacacagc	3180
gcttcttcca	gggcggcctc	cctcgttccc	tacgttgcaa	ccacagcatc	cagtacaacg	3240
cggccggggg	ccccagccc	cagctgggtgc	acacctgcg	ggcctcagct	atcagctcgg	3300
cttttgatcc	agagcccgag	gccctgcgct	tccagctcgc	tacagccctg	caggcgggtg	3360
aggccctctc	gctttgttcc	acccccactg	ccccagctaa	aacctgccag	ggggcccaaa	3420
tgcacgtggc	tggaaatccac	ccctgccctc	aacatccact	gaccatgggc	cagagacttc	3480
agactgagac	ggcccggctg	gcctactcac	ctggcctgtc	cccactccca	tccatccacc	3540
ccccactcct	cacagggaca	cagctctcta	agccaccctt	gttccaacct	ctggatcctt	3600
tccccaggcc	ccagggtgaa	ggtccaacca	ccccaggctg	atgttcagga	actgagtcac	3660
ccgcctctct	tctcccagg	gcacctgcac	tgaggccaca	cccaaggagc	caggaaaccac	3720
tgttggaaac	ctagagaccc	ccaggaacat	gctttctggt	caccagtgga	atgctaaaga	3780
tacatacggt	cacattattt	gaggccccaa	agtgttttga	acattgaatg	agagacagtg	3840
ctaagagcac	cgctttgagg	tcaggcagac	cccagttcaa	atccgaggta	caccactttc	3900
tggctgtggg	accttggggg	caatgtcctg	gtcctctcgg	agcttcagtg	ttcccatctg	3960
caccgcgggc	atgacatcgc	ctgccttgca	gggtgtgcgc	gtacagatgt	tgtctctaaa	4020
accctagcct	ggcacctagt	ggctgcctca	tcaaggctgg	ctgtccctac	aatttatgtg	4080
gaccaagctt	gtccaaccca	tggccacacg	ggcgatgcc	accagaaca	gctttgaaatg	4140
cggcccaaca	caaatttata	aactttctta	aacatttatg	atattttttg	tgattttttt	4200
ttttttttta	gctcatcagc	tatecttagt	gttggtgtat	tttatgtgtg	acccaaggca	4260
attctctctc	ttccagcgtg	gcccacagaa	gccgaagat	aggacacccc	tgatttagac	4320
tgccttgtgt	ccttctctgc	tccagaaccc	agctaccccc	tccccctgct	ttgctttttg	4380
tgcccgtctg	acgctatcct	ctgccctccc	gcacgggtct	tgtgcattgc	tgctatggtc	4440
tcaggagagc	cgttttgac	gtgttgacct	cctgcgtttt	attttaatgg	ttttcctggg	4500

gctgcctgac	tcactggcca	gccccactgg	gagcccttca	ggacacattt	ccttgactgg	4560
gcgtgccctg	cagtcacgc	ctccaacagg	cctgggcagg	aaatgggctt	gctgactctc	4620
tggcaccgtc	ttggctctgc	ctggctaagc	tggcagtggg	ggagctgtga	gcctgggcta	4680
tggccagggc	agccttggga	gaggacaccc	tcatgtcctt	agagtctatc	ctctttgctt	4740
tgcagaggag	aacgaggtcg	gctgccccga	gggctttgag	ctggactccc	agggagcggt	4800
ttgtgtgggt	gagcgcccc	aaccctggca	tggatgtggg	aggcctctca	gcctgggatg	4860
gatggcttct	cccagccagc	tggcaggagg	gcctgggagc	ggagaccacc	agaccccttc	4920
ctgccccaga	cagggacgag	tgctcaggag	gccttagccc	ctgctcccat	gcctgcctta	4980
atgcaaccgg	ccgcttctcc	tgcacctgcc	ccactggctt	cggcctggcc	tgggatgaca	5040
ggaactgcag	aggtgagggg	gctgccggga	ggagggagga	gacgcgctcc	tcagacctga	5100
cccagggtgtg	cagaaggggtc	cccaggggcca	ggaccctggc	tggggacaca	gacctgcagg	5160
gatggccaat	tcttgagggt	tttcatgtca	gcctgggggt	cccaatgcta	tgtccccacc	5220
aggctccttc	ttgctatggg	agctgcagat	gaatgaggcc	caggtatcag	ggggtgatgg	5280
gcagccccag	agacatatgg	gcggctacac	atgtccaccg	cattctgaac	ctgaaccagg	5340
ctcggaagct	ctcccaacac	tcagcatcat	ttccaattga	ctgagactgg	caagtgaagt	5400
gtccccctca	gcaatgttgc	tggatgacaa	atctgacctc	aggtgatggg	gctgacgctg	5460
acccccagtc	tgcacccctg	cactcccacc	gggagggcct	ggtgctgcca	agtctccgct	5520
gggctccaag	ccgggtgccc	aaggggacgt	tgtctgcagc	cttgcatagg	aagctgcagg	5580
cccaaggact	cgggtccctt	ggagtgggcc	ctatgttttg	ggataggagg	caagacaatg	5640
gaaagagcta	gcagaagggg	tggggacctt	cctggcagtg	gctcctgggc	ctgcggacga	5700
agcctctgtg	gataggccgg	gccagggtca	ggtggcgagg	cacgcctggg	gatcatgttc	5760
acacagccgt	ctgcctgat	ctgccccag	atgtggacga	gtgtgcgtgg	gatgctcacc	5820
tctgccgaga	gggacagcgc	tgtgtgaacc	tgtcgggtc	ctaccgctgc	ctccccgact	5880
gtgggccttg	cttccgggtg	gctgatgggg	ccggctgtga	aggtgatggg	ggcacagcat	5940
gcggcctgtc	catactcctg	gaaacccaga	ggttgccagg	gatcagctga	cagggggctg	6000
tgtgtcactg	ggctctgggc	ttccaggaag	actgggactc	ttggcagaag	gagtacagca	6060
aggtcgggga	caaagcctgc	gccaggctct	ggaggctctga	gccctcccct	ggctcctggc	6120
agctggcacc	ttctttgaca	gggtgtttt	ctttctgcac	ctcagcatct	tgtctgcttg	6180
ataaagaggg	agccaggta	gggatggcaa	acacatgctc	cctctgctgc	catccgttct	6240
gttcccccat	atgaatcaag	gccagctag	agaccacctc	tgaatccttc	ttgacgcagc	6300
agcccctgca	gccacagtgg	aacaggttca	gtcagccttt	gagataaaac	ttaggtgcca	6360
cccctggatg	ggtgacctca	atggtccttc	ctgctctaac	agtctatggc	tgtaggaccg	6420
tgggtccacc	cggctcctct	gagagactgc	acgggtggaga	gggaagcatg	gtggagcctg	6480
acccaagggg	atagccatc	gcacctctgt	ggccccagg	gcccttggag	tgcgcgacaa	6540
ctcacggggc	tctcctgcct	gccgccttc	ctgccgcctt	tcctcctttc	tcaccacttt	6600
cttagctctt	cccacatacc	aggctccctt	cctcaccacg	accccatgaa	gaggtcacat	6660
ctttaccctc	tttatggatg	aggaaactga	ggctcagaga	gggagagttc	cttgccccag	6720
ggctagaata	tggagagctc	agcggaaacc	aggactctgc	ccacaaaggg	cctttcagcc	6780
ccttcctttc	tctgggacct	ggaacccctg	tgacctccaa	cctggtataa	ctgggggagg	6840
tgtctgtagg	gcggccatgc	agcctggtgg	cactgaaact	ggagaagggg	acagggagga	6900
tgcccagata	tggaggggga	tggctcgtcc	cttgggggag	gggccctggg	ctagacctcc	6960
ccacaccaga	ccatgcccc	gcctcccaga	tgtggacgaa	tgcttgaggg	ggttggaaga	7020
ctgtcactac	aaccagctct	gcgagaacac	cccaggcggt	caccgctgca	gctgccccag	7080
gggttaccgg	atgcagggcc	ccagcctgcc	ctgcctagg	acggggacac	ccaccctctg	7140
gccacaccgc	tgcagctgcc	ccagggggta	ccggatgcag	ggccccagcc	tgccctgcct	7200
agttacgggg	acaccacccc	tctggccagc	acctcagctc	aggggctgag	ggtgtctaag	7260
gcgccagtgc	tgttgagttc	tgagaataac	caaacagcag	ccgacctttt	gcactcactg	7320
ggtgcctgcc	tgtgcaccaa	aacctcagcc	tgacctgtg	gggtcatctt	ccggggaatt	7380
tcaggagggg	gaggactgtg	gaggcaagtg	ggtgtatctc	agagaggctt	aggagaggga	7440
atggatctaa	ctggggcact	gaagggtcga	gggggagctg	gagtctggga	cgaggctgag	7500
agctggggag	gctgggcctc	tgggagctgt	agtggaatc	ggagaggagg	ctggagttgg	7560
tccgggagag	ggggatgcag	cgtggctcac	atgcagcatg	ggagtggctg	gattctaggg	7620
aatgccaaca	agagagaagg	cagggccagg	caatggctgc	aggctgcagg	ggaacctggg	7680
ccacctgtgc	acacacctga	ccccaccgt	ctgcagatgt	caatgagtgc	ctgcagctgc	7740
ccaaggccctg	cgctaccag	tccacaacc	tcaggggcag	ctaccgctgc	ctgtgcccc	7800
caggccagac	cctccttcgc	gacggcaagg	cctgcacctc	actggagcgg	aatggacaaa	7860
atgtgaccac	cgtcagccac	cgaggccctc	tattgccttg	gctgcggccc	tgggcctcga	7920
tccccggtac	ctcctaccac	gcctgggtct	ctctccgtcc	gggtcccatg	gccctgagca	7980
gtgtggggccg	ggcctggtgc	cctcctgggt	tcacagggca	gaacggagtc	tgcacaggta	8040
aggccaggcc	ctgaccatcc	acgggacact	gccgttatgg	gctcttgggc	ccctagggtg	8100

269

ggtgtgcagg	tgtaacccac	cgagttcaga	aacccagacc	ttccaggcaa	gtgggggtgag	8160
tgggtgtggg	gatgggtggc	tctccaatgc	aggggtgtctc	agagccttgg	ctgtgctatt	8220
gggcaggggg	cttccaagat	ggtgtggact	attttttaaa	ccattttgact	tcaggacact	8280
ttgcccagag	ggagggcac	ctaggcaagt	ggtcctggga	accccccttg	agaaacactc	8340
ctcttagcac	tcagagggaa	agcagtcagg	gagggagatt	ttcaggggtg	aaggagaatg	8400
ttccaggtag	acatgagaat	gtgacaagg	actgctgggt	agaggggggt	gggggtggg	8460
gatggccct	ggaccctgca	gagagggaca	aagaggaggt	ggcctgcccc	agggtgatg	8520
cctcggtatt	cccgcctgga	cggaggggtc	tgcgggggtg	tgctgcttgc	tccttctatg	8580
ccttggtgag	cacggggtag	gtaagggtgg	gctcctccct	ctcagcaagc	acagggactc	8640
ccccaacccc	tgaacctggg	ctgggagggg	caggacaggg	agaaggagca	gggcagctcc	8700
agagcccagc	gggcaggtgt	gtggccacgt	tgggtgtctg	ggctcagtcg	gtctctctgc	8760
ccccatcccc	cacctgcccc	acccccatgc	ccggggccaga	ccttgacgag	tgccgcgtga	8820
ggaacctgtg	tcagcacgcc	tgccgcaaca	ctaggggcag	ctaccagtgc	ctgtgccccg	8880
ccggctaccg	tctgctcccc	agcgggaaga	actgccaggg	tgagccgggc	tcaggccgcc	8940
gccccaaacac	ccgtggggct	agggcaggca	gcgtgggatg	ggacatgtgg	catcttacct	9000
actccgttca	ctccagcccc	ttcacaacta	tcctgtgagg	tggggcgggg	aggcaggctc	9060
agagggggttc	tgtgaacacc	ccaggctccc	acagccacgc	cagggcccat	gctccaaaca	9120
ggagctctga	gatcacgcgg	gcaggctctg	aaagcagccc	tgcaaggcca	atcctagcac	9180
tgctgtgtgt	ccctgggaaa	ctcacttcac	ctctctaagc	ctccggcctc	ctgggttaaat	9240
ggggctagca	cagtgccctc	tcagatagct	gggtgagag	ctgtggaggt	tgagcacaga	9300
gccgcacagc	tgctgctgct	ggtatagtaa	gtgctcttaa	ctcccaaac	gggcacagtt	9360
tcctgtgtgt	gcacaaacgg	ggctggggcc	ggtcatgctg	cttccctcac	tctaaagaac	9420
aggaaccatg	cctgccctgc	ctgtctctgt	ccctcatgct	gccatggagg	tactgaaca	9480
tcctctgaga	agggtggggc	ttccactgag	gaagacagga	tcaggggctc	tgcccgtggg	9540
cagtgggcac	tctgggtctt	cgggcaaaagc	agccaccacg	ggaaaagccc	atctctccca	9600
ggccctccta	cccagcactt	gctcaggagg	ccccacgggt	gcccacctac	acgccctgga	9660
aagccctggc	cccccgagg	agatgagaag	gtgctgcggg	cctccagctg	ggtggctatg	9720
ggtcagactg	gctggggaca	aagggagaag	ggctgcccac	ctcactgggt	ccccaaaggt	9780
acttctcccc	acgcactccc	cccttctcct	ttgctccatc	tttctatctc	cctccccgcg	9840
ttaccaact	tccccatcca	gacatcaacg	agtgcgagga	ggagagcatc	gagtgtggac	9900
ccggccagat	gtgcttcaac	accggtggca	gctaccagtg	tgtggacaca	ccctgtcctg	9960
ccacctaccg	gcagggcccc	agccctgggt	aagggctgag	ttggcagggc	ctcgtgccct	10020
caggaaaagc	acatttttca	gtcactgggg	gtgcaggctg	gccctgtcat	tgtcactccc	10080
cacacaagtg	atgcaggcag	gaacgcacgg	agccctgggg	gcaggagagag	gccagagtgg	10140
gagagaacgg	ggacacagga	gcacacacac	caaaccccag	acacaggacc	accatgcaga	10200
ctcacacaac	cccaggacaa	aactcagaca	cgccagcacc	aaacccatct	cctccacgcc	10260
actcacagcg	gccacggaca	ctcatcaaga	cacacggaga	catggggacc	ttaggggtgg	10320
cagctgctgc	cctggaaagg	tttctcccgg	cgggtgacct	gccccaggcc	ttacaactag	10380
aaacgtaggc	tggggttgga	agcagatgcc	cgcggcaagg	ctaagcgag	tctccacctc	10440
caaccccgcg	cccgcagggc	aaatccagac	tgggtgactt	ggcccagggg	cacatcgctc	10500
ccctgtgtct	gctgggcttc	cctggggcat	ggatcccga	agtccgctgg	agggaacctg	10560
aaagggcagg	cctctggctt	ctctgggctt	cagtttgttg	aactctaaaa	cgggctagcg	10620
tgggagcctg	cagagaaggc	gtgtggggct	ctgcgggaga	aggacgggca	gcgcgtgggc	10680
ggaactgcag	gggctggcag	ggaggtctga	gttacgcgga	tgggccacgc	tccgaccgca	10740
cccccgagtc	cgctgtccg	tgtgtctgtg	ccgcccgcag	gacgtgcttc	cggcgtgct	10800
cgcaggactg	cggcacgggc	ggccctctca	cgctgcagta	ccggctgctg	ccgctgcccc	10860
tgggcgtgcg	cgcaccacac	gacgtggccc	gcctcaccgc	cttctccgag	gtcggcgctc	10920
ccgccaaccg	caccgagctc	agcatgctgg	agcccagacc	ccgcagcccc	ttcgcgctgc	10980
gtccgctgcg	cgcgggcctt	ggcgcggtct	acaccgctcg	cgcgctcacc	cgcgcgggcc	11040
tctaccggct	caccgtgcgt	gctgcggcac	cgcgccacca	aagcgtcttc	gtcttgctca	11100
tcgccgtgtc	ccctacccc	tactaaacgg	gagagggcat	tggcgccgcg	cctggcggtga	11160
cccccgagga	aggggtcgag	gagaagcttg	gtccacgcca	cctgctgtgg	caagcggagc	11220
gtcatcgtct	cccgcctcgt	gcgtcagcga	gaccttgggt	caacacgacc	ctgcgcacag	11280
ccttgacccc	cgacagcgag	gacctgacct	cacagaggga	ggcgtccagg	gcggcccttg	11340
ggtggccagt	ccgcgaggca	gggcccgggg	aagcccggat	cagacctcca	ggtctgatcc	11400
gccccctcagt	gggagcggga	cagggacaca	gggcacctgg	acgcgcggga	gagggggcag	11460
accccgcgct	aggggtggca	gcagctgtcg	cccgccaca	cctgggtggg	tcattctgaa	11520
cctgttgca	atataaagg	attttttttt	aaccaa			11556

270

&lt;211&gt; 267

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 355

tttttttttct	ttttttttga	gttgaggttt	cactcttggt	gcccaggctg	gagtgcattg	60
gtgctatctc	ggctcaccgc	aacctccgcc	tcctgggttc	aagtgattct	cctgcctcag	120
cctcccaggt	agctgggatt	acaggcatgc	gccaccacgc	ccggctaatt	ttgtattttt	180
agtagagatg	gggtttctcc	acattgggtca	ggctgggtctc	aaactcctga	cctcaggtga	240
tctgcccgc	tcggcctccc	aaagtgc				267

&lt;210&gt; 356

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 356

aaattgtaag	cgtaaatatt	ttgttaaaat	tcgcgttaaa	tttttgtaa	atcagctcat	60
ttttaacca	ataggccgaa	atcggaacaa	tccttataa	atcaaaagaa	tagaccgaga	120
taggggttag	tggtgttcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcacccct	240
aatcaagttt	tttggggtcg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgatattag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaaggaa	gggaagaaag	360
cgaaggagc	gggcgctagg	gcgctggcaa	gtgtagcggg	cacgctgcgc	gtaaccacca	420
cacccgcgc	gcttaatgcg	ccgctacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctgtttggga	gggcgacg	tgccggcctc	ttcgctatta	cgccagctgg	cgaaaggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccaggggtt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 357

&lt;211&gt; 606

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 357

gttatatttt	tggtaratca	gctcattttt	taaccaatag	gccgaaatcg	gcaaaatccc	60
ttataaatca	aaagaataga	ccgagatagg	gttgagtgtt	gttccagttt	ggaacaagag	120
tccactatta	aagaacgtgg	actccaacgt	caaagggcga	aaarcctgt	atcagggcga	180
tggtccacta	cgtgaacat	caccctaate	aagttttttg	gggtcgagg	gccgtaaagc	240
actaaatcgg	aaccctaaag	ggagcccccg	atttagagct	tgacggggaa	agccggcgaa	300
cgtggcgaga	aagkaaggga	agaaagcgaa	aggagcgggc	gctagggcgc	tggtcaagtgt	360
agcggtcacg	ctgcgcgtaa	ccaccacacc	cgccgcgctt	aatgcgcgc	tacagggcgc	420
gtccattcgc	cattcaggct	gcgcaactgt	tggaaggggc	gatcgggtcg	ggcctcttcg	480
ctattacgcc	agctggcgaa	agggggatgt	gctgcaaggc	gattaagttg	ggtaacgcca	540
gggttttccc	agtcacgacg	ttgtaaaacg	acggccagtg	aattgtaata	cgactcacta	600
tagggc						606

&lt;210&gt; 358

&lt;211&gt; 628

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 358

aagcgtaata	tttgtaaaat	tcgcgttaaa	ttttgtaaat	cagctcattt	tttaaccaat	60
aggccgaaat	cggaacaaat	ccttataaat	caaaagaata	gaccgagata	gggttgagtg	120
ttgttccagt	ttggaacaag	agtccactat	taaagaacgt	ggactccaac	gtcaaagggc	180
gaaaaaccgt	ctatcagggc	gatggccac	tacgtgaacc	atcacccata	tcaagttttt	240
tggtggctcag	gtgccgtaaa	gcactaaatc	ggaaccctaa	agggagcccc	cgatttagag	300
cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	gaagaaagcg	aaaggagcgg	360
gcgctagggc	gctggcaagt	gtagcgggtc	cgctgcgcgt	aaccaccaca	cccgcgcgc	420



271

ttaatgcgcc	gctacagggc	gcgtccattc	gccattcagg	ctgcgcaact	gttgggaagg	480
gcgatcggtg	cgggcctctt	cgctattacg	ccagctggcg	aaagggggat	gtgctgcaag	540
gcgattaagt	tgggtaacgc	caggggtttc	ccagtcacga	cgttgtaaaa	cgacggccag	600
tgaattgtaa	tacgactcac	tatagggc				628

&lt;210&gt; 359

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 359

aaattgtaag	cgtaaatatt	ttgttaaaat	tcgcgttaaa	tttttgtaa	atcagctcat	60
tttttaacca	ataggccgaa	atcggaacaa	tcccttataa	atcaaaagaa	tagaccgaga	120
tagggttgag	tgttggtcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcaccct	240
aatcaagttt	tttggggtcg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgatattag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaaggaa	gggaagaaag	360
cgaaaggagc	gggcgctagg	gcgctggcaa	gtgtagcgg	cacgctgcgc	gtaaccacca	420
caccgcgcgc	gcttaatgcg	ccgctacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctggtgggaa	gggcgatcgg	tgcgggcctc	ttcgctatta	cgccagctgg	cgaaaggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccaggggtt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 360

&lt;211&gt; 513

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 360

gagtgttggt	ccagtttgga	acaagagtcc	actattaaag	aacgtggact	ccaacgtcaa	60
agggcgaaaa	accgtctatc	agggcgatgg	cccactacgt	gaaccatcac	cctaatacaag	120
ttttttgggg	tcgaggtgcc	gtaaagcact	aaatcggaac	cctaaaggga	gccccgatt	180
tagagcttga	cggggaaaagc	cggcgaaagt	ggcgagaaag	gaagggaaga	aagcgaaagg	240
agcgggcgct	agggcgctgg	caagtgtagc	ggtcacgctg	cgcgtaacca	ccacaccgc	300
cgcgcttaat	gcgccgtac	agggcgcgctc	cattcgccat	tcaggctgcg	caactgttgg	360
gaaggcgcat	cgggtgcgggc	ctcttcgcta	ttacgccagc	tggcgaaagg	gggatgtgct	420
gcaaggcgat	taagttgggt	aacgccaggg	ttttcccagt	cacgacgttg	taaaacgacg	480
gccagtgaat	tgtaatacga	ctcactatag	ggc			513

&lt;210&gt; 361

&lt;211&gt; 612

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 361

ttcgcgttaa	atttttgtta	caatcagctc	attgtttaac	caataggccg	aaatcggcaa	60
aatcccttat	aaatcaaaag	aatagaccga	gatagggttg	agtgtgtgtc	cagtttgga	120
caagagtcca	ctattaaaga	acgtggactc	caacgtcaaa	gggcgaaaaa	ccgtctatca	180
gggcgatggc	ccactacgtg	aaccatcacc	ctaatacaagt	tttttggggg	cgaggtgccg	240
taaagcacta	aatcggaacc	ctaaaggag	cccccgattt	agagcttgac	ggggaagacc	300
ggcgaaacgtg	gcgagaaagg	aagggaagaa	agcgaaagg	gcgggcgcta	gggcgctggc	360
aagtgtagcg	gtcacgctgc	gcgtaaccac	cacaccgcgc	gcgcttaatg	cgccgtatca	420
gggcgcgtcc	attcgccatt	caggtgcgc	aactgttggg	aaggcgatc	ggtgcgggccc	480
tcttcgctat	tacgccagct	ggcgaaagg	ggatgtgctg	caaggcgatt	aagttgggta	540
acgccagggt	tttccagtc	acgacgttgt	aaaacgacgg	ccagtgaatt	gtaatacgac	600
tcactatagg	gc					612

&lt;210&gt; 362

&lt;211&gt; 686

&lt;212&gt; DNA

272

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (95)..(95)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 362

caccaaggcc	agtttggaa	cgaacggcta	ccccgaaatt	aagatactac	agcgtgagtt	60
atgagaaagc	gccacgcttc	ccgaggggaag	aaagncggga	cagttatccg	gtagccggca	120
gggtcgaacc	agaagagcgc	acgaggagct	tccaagggga	aaacgcctgg	tatctttata	180
gtcctgtcgg	gtttcgccac	ctctgacttg	agcgtcgatt	tttgtgatgc	tcgtcagggg	240
ggcggagcct	atggaaaaac	gccagcaacg	cggccttttt	acggttcttg	gccttttgct	300
ggccttttgc	tcacatgttc	tttctgcgt	tatcccctga	ttctgtggat	aaccgtatta	360
ccgcctttga	gtgagctgat	accgctcgcc	gcagccgaac	gaccgagcgc	agcgagtcag	420
tgagcgagga	agcgggaagag	cgcccaatac	gcaaaccgcc	tctcccgcgc	cgttgggcca	480
ttcattaatg	cagctggcac	gacaggtttc	ccgactggaa	agcgggcagt	gagcgcaacg	540
caattaatgt	gagttagctc	actcattagg	caccccaggc	tttacacttt	atgcttccgg	600
ctcgtatgtt	gtgtggaatt	gtgagcggat	aacaatttca	cacaggaaac	agctatgacc	660
atgattacga	attcgagctc	ggtacc				686

&lt;210&gt; 363

&lt;211&gt; 462

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 363

caacgtcaaa	gggcgaaaaa	ccgtctatca	gggcgatggc	ccactacgtg	aaccatcacc	60
ctaataagtt	tttttggggt	cgaggtgccg	taaagcacta	aatcggaacc	ctaaaggagag	120
cccccgattt	agagcttgac	ggggaaagcc	ggcgaaacgtg	gcgagaaagg	aagggaagaa	180
agcgaaagga	gcgggcgcta	gggcgctggc	aagtgtagcg	gtcacgctgc	gcgtaaccac	240
cacacccgcc	gcgcttaatg	cgccgctaca	gggcgcgtcc	attcgccatt	caggtgcgc	300
aactgttggg	aaggggcgatc	ggtgcgggcc	tcttcgmtat	tacgccagct	ggcgaaaggg	360
ggatgtgctg	caaggcgatt	aagttgggta	acgccagggt	tttcccagtc	acgacgttgt	420
aaaacgacgg	ccagtgaatt	gtaatacgac	tcactatagg	gc		462

&lt;210&gt; 364

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 364

aaattgtaag	cgtaaatatt	ttgttaaaat	tcgcgttaaa	tttttggtta	atcagctcat	60
tttttaacca	ataggccgaa	atcggcaaaa	tcccttataa	atcaaaagaa	tagaccgaga	120
taggggttag	tgttgttcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcacccct	240
aatcaagttt	tttggggtcg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgatttag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaaggaa	gggaagaaaag	360
cgaaaggagc	gggcgctagg	gcgctggcaa	gtgtagcggg	cacgctgcgc	gtaaccacca	420
caccgcgcgc	gcttaatgcg	ccgctacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctgttgggaa	gggcgatcgg	tgccggcctc	ttcgctatta	cgccagctgg	cgaaaggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccagggttt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 365

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 365

273

aaattgtaag	cgtaaataatt	ttgttaaaat	tcgcgttaaa	tttttggttaa	atcagctcat	60
tttttaacca	ataggccgaa	atcggcaaaa	tccttataa	atcaaaagaa	tagaccgaga	120
taggggttag	tggtgttcca	gtttggaaca	agagtcact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcacccct	240
aatcaagttt	tttggggctg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgatttag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaaggaa	gggaagaaaag	360
cgaaggagc	gggcgctagg	gcgctggcaa	gtgtagcgg	cacgctgcgc	gtaaccacca	420
cacccgccgc	gcttaatgag	ccgctacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctgttgagg	gggcgatcgg	tgccggcctc	ttcgctatta	cgccagctgg	cgaagggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccaggggtt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 366

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 366

aataccgcat	caggaaattg	taagcggttaa	tattttgtta	aaattcgcgt	taaatttttg	60
ttaaatcagc	tcatttttta	accaataggg	cgaatcggc	aaaatccctt	ataaatcaaa	120
agaatagacc	gagataggg	tgagtgttgt	tccagtttg	aacaagagtc	cactattaaa	180
gaacgtggac	tccaacgtca	aagggcgaaa	aaccgtctat	cagggcgatg	gcccactacg	240
tgaaccatca	ccctaataca	gttttttggg	gtcgaggtgc	cgtaaagcac	taaatcgga	300
ccctaagggg	agccccgat	ttagagcttg	acggggaaa	ccggcgaaac	tgccgagaaa	360
ggaagggaag	aaagcgaaa	gagcggggcg	tagggcgctg	gcaagtgtag	cggtcacgct	420
gcgcgtaacc	accacacccg	ccgcgcttaa	tgccgcgcta	cagggcgcg	ccattcgcca	480
ttcaggctgc	gcaactgttg	ggaagggcga	tcggtgcggg	cctcttcgct	attacgccag	540
ctggcgaaa	ggggatgtgc	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	600
tcacgacggt	gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggc	654

&lt;210&gt; 367

&lt;211&gt; 414

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 367

tgaaccatca	ccctaataca	gttttttggg	gtggaggtgc	cgtaaagcac	taaatcgga	60
ccctaagggg	agccccgat	ttagagcttg	acggggaaa	ccggcgaaac	tgccgagaaa	120
ggaagggaag	aaagcgaaa	gagcggggcg	tagggcgctg	gcaagtgtag	cggtcacgct	180
gcgggtaacc	accacacccg	ccgcgcttaa	tgccgcgcta	cagggcgcg	ccattcgcca	240
ttcaggctgc	gcaactgttg	ggaagggcga	tcggtgcggg	cctyttcgct	attacgccag	300
ctggcgaaa	ggggatgtgc	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	360
tcacgacggt	gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggc	414

&lt;210&gt; 368

&lt;211&gt; 647

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (29)..(29)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 368

cgcacagga	aatgtaagcg	ttaatatnt	gtaaaattcg	cgtaaattt	ttgttaaatc	60
agctcatitt	ttaaccaata	ggccgaaatc	ggcaaaatcc	cttataaatc	aaaagaatag	120
accgagatag	ggttgagtg	tggtccagtt	tggaacaaga	gtccactatt	aaagaacgtg	180
gactccaacg	tcaaagggcg	aaaaaccgtc	tatcagggcg	atggccact	acgtgaacca	240
tcacccta	caagttttt	ggggtcgagg	tgccgtaaag	cactaaatcg	gaaccctaaa	300

274

gggagccccc	gatttagagc	ttgacgggga	aagccggcga	acgtggcgag	aaaggaaggg	360
aagaaagcga	aaggagcggg	cgctagggcg	ctggcaagtg	tagcggtcac	gctgcgcgta	420
accaccacac	ccgccgcgct	taatgcgcgc	ctacagggcg	cgccattcg	ccattcaggc	480
tgcgcaactg	ttgggaaggg	cgatcggtgc	gggcctcttc	gctattacgc	cagctggcga	540
aagggggatg	tgctgcaagg	cgattaagtt	gggtaacgcc	agggttttcc	cagtcacgac	600
gttgtaaaac	gacggccagt	gaattgtaat	acgactcact	atagggc		647

&lt;210&gt; 369

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 369

aaattgtaag	cgtaaatatt	ttgttaaaat	tcgcgttaaa	tttttgtaa	atcagctcat	60
tttttaacca	ataggccgaa	atcggcaaaa	tccsttataa	atcaaaagaa	tagaccgaga	120
taggggttag	tggtgttcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcacccct	240
aatcaagttt	tttggggtcg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgathtag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaagsaa	gggaagaaag	360
cgaaaggagc	gggcgctagg	gcgctggcaa	gtgtagcggg	cacgctgcgc	gtaaccacca	420
cacccgcgcg	gcttaatgcg	ccgytacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctgttgggaa	gggcgatcgg	tgccggcctc	ttcgctatta	cgccagctgg	cgaaaggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccagggttt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 370

&lt;211&gt; 640

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 370

aaattgtaag	cgtaaatatt	ttgttaagat	tcgcgttaaa	tttttgtaa	atcagctcat	60
tttttaacca	ataggccgaa	atcggcaaaa	tcccttataa	atcaaaagaa	tagaccgaga	120
taggggttag	tggtgttcca	gtttggaaca	agagtccact	attaaagaac	gtggactcca	180
acgtcaaagg	gcgaaaaacc	gtctatcagg	gcgatggccc	actacgtgaa	ccatcacccct	240
aatcaagttt	tttggggtcg	aggtgccgta	aagcactaaa	tcggaaccct	aaagggagcc	300
cccgathtag	agcttgacgg	ggaaagccgg	cgaacgtggc	gagaaaggaa	gggaagaaag	360
cgaaaggagc	gggcgctagg	gcgctggcaa	gtgtagcggg	cacgctgcgc	gtaaccacca	420
cacccgcgcg	gcttaatgcg	ccgctacagg	gcgcgtccat	tcgccattca	ggctgcgcaa	480
ctgttgggaa	gggcgatcgg	tgccggcctc	ttcgctatta	cgccagctgg	cgaaaggggg	540
atgtgctgca	aggcgattaa	gttgggtaac	gccagggttt	tcccagtcac	gacgttgtaa	600
aacgacggcc	agtgaattgt	aatacgactc	actatagggc			640

&lt;210&gt; 371

&lt;211&gt; 571

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 371

aataggccga	aatcgcaaaa	atcccttata	aatcaaaaga	atagaccgag	atagggttga	60
gtgttggtcc	agtttggaac	aagagtccac	tattaaagaa	cgtggactcc	aacgtcaaaag	120
ggcgaaaaac	cgtctatcag	ggcgatggcc	cactacgtga	accatcaccc	taatcaagtt	180
ttttggggtc	gaggtgccgt	aaagcactaa	atcggaaccc	ttaaaggagc	ccccgattta	240
gagcttgacg	gggaaagccg	gcgaacgtgg	cgagaaagga	agggaagaaa	gcgaaaggag	300
cgggcgctag	gcgcgtggca	agtgtagcgg	tcacgctgcg	cgtaaccacc	acaccgccc	360
cgcttaatgc	gccgctacag	ggcgctgcca	ttcgccattc	aggctgcgca	actgttggga	420
agggcgatcg	gtgcgggcct	cttcgctatt	acgccagctg	gcgaaagggg	gatgtgctgc	480
aaggcgatta	agttgggtaa	cgccagggtt	ttcccagtc	cgacgttgta	aaacgacggc	540
cagtgaattg	taatacgact	cactataggg	c			571

275

<210> 372  
 <211> 640  
 <212> DNA  
 <213> Homo sapiens

<400> 372  
 aaattgtaag cgtaaataatt ttgttaaaaat tcgcgttaaa tttttgttaa atcagctcat 60  
 tttttaacca ataggccgaa atcggcaaaa tcccttataa atcaaaagaa tagaccgaga 120  
 taggggttag tgttggtcca gtttggaaca agagtccact attaaagaac gtggactcca 180  
 acgtcaaagg gcgaaaaacc gtctatcagg gcgatggccc actacgtgaa ccatcaccct 240  
 aatcaagttt tttggggtcg aggtgccgta aagcactaaa tcggaaccct aaagggagcc 300  
 cccgatttag agcttgacgg ggaaagccgg cgaacgtggc gagaaaggaa gggaagaaag 360  
 cgaaaggagc gggcgctagg gcgctggcaa gtgtagcggc cagctgccc gtaaccacca 420  
 caccgcccgc gcttaatgcg ccgctacagg gcgcgtccat tcgccattca ggctgcgcaa 480  
 ctgttgggaa gggcgatcgg tgcgggcctc ttgcgtatta cgccagctgg cgaaaggggg 540  
 atgtgctgca aggcgattaa gttgggtaac gccagggttt tcccagtcac gacgttgtaa 600  
 aacgacggcc agtgaattgt aatacgactc actatagggc 640

<210> 373  
 <211> 639  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <222> (88)..(88)  
 <223> n equals a,t,g, or c

<400> 373  
 aattgtaagc gtttaataatt tggttaaaatt cgcgttaaat ttttgttaaa tcagctcatt 60  
 ttttaaccaa taggccgaaa tcggcaanat cccttataaa tcaaaaagaat agaccgagat 120  
 aggggttagt gttgttccag tttggaacaa gagtccacta ttaaagaacg tggactccaa 180  
 cgtcaaaggc cgaaaaaccg tctatcaggg cgatggccca ctacgtgaac catcacccta 240  
 atcaagtttt ttggggtcga ggtgccgtaa agcactaaat cggaacccta aagggagccc 300  
 ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc 360  
 gaaaggagcg ggcgctaggc cgctggcaag tgtagcggtc acgctgccc gtaaccaccac 420  
 acccgccgcg cttaatgcgc cgctacaggg cgcgtccatt cgccattcag gctgcgcaac 480  
 tggtgggaag ggcgatcggc gcgggcctct tcgctattac gccagctggc gaaaggggga 540  
 tgtgctgcaa ggcgattaag ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa 600  
 acgacggcca gtgaattgta atacgactca ctatagggc 639

<210> 374  
 <211> 397  
 <212> DNA  
 <213> Homo sapiens

<400> 374  
 atcaagtttt ttggggtcga ggtgccgtga agcattaaat cggaacccta aagggagccc 60  
 ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc 120  
 gaaaggagcg gacgttaggg cgctggcaag tgtagcggc cgtgcgcgta accaccacac 180  
 acgctgcgct taatgcgccg ctacagggcg cgtccattcg ccattcgagg tgcgcaactg 240  
 ttgggaaggg cgatcggcgc gggcctcttc gctattacgc cagctggcga aagggggatg 300  
 tgctgcaagg cgattaagtt gggtaacgcc aggggttttc cagtcacgac gttgtaaaac 360  
 gacggccagt gaattgtaat acgactcact atagggc 397

<210> 375  
 <211> 648  
 <212> DNA  
 <213> Homo sapiens

276

&lt;400&gt; 375

gcacacaggma	attgtaagcg	ttaatatattt	gttaaaattc	gcgttaaatt	tttgttaaat	60
cagctcattt	tttaaccaat	aggccgaaat	cggcaaaatc	ccttataaat	caaaagaata	120
gaccgagata	gggttgagtg	ttgttccagt	ttggaacaag	agtcactat	taaagaacgt	180
ggactccaac	gtcaaagggc	gaaaaaccgt	ctatcagggc	gatggccac	tacgtgaacc	240
atcacccctaa	tcaagttttt	tggggtcgag	gtgccgtaaa	gcactaaatc	ggaaccctaa	300
aggggagcccc	cgatttagag	cttgacgggg	aaagccggcg	aacgtggcga	gaaaggaagg	360
gaagaaagcg	aaaggagcgg	gcgctagggc	gctggcaagt	gtagcggcga	cgctgcgcgt	420
aaccaccaca	cccgcgcgc	ttaatgcgc	gctacagggc	gcgtccattc	gccattcagg	480
ctgcgcaact	gttgggaagg	gcgatcggcg	cgggcctctt	cgctattacg	ccagctggcg	540
aaagggggat	gtgctgcaag	gcgattaagt	tgggtaacgc	cagggttttc	ccagtcacga	600
cgttgtaaaa	cgacggccag	tgaattgtaa	tacgactcac	tatagggc		648

&lt;210&gt; 376

&lt;211&gt; 434

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 376

gggagatggc	cccactaccg	tgaaccatca	ccctaataca	gttttttggg	gtcagaggtgc	60
cgtaaagcac	taaatcgga	ccctaaagg	agccccgat	ttagagcttg	acggggaaaag	120
ccggcgaacg	tggcgagaaa	ggaagggaa	aaagcgaaag	gagcgggcgc	tagggcgctg	180
gcaagtgtag	cggtcacgct	gcgcgtaacc	accacacccg	ccgcgcttaa	tgcgcgcta	240
cagggcgcg	ccattcgcca	ttcaggctgc	gcaactgttg	ggaagggcga	tcggtgcggg	300
cctcttcgct	attacgccag	ctggcgaaag	ggggatgtgc	tgcaaggcga	ttaagttggg	360
taacgccagg	gttttcccag	tcacgacggt	gtaaaacgac	ggccagtga	ttgtaatacg	420
actcactata	gggc					434

&lt;210&gt; 377

&lt;211&gt; 624

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 377

tattttgtta	aaattcgcgt	taaatatttg	ttaaaccagc	tcatttttta	accaataggg	60
ggaaatcgcc	aaaatccctt	ataaatcaaa	agaatagacc	gagataggg	tkagtgttgt	120
tccagtttgg	aacaagagtc	cactattaaa	gaacgtggac	tccaacgtca	aagggcgaaa	180
aaccgtctat	cagggcgatg	gccactacg	tgaaccatca	ccctaataca	gttttttggg	240
gtcagaggtgc	cgtaaagcac	taaatcgga	ccctaaagg	agccccgat	ttagagcttg	300
acgggggaaag	ccggcgaacg	tggcgagaaa	ggaagggaa	aaagcgaaag	gagcgggcgc	360
tagggcgctg	gcaagtgtag	cggtcacgct	gcgcgtaacc	accacacccg	ccgcgcttaa	420
tgcgcgcta	cagggcgcg	ccattcgcca	ttcaggctgc	gcaactgttg	ggaagggcga	480
tcggtgcggg	cctcttcgct	attacgccag	ctggcgaaag	ggggatgtgc	tgcaaggcga	540
ttaagttggg	taacgccagg	gttttcccag	tcacgacggt	gtaaaacgac	ggccagtga	600
ttgtaatacg	actcactata	gggc				624

&lt;210&gt; 378

&lt;211&gt; 509

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 378

gttggtccag	tttggaaaca	gagtcacta	ttaaagaacg	tggactccaa	cgtaaaagg	60
cgaaaaaccg	tctatcagg	cgatggccca	ctacgtgaac	catcacccca	atcaagtttt	120
ttgggggtcga	ggtgccgtaa	agcactaaat	cggaaacccta	aagggagccc	ccgatttaga	180
gcttgacggg	gaaagccggc	gaacgtggcg	agaaaggaa	ggaagaaagc	gaaaggagcg	240
ggcgctaggg	cgctggcaag	tgtagcggc	acgctgcgcg	taaccaccac	acccgcgcgc	300
cttaatgcgc	cgctacagg	cgctccatt	cgccattcag	gctgcgcaac	tgttggaag	360
ggcgatcggt	gcgggcctct	tcgctattac	gccagctggc	gaaaggggga	tgtgtgcaa	420
ggcgattaag	ttgggtaacg	ccagggtttt	cccagtcacg	acgttgtaaa	acgacggcca	480

277

gtgaattgta atacgactca ctatagggc

509

&lt;210&gt; 379

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 379

aaatacgc	at	caggaaattg	taagcg	ttaa	tattttgt	ta	aaattcgc	gt	t	taaattttt	g	60
ttaaatcag	c	tcattttt	ta	accaatag	gc	cgaaatcg	gc	aaaatccc	tt	ataaatcaa	a	120
agaatagac	c	gagatagg	gt	tgagtgt	gt	tccagttt	gg	aacaagag	tc	cactattaa	a	180

gaacgtgg	ac	tc	caacgt	ca	aagggc	gaaa	aaccgt	ct	at	cagggc	gatg	gccact	acg	240	
tgaaccat	ca	cccta	aatca	a	gttttt	ttggg	gtcgag	gt	gc	cgtaa	agcac	t	aaatcgg	aa	300
ccctaaag	gg	agcccc	cgat	ttagag	cttg	acgggg	aaaag	ccggc	gaacg	tggcg	agaaa			360	
ggaaggg	aa	gaagc	gaaa	gagc	gggcgc	tagggc	gctg	gcaag	tgtag	cggtc	acgct			420	
gcgcgt	aacc	accacac	ccg	ccgcg	cttaa	tgcgcg	ct	cagggc	gcgt	ccattc	gcc	a		480	
ttcagg	ctgc	gcaact	gttg	ggaagg	gcga	tcgg	tg	cggg		cctctt	cgt	attac	gccag	540	
ctggc	gaaa	gggat	gtgc	tgca	aggcga	ttag	ttggg	taac	gccag	gtttt	cccag			600	
tcacg	acgt	gt	aaaacg	ac	ggccag	tga	ttgt	aat	acg	actc	actata	gggc		654	

&lt;210&gt; 380

&lt;211&gt; 380

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 380

aggtgcc	gta	aagc	actaat	tg	ggaac	cta	aaagg	gagcc	cccgatt	tag	agctt	gac	gg	60
ggaaagc	cg	gaac	gtggc	gaga	aagg	aa	ggga	agaa	gcgaa	aggagc	gggcg	ctag	g	120
gcgctgg	caa	gtg	tagcgt	cac	gctgc	gc	gta	accac	ca	caccgc	ccgc	gctta	atgc	180
ccgctac	agg	gcgc	gtccat	tcgc	cattca	ggct	gcg	caa	ctgtt	ggg	aa	gggcg	atcgg	240
tgccggg	cctc	ttcg	ctatta	cgcc	agctgg	cgaa	agggg	gg	atgtg	ctgca	aggcg	attaa		300
gttgggt	aac	gccagg	ggtt	tccc	agtcac	gacgtt	gt	taa	aacg	acgg	cc	agtga	attgt	360
aatac	gactc	actat	agggc											380

&lt;210&gt; 381

&lt;211&gt; 546

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (20)..(20)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 381

ttataaat	ca	aaaga	atagn	ccgag	atagg	gttgag	tgtt	gttcc	agttt	ggaaca	agag			60
tccactat	ta	agaac	gtgg	actcc	aacgt	caaagg	gcga	aaaac	cgctc	atcagg	gcga			120
tggccca	cta	cgtga	accat	cacc	cta	aatc	aagtt	ttttt	gggtc	gaggt	gccg	taa	agc	180
actaaat	cgg	aacc	ctaa	ag	ggag	cccc	cg	at	tagag	ct	tgac	gggg	aa	240
cgtggc	gaga	aagga	aggga	agaa	agcga	aggag	cgggc	gctag	gggc	gc	tggca	agt	gt	300
agcgg	tcacg	ctgc	gcgt	aa	ccacc	acacc	cgcc	gcg	ctt	aatgc	gccgc	tacag	ggcgc	360
gtccatt	cgc	cattc	aggc	gcg	caact	gt	tggga	agggc	gatc	gg	tg	cg	ggc	420
ctattac	gcc	agct	ggcga	aggg	ggat	gt	gctgc	aaggc	gatta	ag	ttg	ggta	acg	480
gggtttt	ccc	agtc	acgacg	ttgt	aaaacg	acgg	ccag	tg	aatt	gt	aa	ta	ta	540
tagggc														546

&lt;210&gt; 382

&lt;211&gt; 631

&lt;212&gt; DNA

278

&lt;213&gt; Homo sapiens

&lt;400&gt; 382

ccccacttca	agaactttga	agcgccgcct	acatactcgc	tttgatatct	tgtaccagtg	60
ctgctgcagg	tggccaatta	agtcgtgtct	ttaccggggt	ggactcaagc	gaatagtttc	120
cggataaggc	gcagcggtcg	ggctgaacgg	ggggttcgtg	cacacagccc	agtttgagc	180
gaacgacct	caccgaactg	agatacctac	agcgtgagct	atgagaaagc	gccacgcttc	240
ccgaagggag	aaagggcgac	aggtatccgg	taagcggcag	ggtcggaaca	ggagagcgca	300
cgagggagct	tccaggggga	aacgcctggg	atctttatag	tcctgtcggg	tttcgccacc	360
tctgacttga	gcgtcgattt	ttgtgatgct	cgtcaggggg	gcggagccta	tggaaaaacg	420
ccagcaacgc	ggccttttta	cggttcctgg	ccttttgctg	gccttttgct	cacatgttct	480
ttcctgcggt	atccccctgat	tctgtggata	accgtattac	cgcttttgag	tgagctgata	540
cagctcgccg	cagccgaacg	accgagcgca	gcgagtcagt	gagcgaggaa	gcggaagagc	600
gccaataacg	caaacagcct	ctcgccgcgc	g			631

&lt;210&gt; 383

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 383

aataccgcat	caggaaattg	taagcggtta	tattttggtta	aaattcgcgt	taaatttttg	60
ttaaatcagc	tcatTTTTTT	accaataggc	cgaatcggc	aaaatccctt	ataaatcaaa	120
agaatagacc	gagatagggg	tgagtgttgt	tccagtttgg	aacaagagtc	cactattaaa	180
gaacgtggac	tccaacgtca	aaggggcga	aaccgtctat	cagggcgatg	gccactacg	240
tgaacccatca	ccctaataca	gttttttggg	gtcgaggtgc	cgtaaagcac	taaatcgga	300
ccctaagggg	agcccccgat	ttagagcttg	acggggaaag	ccggcgaaacg	tggcgagaaa	360
ggaagggaa	aaagcgaaag	gagcgggcgc	tagggcgctg	gcaagtgtag	cggtcacgct	420
gcgcgtaacc	accacaccgc	ccgcgcttaa	tgcgcgcta	cagggcgcg	ccattcgcca	480
ttcaggctgc	gcaactgttg	ggaagggcga	tcggtgcggg	cctcttcgct	attacgccag	540
ctggcgaaag	ggggatgtgc	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	600
tcacgacggt	gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggc	654

&lt;210&gt; 384

&lt;211&gt; 19965

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 384

tccggcagtg	cggcggatgt	acggatgatt	cagtggctgg	caggaaagccc	gccctgcccg	60
cccgccagtg	tcagtgggtg	tggcatcagc	ttgggcaggt	gtgcgggctc	aggatggggc	120
ggccgtgggtg	aggaaacctg	gactctcagg	taagcctttc	ccaggggtgc	ctcagtcctc	180
aggctgtccc	ccatccccca	ggagctcctg	gccccactgg	gtgggggtggg	aagaggcctg	240
gatgcctggc	gccccctccc	gcagccccac	tctcacctcg	gcaccaggct	ctgtggcact	300
tcaggggtca	gtttgtttct	gggtttcttg	ccactctctt	gccctcgctt	ttccctgtcc	360
agcctgtgta	gccttggggac	atcccagggg	gggtcccatca	ttgccagaga	ctgggtgaagt	420
aagtggccga	gagccaaaac	agtggctgcc	ctggcctggg	agcctcggtt	tcctcatccg	480
tgaatggga	ctgtaacccc	ctacacaggt	caggggaaaa	cggtgggatt	acaggccagg	540
gccaggtct	tgccccaggt	caggtgaaga	acccccactg	cctccctgcc	cagcccccta	600
cctggccctc	aactctgtcc	ctgggaccag	ggctgtctag	gccccctcctg	caccgcgccg	660
cctccctctc	tcctctccag	ctaggtctcat	ttgaagccca	gagttatttg	gaaaaagcaa	720
caggaccagc	cgggcacggt	ggctcaacct	gtaatcccag	catttgggga	ggccaaggcg	780
ggaggatcat	ttgaagtcag	gagctggaga	ccagcctgag	caacatagtg	agactcccat	840
ctcttttaaaa	aataaaaaata	aaaaaatata	attaaaaact	aaatgaaaaa	accaacagac	900
cccagagcag	agtccagtg	ataaagccat	ccagggtctc	aagccaggct	gccccctccc	960
caaccccag	gtcccccaacc	acagctcagc	tcggagaagg	ctgggagaac	cggcaggggtg	1020
gtctcgagcg	tccttccagg	cgggattcag	acactgtagc	tcctccagcc	cagccccgag	1080
aacttccccg	aagccagctc	ttggcaatcg	ttgttcatat	gaaaactgcc	cacttccctt	1140
tagtgctatt	ttggcctctg	cagaaccgtg	gtctgtggca	gccccactc	cccaccccg	1200
ccagccctgc	cggccccctgg	gggcctcaga	gggtccaccc	tccgctccct	ccacctcagc	1260



ccacctgctt	tcagaacctg	gatgggagag	tgaaagttag	agcgagacag	agacacaaag	1320
ggagacagag	acagagagag	agcacagaat	ttttttaaac	ggagtctcac	tctgttgtcc	1380
aggctggagt	gcagtggcgt	gatctcggct	cactgcaacc	tccacctccc	aggttcaagc	1440
agttctcctg	ccttaccctt	ccaagtagct	ggggactaca	ggcacgtgct	accacacctg	1500
gctaattttt	tattttttat	ttatttttta	ttttttggag	acagtcttgc	tctgtctccc	1560
aggctgggag	tgcagtgggt	caatcttgge	tcactgcaag	ctccacctcc	cgggtacatg	1620
ccattctcct	gcctcagcct	cccagtagc	tgagactaga	ggcgcttgc	accacgaccg	1680
gctaattttt	tgtattttta	gtagagacgg	ggtttcgcca	tgtagccag	gatgggtcta	1740
atctcctgac	tttgtgatct	gcctgcctcg	gcctcccaaa	gtgctgggat	tacaggtgtg	1800
agccaccgtg	cctggcctaa	ttttttatct	ttagtagaga	caggggttca	ccatgttggc	1860
caaggctggc	ttgaactcct	gacctcagat	gatttgccc	cctcagcctc	ccaaagtgtt	1920
gggattacag	gtgtgaacta	ccgcaccccg	ccaacagcgc	aggatgtatt	cagtctgggg	1980
gcagacacat	gactgtttgt	ttaaatttcat	tttttgtttt	tagagatggg	gtcttgcctc	2040
gtcaccacag	ctgggattca	gtgggtgat	cttggctcac	tgcagcttcc	aactcctggg	2100
ctcaagcaat	tctcttgcc	cagtgtccca	agtagctgga	accacaggca	tgtgccactg	2160
cgcctgccta	attttttcat	ttttttgtag	agacagggcc	ttgttacatc	gtccatgctg	2220
gtctcgaact	cctggcctca	agcgatcctc	ctgtctcggc	ctcccagtg	tgagattaca	2280
ggcgtcagcc	accacgcccc	gcctgatccc	attttattta	ttcatttatt	taatttatta	2340
ttattattat	tattattttg	agatggagtc	tcactctgtc	tcccatgctg	gagtgcactg	2400
gcgtgatctc	agctcactgc	aactcactgc	ctcctgagtt	caagtgatcc	tcatgcctca	2460
gcctcccaag	tagctggaat	tacaggcttg	cacctccacg	cctgggtaat	ttttgtatct	2520
ctagtagaaa	caggggttca	ccatgttggc	caagctggtc	tcaaactcaa	gtgatcctcc	2580
tgtctcagcc	tcccaaagta	ttgggattac	agggtgtgag	ccctgtaccc	agcccagcct	2640
cattttatag	atgagaaaac	tgaggcgggg	ggctctcagg	cagaggctag	atttggctcc	2700
atgagccctc	ctgcaagaca	agttgtctca	acctcacaag	cctgagatga	acttggggcca	2760
tgtctggagg	gttgggggta	caccccggtt	tgggggcact	gaggcaagga	gagtcttcag	2820
gagggagaag	ggcagtgccc	aggcgggcca	tggggaaagag	agagcagagc	tttctcctga	2880
caacctcccc	gggtgacgtg	ggtcgtgcca	gtcacacggc	tcagaaattc	acttgttccc	2940
actgactcac	ttggcttttg	gggagaggcc	tgggtggcttc	tctgtgatgc	gcctcttaca	3000
gaggctcagg	gccgcattga	gattccctgt	catcttaccg	cagggatttg	ggaagtccag	3060
agaggctcctg	agacttgtcc	aaagccacac	agctttcaag	ggggacagcc	caggctcctg	3120
tggacctcag	ggggatccca	aggcaggagg	taggcagcct	ggagctcctc	cattattatt	3180
attattatta	ttgagataga	gtttcgctct	tgttgcccag	gctggatgga	gtgcagtggc	3240
gtgatctcag	ctcactgcaa	cctccacctc	cttggttcaa	gcaattctct	gcctcagcct	3300
cctgagtagc	tgggattaca	ggcgcccacc	accacacctg	gctaattttt	tgtattcttt	3360
tttagtagac	acagggtttc	accatcttgg	ccaggctggg	cttgaactcc	tgacctcatg	3420
aaccaccgcg	ctcagcctcc	caaagtgttg	ggattacagg	catgagccac	tgtgcccggc	3480
catttttttt	tttttttttt	tttgagatgg	agtctcgtc	tgttgcccag	gctggagtg	3540
agtggcatga	tctcgcccca	ctgcaacctc	cacctcctag	gttcaagtga	ttctcttgcc	3600
tcagactcct	gattagctgg	gatcacaggc	gtgtgccacc	acaccgggct	aatttttgtg	3660
tttttagtag	agatgggggt	tcaccatggt	ggtcaggcta	gtctcgaact	cccagacctg	3720
tgatctgccc	gccttggcct	cccaaagtgc	tgggattaca	ggcgtgagcc	accacgcctc	3780
gctggagctc	ctccctttta	agtctgtttt	actgctccaa	gcctcacctt	cccagctgt	3840
gggatgggga	gaagccctcc	tcactgggtg	ccagggtggg	aagaacacgg	cgggtggggg	3900
agagtggaca	ctcgggagtg	ttggctccac	aaatgcccac	catactcaac	cccttcagag	3960
acccaccac	cctcaactct	gtccccagcc	atctccaggg	ggccagggtc	ccttattatt	4020
attttttgaa	acggagtcct	actctgttgc	ccaggctgga	gtgcagttag	atgatcacag	4080
ctcactgcag	ccatatatat	gtatatatat	atatatatga	aaaaatatat	ataaatatat	4140
atatatgaaa	aaatatatat	aaatatatat	atgaaaatat	atatataaat	atatatatga	4200
aaatatatat	aaatatatat	atgaaaatat	atatatgaaa	atatatatata	atatatatat	4260
gaaaatatat	atgaaaatat	atatatgaaa	atatatatga	aaatatatat	ataaatatat	4320
atatatgaaa	atatatatat	aaatatatat	atgaaaatat	atatataaat	atatatatga	4380
aaatatatat	ataaatatat	atatatgaaa	atatatatat	aaatatatat	atatgaaaat	4440
atatatatata	atatatatat	atgaaaatat	atatataaat	atatatatat	gaaaatatat	4500
atataaatat	atatatgaaa	atatatatat	aaatatatat	atatgaaaat	atatatatata	4560
atatatatat	atgaaaatat	atataaatat	atatatgaat	atatatatat	atatatgaaa	4620
atatatatat	atgaaaatat	atatataaat	atatatatga	aaatatatat	aaatatatat	4680
atgaatatat	atatatatat	atgaaaatat	atatatatga	aaatatatat	ataaatatat	4740
atatgaaaat	aatatatata	aatatatata	aatatatata	aaaatatata	tatatataaa	4800
aatatatata	tatatatata	taaacatata	tatatataa	tatatatata	tatttttttt	4860

tttttttgt	tttttttgt	agagatggaa	tttcaccgtg	ttgcctaggg	tggtctggag	4920
ctcttgatct	caagcgatcc	tccctgcctc	ggcctcccaa	cgtgctggga	ttataggcgt	4980
gagccaccgc	tccctggccag	ggctctgttc	tagttgcaac	agttcttgga	aaccactcgt	5040
agagggccac	gcctccattc	accaggccac	gggtgggtgg	gtgcgtatgt	tttgctgagg	5100
cctggtcatc	acgctgtggc	tccaaggctg	ggaccagcca	cagaccgaga	agccggctcag	5160
gtgccagcca	gagattcagg	gctccctccc	tctgaacatc	ctgtcttttag	cccactcctg	5220
gcatccagc	tcctgtcatc	ccagccacct	gcagcagtgc	cctaggggccc	catccctctg	5280
cggatcatgc	tcttggggcca	cctccctcaa	gaagccttcc	ctgacctccc	tcctcccagc	5340
ttccaccaca	ggcagaatct	gggcttgtag	ttgtttcagg	aatggaagcc	ccattcccag	5400
gtcctggggg	gaccccaagg	caggaggtgg	gcagagaggg	gtcctgcgaa	gcatagagga	5460
gccctgagtt	gctctggggg	gggcgagggc	ttccgggtgc	gtctgcgtga	gtgggtggcca	5520
cagactgtca	cctccaggag	ccagggtggg	tttactggag	gcaaccact	gtgggttgat	5580
gggcagagcc	aggggttagg	gcaggacact	ggggcctgaa	tcccatcttt	ccacttagca	5640
gacgtgagct	ctctggcctc	agtttctcga	tttgtgaaat	gcagtgaacc	tcgtcctcaa	5700
agggcagttg	tctagattaa	gcgaggctgt	gtgtagggtc	gtgtgcgtgc	acatggggct	5760
gtcttgtggg	cccccagaac	cttcacagcac	ttatcaaggg	tgaagatggc	ccacagggca	5820
gaggtgtttg	tttgggggtca	catgggggtga	acaggactgg	ttctgtcctt	gccagtgca	5880
ggagcggggg	ggggaggtgg	tggtttccgca	gcctaggctc	aggatagggg	ctgtccgagc	5940
acagtggggg	tggtggggtag	gatttctgaa	aaagggggccc	cttgctcacg	ggcacctccc	6000
atttcagcat	cacacagggc	aacaccagga	gccaacatga	gctcggggac	tgaactgctg	6060
tggtccggag	cagcgtgct	gggtgctgtg	gggtggcgag	ccagtctgtg	tggtgcgtgc	6120
tcacgcccag	gtaagcgggg	gtctcggggg	cgtgatgggg	agaaggtgtg	gacagtgcac	6180
ctcagaggcc	ctctcaggcc	cagacgtggc	tggtggtcaga	agaggtggtc	agatgaacct	6240
cgtgatgtga	cccctgaccc	ctaaactgcc	ccctgaagac	aatgggtcagg	tgcacccgag	6300
ggctttggct	ttgtctgggtc	aactgtggta	tctcgagcca	gagagattgc	cccagacgag	6360
ggagggggagg	cgaggttgcc	tggtggcatcc	acttttctag	cctctcctct	tctaaaaaag	6420
ggtagagcaa	tacccttttt	tctttttttt	ggacagagtc	ttgtctgggt	ctcccaggct	6480
ggagggcagt	gatgcaatct	tggtctcactg	taacatccaa	ctctcgggtt	gaagcgattc	6540
tcctgcctca	accccttgag	tagctgggac	tacaggtgcc	tgccaccatg	cctggctaata	6600
ttttgtgttt	ttagtagaga	cggtgtttcc	ccatgttggtc	caggctgggtc	acgaactgct	6660
gacctcatgt	gatcctcccg	cctcggccca	aagtgtctga	attacaggag	ggagccacca	6720
cacctgggtc	caaataattct	ttaatatcag	gtggccgggtg	atgattgaca	gtttggcccc	6780
caagtctctg	ctgagtcctg	ctggagacaa	gacatggcgg	gggtgtctctg	acctcaggtc	6840
gcagctgctc	ccagaccctt	tgctaactct	ggccttttct	tgcagggtgca	aagaggtcag	6900
agaaaatcta	ccagcagaga	agtctgtgag	ttgcctcgat	gtccctagcc	tggtgtattc	6960
atgtgccctg	ggcatggacg	tcctcaaggg	aattcctage	accccatcct	tcaccccttc	7020
actcacacct	cctccgtgcc	aagttctagt	gggtccctag	ccatcagaga	agggagagaa	7080
agtgtccagg	ggctgtccag	gccctgctgt	agcttgggtt	agggaggggt	ttgggaggcg	7140
gggagcctc	ggctgtgggg	ctagccactc	ttcagcttgc	ctgtgaaccc	ctccagaagt	7200
ccaggcactg	ggcaggcac	gatgggtcac	acctgtaatc	ccagcacttt	gggaggccaa	7260
ggcaggtgga	tcacctgagg	tcaggagttt	gagaccagcc	tggccaacat	gggtgaaacct	7320
catttctact	aaaatacaaa	aatgagctgg	gcgtgggtgt	gggtccctct	actcccagct	7380
actctggagg	ctgaggcagc	aggatcactt	gaaccagga	gggtggaggtt	gcagagagcc	7440
gagattgtgc	cactgcactc	cagcctgggc	aaaaaagcaa	gattccgtct	cagaaaagaa	7500
aaaaagaaaa	gaaaaaaaaa	atagaggtcc	accaggcacc	tgtgtcctca	gcctcccttt	7560
gaccccaatc	cccaggggct	agtcogctct	ccccttgcaa	tgcaagagac	agagaacctg	7620
gcacaggggtg	aaatgtgaac	gttgtcggag	actcccctgg	aaaaaactgc	cggagctcag	7680
gggaggatgt	gggcaagtcc	ctcgggggac	cagggaagga	ctgtgagaaa	gacccaggga	7740
agggcagtgg	gttcgacact	gcagactggg	gctgaaaccc	agaacaaccc	aggcacatgg	7800
gcagtggcca	cagggtgtcct	ttgattaaga	gaatggctgt	ggggccagga	aaccttgagg	7860
gtccatgtgc	acccccgagc	agtcactcat	gacccacaca	cgcacacccg	cacacacatc	7920
cttctctatt	tccttttgca	actgaaaaac	cacagtgaga	tttgaaaaata	gaatcttccc	7980
atccttgctc	atcgtggggc	aggggttagac	ctttctgggt	ctttctggcc	acgtggcttt	8040
ctggccgctc	gcaacctccc	ccgatgcccc	ccatgcctt	gactcctcgg	acacttcccc	8100
tctccctca	ggccctgccc	acccccagcc	ccctgattga	tcttagagcc	atagatgggtc	8160
agggccagac	tcagcgtccc	catgtgggag	gtggagggga	gctgtttgggt	cttctccctg	8220
gaatgcctgt	gcctgcctct	ccatctgtca	cctcgggttg	gctcagtcct	accagcctgc	8280
atgaagcgac	tgctgtgagc	acaggctccg	ttcctctgtt	gcttctccca	ggaagccacg	8340
tctgactgac	tctctcctgt	ggatttaggg	tatctctcct	aaatcaggtc	accctgagcc	8400
ccagtcttca	aggagcttgg	aaggctgggc	caggtaacca	ttctgggttca	gaggaggagc	8460

281

ccccaaacct	gctttaataa	tgagctaate	cactccatta	tctgtaatgg	cagcttccat	8520
tttcaagagc	acctcatggg	ccaagatggc	agctgggggtg	ccggccctca	tctctgcatt	8580
cccagcagca	ggaagaaaaga	atgaacaagg	atacaaaagg	tgtctcccag	ttgccagtgc	8640
ccccgtttta	aaagatttat	tggaatatc	aacaaccttg	gcttgaatct	catagaccag	8700
agcttaatcc	atggccacac	tttgggtgcaa	ggaaggctag	gaatagtcta	ttattttatt	8760
ctttattttat	ttagagatgg	agccacattt	acttttggtc	aggctggagt	gcagtagaat	8820
gatcttggtc	cactgcaacc	tctgcctcct	ggcttcaagg	gattctcctg	tctcagcctc	8880
ccgagtagct	gggattacag	gcatgcgcca	ccatgcccgag	ctaatttttg	tatttttagt	8940
agagacgggg	ttttctccat	gttggtcagg	ctggctctga	actcccaacc	tcagggtgatt	9000
cgcttgccct	ggcctcccaa	agccctggga	ttacagggtg	gagccaccat	gccgggtcta	9060
gagtgtgtgc	tttttttttt	tttttttttt	tttttttttt	ttttttttga	gacggagtct	9120
cgctctgtgc	cccaggccag	actgcggact	gcagtggtgc	aatctcggct	cactgcaagc	9180
tccgcttccc	gggttcacgc	cattctcctg	cctcagcctc	ccgagtagct	gggactacag	9240
gcgcccgcga	ccgcgcccgg	ctaatttttt	gtatttttag	tagagacggg	gtgagtgtgt	9300
gcttttttaa	ggaattgcaa	acgctccctg	ggaccagcag	gtgggaggca	gcctcatcgt	9360
cactcctggc	tgaaataatt	taccccaagt	cattgctggg	tccctgagca	cctgccttca	9420
ttcacctca	tgccccagaa	tctcagggtc	acctccacag	ccctgtccac	agaccctcc	9480
tgacctgtct	ccaggggccc	gggacccacc	ggcaggatgt	ggccctgttg	aggccatgtc	9540
agggtagggt	ctggctgaga	gccgggctcc	agccaacacc	cctgtgtgag	gggtgggcac	9600
ccagtgcacg	gagggggccag	agaatgggga	tagcatgggg	agccgtgaga	atgaggcctg	9660
aaagggcagc	agttcctccc	cactgtcgcc	ccagtcgctc	cctctgcttt	cctcctcat	9720
cctgcctgt	ccctccctcc	tgtccctgtg	ttcttgggct	gtgggagtc	aggccaggc	9780
tcagcacagc	ccatgcattt	ccaggcgtga	ggaccaacag	agctttacgg	ggtcccggac	9840
ctactcctgt	gagtctccaa	gtgtccccgg	gttgggctct	gggttggggg	tgtccctatc	9900
aagttatctc	ggtcccccatt	gacctgagac	cgtggccagg	cctgatgtgg	gggatgatg	9960
gggtgagggg	gctgggctag	ctggggggccc	agccaacacc	ccacttcttg	ccctttagtag	10020
tggtcggggc	ggcatggcca	ggacccctgg	cggacatggc	acccacaagg	taggtcacag	10080
tccccagga	agtgacaaga	atgaaagtcc	tggaggtcct	cacctggtga	gcccaggtea	10140
agacctccct	ccctccccga	gtcccagagc	tccagggtcc	agctatgaag	gccccacaag	10200
gggtatgggg	ggatgtgtcc	tgggggggccc	ctcccttaca	gccccctcct	taactccctc	10260
cttccccctc	cctgcaggaa	ggacaagctg	ttgcaattct	accccagcct	ggagggtgag	10320
tggcacaggg	cagggcacag	gacaggccta	gccaaagctg	gactaagaca	ggcgaaaacc	10380
ccatgggaca	ggcgtcgtgc	agtgggggct	gcggggccag	gcgaggcctc	cccaggagag	10440
acacacaggg	tggggcaggg	caggctcctg	gaatcgccct	ggcaggggga	gggtgcacac	10500
tcgcacatgc	cccactgagg	ggacaggggg	cactgcaaa	gctcagacac	gggaaatagc	10560
tggccctgcc	ttgggctgca	gcacccgagc	tgggtgcaaa	gcagggggcca	ggggagaaag	10620
caattagctg	ggtctttctt	ccagatccag	catcttccag	gtaccagaa	ttcagcaaa	10680
gtaggtaggc	tcttgagaa	agggggaggc	catggtgggg	gccacaccca	ggggctcagg	10740
cccaattctc	gctcctccc	gcagggaagc	gacacgggtc	ggaggaagcc	tacatgtgag	10800
tgaccttgat	cctgtccccc	ctgcctcgcc	tctccccctg	ccccacctct	ccccctgcc	10860
cacctctccc	cctgccccac	ctgcctgcca	cagccctggg	cttccctggc	caggaaccac	10920
ctcttgcact	agaacgaggc	atccagggtc	ccctccttct	cctggcaggc	aggcattggg	10980
cgacactggt	gtctcttagg	taaccctggg	tttgggggac	tggactttgc	cctgctctgg	11040
gacacagagt	gtcagggggc	gggagtagag	actcattcag	catcacccag	tcaagacaa	11100
gctacaggac	accagaatc	cctcgggggt	gttgcatcat	ctcacagatg	ggcaaacgat	11160
ggggaatggc	ctaaggtcac	atagcaaggt	ggctcaaccag	gtgcggtggc	tcatgcctgt	11220
aatcccagga	ctttgggagg	ccaaggcagg	cagatcacct	gaggccagga	gttcaagacc	11280
agcctcgcca	acatgggtga	acctcatctc	tactaaaaat	aaaaaattag	ccaggcatgg	11340
tgggtgcgtg	ctgtaatccc	agctactcgg	gaggctgatg	caggagaatc	gcttgaacct	11400
gggaggctga	ggttgcaagt	agccgagatc	atgccactgt	actccagcct	gggtgacaga	11460
gactctgtct	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gtggctccag	ccctggttgg	11520
ctcaggggtc	ccaggaagtg	ggggtggggg	aatcagagag	gagatcctgg	cagaccccca	11580
tggcccccaa	gaggagcaat	gggtgggagc	gcctggcct	caccgcccc	ttatggagcc	11640
cccaaccgga	tctccagcct	gccctgaaac	ctgtgttgta	tatgttttct	tggccagaga	11700
ccccattgcc	atggagtatt	acaactgggg	gcggttctcg	aagccccag	aaggtgaggc	11760
gaaggacaaa	gccggagggt	gaggaagtgg	tgtgggagct	cagggcagaa	gccatacctc	11820
caggcaggag	aggaggctgg	gcctgggttc	gggtaaatcg	gcagagccgg	ttgggtggac	11880
agaaggaggc	tgggtgctga	ggcggggggc	aagaagggat	agggggcggg	cgggtcagcg	11940
tgggagagct	gtgggcacag	ggcgtgggag	agaggagtgg	gccacagggc	agggaaactag	12000
agggctggct	tggggagggt	gggggaggcc	aggtccttgt	caacgaggac	tgagcatctt	12060

ctcctgaccc	cagaaggtac	ctgggatggt	gatccctgca	ggctctgagg	ccaccagaaa	12120
cctggctcgt	gaatgccttt	gctttatagg	aagggcaact	gagaggcccg	gtgtggtggc	12180
tcacccctgt	aatcccagca	ctttgggagg	ctaagggtgg	tggatcacct	gaggtcagga	12240
gttcaagacc	agtgtggcca	acatggtgaa	accccatctc	tacaaaaata	caaaaaaaaa	12300
aaaaaaaaaa	aattagccag	gcatggtggc	acatgcctgt	aatcccagct	acttgggagg	12360
ctgagacagg	agaattgctt	gaacccgga	ggcggaggct	gcagtggagg	aagatcgac	12420
cattgcactc	cagcctgggc	aacagagtga	gactccatct	caaaaaaaaa	aaaaatcccc	12480
ccaaaaaagg	gcaactgagg	actcaggggtg	ggcagtgcct	gctgagaggt	gcatgggcct	12540
gcggtttgaa	tccagctcca	tgacctggct	cctgcctgga	ccatactggg	taggacctg	12600
gtgttggggg	gtcctcttct	gccccccacc	actgccacct	ccatTTTTTT	tttgagacac	12660
agccttgctc	tgtaacccag	gttgagtaca	atgtcacgat	cttgggtcac	tgcaacctcc	12720
gcctcccggg	ttcaagcgat	tttccctgct	cagcctcccg	agtagctgag	attacaggcg	12780
cccgccacca	cgcttgctta	attttttgta	tttttagtag	agacagggtt	tcaccatatt	12840
ggccaggctg	gtcttgaaact	cctgacctca	ggtgatccgc	ccgccttggc	ctcccaaagt	12900
gctgggatta	caggcatgag	ccaccccgcc	aggctggcag	tgctcatttc	ttaggacccc	12960
caacatcact	gatggatttt	gggtggggca	tcagtcagag	cccagcttcc	ccattacaag	13020
gccaaagatg	ggtgccaggc	gctgaggtgc	catactcagc	ctgggtcccc	gagcaaagca	13080
tcctcagcct	gcccctgccc	atctggaaga	gtccagcccc	ttcccggcag	tggtcttagg	13140
gagagctcct	gattatagag	atgaacccct	gaggctgccc	ctgcctccct	ccctctctcc	13200
agccaccgga	catgggcctg	aattgcagcc	cccgagagct	acccctcca	gagtgcata	13260
ggaggggatc	tcagaagaca	gaggctggac	acagtgactc	acgcctgtaa	tcccaacatt	13320
ttgggaagat	tgcttaagct	taggggttca	agaccagcct	gggcaacaca	gcgagatcct	13380
ctctacaaac	aattttaaaa	gttagctggg	cgtgggtggg	catgcctgta	gttccagcta	13440
ctcaggaggc	tgccgggtag	gaagatcggt	tgagccggga	gttggaggct	acagtggagt	13500
gactttgcc	gtgctctcca	gcctgggtga	cagagcaaga	ccgtctcaac	aagaaacaaa	13560
gaagacagct	gagctcaggg	ctcagggaa	agcattgcag	ggcaccaggc	cagcaccct	13620
taggaagctc	atccagaaga	aggcttgagg	tcocggggga	cccagagggc	tagggcttgg	13680
cggaagaggt	cccctgcaaa	gggaaggcag	gacagagcgg	gaggatgagc	caggctttgc	13740
agggtctgcc	cacacccccg	tgcccactcc	tctctctcct	gcagatgatg	atgccaatcc	13800
ctacgagaat	gtgctcattt	gcaagcagaa	aaccacagag	acaggtgagg	ctgcccagcc	13860
agaggcaggc	tggggctggg	agcagcaggc	ctccttgccc	agggtgcccct	gcaactccca	13920
ctgctcaaag	gcccgcctcc	ctttgaagcc	tgaaggctct	cggatcccca	ggtaccttcc	13980
ggtagagcct	tgcccctact	atcctcgga	gcagctctat	tggtcctgg	tgctctgtg	14040
ggactgagcc	aaggggggccc	tattctccct	ctctgcaggt	gcccagcagg	agggcatagg	14100
tggtctctgc	agagggggacc	tcagcctgtc	actggccctg	aagactggcc	ccacttctgg	14160
tctctgtccc	tctgcctccc	cggaagaaga	tgaggaatct	gaggattatc	agaactcagc	14220
atccatccat	cagtggcgcg	agtccaggaa	ggtcatgggt	agggtggccg	gagaagaggc	14280
agggtggtcc	acttagggca	ggcttgaggg	actggcctgg	aagggcaggc	tgaaagtggg	14340
cttccctcca	gccagtcag	ctaaccctgc	agtgatgcct	gggtgcagga	gcagctgcag	14400
agaccttgaa	ccacacagga	cggcccttgg	cagccgcca	gcctccaggg	tggggctcag	14460
tctcccggg	caggccgccc	catccagctg	catgcattga	gtaacgcatt	cacctgctct	14520
cacagcagga	cgatctccgg	caaatcccag	agacaggaca	gacacacacc	gccaggacct	14580
gtcgggcgtg	gcatttcccg	cgggctgttt	tgtggagtct	gggggtctga	gtctggggga	14640
gcagtcattg	gtgtctccat	gtgaaccact	cgatgacctg	tctgcccgc	ggtccacagg	14700
gcaactccag	agagaagcat	cccctggccc	ggtgggaagc	ccagacgagg	aggacgggga	14760
accggattac	gtgaatgggg	agggtggcag	cacagaagcc	tagggcagac	caagaagaaa	14820
ggtacagccc	ctgctctcca	gctgccgtgg	gccaaggatt	ggaggctctg	ccaagctgca	14880
ggacccccaa	tccaagggaa	cagccgagag	tgtgggtgga	ggggccatgg	tgggggctac	14940
agggtgcacc	catgggtgct	ccaagagggc	agcttggcga	ctctgttcc	ctgttctggc	15000
caggggcgtc	aggcagggaa	ttctgggtgac	ttcaggggca	aagaagtggg	caccgggtgg	15060
gtctcccaac	tccactgcat	cctcctggct	gcgaccttgg	accaagtgc	aacctcccag	15120
aaattagttc	ctcacttggt	gcccacctct	cagagaagac	atcgcacaca	cggccgggca	15180
cgttggtctc	cgctgtgaat	cccgccactt	tgggaggccg	aggcaggcag	atcacctgag	15240
gtcacgagtt	cgagaccagc	ctggccaaca	tgggtgaaact	tcatctctac	taaaaacaca	15300
aaaaattagc	caggcatggt	ggtgggtgcc	tgtagtccca	gttagttggg	aggctgaggc	15360
aggagaatca	tttgaacctt	gaaggcgag	gttgcggtga	gttaagatca	catgcactca	15420
accctgggtg	acagagcgag	actccgtctc	aataaataaa	taaaaaaaca	gacattgcac	15480
acaaagcctc	agcccagcag	gcaactcggtc	aatgctggaa	acagacagga	ggcagggagc	15540
ttgggaatat	taacagtggc	tgagacgcgc	tgaggagcca	ccgcaggcca	gtgagatggt	15600
gcggcgctaa	gcgctcacac	gtgcaccatc	tcttagcacc	caaagccaca	gagcagttaa	15660

gccacctgcc	caaggccaca	tcttgaagta	aggggaggag	gagatggaat	ccccagtggt	15720
cagacatcag	acatcaaagc	ctaggctggg	tctactgctt	gggaagcacg	atggaccccc	15780
agagggcctt	gaaggtctgc	caaagtcccc	atctggggaga	cccaggccgt	catctcagcg	15840
agcaggctgg	aggggtgaaa	ccacagtga	cctgggtggt	caagagtcag	ccccagaggc	15900
aggtgcagga	gtttgagcca	aatgtgcaga	gccccacgtc	attcattcaa	ccagtatcca	15960
ctggggccct	gctacgggca	agtccctgctc	taggtgctgg	gaacaccaac	ataaagaaca	16020
gcaaacccct	gaccccttag	aacttgctt	ctggtaggag	agagaaaaca	gatagggctg	16080
gacacagcgg	tcatgcctat	aaatcccagc	acttcgggag	gctgaggcgg	gaggatcctt	16140
tgagcctctg	agtttgaggc	cagcctgggc	aacatagcaa	gacctctctc	tctacaaaaa	16200
cttttttttt	ttttttttga	gacagagtat	cactgtcact	caggctggag	tgcagtggcg	16260
ccatctcggc	tactgcaac	ctccacctcc	tgggttcaag	cgattctcgt	gcctcagcct	16320
tccaagttag	tgggattaca	ggcacacgcc	accatgtcca	gcctctataa	aaacatttaa	16380
aattagccag	gcatgggtgt	ggatgcccta	gagtcacct	gacttgggag	gctgagggtg	16440
gaagatcact	tgagcctggg	aggtcaaggt	tgcaatgagc	catgggtgct	gcagtgcagt	16500
gtggctcgtc	cactgcactc	aagcctgggc	aacagagcaa	gaccccatct	caaaaaaaaaa	16560
atttaaaaat	tagctgggca	tagtgggtgtg	tacctgtagt	cccagctact	tgggaggctg	16620
aggcaggagg	atcgcttgag	cccaggagtt	caaggctaca	gtgagctatg	attgtaccac	16680
tgtacagcca	ggatgacaga	gtgagacctt	gtcaaaaaca	caacaacaac	aagaaaacag	16740
ataagaagac	atggcatgtt	cactgggtgtg	aagtctggca	gagagaaaca	aaacagggaa	16800
gcggggccag	aagtgtgtgtg	gggttgtgtg	caagacgcag	tggtgcaatt	taagggaagg	16860
ggctagggaa	gcctttcaga	gctcccttcc	tcaccccatc	tgggggaagg	acatccaggc	16920
agaggggaca	acagaggccc	caggggtggag	tgagcccccac	aggtctgagc	aaagccaggg	16980
gccagggagg	agcagggtgag	gggaaactag	tggaggtcga	ggccgttggt	ggggaggctg	17040
accaggcagg	gccagcactt	ggggttttac	tgcatgagat	gggagggagg	gagggagata	17100
gaaaggttgt	tttttctttt	tttttttttt	tcgttcttgt	cgcccaggct	gaagtgcaat	17160
ggtgcaatct	tggtcactg	caaactccgc	ctcctgggtt	caagcgatgc	tcctgcctca	17220
gcctcccag	tagctgcgat	tacagggtgtc	tgccaccaca	cccggccaat	ttgtatttat	17280
tttatatttat	tttgtttttt	gagagggagt	ctcgctctgt	cacccaggct	ggagtgcagt	17340
ggcgtgatct	cggctcactg	caacctctgc	ctcctgggtt	caggtttctc	ttgcctcagc	17400
ctcccagata	gctgggatta	caggcacacg	ccacaacacc	tggctaattt	ttgtattttt	17460
agtagagatg	gggtttcacc	atgttggcca	ggctggctctc	aaactcctga	cctaaagtga	17520
tcggcccacc	tcagcctccc	caagtgtctg	gattacaggc	atgagctacc	atgcctggct	17580
aatgggaagg	ttttgtacaa	agactggctg	gatgtttcta	attcaatttt	tctggctgtt	17640
gggcagacaa	atgggtactg	ggagagtggg	tacaggaagc	ccaggaagga	cccaggcact	17700
ggtgccatct	gggcaagggg	tggcagcagt	ggagacaggg	gtaggcaaca	tggtgaaacg	17760
ctgtctctac	ataatatata	aaaatttgcc	aggtgtagt	gcgcatacgt	gtagtcccag	17820
ctactcggag	gttgaggcgg	gaggatagct	tgagtctagg	aggttgagct	gctgtgtgag	17880
ctgtgattgc	accactgcac	tccagcctgg	gccacagagc	aagacgctgt	ctcaaaaaca	17940
aaacaaaaag	aagaggccag	gcgcagtgcc	tcacgcctgt	aatcccagca	ctttggggagg	18000
ctgaggcagg	ctgtatcacct	gaggtcaggga	gtctcgagacc	atcctgggca	acatggggaa	18060
accccatctc	tactaaaaat	acaaaaatta	gccaggtgtg	gtggcgtgtg	cctgtaatcc	18120
cagctactcg	ggaggctgag	gcacgagaat	cacttgaacc	tgggaaggagg	aggttgcagt	18180
gagctaagat	cgccaccattg	cactccagcc	tgggcaacta	cgtcttaaaa	aaaaaaaaaa	18240
aaaaaaaaaa	aaaaaagcca	ggcgcggtgg	ctcacgcctg	taatcccagc	actttgggag	18300
gctgaggcgg	gcggatcaca	aggtcaggag	atcgagacca	tcctggctaa	cacagtgaac	18360
ccccgtctct	actaaaaata	caaaaaatta	gcccggcatg	gtggcaggcg	cctgtagtcc	18420
cagctacttg	ggaggctgag	gcaagagaat	ggcgtgaacc	cgggaggcag	agcttgcagt	18480
gagccgagat	cacgccactg	cactccagcc	tgggagacag	agcaagactc	tgtctcaaaa	18540
acacaaaaac	aaacaaacaa	aatgggccag	gcgtgggtggc	tcacgcctgt	aatcccagca	18600
ctttgggaag	ccgaggtggg	cggatcacga	ggtcaggaga	tcgagaccat	cctgggctaac	18660
atgggtgaaac	cctgtctcta	ctaaaaatac	aaaaaaaaaa	aaaaaaaaatt	agctgggcgt	18720
ggtggcgtag	tcccagctac	ttgggaggct	gaggcaggag	aatggcgtag	acctgagagg	18780
cggagcttgc	agtgagccga	gatcgcgcca	ccgcactcca	gcctgggtga	cagagtgaga	18840
ctccatctca	aaaaaaaaaa	aagaaaccca	gttattgatg	tggcgcttct	gttctcagcc	18900
aggaggcagg	ctcaatgggtg	tcccaaaacc	agtggttatg	gttctcagga	acaaaatact	18960
gatcaaggca	aaacctccttc	tacaaacttt	cctcttcatt	taaggagcca	aggcaaagag	19020
ggaccactgt	gctcatggac	ccatcgctgc	cttccaagga	ccatttccca	gagctactca	19080
acttttaagc	ccctgccatg	gttgctcctg	gaaggagaac	cagccaccct	gaggaccacc	19140
tggccatgcg	tgcacagcct	gggaaaagac	agttactcac	gggagctgca	ggcccgtcac	19200
caagccctct	cccgaaccag	gctttgtggg	gcaggcacct	ggtaccaagg	gtaacccggc	19260

284.

tcctgggtatg	gacgggatg	caggatttag	gataagctgt	cacccagtc	ccataacaaa	19320
accactgtcc	aacactggta	tctgtgttct	tttgtgtctat	gaatttggt	tcctaattgc	19380
tattgttggt	tgctgggggt	ttaaattgatt	gataagcttg	tacagttaac	ttatagaggg	19440
ggagccatat	ttaacattct	ggatttcaga	gtagagattt	ctgtgtgtc	tcctagaaag	19500
cattacatgt	agtttatttc	agcacccttg	ttgggtgggg	ccctggctct	cttccccctt	19560
ggtgggacct	cccccttctt	tgggcttcag	ttcactcagg	aagaaatgag	gctgtcgcca	19620
tctttatgtg	cttccagtg	aaatgtcact	tgctacagac	aatagtgc	gagagtctag	19680
agaagtagtg	accagaacag	ggcagagtag	gtccccctcca	tgccctgaa	tcctcctctg	19740
ctccagggt	ggcctctgca	gagctgatta	aacagtgttg	tgactgtctc	atgggaagag	19800
ctggggccca	gagggacctt	gagtcagaaa	tggtggccaga	aaaagtatct	cctccaacca	19860
aaacatctca	ataaaacat	tttagttgaa	aagcagtgat	tatcctgtgt	ctcctttctc	19920
ctgcttcagg	taaaaaacct	tttataaaaa	tataaaaatt	agccg		19965

&lt;210&gt; 385

&lt;211&gt; 20420

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 385

tcggcgagtg	cgggcgatgt	acggatgatt	cagtggctgg	caggaagccc	gccctgccc	60
cccgcagtg	tcagtgggt	tgccatcagc	ttgggcaggt	gtgcgggctc	aggatggggc	120
ggccgtgggt	aggaaccctg	gactctcagg	taagcctttc	ccaggggtgc	ctcagtcctc	180
aggctgtccc	ccatccccca	ggagctcctg	gccccactgg	gtgggggtgg	aagaggcctg	240
gatgcctggc	gccccctccc	gcagccccac	tctcaccctg	gcaccaggct	ctgtggcact	300
tcaggggtca	gtttgtttct	gggcttcttg	ccactctctt	gccctcgcc	tcctctgtcc	360
agcctgtgta	gccttgggac	atcccagggt	ggteccatca	ttgccagaga	ctggtgaagt	420
aagtggccga	gagccaaaac	agtggctgcc	ctggcctggg	agcctcggtt	tcctcatccg	480
tgaaatggga	ctgtaacccc	ctacacaggt	caggggaaaa	cgggtgggatt	acaggccagg	540
gcccgaggtc	tgccccaggt	caggtgaaga	acccccactg	cctccctgcc	cagcccccta	600
cctggccctc	aactctgtcc	ctgggaccag	ggctgtctag	gccccctcctg	cacccgccc	660
cctccctctc	tcctctccag	ctaggctcat	ttgaagccca	gagttatttg	gaaaaagcaa	720
caggaccagc	cgggcacggg	ggctcaacct	gtaatcccag	catttgggga	ggccaaggcg	780
ggaggatcat	ttgaagtcag	gagctggaga	ccagcctgag	caacatagt	agactcccc	840
ctctttaaaa	aataaaaaata	aaaaaatata	attaaaaact	aatgaaaaa	accaacagac	900
cccagagcag	agtccagtg	ataaagccat	ccagggcttc	aagccaggct	gccccctccc	960
caaccccagt	gtccccaacc	acagctcagc	tcggagaagg	ctgggagaac	cggcagggtg	1020
gtctcgagcg	tccttccagg	cgggattcag	acactgtagc	tcctccagcc	cagccccgag	1080
aacttccccg	aagccagctc	ttggcaatcg	ttgttcatat	gaaaactgcc	cacttccctt	1140
tagtgctatt	ttggcctctg	cagaaccgtg	gtctgtggca	gccccactc	cccaccccgc	1200
ccagcctatc	cgggcctcga	gggctcacc	gggtccacc	tcgctccct	ccacctcagc	1260
ccacctgctt	tcagaacctg	gatgggagag	tgaaagttag	agcgagacag	agacacaaag	1320
ggagacagag	acagagagag	agcacagaat	ttttttaaac	ggagtctcac	tctgttgtcc	1380
aggctggagt	gcagtggcgt	gatctcggct	cactgcaacc	tccacctccc	aggttcaagc	1440
agttctcctg	ccttaccctt	ccaagtagct	ggggactaca	ggcacgtgct	accacacctg	1500
gctaattttt	tattttttat	ttatttttta	ttttttggag	acagtcttgc	tctgtctccc	1560
aggctgggag	tgcagtgggt	caatcttgge	tcactgcaag	ctccacctcc	cgggtacatg	1620
ccattctcct	gcctcagcct	cccagtagc	tgagactaga	ggcgctgcc	accacgaccg	1680
gctaattttt	tgtattttta	gtagagacgg	ggtttcgcca	tgtagccag	gatgggtctca	1740
atctcctgac	tttgtgatct	gcctgcctcg	gcctcccaaa	gtgtgtggat	tacaggtgtg	1800
agccaccgtg	cctggcctaa	ttttttat	tttagtagaga	caggggttca	ccatgttggc	1860
caggctgggtc	ttgaactcct	gacctcagat	gatttgcccc	cctcagcctc	ccaaagtgtt	1920
gggattacag	gtgtgaacta	ccgcacccgg	ccaacagcgc	aggatgtatt	cagtctgggg	1980
gcagacacat	gactgtttgt	taaatttcat	tttttgtttt	tagagatggg	gtcttgctct	2040
gtcaccacag	ctggagttca	gtggtgtgat	cttggctcac	tgacagcttc	aactcctggg	2100
ctcaagcaat	tctcttgctt	cagtgtccca	agtagctgga	accacaggca	tgtgccactg	2160
cgctgccta	attttttcat	ttttttgtag	agacagggcc	ttgttacatc	gtccatgctg	2220
gtctcgaact	cctggcctca	agcgatcctc	ctgtctcggc	ctcccagtg	tgagattaca	2280
ggcgtcagcc	accacgcccc	gcctgatccc	attttattta	ttcatttatt	taatttatta	2340
ttattattat	tattattttg	agatggagtc	tcactctgtc	tcccatgctg	gagtgcactg	2400
gcgtgatctc	agctcactgc	aactcactgc	ctcctgagtt	caagtgattc	tcatgcctca	2460

285

gcctcccaag	tagctggaat	tacaggcttg	cacctccacg	cctggctaata	ttttgtat	2520
ctagtagaaa	caggggttca	ccatgttggt	caagctgggt	tcaaactcaa	gtgatcctcc	2580
tgctctcagcc	tcccaagta	ttgggattac	aggtgtgagt	ccctgtaccc	agcccgacct	2640
cattttatag	atgagaaaac	tgaggcgggg	ggctctcagg	cagaggctag	atttgggtccc	2700
atgagccctc	ctgcaagaca	agttgtcca	acctcacaag	cctgagatga	acttggggcca	2760
tgctggagggt	gttgggggtg	caccccggtt	tgggggcact	gaggcaagga	gagtttcgag	2820
gagggagaa	ggcagtgtcc	aggcggggcca	tggggaagag	agagcagagc	tttcctcgga	2880
caacctccc	gggtgacgtg	ggtcgtgtcca	gtcacacggc	tcagaaattc	acttgttccc	2940
actgactcac	ttggcttttg	gggagaggcc	tgggtggctc	tctgtgatgc	gcctcttaca	3000
gaggctcagg	gccgcatgga	gattccctgt	catcttaccg	cagggatttg	ggaagtccag	3060
agaggctcctg	agacttgtcc	aaagccacac	agctttcaag	ggggacagcc	caggtcctgg	3120
tggacctcag	ggggatcccc	aggcaggagg	taggcagcct	ggagctcctc	cattattatt	3180
attattatta	ttgagataga	gtttcgctct	gtttgccag	gctggatgga	gtgcagtggc	3240
gtgatctcag	ctcactgcaa	cctccacctc	cttgggtcaa	gcaattctct	gcctcagcct	3300
cctgagtagc	tgggattaca	ggcgcccacc	accacacctg	gctaattttt	tgtattcttt	3360
tttagtagac	acagggtttc	accatcttgg	ccaggctggg	cttgaactcc	tgacctcatg	3420
aaccacccgc	ctcagcctcc	caaagtgttg	ggattacagg	catgagccac	tgtgcccggc	3480
catttttttt	tttttttttt	tttgagatgg	agtctcgctc	tgttgcccag	gctggagtgc	3540
agtggcactga	tctcgcccca	ctgcaacctc	accctcctag	gttcaagtga	ttctcttgcc	3600
tcagactcct	gattagctgg	gatcacaggc	gtgtgccacc	acaccggct	aatttttgta	3660
tttttagtag	agatgggggt	tcacatgtt	ggtcaggcta	gtctcgaact	cccgacctcg	3720
tgatctgccc	gccttggcct	cccaaagtgc	tgggattaca	ggcgtgagcc	accacgccct	3780
gctggagctc	ctccctttta	agtcctgttt	actgctccaa	gcctcacctt	ccccagctgt	3840
gggatgggga	gaagccctcc	tcactgggtg	ccagggtggg	aagaacacgg	cgggtggggg	3900
agagtggaca	ctcgggagt	ttggctccac	aaatgcccac	catactcaac	cccttcagag	3960
acccaccac	cctcaactct	gtccccagcc	atctccagg	ggccaggctc	ccttattatt	4020
attttttgaa	acggagtctc	actctgttgc	ccaggctgga	gtgcagttag	atgatcacag	4080
ctcactgcag	ccatatatat	gtatatatat	atatatatga	aaaaatatat	atatatatat	4140
atatatgaaa	aaatatatat	aaatatatat	atgaaaatat	atatataaat	atatatatga	4200
aaatatatat	aaatatatat	ataatatata	taaatatata	tatatataaa	tatatatatg	4260
aaaatatata	taaatatata	tataaatata	tatatgaaaa	tatatatatg	aaaatatata	4320
tgaaaatata	tataaaata	tatatatatg	aaaatatata	tataaatata	tatatgaaaa	4380
tatatatata	aatatatata	tataataaa	tatatataaa	tatatatata	tgaaaatata	4440
tataataata	tatatatatg	aaaatatata	tataaatata	tatatatgaa	aatatatata	4500
taaatatata	tatatgaaaa	tatatatata	aatatatata	tatgaaaata	tatatataaa	4560
tatatatata	tgaaaatata	tataaaata	tatatatgaa	aatatatata	taaatatata	4620
tatgaaaata	tatatataaa	tatatatata	tgaaaatata	tataataata	tatatatatg	4680
aaaatatata	taaatatata	tatgaaaata	tatatatata	tatatatgaa	aatatatata	4740
tatgaaaata	tatatataaa	tatatatatg	aaaataatat	atataaatat	atataaatat	4800
atataaaaat	ataaaaatat	ataaaaatat	atataataac	atataatat	atataatat	4860
aaatatatat	atataatat	tttttttttt	ttttgtattt	ttttttaga	gatggaattt	4920
caccgtgttg	cctaggctgg	tctggagctc	ttgatctcaa	gcgatcctcc	ctgcctcggc	4980
ctcccaacgt	gctgggatta	taggcgtgag	ccaccgctcc	tggccagggt	ctgttcctag	5040
ttgcaacagt	tcttggaac	ccactcgaga	gggccacgcc	tccattcacc	aggccacggg	5100
gggtgggtgtg	cgtatgtttt	gctgaggcct	ggtcatcacg	ctgtggctcc	aaggctggga	5160
ccagccacag	accgagaagc	cggtcagggtg	ccagccagag	attcagggtc	ccctccctct	5220
gaacatctctg	tcttttagccc	atccttggca	tcccagctca	tgtcatccca	gccacctgca	5280
gcagtgcctc	agggccccc	ccctctgccc	atcatgctct	tgggccacct	cctccaagaa	5340
gccttccctg	acctccctcc	tcccagctcc	caccacaggc	agaatctggg	cttgcaattg	5400
tttcaggaat	ggaagcccca	ttcccagggtc	ctggggggac	cccaaggcag	gaggtgggca	5460
gagaggggtc	ctgcgaagca	tagaggagcc	ctgagttgct	ctgggggtggg	cgagggtctc	5520
cgggtgcgtc	tgcgtgagt	gtggccacag	actgtcacct	ccaggagcca	gggtgggttt	5580
actggaggca	accactgtg	ggttgatggg	cagagccagg	gttaggggca	ggacactggg	5640
gcttgaatcc	cctctttcca	cttagcagac	gtgagctctc	tggcctcagt	ttctcgattt	5700
gtgaaatgca	gtgaacctcg	tcctcaaagg	gcagttgtct	agattaagcg	aggctgtgtg	5760
tagggctgtg	tgcgtgcaca	tgggctgtc	ttgtgggccc	ccagaacctt	ccagcactta	5820
tcaaggggtga	agatggccca	cagggcagag	gtgttggttt	ggggtcacat	ggggtgaaca	5880
ggactgggttc	tgtccttgcc	cagtgcagga	gcggggagg	gaggtggtgt	ttccgcagcc	5940
taggctcagg	tatggggctg	tccgagcaca	gtgggggtgt	ggggtaggat	tcctgaaaaa	6000
ggggccccc	gctcacgggc	acctccatt	tcagcatcac	aagaggcaac	accaggagcc	6060

aacatgagct	cggggactga	actgctgtgg	cccggagcag	cgctgctggt	gctgttgggg	6120
gtggcagcca	gtctgtgtgt	gcgctgtctca	cgcccaggta	agcgggggtc	tcggggacgt	6180
gatggggaga	aggtgtggac	agtgcattctc	agaggccctc	tcaggcccag	acgtggctgt	6240
ggtcagaaga	gggtgtcaga	tgaacctcgt	gatgtgacct	ctgaccccta	aactgcccc	6300
tgaagacaat	ggtcaggtgc	acccgagggc	tttggttttg	ctgggtcaac	tgtggtatct	6360
cgagccagag	agattgcccc	agacgagggg	ggggaggcga	ggttgccctgt	ggcatccact	6420
tttctagcct	ctcctcttct	aaaaaagggt	gagcaaatac	ccttttttct	tttttttggg	6480
cagagtcttg	ctctggtctc	ccaggctgga	gggcagtgat	gcaatcttgg	ctcactgtaa	6540
catccaactc	tcgggttgaa	gcgattctcc	tgcctcaacc	ccctgagtag	ctgggactac	6600
aggtgcctgc	caccatgcct	ggctaatttt	tgtgttttta	gtagagacgg	ggtttcccca	6660
tgttgggcag	gctggtcacg	aactgctgac	ctcatgtgat	cctccgcct	cggcccaag	6720
tgctggaatt	acaggaggga	gccaccacac	ctgggtccaa	atattcttta	atatcagggtg	6780
gccggtgatg	attgacagtt	tggcccccaa	gtcctgtctg	agtcctgctg	gagacaagac	6840
atggcggggg	gtgtctgacc	tcaggctcga	gctgctccca	gaccttttgc	taatcctggc	6900
cttttcttgc	aggtgcaaag	aggtcagaga	aaatctacca	gcagagaagt	ctgtgagttg	6960
cctcgatgtc	cctagcctgg	tgtattcatg	tgcctggggc	atggacgtcc	tcaagggaat	7020
tcctagcacc	ccatccttca	ccccttccct	cacacctcct	ccgtgccaa	ttctagtggg	7080
tccttagcca	tcagagaagg	gagagaaagt	gtccaggggc	tgtccaggcc	ctgctgtagc	7140
ttgggttagg	gagggctttg	ggaggcgggg	acgcctgggc	tgtggggcta	gccactcttc	7200
agtctgcctg	tgaagccctc	cagaagtcca	ggcatctggc	caggcacgat	ggttcacacc	7260
tgtaatccca	gcactttggg	aggccaaggc	aggtggatca	cctgagggtc	ggagtttgag	7320
accagcctgg	ccaacatggt	gaaacctcat	ttctactaaa	atacaaaaat	gagctgggcg	7380
tgggtggggg	tcctcttact	cccagctact	ctggaggctg	aggcagcagg	atcacttgaa	7440
cccaggaggt	ggaggttgca	gagagccgag	attgtgccac	tgcactccag	cctgggcaaa	7500
aaagcaagat	tcggtctcag	aaaagaaaaa	aagaaaagaa	aaaaaaaata	gaggtccacc	7560
aggcacctgt	gtcctcagcc	tccttttgac	cccaatcccc	aggggctagt	ccgctctccc	7620
cttgcaatgc	aagagacaga	gaaccgggca	cagggtgaaa	tgtgaacgtt	gtcggagact	7680
ccctgggaaa	aaactgccgg	agctcagggg	aggatgtggg	caagtccctc	gggggaccag	7740
ggaaggactg	tgagaaagac	ccagggaagg	gcagtgggtt	cgacactgca	gactggggct	7800
gaaacccaga	acaacccagg	cacatgggca	gtggccacag	gtgtcctttg	attaagagaa	7860
tggctgtggg	ccagggaaac	cttggagggtc	catgtgcacc	cccagcaggt	cactcatgac	7920
ccacacacgc	acacccgcac	acacatcctt	cctcatttcc	ttttgcaact	gaaaaaacac	7980
agtgagattt	gaaaatagaa	tcttcccctc	cttgtctcat	gtggggccagg	gttagacctt	8040
tctgggtctt	tctggccacg	tggctttctg	gcgcctgca	acctcccccg	atgcccccca	8100
tgcccttgac	tctcgggaca	cttcccctct	cccctcaggc	cctgcccacc	cccagccccc	8160
tgattgatct	tagagccata	gatggtcagg	gccagactca	gcgtccccat	gtgggagggtg	8220
gaggggagct	gtttggtctt	ctccctggaa	tgcctgtgcc	tgcctctcca	tctgtcacct	8280
cggttgggct	cagtcaccac	agcctgcatg	aagcgactgc	tgtgagcaca	ggctccgttc	8340
ctctgttgct	tctcccagga	agccacgtct	gactgactct	ctcctgtgga	tttaggggtat	8400
ctctcctaaa	ctaggtcacc	ctgagcccca	ctcttcaagg	agcttgggaag	gctgggccag	8460
gtacccttcc	tggttcagag	gaggagcccc	caaactgct	ttaataatga	gctaattccac	8520
tccattatct	gtaatggcag	cttccatttt	caagagcacc	tcattggtcca	agatggcagc	8580
tggggtgccg	gccctcatct	ctgcattccc	agcagcagga	agaaagaatg	aacaaggata	8640
caaaggggtg	ctcccagttg	ccagtgcgcc	cgtttaaaaa	gatttatttg	aaatatcaac	8700
aaccttggtc	tgaatctcat	agaccagagc	ttaatccatg	gccacacttt	ggtgcaaggga	8760
aggctaggaa	tagtctatta	tttatttctt	tatttattta	gagatggagc	cacattttact	8820
ttgttccagg	ctggagtcca	gtagaatgat	cttggctcac	tgcaacctct	gctcctgggc	8880
ttcaagcgat	tctcctgtct	cagcctcccc	agtagctggg	attacaggca	tgcgccacca	8940
tgcacagcta	atttttgtat	ttttagtaga	gacgggggtt	tctccatggt	ggtcagggctg	9000
gtcttgaact	cccaacctca	ggtgattcgc	ctgecttggc	ctcccaaagc	cctggggatta	9060
cagggtgtgag	ccaccatgcc	gggtctagag	tgtgtgcttt	tttttttttt	tttttttttt	9120
tttttttttt	tttttttgag	acggagtctc	gctctgtcgc	ccaggccaga	ctgaggactg	9180
cagtgggtgca	atctcggctc	actgcaagct	ccgcttcccc	ggttcacgcc	attctcctgc	9240
ctcagctccc	cgagtacgtg	ggactacagg	cggccgccac	cgccggcgcc	taattttttg	9300
tatttttagt	agagacgggg	tgagtgtgtg	cttttttaag	gaattgcaaa	cgtcccttgg	9360
gaccagcagg	tgggaggcag	cctcatcgtc	actcctggct	gaaataattt	acccaagtc	9420
attgctgggt	ccctgagcac	ctgecttcat	tcacctcat	gccccagaat	ctcagggtcta	9480
cctccacagc	cctgtccaca	gacccctcct	gaccgtctc	caggggcctg	ggaccaccgc	9540
gcaggatgtg	gcctgttgga	ggccatgtca	gggatgggtc	tggctgagag	ccgggctcca	9600
gcccagggcc	ctgtgtgagg	gttgggcacc	cagtgcacgg	agggggccaga	gaatggggat	9660



agcatgggga	gccgtgagaa	tgaggcctga	aagggcagca	gttcctcccc	actgtcgccc	9720
cagtcctgcc	ctctgcttcc	cctcctcatc	cctgcctgtc	cctccctcct	gtccctgtgt	9780
tcttgggctg	tgggagtcga	ggcccaggct	cagcacagcc	catgcatttc	caggcgtagag	9840
gaccaacaga	gctttacggg	gtcccggacc	tactcctgtg	agtctccaag	tgtccccggg	9900
ttgggctctg	ggttgggggt	gtccctatca	agttatctcg	gtccccattg	acctgagacc	9960
gtggccaggc	ctgatgtggg	gggatgatgg	ggtgaggggg	ctgggctagc	tggggggccc	10020
gcaacacccc	acttcttgcc	ctttgtagtg	gtcgggcagg	catggccagg	acctctggcg	10080
gacatggcac	ccacaaggta	ggtcacagtc	ccccaggaag	tgacaagaat	gaaagtcctg	10140
gaggtcctca	cctggtgagc	ccaggtcaag	acctccctcc	ctccccagat	cccagagctc	10200
cagggctcag	ctatgaaggc	cccacaaggg	gtatgggggg	atgtgtcctg	ggggggcctct	10260
cccctacagc	ccctccttta	actccctcct	tccccctccc	tgcaggaagg	acaagctggt	10320
gcaattctac	cccagcctgg	aggggtgagt	gcacagggga	gggacaggga	caggcctagc	10380
caagctggga	ctaagacagg	cgaaaacccc	atgggacagg	cgtcgtgcag	tgggggctgc	10440
ggggccaggc	gaggcctccc	caggagagac	acacaggctg	gggcagggca	ggctcctgga	10500
atcggcctgg	cagggggagg	gtgcacactc	gcacatgccc	cactgagggg	acagggagca	10560
ctgcaaaggc	tcagacacgg	gaaatagctg	gccttgccct	gggctgcagc	acccgagctg	10620
ggtgcaaagc	agggggccagg	ggagaaagca	attagctggg	tctttcttcc	agatccagca	10680
tcttccagg	accagaactt	cagcaaagg	aggtaggctc	ctggagaaag	ggggaggcca	10740
tggtgggggc	cacacccagg	ggctcaggcc	caattctcgc	ctcctcccg	aggaagcaga	10800
caggggtcgg	aggaagccta	catgtgagt	accttgatcc	tgtccccct	gcctcgctc	10860
tccccctggc	ccacctctcc	ccctgcccc	cctctcccc	tgccccacct	gcctgccaca	10920
gccctgggct	tcttgggtcca	ggaaccacct	cttgacttag	aacgaggcat	ccagggtccc	10980
ctccttctcc	tggcaggcag	gcattgggcg	acactgttgt	ctcttaggta	acctggggtt	11040
tgggggactg	gactttgccc	tgtctgggga	cacagagtgt	caggggagg	ggatagagac	11100
tcattcagca	tcacccagtc	aaagacaagc	tacaggacac	ccagaatccc	tcgggggtgt	11160
tgcattcatc	cacagatggg	caaacgatgg	ggaatggcct	aaggtcacat	agcaagggtg	11220
ctcaccaggt	gcggtggctc	atgcctgtaa	tcccaggact	ttgggaggcc	aaggcaggca	11280
gatcacctga	ggccaggagt	tcaagaccag	cctcgccaac	atggtgaaac	ctcatctcta	11340
ctaaaaataa	aaaattagcc	aggcatgggt	gtgcgtgcct	gtaatcccag	ctactcgga	11400
ggctgatgca	ggagaatcgc	ttgaacctgg	gaggctgagg	ttgcagttag	ccgagatcat	11460
gccactgtac	tccagcctgg	gtgacagaga	ctctgtctca	aaaaaaaaaa	aaaaaaaaaa	11520
aaaaaaaaag	tggctccagc	ccctgggtgg	tcaggggtcc	caggaagtgg	gggtggggga	11580
atcagagagg	agatcctggc	agacccccat	ggcccccaag	aggagcaatg	gtgggagcag	11640
ccctggcctc	accgccccct	tatggagccc	ccaacccgat	ctccagcctg	ccctgaaacc	11700
tgtgttgtat	atgttttctt	ggccagagac	cccattgcca	tggagtatta	caactggggg	11760
cggttctcga	agcccccaga	aggtagggcg	aaggacaaag	ccggagggtg	aggaagtgg	11820
gtgggagctc	agggcagaag	ccatacctcc	aggcaggaga	ggaggctggg	cctgggttcg	11880
ggtaaatcgg	cagagccgg	tgggtggaca	gaaggaggct	ggtgctgcag	gcgggggcca	11940
agaagggata	gggggcgggc	gggtcagcgt	gggagagctg	tgggcacagg	gcgtgggaga	12000
gaggagtggg	ccacagggca	gggaactaga	ggcttgcttc	ggggagggtg	ggggaggcca	12060
ggctcctgtc	aacaggagct	gagcatcttc	tcctgacccc	agaaggtagc	tgggatgggt	12120
atccctgcag	gctctgaggc	caccagaaac	ctggctcgctg	aatgcctttg	ctttatagga	12180
agggcaactg	agaggccggg	tgtggtggct	cacccctgta	atcccagcac	tttgggaggc	12240
taaggtgggt	ggatcacctg	aggtcaggag	ttcaagacca	gtgtggccaa	catggtgaaa	12300
ccccatctct	acaaaaatac	aaaaaaaaaa	aaaaaaaaaa	attagccagg	catggtggca	12360
catgcctgta	atcccagcta	cttgggaggc	tgagacagga	gaattgcttg	aacccgggag	12420
gcggaggctg	cagtgcagcca	agatcgacc	attgcactcc	accctgggca	acagagttag	12480
actccatctc	aaaaaaaaaa	aaaatcccc	caaaaaagg	caactgagga	ctcagggtgg	12540
gcagtgcctg	ctgagagggt	catgggcctg	cggtttgaat	ccagctccat	gacctggctc	12600
ctgcctggac	catactgggt	aggaccatgg	tgttgggggg	tcctcttctg	ccccccacca	12660
ctgccacctc	catttttttt	ttgagacaca	gccttgctct	gtcaccagag	ttgagtacaa	12720
tgtcacgata	ttggttcact	gcaacctccg	cctcccggt	tcaagcgatt	ttcctgcctc	12780
agcctcccga	gtagctgaga	ttacaggcgc	ctgccaccac	gcctggctaa	ttttttgtat	12840
tttttagtaga	gacagggttt	caccatattg	gccaggctgg	tcttgaaact	ctgacctcag	12900
gtgatccgcc	gcgcttggcc	tcccaaaagt	ctggggttac	aggcatgagc	caccccgcca	12960
ggctggcagt	gctcattttc	taggaccccc	aacatcactg	atggattttg	ggtggggcat	13020
cagtcagagc	ccagcttccc	cattacaagg	ccaagatggg	gtgccaggcg	ctgagggtgc	13080
atactcagcc	tgggtccccg	agcaaagcat	cctcagcctg	ccctgcccta	tctggaagag	13140
tccagccctc	tcccggcagt	ggctctaggg	agagctcctg	attatagaga	tgaacccctg	13200
aggctgcccc	tgccctccctc	cctctctcca	gccacccggc	atgggcctga	attgcagccc	13260

ccgcagagta	ccccctccag	agtgcataatg	gaggggatct	cagaagacag	aggctggaca	13320
cagtgaactca	cgctgtgaat	cccaacattt	tgggaagatt	gcctaagctt	aggggttcaa	13380
gaccagcctg	ggcaacacag	cgagatcctc	tctacaaaca	attttaaaag	ttagctgggc	13440
gtggtggtgc	atgcctgtag	ttccagctac	tcaggagget	gcggggtagg	aagatcgttt	13500
gagccgggag	ttggaggcta	cagtgaactg	actttgccag	tgctctccag	cctgggtgac	13560
agagcaagac	cgtctcaaca	agaaacaaaag	aagacagagg	agctcagggc	tcagggaaga	13620
gcatgcaggg	gcaccaggcc	agcaccattt	aggaagctca	tccagaagaa	ggcttgagg	13680
cccgggggac	ccagagggct	agggtctggc	ggaagaggtc	ccctgcaaa	ggaaggcagg	13740
acagagcggg	aggatgagcc	aggctttgca	gggtctgccc	acacccccgt	gcccactcct	13800
ctctctcctg	cagatgatga	tgccaattcc	tacgagaatg	tgctcatttg	caagcagaaa	13860
accacagaga	caggtgaggg	tgcccagcca	gaggcaggct	ggggctggga	gcagcaggcc	13920
tccttggcca	ggtgccccctg	cactccccac	tgctcaaagg	ccgccccac	tttgaagcct	13980
gaagctctct	ggatccccag	gtacctttcg	gtagagcctt	gcccactacta	tcctcggagg	14040
caagctctatt	ggctcctggt	gcctctgtgg	cagtgaagcca	aggggggctt	attctccctc	14100
tctgcagggtg	cccagcagga	gggcataggt	ggcctctgca	gaggggacct	cagcctgtca	14160
ctggccctga	agactggccc	cacttctggt	ctctgtccct	ctgctcccc	ggaagaagat	14220
gaggaatctg	aggattatca	gaactcagca	tccatccatc	agtggcgcga	gtccagggaag	14280
gtcatgggta	ggtggccggg	agaagaggca	gggtgggtcca	cttagggcag	gcttgaggga	14340
ctggccctga	agggcaggct	gaaagtgggc	ttccctccag	ccagtccagc	taaccccgcga	14400
gtgatgctct	ggtgcaggag	cagctgcaga	gaccttgaac	cacacaggac	ggcccttggc	14460
agccgccccg	cctccagggt	ggggctcagg	cctcccgggc	agggccgccc	atccagctgc	14520
atgcatggag	taacgcattc	acctgctctc	acagcaggac	gatctccggc	aaatcccaga	14580
gacaggacag	acacacaccg	ccagggacct	gtcgggcgtg	gcatttcccg	cgggctgttt	14640
tgtggagctc	gggggtctga	gtctggggga	gcagtcattg	gtgtctccat	gtgaaccact	14700
cgatgacctg	tctgccccgt	ggtccacagg	gcaactccag	agagaagcat	cccctggccc	14760
ggtgggaagc	ccagacgagg	aggacgggga	accggattac	gtgaatgggg	aggtggcagc	14820
cacagaagcg	tagggcagac	caagaagaaa	ggtacagccc	ctgctctcca	gctgcccgtg	14880
gccaaggatt	ggagggtctt	ccaagctgca	ggacccccaa	tccaagggaa	cagccgagag	14940
tgtgggtgga	ggggccatgg	tgggggctac	agggtgcacc	catgggtgct	ccaagagggc	15000
agcttggcga	ctctgttccct	ctgttctggc	caggggcgtc	aggcagggaa	ttctggtgac	15060
ttcaggggca	aagaagtggg	caccgggtgg	gtctcccaac	tccactgcat	cctcctggct	15120
gcgaccttgg	accaagtgc	aacctcccag	aacttagttc	ctcacttggt	gcccacctct	15180
cagagaagac	atcgccacaca	cgccggggca	cggtggctca	cgctgtgaat	cccggcaact	15240
tgggaggccg	aggcaggcag	atcacctgag	gtcacgagtt	cgagaccagc	ctggccaaca	15300
tgggtgaaact	tcatctctac	taaaaaacaca	aaaaattagc	caggcatggt	ggtgggtgcc	15360
tgtagtccca	gttagttggg	aggctgaggg	aggagaatca	tttgaacctt	gaaggcggag	15420
gttgccgtga	gttaagatca	catgcactca	accctgggtg	acagagcgag	actccgtctc	15480
aataaataaa	taaaaaaaca	gacattgcac	acaaagcctc	agcccagcag	gcactcgggtc	15540
aatgctggaa	acagacagga	ggcagggacg	ttgggaaatg	taacagtggc	tgagacgcgc	15600
tgaggagcca	ccgcaggcca	gtgagatggt	gcggcgctaa	gcgctcacac	gtgcaccatc	15660
tcttagcacc	caaagccaca	gagcagttaa	gccacctgcc	caaggccaca	tcttgaagta	15720
aggggaggag	gagatggaat	ccccagtggt	cagacatcag	acatcaaage	ctaggctggg	15780
tctactgctt	gggaagcacg	atggaccccc	agagggcctt	gaaggctgcc	caaagtcccc	15840
atctggggaga	cccaggccgt	catctcagcg	agcaggctgg	aggggtgaaa	ccacagtga	15900
cctgggtggt	caagagtcag	ccccagaggc	agggtcagga	gtttgagcca	aatgtgcaga	15960
gccccacgtc	attcattcaa	ccagtatcca	ctggggccct	gctacgggca	agtcctgctc	16020
taggtgctgg	gaacaccaac	ataaagaaca	gcaaaccctt	gaccccttag	aacttgcat	16080
ctggtaggag	agagaaaaca	gatagggtcg	gacacagcgg	tcatgcctat	aaatcccagc	16140
acttcgggag	gctgaggcgg	gaggatcctt	tgagcctctg	agtttgaggc	cagcctgggc	16200
aacatagcaa	gacctctctc	tctacaaaaa	cttttttttt	ttttttttga	gacagagtat	16260
cactgtcact	caggctggag	tgcaagtggc	ccatctcggc	tacttgcaac	ctccacctcc	16320
tgggttcaag	cgattctcgt	gcctcagcct	tccaagtagc	tgggattaca	ggcacacgcc	16380
accatgtcca	gcctctataa	aaacatttaa	aattagccag	gcattggtgt	ggatgcccta	16440
gagtcaccct	gacttgggag	gctgaggtgg	gaagatcact	tgagcctggg	aggtcaaggt	16500
tgcaatgagc	catgggtgct	gcagtgaact	gtggtcgtgc	cactgcactc	aagcctgggc	16560
aacagagcaa	gaccccatct	caaaaaaaa	atttataaa	tagctgggca	tagtggtgtg	16620
tacctgtagt	cccagctact	tgggaggctg	aggcaggagg	atcgcttgag	cccaggagtt	16680
caaggctaca	gtgagctatg	attgtaccac	tgtacagcca	ggatgacaga	gtgagaccct	16740
gtcaaaacaa	caacaacaac	aagaaaacag	ataagaagac	atggcatggt	cactgggtgt	16800
aagtctggca	gagagaaaca	aaacagggaa	gcggggcagg	aagtagtgtg	gggttgtggg	16860

caagacgcag	tggtgcaatt	taaggaaggg	ggctagggaa	gcctttcaga	gctcccttcc	16920
tcaccccatc	tgggggaagg	acatccaggg	agaggggaca	acagaggccc	caggggtggag	16980
tgagccccac	aggtctgagc	aaagccaggg	gccagggagg	agcaggtgag	gggaaactag	17040
tgagggtcga	ggccgttggt	ggggaggctg	accaggcagg	gcagcacttg	gggttttact	17100
gcatgagatg	ggagggaggg	agggagatag	aaaggttggt	ttttcttttt	tttttttttt	17160
cgttcctgtc	gcccagggct	aagtgcattg	gcgccatctc	ggctcactgc	aacctccacc	17220
tcctgggttc	aagcgatgct	cctgcctcag	cctcccaggt	agctgcgatt	acaggtgtct	17280
gccaccacac	ccggccaatt	tgtattttatt	ttattttatt	ttgttttttg	agagggagtc	17340
tcgtctctgtc	accagggctg	gagtgcagtg	gcgtgatctc	ggctcactgc	aacctctgcc	17400
tcctgggttc	agggtttctct	tgcctcagcc	tcccagtagt	ctgggattac	aggcacacgc	17460
cacaacacct	ggctaattttt	tgtatttttta	gtagagatgg	ggtttcacca	tgttgccag	17520
gctgggtctca	aactcctgac	ctaaagtgat	cggcccacct	cagcctcccc	aagtgtctggg	17580
attacaggca	tgagctacca	tgcctggcta	atgggaaggt	tttgtacaaa	gactggctgg	17640
atgtttctaa	ttcaatttttt	ctggctgttg	ggcagacaaa	tgggtactgg	gagagtggtg	17700
acaggaagcc	caggaaggac	ccaggcactg	gtgccatctg	ggcaaggggt	ggcagcagtg	17760
gagacagggg	taggcaacat	ggtgaaacgc	tgtctctaca	taataataca	aaatttgcca	17820
ggtgtagtagg	cgcatacgtg	tagtcccagc	tactcggagg	ttgaggcggg	aggatagctt	17880
gagtctagga	ggttgagctg	ctgtgtgagc	tgtgattgca	ccactgcact	ccagcctggg	17940
ccacagagca	agacgctgtc	tcaaaaacaaa	aacaaaaaga	agaggccagg	cgcagtggtc	18000
cacgcctgta	atcccagcac	tttgggaggg	tgaggcaggc	tgatcacctg	aggtcaggag	18060
ttcgagacca	tcctggggcaa	catggggaaa	ccccatctct	actaaaaata	caaaaaattag	18120
ccaggtgtgg	tgccgtgtgc	ctgtaatccc	agctactcgg	gaggtgagg	cacgagaatc	18180
acttgaacct	ggaaggagga	ggttgacgtg	agctaagatc	gcaccattgc	actccagcct	18240
gggcaactac	gtcttaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaagccag	gcgcggtggc	18300
tcacgcctgt	aatcccagca	ctttgggagg	ctgaggcggg	cggatcacaa	ggtcaggaga	18360
tcgagaccat	cctgggctaac	acagtgaaac	cccgtctcta	ctaaaaatac	aaaaaattag	18420
ccgggcatgg	tggcaggcgc	ctgtagtccc	agctacttgg	gaggctgagg	caagagaatg	18480
gcgtgaacct	gggaggcaga	gcttgacgtg	agccgagatc	acgccactgc	actccagcct	18540
gggagacaga	gcaagactct	gtctcaaaaa	cacaaaaaca	aacaaacaaa	atggggccagg	18600
cgtggtggct	cacgcctgta	atcccagcac	tttgggaagc	cgagggtggc	ggatcacgag	18660
gtcaggagat	cgagaccatc	ctgggtaaca	tggtgaaacc	ctgtctctac	taaaaataca	18720
aaaaaaaaaa	aaaaaaaaatta	gctgggcgtg	gtggcgtagt	cccagctact	tgggaggctg	18780
aggcaggaga	atggcggtgaa	cctgagaggg	ggagcttgca	gtgagccgag	atcgcgccac	18840
cgcactccag	cctgggtgac	agagtgcagc	tccatctcaa	aaaaaaaaaa	agaaaccag	18900
ttattgatgt	gcggcttctg	ttctcagcca	ggaggcaggc	tcaatggtgt	cccaaacca	18960
gtggttatgg	ttctcaggaa	caaaatactg	atcaaggcaa	acctccttct	acaaactttc	19020
ctcttcattt	aaggagccaa	ggcaaagagg	gaccactgtg	ctcatggacc	catcgctgcc	19080
ttccaaggac	catttcccag	agctactcaa	cttttaagcc	cctgccatgg	ttgctcctgg	19140
aaggagaacc	agccaccctg	aggaccacct	ggccatgcgt	gcacagcctg	ggaaaagaca	19200
gttactcacg	ggagctgcag	gcccgtcacc	aagccctctc	ccgaccagg	ctttgtgggg	19260
caggcacctg	gtaccaaggg	taaccggctg	cctggtagtg	acggatgcgc	aggatttagg	19320
ataagctgtc	accagctccc	cataacaaaa	ccactgtcca	acactgggat	ctgtgttctt	19380
ttgtgctatg	aatttggtg	cctaattgct	attgttggtt	gctgggggtt	taaatgattg	19440
ataagcttgt	acagtttaact	tatagagggg	gagccatatt	taacattctg	gatttcagag	19500
tagagatttc	tgtgttgtct	cctagaaaagc	attacatgta	gtttattttca	gcatccttgt	19560
tgggtggggc	cctggctctc	ttcccccttg	gtgggacctc	ccctttcttt	gggcttcagt	19620
tcactcagga	agaaatgagg	ctgtogccat	ctttatgtgc	ttccagtggg	aatgtcactt	19680
gctacagaca	atagtgcatg	agagctctaga	gaagttagtg	ccagaacagg	gcagagtagg	19740
tcccctccat	ggccctgaat	cctcctctgc	tccagggctg	gcctctgcag	agctgattaa	19800
acagtgttgt	gactgtctca	tgggaagagc	tggggccag	agggaccttg	agtcagaaat	19860
gttgccagaa	aaagtatctc	ctccaaccaa	aacatctcaa	taaaaccatt	ttagttgaaa	19920
agcagtgatt	atcctgtgtc	tcctttctcc	tgtctcaggt	aaaaaacctt	ttataaaaaat	19980
ataaaaaatta	gcccggcctg	gtgggtgcatg	cctgtagtct	caactacttg	ggaggctgag	20040
gcaggaataat	cacttgaaac	cagaagggtg	cagtgaacta	tgattgcatac	actgcactcc	20100
agcctgggca	agagggagac	cttgtctcaa	aaaacataac	aaaacacggc	caggcacagt	20160
ggctcacgcc	tgtaatccca	gcactttggg	aggctgaggt	gggtggatca	cgaggtcagg	20220
agatcgagac	catcctgact	aacacagtga	aaccggtctc	taataaaaaat	acaaaaaaat	20280
tagccgggca	tggtggcggg	cacctgtagt	cccagctact	tgggaggctg	aggcaggaga	20340
atggcggtgaa	cccgggaggc	ggagcttgca	gtgagccgag	atcgccaccac	tgcactccag	20400
cctggacgaa	agaggggagac					20420

<210> 386  
 <211> 233  
 <212> DNA  
 <213> Homo sapiens

<400> 386  
 cccagcactt tgggaggctg aggtgggtgg atcacgaggt caggagatcg agaccatcct 60  
 gactaacaca gtgaaacccg tctctaataa aaatacaaaa aaattagccg ggcattggtgg 120  
 cgggcacctg tagtcccagc tacttggggag gctgaggcag gagaatggcg tgaacccggg 180  
 agggcggagct tgcagtgagc cgagatcgca ccactgcact ccagcctgga cga 233

<210> 387  
 <211> 11746  
 <212> DNA  
 <213> Homo sapiens

<400> 387  
 gccacaaaac actgcaaggc tttattagct aaaatgtcaa cccacacaca gatcagagac 60  
 gcgccctcagc ttctctgcgc ctttccgccc cgtcacccga tcaatggggg ggaggccaaa 120  
 ctcaaacact tgcggggcac agacgtccca gaagcaaaaca tgcaagtcac gggagtttat 180  
 ttattttaatt tttttcccca gatggagact ctgtcgccea ggctggagtg caatgggtgtg 240  
 atcttggctc actgcaacct ccacctcctg ggttcaagcg attctcctgc cacagcctcc 300  
 cgagtagctg ggattacagg tgcccgccac cacaccagc taatttttat atttttagta 360  
 aagacagggt tccccatgt tggccaggct ggtcttgaac ttctgacctc aggtgatcca 420  
 cctgcctcgg cctcccaaag tgttgggatt acaggcgtga gctaccgtgc ctggccagcc 480  
 actggagttt aaaggacagt catgttggct ccagcctaag gcggcatttt ccccatcag 540  
 aaagccgcgg ctctgttacc tcagaatagg gcacctgtaa gtcagtcagt gaagtctctg 600  
 ctctaactgg ccaccggggc cattgtcttc tgacacagcc ttgccaggag gcctgccatc 660  
 tgcaaaagag agttcactcc ttccgctatt ttcattgtgag tgtatccaat ttctgaaaa 720  
 acaaaacaaa ttcaaatctg gtttaataagt gggggagttc ttttttaaaa tctgaactga 780  
 aaaaaataaa aataaaaaaca gaaacaaact gaactaatgg ttttttcaaa atcagcatga 840  
 ggaattccaa ccccgccggg aaaatgaatg ctaagatgca atggattatg ttacctaata 900  
 gttctatttt tttcttaaaa ggatgctgat agttctttca aagaaactgt taagaaaatg 960  
 ggtggggcga gggggggcgg ggtggtggca cggaaagcca ggctagagga aaatatttat 1020  
 atatctgata aagaacttgc atccagactg tataaagaat tctcaaaaat tcagtaataa 1080  
 agtccaggcg tggtygctca tgccgttaat ccagtgactt tgggagggtca aggcagggtg 1140  
 atcacgagcc caggagttcg agatcagcct gaccaacatg gtaaaacccc atctctacta 1200  
 aaaatacaaa aattagccag gtatgggtggc gcacgcctgt aatcccagct actcgggagg 1260  
 ctgaggcagg agaactcact aaacctggga ggcgaagggt gcagtgaagt gagatagtgc 1320  
 cactgcactc cagctgggc aacagagcaa gctccatct caaaaaataa taagtataa 1380  
 aattcagtaa taaaaatcaa acaacccaat taaaaaatgg gtagatttag acctggagca 1440  
 gtagctcaca cctgtaatcc cagcattctg ggaggctgag gcaggaggat cacttgccca 1500  
 gagttggggc tgggcaacat agcaacaccc aaactctacg aaaaaaagaa aataaaaatg 1560  
 acccaagtgt agtggcacat gcctgcagtc ccagctactc gggagcctga ggtgggagga 1620  
 ttgcttgagc atggaagggt gaggtgcag tgaactatga tcgcaccact gcactccagc 1680  
 ctgggtgaca gagcaagacc ctgtctctca aaaacataaa aaaggtaggc caggcgcagt 1740  
 ggctcacacc tgtaattcta gcactttggg aggccgaggc gggaggatca cttgagccc 1800  
 ggagttcaag accagccttg gcaacacggg gacacccgt ctccaccaa aatataaaaa 1860  
 ttggccgggtc ttaacatgat ctctaaacaa aaaatacagt acaattaaaa taaaaaatgt 1920  
 aaaaatttta aaaaatgggt atatatgaac agatgtttca tcaaagaaga ttctggatgg 1980  
 caaacgagca catgattaaa tgttcagcat agtaattagg gaaatgcaaa ttaaaaggc 2040  
 aatgagatct catcacatgc ctattaggtt attttgttgt tgttgttatt ggttttttt 2100  
 tttttttttt ttttaagatg gagtctcact ctgtgcgcc aagctgtagt gcagggtgt 2160  
 gatctcagct cactgcaacc tccacctcct ggttcaagc gatcctctc cctcagccg 2220  
 ccgagtagct gggattacag gtgtaagcca ctgcatccgg tcattacaca cctattagaa 2280  
 tggcttaaaa accaaactga gcactccatg tgggtgctag gttgaggatc ctccggaatg 2340  
 ctggtgggaa tgacgtgct gcagccactt cggaaaaccg tttggcagtt ccttatcgag 2400  
 taaaacatac acttatcatt ttcccaggca atttcacccc tgggaactta cttgggaaaa 2460  
 agaaaaactt aacatttgca ttcacactaa tccatatatg caaatgttta cactggcttt 2520

attcacagtc	accacaatct	gtaaaccctaa	atgtcctcca	gctgatggac	agataagcaa	2580
actgtggtac	acgcacagga	tggattactt	ctcagtgata	acacggactg	actcatggat	2640
agaagtacca	gcgtggacac	atctgaaagg	catttctgct	acagtgaag	aaagaagcca	2700
gactcacaag	gctaagttct	acatgatccc	atztatatga	tattctggaa	aactgtatcc	2760
catgaaacag	aaactacatc	ggtagtttcc	aagtggtagt	cggggagggg	gctggcttca	2820
aagggacaca	tgagttgttc	tgggatgaca	gattctgcat	cctgatggtg	atagtgtttg	2880
catgactgag	tgcgtttgtc	ctgtacctaa	caggctgaat	tttactctat	gtaaattaaa	2940
cctcaattaa	tctaaccctg	aaaaatcaat	caatcagtc	atacacaaga	gagccttgaa	3000
tgaagaaaat	cagaactgtg	tgaacaaac	ttggctctca	ggacaatcag	ccacgttgat	3060
ctagtttgga	cgtctgtccc	cttccaatct	catttggaat	ttggctccca	atgtggggat	3120
gtttgggtca	tgaggaagat	cccacgtgaa	tggtctgggtg	cccaccccaa	ggtagtgagt	3180
gagttcttga	tcaattaggt	ccctggagag	ctggctgttc	aaatgagcct	ggcacctccc	3240
tccgttctca	acaggtgggc	tctgcagtc	caggtcctca	cttcccttcc	caacatgagc	3300
agaagcagcc	tgaacccctc	cctagaagca	gatgctggca	tcagtctaca	tgtacagcct	3360
gcagaactgt	gagccaaatc	aacctctttt	ctttctacat	taccagctct	ctggtattcc	3420
tttatagtaa	ctcaaaggaa	ctaagacaca	gcctccctcc	cactgcagtt	gggaaacact	3480
gagcaccttc	tagatgccag	gcctgtgagc	agagaaagcg	aagccagggc	ccacagtctt	3540
ttttttttgt	tttgagacag	tctcgctctg	ctgcccaggc	tggagtgcag	tggtgcgac	3600
ttggctcact	gcaacctcca	cctcccaggt	tcaagcgatc	ctcctccctc	agcctcccaa	3660
gtagctggga	ttatatggcg	ttgccaccac	accagctaa	gttttgtatt	tttagtagag	3720
atggggcttt	gccatgttgg	ccaggctggt	ctcaaaactc	tgacctcagg	tgatccgccc	3780
acctcgccct	cccaaagtgc	tgggattaca	ggcatgagcc	accacgcccc	gccatgcccc	3840
gctaattttt	gtatttttag	tagacagagg	ctttcactac	gttggccagg	ctggtctcga	3900
actcctgacc	tcaggtgatc	tgcccacctc	ggcctcccaa	agtgcctggga	ttacaggtgt	3960
ggcccacagc	acccggccac	tatgggccac	attcttgagg	acagaggcat	ttctacattc	4020
tcaccgacct	tgataaactc	cagtttcagg	tattctgcca	tttggaaggt	tttacacact	4080
cgaaagatgt	tgccaatgat	atcttctggt	gagtagccca	gatgccacaa	gtgagcaaga	4140
atctagacaa	aggagacaga	aaaggctgct	taccacttta	aactgtaaga	agacatgtga	4200
ttttgagact	caccacagct	ggtggggccc	acccttcagg	tcacatgggg	gtaccttaac	4260
tgattttcat	ggcagataga	gagataacat	tgcaaagtga	ttgttgtttt	gcttaaataat	4320
ttttttttca	gtaatatataa	gataagagtc	ttgctatat	gtccaggctg	gtcccaaagtt	4380
ccgggctca	agcaatcctc	ctgcctcgac	ctccaaaagt	gctgggatta	caggcatgag	4440
ccactgagcc	cagcctatcg	caaatgtggt	aagctgtggt	gcaaaatggt	ctactaccac	4500
acccatgtaa	tctcttgatc	cggagctctt	aaaatgcttt	attaatctga	tgactaggta	4560
tagcaaaagt	gaaaaagcag	accattcctc	tgctagcttc	atccagctgc	agtcccaatg	4620
caacctctgc	aggacgagcc	tggagcacac	cctgactggg	taatcccagc	ctcctgcttc	4680
ccaccacccc	tgccccaccc	aggctgcagc	gtctggaggc	aggccttttt	gcctttgttt	4740
tggcatcttg	gggtgaattc	aggaggcaga	gaagctctgt	gcccacaaat	ctgaaggctt	4800
tcttcaggtc	tactcaggga	ccctgggccc	gggtctctgc	tcagtctccc	cgccttgcac	4860
tccggtttca	cattgggtgg	aactatgccc	taaaaccagt	caacttccaa	cctagtttgt	4920
tagggggtag	gcagagggaa	accatgactg	gatcaatgac	cttgaaaccac	accaaccaca	4980
ccacacccat	gtggcttgag	gtcgctgaa	ccccagccac	atctgctgga	atctgctcac	5040
agcactcagt	cccattgtga	ggctagaatc	ttcctgctcc	ctcctctcct	ggctagctgg	5100
gggctgctgg	atcccagaat	gcctgtgcct	atgagaatgg	atggggacac	ttcccttaa	5160
ctggagagaa	gatggcttcc	ctggagaagg	agctaggctg	gtctttcctc	ctgactttgg	5220
ctgacaaatt	tctcctgcag	aggatataat	tacaggagaa	aaacaccatt	ttgaattcta	5280
gttctactgc	ttttaacca	tgacttaggg	ctgggcatag	tgacatgtgc	ctgtagtccc	5340
agctacttgg	gaggctgagg	tgggaggatc	gcctgagcct	gagaggtaga	ggctacagtg	5400
agctgtgacc	gcgccagtg	attccggcct	gggcaacaga	gtaagaccct	gtttctacat	5460
aaataaataa	ataaataaat	aaacaaacac	agtgatttag	gacaaggaat	tcagcctctg	5520
aatcagtttt	ctcatcagta	aagtgcaccc	aactcctagc	ataatttttt	ttttccagtt	5580
cctagacaga	ttaacacata	gcctgatatt	aataattttt	tttttttctc	gagacagggt	5640
ctcaccatca	cccaggctgg	ggtacagtgg	cgcaatcaca	gctcactgca	gccttgacct	5700
ccaaggctca	acaaatcctc	ctgcctcagt	ctcccaagta	agatttcaag	aatgaatgga	5760
gtgatgtgta	taatgtccct	ggtaccagaa	gggctcccgc	tctcctctgc	ccaagaagtg	5820
agcggttcct	ctgccaggac	ggggggaagg	aggccaacct	tgtaggcttc	gtcaatgttg	5880
gcattcacac	agtgtcggat	catctccttt	accagcagtg	ggtggggctc	gtcacagacc	5940
tggccaaagg	gaaaggaaag	gcggtcaggg	gctagaaggg	acaatgtgag	cggggaggcc	6000
ccaacagacc	gacttccagg	caatctatgg	gtaaaacttc	tcaacctgtt	gttttcatca	6060
aattctccag	caaccaggat	gagtttgggg	aatgctcctc	tcaccatcaa	agagaagtgc	6120

ttccggcacc	aggaagataa	atttcccaaa	cataagacag	atgaacaaga	gagcaaccaa	6180
gggcctgtga	aggatgtctc	cttggggaca	gcttttaaagt	cacaagtcac	ctgtcttaga	6240
tcacttgggg	ggtcagttgc	ccagaaccac	ttggaattca	ctttagaact	gggaggctct	6300
ttggggccaa	tcccacctcc	accccgaggt	aggaactggc	cttccctaca	aaagggtcccc	6360
cagcctcagc	ctgacaccct	aaacaagggg	tcaggctact	ccagcaggca	ggtgcatggg	6420
gctgggggact	ccgtctctccc	tgacagattc	tccgcagtg	catgaggctc	tgctctgggt	6480
acaatgtcga	cccctacatc	ttcccaatga	aagcctcctg	atgggtccag	aggtcaccca	6540
cacctgccct	tgctttttcc	eggtggaagc	catggtttcc	tgagccctca	gtgacccctc	6600
aagacaaaac	agggccccga	ccatcacccc	tgtttctgag	cgggcctccc	cttcttaagt	6660
ggcctcgaaa	atgcattcac	tgcccagatc	tacccagatg	cttcaaaaat	cgcttgctctg	6720
ttgtccacaa	acctggtaag	aaacagctat	aggctgaaag	cttggacagc	ccttcccagt	6780
ttcttcccc	aaataagggg	gaagtgaatc	tctcaaattg	catttagacg	cggagttatc	6840
aggatgcgga	agcagttttc	aaaagaattc	ccaagagaaa	aatgttttgc	tgacatggga	6900
gagtaagtga	gaaacctttt	cctcagcctg	gctttgaggg	ttactacca	ccctccaggg	6960
gcagaagtgg	ggagcagggc	acagcattgc	agaaaaaacc	caggggtgtg	ggtctgaagg	7020
ctactgggga	acagcacagt	gctcctgcct	gccttttagg	ggccagggga	tcccctgggc	7080
ccacgtcatc	accacaaatg	tgatgggtgag	aacctctgtg	caggggaagt	gctgggatca	7140
aataagacac	gtcagaaatt	gctcgaccct	gggtctgatg	catccgtggg	cctccctcac	7200
ctaccacaca	caggtgacgt	tccaggctcc	ccgaactct	ccagcttgtg	cagcaaagca	7260
gcaataggga	gaggacagac	gggagcaggg	tgggctccct	ggcaccacac	agagcagcta	7320
gatgtccgtc	cccactgcc	gcccagccct	tcagccccc	tgcccccac	aggggaagcac	7380
ggcttctgct	gacagtacca	cccacactag	cgcttgtagc	ttgaacacgt	tctcactgtt	7440
aatgaagcca	aatcctgaga	aggtggactg	caggttggtc	agcgctgtt	caggagcaaa	7500
cacatgtcaa	ggatgatttt	tatatatttt	tctttttgag	tagagacagg	agtctcgcta	7560
tggtgcccag	gctgggtctc	aactcctggg	cttaagcgat	tctccacact	ccgcctccca	7620
agtgtcggga	ttacaggcat	gagccaccgc	accgggccaa	gggtgacttt	tttttttttt	7680
tttttttttt	gagacagagt	ctcactctgt	caccagcat	ggagtgtagt	ggcacaatct	7740
cgagtcactg	caatctccgt	atcccagggt	caagcgattc	ttctgcctcg	gcctcctgag	7800
tagctgggat	tacaggcacc	caccaccatg	cccagctttt	ttttttgaga	cagagtctcg	7860
ctctgtcgcc	caggtctggg	tgacgtgggt	ctatctcagc	tcactgcaag	gtccgcctcc	7920
caggttaatg	ccattctctt	gcctcagcct	cacgagtagc	tgagactaca	ggcgcccacc	7980
accacgcctg	gctaattttt	tgatattttt	gtagagatga	ggtttcacca	tgtaaccag	8040
gctgggtcatg	aactcctgac	ctcgtgatcc	accgccttg	gccttccaaa	gtgttgggat	8100
tataggcggtg	agccactgtg	cctggccatg	cctggccta	tttttaattt	tttttagtag	8160
agatgggatt	tcaccatgtt	ggccaggctg	gtcttgaact	cctgacctca	ggtgatcctc	8220
ctgcctcagc	ctccgggggtg	actttttaaag	ctctgccctt	cctgcctct	cttcttgag	8280
tccgagctag	acagcccact	gtcccaggag	ggtgccaggt	ctctgtctct	ttctcttggt	8340
gtaccttgtg	cagctgtcac	ttccctcccc	ttcccatagg	aaggggcatg	gcaggcacag	8400
gatgcccacg	cttgaattgt	agcagcccac	atacctgcct	catgtctccc	tgggccgtga	8460
agatgatggc	ttctaggccg	tcacagtggt	agggtaacct	ctccttctcg	ataacattca	8520
tcagcctggg	gaggatctgg	gcgtcgggtc	gctttgtgta	ccggaggact	gcacagcggg	8580
actgaatggg	ctctgaacag	agacgggaca	gtagtgaggg	ttccctgcag	aggccggcat	8640
catcctgcta	gctctttggt	cataaggctg	cagctgcaca	atccacacag	cccaggcac	8700
tcaatagaga	cttggttaggc	cggacacgag	ggctcacgcc	tgaatcccag	cactttggga	8760
ggctgaggcg	ggaggatcac	ttgaggacag	gagtttgaga	ccagcctgga	caacatgggt	8820
aaaccccac	tctactaaaa	atacaaaaat	tagctgggtg	tggtgtcgca	cgctctgta	8880
cctagctact	caggaggcta	aggcaagaga	ctcgcttgag	cacgagaggt	ggaggctgaa	8940
gtgagccaag	atcacactac	tgactccag	cctggacaac	agagcgaggc	tgtgtctcca	9000
aaaaaaaaaa	aaaaaaaaag	agagagagag	agacttggt	aacacagggt	gatatgtcaa	9060
ggtgtcaacc	aataagcaat	gacagaggcc	tcagttggca	ctgcccgcac	ggccttggt	9120
agccacgggt	tccagacggg	gaaatgatcc	tccagtagaa	acacatccat	gtgcctgcc	9180
caagctgtta	gatgagtcag	ccctggccca	ggtggactct	ggaattgggtg	tgtgtctggat	9240
gttggccctt	ctgggcacat	gacaattcaa	tctgaatggg	ccaaccaggt	ttctttcttt	9300
ttttttcata	gacaggggtt	tgctgttgcc	caggctgtct	tcgaactcct	ggcctcaagt	9360
agtcttctctg	cctcagcctc	ccaaagtgca	gggattacag	gtgtgagcca	ccatgcctgg	9420
ccagtttctt	tctttctttt	ttttactgag	accaagtctc	tctgttgccc	aggctggagt	9480
gcagtggtgt	gatctaggct	cactgcaacc	tccacctccc	aggttcaagt	gattctcctg	9540
tctcagcctc	ctgagtagct	gggattacag	gcgcacgcta	tcacacccgg	ctaatttttg	9600
tatttttagt	agaaatgggg	tttcaccatg	ttggccaggt	tggtctcgaa	ctccagacct	9660
taggggatcc	acctgcctcg	gcctcccaaa	gtgctgggat	tacaggcatg	agccactgtg	9720

293

ccctgccaaa	tcaagaccta	ggaatgcatt	tttctccatt	tcattgctgg	catctgcaaa	9780
gtggagaata	cttctcatta	aactccacga	gctctccact	agcatggtgc	ctggcggtcta	9840
ctaagaacca	gagttaagcg	ttcgggtgaat	gggttaaatga	atcaatgcac	aaatcagtg	9900
gattttggga	agggaaaaga	atgcaaagga	ttcttgacac	tgctgagagc	cccaccagg	9960
ctggtagcca	tgactttgtg	ggtgccatat	ttggtaatgc	gctcgtcggc	aacagcgggc	10020
tgggtggcaa	gggggttgtc	agatggatga	gctcatatgg	ttggggttca	gcagggcaga	10080
agtgaggcaa	agaaagcggc	tgagagagca	atgaaaaatg	aggaaagagg	acagctgggc	10140
tgtgcaggca	gcctgtgtca	gaaagagaag	gatgggccag	ccgtggtggc	tcacgcctat	10200
aatcccagca	ctttgcgagg	ccgaggtggg	cagaccactt	gaggccaggc	gttctagacc	10260
agcctgggca	acatgggtgaa	acctcgtctc	taagaaaaat	acaaaaatta	gcctggcatg	10320
gtggcacatg	cctgtaatcc	cagctactga	ggaggctgag	gtaggaaaat	cacttgaatc	10380
caggcagcgg	agatagcagt	gagctgaaat	cgcaacactg	cactccagcc	tgggcgacag	10440
agcgagactc	tctctacaaa	aaaaagaaag	agaaggatgt	gaaaccagca	ggaagtgtgac	10500
agactagagc	actcttggga	cctggggcgg	gacaaaacca	tgcaagaagca	gacaggctgc	10560
agggagggag	gtggaagggc	aaacagtaag	gttagagaaa	agacggactg	caggatttga	10620
gagaggagct	tcccggaggc	aacaaattcc	aatgtacaga	tactgcctat	accaagtact	10680
cagagcacat	gaatagcaca	agaaggatat	tggagagcga	ctgtgatcgt	gacaccgtgc	10740
aggggacatc	aacaacatcc	ttgtgcctcc	aagagtgcga	gagggtgata	gaactggggc	10800
tccaatccca	gctgctcttg	cacttgctct	gactttgggg	aaactactca	acctctccaa	10860
gctcgttttc	ttctcttttt	ttccttagat	cctaaacatc	aggataagct	ccagttttct	10920
catctctaaa	ctgaagcgaa	taatacctcc	tcataaggatt	atgtaagatt	aaatttaaaa	10980
gttgattaca	atgggaaaca	tgtgcataat	atatacaatt	tctccttgtc	aattaaaaaa	11040
atataaattt	aaaaacttga	ttatátagt	cttggcccat	gctacacaat	aaaaaaaaatcc	11100
ctactcttcc	agcgctaaag	agccaaggcg	aggccagggtg	cagtggctca	catctgtaat	11160
tccagcactt	tgggaggcgg	aggcaggcga	tcacgagggtc	agacgtttga	gaccagcctg	11220
gccaacatgg	tgaacaccca	tctcttaaaa	aaaaaaaaaa	aaaaaaaaaa	ttagctgggtg	11280
gtggttgtgc	gagcctgtaa	tcccagctac	gcaggaggct	gaagcacaa	aattgcttga	11340
accttgagg	tggaggttgc	agtgatctga	gatcgtgcc	ttgactcca	gcctaggcga	11400
cagagtgaga	ctttgtctca	aaaaaaaaaa	aaaaatccag	gtgtggtggc	acaggcctgt	11460
agtctcagct	actgggaggc	tgaggcagga	agaccacttg	agcacaggag	tttgaggctg	11520
cagtgcagctg	tgatggcacc	actgcactcc	agcctgagcg	aagagggaga	ccacatctat	11580
aaaaaagaaa	aaagcccagt	tgagcaccac	gtggccccc	gccaccgaaa	gctcccactc	11640
accgatgatc	ttatccgaag	cattacaagc	aaggcggaag	cgagtgggtt	tagagtagat	11700
ttccatgggt	ctcctcaagg	cttgctgggc	tccgtcgggc	atgctg		11746

&lt;210&gt; 388

&lt;211&gt; 3248

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 388

gcggctataa	ggggcgagg	ctggcgggcg	ttgctctgcg	ctctgcggct	gacggcgctt	60
ttgtctccgg	tgagttttgt	ggcggaagc	ttctgcgctg	gtgcttagta	accgactttc	120
ctccggactc	ctgcacgacc	tgctcctaca	gccggcgatc	cactcccggc	tgttcccccg	180
gaggtgagcg	gcctgtggg	cttccccggc	tccccacccc	catcgctaga	gtgctcgccg	240
cgctagcagc	ctcgcggttc	agggtcgggg	gtgcgcgcgc	gggatcctct	ctgatcgccc	300
acgccccatc	tggggtcccc	attcagccgt	cagccctggt	ttgtcctaag	gtggtcctaa	360
ctaggatcca	cgtggcccat	cccacgcccc	cagggtgctga	gttaggcata	cctgccatgc	420
cctcccagag	caccttcacg	atctccttgc	tgtcccaaca	cttagcgtgt	tgcgtgttaa	480
ctaccctttg	tctataaggt	ttgcaatgtg	gccctagtat	cttcagggt	acctaacaca	540
ttgcagatat	tcatgggtatg	tttgttaaat	aaatgaactt	gatagatttg	accctcatag	600
agttatattg	acttgcaaaa	agttttagt	taactccaat	ctgtgatgtg	ggagagactt	660
ctaggcagg	tccttttctc	aggcatggt	cttataattc	ccattaccca	ccacccccct	720
gcaaaaggac	tgggcctatt	tcaggaaagt	gactgatgcc	tgcactgtag	cacagggtgt	780
gtgtatttgt	ccttgccagga	acaaaatttt	caataaagta	aatgtttgtt	tgtttgtttt	840
tgagacggag	ttttgctttt	gttgccgagg	ctggagtga	atggcgcgat	cttggtcac	900
tgcaacctct	gcctcccggg	ttcaagcaat	tctgcctcag	cctcccgagt	agctgggatt	960
acaggcatgt	gccactatgc	ccggctaatt	tttgtatttg	tagtagagac	agggtttcac	1020
catgttggtc	aggctggtct	cgaattcctg	acctcagggtg	atccaccgcg	ctcggtctcc	1080
cagagcgctg	ggattacagg	tatgagccac	cgcgcctggc	ctaagaaagt	aaaagtttta	1140

294

agaagtgttc	ttgaattagt	ccaagaagca	acactggctc	cgcagccatg	aagtttgcaa	1200
tgtaaaatat	tcttgagag	ttgctgtgca	actccctggg	ccctgtgtcc	ctcactggct	1260
aagcctctcc	ttcagccctg	tgagaggaca	gaagagtcag	ggctggatgc	atgcatatcc	1320
ccaaaaggct	atagattcat	cctttcctct	tttttctcag	ggctccagagg	cctttcagaa	1380
ggagaaggca	gctctgttcc	tctgcagagg	agtagggctc	tttcagccat	gaagcatgtg	1440
ttgaacctct	acctgttagg	tgtggtactg	accctactct	ccatcttcgt	tagagtgatg	1500
gagtccttag	agggcttact	agagagccca	tcgcctggga	cctcctggac	caccagaagc	1560
caactagcca	acacagagcc	caccaagggc	cttcagacc	atccatccag	aagcatgtga	1620
taagacctcc	ttccatactg	gccatatttt	ggaacactga	cctagacatg	tccagatggg	1680
agtcaccatc	ctagcagaca	agctgagcac	cgttgtaacc	agagaactat	tactaggcct	1740
tgaagaacct	gtctaactgg	atgctcattg	cctgggcaag	gcctgtttag	gccgggtgcg	1800
gtggctcatg	cctgtaatcc	tagcactttg	ggaggctgag	gtgggtggat	cacctgaggt	1860
cagggaattc	agaccgcct	cgccaacccc	atctctacta	aaaatacaaa		1920
agttagctgg	gtgtggtggc	agaggcctgt	aatcccagct	ccttgggagg	ctgaggcggg	1980
agaattgctt	gaacccgggg	acggagggtg	cagtgaagccg	agatcgccact	gctgtaccca	2040
gcctgggcca	cagtgaaga	ctccatctca	aaaaaaaaag	aaaagaaaaa	gcctgtttaa	2100
tgcacagggt	tgagtggatt	gcttatggct	atgagatagg	ttgatctcgc	ccttaccctg	2160
gggtctgggt	tatgctgtgc	tttctcagc	agtatggctc	tgacatctct	tagatgtccc	2220
aacttcagct	gttgggagat	ggtgatattt	tcaaccctac	ttcctaaaca	tctgtctggg	2280
gttccctttg	tcttgaatgt	cttatgctca	attatttggg	gttgagcctc	tcttccacaa	2340
gagctcctcc	atgtttggat	agcagttgaa	gaggttgtgt	gggtgggctg	ttgggagtga	2400
ggatggagt	ttcagtgcct	atctctcatt	ttacatttta	aagtcgttcc	tccaacatag	2460
tgtgtattgg	tctgaagggg	gtgggtggg	gccaaagcct	gctcaagtta	tggacattgt	2520
ggccaccatg	tggcttaaat	gattttttct	aactaataaa	gtggaatata	tatttctact	2580
gtgtgtcatg	ttgacttctg	ctcttgaaat	tcgtggtagg	gagggtctta	atttctagac	2640
ctgagggtta	attttaacat	ctcaatactt	tggagcagga	aagtgcctaa	atcactttgt	2700
ttaaaacata	gtatcagtag	acttctgaat	ttgggggcag	aggcagttgg	gtctgccatg	2760
tatcaaccag	ttatgtgagc	ctaggccacg	attattgcag	gcctgtcatg	actagatctg	2820
taaagaagaa	gaaaaatgat	caccacttcc	agccctctct	cttgagtctc	tggggcaaa	2880
aggactatca	gtccaggagg	ctgtgggctt	tttcttttgt	actcttcagc	gtgttttact	2940
taccacacaa	aaaggctgct	taatttcagat	tgtttctcaa	gtcagttggg	aaagtgtcca	3000
caccacacag	atgattatat	ctgctctccc	agatctaagc	aaacttggcct	ttactcaaaa	3060
gttgaggggg	tttttttttc	ttgtatccat	cactcttgta	cttctgttcc	cacgtacaat	3120
tgtatttact	cctttgccct	tcagaatata	tttattttaca	ctcccatctg	ggcgtgtgca	3180
tcatttttatt	aacttgactg	acttttgcta	aagcgcaaca	atgaagtaca	gtgtcttctg	3240
ttaagcca						3248

&lt;210&gt; 389

&lt;211&gt; 351

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 389

ctggcagtg	tttcgcagct	tgagacctat	ttaataacag	tgtgagagaa	gggtcacaca	60
gtcaagcaaa	aaaacagacg	aaactctggt	atagcgaagg	acccaaagtt	ctgcgggctg	120
agcaggaaa	ttggctccaa	atgtctgcct	gcctgccagc	agacctccag	ccccacctt	180
ctgctttccc	ggcttcccca	ccccctcatt	cccagacagc	cacagccagc	cagccaggaa	240
aggaggggaa	aggtcgcagt	ggggatggct	cctcccttcc	cgtcttagag	cccttcttaa	300
gcagagcccc	ccgagctcgc	tgagatgtgg	aaagtcacag	ggttctttcc	c	351

&lt;210&gt; 390

&lt;211&gt; 415

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 390

gagagcctgc	accttaagtc	tctcctccaa	gtggcttagt	ttaattgaag	tgatctgtgt	60
gccaccaccc	ccttgtgggt	ggatggagcc	atgtcattag	ttctggccaa	tgagctgtga	120
gtggtagtgg	cttgcggttaa	ttctacgtga	gagcatttca	gtgctggaga	aacctgcgag	180
gacctctttt	tccctctgtg	cagtgaccag	cagtgcctcc	tatggaactg	ttcattagt	240



295

taggtcctgg	aatgaggatg	catggcgcag	ggcccttaat	ctgtccaatc	tgactgtgat	300
gtgggagaga	cttctagaca	tgttgctttc	tctagggtat	gttcttatat	ttcccattac	360
ccccacccc	ctgcaaaagg	actgggcctg	ttttgggaag	gtgactgata	ccgcg	415

&lt;210&gt; 391

&lt;211&gt; 1447

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 391

gatttggagg	ggacaaacat	ccaaaccatt	taagtcacag	cactttactc	cgcagtgtga	60
ataacacagg	cattctccta	cataatcaca	gtacagttat	catactctgg	aaattgaata	120
tcatctaata	tactttccat	acccagattt	tcttagattt	cccaatgata	tttcttactg	180
tcctcccttt	agccttcctc	tttctccatt	caggattcta	ccattacatt	tcattttcat	240
gtctcttcag	tctctcttta	gctttgtttt	tctttcttga	tggtgccact	tttaggaggc	300
caggccagtt	gttttgtgaa	agatctgttc	tctttgatat	gtttcatttt	ggatttgttt	360
cattgttttt	gcatgaatgg	attcaggcta	aacatttttg	ggcaggactg	tttattgtat	420
tacctagtga	tgtgttcttt	tcagtccatc	atctggaggc	acctgatggc	agttttccca	480
atattgcgaa	attaagtttg	attattttgt	taaggtagtg	tccaccagat	ctctccattt	540
taaagacatc	cttttctcta	attactcagt	ggactgtaga	gtgatgcttt	gaaactgaat	600
aactaacact	ccctaactca	gtgatttagc	accogttgat	tttttttttt	tgccctgaatc	660
aaatattatt	atagtagttt	taaatggtga	ttttccattt	ctattctttt	gttagctgcc	720
attcttctat	aattttgtct	ttatatttta	ctgggtgtta	agattgctat	tccagctttc	780
ctttgtcttt	tacacctttt	cccattcttt	tatttttttc	catccctttt	tgctctgttt	840
tccaatagat	ggatagaatt	ttctttctct	ggtttaaagg	ttatacattt	gtgtgtgtgt	900
gtgtattctt	agccatttgc	ccttaaaaca	tagagatggg	tattctgtgt	gattaaaaaa	960
actcagtaat	gttactatct	tctctttaat	aagataggta	ctttatttca	ttctgtgttc	1020
ttgggtgagg	tctccctca	cccagtcagg	ttgatgttaa	tctagaattt	ttagtttttt	1080
aaattatcga	tatactttct	gtcttttctt	tttttttcac	tctctctgta	tttgtgtctt	1140
ccccctttac	tctctttccc	ttcatttcct	ctttctcact	ttcttcttct	atttttcact	1200
cttgggtaga	ttatctttta	gaaaacagca	agatattata	taatttactt	tatattctct	1260
ttccaaatga	ttaaagtaat	aattaaaaat	ttttgatatg	tgtgtatgca	aggataggaa	1320
tctctttgta	agtgggaagaa	ctctaccaca	tgcatgagtc	attagtgtgt	taaacactgg	1380
gaagtggctt	taggtccagc	tgggtgctct	gaagaaggta	ggtttcttca	gttctttatg	1440
ttaactg						1447

&lt;210&gt; 392

&lt;211&gt; 1567

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 392

gatttggagg	ggacaaacat	ccaaaccatt	taagtcacag	cactttactc	cgcagtgtga	60
ataacacagg	cattctccta	cataatcaca	gtacagttat	catactctgg	aaattgaata	120
tcatctaata	tactttccat	acccagattt	tcttagattt	cccaatgata	tttcttactg	180
tcctcccttt	agccttcctc	tttctccatt	caggattcta	ccattacatt	tcattttcat	240
gtctcttcag	tctctcttta	gctttgtttt	tctttcttga	tggtgccact	tttaggaggc	300
caggccagtt	gttttgtgaa	agatctgttc	tctttgatat	gtttcatttt	ggatttgttt	360
cattgttttt	gcatgaatgg	attcaggcta	aacatttttg	ggcaggactg	tttattgtat	420
tacctagtga	tgtgttcttt	tcagtccatc	atctgaaggc	acctgatggc	agttttccca	480
atattgcgaa	attaagtttg	attattttgt	taaggtagtg	tccgccagat	ctctccattt	540
taaagtacat	cctttctctt	aattactcag	tggactgtag	agtgatgctt	tgaaactgaa	600
taactaacac	tccctaactc	agtgatattg	caccogttga	tttttttttt	ttgcctgaat	660
caaatattat	tatagtagtt	ttaaattggtg	attttccatt	tctattcttt	tgtagctgc	720
cattcttcta	taattttgtc	tttatatttt	actgggtgtt	aagattgcta	ttccagcttt	780
cctttgtctt	ttacaccttt	tcccattctt	ttattttttt	ccatcccttt	ttgtctgtgt	840
ttccaataga	tggatagaat	tttctttctc	tggtttaaag	gttatacatt	tgtgtgtgtg	900
tgtgtattct	tagccatttg	cccttaaaac	atagagatgg	ttattcctgt	tgattaaaaa	960
aaactcatga	atgttactat	cttctcttta	ataagatagg	tactttattt	cattctgtgt	1020
tcttgggtga	gggtctccct	caccagtcac	agttgatgtt	aactctagaat	tttttagttt	1080

296

ttaaattatc	gatatacttt	ctgtcttttc	cttttttttc	cactctctct	gtattttgtgc	1140
tttccccctt	tactctcttt	cccttcattc	cttctttctc	actttctctt	tctatttttc	1200
actcttgggt	agattatctt	ttagaaaaa	gcaagatatt	atataattta	ctttatattc	1260
tctttccaaa	tgattaaagt	aataattaaa	aatttttgat	atgtgtgtat	gcaaggatag	1320
gaatcctctt	gtaagtggaa	gaactctacc	acatgcattg	gtcatttagt	tgtaaaccac	1380
tggaagtgg	ctttagggtc	agctgggtgc	tctgaagaag	gtaggtttct	tcagttcttt	1440
atgttaactg	tctccttacc	ttaaaaaagg	agtgaagaat	actgactgca	gaggttttgt	1500
gaggattccg	gtaacacaga	agcatagaac	tggaagaaga	tattaatatt	tgccaaaaaa	1560
aaaaaaa						1567

&lt;210&gt; 393

&lt;211&gt; 101

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 393

aggctggagt	gcagtgggtg	aatcttgggt	cacggcaacc	tctgcctccg	gggttcaagt	60
gattctcctg	cctcagtcct	ccgagtagct	gggattacag	g		101

&lt;210&gt; 394

&lt;211&gt; 101

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 394

aggctggagt	gcagtgggtg	aatcttgggt	cacggcaacc	tctgcctccg	gggttcaagt	60
gattctcctg	cctcagtcct	ccgagtagct	gggattacag	g		101

&lt;210&gt; 395

&lt;211&gt; 10427

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 395

atggacttgc	cagtttcaaa	agtttctctga	agtctgaatt	cagtgaggaa	aaccttgagt	60
tctggattgc	ctgtgaggat	tacaagaaga	tcaagtcccc	tgccaagatg	gctgagaagg	120
caaagcaaat	ttatgaagaa	ttcattcaaa	cggaggctcc	taaagagggt	ggctctctggg	180
taggtgggtc	agttaagggc	agctcattag	ctctcaggaa	ggattttacat	ctgagacaca	240
gacctcccg	tggaagccaa	aggctattcc	tatttctgtg	tcgaccacct	tattaagcac	300
ctatttagta	caaaggcaga	gcaacatggt	caagtatata	tgaacaatcc	tggttcagacc	360
gctttctagt	tttatgggtc	tcacctccac	taacctccag	tggaagatcat	accaatgtga	420
aatcttgc	gaattgttga	gtctctgtga	acctcatttc	ttcctttgtg	aaaataagaa	480
taatggagac	tactttatgg	agatgttgtg	aggattaaat	taaatagtgg	gtgtaaaaac	540
ttatacaggt	tgaacatctc	tgatctgaaa	attcaaaatt	cagaatgcct	caaagtctga	600
aactttttca	gcaccatgat	gccacaagtg	gaaaattcca	ctgacctctt	gtgatagggtc	660
tcagtcaaaa	tacagccaaa	acttttttca	tgcccaaaat	tattaaaaat	attacataaa	720
attaccttca	tggttatatg	ataggtatat	atgacacata	aatgaacttt	gtgttttagac	780
ttgggtctca	tattaagata	tcttatctca	ttatgtatat	gtaaatattt	caaaatctca	840
aaaaattcaa	gatctgaaac	atttctgggtc	ccaagcattc	cagataagtg	atgttcaacc	900
agtgtattat	tcctttctct	cactgctatg	aagaaatacc	aaagacttgg	taatttataa	960
aggaaagagg	tttaattgac	tcacagttcc	gcattggatg	ggagacctca	ggaaacttac	1020
aatccagaca	gaaggcacct	cttcacaggg	tggaaggaga	gagaataaaa	gtggagtga	1080
gggggaagcc	ccttataaaa	ccatcagatc	tcgtgagaac	tcactatcac	aagaacagta	1140
taagggaaac	tgccccatg	attcaattat	tgccacctgg	tcctgccctt	gacatgtggg	1200
aattattatg	atttaagggt	agatttgggt	ggggacacag	agccaaacta	tatcaaccag	1260
tatctcagtg	tcggaactga	ttaatgccta	atgagtattt	ctataacttt	tcctttgttt	1320
tcctttccatt	cccattttcta	gtctttcctt	taaacacctc	tccttttttg	tcctttctac	1380
tcctctttat	cctttatttc	cccacttgga	cttttccatt	tacactgtac	ttgggacaat	1440
gggtatattta	ctcatgaaaa	tcaaaatatt	acaagaaaac	agtgttagag	atgttgaaag	1500
ccaatatacc	actgattgac	tattaaagcc	cagatttttg	ttgatttcaa	agaaactttg	1560

gggaagttga	tctgcttttt	tctttgttat	ttataaaacc	acattgaaag	cctattgtgg	1620
aattcaggat	ggccacagca	agccctgttc	atcatggtat	ggtcagggtta	ctctaatttc	1680
acttgtttct	tttaatccag	tctggaaagt	aaatgtttca	tcaagggttg	gagtcagca	1740
eggaggtgat	ctgggcaagc	cttggtgagt	aggcagaaat	ctacttaaga	tgtttgagag	1800
agaaaaactc	ccaaatatcc	cttctctacc	acagatgctc	tagactcctg	gagttccacc	1860
attagatatg	tatttcttta	gttatgagtt	accctaaatg	tgtttgagtg	gatggacaaa	1920
ttatgtacct	tgatactagt	agatgtgctt	cctccatgac	acagggttgg	aggttaggag	1980
tatgagaatg	tacagtactg	tgggtcaaag	ccacgaaaat	gaaaagggtgc	tagaaagaat	2040
ctagatttaa	gtttgatgtg	gatattaatc	ttgaaattct	ctccagatca	ccccttcttc	2100
tcctcaacct	ccaccctaag	cacatatggt	agctctaccc	tacttctggt	accatttgtg	2160
ctgggccatc	ctttcttctg	tcagcatggt	atttctctgt	atatattgac	aagaagatta	2220
atttaacatt	aaattggaca	tgtaattccc	catttcaaag	gattctctga	cttaccttcc	2280
tatcaacttg	acttcctctt	cacagaattc	taagatttgc	tgaaatacct	acaaatagta	2340
gaaacccact	cagataattg	ttagttactc	tgagctctgg	gaaaacatta	ttggttatta	2400
tgaaaatatg	agacattaac	ctaaaatata	attttaaaat	aaacaatacc	atggctagct	2460
gagttatagg	gacaaataaa	ttgtgggtcac	tagttgaaag	actaattaaa	atagccttgc	2520
ccttcattct	aaatgatcta	tgtcttatgca	agagtacaat	agtatacatt	agaccccaat	2580
acaggcatcc	caggattatg	tagaataatg	atcctgagct	gggtattaga	gagaatgtga	2640
atctactccc	tagcacataa	aaagctttca	agaaataatt	ttgagatgaa	agcatgaaaa	2700
tatccaactt	cagacattct	tagatgtggg	actttgggca	agtctctagc	ttaaagctctc	2760
taatcctcag	ttcttttaac	tgtaaccatc	tttgttatat	gtatgtgcac	ctgaagtatg	2820
ttaagtcata	gcttttatta	cttaaaaaat	tctccaactt	ttgtattttg	atgtaaataat	2880
ttactattta	attttgatga	aattgacctt	tataagacct	agattaccca	ggcaaatagt	2940
aatctgaatt	ttgttgctct	gaatactcac	ctcaactcct	taatacaaga	aactgactga	3000
gagatacaat	ggtaaaaaat	ggaattaaat	ttaaacaaga	gaaatggcca	tgtggaagtc	3060
aataagtaga	taattttatac	attgcaaatt	atcatttgac	catatttgaa	attaatgaaa	3120
tgatattggt	tctggataac	taaacagata	aatatgtatc	agaatgactt	attaaagaag	3180
gcttaagcac	ataaaaaatac	caagagaaat	agctgctatt	tgctgggtgga	tactatgtcc	3240
tagaggggtt	taaatacatc	actcctttta	aaaataagat	taggagctac	ttttataatt	3300
tttagaaact	caatcatttg	gaataagcct	gtctaccaag	ctcagtacag	atatataact	3360
aatataagag	aaggaagaag	cattgctttc	agtgtggcgg	gaagaataat	agactgagaa	3420
tgagaaaatc	tatgttaatg	tctcacctct	aatccacact	agctgtttgt	gggcatgtaa	3480
cctgacctct	ttgaggtctt	cacattttaa	ggcagacatt	ggacttcac	aactctgacg	3540
ctgatcccaa	ttctgacaat	ctgatcttcc	aacaggcctg	cataaagtag	attgacctct	3600
ttcacctctg	gaaaatctta	atgtagctca	acgcccctca	tcttagactt	tgaagcacag	3660
ctcagtcctg	ctgtctgttc	tgacctgggt	ccccagggaa	tcatgcattt	tgtctccaac	3720
tctaactaat	agctgcttca	taattctctg	agcccaaaaga	gctctattca	gtaccaaaaa	3780
cctctaacag	cccaggagag	acccaaaacc	tttatcagtg	tttcaattca	caaccatagg	3840
ctgatttggg	ttctatttct	gtcttgttta	cactcaaaat	ccttaaaaaac	cattaaatcg	3900
tacaacatgg	agtataaaga	ttccttttaa	ctcatagtca	gccaagttca	aataggctgt	3960
accttgtaca	actccagagg	aaccattcac	gtagacccta	gtatgggtgc	aatgtagtgg	4020
cctgcactc	aggacatgta	agccacagtg	catcccagtg	ctggagtcta	ctgggttaaaa	4080
ggctgggctc	tgagagccaca	tcaactggatt	tctgaatctt	ctctctacca	ttaatgaact	4140
ttgagtaaat	catgtaacat	ttctgtgcat	ctgtttctct	aactgtaaaa	tgtagacagc	4200
agcatctatt	atacctcata	gagttataag	attaaatgag	ttcatccgtg	caaagtgcct	4260
ggcaccgacc	gagcactcaa	taaatgttaa	tgctgttag	ctgttttcat	tattattctg	4320
tcagaatgac	tgtttctctg	tttggttttg	gaaagaacaa	gttttcttgt	tcttctggag	4380
ccatgcaaaa	ggctcctggat	ccccagacag	aatttacttc	tctctgttca	attcctccaa	4440
tagacgtgaa	accaaatggt	gtgttagaat	tttaaaatta	ggcaccaggg	ccggacgcgg	4500
tggtcacac	ctgtaatccc	agcacttttg	gaggccgagg	caggcagatc	acctgaggtc	4560
aggagtctga	gaccagcctc	accaatgtgg	caaaaccccg	tctctatcaa	aagtacaaaa	4620
attagcccgg	cgtggtggga	catgcctgta	accagctag	ttgggagggt	cgggcagaag	4680
aatcacttga	accgggaagg	cagaggttgc	agtgaaccaa	atggcgccac	tgcaactccag	4740
cctgcctgag	tgacagaact	agactctatc	caacaaaaaa	aaaaaaaaaa	aaaaaagaaa	4800
aaaaagaaaa	agaaaaaagc	accaggacac	ctggattcaa	attctgattc	tctagattca	4860
aatacactta	tcagttctgt	gatcttgggg	aagccactta	accttctgca	tatacatatt	4920
tttttctata	aaaggaaaaga	atcattctta	ggattgttgt	caaggattaa	ataagtaatg	4980
tgtgtgttag	cttctatggg	aggctctgaca	cctgggtgggt	gtctaatacc	ggttggtatgc	5040
atctgttggg	acatcagctg	ccttatccca	tcgcctataa	agtgagaagt	gacatgtctc	5100
agtttttaat	gactttctct	ccctcttatg	ttttattgat	gagaaattcc	acctccctct	5160

tcacccctca	tcaaattcta	taacttaggc	ttatgtagt	accctgtttc	ctggcccaca	5220
ggtgaatatt	gaccacttca	ctaaggacat	cacaatgaag	aacctgggtg	aaccttccct	5280
gagcagcttt	gacatggccc	agaaaagaat	ccatgccctg	atggaaaagg	attctctgcc	5340
tcgctttgtg	cgctctgagt	ttatcagga	gttaatcaag	tagtaattta	gccaggctat	5400
gaaatcatcc	tgtgagttat	ttcctccata	ataaccctgc	atttccatt	aatctacata	5460
tcttcccaca	gcagctttgc	tcagtgtatc	ccacatggga	aaaatcccag	gggatgttgc	5520
ttactctttt	tgcccacact	gctttggata	cttatctact	gtccgaaggc	cttctttccc	5580
cactcaatcc	ttcctgccc	gttattaatt	aagatatctt	cagcttgtag	tcagacacaa	5640
tcagaatcac	agaaaaatcc	tgccctaaggc	aaagaaatat	aagacaagac	tatgatataca	5700
atgaatgtgg	gttaagtaat	agatttccag	ctaaattgg	ctaaaaaaga	atattaagt	5760
tggaacagac	tatttcaaag	gagcttaatt	gatctcactt	gttttagttc	tgatccagg	5820
tggaacaccc	tctaattatt	tctgaacttg	gttataaaaa	gtttataaga	tttttatgaa	5880
gcagccactg	tatgatattt	taagcaata	tggtatttaa	aatattgatc	cttcccttgg	5940
accaccttca	tgtaggttgg	gtattataaa	taagagatac	aacctgaat	atattatgtt	6000
tatacaaaat	caatctgaac	acaattcata	aagatttctc	ttttatacct	tcctcactgg	6060
ccccctccac	ctgcccatag	tcaccaaatt	ctgttttaaa	tcaatgacct	aagatcaaca	6120
atgaagtatt	ttataaatgt	atttatgctg	ctagactgtg	ggccaatgt	ttccattttc	6180
aaattatttt	gaattcttat	gagtttaaaa	tttgtaaaat	tctaaatcca	atcatgtaaa	6240
atgaaactgt	tgctocattg	gagtagtctc	ccacctaaat	atcaagatgg	ctatatgcta	6300
aaaagagaaa	atatgggtcaa	gtctaaaatg	gctaattgtc	ctatgatgct	attatcatag	6360
actaatgaca	tttatcttca	aaacaccaa	ttgtctttag	aaaaattaat	gtgattacag	6420
gtagaggcct	tctaggtgag	acacttttaa	ggtacactgc	attttgcaaa	aaaaaaaaaa	6480
aaaagtaatc	tttttagcaac	ccagtatctc	cttcactatt	tcgcttcctg	cattagcaaa	6540
ttttacttac	agtcaaaagt	gcagatttat	actcctgacg	tgtctcattc	acagctaaat	6600
tattaggccat	aggacttttg	gtaggtttaa	acttttaatt	ctgtatttca	tgattataag	6660
tcttgctaga	attttttcta	atcttttagta	gatttgatta	aataatgatt	cacagaattt	6720
agtaacagaa	tcaaaactaag	ccatgtatga	gggtaatcga	gatgaggata	ttaaactcaa	6780
agaaataggg	tgatttttaa	aggatttaata	aaattctgaa	atgttaagta	gaagattaca	6840
ttgtctagtc	ttgtatttcc	tccttctgtt	gctctctttc	attcacacac	tctcagtttc	6900
tcatatttgt	agctcattta	tttggttatt	tcctaagaat	attgaaagt	aagcaactat	6960
gtgactgtat	tcttcaggta	aacactgact	gcgcttgttg	gattttccct	atttttgtga	7020
cttcaagaat	aataatccct	gctgaatata	tgccatttca	cattctgaaa	ctgggtagag	7080
tggttgggtg	ttctgccaac	aatttgctagt	gggtgtgaatt	cattcatatt	tgccagtatt	7140
gctcacttca	aagaaactcc	ttcatcaagc	agtccagagc	taggccagat	caatgctaca	7200
atcatgaagt	tctcattgca	tgcaattgtg	taggattgac	aaggaaactca	gataaaaaat	7260
tcaggggtgc	acttccagaa	ccagcttcaa	catatgtcta	cattgcccc	aagttaataa	7320
agtgccaaac	ctttactctc	tcatacagcc	agaaatgtta	gaaatccaaa	atcttgggtgc	7380
attatttttt	cataaacgct	aaaacatttg	aagaaacaat	ttaattattt	aaaattcaag	7440
tattttattc	acattatttg	caatatccaa	atgtttaaaa	attcccagat	aatttaactag	7500
ctattacaga	tctcacctag	agggttgatg	ttatgaagac	tccagtggac	tgtactcaca	7560
aattgactgg	acacctatg	aaagtgggta	gacctctcag	cggaaaataa	gaagggtctt	7620
tacctacagg	gcaggacagg	gtcccatgag	agcagttctg	tggagatata	aaaagaatgg	7680
aagaaggaat	gccttatagt	gatattgtga	cattatatct	atatatctac	atatatctat	7740
ctatctatat	ctacatctat	ataatcttac	atttaaaatt	gtattcctac	acatattaga	7800
aactcttcta	ataaatgaag	taaaaaaatt	aaaaagaata	caaatattcc	agccccaat	7860
gagaaatcaa	acatatataa	attgttcaag	aaaatttctt	tgaacacttt	tgaaagtttt	7920
tggaacttta	gaaaagaggg	aaaaaaatcc	agtgttacta	gtaatttcca	tggtaatata	7980
gataaaatata	attcttttaa	ttctgggaaa	ttagaaaaag	tggggtgatc	tttccaggaa	8040
aaacatgtgt	aacatctgct	tatcactcca	gctccctcct	cctcctcctc	tccacgttcc	8100
cttgagtaaa	tgtctgggaa	agcatgaagc	ttgatgcaag	aacctgtt	tactggcggt	8160
ttcctccctt	gtgaaaacgt	aactactggt	gggagtgaat	tgaggatgta	gaaagggtgt	8220
ggaaccaa	tgtggtcaat	ggaaatagga	gaatttggtt	ctcactcttg	agaaaaaac	8280
ccaagattag	cccaggtagt	tgccgtgaac	ttcagttttt	ctgcctgggt	ttgatatagt	8340
ttagggttgg	ggttagatta	agatctaaat	tacatcagga	caaagagaca	gactattaac	8400
tccacagtta	attaaggacg	tatgttccat	gtttatttgt	taaagcagt	tgaatagcct	8460
tcaagcatgt	gaataatctt	ccatcttccc	cgccacacac	acacacacac	actttttgtt	8520
tctttcaggt	agacaccttt	taaaatgcag	aactaactga	ggcatttctc	taactttgct	8580
ttcaaatcaa	taaagtcaaa	tgtatggaaa	cattttgtgc	cctactctcc	ataccccggt	8640
tactcaaatt	ctctactgta	tgaattatgc	tttaagtaga	attcagtgcc	aaggagaact	8700
tggtgaaata	aattattttta	attttttttt	tatcctttac	aaagccatgg	atttttattt	8760

299

gttgatgtgt	gctctgtaca	caagccattt	caataggatg	gagctgttaa	ttatttttcca	8820
aagagtaata	gacatgcaaa	agttttcaata	aaaactgggc	cattaacaaa	taaattaata	8880
aactaataag	cattcccttc	taggtttttg	ccaaactgcc	tatccaataa	caaatttgag	8940
aatcgttgaa	aaagctagtt	atatttcaga	gaaatgattt	tcattattga	aactgttctc	9000
cctagcaggc	cattttccct	ttttcctggg	agtttagcaa	gtttaggaga	gaatagtcac	9060
gaaaagaaaag	ggaagaaaag	ggagaaggga	agaggttaaa	aagtaagtgc	tcagacctat	9120
gaacgtaatc	cctttgctag	aaatatattaa	gagcagctca	gcttggttga	aactgagttt	9180
tgtcatcttc	catatttgca	ggaaggtatt	ttctgacttg	caatgcagct	agatgtaaaa	9240
ttttatttta	tcatoctaga	aagccttgac	tagaaaaatg	aataaatatt	gaggggtttcc	9300
tgtccatata	tggccttgcat	gtgccagaaa	gcagagaata	gaaaatgtaa	tctccaacat	9360
ccaagcatcg	aaacccaagg	ggtaggcaat	tctatgtagg	ttttggacat	gaagtttggt	9420
gcatcttggt	ttatgaatgg	tcaactgcta	ttaaacctct	ctggcttata	gtctcttcac	9480
tctatttagc	aagcacgtat	cgaacacttg	cttcgcacaa	ggctctttag	ttacaatttt	9540
agcagctact	gtttgtgtta	aacacacttt	tcaccaaata	ggttctgagg	caaacgagag	9600
caatgactat	ttaaagaaa	gctttcccag	catcacttac	acatcccaaa	actaaaaaga	9660
tcaactcttc	caactgagaa	aagactcctg	gctttgaatg	gaaacttaca	gcagagagtc	9720
acaggccacg	gcaacaacaa	cgacaacaac	aaacatttgg	aatattattc	tcaactcacg	9780
ttttaataat	acatcttatt	atttttctag	tagagaaact	acaatcagc	ctcttcaaca	9840
tttatataca	gtttaataag	cctcttgcaa	gttacttggt	ctctcacctg	aggtattttt	9900
ttcctcccca	ccttgccctt	gttctctcct	tctcttcttc	cctttgcaag	aggaaatatt	9960
taacataatt	gggtccaact	tcaataatgt	aataattaat	acattaaaag	catttaactt	10020
cctttctaga	aaaatgcaca	ggctaaggca	tagacaaaac	aaagagaaat	gctgagaaat	10080
ttgccactgg	agacaagcaa	tctgaataaa	tatttgccaa	aagttctttt	tatgtcatat	10140
agtgtcagga	tttgaaggag	ctattttttt	ttaatgttgc	aactagcaac	tcacttctcg	10200
aagacacagc	caggagaatg	aagtagaagt	gaaaggttta	taaattccatt	tgtaaagcatt	10260
tatcccatat	atttttaatt	caagaaaaat	tgtgtttatc	tttagaattt	tgtattcaat	10320
actttatgta	ctatgtgact	catgcttctg	gataaataaa	gcaccaaata	tgtatctgta	10380
accacaatca	cacatattat	attaaatata	tatctatata	acagcct		10427

&lt;210&gt; 396

&lt;211&gt; 19859

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 396.

agacttgaac	tgactcattt	cactagaatt	tgttactgaa	catgggtgtt	tttgtttctg	60
ttaggcggtt	agatgccaac	catattacct	cagtccccga	ggacagtttt	gaaggacttg	120
ttcagttacg	gcactctgtg	ctggatgaca	acagcttgac	ggaggtgcct	gtgcaccccc	180
tcagcaatct	gcccacccta	caggcgctga	ccctggctct	caacaagatc	tcaagcatcc	240
ctgactttgc	attttaccaac	ctttcaagcc	tggtagtctt	gtaagtatct	atccctttta	300
attccatata	tttgtgttaa	ttgggttaca	aaaacagatt	tcttctgaca	gattattatc	360
aaggcatctc	gctgaatatg	ctcctgagta	gttagtgctt	tgggagctgc	ttttgtacaa	420
tattaaacag	aataggataa	tttaaaacat	taccagctga	tgataattgt	tgaatctccc	480
taagacaaat	gaccagttat	aatcatgaga	agaaattggg	tcattcagca	cacacttata	540
cagctttttac	gtgtgtccca	gcagcgtatt	caatgtttaa	agaagggaag	tcatttcgag	600
gtgtccatag	aagtttagtc	cagggatatt	tctgtgtttc	cacttgttca	gagagtatgt	660
gatgcagtgt	gttttttaatc	ttccaagaca	taacaaaata	gtgcttcttt	taaaatctgt	720
tggagatctc	actggtgtaa	actacacact	tcctccacac	cattaccctc	atgtcctcag	780
taagagagct	catcaaattt	ttcttcatat	atttaagagc	taatcaaaac	tttattttga	840
tatgaataaa	tattaatctt	ccatgtatgt	accatatttc	cactaaagat	actttctctt	900
tccatgaggt	agtctatggt	tagtgagtct	gtgcagtgtg	catagcaaga	gataactatc	960
caatgtctact	tgttttctgt	ggcacaacaga	aaactgttta	gctgttttag	tgttgatatg	1020
tttagctaca	tcattccttt	acacaccaac	tcagacatat	aaaacaatga	taatagttgc	1080
caatgggaga	tggaaaagtc	attttatgct	ttttttcccc	cttaggcac	ttcataacaa	1140
taaaattaga	agcctgagtc	aacactgttt	tgatggacta	gataacctgg	agaccttgta	1200
agtatatcca	tattttgggc	aactgcattg	tgatattgaa	agtataattt	tatacttcac	1260
tgcagaaaaa	gaaaaaaaata	ttggccttaa	gttcagctcc	ttattaattc	actttgatac	1320
tggatttaaat	tcttgctatc	aaataaccta	attatgaata	ctaacttaag	tccatggcta	1380
aaaattggcaa	agtggtgaatt	gcataatttc	ccccaagaa	tacacattca	aaacagctca	1440
atctacaaag	attttatacct	ttccagaaat	gttggttttg	ttaaatgtat	gacagttttg	1500

300

gaagtttagaa	agttctaaaa	tgaattctgg	atagtggtat	ttttccatg	atctcagt'tg	1560
ccttctaatt	gttaacactg	ggtttgaata	ctatatctgc	ttttacaagt	aacaaatgaa	1620
gattttatat	tctgctatga	tacttttgtt	gttggttcca	cgagctaaag	tgtttgagac	1680
ctctggctgt	ttcaactgta	cattgcacca	ctatataagt	aaaaggcatt	gtgtagctgt	1740
gtataattga	gaataggata	tttatttttg	ttcttttagc	ctatattagt	tgcctttatt	1800
gccttcattc	aaagataatg	taatttttgc	tggtgtgatg	agtaaatgat	tcagagaagg	1860
tcccaattac	atgggtgagt	aaaacctgat	tagaatgctc	agggtatgta	gtattttatt	1920
tgactgaatt	ttctgggttaa	ctgtcaatta	atgagaagac	ttaaaatcct	ttaggactct	1980
attatttcac	ttttctatct	aaattagagg	ataggaaaca	tcaatggata	tatgaaagtt	2040
gaaaatcttg	tagaggatag	ttccaaactc	agatctcctt	tgctaagtgt	gtgagttcta	2100
gtgttataaa	taaaagattg	aataggtttc	ctaactctaa	gctgtgtaca	ctatttcaat	2160
tatgttaaaa	ttaaacctct	tcccagttaa	atttttattt	gccattgttt	cttctctgtt	2220
acaaaaagga	aaaggaacc	taaaaggagc	gttggtgtat	tgagctttta	attttatttt	2280
actttcattc	tgaatacaat	catgcaaato	gtatgccagt	gtgctcttta	tgttaaaaga	2340
aattaaactt	taaacactct	cagaactaag	acttttttagt	acagatcact	atggcttgct	2400
tttctcctaa	ctaattgtaa	attcccaata	attcataact	tgtatgagga	caacagttgt	2460
gtgaatctac	cctgggtcctt	ctgattattt	tttatttttt	tattttttat	tttttttgag	2520
acagagtctc	gctttgtcac	caggctggag	tgagctggca	tgatctcggc	tcactgcaac	2580
ctccgtctcc	caggttcaag	agattctcct	gtctcagctt	ccttagtagc	tgggactaca	2640
ggcatgtgcc	accatgccct	gctaattttg	gtatttttag	tagagatggg	ttttcactat	2700
gttggtccagg	atgggtctga	tctcttgacc	tcagatctcg	cccgctcag	cctcccaaag	2760
tgctgggatt	acaggcatga	accactgtgc	ctggcctcct	tctgattatt	tttatctcag	2820
gtcatcacgc	tgatggtgga	actgaggtea	gctgctctta	taccagaatt	tcaggaagcc	2880
actgtgaact	ccaaatggaa	acctcagttt	cacgctgtca	tttacaatg	gatattcaat	2940
gaattatatt	ctagaatgaa	ttttcagaga	aataccattc	agatgattta	tgtatttaat	3000
gcatcagtaa	tacatgattc	tgaataattt	ttgaacttgt	aagtttcttg	acctaaaaac	3060
atcatggaag	agaaatgatt	tctctctatt	cattattgta	agaaaagggtg	taaatctcag	3120
taaaactccta	catggttttg	aatgacgata	tggttgataa	agaaagatta	ccatacagag	3180
gatatgattt	aaaaaaatc	ttgtctgtaa	caaaatgcct	tatgaattat	gaccactatt	3240
taatatatttg	atatattttc	acccattttt	ttctagagac	ttgaattata	ataacttggtg	3300
ggaatttcct	caggctatta	aagcccttcc	tagccttaaa	gagctgtgag	tattgtctca	3360
ttctctttat	gtcttcatat	ccttgaaact	caccatttaa	tgttccaaca	atgggatttt	3420
agaacatcct	gttccattac	gtatatccat	aatacatgca	cacaaacaca	caaataatca	3480
taaaagttgga	ttgtgttctga	tgacagagac	aattttgagt	atagattgat	gtatagggtt	3540
agatgctggt	aaaacaagaa	ggcctgatat	acagcgtctg	cctttaagga	gcttgtagtc	3600
ttagtcttac	tggggaaact	gatcatgtta	agacagacag	ctgtttctag	gtagaaataa	3660
atgctgaatg	aataggataa	ataaatcatt	ctggaagaat	acctaattga	agtttgaggt	3720
tactgcagaa	aacatcacca	aaaggaagga	gtttgaccag	acttgaaaga	acaaaaatat	3780
ttaaacacag	gaatgagggg	gcatttttgt	ttttattttt	ttttttgatt	gtttgtatgt	3840
tttgagcagg	agtctcactc	tgtcgcccag	ctggagtggt	cacggtgcag	tggcatgac	3900
acagctcact	gcagccttga	cctcccagcc	tcagctgata	ctcccatcct	agcttctctg	3960
gtagctggga	ctgcaggcat	gcaccaccac	gcccagctaa	ttgttaaatt	ttttctagag	4020
ataggggtttc	atcatgttgc	ccatgctggt	ctcaaaactcc	tgggctcaag	tgatccctc	4080
agaatgctgg	gattacaggc	gtgagccact	gtgcctgccc	tgagggaaca	ttctggacgt	4140
cgggtttgtc	atgggttagag	ttagtgaactg	tatatggcac	aacagggact	gtgtgtcatg	4200
agctagt'tga	tgg'ttaacat	tctaagatgc	attgccaaga	ggctaaatc	aggctacagt	4260
gagagagatt	ttgagggttag	aacacctggt	tctcatggtc	taaaagctttt	ttttatgatg	4320
aagcaacaga	taaatgcata	tgagggatct	gatagatacc	aagctaagca	gtgggttaaa	4380
aaagaattag	gtatgatact	gaaaaagata	aaataaaatt	aaaatttgag	atttcctatg	4440
cttttgaaaa	ttttcatgta	gtcattatca	gttgatattt	atataatgct	gaacagcagt	4500
agatacttgg	gttttatttc	gcaagaggat	aatgcatttc	aaaatacttt	tctcctatct	4560
ttctagagga	tttcatagta	attctatttc	tgttatccct	gatggagcat	ttgatggtaa	4620
tccactctta	agaactatgt	aagtattttt	gaaagtttct	tttaatgtat	aattatgtga	4680
agctgtgtcc	gtacaatgcc	aaacaccctg	ataaagaatg	agaagtcagg	attttagata	4740
tatgtacatt	gtgaacatag	ag'ttaatatt	agagtgcctg	tgaacatag	aaaattttac	4800
tttttttgga	tattttcaca	gacatttgta	tgataatcct	ctgtcttttg	tggggaactc	4860
agcatttcac	aatttatctg	atcttcattc	cctgtaagta	tgtgaattta	aaaacaaacc	4920
tggatattta	tacagttggt	ttagtggaaa	acaagaattt	attactggaa	ctccagaaaa	4980
caaaatcttt	aaaatttttt	tctcccttgg	gcagaattta	taattgttct	tatttttgtg	5040
aatactttgc	cacattatca	tactttcaag	tacattcaag	agatgaaact	agttttattt	5100

ttagttatag	ttgcactgta	attttaaact	gtttaaaaca	taaaatatga	aaaaaaat	5160
aaaaattacc	ttgtctttct	caatttcata	aagagtcatt	cgtgggtgcaa	gcatgggtgca	5220
gcagttcccc	aatcttacag	gaactgtcca	cctggaaagt	ctgtaagtaa	ggccctttga	5280
agaggggttg	tataaagata	acactactgg	actgctagca	gggtgccagg	gtcttttagt	5340
gacaatgatg	ggtttatgtt	gattcctccg	gtttcccttt	gtatatatca	tgcatggaga	5400
agaatatatt	gggtatgggg	tcagtgagct	taggcagagt	agagccgatt	atgtggataa	5460
gatctgaaag	gttcacagaa	aatacaaggc	agtaacaaag	tgccaaatta	gaagcagtcg	5520
tttcagaatt	tagaagtggg	ggcattcgat	gtagactatc	acagaaggct	tcacggagga	5580
ggtagaaggt	ttgaatactg	tcaggtttcc	cagagctgag	tgtttaattt	aaggcaggat	5640
tagtaaaact	ggaaatacca	aaagtattct	cagagatagc	atatagatga	gcaaatatag	5700
ctagaattgc	atgtttataa	tagaatgggg	atgggatgga	gaaatcggag	aattgtttgg	5760
tattagatgt	tgaaatgaca	agctttgaac	gttgacacatt	tggttgtggc	agtttcccg	5820
tgagtggctt	gtgcatgagt	ttacagtgct	ttctaagatc	ttgatgacct	cagccctcca	5880
gacagtcagt	tggggcctga	ggcagctagg	acctctagcc	acaggagtct	tactgcagcg	5940
tgccatttaa	atgtttacaat	ggtcacatgt	gacaagatat	tttttaaaaa	agaatttggg	6000
aagcactgag	gtaaggagtt	taaacttgac	tcttaaggca	gttggagggtg	tgagaatgt	6060
ttaagcaggt	aatgtgagga	gggtaaggag	aaagagacta	gagatgggga	gaacagttag	6120
gcggctgtgg	gaatagtcta	cctgaccaga	tgaacacatt	gaattatgac	agctccaggt	6180
ctttaaactca	tcactggatt	tgaccaggga	caaatagcat	ggctgtctctg	agagtcctct	6240
atccctctct	gcctcacttc	actctttttc	tgaagaatt	agatgctaga	aacacaacag	6300
aggaagaaat	aacaggaact	ggtgatagac	tacagaaggg	aggggaataa	gagaacattt	6360
tcgaatgctg	agccagtttg	actgaaagaa	aagacagaaa	caagatttgg	gggcagaatg	6420
caagttggtt	tcaaaggtct	tggtgtgaag	aaggtgacaa	cttgcaatta	actgtgatca	6480
gactgtgtga	ctgtagatta	gtgttttctt	cctgggtccat	gtgggaaatc	aagcccagta	6540
tcaacatcta	atgtcacaa	tggttttgag	ttactgtgaa	gatgatatca	gaattggggg	6600
tcagttcacc	ttcttgcattg	tctaacttta	tggaaataatt	aggccatggg	atgtatagaa	6660
tctagtccat	atgtaaatat	gtgagcactt	attctatatg	ggaataaatt	ttgcttacta	6720
tcttgagttg	aattatttct	tacatgaata	atgtttttcc	gcaggacttt	gacaggtaca	6780
aagataagca	gcatacctaa	taatttgtgt	caagaacaaa	agatgcttag	gactttgtaa	6840
gttggaattct	tcttcccttc	ccctcatacc	ttttgattat	atattcacac	atgttcaatt	6900
ttattttaag	gatctacttt	cataagggtg	ttttgaggta	taattacttc	ttagttgttg	6960
taaaggagca	gatatlttgag	tcatctccag	gggtgggtaat	gtgcatttga	attaggtttt	7020
agggttttga	atatatcata	tacttgtgac	tttattttga	acaaagtaaa	accaagatag	7080
gttcttttct	cattttttct	catcctgctc	tttgtcttta	ttctagtttc	tccaggggta	7140
tctctcctca	tagtctcctt	ctttcatctg	cagcctaagc	agagcctaac	tctttattca	7200
gtctggaatg	aactaaagct	tgctgctttc	taaaaacttt	aggctgacct	agaaactaaa	7260
agtaaaataa	ggatgtaaaa	atgtctccag	aataaacgat	taagttatta	agttgttaat	7320
aagtactcag	tggcaggaga	tagtaacaaa	ataaatgact	gattgattaa	gcaagtaaag	7380
tcacacatcc	acttaacaat	aggaatacat	tctaagaaat	gtgtcatggg	gcaattttgt	7440
catttgtgtga	aaatcataga	gtatgcttac	acaaacctcg	gtgggttctt	ctacacacct	7500
gggtatatatg	atataatctg	ttactcctag	cctacaaacc	tgtacagcat	aatactgtac	7560
tgaatactgt	aggcagttgt	aacataatag	taaatatttg	tatatctaaa	catagaaaag	7620
ttggagcaga	aatatggtat	tatactctta	tggtgaccata	tcattgtata	tggtgtctgt	7680
cattgaccaa	aactgttatt	tggtcatga	ctataattta	gtgatgtagt	ggtgtatcaa	7740
acttaaacat	aatgatcact	gttgaggaaa	aactgcagtg	ggactgaaag	ttaactagtt	7800
ctgggtgttg	atgtaatatata	actgtttttt	aaaatgttga	taagcatacc	atttctctta	7860
gagcttttca	acaaaagaac	atataagtta	tttatgggat	aaacaatatt	gaaaaaatat	7920
aaatttttaa	accgtataaa	tacaaattta	aaaaaatgta	gctttaccac	ttaaatttta	7980
tatatattgt	atatattttct	atatattgcct	atttaatttt	atatattttat	gttatgtact	8040
ttatatatat	actttataga	aatgtatttt	tacatatatt	agtgctctatg	ctcaacaata	8100
tattcttgaa	ctttatcaat	cttaggctta	ttgtatcact	gaggtatttg	agaagctgac	8160
aagtcttagg	aaaaagact	tggttttctt	attcaggcat	atctctttat	tacttatctt	8220
agctctgctt	tcaacgcttc	tgagtaccac	tcttttaata	taatactctg	ataacatagc	8280
attaatttgt	taatttccat	tggtttaagg	gacttgtctt	acaataatat	aagagacctt	8340
ccaagtttta	atgggttgcca	tgctctggaa	gaaatgtgag	ttggcttttg	acttattcct	8400
tttggtgtgg	tgtattgtta	gtttgttgag	catttcgtat	ttttaataga	tggtcttaat	8460
agtaagaaat	tagaaattcc	tgtaatcaga	tgttcccata	aataacatgt	caaattgaac	8520
cagatgtgtt	catgcaacca	gcattgtatta	ggcacttagc	tatcaggcat	cccatgaaac	8580
gctatgcggg	ggggagttgg	aagttagttg	atatttaaaa	gaaatagaag	acaaaaactt	8640
gtccagctat	tgaggggaaac	cagacatgaa	tgccagttcc	catcatgtcc	tgtgttgac	8700

302

agctctgggtg	gaagctgggtt	gggagatggg	aagggggagg	cattaattct	cccattttta	8760
ctctatgtag	tccctgtaact	ttattcctac	ggtatttggtc	atagttgtgt	tgtcttggtt	8820
ccttttctcc	ctgcatcatc	ttccttctct	tatgcctgag	tgggggtgat	gggggaattt	8880
agatagcata	ccagttaatt	cccagtataa	tatgggatga	aataccaatt	agtctctttc	8940
attttataga	tgagaaaagg	gcaattctct	ttcaacaaga	tcactgttac	ataagaatag	9000
ttatttaaat	ttagaaaaaa	ctcaactaag	aaatgcttata	atgttatttt	tcaaaaataga	9060
aagtaacttt	tttctttttc	tctatccctt	tctcttttct	cctcctcctg	ttctcttctt	9120
tgtctttgtc	ttcgtcttct	ttcttcttct	ttttttatatt	agttctttac	agcgtaatca	9180
aatctacca	ataaaggaag	gcacctttca	aggcctgata	tctctaagga	ttctgtaagt	9240
ttgtctatga	ttattaaaga	caataaattt	tttccaaact	atgttaatat	gttggttatga	9300
tttccatggt	actagatata	cttaaagata	taattttaat	ttcagcctga	acaacgtggt	9360
gaaaccccat	ctctactaaa	tacaaaaaat	tagccgggca	tagtgggtgca	tgctgtgaat	9420
cccagctact	cgggaggctg	aggcaggaga	atcggctgaa	ccctggagggt	ggagattgca	9480
gtgagctgag	attgtgccat	tgcaactccag	gctgaaaaag	aagagtgaag	ctccgtctca	9540
aaaaaaaaaa	aaaaagatat	aattttgtgt	caataaatat	tattttttaga	ctttacctaa	9600
aatattattt	tagacattgc	aagattttta	gacttgcaac	tttataaata	atctttcaat	9660
attttttact	ttagctaatt	gtacattggc	aagtagaaaa	atgtgtaatg	tgtataactg	9720
aagtgatgta	gcttggttgt	tttcaagtta	taatagttag	gtttgccaat	tcattagggc	9780
aagggtaggc	agactacagc	ccatggggca	catccagcct	gcttctgggt	ttatcaatta	9840
agtttaattg	aacactgcca	ggcctttatt	attaaagtgc	cgtctaaagc	tgctctcacc	9900
ccactatagc	agaattgagt	agttgcagcg	gagagtatat	gactcacaaa	ggtgaaaata	9960
tttactatct	ggccttctac	agaagaagtt	tgctgacccc	tgcaactggag	tatctatcat	10020
gacaaataga	gttcataagc	cacagaagca	cttacttaaa	aaatcatttg	tatttgacta	10080
catatttggt	ccaggctactc	tcataagcac	ttgggaatat	agaggtgact	gagacaaacc	10140
ttgccactca	ctatcttctc	agaacttttag	cacagaaaca	tagtacacta	aattaatgaa	10200
catttttctt	ttctttttct	tttttttttt	tttttgagac	agggctctct	actcttgctg	10260
ctcaggctag	aatgcagttg	tgtaatcaca	gctcactgca	tcctccaacg	cctgagctca	10320
aacaatcctc	ctgcctcaac	ctcctgaata	gctgagggac	tacagggtgca	caccacaatc	10380
tccagctaat	ttttttcttt	tttttttttt	tggtagagat	ggggctctcc	tatgttgccc	10440
aggcttgctc	caaacacctg	agctcaagtg	atccaccac	cttggcctcc	caaagtgttt	10500
ggattacagg	tgtgagccac	cttggcccagc	acaacatttt	tctattatag	aaaaagtttg	10560
aaaaattgat	agtgaatgaa	attacatata	ttgaatacag	tttttttagta	tatccccctt	10620
aagaaatatg	acatgtactc	tactagaaac	tatttaattg	gtagttgggt	tgctggatca	10680
tctcaagttg	tggtactaact	ttgtgtaage	ctgggcagtc	ataggggaaga	agactggctc	10740
ctagttgcc	tcacttttag	aaactgataa	gtgacactaa	gaagctgggtc	ttttcgtgat	10800
ttggaaccaa	gtgtgttgag	tttcttggtt	atctaggaaa	tatgtctcag	aatgaattta	10860
ctcaatgttt	aaatttcctt	taaggttcag	tgtaagtgtg	ttttagagatt	atttctgttt	10920
tattaattct	ataatatcag	aatttctcag	ggtgtgttcc	tgaatacggg	gctggctgta	10980
ctgttgatgc	aattttttata	tcgtgcttag	gaaaagaagg	gtatctgcag	ccctcctgga	11040
atgctcttgt	ttgcataattg	attgtttgtc	ttctctcggg	gccttatcac	taacctttga	11100
gaaggcaaac	aatacgaagt	ctgtttttat	tttcagcttt	ttcagaaact	gagcttttcc	11160
tcaactgagt	agcagtacca	aagggtatat	catatcattt	atatgtttga	attggtatca	11220
gaatgataaa	gtgggaaaa	tcacacctgt	tttgaacag	atgccagcta	gaattactgc	11280
tgtacagaac	atattccaag	aaatagattg	ttgtgaagga	gaggcattca	acataaacat	11340
gaaaaaatat	tgtctggccaa	gattgaagat	ctttgttatc	ttatcagcga	tatttgtgta	11400
ctacctctaa	ttctaaagta	tagtctaagt	aagtggcatt	ctgagtgttt	atltgaaaga	11460
ttaacatggt	actcttataa	ttgcagagat	ctgagttaga	acctgataca	tgaattcac	11520
agtagagctt	ttgccacact	tgggccaata	actaacctgt	aagtggatga	ttatgcagta	11580
atgtcatgaa	agttagtaact	agtgtatag	aaacatctgt	tttaacattg	tcgaatcaaa	11640
atatttttct	gtttagttat	tccttgtgat	aaatgctaag	ctgtatttat	agtaaaagtc	11700
ttcttaaacy	gcaagataca	tgctagaact	ataatttttag	cacccccact	tgaacttcat	11760
cttagggatc	taatatattat	gatgttaata	cgtgtacaga	tgtttttatg	tgatttatat	11820
attgggcatt	aacttgaagt	ctcattcata	ttttagagat	gtaagtttca	atgaattaac	11880
ttcctttcct	acggaaggcc	tgaatgggct	aaatcaactg	aaacttggtg	gcaacttcaa	11940
gctgaaagaa	gccttagcag	caaaaagact	tgtaaacctc	agggtgtgtt	ttgcttattt	12000
ttcttttttg	ttgaagttat	ggtaggctcc	aaaattacag	agtgtcctgg	ttttttgtct	12060
tggttctcag	attttctgat	aggctataat	ttaaggggtg	tttctacgtc	agtctttgca	12120
aatttggtga	aaaatagaat	atgaacatta	ttccacagtc	tttaagaatg	tgaactggag	12180
cccttgatgg	cctcaaagag	ataatacagc	tattcaccag	aatgggtttt	taatacagtg	12240
gacttttcat	tagcaataag	atggcagaaa	ccatgtaaat	gtgaacctgc	agaaaacaat	12300



gctataatac	ttcatgaagg	ttttagagtt	atgggggact	gcattaaata	taatagagag	12360
tattgttacg	aggccgagcg	tggtggctcg	cacctgtaat	cccagtactt	tggggaaggc	12420
caaggtgggc	tgatcacttg	acaccagcag	ttcaagacca	gcctgggcaa	catgctgaga	12480
cctgtctct	acaaaaaata	taaaagttag	ctggatgtgg	tggcacgtgc	ctgtagtccc	12540
agctacttgg	gaggetgaaa	tgggaggatc	acttcagcct	gggagttcta	ggctgcactg	12600
agctgtgatt	gcgccattac	actatagcct	gggtgacagg	gcaagaccct	gtctctaaaa	12660
aaaagagaga	gaatattatt	gttggagaag	agaataaata	ttttcattac	atttatttaa	12720
accaagtaaa	tatatattaat	ggtataaagt	cacaaatgac	ctggggcatt	aattttaagt	12780
gaaactatca	gtttcgatg	ataaattgtg	catagttaat	acatttataa	aaggagtcac	12840
aagatattac	tttaaattac	agtactgctg	ttaaatttta	aacagtttga	tttacatcca	12900
actgttaaga	gagatcctat	agaaagggag	aaagtctcgt	tgatcatctga	taccagagct	12960
gttttcacag	atgaggaaac	tgaggcccag	agaggatgaa	cgaccagcct	aaagcacatg	13020
acagatcttt	ctgactccta	ggctgagggt	ttcaaagttt	aaaatacttt	tacaaaacaa	13080
aaccataact	goggagttgc	tgttcagtgt	agatttttaca	actttttttt	ccaggtcttt	13140
atcagtacca	tatgcttatac	agtgtgtgtc	attttgggggt	tgtgactcct	atgcaaatlt	13200
aaacacagaa	gataacagcc	tccaggacca	cagtgtggca	caggagaaag	gcaagtgcac	13260
gagtttcaaa	aaatagaaca	ctcctttaag	gcattgatta	aagttcctgt	tattataatt	13320
actttgtgaa	tgatcaatag	gaaatctgtg	agaaaaatgg	cattgtcttg	ccaggtgtga	13380
tggtcatg	ctgtaatctc	agcacttagg	gaggccaagg	cgggagggtc	atlttgaggct	13440
aaagagttcga	gaccagcctg	ggcaacaaag	tgagactctc	tctatataaa	aaatttttaa	13500
actagctgag	tgtagtggca	tgtgcctgta	ttccccacta	cttgggagac	tgagggtggga	13560
gaatcctttg	agcggagccc	aggagttcaa	ggttgcagtg	agctatgatt	gtgccaatgc	13620
attccagact	gggcaacaga	gcaagacctt	gtctctaaaa	aaaacaaaaa	ccaaaaaaaa	13680
caatggcatt	cactatgcta	ccagcatcct	taatattgta	ttgaaccttc	tataaggaga	13740
actcacactt	atatacagag	aaaattgcag	gaaaatatgg	ttcttttgag	ttgcataagg	13800
ttttaattaa	acatgctttg	tgttatatgt	tcagggtactg	ctgatgcagc	aaatgtcaca	13860
agcactcctt	aaaatgaaga	acatagtcaa	ataattatcc	attgtacacc	ttcaacaggt	13920
atgcctggcc	tattttttca	cagttaccca	tgttaaacaa	acattaggca	aatatatcta	13980
aatgtcctgg	gtatagatgt	gatttctgta	atagggatgg	tactagagga	tcctgtgagg	14040
ccttctgatt	tgtgtctttg	cgtaccagcc	agcagcttag	gaattttttg	cagaatctca	14100
ggcccagacc	tactgaatca	gaatctgcat	gttaacaagc	tccccaggt	gaagggttgta	14160
cacgttagaa	tttcagaggg	actttcttaa	tgctccttta	actctgggac	taattctgta	14220
agttagtagt	ctatgcagat	tgtatgtgtg	tgttaattgt	agccttgcc	ttccttattt	14280
ccctcattt	acttcattga	acttcgtagt	cttgggaaag	ttattaaact	gataccacat	14340
atlttggtcat	gattgtcata	gtctgcctaa	tctactagag	aagatgtatt	tataatltta	14400
ctgtaaaagg	aaggcttaaa	tatttttagtc	aaattgtgtg	ctacaaagta	gattcctttg	14460
ltgggtataat	atcacaggat	aatctggaca	ttaatltttat	gactcagaat	tataagtatt	14520
atggattcac	tagtgattgc	tgctgaattg	tgagcttctt	aaggggctgc	gtatgtattt	14580
tatgaatact	ttcttttgta	gagaataagc	tctaagttac	tagataagtg	aatgcagttg	14640
gcaagaatca	tctaagtgtg	tgtaatlttg	tttatgtgt	gttagtgtct	atattaattt	14700
ttaaagggtg	gggtgcagct	tgcttacttg	tctcactgga	gttcatgtgc	cagagaaatgt	14760
acataaagaa	ctgatgatcc	aatgagaagg	gaacagggtt	attaaagggg	gggctggact	14820
tcaacatgca	gcgtttccat	ttcttccacc	ccaaatgtaa	acttgagat	tggccaggag	14880
gaaagctggt	ctgagctcat	ctccttgggc	tgccatgggg	atgaaatgca	ggcctgcctc	14940
cccctactca	gctgtagtaa	cacacagaca	ctgatgtgct	tgctgcagaa	gcaggaagtg	15000
gaggagagct	gggatccttc	tgttagcacc	agaggaggca	gcaggcttcc	aaagacaggg	15060
acgggtggagg	ctgcttccca	ggctlttttg	gaaaagtaac	cttctccacc	cataaaaggg	15120
ttctcaaaag	gtatcctatt	ctctcaggta	gatgagctac	ccctccttcc	atgaaggatg	15180
aglttagata	acagagataa	aggtgataac	gagcttcttc	ttagcacttc	ctgaaggggg	15240
aatagaaagg	aaatttaaaa	taagagtttc	ltgtattatt	tggaagcctg	ataaatgatg	15300
cagaactggc	ttttgaggte	tgtgaatate	ttacaatttt	aaaacatttt	attgggatatg	15360
tcattttcat	gaaagtctat	aaaacatggt	ttttagacag	ltgtaataca	tagttttctt	15420
gtgtttcata	gtcaaaatct	tgtltttctt	ttctaatttt	tcagtaaaac	agttgtaatt	15480
tgtgtcataa	ctagcatgtc	aaagtcagtt	actggaacat	ggagttcagc	gactgaatga	15540
gttcttgcaa	tgctagtttg	tattatgtag	gattlttattg	tacatagctt	tgtatgaata	15600
gttaacatca	ccgagggtga	gtcctagcta	tattatctta	ctgaatggcc	tttgtcagtt	15660
tccttgaaat	atcagtttct	ctggatgaaa	aatggggata	attatactgt	cttaacctgc	15720
ttcatcaggt	tgctlttgaa	agtcataaga	aaatatataa	aaaatatgtg	tagatacata	15780
catatacata	catgattata	aagtatattg	gggctagaaa	ggaagaagaa	aagggagcta	15840
atattttattg	aagtcctaact	atatatccag	catcctgctt	agttccttat	gtgtataatt	15900

ttactttaagc	tgcacaactg	tatgaaacag	gcattattat	ccacaagtga	gaaaatgaat	15960
acagggttaaa	at ttatacaaa	ttttaagttg	ctttcttaag	gtaagaatag	caagttatga	16020
accatctcat	tccagaccct	cagtcaccaa	atacctctta	tgccctagat	attgtgtcat	16080
gtaaatagc	ttagatgcaa	gaaaaaatga	aaaatttcat	ctaaatatca	ctctttatca	16140
aataattta	aaaagaaata	tttatagcct	taccaaata	ttataaaaat	aaattaaagt	16200
cagttttatt	ttaaaatagc	ctgggtccatg	accaaaatat	cttagaacta	gtaatcagtt	16260
cagttttgtt	caagtagaga	gcagat ttaa	ttagtctata	tcattagttt	ttctatcaag	16320
ccatatcatt	ttctaaattg	ttttctaaagt	tatcttttat	ttctctctct	ctgtgtgtgt	16380
tttttttagg	tgcttttaag	ccctgtgaat	atttactggg	aagctggatg	attcgtctta	16440
ctgtgtggtt	cattttcttg	gttgcat tta	ttttcaacct	gcttggtatt	ttaacaacat	16500
ttgcatcttg	tacatcactg	ccttcgtcca	aattgtttat	aggttgatt	tctgtgtcta	16560
acttattcat	gggaatctat	actggcatcc	taacttttct	tgatgctgtg	tcctggggca	16620
gattcgctga	at ttggcatt	tggtgggaaa	ctggcagtg	ctgcaaagta	gctgggtttc	16680
ttgcagtttt	ctcctcagaa	agtgccatat	ttttattaat	gctagcaact	gtcgaaagaa	16740
gcttatctgc	aaaagatata	atgaaaaatg	ggaagagcaa	tcactctcaa	cagttccggg	16800
ttgctgccct	tttggctttc	ctaggtgcta	cagtagcagg	ctgttttccc	cttttccata	16860
gaggggaata	ttctgcatca	cccctttgtt	tgccatttcc	tacaggtgaa	acgccatcat	16920
taggattcac	tgtaacgtta	gtgctattaa	actcactagc	at ttttatta	atggccgtta	16980
tctacactaa	actatactgc	aacttggaac	aagaggacct	ctcagaaaac	tcacaactca	17040
gcatagttaa	gcattgtcgt	tggttaactc	tcaccaattg	catctttttc	tgccctgtgg	17100
cgtttttttc	at ttgcacca	ttgatcactg	caatctctat	cagccccgaa	ataatgaagt	17160
ctgttactct	gata tttttt	ccattgcctg	cttgccctgaa	tcagtcctg	tatgttttct	17220
tcaacccaaa	gtttaaagaa	gactggaagt	tactgaagcg	acgtgttacc	aagaaaagtg	17280
gatcagtttc	agtttccatc	agtagccaag	gtggttgtct	ggaacaggat	ttctactacg	17340
actgtggcat	gtactcacat	ttgcagggca	acctgactgt	ttgcgactgc	tgcgaaatcg	17400
ttcttttaac	aaagccagta	tcattgcaaac	acttgataaa	atcacacagc	tgctcctgcat	17460
tggtcagttg	ttcttgccaa	agacctgagg	gctactggtc	cgactgtggc	acacagtcgg	17520
cccactctga	ttatgcagat	gaagaagatt	cctttgtctc	agacagttct	gaccaggtgc	17580
aggcctgtgg	acgagcctgc	ttctaccaga	gtagaggatt	ccctttgggtg	cgctatgctt	17640
acaatctacc	aagagttaaa	gactgaacta	ctgtgtgtgt	aaccgtttcc	cccgtcaacc	17700
aaaatcagtg	tttatagagt	gaaccctatt	ctcatctttc	atctgggaag	cacttctgta	17760
atcactgcct	gggtgcactt	agaagaagga	gaggtggcag	tttattttct	aaaccagtca	17820
ttttcaaaga	acaggtgcct	aaattataaa	ttggtgaaaa	atgcaatgtc	caagcaatgt	17880
atgatctggt	tgaacaaaa	atatgacttg	aaaaggatct	taggtgtagt	agagcaatat	17940
aatgttagtt	ttttctgata	cataagaagc	aaattttata	ctatttgtgt	attaagcaca	18000
agataaagaa	cagctgttaa	tattttttta	aaatctatct	taaaatgtga	ttttctataa	18060
ctgaagaaaa	tatcttgcta	at ttttaccta	atgtttcatc	cttaatctca	ggacaactta	18120
ctgcagggcc	aaaaaaggga	ctgtcccagc	tagaactgtg	agagtataca	taggcattac	18180
tttattatgt	tttcacttgc	catccttgac	ataagagaac	tataaatttt	gtttaagcaa	18240
tttataaatc	taaaacctga	agatgttttt	aaaaccaaat	taacagctgt	taggttaaaa	18300
aaatagctgg	acatttgttt	tcagtcatta	tacattgctt	tggtccaatc	agtaattttt	18360
tcttaagtgt	tttgtgatta	cactactaga	aaaaaagtaa	aaggctaatt	gctgtgtggg	18420
tttagtcgat	ttggctaaac	tactaactaa	tgtgggggtt	taatagtatc	tgagggattt	18480
ggtggcttca	tgtaatgttc	tcattaatga	atacttcccta	atatcggttg	ctctactaat	18540
at tttccaat	ttgctgggat	gtcacctagc	aatagcttgg	attatataga	aagtaaaactg	18600
tggtcaatac	ttgcattttaa	ttagacgaaa	cggggagtaa	ttatgacacg	aagtacttat	18660
gtttattttc	tagtgagctg	gattatcttg	aacctgtgct	attaaatgga	aattttccata	18720
catcttcccc	atactatttt	ttataaaaaga	gcctattcaa	tagctcagag	gttgaactct	18780
ggttaaacaa	gataaatatg	tattataaaa	aatagaagaa	gaaagaataa	agcttagtcc	18840
tgtgtcttta	aaaattaaaa	at ttttacttg	attcccatct	atgggcttta	gacctattac	18900
tggtggaggt	cttaaagtta	taattgtttca	atatgttttt	tgaacagtg	gctaaatcaa	18960
tagcaaaccc	actgccatat	tagttattct	gaatatacta	aaaaaatcca	gctagattgc	19020
agttttaata	ttaaactgta	catactgtgc	atataatgaa	tttttatctt	atgtaaatata	19080
tttttagaac	acaagttggg	aaatgtggct	tctgttcatt	tcgtttaatt	aaagctacct	19140
cctaaactat	agtggtgccc	agtagcagac	tgttaaattg	tggtttatat	actttttgca	19200
ttgtaaatag	tctttgttgt	acattgtcag	tgtaataaaa	acagaatctt	tgtatatcaa	19260
aatcatgtag	tttgtataaa	atgtgggaag	gatttattta	cagtggtgtg	taattttgtta	19320
aggccaacta	tttacaagtt	ttaaaaattg	ctatcatgta	tatttacaca	tctgataaat	19380
attaaatcat	aacttggtta	gaaactccta	attaaaaggt	tttttccaaa	attcaggtta	19440
ttgaaaactt	ttcattttat	tcattttaaaa	actagaataa	cagatatata	aaagtgttaa	19500

305

tctttgtgct	atatggtatg	aaatacaata	ttgtactcag	tgttttgaat	tattaaagtt	19560
tctagaagc	aatctatttt	gccttaattt	aaaactaggt	atattaatga	atntagtttt	19620
aaagtaagca	aattaaatat	ttgtaagtgg	acagtattag	aagaaatgtt	ggaagtaacc	19680
attagaaaac	actattttga	tatttatttg	taaacatata	agaacatttt	gctgaaactt	19740
agaaataagg	ttttatccta	agtctgaact	atactcatgg	aaaacagatt	atgaaatttc	19800
agaaaaacca	ttgattcaat	ctttatctaa	aaagcaaata	attaaaaaat	ctgcatgat	19859

&lt;210&gt; 397

&lt;211&gt; 630

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 397

tgctttgaca	attatctgca	gcatgtagtg	aaccttggtt	catcttcatc	ctattcacta	60
atccctccca	atccctctgc	cccttgcat	attttgaagc	aaatttaaga	cattatattg	120
tttcatctgt	aaataactaat	gtctagggat	aaatttttaa	agttgcataa	tatatgccac	180
agggttaact	gggtgatgaa	ttatttaagc	aaaagtgaact	cttatataag	tttccagagc	240
cagcaaaaca	taattacctc	aaatatacca	tggccaaagt	actaattgta	tgaaaagatg	300
tcactaagtc	aataccctaa	aacttaagg	gagagacact	cttttataca	tttgtacatt	360
tatatataat	tctaccctac	tcgattatgg	cttctcagct	ccagtaataa	aaaggcactg	420
taagaaatga	ggccgctgga	cttaattatg	ttcaaaccac	agcaccagca	ccatctgact	480
ctgcctcata	cccttggggg	gggtccagcat	tgctagtgc	taatgtcaca	gttggtcata	540
atgatgaccc	tggcgcatca	agaaaagggt	atactttgtt	taggaaaaca	ttttaagggg	600
acaagaagt	atatgacatt	tagattccca				630

&lt;210&gt; 398

&lt;211&gt; 387

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 398

ttcttaattc	caaaattttt	ggaaaaattg	aagaaccttt	aaagccacag	taacattgat	60
tccaggagct	gcttggtttt	tccaacagat	aatttgacct	taataactgt	taattttggt	120
atactgattt	ttcaaaagca	cttaactgct	aagagaagaa	gaaaaagtgt	ctttgcctgt	180
acatgacact	tatatatttt	acttgccctag	aggtaataag	gatgattgaa	aatctattta	240
gattctttat	tgctatacaa	aaatttttaag	tattttctaa	tattttctct	tggtacagaa	300
tcagagtatc	aactaaattt	aatgtctaat	gttagttata	atgtaacatt	ggaagcaaa	360
tagcctattt	gggtcagttt	gtttctt				387

&lt;210&gt; 399

&lt;211&gt; 16037

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 399

cgcgccgagc	gcagcagcag	ggccgggtcc	tgccgctcgg	gggtcggcgt	ccaggctcgg	60
agcgccgac	ggagacggcg	gcagcgtgg	actaggtggc	aggtagggc	gtccccgcgc	120
acggctgggg	taggggacgg	gagtggcgag	cttcagggtcc	accggctgcc	accgagtgat	180
gggaccggag	gacaggagag	gtcgctcagc	caagagcccc	ggggaggcgg	tgcttctctg	240
gtggggctcag	caacgggtctc	tggggggtgc	ctgggagcgg	cagccggtct	ccgccttggc	300
ggcccacagc	caccgcggac	gcctccctcc	cggtatgtct	ctcgctgccc	ttccctggcc	360
gaagccctcc	cctgcagcct	cctccccacc	tgccggccct	gtgttctcac	tgcttctctc	420
tgctctggga	tccgcaggat	gacgtctgtc	ctgcttcttc	actgtccttt	acagtcacca	480
gtctcggcgg	ggcgcatgtg	ctcacgcctg	taatcccagc	actttgggag	gccaaggcgg	540
tcggatcctt	ggagatcagg	agttcgagac	cagtctggca	aacgtggtga	aaaccggtct	600
ctactaaaaa	tacagaaatt	agccgggcat	gggtggccac	gcctgtaata	atgtcagcta	660
tgtgtctgag	caggaaaaatc	acttcaactc	gggaggcaga	ggttgcagtg	agctgggatt	720
gcgccactgc	actccagcct	ggcagacaga	gtgagacttc	gtctcaaaac	aaaaaaaaga	780
aaaacacaaa	aaaaccacca	ccaacaacaa	caaaaaata	aagccaccag	tctcggagtt	840
tcaaatctga	gcactcttat	ccatcttaat	tctttcaata	attcagctaa	acgaatgggg	900

tcctgagaat	ctgcagagcc	aggctcagcg	ctcgccctgca	gagcctgcgg	tctgtgggga	960
ccaccagcaa	gatgaggaat	caccttcggg	aggaagggtc	gtgctgggga	gggtcgcgcc	1020
ggcgggggtca	agagaacctc	ctccagggtg	ggaatcagag	cctccggggc	gcgggtgttg	1080
agggtgagtg	gaattaatgc	cgtgatggac	atggggcctt	ctaaggggga	ccaacagtgt	1140
ttgtgaagag	ttgactttgg	gaggggttca	ggatggccag	agggtggaggc	tgtgacctca	1200
gtgagtctgg	atcaaggag	ggggcagggtg	ggtaagacac	cgttttaaca	aggtggcctt	1260
gagcgccac	ctttgagggg	cctaagggcc	cctgggagat	ttaggaggaa	ggacaagagg	1320
attaagacac	cgctttctga	ggtgccgtgt	ggctgtggcg	tgggggtggc	tgggggagt	1380
ggttgtgttc	attgtccaag	gctctccagc	gctttgcgtg	gcgttttggg	gagcacagat	1440
gaggtgtccc	gacagtgggg	agtggctcta	gggagaccag	aggctcggga	gggggcctgg	1500
gcattagacc	aggcacagaa	tccgaagtgg	gaagaaatgt	gggcgtagag	ggcaggcctt	1560
ggggatgggt	gtgggggagg	agggggagat	ggaaaggagt	cagggagggtc	tcccagggtc	1620
acctggagg	gatcagggtc	catttccaag	tgcaactggga	actgcagcct	gggggtgggg	1680
gttcatttgg	tttcaggcct	gtggccaaga	gacccacccc	ctcacattca	cactttgggtc	1740
tccagtggct	tcacaggcac	cacctccttg	ttctcgctg	ttttactcct	caccttgggc	1800
tgtttcttgc	ctttccattc	tggcgttctg	cagggatcag	atccttcctc	tcacgcacaa	1860
tctacactca	tggcttttgc	tgggagtaat	gagtaaagct	cccaaataga	tgtttctgag	1920
ttaggaagca	cattaaaaac	aaaacaaaac	gaagcaaaaac	cacacaattg	tccaagtccc	1980
actctgtgtt	caagggtcac	atgatgtgca	gaagctgggtg	atgggcagga	gctctgaatg	2040
gagttactgg	gatctcaggc	cgcggtgggc	tggggcaggc	tggctgactg	ggagcagcct	2100
ggctccaccc	cggtctgcc	ggacgcactc	acttgcctct	atggatgaca	gctccttgcc	2160
tcacagctgt	ctgtctctgg	gtcagattca	gcattctcagt	gtcttttgtg	tatcagctga	2220
atgtcagggg	ggccacaggc	tgggtgccag	ttgaaaatct	cacaaggact	ctttgtaaat	2280
gcattgcaaga	ataagaacag	cattttcctc	ctcctccctg	accccatctt	cctcctcaga	2340
tgggacgact	tggtccttac	ggaaagaatt	ggagttcact	gcttcagct	ctgtgtgtgt	2400
gtgtgtgtgt	gtgtgtgaga	gagcgagctc	tgacggcgag	ccagttctgt	tgctatttgt	2460
ggtttgagct	gctgccatca	ccacacttag	ctaattacct	taacatttgc	acttaatttt	2520
tggccggaga	ctaacagaaa	ataaattttt	ctccaattta	aaatacttac	gaactttaag	2580
aagaaaacaa	aaagtacgat	tccaaaattg	ccctgtagta	agtaggtcag	taacattcag	2640
ggagtgtgga	aactgcattt	ctctttattc	ttcccttcca	ggccctgcat	catggaaact	2700
ctttctaattg	caagtgttac	ttttgccata	cgccctttta	agatactgtg	tcaagataac	2760
ccttcgcaca	acgtgttctg	ttctcctgtg	agcatctcct	ctgccctggc	catggttctc	2820
ctaggggcaa	agggaacac	cgcaaccag	atggcccagg	taagcttgcc	cgtccgccag	2880
gagcagggac	tggcctgggc	tgcgtgttct	gtcacagct	tcacactcac	actccagagc	2940
cactgagaaa	ggagggcagg	actggggccc	gagtgtgcac	tggccgtttc	agggaggcgg	3000
gggtccactgg	ggaagaagt	gggcagggca	gggaggcagg	aactctgctc	caccgagatt	3060
tatttggggg	aaactttcct	cggttaatcc	cttggaaaag	accatccaag	ctgtcttgct	3120
ctagcgcaga	atctttcttt	agaaaatgac	actgaaatta	tttgaaacat	aagttgcaaa	3180
gaactacctc	ttttttggag	caagagactt	tgtaactaaa	ctttcattgg	taagggaagt	3240
taattactgt	ttcaggttgt	ttctgtacca	acagctcagg	gagggcatca	acagaaattt	3300
gcaagaagga	ttccagggca	agtgttctat	tacagctgca	cactgtgcag	gtactgtctc	3360
gctcagctct	accaacattc	agagaacctg	tggaaatgat	tcaagatcag	tgcttgtccc	3420
cagacctttg	tggaaaggag	aggagacata	cacgtgagat	gaaaccgaaa	agcgccatcc	3480
ctgagtgcag	gccgctggac	acgccttcat	catgggagtt	gtcctttgtt	caatatgact	3540
gtctttttct	ttgatgacgc	ttttcaatag	tgaattactc	attttaataa	tttcccagct	3600
catttgtgtga	agaaggagg	gtttatgtgt	aaaggctacc	agccttaata	ataagcacag	3660
agaggctctc	taaaagatat	atatatttgg	aaatagggca	ttgcaatgaa	aatacgcatg	3720
ccatggcaag	ctatgtgcac	attcaggggag	gtgaaataac	actaagattt	ttaaaggaaa	3780
aagtaaagag	gattacataa	ttcctttgaa	ataattattt	ttggcaaaaa	gatcaataac	3840
gaagggtgatg	tcagtgtgag	gttggatggg	gagttcctgg	gtagatgtcc	ttgcacaagt	3900
atthttgtgt	gtaaggctgt	gatggccttt	gtgcaagagc	gtagggtttt	agagtccttt	3960
ctgatagttg	tgttatcagg	cattcaagcg	tgagaacctt	ctcttcattg	ccttccctgt	4020
ctggtttgtca	aagggtttttg	gttttgtttt	tttaatttta	gtgactccat	tttgattctg	4080
aagttcctta	tgctgaaatc	tgtatgatct	ttttctatgt	tttaggctca	ctgataaacc	4140
cttatagaaa	gcttttttga	gagcaccaaa	attgtctggg	taccttctta	ggtgtgagac	4200
tgagctctct	ccatggctcc	agtgttcaac	tggatgcttg	tgagacacca	aacatactga	4260
gtacacgttg	ctacctgtaa	catgcaggga	agcggttaatg	gcagcagaaa	tatttttaag	4320
aattatthtat	ttttccttca	ttatataact	ggtaaaagtc	cactataaaa	atthtttaaaa	4380
aataaaagta	gaaggaggga	aaaaatccct	atgaatccat	caaacagaga	caaccaccct	4440
tgataatgta	aagcatcttc	ctccagtcct	atttcttttt	ttttttttcg	agacagagtc	4500

ttgctctgtc	gcccaggctg	gagtgcagtg	gtgcgatctc	agcttactgc	aagctccacc	4560
ccccgagttc	acaccattct	tocacctcag	cctccccgag	agctgggact	acagggtgcc	4620
gccccacgc	ccagctaatt	tttattttta	gtagagacag	ggtttcactg	tgtagatcag	4680
gatggtctcg	atcacctgac	ctcgtgatcc	acccgccttg	gcctcccaaa	gtgctgggat	4740
tacaggcgtg	agccactgcg	cccggcccta	tttcttgatt	ttcacttgac	atthttgtact	4800
ttggtgatta	tatggtatct	ttacttttat	aaatgatttt	tcagctaattg	tgaggattcg	4860
gtgagacagt	ccatgtaaag	caagtgtctc	acatgtgttg	gctatgaata	gtaatagtgg	4920
tgctcacagcc	tcagggtgaa	ttggtcttag	cttttggttc	tgthctattt	gacagggttt	4980
ctcatcaaca	gtctatgagc	tgtctaaagt	aaatttagta	gcttcctctt	ttttctatgt	5040
tatagaacag	tgtgtattgc	atgagaaata	gaaattgctt	gaatattaga	aaaaaaaaatc	5100
cctcaaaaaga	tcatctaagc	cttttttagaa	gtaattctct	ctctccctct	tattttttttt	5160
ttgttcattc	atagtgactg	atagattctg	gttttggttt	gttttggttt	tttttggttt	5220
ttttttgaga	tagagtcctc	gctctgtcac	ccaggctgga	gtgcagtggt	gctatctcag	5280
ctcactacga	cctccaactc	ccgagttcaa	gttcacgtga	ttctcctgcc	tcagcctccc	5340
gagtagctgg	gattacaggc	acatgtcacc	atgcctggct	agtattcata	tttttgactg	5400
gcatttggtg	acttataatc	tgtactttac	tgaaaataat	tatatagagt	ttttgtttta	5460
acattcccctt	tgthttatatt	gctgtaacct	ctttttcaca	tataacttta	ctttgggggtg	5520
ctttttctta	catgtgggtg	gtggctgtct	gttttgatg	tatgtgtgtt	ttcttttaaa	5580
gaaccagcag	ttggattcat	tgatcatttt	gtgtttgtcc	caaaattcct	tgggagtttt	5640
tctgtatctt	ttctaacata	atgattttta	agtttttagca	ttttattact	ttcttggtta	5700
tattgaaaac	aatgctatgt	tttaacttat	ctttggccaa	actctttggt	ctaataata	5760
tcaccatata	tttgattatt	ttctaaatca	tatgtcata	acttatttag	aagaatttgt	5820
ttgtttgttt	gttttttgag	aaggagtctt	gctctgttgc	ccaggctgga	gtgcagtggt	5880
atgaccttgg	ctcactgcaa	cttcgcctc	ctgggttcaa	gtgattctcc	tgccctcagcc	5940
tcccaagtag	ctgggattac	cagcaagcat	caccacaccc	ggctaatttt	cgtattttta	6000
gtagagacag	gatttcgcca	tcttgccag	gctggtcttg	aactcctgac	ctcaagtgat	6060
ctgcccgcct	cgccccccca	aagtgtctgg	attacaggca	tgagccactg	tgcccagcct	6120
agaagaatat	tttaaatatt	tgthttaga	aggatttttt	gtgttttttt	tttttttttg	6180
acatggtctt	gctctgtctc	ctaggctgga	gtgcagcagc	ttgatcatag	ctcactgcag	6240
cctcaaaagtc	ctgggctcca	gcaatcctcc	catctcagcc	ttccaagtag	ctggggaccac	6300
aggcacacac	catcatgccc	agctaagtgg	agatgggac	ttgcaatgtt	gcccaggcta	6360
gctcaaaact	cttgggctca	aacaatcctc	ctgccttggc	ctccaaaagt	gctgggatta	6420
taggcattag	ccactgtgcc	tgccctagaa	aagtatttta	atthttactt	tgaagagtta	6480
attattttaga	aaagtgtttt	cagtaatatt	ttgtagggtga	ttttcatttt	gttggcattt	6540
tattttataat	gctgattttt	tgthtactaca	ttgaagttag	agaatatgat	ctatataatt	6600
ctgtattttca	gaatgtattg	ggatgttgag	acttttctta	tgccccaata	tgtgtgatat	6660
atthttgaaat	atthtaata	cacacatgta	gtccctatag	ggtacaattt	taataactgt	6720
gttattgtct	tattaatcac	attgctcatg	taataatcct	gtttcctttt	gaggattctg	6780
atgattgtat	ttcogtctat	ttttccatgc	atthttcttg	ctthtaactt	tttaactgca	6840
tctttttttt	tcactataaa	tttttagagg	aaatthtcca	ccacttaggg	tacatttata	6900
ttttcctttt	gatgcaagat	tttatcacia	cctcttttct	gagcttttct	caccttgtct	6960
atthttttgtg	tgthtactgat	ctthtaacaa	gogagatcca	ttcaggcaga	atggctacat	7020
ctthttactcg	cctgttttct	gtccctctct	tctcctctcc	ccagccatca	aagagctatc	7080
ttgataaact	ttaaaattat	ctthtcacaa	aggcactgtc	tttaaacaca	gaggaagaca	7140
ttcatcgggc	tttccagtcg	cttctcactg	aagtgaacaa	ggctggcaca	cagtacctgc	7200
tgagaacggc	caacaggctc	tttgagaga	aaacttgtca	gttctctca	gtaagttgaa	7260
tcaatagaac	aataaaagt	gcattcaaca	tacctggtga	tatagagtct	gggagaaaga	7320
ccctagagaa	attgagaaat	ttatgttaac	caatthtaaa	aaattgcact	atthtttttt	7380
ctaagatggg	gtctcactac	gttgcccagg	ctggtcttaa	actcctggct	tcaagtgatc	7440
ctcctgcctg	ttgggattac	agatgtgagc	caccacgccc	agcctaaact	tctttttttt	7500
tttaaaagact	gcaattctat	aattatacct	tgcttagta	ttgcaaaagt	agtctctact	7560
tttcttgaaa	ggtaaaattg	aaaggtaaaa	ttctcaagtt	catttctggt	tattcagggt	7620
tcaatacata	cctattcaca	aactctgata	ttthaacata	tcttcataatg	atcactttta	7680
aagagttatg	tatattcttt	ttattaaaaa	aagataacat	atthtagaatt	tttggaagtt	7740
tgctgacatt	tgthtttagc	aatgcagcct	cactgaacat	ttthctctcc	aaagacgttt	7800
aagggaatcct	gtcttcaatt	ctaccatgct	gagctgaagg	agctttcctt	tatcagagct	7860
gcagaagagt	ccaggaaaca	catcaacacc	tggtgtctca	aaaagaccga	aggtcagaat	7920
gacaagttat	tgacaccttc	tcccaaccgc	tctctctctc	gcggctcttc	ctattcctcc	7980
ttcccgcttc	ttctatcttc	tctctctctc	ctctctctcc	tatccctcct	ccctctctcc	8040
acccacctcc	acctttccac	tccgccccct	ctaatttcac	gggtgtttca	gatggtcaga	8100

gtagtggtga	ctggcagggc	ctcctggcat	actgaacctt	gatggactca	taaaggttct	8160
gatcagacat	tcaggttttc	agcaacagag	atctactttt	gtctattctc	ccaggaccag	8220
agtagctgat	acaaatgtca	aaagagggcc	agccacggtg	gctctcgcct	gtaatcccag	8280
caatttataa	ggccgaagtg	gacatatcac	ttgaggtcag	gagttcgaga	ccagcatgac	8340
caacatgggt	ggaccccccc	ccgcccacaa	tatttactaa	aaatacaaaa	attagccagg	8400
tgtgttgagg	catgcctgta	atcccagctg	cttgggaggc	tgagacatga	gaatcacttg	8460
aacctgggag	gcagaagtgt	tagtgagctg	agatcatgcc	actgaactcc	agcctgtctc	8520
aaaaacaaaa	accaaacaaa	aaacacaaat	gtcaaaagaa	tctcaggcca	ggtttccagt	8580
ttaataactt	gcattaaaat	atactctccc	tggcctgtaa	cattcacatg	tcagggtgact	8640
ccattgtctc	tgcgagaagg	agattggtgg	acagatcttg	cctgaggtat	acacttgggc	8700
tgcctcttcc	taggttctgg	gggacctcca	tcaccattac	ctttacctgc	taagggtcact	8760
cctgactttt	catgtcttcc	acttaagctc	cttttagttg	acttgataag	cctacatttg	8820
attggtttaac	tgccgacctt	ctctcagggc	cttcagtttc	cacagactga	aaataccctc	8880
catttggggt	tgaaccttat	tcatctacat	ttcagaaagt	gacgtgttcc	agtctaggcc	8940
tccaagacca	atgatggtct	gatgaaccat	tcagactcct	ctgcgccaat	tatgcttagt	9000
accaccagga	acatttccat	ttctgtgaat	aaatgagacg	gtaaagaatg	ggagacgttc	9060
ttcgcttaaa	gtctcagcag	ttgtttcccg	cattcctgct	tggagtatct	accacggatg	9120
ctctcttcag	gcagtggggt	agcagggatg	ccctcagttc	attgaaacag	taccacttga	9180
tctccaggga	aagaaggggt	gatctttggt	tgcccacatc	ctcttttcca	gggatgcta	9240
gtgctttggt	gaggggattc	agcaggaata	tctctcccaa	aagcttctgg	aaactcccca	9300
tgtgcccaat	ctcagctctt	cccgctttga	gccgtccatt	ctgggtgctt	ctgacatgtc	9360
catgtatagt	cacagaatgt	tagaactggg	tgtgatcatg	aagggttgga	tcaaacactc	9420
caattaacca	tgtgagacaa	acaccccttc	agcctatcac	atttcctgct	ggtcttggtc	9480
tccaacctgg	tgtaatTTTT	ctactttgta	ccaacctgct	ttcctcgagt	gacttaggta	9540
tctttcacca	tcctcaactt	ggtggatggt	ctcaagggtg	cagtaatcat	gaataccact	9600
catatgtgct	gttttttatt	ctctacataa	caacccaaac	tcagcaaagt	tgaaaacaga	9660
agtttgcttc	tcaactaatg	atccaggatc	atccaatgca	tcaggttctt	ataaaaagca	9720
actgaatgta	gtctctactt	ttcttgaaag	gtaaaattga	agagttgttg	ccgggtagct	9780
caattgatgc	agaaaccagg	ctgggttcttg	tcaatgccat	ctacttcaaa	ggaaagtggg	9840
atgaaccgtt	tgacgaaaca	tacacaaggg	aaatgccctt	taaaataaac	cagggtggggg	9900
aagcttttta	aaatcctgct	agtttgatga	agaagttgaa	tggaaagatt	taactttgta	9960
aaagtgtgaag	tgacataagc	gtaagccaaa	aggaatttga	aacttaaagt	atcttctgaat	10020
gaatttctta	actcagtaga	aaaaaacgga	aggagtataa	gatatttgct	gcataatat	10080
attatatata	cgtatatata	atatatatat	atattatgag	tgttttatca	ctgctcttaa	10140
ctgcctttga	taattttctc	taaaccattg	ctgccacctc	gttttggaag	ctaaagatct	10200
tcctataagc	ccaatttact	tggctagaaa	gcaaaaaaaa	aaaaaaaaaa	gtgttaagggt	10260
agtgtgatat	gtgggagtg	gaggcagtat	agggcagggg	agagggagag	aagggtgaaa	10320
catgtgtctt	taattagtta	tttttaaaat	ttaaagtaagt	tttatttgaa	ttgttaacta	10380
attatcatta	attcagtat	acaggctttt	aataattaaa	cttcatgaca	aagaccttag	10440
ttttgcattt	gaagtaaaac	ttaattgaag	caggcattag	aataatttgc	caaatcttcc	10500
agccccataa	aagatactat	tttaattgaa	ttaaaaaaca	aaagcaggta	accctcctgc	10560
atTTTTtgta	aggtgtactt	taacttaaaa	aaattagttc	tctagttagc	aagggtggga	10620
ggaggagaat	tctaaccctg	gttttagaac	tattttaatt	tttataataa	atgatctgta	10680
tcaatttttt	aaagtattac	gttaataaat	gtaatacttt	gctgagcttc	tatgtgctta	10740
tgcctcttct	gtattttaaa	aaagttattt	cattagagta	tcagaattga	aaagattggg	10800
ttaaaataca	ttactacata	tgtaggctgt	tactcttctc	gagagagtgt	atccatttat	10860
actccctgtc	atgctgttgt	ggaactataa	gtttcatccc	actttatgat	tttttttctc	10920
atatgttggt	ttggataaat	aggaaaaaca	atacacattt	ttttctaat	aaatcaaaac	10980
aaatttgat	ttaatctcat	ttgattatat	tgtcttctta	gatctatttg	ctgagcacia	11040
tttaaattgag	aaacatcttt	ctcctctgga	aaatgtaggg	tatcacattt	tattttgcag	11100
aagaaaacct	ttcccagggt	ggtactgtgt	ctgcttgcaa	tgaagatagg	aaggaaactgg	11160
ttgacttttt	tttttttttt	tttttttttt	tttttttagt	ttaactgggg	catgaatgtg	11220
gcgggtttcca	tcacagggtc	tgaaaacact	cttggaggca	actgcagctc	ttttgaaagt	11280
tttaattgct	tctttcaata	atccttcccc	caggaggagc	aaaggcccagt	gcagatgatg	11340
tatcaggagg	ccacgtttta	gctcgccac	gtgggcgagg	tgcgcgcgca	gctgctggag	11400
ctgccctacg	ccaggaagga	gctgagcctg	ctggtgctgc	tgcctgacga	cggcgtggag	11460
ctcagcacgg	taagaccctg	gctgcgggaa	gaacccaggg	acacctttgc	gggcagaact	11520
cgagtgccac	ttccacctct	catattcacc	ttctgagttg	gcgatgcggc	agacgcacac	11580
tgtgcaggca	cttggcggtg	ggatcgaact	tttgttcaag	gctgactttt	cccaatattg	11640
tctgcgtgat	ctgcctaaact	acacatctca	gtcctctgtt	ttttcatcgc	tagaaggagt	11700

gggcgccggt	taaaatgcct	tttaaaataa	atcaggtagg	aggaagctta	taaaaatcct	11760
gctagtttga	tgaatggcag	actttttaact	ctaaaagcat	aaatgactgc	tcgggggttat	11820
tgccctcctag	agttatgatg	aggataaaat	gtgggtaatt	caggtaacaa	gcttaccaca	11880
ttgcctggca	actagtaaat	gctctacaaa	tgtgatccat	tattacaatc	atcattctta	11940
gcattatgct	tttaaagtct	aggaacctga	aatagagaat	gaggaagtct	taactttgac	12000
ctaacaaggc	tgggaggggg	catccaggga	ggtgtgaagt	ccagttctca	gagggtggga	12060
ccagaggcag	cctctgaggg	cacatccagg	cactcggctt	cctttcagca	tggatctcca	12120
gggtgagaga	gtcaacctag	gcaaatggca	ggcagtggga	ccccatgact	taagaggtct	12180
gtgtgcgcag	cagccattgg	ctctccctct	gcccaccttc	ctgaaactat	gctccggaaa	12240
ctatgcagaa	tctctctggg	gcagataatc	ctctggtaac	ctctctgctc	cggaaactat	12300
gcagaatctc	acctgggaca	gataatcctg	ttggagtgcc	tcacactgag	agccctttcg	12360
tttccaatcc	ttttctttac	tagcaatggt	ttgttgtctt	taaaaagact	atgtttgaaa	12420
aaaaaacaca	gtcgccctggg	cattgacact	tgtcacataa	caagatgtct	ctggagttgt	12480
tggataaggc	gaggacagcc	acagccctcc	tgcctctgac	tgcttggtgt	ctctccccc	12540
tgtcaaggaa	gtggcacatg	ggacatagga	caagtaagag	tgctcacaa	cttctggcag	12600
atgaaggggc	cactgaccc	atgtgaacaa	acaacaccta	cgtgcaagg	gaggaaggga	12660
actgtgagtg	cctgtgcgct	tgtacatgtg	cactgaagtc	ggaatcttaa	agtctaattc	12720
tgggtctttca	ggtggaaaaa	agtctcactt	ttgagaaact	cacagccctg	accaagccag	12780
actgtatgaa	gagtactgag	gttgaagttc	tccttccaaa	atttaacta	caagaggatt	12840
atgacatgga	atctgtgctt	cggcattttg	gaattgttga	tgccttccaa	cagggcaagg	12900
ctgacttgct	ggcaatgtca	gcggagagag	acctgtgtct	gtccaagttc	gtgcacaaga	12960
gttttgtgga	ggtgaatgaa	gaaggcaccc	aggcagcgcc	agcgctgagc	tgctttgtag	13020
ttgcagagtg	ctgcatggaa	tctggcccca	ggttctgtgc	tgaccaccct	ttccttttct	13080
tcatcaggca	caacagagcc	aacagcattc	tgttctgtgg	caggttctca	tcgccataaa	13140
gggtgcactt	acogtgcact	cggccatttc	cctcttcctg	tgtccccaga	ccccactac	13200
agctccaaga	ggatgggcct	agaaagccaa	gtgcaaagat	gagggcagat	tctttacctg	13260
tctgcccctac	tgatttgcca	gcataaattc	atgatgctcc	acactcgctt	atgctactta	13320
atcagaatct	tgagaaaata	gaccataatg	attccctgtt	gtattaaaa	tgcagtccaa	13380
atcccatagg	atggcaagca	aagtctctct	agaattccac	atgcaattca	ctctggcgac	13440
cctgtgcttt	cctgacactg	cgaatacatt	ccttaaccgc	ctgcctcagt	ggtaataaat	13500
ggtgctagat	attgctacta	ttttatagat	ttcctgggtc	ttagccttat	aaaaaaggtt	13560
gtaaaatgta	catttatatt	ttatcttttt	tttttttttt	tttctgagac	gcagtctggc	13620
tctctgtcgc	ccaggctgga	gtgcagtggc	tcgatctcgg	ctcactgcaa	gctccgcctc	13680
ccggggtcac	gccattctcc	tgcctcagcc	tcccagtag	ctgggactac	aggcgccgcg	13740
caccacgccc	ggctaatttt	ttgtattttt	agtagagacg	gggtttcacc	gtgttagcca	13800
ggatggtgtc	gatctcctga	cctcgtgatc	caccgcctc	ggcctcccaa	agtgtgggga	13860
ttacaggctt	gagccaccgc	gcccggctat	attttatctt	ttatcttttt	ctttgacatt	13920
taccaatcac	caagcatgca	ccaaacactg	cttttaggcac	tggggacaca	aaggggacag	13980
agccatcctc	ctttgacacc	tggtcttcag	ttctgtgccc	aacgtatata	gttttgacaa	14040
tgaccagggt	ggactgttta	atgtctttca	acttaccacg	taatcctctt	gtagggatca	14100
catctttctt	tatgatattg	tatttctcta	cctctaacag	taaaaattcc	attcaacctt	14160
taaagctcac	ttcaaattct	tctttgagaa	gtttttcctt	tctccgcaac	cagatgtaca	14220
tatttgaact	ctctttgtac	ttggagggca	cttctttcgt	ggtagttctt	ttatttttat	14280
taatctctgt	atccttagat	agtctcccaa	caaccaaagg	ttgggactct	gtcttacata	14340
tctgggtgcc	cctcatagtg	cagtaataag	taagttgatt	atatacgagc	tatgtaactt	14400
atatttttta	atgggttgat	atcactgagt	tttttttttt	aagaattttt	ttattgaggt	14460
aaacttcaca	taacataaaa	ttaactattt	taaagtgaga	agttcagtcg	cacttagtat	14520
tgttaacaat	gttgcataac	caccaccttt	atttaaaagt	ccaaaaaaa	tgttctctc	14580
taaaaggaaa	ccccatccca	ttaagcagat	actctccatt	ccttccctcc	tccagcccc	14640
agcaaccacc	aatctgcttt	ctgtctctat	ggatttatct	attcttgcta	ttttatataa	14700
attgaattgt	atgagacctt	tttgtgtctg	cttctttcac	ttagtacaag	tttttgagat	14760
ttattttacat	agtagcatgt	atcaacactt	cattttttat	gccaaataaa	attgtattat	14820
gtgttttatag	cacaatttat	ttatccactc	attcattgat	ggactttggg	ttgtttctga	14880
cttttggtcta	ttgggaatag	tgtgtctatg	aatgtttgtg	tacctgtatt	tgtttgaaat	14940
cctatttttgc	attctcttgg	gtatatatct	aggagtggaa	ctgctgggtc	atatgttaat	15000
tctatgttta	gcttttttgag	gaacagacaa	actgttttcc	acagcagttg	aaccattcca	15060
cattcccacc	agcaatgtat	gagaattcca	atctctgtcc	acttcctcac	caacacttat	15120
tatttttctt	ttcctttttt	taaaaaaaat	aagttatggc	catcttagtg	ggtgtgaagt	15180
ggtatctcat	tgtgtttttt	atttgcattt	cctatgtaat	gagctagaaa	ctaaagtaca	15240

310

aactagatgg	gacatccagt	ccctttgata	gataatgctg	agtaaaaaat	gagatgaaag	15300
acatttgttt	gttttttagaa	cacgagtgc	agtttgttaa	aaagcttttag	aggagggaatg	15360
aaaacaaagt	gaagtacact	tagaaaagg	ccaagtggac	atcttggatg	tcaagtgcct	15420
agttcagtat	cttttttttt	tttttttttt	tttttgagac	agtgcctcac	tctgtcaccc	15480
aggctggagt	gtagtggcat	gatctgggct	caactgcaacc	tcctcctcct	ggattcaagc	15540
aattctcttg	cttcagcctc	ccaagtagct	gagactacaa	gcaccaccca	tcacaccag	15600
ctaattttgt	atttttcagt	agagacggg	tttcgccaca	ttggccgtgt	tggctctgaa	15660
ctcctggcct	caagcgatcc	gcctacctca	gcctcccaaa	gtgctaggat	tacaggcata	15720
agccactgag	cccagcccta	gttcagtatc	ttttatgtaa	attacaaaca	tctgcaacat	15780
tatgtatcat	atgcagatac	ttattgcatt	tcttttatta	gtggtgaaag	tgttctatgc	15840
atattattggc	tcttgaattt	cctcatctat	gaattgtcat	tcatacacct	acttttctgc	15900
ttcgttttta	catatgtctt	tgcctattaa	agatattatc	cctctgtttt	atattttctc	15960
tcatctctgt	attgcctttt	aaattttgtt	atgatgtttc	attaataaac	agtgttttgt	16020
tttcctctat	aatcaaaa					16037

&lt;210&gt; 400

&lt;211&gt; 16107

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 400

cgcgccgagc	gcagcagcag	ggcggggtcc	tgcgcctcgg	gggtcggcgt	ccaggctcgg	60
agcgccgac	ggagacggcg	gcagcgctgg	actaggtggc	aggtgagggc	gtccccgcgc	120
acggctgggg	taggggacgg	gagtggcgag	cttcaggtcc	accggctgcc	accgagtgat	180
gggaccggag	gacaggagag	gtcgctcagc	caagagcccc	ggggaggcgg	tgccttctcg	240
gtggggctag	caacggctct	tggggggtgc	ctgggagcgg	cagccggctc	ccgccttggc	300
ggcccacagc	caccgcggac	gcctccctcc	cggatgtctc	ctcgtcgccc	tccctggcc	360
gaagccctcc	cctgcagcct	cctccccacc	tgcggccct	gtgttctcac	tgtcttctc	420
tgtcttggga	tccgcaggat	gacgtctgtc	ctgcttcttc	actgtccttt	acagtcacca	480
gtctcggccg	ggcgagtg	ctcacgcctg	taatcccagc	actttgggag	gccaaggcgg	540
tccgatcctt	ggagatcagg	agttcgagac	cagtctggca	aacgtggtga	aaaccggtct	600
ctactaaaaa	tacagaaatt	agccgggcat	ggtggcccac	gcctgtaata	atgtcagcta	660
tgtgttgagg	caggaaaaatc	acttcaactc	gggaggcaga	ggttgagtg	agctgggatt	720
gcgccactgc	actccagcct	ggcagacaga	gtgagacttc	gtctcaaaac	aaaaaaaaga	780
aaaacacaaa	aaaaccacca	ccaacaacaa	caaaaaata	aagccaccag	tctcgagatt	840
tcaaatctga	gcactcttat	ccatcttaat	tctttcaata	attcagctaa	acgaatgggg	900
tcttgagaat	ctgcagagcc	aggctcagcg	ctcgcctgca	gagcctgcgg	tctgtgggga	960
ccaccagcaa	gatgaggaat	caccttcggg	aggaagggtc	gtgctgggga	gggtcgcgcc	1020
ggcgggggtca	agagaacctc	ctccagggtg	ggaatcagag	cctccggggc	gcgggtgttg	1080
agggtagagt	gaattaatgc	cgtgatggac	atggggcctt	ctaaggggga	ccaacagtgt	1140
ttgtgaagag	ttgactttgg	gaggggttca	ggatggccag	aggtggaggc	tgtgacctca	1200
gtgaggctgg	atcaagggag	ggggcaggtg	ggtaagacac	cgttttaaca	aggtggcttt	1260
gagcggccac	ctttgagggg	cctaagggcc	cctgggagat	ttaggaggaa	ggacaagagg	1320
attaagacac	cgttttctga	ggtgctgtgt	ggctgtggcg	tgggggtggc	tgggggagtg	1380
ggttgtgttc	attgtccaag	gctctccagc	gctttgctgt	gcgttttggg	gagcacagat	1440
gaggtgtccc	gacagtgggg	agtggctcta	gggagaccag	aggctcggga	gggggcctgg	1500
gcattagacc	aggcacagaa	tccgaagtgg	gaagaaatgt	gggcgtagag	ggcaggcctt	1560
ggggatgggt	gtgggggagg	agggggagat	ggaaaggagt	cagggaggtc	tcccaggctc	1620
acctggagga	gtcagggtct	catttccaag	tgcactggga	actgcagcct	gggggtgggg	1680
gttcattttg	tttcaggcct	gtggccaaga	gacccacccc	ctcacattca	cacttttggtc	1740
tccagtggct	tcacaggcac	cacctccttg	ttctcgctgt	ttttactcct	caccttgggc	1800
tgtttcttgc	ctttccattc	tggcgctctg	cagggatcag	atccttcctc	tcacgcacaa	1860
tctacactca	tggcttttgc	tgggagtaat	gagtaaaagt	cccaaataga	tgtttctgag	1920
ttaggaagag	cattaaaaac	aaaacaaaac	gaagcaaaac	cacacaattg	tccaagtccc	1980
actctgtgtt	caagggtcac	atgatgtgca	gaagctgggt	atgggcagga	gctctgaatg	2040
gagttactgg	gatgtcaggc	cgcgtgggcc	tggggcaggc	tggctgactg	ggagcagcct	2100
ggctccaccc	cggctgtcca	ggacgcactc	acttgcctct	atggatgaca	gctccttgcc	2160
tcacagctgt	ctgtctctgg	gtcagattca	gcattctcagt	gtcttttgtg	tatcagctga	2220
atgtcagggg	ggccacaggc	tgggtgcccg	ttgaaaatct	cacaaggact	ctttgtaaat	2280
gcatgcaaga	ataagaacag	cattttcctc	ctcctccctg	acccatttct	cctcctcaga	2340



311

tgggacgac	tggtccttac	ggaaagaatt	ggagttcact	gcttccagct	ctgtgtgtgt	2400
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgagaga	gagcgagctc	tgcaggcgag	2460
ccagttctgt	tgtatttgt	ggtttgagct	gctgccatca	ccacacttag	ctaattacct	2520
taacatttgc	acttaatttt	tggccggaga	ctaacagaaa	ataaattttt	ctccaattta	2580
aaatacttac	gaactttaag	aagaaaacaa	aaagtacgat	tccaaaattg	ccctgtagta	2640
agtaggtcag	taacattcag	ggagtgtgga	aaactgcattt	ctctttatct	ttcccttcca	2700
ggccctgcat	catggaaact	ctttctaatg	caagtgttac	ttttgccata	cgccttttaa	2760
agatactgtg	tcaagataac	ccttcgcaca	acgtgttctg	ttctcctgtg	agcatctcct	2820
ctgccctggc	catggttctc	ctaggggcaa	agggaaacac	cgcaaccag	atggcccagg	2880
taagcttgcc	cgtccgccag	gagcagggac	tggcctgggc	tgcgtgttct	gtcaccagct	2940
tcacactcac	actccagagc	cactgagaaa	ggagggcagg	actggggccc	gagtgtgcac	3000
tggcagcttc	agggagggc	ggccactgg	ggaagaagtg	gggcagggca	gggaggcagg	3060
aactctgtct	caccgagatt	tatttggggg	aaactttcct	cggttaatcc	cttggaaaag	3120
accatccaag	ctgtcttgtc	ctagcgcaga	atctttcttt	agaaaatgac	actgaaatta	3180
tttgaaacat	aagttgcaaa	gaactacctc	ttttttggag	caagagactt	tgtaaactaa	3240
ctttcattgg	taaggaaggt	taatacctgt	ttcaagttgt	ttctgtacca	acagctcagg	3300
gagggcatca	acagaaatth	gcaagaagga	ttccagggca	agtgttctat	tacagctgca	3360
cactgtgcac	gtactgtcca	gctcagtctc	accaacattc	agagaacctg	tggaaatgat	3420
tcaagatcag	tgcttgtccc	cagacctttg	tggaaaggag	aggagacata	cacgtgagat	3480
gaaaccgaaa	agcgcctatcc	ctgagtgcag	gccgctggac	acgccttcat	catgggagtt	3540
gtcctttgtt	caatatgact	gtctttttct	ttgatgagc	ttttcaatag	tgaattactc	3600
attttaataa	tttccagct	cattgtgtga	agaagggagg	gtttatgtgt	aaaggctacc	3660
agccttaata	ataagcacag	agaggctctc	taaaagatat	atatatttgg	aaatagggca	3720
ttgcaatgaa	aatacgcag	ccatggcaag	ctatgtgcac	attcaggggag	gtgaaataac	3780
actaagattt	ttaaaggaaa	aagtaaagag	gattacataa	ttcctttgaa	ataattatth	3840
ttggcaaaaa	gatcaataac	gaagggtgat	tcagtgtgag	gttggatggg	gagttcattg	3900
gtagatgtcc	ttgcacaagt	attttgttgt	gtaaggctgt	gatggccttt	gtgcaagagc	3960
gtagggtttt	agagtccctt	gtgatagtgt	tggtatcagg	cattcaagcg	tgagaacctc	4020
ctcttcatgg	ccttccctgt	ctgtttgtca	aaggtttttg	gttttgtttt	tttaataatta	4080
gtgactccat	tttgattctg	aagttccctta	tgctgaaatc	tgtatgatct	ttttctatgt	4140
tttaggctca	ctgataaacc	cttatagaaa	gcttttttga	gagcaccaaa	attgtctggg	4200
tacttcttta	ggtgtgagac	tgagctctct	ccatggctcc	agtgttcaac	tggatgcttg	4260
tgagacacca	aacataactga	gtacacgttg	ctacctgtaa	catgcaggga	agcgttaattg	4320
gcagcagaaa	tatttttaag	aattattttat	ttttccttca	ttatataact	ggtaaaagtc	4380
cactataaaa	attttttaaaa	aataaaaagta	gaaggaggga	aaaaatccct	atgaatccat	4440
caaacagaga	caaccaccct	tgataatgta	aagcatcttc	ctccagtcct	atttcttttt	4500
ttttttttcg	agacagagtc	ttgctctgtc	gccaggctg	gagtgcagtg	gtgcgatctc	4560
agcttaactgc	aagctccacc	ccccgagttc	acaccattct	tccacctcag	cctcccgagt	4620
agctgggact	acaggtgccc	gcccccacgc	ccagctaat	tttattttta	gtagagacag	4680
ggtttcaactg	tgttagtcag	gatggtctcg	atcacctgac	ctcgtgatec	acccgccttg	4740
gcctcccaaa	gtgctgggat	tacaggcgtg	agccactgag	cccggcccta	tttctgatt	4800
ttcacttgac	attttgtact	ttggtgatta	tatggtatct	ttacttttat	aaatgatttt	4860
tcagctaattg	tgaggattcg	gtgagacagt	ccatgtaaa	caagtgtctca	acatgtgttg	4920
gctatgaata	gtaatagtgg	tgtcacagcc	tcaggtgaaa	ctgggtcttag	cttttggttc	4980
tgttctattt	gacagggttt	ctcatcaaca	gtctatgagc	tgtctaaagt	aaatttagta	5040
gcttctctct	ttttctatgt	tatagaacag	tgtgtattgc	atgagaaaata	gaaattgctt	5100
gaatattaga	aaaaaaaaatc	cctcaaaaaga	tcacttaagc	cttttttagaa	gtaattctct	5160
ctctccctct	tatttttttt	ttgttcattc	attgtgactg	atagattctg	ttttttgttt	5220
gttttggttg	ttttgttttg	ttttttgaga	tagagtatct	gctctgtcac	ccaggctgga	5280
gtgcagtggt	gctatctcag	ctcactacga	cctccaactc	ccgagttcaa	gttcacgtga	5340
ttctcctgcc	tcagcctccc	gagtagctgg	gattacaggc	acatgtcacc	atgcctggct	5400
agtattcata	tttttgactg	gcatttggtg	acttaataatc	tgtactttac	tgaaaaaat	5460
tatatagagt	ttttgtttta	acattccctt	tgtttatatt	gctgtaacct	ctttttcaca	5520
tataacttta	ctttgggggtg	ctttttctta	catgtgggtg	gtggctgtct	gttttgatg	5580
tatgtgtgtt	ttcttttaaa	gaaccagctc	ttggattcat	tgatcatttt	gtgtttgtcc	5640
caaaaattcct	tgggagtttt	tctgtatctt	ttctaacata	atgattttta	agtttttagca	5700
ttttattact	ttcttggtaa	tattgaaaac	aatgctatgt	tttaacttat	ctttggccaa	5760
actctttggg	ctaataatata	tcaccatatt	tttgattatt	ttctaaatca	tatgtcatat	5820
acttatttag	aagaaattgt	ttgtttgttt	gttttttgag	aaggagtctt	gctctgttgc	5880
ccaggctgga	gtgcagtggt	atgaccttgg	ctcactgcaa	cttccgcctc	ctgggttcaa	5940

gtgattctcc	tgccctcagcc	tcccaagtag	ctgggattac	cagcaagcat	caccacaccc	6000
ggctaatttt	cgtattttta	gtagagacag	gatttcgcca	tcttgccag	gctggctctg	6060
aactcctgac	ctcaagtgat	ctgcccgcct	cgcccccca	aagtgctggg	attacaggca	6120
tgagccactg	tgcccagcct	agaagaatat	tttaaataat	tgtttagaag	aggatttttt	6180
gtgttttttt	tttttttttg	acatggctct	gctctgtctc	ctaggctgga	gtgcagcagc	6240
ttgatcatag	ctcactgcag	cctcaaagtc	ctgggctcca	gcaatcctcc	catctcagcc	6300
ttccaagtag	ctgggaccac	aggcacacac	catcatgccc	agctaagtgg	agatgggatc	6360
ttgcaatggt	gcccaggcta	gcctcaaact	cttgggctca	aacaatcctc	ctgccttgge	6420
ctccaaaagt	gctgggatta	taggcatgag	ccactgtgcc	tggcctagaa	aagtatttta	6480
atttttactt	tgaagagtta	attattttaga	aaagtgtttt	cagtaataat	ttgtaggtag	6540
tttttcattt	gttggcattt	tatttataat	gctgattttt	tgttactaca	ttgaagttag	6600
agaataatgt	ctatataatt	ctgtatttca	gaatgtattg	ggatgttgag	actttttctt	6660
tggtcccaata	tgtgtgatat	attttgaaat	atttaataata	cacacatgta	gtccctatag	6720
ggtacaattt	taataactgt	gttattgtct	tattaatcac	attgctcatg	taatatcctt	6780
gtttcctttt	gaggattctg	atgattgtat	ttccgtctat	ttttccatgc	attttttctg	6840
cttttaactt	tttaactgca	tctttttttt	tcactataaa	tttttagaggt	aattttccca	6900
ccacttaggg	tacattttata	ttttcctttt	gatgcaagat	tttatcacia	cctcttttct	6960
gagctttttt	cacccttgte	atttttttgt	tgttactgat	ctttaaacaa	gcgagatcca	7020
ttcaggcaga	atggctacat	cttttactcg	ctctgtttct	gtccctctct	tctcctctcc	7080
ccagccatca	aagagctatc	ttgataactt	ttaaaattat	ctttcacac	aggcactgtc	7140
tttaaacaca	gaggaagaca	ttcatcgggc	tttccagtgc	cttctcactg	aagtgaacaa	7200
ggctggcaca	cagtacctgc	tgagaacggc	caacaggctc	tttgagagaga	aaacttgta	7260
gttccctctca	gtaagttgaa	tcaatagaac	aataaaagtt	gcattcaaca	tacctgggtga	7320
tatagagtct	gggagaaaaga	ccctagagaa	attgagaaat	ttatgttaac	caatttaaaa	7380
aaattgcact	attttttttt	ctaagatggg	gtctcactac	gttgcccagg	ctggctctaa	7440
actcctggtc	tcaagtgate	ctcctgcctg	ttgggattac	agatgtgagc	caccacgccc	7500
agcctaaact	tctttttttt	tttaagact	gcaattctat	aattatacct	tgcattagta	7560
ttgcaaaagt	agtctctact	tttcttgaaa	ggtaaaattg	aaaggtaaaa	ttctcaagtt	7620
catttctggt	tattcagggt	tcaatacata	cctattcaca	aactctgata	ttttaacata	7680
tcttcatatg	atcactttta	aagagtatat	tatatctctt	ttattaaaaa	aagataacat	7740
atttagaatt	tttggaagtt	tgtgacatt	tgtatttagc	aatgcagcct	cactgaacat	7800
ttttctctcc	aaagacgttt	aaggaatcct	gtcttcaatt	ctaccatgct	gagctgaagg	7860
agctttcctt	tatcagagct	gcagaagagt	ccaggaaaca	catcaacacc	tgggtctcaa	7920
aaaagaccga	aggtcagaat	gacaagttat	tgcaccttcc	tcccaaccgc	tcctcctcct	7980
gcggctcttc	ctattcctcc	ttcccgctcc	ttatatectc	tctcctcctc	ctcctcctcc	8040
tatccctcct	ccctctcctc	acccacctcc	acctctccac	tccgccccct	ctaatttcac	8100
gggtgtttca	gatggtcaga	gtagtgttga	ctggcagggc	ctcctggcat	actgaacctt	8160
gatggactca	taaaggttct	gatcagacat	tcagggtttc	agcaacagag	atttactttt	8220
gtctattctc	ccaggaccag	agtagctgat	acaaatgtca	aaagagggcc	agccacgggtg	8280
gctctcgcct	gtaatccag	caatttagaa	ggccgaagtg	gacatatcac	ttgaggtcag	8340
gagttcgaga	ccagcctgac	caacatgggt	ggaccccccc	cccccaacat	ctctactaaa	8400
aatacaaaaa	ttagccaggt	gtggtggccc	atgcctgtaa	tcccagctgc	ttgggaggct	8460
gagacatgag	aatcacttga	acctgggagg	cagaagttgt	agtgagctga	gatcatgcca	8520
ctgaactcca	gcctgtctca	aaaacaaaaa	acaaacaaaa	aaacaaatgt	caaaagaatc	8580
tcaggccagg	tttccagttt	aataacttgc	attaaaaat	actctcctct	gcctgtaaca	8640
ttcacatgtc	aggtgactcc	attgtctctg	cgagaaggag	attgggtggac	agatcttgcc	8700
tgagggtatac	acttgggctg	cctcttccta	ggttctgggg	gacctccatc	accattacct	8760
ttacctgcta	aggtcactcc	tgacttttca	tgtcttccac	ttaaagctcct	ttagtttgac	8820
ttgataagcc	tacatttgat	tggttaactg	ccgacctctc	ctcagggtctg	atcagttcca	8880
cagactgaaa	ataccctcca	tttgggggtg	aaccttatct	atctacattt	cagaaagtga	8940
cgtgttccag	tctaggcctc	caagaccaat	gatggctctga	tgaaccattc	agactcctct	9000
gcgcgaatta	tgtctagtac	caccaggaac	atttccattt	ctgtgaataa	atgagacggt	9060
aaagaatggg	agacgttctt	cgcttaaggt	ctcagcagtt	gtttcccgca	ttcctgcttg	9120
gagtatattac	cacggatgct	ctcttcaggc	agtgggttag	cagggatgcc	ctcagttcat	9180
tgaacagta	ccacttgatc	tccagggaac	gaaggggtga	tctttgtttg	cccacatcct	9240
cttttccagg	gatgcctagt	gctttgttga	ggggattcag	caggaatatc	tctccaaaaa	9300
gcttctggaa	actccccatg	tgcccaatgt	cagctcttcc	cgctttgagc	cgctccattct	9360
gggtgcttct	gacatgtcca	tgtatagtca	cagaatgtta	gaactgggtg	tgatcatgaa	9420
gggttggtgc	aaacactcca	attaacctcc	tgagacaaac	accccttcag	cctatcacat	9480
ttcctgctgg	tcttgttctc	caacctgggtg	taatttttct	actttgtacc	aacctgcttt	9540

313

cctcgagtga	cttaggtatc	tttcaccatc	ctcaacttgg	tggatgttct	caaggtgtca	9600
gtaatcatga	ataccactca	tatgtgctgt	ttttatttct	ctacataaca	acccaaactc	9660
agcaaagtgt	aaaacagaag	tttgcttctc	aactaatgat	ccaggatcat	ccaatgcatc	9720
aggttcttat	aaaaagcaac	tgaatgtagt	ctctactttt	cttgaaaggt	aaaattgaag	9780
agttgttgcc	gggtagctca	attgatgcag	aaaccaggct	ggttcttgtc	aatgccatct	9840
acttcaaagg	aaagtggaa	gaaccgtttg	acgaaacata	cacaaggga	atgcccttta	9900
aaataaacca	gggtggggaa	gcttttttaa	atcctgctag	tttgatgaag	aagttgaatg	9960
gaaagattta	actttgtaaa	agtgtaaagt	acataagcgt	aagccaaaag	gaatttgaaa	10020
cttaaagtat	ttctgaatga	atltcttaac	tcagtagaaa	aaaacggaag	gagttaaaga	10080
tatttgctgc	atatatatat	tatatatacg	tatatataat	atatatatat	tatatatacg	10140
tatatatata	tatttatatat	atatacgtat	atataatata	tatatatata	tgtagtgttt	10200
tatcaactgc	cttaactgcc	tttgataatt	tctcataaac	cattgctgcc	acctagtttt	10260
ggaaactaaa	gatcttccta	taagcccaat	tctactggct	agaaagcaaa	aaaaaaaaaa	10320
aaaagtgtta	aggtagtgtg	atatgtggga	gtgagaggca	gtatagggca	gggtagaggg	10380
agagaaggtg	aaaacatgtg	tctttaatta	gttattttta	aaattaaagt	aagttttgat	10440
ttgaattgtt	aactaattat	cattaattca	gtattttacag	ctttttaata	ttaaaacttc	10500
atgacaaaaga	ccttagtttt	gacattgaag	taaaacttaa	ttaaggcagg	cattagaata	10560
atttgccaaa	tcttcagacc	cctaaaaaga	tactatttta	atgcaattaa	aaaacaaaag	10620
caggtaaccc	tctgcattt	tttgtaaggt	gtactttaac	ttaaaaaat	tagttctcta	10680
gttgcaaaagg	gtgggaggag	gagaattcta	accctgggtt	tagaactatt	ttaattttta	10740
taataaatga	tctgtatcaa	ttttttaaag	tattacatta	ataaatgtaa	tactttgctg	10800
agcttctatg	tgttatgcc	tcttctgtat	tttaaaaaag	ttatttcatt	agagtatcag	10860
aattgaaaag	attgggttaa	aatacattac	tacatatgta	ggtcgttact	ctttctgaga	10920
gagtgtatcc	atttatactc	cctgtcatgc	tgttgtggaa	ctataagttt	catcccactt	10980
tatgattttt	tttctcatat	gttgggttgg	ataaatagga	aaaacaatac	acattttttt	11040
ctaattaaat	caaaacaaat	ttgtatttaa	tttcatttga	ttatatgtgt	ttcttagatc	11100
tatttgctga	gcacaattta	aatgagaaac	atctttctcc	tctggaaaat	gtagggtatc	11160
acattttatt	ttgcagaaga	aaacctttcc	cagggtgtga	ctgtgtctgc	ttgcaatgaa	11220
gataggaagg	aactgggtga	cttttttttt	tttttttttt	tttttttagt	ttaactgggg	11280
catgaatgtg	gcggtttcca	tcacagggtc	tgaaaacact	cttggaggca	actgcagctc	11340
ttttgaaagt	tttaattgcg	tctttcaata	atccttcccc	caggaggagc	aaaggccagt	11400
gcagatgatg	tatcaggagg	ccacgtttaa	gctcgccac	gtgggcgagg	tgcgcgcgca	11460
gctgtggag	ctgccctacg	ccaggaagg	gctgagcctg	ctggtgctgc	tgcttgacga	11520
cggcgtggag	ctcagcacgg	taagaccggg	gctgcgga	gaaccagg	acacctttgc	11580
gggcagaact	cgagtgcac	ttccacctct	catattcacc	ttctgagttg	gcgatgcggc	11640
agacgcacac	tgtgcaggca	cttggcggtg	ggatcgaaact	tttgttcaag	gctgactttt	11700
cccaatattg	tctgctgat	ctgccaaact	acacatctca	gtcctctgtt	ttttcatcgc	11760
tagaaggagt	gggcggcggt	taaaatgcct	tttaaaataa	atcaggtagg	aggaagctta	11820
taaaaatctt	gctagtttga	tgaatggcag	acttttaact	ctaaaagcat	aaatgactgc	11880
tcggggttat	tgcttcctag	agttatgatg	aggataaaat	gtgggttaatt	caggtaacaa	11940
gcttaccaca	ttgcctggca	actagtaaat	gctctacaaa	tgtgatccat	tattacaatc	12000
atcattctta	gcattatgct	tttaaagtct	aggaacctga	aatagagaat	gaggaagtct	12060
taactttgac	ctaacaaggc	tgggaggggg	catccaggga	ggtgtgaagt	ccagttctca	12120
gagggtggga	ccagaggcag	cctctgaggg	cacatccagg	cactcggctt	cctttcagca	12180
tggatctcca	gggtgagaga	gtcaacctag	gcaaattggca	ggcagtggga	ccccatgact	12240
taagaggtct	gtgtgcgag	cagccattgg	ctctccctct	gccaccttc	ctgaaactat	12300
gctcggaaa	ctatgcagaa	tctctctggg	gcagataatc	ctctggtaac	ctctctgctc	12360
cggaaactat	gcagaatctc	acctgggaca	gataatcctg	ttggagtggc	tcacactgag	12420
agccctttcg	tttccaatcc	ttttctttac	tagcaatggg	ttgttgtctt	taaaaagact	12480
atgtttgaaa	aaaaaacaca	gtcgccctggg	cattgacact	tgtcacaata	caagatgtct	12540
ctggagttgt	tggataagga	gaggacagcc	acagccttcc	tgcctctgag	tgttgggtgt	12600
ctctccctct	tgtcaaggaa	gtggcacatg	ggacatagga	caagtaagag	tgtctcacaag	12660
ttctctggcag	atgaaggggc	cactgatcct	atgtgaacaa	acaacaccta	cgtgcaagg	12720
gaggaaggga	actgtgagtg	cctgtgcgct	tgtacatgtg	cactgaagtc	ggaatcttaa	12780
agtctaattc	tgggtctttca	gggtggaaaa	agtctcactt	ttgagaaact	cacagcctgg	12840
accaagccag	actgtatgaa	gagtactgag	gttgaagtgc	tccttccaaa	atttaacta	12900
caagaggatt	atgacatgga	atctgtgctt	cggcatttgg	gaattgttga	tgccttccaa	12960
cagggcaagg	ctgacttgct	ggcaatgtca	gcggagagag	acctgtgtct	gtccaagtct	13020
gtgcacaaga	gttttgtgga	ggtgaatgaa	gaaggcagg	aggcagcggc	agcgtcgagc	13080
tgctttgtag	ttgcagagtg	ctgcattgaa	tctggcccca	ggttctgtgc	tgaccacctt	13140

314

ttccttttct	tcatacaggca	caacagagcc	aacagcattc	tgttctgtgg	caggttctca	13200
tcgccataaa	gggtgcactt	accgtgcact	cggccatttc	cctcttcctg	tgtecccaga	13260
tccccactac	agctccaaga	ggatgggccc	agaaagccaa	gtgcaaagat	gagggcagat	13320
tccttacctg	tctgccctca	tgatttgcca	gcatgaattc	atgatgctcc	acactcgctt	13380
atgctactta	atcagaatct	tgagaaaata	gaccataatg	attccctggt	gtattaaaaa	13440
tgcatgccca	atcccatagg	atggcaagca	aagttcttct	agaattccac	atgcaattca	13500
ctctggcgac	cctgtgcttt	cctgacactg	cgaatacatt	ccttaaccgg	ctgcctcagt	13560
ggtaataaat	ggtgctagat	attgctacta	ttttatagat	ttcctgggtg	ttagccttat	13620
aaaaaaggtt	gtaaaatgta	catttatatt	ttatcttttt	tttttttttt	tttctgagac	13680
gcagtctggc	tctctgtcgc	ccaggctgga	gtgcagtggc	tcgatctctg	ctcactgcaa	13740
gctccgcctc	ccgggttcac	gccattctcc	tgccctcagc	tcccagtagt	ctgggactac	13800
agggcggcgc	caccacgccc	ggctaatttt	ttgtattttt	agtagagacg	gggtttcacc	13860
gtggttagcca	gatttggtgc	gatctcctga	cctcgtgac	caccgcctc	agcctcccaa	13920
agtgtctggg	ttacaggcct	gagccaccgc	gcccggctat	attttatctt	ttatcttttt	13980
ctttgacatt	taccaatcac	caagcatgca	ccaaacactg	ctttaggcac	tggggacaca	14040
aaggggacag	agccatcctc	ctttgacacc	tggtcttcag	ttctgtgccc	aacgtatata	14100
gttttgacaa	tgaccagggt	ggactgttta	atgtctttca	acttaccacg	taatcctctt	14160
gtagggatca	catctttctt	tatgatattg	tatttctcta	cctctaacag	taaaaattcc	14220
attcaacctc	taaagctcac	ttcaaattct	tctttgagaa	gtttttctct	tctccgcaac	14280
cagatgtaca	tatttgaact	ctctttgtac	ttggagggca	cttctttcgt	ggtagttctt	14340
ttatttttat	taatctctgt	atccttagat	agtcctccaa	caaccaaaagg	ttgggactct	14400
gtcttacata	tctgggtgcc	cctcatagtg	cagtaataag	taagttgatt	atatacgagc	14460
tatgtaactt	atatttttta	atggttggat	atcactgagt	tttttttttt	aagaattttt	14520
ttattgaggt	aaacttcaca	taacataaaa	taaactattt	taaagtgaga	agttcagtgc	14580
cacttagtat	tgtaacaat	gttgcataac	caccaccttt	atttaaagtt	ccaaaaaaaa	14640
tgttctcctc	tataaggaaa	ccccatccca	tttagcagat	actctccatt	ccttctctcc	14700
tccagccccc	agcaaccacc	aatctgcttt	ctgtctctat	ggttttatct	attcttgcta	14760
ttttatataa	atcgaattgt	atgagacctt	ttgtgtctgg	cttctttcac	ttagtacaag	14820
tttttgagat	ttattttacat	agtagcatgt	atcaacactt	cattttttatg	gccaaataaa	14880
attgtattat	gtgtttatag	cacaattttat	ttatccactc	attcattgat	ggactttggg	14940
ttgtttctga	ctttttggcta	ttgggaatag	tgctgctatg	aatgtttgtg	tacctgtatt	15000
tgtttgaatg	cctatttttg	attctcttgg	gtatatatct	aggagtggaa	ctgctgggtc	15060
atatgttaat	tctatgttta	gctttttgag	gaacagacaa	actgttttcc	acagcagttg	15120
aaccattcca	cattcccacc	agcaatgtat	gagaattcca	atttctgtcc	acttctcac	15180
caacacttat	tattttcctt	ttcctttttt	taaaaaaaat	aagttatggc	catcttagtg	15240
ggtgtgaagt	ggtatctcat	tgtgtttttt	atttgcattt	cctatgtaat	gagctagaaa	15300
ctaaagtaca	aactagatgg	gacatccagt	ccctttgata	gataatgctg	agtaaaaaat	15360
gagatgaaag	acattttgtt	gttttttagaa	catgagtgc	agtttgtaa	aaagcttttag	15420
aggaggaatg	aaaacaaagt	gaagtacact	tagaaaaggg	ccaagtggac	atcttggatg	15480
tcaagtgcct	agttcagtat	cttttttttt	tttttttttt	tttttgagac	agtgccctac	15540
tctgtcacc	aggctggagt	gtagtggcat	gatctgggct	cactgcaacc	tcctcctcct	15600
ggattcaagc	aattctcttg	cttcagcctc	ccaagttagt	gagactacaa	gcacccacca	15660
ccacaccg	ctaattttgt	atttttcagt	agagacgggg	tttcgccaca	ttggccgtgt	15720
tggtcttgaa	ctcctggcct	caagcaatcc	gcctacctca	gcctcccaaa	gtgctaggat	15780
tacaggcata	agccactgag	cccagcccta	gttcagtatc	ttttatgtaa	attataaaca	15840
tctgcaacat	tatgtatcat	atgcagatac	ttattgcatt	tcttttatta	gtggtgaaag	15900
tgttctatgc	atttattggc	tcttgaattt	cctcatctat	gaattgtcat	tcacacacct	15960
acttttctgc	ttcggtttta	catatgtctt	tgccatttaa	agatattatc	cctctgtttt	16020
atattttctc	tcattcttgt	attgcctttt	aaattttgtt	atgatgtttc	attaataaac	16080
agtgttttgt	tttctctat	aatcaaaa				16107

&lt;210&gt; 401

&lt;211&gt; 466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 401

taaacctctt	ctctttgtga	attacccagc	ctcatgtatg	tggttttttt	ttttatagca	60
acacaaatga	accaagacac	agagggcaca	atcatgacag	aaattcttgt	tccgctctct	120
gttttaattt	agaggttgat	aatatccagt	attggtgagc	atacgagaaa	acaggcatcc	180

315

ttaccttgtg	tgtgggaatg	tggattaagg	gtttttggaa	ggaagtgggc	agccttttca	240
ttttaaatgg	acattctttt	tgggccagca	tctcactttt	agatgtctga	tctacataag	300
tatttgcata	catgcttaga	tatgctaagg	ttttccctgt	agtattttca	aaggcatttt	360
tgcagggtaa	tttaaaaaat	cgtggtaag	aaaaacaaaa	tttaccatct	taagcatttc	420
taagtgtaca	gttagcattg	ttgaatagca	aaaaaggaaa	gaaaaa		466

&lt;210&gt; 402

&lt;211&gt; 466

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 402

taaacctctt	ctcttttgtga	attacccagc	ctcatgtatg	tggttttttt	ttttatagca	60
acacaaatga	accaagacac	agagggcaca	atcatgacag	aaattcttgt	tccgctctct	120
gttttaattt	agaggttgat	aatatccagt	attgggtgagc	atacgagaaa	acaggcatcc	180
ttaccttgtg	tgtgggaatg	tggattaagg	gtttttggaa	ggaagtgggc	agccttttca	240
ttttaaatgg	acattctttt	tgggccagca	tctcactttt	agatgtctga	tctacataag	300
tatttgcata	catgcttaga	tatgctaagg	ttttccctgt	agtattttca	aaggcatttt	360
tgcagggtaa	tttaaaaaat	cgtggtaag	aaaaacaaaa	tttaccatct	taagcatttc	420
taagtgtaca	gttagcattg	ttgaatagca	aaaaaggaaa	gaaaaa		466

&lt;210&gt; 403

&lt;211&gt; 1817

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 403

accaccatgt	cacatgtata	cctatgtaac	acacctgcac	attctgcaca	tgtatcccag	60
aacttaaatt	ataataataa	aaaaagaata	attgggtgat	ggcacatcca	ggtttgccaa	120
agacagtccc	agtttatgct	gttgtcctgg	cattattaat	aatgacactg	cctttaactc	180
tcacaattaa	tttggatgat	aacttatatg	gtaactctgc	taaataaaaa	aaataaaaaat	240
taccatagta	acaggaacct	acttgaaatg	atgcctctgt	ttctattctg	gcttgaattc	300
tgcattcttt	gaggatttgt	agcctcatga	cagaatccta	tctacagggt	atgtatttca	360
tatgattttt	ggctattttt	ttaacaatct	caagcccaat	aataggcagt	gatataagga	420
atgtagttac	tttctcccca	ctttctggca	agttaagttt	agccacctga	tacaagaagg	480
gacattcaga	ggtaggatgg	cacaaagaca	cagggtccac	tggagatcac	tgggaagcagc	540
tgcagcaggg	ttaagagaag	ggagtcaccg	cgagtcttca	gtcaccacac	actaacatca	600
tcagtgaaaa	gttcctgggc	ctgaagatcc	agctatgttg	tttctagtgt	actattttta	660
gtgacagaac	ttggcccaag	cattgaccat	tttggttcct	caataagcct	gattcaacag	720
ggtcaccttt	gaatctgtcc	tccacctttc	caataaacct	attttatgca	tcattcagtg	780
agttattttt	ttattttact	ttttgctgag	aaacatgact	agatttagga	aaaatgtaga	840
atttttactt	tttttcaata	ttttctgggt	tttccagagt	tttcacgtgt	ttcacacctt	900
cctttgcttc	ccaccattcc	cctttctatt	tggaaactaga	gagacatgag	tttgaattct	960
agctgtgtaa	cctgagtcag	ttattttaacc	tctttttgtt	tctgtttctt	tgtctgtaaa	1020
tagcaaaaac	tacaattaac	tttagtcctt	gctgtacacc	aaatgttatc	ttgaaatatt	1080
atacatatta	tatgtaatta	ctactgaaat	gctctaagat	gcctatgtgt	gaatggcatt	1140
gttgtaaaga	ttaaataata	taaggggaag	gtctgcttca	gtgtctggca	tataataaaa	1200
gctattattt	ttacgattat	ttccatctta	tagaagaatt	atcgttcttc	ccttccaaag	1260
ctaataaatg	gacatgtgtt	tatcagacag	aacgtaagag	ctgccaaata	aatagggaat	1320
aggtgctttc	gggagtctag	ggaaataaag	gtcaggggaat	tgttcataaa	athtagtacc	1380
cataaatagc	ctataagtag	attccctagt	ttattctatg	caggaaaata	aagttctacg	1440
gagcacagat	tccaaaacta	attggtcata	aatatcacct	gaaagttag	aaaatgtagc	1500
atcatggacc	tcttttcata	ggttctaaat	cttaatatct	gtgggtgggt	gcaggaatct	1560
agctttgtcta	agtgccctca	gatgactctt	gctgttctag	gctaaaatac	atgtgggttg	1620
gcttcagtgg	acatgttctt	gaagaatggt	tggatgtcac	acattcatac	ttagtatgag	1680
agatgaggtc	ctcctctcat	cattttctta	ggttctcttc	tctccactcc	ttaccctccc	1740
atcacttaca	ataaatcttt	tagaaaatta	gctatacatt	tgtttcatta	taaaaaagaa	1800
agaagataaa	ttaaaaa					1817

&lt;210&gt; 404

&lt;211&gt; 1816

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 404

accacatgt	cacatgtata	cctatgtaac	acacctgcac	attctgcaca	tgtatcccag	60
aacttaaatt	ataataataa	aaaaagaata	attgggtgat	ggcacatcca	ggtttgccaa	120
agacagtcce	agtttatgct	gttgctcctg	cattattaat	aatgacactg	cctttaactc	180
tcacaattaa	tttgatgat	aacttatatg	gtaactctgc	taaataaaaa	aaataaaaaat	240
taccatagta	acaggaacct	acttgaaatg	atgcctctgt	ttctattctg	gcttgaattc	300
tgcattcttt	gaggatttgt	agcctcatga	cagaatccta	tctacagggt	atgtatttca	360
tatgattttt	ggcttttttt	taacaatctc	aagcccaata	ataggcagtg	atataaggaa	420
tgtagtact	ttctccccc	tttctggcaa	gttaagttaa	gccacctgat	acaagaagg	480
acattcagag	gtaggatggc	acaaagacac	aggggtccact	ggagatcact	ggaagcagct	540
gcagcagggt	taagagaagg	gagtcaccgc	gagtccttcag	tcaccacaca	ctaaccatcat	600
cagtgaagg	ttcctgggccc	tgaagatcca	gctatgttgt	ttctagttga	ctattttaag	660
tgacagaact	tgccccaagc	attgaccatt	ttgggttcctc	aataagcctg	attcaacagg	720
gtcacctttg	aatctgtcct	ccacctttcc	aataaaccta	ttttatgcat	cattcagtgga	780
gttatttttt	tattttactt	tttgctgaga	aacatgacta	gatttaggaa	aatgttagaa	840
ttttactttt	ttttcaatat	tttctgggtt	ttccagagtt	ttcacgtgtt	tcacaccttc	900
ctttgcttcc	caccattccc	ctttctattt	ggaactagag	agacatgagt	ttgaattcta	960
gctgtgtaac	ctgagtcagt	tatttaacct	ctttttgttt	ctgtttcttt	gtctgtaaat	1020
agcaaaaact	acaattaact	ttagtccctg	ctgtacacca	aatgttatct	tgaaatatta	1080
tacatattat	atgtaattac	tactgaaatg	ctctaagatg	cctatgtgtg	aatggcattg	1140
ttgtaaagat	taaataatat	aagggaagtg	tctgcttcag	tgtctggcat	ataataaaag	1200
ctattatttt	taogattatt	tccatcttat	agaagaatta	tcgttcttcc	cttccaaagc	1260
taataaatgg	acatgtgttt	atcagacaga	acgtaagagc	tgccaaataa	atagggaata	1320
gggtgctttc	ggagtctagg	gaaataaagg	tcagggaatt	gttcataaaa	tttagtacct	1380
ataaatagcc	tataagtaga	ttccctagtt	tattctatgc	aggaaaataa	agttctacgg	1440
agcacagatt	ccaaaactaa	ttgggtcataa	atatcacctg	aaagtttaga	aaatgtagca	1500
tcatggacct	cttttcatag	gttctaaatc	ttaatatctg	tgggatgggtg	caggaatcta	1560
gctttgctaa	gtgccctcag	atgactcttg	ctgttctagg	ctaaaataca	tgtgggttgg	1620
cttcaatgga	catgttcctg	aagaatgttt	ggatgtcaca	cattcatatt	tagtatgaga	1680
gatgaggtcc	tcctctcatc	attttcttag	gttctcttct	ctccactcct	tacctccca	1740
tcacttacaa	taaatctttt	agaaaattag	ctatacattt	gtttcattat	aaaaaagaaa	1800
gaagataaat	taaaaa					1816

&lt;210&gt; 405

&lt;211&gt; 339

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 405

aggaaacaac	agatgctgga	gaggatgtgg	agaaattgga	aaacttttac	actgttggtg	60
ggagtgtaaa	ttagttcaac	tattgtgaaa	gacagtgtgg	tgattcctca	aggatccaga	120
accagaaata	ccatttgacc	cagcagtcce	attattggat	atatacccaa	aggattataa	180
atcattctac	tctaaagaca	catgcacaca	tatgtttatt	gcagcactat	tcacaatagc	240
aaagacttgg	aaccaatcca	aatgcccac	aatgatagac	tggataaaga	caatgtggca	300
catatacacc	atggaatact	atgcagccat	aaaaaagga			339

&lt;210&gt; 406

&lt;211&gt; 339

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 406

aggaaacaac	agatgctgga	gaggatgtgg	agaaattgga	aaacttttac	actgttggtg	60
ggagtgtaaa	ttagttcaac	tattgtgaaa	gacagtgtgg	tgattcctca	aggatccaga	120
accagaaata	ccatttgacc	cagcagtcce	attattggat	atatacccaa	aggattataa	180
atcattctac	tctaaagaca	catgcacaca	tatgtttatt	gcagcactat	tcacaatagc	240

317

aaagacttgg	aaccaatcca	aatgcccac	aatgatagac	tggataaaga	caatgtggca	300
catatacacc	atggaatact	atgcagccat	aaaaaagga			339

&lt;210&gt; 407

&lt;211&gt; 5596

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 407

ggccagccgg	ctcgccccgg	ggccatggca	gcagcggcta	ctgcagccga	gggggtcccc	60
agtcgggggc	ctcccgggga	agtcattcat	ctgaatgtgg	gaggcaagag	gtgagtgtgg	120
gagactcctg	aggtcccac	ctcgggggcg	ggaagcgggg	tgggagtatc	cgctctcct	180
gggggaatcc	ctgtccatca	agggttgctc	cgccccccc	ccctttggag	gcgcgagatt	240
ctggaaaaac	gcccggggag	ggggaagggg	agggaaccct	ggatcctgcg	ggagggggac	300
gcattcctca	cccgtctctc	ttcatctctt	gcgtccgttt	accttccccg	cccagattca	360
gtacctctcg	ccagactctc	acctggatcc	cagactcctt	cttctccagg	tgatcgggag	420
agcgagtttg	gggcgagggt	aggagggatg	gagagggcgt	gggagacctc	atatccactc	480
ccccggccgt	gacgcctgct	cggtgtccct	tccctgcagt	cttctgagcg	gacgcactctc	540
gacgctgaaa	gatgagaccg	gagcagttag	tcggacaaga	actgaaatgg	gatggggggg	600
agggggttgg	aggaagaggg	gcaggacccc	actcagtcct	gccttttacc	ccatccatcc	660
tctgcccccc	tttcccgtag	atcttcatcg	acagggaccc	tacagtcttc	gcacacccat	720
caactcaact	caactgcgcac	caaagagttg	gatcccaggt	tggcatggaa	aaaggggagg	780
gagtcctcca	ctgtcttcag	tccctgagga	gttctttcac	ctcctctgaa	tgtccacgtg	840
agctccattc	tattagaatt	ctcattcaga	accttgatca	caggccgggc	gcgcggggat	900
tgtcacgcc	tgtaatccca	acactttggg	aggccgaggt	gggaggatca	cttgagccca	960
ggattggaga	ctagcctggg	caacatagcg	agaccccttc	tctaaaaaag	caaacaggca	1020
aaactttcatg	agaatcttga	tcatgttaaa	attttatgtc	cttcgatttc	tccctacaca	1080
cacacacaca	cacacacaca	cacacacaca	cacacacact	caacatttcc	tccacccata	1140
tcatactctc	ttagcatctt	tattccatca	aaactttcta	ccccttgaca	ttctctgtgc	1200
agttttgaaa	attaccctct	cagcattctc	tgttcacccc	cacacctaga	ccctgacctc	1260
tagtcaattc	tactaccagg	gggtgtccac	ggttccagcc	tccctccatga	agcccagttc	1320
tatgggctca	ctcctctggg	taagtgggag	ccccagcta	tcatactcat	tgtatagaaa	1380
accaactctg	tgatctacc	tgccctctct	cccttctctc	cctgaaagag	ggctggggta	1440
gagggtggag	gactgggtat	ggccctggcc	gggtctgtat	tcgtactggg	aggagtattg	1500
gtactctgtg	tagaaagaaa	tggggagggg	gaaatggggg	ggcctcagca	tctccctaag	1560
tcccagcctt	taagtctctc	tggtgcaggt	cgtcgcctgc	agcttcgaga	ggagttggat	1620
cgatcttctt	gtggaaacgt	cctcttcaat	ggttacctgc	cgccaccagg	taggcactcc	1680
caatggaaatg	gaggggcgcg	gaggtgggcc	aaagactaca	tttcccataa	ggctgcagct	1740
ctcgggtgcc	tgtgctgtgc	gtcctgagat	acagtgaggag	gtgtagttcc	ctatcagatg	1800
cttgggctga	tgcttgaaa	ggaagtggga	cacagcattt	cccatgagac	aatgggcccag	1860
ctaactcttg	aggctcagaa	ggatgtcctg	gagccccatg	ggagttgtag	tccgggtttg	1920
gtttctttgt	agggggggct	ttggaagacc	tgggattctt	cgtatggagg	ggagaaatat	1980
taataggaag	ttattgacag	taatgcccac	gatagccagc	ccactggcca	tggaaaggtat	2040
gccccagtg	ttattggaac	taggcttttc	tgattggtag	aagtaacaga	gtagggaaat	2100
ttcatctaca	gctttatttc	cctaactgca	gtcagcacct	gctaccttca	tgaaaagttgc	2160
cagatataaa	gatctgtagt	agtacttttc	caacttagtt	ttatcctggt	ttccgaaaaa	2220
caatcattta	tttattttat	tattttattt	attttatgag	acagggtctg	gctttgtcac	2280
ccaggctgga	gtgcagtggt	gcgatcttgg	ctcactgcaa	cctctgcctc	tcagattcaa	2340
gccatccttc	cacctcagct	ctgccactga	gtagctgaga	ctacaagcac	tcgccaccat	2400
gcccggctaa	taaaaaata	ataatcattt	taaatgcaag	ctttatatta	taaatacaaa	2460
gtaaacatga	aaataaaacc	caaacatagc	agtgttatta	aactctggcc	tgtagcagtg	2520
gctcacacct	gtaatcctag	cagttggagg	ccgagacagg	tggattactt	gagacctgga	2580
gtttgagacc	agcccggtg	acacagcaag	acctcatctc	tactaaaaat	aaaaaaaaat	2640
tagccaggtg	tgggtgtatg	cacctgtggt	cccagctact	taggatgctg	gagtgcgagg	2700
atcgcttgag	cccaggagg	caaggctgca	gtgaactatg	atcactcatt	acaccccagc	2760
ctgggtgaca	gagcgagatg	ctgtctcaaa	acaaaacaaa	acgaaaaaca	actctggcta	2820
gatgctattg	cttgccaagg	gtgcagtcct	ccatttatta	aaagtgaana	ttaggggccag	2880
gcacattggc	tcatgcctgt	aatcccagca	ctttgggagg	ctgaggtggg	tggatcacct	2940
gaggtcagga	gttcgagacc	agcctggcca	acatggtgaa	accttatctc	tgccaaaaat	3000
ataaaagatt	agccatgtgt	cgtggtgggt	gcttgtaatc	tcagctactt	gggaggctga	3060

318

```

ggcaggagaa tcacttgaac ccaggaggca gaggttgag tgagccaaga ttgtgccatt 3120
gcactccagc ctgtgcaaac gagcgaaact ccaactcaaa aaaaaaaaaa aaaaaaaaaa 3180
cgaaaaatta ggtaatactg cagattcatt aatatcacag cagcactaaa ctacgtcttc 3240
ctctgtgctg ggctcaaggg aactgaaagg gaagtaactt gctatgtggt tcagtgtcat 3300
ttcatgtctg gtcactgcac cacttaaaat cttcaccggg agactatgtc ccacacatgg 3360
ggaaatcaat caccgtcata ttttaagtc ttgctgtgtg acagccacga ttacaatgac 3420
tgttacteta cctcttattc tcaactgtagt gttcccagtg aagcggcgga accggcacag 3480
cctagtgggg cctcagcagc taggaggacg gccagccctt gtccgacgga gcaacacgat 3540
gcccccaac cttggcaatg cagggctgct gggccgaatg ctggatgaga aaaccctcc 3600
ctcaccctca ggtacgtttc tatctcgtgg aaggttgggg cagctgtggg gtccctgtga 3660
ccctcttctg atccctactc ttccctcaa ggacaacctg aggagccggg gatggtgcgc 3720
ctggtgtgtg gacaccataa ttggatcgct gtggcctata cccagtttct agtctgtcat 3780
aggtgcttgg ggaggagtg gcaggagtc ccagccctgt tgatgggaag ggcatgcgtt 3840
gaggggttgg gatgtccctt cgatcctaca ggttgaaggga agcctctggc tggcagctgg 3900
tgttttccag ccccgctg gaactggcca tcgaacgact ggcgctcaca gcccggtgc 3960
atggtggggc tttgggtgaa catgacaaga tgggtggcagc agccaccggc agcgagatcc 4020
tgctatgggc tctgcaggcg gaaggcggtg gctccgagat aggtatgacc ccaagccttt 4080
tccagaacct tctgtccttt aaattctact gcctgttaaa atgaccacc ccataaaatc 4140
ctcaaaccga taagaattct ctgctctatt agatctgttt gtgtcattag aatgctccag 4200
cccttcagaa ttctgtatcc tgttagaatt ccctggcttc ctagaaaaat ccaccacat 4260
acaattctcc ctccatcaga attccctgcc ctgttagatc tcttgggtttt gttagaatgc 4320
gctattctgt gtggccatga gaaatgtctg acttggcccg gtgcggtggc tcatgcttgt 4380
aatcccagca ctttgggagg ctgaggcggg cagatcactt gaggtcagga gttcgagacc 4440
cccttggcca acaggggtgaa acccagctct tatttcaaaa atacaaaaaa attagctggg 4500
tgtggtggca cgtgcctgta atcccagcta ctcaggaggt taaggcagga gaatcactgg 4560
aacctgggag gcagatgttg cagtgcagct agatcgacc actgcattcc agcctgagcg 4620
acagagtggg cagagtgaga caccatctca aaaaaaaaaa aaaaacaaaa aaagaaatct 4680
ctgacttatg gctgggcaca gtaactcaca tctgtagtct cagcactttg ggaggccatg 4740
gcaggaggat tgcttgaggc caggagttcg aggtgcctg gagctatgta agccatgatt 4800
gcaccactgc actccagcct ggacaacaga gcaagaccct gtctcaaagc cacagcaaca 4860
aatctcgga cttattaatct gtcccaaat aaatctcagc cctcgtaaga atccctgcc 4920
accagtggag gtttttttgc cttattgcaa atctcagtc tgttagaatt ccagaccgtt 4980
ttagaatccc ataccatct agaaatcttc tggccatttt tatcttctct aattcctgct 5040
ggaatcttca cttttttttt ttttgaaatg gagtcattct ctgttgccca gattggagta 5100
cagtggatg atctcggtc actgcaacct ctgcctcctg gggtcacgca attctccttc 5160
ctcaacctcc caagtagctg gggctacagt tgtgtgctac cacactcagc taatttttat 5220
attttttagt agagatggag tttcatcatg ttggccaggc tgggtctcaa ctccctggct 5280
caaatgatcc gccacctga gcctctcaaa gtgttgggat tacagggtgt agccactgtg 5340
cccagccct gatggaatct tctatccttc aaggattctg tgggtccact gaacctctg 5400
gtccttggag ttcttctct cactctcct cctccatgag gcagggttcc agctgagccc 5460
tttttgccca ctgcaggggt ctttcatctg ggggtgcctg tggaggcctt gttcttctgc 5520
gggaaccagc tcattgctac aagccacaca gggcgcatcg ggggtgtgaa tgccgtcacc 5580
aagcactggc aggtca 5596

```

&lt;210&gt; 408

&lt;211&gt; 384

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 408

```

gagtgaagg ggcctagccc cctgcactcc gccgcctcag agccatgcgg ttaattctctg 60
acttagttta tttttgcaaa acgtcgatct cctcctcccc cgccccgcac ccgcgaaggc 120
ttttaatggg aggggcgtca aagctcaaaa ctgttttctt ctctcctccc cctccagtt 180
gtaaatgcc cttcatgagg ggaggggcga ggggaagccc accctgcag cttctggctg 240
gagcacctcc ctggggagtc gggggatttg gttgtgggca gtcccatgg ccgcctggag 300
aagccgctgg ggccggggg tgtggggcgg tgtggcgggc gcacactgta tgtacctata 360
ataaaccttt tggctttgac ggtc 384

```

&lt;210&gt; 409

&lt;211&gt; 1656



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 409

gggtgacaga	gtgcgactct	gtctcaaaaa	aaaaaaaaag	aaaaaaaaag	aaaaaaagaa	60
aaatgaacat	gctcatgggtg	acctctgggc	aactttgaaa	tagcctcagt	ttctcaacag	120
ccgtgccagg	gggcgggggt	gggggtgtgga	gagtgttaga	gttgagtttc	agcaccagtc	180
cttgaaagtg	cctttcagaa	gaacagggtt	tatcccccaa	acagagagac	agtggtcagt	240
tcaccgtact	tcgggtgcacg	tttgcagacc	tggtgggaag	aggggcatct	tagagccgag	300
accattcac	tcttggcact	ccagggtggag	ctgggccttt	ggggcctgga	tatatccagg	360
gctgcggtatt	ttccccctt	cagggtttaa	tgttcctgtt	tttctacctt	tccctcgag	420
tatacgctca	acggcaagaa	agtggaaagt	gccgtcaaac	agatcatcgc	tggaaaagcc	480
gtggagcaag	gaggtgcttt	ctcgaacccc	gagaccctgg	atctgtaccg	ggacatccct	540
gagctgcagg	gcttctgagt	cagactggct	ggcgtgtcac	tcagccgcac	ccgtgtgcac	600
tgtaactttt	gtgtgctcaa	gaaattatac	agaaacctac	agctgttgta	aaaggatgct	660
cgcaccaagt	gttctgtagg	cttggggagg	gatcgtttct	ctgttttgtt	aaatctgggtg	720
ggtacctgga	tcttccacac	gagtgggatt	ctggccttca	gagaccagga	gggagtgtct	780
gggcgcgagg	tgtggcactg	tggtgagagt	gtgtgtcttt	gcacacacag	tgcagcggga	840
acggtggggc	tggctggtgc	tgaagacaga	cacactcctg	agccaagggtc	ttgtcttcaa	900
cctccccgtc	ccgttgctcc	atcttctct	gtgaagggtgc	aaatcccttt	cttcccttcc	960
catctcaggc	tctcctgttt	tccctcaggg	tccagtatgc	ctttgagctt	tagctgttag	1020
aaaggaaccc	ccgtgacttg	acacagcttt	cacagctggc	tgctaggacc	ggcgggctgg	1080
gtgttcacgt	gtgtctgtgt	catggatgca	atgcaggccc	tggaggactg	tgcgtcaccc	1140
gtcaaccaga	gcgtgcctcc	gggccagctt	ccctccaagg	aatgagtggg	tttcatacag	1200
gatctcttta	ttgcacagac	tgaatggctt	tacatgtttc	taatgtgaat	taggcattgtg	1260
aagcagtggg	tgctccaccg	tgctccctcat	gggtgagccc	tccagctgtg	agccacagga	1320
gtgtgggtcac	cgagtggagg	ccctcctcac	caggaaccgc	atccctgtgc	tgcctccacc	1380
tgagagtgtc	taggggggtc	ttgtcgagat	catgtcatca	gcacccctaa	gtcaagtcac	1440
gggtttccat	agccaggcag	ttggtatgta	caattcagtt	cagcgtatga	acttgtatct	1500
ctaattctgat	gtccattttt	atattttttg	aaactgagca	caatgaaatc	ctttcttgaa	1560
tcatttttct	tttggattat	aaaaatatgg	gggaaagtgc	tatgatgaat	tttatgcaat	1620
aaatgtatac	atgtgtgcac	atgcacccat	gctgtg			1656

&lt;210&gt; 410

&lt;211&gt; 1656

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 410

gggtgacaga	gtgcgactct	gtctcaaaaa	aaaaaaaaag	aaaaaaaaag	aaaaaaagaa	60
aaatgaacat	gctcatgggtg	acctctgggc	aactttgaaa	tagcctcagt	ttctcaacag	120
ccgtgccagg	gggcgggggt	gggggtgtgga	gagtgttaga	gttgagtttc	agcaccagtc	180
cttgaaagtg	cctttcagaa	gaacagggtt	tatcccccaa	acagagagac	agtggtcagt	240
tcaccgtact	tcgggtgcacg	tttgcagacc	tggtgggaag	aggggcatct	tagagccgag	300
accattcac	tcttggcact	ccagggtggag	ctgggccttt	ggggcctgga	tatatccagg	360
gctgcggtatt	ttccccctt	cagggtttaa	tgttcctgtt	tttctacctt	tccctcgag	420
tatacgctca	acggcaagaa	agtggaaagt	gccgtcaaac	agatcatcgc	tggaaaagcc	480
gtggagcaag	gaggtgcttt	ctcgaacccc	gagaccctgg	atctgtaccg	ggacatccct	540
gagctgcagg	gcttctgagt	cagactggct	ggcgtgtcac	tcagccgcac	ccgtgtgcac	600
tgtaactttt	gtgtgctcaa	gaaattatac	agaaacctac	agctgttgta	aaaggatgct	660
cgcaccaagt	gttctgtagg	cttggggagg	gatcgtttct	ctgttttgtt	aaatctgggtg	720
ggtacctgga	tcttccacac	gagtgggatt	ctggccttca	gagaccagga	gggagtgtct	780
gggcgcgagg	tgtggcactg	tggtgagagt	gtgtgtcttt	gcacacacag	tgcagcggga	840
acggtggggc	tggctggtgc	tgaagacaga	cacactcatg	agccaagggtc	ttgtcttcaa	900
cctccccgtc	ccgttgctcc	atcttctct	gtgaagggtgc	aaatcccttt	cttcccttcc	960
catctcaggc	tctcctgttt	tccctcaggg	tccagtatgc	ctttgagctt	tagctgttag	1020
aaaggaaccc	ccgtgacttg	acacagcttt	cacagctggc	tgctaggacc	ggcgggctgg	1080
gtgttcacgt	gtgtctgtgt	catggatgca	atgcaggccc	tggaggactg	tgcgtcaccc	1140
gtcaaccaga	gcgtgcctcc	gggccagctt	ccctccaagg	aatgagtggg	tttcatacag	1200
gatctcttta	ttgcacagac	tgaatggctt	tacatgtttc	taatgtgaat	taggcattgtg	1260

320

aagcagtg	ggg	tgtccaccg	tgtccctcat	gggtgagccc	tccagctgtg	agcccaggca	1320
gtgtgg	tcac	cgagtga	ga ccctcctcac	caggaaccgc	atccctgtgc	tgcctccacc	1380
tgagagt	g	tagggggttc	ttgtcgagat	catgtcatca	gcacccctaa	gtcaagtcac	1440
gggtttccat	agccaggcag	ttggatgtga	caattcagtt	cagcgtatga	acttgtatct		1500
ctaattctgat	gtccattttt	atattttttg	aaactgagca	caatgaaatc	ctttcttgaa		1560
tcatttttct	tttggtattat	aaaaatatgg	gggaaagtgc	tatgatgaat	tttatgcaat		1620
aaatgtatac	atgtgtgcac	atgcacccat	gctgtg				1656

&lt;210&gt; 411

&lt;211&gt; 1152

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 411

aaagcccttc	cacacacctg	atctcagttg	ctctctgtgc	aaaagtcaga	gaggctttcc	60
ctgcatttcc	tgtttgaaca	gtgtcctggc	ctccatcttt	agctttgaca	gtgtttacca	120
tgggggtgct	gaggggtgagt	tcttgtgtat	gtgcacatct	ttctgggtga	gtggaggcct	180
cttgaggaca	ggaaccttgt	gggtctacct	ccttttcttc	ggagctcagc	tgactgctg	240
gcaaaccaga	gatgcttttg	gtgtctgggt	agtgaatggg	gggtggggag	ctggctctgt	300
gacctgggtg	aggcgggaca	aacttgtctt	cctcacaccc	atcttacttc	ctcttatgag	360
gaaaccacaga	gagatgaggg	gtcttgccca	aggaaggggt	gtccatagtc	agctctgcct	420
tctgtctcacc	cagaataaag	acctggggac	cccgcgaggg	tcatggccaa	gtggaatgga	480
ctcctggcat	ttgagggctt	cccgactgca	gccctcaggc	agccatggct	gtcccaagtc	540
cagcgggcct	ttgtctgggt	catggctggg	atgtctggcc	cttctctgaca	ggaggctgct	600
gggtcctctgt	ctacttgggg	acgcctcatg	caggagctgg	tgtgggggtg	ggcagggggg	660
cgggtggcttc	ttcctttctc	tttcccttct	ctctaccttt	tcccctctcc	ccagagaaaa	720
tggtagcagg	atttctttta	agaggatgct	gctgtatttt	gccagcgggt	ggaagggtgc	780
ggtattagct	cccgtgagct	gcacgtggac	ccctgtgtga	agcgtagcag	ggcacagagc	840
aggcgagacg	tttgcatctc	acagcgggag	ggccggcgac	atcacatgaa	gtgacaggca	900
ggcccttgga	agccgggtgct	tagatcctta	attagttcac	acgtcgactg	aattttcaag	960
tgaatgaatt	ttaattacat	ctcaggttaa	aaaaaaaaaa	aggcgccagt	gatcgaggac	1020
tcgtcactgg	gctctgttgc	tcctgaagtt	tcctagccca	caacacacca	acactgccaa	1080
gggtccttct	ggattcaagg	tgaaacacat	gtgccataaa	tcttggagct	ctgaatgttt	1140
ggaaagggcc	cg					1152

&lt;210&gt; 412

&lt;211&gt; 1152

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 412

aaagcccttc	cacacacctg	atctcagttg	ctctctgtgc	aaaagtcaga	gaggctttcc	60
ctgcatttcc	tgtttgaaca	gtgtcctggc	ctccatcttt	agctttgaca	gtgtttacca	120
tgggggtgct	gaggggtgagt	tcttgtgtat	gtgcacatct	ttctgggtga	gtggaggcct	180
cttgaggaca	ggaaccttgt	gggtctacct	ccttttcttc	ggagctcagc	tgactgctg	240
gcaaaccaga	gatgcttttg	gtgtctgggt	agtgaatggg	gggtggggag	ctggctctgt	300
gacctgggtg	aggcgggaca	aacttgtctt	cctcacaccc	atcttacttc	ctcttatgag	360
gaaaccacaga	gagatgaggg	gtcttgccca	aggaaggggt	gtccatagtc	agctctgcct	420
tctgtctcacc	cagaataaag	acctggggac	cccgcgaggg	tcatggccaa	gtggaatgga	480
ctcctggcat	ttgagggctt	cccgactgca	gccctcaggc	agccatggct	gtcccaagtc	540
cagcgggcct	ttgtctgggt	catggctggg	atgtctggcc	cttctctgaca	ggaggctgct	600
gggtcctctgt	ctacttgggg	acgcctcatg	caggagctgg	tgtgggggtg	ggcagggggg	660
cgggtggcttc	ttcctttctc	tttcccttct	ctctaccttt	tcccctctcc	ccagagaaaa	720
tggtagcagg	atttctttta	agaggatgct	gctgtatttt	gccagcgggt	ggaagggtgc	780
ggtattagct	cccgtgagct	gcacgtggac	ccctgtgtga	agcgtagcag	ggcacagagc	840
aggcgagacg	tttgcatctc	acagcgggag	ggccggcgac	atcacatgaa	gtgacaggca	900
ggcccttgga	agccgggtgct	tagatcctta	attagttcac	acgtcgactg	aattttcaag	960
tgaatgaatt	ttaattacat	ctcaggttaa	aaaaaaaaaa	aggcgccagt	gatcgaggac	1020
tcgtcactgg	gctctgttgc	tcctgaagtt	tcctagccca	caacacacca	acactgccaa	1080
gggtccttct	ggattcaagg	tgaaacacat	gtgccataaa	tcttggagct	ctgaatgttt	1140

321

ggaaagggcc cg

1152

&lt;210&gt; 413

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 413

Ala Ser Ser Arg Tyr Gln Asn Phe Ser Lys Gly Ser Arg His Gly Ser  
1 5 10 15

Glu Glu Ala Tyr Ile Asp Pro Ile Ala  
20 25

&lt;210&gt; 414

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 414

Met Glu Tyr Tyr Asn Trp Gly Arg Phe Ser Lys Pro Pro Glu Asp Asp  
1 5 10 15

Asp Ala Asn Ser Tyr  
20

&lt;210&gt; 415

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 415

Glu Asn Val Leu Ile Cys Lys Gln Lys Thr Thr Glu Thr Gly Ala Gln  
1 5 10 15

Gln Glu Gly Ile Gly Gly Leu Cys Arg Gly Asp  
20 25

&lt;210&gt; 416

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 416

Val Arg Cys Ser Arg Pro Gly Ala Lys Arg Ser Glu Lys Ile Tyr Gln  
1 5 10 15

Gln Arg Ser Leu Arg Glu Asp Gln Gln Ser Phe Thr Gly Ser Arg Thr  
20 25 30

Tyr Ser Leu Val Gly Gln Ala Trp Pro Gly Pro Leu Ala Asp Met Ala  
35 40 45

Pro Thr Arg Lys Asp Lys Leu Leu Gln Phe Tyr Pro Ser Leu Glu Asp  
50 55 60

Pro Ala Ser Ser  
65

&lt;210&gt; 417

322

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 417

Leu Ser Leu Ser Leu Ala Leu Lys Thr Gly Pro Thr Ser Gly Leu Cys  
1 5 10 15

Pro Ser Ala Ser Pro Glu Glu Asp Glu Gly Ile  
20 25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number  
**WO 2002/026931 A3**

(51) International Patent Classification<sup>7</sup>: **C07H 21/04**,  
C07K 14/435

(21) International Application Number:  
PCT/US2001/029871

(22) International Filing Date:  
24 September 2001 (24.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/234,925 25 September 2000 (25.09.2000) US  
PCT/US01/00911 12 January 2001 (12.01.2001) US

(71) Applicant (for all designated States except US): **HUMAN  
GENOME SCIENCES, INC.** [US/US]; 9410 Key West  
Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RUBEN, Steven, M.**  
[US/US]; 18528 Heritage Hills Drive, Olney, MD 20832  
(US). **KOMATSOU, George** [US/US]; 9518 Gar-  
wood Street, Silver Spring, MD 20901 (US). **DUAN, D.,  
Roxanne** [US/US]; 5515 Northfield Road, Bethesda, MD  
20817 (US). **ROSEN, Craig, A.** [US/US]; 22400 Rolling  
Hill Lane, Laytonsville, MD 20882 (US). **MOORE, Paul,  
A.** [GB/US]; 19005 Leatherbark Drive, Germantown, MD  
20874 (US). **SHI, Yanggu** [CN/US]; 437 West Side Drive,  
Apt. 102, Gaithersburg, MD 20878 (US). **LAFLEUR,  
David, W.** [US/US]; 3142 Quesada Street, N.W., Wash-  
ington, DC 20015 (US). **OLSEN, Henrik** [DK/US];  
182 Kenrick Place #24, Gaithersburg, MD 20878 (US).  
**BREWER, Laurie, A.** [US/US]; 410 Van Dyke Street,  
Apt. 115, St. Paul, MN 55119 (US). **FLORENCE, Kim-  
berly, A.** [US/US]; 12805 Atlantic Avenue, Rockville, MD

20851 (US). **YOUNG, Paul, E.** [US/US]; 122 Beckwith  
Street, Gaithersburg, MD 20878 (US). **SOPPET, Daniel,  
R.** [US/US]; 15050 Stillfield Place, Centreville, VA 20120  
(US). **ENDRESS, Gregory, A.** [US/US]; 408 Bridge  
Road, Florence, MA 01062 (US). **MUCENSKI, Michael**  
[US/US]; 7870 Dennler Lane, Cincinnati, OH 45247  
(US). **EBNER, Reinhard** [DE/US]; 9906 Shelburne  
Terrace #316, Gaithersburg, MD 20878 (US).

(74) Agents: **HOOVER, Kenley, K.** et al.; Human Genome  
Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
4 March 2004

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: 71 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding re-  
gions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing  
human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating dis-  
eases, disorders, and/or conditions related to these novel human secreted proteins.

WO 2002/026931 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/29871

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C07K 14/435

US CL : 536/23.5; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database NCBI, accession number AC012267, Homo Sapiens Clone, 26 May 2000, see entire document.	1, 5-7
X	WO 00/04140 A1 (HUMAN GENOME SCIENCES, INC.) 27 January 2000, especially pages 223-228, 301-303, and SEQ ID NO's 11, 103, and 195, see entire document.	1-12, 14, 21

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 March 2003 (22.03.2003)

Date of mailing of the international search report

26 JUN 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

*Marjorie A. Moran*  
Marjorie A. Moran

Telephone No. (703) 308-1235

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/29871

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12, 14, 21 and SEQ ID NO's 11 and 104

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

PCT/US01/29871

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-12, 14, and 21 drawn to a nucleic acid molecule, a polypeptide encoded by the nucleic acid molecule, a gene, vector and a recombinant cell comprising the nucleic acid molecule, and a method of making the recombinant cell.

Group II, claim(s) 13, drawn to an isolated antibody.

Group III, claim(s) 15-16, drawn to a polypeptide and a method of making the polypeptide.

Group IV, claim(s) 17, drawn to a method of treating, preventing, or ameliorating a condition using a polypeptide or polynucleotide.

Group V, claim(s) 18, drawn to a method of diagnosis using a polynucleotide.

Group VI, claim(s) 19, drawn to a method of diagnosis using a polypeptide.

Group VII, claim(s) 20 and 23, drawn to a method for identifying a binding partner for a polypeptide.

Group VIII, claim(s) 22, drawn to a method for identifying activity in a biological assay.

Each of Groups I-VIII above is further restricted to a single polynucleotide and/or polypeptide sequence. Each polynucleotide sequence is considered an individual structure, therefore each sequence represents a separate product. As a polypeptide is encoded by a polynucleotide, then the polypeptide so encoded is inextricably linked to the polynucleotide encoding it. For this reason, election of a polynucleotide sequence is considered to include election of the polypeptide encoded.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: polynucleotides recited in the claims (e.g. those comprising SEQ ID NO: 11) are known in the prior art, as are polypeptides comprising SEQ ID NO: 104 (the peptide encoded by SEQ ID NO: 11). See the Search Report. As the sequences are known in the art, the claims do not recite a special technical feature and are not linked by a general inventive concept, and therefore lack unity.



# INTERNATIONAL SEARCH REPORT

PCT/US01/29871

## Continuation of B. FIELDS SEARCHED Item 3:

EST, GENEMBL, GENESEQ, BLOSUM62, PIR\_73, SWISSPROT, USpatents, US published applications  
for: SEQ ID NO's 11 and 104, and oligomers

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

## **IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**